PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Engelhardt, H; Heinz, C; Niederweis, M				Engelhardt, H; Heinz, C; Niederweis, M			A tetrameric porin limits the cell wall permeability of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PORINS; CRYSTAL-STRUCTURE; OUTER-MEMBRANE; PROTEIN; TUBERCULOSIS; CHANNELS; FLUIDITY; CHELONAE; EFFLUX; GENE	Mycobacteria protect themselves with an outer lipid bilayer, which is the thickest biological membrane hitherto known and has an exceptionally low permeability rendering mycobacteria intrinsically resistant against many antibiotics. Pore proteins mediate the diffusion of hydrophilic nutrients across this membrane. Electron microscopy revealed that the outer membrane of Mycobacterium smegmatis contained about 1000 protein pores per mum(2), which are about 50-fold fewer pores per mum(2) than in Gram-negative bacteria. The projection structure of the TV or porin MspA of M. smegmatis was determined at 17 resolution. MspA forms a cone-like tetrameric complex of 10 nm in length with a single central pore. Thus, MspA is drastically different from the trimeric porins of Gram-negative bacteria and represents a new class of channel proteins. The formation of MspA micelles indicated that the ends of MspA have different hydrophobicities. Oriented insertion of MspA into membranes was demonstrated in lipid bilayer experiments, which revealed a strongly asymmetrical voltage gating of MspA channels at -30 mV. The length of MspA is sufficient to span the outer membrane and contributes in combination with the tapering end of the pore and the low number of pores to the low permeability of the cell wall of M. smegmatis for hydrophilic compounds.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Max Planck Inst Biochem, Abt Mol Strukt Biol, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Max Planck Society	Niederweis, M (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.							Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRUNEN M, 1993, EUR J BIOCHEM, V212, P129, DOI 10.1111/j.1432-1033.1993.tb17642.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Fajardo DA, 1998, J BACTERIOL, V180, P4452, DOI 10.1128/JB.180.17.4452-4459.1998; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Gouaux E, 1998, STRUCT FOLD DES, V6, P1221, DOI 10.1016/S0969-2126(98)00122-1; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; HEINZ C, 2003, IN PRESS MEMBRANE PR; Hoiczyk E, 1998, CURR BIOL, V8, P1161, DOI 10.1016/S0960-9822(07)00487-3; Im W, 2002, J MOL BIOL, V319, P1177, DOI 10.1016/S0022-2836(02)00380-7; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Kartmann B, 1999, J BACTERIOL, V181, P6543, DOI 10.1128/JB.181.20.6543-6546.1999; KESSEL M, 1988, J MOL BIOL, V203, P275, DOI 10.1016/0022-2836(88)90108-8; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LIN CM, 1990, BIOCHIM BIOPHYS ACTA, V1038, P382, DOI 10.1016/0167-4838(90)90252-B; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; MAUK MR, 1989, EUR J BIOCHEM, V186, P473, DOI 10.1111/j.1432-1033.1989.tb15231.x; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2001, NANO LETT, V1, P169, DOI 10.1021/nl015503x; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Nikaido H, 2001, SEMIN CELL DEV BIOL, V12, P215, DOI 10.1006/scdb.2000.0247; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; PAUL A, 1992, BIOPHYS J, V61, P172, DOI 10.1016/S0006-3495(92)81825-8; PAUL TR, 1993, ZBL BAKT-INT J MED M, V279, P450; Riess FG, 2001, J MEMBRANE BIOL, V182, P147, DOI 10.1007/s00232-001-0037-x; Saier MH, 2000, J MEMBRANE BIOL, V175, P165, DOI 10.1007/s00232001065; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; SEN K, 1988, J BIOL CHEM, V263, P1182; Senaratne RH, 1998, J BACTERIOL, V180, P3541, DOI 10.1128/JB.180.14.3541-3547.1998; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS JQ, 1993, J BIOL CHEM, V268, P6234	43	58	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37567	37572		10.1074/jbc.M206983200	http://dx.doi.org/10.1074/jbc.M206983200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130659	hybrid			2022-12-27	WOS:000178447100084
J	Andrecht, S; Kolbus, A; Hartenstein, B; Angel, P; Schorpp-Kistner, M				Andrecht, S; Kolbus, A; Hartenstein, B; Angel, P; Schorpp-Kistner, M			Cell cycle promoting activity of JunB through cyclin A activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING PROTEIN; C-JUN; GENE-EXPRESSION; DNA-REPLICATION; A TRANSCRIPTION; DEPENDENT KINASES; MAMMALIAN-CELLS; INDUCTION; GROWTH; FOS	JunB, a major component of the AP-1 transcription factor, is known to act antagonistically to c-Jun in transcriptional regulation and is proposed to be a negative regulator of cell proliferation. Employing fibroblasts derived from E9.5junB(-/-) mouse embryos we provide evidence for a novel cell cycle promoting role of JunB. Despite a normal proliferation rate, primary and immortalized junB(-/-) fibroblasts exhibited an altered cell cycle profile, which was characterized by an increase in the population of S-phase cells, while that of cells in G(2)/M-phase was diminished. This delay in G(2)/M-transition is caused by impaired cyclin A-CDK2 and cyclin B-CDC2 kinase activities and counteracts the accelerated S-phase entry. Cells lacking JunB show severely delayed kinetics of cyclin A mRNA expression due to the loss of proper transcriptional activation mediated via binding of JunB to the CRE element in the cyclin A promoter. Upon reintroduction of an inducible JunB-ER(TM) expression vector the cell cycle distribution and the cell cycle-associated cyclin A-CDK2 kinase activity could be restored. Thus, cyclin A is a direct transcriptional target of JunB driving cell proliferation.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schorpp-Kistner, M (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	marina.schorpp@dkfz-heidelberg.de	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANDRECHT S, 2001, THESIS U HANOVER HAN; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Huet X, 1996, MOL CELL BIOL, V16, P3789; JIANG W, 1993, ONCOGENE, V8, P3447; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; LEHNER CF, 1991, COLD SH Q B, V56, P465; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEWING A, 1993, J CELL SCI, V104, P545; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; THOMAS DB, 1975, CELL, V5, P37, DOI 10.1016/0092-8674(75)90089-6; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	55	71	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35961	35968		10.1074/jbc.M202847200	http://dx.doi.org/10.1074/jbc.M202847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121977	hybrid			2022-12-27	WOS:000178275100026
J	Mignon, P; Steyaert, J; Loris, R; Geerlings, P; Loverix, S				Mignon, P; Steyaert, J; Loris, R; Geerlings, P; Loverix, S			A nucleophile activation dyad in ribonucleases - A combined X-ray crystallographic/ab initio quantum chemical study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-FUNCTIONAL THERMOCHEMISTRY; ACTIVE-SITE; RNASE T1; REACTIVITY INDEXES; CRYSTAL-STRUCTURE; BASES PRINCIPLE; HSAB PRINCIPLE; EXACT-EXCHANGE; SOFT ACIDS; MECHANISM	Ribonucleases (RNases) catalyze the cleavage of the phosphodiester bond in RNA up to 10(15)-fold, as compared with the uncatalyzed reaction. High resolution crystal structures of these enzymes in complex with 3'-mononucleotide substrates demonstrate the accommodation of the nucleophilic 2'-OH group in a binding pocket comprising the catalytic base (glutamate or histidine) and a charged hydrogen bond donor (lysine or histidine). Ab initio quantum chemical calculations performed on such Michaelis complexes of the mammalian RNase A (EC 3.1.27.5) and the microbial RNase T-1 (EC 3.1.27.3) show negative charge build up on the 2'-oxygen upon substrate binding. The increased nucleophilicity results from stronger hydrogen bonding to the catalytic base, which is mediated by a hydrogen bond from the charged donor. This hitherto unrecognized catalytic dyad in ribonucleases constitutes a general mechanism for nucleophile activation in both enzymic and RNA-catalyzed phosphoryl transfer reactions.	Free Univ Brussels, Eenheid Algemene Chem, Fac Wetenschappen, B-1050 Brussels, Belgium; Free Univ Brussels VIB, Dienst Ultrastrukt, B-1640 Rhode St Genese, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Geerlings, P (corresponding author), Free Univ Brussels, Eenheid Algemene Chem, Fac Wetenschappen, Gebouw G,Lokaal 10G709,Pleinlaan 2, B-1050 Brussels, Belgium.	pgeerlin@vub.ac.be	Steyaert, Jan/H-4662-2011; steyaert, jan/GQP-7811-2022; Loris, Remy/GPG-0894-2022; Steyaert, Jean/B-5326-2015	Steyaert, Jan/0000-0002-3825-874X; Steyaert, Jean/0000-0003-2512-4694; Loris, Remy/0000-0002-8862-3338; Mignon, Pierre/0000-0002-5611-8214				Becke AD, 1996, J CHEM PHYS, V104, P1040, DOI 10.1063/1.470829; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; Chattaraj PK, 2001, J PHYS CHEM A, V105, P8815, DOI 10.1021/jp011767w; CORDES F, 1995, J AM CHEM SOC, V117, P10365, DOI 10.1021/ja00146a022; DATKA J, 1985, J PHYS CHEM-US, V89, P3483, DOI 10.1021/j100262a013; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P17386, DOI 10.1021/bi981369s; Frisch M. J., 1998, GAUSSIAN 98; GAZQUEZ JL, 1994, J PHYS CHEM-US, V98, P4591, DOI 10.1021/j100068a018; Geerlings P, 2000, INT J QUANTUM CHEM, V80, P227, DOI 10.1002/1097-461X(2000)80:2<227::AID-QUA17>3.0.CO;2-N; Geerlings P., 1998, ADV QUANTUM CHEM, V33, P303, DOI DOI 10.1016/S0065-3276(08)60442-6; GUILLET V, 1993, FEBS LETT, V330, P137, DOI 10.1016/0014-5793(93)80259-W; HAYDOCK K, 1990, J AM CHEM SOC, V112, P3826, DOI 10.1021/ja00166a016; HERSCHLAG D, 1994, J AM CHEM SOC, V116, P11631, DOI 10.1021/ja00105a001; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; KIRBY AJ, 1970, J CHEM SOC B, P1165, DOI 10.1039/j29700001165; Koch W, 2001, PHARM CHEM J+; LANGENAEKER W, 1995, J PHYS CHEM-US, V99, P6424, DOI 10.1021/j100017a022; LANGENAEKER W, 1994, J PHYS CHEM-US, V98, P3010, DOI 10.1021/j100062a044; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Lott WB, 1998, P NATL ACAD SCI USA, V95, P542, DOI 10.1073/pnas.95.2.542; Loverix S, 2001, METHOD ENZYMOL, V341, P305, DOI 10.1016/S0076-6879(01)41160-8; Madhusudhan MS, 2001, PROTEINS, V45, P30, DOI 10.1002/prot.1120; MENDEZ F, 1994, J AM CHEM SOC, V116, P9298, DOI 10.1021/ja00099a055; MEOTNER M, 1986, J AM CHEM SOC, V108, P7525, DOI 10.1021/ja00284a014; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588; Numata T, 2001, J BIOCHEM-TOKYO, V130, P621, DOI 10.1093/oxfordjournals.jbchem.a003027; Pan YP, 1997, J AM CHEM SOC, V119, P7561, DOI 10.1021/ja9709684; Parr R. G., 1989, DENSITY FUNCTIONAL T, P87; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Sowa GA, 1997, J AM CHEM SOC, V119, P2319, DOI 10.1021/ja963974t; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Steyaert J, 1997, EUR J BIOCHEM, V247, P1, DOI 10.1111/j.1432-1033.1997.t01-1-00001.x; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1993, J MOL BIOL, V229, P770, DOI 10.1006/jmbi.1993.1078; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; Velikyan I, 2001, J AM CHEM SOC, V123, P2893, DOI 10.1021/ja0036312; Vos AM, 2002, J PHYS CHEM B, V106, P2026, DOI 10.1021/jp014015a; Wladkowski BD, 1998, J AM CHEM SOC, V120, P5488, DOI 10.1021/ja972296n; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217; ZEGERS I, 1994, J BIOL CHEM, V269, P127; Zegers I, 1998, NAT STRUCT BIOL, V5, P280, DOI 10.1038/nsb0498-280	48	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36770	36774		10.1074/jbc.M206461200	http://dx.doi.org/10.1074/jbc.M206461200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122018	Green Published, hybrid			2022-12-27	WOS:000178275100126
J	Russelakis-Carneiro, M; Saborio, GP; Anderes, L; Soto, C				Russelakis-Carneiro, M; Saborio, GP; Anderes, L; Soto, C			Changes in the glycosylation pattern of prion protein in murine scrapie - Implications for the mechanism of neurodegeneration in prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE DISTRIBUTION; GLYCOPROTEIN; NEURONS; SPREAD; AGENT; CELLS; PRPC	In prion diseases, the normal prion protein (PrPc) undergoes a conformational change that results in the abnormal form, named scrapie prion protein (PrPsc). The visual system of rodents provides a relatively simple neuronal model in which the cell bodies of neurons are confined to the retina and the axons constitute the optic nerve. We investigated by Western blot the profile of PrPc in the optic nerve and retina of normal hamsters and mice. We found that in the optic nerve the amount of PrPc is significantly higher than in the retina. A less abundant non-glycosylated band was observed in retinas compared with the optic nerve and brain. Similar results were found in the gray and white matter from normal mice and hamsters. After stereotaxic injection of ME7 or 139A in the superior colliculus, a visual target area, the proportion and glycopattern of PrP changed in the retina and optic nerve throughout the course of the disease. Similar results were found in the gray and white matter at terminal stage of scrapie after injection of ME7 and 139A in the dorsal hippocampus. This is the first time that changes in the distribution and glycopattern of PrP have been described in an in vivo model of prion diseases.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		Soto, C (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.							Belichenko PV, 2000, NEUROPATH APPL NEURO, V26, P143, DOI 10.1046/j.1365-2990.2000.026002143.x; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Betmouni S, 1999, NEUROPATH APPL NEURO, V25, P20, DOI 10.1046/j.1365-2990.1999.00153.x; BORCHELT DR, 1994, J BIOL CHEM, V269, P14711; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; FRASER H, 1982, NATURE, V295, P149, DOI 10.1038/295149a0; Gray F, 1999, J NEUROPATH EXP NEUR, V58, P321, DOI 10.1097/00005072-199904000-00002; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; LINDEN R, 1983, BRAIN RES, V272, P145, DOI 10.1016/0006-8993(83)90371-2; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4	20	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36872	36877		10.1074/jbc.M202229200	http://dx.doi.org/10.1074/jbc.M202229200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130636	hybrid			2022-12-27	WOS:000178275100140
J	Tinoco, LW; da Silva, A; Leite, A; Valente, AP; Almeida, FCL				Tinoco, LW; da Silva, A; Leite, A; Valente, AP; Almeida, FCL			NMR structure of PW2 bound to SDS micelles - A tryptophan-rich anticoccidial peptide selected from phage display libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; CIRCULAR-DICHROISM; INDOLICIDIN; MEMBRANE; PROTEIN; ANTIBACTERIAL; MECHANISM; MAGAININS; PROGRAM	PW2 (HPLKQYWWRPSI) was selected from phage display libraries through an alternative panning method using living sporozoites of Eimeria acervulina as target. Synthetic PW2 shows anticoccidial activity against E. acervulina and Eimeria tenella with very low hemolytic activity. It also displays antifungal activity but no activity against bacteria. We present the solution structure of the PW2 bound to SDS micelles. In the absence of an interface, PW2 is in random coil conformation. In micelles, structural calculation shows that Trp-7 forms the hydrophobic core that is important for the peptide folding. Lys-4, Tyr-6, Trp-8, and Arg-9 are in the same surface, possibly facing the micelle interface. This possibility was supported by the fact that chemical shift differences for these residues were more pronounced when compared with PW2 in water and in SDS. PW2 gains structure upon binding to SDS micelles. Lys-4, Tyr-6, Trp-8, and Arg-9 were found to bind to the micelle. Trp-7, Trp-8, and Arg-9 composed the WW+ consensus found in the sequence of the peptides selected with the phage display technique against E. acervulina sporozoites. This suggested that Trp-7, Trp-8, and Arg-9 are probably key residues not only for the peptide interaction with SDS micelles but also for the interaction with E. acervulina sporozoites surface.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl, BR-21941590 Rio De Janeiro, RJ, Brazil; Univ Estadual Campinas, Ctr Biol Mol & Engn Genet, BR-23083970 Campinas, SP, Brazil	Universidade Federal do Rio de Janeiro; Universidade Estadual de Campinas	Almeida, FCL (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl, BR-21941590 Rio De Janeiro, RJ, Brazil.	valente@cnrmn.bioqmed.ufrj.br	Valente, Ana Paula/J-3010-2017; Tinoco, Luzineide W/G-3630-2014; Almeida, Fabio/O-4989-2018	Valente, Ana Paula/0000-0001-7219-1123; Tinoco, Luzineide W/0000-0002-1299-6242; Almeida, Fabio/0000-0001-6046-7006				AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BIERBAUM G, 1985, ARCH MICROBIOL, V141, P249, DOI 10.1007/BF00408067; Bihan TL, 1996, BIOCHEMISTRY-US, V35, P12712, DOI 10.1021/bi960869n; BLOCHET JE, 1993, FEBS LETT, V329, P336, DOI 10.1016/0014-5793(93)80249-T; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; da Silva A, 2002, MOL BIOCHEM PARASIT, V120, P53, DOI 10.1016/S0166-6851(01)00439-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Friedrich CL, 2001, J BIOL CHEM, V276, P24015, DOI 10.1074/jbc.M009691200; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lawyer C, 1996, FEBS LETT, V390, P95, DOI 10.1016/0014-5793(96)00637-0; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Robinson WE, 1998, J LEUKOCYTE BIOL, V63, P94, DOI 10.1002/jlb.63.1.94; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; Tassin S, 1998, BIOCHEMISTRY-US, V37, P3623, DOI 10.1021/bi9723515; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JJ, 1994, BIOCHEMISTRY-US, V33, P7345, DOI 10.1021/bi00189a040; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200; Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3	37	37	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36351	36356		10.1074/jbc.M204225200	http://dx.doi.org/10.1074/jbc.M204225200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130641	hybrid			2022-12-27	WOS:000178275100073
J	Park, HI; Turk, BE; Gerkema, FE; Cantley, LC; Sang, QXA				Park, HI; Turk, BE; Gerkema, FE; Cantley, LC; Sang, QXA			Peptide substrate Specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; ALPHA-1-PROTEINASE INHIBITOR; INTERSTITIAL COLLAGENASE; HUMAN STROMELYSIN-3; CYSTEINE SWITCH; GELATINASE; IDENTIFICATION; MATRILYSIN; INACTIVATION; LIBRARIES	Human endometaselmatrilysin-2/matrix metalloproteinase-26 (MMP-26) is a novel epithelial and cancer-specific metalloproteinase. Peptide libraries were used to profile the substrate specificity of MMP-26 from the P4-P4' sites. The optimal cleavage motifs for MMP-26 were Lys-Pro-Ile/Leu-Ser(P1)-Leu/Met(P1')-Ile/Thr-Ser/Ala-Ser. The strongest preference was observed at the P1' and P2 sites where hydrophobic residues were favored. Proline was preferred at P3, and Serine was preferred at P1. The overall specificity was similar to that of other MMPs with the exception that more flexibility was observed at P1, P2', and P3'. Accordingly, synthetic inhibitors of gelatinases and collagenases inhibited MMP-26 with similar efficacy. A pair of stereoisomers had only a 40-fold difference in K-i(app) values against MMP-26 compared with a 250-fold difference against neutrophil collagenase, indicating that MMP-26 is less stereoselective for its inhibitors. MMP-26 autodigested itself during the folding process. Two of the major autolytic sites were Leu(49)-Thr(50) and Ala(75)-Leu(76), which still left the cysteine switch sequence (PHC82 GVPD) intact. This suggests that Cys(82) may not play a role in the latency of the zymogen. Interestingly, inhibitor titration studies revealed that only similar to5% of the total MMP-26 molecules was catalytically active, indicating that the thiol groups of Cys(82) in the active molecules may be dissociated or removed from the active site zinc ions. MMP-26 cleaved Phe(352)-Leu(353) and Pro(357)-Met(358) in the reactive loop of alpha(1)-proteinase inhibitor and His(140)-Val(141) in insulin-like growth factor-binding protein-1, probably rendering these substrates inactive. Among the fluorescent peptide substrates analyzed, Mca-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 displayed the highest specificity constant (30,000/molar second) with NMP-26. This report proposes a working model for the future studies of pro-MMP-26 activation, the design of inhibitors, and the identification of optimal physiological and pathological substrates of NMP-26 in vivo.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, Chem Res Bldg DLC,Rm 203, Tallahassee, FL 32306 USA.	qxsang@chem.fsu.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL CANCER INSTITUTE [R29CA078646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, F32GM019895] Funding Source: NIH RePORTER; NCI NIH HHS [CA78646] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203, GM56203, GM19895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Copeland R.A., 2000, ENZYMES PRACTICAL IN, P305; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Marchenko ND, 2002, J BIOL CHEM, V277, P18967, DOI 10.1074/jbc.M201197200; MAST AE, 1991, J BIOL CHEM, V266, P15810; Matter H, 1999, J MED CHEM, V42, P1908, DOI 10.1021/jm980631s; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MURPHY G, 1994, J BIOL CHEM, V269, P6632; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; NAGASE H, 1999, J BIOL CHEM, V271, P28509; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; Ohkubo S, 1999, BIOCHEM BIOPH RES CO, V266, P308, DOI 10.1006/bbrc.1999.1816; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; PEI DQ, 1994, J BIOL CHEM, V269, P25849; SANG QX, 2002, IN PRESS HDB PROTEOL; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STACK MS, 1989, J BIOL CHEM, V264, P4277; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Uria JA, 2000, CANCER RES, V60, P4745; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578	42	56	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35168	35175		10.1074/jbc.M205071200	http://dx.doi.org/10.1074/jbc.M205071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12119297	hybrid			2022-12-27	WOS:000178117000066
J	Xu, J; Liu, D; Zhou, SY				Xu, J; Liu, D; Zhou, SY			The role of Asp-462 in regulating Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; CELL-LINE; ACTIVATION; APOPTOSIS; SURVIVAL; MECHANISM; CLEAVAGE; SIGNALS; PDK1	Protein kinase Akt, an important downstream target of phosphatidylinositol 3-kinase, is one of the major survival factors in mammalian cells. It has been shown that phosphorylation of the C-terminal hydrophobic motif is required for Akt activation. The activated Akt then phosphorylates several pro-apoptotic proteins and prevents apoptosis mediated by caspases and the mitochondria. Interestingly, Akt has also been implicated to be a direct substrate of caspases in apoptotic cells induced by Fas (Widmann, C., Gibson, S., and Johnson, G. L. (1998) J. Biol. Chem. 273, 7141-7147) and anoikis (Bachelder, R. E., Wendt, M. A., Fujita, N., Tsuruo, T., and Mercurio, A. M. (2001) J. Biol. Chem. 276, 34702-34707). In this study we showed that cytokine withdrawal resulted in Akt degradation by caspases as well. Furthermore, we demonstrated residue Asp-462 of Akt1 which is just upstream of the hydrophobic motif to be the primary cleavage site. The Akt1 mutant (D462N) that prevented caspase cleavage was more stable during factor withdrawal and enhanced cell survival. The Akt truncation mutant mimicking the caspase cleavage product lost its kinase activity and functioned as a dominant negative to promote cell death. Our results suggest that the balance between Akt and caspase activity controls cell survival. In particular, caspases are able to render Akt inactive and dominantly inhibit the Akt pathway by cleaving off the C-terminal hydrophobic motif. Consequently, the survival signal is quickly down-regulated to allow apoptosis to occur.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	songyang@bcm.tmc.edu			NCI NIH HHS [CA84208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUHK G, 1997, MOL CELL BIOL, V17, P1595; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	34	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35561	35566		10.1074/jbc.M203805200	http://dx.doi.org/10.1074/jbc.M203805200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124386	hybrid			2022-12-27	WOS:000178117000115
J	Botos, I; O'Keefe, BR; Shenoy, SR; Cartner, LK; Ratner, DM; Seeberger, PH; Boyd, MR; Wlodawer, A				Botos, I; O'Keefe, BR; Shenoy, SR; Cartner, LK; Ratner, DM; Seeberger, PH; Boyd, MR; Wlodawer, A			Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; INACTIVATING PROTEIN; BINDING; TYPE-1; CRYSTAL; CYANOBACTERIUM; GLYCOSYLATION; AFFINITY; SYSTEM	The development of anti-human immunodeficiency virus (HIV) microbicides for either topical or ex vivo use is of considerable interest, mainly due to the difficulties in creating a vaccine that would be active against multiple clades of HIV. Cyanovirin-N (CV-N), an 11-kDa protein from the cyanobacterium (blue-green algae) Nostoc ellipsosporum with potent virucidal activity, was identified in the search for such antiviral agents. The binding of CV-N to the heavily glycosylated HIV envelope protein gp120 is carbohydrate-dependent. Since previous CV-N-dimannose structures could not fully explain CVN-oligomannose binding, we determined the crystal structures of recombinant CV-N complexed to Man-9 and a synthetic hexamannoside, at 2.5- and 2.4-Angstrom resolution, respectively. CV-N is a three-dimensional domain-swapped dimer in the crystal structures with two primary sites near the hinge region and two secondary sites on the opposite ends of the dimer. The binding interface is constituted of three stacked alpha1-->2-linked mannose rings for Man-9 and two stacked mannose rings for hexamannoside with the rest of the saccharide molecules pointing to the solution. These structures show unequivocally the binding geometry of high mannose sugars to CV-N, permitting a better understanding of carbohydrate binding to this potential new lead for the design of drugs against AIDS.	NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; NCI, Mol Targets Drug Discovery Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA; SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Univ S Alabama, Coll Med, USA, Canc Res Inst, Mobile, AL 36688 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Massachusetts Institute of Technology (MIT); University of South Alabama	Wlodawer, A (corresponding author), NCI, Macromol Crystallog Lab, NIH, MCL Bldg 536,Rm 5, Frederick, MD 21702 USA.			Botos, Istvan/0000-0002-7702-6749	NCI NIH HHS [N01 CO 12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X; Barrientos LG, 2001, J BIOMOL NMR, V19, P289, DOI 10.1023/A:1011292919947; Bewley CA, 2000, J AM CHEM SOC, V122, P6009, DOI 10.1021/ja000858o; Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949, DOI 10.1124/mol.59.5.949; Botos I, 2002, BIOCHEM BIOPH RES CO, V294, P184, DOI 10.1016/S0006-291X(02)00455-2; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1; Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489; Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esser MT, 1999, J VIROL, V73, P4360, DOI 10.1128/JVI.73.5.4360-4371.1999; GEYER H, 1988, J BIOL CHEM, V263, P11760; Gustafson KR, 1997, BIOCHEM BIOPH RES CO, V238, P223, DOI 10.1006/bbrc.1997.7203; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; LANGE JMA, 1993, LANCET, V342, P1356, DOI 10.1016/0140-6736(93)92258-U; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Mariner JM, 1998, BIOCHEM BIOPH RES CO, V248, P841, DOI 10.1006/bbrc.1998.9060; MERITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Keefe BR, 2000, MOL PHARMACOL, V58, P982, DOI 10.1124/mol.58.5.982; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Rao V. S. R., 1998, CONFORMATION CARBOHY; Ratner DM, 2002, EUR J ORG CHEM, V2002, P826; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704; SHENOY SR, 2002, IN PRESS CHEM BIOL L; SRIKRISHNAN T, 1989, CARBOHYD RES, V186, P167, DOI 10.1016/0008-6215(89)84032-7; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x; Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019; [No title captured]	42	150	162	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34336	34342		10.1074/jbc.M205909200	http://dx.doi.org/10.1074/jbc.M205909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110688	hybrid			2022-12-27	WOS:000177959100105
J	Guengerich, FP; Miller, GP; Hanna, IH; Sato, H; Martin, MV				Guengerich, FP; Miller, GP; Hanna, IH; Sato, H; Martin, MV			Oxidation of methoxyphenethylamines by cytochrome p450 2D6 - Analysis of rate-limiting steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; N-DEALKYLATION REACTIONS; ELECTRON-TRANSFER; RECONSTITUTED SYSTEMS; NUMERICAL-INTEGRATION; OXYGEN ACTIVATION; SUBSTRATE-BINDING; DRUG-METABOLISM; AMINO-ACID; HYDROXYLATION	Cytochrome P450 (P450) 2D6 is involved in the oxidation of a large fraction (similar to30%) of drugs used by humans and also catalyzes the O-demethylation of the model substrates 3- and 4-methoxyphenethylamine followed by subsequent ring hydroxylation to dopamine. Burst kinetics were not observed; rate-limiting step(s) must occur prior to product formation. Rates of reduction of ferric P450 2D6 were stimulated by 3- or 4-methoxyphenethylamine or the inhibitor quinidine; reduction is not the most rate-limiting step. The non-competitive intramolecular deuterium isotope effect, an estimate of the intrinsic isotope effect, for 4-methoxyphenethylamine O-demethylation was 9.6. Intermolecular noncompetitive deuterium isotope effects of 3.1-3.8 were measured for k(cat) and k(cat)/K-m for both O-demethylation reactions, implicating at least partially rate-limiting C-H bond breaking. Simulation of steady-state kinetic data yielded a catalytic mechanism dominated by the rates of (i) Fe2+O2- protonation (plus O-O bond scission) and (ii) C-H bond breaking, consistent with the appearance of the spectral intermediates in the steady state, attributed to iron-oxygen complexes. However, all the rates of individual steps (or rates of combined steps) are considerably higher than k(cat), and the contributions of several steps must be considered in understanding rates of the P450 2D6 reactions.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,Med Res Bldg 1,23rd & Pierc, Nashville, TN 37232 USA.			Miller, Grover P/0000-0002-4743-8187	NATIONAL CANCER INSTITUTE [F32CA079162, R35CA044353, R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019808] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA 79162, R35 CA 44353, R01 CA 90426] Funding Source: Medline; NIEHS NIH HHS [P30 ES 00267] Funding Source: Medline; NIGMS NIH HHS [F32 GM 19808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bell LC, 1997, J BIOL CHEM, V272, P29643, DOI 10.1074/jbc.272.47.29643; Bell-Parikh LC, 1999, J BIOL CHEM, V274, P23833, DOI 10.1074/jbc.274.34.23833; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; BJORKHEM I, 1974, J BIOL CHEM, V249, P6439; BJORKHEM I, 1973, BIOCHEM BIOPH RES CO, V50, P581, DOI 10.1016/0006-291X(73)90879-6; BJORKHEM I, 1982, HEPATIC CYTOCHROME P, P645; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; BROWN HC, 1960, J AM CHEM SOC, V82, P681, DOI 10.1021/ja01488a045; COOK PF, 1993, BIOCHEMISTRY-US, V32, P1795, DOI 10.1021/bi00058a013; CRESPI CL, 1995, PHARMACOGENETICS, V5, P234, DOI 10.1097/00008571-199508000-00007; Daly AK, 1996, PHARMACOGENETICS, V6, P193, DOI 10.1097/00008571-199606000-00001; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; de Groot MJ, 1999, J MED CHEM, V42, P4062, DOI 10.1021/jm991058v; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DIEHL H, 1970, H-S Z PHYSIOL CHEM, V351, P1359, DOI 10.1515/bchm2.1970.351.2.1359; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; Ellis SW, 1996, BIOCHEM J, V316, P647, DOI 10.1042/bj3160647; ESTABROOK RW, 1971, BIOCHEM BIOPH RES CO, V42, P132, DOI 10.1016/0006-291X(71)90372-X; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fersht A, 1999, STRUCTURE MECH PROTE, P159; Filatov M, 1999, ANGEW CHEM INT EDIT, V38, P3510, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3510::AID-ANIE3510>3.0.CO;2-#; FRANKLIN MR, 1982, HEPATIC CYTOCHROME P, P763; FRIEDEN C, 1993, TRENDS BIOCHEM SCI, V18, P58, DOI 10.1016/0968-0004(93)90056-S; GANDER JE, 1982, HEPATIC CYTOCHROME P, P667; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Guengerich F. P., 1995, CYTOCHROME P, P473; GUENGERICH FP, 1987, J BIOL CHEM, V262, P8459; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; Hanna IH, 2001, ARCH BIOCHEM BIOPHYS, V393, P255, DOI 10.1006/abbi.2001.2510; Hanna IH, 2001, J BIOL CHEM, V276, P39553, DOI 10.1074/jbc.M106841200; Higgins L, 1998, BIOCHEMISTRY-US, V37, P7039, DOI 10.1021/bi9729864; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Hiroi T, 1998, BIOCHEM BIOPH RES CO, V249, P838, DOI 10.1006/bbrc.1998.9232; Hutzler JM, 2002, DRUG METAB DISPOS, V30, P355, DOI 10.1124/dmd.30.4.355; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; Johnson K. A., 1992, ENZYMES, P1; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lewis DFV, 2000, BIOCHEM PHARMACOL, V60, P293, DOI 10.1016/S0006-2952(00)00335-X; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; McOmie J. F. W., 1973, ORG SYNTH, VV, P412; Miller GP, 2001, BIOCHEMISTRY-US, V40, P14215, DOI 10.1021/bi0110037; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; Modi S, 1996, BIOCHEMISTRY-US, V35, P4540, DOI 10.1021/bi952742o; Mueller Ernest J., 1995, P83; Nakamura K, 2001, ANAL BIOCHEM, V292, P280, DOI 10.1006/abio.2001.5098; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NOSHIRO M, 1981, EUR J BIOCHEM, V116, P521, DOI 10.1111/j.1432-1033.1981.tb05367.x; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OTTON SV, 1984, LIFE SCI, V34, P73, DOI 10.1016/0024-3205(84)90332-1; PALMER G, 1992, J BIOL CHEM, V267, P665; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; PORTER TD, 1991, J BIOL CHEM, V266, P13469; READ GW, 1973, J MED CHEM, V16, P1292, DOI 10.1021/jm00269a016; Sato H, 2000, J AM CHEM SOC, V122, P8099, DOI 10.1021/ja000838m; Shou MG, 1999, BIOCHEM J, V340, P845, DOI 10.1042/0264-6021:3400845; Toy PH, 1998, J AM CHEM SOC, V120, P9718, DOI 10.1021/ja981990f; Tracy TS, 2002, DRUG METAB DISPOS, V30, P385, DOI 10.1124/dmd.30.4.385; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; WERRINGLOER J, 1980, MICROSOMES DRUG OXID, P469; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578; Yun CH, 2001, BIOCHEMISTRY-US, V40, P4521, DOI 10.1021/bi002906n; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	81	51	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33711	33719		10.1074/jbc.M205146200	http://dx.doi.org/10.1074/jbc.M205146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093814	hybrid			2022-12-27	WOS:000177959100026
J	Kruth, HS; Huang, W; Ishii, I; Zhang, WY				Kruth, HS; Huang, W; Ishii, I; Zhang, WY			Macrophage foam cell formation with native low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; HUMAN ATHEROSCLEROTIC LESIONS; RECEPTOR-MEDIATED ENDOCYTOSIS; FAMILIAL HYPERCHOLESTEROLEMIC SUBJECTS; MOUSE PERITONEAL-MACROPHAGES; TISSUE FACTOR EXPRESSION; CULTURED-CELLS; LIPOPOLYSACCHARIDE STIMULATION; CHOLESTEROL DEPOSITION; HORSERADISH-PEROXIDASE	This investigation has elucidated a mechanism for development of macrophage foam cells when macrophages are incubated with native low density lipoprotein (LDL). LDL is believed to be the main source of cholesterol that accumulates in monocyte-derived macrophages within atherosclerotic plaques, but native LDL has not previously been shown to cause substantial cholesterol accumulation when incubated with macrophages. We have found that activation of human monocyte-derived macrophages with phorbol 12-myristate 13-acetate (PMA) stimulates LDL uptake and degradation and acyl-CoAcholesterol acyltransferase-mediated esterification of LDL-derived cholesterol, resulting in massive macrophage cholesterol accumulation that could exceed 400 nmol/mg of cell protein. Cholesterol accumulation showed a biphasic linear LDL concentration dependence with LDL levels as high as 4 mg/ml, similar to LDL levels in artery intima. Protein kinase C mediated the PMA-stimulated macrophage uptake of LDL because the protein kinase C inhibitors, G66983 and GF109203X, inhibited cholesterol accumulation. LDL receptors did not mediate macrophage cholesterol accumulation because accumulation occurred with reductively methylated LDL and in the presence of an anti-LDL receptor-blocking monoclonal antibody. LDL-induced cholesterol accumulation was not inhibited by antioxidants, was not accompanied by increased LDL binding to macrophages, did not depend on the apoB component of LDL, and was not down-regulated by prior cholesterol enrichment of macrophages. We have shown that the mechanism of LDL uptake by macrophages was PAU-stimulated endocytosis of LDL taken up as part of the bulk phase fluid (i.e. fluid phase endocytosis). The amount of LDL taken up with the bulk phase fluid was measured with [H-3]sucrose and accounted for a minimum. of 83% of the LDL cholesterol delivery and accumulation in PMA-activated macrophages. This novel mechanism of macrophage cholesterol accumulation shows that modification of LDL is not necessary for foam cell formation to occur. In addition, the findings direct attention to macrophage fluid phase endocytosis as a relevant pathway to target for modulating macrophage cholesterol accumulation in atherosclerosis.	NHLBI, Sect Expt Atherosclerosis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kruth, HS (corresponding author), NHLBI, Sect Expt Atherosclerosis, NIH, Bldg 10,Rm 5N-113,10 Ctr Dr,MSC 1422, Bethesda, MD 20892 USA.		Huang, Wei/E-3270-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002832, Z01HL002832] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asmis R, 2000, ATHEROSCLEROSIS, V148, P243, DOI 10.1016/S0021-9150(99)00268-3; AVIRAM M, 1994, ISRAEL J MED SCI, V30, P503; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOCAN TMA, 1986, AM J PATHOL, V123, P413; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHAO FF, 1990, AM J PATHOL, V136, P169; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FOGELMAN AM, 1982, J BIOL CHEM, V257, P4081; FOGELMAN AM, 1986, ATHEROSCLER REV, V14, P109; FUNK JL, 1993, ATHEROSCLEROSIS, V98, P67, DOI 10.1016/0021-9150(93)90224-I; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMBLE W, 1978, J LIPID RES, V19, P1068; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1976, CURR TOP CELL REGUL, V11, P147; HOFF HF, 1978, BIOCHEM BIOPH RES CO, V85, P1424, DOI 10.1016/0006-291X(78)91162-2; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; ISHII I, 1994, BBA-LIPID LIPID MET, V1212, P278, DOI 10.1016/0005-2760(94)90201-1; JAAKKOLA O, 1990, EUR HEART J, V11, P128, DOI 10.1093/eurheartj/11.suppl_E.128; Jones NL, 2000, ARTERIOSCL THROM VAS, V20, P773, DOI 10.1161/01.ATV.20.3.773; Kalayoglu MV, 1999, MICROBES INFECT, V1, P409, DOI 10.1016/S1286-4579(99)80044-6; KNIGHT BL, 1982, EUR J BIOCHEM, V125, P407, DOI 10.1111/j.1432-1033.1982.tb06698.x; KNIGHT BL, 1982, BIOCHEM J, V202, P145, DOI 10.1042/bj2020145; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; Kruth H S, 1997, Subcell Biochem, V28, P319; KRUTH HS, 1994, ATHEROSCLEROSIS, V105, P227, DOI 10.1016/0021-9150(94)90053-1; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; Kruth HS, 2001, FRONT BIOSCI-LANDMRK, V6, pD429, DOI 10.2741/Kruth; LESNIK P, 1992, P NATL ACAD SCI USA, V89, P10370, DOI 10.1073/pnas.89.21.10370; LOPESVIRELLA MF, 1987, ARTERIOSCLEROSIS, V7, P176, DOI 10.1161/01.ATV.7.2.176; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1980, J LIPID RES, V21, P970; OIKNINE J, 1992, ARTERIOSCLER THROMB, V12, P745, DOI 10.1161/01.ATV.12.6.745; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; Rhainds D, 1999, INT J BIOCHEM CELL B, V31, P915, DOI 10.1016/S1357-2725(99)00046-1; ROMA P, 1992, J LIPID RES, V33, P819; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; Rupper A, 2001, BBA-GEN SUBJECTS, V1525, P205, DOI 10.1016/S0304-4165(01)00106-4; SCHECHTER I, 1981, J LIPID RES, V22, P63; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SMITH EB, 1983, BIOCHIM BIOPHYS ACTA, V754, P249, DOI 10.1016/0005-2760(83)90139-X; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; SUNG SSJ, 1983, J CELL PHYSIOL, V116, P21, DOI 10.1002/jcp.1041160105; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; SWANSON JA, 1989, J CELL SCI, V94, P135; TRABER MG, 1980, P NATL ACAD SCI-BIOL, V77, P5466, DOI 10.1073/pnas.77.9.5466; van den Eijnden MMED, 1999, ARTERIOSCL THROM VAS, V19, P384, DOI 10.1161/01.ATV.19.2.384; VANDERWAL AC, 1992, AM J PATHOL, V141, P161; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; Xing XY, 1998, J LIPID RES, V39, P2201; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	57	122	127	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34573	34580		10.1074/jbc.M205059200	http://dx.doi.org/10.1074/jbc.M205059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12118008	hybrid			2022-12-27	WOS:000177959100131
J	Patel, S; Gaspers, LD; Boucherie, S; Memin, E; Stellato, KA; Guillon, G; Combettes, L; Thomas, AP				Patel, S; Gaspers, LD; Boucherie, S; Memin, E; Stellato, KA; Guillon, G; Combettes, L; Thomas, AP			Inducible nitric-oxide synthase attenuates vasopressin-dependent Ca2+ signaling in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ORGAN DYSFUNCTION; CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; ENDOTOXEMIC RATS; PHOSPHOLIPASE-C; CALCIUM SIGNALS; CYTOSOLIC CA2+; ALPHA-SUBUNITS; PERFUSED LIVER; INTACT LIVER	Increases in both Ca2+ and nitric oxide levels are vital for a variety of cellular processes; however, the interaction between these two crucial messengers is not fully understood. Here, we demonstrate that expression of inducible nitric-oxide synthase in hepatocytes, in response to inflammatory mediators, dramatically attenuates Ca2+ signaling by the inositol 1,4,5-trisphosphate-forming hormone, vasopressin. The inhibitory effects of induction were reversed by nitric oxide inhibitors and mimicked by prolonged cyclic GMP elevation. Induction was without effect on Ca2+ signals in response to AlF4- or inositol 1,4,5-trisphosphate, indicating that phospholipase C activation and release of Ca2+ from inositol 1,4,5-trisphosphate-sensitive Ca2+ stores were not targets for nitric oxide inhibition. Vasopressin receptor levels, however, were dramatically reduced in induced cultures. Our data provide a possible mechanism for hepatocyte dysfunction during chronic inflammation.	UCL, Dept Physiol, London WC1E 6BT, England; Univ Med & Dent New Jersey, Dept Pharmacol & Physiol, Newark, NJ 07103 USA; Univ Paris 11, INSERM, Unite Rech U422, F-91405 Orsay, France; CNRS, INSERM, Ctr Pharmacol Endocrinol, Unite Rech U469, F-34094 Montpellier, France	University of London; University College London; Rutgers State University New Brunswick; Rutgers State University Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Patel, S (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	patel.s@ucl.ac.uk	Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013; Combettes, Laurent/L-1842-2013; Patel, Sandip/O-9591-2015	Gaspers, Lawrence/0000-0002-5620-3283; Combettes, Laurent/0000-0002-1376-4574; Patel, Sandip/0000-0001-7247-2013; Thomas, Andrew/0000-0002-9026-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38422] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J EXP BIOL, V200, P315; Bolder U, 1997, GASTROENTEROLOGY, V112, P214, DOI 10.1016/S0016-5085(97)70238-5; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BURGESS GM, 1989, J NEUROCHEM, V53, P1212, DOI 10.1111/j.1471-4159.1989.tb07417.x; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; DUFOUR JFJ, 1995, GASTROENTEROLOGY, V108, P841, DOI 10.1016/0016-5085(95)90459-X; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1994, ARCH SURG-CHICAGO, V129, P166; Guihard G, 1996, BIOCHEM J, V318, P849, DOI 10.1042/bj3180849; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIRATA M, 1990, J BIOL CHEM, V265, P1268; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; INNAMORATI G, 1995, BIOCHEM J, V314, P709; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; MACKMICKING JD, 1995, CELL, V81, P641; McDonald L J, 1995, Adv Pharmacol, V34, P263; MILBOURNE EA, 1995, CELL CALCIUM, V18, P207, DOI 10.1016/0143-4160(95)90065-9; MONEADA S, 1991, PHARMACOL REV, V43, P109; Motoyama K, 1999, AM J PHYSIOL-REG I, V276, pR575, DOI 10.1152/ajpregu.1999.276.2.R575; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Patel S, 2001, Methods Mol Biol, V171, P435; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROELOFSEN H, 1994, GASTROENTEROLOGY, V107, P1075, DOI 10.1016/0016-5085(94)90232-1; ROELOFSEN H, 1995, AM J PHYSIOL-GASTR L, V269, pG427, DOI 10.1152/ajpgi.1995.269.3.G427; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; ROTH BL, 1987, AM J PHYSIOL, V252, pE699, DOI 10.1152/ajpendo.1987.252.5.E699; Ruetten H, 1996, BRIT J PHARMACOL, V118, P261, DOI 10.1111/j.1476-5381.1996.tb15397.x; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Sambrook J., 2002, MOL CLONING LAB MANU; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; WOODS NM, 1990, BIOCHEM J, V265, P613, DOI 10.1042/bj2650613; Yu SM, 1997, BIOCHEM J, V328, P363	61	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33776	33782		10.1074/jbc.M201904200	http://dx.doi.org/10.1074/jbc.M201904200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097323	hybrid			2022-12-27	WOS:000177959100034
J	Takada, T; Noguchi, T; Inagaki, K; Hosooka, T; Fukunaga, K; Yamao, T; Ogawa, W; Matozaki, T; Kasuga, M				Takada, T; Noguchi, T; Inagaki, K; Hosooka, T; Fukunaga, K; Yamao, T; Ogawa, W; Matozaki, T; Kasuga, M			Induction of apoptosis by stomach cancer-associated protein-tyrosine phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; GROWTH; INHIBITION; PHOSPHORYLATION; ADHESION; RECEPTOR; COMPLEX; B/AKT	Stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1), a transmembrane-type protein-tyrosine phosphatase, is thought to inhibit integrin signaling by mediating the dephosphorylation of focal adhesion-associated proteins. Adenovirus-mediated overexpression. of wild-type SAP-1, but not that of a catalytically inactive mutant of this enzyme, has now been shown to induce apoptosis in NIH 3T3 fibroblasts. This effect of SAP-1 was dependent on cellular caspase activities and was preceded by inactivation of two serine-threonine protein kinases, Akt and integrin-linked kinase (ILK), both of which function downstream of phosphoinositide (PI) 3-kinase to promote cell survival. Coexpression of constitutively active forms of PI 3-kinase or Akt (which fully restored Akt and ILK activities) resulted in partial inhibition of SAP-1-induced cell death. Furthermore, expression of a dominant negative mutant of PI 3-kinase did not induce cell death as efficiently as did SAP-1, although this mutant inhibited Akt and ILK activities more effectively than did SAP-1. Overexpression of SAP-1 had no substantial effect on Ras activity. These results suggest that SAP-1 induces apoptotic cell death by at least two distinct mechanisms: inhibition of cell survival signaling mediated by PI 3-kinase, Akt, and ILK and activation of a caspase-dependent proapoptotic pathway.	Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan	Kobe University; Gunma University	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet & Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp	OGAWA, Wataru/AAQ-9586-2020					ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Faraldo MM, 2001, EMBO REP, V2, P431, DOI 10.1093/embo-reports/kve086; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Keane MM, 1996, CANCER RES, V56, P4236; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li FG, 1999, J CELL SCI, V112, P4589; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Liu XS, 2001, NEOPLASIA, V3, P278, DOI 10.1038/sj.neo.7900163; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Noguchi T, 2001, J BIOL CHEM, V276, P15216, DOI 10.1074/jbc.M007208200; O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; van Dijk TB, 2000, BLOOD, V96, P3406; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	50	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34359	34366		10.1074/jbc.M206541200	http://dx.doi.org/10.1074/jbc.M206541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12101188	hybrid			2022-12-27	WOS:000177959100108
J	Troy, CM; Friedman, JE; Friedman, WJ				Troy, CM; Friedman, JE; Friedman, WJ			Mechanisms of p75-mediated death of hippocampal neurons - Role of caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; CELL-DEATH; CYTOCHROME-C; DOWN-REGULATION; FLUORO-JADE; APOPTOTIC PATHWAYS; MESSENGER-RNA; ACTIVATION; EXPRESSION	Neurotrophins support neuronal survival and differentiation via Trk receptors, yet can also induce cell death via the p75 receptor. In these studies, we investigated signaling mechanisms governing p75-mediated death of hippocampal neurons, specifically the role of caspases. Although p75 is structurally a member of the Fas/TNFR1 receptor family, caspase-8 was not required for p75-mediated death, unlike other members of this receptor family. In contrast, p75-mediated neuronal death was associated with mitochondrial loss of cytochrome c and required Apaf-1 and caspase-9, -6, and -3. In particular, caspase-6 plays a central role in mediating neurotrophin-induced death, illuminating a novel role for this caspase. Inhibition of DIABLO/Smac, which blocks inhibitor of apoptosis proteins, protected cells from death, whereas simultaneous inhibition of both DIABLO/Smac and MIAP3 allowed trophin-induced death to proceed. In vivo, pilocarpine-induced seizures, previously shown to up-regulate p75 expression and increase neurotrophin production, caused activation of caspase-6 and -3 and cleavage of poly(ADP-ribose) polymerase in p75-expressing hippocampal neurons. In p75-/- mice, no activated caspase-3 was detected, and there was a marked reduction in the number of dying neurons after pilocarpine treatment compared with wild type mice. Neurotrophin-induced p75-mediated death is likely to play an important role in mediating neuronal loss consequent to brain injury.	Columbia Univ Coll Phys & Surg, Dept Pathol, Taub Inst Study Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Ctr Neurobiol & Behav, New York, NY 10032 USA; D Pharm Ltd, IL-76123 Rehovot, Israel	Columbia University; Columbia University	Friedman, WJ (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	wilmaf@andromeda.rutgers.edu	Troy, Carol/ABC-2771-2020					ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; Farinelli SE, 1998, J NEUROSCI, V18, P5112, DOI 10.1523/JNEUROSCI.18-14-05112.1998; Ferri CC, 1998, J NEUROBIOL, V34, P1; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; FRIEDMAN WJ, 1991, DEV BRAIN RES, V63, P43, DOI 10.1016/0165-3806(91)90065-Q; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Gu CH, 1999, J NEUROSCI, V19, P3043; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hanbury R, 2002, J COMP NEUROL, V444, P291, DOI 10.1002/cne.10104; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KOLIATSOS VE, 1991, BRAIN RES, V549, P297, DOI 10.1016/0006-8993(91)90471-7; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTINEZMURILLO R, 1993, NEUROSCIENCE, V52, P587, DOI 10.1016/0306-4522(93)90408-8; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; SchmidtKastner R, 1996, EXP BRAIN RES, V107, P331; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stefanis L, 1999, J NEUROSCI, V19, P6235; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Troy CM, 2001, ADV CELL AGING GERON, V5, P67; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Troy CM, 1996, J NEUROSCI, V16, P253; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAN H, 1991, J BIOL CHEM, V266, P12099; YAN Q, 1988, J NEUROSCI, V8, P3481; Yoon SO, 1998, J NEUROSCI, V18, P3273; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	74	150	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34295	34302		10.1074/jbc.M205167200	http://dx.doi.org/10.1074/jbc.M205167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097334	hybrid			2022-12-27	WOS:000177959100100
J	Youn, H; Kerby, RL; Thorsteinsson, MV; Clark, RW; Burstyn, JN; Roberts, GP				Youn, H; Kerby, RL; Thorsteinsson, MV; Clark, RW; Burstyn, JN; Roberts, GP			Analysis of the L116K variant of CooA, the heme-containing CO sensor, suggests the presence of an unusual heme ligand resulting in novel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTIONAL ACTIVATOR; RHODOSPIRILLUM-RUBRUM; GENE-EXPRESSION; OXYGEN SENSOR; PROTEIN; BINDING; IDENTIFICATION; HISTIDINE-77; LIGATION; DNA	CooA is the CO-sensing transcriptional activator from Rhodospirillum rubrum, in which CO binding to its heme prosthetic group triggers a conformational change of CooA that allows the protein to bind its cognate target DNA sequence. By a powerful in vivo screening method following the simultaneous randomization of the codons for two C-helix residues, 113 and 116, near the distal heme pocket of CooA, we have isolated a series of novel CooA variants. In vivo, these show very high CO-independent activities (comparable with that of wild-type CooA in the presence of CO) and diminished CO-dependent activities. Sequence analysis showed that this group of variants commonly contains lysine at position 116 with a variety of residues at position 113. DNA-binding analysis of a representative purified variant, L116K CooA, revealed that this protein is competent to bind target DNA with K-d values of 56 nm for Fe(III), 36 nm for Fe(H), and 121 nm for Fe(Il)-CO CooA forms. Electron paramagnetic resonance and electronic absorption spectroscopies, combined with additional mutagenic studies, showed that L116K CooA has a new ligand replacing Pro(2) in both Fe(111) and Fe(11) states. The most plausible replacement ligand is the substituted lysine at position 116, so that the ligands of Fe(111) L116K CooA are Cys(75) and Lys(116) and those in the Fe(H) form are His(77) and Lys(116). A possible explanation for CO-independent activity in L116K CooA is that ligation of Lys(116) results in a repositioning of the C-helices at the CooA dimer interface. This result is consistent with that repositioning being an important aspect of the activation of wild-type CooA by CO.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.			Burstyn, Judith/0000-0003-3245-5563	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65217] Funding Source: Medline; NIGMS NIH HHS [GM 53228] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chiang L W, 1993, PCR Methods Appl, V2, P210; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Leduc J, 2001, J BIOL CHEM, V276, P39968, DOI 10.1074/jbc.M105758200; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; UBBINK M, 1994, BIOCHEMISTRY-US, V33, P10051, DOI 10.1021/bi00199a032; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	24	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33616	33623		10.1074/jbc.M203684200	http://dx.doi.org/10.1074/jbc.M203684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12121986	hybrid			2022-12-27	WOS:000177959100013
J	Schwientek, T; Keck, B; Levery, SB; Jensen, MA; Pedersen, JW; Wandall, HH; Stroud, M; Cohen, SM; Amado, M; Clausen, H				Schwientek, T; Keck, B; Levery, SB; Jensen, MA; Pedersen, JW; Wandall, HH; Stroud, M; Cohen, SM; Amado, M; Clausen, H			The Drosophila gene brainiac encodes a glycosyltransferase putatively involved in glycosphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; UDP-GALACTOSE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; EXPRESSION CLONING; CALLIPHORA-VICINA; MOLECULAR-CLONING; FRINGE; BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE; IDENTIFICATION; MELANOGASTER	The Drosophila genes fringe and brainiac exhibit sequence similarities to glycosyltransferases. Drosophila and mammalian fringe homologs encode UDP-N-acetylglucosamine:fucose-O-Ser 131,3-N-acetylglucosaminyltransferases that modulate the function of Notch family receptors. The biological function of brainiac is less well understood. brainiac is a member of a large homologous mammalian beta3-glycosyltransferase family with diverse functions. Eleven distinct mammalian homologs have been demonstrated to encode functional enzymes forming beta1-3 glycosidic linkages with different UDP donor sugars and acceptor sugars. The putative mammalian homologs with highest sequence similarity to brainiac encode UDP-N-acetylglucosamine:131,3-N-acetylglucosaminyltransferases (beta3GlcNAc-transferases), and in the present study we show that brainiac also encodes a beta3GlcNAc-transferase that uses beta-linked mannose as well as beta-linked galactose as acceptor sugars. The inner disaccharide core structures of glycosphingolipids in mammals (Galbeta1-4Glcbeta1-Cer) and insects (Manbeta1-4Glcbeta1-Cer) are different. Both disaccharide glycolipids served as substrates for brainiac, but glycolipids of insect cells have so far only been found to be based on the GlcNAcbeta1-3Manbeta1-4Glcbeta1-Cer core structure. Infection of High Five(TM) cells with baculovirus containing full coding brainiac cDNA markedly increased the ratio of GlcNAcbeta1-3Manbeta1-4Glcbeta1-Cer glycolipids compared with Galbeta1-4Manbeta1-4Glcbeta1-Cer found in wild type cells. We suggest that brainiac exerts its biological functions by regulating biosynthesis of glycosphingolipids.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; NW Biotherapeut Inc, Bothell, WA 98021 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Copenhagen; University System Of New Hampshire; University of New Hampshire; European Molecular Biology Laboratory (EMBL)	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	henrik.clausen@odont.ku.dk	Cohen, Stephen M/G-9930-2011; clausen, henrik/AAD-8016-2021	Cohen, Stephen M/0000-0003-2858-9163; Wandall, Hans H./0000-0003-0240-9232; Clausen, Henrik/0000-0002-0915-5055	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351, P20RR016459] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16459, P41 RR05351] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; DENNIS RD, 1985, EUR J BIOCHEM, V146, P51, DOI 10.1111/j.1432-1033.1985.tb08618.x; DENNIS RD, 1993, ADV LIPID RES, V26, P321; Egan S, 2000, GLYCOCONJUGATE J, V17, P867, DOI 10.1023/A:1010921313314; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Gerdt S, 1997, GLYCOBIOLOGY, V7, P265, DOI 10.1093/glycob/7.2.265; Goode S, 1997, COLD SPRING HARB SYM, V62, P177; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEV BIOL, V178, P35, DOI 10.1006/dbio.1996.0196; Hakamori S, 1998, ACTA ANAT, V161, P79; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hellberg A, 2002, J BIOL CHEM, V277, P29455, DOI 10.1074/jbc.M203047200; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P1069, DOI 10.1021/bi00119a016; Lopez-Schier H, 2001, GENE DEV, V15, P1393, DOI 10.1101/gad.200901; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; SAITO T, 1971, J LIPID RES, V12, P257; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; WIELS J, 1991, INT IMMUNOL, V3, P1289, DOI 10.1093/intimm/3.12.1289; Wuhrer M, 2000, BIOCHEM J, V348, P417, DOI 10.1042/0264-6021:3480417; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	50	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32421	32429		10.1074/jbc.M206213200	http://dx.doi.org/10.1074/jbc.M206213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12130651	hybrid			2022-12-27	WOS:000177859000005
J	Jiang, XC; Tall, AR; Qin, S; Lin, M; Schneider, M; Lalanne, F; Deckert, V; Desrumaux, C; Athias, A; Witztum, JL; Lagrost, L				Jiang, XC; Tall, AR; Qin, S; Lin, M; Schneider, M; Lalanne, F; Deckert, V; Desrumaux, C; Athias, A; Witztum, JL; Lagrost, L			Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TOCOPHEROL TRANSFER; LOW-DENSITY-LIPOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPID TRANSFER PROTEIN; APOLIPOPROTEIN-E; OXIDIZED LDL; PLASMA; ATHEROSCLEROSIS; MICE; RECEPTOR	Vitamin E is a lipophilic anti-oxidant that can prevent the oxidative damage of atherogenic lipoproteins. However, human trials with vitamin E have been disappointing, perhaps related to ineffective levels of vitamin E in atherogenic apoB-containing lipoproteins. Phospholipid transfer protein (PLTP) promotes vitamin E removal from atherogenic lipoproteins in vitro, and PLTP deficiency has recently been recognized as an anti-atherogenic state. To determine whether PLTP regulates lipoprotein vitamin E content in vivo, we measured a-tocopherol content and oxidation parameters of lipoproteins from PLTP-deficient mice in wild type, apoE-deficient, low density lipoprotein (LDL) receptor-deficient, or apoB/cholesteryl ester transfer protein transgenic backgrounds. In all four backgrounds, the vitamin E content of very low density lipoprotein (VLDL) and/or LDL was significantly increased in PLTP-deficient mice, compared with controls with normal plasma PLTP activity. Moreover, PLTP deficiency produced a dramatic delay in generation of conjugated dienes in oxidized apoB-containing lipoproteins as well as markedly lower titers of plasma IgG autoantibodies to oxidized LDL. The addition of purified PLTP to deficient plasma lowered the vitamin E content of VLDL plus LDL and normalized the generation of conjugated dienes. The data show that PLTP regulates the bioavailability of vitamin E in atherogenic lipoproteins and suggest a novel strategy for achieving more effective concentrations of antioxidants in lipoproteins, independent of dietary supplementation.	Fac Med Dijon, INSERM U498, F-21079 Dijon, France; Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; Columbia Univ, Div Mol Med, Dept Med, New York, NY 10032 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University; University of California System; University of California San Diego	Lagrost, L (corresponding author), Fac Med Dijon, INSERM U498, 7 Bd Jeanne Arc,BP 87900, F-21079 Dijon, France.	laurent.lagrost@u-bourgogne.fr	Desrumaux, Catherine/O-1925-2018; Tall, Alan/AAT-8528-2021	DECKERT, Valerie/0000-0001-5728-1710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, P01HL054591, R01HL064735, P50HL056989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54591, HL56984, HL56989, HL64735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; Cyrus T, 2001, CIRCULATION, V103, P2277; Desrumaux C, 1999, FASEB J, V13, P883, DOI 10.1096/fasebj.13.8.883; Desrumaux C, 1999, ARTERIOSCL THROM VAS, V19, P266, DOI 10.1161/01.ATV.19.2.266; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; GRANOT E, 1988, LIPIDS, V23, P17, DOI 10.1007/BF02535298; Halevy D, 1997, ARTERIOSCL THROM VAS, V17, P1432, DOI 10.1161/01.ATV.17.7.1432; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JEZEQUELCUER M, 1995, ANN BIOL CLIN-PARIS, V53, P343; JIANG XC, 1993, J BIOL CHEM, V268, P27406; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; LAGROST L, 1994, J LIPID RES, V35, P825; Leonard SW, 2002, AM J CLIN NUTR, V75, P555, DOI 10.1093/ajcn/75.3.555; Linton MF, 2001, CURR OPIN LIPIDOL, V12, P489, DOI 10.1097/00041433-200110000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Meade T, 1999, EUR HEART J, V20, P725; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; MILLER KW, 1985, ANAL BIOCHEM, V145, P21, DOI 10.1016/0003-2697(85)90321-5; Mironova MA, 2000, DIABETES, V49, P1033, DOI 10.2337/diabetes.49.6.1033; Oram JF, 2001, J BIOL CHEM, V276, P39898, DOI 10.1074/jbc.M106984200; Palinski W, 2000, J INTERN MED, V247, P371, DOI 10.1046/j.1365-2796.2000.00656.x; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P1569, DOI 10.1161/01.ATV.15.10.1569; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Polidori MC, 2000, DIABETES-METAB RES, V16, P15, DOI 10.1002/(SICI)1520-7560(200001/02)16:1<15::AID-DMRR71>3.3.CO;2-2; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Riemens SC, 1998, DIABETOLOGIA, V41, P929, DOI 10.1007/s001250051009; Sakr SW, 2001, J BIOL CHEM, V276, P37649, DOI 10.1074/jbc.M105129200; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SEGREST JP, 1983, METHOD ENZYMOL, V128, P78; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Song L, 2001, J CLIN INVEST, V108, P251, DOI 10.1172/JCI11380; STEINBERG D, 1989, NEW ENGL J MED, V321, P1196; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TALL AR, 1985, J LIPID RES, V26, P842; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Thomas SR, 2001, ARTERIOSCL THROM VAS, V21, P585, DOI 10.1161/01.ATV.21.4.585; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; TRABER MG, 1984, AM J CLIN NUTR, V40, P747, DOI 10.1093/ajcn/40.4.747; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; Traber MG, 1999, ANNU REV NUTR, V19, P343, DOI 10.1146/annurev.nutr.19.1.343; Tsimikas S, 2001, ARTERIOSCL THROM VAS, V21, P95, DOI 10.1161/01.ATV.21.1.95; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	61	106	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31850	31856		10.1074/jbc.M205077200	http://dx.doi.org/10.1074/jbc.M205077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105225	hybrid			2022-12-27	WOS:000177718700069
J	Murga, C; Barber, DF				Murga, C; Barber, DF			Molecular mechanisms of pre-T cell receptor-induced survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; ALPHA-BETA; DNA-DAMAGE; PT-ALPHA; BCL-2 PROTOONCOGENE; IMMATURE THYMOCYTES; ALLELIC EXCLUSION; DEFICIENT MICE; CD95 FAS/APO-1; P53	En route to maturing as T cell receptor (TCR) alphabeta-expressing cells, the development of thymocytes is contingent on expression of a pre-TCR complex comprising a TCRbeta chain paired with a surrogate TCRalpha chain, pre-Talpha (pTalpha). The pre-TCR has been proposed to promote cell survival, proliferation, differentiation, and lineage commitment. However, the precise molecular mechanisms governing this variety of effects remain elusive. Here, we present a cellular system designed to biochemically dissect signals elicited upon pre-TCR expression. Using the T cell line 4G4 stably transfected with one of the two known pTalpha isoforms or selective pTalpha deletion mutants and TCRbeta, we were able to observe that expression of a functional pre-TCR complex is sufficient to control the levels of surface Fas protein, the stimulation of mitogen-activated and stress-regulated kinases, and the activation status of the p53 antionco-gene. We demonstrate that this regulation has a major impact on the expression of important regulators of apoptosis, such as Bcl-2 family members, and the cell cycle, such as p21(WAF). Furthermore, we show here that cells expressing a functional pre-TCR are more resistant to different types of DNA damage-induced apoptosis and that these effects are contingent on an intact cytoplasmic tail of pTalpha. We finally propose that the presence of a functional pre-TCR complex triggers many intracellular pathways capable of driving and ensuring thymocyte survival in the presence of DNA damage.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Murga, C (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Campus Cantoblanco, E-28049 Madrid, Spain.	cmurga@cbm.uam.es	Murga, Cristina/E-1965-2014; Barber, Domingo F./G-1257-2010	Murga, Cristina/0000-0002-8964-4077; Barber, Domingo F./0000-0001-8824-5405				Aifantis I, 2002, NAT IMMUNOL, V3, P483, DOI 10.1038/ni779; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; ANDJELIC S, 1993, J EXP MED, V178, P1745, DOI 10.1084/jem.178.5.1745; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ayroldi E, 1997, BLOOD, V89, P3717, DOI 10.1182/blood.V89.10.3717.3717_3717_3726; Barber DF, 1998, J IMMUNOL, V161, P11; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; DUDLEY EC, 1995, CURR BIOL, V5, P659, DOI 10.1016/S0960-9822(95)00131-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gibbons D, 2001, J EXP MED, V194, P695, DOI 10.1084/jem.194.5.695; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GRATIOTDEANS J, 1993, J IMMUNOL, V151, P83; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; Hayday AC, 1999, SEMIN IMMUNOL, V11, P239, DOI 10.1006/smim.1999.0180; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Kraus-Berthier L, 2000, CLIN CANCER RES, V6, P297; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MIYASHITA T, 1995, CELL, V80, P293; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Mulroy T, 2001, EUR J IMMUNOL, V31, P3056, DOI 10.1002/1521-4141(2001010)31:10<3056::AID-IMMU3056>3.0.CO;2-B; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; O'Connor L, 2000, CANCER RES, V60, P1217; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Sen J, 1996, J IMMUNOL, V156, P4535; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SICILIANO JD, 1997, GENE DEV, V11, P3471; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sunder-Plassmann R, 1998, J BIOL CHEM, V273, P24249, DOI 10.1074/jbc.273.37.24249; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; Trop S, 1999, EUR J IMMUNOL, V29, P2187, DOI 10.1002/(SICI)1521-4141(199907)29:07<2187::AID-IMMU2187>3.3.CO;2-4; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; von Boehmer H, 1998, IMMUNOL REV, V165, P111; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Xu Y, 1996, P NATL ACAD SCI USA, V93, P2169, DOI 10.1073/pnas.93.5.2169; Yasutomo K, 1997, J IMMUNOL, V158, P4729	56	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39156	39162		10.1074/jbc.M203553200	http://dx.doi.org/10.1074/jbc.M203553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12114514	hybrid			2022-12-27	WOS:000178662500014
J	Allen, MP; Xu, M; Linseman, DA; Pawlowski, JE; Bokoch, GM; Heidenreich, KA; Wierman, ME				Allen, MP; Xu, M; Linseman, DA; Pawlowski, JE; Bokoch, GM; Heidenreich, KA; Wierman, ME			Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires Rac activation of the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; TRANSCRIPTION FACTOR MEF2C; RHO-FAMILY GTPASES; PROTEIN-KINASE; GROWTH-FACTOR; SURVIVAL ACTIVITIES; CELL-PROLIFERATION; MAMMALIAN-CELLS; NUCLEAR FACTOR	Recent studies suggest that adhesion-related kinase (Ark) plays a role in gonadotropin-releasing hormone (GnRH) neuronal physiology. Ark promotes migration of GnRH neurons via Rae GTPase and concomitantly suppresses GnRH gene expression via homeodomain and myocyte enhancer factor-2 (MEF2) transcription factors. Here, we investigated the signaling cascade required for Ark inhibition of the GnRH promoter in GT1-7 GnRH neuronal cells. Ark repression was blocked by the MEK/ERK pathway inhibitor, PD98059, and dominant negative MEK1 but was unaffected by dominant negative Ras. Inhibitors of the Rho family GTPases, Clostridium difficile toxin B (Rho/Rac/Cdc42 inhibitor) and Clostridium sordellii lethal toxin (Rac/Cdc42 inhibitor), blocked Ark inhibition of GnRH transcription. Moreover, dominant negative Rae blunted both Ark activation of ERK and repression of the GnRH promoter, demonstrating an essential role for Rae in coupling Ark to ERK activation. Like Ark, a constitutively active mutant of Rae suppressed GnRH transcription in an ERK-dependent manner. Finally, Ark-mediated repression was significantly attenuated by a dominant negative MEF2C, whereas repression induced by constitutively active Rae was unaffected, indicating that MEF2 proteins are not targets of the Ark --> Rac --> MEK --> ERK cascade. The data suggest that Ark suppresses GnRH gene expression via the coordinated activation of a Rac ---> ERK signaling pathway and a distinct MEF2-dependent mechanism.	Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Scripps Research Institute; Scripps Research Institute	Wierman, ME (corresponding author), Vet Affairs Med Ctr, Res Serv, 1055 Clermont St,Box 111H, Denver, CO 80220 USA.		Linseman, Daniel/L-3846-2019		NICHD NIH HHS [HD31191-04, HD08667-02] Funding Source: Medline; NIGMS NIH HHS [GM44428] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD031191, F32HD008667, R01HD031191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191; Allen MP, 2000, J BIOL CHEM, V275, P39662, DOI 10.1074/jbc.M007097200; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Fang ZQ, 1998, ENDOCRINOLOGY, V139, P3654, DOI 10.1210/en.139.8.3654; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hullinger TG, 2001, J BIOL CHEM, V276, P46807, DOI 10.1074/jbc.M103176200; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Li RH, 1996, J NEUROSCI, V16, P2012; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Linseman DA, 2001, J BIOL CHEM, V276, P39123, DOI 10.1074/jbc.M103959200; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1996, CANCER SURV, V27, P101; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MING CW, 2001, ARTERIOSCLER THROMB, V21, P1592; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Rafty LA, 2000, J BIOL CHEM, V275, P11478, DOI 10.1074/jbc.275.15.11478; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schiavo G, 2001, NAT REV MOL CELL BIO, V2, P530, DOI 10.1038/35080089; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang Y, 1999, MOL CELL BIOL, V19, P1881; VAN AL, 1997, GENE DEV, V11, P2295; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WETSEL WC, 1995, CELL MOL NEUROBIOL, V15, P43, DOI 10.1007/BF02069558; WETSEL WC, 1992, P NATL ACAD SCI USA, V89, P4149, DOI 10.1073/pnas.89.9.4149; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WRAY S, 1994, DEV BIOL, V166, P349, DOI 10.1006/dbio.1994.1320; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Yoshida K, 1995, J NEUROSCI, V15, P7769; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200	75	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38133	38140		10.1074/jbc.M200826200	http://dx.doi.org/10.1074/jbc.M200826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138087	hybrid			2022-12-27	WOS:000178529600022
J	Moller, JV; Lenoir, G; Marchand, C; Montigny, C; le Maire, M; Toyoshima, C; Juul, BS; Champeil, P				Moller, JV; Lenoir, G; Marchand, C; Montigny, C; le Maire, M; Toyoshima, C; Juul, BS; Champeil, P			Calcium transport by sarcoplasmic reticulum Ca2+-ATPase - Role of the A domain and its C-terminal link with the transmembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING; CROSS-LINKING; HIGH-AFFINITY; CA2+ BINDING; CONFORMATIONAL TRANSITIONS; FLUORESCEIN ISOTHIOCYANATE; PHOSPHOENZYME INTERMEDIATE	After treatment of sarcoplasmic reticulum Ca2+-ATPase with proteinase K (PK) in the presence of Ca2+ and a protecting non-phosphorylated ligand (e.g. adenosine 5'-(beta,gamma-methylenetriphosphate), we were able to prepare in high yield an ATPase species that only differs from intact ATPase because of excision of the MAATE(243) sequence from the loop linking the A domain with the third transmembrane segment. The PK-treated ATPase was unable to transport Ca2+ and to catalyze ATP hydrolysis, but it could bind two calcium ions with high affinity and react with ATP to form a classical ADP-sensitive phosphoenzyme, Ca(2)E1P, with occluded Ca2+. The ability of Ca(2)E1P to become converted to the Ca2+-free ADP-insensitive form, E2P, was strongly reduced, as was the ability of PK-treated ATPase to react with orthovanadate or to form an E2P intermediate from inorganic phosphate in the absence of Ca2+. PK-treated ATPase also reacted with thapsigargin to form a complex with altered properties, and the tryptic cleavage "T2' site in the A domain was no longer protected in the absence of Ca2+. It is probable that disrupting the C-terminal link of the A domain with the transmembrane region severely compromises reorientation of A and P domains and the functionally critical cross-talk of these domains with the membrane-bound Ca2+ ions.	Univ Paris Sud, Serv Biophys Fonct Membranaires, DBJC, CEA,URA 2096,CNRS,LRA 17V, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, IFR 46, F-91191 Gif Sur Yvette, France; Univ Aarhus, Dept Biophys, DK-8000 Aarhus C, Denmark; CNRS, Inst Biochim & Biophys Mol & Cellulaire, Equipe Chimie Prot, UMR 8619,CNRS, F-91405 Orsay, France; Univ Paris 11, IFR 46, F-91405 Orsay, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), Univ Paris Sud, Serv Biophys Fonct Membranaires, DBJC, CEA,URA 2096,CNRS,LRA 17V, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Toyoshima, Chikashi/R-4153-2019; MARCHAND, Christophe H/B-5854-2008; Lenoir, Guillaume/I-4002-2019	MARCHAND, Christophe H/0000-0002-0729-3841; Lenoir, Guillaume/0000-0002-8759-5179				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; FORGE V, 1993, J BIOL CHEM, V268, P10953; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; IMAMURA Y, 1986, J BIOCHEM, V100, P133, DOI 10.1093/oxfordjournals.jbchem.a121685; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; Inesi G, 1997, ANN NY ACAD SCI, V834, P207, DOI 10.1111/j.1749-6632.1997.tb52252.x; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; INESI G, 1987, J BIOL CHEM, V262, P16338; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; Ogawa H, 2000, FEBS LETT, V471, P99, DOI 10.1016/S0014-5793(00)01374-0; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1982, J BIOL CHEM, V257, P6120; PORTILLO F, 1995, BIOMEMBRANE, V6, P225; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; Schepens I, 2000, J BIOL CHEM, V275, P35792, DOI 10.1074/jbc.M006526200; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1991, J BIOL CHEM, V266, P18839; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZHANG Z, 1995, J BIOL CHEM, V270, P16283; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	70	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38647	38659		10.1074/jbc.M204603200	http://dx.doi.org/10.1074/jbc.M204603200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138099	hybrid			2022-12-27	WOS:000178529600082
J	Lemercier, G; Dutoya, S; Luo, SH; Ruiz, FA; Rodrigues, CO; Baltz, T; Docampo, R; Bakalara, N				Lemercier, G; Dutoya, S; Luo, SH; Ruiz, FA; Rodrigues, CO; Baltz, T; Docampo, R; Bakalara, N			A vacuolar-type H+-pyrophosphatase governs maintenance of functional acidocalcisomes and growth of the insect and mammalian forms of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; DOUBLE-STRANDED-RNA; INTRACELLULAR PH; CA2+ STORAGE; CRUZI; POLYPHOSPHATE; PURIFICATION; CLONING; COMPARTMENT; INHIBITION	Vacuolar proton pyrophosphatases (V-H+-PPases) are electrogenic proton pumps found in many organisms of considerable industrial, environmental, and clinical importance. V-H+-PPases of several parasites were shown to be associated with acidic vacuoles named acidocalcisomes, which contain polyphosphate and calcium. In this work we functionally characterized a Trypanosoma brucei V-H+-PPase gene by using double-stranded RNA interference methodology to produce inducible V-H+-PPase-deficient strains of procyclic and bloodstream forms (PFiVP1 and BFiVP1). Acidocalcisomes of these mutated parasites lost acidity and contained 90% less polyphosphate. PFiVP1 did not release calcium after the addition of nigericin, and its total acidity was reduced by 70%. This mutant also failed to stabilize its intracellular pH on exposure to external basic pH > 7.4 and recovered from intracellular acidification at a slower rate and to a more acidic final intracellular pH. In the absence of T. brucei V-H+-PPase expression, PFiVP1 and BFiVP1 grew at a slower rate with doubling times of 27 h instead of 15 h, and 10 h instead of 7.5 h, respectively. Moreover, BFiVP1 could not grow over 5 x 10(5) cells/ml corresponding to a cell density reduction of five times for bloodstream form stationary phase growth.	CNRS, Mol Parasitol Lab, Unite Mixte 5016, CNRS, F-33076 Bordeaux, France; Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	Centre National de la Recherche Scientifique (CNRS); University of Illinois System; University of Illinois Urbana-Champaign	Bakalara, N (corresponding author), CNRS, Mol Parasitol Lab, Unite Mixte 5016, CNRS, Batiment 3A,146 Rue Leo Saignat, F-33076 Bordeaux, France.	bakalara@u-bordeaux2.fr	Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015				Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; BRUN R, 1979, ACTA TROP, V36, P387; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; Cuvillier A, 2000, J CELL SCI, V113, P2065; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Dutoya S, 2001, J BIOL CHEM, V276, P49117, DOI 10.1074/jbc.M105962200; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gaxiola RA, 2001, P NATL ACAD SCI USA, V98, P11444, DOI 10.1073/pnas.191389398; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; KIM YC, 1994, PLANT PHYSIOL, V106, P375, DOI 10.1104/pp.106.1.375; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; LIU CM, 1978, J BIOL CHEM, V253, P5892; LORENZ B, 1994, J BIOL CHEM, V269, P22198; MADDY AH, 1976, J THEOR BIOL, V62, P315, DOI 10.1016/0022-5193(76)90123-5; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; Nolan DP, 2000, EUR J BIOCHEM, V267, P4601, DOI 10.1046/j.1432-1327.2000.01476.x; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanderheyden N, 2000, BIOCHEM J, V346, P53, DOI 10.1042/0264-6021:3460053; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; Vercesi AE, 1997, BIOCHEM J, V328, P479; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	45	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37369	37376		10.1074/jbc.M204744200	http://dx.doi.org/10.1074/jbc.M204744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12121996	hybrid			2022-12-27	WOS:000178447100059
J	Trinel, PA; Maes, E; Zanetta, JP; Delplace, F; Coddeville, B; Jouault, T; Strecker, G; Poulain, D				Trinel, PA; Maes, E; Zanetta, JP; Delplace, F; Coddeville, B; Jouault, T; Strecker, G; Poulain, D			Candida albicans phospholipomannan, a new member of the fungal mannose inositol phosphoceramide family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SABOURAUD LIQUID-MEDIUM; YEAST EXTRACT; HEPTAFLUOROBUTYRATE DERIVATIVES; SPHINGOLIPIDS; SEROTYPE; STRAINS; LIPOARABINOMANNAN; OLIGOMANNOSIDES; CHROMATOGRAPHY; TEMPERATURE	The pathogenic yeast Candida albicans has the ability to synthesize unique sequences of beta-1,2-oligomannosides that act as adhesins, induce cytokine production, and generate protective antibodies. Depending on the growth conditions, beta-1,2-oligomannosides are associated with different carrier molecules in the cell wall. Structural evidence has been obtained for the presence of these residues in the polysaccharide moiety of the glycolipid, phospholipomannan (PLM). In this study, the refinement of purification techniques led to large quantities of PLM being extracted from Candida albicans cells. A combination of methanolysis, gas chromatography, mass spectrometry, and nuclear magnetic resonance analyses allowed the complete structure of PLM to be deduced. The lipid moiety was shown to consist of a phytoceramide associating a C-18/C-20 phytosphingosine and C-25, C-26, or mainly C-24 hydroxy fatty acids. The spacer linking the glycan part was identified as a unique structure: -Man-P-Man-Ins-P-. Therefore, in contrast to the major class of membranous glycosphingolipids represented by mannose diinositol phosphoceramide, which is derived from mannose inositol phosphoceramide by the addition of inositol phosphate, PLM seems to be derived from mannose inositol phosphoceramide by the addition of mannose phosphate. In relation to a previous study of the glycan part of the molecule, the assignment of the second phosphorus position leads to the definition of PLM beta-1,2-oligomannosides as unbranched linear structures that may reach up to 19 residues in length. Therefore, PLM appears to be a new type of glycosphingolipid, which is glycosylated extensively through a unique spacer. The conferred hydrophilic properties allow PLM to diffuse into the cell wall in which together with mannan it presents C. albicans beta-1,2-oligomannosides to host cells.	Fac Med, INSERM, Lab Mycol Fondamentale & Appl, F-59037 Lille, France; Univ Sci & Technol Lille, Chim Biol Lab, UMR 8576, CNRS,Lab Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Poulain, D (corresponding author), Fac Med, INSERM, Lab Mycol Fondamentale & Appl, EPI 9915,Pole Rech, F-59037 Lille, France.	dan_poulain@compuserve.com	Jouault, Thierry/I-1071-2018; Jouault, Thierry/J-7437-2012; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Poulain, Daniel/0000-0002-0729-5468				Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARNES PF, 1992, J IMMUNOL, V149, P541; BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DeBernardis F, 1997, INFECT IMMUN, V65, P3399, DOI 10.1128/IAI.65.8.3399-3405.1997; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Hakomori S, 1996, CANCER RES, V56, P5309; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Jennemann R, 2001, EUR J BIOCHEM, V268, P1190, DOI 10.1046/j.1432-1327.2001.01963.x; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; LI RK, 1993, J BIOL CHEM, V268, P18293; Mandala SM, 1997, J BIOL CHEM, V272, P32709, DOI 10.1074/jbc.272.51.32709; Masuoka J, 1999, GLYCOBIOLOGY, V9, P1281, DOI 10.1093/glycob/9.11.1281; MATSUBARA T, 1987, CHEM PHYS LIPIDS, V43, P1, DOI 10.1016/0009-3084(87)90012-0; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; OKAWA Y, 1994, FEBS LETT, V345, P167, DOI 10.1016/0014-5793(94)00434-X; Okawa Y, 1996, CLIN DIAGN LAB IMMUN, V3, P331, DOI 10.1128/CDLI.3.3.331-336.1996; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P327, DOI 10.1016/S0732-8893(97)00240-X; Pons A, 2000, ANAL BIOCHEM, V284, P201, DOI 10.1006/abio.2000.4686; Pons A, 2002, J LIPID RES, V43, P794; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; SCHNAAR RL, 1994, PROG BRAIN RES, V101, P185; Schofield L, 1996, IMMUNOL CELL BIOL, V74, P555, DOI 10.1038/icb.1996.89; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1999, J BIOL CHEM, V274, P30520, DOI 10.1074/jbc.274.43.30520; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; Yoshida A, 1997, INFECT IMMUN, V65, P1953, DOI 10.1128/IAI.65.5.1953-1955.1997; Zanetta JP, 1999, GLYCOBIOLOGY, V9, P255, DOI 10.1093/glycob/9.3.255; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Zhong WY, 2000, ANTIMICROB AGENTS CH, V44, P651, DOI 10.1128/AAC.44.3.651-653.2000	42	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37260	37271		10.1074/jbc.M202295200	http://dx.doi.org/10.1074/jbc.M202295200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138092	hybrid			2022-12-27	WOS:000178447100047
J	Ghahremani, MH; Keramaris, E; Shree, T; Xia, ZG; Davis, RJ; Flavell, R; Slack, RS; Park, DS				Ghahremani, MH; Keramaris, E; Shree, T; Xia, ZG; Davis, RJ; Flavell, R; Slack, RS; Park, DS			Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; TRANSCRIPTION FACTOR E2F1; JUN NH2-TERMINAL KINASE; PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; NERVOUS-SYSTEM; PC12 CELLS; RETINOBLASTOMA PROTEIN; CYTOSINE-ARABINOSIDE	DNA damage, an important initiator of neuronal death, has been implicated in numerous neurodegenerative conditions. We previously delineated several pathways that control embryonic cortical neuronal death evoked by the DNA-damaging agent, camptothecin. In this model, the tumor suppressor p53 and cyclin-dependent kinases (CDKs) are activated independently and cooperate to mediate the conserved death pathway. To further our understanding, we presently examined whether the c-Jun/JNK pathway modulates death and whether this pathway is regulated by CDKs, p53, and Bax. We show that c-Jun/JNK is activated following DNA damage. Moreover, the c-Jun pathway is one mediator of death, because expression of dominant negative c-Jun and cdc42, and JNK pathway inhibitors are neuroprotective. Although previous evidences indicate that JNK3 is required for neuronal death under certain conditions, we show that JNK3 deficiency only partially mediates c-Jun phosphorylation and its deficiency does not protect neurons from death. Interestingly, we provide evidence that CDK activity regulates c-Jun but does not affect upstream pathways that lead to JNK phosphorylation. Finally, c-Jun activation is independent of p53 and Bax. Accordingly, we propose that c-Jun is regulated by the JNK and CDK pathways and that both must be activated for efficient c-Jun activation to occur.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Univ Washington, Grad Program Neurobiol & Behav, Dept Environm Hlth & Pharmacol, Seattle, WA 98195 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Ottawa; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Yale University	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca	Ghahremani, Mohammad H/F-1615-2013	Ghahremani, Mohammad H/0000-0001-5051-6214; Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784; Shree, Tanaya/0000-0003-0694-3512				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Athanasiou MC, 1998, MOL CELL NEUROSCI, V12, P16, DOI 10.1006/mcne.1998.0699; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Buschmann T, 2000, CANCER RES, V60, P896; Chauhan D, 1999, CANCER RES, V59, P1192; Chen J, 1997, J NEUROCHEM, V69, P232; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Coffey ET, 2000, J NEUROSCI, V20, P7602; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dragunow M, 2000, MOL BRAIN RES, V83, P20, DOI 10.1016/S0169-328X(00)00191-1; Eilers A, 1998, J NEUROSCI, V18, P1713; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Fuchs SY, 1996, ONCOGENE, V13, P1531; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Grunewald T, 1999, NAT MED, V5, P1354, DOI 10.1038/70918; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson MD, 1999, J NEUROSCI, V19, P2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; MANSFIELD SH, 1994, AM J NEURORADIOL, V15, P1178; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Prives C, 1999, J PATHOL, V187, P112; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Stefanis L, 1999, J NEUROSCI, V19, P6235; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOGEL H, 1993, CANCER, V71, P1303, DOI 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WINKELMAN MD, 1983, ANN NEUROL, V14, P520, DOI 10.1002/ana.410140505; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	87	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35586	35596		10.1074/jbc.M204362200	http://dx.doi.org/10.1074/jbc.M204362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12091388	hybrid			2022-12-27	WOS:000178117000118
J	Olah, Z; Karai, L; Iadarola, MJ				Olah, Z; Karai, L; Iadarola, MJ			Protein kinase C alpha is required for vanilloid receptor 1 activation - Evidence for multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; ROOT GANGLION NEURONS; RAT SENSORY NEURONS; CAPSAICIN RECEPTOR; PHORBOL ESTER; MICE LACKING; ADULT-RAT; EPSILON; CELLS; PAIN	Activation of vanilloid receptor (VR1) by protein kinase C (PKC) was investigated in cells ectopically expressing VR1 and primary cultures of dorsal root ganglion neurons. Submicromolar phorbol 12,13-dibutyrate (PDBu), which stimulates PKC, acutely activated Ca2+ uptake in VR1-expressing cells at pH 5.5, but not at mildly acidic or neutral pH. PDBu was antagonized by bisindolylmaleimide, a PKC inhibitor, and ruthenium red, a VR1 ionophore blocker, but not capsazepine, a vanilloid antagonist indicating that catalytic activity of PKC is required for PDBu activation of VR1 ion conductance, and is independent of the vanilloid site. Chronic PDBu dramatically down-regulated PKCalpha in dorsal root ganglion neurons or the VR1 cell lines, whereas only partially influencing PKCbeta, -delta, -epsilon, and zeta. Loss of PKCalpha correlated with loss of response to acute re-challenge with PDBu. Anandamide, a VR1 agonist in acidic conditions, acts additively with PDBu and remains effective after chronic PKC down-regulation. Thus, two independent VR1 activation pathways can be discriminated: M direct ligand binding (anandamide, vanilloids) or (ii) extracellular ligands coupled to PKC by intracellular signaling. Experiments in cell lines co-expressing VR1 with different sets of PKC isozymes showed that acute PDBu-induced activation requires PKCalpha, but not PKCepsilon. These studies suggest that PKCalpha in sensory neurons may elicit or enhance pain during inflammation or ischemia.	NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mech Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Olah, Z (corresponding author), NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mech Branch, NIH, 49 Convent Dr,MSC-4410, Bethesda, MD 20892 USA.	zoltan.olah@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Basbaum AI, 1999, P NATL ACAD SCI USA, V96, P7739, DOI 10.1073/pnas.96.14.7739; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Hudson LJ, 2001, EUR J NEUROSCI, V13, P2105, DOI 10.1046/j.0953-816x.2001.01591.x; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Iadarola MJ, 1997, SCIENCE, V278, P239, DOI 10.1126/science.278.5336.239; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Khasar SG, 1999, J NEUROPHYSIOL, V81, P1104, DOI 10.1152/jn.1999.81.3.1104; Kiss Z, 1999, ARCH BIOCHEM BIOPHYS, V363, P121, DOI 10.1006/abbi.1998.1066; Kiss Z, 1999, FEBS LETT, V447, P209, DOI 10.1016/S0014-5793(99)00295-1; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEWIN GR, 1993, J NEUROSCI, V13, P2136; Ma WY, 2001, EUR J NEUROSCI, V13, P1125, DOI 10.1046/j.1460-9568.2001.01475.x; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MCGUIRK SM, 1992, NEUROSCIENCE, V49, P117, DOI 10.1016/0306-4522(92)90079-H; McLatchie LM, 2001, BRIT J PHARMACOL, V132, P899, DOI 10.1038/sj.bjp.0703900; Mendell LM, 1999, PAIN, pS127, DOI 10.1016/S0304-3959(99)00146-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Polgar E, 1999, BRAIN RES, V833, P71, DOI 10.1016/S0006-8993(99)01500-0; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; ROTH BL, 1989, J NEUROCHEM, V52, P215, DOI 10.1111/j.1471-4159.1989.tb10919.x; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SCHEPELMANN K, 1993, EXP BRAIN RES, V92, P391; Shu XQ, 1999, NEUROSCI LETT, V274, P159, DOI 10.1016/S0304-3940(99)00701-6; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Spiegel S, 1999, FEBS LETT, V454, P137, DOI 10.1016/S0014-5793(99)00796-6; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Walpole CSJ, 1996, J MED CHEM, V39, P2939, DOI 10.1021/jm960139d; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Winston J, 2001, PAIN, V89, P181, DOI 10.1016/S0304-3959(00)00370-5; WINTER J, 1990, BRAIN RES, V520, P131, DOI 10.1016/0006-8993(90)91698-G	50	92	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35752	35759		10.1074/jbc.M201551200	http://dx.doi.org/10.1074/jbc.M201551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095983	hybrid			2022-12-27	WOS:000178117000138
J	Santra, M; Reed, CC; Iozzo, RV				Santra, M; Reed, CC; Iozzo, RV			Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CYCLIN-DEPENDENT KINASES; CHICK-EMBRYO FIBROBLASTS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; DOWN-REGULATION; RIBONUCLEASE INHIBITOR; EXTRACELLULAR DOMAIN; LIGAND-BINDING; PROTEOGLYCAN DECORIN	Decorin, a small leucine-rich proteoglycan, is a key regulator of tumor growth by acting as an antagonist of the epidermal growth factor receptor (EGFR) tyrosine kinase. To search for cell surface receptors interacting with decorin, we generated a decorin/alkaline phosphatase chimeric protein and used it to screen a cDNA library by expression cloning. We identified two strongly reactive clones that encoded either the full-length EGFR or its ectodomain. A physiologically relevant interaction between decorin and EGFR was confirmed in the yeast two-hybrid system and further validated by experiments using EGF/EGFR interaction and transient cell transfection assays. Using a panel of deletion mutants, decorin binding was mapped to a narrow region of the EGFR within its ligand-binding L2 domain. Moreover, the central leucine-rich repeat 6 of decorin was required for interaction with the EGFR. Site-directed mutagenesis of the EGFR L2 domain showed that a cluster of residues, His(394)-Ile(402), was essential for both decorin and EGF binding. In contrast, K465, previously shown to be cross-linked to epidermal growth factor (EGF), was required for EGF but not for decorin binding. Thus, decorin binds to a discrete region of the EGFR, partially overlapping with but distinct from the EGF-binding domain. These findings could lead to the generation of protein mimetics capable of suppressing EGFR function.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Wahab N, 2002, BIOCHEM J, V362, P643, DOI 10.1042/0264-6021:3620643; ADANY R, 1990, J BIOL CHEM, V265, P11389; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Laine P, 2000, BIOCHEM J, V349, P19, DOI 10.1042/0264-6021:3490019; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Nash MA, 1999, CANCER RES, V59, P6192; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Shridhar V, 2001, CANCER RES, V61, P5895; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; ULLRICH A, 1990, CELL, V61; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454	77	179	193	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35671	35681		10.1074/jbc.M205317200	http://dx.doi.org/10.1074/jbc.M205317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105206	hybrid			2022-12-27	WOS:000178117000128
J	Tsuneoka, M; Koda, Y; Soejima, M; Teye, K; Kimura, H				Tsuneoka, M; Koda, Y; Soejima, M; Teye, K; Kimura, H			A novel Myc target gene, mina53, that is involved in cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; RIBOSOME BIOGENESIS; MYC/MAX/MAD NETWORK; PROTEIN-SYNTHESIS; CYCLIN D2; EXPRESSION; GROWTH; DIFFERENTIATION; INDUCTION; DNA	Myc is a ubiquitous mediator of cell proliferation and can transactivate the expression of various genes through E-box sites. Here we report a novel gene, mina53 ((M) under bar yc-induced (n) under bar uclear (a) under bar ntigen with a molecular mass of 53 kDa). The mina53 gene encodes a protein with a molecular weight of 53 kDa, which is localized in the nucleus and with part of the protein concentrated in the nucleolus. When serum-starved cells were activated by serum, the level of c-myc mRNA was elevated, an an increase in mina53 mRNA followed the elevation of c-myc mRNA. When expression of c-myc was reduced in human promyelocytic leukemia HL60 cells by phorbol 12-myristate 13-acetate, the expression of mina53 mRNA and protein was reduced. The expression of mina53 mRNA and Mina53 protein was induced by ectopic introduction of wild type c-Myc but not by a mutant c-Myc lacking the transactivation domain. When c-Myc in the c-MycER chimeric protein was activated, mina53 mRNA was increased, even in the presence of an inhibitor for protein synthesis. E-box sites are present in a region proximal to the transcription initiation sites of the mina53 gene. The gene expression from the mina53 promoter was elevated by c-Myc through E-box sites. c-Myc protein bound to the mina53 promoter region in vivo in HL60 cells in the proliferating phase but not after treatment of cells with phorbol 12-myristate 13-acetate. Specific inhibition of mina53 expression by an RNA interference method severely suppressed cell proliferation. Taken together, these results indicate that mina53 is a direct target gene of Myc, suggesting that mina53 is involved in mammalian cell proliferation.	Kurume Univ, Sch Med, Dept Forens Med, Div Human Genet, Kurume, Fukuoka 8300011, Japan	Kurume University	Tsuneoka, M (corresponding author), Kurume Univ, Sch Med, Dept Forens Med, Div Human Genet, Kurume, Fukuoka 8300011, Japan.	tsuneoka@med.kurume-u.ac.jp	Hu, Ruogu/B-2203-2008; Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; HOZUMI M, 1983, ADV CANCER RES, V38, P121, DOI 10.1016/S0065-230X(08)60189-X; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; NOTI JD, 1995, MOL IMMUNOL, V32, P361, DOI 10.1016/0161-5890(94)00164-V; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Sunaga S, 1997, MOL REPROD DEV, V46, P109, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;109::AID-MRD1&gt;3.0.CO;2-U; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	44	92	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35450	35459		10.1074/jbc.M204458200	http://dx.doi.org/10.1074/jbc.M204458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12091391	hybrid			2022-12-27	WOS:000178117000101
J	Yarov-Yarovoy, V; McPhee, JC; Idsvoog, D; Pate, C; Scheuer, T; Catterall, WA				Yarov-Yarovoy, V; McPhee, JC; Idsvoog, D; Pate, C; Scheuer, T; Catterall, WA			Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel alpha subunit in voltage-dependent gating and drug block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; LOCAL-ANESTHETIC AFFINITIES; RAT HIPPOCAMPAL-NEURONS; FAST INACTIVATION; MOLECULAR DETERMINANTS; K+-CHANNEL; DOMAIN-IV; RECEPTOR-SITE; ANTIARRHYTHMIC DRUGS; ACUTE STROKE	Alanine-scanning mutagenesis of transmembrane segments IS6 and IIS6 of the rat brain Na(v)1.2 channel a subunit identified mutations N418A in IS6 and L975A in IIS6 as causing strong positive shifts in the voltage dependence of activation. In contrast, mutations V424A in IS6 and L983A in IIS6 caused strong negative shifts. Most IS6 mutations opposed inactivation from closed states, but most IIS6 mutations favored such inactivation. Mutations L421C and L983A near the intracellular ends of IS6 and IIS6, respectively, exhibited significant sustained Na+ currents at the end of 30-ms depolarizations, indicating a role for these residues in Na+ channel fast inactivation. These residues, in combination with residues at the intracellular end of IVS6, are well situated to form an inactivation gate receptor. Mutation I409A in IS6 reduced the affinity of the local anesthetic etidocaine for the inactivated state by 6-fold, and mutations I409A and N418A reduced use-dependent block by etidocaine. No IS6 or IIS6 mutations studied affected inactivated-state affinity or use-dependent block by the neuroprotective drug sipatrigine (compound 619C89). These results suggest that the local anesthetic receptor site is formed primarily by residues in segments IIIS6 and IVS6 with the contribution of a single amino acid in segment IS6.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, POB 357280, Seattle, WA 98195 USA.		Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834	PHS HHS [R-01 N515751] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; Calabresi P, 2000, EXP NEUROL, V162, P171, DOI 10.1006/exnr.2000.7285; Carter AJ, 2000, P NATL ACAD SCI USA, V97, P4944, DOI 10.1073/pnas.040577097; CATTERALL WA, 1986, TRENDS NEUROSCI, V9, P7, DOI 10.1016/0166-2236(86)90004-4; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cohen S A, 1993, Int Rev Cytol, V137C, P55; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Filatov GN, 1998, J GEN PHYSIOL, V111, P703, DOI 10.1085/jgp.111.6.703; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; Hille B., 2001, IONIC CHANNELS EXCIT, P814; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Kontis KJ, 1997, J GEN PHYSIOL, V110, P391, DOI 10.1085/jgp.110.4.391; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CC, 1994, MOL PHARMACOL, V46, P716; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; Lerche H, 1997, J PHYSIOL-LONDON, V505, P345, DOI 10.1111/j.1469-7793.1997.345bb.x; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Liu GY, 1998, BIOPHYS J, V74, pA399; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muir K W, 1995, Ann N Y Acad Sci, V765, P328, DOI 10.1111/j.1749-6632.1995.tb16605.x; Muir KW, 1998, CEREBROVASC DIS, V8, P31, DOI 10.1159/000015812; Muir KW, 2000, CEREBROVASC DIS, V10, P431, DOI 10.1159/000016103; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; Ragsdale DS, 1996, P NATL ACAD SCI USA, V93, P9270, DOI 10.1073/pnas.93.17.9270; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sheets MF, 1999, BIOPHYS J, V77, P747, DOI 10.1016/S0006-3495(99)76929-8; Smith MR, 1997, BIOPHYS J, V73, P1885, DOI 10.1016/S0006-3495(97)78219-5; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Tang LH, 1998, J GEN PHYSIOL, V111, P639, DOI 10.1085/jgp.111.5.639; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 1998, PFLUG ARCH EUR J PHY, V435, P293; Wang SY, 1997, BIOPHYS J, V72, P1633, DOI 10.1016/S0006-3495(97)78809-X; Wang SY, 2000, BIOPHYS J, V79, P1379, DOI 10.1016/S0006-3495(00)76390-9; Weiser T, 1999, MOL PHARMACOL, V56, P1238, DOI 10.1124/mol.56.6.1238; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; Xie XM, 1996, NEUROSCIENCE, V73, P951, DOI 10.1016/0306-4522(96)00092-9; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yarov-Yarovoy V, 2001, J BIOL CHEM, V276, P20, DOI 10.1074/jbc.M006992200; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	71	175	179	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35393	35401		10.1074/jbc.M206126200	http://dx.doi.org/10.1074/jbc.M206126200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130650	hybrid			2022-12-27	WOS:000178117000095
J	Layer, G; Verfurth, K; Mahlitz, E; Jahn, D				Layer, G; Verfurth, K; Mahlitz, E; Jahn, D			Oxygen-independent coproporphyrinogen-III oxidase HemN from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTER; LYASE-ACTIVATING ENZYME; RADICAL MECHANISMS; BIOTIN SYNTHASE; RIBONUCLEOTIDE REDUCTASE; IN-VITRO; PROTEIN; PURIFICATION; ADENOSYLMETHIONINE; CLUSTERS	In bacteria the oxygen-independent coproporphyrinogen-III oxidase catalyzes the oxygen-independent conversion of coproporphyrinogen-Ill to protoporphyrinogen-IX. The Escherichia coli hemN gene encoding a putative part of this enzyme was overexpressed in E. coli. Anaerobically purified HemN is a monomeric protein with a native M-r = 52,000 +/- 5,000. A newly established anaerobic enzyme assay was used to demonstrate for the first time in vitro coproporphyrinogen-Ill oxidase activity for recombinant purified HemN. The enzyme requires S-adenosyl-L-methionine (SAM), NAD(P)H, and additional cytoplasmatic components for catalysis. An oxygen-sensitive iron-sulfur cluster was identified by absorption spectroscopy and iron analysis. Cysteine residues Cys(62), Cys(66), and Cys(69), which are part of the conserved CXXXCXXC motif found in all HemN proteins, are essential for iron-sulfur cluster formation and enzyme function. Completely conserved residues Tyr(56) and His(58), localized closely to the cysteine-rich motif, were found to be important for iron-sulfur cluster integrity. Mutation of Gly(111) and Gly(113), which are part of the potential GGGTP S-adenosyl-L-methionine binding motif, completely abolished enzymatic function. Observed functional properties in combination with a recently published computer-based enzyme classification (Sofia, H. J., Chen, G., Hetzler, B. G., Reyes-Spindola, J. F., and Miller, N. E. (2001) Nucleic Acids Res. 29,10971106) identifies HemN as "Radical SAM enzyme." An appropriate enzymatic mechanism is suggested.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Mikrobiol, D-38106 Braunschweig, Germany; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Braunschweig University of Technology; University of Freiburg	Jahn, D (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Mikrobiol, Spielmannstr 7, D-38106 Braunschweig, Germany.			Jahn, Dieter/0000-0002-4064-9205				BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; CHADWICK DJ, 1994, CIBA F SYMP, V180, P131; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; COOMBER SA, 1992, MOL MICROBIOL, V6, P3159, DOI 10.1111/j.1365-2958.1992.tb01772.x; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; FRIEDMANN HC, 1992, ENCY MICROBIOLOGY, V3, P1; GRANDCHAMP B, 1982, ENZYME, V28, P196, DOI 10.1159/000459102; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; Harwood C.R., 1990, MOL BIOL METHODS BAC, P548; Homuth G, 1999, J BACTERIOL, V181, P5922, DOI 10.1128/JB.181.19.5922-5929.1999; JACKSON AH, 1980, INT J BIOCHEM, V12, P681, DOI 10.1016/0020-711X(80)90144-5; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; JORDAN PM, 1981, NEW COMPREHENSIVE BI, V19, P1; KEITHLY JH, 1983, J BACTERIOL, V154, P838, DOI 10.1128/JB.154.2.838-845.1983; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Labbe P, 1997, METHOD ENZYMOL, V281, P367; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; Medlock AE, 1996, J BIOL CHEM, V271, P32507, DOI 10.1074/jbc.271.51.32507; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; POULSON R, 1974, J BIOL CHEM, V249, P6367; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SEEHRA JS, 1983, BIOCHEM J, V209, P709, DOI 10.1042/bj2090709; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; TAIT GH, 1972, BIOCHEM J, V128, P1159, DOI 10.1042/bj1281159; TAIT GH, 1969, BIOCHEM BIOPH RES CO, V37, P116, DOI 10.1016/0006-291X(69)90888-2; TAIT GH, 1970, BIOCHEM J, V118, P28; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; TROUP B, 1995, J BACTERIOL, V177, P3326, DOI 10.1128/jb.177.11.3326-3331.1995; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; XU KP, 1994, J BACTERIOL, V176, P3196, DOI 10.1128/jb.176.11.3196-3203.1994; YOSHINAGA T, 1980, J BIOL CHEM, V255, P4722	40	104	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34136	34142		10.1074/jbc.M205247200	http://dx.doi.org/10.1074/jbc.M205247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114526	hybrid			2022-12-27	WOS:000177959100080
J	Ren, J; Datta, R; Shioya, H; Li, YQ; Oki, EJ; Biedermann, V; Bharti, A; Kufe, D				Ren, J; Datta, R; Shioya, H; Li, YQ; Oki, EJ; Biedermann, V; Bharti, A; Kufe, D			p73 beta is regulated by protein kinase C delta catalytic fragment generated in the apoptotic response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; PROTEOLYTIC ACTIVATION; IONIZING-RADIATION; INDUCE APOPTOSIS; P53 HOMOLOG; P73; CELLS; CLEAVAGE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE	Protein kinase C (PKC) delta is cleaved by caspase-3 to a kinase-active catalytic fragment (PKCdeltaCF) in the apoptotic response of cells to DNA damage. Expression of PKCdeltaCF contributes to the induction of apoptosis by mechanisms that are presently unknown. Here we demonstrate that PKCdeltaCF associates with p73beta, a structural and functional homologue of the p53 tumor suppressor. The results show that PKCdeltaCF phosphorylates the p73beta transactivation and DNA-binding domains. One PKCdeltaCF-phosphorylation site has been mapped to Ser-289 in the p73beta DNA-binding domain. PKCdeltaCF-mediated phosphorylation of p73beta is associated with accumulation of p73beta and induction of p73beta-mediated transactivation. By contrast, PKCdeltaCF-induced activation of p73beta is attenuated by mutating Ser-289 to Ala (S289A). The results also demonstrate that PKCdeltaCF stimulates p73beta-mediated apoptosis and that this response is attenuated with the p73beta(S289A) mutant. These findings demonstrate that cleavage of PKCdelta to PKCdeltaCF induces apoptosis by a mechanism in part dependent on PKCdeltaCF-mediated phosphorylation of the p73beta Ser-289 site.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Bharti, Ajit/0000-0001-7972-6688	NCI NIH HHS [CA 55241] Funding Source: Medline; NIGMS NIH HHS [GM 58200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOYER JC, 1995, CANCER RES, V55, P6063; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gong JG, 1999, NATURE, V399, P806; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; ONO Y, 1988, J BIOL CHEM, V263, P6927; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1998, CANCER RES, V58, P5061	41	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33758	33765		10.1074/jbc.M110667200	http://dx.doi.org/10.1074/jbc.M110667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097319	hybrid			2022-12-27	WOS:000177959100032
J	Samanani, N; Facchini, PJ				Samanani, N; Facchini, PJ			Purification and characterization of norcoclaurine synthase - The first committed enzyme in benzylisoquinoline alkaloid biosynthesis in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; (S)-NORLAUDANOSOLINE SYNTHASE; COPTIS-JAPONICA; CELL-CULTURES; LOCALIZATION; RETICULINE; PROTEINS; REVISION; PATHWAY	Norcoclaurine synthase (NCS; EC 4.2.1.78) catalyzes the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) as the first committed step in benzylisoquinoline alkaloid biosynthesis in plants. NCS was purified 1590-fold to homogeneity from cell suspension cultures of meadow rue (Thalictrum flavum ssp. glaucum). The purification procedure, which resulted in a 4.2% yield, involved hydrophobic interaction, anion exchange, hydroxyapatite, and gel filtration chromatography. Purified NCS displayed native and denatured molecular masses of similar to28 and 15 kDa, respectively, suggesting that the enzyme is composed of two subunits. Two-dimensional polyacrylamide gel electrophoresis revealed two major and two minor isoforms with pI values between 5.5 and 6.2. NCS activity was maximal at pH 6.5 to 7.0 and temperatures between 42 and 55 degreesC and was not affected by divalent cations. The enzyme showed hyperbolic saturation kinetics for 4-HPAA (K-m = 335 muM) but sigmoidal saturation kinetics for dopamine (Hill coefficient = 1.8) suggesting cooperativity between the dopamine binding sites on each subunit; thus, NCS might play a regulatory, or rate-limiting, role in controlling the rate of pathway flux in benzylisoquinoline alkaloid biosynthesis. Product inhibition kinetics performed at saturating levels of one substrate and with norlaudanosoline as the inhibitor showed that NCS follows an iso-ordered bi-uni mechanism with 4-HPAA binding before dopamine. NCS activity was highest in soluble protein extracts from roots followed by stems, leaves, and flower buds.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Facchini, PJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	pfacchin@ucalgary.ca	Samanani, Nailish/ABC-3660-2020	Facchini, Peter/0000-0002-7693-290X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; De-Eknamkul W, 2000, PHYTOCHEMISTRY, V55, P177, DOI 10.1016/S0031-9422(00)00260-0; Facchini PJ, 2001, ANNU REV PLANT PHYS, V52, P29, DOI 10.1146/annurev.arplant.52.1.29; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; KAPOOR M, 1977, CAN J BIOCHEM CELL B, V55, P43, DOI 10.1139/o77-008; KUTCHAN TM, 1986, PLANT PHYSIOL, V81, P161, DOI 10.1104/pp.81.1.161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEIJER AH, 1993, J PLANT RES, P145; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; PFITZNER U, 1989, PLANTA MED, P525, DOI 10.1055/s-2006-962086; Plowman K. M., 1972, ENZYME KINETICS; ROBERTS MF, 1983, ARCH BIOCHEM BIOPHYS, V222, P599, DOI 10.1016/0003-9861(83)90558-1; RUEFFER M, 1981, FEBS LETT, V129, P5, DOI 10.1016/0014-5793(81)80742-9; RUEFFER M, 1987, Z NATURFORSCH C, V42, P319; Samanani N, 2001, PLANTA, V213, P898, DOI 10.1007/s004250100581; SATO F, 1994, EUR J BIOCHEM, V225, P125, DOI 10.1111/j.1432-1033.1994.00125.x; SCHUMACHER HM, 1983, PLANTA MED, V48, P212, DOI 10.1055/s-2007-969923; Segel IH, 1975, ENZYME KINETICS BEHA; STADLER R, 1989, PHYTOCHEMISTRY, V28, P1083, DOI 10.1016/0031-9422(89)80187-6; STADLER R, 1990, LIEBIGS ANN CHEM, P555; STADLER R, 1987, TETRAHEDRON LETT, V28, P1251, DOI 10.1016/S0040-4039(00)95338-3	25	81	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33878	33883		10.1074/jbc.M203051200	http://dx.doi.org/10.1074/jbc.M203051200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107162	hybrid			2022-12-27	WOS:000177959100047
J	Ghosh, A; Shieh, JJ; Pan, CJ; Sun, MS; Chou, JY				Ghosh, A; Shieh, JJ; Pan, CJ; Sun, MS; Chou, JY			The catalytic center of glucose-6-phosphatase - HIS176 is the nucleophile forming the phosphohistidine-enzyme intermediate during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE IA; ACTIVE-SITE; CURVULARIA-INAEQUALIS; MESSENGER-RNA; GENE; IDENTIFICATION; PHOSPHATASE; MUTATIONS; CHLOROPEROXIDASE; EXPRESSION	Glucose-6-phosphatase (G6Pase), a key enzyme in glucose homeostasis, is anchored to the endoplasmic reticulum. by nine transmembrane helices. The amino acids comprising the catalytic center of G6Pase include Lys(76), Arg(83), His(119), Arg(170) and His(176). During catalysis, a His residue in G6Pase becomes phosphorylated generating an enzyme-phosphate intermediate. It was predicted that His(176) would be the amino acid that acts as a nucleophile forming a phosphohistidine-enzyme intermediate, and His(119) would be the amino acid that provides the proton needed to liberate the glucose moiety. However, the phosphate acceptor in G6Pase has eluded molecular characterization. To identify the His residue that covalently bound the phosphate moiety, we generated recombinant adenoviruses carrying G6Pase wild type and active site mutants. A 40-kDa [P-32]phosphate-G6Pase intermediate was identified after incubating [P-32]glucose 6-phosphate with microsomes expressing wild type but not with microsomes expressing either H119A or H176A mutant G6Pase. Human G6Pase contains five methionine residues at positions 1, 5, 121, 130, and 279. After cyanogen bromide cleavage, His' 19 is predicted to be within a 116-amino acid peptide of 13.5 kDa with an isoelectric point of 5.3 (residues 6-121), and His 176 is predicted to be within a 149-amino acid peptide of 16.8 kDa with an isoelectric point of 9.3 (residues 131-279). We show that after digestion of a non-glycosylated [P-32] phosphate-G6Pase intermediate by cyanogen bromide, the [P-32]phosphate remains bound to a peptide of 17 kDa with an isoelectric point above 9, demonstrating that His(176) is the phosphate acceptor in G6Pase.	NICHD, Heritable Disorders Branch, Sect Cellular Differentiat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, Sect Cellular Differentiat, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.		Shieh, Jeng-Jer/AAX-6903-2020	Shieh, Jeng-Jer/0000-0001-8412-3603	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akanuma J, 2000, AM J MED GENET, V91, P107, DOI 10.1002/(SICI)1096-8628(20000313)91:2<107::AID-AJMG5>3.3.CO;2-P; Chou Janice Yang, 2001, Current Molecular Medicine (Hilversum), V1, P25; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Cordoba OL, 1997, J BIOCHEM BIOPH METH, V35, P1, DOI 10.1016/S0165-022X(97)00018-3; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; CRIMMINS DL, 1996, CURRENT PROTOCOLS PR; FELDMAN F, 1972, BIOCHIM BIOPHYS ACTA, V268, P698, DOI 10.1016/0005-2744(72)90274-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hemrika W, 1999, J BIOL CHEM, V274, P23820, DOI 10.1074/jbc.274.34.23820; Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9; Hemrika W, 1997, P NATL ACAD SCI USA, V94, P2145, DOI 10.1073/pnas.94.6.2145; Huner G, 1998, J INHERIT METAB DIS, V21, P445, DOI 10.1023/A:1005339616074; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; Kozak L, 2000, Hum Mutat, V16, P89; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; MITHIEUX G, 1995, J BIOCHEM-TOKYO, V117, P908, DOI 10.1093/oxfordjournals.jbchem.a124795; NORDLIE RC, 1966, J BIOL CHEM, V241, P3136; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P21658, DOI 10.1074/jbc.273.34.21658; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Scriver C.R., 2001, METABOLIC MOL BASIS, VEighth; SELDEN RF, 1994, CURRENT PROTOCOLS MO; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2002, J BIOL CHEM, V277, P5047, DOI 10.1074/jbc.M110486200; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; Stukey J, 1997, PROTEIN SCI, V6, P469; Wu M C, 2000, Hum Mutat, V16, P447, DOI 10.1002/1098-1004(200011)16:5<447::AID-HUMU17>3.0.CO;2-M	32	75	80	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32837	32842		10.1074/jbc.M201853200	http://dx.doi.org/10.1074/jbc.M201853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093795	hybrid			2022-12-27	WOS:000177859000058
J	Hardy, S; Brand, M; Mittler, G; Yanagisawa, J; Kato, S; Meisterernst, M; Tora, L				Hardy, S; Brand, M; Mittler, G; Yanagisawa, J; Kato, S; Meisterernst, M; Tora, L			TATA-binding protein-free TAF-containing complex (TFTC) and p300 are both required for efficient transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; ADENOVIRAL ONCOPROTEIN E1A; RNA-POLYMERASE-II; NUCLEOSOME ACETYLATION; ESTROGEN-RECEPTOR; TAF(II)-CONTAINING COMPLEXES; GENE-EXPRESSION; STIMULATION; DOMAIN; COACTIVATOR	Initiation of transcription of protein-encoding genes by RNA polymerase II was thought to require transcription factor TFIID, a complex comprising the TATA-binding protein (TBP) and TBP-associated factors (TAFs). In the presence of TBP-free TAF complex (TIFTC), initiation of polymerase II transcription can occur in the absence of TFIID. TFTC contains several subunits that have been shown to play the role of transcriptional coactivators, including the GCN5 histone acetyltransferase (HAT), which acetylates historic H3 in a nucleosomal context. Here we analyze the coactivator function of TFTC. We show direct physical interactions between TFTC and the two distinct activation regions (H1 and H2) of the VP16 activation domain, whereas the HAT-ontaining coactivators, p300/CBP (CREB-binding protein), interact only with the H2 subdomain of VP16. Accordingly, cell transfection experiments demonstrate the requirement of both p300 and TFTC for maximal transcriptional activation by GAL-VP16. In agreement with this finding, we show that in vitro on a chromatinized template human TFTC mediates the transcriptional activity of the VP16 activation domain in concert with p300 and in an acetyl-CoA-dependent manner. Thus, our results suggest that these two HAT-containing co-activators, p300 and TFTC, have complementary rather than redundant roles during the transcriptional activation process.	Inst Genet & Biol Mol & Cellulaire, UMR 7104, Dept Transcript & Post Transcript Control Gene Re, Communaute Urbaine Strasbourg, F-67404 Illkirch Graffenstaden, France; Natl Res Ctr Environm & Hlth, Dept Gene Express, D-81377 Munich, Germany; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Munich; University of Tokyo	Tora, L (corresponding author), Inst Genet & Biol Mol & Cellulaire, UMR 7104, Dept Transcript & Post Transcript Control Gene Re, Communaute Urbaine Strasbourg, Boite Postale 10142, F-67404 Illkirch Graffenstaden, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Candau R, 1996, MOL CELL BIOL, V16, P593; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Goodman RH, 2000, GENE DEV, V14, P1553; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Ikeda K, 2002, GENES CELLS, V7, P49, DOI 10.1046/j.1356-9597.2001.00492.x; Ikeda K, 1999, MOL CELL BIOL, V19, P855; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meisterernst M, 2002, SCIENCE, V295, P984, DOI 10.1126/science.1069485; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steger DJ, 1997, METHODS, V12, P276, DOI 10.1006/meth.1997.0479; Steger DJ, 1999, METHODS, V19, P410, DOI 10.1006/meth.1999.0877; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	66	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32875	32882		10.1074/jbc.M205860200	http://dx.doi.org/10.1074/jbc.M205860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12107188	hybrid			2022-12-27	WOS:000177859000064
J	Gomes, CM; Giuffre, A; Forte, E; Vicente, JB; Saraiva, LM; Brunori, M; Teixeira, M				Gomes, CM; Giuffre, A; Forte, E; Vicente, JB; Saraiva, LM; Brunori, M; Teixeira, M			A novel type of nitric-oxide reductase - Escherichia coli flavorubredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; DESULFOVIBRIO-GIGAS; RUBREDOXIN; DENITRIFICATION; PURIFICATION; ARCHAEON; OXIDASES; PROTEIN; OXYGEN; FAMILY	Escherichia coli flavorubredoxin is a member of the family of the A-type flavoproteins, which are built by two core domains: a metallo-beta-lactamase-like domain, at the N-terminal region, harboring a non-heme di-iron site, and a flavodoxin-like domain, containing one FMN moiety. The enzyme from E. coli has an extra module at the C terminus, containing a rubredoxin-like center. The A-type flavoproteins are widespread among strict and facultative anaerobes, as deduced from the analysis of the complete prokaryotic genomes. In this report we showed that the recombinant enzyme purified from E. coli has nitric-oxide reductase activity with a turnover number of similar to15 mol of NO-mol enzyme(-1)-s(-1), which was well within the range of those determined for the canonical heme b(3)-Fe-B containing nitric-oxide reductases (e.g. similar to10-50 mol NO-mol enzyme(-1.)s(-1) for the Paracoccus denitrificans NOR). Furthermore, it was shown that the activity was due to the A-type flavoprotein core, as the rubredoxin domain alone exhibited no activity. Thus, a novel family of prokaryotic NO reductases, with a non-heme di-iron site as the catalytic center, was established.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Qeiras, Portugal; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, P-2825114 Lisbon, Portugal; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	Universidade Nova de Lisboa; Universidade Nova de Lisboa; Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Teixeira, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, APT 127,2780-156, P-2780156 Qeiras, Portugal.	miguel@itqb.unl.pt	Teixeira, Miguel/A-9098-2011; Forte, Elena/K-6015-2015; Saraiva, Ligia M/H-8537-2012; Teixeira, Miguel/M-1509-2019; Vicente, João B/B-9623-2014; Giuffrè, Alessandro/K-4341-2015; Vicente, Joao B/L-8732-2016; Gomes, Cláudio M./A-8152-2008	Teixeira, Miguel/0000-0003-4124-6237; Saraiva, Ligia M/0000-0002-0675-129X; Teixeira, Miguel/0000-0003-4124-6237; Vicente, João B/0000-0003-3919-8280; Giuffrè, Alessandro/0000-0001-5301-0681; Gomes, Cláudio M./0000-0003-4662-6933; Brunori, Maurizio/0000-0002-7795-1635; Vicente, Joao/0000-0001-5244-8059; FORTE, Elena/0000-0001-9049-6916				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN L, 1993, BIOCHEM BIOPH RES CO, V193, P100, DOI 10.1006/bbrc.1993.1595; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Forte E, 2001, EUR J BIOCHEM, V268, P6486, DOI 10.1046/j.0014-2956.2001.02597.x; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Gomes C.M., 1999, FLAVINS FLAVOPROTEIN, P219; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; Gomes CM, 2002, PROTEIN SCI, V11, P707, DOI 10.1110/ps.31202; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Jouanneau Y, 2000, EUR J BIOCHEM, V267, P780, DOI 10.1046/j.1432-1327.2000.01056.x; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Moore DD, 1995, GLOB MOB SURV; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; WASSERFALLEN A, 1995, J BACTERIOL, V177, P2436, DOI 10.1128/jb.177.9.2436-2441.1995; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	35	172	176	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25273	25276		10.1074/jbc.M203886200	http://dx.doi.org/10.1074/jbc.M203886200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12101220	hybrid			2022-12-27	WOS:000176747000056
J	Chen, TP; Ueda, Y; Xie, SP; Li, E				Chen, TP; Ueda, Y; Xie, SP; Li, E			A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CYTOSINE-5 METHYLTRANSFERASES; EMBRYONIC STEM-CELLS; DE-NOVO; MAMMALIAN DEVELOPMENT; GERM-LINE; GENE; LETHALITY; MUTATION; CLONING; DOMAIN	Previous studies have shown that the Dnmt3b gene encodes multiple variants via alternative splicing. However, only one form of Dnmt3a has been identified to date. We report here the discovery of a small form of Dnmt3a, denoted Dnmt3a2, from both human and mouse. The transcript encoding Dnmt3a2 is initiated from a downstream intronic promoter. As a result, the Dnmt3a2 protein lacks the N-terminal 223 (human) or 219 (mouse) amino acid residues of the full-length Dnmt3a. Recombinant Dnmt3a2 protein displayed similar cytosine methyltransferase activity as Dnmt3a in vitro. However, Dnmt3a and Dnmt3a2 exhibited strikingly different subcellular localization patterns. Unlike Dnmt3a, which was concentrated on heterochromatin, Dnmt3a2 displayed a localization pattern suggestive of euchromatin association. Dnmt3a2 is the predominant form in embryonic stem cells and embryonal carcinoma cells and can also be detected from testis, ovary, thymus, and spleen, whereas Dnmt3a is expressed at low levels ubiquitously. Comparison of human embryonal carcinoma cell lines with breast/ovarian cancer cell lines indicates that DNMT3A2 expression correlates with high de novo methylation activity. These findings suggest that Dnmt3a and Dnmt3a2 may have distinct DNA targets and different functions in development.	Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Li, E (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494	NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER; NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hata K, 2002, DEVELOPMENT, V129, P1983; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	28	263	279	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38746	38754		10.1074/jbc.M205312200	http://dx.doi.org/10.1074/jbc.M205312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138111	hybrid			2022-12-27	WOS:000178529600094
J	Lai, YR; Bakken, AH; Unadkat, JD				Lai, YR; Bakken, AH; Unadkat, JD			Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells - Localization and vectorial transport studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRANSPORT; MEMBRANE-VESICLES; BRUSH-BORDER; ADENOSINE TRANSPORT; MICE; SYSTEMS; LINE	To test the hypothesis that human concentrative and equilibrative nucleoside transporters (hCNT1 and hENT1) are present on the apical and basolateral membrane, respectively, we constructed a Madin-Darby canine kidney (MDCK) cell line that simultaneously and stably expresses recombinant hCNT1 and hENT1 gene products tagged with CFP and YFP fluorescent proteins, respectively. Using a confocal microscope, both hCNT1-CFP and hENT1-YFP were found to be distributed uniformly on the plasma membrane of undifferentiated MDCK cells. Upon differentiation of the MDCK cells on Transwell. filter inserts, hCNT1-CFP was visualized exclusively on the apical membrane, whereas hENT1-YFP appeared predominantly on the basolateral membrane. As differentiation proceeded, there was an increase in alkaline phosphatase activity, and activity of hENT1 in the apical compartment decreased while hCNT1 activity remained constant. These results suggest that, on differentiation, hENT1 is sorted to the basolateral membrane. This was confirmed when the hCNT1-mediated uptake of [3 H]uridine from the apical compartment of the differentiated cells was found to be similar to20-fold higher and that for hENT1 was similar to4-fold lower than the corresponding uptake from the basal compartment. As observed in vivo, the net transport of [H-3]adenosine was from the apical to the basal compartment, whereas that for C-14-deoxyadenosine was from the basal to the apical compartment. In summary, we have shown for the first time that hCNT1 and hENT1 are expressed in polarized MDCK cells on the apical and basolateral membrane, respectively, allowing vectorial transport in both directions depending on the relative activity (ratio of maximal transporter activity to affinity) of each transporter for their substrates.	Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Unadkat, JD (corresponding author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.		Lai, Yurong/ABG-4485-2021; Lai, Yurong/GWV-6243-2022	Lai, Yurong/0000-0001-9505-333X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054447] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM54447] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chandrasena G, 1997, BIOCHEM PHARMACOL, V53, P1909, DOI 10.1016/S0006-2952(97)00170-6; DOHERTY AJ, 1993, BIOCHIM BIOPHYS ACTA, V1147, P214, DOI 10.1016/0005-2736(93)90006-L; FRANCO R, 1990, BIOCHIM BIOPHYS ACTA, V1024, P241, DOI 10.1016/0005-2736(90)90350-W; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GUTIERREZ MM, 1992, BIOCHIM BIOPHYS ACTA, V1105, P1, DOI 10.1016/0005-2736(92)90156-G; Jackson EK, 2001, AM J PHYSIOL-RENAL, V281, pF597, DOI 10.1152/ajprenal.2001.281.4.F597; KUTTESCH JF, 1982, CANCER CHEMOTH PHARM, V8, P221; KUTTESCH JF, 1982, BIOCHEM PHARMACOL, V31, P3387, DOI 10.1016/0006-2952(82)90616-5; Lum PY, 2000, CANCER CHEMOTH PHARM, V45, P273, DOI 10.1007/s002800050040; Mangravite LM, 2001, AM J PHYSIOL-RENAL, V280, pF879, DOI 10.1152/ajprenal.2001.280.5.F879; NELSON JA, 1988, DRUG METAB DISPOS, V16, P789; NELSON JA, 1983, BIOCHEM PHARMACOL, V32, P2323, DOI 10.1016/0006-2952(83)90180-6; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Schaner ME, 1999, J PHARMACOL EXP THER, V289, P1487; TRIMBLE ME, 1984, AM J PHYSIOL, V246, pF794, DOI 10.1152/ajprenal.1984.246.6.F794; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; Ward JL, 1999, BBA-BIOMEMBRANES, V1419, P15, DOI 10.1016/S0005-2736(99)00045-0; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223	20	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37711	37717		10.1074/jbc.M204986200	http://dx.doi.org/10.1074/jbc.M204986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12097333	hybrid			2022-12-27	WOS:000178447100103
J	Litowski, JR; Hodges, RS				Litowski, JR; Hodges, RS			Designing heterodimeric two-stranded alpha-helical coiled-coils - Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; DE-NOVO DESIGN; SYNTHETIC MODEL PROTEINS; OLIGOMERIZATION-STATE; ELECTROSTATIC INTERACTIONS; CHAIN-LENGTH; DIMERIZATION SPECIFICITY; THERMODYNAMIC SCALE; HEPTAD POSITIONS; HYBRID HYDROGELS	The E/K coli, a heterodimeric colied-coli, has been designed as a universal peptide capture and delivery system for use in applications such as biosensors and as an expression and affinity purification tag. In this design, heterodimer formation is specified through the placement of charged residues at the e and g positions of the heptad repeat such that the E coli contains all glutamic acid residues at these positions, and the K coli contains all lysine residues at these positions. The affinity and stability of the E/K coli have been modified to allow a greater range of conditions for association and dissociation. Increasing the hydrophobicity of the colied-coli core, by substituting isoleucine for valine, gave increases in stability of 2.81 and 3.73 kcal/mol (0.47 kcal/ mol/substitution). Increasing the alpha-helical propensity of residues outside the core, by substituting alanine for serine, yielded increases in stability of 2.68 and 3.28 kcal/mol (0.41 and 0.45 kcal/mol/substitution). These sequence changes yielded a series of heterodimeric colied-colis whose stabilities varied from 6.8 to 11.2 kcal/mol, greatly expanding their scope for use in protein engineering and biomedical applications.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alberta	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Box B121,4200 E 9th Ave, Denver, CO 80262 USA.	robert.hodges@uchsc.edu						Arndt KM, 2001, J MOL BIOL, V312, P221, DOI 10.1006/jmbi.2001.4915; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Behncken SN, 2000, J BIOL CHEM, V275, P17000, DOI 10.1074/jbc.275.22.17000; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Catimel B, 2001, J PEPT RES, V58, P493, DOI 10.1034/j.1399-3011.2001.10973.x; Cedervall T, 1997, BIOCHEMISTRY-US, V36, P4987, DOI 10.1021/bi962971q; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Chao HM, 1998, J CHROMATOGR B, V715, P307, DOI 10.1016/S0378-4347(98)00172-8; Chao HM, 1996, BIOCHEMISTRY-US, V35, P12175, DOI 10.1021/bi9530604; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; Erickson B. W., 1976, PROTEINS, VII, P255; Fairman R, 1996, BIOCHEMISTRY-US, V35, P2824, DOI 10.1021/bi952784c; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FERSHT AR, 1993, CURR OPIN STRUC BIOL, V3, P75, DOI 10.1016/0959-440X(93)90205-Y; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P510, DOI 10.1038/nsb0696-510; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Holtzer ME, 1997, BIOPHYS J, V73, P1031, DOI 10.1016/S0006-3495(97)78136-0; Houston ME, 1996, J MOL BIOL, V262, P270, DOI 10.1006/jmbi.1996.0512; Jelesarov I, 1996, J MOL BIOL, V263, P344, DOI 10.1006/jmbi.1996.0579; Karplus PA, 1997, PROTEIN SCI, V6, P1302; Kiyokawa T, 2000, BIOPOLYMERS, V55, P407, DOI 10.1002/1097-0282(2000)55:5<407::AID-BIP1015>3.3.CO;2-P; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Kohn WD, 1998, TRENDS BIOTECHNOL, V16, P379, DOI 10.1016/S0167-7799(98)01212-8; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125; KOHN WD, 1995, PROTEIN SCI, V4, P237; Krittanai C, 2000, PROTEINS, V39, P132, DOI 10.1002/(SICI)1097-0134(20000501)39:2<132::AID-PROT3>3.0.CO;2-2; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; KWOK SC, 1998, P 25 EUR PEPT S, P34; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Litowski JR, 1999, J PEPT RES, V54, P1, DOI 10.1034/j.1399-3011.1999.00066.x; Liu JF, 2001, PROTEIN SCI, V10, P1970, DOI 10.1110/ps.10101; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; Miceli R, 1996, Drug Des Discov, V13, P95; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; Muller KM, 2000, METHOD ENZYMOL, V328, P261; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NAUTIYAL S, 1995, BIOCHEMISTRY-US, V34, P11645, DOI 10.1021/bi00037a001; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Pace C N, 1986, Methods Enzymol, V131, P266; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Padmanabhan S, 1996, J MOL BIOL, V257, P726, DOI 10.1006/jmbi.1996.0197; Petka WA, 1998, SCIENCE, V281, P389, DOI 10.1126/science.281.5375.389; Schnarr NA, 2001, J AM CHEM SOC, V123, P11081, DOI 10.1021/ja015912v; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Tang A, 2001, J CONTROL RELEASE, V72, P57, DOI 10.1016/S0168-3659(01)00262-0; Tripet B, 1996, PROTEIN ENG, V9, P1029, DOI 10.1093/protein/9.11.1029; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Vu C, 2001, PROTEIN SCI, V10, P631, DOI 10.1110/ps.41101; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Walshaw J, 2001, PROTEIN SCI, V10, P668, DOI 10.1110/ps.36901; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; WOLBER V, 1992, BIO-TECHNOL, V10, P900, DOI 10.1038/nbt0892-900; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Wu ZN, 1999, PROTEIN SCI, V8, P482; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN PEPTIDE LETT, V1, P114; ZHU BY, 1993, PROTEIN SCI, V2, P383; ZHU BY, 1992, INT J PEPT PROT RES, V40, P171	88	232	277	2	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37272	37279		10.1074/jbc.M204257200	http://dx.doi.org/10.1074/jbc.M204257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138097	hybrid			2022-12-27	WOS:000178447100048
J	Takanami-Ohnishi, Y; Amano, S; Kimura, S; Asada, S; Utani, A; Maruyama, M; Osada, H; Tsunoda, H; Irukayama-Tomobe, Y; Goto, K; Karin, M; Sudo, T; Kasuya, Y				Takanami-Ohnishi, Y; Amano, S; Kimura, S; Asada, S; Utani, A; Maruyama, M; Osada, H; Tsunoda, H; Irukayama-Tomobe, Y; Goto, K; Karin, M; Sudo, T; Kasuya, Y			Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MAP KINASE; MESSENGER-RNA; FACTOR-ALPHA; GAMMA PRODUCTION; MURINE MODEL; T-CELLS; EXPRESSION; CYTOKINE; INDUCTION	The present study was designed to elucidate the role of p38 mitogen-activated protein kinase (p38) in the pathogenesis of inflammation, using a mouse contact hypersensitivity (CHS) model induced by 2,4-dinitro-1-fluorobenzene (DNFB). Ear swelling was induced by challenge with DNFB, accompanied by infiltration of mononuclear cells, neutrophils, and eosinophils and a marked increase in mRNA levels of cytokines such as interleukin (IL)-2, interferon (IFN)-gamma, IL-4, IL-5, IL-1beta, IL-18, and tumor necrosis factor-alpha in the challenged ear skin. Both ear swelling and the number of infiltrated cells in DNFB-challenged ear skin were significantly inhibited by treatment with SB202190, a p38 inhibitor. Furthermore, the DNFB-induced expression of all cytokines except IL-4 was significantly inhibited by treatment with SB202190. Ribonuclease protection assay revealed that the mRNA levels of chemokines such as IP-10 and MCP-1 in ear skin were markedly increased at 24 h after challenge with DNFB. The induction of these chemokines was significantly inhibited by treatment with SB202190. In p38alpha +/- mice, both ear swelling and infiltration of cells induced by DNFB were reduced compared with those in wild-type mice. However, induction of cytokines by DNFB was also observed in p38alpha +/- mice, although the induction of IFN-gamma, IL-5, and IL-18 was typically reduced compared with that in wild-type mice. Challenge with DNFB slightly induced IP-10 and MCP-1 mRNA in p38alpha +/- mice, with weaker signals than those in SB202190-treated wild-type mice. These results suggest that p38 plays a key role in CHS and is an important target for the treatment of CHS.	Chiba Univ, Dept Biochem & Mol Pharmacol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Dept Dermatol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Obstet & Gynecol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Cardiol, Inst Clin Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Dept Pharmacol, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Chiba University; Chiba University; RIKEN; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of California System; University of California San Diego	Kasuya, Y (corresponding author), Chiba Univ, Dept Biochem & Mol Pharmacol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	kasuya@faculty.chiba-u.jp	Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Kasuya, Yoshitoshi/0000-0003-0614-5836; Kimura, Sadao/0000-0001-6768-7474				Abe M, 1996, J INVEST DERMATOL, V107, P360, DOI 10.1111/1523-1747.ep12363337; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Foey AD, 1998, J IMMUNOL, V160, P920; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Hale KK, 1999, J IMMUNOL, V162, P4246; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KONDO S, 1995, J INVEST DERMATOL, V105, P334, DOI 10.1111/1523-1747.ep12320329; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mori A, 1999, J IMMUNOL, V163, P4763; Nagai H, 1999, J PHARMACOL EXP THER, V288, P43; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Rand ML, 1996, AM J PATHOL, V148, P855; Riemann H, 1996, J IMMUNOL, V156, P1799; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schwarz T, 1995, RES IMMUNOL, V146, P494, DOI 10.1016/0923-2494(96)83022-7; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Stoll S, 1997, J IMMUNOL, V159, P298; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tomobe YI, 2000, LIPIDS, V35, P61, DOI 10.1007/s11745-000-0495-0; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; Yamazaki S, 1997, YAKUGAKU ZASSHI, V117, P155, DOI 10.1248/yakushi1947.117.3_155; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	48	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37896	37903		10.1074/jbc.M207326200	http://dx.doi.org/10.1074/jbc.M207326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138127	hybrid			2022-12-27	WOS:000178447100126
J	Hirohawa, G; Kiel, MC; Muto, A; Kawai, G; Igarashi, K; Kaji, H; Kaji, A				Hirohawa, G; Kiel, MC; Muto, A; Kawai, G; Igarashi, K; Kaji, H; Kaji, A			Binding of ribosome recycling factor to ribosomes, comparison with tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; ELONGATION-FACTOR-G; SOLUBLE RIBONUCLEIC-ACID; DEACYLATED TRANSFER-RNA; CRYSTAL-STRUCTURE; MESSENGER-RNA; FACTOR RRF; 70S RIBOSOME; 4TH STEP; E-SITE	The prokaryotic post-termination ribosomal complex is disassembled by ribosome recycling factor (RRF) and elongation factor G. Because of the structural similarity of RRF and tRNA, we compared the biochemical characteristics of RRF binding to ribosomes with that of tRNA. Unesterified tRNA inhibited the disassembly of the post-termination complex in a competitive manner with RRF, suggesting that RRF binds to the A-site. Approximately one molecule of ribosome-bound RRF was detected after isolation of the RRF-ribosome complex. RRF and unesterified tRNA similarly inhibited the binding of N-acetylphenylalanyl-tRNA to the P-site of nonprogrammed but not programmed ribosomes. Under the conditions in which unesterified tRNA binds to both the P- and E-sites of non-programmed ribosomes, RRF inhibited 50% of the tRNA binding, suggesting that RRF does not bind to the E-site. The results are consistent with the notion that a single RRF binds to the A- and P-sites in a somewhat analogous manner to the A/P-site bound peptidyl tRNA. The binding of RRF and tRNA to ribosomes was influenced by Mg2+ and NH4+ ions in a 4 similar manner.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Clin Biochem, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Dept Ind Chem, Narashino, Chiba 2758588, Japan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	University of Pennsylvania; Chiba University; Chiba Institute of Technology; Jefferson University	Kaji, A (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Room 203B,Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	kaji@mail.med.upenn.edu		Igarashi, Kazuei/0000-0003-3751-3187	CGH CDC HHS [1-R01-GH-60429-01A2] Funding Source: Medline	CGH CDC HHS		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BONINCONTRO A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P27, DOI 10.1016/0167-4781(93)90088-U; CANNON M, 1963, J MOL BIOL, V7, P360, DOI 10.1016/S0022-2836(63)80030-3; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CELANO B, 1988, EUR J BIOCHEM, V178, P351, DOI 10.1111/j.1432-1033.1988.tb14457.x; CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; Frank J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P45; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; HIRASHIM.A, 1970, BIOCHEM BIOPH RES CO, V41, P877, DOI 10.1016/0006-291X(70)90165-8; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; IGARASHI K, 1970, EUR J BIOCHEM, V14, P41, DOI 10.1111/j.1432-1033.1970.tb00258.x; IGARASHI K, 1967, P NATL ACAD SCI USA, V58, P1971, DOI 10.1073/pnas.58.5.1971; Inokuchi Y, 2000, EMBO J, V19, P3788, DOI 10.1093/emboj/19.14.3788; Janosi L, 2000, J MOL BIOL, V295, P815, DOI 10.1006/jmbi.1999.3401; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; Kaji A, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P527; Kaji A, 2001, COLD SPRING HARB SYM, V66, P515, DOI 10.1101/sqb.2001.66.515; KAJI A, 1963, BIOCHEM BIOPH RES CO, V13, P186, DOI 10.1016/0006-291X(63)90279-1; KAJI A, 1968, METHODS ENZYMOLOGY B, V12, P692; KAJI H, 1966, J BIOL CHEM, V241, P1251; KAJI H, 1966, J MOL BIOL, V18, P219, DOI 10.1016/S0022-2836(66)80242-5; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Kim KK, 2000, EMBO J, V19, P2362, DOI 10.1093/emboj/19.10.2362; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUNG HF, 1977, P NATL ACAD SCI USA, V74, P3217, DOI 10.1073/pnas.74.8.3217; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; PESTKA S, 1966, J MOL BIOL, V21, P145, DOI 10.1016/0022-2836(66)90085-4; Rao AR, 2001, EMBO J, V20, P2977, DOI 10.1093/emboj/20.11.2977; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1980, BIOCHEM INT, V1, P297; Rodnina PV, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P301; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; Spirin AS, 1999, RIBOSOMES; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; SUZUKA I, 1966, P NATL ACAD SCI USA, V55, P1483, DOI 10.1073/pnas.55.6.1483; TANAKA S, 1972, J BIOL CHEM, V247, P45; Toyoda T, 2000, RNA, V6, P1432, DOI 10.1017/S1355838200001060; TRAUB P, 1969, J MOL BIOL, V40, P391, DOI 10.1016/0022-2836(69)90161-2; Wilson DN, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P495; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	61	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35847	35852		10.1074/jbc.M206295200	http://dx.doi.org/10.1074/jbc.M206295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138121	hybrid			2022-12-27	WOS:000178275100013
J	Krasnoperov, V; Bittner, MA; Mo, WJ; Buryanovsky, L; Neubert, TA; Holz, RW; Ichtchenko, K; Petrenko, AG				Krasnoperov, V; Bittner, MA; Mo, WJ; Buryanovsky, L; Neubert, TA; Holz, RW; Ichtchenko, K; Petrenko, AG			Protein-tyrosine phosphatase-sigma is a novel member of the functional family of alpha-latrotoxin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CALCIUM-INDEPENDENT RECEPTOR; WIDOW SPIDER VENOM; TRANSMITTER RELEASE; COUPLED RECEPTORS; PTP-SIGMA; PLASMA-MEMBRANE; MICE LACKING; SECRETION; EXOCYTOSIS	Receptor-like protein-tyrosine phosphatase sigma (PTPsigma) is essential for neuronal development and function. Here we report that PTPsigma is a target of a-latrotoxin, a strong stimulator of neuronal exocytosis. a-Latrotoxin binds to the cell adhesion-like extracellular region of PTPsigma. This binding results in the stimulation of exocytosis. The toxin-binding site is located in the C-terminal part of the PTPsigma ectodomain and includes two fibronectin type III repeats. The intracellular catalytic domains of PTPsigma are not required for the alpha-latrotoxin binding and secretory response triggered by the toxin in chromaffin cells. These features of PTPsigma resemble two other previously described alpha-latrotoxin receptors, neurexin and CIRL. Thus, alpha-latrotoxin represents an unusual example of the neurotoxin that has three independent, equally potent, and yet structurally distinct targets. The known structural and functional characteristics of PTPsigma, neurexin, and CIRL suggest that they define a functional family of neuronal membrane receptors with complementary or converging roles in presynaptic function via a mechanism that involves cell-to-cell and cell-to-matrix interaction.	NYU, Med Ctr, Dept Pharmacol, Sch Med, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosci, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; Univ Michigan, Med Ctr, Dept Pharmacol, Ann Arbor, MI 48109 USA	New York University; New York University; New York University; New York University; University of Michigan System; University of Michigan	Petrenko, AG (corresponding author), NYU, Med Ctr, Dept Pharmacol, Sch Med, 550 1st Ave,MSB-320A, New York, NY 10016 USA.			Ichtchenko, Konstantin/0000-0002-2198-1325	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098, R01NS034937] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK27959] Funding Source: Medline; NIGMS NIH HHS [R01GM59699] Funding Source: Medline; NINDS NIH HHS [R01NS35098, R01NS34937] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Bittner MA, 1998, J NEUROSCI, V18, P2914; CECCARELLI B, 1979, J CELL BIOL, V81, P163, DOI 10.1083/jcb.81.1.163; DUNN LA, 1983, J BIOL CHEM, V258, P4989; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Khvotchev M, 2000, EMBO J, V19, P3250, DOI 10.1093/emboj/19.13.3250; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, BRAIN RES, V799, P55, DOI 10.1016/S0006-8993(98)00467-3; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; PAN MG, 1993, J BIOL CHEM, V268, P19284; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1993, FEBS LETT, V325, P81, DOI 10.1016/0014-5793(93)81418-Y; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tobaben S, 2002, J BIOL CHEM, V277, P6359, DOI 10.1074/jbc.M111231200; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WICK PF, 1993, J BIOL CHEM, V268, P10983; WILSON SP, 1995, ANAL BIOCHEM, V226, P212, DOI 10.1006/abio.1995.1216; YAN H, 1993, J BIOL CHEM, V268, P24880; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	45	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35887	35895		10.1074/jbc.M205478200	http://dx.doi.org/10.1074/jbc.M205478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12110683	hybrid			2022-12-27	WOS:000178275100018
J	Mello, LV; de Groot, BL; Li, SL; Jedrzejas, MJ				Mello, LV; de Groot, BL; Li, SL; Jedrzejas, MJ			Structure and flexibility of Streptococcus agalactiae hyaluronate lyase complex with its substrate - Insights into the mechanism of processive degradation of hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; ESSENTIAL DYNAMICS; DOMAIN MOTIONS; ACTION PATTERN; EXPRESSION; GENE; SITE; MUTAGENESIS	Streptococcus agalactiae hyaluronate lyase degrades primarily hyaluronan, the main polysaccharide component of the host connective tissues, into unsaturated disaccharide units as the end product. Such function of the enzyme destroys the normal connective tissue structure of the host and exposes the tissue cells to various bacterial toxins. The crystal structure of hexasaccharide hyaluronan complex with the S. agalactiae hyaluronate lyase was determined at 2.2 Angstrom resolution; the mechanism of the catalytic process, including the identification of specific residues involved in the degradation of hyaluronan, was clearly identified. The enzyme is composed structurally and functionally from two distinct domains, an alpha-helical alpha-domain and a beta-sheet beta-domain. The flexibility of the protein was investigated by comparing the crystal structures of the S. agalactiae and the Streptococcus pneumoniae enzymes, and by using essential dynamics analyses of CONCOORD computer simulations. These revealed important modes of flexibility, which could be related to the protein function. First, a rotation/twist of the a-domain relative to the beta-domain is potentially related to the mechanism of processivity of the enzyme; this twist motion likely facilitates shifting of the ligand along the catalytic site cleft in order to reposition it to be ready for further cleavage. Second, a movement of the alpha- and beta-domains with respect to each other was found to contribute to a change in electrostatic characteristics of the enzyme and appears to facilitate binding of the negatively charged hyaluronan ligand. Third, an opening/closing of the substrate binding cleft brings a catalytic histidine closer to the cleavable substrate beta1,4,-glycosidic bond. This opening/closing mode also reflects the main conformational difference between the crystal structures of the S. agalactiae and the S. pneumoniae hyaluronate lyases.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; EMBRAPA, Natl Ctr Genet Resources & Biotechnol, Cenargen, BR-70770900 Brasilia, DF, Brazil; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Max Planck Society; University of Alabama System; University of Alabama Birmingham	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COURTISS EH, 1995, PLAST RECONSTR SURG, V95, P876, DOI 10.1097/00006534-199595050-00017; de Groot BL, 1999, J MOL BIOL, V286, P1241, DOI 10.1006/jmbi.1998.2568; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gase K, 1998, BBA-GENE STRUCT EXPR, V1398, P86, DOI 10.1016/S0167-4781(98)00045-1; GREILING H, 1975, CONNECT TISSUE RES, V3, P135, DOI 10.3109/03008207509152171; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 1997, PROTEINS, V27, P425, DOI 10.1002/(SICI)1097-0134(199703)27:3<425::AID-PROT10>3.0.CO;2-N; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2000, ACTA CRYSTALLOGR D, V56, P460, DOI 10.1107/S0907444900000706; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kleinjung J, 2000, FEBS LETT, V470, P257, DOI 10.1016/S0014-5793(00)01295-3; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labrou NE, 2001, BIOCHEM J, V358, P101, DOI 10.1042/0264-6021:3580101; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LIN B, 1994, J BIOL CHEM, V269, P30113; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Rolland K, 1999, J CLIN MICROBIOL, V37, P1892, DOI 10.1128/JCM.37.6.1892-1898.1999; Schappach A, 2001, PHARMAZIE, V56, P435; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	53	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36678	36688		10.1074/jbc.M205140200	http://dx.doi.org/10.1074/jbc.M205140200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130645	hybrid, Green Submitted			2022-12-27	WOS:000178275100114
J	Nusser, N; Gosmanova, E; Zheng, Y; Tigyi, G				Nusser, N; Gosmanova, E; Zheng, Y; Tigyi, G			Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURITE RETRACTION; GUANOSINE TRIPHOSPHATASES; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION; FAMILY GTPASES; AXON GUIDANCE; RAS; KINASE; PROTEIN; ACTIVATION	In PC12 rat pheochromocytoma cells, nerve growth factor (NGF)-induced neuronal differentiation is blocked by constitutively active dominant mutants of RhoA but augmented by negative ones, suggesting a not yet elucidated inhibitory signaling link between NGF receptors and RhoA. Here we show that NGF treatment rapidly translocates RhoA from the plasma membrane to the cytosol and simultaneously decreases RhoA affinity to its target Rho-associated kinase (ROK), a key mediator of neurite outgrowth. This effect was transient, because after 2 days of NGF treatment, RhoA relocated from the cytosol to the plasma membrane, and its GTP loading returned to a level found in undifferentiated cells. Inhibition of RhoA is mediated by activation of the TrkA receptor, because NGF failed to induce RhoA translocation and inhibition of ROK binding in nnr5 cells that lack TrkA, whereas the inhibition was reconstituted in receptor add-back B5 cells. In MM17-26 cells, which due to expression of dominant negative Ras do not differentiate, NGF-stimulated transient RhoA inhibition was unaffected. The inhibitory pathway from TrkA to RhoA involves phosphatidylinositol-3-kinase (PI3K), because the inhibitors LY294002 or wortmannin prevented NGF-induced RhoA translocation and increased RhoA association with ROK. Furthermore, inhibition of PI3K significantly - reduced NGF-mediated Rac1 activation, whereas dominant negative Rac1 abolished the inhibitory signaling to RhoA. Taken together, these data indicate that NGF-mediated activation of TrkA receptor stimulates PI3K, which in turn increases Racl activity to induce transient RhoA inactivation during the initial phase of neurite outgrowth.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Pecs, Sch Med, Dept Biol, H-7643 Pecs, Hungary	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Pecs	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boglari G, 2001, EUR J NEUROSCI, V14, P1445, DOI 10.1046/j.0953-816x.2001.01787.x; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P537; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	37	101	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35840	35846		10.1074/jbc.M203617200	http://dx.doi.org/10.1074/jbc.M203617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133829	hybrid			2022-12-27	WOS:000178275100012
J	Tan, SL; Tareen, SU; Melville, MW; Blakely, CM; Katze, MG				Tan, SL; Tareen, SU; Melville, MW; Blakely, CM; Katze, MG			The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA-BINDING; VIRUS NS1 PROTEIN; TRANSLATION INITIATION; REGULATORY SUBUNIT; MALIGNANT-TRANSFORMATION; GAMMA(1)34.5 PROTEIN; INTERFERON; PHOSPHATASE; ACTIVATION; PHOSPHORYLATION	The PKR protein kinase is among the best-studied effectors of the host interferon (IFN)-induced antiviral and antiproliferative response system. In response to stress signals, including virus infection, the normally latent PKR becomes activated through autophosphorylation and dimerization and phosphorylates the eIF2alpha translation initiation factor subunit, leading to an inhibition of mRNA translation initiation. While numerous virally encoded or modulated proteins that bind and inhibit PKR during virus infection have been studied, little is known about the cellular proteins that counteract PKR activity in uninfected cells. Overexpression of PKR in yeast also leads to an inhibition of eIF2alpha-dependent protein synthesis, resulting in severe growth suppression. Screening of a human cDNA library for clones capable of counteracting the PKR-mediated growth defect in yeast led to the identification of the catalytic subunit (PP1(C)) of protein phosphatase 1alpha. PP1(C) reduced double-stranded RNA-mediated auto-activation of PKR and inhibited PKR transphosphorylation activities. A specific and direct interaction between PP1(C) and PKR was detected, with PP1C binding to the N-terminal regulatory region regardless of the double-stranded RNA-binding activity of PKR. Importantly, a consensus motif shared by many PP1(C)-interacting proteins was necessary for PKR binding to PP1(C). The PKR-interactive site was mapped to a C-terminal non-catalytic region that is conserved in the PP1(C)2 isoform. Indeed, co-expression of PP1(C) or PP1(C)2 inhibited PKR dimer formation in Escherichia coli. Interestingly, co-expression of a PP1(C) mutant lacking the catalytic domain, despite retaining its ability to bind PKR, did not prevent PKR dimerization. Our findings suggest that PP1(C) modulates PKR activity via protein dephosphorylation and subsequent disruption of PKR dimers.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tan, SL (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Infect Dis Res, Indianapolis, IN 46285 USA.	tan_seng-lai@lilly.com			NIAID NIH HHS [AI22646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Cohen PTW, 2002, J CELL SCI, V115, P241; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HERSHEY J, 1996, TRANSLATIONAL CONTRO, P139; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PETRYSHYN R, 1982, P NATL ACAD SCI-BIOL, V79, P6512, DOI 10.1073/pnas.79.21.6512; Ragolia L, 2000, J BIOL CHEM, V275, P26102, DOI 10.1074/jbc.M001955200; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Salzberg S, 2000, EXP CELL RES, V254, P45, DOI 10.1006/excr.1999.4721; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; Tam NWN, 1999, EUR J BIOCHEM, V262, P149, DOI 10.1046/j.1432-1327.1999.00360.x; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1998, J INTERF CYTOK RES, V18, P757, DOI 10.1089/jir.1998.18.757; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tan SL, 1998, METHODS, V15, P207, DOI 10.1006/meth.1998.0625; Taylor DR, 2001, J VIROL, V75, P1265, DOI 10.1128/JVI.75.3.1265-1273.2001; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang J, 2002, J BIOL CHEM, V277, P46035, DOI 10.1074/jbc.M208519200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	63	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36109	36117		10.1074/jbc.M205109200	http://dx.doi.org/10.1074/jbc.M205109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138106	hybrid			2022-12-27	WOS:000178275100045
J	Todt, JC; Hu, B; Punturieri, A; Sonstein, J; Polak, T; Curtis, JL				Todt, JC; Hu, B; Punturieri, A; Sonstein, J; Polak, T; Curtis, JL			Activation of protein kinase C beta II by the stereo-specific phosphatidylserine receptor is required for phagocytosis of apoptotic thymocytes by resident murine tissue macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY IMMUNE-RESPONSE; ALVEOLAR MACROPHAGES; IN-VITRO; T-CELLS; MEMBRANE PHOSPHATIDYLSERINE; ARACHIDONATE METABOLISM; HUMAN NEUTROPHILS; NADPH OXIDASE; PKC ISOFORMS; ANNEXIN-V	We showed previously that protein kinase C (PKC) is required for phagocytosis of apoptotic leukocytes by murine alveolar (AMO) and peritoneal macrophages (PMphi) and that such phagocytosis is markedly lower in AMO compared with PMphi. In this study, we examined the roles of individual PKC isoforms in phagocytosis of apoptotic thymocytes by these two Mphi populations. By immunoblotting, Mphi expressed equivalent PKC eta but lower amounts of other isoforms (alpha, betaI, betaII, delta, epsilon, mu, and zeta), with the greatest difference in betaII expression. A requirement for PKC betaII for phagocytosis was demonstrated collectively by phorbol 12-myristate 13-acetate-induced depletion of PKC beta11, by dose-response to PKC inhibitor Ro-32-0432, and by use of PKC beta11 myristoylated peptide as a blocker. Exposure of PMphi to phosphatidylserine (PS) liposomes specifically induced translocation of PKC beta11 and other isoforms to membranes and cytoskeleton. Both AMO and PMphi expressed functional PS receptor, blockade of which inhibited PKC beta11 translocation. Our results indicate that murine tissue Mphi require PKC beta11 for phagocytosis of apoptotic cells, which differs from the PKC isoform requirement previously described in Mphi phagocytosis of other particles, and imply that a crucial action of the PS receptor in this process is PKC 1311 activation.	Vet Affairs Med Ctr, Pulm & Crit Care Med Sect 506111G, Med Serv, Ann Arbor, MI 48105 USA; Univ Michigan, Hlth Care Syst, Grad Program Immunol, Ann Arbor, MI 48105 USA; Univ Michigan, Hlth Care Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48105 USA; Univ Michigan, Hlth Care Syst, Ctr Comprehens Canc, Ann Arbor, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Curtis, JL (corresponding author), Vet Affairs Med Ctr, Pulm & Crit Care Med Sect 506111G, Med Serv, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.			Curtis, Jeffrey/0000-0001-5191-4847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061577, R01HL056309] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061577-03, R01 HL056309-06, R01 HL061577-04, R01 HL056309, R01 HL061577-02, R01 HL056309-05, R01 HL056309-04, R0-1 HL6157, R01 HL56309] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Ahnadi CE, 2000, J LEUKOCYTE BIOL, V68, P293; AKBAR AN, 1994, J EXP MED, V180, P1943, DOI 10.1084/jem.180.5.1943; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BALTER MS, 1989, J IMMUNOL, V142, P602; BIGBY TD, 1987, J IMMUNOL, V138, P1546; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Breton A, 2000, BIOCHEM BIOPH RES CO, V276, P472, DOI 10.1006/bbrc.2000.3511; Brody AR, 1998, J LAB CLIN MED, V131, P391, DOI 10.1016/S0022-2143(98)90138-X; Brumell JH, 1999, J IMMUNOL, V163, P3388; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Corsini E, 2001, IMMUNOL LETT, V76, P89, DOI 10.1016/S0165-2478(00)00327-8; CURTIS JL, 1995, AM J RESP CELL MOL, V12, P520, DOI 10.1165/ajrcmb.12.5.7537969; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HANCE AJ, 1985, J IMMUNOL, V134, P284; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; Heale JP, 2001, J LEUKOCYTE BIOL, V69, P158; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HOMBURG CHE, 1995, BLOOD, V85, P532; Hu B, 2002, J LEUKOCYTE BIOL, V71, P881; Hu B, 2000, J IMMUNOL, V165, P2124, DOI 10.4049/jimmunol.165.4.2124; Keenan C, 1997, FEBS LETT, V415, P101, DOI 10.1016/S0014-5793(97)01104-6; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Larsen EC, 2000, J IMMUNOL, V165, P2809, DOI 10.4049/jimmunol.165.5.2809; Licht R, 1999, J IMMUNOL METHODS, V223, P237, DOI 10.1016/S0022-1759(98)00212-9; LIPSCOMB MF, 1986, J IMMUNOL, V136, P497; LIPSCOMB MF, 1997, LUNG MACROPHAGES DEN, V107; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Mancuso P, 2000, AM J RESP CELL MOL, V23, P727, DOI 10.1165/ajrcmb.23.6.4246; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonald PP, 1999, J IMMUNOL, V163, P6164; Melendez AJ, 1999, IMMUNOLOGY, V96, P457; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; Mochly-Rosen D, 1998, FASEB J, V12, P35; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nixon JB, 1999, J IMMUNOL, V163, P4574; PERRY DG, 1995, J IMMUNOL METHODS, V181, P269, DOI 10.1016/0022-1759(95)00011-X; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; Platt N, 1999, IMMUNOL LETT, V65, P15, DOI 10.1016/S0165-2478(98)00118-7; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RAZ A, 1981, CANCER RES, V41, P487; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHLEGEL RA, 1993, IMMUNOL LETT, V36, P283, DOI 10.1016/0165-2478(93)90101-7; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Slater SJ, 2000, BIOCHEMISTRY-US, V39, P271, DOI 10.1021/bi9916527; St-Denis A, 1999, J IMMUNOL, V163, P5505; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Stern M, 1996, AM J PATHOL, V149, P911; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Tait JF, 1999, J BIOL CHEM, V274, P3048, DOI 10.1074/jbc.274.5.3048; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; Uchimura E, 1997, BIOCHEM BIOPH RES CO, V239, P799, DOI 10.1006/bbrc.1997.7556; UPHAM JW, 1995, IMMUNOLOGY, V84, P142; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; YOSHIKAWA K, 1991, MICROBIOL IMMUNOL, V35, P803, DOI 10.1111/j.1348-0421.1991.tb01613.x; ZAR JH, 1974, BIOSTAT ANAL, P122	82	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35906	35914		10.1074/jbc.M202967200	http://dx.doi.org/10.1074/jbc.M202967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114511	hybrid, Green Accepted			2022-12-27	WOS:000178275100020
J	Baldin, V; Pelpel, K; Cazales, M; Cans, C; Ducommun, B				Baldin, V; Pelpel, K; Cazales, M; Cans, C; Ducommun, B			Nuclear localization of CDC25B1 and serine 146 integrity are required for induction of mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PHOSPHATASE; PHOSPHORYLATION; ACTIVATION; TYROSINE; TRIGGERS; PROTEIN; PHASE; TRANSITION; HOMOLOG	CDC25B phosphatases are essential regulators that control cyclin-dependent kinases activities at the entry into mitosis. In this study, we demonstrate that serine 146 is required for two crucial features of CDC25B1. It is essential for CDC25B1 to function as a mitotic inducer and to prevent CDC25B1 export from the nucleus. We also show that serine 146 is phosphorylated in vitro by CDK1-cyclin B. However, phosphorylation of CDC25B does not stimulate its phosphatase activity, and mutation of serine 146 had no effect on its catalytic activity. Serine 146 phosphorylation is proposed to be a key event in the regulation of the CDC25B function in the initiation of mammalian mitosis.	Univ Toulouse 3, LBCMCP, CNRS, UMR5088, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ducommun, B (corresponding author), Univ Toulouse 3, LBCMCP, CNRS, UMR5088, 118 Route Narbonne, F-31077 Toulouse, France.	ducommun@cict.fr	BALDIN, Véronique/Y-8397-2019; Cans, Christine/M-6153-2014; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; Cans, Christine/0000-0003-3071-9959; DUCOMMUN, Bernard/0000-0002-7126-8368				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lammer C, 1998, J CELL SCI, V111, P2445; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Takemasa I, 2000, CANCER RES, V60, P3043; Wegener S, 2000, EUR J CELL BIOL, V79, P810, DOI 10.1078/0171-9335-00115	30	21	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35176	35182		10.1074/jbc.M204430200	http://dx.doi.org/10.1074/jbc.M204430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107172	hybrid, Green Published			2022-12-27	WOS:000178117000067
J	Gallinaro, L; Crovatto, K; Rampazzo, C; Pontarin, G; Ferraro, P; Milanesi, E; Reichard, P; Bianchi, V				Gallinaro, L; Crovatto, K; Rampazzo, C; Pontarin, G; Ferraro, P; Milanesi, E; Reichard, P; Bianchi, V			Human mitochondrial 5 '-deoxyribonucleotidase - Overproduction in cultured cells and functional aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-M 5'-NUCLEOTIDASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; THYMIDINE KINASE; MAMMALIAN-CELLS; PROTEIN; GENE; CDNA; ENZYME; 5'(3')-DEOXYRIBONUCLEOTIDASE	Deoxynucleoside triphosphates (dNTPs) used for mitochondrial DNA replication are mainly formed by phosphorylation of deoxynucleosides imported into mitochondria from the cytosol. We earlier obtained evidence for a mitochondrial 5'-nucleotidase (dNT2) with a pronounced specificity for dUMP and dTMP and suggested that the enzyme protects mitochondrial DNA replication from excess dTTP. In humans, accumulation of dTTP causes a mitochondrial. genetic disease. We now establish that dNT2 in vivo indeed is located in mitochondria. The native enzyme shows the same substrate specificity and affinity for inhibitors as the recombinant dNT2. We constructed ponasterone-inducible cell lines overproducing dNT2 with and without the green fluorescent protein (GFP) linked to its C terminus. The fusion protein occurred in mitochondria mostly in an inactive truncated form, with only a short C-terminal fragment of dNT2 linked to GFP. No truncation occurred when dNT2 and GFP were not linked. The cell mitochondria then contained a large excess of active dNT2 with or without the mitochondrial presequence. After removal of ponasterone overproduced dNT2 disappeared only slowly from the cells, whereas dNT2-mRNA was lost rapidly. Overproduction of dNT2 did not lead to an increased excretion of pyrimidine deoxyribonucleosides, in contrast to overproduction of the corresponding cytosolic deoxynucleotidase, suggesting that the mitochondrial enzyme does not affect overall cellular deoxynucleotide turnover.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy; Karolinska Inst, Dept Biochem, S-17177 Stockholm, Sweden	University of Padua; University of Padua; Karolinska Institutet	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.				Telethon [GP0140Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Amici A, 2000, BLOOD, V96, P1596, DOI 10.1182/blood.V96.4.1596.h8001596_1596_1598; Ausenda C, 1996, Methods Enzymol, V264, P122, DOI 10.1016/S0076-6879(96)64013-0; BEASLEY E M, 1992, Current Opinion in Cell Biology, V4, P646, DOI 10.1016/0955-0674(92)90084-P; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; Endova M, 1998, TETRAHEDRON, V54, P11187, DOI 10.1016/S0040-4020(98)00654-1; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Gazziola C, 1999, EXP CELL RES, V253, P474, DOI 10.1006/excr.1999.4681; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Lee C. P., 1993, V2, P41; Liboska R, 1996, COLLECT CZECH CHEM C, V61, P313, DOI 10.1135/cccc19960313; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 2002, BIOCHEM BIOPH RES CO, V293, P258, DOI 10.1016/S0006-291X(02)00206-1; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Sala-Newby GB, 2001, BBA-GENE STRUCT EXPR, V1521, P12, DOI 10.1016/S0167-4781(01)00278-0; Sambrook J., 2002, MOL CLONING LAB MANU; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6	30	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35080	35087		10.1074/jbc.M203755200	http://dx.doi.org/10.1074/jbc.M203755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124385	hybrid			2022-12-27	WOS:000178117000054
J	Morales, O; Faulds, MH; Lindgren, UJ; Haldosen, LA				Morales, O; Faulds, MH; Lindgren, UJ; Haldosen, LA			1 alpha,25-dihydroxyvitamin D-3 inhibits GH-induced expression of SOCS-3 and CIS and prolongs growth hormone signaling via the Janus kinase (JAK2)/signal transducers and activators of transcription (STAT5) system in osteoblast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; BODY GROWTH; RECEPTOR; LIVER; RAT; PROTEINS; MICE; BONE; SUPPRESSOR; MECHANISMS	Growth hormone (GH) and 1alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) are regulators of bone growth and bone metabolism. In target cells, GH activates several signaling pathways, among them the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway. GH mainly activates JAK2 and STAT5a and b. The effects of 1,25-(OH)(2)D-3 are mediated via a nuclear receptor, the vitamin D receptor, which, when bound by 1,25-(OH)(2)D-3, activates the transcription of target genes. In earlier studies (Morel, G., Chavassieux, P., Barenton, B., Dubois, P. M., Meunier, P. J., and Boivin, G. (1993) Cell Tissue Res. 273, 279-286) synergistic interaction between 1,25-(OH)(2)D-3 and GH regarding expression of osteoblastic markers has been described. The UMR 106 cell line is a rat osteosarcoma cell line with osteoblast-like properties. We have recently shown (Morales, O., Lindgren, U., and Haldosen, L. A. (2000) J. Bone Miner. Res. 15, 2284-2290) that UMR 106 cells express a GH-responsive JAK2/STAT5 signaling system. These cells also express the vitamin D receptor and respond to 1,25(OH)(2)D-3. In the present study we have investigated whether 1,25-(OH)(2)D-3 influences GH signaling via the JAK2/STAT5 pathway in UMR 106 cells. We found that 1,25-(OH)(2)D-3 prolonged GH signaling via the JAK2/STAT5 pathway. Pretreatment of cells with 1,25-(OH)(2)D-3 was also necessary in order to detect GH-induced STAT5 transcriptional response. Furthermore, the pretreatment of cells with 1,25-(OH)(2)D-3 rendered to the cells the capacity to respond to repetitive GH-stimulation. In UMR 106 cells, GH induced the expression of the JAK/STAT negative regulatory proteins SOCS-3 and CIS. Interestingly, pretreatment with 1,25-(OH)(2)D-3 inhibited GH-induced expression of these proteins. From these results we propose that 1,25-(OH)(2)D-3 has an inhibitory effect on negative regulatory pathways acting on JAK2 and/or STAT5 in UMR 106 cells and that this, in all or partly, explains the effects of 1,25-(OH)(2)D-3 on GH-signaling via the JAK/STAT pathway.	Huddinge Univ Hosp, Karolinska Inst, Dept Orthoped Surg, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Haldosen, LA (corresponding author), Huddinge Univ Hosp K54, Dept Orthoped Surg, S-14186 Huddinge, Sweden.	Lars-Arne.Haldosen@mednut.ki.se						BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHENU C, 1990, BONE, V11, P81, DOI 10.1016/8756-3282(90)90054-3; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gerland K, 2000, MOL CELL ENDOCRINOL, V168, P1, DOI 10.1016/S0303-7207(00)00314-2; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Horvat S, 2001, GENOMICS, V72, P209, DOI 10.1006/geno.2000.6441; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jaffe CA, 1998, J CLIN INVEST, V102, P153, DOI 10.1172/JCI2908; JANSSON JO, 1982, ACTA ENDOCRINOL-COP, V99, P24, DOI 10.1530/acta.0.0990024; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Langub MC, 2000, BONE, V27, P383, DOI 10.1016/S8756-3282(00)00335-5; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Mee AP, 1996, BONE, V18, P295, DOI 10.1016/8756-3282(96)00011-7; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; MODE A, 1993, J REPROD FERTIL, P77; Morales O, 2000, J BONE MINER RES, V15, P2284, DOI 10.1359/jbmr.2000.15.11.2284; MOREL G, 1993, CELL TISSUE RES, V273, P279, DOI 10.1007/BF00312829; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3	35	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34879	34884		10.1074/jbc.M204819200	http://dx.doi.org/10.1074/jbc.M204819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107179	hybrid			2022-12-27	WOS:000178117000030
J	Pan, ZZ; Bruening, W; Giasson, BI; Lee, VMY; Godwin, AK				Pan, ZZ; Bruening, W; Giasson, BI; Lee, VMY; Godwin, AK			gamma-Synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT ALPHA-SYNUCLEIN; SPORADIC PARKINSONS-DISEASE; LEWY BODIES; SIGNALING PATHWAYS; INDUCED ACTIVATION; ULTRAVIOLET-LIGHT; KINASE JNK; WILD-TYPE; EXPRESSION; BREAST	Synucleins are a family of highly conserved small proteins predominantly expressed in neurons. Recently we and others have found that gamma-synuclein is dramatically up-regulated in the vast majority of late-stage breast and ovarian cancers and that gamma-synuclein over-expression can enhance tumorigenicity. In the current study, we have found that gamma-synuclein is associated with two major mitogen-activated kinases (MAPKs), i.e. (e) under bar xtracellular signal-(r) under bar egulated protein (k) under bar inases (ERK1/2) and c-(J) under bar un (N) under bar -terminal (k) under bar inase 1 (JNK1), and have shown that over-expression of gamma-synuclein leads to constitutive activation of ERK1/2 and down-regulation of JNK1 in response to a host of environmental stress signals, including UV, arsenate, and heat shock. We also tested the effects of gamma-synuclein on apoptosis and activation of JNK and ERK in response to several chemotherapy drugs. We have found that gamma-synuclein-expressing cells are significantly more resistant to the chemotherapeutic drugs paclitaxel and vinblastine as compared with the parental cells. The resistance to paclitaxel can be partially obliterated when ERK activity is inhibited using a MEK1/2 inhibitor. Activation of JNK and its downstream caspase-3 by paclitaxel or vinblastine is significantly down-regulated in gamma-synuclein-expressing cells, indicating that the paclitaxel- or vinblastine-activated apoptosis pathway is blocked by gamma-synuclein. In contrast to paclitaxel and vinblastine, etoposide does not activate JNK, and gamma-synuclein over-expression has no apparent effect on this drug-induced apoptosis. Taken together, our data indicate that oncogenic activation of y-synuclein contributes to the development of breast and ovarian cancer by promoting tumor cell survival under adverse conditions and by providing res stance to certain chemotherapeutic drugs.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis, Philadelphia, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania	Godwin, AK (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave,Rm W322, Philadelphia, PA 19111 USA.	A_Godwin@fccc.edu	Pan, Zhong-Zong/B-6964-2012		NCI NIH HHS [P50 CA83638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; BOVE B, 2002, BREAST CANC PROGNOSI; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Buchman VL, 1998, J NEUROSCI, V18, P9335; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Giasson BI, 2001, EXP NEUROL, V172, P354, DOI 10.1006/exnr.2001.7805; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Mandlekar S, 2000, CANCER RES, V60, P5995; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Mizuno Y, 1998, ANN NEUROL, V44, pS99, DOI 10.1002/ana.410440715; Mukaetova-Ladinska EB, 2000, J NEUROPATH EXP NEUR, V59, P408, DOI 10.1093/jnen/59.5.408; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Shahin MS, 2000, CANCER, V89, P2006, DOI 10.1002/1097-0142(20001101)89:9<2006::AID-CNCR18>3.3.CO;2-Z; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; THORLACIUS S, 1995, EUR J CANCER, V31A, P1856, DOI 10.1016/0959-8049(95)00399-4; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	65	109	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35050	35060		10.1074/jbc.M201650200	http://dx.doi.org/10.1074/jbc.M201650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121974	hybrid			2022-12-27	WOS:000178117000051
J	Berwick, DC; Hers, I; Heesom, KJ; Moule, SK; Tavare, JM				Berwick, DC; Hers, I; Heesom, KJ; Moule, SK; Tavare, JM			The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INSULIN-STIMULATED PHOSPHORYLATION; EPIDIDYMAL FAT-CELLS; ADIPOSE-TISSUE; MOLECULAR-CLONING; SIGNALING PATHWAYS; ACTIVATION; PEPTIDE; SURVIVAL; TRANSLOCATION	Protein kinase B (Akt) plays a central role in cellular regulation, although many of the physiologically relevant substrates for the kinase remain to be identified. In this study, we have isolated a protein from primary epididymal adipocytes with an apparent molecular weight of 125,000. This protein exhibited immunoreactivity, in an insulin-dependent manner, with a phosphospecific antibody raised against the protein kinase B substrate consensus sequence RXRXX(pS/pT) as well as a phosphospecific antibody that recognizes serine 21/9 of GSK-3alpha/beta. MALDI-TOF mass spectrometry revealed the protein to be ATP-citrate lyase, suggesting that the two phosphospecific antibodies recognize phosphoserine 454, a previously reported insulin- and isoproterenol-stimulated ATP-citrate lyase phosphorylation site. Indeed, both insulin and isoproterenol stimulated the phosphorylation of this protein on the site recognized by the phosphospecific antibodies in a wortmannin-sensitive and -insensitive manner, respectively. In addition, transient expression of a constitutively active protein kinase B in primary adipocytes mimicked the effect of insulin on ATP-citrate lyase phosphorylation. Furthermore, ATP-citrate lyase was phosphorylated in vitro by recombinant protein kinase B on the same site. Taken together, these results demonstrate that serine 454 of ATP-citrate lyase is a novel and major in vivo substrate for protein kinase B.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Tavare, JM (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.		Berwick, Dan/J-2378-2012; Berwick, Dan/AAJ-7779-2021; Hers, Ingeborg/ABG-3357-2020	Berwick, Dan/0000-0002-7144-7841; Berwick, Dan/0000-0002-7144-7841; Hers, Ingeborg/0000-0002-6467-5715				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; AVRUCH J, 1985, MOL BASIS INSULIN AC, P263; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BENJAMIN WB, 1974, BIOCHIM BIOPHYS ACTA, V351, P28, DOI 10.1016/0005-2795(74)90063-4; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BROWNSEY RW, 1984, BIOCHEM J, V218, P733, DOI 10.1042/bj2180733; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Heesom KJ, 1997, DIABETOLOGIA, V40, pB3, DOI 10.1007/BF03168179; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Lawlor MA, 2001, J CELL SCI, V114, P2903; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PENTYALA SN, 1995, BIOCHEMISTRY-US, V34, P10961, DOI 10.1021/bi00035a001; PIERCE MW, 1981, J BIOL CHEM, V256, P8867; PIERCE MW, 1982, J BIOL CHEM, V257, P681; Potapova IA, 2000, BIOCHEMISTRY-US, V39, P1169, DOI 10.1021/bi992159y; RAMAKRISHNA S, 1979, J BIOL CHEM, V254, P9232; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; RAMAKRISHNA S, 1989, BIOCHEMISTRY-US, V28, P856, DOI 10.1021/bi00428a067; RAMAKRISHNA S, 1984, BIOCHEM BIOPH RES CO, V122, P1047, DOI 10.1016/0006-291X(84)91197-5; RAMAKRISHNA S, 1985, J BIOL CHEM, V260, P2280; RAMAKRISHNA S, 1983, J BIOL CHEM, V258, P4950; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; RANGANATHAN NS, 1980, ARCH BIOCHEM BIOPHYS, V204, P52, DOI 10.1016/0003-9861(80)90006-5; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; YU KT, 1990, BIOCHEM J, V268, P539, DOI 10.1042/bj2680539; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	45	263	278	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33895	33900		10.1074/jbc.M204681200	http://dx.doi.org/10.1074/jbc.M204681200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107176	hybrid			2022-12-27	WOS:000177959100050
J	Cheng, HC; Shih, HM; Chern, YJ				Cheng, HC; Shih, HM; Chern, YJ			Essential role of cAMP-response element-binding protein activation by A(2A) adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA PC12 CELLS; SIGNAL-TRANSDUCTION; CYCLIC-AMP; KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SURVIVAL; CREB	We found in the present study that stimulation of the A(2A) adenosine receptor (A(2A)-R) using an A(2A)-selective agonist (CGS21680) rescued the blockage of nerve growth factor (NGF)-induced neurite outgrowth when the NGF-evoked MAPK cascade was suppressed by an MEK inhibitor (PD98059) or by a dominant-negative MAPK mutant (dnMAPK). This action of A(2A)-R (designated as the A(2A)-rescue effect) can be blocked by two inhibitors of protein kinase A (PKA) and was absent in a PKA-deficient PC12 variant. Activation of the cAMP/ PKA pathway by forskolin exerted the same effect as that by A(2A)-R stimulation. PKA, thus, appears to mediate the A(2A)-rescue effect. Results from cAMP-response element-binding protein (CREB) phosphorylation at serine 133, trans-reporting assays, and overexpression of two dominant-negative CREB mutants revealed that A(2A)-R stimulation led to activation of CREB in a PKA-dependent manner and subsequently reversed the damage of NGF-evoked neurite outgrowth by PD98059 or dnMAPK. Expression of an active mutant of CREB readily rescued the NGF-induced neurite outgrowth impaired by dnMAPK, further strengthening the importance of CREB in the NGF-mediated neurite outgrowth process. Moreover, simultaneous activation of the A(2A)-R/PKA/ CREB-mediated and the phosphatidylinositol 3-kinase pathways caused neurite outgrowth that was not suppressed by a selective inhibitor of TrkA, indicating that transactivation of TrkA was not involved. Collectively, CREB functions in conjunction with the phosphatidylinositol 3-kinase pathway to mediate the neurite outgrowth process in PC12 cells.	Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 11221, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 11529, Taiwan.		chern, yijuang/S-7013-2018; Shih, Hsiu-Ming/S-7023-2018	chern, yijuang/0000-0002-5842-5429; 				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERG MM, 1992, J BIOL CHEM, V267, P13; Bizon JL, 1999, J COMP NEUROL, V408, P283; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cesare D., 1999, TRENDS BIOCHEM SCI, V24, P281; Chang YH, 1997, J NEUROCHEM, V69, P1300; Chen WS, 2001, MOL CELL BIOL, V21, P4636, DOI 10.1128/MCB.21.14.4636-4646.2001; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cochran B H, 1993, NIDA Res Monogr, V125, P3; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Etienne S, 1999, J IMMUNOL, V163, P3636; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Gibbs RB, 1997, BRAIN RES, V753, P141, DOI 10.1016/S0006-8993(97)00006-1; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gubitz AK, 1996, J NEUROCHEM, V67, P374; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hans A, 2001, J BIOL CHEM, V276, P7258, DOI 10.1074/jbc.M005107200; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; KIRK IP, 1994, J NEUROCHEM, V62, P960; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lambeng N, 1999, BRAIN RES, V821, P60, DOI 10.1016/S0006-8993(99)01061-6; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lee YC, 1999, J NEUROCHEM, V73, P1790, DOI 10.1046/j.1471-4159.1999.0731790.x; MOBLEY WC, 1989, NEURON, V3, P655, DOI 10.1016/0896-6273(89)90276-6; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Ribeiro JA, 1999, EUR J PHARMACOL, V375, P101, DOI 10.1016/S0014-2999(99)00230-7; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SETH A, 1992, J BIOL CHEM, V267, P24796; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SOBREVIELA T, 1994, J COMP NEUROL, V350, P587, DOI 10.1002/cne.903500407; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200	69	76	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33930	33942		10.1074/jbc.M201206200	http://dx.doi.org/10.1074/jbc.M201206200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114502	hybrid			2022-12-27	WOS:000177959100055
J	Brown, LJ; Koza, RA; Marshall, L; Kozak, LP; MacDonald, MJ				Brown, LJ; Koza, RA; Marshall, L; Kozak, LP; MacDonald, MJ			Lethal Hypoglycemic ketosis and glyceroluria in mice lacking both the mitochondrial and the cytosolic glycerol phosphate dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEFICIENCY; 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; MILK-COMPOSITION; GENE-EXPRESSION; METABOLISM; GLUCOSE; FAT; GLUCONEOGENESIS; KETOGENESIS; SECRETION	The activities of either the mitochondrial or cytosolic glycerol phosphate dehydrogenase (mGPD, cGPD) plus that of glycerol kinase are required for the use of glycerol in aerobic metabolism and gluconeogenesis. A knockout mouse lacking mGPD has reduced body weight and fertility but shows remarkably normal liver and muscle metabolite levels. The BALB/cHeA mouse strain, which lacks cGPD, breeds well and is phenotypically normal, although it demonstrates metabolite abnormalities in certain tissues. Crosses were made between these two strains, and mice were generated that lacked both dehydrogenases. These mice, although active and nursing well for several days, failed to grow, and usually died within the first week. Liver glycerol phosphate levels were elevated 30-fold, whereas liver ATP, ADP, and AMP levels were reduced by 30-40%. Plasma glycerol was elevated 30- to 50-fold to 30-50 mm, and urine glycerol exceeded 0.45 m (4% w/v). GPD-deficient mice were hypoglycemic, had a 50% increase in plasma free fatty acids, and developed ketonuria within the first day of life. Uncoupling protein-1 mRNA in brown adipose tissue was reduced 60%. These mice share some features of both glycerol kinase deficiency and hereditary fructose intolerance, suggesting the phenotype may be due to the combined effects of the loss of a gluconeogenic substrate, the osmotic effects of glycerol, and the metabolic effects of the accumulation of a phosphorylated metabolite.	Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	University of Wisconsin System; University of Wisconsin Madison; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Brown, LJ (corresponding author), Univ Wisconsin, Dept Pediat, 3550 MSC,1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER; NICHD NIH HHS [HD008431] Funding Source: Medline; NIDDK NIH HHS [DK 28348] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1968, BIOCHEM BIOPH RES CO, V30, P100, DOI 10.1016/0006-291X(68)90719-5; BERRY MN, 1973, EUR J BIOCHEM, V33, P407, DOI 10.1111/j.1432-1033.1973.tb02697.x; Brown LJ, 2002, J BIOL CHEM, V277, P32892, DOI 10.1074/jbc.M202408200; BURCH HB, 1970, J BIOL CHEM, V245, P2092; COOK JR, 1982, DEV BIOL, V92, P440, DOI 10.1016/0012-1606(82)90189-0; DELZER PR, 1983, CALCIFIED TISSUE INT, V35, P750, DOI 10.1007/BF02405118; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GITZELMANN R, 1995, METABOLIC MOL BASES, P905; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; HAYMOND MW, 1983, CLIN ENDOCRINOL META, V12, P447, DOI 10.1016/S0300-595X(83)80051-6; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Huq AHMM, 1997, HUM MOL GENET, V6, P1803, DOI 10.1093/hmg/6.11.1803; Jost B, 1999, NAT BIOTECHNOL, V17, P160, DOI 10.1038/6158; KNIGHT CH, 1986, COMP BIOCHEM PHYS A, V84, P127, DOI 10.1016/0300-9629(86)90054-X; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; LEE YP, 1965, J BIOL CHEM, V240, P1427; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; MASSON S, 1993, BIOCHEMISTRY-US, V32, P1025, DOI 10.1021/bi00055a005; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MORISCOT A, 1993, AM J PHYSIOL, V265, pE81, DOI 10.1152/ajpendo.1993.265.1.E81; NAGASAWA H, 1989, P SOC EXP BIOL MED, V191, P78, DOI 10.3181/00379727-191-42892; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P262; PROCHAZKA M, 1989, J BIOL CHEM, V264, P4679; ROBINSON J, 1969, BIOCHEM J, V112, P455, DOI 10.1042/bj1120455; Sjarif DR, 1998, J MED GENET, V35, P650, DOI 10.1136/jmg.35.8.650; Soumano K, 2000, MOL CELL ENDOCRINOL, V165, P7, DOI 10.1016/S0303-7207(00)00276-8; TETER BB, 1992, LIPIDS, V27, P912, DOI 10.1007/BF02535872; Walker AP, 1996, AM J HUM GENET, V58, P1205; WAPNIR RA, 1985, BIOCHEM MED METAB B, V33, P141, DOI 10.1016/0006-2944(85)90022-5; WAPNIR RA, 1982, METABOLISM, V31, P1057, DOI 10.1016/0026-0495(82)90152-4; WAPNIR RA, 1987, BIOCHEM MED METAB B, V37, P228, DOI 10.1016/0885-4505(87)90031-4; WILLIAMSON DH, 1969, BIOCHEM J, V114, P575, DOI 10.1042/bj1140575	39	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32899	32904		10.1074/jbc.M202409200	http://dx.doi.org/10.1074/jbc.M202409200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093800	hybrid			2022-12-27	WOS:000177859000067
J	Cui, W; Aslam, S; Fletcher, J; Wylie, D; Clinton, M; Clark, AJ				Cui, W; Aslam, S; Fletcher, J; Wylie, D; Clinton, M; Clark, AJ			Stabilization of telomere length and karyotypic stability are directly correlated with the level of hTERT gene expression in primary fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-CELLS; LIFE-SPAN; REPLICATIVE SENESCENCE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; CANCER; RNA; IMMORTALIZATION; DYSFUNCTION; INSTABILITY	Telomere shortening and lack of telomerase activity have been implicated in cellular senescence in human fibroblasts. Expression of the human telomerase (hTERT) gene in sheep fibroblasts reconstitutes telomerase activity and extends their lifespan. However, telomere length is not maintained in all cell lines, even though in vitro telomerase activity is restored in all of them. Cell lines expressing higher levels of hTERT mRNA do not exhibit telomere erosion or genomic instability. By contrast, fibroblasts expressing lower levels of hTERT do exhibit telomere shortening, although the telomeres eventually stabilize at a shorter length. The shorter telomere lengths and the extent of karyotypic abnormalities are both functions of hTERT expression level. We conclude that telomerase activity is required to bypass senescence but is not sufficient to prevent telomere erosion and genomic instability at lower levels of expression.	Roslin Inst, Dept Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Clark, AJ (corresponding author), Roslin Inst, Dept Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland.		Cui, Wei/AAD-1690-2019	Cui, Wei/0000-0003-2019-380X				Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cascio SM, 2001, ARTIF ORGANS, V25, P529, DOI 10.1046/j.1525-1594.2001.025007529.x; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Hodes R, 2001, P NATL ACAD SCI USA, V98, P7649, DOI 10.1073/pnas.151267698; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wright WE, 1996, DEV GENET, V18, P173; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yi XM, 2001, NUCLEIC ACIDS RES, V29, P4818, DOI 10.1093/nar/29.23.4818; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	34	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38531	38539		10.1074/jbc.M205981200	http://dx.doi.org/10.1074/jbc.M205981200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12122013	hybrid			2022-12-27	WOS:000178529600069
J	Shibayama, N; Miura, S; Tame, JRH; Yonetani, T; Park, SY				Shibayama, N; Miura, S; Tame, JRH; Yonetani, T; Park, SY			Crystal structure of horse carbonmonoxyhemoglobin-bezafibrate complex at 1.55-angstrom resolution - A novel allosteric binding site in R-state hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; T-STATE; INOSITOL HEXAPHOSPHATE; QUATERNARY STRUCTURES; HUMAN METHEMOGLOBIN; LIGAND-BINDING; OXYGEN; EFFECTORS; KINETICS; AFFINITY	Bezafibrate, an antilipidemic drug, is known as a potent allosteric effector of hemoglobin. The previously proposed mechanism for the allosteric potency of this drug was that it stabilizes and constrains the T-state of hemoglobin by specifically binding to the large central cavity of the T-state. Here we report a new allosteric binding site of fully liganded R-state hemoglobin for this drug. The high resolution crystal structure of horse carbonmonoxyhemoglobin in complex with bezafibrate reveals that the bezafibrate molecule lies near the surface of the E-helix of each a subunit and the complex maintains the quaternary structure of the R-state. Binding is caused by the close fit of bezafibrate into the binding pocket, which is composed of some hydrophobic residues and the heme edge, suggesting the importance of hydrophobic interactions. Upon binding of bezafibrate, the distance between Fe and the Ne, of distal His E7(alpha58) is shortened by 0.22 Angstrom in the a subunit, whereas no significant structural changes are transmitted to the 13 subunit. Oxygen equilibrium studies of R-state-locked hemoglobin with bezafibrate in a wet porous sol-gel indicate that bezafibrate selectively lowers the oxygen affinity of one type of subunit within the R-state, consistent with the structural data. These results disclose a new allosteric mechanism of bezafibrate and offer the first demonstration of how the allosteric effector interacts with R-state hemoglobin.	Jichi Med Sch, Div Biophys, Dept Physiol, Minami Kawachi, Tochigi 3290498, Japan; Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Johnson Res Fdn, Philadelphia, PA 19104 USA	Jichi Medical University; Tokyo University of Science; Yokohama City University; University of Pennsylvania; University of Pennsylvania	Shibayama, N (corresponding author), Jichi Med Sch, Div Biophys, Dept Physiol, Yakushiji 3311-1, Minami Kawachi, Tochigi 3290498, Japan.	shibayam@jichi.ac.jp		Shibayama, Naoya/0000-0002-2208-1126				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; BOLTON W, 1968, J MOL BIOL, V33, P283, DOI 10.1016/0022-2836(68)90294-5; BRUNGER AT, 1996, XPLOR VERSION 3 851; Coletta M, 1999, J BIOL CHEM, V274, P6865, DOI 10.1074/jbc.274.11.6865; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IMAIZUMI K, 1979, J BIOCHEM, V86, P1829, DOI 10.1093/oxfordjournals.jbchem.a132705; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MEHANNA AS, 1990, BIOCHEMISTRY-US, V29, P3944, DOI 10.1021/bi00468a022; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mueser TC, 2000, BIOCHEMISTRY-US, V39, P15353, DOI 10.1021/bi0012944; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; NOBLE RW, 1989, BIOCHEMISTRY-US, V28, P5293, DOI 10.1021/bi00438a056; NOBLE RW, 1989, BIOCHEMISTRY-US, V28, P5288, DOI 10.1021/bi00438a055; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1983, LANCET, V2, P881; RANDAD RS, 1991, J MED CHEM, V34, P752, DOI 10.1021/jm00106a041; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shibayama N, 1999, J MOL BIOL, V285, P1383, DOI 10.1006/jmbi.1998.2407; Shibayama N, 1999, J AM CHEM SOC, V121, P444, DOI 10.1021/ja983652k; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 2001, FEBS LETT, V492, P50, DOI 10.1016/S0014-5793(01)02225-6; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4	36	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38791	38796		10.1074/jbc.M205461200	http://dx.doi.org/10.1074/jbc.M205461200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12122004	hybrid			2022-12-27	WOS:000178529600099
J	Garcia, S; Prado, M; Degano, R; Dominguez, A				Garcia, S; Prado, M; Degano, R; Dominguez, A			A copper-responsive transcription factor, CRF1, mediates copper and cadmium resistance in Yarrowia lipolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; UPSTREAM ACTIVATION SEQUENCES; CU,ZN SUPEROXIDE-DISMUTASE; SACCHAROMYCES-CEREVISIAE; YEAST METALLOTHIONEIN; ESCHERICHIA-COLI; CANDIDA-GLABRATA; GENE-EXPRESSION; IDENTIFICATION; FIBROBLASTS	The dimorphic yeast Yarrowia lipolytica is more resistant to high copper concentrations than Saccharomyces cerevisiae. This differential tolerance to copper ions has been observed in several strains arising from non-related isolates. To investigate the molecular basis of this resistance, we obtained several copper-sensitive mutants. By complementation of one of them, we isolated the YlCRF1 gene encoding for a copper-binding transcription factor of 411 amino acids homologous to ScAce1p, CgAmt1p, and ScMac1p. Naturally occurring copper-sensitive strains lack the CRF1 allele. The YlCRF1 transcript is not induced by the addition of copper to the medium. Gene disruption demonstrated that YlCRF1 is responsible for a 4- to 5-fold increase in Y. lipolytica copper tolerance. We further show that strain Deltacrf1 is more sensitive to cadmium but not to other metals. The role of YlCrf1p as a copper-sensitive transcription factor is supported by the finding that the protein is immunolocalized in the nucleus during growth in copper-supplemented but not in copper-free medium. However, in contrast to the S. cerevisiae strain mutated in the metallothionein transcription activator ACE1, Y. lipolytica strain Deltacrf7 is still able to increase metallothionein (MTP) mRNA levels in response to copper addition. CRF1 deletion does not affect superoxide dismutase (SOD) activity either. Our data suggest the existence of one or more different target genes for Crf1p, other than MTP or SOD1, and support its role as a novel copper-responsive transcription factor involved in metal detoxification.	Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, Salamanca 37071, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Dominguez, A (corresponding author), Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, Salamanca 37071, Spain.		García-Sánchez, Susana/AAM-5901-2020	Degano, Rosa Maria/0000-0003-3458-7252				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Barth G, 1996, NONCONVENTIONAL YEAS, P313, DOI [DOI 10.1007/978-3-642-79856-6_10, 10.1007/978-3-642-79856-6_10]; BUCHMAN C, 1990, MOL CELL BIOL, V10, P477; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Dominguez A, 2000, Contrib Microbiol, V5, P151; EVANS CF, 1990, MOL CELL BIOL, V10, P426, DOI 10.1128/MCB.10.1.426; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FOGEL S, 1988, J BASIC MICROB, V28, P147, DOI 10.1002/jobm.3620280302; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; GECO MA, 1990, J BACTERIOL, V172, P317; GEORGE GN, 1988, J BIOL CHEM, V263, P8199; HAGAN IM, 1988, J CELL SCI, V89, P343; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lippard SJ, 1999, SCIENCE, V284, P748, DOI 10.1126/science.284.5415.748; MEHRA RK, 1992, GENE, V114, P75, DOI 10.1016/0378-1119(92)90709-X; MEHRA RK, 1988, P NATL ACAD SCI USA, V85, P8815, DOI 10.1073/pnas.85.23.8815; Miller J.H., 1972, EXPT MOL GENETICS; NICAUD JM, 1989, CURR GENET, V23, P450; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; Sherman F., 1986, METHODS YEAST GENETI; Strain J, 1996, MOL GEN GENET, V251, P139; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; THIELE D, 1988, MOL CELL BIOL, V6, P1158; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; TorresGuzman JC, 1997, MOL CELL BIOL, V17, P6283, DOI 10.1128/MCB.17.11.6283; Weissman Z, 2000, P NATL ACAD SCI USA, V97, P3520, DOI 10.1073/pnas.97.7.3520; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848	48	38	41	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37359	37368		10.1074/jbc.M201091200	http://dx.doi.org/10.1074/jbc.M201091200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12114501	hybrid			2022-12-27	WOS:000178447100058
J	Steward, N; Ito, M; Yamaguchi, Y; Koizumi, N; Sano, H				Steward, N; Ito, M; Yamaguchi, Y; Koizumi, N; Sano, H			Periodic DNA methylation in maize nucleosomes and demethylation by environmental stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H1; RICE; INHERITANCE; METHYLTRANSFERASE; GLYCOSYLASE; CELLS; GENE	When maize seedlings were exposed to cold stress, a genome-wide demethylation occurred in root tissues. Screening of genomic DNA identified one particular fragment that was demethylated during chilling. This 1.8-kb fragment, designated ZmMI1, contained part of the coding region of a putative protein and part of a retrotransposon-like sequence. ZmMI1 was transcribed only under cold stress. Direct methylation mapping revealed that hypomethylated regions spanning 150 bases alternated with hypermethylated regions spanning 50 bases. Analysis of nuclear DNA digested with micrococcal nuclease indicated that these regions corresponded to nucleosome cores and linkers, respectively. Cold stress induced severe demethylation in core regions but left linker regions relatively intact. Thus, methylation and demethylation were periodic in nucleosomes. The following biological significance is conceivable. First, because DNA methylation in nucleosomes induces alteration of gene expression by changing chromatin structures, vast demethylation may serve as a common switch for many genes that are simultaneously controlled upon environmental cues. Second, because artificial demethylation induces heritable changes in plant phenotype (Sano, H., Kamada, I., Youssefian, S., Katsumi, M., and Wabilko, H. (1990) Mol. Gen. Genet. 220, 441-447), altered DNA methylation may result in epigenetic inheritance, in which gene expression is modified without changing the nucleotide sequence.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan.	sano@gtc.aist-nara.ac.jp	Yamaguchi, Yube/B-9594-2012; Ito, Mikako/I-1941-2012					Ananiev EV, 1998, P NATL ACAD SCI USA, V95, P10785, DOI 10.1073/pnas.95.18.10785; Bennetzen JL, 2000, PLANT MOL BIOL, V42, P251, DOI 10.1023/A:1006344508454; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; CULLIS CA, 1983, CRC CR REV PLANT SCI, V1, P117, DOI 10.1080/07352688309382174; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DENNIS ES, 1990, PHILOS T ROY SOC B, V326, P217, DOI 10.1098/rstb.1990.0006; DURRANT A, 1962, HEREDITY, V17, P27, DOI 10.1038/hdy.1962.2; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; FUKUI K, 1991, THEOR APPL GENET, V81, P589, DOI 10.1007/BF00226723; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; Holliday R, 1993, EXS, V64, P452; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jost JP, 2001, NUCLEIC ACIDS RES, V29, P4452, DOI 10.1093/nar/29.21.4452; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; Ohmido N, 1997, PLANT MOL BIOL, V35, P963, DOI 10.1023/A:1005822504690; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Riggs A.D., 1996, COLD SPRING HARBOR M, V32, P29; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SANO H, 1990, MOL GEN GENET, V220, P441, DOI 10.1007/BF00391751; SANO H, 1988, BIOCHIM BIOPHYS ACTA, V951, P157, DOI 10.1016/0167-4781(88)90036-X; SMITH JM, 1990, J THEOR BIOL, V143, P41, DOI 10.1016/S0022-5193(05)80286-3; Smith SS, 2000, J MOL BIOL, V302, P1, DOI 10.1006/jmbi.2000.4046; Steward N, 2000, NUCLEIC ACIDS RES, V28, P3250, DOI 10.1093/nar/28.17.3250; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; Toyota M, 1999, CANCER RES, V59, P2307; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; YAMAGUCHI J, 1992, CELL STRUCT FUNCT, V17, P87, DOI 10.1247/csf.17.87; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhu B, 2001, P NATL ACAD SCI USA, V98, P5031, DOI 10.1073/pnas.091097298; Zluvova J, 2001, J EXP BOT, V52, P2265, DOI 10.1093/jexbot/52.365.2265	42	267	330	1	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37741	37746		10.1074/jbc.M204050200	http://dx.doi.org/10.1074/jbc.M204050200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12124387	hybrid			2022-12-27	WOS:000178447100106
J	Bultel-Brienne, S; Lestavel, S; Pilon, A; Laffont, I; Tailleux, A; Fruchart, JC; Siest, G; Clavey, V				Bultel-Brienne, S; Lestavel, S; Pilon, A; Laffont, I; Tailleux, A; Fruchart, JC; Siest, G; Clavey, V			Lipid free apolipoprotein E binds to the class B type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; HIGH-AFFINITY RECEPTOR; APOE-DEFICIENT MICE; SELECTIVE UPTAKE; CELL-SURFACE; HEPATIC LIPASE; A-I; ADRENOCORTICAL-CELLS; HDL RECEPTOR	The Class B type I scavenger receptor I (SR-BI) is a physiologically relevant high density lipoprotein (HDL) receptor that can mediate selective cholesteryl ester (CE) uptake by cells. Direct interaction of apolipoprotein E (apoE) with this receptor has never been demonstrated, and its implication in CE uptake is still controversial. By using a human adrenal cell line (NCI-H295R), we have addressed the role of apoE in binding to SR-BI and in selective CE uptake from lipoproteins to cells. This dell line does not secrete apoE and SR-BI is its major HDL-binding protein. We can now provide evidence that 1) free apoE is a ligand for SR-BI, 2) apoE associated to lipids or in lipoproteins does not modulate binding or CE-selective uptake by the SR-BI pathway, and 3) the direct interaction of free apoE to SR-BI leads to an increase in CE uptake from lipoproteins of both low and high densities. We propose that this direct interaction could modify SR-BI structure in cell membranes and potentiate CE uptake.	Univ Lille 2, Inst Pasteur, INSERM U545, Fac Pharm, F-59019 Lille, France; Univ Nancy 1, Fac Pharm, Ctr Medicament, INSERM U525,Equipe 4, F-54000 Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Clavey, V (corresponding author), Fac Sci Pharmaceut & Biol, INSERM U545, 3 Rue Prof Laguesse,BP 83, F-59006 Lille, France.		TAILLEUX, Anne/R-5530-2018; Lestavel, Sophie/B-4658-2017	TAILLEUX, Anne/0000-0003-1430-2627; Lestavel, Sophie/0000-0001-7839-4757; SIEST, Gerard/0000-0002-3001-760X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Amar MJA, 1998, J LIPID RES, V39, P2436; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Boisvert WA, 1999, J LIPID RES, V40, P806; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY WA, 1982, BIOCHEM BIOPH RES CO, V109, P1360, DOI 10.1016/0006-291X(82)91927-1; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P524, DOI 10.1021/bi9819778; Calvo D, 1998, J LIPID RES, V39, P777; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; Collet X, 1999, J LIPID RES, V40, P1185; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUM DW, 1993, CLIN CHEM, V39, P333; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jolivalt C, 2000, FREE RADICAL BIO MED, V28, P129, DOI 10.1016/S0891-5849(99)00232-4; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEROY A, 1988, J IMMUNOASSAY, V9, P309, DOI 10.1080/01971528808053219; Li XP, 2002, J BIOL CHEM, V277, P21149, DOI 10.1074/jbc.M200658200; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maurer AM, 1996, J LAB CLIN MED, V127, P382, DOI 10.1016/S0022-2143(96)90186-9; MAZZONE T, 1994, J LIPID RES, V35, P1345; MULDER M, 1993, J BIOL CHEM, V268, P9369; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; RALL SC, 1986, METHOD ENZYMOL, V128, P273; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1990, BIOCHIM BIOPHYS ACTA, V1043, P318, DOI 10.1016/0005-2760(90)90033-T; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; Swarnakar S, 1998, J BIOL CHEM, V273, P12140, DOI 10.1074/jbc.273.20.12140; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; von Eckardstein A, 2000, CURR OPIN CARDIOL, V15, P348, DOI 10.1097/00001573-200009000-00007; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WILLIAMS DL, 1995, J LIPID RES, V36, P745; Xu SZ, 1997, J LIPID RES, V38, P1289	61	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36092	36099		10.1074/jbc.M201943200	http://dx.doi.org/10.1074/jbc.M201943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138091	hybrid			2022-12-27	WOS:000178275100043
J	Derand, R; Bulteau-Pignoux, L; Becq, F				Derand, R; Bulteau-Pignoux, L; Becq, F			The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; ATPASE ACTIVITY; CL CHANNEL; PHOSPHORYLATION; ACTIVATION; PROTEIN; HYDROLYSIS; MECHANISMS; CELLS	Loss of cystic fibrosis transmembrane conductance regulator (CFTR) channel activity explains most of the manifestations of the cystic fibrosis (CF) disease. To understand the consequences of CF mutations on CFTR channel activity, we compared the pharmacological properties of wild-type (wt) and G551D-CFTR. Dose-dependent relationships of wt-CFTR activated by genistein follows a non-Michaelis-Menten behavior consistent with the presence of two binding sites. With phosphorylated CFTR, a high affinity site for genistein is the activator (K-s approximate to 3 muM), whereas a second site of low affinity (K-i approximate to 75 muM) is the inhibitor. With non-phosphorylated CFTR, K-s was increased (K-s approximate to 12 muM), but K, was not affected (K-i approximate to 70 muM). In G551D-CFTR cells, channel activity was recovered by co-application of forskolin and genistein in a dose-dependent manner. A further stimulation of G551D-CFTR channel activity was measured at concentrations from 30 pm to 1 mm. The dose response is described by a classical Michaelis-Menten kinetics with only a single apparent site (K-m approximate to 11 muM). Our results suggest glycine 551 in NBD1 as an important location within the low affinity inhibitory site for genistein and offers new evidence for pharmacological alteration caused by an NBD1 mutation of CFTR. This study also reveals how a mutation of an ion channel converts a non-Michaelis-Menten behavior (two binding sites) into a classical Michaelis-Menten model (one binding site).	Univ Poitiers, LBSC, CNRS, UMR 6558, F-86022 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, LBSC, CNRS, UMR 6558, 40 Ave Recteur Pineau, F-86022 Poitiers, France.		Becq, Frederic/P-9233-2016	Becq, Frederic/0000-0003-3915-0973				BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; Bronnikov GE, 1999, J BIOL CHEM, V274, P37770, DOI 10.1074/jbc.274.53.37770; Bulteau L, 2000, AM J PHYSIOL-CELL PH, V279, pC1925, DOI 10.1152/ajpcell.2000.279.6.C1925; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Derand R, 2001, AM J PHYSIOL-CELL PH, V281, pC1657, DOI 10.1152/ajpcell.2001.281.5.C1657; GABSDY DC, 1999, PHYSIOL REV, V79, pS78; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Illek B, 1999, AM J PHYSIOL-CELL PH, V277, pC833, DOI 10.1152/ajpcell.1999.277.4.C833; Johnen G, 1995, P NATL ACAD SCI USA, V92, P12384, DOI 10.1073/pnas.92.26.12384; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Leung GPH, 2000, BIOL REPROD, V62, P143, DOI 10.1095/biolreprod62.1.143; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; LOGAN J, 1994, J CLIN INVEST, V94, P228, DOI 10.1172/JCI117311; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; McAndrew RS, 1998, BBA-LIPID LIPID MET, V1390, P21, DOI 10.1016/S0005-2760(97)00166-5; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Obayashi K, 1999, PFLUG ARCH EUR J PHY, V438, P269, DOI 10.1007/s004240050909; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; QUINTON PM, 1999, PHYSIOL REV, V79, P3; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Reenstra WW, 1996, AM J PHYSIOL-CELL PH, V271, pC650, DOI 10.1152/ajpcell.1996.271.2.C650; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6; Schultz BD, 1999, PHYSL REV S, V79, P109; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; 1983, BIOCH J, V213, P561	33	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35999	36004		10.1074/jbc.M206121200	http://dx.doi.org/10.1074/jbc.M206121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124395	hybrid			2022-12-27	WOS:000178275100030
J	Yang, BX; Verkman, AS				Yang, BX; Verkman, AS			Analysis of double knockout mice lacking aquaporin-1 and urea transporter UT-B - Evidence for UT-B-facilitated water transport in erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; URINARY CONCENTRATING ABILITY; NULL MICE; REFLECTION COEFFICIENT; SLC14A2 GENE; PERMEABILITY; CLONING; PROTEIN; CHANNEL; MEMBRANE	We reported increased water permeability and a low urea reflection coefficient in Xenopus oocytes expressing urea transporter UT-B (former name UT3), suggesting that water and urea share a common aqueous pathway (Yang, B., and Verkman, A. S. (1998) J. Biol. Chem. 273, 9369-9372). Although increased water permeability was confirmed in the Xenopus oocyte expression system, it has been argued (Sidoux-Walter, F., Lucien, N., Olives, B., Gobin, R., Rousselet, G., Kamsteeg, E. J., Ripoche, P., Deen, P. M., Cartron, J. P., and Bailly, P. (1999) J. Biol. Chem. 274, 30228-30235) that UT-B does not transport water when expressed at normal levels in mammalian cells such as erythrocytes. To quantify UT-B-mediated water transport, we generated double knockout mice lacking UT-B and the major erythrocyte water channel, aquaporin-1 (AQP1). The mice had reduced survival, retarded growth, and defective urinary concentrating ability. However, erythrocyte size and morphology were not affected. Stopped-flow light scattering measurements indicated erythrocyte osmotic water permeabilities (in cm/s x 0.01, 10degreesC): 2.1 +/- 0.2 (wild-type mice), 2.1 +/- 0.05 (UT-B null), 0.19 +/- 0.02 (AQP1 null), and 0.045 +/- 0.009 (AQP1/UT-B null). The low water permeability found in AQP1/UT-B null erythrocytes was also seen after HgCl2 treatment of UT-B null erythrocytes or phloretin treatment of AQP1 null erythrocytes. The apparent activation energy for UT-B-mediated water transport was low, <2 kcal/mol. Estimating 14,000 UT-B molecules per mouse erythrocyte, the UT-B-dependent P-f Of 0.15 X 10(-4) cm/s indicated a substantial single channel water permeability of UT-B of 7.5 x 10(-14) cm(3)/s, similar to that of AQP1. These results provide direct functional evidence for UT-B-facilitated water transport in erythrocytes and suggest that urea traverses an aqueous pore in the UT-B protein.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yang, BX (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL60288, HL58198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CHASAN B, 1985, BIOCHIM BIOPHYS ACTA, V821, P56, DOI 10.1016/0005-2736(85)90152-X; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DIX JA, 1984, BIOCHIM BIOPHYS ACTA, V773, P219, DOI 10.1016/0005-2736(84)90085-3; EDWARDSMOULDS J, 1988, VOX SANG, V55, P181, DOI 10.1111/j.1423-0410.1988.tb05089.x; Fenton RA, 2002, AM J PHYSIOL-RENAL, V282, pF630, DOI 10.1152/ajprenal.00264.2001; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; LEVITT DG, 1983, J GEN PHYSIOL, V81, P239, DOI 10.1085/jgp.81.2.239; Lucien N, 2002, J BIOL CHEM, V277, P34101, DOI 10.1074/jbc.M205073200; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACEY RI, 1984, AM J PHYSIOL, V246, P195; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MAYRAND RR, 1983, J GEN PHYSIOL, V81, P221, DOI 10.1085/jgp.81.2.221; Nakayama Y, 2001, BBA-GENE STRUCT EXPR, V1518, P19, DOI 10.1016/S0167-4781(00)00311-0; OLIVES B, 1994, J BIOL CHEM, V269, P31649; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; Pallone TL, 2000, J CLIN INVEST, V105, P215, DOI 10.1172/JCI8214; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Timmer RT, 2001, AM J PHYSIOL-CELL PH, V281, pC1318, DOI 10.1152/ajpcell.2001.281.4.C1318; Toon MR, 1996, J MEMBRANE BIOL, V153, P137, DOI 10.1007/s002329900117; TRINHTRANGTAN MM, 2002, IN PRESS AM J PHYSL; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF1030, DOI 10.1152/ajprenal.2000.278.6.F1030; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 2002, EXP NEPHROL, V10, P235; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	40	97	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36782	36786		10.1074/jbc.M206948200	http://dx.doi.org/10.1074/jbc.M206948200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133842				2022-12-27	WOS:000178275100128
J	Bibillo, A; Eickbush, TH				Bibillo, A; Eickbush, TH			High processivity of the reverse transcriptase from a non-long terminal repeat retrotransposon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; HUMAN-IMMUNODEFICIENCY; AVIAN-MYELOBLASTOSIS; CRYSTAL-STRUCTURE; TEMPLATE BINDING; RNA; R2; HIV-1; ACCURACY; ELEMENTS	R2 is a retrotransposable element that specifically inserts into the 28 S rRNA genes of arthropods. The element encodes a single protein with endonuclease activity that cleaves the 28 S gene target site and reverse transcriptase (RT) activity that uses the cleaved DNA to prime reverse transcription. Here we compare various properties of the R2 RT activity with those of the well characterized retroviral RT, avian myeloblastosis virus (AMV). In processivity assays using heterogeneous RNA templates, R2 RT can synthesize cDNA over twice the length of that synthesized by AMV RT and can synthesize cDNA over 4 times longer than AMV RT in assays with poly(rA) templates. The higher processivity of R2 RT compared with retroviral RTs is a result of the slower rate of dissociation of the enzyme from RNA templates. The elongation rates of the two enzymes are similar. Finally, a highly distinct property of the R2 RT, compared with retroviral enzymes, is its ability to displace RNA strands annealed to RNA templates during cDNA synthesis. We suggest that both the higher processivity and displacement properties of R2 RT compared with retroviral RT result from the greater affinity of the R2 protein for the RNA template upstream of its active site.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Eickbush, TH (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	eick@mail.rochester.edu			NIGMS NIH HHS [GM42790] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; Bibillo A, 2002, J MOL BIOL, V316, P459, DOI 10.1006/jmbi.2001.5369; BLANCO L, 1989, J BIOL CHEM, V264, P8935; Boeke J. D., 1997, P343; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; Burke WD, 1999, MOL BIOL EVOL, V16, P502, DOI 10.1093/oxfordjournals.molbev.a026132; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; Eickbush T.H., 2002, MOBILE DNA, P813; EICKBUSH TH, 2002, MOBILE DNA, P111; George JA, 1996, GENETICS, V142, P853; GREGERSON DS, 1980, BIOCHEMISTRY-US, V19, P301, DOI 10.1021/bi00543a008; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JAKUBCZAK JL, 1992, GENETICS, V131, P129; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Luan DD, 1996, MOL CELL BIOL, V16, P4726; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Malik HS, 2001, GENOME RES, V11, P1187, DOI 10.1101/gr.185101; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McClure W R, 1980, Methods Enzymol, V64, P277; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yang J, 1998, MOL CELL BIOL, V18, P3455, DOI 10.1128/MCB.18.6.3455; Yang J, 1999, P NATL ACAD SCI USA, V96, P7847, DOI 10.1073/pnas.96.14.7847; YU H, 1992, J BIOL CHEM, V267, P10888	39	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34836	34845		10.1074/jbc.M204345200	http://dx.doi.org/10.1074/jbc.M204345200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12101182	hybrid			2022-12-27	WOS:000178117000025
J	Du, XY; Clemetson, JM; Navdaev, A; Magnenat, EM; Wells, TNC; Clemetson, KJ				Du, XY; Clemetson, JM; Navdaev, A; Magnenat, EM; Wells, TNC; Clemetson, KJ			Ophioluxin, a convulxin-like C-type lectin from Ophiophagus hannah (King cobra) is a powerful platelet activator via glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; VON-WILLEBRAND-FACTOR; AMINO-ACID-SEQUENCE; MALAYAN PIT VIPER; COLLAGEN RECEPTOR; SNAKE-VENOM; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); PHOSPHOLIPASE C-GAMMA-2; BETA-SUBUNIT	Ophioluxin, a potent platelet agonist, was purified from the venom of Ophiophagus hannah (King cobra). Under nonreducing conditions it has a mass of 85 kDa, similar to convulxin, and on reduction gives two subunits with masses of 16 and 17 kDa, slightly larger than those of convulxin. The N-terminal sequences of both subunits are very similar to those of convulxin and other C-type lectins. Ophioluxin induces a pattern of tyrosine-phosphorylated proteins in platelets like that caused by convulxin, when using appropriate concentrations based on aggregation response, because it is about 2-4 times more powerful as agonist than the latter. Ophioluxin and convulxin induce [Ca2+](i) elevation both in platelets and in Dami megakaryocytic cells, and each of these C-type lectins desensitizes responses to the other. Convulxin agglutinates fixed platelets at 2 mug/ml, whereas ophioluxin does not, even at 80 mug/ml. Ophioluxin resembles convulxin more than echicetin or alboaggregin B because polyclonal anti-ophioluxin antibodies recognize both ophioluxin and convulxin, but not echicetin, and platelets adhere to and spread on ophioluxin- or convulxin-precoated surfaces in the same way that is clearly different from their behavior on an alboaggregin B surface. Immobilized ophioluxin was used to isolate the glycoprotein VI-Fcgamma complex from resting platelets, which also contained Fyn, Lyn, Syk, LAT, and SLP76. Ophioluxin is the first multiheterodimeric, convulxin-like snake C-type lectin, as well as the first platelet agonist, to be described from the Elapidae snake family.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Serono Pharmaceut Res Inst SA, CH-1228 Geneva, Switzerland	University of Bern	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.			Wells, Timothy/0000-0001-9796-847X				Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Andrews RK, 2000, TOXICON, V38, P775, DOI 10.1016/S0041-0101(99)00187-7; ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Chiang TM, 1997, J CLIN INVEST, V100, P2079, DOI 10.1172/JCI119741; Chung CH, 2001, BIOCHEM BIOPH RES CO, V285, P689, DOI 10.1006/bbrc.2001.5228; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 1998, PLATELETS, V9, P165, DOI 10.1080/09537109876636; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Clemetson KJ, 2001, HAEMOSTASIS, V31, P148; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Du XY, 2002, THROMB HAEMOSTASIS, V87, P692, DOI 10.1055/s-0037-1613067; Du XY, 2001, THROMB HAEMOSTASIS, V86, P1277, DOI 10.1055/s-0037-1616062; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Hamako J, 1996, BIOCHEM BIOPH RES CO, V226, P273, DOI 10.1006/bbrc.1996.1345; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; KIRBY EP, 1975, J CLIN INVEST, V56, P491, DOI 10.1172/JCI108116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAS G, 1985, BIOCHIMIE, V67, P1231, DOI 10.1016/S0300-9084(85)80132-2; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; PENG ML, 1991, BIOCHEMISTRY-US, V30, P11529, DOI 10.1021/bi00113a007; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; PENG ML, 1993, BLOOD, V81, P2321; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Polgar J, 1997, BIOCHEM J, V323, P533, DOI 10.1042/bj3230533; RUAN CG, 1987, BLOOD, V69, P570; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Tsai IH, 2001, ARCH BIOCHEM BIOPHYS, V394, P236, DOI 10.1006/abbi.2001.2524; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	50	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35124	35132		10.1074/jbc.M204372200	http://dx.doi.org/10.1074/jbc.M204372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130642	hybrid			2022-12-27	WOS:000178117000060
J	Karlson, D; Nakaminami, K; Toyomasu, T; Imai, R				Karlson, D; Nakaminami, K; Toyomasu, T; Imai, R			A cold-regulated nucleic acid-binding protein of winter wheat shares a domain with bacterial cold shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-RECOGNITION MOTIF; GLYCINE-RICH PROTEINS; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; LOW-TEMPERATURE; DIFFERENTIAL EXPRESSION; FUNCTIONAL-PROPERTIES; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; MESSENGER-RNA	The molecular mechanisms of cold acclimation are still largely unknown; however, it has been established that overwintering plants such as winter wheat increases freeze tolerance during cold treatments. In prokaryotes, cold shock proteins are induced by temperature downshifts and have been proposed to function as RNA chaperones. A wheat cDNA encoding a putative nucleic acid-binding protein, WCSP1, was isolated and found to be homologous to the predominant CspA of Escherichia coli. The putative WCSP1 protein contains a three-domain structure consisting of an N-terminal cold shock domain with two internal conserved consensus RNA binding domains and an internal glycine-rich region, which is interspersed with three C-terminal CX2CX4HX4C (CCHC) zinc fingers. Each domain has been described independently within several nucleotide-binding proteins. Northern and Western blot analyses showed that WCSP1 mRNA and protein levels steadily increased during cold acclimation, respectively. WCSP1 induction was cold-specific because neither abscisic acid treatment, drought, salinity, nor heat stress induced WCSP1 expression. Nucleotide binding assays determined that WCSP1 binds ssDNA, dsDNA, and RNA homopolymers. The capacity to bind dsDNA was nearly eliminated in a mutant protein lacking C-terminal zinc fingers. Structural and expression similarities to E. coli CspA suggest that WCSP1 may be involved in gene regulation during cold acclimation.	Natl Agr Res Ctr Hokkaido Reg, Winter Stress Lab, Toyohira Ku, Sapporo, Hokkaido 0628555, Japan; Iwate Univ, United Grad Sch Agr Sci, Morioka, Iwate 0208550, Japan; Yamagata Univ, Dept Bioresources, Tsuruoka 9978555, Japan	National Agriculture & Food Research Organization - Japan; Iwate University; Yamagata University	Imai, R (corresponding author), Natl Agr Res Ctr Hokkaido Reg, Winter Stress Lab, Toyohira Ku, Hitsujigaoka 1, Sapporo, Hokkaido 0628555, Japan.	rzi@affrc.go.jp	Nakaminami, Kentaro/C-9069-2017; Karlson, Dale/A-7617-2013	Nakaminami, Kentaro/0000-0003-2713-8280; 				Alba MM, 1998, TRENDS PLANT SCI, V3, P15, DOI 10.1016/S1360-1385(97)01151-5; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; BERGERON D, 1993, BIOCHIM BIOPHYS ACTA, V1216, P123, DOI 10.1016/0167-4781(93)90047-H; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; CATTIVELLI L, 1990, PLANT PHYSIOL, V93, P1504, DOI 10.1104/pp.93.4.1504; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CRESPI MD, 1991, PLANT PHYSIOL, V96, P887, DOI 10.1104/pp.96.3.887; DANYLUK J, 1994, FEBS LETT, V344, P20, DOI 10.1016/0014-5793(94)00353-X; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dunn MA, 1996, PLANT MOL BIOL, V30, P947, DOI 10.1007/BF00020806; DUNN MA, 1991, MOL GEN GENET, V229, P389, DOI 10.1007/BF00267460; Etchegaray JP, 1999, J BACTERIOL, V181, P1827, DOI 10.1128/JB.181.6.1827-1830.1999; Ferullo JM, 1997, PLANT MOL BIOL, V33, P625, DOI 10.1023/A:1005781301718; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GILMOUR SJ, 1992, PLANT MOL BIOL, V18, P13, DOI 10.1007/BF00018452; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAHAM D, 1982, ANNU REV PLANT PHYS, V33, P347, DOI 10.1146/annurev.pp.33.060182.002023; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; Hanano S, 1996, PLANT MOL BIOL, V31, P57, DOI 10.1007/BF00020606; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hirayama T, 1997, FEBS LETT, V413, P16, DOI 10.1016/S0014-5793(97)00871-5; Horvath DP, 1998, PLANT MOL BIOL, V38, P531, DOI 10.1023/A:1006050208670; HOUDE M, 1995, PLANT J, V8, P583, DOI 10.1046/j.1365-313X.1995.8040583.x; HOUDE M, 1992, PLANT PHYSIOL, V99, P1381, DOI 10.1104/pp.99.4.1381; JARILLO JA, 1994, PLANT MOL BIOL, V25, P693, DOI 10.1007/BF00029607; Jiang WN, 1997, J BIOL CHEM, V272, P196; Karlin S, 1998, J MOL EVOL, V47, P565, DOI 10.1007/PL00006413; Keresztessy Z, 1998, PLANT J, V14, P523, DOI 10.1046/j.1365-313X.1998.00149.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KINGSLEY PD, 1994, PLANT CELL, V6, P1522, DOI 10.1105/tpc.6.11.1522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FJS, 1993, J BIOL CHEM, V268, P15080; Li JJ, 2001, PLANT CELL, V13, P2269, DOI 10.1105/tpc.13.10.2269; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Manival X, 2001, NUCLEIC ACIDS RES, V29, P2223, DOI 10.1093/nar/29.11.2223; MONROY AF, 1993, PLANT PHYSIOL, V102, P873, DOI 10.1104/pp.102.3.873; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Ni Z, 2000, MOL GEN GENET, V263, P934, DOI 10.1007/PL00008693; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; OBOKATA J, 1991, PLANT MOL BIOL, V17, P953, DOI 10.1007/BF00037080; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pearce RS, 1999, PLANT GROWTH REGUL, V29, P47, DOI 10.1023/A:1006291330661; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SATO N, 1995, NUCLEIC ACIDS RES, V23, P2161; SATO SM, 1991, DEVELOPMENT, V112, P747; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; TANABE H, 1992, J BACTERIOL, V174, P3867, DOI 10.1128/jb.174.12.3867-3873.1992; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; Thieringer HA, 1998, BIOESSAYS, V20, P49; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uemura M, 1996, PLANT PHYSIOL, V111, P313, DOI 10.1104/pp.111.1.313; Veit B, 1998, NATURE, V393, P166, DOI 10.1038/30239; Wang N, 2000, MOL MICROBIOL, V38, P526, DOI 10.1046/j.1365-2958.2000.02146.x; WEBB JR, 1993, J BIOL CHEM, V268, P13994; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFRAIM LA, 1993, PLANT PHYSIOL, V101, P1275, DOI 10.1104/pp.101.4.1275; Xia B, 2001, MOL MICROBIOL, V40, P179, DOI 10.1046/j.1365-2958.2001.02372.x; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254	66	116	136	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35248	35256		10.1074/jbc.M205774200	http://dx.doi.org/10.1074/jbc.M205774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122010	hybrid			2022-12-27	WOS:000178117000076
J	Saito, M; Ishikawa, F				Saito, M; Ishikawa, F			The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; HISTONE DEACETYLATION; COMPLEX; CHROMATIN; MECP2; REPRESSION; PROTEINS	Although mammalian MBD3 contains the mCpG-binding domain (MBD) and is highly homologous with the authentic mCpG-binding protein MBD2, it was reported that the protein does not bind to mCpG specifically. Using recombinant human wild type and mutant MBD3 proteins, we demonstrated that atypical amino acids found in MBD3 MBD, namely, His-30 and Phe-34, are responsible for the inability of MBD3 to bind to mCpG. Interestingly, although H30K/F34Y MBD3 mutant protein binds to mCpG efficiently in vitro, it was not localized at the mCpG-rich pericentromeric regions in mouse cells. We also showed that Y34F MBD2b MBD, which possesses not the mCpG-specific DNA-binding activity but the nonspecific DNA-binding activity, was localized at the pericentromeric regions. These results suggested that the mCpG-specific DNA-binding activity is largely dispensable, and another factor(s) is required for the localization of MBD proteins in vivo. MBD3 was identified as a component of the NuRD/Mi2 complex that shows chromatin remodeling and histone deacetylase activities. We demonstrated that MBD3 MBD is necessary and sufficient for binding to HDAC1 and MTA2, two components of the NuRD/Mi2 complex. It was therefore suggested that mCpG-binding-defective MBD3 has evolutionarily conserved its MBD because of the secondary role played by the MBD in protein-protein interactions.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Lab Mol & Cellular Assembly,Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat, Kyoto 6068502, Japan	Tokyo Institute of Technology; Kyoto University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Lab Mol & Cellular Assembly,Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Feng Q, 2001, GENE DEV, V15, P827; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	23	127	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35434	35439		10.1074/jbc.M203455200	http://dx.doi.org/10.1074/jbc.M203455200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124384	hybrid			2022-12-27	WOS:000178117000099
J	Hannum, C; Kulaeva, OI; Sun, H; Urbanowski, JL; Wendus, A; Stillman, DJ; Rolfes, RJ				Hannum, C; Kulaeva, OI; Sun, H; Urbanowski, JL; Wendus, A; Stillman, DJ; Rolfes, RJ			Functional mapping of Bas2 - Identification of activation and Bas-1 interaction domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; PROTEIN-PROTEIN INTERACTIONS; HYDROPHOBIC AMINO-ACIDS; SWI5 ZINC-FINGER; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; HO PROMOTER; HOMEODOMAIN PROTEIN; HIS4 TRANSCRIPTION; IN-VIVO	The transcriptional activator protein Bas2 is required to express more than 20 genes in pathways for purine nucleotide and histidine biosynthesis, phosphate utilization, and the HO endonuclease by acting with co-regulator proteins Bas1, Pho4, and Swi5. The role that Bas2 plays in transcriptional activation may be to unmask latent activation domains in the co-regulator and to promote ternary complex formation between Bas2, the coregulator, and DNA. We show that Bas2 also contributes to transcriptional activation by providing an activation domain. We localize this domain in Bas2 to the C-terminal 156 amino acids using deletion analysis and fusion to a heterologous DNA binding domain. Additionally, we show that Bas2 makes direct contacts with Bas1. This interaction is detected by co-immunoprecipitation and by two-hybrid analysis. We localize the interaction region to the central portion of Bas2, from amino acids 112 to 404.	Georgetown Univ, Dept Biol, Washington, DC 20057 USA; Univ Utah, Hlth Sci Ctr, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Georgetown University; Utah System of Higher Education; University of Utah	Rolfes, RJ (corresponding author), Georgetown Univ, Dept Biol, Box 571229, Washington, DC 20057 USA.	rolfesr@georgetown.edu	Studitskaia, Olga/D-8551-2014	Studitskaia, Olga/0000-0001-5417-9964; Stillman, David/0000-0002-5268-2416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Bhoite LT, 1998, MOL CELL BIOL, V18, P6436, DOI 10.1128/MCB.18.11.6436; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BRAZAS RM, 1995, J BIOL CHEM, V270, P29151, DOI 10.1074/jbc.270.49.29151; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; JIANG YW, 1995, GENETICS, V140, P103; Justice MC, 1997, NUCLEIC ACIDS RES, V25, P4730, DOI 10.1093/nar/25.23.4730; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; Pinson B, 2000, NUCLEIC ACIDS RES, V28, P4665, DOI 10.1093/nar/28.23.4665; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Shao DL, 1996, MOL GEN GENET, V251, P358, DOI 10.1007/BF02172527; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Vashee S, 1998, CURR BIOL, V8, P452, DOI 10.1016/S0960-9822(98)70179-4; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; Zhang F, 1997, MOL CELL BIOL, V17, P3272, DOI 10.1128/MCB.17.6.3272	35	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34003	34009		10.1074/jbc.M206168200	http://dx.doi.org/10.1074/jbc.M206168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110691	hybrid			2022-12-27	WOS:000177959100064
J	Rizzo, MA; Magnuson, MA; Drain, PF; Piston, DW				Rizzo, MA; Magnuson, MA; Drain, PF; Piston, DW			A functional link between glucokinase binding to insulin granules and conformational alterations in response to glucose and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PANCREATIC BETA-CELLS; LIVING CELLS; IN-VIVO; INTRACELLULAR BINDING; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVITY; SECRETING CELLS; ENERGY-TRANSFER; ISLETS	Glucokinase (GK) activity is essential for the physiological regulation of insulin secretion by glucose. Because the enzyme exerts nearly total control over glucose metabolism in the beta-cell, even small changes in GK activity exert effects on glucose-stimulated insulin secretion and, consequently, the blood glucose concentration. Using quantitative imaging of multicolor fluorescent proteins fused to GK, we found that the association of GK with insulin granules is regulated by glucose in the beta-cell. Glucose stimulation increased the rate of fluorescence recovery after photobleaching of GK to insulin granules, indicating that GK is released into the cytoplasm after glucose stimulation. Changes in fluorescence resonance energy transfer between two different fluorescent protein variants inserted on opposing ends of GK were observed after glucose stimulation and correlated with increased enzyme activity. Furthermore, glucose-stimulated changes in GK regulation were blocked by two inhibitors of insulin secretion. Insulin treatment restored GK regulation in inhibited cells and stimulated GK translocation and activation by itself. Together, these data support a model for post-translational regulation of GK whereby insulin regulates both the association of GK with secretory granules and the activity of the enzyme within the pancreatic beta-cell.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Piston, DW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	dave.piston@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499	NCI NIH HHS [CA 86283] Funding Source: Medline; NIDDK NIH HHS [DK 42502, DK 53434, DK 60275, DK 42612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA086283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612, R01DK053434, F32DK060275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; CHEN C, 1994, DIABETES, V43, P684, DOI 10.2337/diabetes.43.5.684; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; Fernandez-Mejia C, 2001, ENDOCRINOLOGY, V142, P1448, DOI 10.1210/en.142.4.1448; Gasa R, 2000, BIOCHEM BIOPH RES CO, V268, P491, DOI 10.1006/bbrc.2000.2150; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Gromada J, 1996, BRIT J PHARMACOL, V118, P769, DOI 10.1111/j.1476-5381.1996.tb15466.x; Gromada J, 1996, BIOCHEM J, V314, P339, DOI 10.1042/bj3140339; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Henkel AW, 1996, J NEUROSCI, V16, P3960; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015; Mahajan NP, 1999, CHEM BIOL, V6, P401, DOI 10.1016/S1074-5521(99)80051-9; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Noma Y, 1996, ENDOCRINOLOGY, V137, P1485, DOI 10.1210/en.137.4.1485; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Patterson G, 2001, J CELL SCI, V114, P837; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Piston DW, 1999, J BIOL CHEM, V274, P1000, DOI 10.1074/jbc.274.2.1000; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Stubbs M, 2000, DIABETES, V49, P2048, DOI 10.2337/diabetes.49.12.2048; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Tiedge M, 1999, DIABETES, V48, P514, DOI 10.2337/diabetes.48.3.514; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Truong K, 2001, NAT STRUCT BIOL, V8, P1069, DOI 10.1038/nsb728; van Roessel P, 2002, NAT CELL BIOL, V4, pE15, DOI 10.1038/ncb0102-e15; Vanhoutte C, 1998, MOL GENET METAB, V63, P176, DOI 10.1006/mgme.1997.2655; Vasudevan C, 1998, J CELL SCI, V111, P1277; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Watkins S, 2002, TRAFFIC, V3, P461, DOI 10.1034/j.1600-0854.2002.30703.x; Xu X, 1998, NUCLEIC ACIDS RES, V26, P2034, DOI 10.1093/nar/26.8.2034; YIN L, 1992, DIABETES, V41, P792; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	52	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34168	34175		10.1074/jbc.M112478200	http://dx.doi.org/10.1074/jbc.M112478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12101177	hybrid			2022-12-27	WOS:000177959100084
J	Kim, YB; Shulman, GI; Kahn, BB				Kim, YB; Shulman, GI; Kahn, BB			Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PLECKSTRIN HOMOLOGY DOMAIN; SKELETAL-MUSCLE; MOLECULAR-CLONING; IN-VIVO; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SUPPRESSING GLYCOLYSIS; GLUT4 TRANSLOCATION	To determine the mechanism(s) for insulin resistance induced by fatty acids, we measured the ability of insulin to activate phosphoinositide 3-kinase (PI3K) and multiple distal pathways in rats. Following a 5-h infusion of lipid or glycerol (control), rats underwent a euglycemic hyperinsulinemic clamp. Insulin stimulated IRS-1-associated PI3K activity in muscle of glycerol-infused rats 2.4-fold but had no effect in lipid-infused rats. IRS-2- and phosphotyrosine-associated PI3K activity were increased 3.5- and 4.8-fold, respectively, by insulin in glycerol-infused rats but only 1.6- and 2.3-fold in lipidin-fused rats. Insulin increased Akt1 activity 3.9-fold in glycerol-infused rats, and this was impaired 41% in lipid-infused rats. Insulin action on Akt2 and p70S6K were not impaired, whereas activation of protein kinase C lambda/zeta activity was reduced 47%. Insulin inhibited glycogen synthase kinase 3alpha (GSK-3alpha) activity by 30% and GSK-3beta activity by similar to65% and increased protein phosphatase-1 activity by 40-47% in both glycerol- and lipid-infused rats. Insulin stimulated glycogen synthase activity 2.0. fold in glycerol-infused rats but only 1.4-fold in lipidin-fused rats. Thus, 1) elevation of fatty acids differentially affects insulin action on pathways distal to PI3K, impairing activation of Akt1 and protein kinase C lambda/zeta and 2) insulin action on glycogen synthase can be regulated independent of effects on GSK-3 and protein phosphatase-1 activity in vivo.	Beth Israel Deaconess Med Ctr, Diabet Unit, Div Endocrinol & Metab, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University; Yale University	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Diabet Unit, Div Endocrinol & Metab, Dept Med, 99 Brookline Ave, Boston, MA 02215 USA.		Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NIDDK NIH HHS [P30 DK45735, R01 DK40936, R01 DK040936, R01 DK043051, DK43051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043051, R01DK040936, P30DK045735, R01DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Choi CS, 2002, AM J PHYSIOL-ENDOC M, V283, pE233, DOI 10.1152/ajpendo.00557.2001; Choi WS, 2000, BBA-GEN SUBJECTS, V1475, P225, DOI 10.1016/S0304-4165(00)00068-4; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFronzo RA, 1997, DIABETES REV, V5, P177; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kanoh Y, 2000, J BIOL CHEM, V275, P16690, DOI 10.1074/jbc.M000287200; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim JK, 1996, DIABETES, V45, P446, DOI 10.2337/diabetes.45.4.446; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kim YB, 2001, DIABETES, V50, pA62; Kim YB, 2000, DIABETES, V49, P847, DOI 10.2337/diabetes.49.5.847; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Lawrence JC, 1997, BIOCHEM SOC T, V25, P14, DOI 10.1042/bst0250014; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; OKADA T, 1994, J BIOL CHEM, V269, P3568; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; ROACH PJ, 1977, MOL CELL BIOCHEM, V15, P179, DOI 10.1007/BF01734108; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Skurat AV, 1996, BIOCHEM J, V313, P45, DOI 10.1042/bj3130045; SKURAT AV, 1995, J BIOL CHEM, V270, P12491, DOI 10.1074/jbc.270.21.12491; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Wojtaszewski JFP, 1999, J CLIN INVEST, V104, P1257, DOI 10.1172/JCI7961; Wojtazsewski JFP, 2001, DIABETES, V50, P265, DOI 10.2337/diabetes.50.2.265; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	73	72	75	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32915	32922		10.1074/jbc.M204710200	http://dx.doi.org/10.1074/jbc.M204710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12095990	hybrid			2022-12-27	WOS:000177859000069
J	Li, D; Zimmerman, TL; Thevananther, S; Lee, HY; Kurie, JM; Karpen, SJ				Li, D; Zimmerman, TL; Thevananther, S; Lee, HY; Kurie, JM; Karpen, SJ			Interleukin-1 beta-mediated suppression of RXR : RAR transactivation of the Ntcp promoter is JNK-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; X-RECEPTOR ALPHA; BILE-ACID; NUCLEAR RECEPTOR; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; PROTEIN; LIVER; INHIBITION	Bile flow is rapidly and markedly reduced in hepatic inflammation, correlating with suppression of critical hepatic bile acid transporter gene expression, including the principal hepatic bile acid importer, the Na+/tauro-cholate co-transporting polypeptide (Ntcp, Slc10a1). Endotoxin treatment of rats and interleukin-1beta (IL-1beta) treatment of liver-derived HepG2 cells leads to a marked decline in the nuclear binding activity of a main Ntcp gene regulator, the nuclear receptor heterodimer retinoid X receptor:retinoic acid receptor (RXR:RAR). How IL-1beta signaling leads to reduced RXR:RAR nuclear binding activity its unknown, and we sought to determine whether mitogen-activated protein kinase (MAPK) pathways were involved. IL-1beta treatment of cultured primary rat hepatocytes markedly reduced Ntcp RNA levels and Ntcp promoter activity in transiently transfected HepG2 cells. Pretreatment with inhibitors of extracellular signal-regulated kinase (ERK, PD98059) or p38 MAPK (SB203580) did not affect IL-1beta-mediated suppression of Ntcp gene expression, whereas curcumin, a derivative of the spice turmeric and a recently described inhibitor of c-Jun N-terminal kinase (JNK), completely ameliorated the effects of IL-1beta. Co-transfection of a JNK expression plasmid inhibited RXR:RAR-mediated activation of the Ntcp promoter, while a dominant negative JNK expression plasmid completely blocked IL-1beta-mediated suppression. Curcumin, but not PD98059 or SB203580, inhibited IL-1beta-mediated suppression of nuclear RXR:RAR binding activity, which correlated with inhibition of JNK phosphorylation and phospho-JNK-mediated phosphorylation of RXR. Taken together, these data provide evidence supporting a novel player (JNK), as well as its inhibitor (curcumin), in inflammation-mediated regulation of hepatobiliary transporters and correlate JNK-dependent RXR phosphorylation with reduced RXR-dependent hepatic gene expression.	Baylor Coll Med, Texas Childrens Liver Ctr, Dept Pediat GI & Nutr, Houston, TX 77030 USA; MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Karpen, SJ (corresponding author), Baylor Coll Med, Texas Childrens Liver Ctr, Dept Pediat GI & Nutr, 1 Baylor Plaza, Houston, TX 77030 USA.	skarpen@bcm.tme.edu		Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [CA80696] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239-04, R01 DK056239, DK56239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Babu PS, 1997, MOL CELL BIOCHEM, V166, P169, DOI 10.1023/A:1006819605211; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Commandeur JNM, 1996, XENOBIOTICA, V26, P667, DOI 10.3109/00498259609046741; Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Deters M, 1999, PLANTA MED, V65, P610, DOI 10.1055/s-1999-14033; Deters M, 2000, PLANTA MED, V66, P429, DOI 10.1055/s-2000-8584; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karpen SJ, 1996, GASTROENTEROLOGY, V110, pA1229; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; KARPEN SJ, 2001, HEPATOBILIARY TRANSP, P22; Kim PK, 2000, SHOCK, V14, P176, DOI 10.1097/00024382-200014020-00017; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Moseley RH, 1997, GASTROENTEROLOGY, V112, P302, DOI 10.1016/S0016-5085(97)70250-6; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; SRINIVASAN K, 1991, INT J VITAM NUTR RES, V61, P364; Talalay P, 2001, ACAD MED, V76, P238, DOI 10.1097/00001888-200103000-00010; Trauner M, 1999, J HEPATOL, V31, P165, DOI 10.1016/S0168-8278(99)80179-2; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Trauner M, 1999, J GASTROEN HEPATOL, V14, P946, DOI 10.1046/j.1440-1746.1999.01982.x; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Zollner G, 2002, AM J PHYSIOL-GASTR L, V282, pG184, DOI 10.1152/ajpgi.00215.2001; Zollner G, 2001, HEPATOLOGY, V33, P633, DOI 10.1053/jhep.2001.22646	54	98	99	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31416	31422		10.1074/jbc.M204818200	http://dx.doi.org/10.1074/jbc.M204818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105223	hybrid			2022-12-27	WOS:000177718700018
J	Kucera, T; Waltner-Law, M; Scott, DK; Prasad, R; Granner, DK				Kucera, T; Waltner-Law, M; Scott, DK; Prasad, R; Granner, DK			A point mutation of the AF2 transactivation domain of the glucocorticoid receptor disrupts its interaction with steroid receptor coactivator 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; TRANS-ACTIVATION DOMAINS; THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; RESPONSE UNIT; ACCESSORY FACTORS; FUNCTIONAL DOMAINS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR	Glucocorticoids cause a 10-fold increase in hepatic phosphoenolpyruvate carboxykinase (PEPCK) gene transcription through two low affinity glucocorticoid receptor (GR) binding sites and a complex array of accessory factor DNA elements and associated proteins. To analyze how co-activators interact with the GR in this context, we took advantage of the C656G GR mutant that binds ligand with very high affinity. This GR activates PEPCK gene transcription at a 500-fold lower dexamethasone concentration than does wild type GR. Transfected C656G GR containing additional mutations or deletions was tested on PEPCK gene expression in H4IIE hepatoma cells. We found that the AF2 domain is the only one of the three defined transactivation domains in GR that is required for PEPCK gene expression and that mutation of this domain disrupts the direct interaction of GR with steroid receptor coactivator 1 (SRC-1). These data help define the functional interaction between GR and SRC-1 and further define the role of the GR in glucocorticoid-mediated expression of the PEPCK gene.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu						ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, COLD SPRING HARB SYM, V53, P813, DOI 10.1101/SQB.1988.053.01.092; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gong WR, 1997, MOL ENDOCRINOL, V11, P1476, DOI 10.1210/me.11.10.1476; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; Milhon J, 1997, MOL ENDOCRINOL, V11, P1795, DOI 10.1210/me.11.12.1795; ONATE SA, 1995, SCIENCE, V270, P1354; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Ray DW, 1999, MOL ENDOCRINOL, V13, P1855, DOI 10.1210/me.13.11.1855; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775	46	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26098	26102		10.1074/jbc.M204013200	http://dx.doi.org/10.1074/jbc.M204013200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12118039	hybrid			2022-12-27	WOS:000176908700036
J	Mysorekar, IU; Lorenz, RG; Gordon, JI				Mysorekar, IU; Lorenz, RG; Gordon, JI			A gnotobiotic transgenic mouse model for studying interactions between small intestinal enterocytes and intraepithelial lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; EPITHELIAL-CELL TYPES; C-KIT; GASTROINTESTINAL ECOSYSTEM; GUT CRYPTOPATCHES; FLT3 LIGAND; T-CELLS; GAMMA; DIFFERENTIATION; MICE	The mouse intestinal epithelium undergoes continuous renewal throughout life. Intraepithelial lymphocytes (IELs) represent a significant fraction of this epithelium and play an important role in intestinal mucosal barrier function. We have generated a germfree transgenic mouse model to examine the effects of a genetically engineered proliferative abnormality in the principal epithelial cell lineage (enterocytes) on IEL census and on IEL-enterocytic cross-talk. SV40 large T antigen (TAgWt) or a mutant derivative (TAgK107/8) that does not bind pRB was expressed in small intestinal villus enterocytes under the control of elements from the intestinal fatty acid binding protein gene (Fabpi). Quantitative immunohistochemical and flow cytometric analyses of conventionally raised and germ-free FVB/N Fabpi-TAgWt, Fabpi-TAgK107/8, and nontransgenic mice disclosed that forced reentry of enterocytes into the cell cycle is accompanied by an influx of thymically educated alphabeta T cell receptor (TCR)(+) CD4(+) and alphabeta TCR+ CD8alphabeta(+) IELs and a decrease in intestinally derived gammadelta TCR+ CD8alphaalpha IELs. Real time quantitative reverse transcriptase-PCR studies of jejunal villus epithelium recovered from germ-free transgenic and normal mice by laser capture microdissection and gammadelta TCR+ jejunal IELs purified by flow cytometry disclosed that the proliferative abnormality is accompanied by decreased expression of enterocytic interleukin-7 as well as IEL interleukin-7Ralpha and transforming growth factor beta3. The analysis also revealed that normal villus epithelium expresses Fins-like tyrosine kinase 3 (Flt3), a known regulator of hematopoietic stem cell proliferation and neuronal cell survival, and its ligand (Flt3L). Epithelial expression of this receptor and its ligand is reduced by the proliferative abnormality, whereas IEL expression of Flt3L remains constant. Together, these findings demonstrate that changes in the proliferative status of the intestinal epithelium affects maturation of gammadelta TCR+ IELs and produces an influx of alphabeta TCR+ IELs even in the absence of a microflora.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu	Mysorekar, Indira U./GRS-4574-2022; Lorenz, Robin G/AAJ-1499-2021	Mysorekar, Indira U./0000-0003-3917-8677; Lorenz, Robin G/0000-0002-2514-9819	NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; Brazel CY, 2001, MOL CELL NEUROSCI, V18, P381, DOI 10.1006/mcne.2001.1033; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1969, AM J ANAT, V126, P507, DOI 10.1002/aja.1001260409; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; COHN SM, 1984, J BIOL CHEM, V259, P2456; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; Fahrer AM, 2001, P NATL ACAD SCI USA, V98, P10261, DOI 10.1073/pnas.171320798; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Fujihashi K, 1997, EUR J IMMUNOL, V27, P2133, DOI 10.1002/eji.1830270903; GODFREY DI, 1992, J IMMUNOL, V149, P2281; Gordon JI, 1997, AM J PHYSIOL-GASTR L, V273, pG565, DOI 10.1152/ajpgi.1997.273.3.G565; HERMISTON ML, 1995, AM J PHYSIOL-GASTR L, V268, pG813, DOI 10.1152/ajpgi.1995.268.5.G813; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; HOYNE GF, 1993, IMMUNOLOGY, V80, P204; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; Laky K, 2000, J EXP MED, V191, P1569, DOI 10.1084/jem.191.9.1569; Lambolez F, 2002, J EXP MED, V195, P437, DOI 10.1084/jem.20010798; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; McCracken VJ, 2001, CELL MICROBIOL, V3, P1, DOI 10.1046/j.1462-5822.2001.00090.x; McKaig BC, 1999, AM J PHYSIOL-GASTR L, V276, pG1087, DOI 10.1152/ajpgi.1999.276.5.G1087; Moore TA, 1996, J IMMUNOL, V157, P2366; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; NICHOLS DB, 1974, J HISTOCHEM CYTOCHEM, V22, P929, DOI 10.1177/22.10.929; Ohbo K, 1996, INT IMMUNOL, V8, P951, DOI 10.1093/intimm/8.6.951; Oida T, 2000, J IMMUNOL, V164, P3616, DOI 10.4049/jimmunol.164.7.3616; Omori M, 1997, AM J PATHOL, V150, P1179; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROSNET O, 1991, ONCOGENE, V6, P1641; Shah AJ, 1996, BLOOD, V87, P3563, DOI 10.1182/blood.V87.9.3563.bloodjournal8793563; Shires J, 2001, IMMUNITY, V15, P419, DOI 10.1016/S1074-7613(01)00192-3; STAPPENBECK TS, 2002, METHOD ENZYMOL, V31, P559; Stein S A, 1991, Thyroid, V1, P257, DOI 10.1089/thy.1991.1.257; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; Suzuki K, 2000, IMMUNITY, V13, P691, DOI 10.1016/S1074-7613(00)00068-6; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Wong MH, 2000, P NATL ACAD SCI USA, V97, P12601, DOI 10.1073/pnas.230237997; Yamamoto M, 1998, J IMMUNOL, V160, P2188; YAMAMOTO M, 1993, J IMMUNOL, V150, P106	57	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37811	37819		10.1074/jbc.M205300200	http://dx.doi.org/10.1074/jbc.M205300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138109	hybrid			2022-12-27	WOS:000178447100116
J	Collins, A; Larson, M				Collins, A; Larson, M			Differential sensitivity of inward rectifier K+ channels to metabolic inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; MOLECULAR-CLONING; CURRENTS; HEART; ACTIVATION; MECHANISM; ISCHEMIA; RABBIT	Inhibition of inward rectifier K+ channels under ischemic conditions may contribute to electrophysiological consequences of ischemia such as cardiac arrhythmia. Ischemia causes metabolic inhibition, and the use of metabolic inhibitors is one experimental method of simulating ischemia. The effects of metabolic inhibitors on the activity of inward rectifier K+ channels K(ir)2.1,K(ir)2.2, and K(ir)2.3 were studied by heterologous expression in Xenopus oocytes and two-electrode voltage clamp. 10 mum carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) inhibited K(ir)2.2 and K(ir)2.3 currents but was without effect on K(ir)2.1 currents. The rate of decline of current in FCCP was faster for K(ir)2.3 than for K(ir)2.2. K(ir)2.3 was inhibited by 3 mm sodium azide (NaN4), whereas K(ir)2.1 and K(ir)2.2 were not K(ir)2.2 was inhibited by 10 mm NaN3. All three of these inward rectifiers were inhibited by lowering the pH of the solution perfusing inside-out membrane patches. K(ir)2.3 was most sensitive to pH (pK = 6.9), whereas K(ir)2.1 was least sensitive (pK = 5.9). For K(ir)2.2 the pK was 6.2. These results demonstrate the differential sensitivity of these inward rectifiers to metabolic inhibition and internal pH. The electrophysiological response of a particular cell type to ischemia may depend on the relative expression levels of different inward rectifier genes.	Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA	Oregon State University	Collins, A (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, 15th Jefferson, Corvallis, OR 97331 USA.							BENZ R, 1983, BIOPHYS J, V41, P381, DOI 10.1016/S0006-3495(83)84449-X; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Henry P, 1996, CARDIOVASC RES, V32, P930; Hilgemann Donald W., 1995, P307; HILLE B, 2001, ION CHANNELS EXCITAB, P149; Inanobe A, 2002, AM J PHYSIOL-CELL PH, V282, pC1396, DOI 10.1152/ajpcell.00615.2001; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu GX, 2001, J PHYSIOL-LONDON, V532, P115, DOI 10.1111/j.1469-7793.2001.0115g.x; Lopatin AN, 2001, J MOL CELL CARDIOL, V33, P625, DOI 10.1006/jmcc.2001.1344; MADUH EU, 1990, TOXICOL APPL PHARM, V106, P201, DOI 10.1016/0041-008X(90)90240-U; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; Stonehouse AH, 1999, HISTOCHEM CELL BIOL, V112, P457, DOI 10.1007/s004180050429; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; TROMBALLA HW, 1981, BIOCHIM BIOPHYS ACTA, V636, P98, DOI 10.1016/0005-2728(81)90080-3; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P174, DOI 10.1021/bi00052a023; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Verkerk AO, 1996, J MOL CELL CARDIOL, V28, P2443, DOI 10.1006/jmcc.1996.0237; Wang ZG, 1998, CIRCULATION, V98, P2422, DOI 10.1161/01.CIR.98.22.2422; Zaritsky JJ, 2001, J PHYSIOL-LONDON, V533, P697, DOI 10.1111/j.1469-7793.2001.t01-1-00697.x	27	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35815	35818		10.1074/jbc.M206032200	http://dx.doi.org/10.1074/jbc.M206032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118013	hybrid			2022-12-27	WOS:000178275100008
J	E, XP; Zhang, L; Lu, JY; Tso, P; Blaner, WS; Levin, MS; Li, E				E, XP; Zhang, L; Lu, JY; Tso, P; Blaner, WS; Levin, MS; Li, E			Increased neonatal mortality in mice lacking cellular retinol-binding protein II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; RAT SMALL-INTESTINE; TISSUE-SPECIFIC EXPRESSION; DEVELOPMENTAL REGULATION; EMBRYONIC-DEVELOPMENT; NORMAL-PREGNANCY; ACID RECEPTORS; LUNG; METABOLISM; ABSORPTION	Cellular retinol-binding protein II (CRBP H) is a member of the cellular retinol-binding protein family, which is expressed primarily in the small intestine. To investigate the physiological role of CRBP II, the gene encoding CRBP II was inactivated. The saturable component of intestinal retinol uptake is impaired in CRBP II-/- mice. The knockout mice, while maintained on a vitamin A-enriched diet, have reduced (40%) hepatic vitamin A stores but grow and reproduce normally. However, reducing maternal dietary vitamin A to marginal levels during the latter half of gestation results in 100% mortality/litter within 24 h after birth in the CRBP II-/- line but no mortality in the wild type line. The neonatal mortality in heterozygote offspring of CRBP II-/- dams (79 +/- 21% deaths/litter) was increased as compared with the neonatal mortality in heterozygote offspring of wild type dams (29 +/- 25% deaths per litter, p < 0.05). Maternal CRBP II was localized by immunostaining in the placenta at 18 days postcoitum as well as in the small intestine. These studies suggest that both fetal as well as maternal CRBP II are required to ensure adequate delivery of vitamin A to the developing fetus when dietary vitamin A is limiting.	Washington Univ, Sch Med, Div Gastroenterol, Dept Med, St Louis, MO 63110 USA; St Louis Vet Affairs Adm Med Ctr, St Louis, MO 63106 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Washington University (WUSTL); Washington University (WUSTL); University System of Ohio; University of Cincinnati; Columbia University	Li, E (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Med, Campus Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.	eli@im.wustl.edu			NIDDK NIH HHS [DK52444, DK50446, DK40172, DK 56341, DK 52574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK050446, R01DK040172, R29DK040172, P30DK056341, R01DK052444] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antipatis C, 2000, BRIT J NUTR, V84, P125; Antipatis C, 1998, AM J PHYSIOL-LUNG C, V275, pL1184, DOI 10.1152/ajplung.1998.275.6.L1184; Barua AB, 1998, J NUTR BIOCHEM, V9, P8, DOI 10.1016/S0955-2863(97)00133-2; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BRUINSE HW, 1995, EUR J OBSTET GYN R B, V61, P31, DOI 10.1016/0028-2243(95)02150-Q; Chailley-Heu B, 1999, AM J RESP CELL MOL, V21, P89, DOI 10.1165/ajrcmb.21.1.3563; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cikot RJLM, 2001, BRIT J NUTR, V85, P49, DOI 10.1079/BJN2000209; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; Dann WJ, 1932, BIOCHEM J, V26, P1072, DOI 10.1042/bj0261072; DARLOW BA, 2001, COCHRANE DATABASE SY, V2; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEW SE, 1994, BIOCHEMISTRY-US, V33, P12340, DOI 10.1021/bi00206a042; Dickman ED, 1997, DEVELOPMENT, V124, P3111; DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; GARDNER EM, 1993, J NUTR, V123, P1435; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; Harrison EH, 2001, J NUTR, V131, P1405, DOI 10.1093/jn/131.5.1405; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Hind M, 2002, AM J PHYSIOL-LUNG C, V282, pL468, DOI 10.1152/ajplung.00196.2001; HOLLANDER D, 1981, J LAB CLIN MED, V97, P449; HOLLANDER D, 1977, AM J PHYSIOL, V232, pE471, DOI 10.1152/ajpendo.1977.232.5.E471; ISMADI SD, 1982, INT J VITAM NUTR RES, V52, P111; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; Levin Marc Stephen, 1994, P1957; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1993, J BIOL CHEM, V268, P8267; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; Lindberg LA, 1999, RES VET SCI, V66, P259, DOI 10.1053/rvsc.1998.0280; MACDONALD PN, 1988, J BIOL CHEM, V263, P19478; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MOORE T, 1971, INT J VITAM NUTR RES, V41, P301; Napoli JL, 2000, NUTR REV, V58, P230, DOI 10.1111/j.1753-4887.2000.tb01870.x; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P823; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; QUICK TC, 1989, J LIPID RES, V30, P1049; RABINOVITCH M, 1998, COMPREHENSIVE CARDIO, P3001; ROSS AC, 1990, METHOD ENZYMOL, V189, P442; Sapin V, 1997, DEV DYNAM, V208, P199, DOI 10.1002/(SICI)1097-0177(199702)208:2<199::AID-AJA7>3.0.CO;2-D; TAKAHASHI YI, 1977, AM J PHYSIOL, V233, pE263, DOI 10.1152/ajpendo.1977.233.4.E263; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang JL, 1997, J NUTR, V127, P1297, DOI 10.1093/jn/127.7.1297; Wellik DM, 1997, AM J PHYSIOL-ENDOC M, V272, pE25, DOI 10.1152/ajpendo.1997.272.1.E25; White JC, 1998, P NATL ACAD SCI USA, V95, P13459, DOI 10.1073/pnas.95.23.13459; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	55	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36617	36623		10.1074/jbc.M205519200	http://dx.doi.org/10.1074/jbc.M205519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138113	hybrid			2022-12-27	WOS:000178275100106
J	Huigsloot, M; Tijdens, IB; Mulder, GJ; de Water, BV				Huigsloot, M; Tijdens, IB; Mulder, GJ; de Water, BV			Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CHEMICALLY-INDUCED APOPTOSIS; TRANSMEMBRANE DEPOLARIZATION; NEUROBLASTOMA-CELLS; CASPASE ACTIVATION; TUMOR-CELLS; IN-VITRO; X-L; PROTEIN	Various anticancer drugs cause mitochondrial perturbations in association with apoptosis. Here we investigated the involvement of caspase- and Bcl-2-dependent pathways in doxorubicin-induced mitochondrial perturbations and apoptosis. For this purpose, we set up a novel three-color flow cytometric assay using rhodamine 123, annexin V-allophycocyanin, and propidium iodide to assess the involvement of the mitochondria in apoptosis caused by doxorubicin in the breast cancer cell line MTLn3. Doxorubicin-induced apoptosis was preceded by up-regulation of CD95 and CD95L and a collapse of mitochondrial membrane potential (Atk) occurring prior to phosphatidylserine externalization. This drop in Deltapsi was independent of caspase activity, since benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone did not inhibit it. Benzyloxycarbonyl-Val-Ala-DLAsp-fluoromethylketone also blocked activation of caspase-8, thus excluding an involvement of the death receptor pathway in Deltapsi dissipation. Furthermore, although overexpression of Bcl-2 in MTLn3 cells inhibited apoptosis, dissipation of Deltapsi was still observed. No decrease in Deltapsi was observed in cells undergoing etoposide-induced apoptosis. Immunofluorescent analysis of Deltapsi and cytochrome c localization on a cell-to-cell basis indicates that the collapse of Deltapsi and cytochrome c release are mutually independent in both normal and Bcl2-overexpressing cells. Together, these data indicate that doxorubicin-induced dissipation of the mitochondrial membrane potential precedes phosphatidylserine externalization and is independent of a caspase- or Bcl2-controlled checkpoint.	Leiden Univ, LACDR, Div Toxicol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	de Water, BV (corresponding author), Leiden Univ, LACDR, Div Toxicol, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	b.water@LACDR.LeidenUniv.nl						Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong JS, 2001, EXP CELL RES, V262, P170, DOI 10.1006/excr.2000.5091; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brustugun OT, 1998, CELL DEATH DIFFER, V5, P660, DOI 10.1038/sj.cdd.4400399; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Cosulich SC, 1999, CURR BIOL, V9, P147, DOI 10.1016/S0960-9822(99)80068-2; Decaudin D, 1997, CANCER RES, V57, P62; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gille L, 1997, FREE RADICAL BIO MED, V23, P775, DOI 10.1016/S0891-5849(97)00025-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HARDY R, 1986, PURIFICATION COUPLIN; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huigsloot M, 2001, BIOCHEM PHARMACOL, V62, P1087, DOI 10.1016/S0006-2952(01)00755-9; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Kakeji Y, 1997, INT J RADIAT ONCOL, V37, P1115, DOI 10.1016/S0360-3016(96)00573-1; Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; MIMNAUGH EG, 1985, BIOCHEM PHARMACOL, V34, P847, DOI 10.1016/0006-2952(85)90766-X; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perkins CL, 2000, CANCER RES, V60, P1645; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Robles AI, 2001, CANCER RES, V61, P6660; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Toyota N, 1998, INT J CANCER, V76, P499; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WELCH DR, 1983, INVAS METAST, V3, P65; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan Y, 1999, ONCOGENE, V18, P6505, DOI 10.1038/sj.onc.1203060; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhuang JG, 1998, TOXICOL LETT, V103, P121, DOI 10.1016/S0378-4274(98)00296-3; ZOETEWEIJ JP, 1993, J BIOL CHEM, V268, P3384	75	88	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35869	35879		10.1074/jbc.M200378200	http://dx.doi.org/10.1074/jbc.M200378200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107157	Green Published, hybrid			2022-12-27	WOS:000178275100016
J	Stoica, GE; Kuo, A; Powers, C; Bowden, ET; Sale, EB; Riegel, AT; Wellstein, A				Stoica, GE; Kuo, A; Powers, C; Bowden, ET; Sale, EB; Riegel, AT; Wellstein, A			Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE GENE; PHOSPHATASE ZETA/RPTP-BETA; ANGIOGENIC FACTOR MIDKINE; ACTIVATED PROTEIN-KINASE; MOLECULE HB-GAM; HEPARIN-BINDING; RETINOIC ACID; FACTOR PLEIOTROPHIN; TUMOR-GROWTH; TERATOCARCINOMA SYSTEM	Midkine (MK) is a developmentally regulated, secreted growth factor homologous to pleiotrophin (PTN). To investigate the potential role of MK in tumor growth, we expressed MK in human SW-13 cells and studied receptor binding, signal transduction, and activity of MK. The MK protein stimulates soft agar colony formation in vitro and tumor growth of SW-13 cells in athymic nude mice, as well as proliferation of human endothelial cells from brain microvasculature and umbilical vein (HUVEC) in the low ng/ml range. MK binds to anaplastic lymphoma kinase (ALK), the receptor for PTN, with an apparent K-d of 170 pm in intact cells, and this receptor binding of MK is competed by PTN with an apparent Kd of similar to20 pM. Monoclonal antibodies raised against the extracellular ligand-binding domain of ALK inhibit ALK receptor binding of MK as well as MK-stimulated colony formation of SW-13 cells. Furthermore, MK stimulates ALK phosphorylation in WI-38 human fibroblasts and activates PI3-kinase and MAP kinase signal transduction in WI-38, HLTVEC, neuroblastoma (SH SY-5Y) an glioblastoma (U87MG) cells that express the ALK protein. We conclude that MK can act as a growth, survival, and angiogenic factor during tumorigenesis and signals through the ALK receptor.	Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	wellstea@georgetown.edu	Powers, Ciaran/E-3890-2011	Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; FANG WJ, 1992, J BIOL CHEM, V267, P25889; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; Harroch S, 2000, MOL CELL BIOL, V20, P7706, DOI 10.1128/MCB.20.20.7706-7715.2000; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; KITAMURA M, 1993, AM J PATHOL, V142, P425; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; Kojima S, 1997, SEIKAGAKU, V69, P104; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Konishi N, 1999, ONCOLOGY-BASEL, V57, P253, DOI 10.1159/000012039; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Laaroubi Khalid, 1995, Progress in Growth Factor Research, V6, P25; LAI SP, 1992, BIOCHEM BIOPH RES CO, V187, P1113, DOI 10.1016/0006-291X(92)91312-E; LAI SP, 1995, GENE, V153, P301, DOI 10.1016/0378-1119(94)00674-H; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; OBrien T, 1996, CANCER RES, V56, P2515; OSTRANDER M, 1992, BIOCHEM BIOPH RES CO, V189, P1189, DOI 10.1016/0006-291X(92)92330-Z; Owada K, 1999, J NEUROCHEM, V73, P2084; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Qiu LB, 2000, BIOCHEMISTRY-US, V39, P5977, DOI 10.1021/bi991519e; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 2000, ONCOGENE, V19, P3988, DOI 10.1038/sj.onc.1203742; SEKIGUCHI K, 1995, J BIOCHEM-TOKYO, V118, P94, DOI 10.1093/oxfordjournals.jbchem.a124898; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Takada T, 1997, BIOCHEM BIOPH RES CO, V241, P756, DOI 10.1006/bbrc.1997.7873; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TOMOMURA M, 1990, BIOCHEM BIOPH RES CO, V171, P603, DOI 10.1016/0006-291X(90)91189-Y; TSUTSUI J, 1993, CANCER RES, V53, P1281; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; Wang SY, 1998, DEV BRAIN RES, V106, P205, DOI 10.1016/S0165-3806(97)00213-7; Weber D, 2000, CANCER RES, V60, P5284; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Yamakawa T, 1999, CANCER LETT, V135, P91; YASUHARA O, 1993, BIOCHEM BIOPH RES CO, V192, P246, DOI 10.1006/bbrc.1993.1406; ZHANG L, 1995, J CELL SCI, V108, P323	72	268	291	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35990	35998		10.1074/jbc.M205749200	http://dx.doi.org/10.1074/jbc.M205749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122009	hybrid			2022-12-27	WOS:000178275100029
J	Torigoe, T; Izumi, H; Ishiguchi, H; Uramoto, H; Murakami, T; Ise, T; Yoshida, Y; Tanabe, M; Nomoto, M; Itoh, H; Kohno, K				Torigoe, T; Izumi, H; Ishiguchi, H; Uramoto, H; Murakami, T; Ise, T; Yoshida, Y; Tanabe, M; Nomoto, M; Itoh, H; Kohno, K			Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS SP1; TUMOR-CELLS; CISPLATIN RESISTANCE; DRUG-RESISTANCE; PROTON PUMP; V-ATPASES; IN-VIVO; DNA; PLASMA; PH	We have isolated two overlapping genomic clones that contain the 5'-terminal portion of the human vacuolar H+-ATPase c subunit (ATP6L) gene. The sequence preceding the transcription initiation site, which is GC-rich, contains four GC boxes and one Oct1-binding site, but there is no TATA box or CCAAT box. In vivo footprint analysis in human cancer cells shows that two GC boxes and the Oct1-binding site are occupied by Sp1 and Oct1, respectively. We show here that treatment with anticancer agents enhances ATP6L expression. Although cisplatin did not induce ATP6L promoter activity, it altered ATP6L mRNA stability. On the other hand, the DNA topoisomerase 11 inhibitor, TAS-103, strongly induced promoter activity, and this effect was completely eradicated when a mutation was introduced into the Oct1-binding site. Treatment with TAS-103 increased the levels of both Sp1/Sp3 and Oct1 in nuclear extracts. Cooperative binding of Sp1 and Oct1 to the promoter is required for promoter activation by TAS-103. Incubation of a labeled oligonucleotide probe encompassing the -73/-68 GC box and -64/-57 Oct1-binding site with a nuclear extract from drug-treated KB cells yielded higher levels of the specific DNA-protein complex than an extract of untreated cells. Thus, the two transcription factors, Sp1 and Oct1 interact, in an adaptive response to DNA damage, by up-regulating expression of the vacuolar H+-ATPase genes. Furthermore, combination of the vacuolar H+-ATPase (V-ATPase) inhibitor, bafilomycin A1, with TAS-103 enhanced apoptosis of KB cells with an associated increase in caspase-3 activity. Our data suggest that the induction of V-ATPase expression is an anti-apoptotic defense, and V-ATPase inhibitors in combination with low-dose anticancer agents may provide a new therapeutic approach.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.			Yoshida, Yoichiro/0000-0001-6583-7352				Azuma R, 1997, J CHROMATOGR B, V691, P179, DOI 10.1016/S0378-4347(96)00449-5; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Byl JAW, 1999, BIOCHEMISTRY-US, V38, P15573; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; FURUYA Y, 1994, CANCER LETT, V81, P95, DOI 10.1016/0304-3835(94)90170-8; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Ise T, 1999, CANCER RES, V59, P342; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; Kluza J, 2000, CANCER RES, V60, P4077; Koike K, 1996, JPN J CANCER RES, V87, P765, DOI 10.1111/j.1349-7006.1996.tb00290.x; KONISHI T, 1995, J BIOCHEM-TOKYO, V118, P1021, DOI 10.1093/jb/118.5.1021; LAURENCOT CM, 1995, ONCOL RES, V7, P363; Malone CS, 2000, J IMMUNOL, V164, P2550, DOI 10.4049/jimmunol.164.5.2550; Martinez-Zaguilan R, 1998, J CELL PHYSIOL, V176, P196, DOI 10.1002/(SICI)1097-4652(199807)176:1<196::AID-JCP21>3.0.CO;2-4; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; NAKAGAWA M, 1993, J UROLOGY, V150, P1970, DOI 10.1016/S0022-5347(17)35948-7; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; NOMOTO M, 1995, BBA-GENE STRUCT EXPR, V1264, P35, DOI 10.1016/0167-4781(95)00158-D; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Rundlof AK, 2001, J BIOL CHEM, V276, P30542, DOI 10.1074/jbc.M101452200; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SCHLAPPACK OK, 1991, BRIT J CANCER, V64, P663, DOI 10.1038/bjc.1991.378; SHEN DW, 1995, BRIT J CANCER, V71, P676, DOI 10.1038/bjc.1995.134; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Torigoe T, 2002, ANTI-CANCER DRUG, V13, P237, DOI 10.1097/00001813-200203000-00005; Wang SP, 2002, J BIOL CHEM, V277, P8827, DOI 10.1074/jbc.M111959200; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wieczorek H, 2000, J EXP BIOL, V203, P127; Zhao HC, 2000, CANCER RES, V60, P6276	47	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36534	36543		10.1074/jbc.M202605200	http://dx.doi.org/10.1074/jbc.M202605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133827	hybrid			2022-12-27	WOS:000178275100096
J	Verde, C; Carratore, V; Riccio, A; Tamburrini, M; Parisi, E; di Prisco, G				Verde, C; Carratore, V; Riccio, A; Tamburrini, M; Parisi, E; di Prisco, G			The functionally distinct hemoglobins of the Arctic spotted wolffish Anarhichas minor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FISH PAGOTHENIA-BERNACCHII; OXYGEN-BINDING PROPERTIES; CRYSTAL-STRUCTURE; ANTARCTIC FISHES; HUMAN DEOXYHEMOGLOBIN; EXTREME ENVIRONMENTS; ANGSTROM RESOLUTION; TREMATOMUS-NEWNESI; SINGLE HEMOGLOBIN	The Arctic fish Anarhichas minor, a benthic sedentary species, displays high hemoglobin multiplicity. The three major hemoglobins (Hb 1, Hb 2, and Hb, 3) show important functional differences in pH and organophosphate regulation, subunit cooperativity, and response of oxygen binding to temperature. Hb 1 and Hb 2 display a low, effector-enhanced Bohr effect and no Root effect. In contrast, Hb 3 displays pronounced Bohr and Root effects, accompanied by strong organophosphate regulation. Hb 1 has the beta (beta(1)) chain in common with Hb 2; Hb 3 and Hb 2 share the alpha (alpha(2)) chain. The amino acid sequences have been established. Several substitutions in crucial positions were observed, such as Cys in place of C-terminal His in the beta(1) chain of Hb 1 and Rb 2. In Rb 3, Val E11 of the beta(2) chain is replaced by Ile. Homology modeling revealed an unusual structure of the Hb 3 binding site of inositol hexakisphoshate. Phylogenetic analysis indicated that only Hb 2 displays higher overall similarity with the major Antarctic hemoglobins. The oxygen transport system of A minor differs remarkably from those of Antarctic Notothenioidei, indicating distinct evolutionary pathways in the regulatory mechanisms of the fish respiratory system in the two polar environments.	CNR, Inst Prot Biochem, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	di Prisco, G (corresponding author), CNR, Inst Prot Biochem, Via Marconi 12, I-80125 Naples, Italy.			TAMBURRINI, MAURIZIO/0000-0001-5987-0957; VERDE, Cinzia/0000-0001-6185-282X				ANTONINI E, 1977, HEMOGLOBIN MYOGLOBIN, P178; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BAJORATH J, 1993, PROTEIN SCI, V2, P1798, DOI 10.1002/pro.5560021103; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; Cheng CHC, 1998, CURR OPIN GENET DEV, V8, P715, DOI 10.1016/S0959-437X(98)80042-7; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; Coletta M, 1996, J BIOL CHEM, V271, P29859, DOI 10.1074/jbc.271.47.29859; d'Avino R., 1991, P15; DAVINO R, 1994, J BIOL CHEM, V269, P9675; DAVINO R, 1992, POLAR BIOL, V12, P135, DOI 10.1007/BF00239974; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAVINO R, 1988, COMP BIOCHEM PHYS B, V90, P579, DOI 10.1016/0305-0491(88)90298-2; di Prisco G, 2000, J MARINE SYST, V27, P253, DOI 10.1016/S0924-7963(00)00071-3; di Prisco Guido, 1998, P339; DIPRISCO G, 1991, TRENDS BIOCHEM SCI, V16, P471, DOI 10.1016/0968-0004(91)90182-U; DIPRISCO G, 1988, COMP BIOCHEM PHYS B, V90, P631, DOI 10.1016/0305-0491(88)90304-5; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Imai K., 1982, ALLOSTERIC EFFECTS H; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; KUMAR S, 2000, MEGA MOL EVOLUTIONAR; Landon, 1977, Methods Enzymol, V47, P145; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; Mazzarella L, 1999, J MOL BIOL, V287, P897, DOI 10.1006/jmbi.1999.2632; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; Naoi Y, 2001, J MOL BIOL, V307, P259, DOI 10.1006/jmbi.2000.4446; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Riccio A, 2000, J FISH BIOL, V57, P20, DOI 10.1006/jfbi.2000.1611; RICHARD V, 1993, J MOL BIOL, V233, P270, DOI 10.1006/jmbi.1993.1505; ROBERT CH, 1988, BIOCHEMISTRY-US, V27, P6835, DOI 10.1021/bi00418a028; SHIH DTB, 1993, J MOL BIOL, V230, P1291; Stam WW, 1997, J MOL EVOL, V45, P437, DOI 10.1007/PL00006248; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 1998, PAUPASTERISK PHYLOGE; Tamburrini M, 2000, EUR J BIOCHEM, V267, P6089, DOI 10.1046/j.1432-1327.2000.01699.x; TAMBURRINI M, 1994, J MOL BIOL, V237, P615, DOI 10.1006/jmbi.1994.1259; TAMBURRINI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P295, DOI 10.1016/0003-9861(92)90082-8; Tamburrini M, 1996, J BIOL CHEM, V271, P23780, DOI 10.1074/jbc.271.39.23780; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; Zhao YQ, 1998, J BIOL CHEM, V273, P14745, DOI 10.1074/jbc.273.24.14745; ZUIDERWEG ERP, 1979, EUR J BIOCHEM, V94, P297, DOI 10.1111/j.1432-1033.1979.tb12895.x	48	39	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36312	36320		10.1074/jbc.M202474200	http://dx.doi.org/10.1074/jbc.M202474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118003	hybrid			2022-12-27	WOS:000178275100068
J	Cowart, LA; Wei, SZ; Hsu, MH; Johnson, EF; Krishna, MU; Falck, JR; Capdevila, JH				Cowart, LA; Wei, SZ; Hsu, MH; Johnson, EF; Krishna, MU; Falck, JR; Capdevila, JH			The CYP4A Isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PRESSURE REGULATION; ARACHIDONIC-ACID; MOLECULAR MECHANISMS; TARGETED DISRUPTION; OMEGA-HYDROXYLASE; SEMINAL-VESICLES; CYTOCHROMES P450; BETA-OXIDATION; FATTY-ACIDS; PPAR-GAMMA	Cytochromes P450 of the CYP2C and CYP4A gene subfamilies metabolize arachidonic acid to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs) and to 19- and 20-hydroxyeicosatetraenoic acids (HETEs), respectively. Abundant functional studies indicate that EETs and HETEs display powerful and often opposing biological activities as mediators of ion channel activity and regulators of vascular tone and systemic blood pressures. Incubation of 8,9-,11,12-, and 14,15-EETs with microsomal and purified forms of rat CYP4A isoforms led to rapid NADPH-dependent metabolism to the corresponding 19- and 20-hydroxylated EETs. Comparisons of reaction rates and catalytic efficiency with those of arachidonic and lauric acids showed that EETs are one of the best endogenous substrates so far described for rat CYP4A isoforms. CYP4A1 exhibited a preference for 8,9-EET, whereas CYP4A2, CYP4A3, and CYP4A8 preferred 11,12-EET. In general, the closer the oxido ring is to the carboxylic acid functionality, the higher the rate of EET metabolism and the lower the regiospecificity for the EET omega-carbon. Analysis of cis-parinaric acid displacement from the ligand-binding domain of the human peroxisome proliferator-activated receptor-alpha showed that omega-hydroxylated 14,15-EET bound to this receptor with high affinity (K-i = 3 +/- 1 nM). Moreover, at 1 muM, the omega-alcohol of 14,15-EET or a 1:4 mixture of the omega-alcohols of 8,9- and 11,12-EETs activated human and mouse peroxisome proliferator-activated receptor-alpha in transient transfection assays, suggesting a role for them as endogenous ligands for these orphan nuclear receptors.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Vanderbilt University; Vanderbilt University; Scripps Research Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Capdevila, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Med Ctr N S-3223,1161 21st Ave S, Nashville, TN 37232 USA.	jorge.capdevila@mcmail.vanderbilt.edu		Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL07323] Funding Source: Medline; NICHD NIH HHS [HD04445] Funding Source: Medline; PHS HHS [38226, 31278, 37922] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bylund J, 2000, J BIOL CHEM, V275, P21844, DOI 10.1074/jbc.M001712200; Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1988, ARCH BIOCHEM BIOPHYS, V261, P122, DOI 10.1016/0003-9861(88)90111-7; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; Fang X, 2001, J BIOL CHEM, V276, P14867, DOI 10.1074/jbc.M011761200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GONZALEZ FJ, 1993, PHARMACOGENETICS, V3, P51, DOI 10.1097/00008571-199302000-00006; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Helvig C, 1998, BIOCHEMISTRY-US, V37, P12546, DOI 10.1021/bi981048g; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; HOFMANN CA, 1992, DIABETES CARE, V15, P1075, DOI 10.2337/diacare.15.8.1075; Holla VR, 2001, P NATL ACAD SCI USA, V98, P5211, DOI 10.1073/pnas.081627898; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; HSU MH, 1995, MOL PHARMACOL, V48, P559; HUNNINGHAKE DB, 1987, AM J MED, V83, P44, DOI 10.1016/0002-9343(87)90870-9; Imig JD, 2000, AM J PHYSIOL-RENAL, V279, pF965, DOI 10.1152/ajprenal.2000.279.6.F965; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1991, J BIOL CHEM, V266, P7561; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; Maier KG, 2001, CURR OPIN NEPHROL HY, V10, P81, DOI 10.1097/00041552-200101000-00013; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; Murakami K, 1999, BIOCHEM BIOPH RES CO, V260, P609, DOI 10.1006/bbrc.1999.0951; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1984, J BIOL CHEM, V259, P2716; Palmer CNA, 1998, FEBS LETT, V431, P476, DOI 10.1016/S0014-5793(98)00818-7; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Sinal CJ, 2000, J BIOL CHEM, V275, P40504, DOI 10.1074/jbc.M008106200; STROMSTEDT M, 1990, DNA CELL BIOL, V9, P569, DOI 10.1089/dna.1990.9.569; Wang MH, 1996, ARCH BIOCHEM BIOPHYS, V336, P240, DOI 10.1006/abbi.1996.0554; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402	60	158	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35105	35112		10.1074/jbc.M201575200	http://dx.doi.org/10.1074/jbc.M201575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124379	hybrid			2022-12-27	WOS:000178117000057
J	Dennis, MS; Zhang, M; Meng, YG; Kadkhodayan, M; Kirchhofer, D; Combs, D; Damico, LA				Dennis, MS; Zhang, M; Meng, YG; Kadkhodayan, M; Kirchhofer, D; Combs, D; Damico, LA			Albumin binding as a general strategy for improving the pharmacokinetics of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE EXOSITE INHIBITORS; POLYETHYLENE-GLYCOL; FAB FRAGMENTS; AFFINITY; CONJUGATION; ANTIBODY	Plasma protein binding can be an effective means of improving the pharmacokinetic properties of otherwise short lived molecules. Using peptide phage display, we identified a series of peptides having the core sequence DICLPRWGCLW that specifically bind serum albumin from multiple species with high affinity. These peptides bind to albumin with 1:1 stoichiometry at a site distinct from known small molecule binding sites. Using surface plasmon resonance, the dissociation equilibrium constant of peptide SA21 (Ac-RLIEDICLPRWGCLWEDD-NH2) was determined to be 266+/-8, 320+/-22, and 467+/-47 nM for rat, rabbit, and human albumin, respectively. SA21 has an unusually long half-life of 2.3 h when injected by intravenous bolus into rabbits. A related sequence, fused to the anti-tissue factor Fab of D3H44 (Presta, L., Sims, P., Meng, Y. G., Moran, P., Bullens, S., Bunting, S., Schoenfeld, J., Lowe, D., Lai, J., Rancatore, P., Iverson, M., Lim, A., Chisholm, V., Kelley, R. F., Riederer, M., and Kirchhofer, D. (2001) Thromb. Haemost. 85, 379-389), enabled the Fab to bind albumin with similar affinity to that of SA21 while retaining the ability of the Fab to bind tissue factor. This interaction with albumin resulted in reduced in vivo clearance of 25- and 58-fold in mice and rabbits, respectively, when compared with the wild-type D3H44 Fab. The half-life was extended 37-fold to 32.4 h in rabbits and 26-fold to 10.4 h in mice, achieving 25-43% of the albumin half-life in these animals. These half-lives exceed those of a Fab'(2) and are comparable with those seen for polyethylene glycol-conjugated Fab molecules, immunoadhesins, and albumin fusions, suggesting a novel and generic method for improving the pharmacokinetic properties of rapidly cleared proteins.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Assay & Automat Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Genentech Inc, Dept Clin & Expt Pharmacol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dennis, MS (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.							Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dennis MS, 2001, BIOCHEMISTRY-US, V40, P9513, DOI 10.1021/bi010591l; FRIEDMAN AJ, 1990, GONADOTROPIN RELEASI, P1; HATTON MWC, 1993, J THEOR BIOL, V161, P481, DOI 10.1006/jtbi.1993.1068; JAIN RK, 1989, JNCI-J NATL CANCER I, V81, P570, DOI 10.1093/jnci/81.8.570; Kelley Robert F., 1994, Methods (Orlando), V6, P111, DOI 10.1006/meth.1994.1014; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KOEHLER MFT, 2002, IN PRESS BIOORG MED; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725; Lee LS, 1999, BIOCONJUGATE CHEM, V10, P973, DOI 10.1021/bc990076o; LEE VHL, 1990, PEPTIDE PROTEIN DRUG, P1; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Makrides SC, 1996, J PHARMACOL EXP THER, V277, P534; Markussen J, 1996, DIABETOLOGIA, V39, P281; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Peters T., 1996, ALL ALBUMIN; Presta L, 2001, THROMB HAEMOSTASIS, V85, P379; RODRIGUES ML, 1993, J IMMUNOL, V151, P6954; ROWLAND M, 1988, CLIN PHARMACOKINETIC; Sjolander A, 1997, J IMMUNOL METHODS, V201, P115, DOI 10.1016/S0022-1759(96)00217-7; STEVENS DK, 1992, FUND APPL TOXICOL, V19, P336, DOI 10.1016/0272-0590(92)90171-D; Syed S, 1997, BLOOD, V89, P3243, DOI 10.1182/blood.V89.9.3243; TANAKA H, 1991, CANCER RES, V51, P3710; TIMSINA MP, 1990, J PHARM PHARMACOL, V42, P572, DOI 10.1111/j.2042-7158.1990.tb07061.x; Wu AM, 2000, Q J NUCL MED, V44, P268; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904	33	354	705	0	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35035	35043		10.1074/jbc.M205854200	http://dx.doi.org/10.1074/jbc.M205854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12119302	hybrid			2022-12-27	WOS:000178117000049
J	Penner, AS; Rock, MJ; Kielty, CM; Shipley, JM				Penner, AS; Rock, MJ; Kielty, CM; Shipley, JM			Microfibril-associated glycoprotein-2 interacts with fibrillin-1 and fibrillin-2 suggesting a role for MAGP-2 in elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARFAN-SYNDROME; EXTRACELLULAR MICROFIBRILS; DEVELOPMENTAL EXPRESSION; DNA TRANSFECTION; TERMINAL DOMAINS; VI COLLAGEN; COMPONENT; PROTEINS; GENE; TROPOELASTIN	Elastic fibers are composed of the protein elastin and a network of 10-12 nm microfibrils. The microfibrillar proteins include, among others, the fibrillins and microfibril-associated glycoproteins-1 and -2 (MAGP-1 and MAGP-2). Little is known about how microfibrillar proteins interact to support fiber assembly. We used the C-terminal half of MAGP-2 in a yeast two-hybrid library screen to identify relevant ligands. Six of 13 positive clones encoded known microfibrillar proteins, including fibrillin-1 and -2. Deletion analysis of partial fibrillin-1 and -2 clones revealed a calcium-binding epidermal growth factor repeat-containing region near the C terminus responsible for binding. This region is distinct from the region of fibrillin-1 reported by others to bind MAGP-1. The MAGP-2 bait was unable to interact productively with other epidermal growth factor repeats in fibrillin-1, demonstrating specificity of the interaction. Deletion analysis of the MAGP-2 bait demonstrated that binding occurred in a core region containing 48% identity and 7 conserved cysteine residues with MAGP-1. Immunoprecipitation of MAGP-2 from transfected COS-7 cells resulted in the coprecipitation of fibrillin. These results demonstrate that MAGP-2 specifically interacts with fibrillin-1 and -2 and suggest that MAGP-2 may help regulate microfibrillar assembly. The results also demonstrate the utility of the yeast two-hybrid system to study protein-protein interactions of the extracellular matrix.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	Barnes-Jewish Hospital; Washington University (WUSTL); University of Manchester	Shipley, JM (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Pulm & Crit Care Med, 216 S Kingshighway Blvd, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Ashworth JL, 1999, J CELL SCI, V112, P4163; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CLARE EG, 1987, CONNECTIVE TISSUE DI, P55; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Doliana R, 2001, J BIOL CHEM, V276, P12003, DOI 10.1074/jbc.M011591200; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Fauvel-Lafeve F, 1999, INT REV CYTOL, V188, P1; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Frankfater C, 2000, MAMM GENOME, V11, P191, DOI 10.1007/s003350010036; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GODFREY M, 1990, AM J HUM GENET, V46, P652; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hanssen E, 1998, BIOL CELL, V90, P223, DOI 10.1016/S0248-4900(98)80018-X; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1993, J CELL SCI, V106, P167; Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756-3282(00)00292-1; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MIYAZAKI J, 1989, GENE, V79, P269; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Raghunath M, 1999, J INVEST DERMATOL, V112, P97, DOI 10.1046/j.1523-1747.1999.00483.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Ross JM, 1998, THROMB HAEMOSTASIS, V79, P155; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, 1990, ELASTIN CHEM BIOL AS, P213; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Sterzel RB, 2000, KIDNEY INT, V58, P1588, DOI 10.1046/j.1523-1755.2000.00320.x; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	54	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35044	35049		10.1074/jbc.M206363200	http://dx.doi.org/10.1074/jbc.M206363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122015	hybrid			2022-12-27	WOS:000178117000050
J	Segall, L; Lane, LK; Blostein, R				Segall, L; Lane, LK; Blostein, R			New insights into the role of the N terminus in conformational transitions of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; SODIUM-PUMP REGULATION; NA+-K+-ATPASE; ALPHA-SUBUNIT; STRUCTURE PREDICTION; MOLECULAR-CLONING; SARCOPLASMIC-RETICULUM; CHYMOTRYPTIC CLEAVAGE	The deletion of 32 residues from the N terminus of the alpha1 catalytic subunit of the rat Na,K-ATPase (mutant alpha1M32) shifts the E-1/E-2 conformational equilibrium toward E-1, and the combination of this deletion with mutation E233K in the M2-M3 loop acts synergistically to shift the conformation further toward E, (Boxenbaum, N., Daly, S. E., Javaid, Z. Z., Lane, L. K., and Blostein, R. (1998) J. Biol. Chem. 273, 23086-23092). To delimit the region of the cytoplasmic N terminus involved in these interactions, the consequences of a series of N-terminal deletions of alpha1 beyond Delta32 were evaluated. Criteria to assess shifts in conformational equilibrium were based on effects of perturbation of the entire catalytic cycle ((i) sensitivity to vanadate inhibition, (ii) K+ sensitivity of Na-ATPase measured at micromolar ATP, (iii) changes in K'(ATP), and (iv) catalytic turnover), as well as estimates of the rates of the conformational transitions of phospho- and dephosphoenzyme (E1P --> E2P and E-2(K+) --> E-1 + K+). The results show that, compared with alpha1M32, the deletion of up to 40 residues (alpha1M40) further shifts the poise toward E-1. Remarkably, further deletions (mutants alpha1M46, alpha1M49, and alpha1M56) reverse the effect, such that these mutants increasingly resemble the wild type alpha1. These results suggest novel intramolecular interactions involving domains within the N terminus that impact the manner in which the N terminus/M2-M3 loop regulatory domain interacts with the M4-M5 catalytic loop to effect E-1 <-> E-2 transitions.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA	McGill University; University of Cincinnati	Blostein, R (corresponding author), Montreal Gen Hosp, Res Inst, 1650 Cedar Ave,Rm L11-132, Montreal, PQ H3G 1A4, Canada.	Rhoda.Blostein@mcgill.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49204] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1977, BIOCHIM BIOPHYS ACTA, V466, P97, DOI 10.1016/0005-2736(77)90211-5; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P207, DOI 10.1111/j.1749-6632.1982.tb25743.x; JORGENSEN PL, 1978, BIOCHIM BIOPHYS ACTA, V507, P8, DOI 10.1016/0005-2736(78)90369-3; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1980, BIOCHIM BIOPHYS ACTA, V597, P305, DOI 10.1016/0005-2736(80)90108-X; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KLODOS I, 1994, J BIOL CHEM, V269, P1734; LANE LK, 1993, J BIOL CHEM, V268, P17930; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malmstrom S, 1997, FEBS LETT, V400, P324, DOI 10.1016/S0014-5793(96)01448-2; Markwell M A, 1981, Methods Enzymol, V72, P296; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; MUTOH Y, 1992, BIOCHEM INT, V26, P775; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STULTZ CM, 1997, ADV MOL CEL A&B, V22, P447; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Therien AG, 1999, AM J PHYSIOL-CELL PH, V277, pC891, DOI 10.1152/ajpcell.1999.277.5.C891; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35202	35209		10.1074/jbc.M206115200	http://dx.doi.org/10.1074/jbc.M206115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110690	hybrid			2022-12-27	WOS:000178117000070
J	Thomas, DDH; Kaspar, KM; Taft, WB; Weng, N; Rodenkirch, LA; Groblewski, GE				Thomas, DDH; Kaspar, KM; Taft, WB; Weng, N; Rodenkirch, LA; Groblewski, GE			Identification of annexin VI as a Ca2+-sensitive CRHSP-28-binding protein in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC COMPARTMENT; MEMBRANE RETRIEVAL; EXOCRINE PANCREAS; GENE FAMILY; TPD52 GENE; RAT; SECRETION; EXOCYTOSIS; CLONING; ACTIN	CRHSP-28 is a member of the tumor protein D52 protein family that was recently shown to regulate Ca2+- stimulated secretory activity in streptolysin-O-permeabilized acinar cells (Thomas, D. H., Taft, W. B., Kaspar, K. M., and Groblewski, G. E. (2001) J. Biol. Chem. 276, 28866-28872). In the present study, the Ca2+-sensitive phospholipid-binding protein annexin VI was purified from rat pancreas as a CRHSP-28-binding protein. The interaction between CRHSP-28 and annexin VI was demonstrated by coimmunoprecipitation and gel-overlay assays and was shown to require low micromolar levels of free Ca2+, indicating these molecules likely interact under physiological conditions. Immunofluorescence microscopy confirmed a dual localization of CRHSP-28 and annexin VI, which appeared in a punctate pattern in the supranuclear and apical cytoplasm of acini. Stimulation of cells for 5 min with the secretagogue cholecystokinin enhanced the colocalization of CRHSP-28 and annexin VI within regions of acini immediately below the apical plasma membrane. Tissue fractionation revealed that CRHSP-28 is a peripheral membrane protein that is highly enriched in smooth microsomal fractions of pancreas. Further, the content of CRHSP-28 in microsomes was significantly reduced in pancreatic tissue obtained from rats that had been infused with a secretory dose of cholecystokinin for 40 min, demonstrating that secretagogue stimulation transiently alters the association of CRHSP-28 with membranes in cells. Collectively, the Ca2+-dependent binding of CRHSP-28 and annexin VI, together with their colocalization in the apical cytoplasm, is consistent with a role for these molecules in acinar cell membrane trafficking events that are essential for digestive enzyme secretion.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Groblewski, GE (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.							Avila-Sakar AJ, 2000, J STRUCT BIOL, V130, P54, DOI 10.1006/jsbi.2000.4246; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Groblewski GE, 1999, AM J PHYSIOL-GASTR L, V276, pG219, DOI 10.1152/ajpgi.1999.276.1.G219; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; Hawkins TE, 2000, CELL BIOCHEM BIOPHYS, V33, P275, DOI 10.1385/CBB:33:3:275; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Kamal A, 1998, J CELL BIOL, V142, P937, DOI 10.1083/jcb.142.4.937; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; Kleene R, 1999, J CELL SCI, V112, P2539; LAVIALLE F, 2000, BIOCHIM BIOPHYS ACTA, V1464, P82; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nourse CR, 1998, BBA-GENE STRUCT EXPR, V1443, P155, DOI 10.1016/S0167-4781(98)00211-5; Ortega D, 1998, J CELL SCI, V111, P261; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Sathasivam P, 2001, BIOCHEM BIOPH RES CO, V288, P56, DOI 10.1006/bbrc.2001.5721; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; Thomas DDH, 2001, J BIOL CHEM, V276, P28866, DOI 10.1074/jbc.M102214200; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; Valentijn JA, 2000, BIOCHEM BIOPH RES CO, V268, P847, DOI 10.1006/bbrc.2000.2221; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; Valentijn KM, 1999, J CELL SCI, V112, P81; WEINMAN JS, 1994, CELL TISSUE RES, V278, P389, DOI 10.1007/BF00414181; Williams JA, 1997, DIGESTION, V58, P42, DOI 10.1159/000201524; Williams John A., 1993, P167; Wilson SHD, 2001, GENOMICS, V76, P81, DOI 10.1006/geno.2001.6610; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676	41	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35496	35502		10.1074/jbc.M110917200	http://dx.doi.org/10.1074/jbc.M110917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105190	hybrid			2022-12-27	WOS:000178117000107
J	Velichko, S; Wagner, TC; Turkson, J; Jove, R; Croze, E				Velichko, S; Wagner, TC; Turkson, J; Jove, R; Croze, E			STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c - Activation of multiple stats proceeds through the redundant usage of two tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ALPHA-INTERFERON; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; GENE-REGULATION; PHOSPHORYLATION; PROTEIN; GROWTH; 3-KINASE; DOCKING	Human type I interferons (IFNs) play an important role in the regulation of antiviral defense mechanisms, immunomodulatory activities, and growth control. Recent efforts have demonstrated the importance of IFNs in the activation of signal transducers and activators of transcription (STATs). The role of STAT1 and STAT2 in IFN-dependent JAK-STAT signaling is well established; however, the role of STAT3 and its activation by IFNs remains unclear. Understanding the IFN-dependent regulation of STAT3 is of increasing interest because recent studies have demonstrated that STAT3 may play a role in cancer. Studies have revealed that STAT3 is constitutively active in a number of cancer cell lines and that overexpression of an active form of STAT3 transforms normal fibroblasts. Therefore, STAT3 exhibits properties indicative of known oncogenes. In this report, we define the role of the type I IFN receptor in STAT3 activation and identify for the first time tyrosine residues present in the cytoplasmic domain of IFNAR2c that are critical for STAT3 activation. The regulation of STAT3 activation by IFNs was measured in a human lung fibrosarcoma cell line lacking IFNAR2c but stably expressing various IFNAR2c tyrosine mutants. We show here that in addition to IFN-dependent tyrosine phosphorylation of STAT3, activation using a STAT3-dependent electrophoretic mobility shift assay and a STAT3-specific reporter can also be demonstrated. Furthermore, we demonstrate that type I IFN-dependent activation of STAT3 proceeds through a novel mechanism that is dependent on two tyrosines, Tyr(337) and Tyr(512), present in IFNAR2c and contained within a conserved six-amino acid residue motif, GxGYxM. Surprisingly, both tyrosines were previously shown to be required for type I IFN-dependent STAT1 and STAT2 activation. Our results reveal that type I IFNs activate multiple STATs via the overlapping usage of two tyrosine residues located in the cytoplasmic domain of IFNAR2c.	Berlex Biosci Inc, Dept Immunol, Richmond, CA 94804 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Croze, E (corresponding author), Berlex Biosci Inc, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94804 USA.							Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Collum RG, 2000, P NATL ACAD SCI USA, V97, P10120, DOI 10.1073/pnas.170192197; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; Nguyen VP, 2002, J BIOL CHEM, V277, P9713, DOI 10.1074/jbc.m111161200; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Russell-Harde D, 2000, J BIOL CHEM, V275, P23981, DOI 10.1074/jbc.M002518200; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su L, 2000, J BIOL CHEM, V275, P12661, DOI 10.1074/jbc.275.17.12661; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; UZE G, 1996, J INTERFERON CYTOKIN, V15, P3; Wagner TC, 2002, J BIOL CHEM, V277, P1493, DOI 10.1074/jbc.M108928200; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; WANGER BJ, 1990, EMBO J, V9, P4477; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	38	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35635	35641		10.1074/jbc.M204578200	http://dx.doi.org/10.1074/jbc.M204578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105218	hybrid			2022-12-27	WOS:000178117000123
J	Weingartner, M; Siegmund, D; Schlecht, U; Fotin-Mleczek, M; Scheurich, P; Wajant, H				Weingartner, M; Siegmund, D; Schlecht, U; Fotin-Mleczek, M; Scheurich, P; Wajant, H			Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEATH DOMAIN KINASE; CELL-DEATH; CYTOTOXICITY; ACTIVATION; INDUCTION; P75; RIP; LYMPHOCYTES; INVOLVEMENT	The heat shock protein 90 (Hsp-90) inhibitor, geldanamycin, and the proteasome inhibitor, MG-132, both inhibited tumor necrosis factor receptor 1 (TNF-R1)- but not TRAIL-induced apoptosis in Kym-1 cells, suggesting that TNF-R1-induced cell death is dependent on NF-kappaB activation in this model. Triggering of TNF-R1 by agonistic antibodies led to cell-type specific induction of endogenous TNF and apoptosis, the latter of which was abrogated by neutralizing TNF specific antibodies. TNF-R1-stimulated cells expressed TNF mainly in a cell-associated form, suggesting that the endogenously produced TNF act in its membrane-bound form. Geldanamycin failed to inhibit apoptosis induction by a combination of agonistic TNF-R1- and TNF-R2-specific antibodies, indicating that both TNF receptors co-operate in TNF-R1-triggered apoptosis in Kym-1 cells. Thus, TNF-R1 stimulation can elicit a strong and rapid apoptotic response via induction of membrane TNF and subsequent cooperation of TNF-R1 and TNF-R2. Moreover, we give evidence that this mechanism circumvents the need of the prolonged presence of exogenous soluble TNF for TNF-R1-mediated apoptosis induction.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandrung 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Declercq W, 1998, J IMMUNOL, V161, P390; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VERCAMMEN D, 1995, CYTOKINE, V7, P463, DOI 10.1006/cyto.1995.0063; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weiss T, 1997, J IMMUNOL, V158, P2398; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	34	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34853	34859		10.1074/jbc.M205149200	http://dx.doi.org/10.1074/jbc.M205149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105203	hybrid			2022-12-27	WOS:000178117000027
J	D'Agostino, DM; Ranzato, L; Arrigoni, G; Cavallari, I; Belleudi, F; Torrisi, MR; Silic-Benussi, M; Ferro, T; Petronilli, V; Marin, O; Chieco-Bianchi, L; Bernardi, P; Ciminale, V				D'Agostino, DM; Ranzato, L; Arrigoni, G; Cavallari, I; Belleudi, F; Torrisi, MR; Silic-Benussi, M; Ferro, T; Petronilli, V; Marin, O; Chieco-Bianchi, L; Bernardi, P; Ciminale, V			Mitochondrial alterations induced by the p13(II) protein of human T-cell leukemia virus type 1 - Critical role of arginine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; OPEN READING FRAMES; LIVER-MITOCHONDRIA; RAT-LIVER; HTLV-I; VIRAL INFECTIVITY; MESSENGER-RNAS; X PROTEIN; G4; IMMORTALIZATION	Human T-cell leukemia virus type 1 encodes a number of "accessory" proteins of unclear function; one of these proteins, p13(II), is targeted to mitochondria and disrupts mitochondrial morphology. The present study was undertaken to unravel the function of p13(II) through (i) determination of its submitochondrial localization and sequences required to alter mitochondrial morphology and (ii) an assessment of the biophysical and biological properties of synthetic peptides spanning residues 9-41 (p13(9-41)), which include the amphipathic mitochondrial-targeting sequence of the protein. p13(9-41) folded into an a helix in micellar environments. Fractionation an immunogold labeling indicated that full-length p13(II) accumulates in the inner mitochondrial membrane. p13(9-41) induced energy-dependent swelling of isolated mitochondria by increasing inner membrane permeability to small cations (Na+, K+) and released Ca2+ from Ca2+-preloaded mitochondria. These effects as well as the ability of full-length p13(II) to alter mitochondrial morphology in cells required the presence of four arginines, forming the charged face of the targeting signal. The mitochondrial effects of p13(9-41) were insensitive to cyclosporin A, suggesting that full-length p13(II) might alter mitochondrial permeability through a permeability transition pore-independent mechanism, thus distinguishing it from the mitochondrial proteins Vpr and X of human immunodeficiency virus type 1 and hepatitis B virus, respectively.	Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy; Univ Padua, CNR, Inst Neurosci, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, Dept Biol Chem, I-35121 Padua, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Sapienza University Rome	Ciminale, V (corresponding author), Univ Padua, Dipartimento Sci Oncol & Chirurg, Via Gattemelata 64, I-35128 Padua, Italy.	v.ciminale@unipd.it	Silic-Benussi, Micol/K-4747-2016; Cavallari, Ilaria/D-7149-2018; Petronilli, Valeria/C-3558-2015; Ciminale, Vincenzo/L-1416-2016; Bernardi, Paolo/C-3656-2008; D'Agostino, Donna/AAW-1765-2021; Arrigoni, Giorgio/A-3535-2014	Silic-Benussi, Micol/0000-0001-8561-1027; Cavallari, Ilaria/0000-0002-7430-9137; Petronilli, Valeria/0000-0003-4026-6404; Ciminale, Vincenzo/0000-0001-6197-1802; Bernardi, Paolo/0000-0001-9187-3736; D'Agostino, Donna/0000-0002-3451-5622; Arrigoni, Giorgio/0000-0002-4103-2733				Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Boya P, 2001, EMBO J, V20, P4325, DOI 10.1093/emboj/20.16.4325; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1999, J VIROL, V73, P9642, DOI 10.1128/JVI.73.11.9642-9649.1999; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; DORDICK RS, 1980, J BIOL CHEM, V255, P299; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Green P. L., 2001, FIELDS VIROLOGY, P1941; Hou XH, 2000, VIROLOGY, V277, P127, DOI 10.1006/viro.2000.0604; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Kerkhofs P, 1998, J VIROL, V72, P2554, DOI 10.1128/JVI.72.3.2554-2559.1998; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128/JVI.76.3.1400-1414.2002; Lu Y, 1997, J BIOL CHEM, V272, P13555, DOI 10.1074/jbc.272.21.13555; Marin O, 1997, BIOCHEMISTRY-US, V36, P7192, DOI 10.1021/bi962885q; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532	44	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34424	34433		10.1074/jbc.M203023200	http://dx.doi.org/10.1074/jbc.M203023200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093802	hybrid			2022-12-27	WOS:000177959100115
J	Hyogo, H; Roy, S; Paigen, B; Cohen, DE				Hyogo, H; Roy, S; Paigen, B; Cohen, DE			Leptin promotes biliary cholesterol elimination during weight loss in ob/ob mice by regulating the enterohepatic circulation of bile salts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALLSTONE FORMATION; HEPATIC CHOLESTEROL; ACID SYNTHESIS; MODEL BILE; OBESE; HEPATOCYTES; ABSORPTION; LECITHIN; 7-ALPHA-HYDROXYLASE; GLUCONEOGENESIS	Leptin administration to obese C57BL/6J (ob/ob) mice results in weight loss by reducing body fat. Because adipose tissue is an important storage depot for cholesterol, we explored evidence that leptin-induced weight loss in ob/ob mice was accompanied by transport of cholesterol to the liver and its elimination via bile. Consistent with mobilization of stored cholesterol, cholesterol concentrations in adipose tissue remained unchanged during weight loss. Plasma cholesterol levels fell sharply, and microscopic analyses of gallbladder bile revealed cholesterol crystals as well as cholesterol gallstones. Surprisingly, leptin reduced biliary cholesterol secretion rates without affecting secretion rates of bile salts or phospholipids. Instead, cholesterol supersaturation of gallbladder bile was due to marked decreases in bile salt hydrophobicity and not to hypersecretion of biliary cholesterol per se, such as occurs in humans during weight loss. In addition to regulating bile salt composition, leptin treatment decreased bile salt pool size. The smaller, more hydrophilic bile salt pool was associated with substantial decreases in intestinal cholesterol absorption. Within the liver, leptin treatment reduced the activity of 3-hydroxy-3-methylglutaryl-CoA reductase, but it did not change activities of cholesterol 7alpha-hydroxylase or acyl-CoA:cholesterol acyltransferase. These data suggest that leptin regulates biliary lipid metabolism to promote efficient elimination of excess cholesterol stored in adipose tissue. Cholesterol gallstone formation during weight loss in ob/ob mice appears to represent a pathologic consequence of an adaptive response that prevents absorption of biliary and dietary cholesterol.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Biochem, Bronx, NY 10461 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Jackson Laboratory	Cohen, DE (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Ullmann 625,1300 Morris Pk Ave, Bronx, NY 10461 USA.	dcohen@aecom.yu.edu			NIDDK NIH HHS [DK 51568, DK 48873] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048873, R55DK051568, R01DK048873, R01DK051568] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiston S, 1999, DIABETES, V48, P15, DOI 10.2337/diabetes.48.1.15; AKIYOSHI T, 1986, J LIPID RES, V27, P915; ANGEL A, 1974, J LIPID RES, V15, P491; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; Bouchard G, 2002, J LIPID RES, V43, P1105, DOI 10.1194/jlr.M200102-JLR200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; Carey Martin C., 1994, P719; Carey MC, 1997, GUT, V41, P721, DOI 10.1136/gut.41.5.721; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; COHEN DE, 1991, J LIPID RES, V32, P1291; COHEN DE, 1990, J LIPID RES, V31, P55; COHEN DE, 1999, CURR OPIN LIPIDOL, V235, P111; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; GLOMSET JA, 1968, J LIPID RES, V9, P155; Goldblatt MI, 2002, J GASTROINTEST SURG, V6, P438, DOI 10.1016/S1091-255X(01)00046-4; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEUMAN DM, 1989, J LIPID RES, V30, P719; Igel M, 2002, LIPIDS, V37, P153, DOI 10.1007/s11745-002-0875-5; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; Mardones P, 2001, J LIPID RES, V42, P170; MASHIGE F, 1981, CLIN CHEM, V27, P1352; Nemecz M, 1999, HEPATOLOGY, V29, P166, DOI 10.1002/hep.510290110; NERVI FO, 1978, BIOCHIM BIOPHYS ACTA, V529, P212, DOI 10.1016/0005-2760(78)90064-4; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PATTON GM, 1987, CHROMATOGRAPHY LIPID, P311; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Sakomoto M, 2002, BIOCHEM J, V362, P105, DOI 10.1042/0264-6021:3620105; Schwarz M, 1998, J LIPID RES, V39, P1833; Sehayek E, 2001, J LIPID RES, V42, P1250; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; SHEFER S, 1986, METHODS ASSAY, P43; SHIFFMAN ML, 1991, AM J GASTROENTEROL, V86, P1000; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; SMITH JL, 1986, CLIN CHIM ACTA, V158, P271, DOI 10.1016/0009-8981(86)90291-3; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; van der Meer R, 1985, CHOLESTEROL METABOLI; VanPatten S, 2001, AM J PHYSIOL-GASTR L, V281, pG393, DOI 10.1152/ajpgi.2001.281.2.G393; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Wang DP, 1996, J LIPID RES, V37, P1831; Wang DQH, 1996, J LIPID RES, V37, P606; Wang DQH, 1999, HEPATOLOGY, V30, p395A	48	62	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34117	34124		10.1074/jbc.M203912200	http://dx.doi.org/10.1074/jbc.M203912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114517	hybrid			2022-12-27	WOS:000177959100078
J	Kanelakis, KC; Shewach, DS; Pratt, WB				Kanelakis, KC; Shewach, DS; Pratt, WB			Nucleotide binding states of hsp70 and hsp90 during sequential steps in the process of glucocorticoid receptor hsp90 heterocomplex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE HSC70; ATP-BINDING; STEROID-BINDING; PROGESTERONE-RECEPTOR; RETICULOCYTE LYSATE; HEAT-SHOCK-PROTEIN-90; COMPLEX; DOMAIN; RECONSTITUTION	A minimal system of five purified proteins, hsp90, hsp70, Hop, hsp40, and p23, assembles glucocorticoid receptor (GR)(.)hsp90 heterocomplexes and causes the simultaneous opening of the steroid binding cleft to access by steroid. The first step in assembly is the ATP-dependent and hsp40 (YDJ-1)-dependent binding of hsp70 to the GR, which primes the receptor for subsequent ATP-dependent activation by hsp90, Hop, and p23 (Morishima, Y., Murphy, P. J. M., Li, D. P., Sanchez, E. R., and Pratt, W. B. (2000) J. Biol. Chem. 275,18054-18060). Here we have examined the nucleotide-bound states of the two essential chaperones in each step. We show that it is the ATP-bound state of hsp70 that interacts initially with the GR. After rapid priming and washing, the primed GR(.)hsp70 complex rapidly binds hsp90 in the second step reaction in a nucleotide-independent manner. The rate-limiting step is the ATP-dependent opening of the steroid binding cleft after hsp90 binding. This activating step requires the N-terminal ATP-binding site of hsp90, but we cannot establish any role for a C-terminal ATP-binding site in steroid binding cleft opening. The reported specific inhibitors of the C-terminal ATP site on hsp90 inhibit the generation of steroid binding, but they have other effects in this multiprotein system that could explain the inhibition.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R56CA076581, R01CA076581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76581] Funding Source: Medline; NIDDK NIH HHS [DK 31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boucher PD, 1998, HUM GENE THER, V9, P801, DOI 10.1089/hum.1998.9.6-801; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Itoh H, 1999, BIOCHEM J, V343, P697, DOI 10.1042/0264-6021:3430697; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMID SL, 1985, J BIOL CHEM, V260, P57; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	42	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33698	33703		10.1074/jbc.M204164200	http://dx.doi.org/10.1074/jbc.M204164200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093808	hybrid			2022-12-27	WOS:000177959100024
J	Lucien, N; Sidoux-Walter, F; Roudier, N; Ripoche, P; Huet, M; Trinh-Trang-Tan, MM; Cartron, JP; Bailly, P				Lucien, N; Sidoux-Walter, F; Roudier, N; Ripoche, P; Huet, M; Trinh-Trang-Tan, MM; Cartron, JP; Bailly, P			Antigenic and functional properties of the human red blood cell urea transporter hUT-B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIP28 WATER CHANNEL; MOLECULAR CHARACTERIZATION; HUMAN-ERYTHROCYTES; PROTEIN; EXPRESSION; CLONING; KIDNEY; GENE; PERMEABILITY; AQUAPORIN-2	The Kidd (JK) blood group locus encodes the urea transporter hUT-B1, which is expressed on human red blood cells and other tissues. The common JK*A/JK*B blood group polymorphism is caused by a single nucleotide transition G838A changing Asp-280 to Asn-280 on the polypeptide, and transfection of erythroleukemic K562 cells with hUT-B1 cDNAs carrying either the G838 or the A838 nucleotide substitutions resulted in the isolation of stable clones that expressed the Jk(a) or Jk(b) antigens, respectively, thus providing the first direct demonstration that the hUT-B1 gene encodes the Kidd blood group antigens. In addition, immunochemical analysis of red blood cells demonstrated that hUT-B1 also exhibits ABO determinants attached to the single N-linked sugar chain at Asn-211. Moreover, immunoadsorption studies, using inside-out and right-side-out red cell membrane vesicles as competing antigen, demonstrated that the C- and N-terminal ends of hUT-B1 are oriented intracellularly. Mutagenesis and functional studies by expression in Xenopus oocytes revealed that both cysteines Cys-25 and Cys-30 (but not alone) are essential for plasma membrane addressing. Conversely, the transport function was not affected by the JK*A/JK*B polymorphism, C-terminal deletion (residues 360389), or mutation of the extracellular N-glycosylation consensus site and remains poorly para-chloromercuribenzene sulfonate (pCMBS)-sensitive. However, transport studies by stopped flow light scattering using JkK562 transfectants demonstrated that the hUT-B1-mediated urea transport is pCMBS-sensitive in an erythroid context, as reported previously for the transporter of human red blood cells. Mutagenesis analysis also indicated that Cys-151 and Cys-236, at least alone, are not involved in pCMBS inhibition. Altogether, these antigenic, topologic, and functional properties might have implications into the physiology of hUT-B1 and other members of the urea transporter family.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.							ANSTEE DJ, 1990, VOX SANG, V58, P1, DOI 10.1111/j.1423-0410.1990.tb02049.x; Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; Bagnasco SM, 2000, CELL PHYSIOL BIOCHEM, V10, P379, DOI 10.1159/000016377; Bai LQ, 1996, J BIOL CHEM, V271, P5171; Baumgarten R, 1998, J AM SOC NEPHROL, V9, P1553; BLOY C, 1987, BLOOD, V69, P1491; BOYLE JM, 1985, EMBO J, V4, P3093, DOI 10.1002/j.1460-2075.1985.tb04050.x; DANIELS G, 1995, HUMAN BLOOD GROUPS, P440; Fenton RA, 1999, CYTOGENET CELL GENET, V87, P95, DOI 10.1159/000015401; Fenton RA, 2000, AM J PHYSIOL-CELL PH, V279, pC1425, DOI 10.1152/ajpcell.2000.279.5.C1425; Fievet B, 1998, P NATL ACAD SCI USA, V95, P10996, DOI 10.1073/pnas.95.18.10996; FUKUDA M, 1981, J SUPRAMOL STR CELL, V17, P313, DOI 10.1002/jsscb.380170403; Gerbeau P, 1999, PLANT J, V18, P577, DOI 10.1046/j.1365-313x.1999.00481.x; Iolascon A, 1996, HAEMATOLOGICA, V81, P543; Irshaid NM, 2002, BRIT J HAEMATOL, V116, P445, DOI 10.1046/j.1365-2141.2002.03238.x; JENKINS DE, 1977, TRANSFUSION, V17, P110, DOI 10.1046/j.1537-2995.1977.17277151914.x; LAIZE V, 1995, FEBS LETT, V373, P269, DOI 10.1016/0014-5793(95)01060-R; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; Lucien N, 2002, BLOOD, V99, P1079, DOI 10.1182/blood.V99.3.1079; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MACEY RI, 1988, AM J PHYSIOL, V254, pG669; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Olives B, 1997, HUM MOL GENET, V6, P1017, DOI 10.1093/hmg/6.7.1017; OLIVES B, 1994, J BIOL CHEM, V269, P31649; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; PINKERTON F J, 1959, Vox Sang, V4, P155; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Promeneur D, 1996, J AM SOC NEPHROL, V7, P852; RACE RR, 1975, BLOOD GROUPS MAN, P178; Rousselet G, 1996, AM J PHYSIOL-RENAL, V270, pF554, DOI 10.1152/ajprenal.1996.270.3.F554; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 1997, AM J PHYSIOL-RENAL, V273, pF321, DOI 10.1152/ajprenal.1997.273.3.F321; Sidoux-Walter F, 2000, BLOOD, V96, P1566, DOI 10.1182/blood.V96.4.1566.h8001566_1566_1573; Sidoux-Walter F, 1999, J BIOL CHEM, V274, P30228, DOI 10.1074/jbc.274.42.30228; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; Smith CP, 2001, J MEMBRANE BIOL, V183, P1, DOI 10.1007/s00232-001-0048-7; Steck T L, 1974, Methods Enzymol, V31, P172; TIMMER RT, 2001, AM J PHYSIOL, V281, pG1318; TRINHTRANGTAN MM, 2002, IN PRESS AM J PHYSL, V280; Tsukaguchi H, 1998, AM J PHYSIOL-RENAL, V275, pF319, DOI 10.1152/ajprenal.1998.275.3.F319; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Xu YC, 1997, KIDNEY INT, V51, P138, DOI 10.1038/ki.1997.17; Yang B, 2002, J BIOL CHEM, V277, P10633, DOI 10.1074/jbc.M200207200; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	51	50	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34101	34108		10.1074/jbc.M205073200	http://dx.doi.org/10.1074/jbc.M205073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093813	hybrid			2022-12-27	WOS:000177959100076
J	Nishino, T; Pusey, CD; Domin, J				Nishino, T; Pusey, CD; Domin, J			Elevated Akt phosphorylation as an indicator of renal tubular epithelial cell stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; OSMOTIC-STRESS; SURVIVAL; MITOGEN; APOPTOSIS; NECROSIS	Characterization of the phosphoinositide 3-kinase-signaling pathway in a human renal tubular epithelial cell (TEC) line HKC-8 revealed high levels of Akt phosphorylation in serum-starved cultures. In contrast to Erk1/2, little additional phosphorylation of Akt was observed after cytokine or serum stimulation. Replacement of the conditioned medium attenuated Akt phosphorylation such that 90 min after the addition of warmed serum-free media, Akt phosphorylation. had fallen sufficiently to allow an epidermal growth factor-stimulated increase to be detected readily. Although the mechanism by which the phosphoinositide 3-kinase/Akt pathway is activated in serum-starved TEC is unknown, the mediator responsible is secreted from these cells. Thus, conditioned media removed from a dish of quiescent TECs stimulated Akt phosphorylation in washed TEC cultures within 10 min. Biochemical characterization of the bioactive agent identified a heat labile factor of small apparent molecular mass. The basal level of Akt phosphorylation observed in serum-starved cultures was inhibited by wortmannin at concentrations that demonstrated its dependence on 3-phosphoinositide synthesis (IC50 = 8 nm). Regular removal of conditioned media from TEC cultures and its replacement with serum free media resulted in a sustained attenuation of Akt phosphorylation. Interestingly, after 5 days of this treatment, washed TEC cultures contained a greater number of viable cells than cultures maintained in conditioned media throughout. This observation was not explained by a difference in the rate of DNA synthesis. Instead, the number of cells undergoing apoptosis increased markedly in the unwashed cultures. Consequently, we propose that in HKC-8 cells Akt phosphorylation is up-regulated in an effort to minimize cell death. This stress-activated response is initiated by a factor secreted into the conditioned medium that stimulates the phosphoinositide 3-kinase signaling pathway.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Renal Sect, London W12 0NN, England	Imperial College London	Domin, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Renal Sect, Du Cane Rd, London W12 0NN, England.	j.domin@ic.ac.uk						BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burton CJ, 1999, NEPHROL DIAL TRANSPL, V14, P2628, DOI 10.1093/ndt/14.11.2628; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HOMMA T, 1995, J CLIN INVEST, V96, P1018, DOI 10.1172/JCI118087; Igleslas J, 1999, AM J PHYSIOL-RENAL, V277, pF711, DOI 10.1152/ajprenal.1999.277.5.F711; Kanellis J, 2000, AM J PHYSIOL-RENAL, V278, pF905, DOI 10.1152/ajprenal.2000.278.6.F905; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li NX, 2000, METHOD ENZYMOL, V319, P273; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RISDON RA, 1968, LANCET, V2, P363; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Schainuck L I, 1970, Hum Pathol, V1, P631, DOI 10.1016/S0046-8177(70)80061-2; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki K, 2001, CANCER RES, V61, P5396; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	46	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33943	33949		10.1074/jbc.M201338200	http://dx.doi.org/10.1074/jbc.M201338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114503	hybrid			2022-12-27	WOS:000177959100056
J	Jakubowski, H				Jakubowski, H			Homocysteine is a protein amino acid in humans - Implications for homocysteine-linked disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOLOGICAL CONSEQUENCES; PLASMA HOMOCYSTEINE; POSSIBLE MECHANISM; THIOLACTONE; PARAOXONASE	Homocysteine is thought to be a non-protein amino acid. However, in vitro studies suggest that homocysteine is likely to be incorporated by indirect mechanisms into proteins in living organisms. Here I show that homocysteine is a protein amino acid in humans. Homocysteine bound by amide or peptide linkages (Hcy-N-protein) is present in human hemoglobin, serum albumin, and gamma-1-globulins. 1 molecule of homocysteine per 1000 or 1670 molecules of methionine was present in hemoglobin or albumin, respectively. Other proteins, such as low density lipoprotein, high density lipoprotein, transferrin, antitrypsin, and fibrinogen, contained lower amounts of Hcy-N-protein. In human plasma, levels of Hcy-N-protein represented from 0.3 to 23% of total homocysteine. Thus, Hcy-N-protein is a significant component of homocysteine metabolism in humans, possibly contributing to adverse effects of homocysteine on human cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Int Ctr Publ Hlth, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Int Ctr Publ Hlth, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				Anderson JL, 2000, CIRCULATION, V102, P1227, DOI 10.1161/01.CIR.102.11.1227; Baernstein HD, 1934, J BIOL CHEM, V106, P451; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Ferguson E, 1998, J LIPID RES, V39, P925; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P21; Jakubowski H, 2001, J NUTR, V131, p2983S, DOI 10.1093/jn/131.11.2983S; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J BIOL CHEM, V275, P21813, DOI 10.1074/jbc.C000280200; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2002, AMINOACYL TRNA SYNTH; JAKUBOWSKI H, 2001, ENCY LIFE SCI, V18, P441; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; Malinski T, 1996, PHYSIOL RES, V45, P279; Mercie P, 2000, APOPTOSIS, V5, P403, DOI 10.1023/A:1009652011466; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Mudd SH, 2000, ARTERIOSCL THROM VAS, V20, P1704, DOI 10.1161/01.ATV.20.7.1704; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; RACKER E, 1955, J BIOL CHEM, V217, P867; Riegel B, 1935, J BIOL CHEM, V112, P149; ROSENBLATT D, 2001, METABOLIC MOL BASES, V2, P3897; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; Ueland PM, 2000, AM J CLIN NUTR, V72, P324	32	157	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30425	30428		10.1074/jbc.C200267200	http://dx.doi.org/10.1074/jbc.C200267200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12093791	hybrid			2022-12-27	WOS:000177579800005
J	Korkmaz, B; Attucci, S; Hazouard, E; Ferrandiere, M; Jourdan, ML; Brillard-Bourdet, M; Juliano, L; Gauthier, F				Korkmaz, B; Attucci, S; Hazouard, E; Ferrandiere, M; Jourdan, ML; Brillard-Bourdet, M; Juliano, L; Gauthier, F			Discriminating between the activities of human neutrophil elastase and proteinase 3 using serpin-derived fluorogenic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; CYTOKINE RESPONSE MODIFIER; NECROSIS-FACTOR-ALPHA; CATHEPSIN-G; REACTIVE-SITE; ALPHA-1-PROTEINASE INHIBITOR; ACTIVATED NEUTROPHILS; CATALYTIC ACTIVITY; SERINE PROTEINASE; CYSTIC-FIBROSIS	Human neutrophil elastase (HNE) has long been linked to the pathology of a variety of inflammatory diseases and therefore is a potential target for therapeutic intervention. At least two other serine proteases, proteinase 3 (Pr3) and cathepsin G, are stored within the same neutrophil primary granules as HNE and are released from the cell at the same time at inflammatory sites. HNE and Pr3 are structurally and functionally very similar, and no substrate is currently available that is preferentially cleaved by Pr3 rather than HNE. Discrimination between these two proteases is the first step in elucidating their relative contributions to the development and spread of inflammatory diseases. Therefore, we have prepared new fluorescent peptidyl substrates derived from natural target proteins of the serpin family. This was done because serpins are rapidly cleaved within their reactive site loop whether they act as protease substrates or inhibitors. The hydrolysis of peptide substrates reflects the specificity of the parent serpin including those from a-l-protease inhibitor and monocyte neutrophil elastase inhibitor, two potent inhibitors of elastase and Pr3. More specific substrates for these proteases were derived from the reactive site loop of plasminogen activator inhibitor 1, proteinase inhibitors 6 and 9, and from the related viral cytokine response modifier A (CrmA). This improved specificity was obtained by using a cysteinyl residue at P1 for Pr3 and an Ile residue for HNE and because of occupation of protease S' subsites. These substrates enabled us to quantify nanomolar concentrations of HNE and Pr3 that were free in solution or bound at the neutrophil surface. As membrane-bound proteases resist inhibition by endogenous inhibitors, measuring their activity at the surface of neutrophils may be a great help in understanding their role during inflammation.	Univ Tours, INSERM EMI U0010, F-37032 Tours, France; Univ Tours, INSERM EMI U0211, F-37032 Tours, France; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Universidade Federal de Sao Paulo (UNIFESP)	Gauthier, F (corresponding author), Univ Tours, INSERM EMI U0010, 2Bis Blvd Tonnelle, F-37032 Tours, France.		Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; KORKMAZ, BRICE/0000-0002-5159-8706				ALLEN DH, 1995, J BIOL CHEM, V270, P1408, DOI 10.1074/jbc.270.3.1408; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; BLONDIN J, 1972, AM REV RESPIR DIS, V106, P477, DOI 10.1164/arrd.1972.106.3.477; BLOW AMJ, 1977, BIOCHEM J, V161, P13, DOI 10.1042/bj1610013; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; CARP H, 1980, J CLIN INVEST, V66, P987, DOI 10.1172/JCI109968; CHAGAS JR, 1991, ANAL BIOCHEM, V192, P419, DOI 10.1016/0003-2697(91)90558-B; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; CSERNOK E, 1994, CLIN EXP IMMUNOL, V95, P244; Dahlen JR, 1998, BIOCHEM BIOPH RES CO, V244, P172, DOI 10.1006/bbrc.1998.8225; Dahlen JR, 1999, BBA-MOL CELL RES, V1451, P233, DOI 10.1016/S0167-4889(99)00095-6; Duranton J, 2000, FEBS LETT, V473, P154, DOI 10.1016/S0014-5793(00)01512-X; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; EVANGELISTA V, 1991, BLOOD, V77, P2379; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; HUBBARD RC, 1991, LUNG SCI F, V2, P1775; KAM CM, 1992, FEBS LETT, V297, P119, DOI 10.1016/0014-5793(92)80340-M; LESTIENNE P, 1980, J BIOL CHEM, V255, P9289; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LUDEMANN J, 1990, J EXP MED, V171, P357, DOI 10.1084/jem.171.1.357; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; OLIVEIRA MCF, 1992, ANAL BIOCHEM, V203, P39, DOI 10.1016/0003-2697(92)90040-E; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAO NV, 1991, J BIOL CHEM, V266, P9540; RAY CA, 1992, CELL, V69, P697; Rehault S, 1999, J BIOL CHEM, V274, P13810, DOI 10.1074/jbc.274.20.13810; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scott FL, 1999, BLOOD, V93, P2089, DOI 10.1182/blood.V93.6.2089.406k10_2089_2097; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P1301, DOI 10.1021/bi00379a015; SUGIMORI T, 1995, AM J RESP CELL MOL, V13, P314, DOI 10.1165/ajrcmb.13.3.7654387; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; TETLEY TD, 1993, THORAX, V48, P560, DOI 10.1136/thx.48.5.560; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535	50	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39074	39081		10.1074/jbc.M202918200	http://dx.doi.org/10.1074/jbc.M202918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12114510	hybrid			2022-12-27	WOS:000178662500005
J	Muthumani, K; Hwang, DS; Desai, BM; Zhang, DH; Dayes, N; Green, DR; Weiner, DB				Muthumani, K; Hwang, DS; Desai, BM; Zhang, DH; Dayes, N; Green, DR; Weiner, DB			HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 VPR; VIRAL-PROTEIN-R; IMMUNODEFICIENCY-VIRUS; CYTOCHROME-C; IN-VIVO; CYCLE; ACTIVATION; MACROPHAGES; INHIBITION; EXPRESSION	Human immunodeficiency virus, type 1 (HIV-1), vpr gene encodes a 14-kDa virion-associated protein, which exhibits significant effects on human cells. One important property of Vpr is its ability to induce apoptosis during infection. Apoptotic induction is likely to play a role in the pathogenesis of AIDS. However, the pathway of apoptosis is not clearly defined. In this report we investigate the mechanism of apoptosis induced by HIV-1 Vpr using a Vpr pseudotype viral infection system or adeno delivery of Vpr in primary human lymphoid cells and T-cells. With either vector, HIV-1 Vpr induced cell cycle arrest at the G(2)/M phase and apoptosis in lymphoid target cells. Furthermore, we observed that with both vectors, caspase 9, but not caspase 8, was activated following infection of human peripheral blood mononuclear cell with either Vpr-positive HIV virions or adeno-delivered Vpr. Activation of the caspase 9 pathway resulted in caspase 3 activation and apoptosis in human primary cells. These effects were coincident with the disruption of the mitochondrial transmembrane potential and induction of cytochrome c release by Vpr. The Vpr-induced signaling pathway did not induce CD95 or CD95L expression. Bcl-2 overexpressing cells succumb to Vpr-induced apoptosis. These studies illustrate that Vpr induces a mitochondria-dependent apoptotic pathway that is distinct from apoptosis driven by the Fas-FasL pathway.	Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, Philadelphia, PA 19104 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Viral Genomix, Philadelphia, PA 19104 USA	University of Pennsylvania; La Jolla Institute for Immunology	Weiner, DB (corresponding author), Univ Penn, Dept Pathol & Lab Med, Stellar Chance Labs 505, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Muthumani, Kar/C-8252-2017; Weiner, David B/H-8579-2014; Muthumani, Kar/AAQ-4939-2020; Muthumani, Karuppiah/D-1092-2009; Green, Douglas R/N-8083-2018	Muthumani, Kar/0000-0002-6807-2065; Muthumani, Kar/0000-0002-6807-2065; Green, Douglas R/0000-0002-7332-1417				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; BOON B, 1998, SCIENCE, V281, P266; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; Lee JW, 1997, J IMMUNOL, V159, P3211; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, TRANSACTIVATING FUNC, P209; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Muthumani K, 2000, DNA CELL BIOL, V19, P179, DOI 10.1089/104454900314564; Muthumani K, 2000, J LEUKOCYTE BIOL, V68, P366; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Stewart SA, 1999, P NATL ACAD SCI USA, V96, P12039, DOI 10.1073/pnas.96.21.12039; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	119	123	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37820	37831		10.1074/jbc.M205313200	http://dx.doi.org/10.1074/jbc.M205313200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12095993	hybrid			2022-12-27	WOS:000178447100117
J	Bertoldi, M; Gonsalvi, M; Contestabile, R; Voltattorni, CB				Bertoldi, M; Gonsalvi, M; Contestabile, R; Voltattorni, CB			Mutation of tyrosine 332 to phenylalanine converts dopa decarboxylase into a decarboxylation-dependent oxidative deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID DECARBOXYLASE; ACTIVE-SITE; FLEXIBLE LOOP; 3,4-DIHYDROXYPHENYLALANINE DECARBOXYLASE; ASPARTATE-AMINOTRANSFERASE; REACTION SPECIFICITY; RESIDUES; SEROTONIN; MOBILE	A flexible loop (residues 328-339), presumably covering the active site upon substrate binding, has been revealed in 3,4-dihydroxyphenylalanine decarboxylase by means of kinetic and structural studies. The function of tyrosine 332 has been investigated by substituting it with phenylalanine. Y332F displays coenzyme content and spectroscopic features identical to those of the wild type. Unlike wild type, during reactions with L-aromatic amino acids under both aerobic and anaerobic conditions, Y332F does not catalyze the formation of aromatic amines. However, analysis of the products shows that in aerobiosis, L-aromatic amino acids are converted into the corresponding aromatic aldehydes, ammonia, and CO2 with concomitant O-2 consumption. Therefore, substitution of Tyr-332 with phenylalanine results in the suppression of the original activity and in the generation of a decarboxylation-dependent oxidative deaminase activity. In anaerobiosis, Y332F catalyzes exclusively a decarboxylation-dependent transamination of L-aromatic amino acids. A role of Tyr-332 in the Calpha protonation. step that catalyzes the formation of physiological products has been proposed. Furthermore, Y332F catalyzes oxidative deamination of aromatic amines and half-transamination of D-aromatic amino acids with k(cat) values comparable with those of the wild type. However, for all the mutant-catalyzed reactions, an increase in K-m values is observed, suggesting that Y --> F replacement also affects substrate binding.	Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	University of Verona; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Voltattorni, CB (corresponding author), Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, Strade Le Grazie,8, I-37134 Verona, Italy.		Bertoldi, Mariarita/F-1154-2010; Contestabile, Roberto/J-3467-2019	Bertoldi, Mariarita/0000-0002-2337-9928; Contestabile, Roberto/0000-0002-5235-9993				Bertoldi M, 2001, PROTEIN SCI, V10, P1178, DOI 10.1110/ps.46601; Bertoldi M, 2000, BIOCHEM J, V352, P533, DOI 10.1042/0264-6021:3520533; Bertoldi M, 2001, EUR J BIOCHEM, V268, P2975, DOI 10.1046/j.1432-1327.2001.02187.x; Bertoldi M, 1999, J BIOL CHEM, V274, P5514, DOI 10.1074/jbc.274.9.5514; Bertoldi M, 1996, J BIOL CHEM, V271, P23954, DOI 10.1074/jbc.271.39.23954; Bertoldi M, 1998, BIOCHEMISTRY-US, V37, P6552, DOI 10.1021/bi9718898; Burkhard P, 2001, NAT STRUCT BIOL, V8, P963, DOI 10.1038/nsb1101-963; CHARTERIS A, 1975, ANAL BIOCHEM, V66, P365, DOI 10.1016/0003-2697(75)90604-1; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; Contestabile R, 2000, J BIOL CHEM, V275, P3879, DOI 10.1074/jbc.275.6.3879; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; Graber R, 1999, J BIOL CHEM, V274, P31203, DOI 10.1074/jbc.274.44.31203; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Ishii S, 1998, PROTEIN SCI, V7, P1802, DOI 10.1002/pro.5560070816; Ishii S, 1996, J BIOCHEM, V120, P369; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Krell T, 2001, PROTEIN SCI, V10, P1137, DOI 10.1110/ps.52501; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; Moore PS, 1996, BIOCHEM J, V315, P249, DOI 10.1042/bj3150249; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SHERALD AF, 1973, ANAL BIOCHEM, V56, P300, DOI 10.1016/0003-2697(73)90194-2; TANCINI B, 1988, ARCH BIOCHEM BIOPHYS, V260, P569, DOI 10.1016/0003-9861(88)90483-3; VACCA RA, 1995, EUR J BIOCHEM, V227, P481, DOI 10.1111/j.1432-1033.1995.tb20413.x; Zgiby S, 2002, J MOL BIOL, V315, P131, DOI 10.1006/jmbi.2001.5237	28	53	55	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36357	36362		10.1074/jbc.M204867200	http://dx.doi.org/10.1074/jbc.M204867200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118007	hybrid			2022-12-27	WOS:000178275100074
J	Nash, MS; Schell, MJ; Atkinson, PJ; Johnston, NR; Nahorski, SR; Challiss, RAJ				Nash, MS; Schell, MJ; Atkinson, PJ; Johnston, NR; Nahorski, SR; Challiss, RAJ			Determinants of metabotropic glutamate receptor-5-mediated Ca2+ and inositol 1,4,5-trisphosphate oscillation frequency - Receptor density versus agonist concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALCIUM OSCILLATIONS; EXPRESSION LEVEL; HOMER; PHOSPHOINOSITIDE; PHOSPHORYLATION; ACTIVATION; INHIBITION; FEEDBACK; 1-ALPHA	Diverse patterns of Ca-i(2+) release differentially regulate Ca2+-sensitive enzymes and gene transcription, and generally the extent of agonist activation of phospholipase C-linked G protein-coupled receptors determines the type of Ca2+ signal. We have studied global Ca2+ oscillations arising through activation of the metabotropic glutamate receptor mGluR5a expressed in Chinese hamster ovary cells and find that these oscillations are largely insensitive to agonist concentration. Using an inducible receptor expression system and a non-competitive antagonist, in coWunction with the translocation of eGFP-PHPLCdelta, to monitor inositol 1,4,5-trisphosphate (InsP,) oscillations in single cells, we show that mGluR5a density determines the frequency of these oscillations. The predominant underlying mechanism resulted from a negative feedback loop whereby protein kinase C (PKC) inhibited InsP(3) generation. Down-regulation of PKC by prolonged exposure to phorbol ester revealed a second form of Ca-i(2+) oscillation at low agonist concentrations. These Ca-i(2+) signals showed features typical of classic repetitive Ca2+-induced Ca2+ release and were sensitive to agonist concentration. Therefore, a single receptor can stimulate two types of InsP(3)-mediated Ca2+ signal dependent upon feedback inhibition, producing two distinct means of controlling the final pattern of Ca-i(2+) release. Our results have physiological implications for Ca2+ signaling in general and emphasize the importance of mGluR5 surface expression for modulating synaptic plasticity.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Leicester; University of Cambridge	Nash, MS (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.	msn2@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848; Schell, Michael/0000-0003-1553-3582				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Ango F, 2000, J NEUROSCI, V20, P8710; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Ciruela F, 2000, MOL CELL NEUROSCI, V15, P36, DOI 10.1006/mcne.1999.0808; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dupont G, 2000, BBA-MOL CELL RES, V1498, P134, DOI 10.1016/S0167-4889(00)00090-2; Ehlers MD, 1999, CURR BIOL, V9, pR848, DOI 10.1016/S0960-9822(00)80043-3; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hermans E, 1999, BRIT J PHARMACOL, V126, P873, DOI 10.1038/sj.bjp.0702359; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hermans E, 1998, J NEUROCHEM, V70, P1772; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hubert GW, 2001, J NEUROSCI, V21, P1838, DOI 10.1523/JNEUROSCI.21-06-01838.2001; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Leung YM, 2002, BBA-MOL CELL RES, V1589, P93, DOI 10.1016/S0167-4889(02)00161-1; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Muyderman H, 2001, J BIOL CHEM, V276, P46504, DOI 10.1074/jbc.M103849200; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Nash MS, 2001, J NEUROCHEM, V77, P1664, DOI 10.1046/j.1471-4159.2001.00405.x; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Okabe S, 2001, J NEUROSCI, V21, P9561, DOI 10.1523/JNEUROSCI.21-24-09561.2001; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Petersen OH, 1999, TRENDS NEUROSCI, V22, P488, DOI 10.1016/S0166-2236(99)01456-3; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schuster S, 2002, EUR J BIOCHEM, V269, P1333, DOI 10.1046/j.0014-2956.2001.02720.x; Selkirk JV, 2001, NEUROPHARMACOLOGY, V40, P645, DOI 10.1016/S0028-3908(00)00208-2; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; ZHANG BX, 1992, J BIOL CHEM, V267, P24387	56	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35947	35960		10.1074/jbc.M205622200	http://dx.doi.org/10.1074/jbc.M205622200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119301	hybrid			2022-12-27	WOS:000178275100025
J	Veenendaal, AKJ; van der Does, C; Driessen, AJM				Veenendaal, AKJ; van der Does, C; Driessen, AJM			The core of the bacterial translocase harbors a tilted transmembrane segment 3 of SecE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; MEMBRANE TRANSLOCATION; CATALYTIC CYCLE; CROSS-LINKING; SECYEG; MACHINERY; PRLA; RECONSTITUTION	The bacterial translocase mediates the translocation and membrane integration of proteins. The integral membrane proteins SecY and SecE are conserved core subunits of the translocase. Previous cysteine-scanning studies showed that the transmembrane segment (TMS) 3 of SecE contacts TMS 2 and 7 of SecY, and TMS 3 of another SecE. We now demonstrate that SecE also contacts,TMS 10 of SecY. Combining all available cysteine-scanning mutagenesis data, a three-dimensional model has been built in which the positions of the helices that form the central core of the bacterial translocase are mapped. Remarkably, this model reveals that TMS 3 of SecE is strongly tilted relative to SecY.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	aj.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; HANADA M, 1994, J BIOL CHEM, V269, P23625; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393	30	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36640	36645		10.1074/jbc.M205713200	http://dx.doi.org/10.1074/jbc.M205713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138117	hybrid, Green Published			2022-12-27	WOS:000178275100109
J	Ahel, I; Stathopoulos, C; Ambrogelly, A; Sauerwald, A; Toogood, H; Hartsch, T; Soll, D				Ahel, I; Stathopoulos, C; Ambrogelly, A; Sauerwald, A; Toogood, H; Hartsch, T; Soll, D			Cysteine activation is an inherent in vitro property of Prolyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; GENETIC-CODE; AMINO-ACIDS; METHANOCOCCUS-JANNASCHII; EDITING MECHANISM; PROTEIN-SYNTHESIS; BIOSYNTHESIS; SPECIFICITY	Aminoacyl-tRNA synthetases are well known for their remarkable precision in substrate selection during aminoacyl-tRNA formation. Some synthetases enhance the accuracy of this process by editing mechanisms that lead to hydrolysis of incorrectly activated and/or charged amino acids. Prolyl-tRNA synthetases (ProRSs) can be divided into two structurally divergent groups, archaeal-type and bacterial-type enzymes. A striking difference between these groups is the presence of an insertion domain (similar to180 amino acids) in the bacterial-type ProRS. Because the archaeal-type ProRS enzymes have been shown to recognize cysteine, we tested selected ProRSs from all three domains of life to determine whether cysteine activation is a general property of ProRS. Here we show that cysteine is activated by recombinant ProRS enzymes from the archaea Methanocaldococcus jannaschii and Methanothermobacter thermautotrophicus, from the eukaryote Saccharomyces cerevisiae, and from the bacteria Aquifex aeolicus, Borrelia burgdorferi, Clostridium sticklandii, Cytophaga hutchinsonii, Deinococcus radiodurans, Escherichia coli, Magnetospirillum magnetotacticum, Novosphingobium aromaticivorans, Rhodopseudomonas palustris, and Thermus thermophilus. This non-cognate amino acid was efficiently acylated in vitro onto tRNA Pro, and the misacylated Cys-tRNA(Pro) was not edited by ProRS. Therefore, ProRS exhibits a natural level of mischarging that is to date unequalled among the aminoacyl-tRNA synthetases.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	Yale University; Yale University; University of Gottingen	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Stathopoulos, Constantinos/0000-0002-5699-4118; Ahel, Ivan/0000-0002-9446-3756; Toogood, Helen/0000-0003-4797-0293				Ambrogelly A, 2002, J BIOL CHEM, V277, P34749, DOI 10.1074/jbc.M206929200; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Brooks DJ, 2002, MOL CELL PROTEOMICS, V1, P125, DOI 10.1074/mcp.M100001-MCP200; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; Burke B, 2001, J BIOL CHEM, V276, P20286, DOI 10.1074/jbc.M100456200; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; de Pouplana LR, 2001, J MOL EVOL, V53, P261, DOI 10.1007/s002390010216; Di Giulio M, 1999, J MOL EVOL, V49, P1, DOI 10.1007/PL00006522; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Doring V, 1998, GENETICS, V150, P543; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Feng L, 2002, EXTREMOPHILES, V6, P167, DOI 10.1007/s007920100245; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1245, DOI 10.1021/bi00574a020; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; GILLAM I, 1967, BIOCHEMISTRY-US, V6, P3043, DOI 10.1021/bi00862a011; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Jacquin-Becker C, 2002, FEBS LETT, V514, P34, DOI 10.1016/S0014-5793(02)02331-1; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Kabisch UC, 1999, J BIOL CHEM, V274, P8445, DOI 10.1074/jbc.274.13.8445; LEE ML, 1969, J BIOL CHEM, V244, P223; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Newberry KJ, 2002, EMBO J, V21, P2778, DOI 10.1093/emboj/21.11.2778; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; RIVERA JA, 1984, CAN J BIOCHEM CELL B, V62, P507, DOI 10.1139/o84-068; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, BIOCHEMISTRY-US, V40, P46, DOI 10.1021/bi002108x; Trifonov EN, 2000, GENE, V261, P139, DOI 10.1016/S0378-1119(00)00476-5; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712	45	55	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34743	34748		10.1074/jbc.M206928200	http://dx.doi.org/10.1074/jbc.M206928200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130657	hybrid			2022-12-27	WOS:000178117000013
J	Harris, RG; White, E; Phillips, ES; Lillycrop, KA				Harris, RG; White, E; Phillips, ES; Lillycrop, KA			The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-I; C-MYC; DNA-BINDING; E-BOX; CELL-DIFFERENTIATION; MOUSE EMBRYO; GENE; GROWTH; MAX; TRANSCRIPTION	N-Myc is a member of the Myc family of transcription factors that have been shown to play a pivotal role in cell proliferation and differentiation. In this report, we have investigated the relationship between N-Myc and the developmental control gene Pax-3. Using transient transfection assays, we show that the Pax-3 promoter is activated by both N-Myc-Max and c-Myc-Max. Moreover, we show that Myc regulation of Pax-3 promoter activity is dependent upon a noncanonical E box site in the 5' promoter region of Pax-3. In addition, we show that ectopic expression of both N-Myc and c-Myc leads to increased expression of Pax-3 mRNA. Furthermore, we show that Pax-3 mRNA expression is cell cycle-regulated and that the 5' promoter region of Pax-3 (bp - 1578 to +56) can direct cell cycle-dependent gene expression with kinetics similar to that of the endogenous transcript. Site-directed mutagenesis of the E box site within the Pax-3 promoter significantly altered the pattern of expression through the cell cycle. These results suggest that the Myc family of transcription factors may modulate Pax-3 expression in vivo.	Univ Southampton, Sch Biol Sci, Dept Biochem & Mol Biol, Southampton SO16 7PX, Hants, England	University of Southampton	Lillycrop, KA (corresponding author), Univ Southampton, Sch Biol Sci, Dept Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	KAL@soton.ac.uk		Lillycrop, Karen/0000-0001-7350-5489				AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Barr FG, 1999, CANCER RES, V59, P5443; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Breit S, 2000, CANCER RES, V60, P4596; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chambery D, 1999, CANCER RES, V59, P2898; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FOY C, 1990, AM J HUM GENET, V46, P1017; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GORMALLY J, 1980, MOL INTERACTIONS, V2, P143; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HOTH CF, 1993, AM J HUM GENET, V52, P455; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KATO K, 1991, DEV GROWTH DIFFER, V33, P29; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Malynn BA, 2000, GENE DEV, V14, P1390; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORASCA L, 1986, ANIMAL CELL CULTURE, P125; Natoli TA, 1997, DEVELOPMENT, V124, P617; OWIGGAN N, 1998, ONCOGENE, V18, P227; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; Reeves FC, 1998, FEBS LETT, V422, P118, DOI 10.1016/S0014-5793(97)01598-6; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RUSSELL WL, 1947, GENETICS, V32, P102; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Scholl FA, 2001, CANCER RES, V61, P823; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; SIAMON DJ, 1986, SCIENCE, V232, P768; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227	54	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34815	34825		10.1074/jbc.M109609200	http://dx.doi.org/10.1074/jbc.M109609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095979	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000178117000023
J	Mao, JH; Maye, P; Kogerman, P; Tejedor, FJ; Toftgard, R; Xie, W; Wu, GQ; Wu, DQ				Mao, JH; Maye, P; Kogerman, P; Tejedor, FJ; Toftgard, R; Xie, W; Wu, GQ; Wu, DQ			Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEDGEHOG SIGNALING PATHWAY; SYNDROME CRITICAL REGION; CUBITUS-INTERRUPTUS; PROTEIN-KINASE; SONIC HEDGEHOG; DUAL-SPECIFICITY; PHOSPHORYLATION SITE; BINDING PROTEIN; HUMAN HOMOLOG; IN-VITRO	To investigate the cellular role of dual specificity Yak1-related kinase (Dyrk) 1, a nuclear localized dual specificity protein kinase, we examined its effect on transcriptional regulation using reporter gene assays. We found that Dyrk1 can substantially enhance Gli1-dependent, but not LEF-1-, c-Jun-, or Elk-dependent, gene transcription. In part, Dyrk1 does this through retaining Gli1 in the nucleus. However, we also demonstrate that Dyrk1 can enhance the transcriptional activity of Gli1-AHA, a nuclear export mutant, suggesting that Dyrk1 may be more directly involved in regulating the transcriptional activity of Gli1. In addition, Dyrk1 acted synergistically with Sonic hedgehog (Shh) to induce gene transcription and differentiation in mouse C3H10T1/2 cells. The failure of Shh to stimulate Dyrk1 kinase activity suggests that Dyrk1 may not be directly regulated by the Shh signaling pathway but functionally interacts with it. Thus, Gli1 transcriptional activity may be subjected to further regulation in the cell nucleus by a pathway distinct from Shh signaling, one mediated by Dyrk1.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Karolinska Inst, Dept Biosci, SE-14157 Huddinge, Sweden; Novum, Ctr Nutr & Toxicol, SE-14157 Huddinge, Sweden; Tallinn Univ Technol, NICPB, EE-200108 Tallinn, Estonia; Tallinn Univ Technol, Ctr Gene Technol, EE-200108 Tallinn, Estonia; Univ Miguel Hernandezy, CSIC, Inst Neurociencias, Unidad Neurobiol Desarrollo, Alicante 03550, Spain; Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; SE Univ, Sch Med, Dept Genet, Nanjing 210018, Peoples R China; Vanderbilt Univ, Dept Med Med Genet, Nashville, TN 37232 USA	University of Connecticut; Karolinska Institutet; Karolinska Institutet; National Institute of Chemical Physics & Biophysics (NICPB); Tallinn University of Technology; Tallinn University of Technology; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); University of Rochester; Southeast University - China; Vanderbilt University	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, MC3301,263 Farmington Ave, Farmington, CT 06030 USA.	dwu@neuron.uchc.edu	Kogerman, Priit/B-6333-2008	Maye, Peter/0000-0003-0098-4399; Tejedor, Francisco J/0000-0003-1942-2580				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 2000, MOL CELL BIOL, V20, P1616, DOI 10.1128/MCB.20.5.1616-1625.2000; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HARTLEY AD, 1994, GENETICS, V136, P465; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Methot N, 2000, DEVELOPMENT, V127, P4001; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Muller B, 2000, DEVELOPMENT, V127, P2999; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shang EY, 2000, MOL REPROD DEV, V55, P372, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;372::AID-MRD3&gt;3.0.CO;2-A; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Stone DM, 1999, J CELL SCI, V112, P4437; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	50	152	155	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35156	35161		10.1074/jbc.M206743200	http://dx.doi.org/10.1074/jbc.M206743200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12138125	hybrid			2022-12-27	WOS:000178117000064
J	Santos, M; Bravo, A; Lopez, C; Paramio, JM; Jorcano, JL				Santos, M; Bravo, A; Lopez, C; Paramio, JM; Jorcano, JL			Severe abnormalities in the oral mucosa induced by suprabasal expression of epidermal keratin K10 in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACHYONYCHIA-CONGENITA TYPE-2; MOUSE SKIN KERATINOCYTES; INTERMEDIATE FILAMENTS; STRATIFIED EPITHELIA; HAIR FOLLICLE; BASAL CELLS; DISEASE; GENE; CYTOKERATINS; PHENOTYPE	Previous studies have demonstrated that keratin K10 plays an important role in mediating cell signaling processes, since the ectopic expression of this keratin induces cell cycle arrest in proliferating cells in vitro and in vivo. However, apart from its well known function of providing epithelial cells with resilience to mechanical trauma, little is known about its possible roles in nondividing cells. To investigate what these might be, transgenic mice were generated in which the expression of K10 was driven by bovine K6beta gene control elements (bK6betahK10). The transgenic mice displayed severe abnormalities in the tongue and palate but not in other K6-expressing cells such as those of the esophagus, nails, and hair follicles. The lesions in the tongue and palate included the cytolysis of epithelial suprabasal cells associated with an acute inflammatory response and lymphocyte infiltration. The alterations in the oral mucosa caused the death of transgenic pups soon after birth, probably because suckling was impaired. These anomalies, together with others found in the teeth, are reminiscent of the lesions observed in some patients with pachyonychia congenita, an inherited epithelial fragility associated with mutations in keratins K6 and K16. Although no epithelial fragility was observed in the bK6betahK10 oral epithelia of the experimental mice, necrotic processes were seen. Collectively, these data show that the carefully regulated tissue- and differentiation-specific patterns displayed by the keratin genes have dramatic consequences on the biological behavior of epithelial cells and that changes in the specific composition of the keratin intermediate filament cytoskeleton can affect their physiology, in particular those of the oral mucosa.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Univ Santiago de Compostela, Sch Vet, Dept Anim Pathol, Lugo 27002, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela	Paramio, JM (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Av Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Moral, Ana María Bravo/AAD-3339-2021; Santos, Mirentxu/AAA-1727-2020; Sández, Ceferino M. López/A-6269-2010	Paramio, Jesus M/0000-0001-7520-3177; Moral, Ana María Bravo/0000-0002-5282-8921; Sández, Ceferino M. López/0000-0002-9151-3180				Arin MJ, 2001, TRENDS MOL MED, V7, P422, DOI 10.1016/S1471-4914(01)02095-0; BLESSING M, 1993, J CELL BIOL, V120, P743, DOI 10.1083/jcb.120.3.743; BOWDEN PE, 1995, NAT GENET, V10, P363, DOI 10.1038/ng0795-363; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; GORHN RJ, 1990, OXF MONOGR MED GENET, V19, P445; HUME WJ, 1976, J CELL SCI, V22, P149; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Lim Tuk-Woo, 1999, Journal of Dermatology (Tokyo), V26, P677; LINDBERG K, 1990, DIFFERENTIATION, V45, P230, DOI 10.1111/j.1432-0436.1990.tb00477.x; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; MCGOWAN KM, 1998, SUBCELLULAR BIOCH IN, P141; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; PURKIS PE, 1990, J CELL SCI, V97, P39; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Ramirez A, 2001, GENETICS, V158, P341; Ravindranath RMH, 2001, J BIOL CHEM, V276, P36586, DOI 10.1074/jbc.M104656200; Reichelt J, 2001, MOL BIOL CELL, V12, P1557, DOI 10.1091/mbc.12.6.1557; Rothnagel JA, 1999, DIFFERENTIATION, V65, P119, DOI 10.1046/j.1432-0436.1999.6520119.x; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Smith FJD, 1998, HUM MOL GENET, V7, P1143, DOI 10.1093/hmg/7.7.1143; Smith FJD, 1997, J INVEST DERMATOL, V108, P220, DOI 10.1111/1523-1747.ep12335315; Takahashi K, 1999, J DERMATOL SCI, V21, P73, DOI 10.1016/S0923-1811(99)00023-7; Takahashi K, 1996, P NATL ACAD SCI USA, V93, P14776, DOI 10.1073/pnas.93.25.14776; Takahashi K, 1998, GENOMICS, V53, P170, DOI 10.1006/geno.1998.5476; Takahashi K, 1997, J BIOL CHEM, V272, P11979, DOI 10.1074/jbc.272.18.11979; Wawersik M, 2000, MOL BIOL CELL, V11, P3315, DOI 10.1091/mbc.11.10.3315; Wawersik MJ, 2001, MOL BIOL CELL, V12, P3439, DOI 10.1091/mbc.12.11.3439; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Wojcik SM, 1999, DIFFERENTIATION, V65, P97, DOI 10.1046/j.1432-0436.1999.6520097.x; Wojcik SM, 2001, J CELL BIOL, V154, P619, DOI 10.1083/jcb.200102079; Wong P, 2000, J CELL BIOL, V150, P921, DOI 10.1083/jcb.150.4.921	46	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35371	35377		10.1074/jbc.M205143200	http://dx.doi.org/10.1074/jbc.M205143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12119299	hybrid			2022-12-27	WOS:000178117000092
J	Zhao, L; Cuff, CA; Moss, E; Wille, U; Cyrus, T; Klein, EA; Pratico, D; Rader, DJ; Hunter, CA; Pure, E; Funk, CD				Zhao, L; Cuff, CA; Moss, E; Wille, U; Cyrus, T; Klein, EA; Pratico, D; Rader, DJ; Hunter, CA; Pure, E; Funk, CD			Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOE-DEFICIENT MICE; ANTIGEN-PRESENTING CELLS; NF-KAPPA-B; PERITONEAL-MACROPHAGES; LIPID-PEROXIDATION; P40 EXPRESSION; GROWTH-FACTOR; IN-VIVO; IL-12	Targeted gene disruption or overexpression of 12/15-lipoxygenase in mice on the genetic background of apolipoprotein E or low density lipoprotein-receptor (LDL-R) deficiency has implicated 12/15-lipoxygenase in atherogenesis. The data support indirectly a role for 12/15-lipoxygenase in the oxidative modification of low density lipoprotein. In this study we set out to explore other potential mechanisms for 12/15-lipoxygenase in atherosclerosis using apolipoprotein B mRNA editing catalytic polypeptide-1/LDL-R double-deficient mice, a model highly related to the human condition of familial hypercholesterolemia. 12/15-Lipoxygenase deficiency in this strain led to approximate to50% decrease in aortic lesions in male and female mice at 8 months on a chow diet in the absence of cholesterol differences. While studying 12/15-lipoxygenase-deficient macrophages in culture, we discovered a remarkable selective defect (75-90% decrease) in interleukin-12 production but not in tumor necrosis factor-alpha or nitric oxide release, in response to lipopolysaccharide in the presence or absence of interferon-gamma priming. The lipopolysaccharide/interferon-gamma response was associated with a 33-50% decrease in nuclear interferon consensus sequence-binding protein, which is consistent with interferon consensus sequence-binding protein containing protein complex-dependent regulation of the interleukin-12 p40 gene. The decrease in interleukin-12 production was recapitulated in vivo in mouse aortas of the triple knockout group and was reflected in a marked decrease in interferon-gamma expression. The data provide support for a novel mechanism linking the 12/15-lipoxygenase pathway to a known immunomodulatory Th1 cytokine in atherogenesis.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Ludwig Inst Canc Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; University of Pennsylvania; Ludwig Institute for Cancer Research; University of Pennsylvania; University of Pennsylvania	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010; Pratico, Domenico/ABA-9590-2020; Hunter, Christopher/H-1970-2011	Klein, Eric/0000-0003-3941-6233; Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057811, R01HL065507, R01HL053558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045813, R01AI042334, R21AI045813] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53558, HL57811, HL65507] Funding Source: Medline; NIAID NIH HHS [AI42334, AI45813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Becker C, 2001, J IMMUNOL, V167, P2608, DOI 10.4049/jimmunol.167.5.2608; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Cyrus T, 2001, CIRCULATION, V103, P2277; DING AH, 1988, J IMMUNOL, V141, P2407; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hino A, 1996, EUR J IMMUNOL, V26, P623, DOI 10.1002/eji.1830260318; Hodge-Dufour J, 1998, P NATL ACAD SCI USA, V95, P13806, DOI 10.1073/pnas.95.23.13806; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Kayanoki Y, 1999, BIOCHEM BIOPH RES CO, V259, P50, DOI 10.1006/bbrc.1999.0723; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Ma XJ, 2000, J IMMUNOL, V164, P1722, DOI 10.4049/jimmunol.164.4.1722; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Quinones M, 2000, J EXP MED, V192, P507, DOI 10.1084/jem.192.4.507; Rader DJ, 1998, NAT MED, V4, P899, DOI 10.1038/nm0898-899; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; VANDERPOUWKRAAN TC, 1995, J EXP MED, V181, P775; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	38	84	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35350	35356		10.1074/jbc.M205738200	http://dx.doi.org/10.1074/jbc.M205738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122008	hybrid			2022-12-27	WOS:000178117000089
J	Wang, JY; Gambhir, A; Hangyas-Mihalyne, G; Murray, D; Golebiewska, U; McLaughlin, S				Wang, JY; Gambhir, A; Hangyas-Mihalyne, G; Murray, D; Golebiewska, U; McLaughlin, S			Lateral sequestration of phosphatidylinositol 4,5-bisphosphate by the basic effector domain of myristoylated alanine-rich C kinase substrate is due to nonspecific electrostatic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROMINENT CELLULAR SUBSTRATE; MONOLAYER SURFACE PRESSURE; CALMODULIN-BINDING DOMAIN; INOSITOL TRISPHOSPHATE; PHOSPHOLIPASE-C; ACIDIC LIPIDS; ACTIN CYTOSKELETON; MEMBRANE-BINDING; PLASMA-MEMBRANE; BOVINE BRAIN	A peptide corresponding to the basic (+13), unstructured effector domain of myristoylated alanine-rich C kinase substrate (MARCKS) binds strongly to membranes containing phosphatidylinositol 4,5-bisphosphate (PIP2). Although aromatic residues contribute to the binding, three experiments suggest the binding is driven mainly by nonspecific local electrostatic interactions. First, peptides with 13 basic residues, Lys-13 and Arg-13, bind to PIP2-containing vesicles with the same high affinity as the effector domain peptide. Second, removing basic residues from the effector domain peptide reduces the binding energy by an amount that correlates with the number of charges removed. Third, peptides corresponding to a basic region in GAP43 and MARCKS effector domain-like regions in other proteins (e.g. MacMARCKS, adducin, Drosophila A kinase anchor protein 200, and N-methyl-D-aspartate receptor) also bind with an energy that correlates with the number of basic residues. Kinetic measurements suggest the effector domain binds to several PIP2. Theoretical calculations show the effector domain produces a local positive potential, even when bound to a bilayer with 33% monovalent acidic lipids, and should thus sequester PIP2 laterally. This electrostatic sequestration was observed experimentally using a phospholipase C assay. Our results are consistent with the hypothesis that MARCKS could reversibly sequester much of the PIP2 in the plasma membrane.	SUNY Stony Brook, HSC, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University	McLaughlin, S (corresponding author), SUNY Stony Brook, HSC, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	smcl@epo.som.sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444, R37GM024971, R01GM024971] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008444, GM 24971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BenTal N, 1997, BIOPHYS J, V73, P1717, DOI 10.1016/S0006-3495(97)78203-1; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Bradshaw JP, 1999, BIOCHEMISTRY-US, V38, P8393, DOI 10.1021/bi990338+; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Buser CA, 1998, METH MOL B, V84, P267; CAFISO D, 1989, METHOD ENZYMOL, V171, P342; Cantor C.R., 1980, BIOPHYS CHEM; CARNIE S, 1983, BIOPHYS J, V44, P325, DOI 10.1016/S0006-3495(83)84306-9; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; Corradin S, 1999, J BIOL CHEM, V274, P16782, DOI 10.1074/jbc.274.24.16782; Cremona O, 2001, J CELL SCI, V114, P1041; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GOMEZ LL, 2002, IN PRESS J NEUROSCI; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTSEL SC, 1986, BIOCHEMISTRY-US, V25, P8214, DOI 10.1021/bi00373a014; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hilgemann D.W., 2001, SCI STKE, V2001, P1; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Hunter R. J., 1981, ZETA POTENTIAL COLLO, DOI 10.1016/B978-0-12-361961-7.50006-7; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; MANENTI S, 1992, J BIOL CHEM, V267, P22310; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MATHIAS RT, 1992, NATO ADV SCI I C-MAT, V335, P473; Matsubara M, 1998, FEBS LETT, V421, P203, DOI 10.1016/S0014-5793(97)01557-3; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; May S, 2000, BIOPHYS J, V79, P1747, DOI 10.1016/S0006-3495(00)76427-7; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murray D, 2002, CURR TOP MEMBR, V52, P277; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PEITZSCH RM, 1995, BIOPHYS J, V68, P729, DOI 10.1016/S0006-3495(95)80253-5; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Schiller J, 1999, ANAL BIOCHEM, V267, P46, DOI 10.1006/abio.1998.3001; Sciorra VA, 2000, FR MOLEC B, V27, P268; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Sechi AS, 2000, J CELL SCI, V113, P3685; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Singleton DR, 1997, J CELL SCI, V110, P2099; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; Stephens L, 2000, FR MOLEC B, V27, P32; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; Victor K, 1999, BIOCHEMISTRY-US, V38, P12527, DOI 10.1021/bi990847b; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; WIMLEY WC, 1993, ANAL BIOCHEM, V213, P213, DOI 10.1006/abio.1993.1411; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; WINISKI AP, 1986, BIOCHEMISTRY-US, V25, P8206, DOI 10.1021/bi00373a013; Zhou C, 1997, BIOCHEMISTRY-US, V36, P15925, DOI 10.1021/bi9716175	118	181	182	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34401	34412		10.1074/jbc.M203954200	http://dx.doi.org/10.1074/jbc.M203954200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097325	hybrid			2022-12-27	WOS:000177959100113
J	Xiang, Y; Rybin, VO; Steinberg, SF; Kobilka, B				Xiang, Y; Rybin, VO; Steinberg, SF; Kobilka, B			Caveolar localization dictates physiologic signaling of beta(2)-adrenoceptors in neonatal cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; BETA-2-ADRENERGIC RECEPTORS; TARGETED DISRUPTION; COLOCALIZATION; APOPTOSIS; PATHWAY; GENE; MICE	There is a growing body of evidence that G protein-coupled receptors function in the context of plasma membrane signaling compartments. These compartments may facilitate interaction between receptors and specific downstream signaling components while restricting access to other signaling molecules. We recently reported that beta(1)- and beta(2)-adrenergic receptors (AR) regulate the intrinsic contraction rate in neonatal mouse myocytes through distinct signaling pathways. By studying neonatal myocytes isolated from beta(1)AR and beta(2)AR knockout mice, we found that stimulation of the beta(1)AR leads to a protein kinase A-dependent increase in the contraction rate. In contrast, stimulation of the beta(2)AR has a biphasic effect on the contraction rate. The biphasic effect includes an initial protein kinase A-independent increase in the contraction rate followed by a sustained decrease in the contraction rate that can be blocked by pertussis toxin. Here we present evidence that caveolar localization is required for physiologic signaling by the beta(2)AR but not the beta(1)AR in neonatal cardiac myocytes. Evidence for beta(2)AR localization to caveolae includes co-localization by confocal imaging, co-immunoprecipitation of the beta(2)AR and caveolin 3, and co-migration of the beta(2)AR with a caveolin-3-enriched membrane fraction. The beta(2)AR-stimulated increase in the myocyte contraction rate is increased by similar to2-fold and markedly prolonged by filipin, an agent that disrupts lipid rafts such as caveolae and significantly reduces co-immunoprecipitation of beta(2)AR and caveolin 3 and comigration of beta(2)AR and caveolin-3 enriched membranes. In contrast, filipin has no effect on G,AR signaling. These observations suggest that beta(2)ARs are normally restricted to caveolae in myocyte membranes and that this localization is essential for physiologic signaling of this receptor subtype.	Stanford Med Ctr, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Howard Hughes Medical Institute; Stanford University; Columbia University	Kobilka, B (corresponding author), Stanford Med Ctr, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.			Kobilka, Brian/0000-0001-5958-3990				Aprigliano Octavio, 1997, American Journal of Physiology, V272, pH2726; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Devic E, 2001, MOL PHARMACOL, V60, P577; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Razani B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241, DOI 10.1152/ajpcell.2001.281.4.C1241; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Schlegel A, 2001, J CELL PHYSIOL, V186, P329, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1045>3.0.CO;2-0; Steinberg SF, 1999, CIRC RES, V85, P1101; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	21	195	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34280	34286		10.1074/jbc.M201644200	http://dx.doi.org/10.1074/jbc.M201644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097322	hybrid			2022-12-27	WOS:000177959100098
J	Sane, PV; Ivanov, AG; Sveshnikov, D; Huner, NPA; Oquist, G				Sane, PV; Ivanov, AG; Sveshnikov, D; Huner, NPA; Oquist, G			A transient exchange of the photosystem II reaction center protein D1 : 1 with D1 : 2 during low temperature stress of Synechococcus sp PCC 7942 in the light lowers the redox potential of Q(B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; HERBICIDE-RESISTANT MUTANTS; 2 FORMS; ENERGY-DISSIPATION; DISTINCT FORMS; GLOW PEAKS; CYANOBACTERIUM; PHOTOINHIBITION; RESPONSES; TURNOVER	Upon exposure to low temperature under constant light conditions, the cyanobacterium Synechococcus sp. PCC 7942 exchanges the photosystem II reaction center D1 protein form I (D1:1) with D1 protein form 2 (D1:2). This exchange is only transient, and after acclimation to low temperature the cells revert back to D1:1, which is the preferred form in acclimated cells (Campbell, D., Zhou, G., Gustafsson, P., Oquist, G., and Clarke, A. K. (1995) EMBO J. 14, 5457-5466). In the present work we use thermoluminescence to study charge recombination events between the acceptor and donor sides of photosystem II in relation to D1 replacement. The data indicate that in cold-stressed cells exhibiting D1:2, the redox potential of Q(B) becomes lower approaching that of Q(A). This was confirmed by examining the Synechococcus sp. PCC 7942 inactivation mutants R2S2C3 and R2K1, which possess only D1:1 or D1:2, respectively. In contrast, the recombination of Q(A)(-) with the S-2 and S-3 states did not show any change in their redox characteristics upon the shift from D1:1 to D1:2. We suggest that the change in redox properties of Q(B) results in altered charge equilibrium in favor of Q(A). This would significantly increase the probability of Q(A)(-) and P680(+) recombination. The resulting non-radiative energy dissipation within the reaction center of PSII may serve as a highly effective protective mechanism against photodamage upon excessive excitation. The proposed reaction center quenching is an important protective mechanism because antenna and zeaxanthin cycle-dependent quenching are not present in cyanobacteria. We suggest that lowering the redox potential of Q(B) by exchanging D1:1 for D1:2 imparts the increased resistance to high excitation pressure induced by exposure to either low temperature or high light.	Umea Univ, Plant Sci Grp, Dept Plant Physiol, S-90187 Umea, Sweden; Univ Western Ontario, Dept Plant Sci, London, ON N6H 5B7, Canada	Umea University; Western University (University of Western Ontario)	Oquist, G (corresponding author), Umea Univ, Plant Sci Grp, Dept Plant Physiol, S-90187 Umea, Sweden.	gunnar.oquist@plantphys.umu.se		Ivanov, Alexander G./0000-0001-7100-9211; Ivanov, Alexander/0000-0001-7910-5494				Bukhov NG, 2001, PLANTA, V212, P749, DOI 10.1007/s004250000486; Campbell D, 1996, PLANT SCI, V115, P183, DOI 10.1016/0168-9452(96)04344-0; Campbell D, 1998, P NATL ACAD SCI USA, V95, P364, DOI 10.1073/pnas.95.1.364; CAMPBELL D, 1995, EMBO J, V14, P5457, DOI 10.1002/j.1460-2075.1995.tb00232.x; Campbell D, 1996, PHOTOSYNTH RES, V47, P131, DOI 10.1007/BF00016176; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P9973, DOI 10.1073/pnas.90.21.9973; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P11985, DOI 10.1073/pnas.90.24.11985; CLARKE AK, 1995, PLANTA, V197, P553; DEMETER S, 1985, BIOCHIM BIOPHYS ACTA, V806, P16, DOI 10.1016/0005-2728(85)90077-5; DEMMIGADAMS B, 1990, PLANTA, V180, P582, DOI 10.1007/BF02411457; DEVAULT D, 1990, PHOTOSYNTH RES, V24, P175, DOI 10.1007/BF00032597; ETIENNE AL, 1990, BIOCHIM BIOPHYS ACTA, V1015, P435, DOI 10.1016/0005-2728(90)90076-G; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; GLEITER HM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P135, DOI 10.1016/0005-2728(92)90002-J; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; Herbert SK, 1995, PHOTOSYNTH RES, V46, P277, DOI 10.1007/BF00020441; Inoue Y, 1996, BIOPHYSICAL TECHNIQU, P93; Ivanov AG, 2002, PLANTA, V215, P457, DOI 10.1007/s00425-002-0765-x; Ivanov AG, 2001, PLANTA, V213, P575, DOI 10.1007/s004250100522; Keranen M, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1145; KLESS H, 1993, Z NATURFORSCH C, V48, P185; Komenda J, 2000, BBA-BIOENERGETICS, V1457, P243, DOI 10.1016/S0005-2728(00)00105-5; Komenda J, 1999, J PHOTOCH PHOTOBIO B, V48, P114, DOI 10.1016/S1011-1344(99)00025-1; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; KRUPA Z, 1991, PHYSIOL PLANTARUM, V82, P1; MAENPAA P, 1995, PLANT PHYSIOL, V107, P187, DOI 10.1104/pp.107.1.187; MEYERS SR, 1993, BIOCHEMISTRY-US, V32, P1454; Minagawa J, 1999, BIOCHEMISTRY-US, V38, P770, DOI 10.1021/bi981217x; MURATA N, 1995, BIOCHEM J, V308, P1; NIXON PJ, 1995, J BIOL CHEM, V270, P14919, DOI 10.1074/jbc.270.25.14919; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; OHAD N, 1990, Z NATURFORSCH C, V45, P402; Oquist G, 1995, PHOTOSYNTH RES, V46, P151, DOI 10.1007/BF00020425; Porankiewicz J, 1998, PHYSIOL PLANTARUM, V104, P405, DOI 10.1034/j.1399-3054.1998.1040316.x; Prasil O, 1996, PHOTOSYNTH RES, V48, P395, DOI 10.1007/BF00029472; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sane P. V., 1986, Light emission by plants and bacteria, P329; SANE PV, 1983, INDIAN J EXP BIOL, V21, P401; Sippola K, 1998, EUR J BIOCHEM, V251, P641, DOI 10.1046/j.1432-1327.1998.2510641.x; Sugiura M, 1999, PLANT CELL PHYSIOL, V40, P1219, DOI 10.1093/oxfordjournals.pcp.a029510; Tal S, 1999, J PHOTOCH PHOTOBIO B, V48, P120, DOI 10.1016/S1011-1344(99)00040-8; Vass I, 1996, PHOTOSYNTH RES, V48, P117, DOI 10.1007/BF00041002; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Vavilin DV, 2000, BIOCHEMISTRY-US, V39, P14831, DOI 10.1021/bi001679m; Xiong J, 1998, PHOTOSYNTH RES, V56, P229, DOI 10.1023/A:1006061918025	46	54	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32739	32745		10.1074/jbc.M200444200	http://dx.doi.org/10.1074/jbc.M200444200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105211	hybrid			2022-12-27	WOS:000177859000045
J	Yuan, J; Kight, A; Goforth, RL; Moore, M; Peterson, EC; Sakon, J; Henry, R				Yuan, J; Kight, A; Goforth, RL; Moore, M; Peterson, EC; Sakon, J; Henry, R			ATP stimulates signal recognition particle (SRP)/FtsY-supported protein integration in chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL INTEGRATION; HOMOLOG ALBINO3; TRANSPORT; IMPORT; THYLAKOIDS; INSERTION; SUBUNIT; BINDING; REQUIREMENTS; PATHWAYS	The signal recognition particle (SRP) and its receptor (FtsY in prokaryotes) are essential for cotranslational protein targeting to the endoplasmic reticulum in eukaryotes and the cytoplasmic membrane in prokaryotes. An SRP/FtsY-like protein targeting/integration pathway in chloroplasts mediates the posttranslational integration of the light-harvesting chlorophyll a/b-binding protein (LHCP) into thylakoid membranes. GTP, chloroplast SRP (cpSRP), and chloroplast FtsY (cpFtsY) are required for LHCP integration into thylakoid membranes. Here, we report the reconstitution of the LHCP integration reaction with purified recombinant proteins and salt-washed thylakoids. Our data demonstrate that cpSRP and cpFtsY are the only soluble protein components required for LHCP integration. In addition, our studies reveal that ATP, though not absolutely required, remarkably stimulates LHCP integration into salt. washed thylakoids. ATP stimulates LHCP integration by a mechanism independent of the thylakoidal pH gradient (DeltapH) and exerts no detectable effect on the formation of the soluble LHCP-cpSRP-targeting complex. Taken together, our results indicate the participation of a thylakoid ATP-binding protein in LHCP integration.	Univ Arkansas, Dept Sci Biol, Fayetteville, AR 72701 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas System; University of Arkansas Fayetteville	Henry, R (corresponding author), Univ Arkansas, Dept Sci Biol, Fayetteville, AR 72701 USA.	rahenry@uark.edu	Sakon, Joshua/N-2289-2014; Peterson, Eric/I-3082-2013	Sakon, Joshua/0000-0002-8373-969X; 	NCRR NIH HHS [1 P20RR15569-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; YUAN JG, 1994, J BIOL CHEM, V269, P18463	24	26	27	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32400	32404		10.1074/jbc.M206192200	http://dx.doi.org/10.1074/jbc.M206192200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105232	hybrid			2022-12-27	WOS:000177718700136
J	Zheng, YJ; Furukawa, T; Ogura, T; Tajimi, K; Inagaki, N				Zheng, YJ; Furukawa, T; Ogura, T; Tajimi, K; Inagaki, N			M phase-specific expression and phosphorylation-dependent ubiquitination of the ClC-2 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CHLORIDE CHANNEL; PROTEOLYTIC PATHWAY; ASCIDIAN EMBRYOS; VOLTAGE; VOLUME; CLONING; BINDING; PROTEASOME; SEQUENCES	Cl- channel activities vary during the cell cycle and are thought to play various roles including regulation of cell volume. We have shown previously that ClC-2 channels are directly phosphorylated and functionally regulated by the M phase-specific cyclin-dependent kinase p34(cdc2)/cyclin B. We investigate here to determine whether the expression levels of ClC-2 channel protein vary during the cell cycle. Immunoblot and immunocytochemical analyses of cells cycle-synchronized by serum depletion/replenishment reveal that ClC-2 channel protein is expressed predominantly at M phase in cells with two nuclei and a clear constriction ring, whereas RNA blot analysis shows that ClC-2 mRNA expression does not change during the cell cycle. Ubiquitin assays reveal that the ClC-2 channels are ubiquitinated at M phase, whereas the magnitude of ubiquitination is suppressed by incubation with olomoucine, an inhibitor of p34(cdc2)/cyclin B, and it is almost completely abolished in ClC-2 channels having an S632A mutation, which cannot be phosphorylated by p34(cdc2)/cyclin B, indicating that ubiquitination of ClC-2 channels requires phosphorylation by M phase-specific p34(cdc2)/cyclin B. Regulation at the post-transcriptional level, including phosphorylation-dependent ubiquitination, may contribute to M phase-specific expression of ClC-2 channels. Cell cycle-dependent regulation of expression at the protein level in addition to the regulation of function suggests that the ClC-2 channel plays a physiological role in the cell cycle.	Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Emergency Med, Akita 0108543, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chuo Ku, Chiba 2608670, Japan; CREST, Japan Sci & Technol Corp, Akita 0108543, Japan	Akita University; Akita University; Chiba University; Japan Science & Technology Agency (JST)	Inagaki, N (corresponding author), Akita Univ, Sch Med, Dept Physiol, 1-1-1 Hondo, Akita 0108543, Japan.	inagaki@med.akita-u.ac.jp	furukawa, tetsushi/ABD-3178-2020	Inagaki, Nobuya/0000-0001-8261-2593				BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOMBS JL, 1992, DEV BIOL, V153, P272, DOI 10.1016/0012-1606(92)90112-T; Furukawa T, 2002, J PHYSIOL-LONDON, V540, P883; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; FURUKAWA T, 1995, FEBS LETT, V375, P56, DOI 10.1016/0014-5793(95)01178-H; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hochegger H, 2001, DEVELOPMENT, V128, P3795; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; LARSSON O, 1986, J CELL PHYSIOL, V127, P267, DOI 10.1002/jcp.1041270212; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; SAITO Y, 1990, NEUROSCI LETT, V120, P1, DOI 10.1016/0304-3940(90)90153-Z; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VILLAZ M, 1995, J PHYSIOL-LONDON, V488, P689, DOI 10.1113/jphysiol.1995.sp021000; VOETS T, 1995, PFLUG ARCH EUR J PHY, V431, P132, DOI 10.1007/BF00374387; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865	35	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32268	32273		10.1074/jbc.M202105200	http://dx.doi.org/10.1074/jbc.M202105200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105212	hybrid			2022-12-27	WOS:000177718700121
J	Besteiro, S; Biran, M; Biteau, N; Coustou, V; Baltz, T; Canioni, P; Bringaud, F				Besteiro, S; Biran, M; Biteau, N; Coustou, V; Baltz, T; Canioni, P; Bringaud, F			Succinate secreted by Trypanosoma brucei is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; LEISHMANIA-MEXICANA MEXICANA; PENTOSE-PHOSPHATE PATHWAY; CARBOHYDRATE-METABOLISM; PYRUVATE-KINASE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PROCYCLIC TRYPOMASTIGOTES; PHOSPHOGLYCERATE KINASE; AFFINITY-CHROMATOGRAPHY; ENERGY-METABOLISM	In all trypanosomatids, including Trypanosoma brucei, glycolysis takes place in peroxisome-like organelles called glycosomes. These are closed compartments wherein the energy and redox (NAD(+)/NADH) balances need to be maintained. We have characterized a T. brucei gene called FRDg encoding a protein 35% identical to Saccharomyces cerevisiae fumarate reductases. Microsequencing of FRDg purified from glycosome preparations, immunofluorescence, and Western blot analyses clearly identified this enzyme as a glycosomal protein that is only expressed in the procyclic form of T. brucei but is present in all the other trypanosomatids studied, i.e. Trypanosoma congolense, Crithidia fasciculata and Leishmania amazonensis. The specific inactivation of FRDg gene expression by RNA interference showed that FRDg is responsible for the NADH-dependent fumarate reductase activity detected in glycosomal fractions and that at least 60% of the succinate secreted by the T. brucei procyclic form (in the presence Of D-glucose as the sole carbon source) is produced in the glycosome by FRDg. We conclude that FRDg plays a key role in the energy metabolism by participating in the maintenance of the glycosomal NAD(+)/NADH balance. We have also detected a significant pyruvate kinase activity in the cytosol of the T. brucei procyclic cells that was not observed previously. Consequently, we propose a revised model of glucose metabolism in procyclic trypanosomes that may also be valid for all other trypanosomatids except the T. brucei bloodstream form. Interestingly, H. Gest has hypothesized previously (Gest, H. (1980) FEMS Microbiol. Lett. 7, 73-77) that a soluble NADH-dependent fumarate reductase has been present in primitive organisms and evolved into the present day fumarate reductases, which are quinol-dependent. FRDg may have the characteristics of such an ancestral enzyme and is the only NADH-dependent fumarate reductase characterized to date.	Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bringaud, F (corresponding author), Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Besteiro, Sébastien/F-3622-2014	Besteiro, Sébastien/0000-0003-1853-1494; Biteau, Nicolas/0000-0003-1301-0665				Adje CA, 1997, MOL BIOCHEM PARASIT, V90, P155, DOI 10.1016/S0166-6851(97)00152-7; ADROHER FJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P252, DOI 10.1016/0003-9861(88)90030-6; Arikawa Y, 1998, FEMS MICROBIOL LETT, V165, P111, DOI 10.1111/j.1574-6968.1998.tb13134.x; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; Bastin P, 2000, J CELL SCI, V113, P3321; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; BOWMAN IBR, 1963, COMP BIOCHEM PHYSIOL, V9, P105, DOI 10.1016/0010-406X(63)90014-8; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; CAZZULO JJ, 1989, FEMS MICROBIOL LETT, V59, P259, DOI 10.1111/j.1574-6968.1989.tb03121.x; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Chen M, 2001, ANTIMICROB AGENTS CH, V45, P2023, DOI 10.1128/AAC.45.7.2023-2029.2001; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; DENICOLASEOANE A, 1992, MOL BIOCHEM PARASIT, V54, P43, DOI 10.1016/0166-6851(92)90093-Y; Denise H, 1999, EUR J BIOCHEM, V259, P339, DOI 10.1046/j.1432-1327.1999.00048.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; GEST H, 1980, FEMS MICROBIOL LETT, V7, P73, DOI 10.1111/j.1574-6941.1980.tb01579.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HUNTER FRISSELL R., 1960, EXPTL PARASITOL, V9, P271, DOI 10.1016/0014-4894(60)90035-7; HYDE GE, 1991, J BIOL CHEM, V266, P23542; Kohl L, 1996, MOL BIOCHEM PARASIT, V76, P159, DOI 10.1016/0166-6851(95)02556-1; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Marche S, 2000, MOL BIOCHEM PARASIT, V106, P83, DOI 10.1016/S0166-6851(99)00204-2; MARR JJ, 1980, BIOCH PHYSL PROTOZOA, V3, P313; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; MISSET O, 1987, EUR J BIOCHEM, V162, P501, DOI 10.1111/j.1432-1033.1987.tb10668.x; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; MURATSUBAKI H, 1994, PREP BIOCHEM, V24, P289, DOI 10.1080/10826069408010100; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Obungu VH, 1999, INDIAN J BIOCHEM BIO, V36, P305; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PEALING SL, 1992, BIOCHEMISTRY-US, V31, P12132, DOI 10.1021/bi00163a023; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS CA, 1987, ACTA TROP, V44, P293; RYLEY JF, 1962, BIOCHEM J, V85, P211, DOI 10.1042/bj0850211; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; TAYLOR AER, 1978, IN VITRO METHODS PAR; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tielens AGM, 1999, PARASITOL TODAY, V15, P347, DOI 10.1016/S0169-4758(99)01480-5; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; TURRENS JF, 1989, BIOCHEM J, V259, P363, DOI 10.1042/bj2590363; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIERENGA RK, 1987, EMBO J, V6, P215, DOI 10.1002/j.1460-2075.1987.tb04741.x; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	68	103	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38001	38012		10.1074/jbc.M201759200	http://dx.doi.org/10.1074/jbc.M201759200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138089	hybrid, Green Published			2022-12-27	WOS:000178529600006
J	Blanquart, C; Barbier, O; Fruchart, JC; Staels, B; Glineur, C				Blanquart, C; Barbier, O; Fruchart, JC; Staels, B; Glineur, C			Peroxisome proliferator-activated receptor alpha (PPAR alpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; DEGRADATION; IDENTIFICATION; GAMMA; ELEMENT; PROTEIN; PATHWAY; DOMAIN; CELLS; PCR	Peroxisome proliferator activated-receptor alpha (PPARalpha) is a ligand-activated transcription factor belonging to the nuclear receptor family. PPARalpha is implicated in the regulation of lipid and glucose metabolism and in the control of inflammatory response. Recently, it has been demonstrated that a number of nuclear receptors are degraded by the ubiquitin-proteasome pathway. Since PPARa exhibits a circadian expression rhythm and since PPARa is rapidly regulated under certain pathophysiological conditions such as the acute phase inflammatory response, we hypothesized that PPARalpha protein levels must be under tight control. Here, we studied the mechanisms controlling PPARalpha protein levels and their consequences on the transcriptional control of PPARalpha target genes. Using pulse-chase experiments, it is shown that PPARalpha is a short-lived protein and that addition of its ligands stabilizes this nuclear receptor. By transient cotransfection experiments using expression vectors for PPARalpha and hemagglutinin-tagged ubiquitin, it is demonstrated that PPARalpha protein is ubiquitinated and that its ligands decrease the ubiquitination of this nuclear receptor, thus providing a mechanism for the ligand-dependent stabilization observed in pulse-chase experiments. In addition, treatment with MG132, a selective proteasome inhibitor, increases the level of ubiquitinated PPARalpha and inhibits its degradation in transfected cells. Furthermore, MG132 treatment enhances the level of endogenous PPARalpha in HepG2 cells. Finally, transient transfection and quantitative reverse transcription-PCR show that inhibition of PPARalpha degradation increases its transcriptional activation and expression of target genes such as apoA-II and fatty acid transport protein (FATP). Taken together, these data demonstrate that PPARalpha is degraded by the ubiquitin-proteasome system in a ligand-dependent manner. Regulation of its degradation provides a novel regulatory mechanism of transcriptional activity of this nuclear receptor.	Inst Pasteur, INSERM, UR 545, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille	Glineur, C (corresponding author), Inst Pasteur, INSERM, UR 545, Dept Atherosclerose, 1 Rue Pr Calmette, F-59019 Lille, France.	Corine.Glineur@pasteur-lille.fr	Blanquart, Christophe/K-5956-2015; Blanquart, Christophe/ABG-7260-2020; Staels, Bart/N-9497-2016	Blanquart, Christophe/0000-0002-0917-3747; Blanquart, Christophe/0000-0002-0917-3747; Staels, Bart/0000-0002-3784-1503; Barbier, Olivier/0000-0002-3067-1134				Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Boudjelal M, 2000, CANCER RES, V60, P2247; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirotani M, 2001, BIOCHEM BIOPH RES CO, V288, P106, DOI 10.1006/bbrc.2001.5739; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Schoonjans K, 1996, J LIPID RES, V37, P907; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Turgeon JL, 2000, ENDOCRINOLOGY, V141, P3422, DOI 10.1210/en.141.9.3422; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Webster JC, 1997, J BIOL CHEM, V272, P9287	30	107	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37254	37259		10.1074/jbc.M110598200	http://dx.doi.org/10.1074/jbc.M110598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12118000	hybrid			2022-12-27	WOS:000178447100046
J	Borman, AM; Michel, YM; Malnou, CE; Kean, KM				Borman, AM; Michel, YM; Malnou, CE; Kean, KM			Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; POLY(A)-BINDING PROTEIN; POLY(A)-TAIL-PROMOTED TRANSLATION; DEPENDENT TRANSLATION; CAP-POLY(A) SYNERGY; INITIATION-FACTORS; TAIL; YEAST; INCREASES; EXTRACTS	The 5' cap and 3' poly(A) tail of classical eukaryotic mRNAs functionally communicate to synergistically enhance translation initiation. Synergy has been proposed to result in part from facilitated ribosome recapture on circularized mRNAs. Here, we demonstrate that this is not the case. In poly(A)-dependent, ribosome-depleted rabbit reticulocyte lysates, the addition of exogenous poly(A) chains of physiological length dramatically stimulated translation of a capped, nonpolyadenylated mRNA. When the poly(A):RNA ratio approached 1, exogenous poly(A) stimulated translation to the same extent as the presence of a poly(A) tail at the mRNA 3' end. In addition, exogenous poly(A) significantly improved translation of capped mRNAs carrying short poly(A,,) tails. Trans stimulation of translation by poly(A) required the eIF4G-poly(A)-binding protein interaction and resulted in increased affinity of eIF4E for the mRNA cap, exactly as we recently described for cap-poly(A) synergy. These results formally demonstrate that mRNA circularization per se is not the cause of cap-poly(A) synergy at least in vitro.	Inst Pasteur, CNRS URA 1966, Unite Postulante RTEV, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Postulante RTEV, 25 Rue Dr Roux, F-75724 Paris 15, France.	Kathiemb@pasteur.fr	Borman, Andy/H-3663-2019; MALNOU, Cécile E/K-1569-2014; MALNOU, Cécile/O-9970-2019	Borman, Andy/0000-0003-0585-5721; MALNOU, Cécile E/0000-0002-1223-0247; MALNOU, Cécile/0000-0002-1223-0247				BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P6485, DOI 10.1093/nar/17.16.6485; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Marczinke B, 1998, J MOL BIOL, V284, P205, DOI 10.1006/jmbi.1998.2186; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Michel YM, 2001, MOL CELL BIOL, V21, P4097, DOI 10.1128/MCB.21.13.4097-4109.2001; Morley SJ, 1997, RNA, V3, P1085; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Searfoss A, 2001, MOL CELL BIOL, V21, P4900, DOI 10.1128/MCB.21.15.4900-4908.2001; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	30	37	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36818	36824		10.1074/jbc.M205065200	http://dx.doi.org/10.1074/jbc.M205065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138105	hybrid			2022-12-27	WOS:000178275100133
J	Kim, S; Zagozdzon, R; Meisler, A; Baleja, JD; Fu, YG; Avraham, S; Avraham, H				Kim, S; Zagozdzon, R; Meisler, A; Baleja, JD; Fu, YG; Avraham, S; Avraham, H			Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; SH2 DOMAIN; TYROSINE KINASE; PHOSPHOTYROSINE RECOGNITION; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; C-SRC; PROTEIN; BINDING; CELLS	Our previous studies demonstrated that Csk homologous kinase (CHK) acts as a negative growth regulator of human breast cancer through inhibition of ErbB-2/neu-mediated Src family kinase activity (Bougeret, C., Jiang, S., Keydar, I., and Avraham, H. (2001) J. Biol. Chem. 276, 33711-33720. The interaction between the CHK SH2 domain and Tyr(P)(1248) of the ErbB-2 receptor has been shown to be specific and critical for CHK function. In this report, we investigated whether the interaction of the CHK SH2 domain and ErbB-2 is directly related to the inhibition of heregulin-stimulated Src kinase activity. We constructed three CHK SH2 domain binding mutants: G129R (enhanced binding), R147K (inhibited binding), and R147A (disrupted binding). NMR spectra for the domains of each construct were used to evaluate their interaction with a Tyr(P)(1248)-containing ErbB-2 peptide. G129R showed enhanced binding to ErbB-2, whereas binding was completely disrupted by R147A. The enhanced binding mutant showed chemical shift changes at the same residues as wild-type CHK, indicating that this mutant has the same binding characteristics as the wild-type protein. Furthermore, inhibition of heregulin-stimulated Src kinase activity was markedly diminished by R147A, whereas G129R-mediated inhibition was stronger as compared with wild-type CHK. These results indicate that the specific interaction of CHK and ErbB-2 via the SH2 domain of CHK is directly related to the growth inhibitory effects of CHK. These new CHK high affinity binding constructs may serve as good candidates for inhibition of the ErbB-2/Src transduction pathway in gene therapy studies in breast cancer.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Tufts University	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu	Kim, Soyoun/Y-1276-2018; Zagozdzon, Radoslaw/AAC-4298-2019; Zagozdzon, Radoslaw/K-2141-2012	Zagozdzon, Radoslaw/0000-0002-7957-2372; Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R21CA087290, R01CA076226] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76226, CA 87290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hoedemaeker FJ, 1999, J MOL BIOL, V292, P763, DOI 10.1006/jmbi.1999.3111; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Mainville CA, 2001, J VIROL, V75, P1816, DOI 10.1128/JVI.75.4.1816-1823.2001; Matsuo H, 1996, J MAGN RESON SER B, V113, P190, DOI 10.1006/jmrb.1996.0175; Mattsson PT, 2000, J IMMUNOL, V164, P4170, DOI 10.4049/jimmunol.164.8.4170; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MURTHY TVS, 2001, PROTEIN DATA BANK; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Rajagopal P, 1997, PROTEIN SCI, V6, P2624; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	34	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36465	36470		10.1074/jbc.M206018200	http://dx.doi.org/10.1074/jbc.M206018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122014	hybrid			2022-12-27	WOS:000178275100088
J	Murata, Y; Sun-Wada, GH; Yoshimizu, T; Yamamoto, A; Wada, Y; Futai, M				Murata, Y; Sun-Wada, GH; Yoshimizu, T; Yamamoto, A; Wada, Y; Futai, M			Differential localization of the vacuolar H+ pump with G subunit isoforms (G1 and G2) in mouse neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; SYNAPTIC VESICLES; MOLECULAR-CLONING; PROTON PUMP; V-ATPASE; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; 116-KDA SUBUNIT; GENE; EXPRESSION	Vacuolar H+-ATPases (V-ATPases), a family of multimeric proton pumps, are involved in a wide variety of physiological processes. We have identified two mouse genes, Atp6g1 and Atp6g2, encoding the G1 and G2 isoforms of the V-ATPase G subunit, respectively. G1 was distributed ubiquitously in the tissues examined, whereas G2 was specifically distributed in central nervous system neurons. G1 was expressed at an early embryonic stage, whereas G2 transcription was significantly induced at 10.5 days postcoitus (embryonic day 10.5, ie. 2 days before axon outgrowth). Both G1 and G2 were strongly expressed in cortical and hippocampal neurons, cerebellar granule cells, and Purkinje cells. Immunohistochemistry with isoform-specific antibodies revealed that G2 was localized in cell bodies, dendrites, and axons. In addition, electron microscopy and subcellular fractionation indicated that G2 was localized in synaptic vesicles, whereas G1 was not detectable. G1 and G2 exhibit 62% identity, and both isoforms were immunoprecipitated with the c and A subunits of V-ATPase. G2 could complement the yeast deletion mutant Deltavma10, which lacks the G subunit. The V-ATPases containing the G1 and G2 isoforms, respectively, showed similar K-m(ATP) values and maximal velocity. These results indicate that G1 and G2 are bona fide subunits of V-ATPases and that the enzyme with the G2 isoform. is involved in synaptic vesicle acidification.	Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan	Osaka University; Japan Science & Technology Agency (JST); Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, Mihogaoka 8-1, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	Yoshimizu, Takao/A-1339-2011	Yoshimizu, Takao/0000-0002-2553-8195				BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Crider BP, 1997, J BIOL CHEM, V272, P10721; FULDNER HH, 1982, EUR J BIOCHEM, V121, P519, DOI 10.1111/j.1432-1033.1982.tb05817.x; Futai M, 2000, J EXP BIOL, V203, P107; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GRAHAM J, 1994, ANAL BIOCHEM, V220, P367, DOI 10.1006/abio.1994.1351; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; HUBER G, 1984, J NEUROSCI, V4, P151; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; MICHAELSON DM, 1980, LIFE SCI, V27, P39, DOI 10.1016/0024-3205(80)90017-X; Morel N, 1998, J NEUROCHEM, V71, P1702; MORIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P443, DOI 10.1016/S0006-291X(05)81078-2; MORIYAMA Y, 1992, J EXP BIOL, V172, P171; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Neville MJ, 1999, J IMMUNOL, V162, P4745; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; NORNES HO, 1978, BRAIN RES, V159, P1, DOI 10.1016/0006-8993(78)90105-1; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; REYNOLDS R, 1989, NEUROSCIENCE, V28, P181, DOI 10.1016/0306-4522(89)90242-X; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STADLER H, 1984, EMBO J, V3, P3333, DOI 10.1002/j.1460-2075.1984.tb02300.x; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Sun-Wada GH, 2000, J BIOCHEM-TOKYO, V127, P703, DOI 10.1093/oxfordjournals.jbchem.a022660; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; SWALLOW CJ, 1990, SURGERY, V108, P363; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	54	56	59	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36296	36303		10.1074/jbc.M200586200	http://dx.doi.org/10.1074/jbc.M200586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133826	hybrid			2022-12-27	WOS:000178275100066
J	Tabuchi, A; Sakaya, H; Kisukeda, T; Fushiki, H; Tsuda, M				Tabuchi, A; Sakaya, H; Kisukeda, T; Fushiki, H; Tsuda, M			Involvement of an upstream stimulatory factor as well as cAMP-responsive element-binding protein in the activation of brain-derived neurotrophic factor gene promoter I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-DEPENDENT SURVIVAL; TRANSCRIPTION FACTOR USF; DNA-BINDING; CALCIUM REGULATION; RAT-BRAIN; FAMILY; CREB; EXPRESSION; BDNF; IDENTIFICATION	The use of different brain-derived neurotrophic factor (BDNF) gene promoters results in the differential production of 5'-alternative transcripts, suggesting versatile functions of BDNF in neurons. Among four BDNF promoters I, II, III, and IV (BDNF-PI, -PII, -PIII, and -PIV, BDNF-PI was markedly activated, as well as BDNF-PIII, by Ca2+ signals evoked via neuronal activity. However, little is known about the mechanisms for the transcriptional activation of BDNF-PI. Using rat cortical neurons in culture, we assigned the promoter sequences responsible for the Ca2+ signal-mediated activation of BDNF-PI and found that the Ca2+-responsive elements were located in two separate (distal and proximal) regions and that the DNA sequences in the proximal region containing cAMP-responsive element (CRE), which is overlapped by the upstream stimulatory factor (USF)-binding element, were largely responsible for the activation of BDNF-PI. CRE-binding protein (CREB) family transcription factors and USF1/USF2 bind to this overlapping site, depending upon their preferred sequences which also control the magnitude of the activation. Overexpression of dominant negative CREB or USF reduced the BDNF-PI activation. These findings support that not only CREB but also USF1/USF2 contributes to Ca2+ signal-mediated activation of BDNF-PI through the recognition of an overlapping CRE and USF-binding element.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sugitani, Toyama 9300194, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1500002, Japan	University of Toyama; Japan Science & Technology Agency (JST)	Tsuda, M (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, 2630 Sugitani, Sugitani, Toyama 9300194, Japan.	tsuda@ms.toyama-mpu.ac.jp						Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; CHATTON B, 1994, ONCOGENE, V9, P375; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Tabuchi A, 2000, J BIOL CHEM, V275, P17269, DOI 10.1074/jbc.M909538199; Tabuchi A, 1998, BIOCHEM BIOPH RES CO, V253, P818, DOI 10.1006/bbrc.1998.9854; Takahashi K, 2001, BIOSCI BIOTECH BIOCH, V65, P56, DOI 10.1271/bbb.65.56; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu YL, 2001, BIOL REPROD, V65, P1565, DOI 10.1095/biolreprod65.5.1565; Xia ZG, 2002, NEURON, V33, P315, DOI 10.1016/S0896-6273(02)00578-0	38	165	170	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35920	35931		10.1074/jbc.M204784200	http://dx.doi.org/10.1074/jbc.M204784200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114522	hybrid			2022-12-27	WOS:000178275100022
J	Bowen, H; Biggs, TE; Phillips, E; Baker, ST; Perry, VH; Mann, DA; Barton, CH				Bowen, H; Biggs, TE; Phillips, E; Baker, ST; Perry, VH; Mann, DA; Barton, CH			c-Myc represses and Miz-1 activates the murine Natural resistance-associated protein 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NRAMP1 GENE; NATURAL-RESISTANCE; MACROPHAGE PROTEIN-1; INTRACELLULAR PARASITES; INITIATOR ELEMENT; H-FERRITIN; IN-VIVO; INFECTION; EXPRESSION; SEQUENCE	Iron is essential for growth, and impaired iron homoeostasis through a non-conserved mutation within murine Nramp1, also termed Slc11a1, contributes to susceptibility to infection. Nramp1 depletes the macrophage cytosol of iron, with effects on iron-regulated gene expression and iron-dependent processes. Wu and colleagues (Wu, K.-J., Polack, A., and Dalla-Favera, R. (1999) Science 283, 676-679) showed converse control of iron regulatory protein expression (IRP2) and H-ferritin by c-Myc, suggesting a role for c-Myc in enhancing cytoplasmic iron levels for growth. We investigated if c-Myc also regulates Nramp1 expression. We show an inverse correlation with cell growth, and in co-transfection experiments c-Myc represses the Nramp1 promoter. Within the Nramp1 promoter we identified six non-canonical E boxes, which are not important for c-Myc repression. By deletion analysis the repressor site maps to one or more initiator elements flanking the transcriptional initiation site. Co-transfections with the c-Myc interacting zinc finger protein (Miz-1) show that Miz-1 can overcome c-Myc repression of Nramp1, and, from a deletion construct lacking E box sites, Miz-1 activates the Nramp1 promoter. These studies reinforce the link between c-Myc and iron regulation and provide further evidence that c-Myc negatively regulates genes that decrease the iron content of the cytosol. The results provide further support for a divalent cation antiporter function for Nramp1.	Univ Southampton, CNS Inflammat Grp, Southampton SO16 7PX, Hants, England; Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat Allergy & Repair, Liver Grp, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Barton, CH (corresponding author), Univ Southampton, CNS Inflammat Grp, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	CHB@soton.ac.uk	Perry, V. Hugh/Y-2935-2019	Mann, Derek/0000-0003-0950-243X				Ables GP, 2001, J INTERF CYTOK RES, V21, P53, DOI 10.1089/107999001459169; Atkinson PGP, 1997, BIOCHEM J, V325, P779, DOI 10.1042/bj3250779; Baker ST, 2000, J LEUKOCYTE BIOL, V67, P501, DOI 10.1002/jlb.67.4.501; Banan A, 2001, AM J PHYSIOL-GASTR L, V281, pG833, DOI 10.1152/ajpgi.2001.281.3.G833; BARRERA LF, 1994, IMMUNOLOGY, V82, P457; BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BARTON CH, 1995, MOL MED, V1, P267, DOI 10.1007/BF03401551; Biggs TE, 2001, EUR J IMMUNOL, V31, P2060, DOI 10.1002/1521-4141(200107)31:7<2060::AID-IMMU2060>3.0.CO;2-L; Blackwell JM, 2000, MICROBES INFECT, V2, P317, DOI 10.1016/S1286-4579(00)00295-1; BLACKWELL JM, 1995, MOL MED, V1, P194, DOI 10.1007/BF03401567; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blocker A, 1998, J CELL SCI, V111, P303; BRADLEY DJ, 1974, NATURE, V250, P353, DOI 10.1038/250353a0; Cellier M, 1997, J LEUKOCYTE BIOL, V61, P96, DOI 10.1002/jlb.61.1.96; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dlaska M, 1999, J IMMUNOL, V162, P6171; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; FORMICA S, 1994, IMMUNOLOGY, V82, P42; Gomes MS, 1998, IMMUNOLOGY, V95, P165; Goswami T, 2001, BIOCHEM J, V354, P511, DOI 10.1042/0264-6021:3540511; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GOVONI G, 1995, GENOMICS, V27, P9, DOI 10.1006/geno.1995.1002; GROS P, 1981, J IMMUNOL, V127, P2417; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237; Kojima Y, 2001, TISSUE ANTIGENS, V58, P379, DOI 10.1034/j.1399-0039.2001.580606.x; Kuhn DE, 1999, J LEUKOCYTE BIOL, V66, P113, DOI 10.1002/jlb.66.1.113; Kyriakou D, 1998, EUR J HAEMATOL, V60, P21; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Loulergue C, 1998, GENE, V225, P47, DOI 10.1016/S0378-1119(98)00531-9; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Mulero V, 2002, BIOCHEM J, V363, P89, DOI 10.1042/0264-6021:3630089; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PLANT J, 1974, NATURE, V248, P345, DOI 10.1038/248345a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roig EA, 2002, J LEUKOCYTE BIOL, V71, P890; Searle S, 1999, J MED GENET, V36, P295; Searle S, 1998, J CELL SCI, V111, P2855; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tokuraku K, 1998, FEBS LETT, V428, P63, DOI 10.1016/S0014-5793(98)00488-8; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	51	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34997	35006		10.1074/jbc.M204232200	http://dx.doi.org/10.1074/jbc.M204232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110671	hybrid			2022-12-27	WOS:000178117000044
J	Chen, JL; Ahluwalia, JP; Stamnes, M				Chen, JL; Ahluwalia, JP; Stamnes, M			Selective effects of calcium chelators on anterograde and retrograde protein transport in the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; SHIGA TOXIN; MEMBRANE-FUSION; B-FRAGMENT; CA2+ STORE; GTP; TRAFFICKING; EXOCYTOSIS; SECRETION	Calcium plays a regulatory role in several aspects of protein trafficking in the cell. Both vesicle fusion and vesicle formation can be inhibited by the addition of calcium chelators. Because the effects of calcium chelators have been studied predominantly in cell-free systems, it is not clear exactly which transport steps in the secretory pathway are sensitive to calcium levels. In this regard, we have studied the effects of calcium chelators on both anterograde and retrograde protein transport in whole cells. Using both cytochemical and biochemical analyses, we find that the anterograde-directed exit of vesicular stomatitis virus G protein and the retrograde-directed exit of Shiga toxin from the Golgi apparatus are both inhibited by calcium chelation. The exit of vesicular stomatitis virus G from a pre-Golgi compartment and the exit of Shiga toxin from an endosomal compartment are sensitive to the membrane-permeant calcium chelator 1,2-bis(2-amino phenoxy)ethane-N,N,N',N'-tetraacetic acid-tetrakis (acetoxymethyl ester) (BAPTA-AM). By contrast, endoplasmic reticulum exit and endocytic internalization from the plasma membrane are not affected by BAPTA. Together, our data show that some, but not all, trafficking steps in the cell may be regulated by calcium. These studies provide a framework for a more detailed analysis of the role of calcium as a regulatory agent during protein transport.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Stamnes, M (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Chen, Ji-Long/AAJ-2134-2021	Chen, Ji-Long/0000-0002-4274-0563; Stamnes, Mark/0000-0002-5869-7985				Ahluwalia JP, 2001, J BIOL CHEM, V276, P34148, DOI 10.1074/jbc.M105398200; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Bootman MD, 2001, J CELL SCI, V114, P2213; Brunger AT, 2001, CURR OPIN STRUC BIOL, V11, P163, DOI 10.1016/S0959-440X(00)00186-X; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; COORSSEN JR, 1993, FEBS LETT, V316, P170, DOI 10.1016/0014-5793(93)81209-I; Duncan JS, 1996, BIOCHEM J, V317, P487, DOI 10.1042/bj3170487; George CH, 1998, J BIOL CHEM, V273, P29822, DOI 10.1074/jbc.273.45.29822; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jakob C A, 2001, Results Probl Cell Differ, V33, P1; Johannes L, 2000, TRAFFIC, V1, P119, DOI 10.1034/j.1600-0854.2000.010204.x; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Morel-Huaux VM, 2002, EUR J CELL BIOL, V81, P87, DOI 10.1078/0171-9335-00224; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Sandvig K, 2000, EUR J CELL BIOL, V79, P447, DOI 10.1078/0171-9335-00071; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743	43	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35682	35687		10.1074/jbc.M204157200	http://dx.doi.org/10.1074/jbc.M204157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12114519	hybrid			2022-12-27	WOS:000178117000129
J	McLaughlin, JN; Thulin, CD; Bray, SM; Martin, MM; Elton, TS; Willardson, BM				McLaughlin, JN; Thulin, CD; Bray, SM; Martin, MM; Elton, TS; Willardson, BM			Regulation of angiotensin II-induced G protein signaling by phosducin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ADENYLYL-CYCLASE; RECEPTOR COUPLES; KINASE-II; BINDING; ACTIVATION; PHOSPHORYLATION; TRANSDUCIN	Phosducin-like protein (PhLP) is a broadly expressed member of the phosducin (Pd) family of G protein betagamma subunit (Gbetagamma)-binding proteins. Though PhLP has been shown to bind Gbetagamma in vitro, little is known about its physiological function. In the present study, the effect of PhLP on angiotensin II (Ang II) signaling was measured in Chinese hamster ovary cells expressing the type 1 Ang II receptor and various amounts of PhLP. Up to 3.6-fold overexpression of PhLP had no effect on Ang II-stimulated inositol trisphosphate (IP3) formation, whereas further increases caused an abrupt decrease in IP3 production with half-maximal inhibition occurring at 6-fold PhLP overexpression. This threshold level for inhibition corresponds to the cellular concentration of cytosolic chaperonin complex, a recently described binding partner that preferentially binds PhLP over Gbetagamma. Results of pertussis toxin sensitivity, GTPgammaS binding, and immunoprecipitation experiments suggest that PhLP inhibits phospholipase Cbeta activation by dual mechanisms: (i) steric blockage of Gbetagamma activation of PLCbeta and (ii) interference with Gbetagamma-dependent cycling of G(q)alpha by the receptor. These results suggest that G protein signaling may be regulated through controlling the cellular concentration of free PhLP by inducing its expression or by regulating its binding to the chaperonin.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Brigham Young University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	barry_willardson@byu.edu		Bray, Steven/0000-0002-0854-8121; Willardson, Barry/0000-0002-8503-2268	NATIONAL EYE INSTITUTE [R01EY012287] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048848, R29HL048848] Funding Source: NIH RePORTER; NEI NIH HHS [EY12287] Funding Source: Medline; NHLBI NIH HHS [HL48848] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DeLapp NW, 1999, J PHARMACOL EXP THER, V289, P946; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FOLKOW B, 1958, ACTA PHYSIOL SCAND, V44, P255, DOI 10.1111/j.1748-1716.1958.tb01626.x; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HIMES VB, 1990, METABOLIC STUDY CHIN; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lazarov ME, 1999, BBA-GENE STRUCT EXPR, V1446, P253, DOI 10.1016/S0167-4781(99)00098-6; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; Malmberg A, 2000, J NEUROCHEM, V75, P1283, DOI 10.1046/j.1471-4159.2000.751283.x; Martin MM, 1995, REGUL PEPTIDES, V60, P135, DOI 10.1016/0167-0115(95)00123-9; Martin MM, 2001, MOL ENDOCRINOL, V15, P281, DOI 10.1210/me.15.2.281; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; PARK DG, 1993, J BIOL CHEM, V268, P4573; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; Schelling JR, 1997, AM J PHYSIOL-CELL PH, V272, pC1558, DOI 10.1152/ajpcell.1997.272.5.C1558; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thulin CD, 1999, MOL VIS, V5, pU13; Touyz RM, 2000, PHARMACOL REV, V52, P639; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; WEST RE, 1985, J BIOL CHEM, V260, P4428; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	71	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34885	34895		10.1074/jbc.M205583200	http://dx.doi.org/10.1074/jbc.M205583200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107186	hybrid			2022-12-27	WOS:000178117000031
J	Dunn, J; Elias, CL; Le, HD; Omelchenko, A; Hryshko, LV; Lytton, J				Dunn, J; Elias, CL; Le, HD; Omelchenko, A; Hryshko, LV; Lytton, J			The molecular determinants of ionic regulatory differences between brain and kidney Na+/Ca2+ exchanger (NCX1) isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; ALTERNATIVELY SPLICED ISOFORMS; NA-CA EXCHANGER; INHIBITORY PEPTIDE; SARCOLEMMAL VESICLES; CA2+-BINDING DOMAIN; DYNAMIC PROPERTIES; STEADY-STATE; XIP	The Na+/Ca2+ exchanger gene NCX1 undergoes alternative splicing leading to several isoforms that differ in a small portion of the large cytoplasmic loop. This loop is involved in many regulatory processes of NCX1, including ionic regulation by the transported substrates Na+ and Ca2+. High intracellular Ca2+ can alleviate intracellular Na+-dependent inactivation in exon A (NCX1.4)-containing isoforms but not in those containing the mutually exclusive exon B (NCX1.3). Giant excised patches from Xenopus oocytes expressing various NCX1 constructs were used to examine the specific amino acids responsible for these observed regulatory differences. Using a chimeric approach, the region responsible was narrowed down to the small central part of exon A (IDDEEYEKNKTF). Replacing the second aspartic acid of this sequence with arginine (the corresponding amino acid in exon B) in an exon A background completely prevented the effect of Ca2+ on intracellular Na+-dependent inactivation. Mutating the second lysine to cysteine (exon B) had a similar, but only partial, effect. The converse double mutant, but neither single mutation alone, introduced into an exon B background (arginine to aspartic acid and cysteine to lysine) was able to restore the NCX1.4 regulatory phenotype. These data demonstrate that aspartic acid 610 and lysine 617 (using the rat NCX1.4 numbering scheme) are critical molecular determinants.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Manitoba, Fac Med, Dept Physiol, Inst Cardiovasc Sci,St Boniface Gen Hosp,Res Ctr, Winnipeg, MB R2H 2A6, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Cardiovasc Res Grp, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Hryshko, Larry/0000-0003-1079-8549; Lytton, Jonathan/0000-0003-4770-2512				BERS DM, 1994, METHOD CELL BIOL, V40, P3; Dyck C, 1999, J GEN PHYSIOL, V114, P701, DOI 10.1085/jgp.114.5.701; Gatto C, 1996, ANN NY ACAD SCI, V779, P284, DOI 10.1111/j.1749-6632.1996.tb44796.x; Hale CC, 1997, BIOCHEM BIOPH RES CO, V236, P113, DOI 10.1006/bbrc.1997.6912; Hale CC, 1996, ANN NY ACAD SCI, V779, P171, DOI 10.1111/j.1749-6632.1996.tb44785.x; He SW, 1998, J NEUROSCI, V18, P4833; He Z, 1997, J MEMBRANE BIOL, V156, P149, DOI 10.1007/s002329900197; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hryshko LV, 1996, J GEN PHYSIOL, V108, P67, DOI 10.1085/jgp.108.1.67; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LEVITSKY DO, 1996, MOL CELL BIOCHEM, V160, P27; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Omelchenko A, 1998, J GEN PHYSIOL, V111, P691, DOI 10.1085/jgp.111.5.691; Ottolia M, 2001, J BIOL CHEM, V276, P19603, DOI 10.1074/jbc.M101489200; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Philipson KD, 1996, ANN NY ACAD SCI, V779, P20, DOI 10.1111/j.1749-6632.1996.tb44766.x; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; SHANNON TR, 1994, AM J PHYSIOL, V266, pC1350, DOI 10.1152/ajpcell.1994.266.5.C1350; Trac M, 1997, J GEN PHYSIOL, V109, P361, DOI 10.1085/jgp.109.3.361; Xu WY, 1997, ARCH BIOCHEM BIOPHYS, V341, P273, DOI 10.1006/abbi.1997.9954	33	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33957	33962		10.1074/jbc.M206677200	http://dx.doi.org/10.1074/jbc.M206677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12118014	hybrid			2022-12-27	WOS:000177959100058
J	Khaled, M; Larribere, L; Bille, K; Aberdam, E; Ortonne, JP; Ballotti, R; Bertolotto, C				Khaled, M; Larribere, L; Bille, K; Aberdam, E; Ortonne, JP; Ballotti, R; Bertolotto, C			Glycogen synthase kinase 3 beta is activated by cAMP and plays an active role in the regulation of melanogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING HORMONE; MICROPHTHALMIA GENE-PRODUCT; DEPENDENT PROTEIN-KINASE; MCCUNE-ALBRIGHT SYNDROME; TRANSCRIPTION FACTOR; CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; CARNEY COMPLEX; ION CHANNELS; RED HAIR	In human and mouse, cAMP plays a key role in the control of pigmentation. cAMP, through the activation of protein kinase A, increases the expression of microphthalmia-associated transcription factor (MITF), which in turn stimulates tyrosinase gene expression, to allow melanin synthesis. Beyond this simplified scheme, cAMP inhibits phosphatidylinositol 3-kinase (PI3K), and inhibition of PI3K, by a specific inhibitor, stimulates melanogenesis. However, the link between the PI3K pathway and melanogenesis remained to be elucidated. In this report, we showed that cAMP, through a protein kinase A-independent mechanism, led to inhibition of AKT phosphorylation and activity. Consistent with the role of AKT in the regulation of glycogen synthase kinase 3beta (GSK3beta), cAMP decreased the phosphorylation of GSK3beta and stimulated its activity. Further, experiments were performed to investigate the role of GSK3beta in the regulation of MITF expression and function. We observed that GSK3beta regulated neither MITF promoter activity nor the intrinsic transcriptional activity of MITF but synergized with MITF to activate the tyrosinase promoter. Additionally, lithium, a GSK3beta inhibitor, impaired the response of the tyrosinase promoter to cAMP, and cAMP increased the binding of MITF to the M-box. Taking into account that GSK3beta phosphorylates MITF and increases the ability of MITF to bind its target sequence, our results indicate that activation of GSK3beta by cAMP facilitates MITF binding to the tyrosinase promoter, thereby leading to stimulation of melanogenesis.	INSERM U385, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bertolotto, C (corresponding author), INSERM U385, IFR 50,28 Ave Valombrose, F-06107 Nice 2, France.	bertolot@unice.fr	khaled, mehdi/C-4854-2012; Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013	khaled, mehdi/0000-0002-9880-858X; Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Casey M, 2000, J CLIN INVEST, V106, pR31, DOI 10.1172/JCI10841; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Garcia J.J., 2000, REC RES DEV BIOENE 1, V1, P21; Goding CR, 1997, CELL GROWTH DIFFER, V8, P935; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1994, J CELL SCI, V107, P205; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAMERSON CL, 1998, PIGMENTORY SYSTEM PH, P1695; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; MATTHEWS G, 1991, TRENDS PHARMACOL SCI, V12, P245, DOI 10.1016/0165-6147(91)90563-8; PEARS JS, 1992, BRIT J DERMATOL, V126, P286, DOI 10.1111/j.1365-2133.1992.tb00660.x; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Prota G, 1988, Prog Clin Biol Res, V256, P101; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SOWERS JR, 1985, CUTIS, V36, P351; SOWESR JR, 1985, CUTIS, V36, P354; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wu M, 2000, GENE DEV, V14, P301; Yasumoto K, 1997, J BIOL CHEM, V272, P503	47	147	154	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33690	33697		10.1074/jbc.M202939200	http://dx.doi.org/10.1074/jbc.M202939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093801	hybrid			2022-12-27	WOS:000177959100023
J	McHugh, L; Hu, S; Lee, BK; Santora, K; Kennedy, PE; Berger, EA; Pastan, I; Hamer, DH				McHugh, L; Hu, S; Lee, BK; Santora, K; Kennedy, PE; Berger, EA; Pastan, I; Hamer, DH			Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODY; HAIRY-CELL LEUKEMIA; RECOMBINANT IMMUNOTOXIN; CD4-PSEUDOMONAS EXOTOXIN; HIV-INFECTION; TYPE-1; ERADICATION; RESERVOIRS; GLYCOPROTEIN	HIV-infected cells are selectively killed by an immunotoxin in which a truncated form of Pseudomonas exotoxin A is joined to the variable region of a broadly neutralizing antibody (3B3) that recognizes the viral envelope glycoprotein (Env). To improve the efficacy of this molecule, we used three-dimensional structural information and phage selection data to design 23 single and multiple point mutations in the antibody variable region sequences that contact Env. Substituting an aromatic residue for an aspartate in the third complementarity-determining region of V-H increased the potency of the immunotoxin by similar to10-fold in a cell-killing assay. Detailed analysis of one such mutant, N31H/Q100eY, revealed both a higher affinity for monomeric and cell surface Env and an increased stability against aggregation compared with the starting immunotoxin. Conversion to a disulfide-linked two-chain format further stabilized the protein. N31H/Q100eY retained the ability to bind to Env from multiple viral isolates, to inhibit Env-mediated cell fusion, and to limit spreading viral infection in peripheral blood mononuclear cells. Such site-directed mutants may increase the utility of immunotoxins for reducing or eradicating persistent HIV-1 infection in humans.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hamer, DH (corresponding author), NIAID, Viral Dis Lab, NIH, Bldg 37,Rm 6002,37 Convent Dr, Bethesda, MD 20892 USA.		pastan, ira/P-9319-2019; Hamer, Dean H/L-1248-2015	pastan, ira/0000-0002-9223-0270; Hamer, Dean H/0000-0002-6211-5781	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000538, ZIAAI000538] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHORN P, 1990, P NATL ACAD SCI USA, V87, P8889, DOI 10.1073/pnas.87.22.8889; ASHORN P, 1991, J INFECT DIS, V163, P703, DOI 10.1093/infdis/163.4.703; BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; Bera TK, 1998, MOL MED, V4, P384, DOI 10.1007/BF03401745; Berger EA, 1998, P NATL ACAD SCI USA, V95, P11511, DOI 10.1073/pnas.95.20.11511; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Brinkmann U, 2001, EXPERT OPIN BIOL TH, V1, P693, DOI 10.1517/14712598.1.4.693; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Butera ST, 2000, ANTIVIR RES, V48, P143, DOI 10.1016/S0166-3542(00)00133-9; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Goldstein H, 2000, J INFECT DIS, V181, P921, DOI 10.1086/315351; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Kessler JA, 1997, AIDS RES HUM RETROV, V13, P575, DOI 10.1089/aid.1997.13.575; Kreitman RJ, 1999, BLOOD, V94, P3340, DOI 10.1182/blood.V94.10.3340.422k19_3340_3348; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Pincus SH, 1996, ANTIVIR RES, V33, P1, DOI 10.1016/S0166-3542(96)00995-3; Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256; Reiter Y, 1996, CLIN CANCER RES, V2, P245; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Sonza S, 2001, AIDS PATIENT CARE ST, V15, P511, DOI 10.1089/108729101753205676; Thrush GR, 1996, ANNU REV IMMUNOL, V14, P49, DOI 10.1146/annurev.immunol.14.1.49; VANQIJEN MGC, 1997, J DRUG TARGET, V5, P75; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	26	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34383	34390		10.1074/jbc.M205456200	http://dx.doi.org/10.1074/jbc.M205456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12119300	hybrid			2022-12-27	WOS:000177959100111
J	McIntosh, JM; Dowell, C; Watkins, M; Garrett, JE; Yoshikami, D; Olivera, BM				McIntosh, JM; Dowell, C; Watkins, M; Garrett, JE; Yoshikami, D; Olivera, BM			alpha-Conotoxin GIC from Conus geographus, a novel peptide antagonist of nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN TOBACCO SICKNESS; NEURONAL BUNGAROTOXIN; SUBUNIT; DETERMINANTS; SENSITIVITY; LOPHOTOXIN; INHIBITION	Many venomous organisms produce toxins that disrupt neuromuscular communication to paralyze their prey. One common class of such toxins comprises nicotinic acetylcholine receptor antagonists (nAChRs). Thus, most toxins that act on nAChRs are targeted to the neuromuscular subtype. The toxin characterized in this report, alpha-conotoxin GIC, is a most striking exception. The 16-amino acid peptide was identified from a genomic DNA clone from Conus geographus. The predicted mature toxin was synthesized, and synthetic toxin was used in all studies described. alpha-Conotoxin GIC shows no paralytic activity in fish or mice. Furthermore, even at concentrations up to 100 mum, the peptide has no detectable effect on the human muscle nicotinic receptor subtype heterologously expressed in Xenopus oocytes. In contrast, the toxin has high affinity (IC50 approximate to1.1 nm) for the human alpha3beta2 subunit combination, making it the most neuronally selective nicotinic antagonist characterized thus far. Although alpha-conotoxin GIC shares some sequence similarity with alpha-conotoxin MII, which is also a potent alpha3beta2 nicotinic antagonist, it is much less hydrophobic, and the kinetics of channel block are substantially different. It is noteworthy that the nicotinic ligands in C. geographus venom fit an emerging pattern in venomous predators, with one nicotinic antagonist targeted to the muscle subtype (thereby causing paralysis) and a second nicotinic antagonist targeted to the alpha3beta2 nAChR subtype (possibly inhibiting the fight-or-flight response).	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Cognetix Inc, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 So 1400 East, Salt Lake City, UT 84112 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48677] Funding Source: Medline; NIMH NIH HHS [MH 53631] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; Arcury TA, 2001, J OCCUP ENVIRON MED, V43, P601, DOI 10.1097/00043764-200107000-00006; BALLARD T, 1995, ARCH ENVIRON HEALTH, V50, P384, DOI 10.1080/00039896.1995.9935972; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P65; D'Alessandro A, 2001, ARCH ENVIRON HEALTH, V56, P257, DOI 10.1080/00039890109604451; Harvey SC, 1996, J NEUROSCI, V16, P3798; HAYASHI E, 1984, J NEUROCHEM, V42, P1491, DOI 10.1111/j.1471-4159.1984.tb02817.x; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Luetje CW, 1998, MOL PHARMACOL, V53, P1112; Luo SQ, 1998, J NEUROSCI, V18, P8571; Majak W, 2000, J RANGE MANAGE, V53, P207, DOI 10.2307/4003284; McIndoo NE, 1916, J AGRIC RES, V7, P89; McIntosh J M, 1999, Methods Enzymol, V294, P605; McIntosh JM, 2000, EUR J PHARMACOL, V393, P205, DOI 10.1016/S0014-2999(99)00887-0; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; PAPKE RL, 1993, P ROY SOC B-BIOL SCI, V252, P141, DOI 10.1098/rspb.1993.0058; Schoenfeld RA, 1999, THESIS U UTAH; Tavazoie SF, 1997, BRIT J PHARMACOL, V120, P995, DOI 10.1038/sj.bjp.0700993; TAYLOR P, 1990, P166; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664	24	99	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33610	33615		10.1074/jbc.M205102200	http://dx.doi.org/10.1074/jbc.M205102200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114524	hybrid			2022-12-27	WOS:000177959100012
J	Xiang, Y; Devic, E; Kobilka, B				Xiang, Y; Devic, E; Kobilka, B			The PDZ binding motif of the beta(1) adrenergic receptor modulates receptor trafficking and signaling in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTORS; TARGETED DISRUPTION; PROTEIN-KINASE; COMPLEX; SAP97; INTERNALIZATION; ASSOCIATION; EXPRESSION; INTERACTS; CHANNELS	beta(1) and beta(2) adrenergic receptors (AR) regulate the intrinsic contraction rate in neonatal mouse cardiac myocytes through distinct signaling pathways. It has been shown that stimulation of beta(1)ARs leads to a protein kinase A-dependent increase in contraction rate. In contrast, stimulation of beta(2)ARs has a biphasic effect on contraction rate, with an initial protein kinase A-independent increase followed by a sustained decrease that is blocked by pertussis toxin. The beta(2)AR undergoes agonist-induced endocytosis in cardiac myocytes while the beta(1)AR remains on the cell surface. It has been shown that a PDZ domain binding motif at the carboxyl terminus of beta(1)AR interacts with the postsynaptic density protein PSD-95 when both are expressed in HEK293 cells. We found that mutation of this PDZ binding motif in the beta(1)AR (beta(1)AR-PDZ) enabled agonist-induced internalization in cardiac myocytes. Moreover, stimulation of beta(1)AR-PDZ had a biphasic effect on the myocyte contraction rate similar to that observed following stimulation of the beta(2)AR. The secondary decrease in the contraction rate was mediated by G(i) and could be blocked by pertussis toxin. Furthermore, a non-selective endocytosis inhibitor, concanavalin A, inhibited the internalization of wild type beta(2)AR and the mutated beta(1)AR-PDZ, and blocked the coupling of both receptors to G(i). Finally, treating myocytes with a membrane-permeable peptide representing beta(1)AR PDZ motif caused the endogenous beta(1)AR to behave like beta(1)AR-PDZ. These studies suggest that association of the beta(1)AR with PSD-95 or a related protein dictates signaling specificity by retaining the receptor at the cell surface and preventing interaction with G(i).	Stanford Univ, Med Ctr,Howard Hughes Med Inst, Beckman Ctr, Dept Mol & Cellular Physiol, Palo Alto, CA 94043 USA	Howard Hughes Medical Institute; Stanford University	Kobilka, B (corresponding author), Stanford Univ, Med Ctr,Howard Hughes Med Inst, Beckman Ctr, Dept Mol & Cellular Physiol, B157, Palo Alto, CA 94043 USA.			Kobilka, Brian/0000-0001-5958-3990				Aprigliano Octavio, 1997, American Journal of Physiology, V272, pH2726; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Devic E, 2001, MOL PHARMACOL, V60, P577; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Gee SH, 1998, J NEUROSCI, V18, P128; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Leonoudakis D, 2001, J CELL SCI, V114, P987; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Maruoka ND, 2000, FEBS LETT, V473, P188, DOI 10.1016/S0014-5793(00)01521-0; MICHEL MC, 1990, BRIT J CLIN PHARMACO, V30, pS37, DOI 10.1111/j.1365-2125.1990.tb05466.x; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Reuver SM, 1998, J CELL SCI, V111, P1071; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Xiao R P, 2001, Sci STKE, V2001, pre15, DOI 10.1126/stke.2001.104.re15; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	36	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33783	33790		10.1074/jbc.M204136200	http://dx.doi.org/10.1074/jbc.M204136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097326	hybrid			2022-12-27	WOS:000177959100035
J	Zhang, ZX; Jiang, YF; Quinn, SJ; Krapcho, K; Nemeth, EF; Bai, M				Zhang, ZX; Jiang, YF; Quinn, SJ; Krapcho, K; Nemeth, EF; Bai, M			L-phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor through distinct sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; ACTIVATING MUTATIONS; BRAIN-FUNCTION; CA2+	The extracellular calcium (Ca-o(2+))-sensing receptor (CaR) can be potentiated by allosteric activators including calcimimetics and L-amino acids. In this study, we found that many mutations had differential effects on the functional modulation of the CaR by these two allosteric activators, supporting the idea that these modulators act through distinct sites. 10 MM L-phenylalanine and 1 muM NPS R-467, submaximal doses of the two agents, each elicited similar modulation of R185Q. However, there are different relative potencies for these two modulators with some receptors being more responsive to L-phenylalanine and others being more responsive to NPS R-467. The responsiveness of the CaR to Ca-o(2+) appears to be essential to observe the potentiating action Of L-phenylalanine but not of NPS R-467 on the receptor. NPS R-467 reduces the Hill coefficients of the wild-type as well as mutant receptors, suggesting that engagement of all Ca2+ binding sites is not required when the receptor is activated by NPS R-467. In contrast, L-phenylalanine has little effect on the Hill coefficients of mutant receptors. The two-site model is further supported by the observation that these two classes of modulators exert a synergistic effect on CaRs with inactivating mutations that are responsive to both modulators.	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Membrane Biol Program, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; NPS Pharmaceut Inc, Salt Lake City, UT 84108 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.		Centeno, Patricia Pacios/O-8368-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054934] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54934] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200	9	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33736	33741		10.1074/jbc.M200978200	http://dx.doi.org/10.1074/jbc.M200978200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114500	hybrid			2022-12-27	WOS:000177959100029
J	Burysek, L; Syrovets, T; Simmet, T				Burysek, L; Syrovets, T; Simmet, T			The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and Janus kinase (JAK)/STAT signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; TRANSCRIPTION FACTOR; CHEMOATTRACTANT PROTEIN-1; 5-LIPOXYGENASE PATHWAY; TRANSDUCTION PATHWAYS; COUPLED RECEPTORS; GAMMA INDUCTION; TERMINAL KINASE; GENE-EXPRESSION; CELLS	The mechanism of proinflammatory activation of human monocytes by plasmin is unknown. Here we demonstrate that in human primary monocytes, plasmin stimulates mitogen-activated protein kinase (MAPK) signaling via phosphorylation of MAPK kinase 3/6 (MKK3/6) and p38 MAPK that triggers subsequent DNA binding of transcription factor activator protein-1 (AP-1). The AP-1 complex contained phosphorylated c-Jun and ATF2, and its DNA binding activity was blocked by the p38 MAPK inhibitor SB203580. In addition, plasmin elicits Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, as detected by phosphorylation of JAK1 tyrosine kinase and STAT1 and STAT3 proteins. Plasmin-induced DNA binding of STAT1 and STAT3 was blocked by SB203580 and AG490, inhibitors of p38 MAPK and JAK, respectively, but not by U0126, an inhibitor of MKK1/2. DNA binding of NF-kappaB remained unaffected by any of these inhibitors. The plasmin-induced signaling led to expression of monocyte chemoattractant protein-1 (MCP-1) and CD40, which required activation of both p38 MAPK and JAK/STAT signaling pathways. Additionally, signaling through both p38 MAPK and JAK is involved in the plasmin-mediated monocyte migration, whereas the formylmethionylleucylphenylalanine-induced chemotaxis remained unaffected. Taken together, our data demonstrate a novel function of the serine protease plasmin in a proinflammatory signaling network.	Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany	Ulm University	Simmet, T (corresponding author), Univ Ulm, Dept Pharmacol Nat Prod & Clin Pharmacol, Helmholtzstr 20, D-89081 Ulm, Germany.	thomas.simmet@medizin.uni-ulm.de	Burýšek, Ladislav/M-7369-2019; Syrovets, Tatiana/J-4594-2019	Syrovets, Tatiana/0000-0002-6751-2233				ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Brandes RP, 2001, THROMB HAEMOSTASIS, V85, P1104; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Carter AB, 2001, J BIOL CHEM, V276, P33826, DOI 10.1074/jbc.M100209200; COLOTTA F, 1992, J IMMUNOL, V148, P760; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Craxton A, 1998, J IMMUNOL, V161, P3225; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Gollob JA, 1999, J IMMUNOL, V162, P4472; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; Hale KK, 1999, J IMMUNOL, V162, P4246; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; KAPLAN AP, 1987, BLOOD, V70, P1; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mitsui H, 1998, HEPATOLOGY, V27, P1362, DOI 10.1002/hep.510270524; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Niculescu F, 1999, IMMUNOPHARMACOLOGY, V42, P187, DOI 10.1016/S0162-3109(99)00014-4; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Renshaw MW, 2000, ONCOGENE, V19, P3216, DOI 10.1038/sj.onc.1203667; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; RYAN TJ, 1992, J CELL PHYSIOL, V151, P255, DOI 10.1002/jcp.1041510206; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; SEINO Y, 1995, CYTOKINE, V7, P575, DOI 10.1006/cyto.1995.0078; Shigeta O, 1997, CIRCULATION, V96, P569; Siddiqa A, 2001, NATURE, V410, P383, DOI 10.1038/35066602; Song S, 2000, BRIT J HAEMATOL, V109, P851, DOI 10.1046/j.1365-2141.2000.02126.x; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Waas WF, 2001, J BIOL CHEM, V276, P5676, DOI 10.1074/jbc.M008787200; Weide I, 1996, THROMB HAEMOSTASIS, V76, P561; WEIDE I, 1994, BLOOD, V83, P1941; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Ydrenius L, 1997, BIOCHEM BIOPH RES CO, V235, P445, DOI 10.1006/bbrc.1997.6822; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	72	138	143	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33509	33517		10.1074/jbc.M201941200	http://dx.doi.org/10.1074/jbc.M201941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093796	hybrid			2022-12-27	WOS:000177859000141
J	Chopra, S; de Mattos, SF; Lam, EWF; Mann, DJ				Chopra, S; de Mattos, SF; Lam, EWF; Mann, DJ			Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITOR P27; CELL-CYCLE; COP9 SIGNALOSOME; PHOSPHORYLATION; DEGRADATION; QUIESCENCE; REGULATOR; AP-1; EXIT	The cyclin-dependent kinase (cdk) inhibitor P27(Kip1) is a central mediator in the imposition and maintenance of quiescence through the sequestration of G(1)-specific cyclin-cdk complexes. Previous studies have implicated the c-Jun co-activator protein Jab1 as a regulator of intracellular p27(Kip1) levels. Jab1 has been reported to interact with p27(Kip1) and cause its translocation to the cytoplasm as a prelude to the degradation of the cdk inhibitor. Here we describe experiments that showing phosphorylation of p27(Kip1) at serine 10 leads to the suppression of Jab1 levels with the concomitant inhibition of c-Jun-dependent transcription. This repression is minimized upon quiescence exit through the rapid and preferential loss of the serine 10-phosphorylated form of p27(Kip1) following serum stimulation. Our results, therefore, demonstrate an additional role for p27(Kip1) in the modulation of c-Jun-dependent transcription via Jab1.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; Hammersmith Hosp, Sect Canc Cell Biol, Imperial Coll, Sch Med, London W12 0NN, England; Canc Res United Kingdom Labs, Dept Canc Med, London W12 0NN, England	Imperial College London; Imperial College London; Cancer Research UK	Mann, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Exhibit Rd, London SW7 2AY, England.	d.mann@ic.ac.uk	de Mattos, Silvia Fernández/K-5153-2014; Lam, Eric W-F/AAW-8566-2020	de Mattos, Silvia Fernández/0000-0003-4144-3687; Lam, Eric W-F/0000-0003-1274-3576				Bech-Otschir D, 2002, J CELL SCI, V115, P467; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; JOOSS K, 1995, ONCOGENE, V10, P1529; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334	30	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32413	32416		10.1074/jbc.C200311200	http://dx.doi.org/10.1074/jbc.C200311200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12119282	hybrid			2022-12-27	WOS:000177859000003
J	Hidaka, K; Caffrey, JJ; Hua, L; Zhang, T; Falck, JR; Nickel, GC; Carrel, L; Barnes, LD; Shears, SB				Hidaka, K; Caffrey, JJ; Hua, L; Zhang, T; Falck, JR; Nickel, GC; Carrel, L; Barnes, LD; Shears, SB			An adjacent pair of human NUDT genes on chromosome X are preferentially expressed in testis and encode two new isoforms of diphosphoinositol polyphosphate phosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL HEXAKISPHOSPHATE KINASE; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; HYDROLASES; FAMILY; PENTAKISPHOSPHATE; IDENTIFICATION; INTEGRITY; COATOMER	Combinatorial expression of the various isoforms of diphosphoinositol synthases and phosphohydrolases determines the rates of phosphorylation/dephosphorylation cycles that have been functionally linked to vesicle trafficking, stress responses, DNA repair, and apoptosis. We now describe two new 19-kDa diphosphoinositol polyphosphate phosphohydrolases (DIPPs), named types 3alpha and 3beta, which possess the canonical Nudix-type catalytic motif flanked on either side by short Gly-rich sequences. The two enzymes differ only in that Pro-89 in the a form is replaced by Arg-89 in the 13 form, making the latter similar to2-fold more active in vitro. Another Nudix substrate, diadenosine hexaphosphate, was hydrolyzed less efficiently (k(cat)/K-m = 0.2 x 10(5) M-1 s(-1)) compared with diphosphoinositol polyphosphates (k(cat)/K-m = 2-40 x 10(5) M-1 s(-1)). Catalytic activity in vivo was established by individual overexpression of the human (h) DIPP3 isoforms in HEK293 cells, which reduced cellular levels of diphosphoinositol polyphosphates by 40-50%. The hDIPP3 mRNA is preferentially expressed in testis, accompanied by relatively weak expression in the brain, contrasting with hDIPP1 and hDIPP2 which are widely expressed. The hDIPP3 genes (NUDT10 encodes hDIPP3alpha; NUDT11 encodes hDIPP3beta) are only 152 kbp apart at p11.22 on chromosome X and probably arose by duplication. Transcription of both genes is inactivated on one of the X chromosomes of human females to maintain appropriate gene dosage. The hDIPP3 pair add tissue-specific diversity to the molecular mechanisms regulating diphosphoinositol polyphosphate turnover.	NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; University of Texas System; University of Texas Health San Antonio	Shears, SB (corresponding author), NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	shears@niehs.nih.gov	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916; Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abel K, 2001, J CELL SCI, V114, P2207; Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Caffrey JJ, 2001, GENE, V269, P53, DOI 10.1016/S0378-1119(01)00446-2; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Cartwright JL, 2002, J VIROL, V76, P1415, DOI 10.1128/JVI.76.3.1415-1421.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CROMPTON IE, 1986, BIOCHEM J, V239, P221, DOI 10.1042/bj2390221; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Holden CP, 1996, J NEUROCHEM, V67, P574; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; Jovanovic A, 1998, FEBS LETT, V423, P314, DOI 10.1016/S0014-5793(98)00114-8; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Miras-Portugal MT, 1998, FEBS LETT, V430, P78, DOI 10.1016/S0014-5793(98)00560-2; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Otto SP, 2002, ADV GENET, V46, P451; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Xu WL, 2002, J BIOL CHEM, V277, P23181, DOI 10.1074/jbc.M203325200; Xu WL, 2001, MOL MICROBIOL, V39, P286, DOI 10.1046/j.1365-2958.2001.02267.x; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569; Yang XN, 1999, J BIOL CHEM, V274, P35434, DOI 10.1074/jbc.274.50.35434; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	38	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32730	32738		10.1074/jbc.M205476200	http://dx.doi.org/10.1074/jbc.M205476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105228	hybrid			2022-12-27	WOS:000177859000044
J	Liu, L; Schwartz, BR; Tupper, J; Lin, N; Winn, RK; Harlan, JM				Liu, L; Schwartz, BR; Tupper, J; Lin, N; Winn, RK; Harlan, JM			The GTPase rap1 regulates phorbol 12-myristate 13-acetate-stimulated but not ligand-induced beta(1) integrin-dependent leukocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIFFERENTIAL REGULATION; ADP-RIBOSYLATION; T-LYMPHOCYTES; CELL-ADHESION; ACTIVATION; RHO; BINDING; AVIDITY; INHIBITION	Leukocyte migration from bloodstream to tissue requires rapid, coordinated regulation of integrin-dependent adhesion and de-adhesion. In a previous study we demonstrated that inhibition of protein geranylgeranylation inhibited phorbol ester-stimulated avidity modulation of beta(1) integrin in several leukocyte cell lines. Both RhoA and Rap1 require post-translational modification by geranylgeranylation for full function. In this report we identify Rap1, not RhoA, as a critical geranylgeranylated protein mediating phorbol ester-stimulated beta(1) and beta(2) integrin-dependent adhesion of Jurkat cells. Overexpression of the Rap1-specific GTPase-activating protein, SPA-1, or inactivated form of Rap1 (N17Rap1) blocked phorbol ester-stimulated adhesion of Jurkat cells to fibronectin (alpha(4)beta(1)) and ICAM-1 (alpha(L)beta(2)). With high concentrations of fibronectin as ligand, Jurkat cells adhered spontaneously without phorbol ester stimulation. Unlike the phorbol ester-stimulated adhesion, adhesion induced by high density ligand was not dependent upon Rap1 activation or actin cytoskeleton reorganization. Thus, the "inside-out" adhesion signal induced by phorbol ester and the "outside-in" signal induced by high density ligand involve different pathways.	Univ Washington, Harborview Med Ctr, Div Hematol, Dept Med, Seattle, WA 98104 USA; Univ Washington, Dept Surg, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Liu, L (corresponding author), Univ Washington, Harborview Med Ctr, Div Hematol, Dept Med, 325 9Th Ave,Box 359756, Seattle, WA 98104 USA.	liliu@u.washington.edu			NHLBI NIH HHS [HL 18645, HL 30542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEPFELBACHER M, 1995, FEBS LETT, V363, P78, DOI 10.1016/0014-5793(95)00285-H; Anderson SI, 2000, J CELL SCI, V113, P2737; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bleijs DA, 2001, J BIOL CHEM, V276, P10338, DOI 10.1074/jbc.M008967200; Buckley CD, 1998, MOL MEMBR BIOL, V15, P167, DOI 10.3109/09687689709044318; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu L, 1999, J BIOL CHEM, V274, P33334, DOI 10.1074/jbc.274.47.33334; Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330; Petruzzelli L, 1998, J IMMUNOL, V160, P4208; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Schwartz BR, 1999, J IMMUNOL, V162, P4842; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Woodside DG, 1998, J EXP MED, V188, P1211, DOI 10.1084/jem.188.7.1211; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	37	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40893	40900		10.1074/jbc.M206208200	http://dx.doi.org/10.1074/jbc.M206208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12091396	hybrid			2022-12-27	WOS:000178791400095
J	Maturana, A; Van Haasteren, G; Piuz, I; Castelbou, C; Demaurex, N; Schlegel, W				Maturana, A; Van Haasteren, G; Piuz, I; Castelbou, C; Demaurex, N; Schlegel, W			Spontaneous calcium oscillations control c-fos transcription via the serum response element in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE LIVING CELLS; GENE-EXPRESSION; MAP KINASE; DEPENDENT TRANSCRIPTION; PITUITARY GONADOTROPHS; CREB PHOSPHORYLATION; PROTEIN; ACTIVATION; CHANNEL; NEURONS	In excitable cells the localization of Ca2+ signals plays a central role in the cellular response, especially in the control of gene transcription. To study the effect of localized Ca2+ signals on the transcriptional activation of the c-fos oncogene, we stably expressed various c-fos beta-lactamase reporter constructs in pituitary AtT20 cells. A significant, but heterogenous expression of c-fos beta-lactamase was observed in unstimulated cells, and a further increase was observed using KCI depolarization, epidermal growth factor (EGF), pituitary adenylate cyclase-activating polypeptide (PACAP), and serum. The KCI response was almost abolished by a nuclear Ca2+ clamp, indicating that a rise in nuclear Ca2+ is required. In contrast, the basal expression was not affected by the nuclear Ca2+ clamp, but it was strongly reduced by nifedipine, a specific antagonist of L-type Ca2+ channels. Spontaneous Ca2+ oscillations, blocked by nifedipine, were observed in the cytosol but did not propagate to the nucleus, suggesting that a rise in cytosolic Ca2+ is sufficient for basal c-fos expression. Inactivation of the c-fos promoter cAMP/Ca2+ response element (CRE) had no effect on basal or stimulated expression, whereas inactivation of the serum response element (SRE) had the same marked inhibitory effect as nifedipine. These experiments suggest that in AtT20 cells spontaneous Ca2+ oscillations maintain a basal c-fos transcription through the serum response element. Further induction of c-fos expression by depolarization requires a nuclear Ca2+ increase.	Univ Geneva, Fdn Rech Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Schlegel, W (corresponding author), Univ Geneva, Fdn Rech Med, 64 Av Roseraie, CH-1211 Geneva 4, Switzerland.			Demaurex, Nicolas/0000-0002-9933-6772				Ahn S, 2000, ANNU REV PHYSIOL, V62, P803, DOI 10.1146/annurev.physiol.62.1.803; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; DOUGLAS WW, 1963, NATURE, V197, P81, DOI 10.1038/197081b0; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P453, DOI DOI 10.1111/J.1476-5381.1968.TB08474.X; Fiekers JF, 1996, CELL CALCIUM, V19, P327, DOI 10.1016/S0143-4160(96)90073-1; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Johnson CM, 1997, J NEUROSCI, V17, P6189; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LI YX, 1995, BIOPHYS J, V69, P785, DOI 10.1016/S0006-3495(95)79952-0; Mellstrom B, 2001, CURR OPIN NEUROBIOL, V11, P312, DOI 10.1016/S0959-4388(00)00213-0; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Mollard P, 1996, TRENDS ENDOCRIN MET, V7, P361, DOI 10.1016/S1043-2760(96)00186-5; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Sokol DL, 1998, P NATL ACAD SCI USA, V95, P11538, DOI 10.1073/pnas.95.20.11538; STOJILKOVIC SS, 1993, J BIOL CHEM, V268, P7713; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsuji A, 2000, BIOPHYS J, V78, P3260, DOI 10.1016/S0006-3495(00)76862-7; van Haasteren G, 2000, NEUROENDOCRINOLOGY, V72, P368, DOI 10.1159/000054606; Villalobos C, 1999, MOL ENDOCRINOL, V13, P1718, DOI 10.1210/me.13.10.1718; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	46	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39713	39721		10.1074/jbc.M200464200	http://dx.doi.org/10.1074/jbc.M200464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12121970	hybrid, Green Published			2022-12-27	WOS:000178662500085
J	Pandini, G; Frasca, F; Mineo, R; Sciacca, L; Vigneri, R; Belfiore, A				Pandini, G; Frasca, F; Mineo, R; Sciacca, L; Vigneri, R; Belfiore, A			Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; THYROID-CANCER; SKELETAL-MUSCLE; PROTEIN-KINASE; MESSENGER-RNA; HIGH-AFFINITY; BETA-SUBUNIT; IGF-II	The insulin receptor (IR) and the insulin-like growth factor I receptor (IGF-IR) have a highly homologous structure, but different biological effects. Insulin and IGF-I half-receptors can heterodimerize, leading to the formation of insulin/IGF-I hybrid receptors (Hybrid-Rs) that bind IGF-I with high affinity. As the IR exists in two isoforms (IR-A and IR-B), we evaluated whether the assembly of the IGF-IR with either IR-A or IR-B moieties may differently affect Hybrid-R signaling and biological role. Three different models were studied: (a) 3T3-like mouse fibroblasts with a disrupted IGF-IR gene (R-cells) cotransfected with the human IGF-IR and with either the IR-A or IR-B cDNA, (b) a panel of human cell lines variably expressing the two IR isoforms; and (c) HepG2 human hepatoblastoma cells predominantly expressing either IR-A or IR-B, depending on their differentiation state. We found that Hybrid-Rs containing IR-A (Hybrid-Rs(A)) bound to and were activated by IGF-I, IGF-II, and insulin. By binding to Hybrid-Rs(A), insulin activated the IGF-I half-receptor beta-subunit and the IGF-IR-specific substrate CrkII. In contrast, Hybrid-Rs(B) bound to and were activated with high affinity by IGF-I, with low affinity by IGF-II, and insignificantly by insulin. As a consequence, cell proliferation and migration in response to both insulin and IGFs were more effectively stimulated in Hybrid-R-A-containing cells than in Hybrid-R-B-containing cells. The relative abundance of IR isoforms therefore affects IGF system activation through Hybrid-Rs, with important consequences for tissue-specific responses to both insulin and IGFs.	Univ Catanzaro, Policlin Mater Domini, Dipartimento Med Clin & Sperimentale, I-88100 Catanzaro, Italy; Ist Mediterraneo Oncol, I-95100 Catania, Italy; Univ Catania, Osped Garibaldi, Ist Med Interna Malattie Endocrine & Metab, I-95123 Catania, Italy	Magna Graecia University of Catanzaro; Mediterranean Institute of Oncology; University of Catania	Belfiore, A (corresponding author), Univ Catanzaro, Policlin Mater Domini, Dipartimento Med Clin & Sperimentale, Via T Campanella 115, I-88100 Catanzaro, Italy.		Sciacca, Laura/B-9368-2014; SCIACCA, Laura/AAS-2896-2020; Frasca, Francesco/J-1332-2018; Belfiore, Antonino/B-4652-2011; Pandini, Giuseppe/AAB-9650-2019; Vigneri, Riccardo/M-3968-2017	Sciacca, Laura/0000-0002-3258-7200; SCIACCA, Laura/0000-0002-3258-7200; Frasca, Francesco/0000-0002-5556-3201; Belfiore, Antonino/0000-0002-6181-4193; Pandini, Giuseppe/0000-0003-3747-7649; Vigneri, Riccardo/0000-0002-4401-3140				Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; BASERGA R, 1995, CANCER RES, V55, P249; Belfiore A, 1999, BIOCHIMIE, V81, P403, DOI 10.1016/S0300-9084(99)80088-1; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Federici M, 1996, J CLIN INVEST, V98, P2887, DOI 10.1172/JCI119117; Federici M, 1998, J CLIN ENDOCR METAB, V83, P2911, DOI 10.1210/jc.83.8.2911; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; FLIER JS, 1993, J CLIN ENDOCR METAB, V76, P1533, DOI 10.1210/jc.76.6.1533; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Koval AP, 1998, BIOCHEM J, V330, P923; KULL FC, 1983, J BIOL CHEM, V258, P6561; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Pandini G, 1999, CLIN CANCER RES, V5, P1935; PAPA V, 1993, CANCER RES, V53, P3736; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P537, DOI 10.1101/SQB.1988.053.01.062; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Sbraccia P, 1996, DIABETOLOGIA, V39, P220, DOI 10.1007/BF00403966; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SEELY BL, 1995, ENDOCRINOLOGY, V136, P1635, DOI 10.1210/en.136.4.1635; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; Spampinato D, 2000, J CLIN ENDOCR METAB, V85, P4219, DOI 10.1210/jc.85.11.4219; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2001, J CLIN PATHOL-MOL PA, V54, P121, DOI 10.1136/mp.54.3.121; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	50	358	385	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39684	39695		10.1074/jbc.M202766200	http://dx.doi.org/10.1074/jbc.M202766200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12138094	hybrid			2022-12-27	WOS:000178662500082
J	Schmid, VHR; Potthast, S; Wiener, M; Bergauer, V; Paulsen, H; Storf, S				Schmid, VHR; Potthast, S; Wiener, M; Bergauer, V; Paulsen, H; Storf, S			Pigment binding of photosystem I light-harvesting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARLEY HORDEUM-VULGARE; CHLOROPHYLL B-LESS; COMPLEX-I; VITRO RECONSTITUTION; ENERGY-TRANSFER; INDUCED BIOGENESIS; GREEN-ALGA; LHC-I; ANTENNA; STOICHIOMETRY	Light-harvesting complexes (LHC) of higher plants are composed of at least 10 different proteins. Despite their pronounced amino acid sequence homology, the LHC of photosystem II show differences in pigment binding that are interpreted in terms of partly different functions. By contrast, there is only scarce knowledge about the pigment composition of LHC of photosystem 1, and consequently no concept of potentially different functions of the various LHCI exists. For better insight into this issue, we isolated native LHCI-730 and LHCI-680. Pigment analyses revealed that LHCI-730 binds more chlorophyll and violaxanthin than LHCI-680. For the first time all LHCI complexes are now available in their recombinant form; their analysis allowed further dissection of pigment binding by individual LHCI proteins and analysis of pigment requirements for LHCI formation. By these different approaches a correlation between the requirement of a single chlorophyll species for LHC formation and the chlorophyll a/b ratio of LHCs could be detected, and indications regarding occupation of carotenoid-binding sites were obtained. Additionally the reconstitution approach allowed assignment of spectral features observed in native LHCI-680 to its components Lhca2 and Lhca3. It is suggested that excitation energy migrates from chlorophyll(s) fluorescing at 680 (Lhca3) via those fluorescing at 686/702 nm (Lhca2) or 720 nm (Lhca3) to the photosystem I core chlorophylls.	Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Schmid, VHR (corresponding author), Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	vschmid@mail.uni-mainz.de	Paulsen, Harald/D-3742-2011					Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; ANANDAN S, 1993, PLANT PHYSIOL, V101, P227, DOI 10.1104/pp.101.1.227; ANDERSON JM, 1984, PHOTOBIOCH PHOTOBIOP, V8, P221; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BASSI R, 1992, J BIOL CHEM, V267, P25714; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Bishop NI, 1996, J PHOTOCH PHOTOBIO B, V36, P279, DOI 10.1016/S1011-1344(96)07381-2; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAMMARATA KV, 1992, PHOTOSYNTH RES, V33, P235, DOI 10.1007/BF00030034; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Cinque G, 2000, PHOTOSYNTH RES, V64, P233, DOI 10.1023/A:1006467617697; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Croce R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P421; Damm I, 1990, CURRENT RES PHOTOSYN, VII, P607; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P841, DOI 10.1104/pp.106.3.841; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOBETS B, 1994, BBA-BIOENERGETICS, V1188, P75, DOI 10.1016/0005-2728(94)90024-8; Grabowski B, 2000, PHOTOSYNTH RES, V63, P85, DOI 10.1023/A:1006357107247; HARRISON MA, 1993, PHOTOSYNTH RES, V38, P141, DOI 10.1007/BF00146413; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; IKEUCHI M, 1991, PLANT CELL PHYSIOL, V32, P103; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JIA YW, 1992, BIOPHYS J, V63, P259, DOI 10.1016/S0006-3495(92)81589-8; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1984, FEBS LETT, V168, P10, DOI 10.1016/0014-5793(84)80197-0; LEE ALC, 1995, PLANT PHYSIOL, V107, P565, DOI 10.1104/pp.107.2.565; MARQUARDT J, 1993, PLANTA, V191, P265, DOI 10.1007/BF00199759; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Melkozernov AN, 1998, J PHYS CHEM B, V102, P8183, DOI 10.1021/jp9810466; Melkozernov AN, 2002, J PHYS CHEM B, V106, P4313, DOI 10.1021/jp014271n; MELKOZERNOV AN, 2001, P 12 INT C PHOT; MEYER M, 1993, Z NATURFORSCH C, V48, P461; MORISHIGE DT, 1995, PHOTOSYNTH RES, V44, P183, DOI 10.1007/BF00018308; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PALSSON LO, 1995, BBA-BIOENERGETICS, V1230, P1, DOI 10.1016/0005-2728(95)00029-I; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 2002, HEME CHLOROPHYLL BIL, P235; PETER GF, 1991, J BIOL CHEM, V266, P16745; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Polle JEW, 2001, PLANT CELL PHYSIOL, V42, P482, DOI 10.1093/pcp/pce058; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Rupprecht J, 2000, PHOTOSYNTH RES, V63, P217, DOI 10.1023/A:1006499517613; Sambrook KJ, 1989, MOL CLONING LAB MANU; SCHAFER C, 1994, J PHOTOCH PHOTOBIO B, V22, P67, DOI 10.1016/1011-1344(93)06952-Y; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid V, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P425; SCHMID V, 1994, PLANTA, V192, P473, DOI 10.1007/BF00203584; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SIGRIST M, 1994, PLANT PHYSIOL, V104, P135, DOI 10.1104/pp.104.1.135; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THAYER SS, 1992, PHOTOSYNTH RES, V33, P213, DOI 10.1007/BF00030032; THORNBER JP, 1993, BIOCHEM SOC T, V21, P15, DOI 10.1042/bst0210015; TJUS SE, 1995, PHOTOSYNTH RES, V45, P41, DOI 10.1007/BF00032234; WHITE MJ, 1988, PHOTOSYNTH RES, V15, P195, DOI 10.1007/BF00047352; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	76	68	74	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37307	37314		10.1074/jbc.M205889200	http://dx.doi.org/10.1074/jbc.M205889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12095996	hybrid			2022-12-27	WOS:000178447100052
J	Shimizu, K; Hashimoto, K; Kirchner, JM; Nakai, W; Nishikawa, H; Resnick, MA; Sugino, A				Shimizu, K; Hashimoto, K; Kirchner, JM; Nakai, W; Nishikawa, H; Resnick, MA; Sugino, A			Fidelity of DNA polymerase epsilon holoenzyme from budding yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; 5' EXONUCLEASE ACTIVITY; SCHIZOSACCHAROMYCES-POMBE; CATALYTIC DOMAINS; REPLICATION FORK; CHROMOSOMAL DNA; S-PHASE; DELTA; SUBUNIT; GENE	DNA polymerases delta and epsilon (pol delta and epsilon) are the major replicative polymerases and possess 3'-5' proofreading exonuclease activities that correct errors arising during DNA replication in the yeast Saccharomyces cerevisiae. This study measures the fidelity of the holoenzyme of wild-type pol epsilon, the 3'-5' exonuclease-deficient pol2-4, a +1 frameshift mutator for homonucleotide runs, pol2C1089Y, and pol2C1089Y pol2-4 enzymes using a synthetic 30-mer primer/100-mer template. The nucleotide substitution rate for wild-type pol epsilon was 0.47 x 10(-5) for G:G mismatches, 0.15 x 10(-5) for T:G mismatches, and less than 0.01 x 10(-5) for A:G mismatches. The accuracy for A opposite G was not altered in the exonuclease-deficient pol2-4 pol epsilon; however, G:G and T:G misincorporation rates increased 40- and 73-fold, respectively. The pol2C1089Y pol c mutant also exhibited increased G:G and T:G misincorporation rates, 22- and 10-fold, respectively, whereas A:G misincorporation did not differ from that of wild type. Since the fidelity of the double mutant pol2-4 pol2C1089Y was not greatly decreased, these results suggest that the proofreading 3'-5' exonuclease activity of pol2C1089Y pol epsilon is impaired even though it retains nuclease activity and the mutation is not in the known exonuclease domain.	Osaka Univ, Dept Biochem & Mol Biol, Microbial Dis Res Inst, Osaka 5650871, Japan; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sugino, A (corresponding author), Osaka Univ, Labs Biomol Networks, Grad Sch Frontier Biosci, 3-1 Yamada Oka, Osaka 5650871, Japan.		resnick, Michael/F-1668-2019	resnick, Michael/0000-0002-8473-7506				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Chen XL, 2000, J BIOL CHEM, V275, P17677, DOI 10.1074/jbc.M910278199; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kirchner JM, 2000, GENETICS, V155, P1623; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846; Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Washington MT, 2001, P NATL ACAD SCI USA, V98, P8355, DOI 10.1073/pnas.121007298; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	40	33	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37422	37429		10.1074/jbc.M204476200	http://dx.doi.org/10.1074/jbc.M204476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12124389	hybrid			2022-12-27	WOS:000178447100066
J	Christensen, MO; Barthelmes, HU; Boege, F; Mielke, C				Christensen, MO; Barthelmes, HU; Boege, F; Mielke, C			The N-terminal domain anchors human topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; DIGITAL IMAGING MICROSCOPY; DNA TOPOISOMERASE; SCLERODERMA SERA; TRANSCRIPTION; LOCALIZATION; AUTOANTIBODY; PROTEINS; IDENTIFICATION; EXPRESSION	DNA topoisomerase I releases torsion stress created by DNA transcription. In principle, this activity is required in the nucleoplasm for mRNA synthesis and in the nucleoli for rRNA synthesis. Yet, topoisomerase I is mostly a nucleolar protein. Current belief holds that this preference is triggered by the N-terminal domain of the enzyme, which constitutes a nucleolar import signal. Contradicting this view, we show here that nucleolar accumulation of various fragments of topoisomerase I is correlated with their lesser mobility in this compartment and not with the N-terminal domain being intact or present. Therefore, the N-terminal domain is not likely a nucleolar import signal. We show that it rather serves as an adaptor that anchors a subpopulation of topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes. Thus, it provides a steady association of topoisomerase I with the rDNA and with RNA polymerase I, which is maintained in a living cell during the entire cell cycle.	Univ Wurzburg, Med Poliklin, Dept Clin Chem, D-97070 Wurzburg, Germany	University of Wurzburg	Mielke, C (corresponding author), Univ Wurzburg, Med Poliklin, Dept Clin Chem, Klin Str 6-8, D-97070 Wurzburg, Germany.		Boege, Fritz/H-3261-2019					BAKER SD, 1995, CYTOMETRY, V19, P134, DOI 10.1002/cyto.990190208; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Lisby M, 2001, J BIOL CHEM, V276, P20220, DOI 10.1074/jbc.M010991200; Mais C, 2001, J CELL SCI, V114, P709; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mielke C, 2000, GENE, V254, P1, DOI 10.1016/S0378-1119(00)00294-8; MIKELSAAR AV, 1977, HUM GENET, V37, P73, DOI 10.1007/BF00293774; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Seither P, 1998, J MOL BIOL, V275, P43, DOI 10.1006/jmbi.1997.1434; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Stanek D, 2001, CHROMOSOMA, V110, P460, DOI 10.1007/s00412-001-0172-2; Suja JA, 1997, CHROMOSOMA, V105, P459, DOI 10.1007/BF02510483; Wadkins RM, 1998, EXP CELL RES, V241, P332, DOI 10.1006/excr.1998.4033; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35932	35938		10.1074/jbc.M204738200	http://dx.doi.org/10.1074/jbc.M204738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119295	hybrid			2022-12-27	WOS:000178275100023
J	Sasaki, T; Taoka, M; Ishiguro, K; Uchida, A; Saito, T; Isobe, T; Hisanaga, S				Sasaki, T; Taoka, M; Ishiguro, K; Uchida, A; Saito, T; Isobe, T; Hisanaga, S			In vivo and in vitro phosphorylation at Ser-493 in the glutamate (E)-segment of neurofilament-H subunit by glycogen synthase kinase 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL DOMAIN; CDC2 KINASE; NF-H; PROTEIN; IDENTIFICATION; SITES; DEPHOSPHORYLATION; KINASE-3-BETA; LOCALIZATION; DEFICIENCY	Neurofilament (NF), a major neuronal intermediate filament, is composed of three subunits, NF-L, NF-M, and NF-H. All three subunits contain a well conserved glutamate (E)-rich region called "E-segment" in the N terminus of the tail region. Although the E-segments of NF-L and NF-M are phosphorylated by casein kinases, it has not been observed in NF-H. Using mass spectrometric analysis, we identified phosphorylation of the E-segment of NF-H, prepared from rat spinal cords, at Ser-493 and Ser-501 in the Ser-Pro sequences. The E-segment kinase was isolated from rat brain extract using column chromatography and identified as glycogen synthase kinase (GSK) 3beta. GSK3beta was shown to phosphorylate at Ser-493 in vitro by phosphopeptide mapping and site-directed mutagenesis, and in vivo in HEK293 cells using the phospho-Ser-493 antibody, but did not phosphorylate Ser-501. GSK3beta preferred Ser-493 to the KSP-repeated sequences for phosphorylation sites in the NF-H tail domain. Moreover, Ser-493 was a better phosphorylation site for GSK3beta than other proline-directed protein kinases, Cdk5/p35 and ERK. GSK3beta in the spinal cord extract was associated with NF cytoskeletons. Taken together, we concluded that Ser-493 in the E-segment of NF-H is phosphorylated by GSK3beta in rat spinal cords.	Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Integrated Prote Syst Project,MEXT, Hachioji, Tokyo 1920397, Japan	Tokyo Metropolitan University; Tokyo Metropolitan University; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Tokyo Metropolitan University	Sasaki, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, Grad Sch Sci, Minami Ohsawa, Hachioji, Tokyo 1920397, Japan.	sasaki-takahiro@c.metro-u.ac.jp	Isobe, Toshiaki/Q-9279-2017; Uchida, Atsuko/E-3081-2010	Uchida, Atsuko/0000-0002-4658-1504; Taoka, Masato/0000-0001-5554-4951				Bajaj NPS, 1997, J NEUROCHEM, V69, P737; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIN SSM, 1990, J NEUROSCI, V10, P3714; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; Guidato S, 1996, J NEUROCHEM, V66, P1698; Hashimoto R, 2000, J NEUROCHEM, V75, P373, DOI 10.1046/j.1471-4159.2000.0750373.x; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; HISANAGA SI, 1995, CELL MOTIL CYTOSKEL, V31, P283, DOI 10.1002/cm.970310405; Hollander BA, 1996, J NEUROCHEM, V66, P412; HOLLANDER BA, 1992, BRAIN RES, V599, P237, DOI 10.1016/0006-8993(92)90397-R; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NAKAMURA Y, 1993, EUR J BIOCHEM, V212, P565, DOI 10.1111/j.1432-1033.1993.tb17694.x; Nakamura Y, 1999, FEBS LETT, V455, P83, DOI 10.1016/S0014-5793(99)00832-7; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Shaw G, 1997, J NEUROCHEM, V69, P1729; SHAW G, 1998, NEUROFILAMENTS; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Veeranna, 1998, J NEUROSCI, V18, P4008; XU ZS, 1990, J NEUROSCI, V10, P1838; Yabe JT, 2001, J NEUROSCI, V21, P2195; YAMASAKI H, 1991, ACTA NEUROPATHOL, V82, P427, DOI 10.1007/BF00293376; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	43	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36032	36039		10.1074/jbc.M206674200	http://dx.doi.org/10.1074/jbc.M206674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130654	hybrid			2022-12-27	WOS:000178275100035
J	Van Nostrand, WE; Melchor, JP; Keane, DM; Saporito-Irwin, SM; Romanov, G; Davis, J; Xu, F				Van Nostrand, WE; Melchor, JP; Keane, DM; Saporito-Irwin, SM; Romanov, G; Davis, J; Xu, F			Localization of a fibrillar amyloid beta-protein binding domain on its precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PATHOLOGICAL PROPERTIES; MUSCLE-CELLS; DUTCH-TYPE; SECRETASE; CLEAVAGE; AGGREGATION; CDNA; IDENTIFICATION; ACCUMULATION	Deposition of fibrillar amyloid-beta protein (Abeta) in senile plaques and in the walls of cerebral blood vessels is a key pathological feature of Alzheimer's disease and certain related disorders. Fibrillar Abeta deposition is intimately associated with neuronal and cerebrovascular cell death both in vivo and in vitro. Similarly, accumulation of the Abeta protein precursor (AbetaPP) is also observed at sites of fibrillar Abeta deposition. Recently, we reported that fibrillar Abeta, but not unassembled Abeta, promotes the specific binding of AbetaPP through its cysteine-rich, amino-terminal region (Melchor, J. P., and Van Nostrand, W. E. (2000) J. Biol. Chem. 275,9782-9791). In the present study we sought to determine the precise site on AbetaPP that facilitates its binding to fibrillar Abeta. A series of synthesized overlapping peptides spanning the cysteine-rich, amino-terminal region of AbetaPP were used as competitors for AbetaPP binding to fibrillar Abeta. A peptide spanning residues 105-119 of AbetaPP competitively inhibited AbetaPP binding to fibrillar Abeta in a solid-phase binding assay and on the surface of cultured human cerebrovascular smooth muscle cells. Alanine-scanning mutagenesis of residues 105-117 within glutathione S-transferase (GST)-AbetaPP-(18-119) revealed that His(110), Val(112), and Ile(113) are key residues that facilitate AbetaPP binding to fibrillar Abeta. These specific residues belong to a common beta-strand within this region of AbetaPP. Wildtype GST-AbetaPP-(18-119) protected cultured human cerebrovascular smooth muscle cells from Abeta-induced toxicity whereas H110A mutant GST-AbetaPP-(18-119) did not. Wild-type GST-AbetaPP-(18-119) bound to different isoforms of fibrillar Abeta and fibrillar amylin peptides whereas H110A mutant and I113A mutant GST-AbetaPP(18-119) were substantially less efficient binding to each fibrillar peptide. We conclude that His(110), Val(112), and Ile(113), residing in a common beta-strand region within AbetaPP-(18-119), comprise a domain that mediates the binding of AbetaPP to fibrillar peptides.	SUNY Stony Brook, Hlth Sci Ctr, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Van Nostrand, WE (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Med, HSC T-15-081, Stony Brook, NY 11794 USA.	William.VanNostrand@stonybrook.edu			NHLBI NIH HHS [HL49566] Funding Source: Medline; NINDS NIH HHS [NS35781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURDICK D, 1992, J BIOL CHEM, V267, P546; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; Davis J, 1999, AMYLOID, V6, P157, DOI 10.3109/13506129909007321; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MBEBI C, 2002, IN PRESS J BIOL CHEM; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Melchor JP, 2000, J BIOL CHEM, V275, P9782, DOI 10.1074/jbc.275.13.9782; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Van Nostrand WE, 1998, J NEUROCHEM, V70, P216; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANGOOL D, 1995, DEMENTIA, V6, P63, DOI 10.1159/000106923; VanNostrand WE, 1996, ANN NY ACAD SCI, V777, P297; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1994, AMYLOID, V1, P1, DOI 10.3109/13506129409148618; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wagner MR, 2000, BIOCHEMISTRY-US, V39, P7420, DOI 10.1021/bi0002840; WANG R, 1991, J BIOL CHEM, V266, P16960; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V58, P699, DOI 10.1136/jnnp.58.6.699; WISNIEWSKI HM, 1995, NEUROSCI LETT, V183, P120, DOI 10.1016/0304-3940(94)11129-7; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	43	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36392	36398		10.1074/jbc.M204676200	http://dx.doi.org/10.1074/jbc.M204676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107175	hybrid			2022-12-27	WOS:000178275100079
J	Guo, ZH; Liu, LX; Cafiso, D; Castle, D				Guo, ZH; Liu, LX; Cafiso, D; Castle, D			Perturbation of a very late step of regulated exocytosis by a secretory carrier membrane protein (SCAMP2)-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-GAMMA-S; SNARE COMPLEX; MAST-CELLS; VESICLE EXOCYTOSIS; SCAMP1 FUNCTION; FUSION; PHOSPHORYLATION; TRAFFICKING; ASSOCIATION; RELEASE	Secretory carrier membrane proteins (SCAMPs) are conserved four transmembrane-spanning proteins associated with recycling vesicular carriers. In mast cells, as in other cell types, SCAMPs 1 and 2 are present in secretory granule membranes and other intracellular membranes. We now demonstrate a population of these SCAMPs in plasma membranes. Although small, this population partially colocalizes with SNARE proteins SNAP-23 and syntaxin 4. A fraction of SCAMPs 1 and 2 also coimmunoprecipitates with SNAP-23. An oligopeptide, E peptide, within the cytoplasmic segment linking the second and third transmembrane spans, particularly of SCAMP2, potently inhibits exocytosis in streptolysin O-permeabilized mast cells. The E peptide is unique to SCAMPs and highly conserved among SCAMP isoforms, and minor changes in its sequence abrogate inhibition. It blocks fusion beyond the putative docking step where granules contact the cell surface and each other during compound exocytosis. Blockade is also beyond Ca2+/ATP-dependent relocation of SNAP-23, which regulates compound exocytosis, and beyond ATP-dependent priming of fusion. Kinetic ordering of exocytotic inhibitors has shown that E peptide acts later than other perturbants at a stage closely associated with membrane fusion. These findings identify a new reagent for analyzing the final stage of exocytosis and point to the likely action of SCAMP2 in this process.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Castle, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA.				NIAID NIH HHS [AI47150] Funding Source: Medline; NIDCR NIH HHS [DE09655] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009655] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Fernandez-Chacon R, 2000, J NEUROSCI, V20, P7941; Fernandez-Chacon R, 2000, J BIOL CHEM, V275, P12752, DOI 10.1074/jbc.275.17.12752; Fernandez-Chacon R, 1999, J BIOL CHEM, V274, P32551, DOI 10.1074/jbc.274.46.32551; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Grote E, 2000, J CELL BIOL, V151, P453, DOI 10.1083/jcb.151.2.453; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hubbard C, 2000, MOL BIOL CELL, V11, P2933, DOI 10.1091/mbc.11.9.2933; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P222, DOI 10.1016/0167-4889(93)90048-T; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Singleton DR, 1997, J CELL SCI, V110, P2099; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661; Wu TT, 1997, J CELL SCI, V110, P1533; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4	39	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35357	35363		10.1074/jbc.M202259200	http://dx.doi.org/10.1074/jbc.M202259200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124380	hybrid			2022-12-27	WOS:000178117000090
J	Lee, CG; Homer, RJ; Cohn, L; Link, H; Jung, S; Craft, JE; Graham, BS; Johnson, TR; Elias, JA				Lee, CG; Homer, RJ; Cohn, L; Link, H; Jung, S; Craft, JE; Graham, BS; Johnson, TR; Elias, JA			Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; EOSINOPHILIC INFLAMMATION; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; IL-10 PRODUCTION; MURINE MODEL; MICE; EXPRESSION; MUCIN; CELLS	To address the complex chronic effector properties of interleukin (IL)-10, we generated transgenic mice in which IL-10 was overexpressed in the lung. In these mice, IL-10 inhibited endotoxin-induced tumor necrosis factor production and neutrophil accumulation. IL-10 also caused mucus metaplasia, B and T cell-rich inflammation, and subepithelial fibrosis and augmented the levels of mRNA encoding Gob-5, mucins, and IL-13. In mice bred to have null mutations of IL-13, IL-4Ralpha, or STAT-6, transgenic IL-10 did not induce mucus metaplasia but did induce inflammation and fibrosis. IL-10 was also a critical mucin regulator of virus-induced mucus metaplasia. Thus, IL-10, although inhibiting lipopolysaccharide-induced inflammation, also causes mucus metaplasia, tissue inflammation, and airway fibrosis. These responses are mediated by multiple mechanisms with mucus metaplasia being dependent on and the inflammation and fibrosis being independent of an IL-13/IL-4Ralpha/STAT-6 activation pathway.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Vet Adm Connecticut Hlth Care Syst, Lab Med Serv, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Pediat, Sect Resp Med, New Haven, CT 06520 USA; Hanyang Univ, Coll Med, Div Rheumatol, Seoul 133792, South Korea; Hosp Rheumat Dis, Seoul 133792, South Korea; Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06520 USA; Vanderbilt Univ, Div Infect Dis, Sch Med, Nashville, TN 37232 USA	Yale University; Yale University; Yale University; Hanyang University; Yale University; Vanderbilt University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI,POB 208057, New Haven, CT 06520 USA.	jack.elias@yale.edu	homer, robert/P-3884-2019; Graham, Barney S./AAC-5898-2019; Lee, Chun Geun/AAC-2838-2021	homer, robert/0000-0002-2055-5885; Graham, Barney S./0000-0001-8112-0853; Lee, Chun Geun/0000-0002-9514-3658	NHLBI NIH HHS [HL-61904, HL-56389, HL-6404, HL-64242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056389, R01HL061904, P50HL056389, R01HL064242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005029, ZIAAI005029] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai T, 2000, AM J PHYSIOL-LUNG C, V278, pL914, DOI 10.1152/ajplung.2000.278.5.L914; Berman RM, 1996, J IMMUNOL, V157, P231; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Brandtzaeg P, 1996, J EXP MED, V184, P51, DOI 10.1084/jem.184.1.51; Chmiel JF, 1999, AM J RESP CRIT CARE, V160, P2040, DOI 10.1164/ajrccm.160.6.9901043; CHUNG KF, 1998, EUR RESPIR REV, V8, P999; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; Cohn L, 1999, J IMMUNOL, V162, P6178; Colavita AM, 2000, J ALLERGY CLIN IMMUN, V106, P880, DOI 10.1067/mai.2000.110475; Corne JM, 2001, AM J RESP CRIT CARE, V163, P1101, DOI 10.1164/ajrccm.163.5.9902047; DEBEAUX AC, 1995, J INTERF CYTOK RES, V15, P441, DOI 10.1089/jir.1995.15.441; Donaldson DD, 2001, PROG RESPIR RES, V31, P260; Dosanjh AK, 1998, J INTERF CYTOK RES, V18, P851, DOI 10.1089/jir.1998.18.851; Eppinger MJ, 1996, J THORAC CARDIOV SUR, V112, P1301, DOI 10.1016/S0022-5223(96)70144-7; Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; GREENBERGER MJ, 1995, J IMMUNOL, V155, P722; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1998, J IMMUNOL, V160, P3188; Halse AK, 1999, SCAND J IMMUNOL, V49, P533; Huaux F, 1998, AM J RESP CELL MOL, V18, P51, DOI 10.1165/ajrcmb.18.1.2911; ITOH K, 1995, J IMMUNOL, V154, P4341; Jeannin P, 1998, J IMMUNOL, V160, P3555; Johnson TR, 1998, J VIROL, V72, P2871, DOI 10.1128/JVI.72.4.2871-2880.1998; Johnson TR, 1999, J VIROL, V73, P8485, DOI 10.1128/JVI.73.10.8485-8495.1999; Koulis A, 2000, CLIN EXP ALLERGY, V30, P747; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee MS, 1996, J EXP MED, V183, P2663, DOI 10.1084/jem.183.6.2663; Lin TJ, 1997, J IMMUNOL, V159, P4015; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Magnan A, 1998, ALLERGY, V53, P1092, DOI 10.1111/j.1398-9995.1998.tb03821.x; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MORITANI M, 1994, INT IMMUNOL, V6, P1927, DOI 10.1093/intimm/6.12.1927; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; Parmley RR, 1998, J CLIN INVEST, V102, P1798, DOI 10.1172/JCI3820; Qian SG, 1996, TRANSPLANTATION, V62, P1709, DOI 10.1097/00007890-199612270-00002; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Saito I, 1999, J IMMUNOL, V162, P2488; Sawa T, 1997, J IMMUNOL, V159, P2858; SHANLEY TP, 1995, J IMMUNOL, V154, P3454; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Steinhauser ME, 1999, J IMMUNOL, V162, P392; STORDEUR P, 2000, EUR RESPIR REV, V70, P142; Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; vanderPoll T, 1996, J INFECT DIS, V174, P994, DOI 10.1093/infdis/174.5.994; Vora M, 1996, J EXP MED, V184, P821, DOI 10.1084/jem.184.3.821; Wang JM, 2000, J IMMUNOL, V165, P2222, DOI 10.4049/jimmunol.165.4.2222; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WOGENSEN L, 1994, J EXP MED, V179, P1379, DOI 10.1084/jem.179.4.1379; WOGENSEN L, 1993, J EXP MED, V178, P175, DOI 10.1084/jem.178.1.175; WU K, 1994, J BIOL CHEM, V269, P11950; Yang X, 2000, EUR J IMMUNOL, V30, P382, DOI 10.1002/1521-4141(200002)30:2<382::AID-IMMU382>3.0.CO;2-L; Yu CJ, 1998, AM J RESP CELL MOL, V18, P643, DOI 10.1165/ajrcmb.18.5.3051; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	73	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35466	35474		10.1074/jbc.M206395200	http://dx.doi.org/10.1074/jbc.M206395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107190	hybrid			2022-12-27	WOS:000178117000103
J	Li, PTX; Gollnick, P				Li, PTX; Gollnick, P			Using hetero-11-mers composed of wild type and mutant subunits to study tryptophan binding to TRAP and its role in activating RNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATION PROTEIN TRAP; TRP LEADER RNA; BACILLUS-SUBTILIS BINDS; UNKNOWN FUNCTION; OPERON; EXPRESSION; NUCLEOTIDES; TRANSLATION; INITIATION; FEATURES	Expression of genes involved in tryptophan metabolism in Bacillus subtilis is regulated by the TRAP protein in response to changes in L-tryptophan levels. TRAP binding to several RNA targets that contain between 9 and 11 (GIU)AG repeats regulates transcription and/or translation of these genes. TRAP consists of 11 identical subunits and is activated to bind RNA by binding up to 11 molecules of tryptophan. To investigate the mechanism by which tryptophan binding activates TRAP, we generated hetero-11-mers containing different proportions of subunits from wild type (WT) TRAP that bind tryptophan and from a mutant TRAP (Thr(25) to Ala) defective in tryptophan binding. Studies of these hetero-11-mers show that tryptophan-binding sites created from active subunits bind tryptophan with similar affinity to those in WT homo-11-mers, whereas sites containing the T25A substitution do not bind tryptophan. Hetero-11-mers with very few (one or two) bound tryptophans show only 10-fold lower affinity than WT TRAP for an RNA with 11 GAG repeats, whereas TRAP with no bound tryptophan shows no detectable binding to this RNA. We also demonstrate that tryptophan binding induces a conformational change in TRAP in the vicinity of the RNA-binding site, suggesting a possible mechanism for activation of RNA binding.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gollnick, P (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.				NIGMS NIH HHS [GM62750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P864; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; Elliott MB, 2001, RNA, V7, P85, DOI 10.1017/S135583820100173X; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; Henner Dennis, 1993, P269; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; Li PTX, 2002, J BIOL CHEM, V277, P11838, DOI 10.1074/jbc.M110860200; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; Segel I. H., 1975, ENZYME KINETICS, P360; Valbuzzi A, 2002, J BIOL CHEM, V277, P10608, DOI 10.1074/jbc.M111813200; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; Xirasagar S, 1998, J BIOL CHEM, V273, P27146, DOI 10.1074/jbc.273.42.27146; Yakhnin AV, 2000, J BIOL CHEM, V275, P4519, DOI 10.1074/jbc.275.6.4519; Yakhnin H, 2001, J BACTERIOL, V183, P5918, DOI 10.1128/JB.183.20.5918-5926.2001; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	30	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35567	35573		10.1074/jbc.M205910200	http://dx.doi.org/10.1074/jbc.M205910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133840	hybrid			2022-12-27	WOS:000178117000116
J	Altier, C; Dubel, SJ; Barrere, C; Jarvis, SE; Stotz, SC; Spaetgens, RL; Scott, JD; Cornet, V; De Waard, M; Zamponi, GW; Nargeot, J; Bourinet, E				Altier, C; Dubel, SJ; Barrere, C; Jarvis, SE; Stotz, SC; Spaetgens, RL; Scott, JD; Cornet, V; De Waard, M; Zamponi, GW; Nargeot, J; Bourinet, E			Trafficking of L-type calcium channels mediated by the postsynaptic scaffolding protein AKAP79	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT POTENTIATION; CA2+ CHANNELS; ANCHORING PROTEINS; REGULATORY SUBUNIT; BETA-SUBUNIT; KINASE; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; CA(V)1.2	Accurate calcium signaling requires spatial and temporal coordination of voltage-gated calcium channels (VGCCs) and a variety of signal transduction proteins. Accordingly, regulation of L-type VGCCs involves the assembly of complexes that include the channel subunits, protein kinase A (PKA), protein kinase A anchoring proteins (AKAPs), and beta2-adrenergic receptors, although the molecular details underlying these interactions remain enigmatic. We show here, by combining extracellular epitope splicing into the channel pore-forming subunit and immunoassays with whole cell and single channel electrophysiological recordings, that AKAP79 directly regulates cell surface expression of L-type calcium channels independently of PKA. This regulation involves a short polyproline sequence contained specifically within the II-III cytoplasmic loop of the channel. Thus we propose a novel mechanism whereby AKAP79 and L-type VGCCs function as components of a biosynthetic mechanism that favors membrane incorporation of organized molecular complexes in a manner that is independent of PKA phosphorylation events.	Physiopathol Canaux Ion Inst Genet Humaine, CNRS UPR1142, F-34396 Montpellier 5, France; Univ Calgary, Neurosci Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Fac Med Nord, INSERM U464, F-13916 Marseille, France; INSERM EM199 31, F-38054 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Calgary; Howard Hughes Medical Institute; Oregon Health & Science University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bourinet, E (corresponding author), Physiopathol Canaux Ion Inst Genet Humaine, CNRS UPR1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.		De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Nargeot, Joel/0000-0003-2893-5636; Barrere, Christian/0000-0001-8710-0976				Altier C, 2001, NEUROPHARMACOLOGY, V40, P1050, DOI 10.1016/S0028-3908(01)00025-9; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; Cassano S, 1999, J BIOL CHEM, V274, P32574, DOI 10.1074/jbc.274.46.32574; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charnet P, 1995, BIOCHIMIE, V77, P957, DOI 10.1016/0300-9084(95)80008-5; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; HALL DD, 2001, A2719 SOC NEUR M SAN; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hulme JT, 2001, J BIOL CHEM, V30, P30; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; Stotz SC, 2001, J BIOL CHEM, V276, P33001, DOI 10.1074/jbc.M104387200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; Zhong JM, 1999, AM J PHYSIOL-CELL PH, V277, pC840	37	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33598	33603		10.1074/jbc.M202476200	http://dx.doi.org/10.1074/jbc.M202476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114507	hybrid, Green Published			2022-12-27	WOS:000177959100010
J	Carmichael, J; Sugars, KL; Bao, YP; Rubinsztein, DC				Carmichael, J; Sugars, KL; Bao, YP; Rubinsztein, DC			Glycogen synthase kinase-3 beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRANUCLEAR INCLUSIONS; TRANSGENIC MICE; BETA-CATENIN; NEUROLOGICAL PHENOTYPE; GENE-EXPRESSION; CHRONIC LITHIUM; HEAT-SHOCK; DEATH; EXCITOTOXICITY; TRANSCRIPTION	Huntington's disease is one of nine known neurodegenerative disorders caused by an expanded polyglutamine (poly(Q)) tract in the disease protein. These diseases are associated with intraneuronal protein aggregates. Heat-inducible chaperones like HSP70 and HSP27 suppress poly(Q) aggregation and/or toxicity/cell death. Heat shock transcription factors, including HSF-1, regulate HSP70 and HSP27 expression. HSF-1 activity is reduced by glycogen synthase kinase-3 (GSK-3) and enhanced by GSK-3 inhibitors, like lithium. Thus, we hypothesized that lithium treatment may partially rescue death in Huntington's disease cell models. LiCl reduced poly(Q) toxicity in neuronal and nonneuronal cell lines, but this was not associated with elevation of HSP70 or HSP27. The protective effect of lithium involved GSK-3beta inhibition, since poly(Q) toxicity was also reduced by SB216763, a GSK-3beta inhibitor, and by overexpression of a dominant-negative GSK-3beta mutant. LiCl and SB216763 increased beta-catenin-dependent T-cell factor-mediated transcription. Since beta-catenin overexpression protected cells from poly(Q) toxicity, we tested whether this pathway was impaired by a poly(Q) expansion mutation. Cells expressing expanded repeats had reduced beta-catenin levels associated with a parallel decrease in T-cell factor-mediated transcription, compared with cells expressing wild type constructs. Since LiCl can protect against polyglutamine toxicity in cell lines, it is an excellent candidate for further in vivo therapeutic trials.				dcr1000@cus.cam.ac.uk	Rubinsztein, David C/C-3472-2011					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Ho LW, 2001, PSYCHOL MED, V31, P3, DOI 10.1017/S0033291799002871; Ikonomov OC, 1999, AM J PSYCHIAT, V156, P1506, DOI 10.1176/ajp.156.10.1506; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829	33	178	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33791	33798		10.1074/jbc.m204861200	http://dx.doi.org/10.1074/jbc.m204861200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097329	hybrid			2022-12-27	WOS:000177959100036
J	Kitamura, H; Wu, WI; Voelker, DR				Kitamura, H; Wu, WI; Voelker, DR			The C2 domain of phosphatidylserine decarboxylase 2 is not required for catalysis but is essential for in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NULL ALLELE; TRANSPORT; YEAST; GENE; CLONING; AMINOGLYCEROPHOSPHOLIPIDS; EXPRESSION; METABOLISM	Phosphatidylserine decarboxylase 2 (Psd2p) is currently being used to study lipid trafficking processes in intact and permeabilized yeast cells. The Psd2p contains a C2 homology domain and a putative Golgi retention/ localization (GR) domain. C2 domains play important functions in membrane binding and docking reactions involving phospholipids and proteins. We constructed a C2 domain deletion variant (M) and a GR deletion variant (GRDelta) of Psd2p and examined their effects on in vivo function and catalysis. Immunoblotting confirmed that the predicted immature and mature forms of Psd2(C2Delta)p, Psd2(GRDelta)p, and wild type Psd2p were produced in vivo and that the proteins localized normally. Enzymology revealed that the Psd2(C2Delta)p and Psd2(GRDelta)p were catalytically active and could readily be expressed at levels 10-fold higher than endogenous Psd2p. Both Psd2p and Psd2(GRDelta)p expression complemented the growth defect of psd1Deltapsd2Delta strains and resulted in normal aminoglycerophospholipid metabolism. In contrast, the Psd2(C2Delta)p failed to complement psd1Deltapsd2Delta strains, and [H-3]serine labeling revealed a severe defect in the formation of PtdEtn in both intact and permeabilized cells, indicative of disruption of lipid trafficking. These findings identify an essential, noncatalytic function of the C2 domain of Psd2p and raise the possibility that it plays a direct role in membrane docking and/or PtdSer transport to the enzyme.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA.		Kitamura, Hidemitsu/A-8184-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; CUI Z, 1993, J BIOL CHEM, V268, P16655; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kuge O, 1996, BIOCHEM J, V319, P33, DOI 10.1042/bj3190033; LI QX, 1988, J BIOL CHEM, V263, P11516; Mehrotra B, 2000, BIOCHEMISTRY-US, V39, P9679, DOI 10.1021/bi000487o; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHTA A, 1981, J BIOL CHEM, V256, P2219; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Voelker DR, 1997, BBA-LIPID LIPID MET, V1348, P236, DOI 10.1016/S0005-2760(97)00101-X; Voelker DR, 2000, BBA-MOL CELL BIOL L, V1486, P97, DOI 10.1016/S1388-1981(00)00051-2; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; Voelker DR, 1996, BIOCH LIPIDS LIPOPRO, P391; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WEISS SB, 1958, J BIOL CHEM, V231, P53; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Wu WI, 2002, SEMIN CELL DEV BIOL, V13, P185, DOI 10.1016/S1084-9521(02)00047-2; Wu WI, 2001, J BIOL CHEM, V276, P7114, DOI 10.1074/jbc.M010278200	33	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33720	33726		10.1074/jbc.M205672200	http://dx.doi.org/10.1074/jbc.M205672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093819	hybrid			2022-12-27	WOS:000177959100027
J	Li, XP; Gilmore, AM; Niyogi, KK				Li, XP; Gilmore, AM; Niyogi, KK			Molecular and global time-resolved analysis of a psbS gene dosage effect on pH- and xanthophyll cycle-dependent nonphotochemical quenching in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A FLUORESCENCE; VIOLAXANTHIN DE-EPOXIDASE; 22 KDA PROTEIN; ENERGY-DISSIPATION; LIFETIME DISTRIBUTIONS; THERMAL DISSIPATION; ARABIDOPSIS MUTANTS; PIGMENT COMPOSITION; ANTENNA COMPLEX; LIGHT ENERGY	Photosynthetic light harvesting in plants is regulated by a pH- and xanthophyll-dependent nonphotochemical quenching process (qE) that dissipates excess absorbed light energy and requires the psbS gene product. An Arabidopsis thaliana mutant, npq4-1, lacks qE because of a deletion of the psbS gene, yet it exhibits a semidominant phenotype. Here it is shown that the semidominance is due to a psbS gene dosage effect. Diploid Arabidopsis plants containing two psbS gene copies (wild-type), one psbS gene (npq4-1/NPQ4 heterozygote), and no psbS gene (npq4-1/npq4-1 homozygote) were compared. Heterozygous plants had 56% of the wild-type psbS mRNA level, 58% of the wild-type PsbS protein level, and 60% of the wild-type level of qE. Global analysis of the chlorophyll a fluorescence lifetime distributions revealed three components in wild-type and heterozygous plants, but only a single long lifetime component in npq4-1. The short lifetime distribution associated with qE was inhibited by more than 40% in heterozygous plants compared with the wild type. Thus, the extent of qE measured as either the fractional intensities of the PSII chlorophyll a fluorescence lifetime distributions or steady state intensities was stoichiometrically related to the amount of PsbS protein.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Australian Natl Univ, Res Sch Biol Sci, Inst Adv Studies, Ecosyst Dynam Grp, Canberra, ACT 2601, Australia	University of California System; University of California Berkeley; Australian National University	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu						ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; Andersson J, 2001, PLANT CELL, V13, P1193, DOI 10.1105/tpc.13.5.1193; [Anonymous], 1995, ECOPHYSIOLOGY PHOTOS; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BEECHEM JM, 1983, BIOCHEMISTRY-US, V22, P6054, DOI 10.1021/bi00295a002; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bevington P. R, 1969, DATA REDUCTION ERROR; BILGER W, 1990, PHOTOSYNTH RES, V25, P173, DOI 10.1007/BF00033159; Boekema EJ, 2000, BIOCHEMISTRY-US, V39, P12907, DOI 10.1021/bi0009183; Bugos RC, 1996, P NATL ACAD SCI USA, V93, P6320, DOI 10.1073/pnas.93.13.6320; Bukhov NG, 2001, PLANTA, V212, P739, DOI 10.1007/s004250000485; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Demmig-Adams B, 1998, PLANT CELL PHYSIOL, V39, P474, DOI 10.1093/oxfordjournals.pcp.a029394; DemmigAdams B, 1996, PLANTA, V198, P460, DOI 10.1007/BF00620064; DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339; DEMMIGADAMS B, 1994, AUST J PLANT PHYSIOL, V21, P575, DOI 10.1071/PP9940575; Dominici P, 2002, J BIOL CHEM, V277, P22750, DOI 10.1074/jbc.M200604200; Draper NR., 1998, WILEY SERIES PROBABI, V3rd ed.; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; Gilmore AM, 1999, CONCEPTS IN PHOTOBIOLOGY, P513; GILMORE AM, 1995, P NATL ACAD SCI USA, V92, P2273, DOI 10.1073/pnas.92.6.2273; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; GILMORE AM, 1995, PLANTA, V197, P646, DOI 10.1007/BF00191573; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Gilmore AM, 2001, PHOTOCHEM PHOTOBIOL, V74, P291, DOI 10.1562/0031-8655(2001)074<0291:TROTAA>2.0.CO;2; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Gilmore AM, 2001, PHOTOSYNTH RES, V67, P89, DOI 10.1023/A:1010657000548; Gilmore AM, 1996, PHOTOCHEM PHOTOBIOL, V64, P552, DOI 10.1111/j.1751-1097.1996.tb03105.x; Gilmore AM, 2000, PHILOS T ROY SOC B, V355, P1371, DOI 10.1098/rstb.2000.0699; GOVINDJEE, 1995, AUST J PLANT PHYSIOL, V22, P131, DOI 10.1071/PP9950131; GOVINDJEE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P173, DOI 10.1016/0005-2728(90)90017-X; HAGER A, 1969, PLANTA, V89, P224, DOI 10.1007/BF00385028; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P673, DOI 10.1111/j.1365-3040.1993.tb00485.x; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; KIM S, 1994, BBA-BIOENERGETICS, V1188, P339, DOI 10.1016/0005-2728(94)90054-X; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; LI XP, 2002, IN PRESS FUNCT PLANT; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Muller-Moule P, 2002, PLANT PHYSIOL, V128, P970, DOI 10.1104/pp.010924; Munekage Y, 2001, PLANT J, V28, P351, DOI 10.1046/j.1365-313X.2001.01178.x; Nield J, 2000, PHILOS T R SOC B, V355, P1337, DOI 10.1098/rstb.2000.0695; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Niyogi KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Peterson RB, 2000, PLANTA, V210, P205, DOI 10.1007/PL00008127; Peterson RB, 2001, PLANTA, V214, P142, DOI 10.1007/s004250100601; Richter M, 1999, BIOCHEMISTRY-US, V38, P12718, DOI 10.1021/bi983009a; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; Shikanai T, 1999, PLANT CELL PHYSIOL, V40, P1134, DOI 10.1093/oxfordjournals.pcp.a029498; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Walters RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/pnas.93.24.14204; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639	69	78	82	2	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33590	33597		10.1074/jbc.M204797200	http://dx.doi.org/10.1074/jbc.M204797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110676	hybrid			2022-12-27	WOS:000177959100009
J	Delaney, KA; Murph, MM; Brown, LM; Radhakrishna, H				Delaney, KA; Murph, MM; Brown, LM; Radhakrishna, H			Transfer of M-2 muscarinic acetylcholine receptors to clathrin-derived early endosomes following clathrin-independent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR-6; PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PLASMA-MEMBRANE; EXCHANGE FACTOR; M2 SUBTYPES; INTERNALIZATION; ARF6; DYNAMIN	Upon agonist stimulation, many G protein-coupled receptors such as beta(2)-adrenergic receptors are internalized via beta-arrestin- and clathrin-dependent mechanisms, whereas others, like M-2 muscarinic acetylcholine receptors (mAChRs), are internalized by clathrin- and arrestin-independent mechanisms. To gain further insight into the mechanisms that regulate M-2 mAChR endocytosis, we investigated the post-endocytic trafficking of M-2 mAChRs in HeLa cells and the role of the ADP-ribosylation factor 6 (Arf6) GTPase in regulating M-2 mAChR internalization. Here, we report that M-2 mAChRs are rapidly internalized by a clathrin-independent pathway that is inhibited up to 50% by expression of either GTPase-defective Arf6 Q67L or an upstream Arf6 activator, Galpha(q) Q209L. In contrast, M-2 mAChR internalization was not affected by expression of dominant-negative dynamin 2 K44A, which is a known inhibitor of clathrin-dependent endocytosis. Nevertheless, M-2 mAChRs, which are initially internalized in structures that lack clathrin-dependent endosomal markers, quickly localize to endosomes that contain the clathrin-dependent, early endosomal markers early endosome autoantigen-1, transferrin receptor, and GTPase-defective Rab5 Q79L, which is known to swell early endosomal compartments. These results suggest that M2 mAChRs initially internalize via an Arf6-associated, clathrin-independent pathway but then quickly merge with the clathrin endocytic pathway at the level of early endosomes.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Petit Int Bioengn & Biosci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Radhakrishna, H (corresponding author), Georgia Inst Technol, Sch Biol, 315 Ferst Dr, Atlanta, GA 30332 USA.				NHLBI NIH HHS [HL 67134] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RANDAZZO P, 2000, SCI STKE; Roseberry AG, 2001, J CELL SCI, V114, P739; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Tsuga H, 1998, J BIOCHEM-TOKYO, V124, P863, DOI 10.1093/oxfordjournals.jbchem.a022191; van Koppen CJ, 2001, BIOCHEM SOC T, V29, P505, DOI 10.1042/BST0290505; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	43	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33439	33446		10.1074/jbc.M205293200	http://dx.doi.org/10.1074/jbc.M205293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093817	hybrid			2022-12-27	WOS:000177859000133
J	Liang, XQ; Lu, Y; Neubert, TA; Resh, MD				Liang, XQ; Lu, Y; Neubert, TA; Resh, MD			Mass spectrometric analysis of GAP-43/neuromodulin reveals the presence of a variety of fatty acylated species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; GROWTH-ASSOCIATED PROTEIN; PLASMA-MEMBRANE; NEUROMODULIN GAP-43; NEURONAL POLARITY; CONE PROTEIN; PALMITOYLATION; G0; PHOSPHOPROTEIN; B-50/GAP-43	GAP-43 (neuromodulin) is a protein kinase C substrate that is abundant in developing and regenerating neurons. Thioester-linked palmitoylation at two cysteines near the GAP-43 N terminus has been implicated in directing membrane binding. Here, we use mass spectrometry to examine the stoichiometry of palmitoylation and the molecular identity of the fatty acid(s) attached to GAP-43 in vivo. GAP-43 expressed in either PC12 or COS-1 cells was acetylated at the N-terminal methionine. Approximately 35% of the N-terminal GAP-43 peptides were also modified by palmitate and/or stearate on Cys residues. Interestingly, a variety of acylated species was detected, in which one of the Cys residues was acylated by either palmitate or stearate, or both Cys residues were acylated by palmitates or stearates or a combination of palmitate and stearate. Depalmitoylation of membrane-bound GAP-43 did not release the protein from the membrane, implying that additional forces function to maintain membrane binding. Indeed, mutation of four basic residues within the N-terminal domain of GAP-43 dramatically reduced membrane localization of GAP-43 without affecting palmitoylation. These data reveal the heterogeneous nature of S-acylation in vivo and illustrate the power of mass spectrometry for identification of key regulatory protein modifications.	Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Memorial Sloan Kettering Cancer Center; New York University; New York University	Resh, MD (corresponding author), Mem Sloan Kettering Inst Canc Res, Cell Biol & Genet Program, 1275 York Ave, Box 143, New York, NY 10021 USA.			Resh, Marilyn/0000-0001-6118-9466	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR14662-01] Funding Source: Medline; NIGMS NIH HHS [GM/CA 57966] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1993, J NEUROCHEM, V60, P368, DOI 10.1111/j.1471-4159.1993.tb05862.x; DEMAR JC, 1997, J BIOL CHEM, V272, P31326; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GORDONWEEKS PR, 1989, TRENDS NEUROSCI, V12, P363, DOI 10.1016/0166-2236(89)90073-8; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LUC B, 1995, METHOD ENZYMOL, V250, P454; Ma YL, 2001, RAPID COMMUN MASS SP, V15, P1693, DOI 10.1002/rcm.426; McLaughlin RE, 1999, BBA-MOL CELL RES, V1451, P82, DOI 10.1016/S0167-4889(99)00074-9; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159	36	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33032	33040		10.1074/jbc.M204607200	http://dx.doi.org/10.1074/jbc.M204607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105219	hybrid			2022-12-27	WOS:000177859000083
J	Semel, AC; Seales, EC; Singhal, A; Eklund, EA; Colley, KJ; Bellis, SL				Semel, AC; Seales, EC; Singhal, A; Eklund, EA; Colley, KJ; Bellis, SL			Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GROWTH FACTOR-BETA; CELL-ADHESION RECEPTORS; CARCINOMA CACO-2 CELLS; COLON EPITHELIAL-CELLS; ALTERED GLYCOSYLATION; INCREASED EXPRESSION; BIOLOGICAL-ACTIVITY; SIALIDASE TREATMENT; LEUKEMIA-CELLS	Despite numerous reports suggesting that beta(1) integrin receptors undergo differential glycosylation, the potential role of N-linked carbohydrates in modulating integrin function has been largely ignored. In the present study, we find that beta(1) integrins are differentially glycosylated during phorbol ester (PMA)-stimulated differentiation of myeloid cells along the monocyte/macrophage lineage. PMA treatment of two myeloid cell lines, U937 and THP-1, induces a down-regulation in expression of the ST6Gal I sialyltransferase. Correspondingly, the beta(1) integrin subunit becomes hyposialylated, suggesting that the beta(1) integrin is a substrate for this enzyme. The expression of hyposialylated beta(1) integrin isoforms is temporally correlated with enhanced binding of myeloid cells to fibronectin, and, importantly, fibronectin binding is inhibited when the Golgi disrupter, brefeldin A, is used to block the expression of the hyposialylated form. Consistent with the observation that cells with hyposialylated integrins are more adhesive to fibronectin, we demonstrate that the enzymatic removal of sialic acid residues from purified alpha(5)beta(1), integrins stimulates fibronectin binding by these integrins. These data support the hypothesis that unsialylated beta(1) integrins are more adhesive to fibronectin, although desialylation of a, subunits could also contribute to increased fibronectin binding. Collectively our results suggest a novel mechanism for regulation of the beta(1) integrin family of cell adhesion receptors.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Northwestern Univ, Lakeside Vet Adm Hosp, Sch Med, Chicago, IL 60611 USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Alabama System; University of Alabama Birmingham; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bellis, SL (corresponding author), Univ Alabama, Dept Physiol & Biophys, Rm 982A McCallum Bldg,1918 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA084248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84248] Funding Source: Medline; NHLBI NIH HHS [HL5400] Funding Source: Medline; NIAMS NIH HHS [5 P60 AR 20614-23] Funding Source: Medline; NIGMS NIH HHS [R01 GM48143] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asada M, 1997, CANCER RES, V57, P1073; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; Boles BK, 2000, AM J PHYSIOL-LUNG C, V278, pL703, DOI 10.1152/ajplung.2000.278.4.L703; Braut-Boucher F, 1998, LEUKEMIA RES, V22, P947, DOI 10.1016/S0145-2126(98)00094-0; DALLOLIO F, 1992, BIOCHEM BIOPH RES CO, V184, P1405, DOI 10.1016/S0006-291X(05)80039-7; DALLOLIO F, 1990, BIOCHEM J, V270, P519, DOI 10.1042/bj2700519; DallOlio F, 1996, GLYCOCONJUGATE J, V13, P115, DOI 10.1007/BF01049687; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Jasiulionis MG, 1996, CANCER RES, V56, P1682; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KIM LT, 1992, J CELL SCI, V103, P743; Laouar A, 1999, J IMMUNOL, V162, P407; Le Marer N, 1999, J CELL PHYSIOL, V179, P315, DOI 10.1002/(SICI)1097-4652(199906)179:3<315::AID-JCP9>3.0.CO;2-U; LENTER M, 1994, J BIOL CHEM, V269, P12263; LEPPA S, 1995, CELL GROWTH DIFFER, V6, P853; MOSS L, 1994, GLYCOBIOLOGY, V4, P567, DOI 10.1093/glycob/4.5.567; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; OZ OK, 1989, INT J CANCER, V44, P343, DOI 10.1002/ijc.2910440226; Pretzlaff RK, 2000, CELL ADHES COMMUN, V7, P491, DOI 10.3109/15419060009040306; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; Taniguchi A, 1998, FEBS LETT, V441, P191, DOI 10.1016/S0014-5793(98)01548-8; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; VANDEWATER L, 1988, CANCER RES, V48, P5730; VEIGA SS, 1995, INT J CANCER, V61, P420, DOI 10.1002/ijc.2910610324; VERTINOBELL A, 1994, DEV BIOL, V165, P126, DOI 10.1006/dbio.1994.1240; VONLAMPE B, 1993, GUT, V34, P829, DOI 10.1136/gut.34.6.829; WADSWORTH S, 1993, J IMMUNOL, V150, P847; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	43	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32830	32836		10.1074/jbc.M202493200	http://dx.doi.org/10.1074/jbc.M202493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091385	hybrid			2022-12-27	WOS:000177859000057
J	Zhang, Y; Dufau, ML				Zhang, Y; Dufau, ML			Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP1 SITES; REGULATE TRANSCRIPTION; CHROMATIN STRUCTURE; TRICHOSTATIN-A; REPRESSION; ACTIVATION; PROMOTER; ACETYLATION; EXPRESSION; INHIBITOR	Modification of chromatin structure by histone acetylases and deacetylases is an important mechanism in modulation of eukaryotic gene transcription. The present study investigated regulation of the human luteinizing hormone receptor (hLHR) gene by historic deacetylases. Inhibition of histone deacetylases (HDACs) by trichostatin A (TSA) increased hLHR promoter activity by 40-fold in JAR cells and markedly elevated endogenous hLHR mRNA levels. Acetylated histones H3 and H4 accumulated in TSA-treated cells and associated predominantly with the hLHR promoter. Furthermore, TSA significantly enhanced the recruitment of RNA polymerase 11 to the promoter. One of the two Sp1 sites essential for basal promoter activity was identified as critical for the TSA effect, but the binding of Sp1/Sp3 to this site remained unchanged in the absence or presence of TSA. A multiprotein complex was recruited to the hLHR promoter via interaction with Sp1 and Sp3, in which HDAC1 and HDAC2 were docked directly to Sp1-bound DNA and indirectly to Sp3-bound DNA through RbAp48, while mSin3A interacted with both HDACs. HDAC1 and HDAC2 were shown to potently repress the hLHR gene transcription, and mSin3A potentiated the inhibition mediated by HDAC1. Our studies have demonstrated that the HDAC-mSin3A complex has an important role in the regulation of hLHR gene transcription by interaction with Sp1/Sp3 and by region-specific changes in histone acetylation and polymerase 11 recruitment within the hLHR promoter.	NICHD, Endocrinol & Reprod Res Branch, Sect Mol Endocrinol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Endocrinol & Reprod Res Branch, Sect Mol Endocrinol, NIH, Bldg 49,Rm 6A036,49 Convent Dr MSC 4510, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Catt KJ, 1991, REPROD ENDOCRINOLOGY, P105; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; Geng Y, 1999, BIOCHEM BIOPH RES CO, V263, P366, DOI 10.1006/bbrc.1999.1374; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang EY, 2000, GENE DEV, V14, P45; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; Sowa Y, 1999, CANCER RES, V59, P4266; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai-Morris CH, 1998, J CLIN ENDOCR METAB, V83, P288, DOI 10.1210/jc.83.1.288; TSAIMORRIS CH, 1994, J BIOL CHEM, V269, P15868; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; TSAIMORRIS CH, 1995, J BIOL CHEM, V270, P7487, DOI 10.1074/jbc.270.13.7487; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 2000, J BIOL CHEM, V275, P2763, DOI 10.1074/jbc.275.4.2763; Zhang Y, 2001, MOL ENDOCRINOL, V15, P1891, DOI 10.1210/me.15.11.1891	49	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33431	33438		10.1074/jbc.M204417200	http://dx.doi.org/10.1074/jbc.M204417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091390	hybrid			2022-12-27	WOS:000177859000132
J	Thoden, JB; Huang, XY; Raushel, FM; Holden, HM				Thoden, JB; Huang, XY; Raushel, FM; Holden, HM			Carbamoyl-phosphate synthetase - Creation of an escape route for ammonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SUBSTRATE; GLUTAMINE; SUBUNIT; PRODUCT; TUNNEL; SYNTHASE; PROGRAM; JOURNEY	Carbamoyl-phosphate synthetase catalyzes the production of carbamoyl phosphate through a reaction mechanism requiring one molecule of bicarbonate, two molecules of MgATP, and one molecule of glutamine. The enzyme from Escherichia coli is composed of two polypeptide chains. The smaller of these belongs to the Class I amidotransferase superfamily and contains all of the necessary amino acid side chains required for the hydrolysis of glutamine to glutamate and ammonia. Two homologous domains from the larger subunit adopt conformations that are characteristic for members of the ATP-grasp superfamily. Each of these ATP-grasp domains contains an active site responsible for binding one molecule of MgATP. High resolution x-ray crystallographic analyses have shown that, remarkably, the three active sites in the E. coli enzyme are connected by a molecular tunnel of similar to100 Angstrom in total length. Here we describe the high resolution x-ray crystallographic structure of the G359F (small subunit) mutant protein of carbamoyl phosphate synthetase. This residue was initially targeted for study because it resides within the interior wall of the molecular tunnel leading from the active site of the small subunit to the first active site of the large subunit. It was anticipated that a mutation to the larger residue would "clog" the ammonia tunnel and impede the delivery of ammonia from its site of production to the site of utilization. In fact, the G359F substitution resulted in a complete change in the conformation of the loop delineated by Glu-355 to Ala-364, thereby providing an "escape" route for the ammonia intermediate directly to the bulk solvent. The substitution also effected the disposition of several key catalytic amino acid side chains in the small subunit active site.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK30343] Funding Source: Medline; NIGMS NIH HHS [GM55513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030343, R56DK030343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KS, 1999, METHOD ENZYMOL, V308, P111; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; Holden HM, 1999, CELL MOL LIFE SCI, V56, P507, DOI 10.1007/s000180050448; Huang XY, 2000, J BIOL CHEM, V275, P26233, DOI 10.1074/jbc.275.34.26233; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; Huang XY, 2000, BIOCHEMISTRY-US, V39, P3240, DOI 10.1021/bi9926173; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599	34	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39722	39727		10.1074/jbc.M206915200	http://dx.doi.org/10.1074/jbc.M206915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12130656	hybrid			2022-12-27	WOS:000178662500086
J	Bisello, A; Chorev, M; Rosenblatt, M; Monticelli, L; Mierke, DF; Ferrari, SL				Bisello, A; Chorev, M; Rosenblatt, M; Monticelli, L; Mierke, DF; Ferrari, SL			Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AGONIST-INDUCED INTERNALIZATION; PHOTOAFFINITY CROSS-LINKING; BETA(2) ADRENERGIC-RECEPTOR; FIRST EXTRACELLULAR LOOP; 3RD INTRACELLULAR LOOP; BINDING DOMAIN; REGULATORY PROTEINS; PTH/PTHRP RECEPTOR; CYTOPLASMIC LOOP	For many G protein-coupled receptors, agonist-induced activation is followed by desensitization, internalization, and resensitization. In most cases, these processes are dependent upon interaction of agonist-occupied receptor with cytoplasmic beta-arrestins. The ligand-induced intramolecular rearrangements of the receptor responsible for the desensitized versus active conformational states, which dictate both the pharmacological properties of ligands and the biological activity of G protein-coupled receptors, have not been fully elucidated. Here, we identify specific interactions between parathyroid hormone (PTH)-related protein and the human PTH type 1 receptor (PTH1Rc) and the related receptor conformational changes that lead to beta-arrestin-2-mediated desensitization. PTH-related protein analogs modified at position 1 induced selective stabilization of the active G protein-coupled state of the receptor, resulting in lack of beta-arrestin-2 recruitment to the cell membrane, sustained cAMP signaling, and absence of ligand-receptor complex internalization. Mechanistically, the ligands modified at position 1, interacting with the extracellular end of helix VI of PTH1Rc, produced a translocation of transmembrane helices V and VI that differed from that induced by the cognate agonist, resulting in significantly different conformations of the third intracellular loop. These results show how specific interactions between PTH1Rc and its ligands may stabilize distinct conformational states, representing either the active G protein-coupled or a desensitized beta-arrestin-coupled receptor state. In addition, they establish that sustained biological activity of PTH1Rc may be induced by appropriately designed agonist ligands.	Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA 15261 USA; Beth Israel Deaconess Med Ctr, Dept Med, Bone & Mineral Metab Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Providence, RI 02912 USA; Univ Hosp Geneva, Dept Internal Med, Div Bone Dis, CH-1211 Geneva 14, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Brown University; University of Geneva	Bisello, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol & Metab, E1140 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.		Ferrari, Serge/ABD-2730-2020; Monticelli, Luca/C-4608-2008	Ferrari, Serge/0000-0002-1372-4417; Monticelli, Luca/0000-0002-6352-4595	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047940] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47940] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Chorev Michael, 1996, P305; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fitzpatrick Lorraine A., 1996, P339; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; John MR, 2001, BONE, V28, P182, DOI 10.1016/S8756-3282(00)00419-1; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Lee KB, 2000, J BIOL CHEM, V275, P9284, DOI 10.1074/jbc.275.13.9284; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Mierke DF, 1996, J AM CHEM SOC, V118, P8998, DOI 10.1021/ja960454p; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Onaran HO, 1999, TRENDS PHARMACOL SCI, V20, P274, DOI 10.1016/S0165-6147(99)01364-4; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Pellegrini M, 1996, BIOPOLYMERS, V40, P653, DOI 10.1002/(SICI)1097-0282(1996)40:6<653::AID-BIP5>3.0.CO;2-V; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; Riccobene TA, 1999, J THEOR BIOL, V200, P207, DOI 10.1006/jtbi.1999.0988; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Rolz C, 2001, BIOPHYS CHEM, V89, P119, DOI 10.1016/S0301-4622(00)00222-2; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Scaramellini C, 1998, ANN NY ACAD SCI, V861, P97; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; VANDERSPOEL D, 1996, GROMACS USER MANUAL; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Waelbroeck M, 1999, TRENDS PHARMACOL SCI, V20, P477, DOI 10.1016/S0165-6147(99)01394-2; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	50	81	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38524	38530		10.1074/jbc.M202544200	http://dx.doi.org/10.1074/jbc.M202544200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12107160				2022-12-27	WOS:000178529600068
J	Su, LF; Wang, Z; Garabedian, MJ				Su, LF; Wang, Z; Garabedian, MJ			Regulation of GRIP1 and CBP coactivator activity by Rho GDI modulates estrogen receptor transcriptional enhancement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; KINASE PATHWAY; ACTIVATION; BINDING; ALPHA; PHOSPHORYLATION; PROTEIN; COMPLEX; P300; TRANSACTIVATION	Estrogen receptor alpha (ER) coordinates gene expression with cellular physiology in part by controlling receptor-cofactor interactions in response to extracellular signals. We have previously shown that the Rho signaling pathway modulates ER transcriptional activation. We now demonstrate that Rho GDI-dependent increase in ER transactivation is dependent on the ER AF-2 coactivator binding site, prompting us to examine regulation of receptor coactivators by Rho GDI. Indeed, Rho GDI cooperates with GRIP1 to increase ER ligand-independent and ligand-dependent transactivation and also enhances GRIP1 transcriptional activity when GRIP1 is tethered to DNA. The GRIP1 activation domain 1 (AD1), which binds CBP/p300, is necessary for Rho GDI to modulate GRIP1 activity. Using E1A to inhibit the endogenous CBP/p300 and a Gal4-CBP fusion protein to assay CBP activity, we rind that the effect of Rho GDI on ER transactivation is CBP/p300-dependent. Importantly, the ability of CBP/p300 to transduce the Rho GDI signal to ER occurs through both GRIP1-dependent and -independent pathways. These data suggest a complex interplay between ER transcriptional activation and the Rho signaling pathways through modulation of receptor cofactors, which may have evolved to coordinate receptor-dependent gene expression with Rho-regulated events, such as cell migration. We speculate that dysregulation of the Rho-ER axis may participate in cancer progression.	NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA.				NIGMS NIH HHS [T32 GM07308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Bilodeau D, 1999, BIOCHEM CELL BIOL, V77, P59, DOI 10.1139/bcb-77-1-59; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Mak HY, 1999, MOL CELL BIOL, V19, P3895; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; ONATE SA, 1995, SCIENCE, V270, P1354; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; van Golen KL, 2000, CANCER RES, V60, P5832; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37037	37044		10.1074/jbc.M111607200	http://dx.doi.org/10.1074/jbc.M111607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138084	hybrid			2022-12-27	WOS:000178447100019
J	Rubin, H; Ravid, S				Rubin, H; Ravid, S			Polarization of myosin II heavy chain-protein kinase C in chemotaxing Dictyostelium cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; LEADING-EDGE; FUSION PROTEIN; LIVING CELLS; IN-VIVO; CHEMOATTRACTANT; DYNAMICS; LOCALIZATION; ACTIVATION; PHOSPHORYLATION	Eukaryotic cells need morphological polarity to carry out chemotaxis (Parent, C. A., Blacklock, B. J., Froehlich, W. M., Murphy, D. B., and Devreotes, P. N. (1998) Cell 95, 81-91; Jin, T., Zhang, N., Long, Y., Parent, C., and Devreotes, P. N. (2000) Science 287, 1034-1036; Servant, G., Weiner, O. D., Herzmark, P., Balla, T., Sedat, J. W., and Bourne, H. R. (2000) Science 287, 1037-1040), but sensing direction does not require polarization of chemoattractant receptors. When cells are exposed to a gradient of chemoattractant, activation occurs selectively at the stimulated edge. Such localized activation, transmitted by the recruitment of cytosolic proteins, may be a general mechanism for gradient sensing by G protein-linked chemotactic systems. Here we show that in Dictyostelium discoideum cells exposed to a cAMP gradient the myosin 11 heavy chain kinase (MHC-PKC) and myosin H translocate to opposite ends of the cell. We further show that MHC-PKC C1 domain is responsible for the localization of MHC-PKC to the cell leading edge, but it is not sufficient to promote cell polarization. Our findings suggest a mechanism by which MHC-PKC regulates myosin H, allowing cell polarization and movement in the direction of the cAMP source.	Hebrew Univ Jerusalem, Dept Biochem, Hadassah Med Sch, Inst Med Sci, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Ravid, S (corresponding author), Hebrew Univ Jerusalem, Dept Biochem, Hadassah Med Sch, Inst Med Sci, IL-91120 Jerusalem, Israel.	ravid@md.huji.ac.il						AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; Aizawa H, 1997, J CELL SCI, V110, P2333; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chu QA, 1996, CELL MOTIL CYTOSKEL, V35, P254, DOI 10.1002/(SICI)1097-0169(1996)35:3<254::AID-CM7>3.0.CO;2-8; Dembinsky A, 1996, J CELL BIOL, V134, P911, DOI 10.1083/jcb.134.4.911; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALCHOW D, 1981, EUR J BIOCHEM, V117, P213; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SPUDICH JA, 1989, CELL REGUL, V1, P1; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P3; TRINKAUS JP, 1984, CELL ORGANS FORCE SH; WANG M, 1988, DEV BIOL, V128, P72, DOI 10.1016/0012-1606(88)90268-0; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; ZIGMOND SH, 1988, METHOD ENZYMOL, V162, P65	36	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36005	36008		10.1074/jbc.M205986200	http://dx.doi.org/10.1074/jbc.M205986200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130648	hybrid			2022-12-27	WOS:000178275100031
J	Sum, CS; Park, PSH; Wells, JW				Sum, CS; Park, PSH; Wells, JW			Effects of N-ethylmaleimide on conformational equilibria in purified cardiac muscarinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; GUANINE-NUCLEOTIDES; SULFHYDRYL-GROUPS; OCCUPANCY MODEL; LIGAND-BINDING	Muscarinic receptors purified from porcine atria and devoid of G protein underwent a 9-27-fold decrease in their apparent affinity for the antagonists quinuclidinyl. benzilate, N-methylscopolamine, and scopolamine when treated with the thiol-selective reagent N-ethylmaleimide. Their apparent affinity for the agonists carbachol and oxotremorine-M was unchanged. Conversely, the rate of alkylation by N-ethylmaleimide, as monitored by the binding of [H-3]quinuclidinyl benzilate, was decreased by antagonists while agonists were without effect. The receptor also underwent a time-dependent inactivation that was hastened by N-ethylmaleimide but slowed by quinuclidinyl benzilate and N-methylscopolamine. The destabilizing effect of N-ethylmaleimide was counteracted fully or nearly so at saturating concentrations of each antagonist and the agonist carbachol. Similar effects occurred with human M-2 receptors differentially tagged with the c-Myc and FLAG epitopes, coexpressed in Sf9 cells, and extracted in digitonin/cholate. The degree of coimmunoprecipitation was unchanged by N-ethylmaleimide, which therefore was without discernible effect on oligomeric size. The data are quantitatively consistent with a model in which the purified receptor from porcine atria interconverts spontaneously between two states (i.e. R reversible arrow R*). Antagonists favor the R state; agonists and N-ethylmaleimide favor the comparatively unstable R* state, which predominates after purification. Occupancy by a ligand stabilizes both states, and antagonists impede alkylation by favoring R over R*. Similarities with constitutively active receptors suggest that R and R* are akin to the inactive and active states, respectively. Purify M-2 receptors therefore appear to exist predominantly in their active state.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Wells, JW (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.							Armstrong D, 2001, J BIOL CHEM, V276, P22621, DOI 10.1074/jbc.M006936200; ARONSTAM RS, 1977, EUR J PHARMACOL, V46, P279, DOI 10.1016/0014-2999(77)90344-2; ASANO T, 1986, MOL PHARMACOL, V29, P244; BERRIE CP, 1985, BRIT J PHARMACOL, V85, P697, DOI 10.1111/j.1476-5381.1985.tb10566.x; BIRDSALL NJM, 1986, BRIT J PHARMACOL, V87, P307, DOI 10.1111/j.1476-5381.1986.tb10819.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DUNLAP J, 1984, J NEUROCHEM, V43, P214, DOI 10.1111/j.1471-4159.1984.tb06699.x; EHLERT FJ, 1981, FED PROC, V40, P153; EHLERT FJ, 1980, J SUPRAMOL STR CELL, V14, P149, DOI 10.1002/jss.400140204; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA T, 1982, BIOMED RES-TOKYO, V3, P695, DOI 10.2220/biomedres.3.695; HAGA T, 1982, PHARM BIOCH ASPECTS, P43; HULME EC, 1983, J RECEPTOR RES, V3, P301, DOI 10.3109/10799898309041943; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; KORN SJ, 1983, J PHARMACOL EXP THER, V224, P118; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; Park P, 2001, EUR J PHARMACOL, V421, P11, DOI 10.1016/S0014-2999(01)00998-0; Park PSH, 2002, BIOCHEMISTRY-US, V41, P5588, DOI 10.1021/bi011746s; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; Press W., 1992, NUMERICAL RECIPES FO; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Sum CS, 2001, BIOCHEM PHARMACOL, V62, P829; TIBERI M, 1994, J BIOL CHEM, V269, P27925; VANDERHEYDEN P, 1984, BIOCHEM PHARMACOL, V33, P2981, DOI 10.1016/0006-2952(84)90597-5; VANDERHEYDEN P, 1988, VISION RES, V28, P247, DOI 10.1016/0042-6989(88)90151-4; VAUQUELIN G, 1990, ARCH INT PHARMACOD T, V307, P5; VAUQUELIN G, 1982, EUR J BIOCHEM, V125, P117, DOI 10.1111/j.1432-1033.1982.tb06658.x; WEI JW, 1980, N-S ARCH PHARMACOL, V314, P51, DOI 10.1007/BF00498431; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; WINSLOW JW, 1987, J BIOL CHEM, V262, P4501; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	51	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36188	36203		10.1074/jbc.M201731200	http://dx.doi.org/10.1074/jbc.M201731200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119286	hybrid			2022-12-27	WOS:000178275100055
J	Xu, XL; Lockamy, VL; Chen, KJ; Huang, Z; Shields, H; King, SB; Ballas, SK; Nichols, JS; Gladwin, MT; Noguchi, CT; Schechter, AN; Kim-Shapiro, DB				Xu, XL; Lockamy, VL; Chen, KJ; Huang, Z; Shields, H; King, SB; Ballas, SK; Nichols, JS; Gladwin, MT; Noguchi, CT; Schechter, AN; Kim-Shapiro, DB			Effects of iron nitrosylation on sickle cell hemoglobin solubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NITRIC-OXIDE HEMOGLOBIN; DEOXYHEMOGLOBIN-S; OXYGEN-BINDING; LIGAND-BINDING; SPIN-RESONANCE; TREATED RATS; IN-VIVO; TRANSPORT; 2,3-DIPHOSPHOGLYCERATE	One mechanism by which nitric oxide (NO) has been proposed to benefit patients with sickle cell disease is by reducing intracellular polymerization of sickle hemoglobin (HbS). In this study we have examined the ability of nitric oxide to inhibit polymerization by measuring the solubilizing effect of iron nitrosyl sickle hemoglobin (HbS-NO). Electron paramagnetic resonance spectroscopy was used to confirm that, as found in vivo, the primary type of NO ligation produced in our partially saturated NO samples is pentacoordinate a-nitrosyl. Linear dichroism spectroscopy and delay time measurements were used to confirm polymerization. Based on sedimentation studies we found that, although fully ligated (100% tetranitrosyl) HbS is very soluble, the physiologically relevant, partially ligated species do not provide a significant solubilizing effect. The average solubilizing effect of 26% NO saturation was 0.045; much less than the 0.15 calculated for the effect of 26% oxygen saturation. Given the small amounts of NO-ligated hemoglobin achievable through any kind of NO therapy, we conclude that NO therapy does not benefit patients through any direct solubilizing effect.	Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Wake Forest Univ, Dept Chem, Winston Salem, NC 27109 USA; Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; NIH, Warren G Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA; NIH, Biol Chem Lab, Bethesda, MD 20892 USA	Wake Forest University; Wake Forest University; Jefferson University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Kim-Shapiro, DB (corresponding author), Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA.	shapiro@wfu.edu	Kim-Shapiro, Daniel/HGA-2682-2022	Lockamy, Virginia/0000-0002-6545-7859; Schechter, Alan N/0000-0002-5235-9408	NCRR NIH HHS [RR15018] Funding Source: Medline; NHLBI NIH HHS [R01 HL058091, HL58091, HL62198, R29 HL058091] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R41RR015018] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058091, R37HL058091, R01HL062198, R29HL058091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025093, Z01DK025021] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold EV, 1996, METHOD ENZYMOL, V269, P41; Atz AM, 1997, ANESTHESIOLOGY, V87, P988, DOI 10.1097/00000542-199710000-00037; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; BRIEHL RW, 1975, J MOL BIOL, V96, P733, DOI 10.1016/0022-2836(75)90149-7; BRIEHL RW, 1974, J MOL BIOL, V89, P759, DOI 10.1016/0022-2836(74)90050-3; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMULITRAT W, 1994, MOL PHARMACOL, V46, P391; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; Embury Stephen H., 1994, P311; ERIKSSON LEG, 1994, BIOCHEM BIOPH RES CO, V203, P176, DOI 10.1006/bbrc.1994.2165; GERACI G, 1969, J BIOL CHEM, V244, P4664; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Gladwin MT, 2001, SEMIN HEMATOL, V38, P333, DOI 10.1053/shem.2001.27574; Gladwin MT, 2001, FREE RADICAL RES, V35, P175, DOI 10.1080/10715760100300721; Head CA, 1997, J CLIN INVEST, V100, P1193, DOI 10.1172/JCI119631; HILLE R, 1979, J BIOL CHEM, V254, P2110; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; HUANG TH, 1979, J BIOL CHEM, V254, P1467; Huang Z, 2002, BIOCHEM BIOPH RES CO, V292, P812, DOI 10.1006/bbrc.2002.6730; Huang Z, 2001, BBA-GEN SUBJECTS, V1568, P252, DOI 10.1016/S0304-4165(01)00227-6; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; Jiang JJ, 1997, MOL PHARMACOL, V52, P1081, DOI 10.1124/mol.52.6.1081; KAPERONIS AA, 1979, BR J HEMATOL, V43, P472; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; McDade WA, 1997, ANESTHESIOLOGY, V87, pA512, DOI 10.1097/00000542-199709001-00512; McDade WA, 1999, ANESTHESIOLOGY, V91, pU348; MOORE EG, 1976, J BIOL CHEM, V251, P2788; NOGUCHI CT, 1985, ANNU REV BIOPHYS BIO, V14, P239, DOI 10.1146/annurev.biophys.14.1.239; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERUTZ MF, 1976, BIOCHEMISTRY-US, V15, P378, DOI 10.1021/bi00647a022; POILLON WN, 1985, J BIOL CHEM, V260, P3897; POILLON WN, 1990, BLOOD, V76, P1028; REIN H, 1972, FEBS LETT, V24, P24, DOI 10.1016/0014-5793(72)80817-2; SHAPIRO DB, 1995, J BIOL CHEM, V270, P26078, DOI 10.1074/jbc.270.44.26078; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; SUNSHINE HR, 1982, J MOL BIOL, V158, P251, DOI 10.1016/0022-2836(82)90432-6; SZABO A, 1976, BIOCHEMISTRY-US, V15, P4427, DOI 10.1021/bi00665a013; TOMITA S, 1971, J BIOL CHEM, V246, P547; TRITTELVITZ E, 1972, EUR J BIOCHEM, V31, P578, DOI 10.1111/j.1432-1033.1972.tb02568.x; UEDA Y, 1979, BLOOD, V53, P472; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	46	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36787	36792		10.1074/jbc.M205350200	http://dx.doi.org/10.1074/jbc.M205350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138112	hybrid			2022-12-27	WOS:000178275100129
J	Abdel-Hafiz, H; Takimoto, GS; Tung, L; Horwitz, KB				Abdel-Hafiz, H; Takimoto, GS; Tung, L; Horwitz, KB			The inhibitory function in human progesterone receptor N termini binds SUMO-1 protein to regulate autoinhibition and transrepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; DNA-BINDING; IN-VITRO; C-JUN; TRANSCRIPTIONAL AGONISTS; HINGE REGION; A-RECEPTORS; B-RECEPTORS; ACTIVATION; PHOSPHORYLATION	Although most studies of progesterone receptors (PR) and their two isoforms, PR-A and PR-B, focus on transcriptional stimulation, the receptors exhibit important inhibitory properties. Autoinhibition refers to an inhibitory function located in the PR N terminus, whose deletion increases transcriptional activity at least 6-10-fold. Transrepression refers to the ability of PR-A to suppress the transcriptional activity of PR-B and other nuclear receptors, including estrogen receptors. Self-squelching refers to the observation in transient transfection assays that increasing receptor concentrations paradoxically decrease transcriptional activity. Using a series of N-terminal deletion mutants constructed in both PR isoforms, we have mapped their autoinhibitory and transrepressor activities to a small ubiquitin-like modifier (SUMO-1) protein consensus-binding motif, (IKEE)-I-387, located in the N terminus upstream of AF1. Self-squelching does not involve this site. SUMO-1 binds PR covalently at (IKEE)-I-387, but only if the C-terminal, liganded, hormone-binding domain is also present. A single point K388R mutation within the (IKEE)-I-387 motif in either PR-A or PR-B leads to a loss of autoinhibitory and transrepressor functions of the liganded, full-length receptors. We conclude that autoinhibition and transrepression involve N-terminal sumoylation combined with intramolecular N/C-terminal communication.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Mol Biol Program, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Abdel-Hafiz, H (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Med Endocrinol, Box B151,4200 E 9th Ave, Denver, CO 80262 USA.	hany.abdel-hafiz@uchsc.edu		Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26869] Funding Source: Medline; NIDDK NIH HHS [DK 48238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arnett-Mansfield RL, 2001, CANCER RES, V61, P4576; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Courey AJ, 2001, GENE DEV, V15, P2786; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; Huse B, 1998, MOL ENDOCRINOL, V12, P1334, DOI 10.1210/me.12.9.1334; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; KRETT NL, 1988, BIOCHEM BIOPH RES CO, V157, P278, DOI 10.1016/S0006-291X(88)80044-5; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, NAT CELL BIOL, V2, pE161, DOI 10.1038/35023639; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; MOHAMED MK, 1994, J STEROID BIOCHEM, V51, P241, DOI 10.1016/0960-0760(94)90036-1; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; Tung L, 2001, J BIOL CHEM, V276, P39843, DOI 10.1074/jbc.M106843200; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200	51	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33950	33956		10.1074/jbc.M204573200	http://dx.doi.org/10.1074/jbc.M204573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114521	hybrid			2022-12-27	WOS:000177959100057
J	Goldberg, HJ; Whiteside, CI; Fantus, IG				Goldberg, HJ; Whiteside, CI; Fantus, IG			The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase c-beta I and -delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; O-LINKED GLCNAC; HIGH GLUCOSE; TYROSINE PHOSPHORYLATION; N-ACETYLGLUCOSAMINE; MESANGIAL CELLS; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; MATRIX COMPONENTS; INDUCED APOPTOSIS; EXPRESSION	Increased flux through the hexosamine biosynthesis pathway (HBP) has been shown to stimulate the expression of a number of genes. We previously demonstrated in glomerular mesangial and endothelial cells that both high glucose concentrations and glucosamine activated the plasminogen activator inhibitor-1 (PAI-1) gene promoter through the transcription factor, Sp1; and that the glutamine:fructose-6-phosphate amidotransferase inhibitor, 6-diazo-5-oxonorleucine, inhibited the effect of high glucose, but not that of glucosamine. Here, we examined the role of protein kinase C (PKC) isoforms in the regulation of the PAI-1 promoter and Sp1 transcriptional activity by the HBP. In transient transfections, exposure to 2 mm glucosamine or 20 mm glucose for 4 days increased the activities of a PAI-1 promoter-luciferase reporter gene as well as the Sp1 transcriptional activation domain fused to the GAL4 DNA-binding domain cotransfected with a GAL4 promoter-luciferase reporter. Cotransfected dominant negative PKC-betaI and -delta completely blocked the induction of PAI-1 promoter transcription by both sugars, whereas only dominant negative PKC-beta1 interfered with Sp1-GAL4 activation. Both glucosamine and high glucose stimulated the in vitro kinase activity of immunoprecipitated PKC-betaI and -5. Furthermore, 6-diazo-5-oxonorleucine suppressed high glucose-induced PKC kinase activity and Sp1-GAL4 transcriptional activation. These findings demonstrate a requirement for the PKC-betaI and -delta signal transduction pathways in HBP-induced transcription.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Hlth Network, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Fantus, IG (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Suite 780, Toronto, ON M5G 1X5, Canada.	fantus@mshri.on.ca						Akimoto Y, 2000, DIABETOLOGIA, V43, P1239, DOI 10.1007/s001250051519; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; Amiri F, 1999, AM J PHYSIOL-RENAL, V276, pF691, DOI 10.1152/ajprenal.1999.276.5.F691; Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Boehmelt G, 2000, J BIOL CHEM, V275, P12821, DOI 10.1074/jbc.275.17.12821; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; CHUPRETA S, 2000, AM J PHYSIOL, V278, pC696; Cohen MP, 1999, AM J PHYSIOL-RENAL, V276, pF684, DOI 10.1152/ajprenal.1999.276.5.F684; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniels MC, 2000, AM J MED SCI, V319, P138, DOI 10.1097/00000441-200003000-00002; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Filippis A, 1997, BIOCHEM J, V324, P981, DOI 10.1042/bj3240981; FUMO P, 1994, AM J PHYSIOL-RENAL, V267, pF632, DOI 10.1152/ajprenal.1994.267.4.F632; Glogowski EA, 1999, KIDNEY INT, V55, P486, DOI 10.1046/j.1523-1755.1999.00284.x; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; Goldberg HJ, 2000, DIABETES, V49, P863, DOI 10.2337/diabetes.49.5.863; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 2000, BIOCHEM J, V350, P109, DOI 10.1042/0264-6021:3500109; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hua H, 2001, DIABETES, V50, P2376, DOI 10.2337/diabetes.50.10.2376; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishii H, 1998, DIABETOLOGIA, V41, P362, DOI 10.1007/s001250050916; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; James LR, 2000, AM J PHYSIOL-RENAL, V279, pF718, DOI 10.1152/ajprenal.2000.279.4.F718; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KIKKAWA R, 1994, DIABETOLOGIA, V37, P838, DOI 10.1007/BF00404342; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kolm-Litty V, 1998, EXP CLIN ENDOCR DIAB, V106, P377, DOI 10.1055/s-0029-1212002; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Nerlich AG, 1998, DIABETES, V47, P170, DOI 10.2337/diabetes.47.2.170; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Popoff IJ, 1999, MOL IMMUNOL, V36, P1005, DOI 10.1016/S0161-5890(99)00128-5; Ren S, 2000, AM J PHYSIOL-ENDOC M, V278, pE656, DOI 10.1152/ajpendo.2000.278.4.E656; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Schleicher ED, 2000, KIDNEY INT, V58, pS13, DOI 10.1046/j.1523-1755.2000.07703.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Singh LP, 2001, DIABETES, V50, P2355, DOI 10.2337/diabetes.50.10.2355; Singh LP, 2000, AM J PHYSIOL-RENAL, V279, pF646, DOI 10.1152/ajprenal.2000.279.4.F646; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Takabe W, 2001, J BIOL CHEM, V276, P40497, DOI 10.1074/jbc.M104882200; Takemoto M, 1999, BIOCHEM BIOPH RES CO, V258, P722, DOI 10.1006/bbrc.1999.0701; Tan J, 1998, BIOCHEM J, V336, P49, DOI 10.1042/bj3360049; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wu G, 2001, DIABETOLOGIA, V44, P196, DOI 10.1007/s001250051599; Wu GY, 2001, BIOCHEM J, V353, P245, DOI 10.1042/0264-6021:3530245; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	92	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33833	33841		10.1074/jbc.M112331200	http://dx.doi.org/10.1074/jbc.M112331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105191	hybrid			2022-12-27	WOS:000177959100041
J	Grefhorst, A; Elzinga, BM; Voshol, PJ; Plosch, T; Kok, T; Bloks, VW; van der Sluijs, FH; Havekes, LM; Romijn, JA; Verkade, HJ; Kuipers, F				Grefhorst, A; Elzinga, BM; Voshol, PJ; Plosch, T; Kok, T; Bloks, VW; van der Sluijs, FH; Havekes, LM; Romijn, JA; Verkade, HJ; Kuipers, F			Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; TRANSGENIC MICE; APOLIPOPROTEIN-E; OXYSTEROL RECEPTORS; CHOLESTEROL EFFLUX; ACID METABOLISM; GENE-EXPRESSION; LXR-ALPHA; MACROPHAGES; SECRETION	The oxysterol-activated liver X receptor (LXR) provides a link between sterol and fatty acid metabolism; activation of LXR induces transcription of lipogenic genes. This study shows that induction of the lipogenic genes Srebp-1c, Fas, and Acc1 upon administration of the synthetic LXR agonist T0901317 to C57BL/6J mice (10 mg/kg/day, 4 days) is associated with massive hepatic steatosis along the entire liver lobule and a 2.5-fold increase in very low density lipoprotein-triglyceride (VLDL-TG) secretion. The increased VLDL-TG secretion was fully accounted for by formation of larger (129 +/- 9 nm versus 94 +/- 12 nm, a 2.5-fold increase of particle volume) TG-rich particles. Stimulation of VLDL-TG secretion did not lead to elevated plasma TG levels in C57BL/6J mice, indicating efficient particle metabolism and clearance. However, T0901317 treatment did lead to severe hypertriglyceridemia in mouse models of defective TG-rich lipoprotein clearance, i.e. APOE*3-Leiden transgenic mice (3.2-fold increase) and apoE-/- LDLr-/- double knockouts (12-fold increase). Incubation of rat hepatoma McA-RH7777 cells with T0901317 also resulted in intracellular TG accumulation and enhanced TG secretion. We conclude that, in addition to raising high density lipoprotein cholesterol concentrations, pharmacological LXR activation in mice leads to development of hepatic steatosis and secretion of atherogenic, large TG-rich VLDL particles.	Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol & Diabet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Internal Med, NL-2300 RA Leiden, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kuipers, F (corresponding author), Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, Rm Y2115,CMC 4,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	f.kuipers@med.rug.nl	Bloks, Vincent/A-7609-2012; Plösch, Torsten/X-6808-2019	Bloks, Vincent/0000-0001-6493-7482; Plösch, Torsten/0000-0002-9305-4045; Kuipers, Folkert/0000-0003-2518-737X; Verkade, Henkjan J/0000-0002-7034-2861				Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Costet P, 2000, J BIOL CHEM, V275, P28240; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Edwards PA, 2002, J LIPID RES, V43, P2; Fayard E, 2001, CURR OPIN LIPIDOL, V12, P113, DOI 10.1097/00041433-200104000-00004; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GUZMAN M, 1989, BIOCHEM J, V264, P107, DOI 10.1042/bj2640107; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Huuskonen J, 2001, ATHEROSCLEROSIS, V155, P269, DOI 10.1016/S0021-9150(01)00447-6; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEPAGE G, 1986, J LIPID RES, V27, P114; Lewis GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIE J, 2002, IN PRESS EUR J CLIN; Lin HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; MAK PA, 2002, IN PRESS J BIOL CHEM, V277; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; Miyake JH, 2001, J BIOL CHEM, V276, P23304, DOI 10.1074/jbc.M101853200; Parks EJ, 1999, J CLIN INVEST, V104, P1087, DOI 10.1172/JCI6572; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Song C, 2001, STEROIDS, V66, P673, DOI 10.1016/S0039-128X(01)00132-5; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Teusink B, 2001, J BIOL CHEM, V276, P40693, DOI 10.1074/jbc.M106396200; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	50	400	414	4	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34182	34190		10.1074/jbc.M204887200	http://dx.doi.org/10.1074/jbc.M204887200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097330	Green Published, hybrid			2022-12-27	WOS:000177959100086
J	Martin, J; Eynstone, LV; Davies, M; Williams, JD; Steadman, R				Martin, J; Eynstone, LV; Davies, M; Williams, JD; Steadman, R			The role of ADAM 15 in glomerular mesangial cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRIN; EXTRACELLULAR-MATRIX; MEMBRANE-PROTEINS; GROWTH-FACTOR; GENE FAMILY; IN-VITRO; ADHESION; DOMAIN; PROLIFERATION; METARGIDIN	Mesangial cells (MC) occupy the core of the renal glomerulus and are surrounded by a mesangial matrix. In certain diseases, MC migrate through this matrix into the pericapillary space. The mechanisms involved, however, are poorly understood. Members of the ADAM (A Disintegrin And Metalloproteinase) family of membrane proteins have the potential to be key modulators of cell-matrix interactions through the activities of their constituent domains. We have studied the possible role of ADAM 15 in human (H) MC migration in vitro. HMC ADAM 15 was expressed at low levels in serum-free medium but was increased during migration. Antibodies to the individual domains of ADAM 15 and the incorporation of antisense ADAM 15, (but not control oligonucleotide) inhibited this migration. Furthermore, inhibition of migration by the broad spectrum metalloproteinase inhibitor BB3103, demonstrated that metalloproteinase activity was essential for migration. ADAM 15, extracted from MIC membranes, was an active metalloproteinase, which degraded both type IV collagen and gelatin prepared from fibrillar collagen. Activity was inhibited by EDTA but not by phenylmethylsulfonyl fluoride. This is the first report of the potential of ADAM 15 for involvement in the restructuring of the mesangial matrix and in the migration of MC in disease.	Univ Wales Coll Med, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Martin, J (corresponding author), Univ Wales Coll Med, Inst Nephrol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Steadman, Robert/O-1614-2016	Steadman, Robert/0000-0002-1303-2496				Banas B, 1999, J AM SOC NEPHROL, V10, P2314; BARNES JL, 1994, LAB INVEST, V70, P460; BARNES JL, 1991, AM J PATHOL, V138, P859; BARNES JL, 1990, LAB INVEST, V62, P379; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CAMERON S, OXFORD TXB CLIN NEPH, V1, P388; Cho CH, 2000, DEV BIOL, V222, P289, DOI 10.1006/dbio.2000.9703; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Haseley LA, 1999, KIDNEY INT, V56, P964, DOI 10.1046/j.1523-1755.1999.00641.x; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Mahimkar RM, 2000, J AM SOC NEPHROL, V11, P595, DOI 10.1681/ASN.V114595; MAHIMKAR RM, 1997, J AM SOC NEPHROL, V8, P426; MARTIN J, 1994, KIDNEY INT, V46, P877, DOI 10.1038/ki.1994.345; Martin J, 1998, J AM SOC NEPHROL, V9, P1629; Martin J, 2001, J AM SOC NEPHROL, V12, P88, DOI 10.1681/ASN.V12188; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; PERSON JM, 1988, AM J PATHOL, V133, P609; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; TARABOLETTI G, 1992, LAB INVEST, V67, P566; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	35	97	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33683	33689		10.1074/jbc.M200988200	http://dx.doi.org/10.1074/jbc.M200988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091380	hybrid			2022-12-27	WOS:000177959100022
J	Bochud-Allemann, N; Schneider, A				Bochud-Allemann, N; Schneider, A			Mitochondrial substrate level phosphorylation is essential for growth of procyclic Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; RESPIRATORY-CHAIN; ENERGY-METABOLISM; ENZYME-ACTIVITIES; BLOOD-STREAM; CYCLE; GENES; EVOLUTION; SUCCINATE; ROTENONE	Oxidative phosphorylation and substrate level phosphorylation catalyzed by succinyl-CoA synthetase found in the citric acid and the acetate:succinate CoA transferase/succinyl-CoA synthetase cycle contribute to mitochondrial ATP synthesis in procyclic Trypanosoma brucei. The latter pathway is specific for trypanosome but also found in hydrogenosomes. In organello ATP production was studied in wild-type and in RNA interference cell lines ablated for key enzymes of each of the three pathways. The following results were obtained: 1) ATP production in the acetate:succinate CoA transferase/succinyl-CoA synthetase cycle was directly demonstrated. 2) Succinate dehydrogenase appears to be the only entry point for electrons of mitochondrial substrates into the respiratory chain; however, its activity could be ablated without causing a growth phenotype. 3) Growth of procyclic T. brucei was not affected by the absence of either a functional citric acid or the acetate: succinate CoA transferase/succinyl-CoA synthetase cycle. However, interruption of both pathways in the same cell line resulted in a growth arrest. In summary, these results show that oxygen-independent substrate level phosphorylation either linked to the citric acid cycle or tied into acetate production is essential for growth of procyclic T. brucei, a situation that may reflect an adaptation to the partially hypoxic conditions in the insect host.	Univ Fribourg, Dept Biol Zool, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneider, A (corresponding author), Univ Fribourg, Dept Biol Zool, Chemin Musee 10, CH-1700 Fribourg, Switzerland.	andre.schneider@unifr.ch						Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Beattie DS, 1996, EUR J BIOCHEM, V241, P888, DOI 10.1111/j.1432-1033.1996.00888.x; Beverley S M, 1993, Methods Mol Biol, V21, P333; BIENEN EJ, 1991, EXP PARASITOL, V73, P403, DOI 10.1016/0014-4894(91)90064-4; BRUN R, 1979, ACTA TROP, V36, P289; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; Fang J, 2002, BIOCHEMISTRY-US, V41, P3065, DOI 10.1021/bi015989w; Fang J, 2001, EUR J BIOCHEM, V268, P3075, DOI 10.1046/j.1432-1327.2001.02205.x; Hauser R, 1996, J CELL SCI, V109, P517; Hernandez FR, 1998, MOL BIOCHEM PARASIT, V93, P135, DOI 10.1016/S0166-6851(98)00015-2; Hunger-Glaser I, 1999, MOL BIOCHEM PARASIT, V100, P53, DOI 10.1016/S0166-6851(99)00032-8; Kurland CG, 2000, MICROBIOL MOL BIOL R, V64, P786, DOI 10.1128/MMBR.64.4.786-820.2000; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; Przybyla-Zawislak B, 1998, EUR J BIOCHEM, V258, P736, DOI 10.1046/j.1432-1327.1998.2580736.x; Schnaufer A, 2002, INT J PARASITOL, V32, P1071, DOI 10.1016/S0020-7519(02)00020-6; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; TURRENS JF, 1989, BIOCHEM J, V259, P363, DOI 10.1042/bj2590363; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	29	148	152	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32849	32854		10.1074/jbc.M205776200	http://dx.doi.org/10.1074/jbc.M205776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12095995	hybrid			2022-12-27	WOS:000177859000060
J	Hazra, TK; Kow, YW; Hatahet, Z; Imhoff, B; Boldogh, I; Mokkapati, SK; Mitra, S; Izumi, T				Hazra, TK; Kow, YW; Hatahet, Z; Imhoff, B; Boldogh, I; Mokkapati, SK; Mitra, S; Izumi, T			Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; DEAMINATED CYTOSINES; DAMAGE; MECHANISMS; RADICALS; MUTATION; HOMOLOG; PROTEIN	Two candidate human orthologs of Escherichia coli MutM/Nei were recently identified in the human genome database, and one of these, NEH1, was characterized earlier (Hazra, T. K., Izumi, T., Boldogh, I., Imhoff, B., Kow, Y. W., Jaruga, P., and Dizdaroglu, M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 3523-3528). Here we report characterization of the second protein, originally named NEH2 and now renamed NEIL2 (Nei-like). The 37-kDa wild-type NEIL2 expressed in and purified from E. coli has DNA glycosylase/AP lyase activity, primarily for excising oxidative products of cytosine, with highest activity for 5-hydroxyuracil, one of the most abundant and mutagenic lesions induced by reactive oxygen species, and with lower activity for 5,6-dihydrouracil and 5-hydroxycytosine. It has negligible or undetectable activity with 8-oxoguanine, thymine glycol, 2-hydroxyadenine, hypoxanthine, and xanthine. NEIL2 is similar to NEIL1 in having N-terminal Pro as the active site. However, unlike NEIL1, its expression was independent of the cell cycle stage in fibroblasts, and its highest expression was observed in the testes and skeletal muscle. Despite the absence of a putative nuclear localization signal, NEIL2 was predominantly localized in the nucleus. These results suggest that NEIL2 is involved in global genome repair mainly for removing oxidative products of cytosine.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Emory Univ, Div Canc Biol, Atlanta, GA 30335 USA; Univ Texas Hlth Sci Ctr, Tyler, TX 75708 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Emory University; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Hazra, TK (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Route 1079, Galveston, TX 77555 USA.				NCI NIH HHS [CA 90860, R01 CA084461, CA 81063] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081063, R01CA084461, R56CA090860, R01CA090860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; Dizdaroglu M, 1996, NUCLEIC ACIDS RES, V24, P418, DOI 10.1093/nar/24.3.418; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; HABRAKEN Y, 1987, J BIOCH, V171, P59; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Imai K, 1998, GENE, V222, P287, DOI 10.1016/S0378-1119(98)00485-5; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P3930, DOI 10.1093/nar/22.19.3930; SCHAAPER RM, 1987, J MOL BIOL, V198, P187, DOI 10.1016/0022-2836(87)90305-6; Seibel BA, 2002, J EXP BIOL, V205, P297; TATSUKA M, 1995, DNA CELL BIOL, V14, P37, DOI 10.1089/dna.1995.14.37; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; Wang D, 1997, BIOCHEMISTRY-US, V36, P8628, DOI 10.1021/bi970341y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	28	269	274	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30417	30420		10.1074/jbc.C200355200	http://dx.doi.org/10.1074/jbc.C200355200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12097317	hybrid			2022-12-27	WOS:000177579800003
J	Zschocke, J; Manthey, D; Bayatti, N; van der Burg, B; Goodenough, S; Behl, C				Zschocke, J; Manthey, D; Bayatti, N; van der Burg, B; Goodenough, S; Behl, C			Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HUMAN BREAST-CANCER; DNA-METHYLTRANSFERASE; DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; TYROSINE KINASE; PLASMA-MEMBRANE	Estrogen receptors (ERalpha/ERbeta) are expressed in neuronal cells and exhibit a variety of activities in the central nervous system. ER activity is regulated in a ligand-dependent manner and by co-regulatory factors. Caveolin-1 is a recently identified co-activator of ERalpha mediating the ligand-independent activation of this steroid receptor. Here the influence of ERs on caveolin expression in human neuroblastoma SK-N-MC cells as well as in rodent brain was investigated. We found that ectopic expression of ERalpha in SK-N-MC cells (SK-ERalpha) leads to a ligand-independent transcriptional suppression of caveolin-1/-2 genes. This suppression is specifically mediated by ERalpha and not ERbeta because ERbeta counteracts the observed caveolin-silencing process. Interestingly, decreased caveolin expression in SK-ERalpha is accompanied by changes in the methylation pattern of caveolin promoters. The analysis of selected promoter regions of the human caveolin-1 gene showed that certain CpG dinucleotides were hypermethylated in SK-ERalpha cells, whereas the same sites were unmethylated in control, ERbeta-, and ERalpha/beta co-expressing SK-N-MC cells. Inhibition of DNA methylation or histone deacetylation led to partial re-expression of caveolin-1/-2 genes in SK-ERalpha. In vivo analysis revealed a down-regulation of caveolin-1 expression after long term estrogen exposure in certain regions of the mouse brain. In conclusion, we have shown for the first time that ERalpha and not ERbeta silences caveolin-1/-2 expression in an epigenetic fashion in neuronal cells. The observed mechanism of gene silencing by ERalpha may have implications for the transcriptional regulation of further ERalpha target genes.	Max Planck Inst Psychiat, Neurodegenerat Grp, D-80804 Munich, Germany; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Max Planck Society; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Behl, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany.	chris@mpipsykl.mpg.de	Zschocke, Johannes/C-5885-2013	Zschocke, Johannes/0000-0002-0046-8274; Behl, Christian/0000-0001-8453-2378				Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Braun JEA, 2000, J NEUROSCI, V20, P5997, DOI 10.1523/JNEUROSCI.20-16-05997.2000; Cameron PL, 1997, J NEUROSCI, V17, P9520; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; DRYDEN GL, 1977, SCIENCE, V197, P782, DOI 10.1126/science.887921; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HERMAN JG, 1995, CANCER RES, V55, P4525; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Jayachandran M, 2001, AM J PHYSIOL-HEART C, V281, pH1327, DOI 10.1152/ajpheart.2001.281.3.H1327; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kamiya K, 1996, EXP CLIN ENDOCR DIAB, V104, P111, DOI 10.1055/s-0029-1211432; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McLachlan JA, 2001, TOXICOL LETT, V120, P161, DOI 10.1016/S0378-4274(01)00295-8; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Pelligrino DA, 2000, BIOCHEM BIOPH RES CO, V269, P165, DOI 10.1006/bbrc.2000.2206; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Turi A, 2001, CELL BIOL INT, V25, P785, DOI 10.1006/cbir.2001.0769; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	62	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38772	38780		10.1074/jbc.M205664200	http://dx.doi.org/10.1074/jbc.M205664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138116	hybrid			2022-12-27	WOS:000178529600097
J	Chen, FS; Gu, YJ; Hasegawa, H; Ruan, XY; Arawaka, S; Fraser, P; Westaway, D; Mount, H; St George-Hyslop, P				Chen, FS; Gu, YJ; Hasegawa, H; Ruan, XY; Arawaka, S; Fraser, P; Westaway, D; Mount, H; St George-Hyslop, P			Presenilin 1 mutations activate gamma(42)-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; CAENORHABDITIS-ELEGANS; INTRACELLULAR DOMAIN; TRANSMEMBRANE DOMAIN; PROTEOLYTIC RELEASE; BETA-PROTEIN; IN-VIVO; CELLS; MUTANT	The presenilin 1 (PS1) and presenilin 2 (PS2) proteins are necessary for proteolytic cleavage of the amyloid precursor protein (APP) within its transmembrane domain. One of these cleavage events (termed gamma-secretase) generates the C-terminal end of the Abeta-peptide by proteolysis near residue 710 or 712 of APP(770). Another event (termed gamma-like or E-secretase cleavage) cleaves near residue 721 at similar to2-5 residues inside the cytoplasmic membrane boundary to generate a series of stable, C-terminal APP fragments. This latter cleavage is analogous to S3-cleavage of Notch. We report here that specific mutations in the N terminus, loop, or C terminus of PS1 all increase the production of Abeta(42) but cause inhibition of both E-secretase cleavage of APP and S3-cleavage of Notch. These data support the hypothesis that epsilon-cleavage of APP and S3-cleavage of Notch are similar events. They also argue that, although both the gamma-site and the epsilon-site cleavage of APP are presenilin-dependent, they are likely to be independent catalytic events.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Hlth Network, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W,Tanz Neurosci Bldg, Toronto, ON M5S 3H2, Canada.		Mount, Howard/B-4097-2013; Fraser, Paul J. B./D-1755-2012	Arawaka, Shigeki/0000-0002-1505-3012				Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Okochi M, 2000, J BIOL CHEM, V275, P40925, DOI 10.1074/jbc.M005254200; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Rogaeva EA, 2001, NEUROLOGY, V57, P621, DOI 10.1212/WNL.57.4.621; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035	29	98	100	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36521	36526		10.1074/jbc.M205093200	http://dx.doi.org/10.1074/jbc.M205093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119298	hybrid			2022-12-27	WOS:000178275100094
J	Sagara, Y; Ishige, K; Tsai, C; Maher, P				Sagara, Y; Ishige, K; Tsai, C; Maher, P			Tyrphostins protect neuronal cells from oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITORS; GLUTAMATE TOXICITY; NEURODEGENERATIVE DISEASES; BUTHIONINE SULFOXIMINE; GLUTATHIONE SYNTHESIS; ANTIOXIDANT STATUS; POTENT INHIBITORS; FOREBRAIN NEURONS; EGF RECEPTOR; NERVE-CELLS	Tyrphostins are a family of tyrosine kinase inhibitors originally synthesized as potential anticarcinogenic compounds. Because tyrphostins have chemical structures similar to those of the phenolic antioxidants, we decided to test the protective efficacy of tyrphostins against oxidative stress-induced nerve cell death (oxytosis). Many commercially available tyrphostins, at concentrations ranging from 0.5 to 200 muM, protect both HT-22 hippocampal cells and rat primary neurons from oxytosis brought about by treatment with glutamate, as well as by treatment with homocysteic acid and buthionine sulfoximine. The tyrphostins protect nerve cells by three distinct mechanisms. Some tyrphostins, such as A25, act as antioxidants and eliminate the reactive oxygen species that accumulate as a result of glutamate treatment. These tyrphostins also protect cells from hydrogen peroxide and act as antioxidants in an in vitro assay. In contrast, tyrphostins A9 and AG126 act as mitochondrial uncouplers, collapsing the mitochondrial membrane potential and thereby reducing the generation of reactive oxygen species from mitochondria during glutamate toxicity. Finally, the third group of tyrphostins does not appear to be effective as antioxidants but rather protects cells by increasing the basal level of cellular glutathione. Therefore, the effects of tyrphostins on cells are not limited to their ability to inhibit tyrosine kinases.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Nihon Univ, Coll Pharm, Dept Pharmacol, Funabashi, Chiba 2748555, Japan; Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Nihon University; Scripps Research Institute	Sagara, Y (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, MTF345,9500 Gilman Dr, La Jolla, CA 92093 USA.	ysagara@ucsd.edu			NIA NIH HHS [AG01029] Funding Source: Medline; NINDS NIH HHS [NS28212] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe K, 1996, J NEUROCHEM, V67, P2074; Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Andreis PG, 2000, ENDOCR RES, V26, P319, DOI 10.3109/07435800009066170; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; BASS DA, 1983, J IMMUNOL, V130, P1910; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Bomzon A, 2001, PHARMACOL THERAPEUT, V89, P295, DOI 10.1016/S0163-7258(01)00129-2; BURGER AM, 1995, CANCER RES, V55, P2794; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Duffy S, 1998, J NEUROCHEM, V71, P69; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; KUMAR N, 1995, PHARMACEUT RES, V12, P1708, DOI 10.1023/A:1016213721861; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Maher P, 1996, J NEUROSCI, V16, P6394; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; Marhaba R, 1996, J IMMUNOL, V157, P1468; Mari M, 2002, FREE RADICAL BIO MED, V32, P73, DOI 10.1016/S0891-5849(01)00759-6; MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407; Mollace V, 2001, TRENDS NEUROSCI, V24, P411, DOI 10.1016/S0166-2236(00)01819-1; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nichols MR, 1999, ARCH BIOCHEM BIOPHYS, V366, P224, DOI 10.1006/abbi.1999.1200; Pratico D, 2001, TRENDS CARDIOVAS MED, V11, P112, DOI 10.1016/S1050-1738(01)00099-8; RAMDAS L, 1994, CANCER RES, V54, P867; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; Sagara Y, 1999, J NEUROCHEM, V73, P2524, DOI 10.1046/j.1471-4159.1999.0732524.x; Sagara Y, 1998, J NEUROCHEM, V71, P1002, DOI 10.1046/j.1471-4159.1998.71031002.x; Sagara Y, 1998, J NEUROSCI, V18, P6662; Sagara Y, 1998, FREE RADICAL BIO MED, V24, P1375, DOI 10.1016/S0891-5849(97)00457-7; Sagara Y, 1996, J NEUROSCI, V16, P497; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Seyfried J, 1999, NEUROSCI LETT, V264, P1, DOI 10.1016/S0304-3940(99)00107-X; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YONEDA T, 1991, CANCER RES, V51, P4430	68	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36204	36215		10.1074/jbc.M203895200	http://dx.doi.org/10.1074/jbc.M203895200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121989	hybrid			2022-12-27	WOS:000178275100056
J	Ding, L; Wang, HM; Lang, WH; Xiao, L				Ding, L; Wang, HM; Lang, WH; Xiao, L			Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-EPSILON; CARCINOMA; ACTIVATION; DELTA; PHOSPHORYLATION; DEATH; OVEREXPRESSION; TRANSFORMATION; EXPRESSION; ALPHA	The serine/threonine protein kinase C (PKC) has been implicated in the regulation of drug resistance and cell survival in many types of cancer cells. However, the one or more precise mechanisms remain elusive. In this study, we have identified and determined the mechanism by which PKC-epsilon, a novel PKC isoform, modulates drug resistance in lung cancer cells. Western blot analysis demonstrates that expression of PKC-epsilon, but not other PKC isoforms, is associated with the chemo-resistant phenotype of non-small cell lung cancer (NSCLC) cell lines. Northern blotting and nuclear run-on transcription analysis further reveals that the failure of expression of PKC-epsilon in the chemo-sensitive phenotype of small cell lung cancer (SCLC) cells results from transcriptional inactivation of the gene. Importantly, forced expression of PKC-epsilon in NCI-H82 human SCLC cells confers a significant resistance to the chemotherapeutic drugs, etoposide and doxorubicin. Resistance is characterized by a significant reduction in apoptosis in PKC-epsilon-expressing cells. Treatment of NCI-H82 cells with etoposide induces a series of time-dependent events, including the release of cytochrome c from the mitochondria to the cytosol, activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase (PARP). All of these events are blocked by PKC-epsilon expression. Furthermore, caspase-specific inhibitors, z-VAD-fink and z-DEVD-fmk, significantly attenuate the accumulation of sub-G(1) population and block the PARP cleavage in response to etoposide. These results suggest that PKC-epsilon prevents cells from undergoing apoptosis through inhibition of the mitochondrial-dependent caspase activation, thereby leading to cell survival. Finally, down-regulation of PKC-epsilon expression by the antisense cDNA in NSCLC cells results in increased sensitivity to etoposide. Taken together, our findings suggest an important role for PKC-epsilon in regulating survival of lung cancer cells.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Xiao, L (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd,POB 100232, Gainesville, FL 32610 USA.	lxiao@ufl.edu			NCI NIH HHS [R01-CA88815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELOFF MD, 1979, AM J MED, V66, P757, DOI 10.1016/0002-9343(79)91113-6; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Baines CP, 2001, CIRCULATION, V104, P102; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; BASU A, 1995, INT J CANCER, V63, P597, DOI 10.1002/ijc.2910630422; BASU A, 1995, INT J CANCER, V62, P457, DOI 10.1002/ijc.2910620416; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cacace AM, 1996, ONCOGENE, V13, P2517; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Facchini FM, 1999, LUNG BIOL HEALTH DIS, V124, P611; Flescher E, 2002, CELL SIGNAL, V14, P37, DOI 10.1016/S0898-6568(01)00215-7; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohnuma Y, 2002, AM J PHYSIOL-HEART C, V283, pH440, DOI 10.1152/ajpheart.00434.2001; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Soues S, 2001, CANCER CHEMOTH PHARM, V47, P133, DOI 10.1007/s002800000227; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VOLM M, 1995, ANTICANCER RES, V15, P463; Wang J, 2000, J CELL SCI, V113, P753; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Wu DQ, 2002, CANCER RES, V62, P2423; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiao L, 2000, CANCER RES, V60, P400; Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691	44	89	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35305	35313		10.1074/jbc.M201460200	http://dx.doi.org/10.1074/jbc.M201460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121973	hybrid			2022-12-27	WOS:000178117000084
J	Linden, HM; Kaushansky, K				Linden, HM; Kaushansky, K			The glycan domain of thrombopoietin (TPO) acts in trans to enhance secretion of the hormone and other cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOPOIETIN; HEMATOPOIETIC STEM-CELLS; COLONY-STIMULATING FACTOR; PROTEASE PRO-REGION; C-TERMINAL REGION; MEGAKARYOCYTE GROWTH; MPL-LIGAND; ENDOPLASMIC-RETICULUM; IN-VITRO; TYROSINE PHOSPHORYLATION	Thrombopoietin (TPO), the primary regulator of platelet production, is composed of an amino-terminal 152 amino acids, sufficient for activity, and a carboxyl-terminal region rich in carbohydrates (183 residues) that enhances secretion of the molecule. Full-length TPO is secreted at levels 10-20-fold greater than truncated TPO. By introducing into mammalian cells a novel cDNA encoding the TPO secretory leader linked to its carboxyl-terminal domain (TPO glycan domain (TGD)), we tested whether TGD could function in trans to enhance secretion of TPO. The artificial TGD was secreted, inactive in proliferation assays, and did not inhibit TPO activity. However, when co-transfected with a cDNA encoding truncated TPO, TGD enhanced secretion 4-fold, measured by specific bioassay and immunoassay. TGD also enhanced secretion of granulocyte monocyte colony-stimulating factor and stem cell factor but did not affect the production of erythropoietin, interleukin-3, growth hormone, or of full-length TPO. To localize TGD function, we added an endoplasmic reticulum (ER) retention signal to TGD and, separately, deleted the secretory leader. Deletion of the secretory leader attenuated the secretory function of TGD, whereas addition of the ER retention signal did not alter its function. To investigate the physiologic role of TGD in folding and proteasomal protection, we tested full-length and truncated TPO in assays of protein refolding, and we examined protein stability in the presence of proteasome inhibitors. We found that truncated TGD re-folds readily and that proteasome-mediated degradation contributes to the poor secretion of truncated TPO. We conclude that TGD enhances secretion of TPO and can additionally function as an inter-molecular chaperone, in part because of its ability to prevent degradation of the hormone. The cellular location of TGD action is likely to be within the ER or earlier in the secretory pathway.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Calif San Diego, Med Ctr, 402 Dickinson St,Ste 380, San Diego, CA 92103 USA.				NCI NIH HHS [R01CA31615] Funding Source: Medline; NIDDK NIH HHS [R01DK49855, K08DK02665-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002665, R01DK049855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn HK, 1999, BIOCHEM MOL BIOL INT, V47, P729; Akahori H, 1996, BRIT J HAEMATOL, V94, P722, DOI 10.1046/j.1365-2141.1996.d01-1842.x; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Baier K, 1996, EUR J BIOCHEM, V241, P750, DOI 10.1111/j.1432-1033.1996.00750.x; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Basser RL, 2000, J CLIN ONCOL, V18, P2852, DOI 10.1200/JCO.2000.18.15.2852; Beer HD, 1996, BIOCHEM J, V319, P351, DOI 10.1042/bj3190351; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; DEBILI N, 1995, BLOOD, V86, P2516; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hamburger JB, 1998, PROTEINS, V32, P495, DOI 10.1002/(SICI)1097-0134(19980901)32:4<495::AID-PROT7>3.3.CO;2-2; Haynes RL, 1997, J BIOL CHEM, V272, P17126, DOI 10.1074/jbc.272.27.17126; Hoffman RC, 1996, BIOCHEMISTRY-US, V35, P14849, DOI 10.1021/bi961075b; HUNT P, 1995, BLOOD, V86, P540, DOI 10.1182/blood.V86.2.540.bloodjournal862540; JOURNET AM, 1993, THROMB HAEMOSTASIS, V70, P1053; JOURNET AM, 1993, EUR J CELL BIOL, V60, P31; Kato T, 1997, P NATL ACAD SCI USA, V94, P4669, DOI 10.1073/pnas.94.9.4669; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kaushansky K, 1998, NEW ENGL J MED, V339, P746, DOI 10.1056/NEJM199809103391107; KAUSHANSKY K, 1987, BIOCHEMISTRY-US, V26, P4861, DOI 10.1021/bi00389a038; KAUSHANSKY K, 1995, J CLIN INVEST, V96, P1683, DOI 10.1172/JCI118210; Kaushansky K, 1996, EXP HEMATOL, V24, P265; Kobayashi M, 1996, BLOOD, V88, P429, DOI 10.1182/blood.V88.2.429.bloodjournal882429; LEE YC, 1992, FEMS MICROBIOL LETT, V92, P73, DOI 10.1016/0378-1097(92)90544-X; Linden HM, 2000, BIOCHEMISTRY-US, V39, P3044, DOI 10.1021/bi991756h; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Matous JV, 1996, BLOOD, V88, P437, DOI 10.1182/blood.V88.2.437.bloodjournal882437; MCCARTY JM, 1995, BLOOD, V86, P3668, DOI 10.1182/blood.V86.10.3668.bloodjournal86103668; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Muto T, 2000, J BIOL CHEM, V275, P12090, DOI 10.1074/jbc.275.16.12090; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; Piacibello W, 1997, BLOOD, V89, P2644, DOI 10.1182/blood.V89.8.2644; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Somlo G, 1999, BLOOD, V93, P2798; Tahara T, 1998, STEM CELLS, V16, P54, DOI 10.1002/stem.160054; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; VALORE EV, 1992, BLOOD, V79, P1538; VALVERDE V, 1995, J BIOL CHEM, V270, P15821, DOI 10.1074/jbc.270.26.15821; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; Wang Q, 2000, BLOOD, V96, P2093; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; ZEIGLER FC, 1994, BLOOD, V84, P4045, DOI 10.1182/blood.V84.12.4045.bloodjournal84124045; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	60	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35240	35247		10.1074/jbc.M201297200	http://dx.doi.org/10.1074/jbc.M201297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12101178	hybrid			2022-12-27	WOS:000178117000075
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			Copper, zinc superoxide dismutase and H2O2 - Effects of bicarbonate on inactivation and oxidations of NADPH and urate, and on consumption of H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NO	Copper,zinc superoxide dismutase (Cu,Zn-SOD) catalyzes the HCO3--dependent oxidation of diverse substrates. The mechanism of these oxidations involves the generation of a strong oxidant, derived from H2O2, at the active site copper. This bound oxidant then oxidizes HCO3- to a strong and diffusible oxidant, presumably the carbonate anion radical that leaves the active site and then oxidizes the diverse substrates. Cu,Zn-SOD is also subject to inactivation by H2O2. It is now demonstrated that the rates of HCO3--dependent oxidations of NADPH and urate exceed the rate of inactivation of the enzyme by similar to100-fold. Cu,Zn-SOD is also seen to catalyze a HCO3-. dependent consumption of the H2O2 and that HCO3- does not protect Cu,Zn-SOD against inactivation by H2O2. A scheme of reactions is offered in explanation of these observations.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	fridovich@biochem.duke.edu			NIDDK NIH HHS [R01 DK 59868] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059868] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CABELLI DE, 1989, J BIOL CHEM, V264, P9967; CABELLI DE, 1986, CHEM BIOL MED, P181; EVERETT AJ, 1953, T FARADAY SOC, V49, P410, DOI 10.1039/tf9534900410; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; HICKS M, 1993, FREE RADICAL RES COM, V18, P337, DOI 10.3109/10715769309147501; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Jewett SL, 2000, BIOCHEM BIOPH RES CO, V274, P57, DOI 10.1006/bbrc.2000.3092; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 2002, ARCH BIOCHEM BIOPHYS, V402, P166, DOI 10.1016/S0003-9861(02)00074-7; Liochev SI, 2001, J BIOL CHEM, V276, P35253, DOI 10.1074/jbc.M104237200; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; YIM MB, 1993, J BIOL CHEM, V268, P4099	16	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34674	34678		10.1074/jbc.M204726200	http://dx.doi.org/10.1074/jbc.M204726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107177	hybrid			2022-12-27	WOS:000178117000005
J	Persson, KEM; Villoutreix, BO; Thamlitz, AM; Knobe, KE; Stenflo, J				Persson, KEM; Villoutreix, BO; Thamlitz, AM; Knobe, KE; Stenflo, J			The N-terminal epidermal growth factor-like domain of coagulation factor IX - Probing its functions in the activation of factor IX and factor X with a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; DEPENDENT PROTEIN-S; VIIA TISSUE FACTOR; CALCIUM-BINDING; HEMOPHILIA-B; FACTOR-XIA; ENZYME-ACTIVITY; LIGHT-CHAIN; MODULE; SITE	The absence or reduced activity of coagulation factor IX (FIX) causes the severe bleeding disorder hemophilia B. FIX contains an N-terminal Gla domain followed by two epidermal growth factor-like (EGF) domains and a serine protease domain. In this study, the epitope of monoclonal antibody AW, which is directed against the C-terminal part of the first EGF domain in human FIX, was defined, and the antibody was used to study interactions between the EGF domain of FIX and other coagulation proteins. Antibody AW completely blocks activation of FIX by activated factor XI, but activation by activated factor FVII-tissue factor is inhibited only slightly. The antibody also causes a marginal reduction in the apparent k(cat) for factor X both in the presence and absence of activated factor VIII. Based on these results, we produced a preliminary model of the structure of the activated factor IX-activated factor VIII-AW complex on the surface of phospholipid. The model suggests that in the Xase complex, EGF1 of activated factor IX is not involved in direct binding to activated factor VIII. Studies of the interaction of antibody AW with a mutated FIX molecule (R94D) also suggest that the Glu(78)-Arg(94) salt bridge is not important for maintaining the structure of FIX.	Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Lund Univ, Univ Hosp, Dept Pediat, S-20502 Malmo, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Stenflo, J (corresponding author), Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015	Villoutreix, Bruno/0000-0002-6456-7730; Persson, Kristina E M/0000-0003-2661-3115				ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BYRNE R, 1980, J BIOL CHEM, V255, P5336; Celie PHN, 2000, J BIOL CHEM, V275, P229, DOI 10.1074/jbc.275.1.229; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; HAMAGUCHI N, 1994, THROMB HAEMOSTASIS, V72, P856; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hertzberg MS, 1999, BLOOD, V94, P156, DOI 10.1182/blood.V94.1.156.413k15_156_163; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; Kamata K, 1998, P NATL ACAD SCI USA, V95, P6630, DOI 10.1073/pnas.95.12.6630; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Leonard BJN, 2000, J BIOL CHEM, V275, P34894, DOI 10.1074/jbc.M001166200; LIN SW, 1990, J BIOL CHEM, V265, P144; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOZIER JN, 1990, BLOOD, V75, P1097; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OLSEN ENH, 2001, THROMB HAEMOSTASIS S, V86; PARHAM P, 1986, CELLULAR IMMUNOLOGY; Perera L, 2001, THROMB HAEMOSTASIS, V85, P596, DOI 10.1055/s-0037-1615639; Persson KEM, 2001, BIOCHEM BIOPH RES CO, V286, P1039, DOI 10.1006/bbrc.2001.5398; Persson KEM, 1998, FEBS LETT, V421, P100, DOI 10.1016/S0014-5793(97)01546-9; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Stenberg Y, 1998, EUR J BIOCHEM, V251, P558, DOI 10.1046/j.1432-1327.1998.2510558.x; Stenberg Y, 1997, EUR J BIOCHEM, V248, P163, DOI 10.1111/j.1432-1033.1997.t01-1-00163.x; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WALLMARK A, 1985, P NATL ACAD SCI USA, V82, P3839, DOI 10.1073/pnas.82.11.3839; Wilkinson FH, 2002, J BIOL CHEM, V277, P5725, DOI 10.1074/jbc.M107027200; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574; Zhong DG, 2002, J BIOL CHEM, V277, P3622, DOI 10.1074/jbc.M111202200	44	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35616	35624		10.1074/jbc.M205930200	http://dx.doi.org/10.1074/jbc.M205930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105230	hybrid			2022-12-27	WOS:000178117000121
J	Pioli, PA; Hamilton, BJ; Connolly, JE; Brewer, G; Rigby, WFC				Pioli, PA; Hamilton, BJ; Connolly, JE; Brewer, G; Rigby, WFC			Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; NUCLEAR RIBONUCLEOPROTEIN A1; IN-VIVO; HNRNP-D; GENE-EXPRESSION; GROWTH-FACTOR; SUBUNIT GENE; C-PROTEINS; IDENTIFICATION; DEGRADATION	Post-transcriptional pathways provide a major means of regulating eukaryotic gene expression. Reiterations of the AU-rich element (ARE) within the 3'-untranslated region of many cytokine and proto-oncogene mRNAs serve as signals for rapid degradation and translational repression. The identification of this cis-acting stability determinant has fueled the search for ARE-binding proteins (AUBP) that function as trans-acting factors that transduce this function. Previous work identified heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as a major AUBP capable of binding the ARE of granulocyte-macrophage colony stimulating factor (GM-CSF) RNA in the context of a full-length mRNA. We report here that functional studies failed to indicate a role for hnRNP A1 in ARE-dependent mRNA turnover. In an effort to identify other functionally relevant AUBP, the major GMCSF ARE-specific binding protein in cells lacking hnRNP A1 was purified from CB3 mouse erythroleukemia cells. Microsequencing identified this protein as the glycolytic enzyme lactate dehydrogenase (LDH) M. RNA binding by LDH was shown to occur in the NAD(+)-binding region (Rossmann fold). Polysome gradient analysis demonstrates that LDH is found in the translationally active fraction. Polysomal localization of LDH was dependent on RNA binding. Moreover, polysomal LDH exists in a complex with AUF1 and hsp-70, which has been implicated previously in the regulation of mRNA turnover. The interaction between LDH and AUF1 is direct as it can be demonstrated in vitro with purified proteins. Collectively these data implicate a role for LDH in the post-transcriptional regulation of gene expression.	Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Microbiol, Lebanon, NH 03756 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Dartmouth College; Dartmouth College; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rigby, WFC (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA.		Connolly, John/B-8099-2014		NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52443] Funding Source: Medline; PHS HHS [R01 A134928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CHUNG KC, 1995, MOL CELL BIOL, V15, P6139; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gao FB, 1996, J CELL SCI, V109, P579; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hamilton BJ, 1999, BIOCHEM BIOPH RES CO, V261, P646, DOI 10.1006/bbrc.1999.1040; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; HENICS T, 1994, J BIOL CHEM, V269, P5377; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HENTZE MW, 1991, CURR STUD HEMATOL BL, V58, P115; HUANG D, 1995, MOL CELL ENDOCRINOL, V108, P87, DOI 10.1016/0303-7207(94)03459-7; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY A, 1976, CLIN CHEM, V22, P1723; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P244; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; Micheli V, 1997, METHOD ENZYMOL, V280, P211; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; OFARRELL HK, 1977, CLIN CHEM, V23, P1853; ROSSMANN RG, 1975, ENZYMES, P62; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Zhang QH, 2002, SCIENCE, V295, P1895	44	68	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35738	35745		10.1074/jbc.M204002200	http://dx.doi.org/10.1074/jbc.M204002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107167	hybrid			2022-12-27	WOS:000178117000136
J	Thongboonkerd, V; Gozal, E; Sachleben, LR; Arthur, JM; Pierce, WM; Cai, J; Chao, J; Bader, M; Pesquero, JB; Gozal, D; Klein, JB				Thongboonkerd, V; Gozal, E; Sachleben, LR; Arthur, JM; Pierce, WM; Cai, J; Chao, J; Bader, M; Pesquero, JB; Gozal, D; Klein, JB			Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBSTRUCTIVE SLEEP-APNEA; HUMAN TISSUE KALLIKREIN; REDUCES BLOOD-PRESSURE; CHRONIC EPISODIC HYPOXIA; INTERMITTENT HYPOXIA; BINDING PROTEIN; GENOMIC CONSEQUENCES; VASCULAR REACTIVITY; NITRIC-OXIDE; RATS	Obstructive sleep apnea syndrome (OSAS), a disorder characterized by episodic hypoxia (EH) during sleep, is associated with systemic hypertension. We used proteomic analysis to examine differences in rat kidney protein expression during EH, and their potential relationship to EH-induced hypertension. Young male Sprague-Dawley rats were exposed to either EH or sustained hypoxia (SH) for 14 (EH14/SH14) and 30 (EH30/SH30) days. Mean arterial blood pressure was significantly increased only in EH30 (p < 0.0002). Kidney proteins were resolved by two-dimensional-PAGE and were identified by MALDI-MS. Renal expression of kallistatin, a potent vasodilator, was down-regulated in all animals. Expression of &alpha;-1-antitrypsin, an inhibitor of kallikrein activation, was up-regulated in EH but down-regulated in SH. Western blotting showed significant elevation of B-2-bradykinin receptor expression in all normotensive animals but remained unchanged in hypertensive animals. Proteins relevant to vascular hypertrophy, such as smooth muscle myosin and protein-disulfide isomerase were up-regulated in EH30 but were down-regulated in SH30. These data indicate that EH induces changes in renal protein expression consistent with impairment of vasodilation mediated by the kallikrein-kallistatin pathway and vascular hypertrophy. In contrast, SH-induced changes suggest the kallikrein- and bradykinin-mediated compensatory mechanisms for prevention of hypertension and vascular remodeling. To test the hypothesis suggested by the proteomic data, we measured the effect of EH on blood pressure in transgenic hKLK1 rats that overexpress human kallikrein. Transgenic hKLK1 animals were protected from EH-induced hypertension. We conclude that EH-induced hypertension may result, at least in part, from altered regulation of the renal kallikrein system.	Univ Louisville, Kidney Dis Program, Core Proteom Lab, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Dept Pediat, Kosair Childrens Hosp Res Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Max Delbruck Ctr Mol Med, Berlin, Germany; Escola Paulista Med, Dept Biophys, Sao Paulo, Brazil; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Vet Adm Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP); Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Thongboonkerd, V (corresponding author), Univ Louisville, Kidney Dis Program, Core Proteom Lab, Dept Med, 570 S Preston St, Louisville, KY 40202 USA.		Bader, Michael/K-2124-2013; Klein, Jon/B-9833-2013; Thongboonkerd, Visith/C-6920-2009; Gozal, David/M-9492-2017; Pesquero, Joao/C-1470-2012; Gozal, David/ABH-3805-2020	Thongboonkerd, Visith/0000-0001-7865-0765; Pesquero, Joao/0000-0002-4507-632X; Bader, Michael/0000-0003-4780-4164; Arthur, John/0000-0003-4342-4762	NCRR NIH HHS [RR15576] Funding Source: Medline; NHLBI NIH HHS [HL66358, HL65270, HL63912] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015576] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063912, R01HL065270, R01HL066358] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO J, 1990, J BIOL CHEM, V265, P16394; Chao J, 1992, Agents Actions Suppl, V38 ( Pt 1), P174; Chao JL, 1997, J CLIN INVEST, V100, P11, DOI 10.1172/JCI119502; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; Chen LM, 1997, HUM GENE THER, V8, P341, DOI 10.1089/hum.1997.8.3-341; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; Chen LM, 1996, J BIOL CHEM, V271, P27590, DOI 10.1074/jbc.271.44.27590; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Duchna HW, 2000, AM J RESP CRIT CARE, V161, P187, DOI 10.1164/ajrccm.161.1.9810062; Fletcher EC, 1999, HYPERTENSION, V34, P309, DOI 10.1161/01.HYP.34.2.309; Fletcher EC, 2001, J APPL PHYSIOL, V90, P1600, DOI 10.1152/jappl.2001.90.4.1600; FLETCHER EC, 1995, J SLEEP RES, V4, P71, DOI 10.1111/j.1365-2869.1995.tb00191.x; GISLASON T, 1995, CHEST, V107, P963, DOI 10.1378/chest.107.4.963; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; Gozal D, 1996, J APPL PHYSIOL, V81, P2068, DOI 10.1152/jappl.1996.81.5.2068; Grote L, 2000, J HYPERTENS, V18, P679, DOI 10.1097/00004872-200018060-00004; HALLETT M, 1995, ASAIO J, V41, pM435, DOI 10.1097/00002480-199507000-00047; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Ishii T, 2001, ATHEROSCLEROSIS, V158, P215, DOI 10.1016/S0021-9150(01)00416-6; Kanagy NL, 2001, HYPERTENSION, V37, P511, DOI 10.1161/01.HYP.37.2.511; Kato M, 2000, CIRCULATION, V102, P2607; KENT BB, 1972, CARDIOLOGY, V57, P295, DOI 10.1159/000169528; Madeddu P, 1987, Agents Actions Suppl, V22, P373; Marcus CL, 1998, AM J RESP CRIT CARE, V157, P1098, DOI 10.1164/ajrccm.157.4.9704080; Matsuda R, 2000, CLIN CHIM ACTA, V298, P29, DOI 10.1016/S0009-8981(00)00218-7; Mizutani T, 1998, MECH AGEING DEV, V105, P151, DOI 10.1016/S0047-6374(98)00094-3; Nation BR, 1996, BRIT J BIOMED SCI, V53, P247; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Partinen M, 1995, Curr Opin Pulm Med, V1, P482, DOI 10.1097/00063198-199511000-00009; Patterson SD, 2000, PHYSIOL GENOMICS, V2, P59, DOI 10.1152/physiolgenomics.2000.2.2.59; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; Redline S, 1999, OTOLARYNG CLIN N AM, V32, P303, DOI 10.1016/S0030-6665(05)70132-8; Redline Susan, 1993, Ear Nose and Throat Journal, V72, P20; Remsburg S, 1999, J APPL PHYSIOL, V87, P1148, DOI 10.1152/jappl.1999.87.3.1148; Remy-Martin JP, 1999, EXP HEMATOL, V27, P1782, DOI 10.1016/S0301-472X(99)00122-8; Schweda F, 2000, NEPHROL DIAL TRANSPL, V15, P11, DOI 10.1093/ndt/15.1.11; Sica AL, 2000, RESP PHYSIOL, V121, P173, DOI 10.1016/S0034-5687(00)00126-2; Silva JA, 2000, FASEB J, V14, P1858; Tahawi Z, 2001, J APPL PHYSIOL, V90, P2007, DOI 10.1152/jappl.2001.90.5.2007; Thongboonkerd V, 2002, J BIOL CHEM, V277, P16599, DOI 10.1074/jbc.M200746200; Tsuchida S, 1999, KIDNEY INT, V56, P509, DOI 10.1046/j.1523-1755.1999.00574.x; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; WANG C, 1995, J CLIN INVEST, V95, P1710, DOI 10.1172/JCI117847; Worsnop CJ, 1998, AM J RESP CRIT CARE, V157, P111, DOI 10.1164/ajrccm.157.1.9609063; Yoneyama T, 1998, VIRCHOWS ARCH, V433, P549, DOI 10.1007/s004280050288; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	51	65	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34708	34716		10.1074/jbc.M203799200	http://dx.doi.org/10.1074/jbc.M203799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121987	hybrid			2022-12-27	WOS:000178117000009
J	Aggeler, R; Coons, J; Taylor, SW; Ghosh, SS; Garcia, JJ; Capaldi, RA; Marusich, MF				Aggeler, R; Coons, J; Taylor, SW; Ghosh, SS; Garcia, JJ; Capaldi, RA; Marusich, MF			A functionally active human F1F0 ATPase can be purified by immunocapture from heart tissue and fibroblast cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA MUTATIONS; INHIBITOR PROTEIN; COMPLEX-I; SYNTHASE; SUBUNIT; PURIFICATION; DISEASE; MTDNA; F1F0-ATPASE; F1-ATPASE	Human mitochondrial F1F0 ATP synthase was isolated with a one-step immunological approach, using a monoclonal antibody against F-1 in a 96-well microplate activity assay system, to establish a method for fast high throughput screening of inhibitors, toxins, and drugs with very small amounts of enzyme. For preparative purification, mitochondria from human heart tissue as well as cultured fibroblasts were solubilized with dodecyl-beta-D-maltoside, and the F1F0 was isolated with anti-F-1 monoclonal antibody coupled to protein G-agarose beads. The immunoprecipitated F1F0 contained a full complement of subunits that were identified with specific antibodies against five of the subunits (alpha, beta, OSCP, d, and IF1) and by MALDI-TOF and/or LC/MS/MS for all subunits except subunit c, which could not be resolved by these methods because of the limits of detection. Microscale immunocapture of F1F0 from detergent-solubilized mitochondria or whole cell fibroblast extracts was performed using anti-F-1 monoclonal antibody immobilized on 96-well microplates. The captured complex V displayed ATP hydrolysis activity that was fully oligomycin and inhibitor protein IF1-sensitive. Moreover, IF1 could be co-isolated with F1F0 when the immunocapture procedure was carried out at pH 6.5 but was absent when the ATP synthase was isolated at pH 8.0. Immunocaptured F1F0 lacking IF1 could be inhibited by more than 90% by addition of recombinant inhibitor protein, and conversely, F1F0 containing IF1 could be activated more than 10-fold by brief exposure to pH 8.0, inducing the release of inhibitor protein. With this microplate system an ATP hydrolysis assay of complex V could be carried out with as little as 10 ng of heart mitochondria/well and as few as 3 X 10(4) cells/well from fibroblast cultures. The system is therefore suitable to screen patient-derived samples for alterations in amount or functionality of both the F1F0 ATPase and IF1.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; MitoKor, San Diego, CA 92121 USA; Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico	University of Oregon; National Institute of Cardiology - Mexico	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.		Hu, Ruogu/B-2203-2008; Marusich, Michael/AAQ-3447-2020		NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Berggren K, 2000, ELECTROPHORESIS, V21, P2509, DOI 10.1002/1522-2683(20000701)21:12<2509::AID-ELPS2509>3.3.CO;2-0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Green DW, 2000, BBA-BIOENERGETICS, V1458, P343, DOI 10.1016/S0005-2728(00)00085-2; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; Ko YH, 2002, MITOCHONDRION, V1, P339, DOI 10.1016/S1567-7249(01)00036-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZMEDIAVILLA C, 1993, EUR J BIOCHEM, V215, P487, DOI 10.1111/j.1432-1033.1993.tb18058.x; LUTTER R, 1993, BIOCHEM J, V295, P799, DOI 10.1042/bj2950799; MARUSICH MF, 1988, J IMMUNOL METHODS, V114, P155, DOI 10.1016/0022-1759(88)90167-6; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MCGEOCH JE, 2001, EUR J PEDIAT NEURO A, V5, P1447; Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; ROUSLIN W, 1991, J BIOENERG BIOMEMBR, V23, P873, DOI 10.1007/BF00786006; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200; vanRaaij MJ, 1996, BIOCHEMISTRY-US, V35, P15618, DOI 10.1021/bi960628f; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Walker JE, 1995, METHOD ENZYMOL, V260, P163, DOI 10.1016/0076-6879(95)60136-8; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; YAMADA EW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P143, DOI 10.1016/0925-4439(92)90093-3; ZHANG FX, 1995, J NEUROCHEM, V65, P2812; ZIEGLER M, 1993, J BIOL CHEM, V268, P25320	42	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33906	33912		10.1074/jbc.M204538200	http://dx.doi.org/10.1074/jbc.M204538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110673				2022-12-27	WOS:000177959100052
J	Bjorkholm, BM; Guruge, JL; Oh, JD; Syder, AJ; Salama, N; Guillemin, K; Falkow, S; Nilsson, C; Falk, PG; Engstrand, L; Gordon, JI				Bjorkholm, BM; Guruge, JL; Oh, JD; Syder, AJ; Salama, N; Guillemin, K; Falkow, S; Nilsson, C; Falk, PG; Engstrand, L; Gordon, JI			Colonization of germ-free transgenic mice with genotyped Helicobacter pylori strains from a case-control study of gastric cancer reveals a correlation between host responses and HsdS components of type I restriction-modification systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; INFECTION; MICROARRAY; ADENOCARCINOMA; IDENTIFICATION; VIRULENCE; DIVERSITY; RISK	Helicobacter pylori infects the stomachs of half of all humans. It has a relatively benign relationship with most hosts but produces severe pathology, including gastric cancer, in others. Identifying the relative contributions of host, microbial, and environmental factors to the outcome of infection has been challenging. Here we describe one approach for identifying microbial genes that affect the magnitude of host responses to infection. Single colony purified H. pylori isolates were obtained from 25 cases and 71 controls in a Swedish case-control study of gastric cancer. Strains were first phenotyped based on their ability to produce adhesins that recognize two classes of human gastric epithelial receptors. Thirteen binding strains and two non-binding controls were then subjected to whole genome genotyping using H. pylori DNA microarrays. A cohort of "variable" genes was identified based on a microarray-determined call of "absent" in at least one member of the strain panel. Each strain was subsequently introduced into two types of germ-free transgenic mice, each programmed to express a different host factor postulated to pose increased risk for development of severe pathology. Expression of biomarkers of host defense was quantitated 4 weeks after inoculation, and the magnitude of the response correlated with bacterial genotype. The proportion of genes encoding HsdS homologs (specificity subunit of heterooligomeric type I restriction-modification systems) was significantly higher in the pool of 18 variable genes whose presence directly correlated with a robust host response than their proportion in the remaining 352 members of the variable gene pool. This suggests that the functions of these HsdS homologs may include control of expression of microbial determinants that affect the extent of gastric responses to this potentially virulent pathogen.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Karolinska Inst, Dept Med, S-17177 Stockholm, Sweden; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Swedish Inst Infect Dis Control, S-17182 Solna, Sweden; AstraZeneca Res & Dev, S-43183 Molndal, Sweden	Washington University (WUSTL); Karolinska Institutet; Stanford University; Swedish Institute for Infectious Disease Control; AstraZeneca	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.		Salama, Nina Reda/AAG-2437-2019	Salama, Nina Reda/0000-0003-2762-1424; Guillemin, Karen/0000-0001-6004-9955	NIDDK NIH HHS [DK 58529] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058529] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alm RA, 1999, J MOL MED, V77, P834, DOI 10.1007/s001099900067; Ang S, 2001, INFECT IMMUN, V69, P1679, DOI 10.1128/IAI.69.3.1679-1686.2001; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Azuma T, 1998, CANCER, V82, P1013, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1013::AID-CNCR2>3.0.CO;2-F; Bijlsma JJE, 2000, J INFECT DIS, V182, P1566, DOI 10.1086/315855; Bjorkholm B, 2001, INFECT IMMUN, V69, P7832, DOI 10.1128/IAI.69.12.7832-7838.2001; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Kaetzel CS, 2001, CURR BIOL, V11, pR35, DOI 10.1016/S0960-9822(00)00041-5; Lee JE, 1996, GASTROENTEROLOGY, V111, P426, DOI 10.1053/gast.1996.v111.pm8690208; MITCHELL H, 2001, HOLICOBACTER PYLORI, V1, P7; Murray NE, 2000, MICROBIOL MOL BIOL R, V64, P412, DOI 10.1128/MMBR.64.2.412-434.2000; Ogura K, 2000, J EXP MED, V192, P1601, DOI 10.1084/jem.192.11.1601; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Rokbi B, 2001, INFECT IMMUN, V69, P4759, DOI 10.1128/IAI.69.8.4759-4766.2001; Sakai T, 2000, BUNSEKI KAGAKU, V49, P745, DOI 10.2116/bunsekikagaku.49.745; Salama N, 2000, P NATL ACAD SCI USA, V97, P14668, DOI 10.1073/pnas.97.26.14668; Syder AJ, 1999, MOL CELL, V3, P263, DOI 10.1016/S1097-2765(00)80454-2; Takashima M, 2001, GUT, V48, P765, DOI 10.1136/gut.48.6.765; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Xu Q, 2000, P NATL ACAD SCI USA, V97, P9671, DOI 10.1073/pnas.97.17.9671	28	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34191	34197		10.1074/jbc.M203613200	http://dx.doi.org/10.1074/jbc.M203613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105196	hybrid			2022-12-27	WOS:000177959100087
J	Dillner, NB; Sanders, MM				Dillner, NB; Sanders, MM			Upstream stimulatory factor (USF) is recruited into a steroid hormone-triggered regulatory circuit by the estrogen-inducible transcription factor delta EF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE INTERACTION; OVALBUMIN GENE; ELEMENTS; ACTIVATION; EXPRESSION; BOX	In the past decade, investigation into steroid hormone signaling has focused on the mechanisms of steroid hormone receptors as they act as signaling molecules and transcription factors in cells. However, the majority of hormone-responsive genes are not directly regulated by hormone receptors. These genes are termed secondary response genes. To explore the molecular mechanisms by which the steroid hormone estrogen regulates secondary response genes, the ovalbumin (Ov) gene was analyzed. Three protein-protein complexes (Chirp-I, -II, -III), which do not contain the estrogen receptor, are induced by estrogen to bind to the 5'-flanking region of the Ov gene. The Chirp-III DNA binding site, which is required for estrogen induction, binds a complex of proteins that contains the estrogen-inducible transcription factor deltaEF1. Experiments undertaken to identify proteins complexed with deltaEF1 led to the elucidation of a novel mechanism of action of upstream stimulatory factor-I (USF-1), which involves its tethering to the Ov gene 5'-flanking region by deltaEF1. Gel mobility shift assays and co-immunoprecipitation experiments identify USF-1 as a component of Chirp-III. However, USF-1 is not able to bind to the Chirp-III site independently. In addition, USF-1 overexpression is able to induce Ov gene promoter activity in transfection experiments. USF-1 can also potentiate the induction of the Ov gene by the transcription factor deltaEF1. Moreover, mutating the deltaEF1 binding sites in the 5'-flanking region of the Ov gene abrogates induction of the gene by USF-1. These data begin to establish a molecular mechanism by which hormone-inducible transcription factors and ubiquitous transcription factors cooperate to regulate estrogen-induced secondary response gene expression.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Sanders, MM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-1555 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	sande001@umn.edu			NIDDK NIH HHS [R01 DK 40082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arao Y, 1996, J BIOCHEM-TOKYO, V120, P710; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chamberlain EM, 1999, MOL CELL BIOL, V19, P3600; Dean DM, 2001, DNA CELL BIOL, V20, P27, DOI 10.1089/10445490150504675; Dean DM, 1996, MOL ENDOCRINOL, V10, P1489, DOI 10.1210/me.10.12.1489; Dillner NB, 2002, MOL CELL ENDOCRINOL, V192, P85, DOI 10.1016/S0303-7207(02)00088-6; DILLNER NB, 2000, RRD MOLEC CELL BIOL, V1, P93; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Ikeda K, 1998, GENE, V216, P155, DOI 10.1016/S0378-1119(98)00307-2; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; MANELSDORF DJ, 1995, CELL, V83, P835; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SANDERS MM, 1985, ENDOCRINOLOGY, V116, P398, DOI 10.1210/endo-116-1-398; SANDERS MM, 1986, MOL GENETICS MAMMALI, P183; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; Sensenbaugh K. R., 1996, Gene expression and nutrition: from cells to whole body, P45; Sensenbaugh KR, 1999, DNA CELL BIOL, V18, P147, DOI 10.1089/104454999315538; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SWANECK GE, 1979, P NATL ACAD SCI USA, V76, P1049, DOI 10.1073/pnas.76.3.1049; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Xing WR, 1998, MOL ENDOCRINOL, V12, P1310, DOI 10.1210/me.12.9.1310	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33890	33894		10.1074/jbc.M204399200	http://dx.doi.org/10.1074/jbc.M204399200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107170	hybrid			2022-12-27	WOS:000177959100049
J	Zhang, LW; Soares, MP; Guan, YF; Matheravidathu, S; Wnek, R; Johnson, KE; Meisher, A; Iliff, SA; Mudgett, JS; Springer, MS; Daugherty, BL				Zhang, LW; Soares, MP; Guan, YF; Matheravidathu, S; Wnek, R; Johnson, KE; Meisher, A; Iliff, SA; Mudgett, JS; Springer, MS; Daugherty, BL			Functional expression and characterization of macaque C-C chemokine receptor 3 (CCR3) and generation of potent antagonistic anti-macaque CCR3 monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CHEMOATTRACTANT CYTOKINE; MESSENGER-RNA EXPRESSION; AIRWAY HYPERRESPONSIVENESS; EOTAXIN RECEPTOR; T-CELLS; BRONCHOALVEOLAR LAVAGE; ALLERGIC INFLAMMATION; CHEMOTACTIC CYTOKINES; MOLECULAR-CLONING; IL-8 RECEPTOR	Eosinophils are major effector cells implicated in a number of chronic inflammatory diseases in humans, particularly bronchial asthma and allergic rhinitis. The beta-chemokine receptor C-C chemokine receptor 3 (CCR3) provides a mechanism for the selective recruitment of eosinophils into tissue and thus has recently become an attractive biological target for therapeutic intervention. In order to develop in vivo models of inflammatory diseases, it is essential to identify and characterize the homologues of human eotaxin (C-C chemokine ligand 11) and CCR3 from other species, such as non-human primates. Accordingly, we cloned the macaque eotaxin and CCR3 genes and revealed that they were 91 and 92% identical at the amino acid level to their human homologues, respectively. Macaque CCR3 expressed in the murine pre-B L1-2 cell line bound macaque eotaxin with high affinity (K-d = 0.1 nM) and exhibited a robust eotaxin-induced Ca2+ flux and chemotaxis. Characterization of beta-chemokines on native macaque CCR3 on eosinophils was performed by means of eotaxin-induced shape change in whole blood using a novel signaling assay known as gated autofluorescence forward scatter. Additionally, mAbs were raised against macaque CCR3 using two different immunogens: a 30-amino acid synthetic peptide derived from the predicted NH2 terminus of macaque CCR3 and intact macaque CCR3-transfected cells. These anti-macaque CCR3 monoclonal antibodies exhibited potent antagonist activity in receptor binding and functional assays. The characterization of the macaque eotaxin/CCR3 axis and development of antagonistic anti-macaque CCR3 monoclonal antibodies will facilitate the development of CCR3 small molecule antagonists with the hope of ameliorating chronic inflammatory diseases in humans.	Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Daugherty, BL (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, Mail Code RY980W-107,126 E Lincoln Ave, Rahway, NJ 07065 USA.	bruce_daugherty@merck.com						ALAM R, 1993, J IMMUNOL, V150, P3442; Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957-8967.2001; Barnes PJ, 2002, ANNU REV PHARMACOL, V42, P81, DOI 10.1146/annurev.pharmtox.42.111901.111143; Beck L, 1998, J ALLERGY CLIN IMMUN, V101, pS36; Beck LA, 1997, J IMMUNOL, V159, P2962; Benarafa C, 2000, VET IMMUNOL IMMUNOP, V76, P283, DOI 10.1016/S0165-2427(00)00222-1; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; CHIHARA J, 1994, INT ARCH ALLERGY IMM, V104, P52, DOI 10.1159/000236752; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; Conroy DM, 2001, RESP RES, V2, P150, DOI 10.1186/rr52; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; EBISAWA M, 1994, J IMMUNOL, V153, P2153; ELSNER J, 1995, J INVEST DERMATOL, V105, P231, DOI 10.1111/1523-1747.ep12317519; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Frade JMR, 1997, J IMMUNOL, V159, P5576; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846, DOI 10.1002/jlb.65.6.846; GUNDEL R H, 1991, Journal of Allergy and Clinical Immunology, V87, P308, DOI 10.1016/0091-6749(91)91957-U; GUNDEL RH, 1990, J APPL PHYSIOL, V68, P779, DOI 10.1152/jappl.1990.68.2.779; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; GUNDEL RH, 1992, AM REV RESPIR DIS, V146, P369, DOI 10.1164/ajrccm/146.2.369; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Jiang Y, 1998, J NEUROIMMUNOL, V86, P1, DOI 10.1016/S0165-5728(98)00005-8; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; Jopling LA, 2002, J BIOL CHEM, V277, P6864, DOI 10.1074/jbc.M109974200; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kim J, 2001, J IMMUNOL, V167, P2808, DOI 10.4049/jimmunol.167.5.2808; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Klein RS, 1999, J IMMUNOL, V163, P1636; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lilly CM, 2001, AM J RESP CELL MOL, V25, P673, DOI 10.1165/ajrcmb.25.6.f222; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MANIATIS T., 1982, MOL CLONING LABORATO, P382; Margulies BJ, 2001, AIDS RES HUM RETROV, V17, P981, DOI 10.1089/088922201750290104; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Sol N, 1998, VIROLOGY, V240, P213, DOI 10.1006/viro.1997.8928; Stellato C, 2001, J IMMUNOL, V166, P1457, DOI 10.4049/jimmunol.166.3.1457; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; TURNER CR, 1994, PULM PHARMACOL THER, V7, P49, DOI 10.1006/pulp.1994.1005; Turner CR, 1996, INFLAMM RES, V45, P239, DOI 10.1007/BF02259610; TURNER CR, 1994, AM J RESP CRIT CARE, V149, P1153, DOI 10.1164/ajrccm.149.5.8173755; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wade-Evans AM, 2001, AIDS RES HUM RETROV, V17, P371, DOI 10.1089/08892220150503744; WEGNER CD, 1993, J ALLERGY CLIN IMMUN, V91, P917, DOI 10.1016/0091-6749(93)90350-O; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Westmoreland SV, 1998, AM J PATHOL, V152, P659; Williams CMM, 1998, IMMUNOGENETICS, V47, P178, DOI 10.1007/s002510050345; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Young SS, 1999, INT ARCH ALLERGY IMM, V120, P209, DOI 10.1159/000024269; Zeibecoglou K, 1999, ALLERGY, V54, P730, DOI 10.1034/j.1398-9995.1999.00058.x; Zhang LQ, 1998, J VIROL, V72, P5035, DOI 10.1128/JVI.72.6.5035-5045.1998; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zimmermann N, 2000, BLOOD, V96, P2346	89	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33799	33810		10.1074/jbc.M205488200	http://dx.doi.org/10.1074/jbc.M205488200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12101185	hybrid			2022-12-27	WOS:000177959100037
J	Dhami, GK; Anborgh, PH; Dale, LB; Sterne-Marr, R; Ferguson, SSG				Dhami, GK; Anborgh, PH; Dale, LB; Sterne-Marr, R; Ferguson, SSG			Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DESENSITIZATION; RAPID DESENSITIZATION; INTERNALIZATION; 1A; ENDOCYTOSIS; SPECIFICITY; INHIBITION; DOMAIN; CELLS	The accepted paradigm for G protein-coupled receptor kinase (GRK)-mediated desensitization of G protein-coupled receptors involves GRK-mediated receptor phosphorylation followed by the binding of arrestin proteins. Although GRKs contribute to metabotropic glutamate receptor 1 (mGluR1) inactivation, 13-arrestins do not appear to be required for mGluR1 G protein uncoupling. Therefore, we investigated whether the phosphorylation of serine and threonine residues localized within the C terminus of mGluR1a is sufficient to allow GRK2-mediated attenuation of mGluR1a signaling. We find that the truncation of the mGluR1a C-terminal tail prevents mGluR1a phosphorylation and that GRK2 does not contribute to the phosphorylation of an mGluR1 splice variant (mGluR1b). However, mGluR1a-866Delta- and mGluR1b-stimulated inositol phosphate formation is attenuated following GRK2 expression. The expression of the GRK2 C-terminal domain to block membrane translocation of endogenous GRK2 increases mGluR1a-866Delta- and mGluR1b-stimulated inositol phosphate formation, presumably by blocking membrane translocation of GRK2. In contrast, expression of the kinase-deficient GRK2-K220R mutant inhibits inositol phosphate formation by these unphosphorylated receptors. Expression of the GRK2 N-terminal domain (residues 45-185) also attenuates both constitutive and agonist-stimulated mGluR1a, mGluR1a-866A, and mGluR1b signaling, and the GRK2 N terminus co-precipitates with mGluR1a. Taken together, our observations indicate that attenuation of mGluR1 signaling by GRK2 is phosphorylation-independent and that the interaction of the N-terminal domain of GRK2 with mGluR1 contributes to the regulation of mGluR1 G protein coupling.	John P Robarts Res Inst, Cell Biol Res Grp, Dept Pharmacol, London, ON N6A 5K8, Canada; John P Robarts Res Inst, Cell Biol Res Grp, Dept Toxicol, London, ON N6A 5K8, Canada; John P Robarts Res Inst, Cell Biol Res Grp, Dept Physiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5K8, Canada; Siena Coll, Biol Dept, Loudonville, NY 12211 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, Dept Pharmacol, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.	ferguson@rri.ca						Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Calabresi P, 1999, EXP NEUROL, V158, P97, DOI 10.1006/exnr.1999.7092; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chan WY, 2001, MOL CELL NEUROSCI, V17, P577, DOI 10.1006/mcne.2001.0965; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	34	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25266	25272		10.1074/jbc.M203593200	http://dx.doi.org/10.1074/jbc.M203593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12101219	hybrid			2022-12-27	WOS:000176747000055
J	Ruas, JL; Poellinger, L; Pereira, T				Ruas, JL; Poellinger, L; Pereira, T			Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation - identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR PROTEIN; ESTROGEN-RECEPTOR-ALPHA; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; LIVING CELLS; HIF-ALPHA; DOMAINS; RECRUITMENT	The hypoxia-inducible factor-1alpha (HIF-1alpha) is a key regulator of adaptive responses to hypoxia. HIF-1alpha has two independent transactivation domains (TADs). Whereas the N-terminal TAD (N-TAD) also constitutes a degradation box, the C-terminal TAD (C-TAD) functions in a strictly hypoxia-inducible fashion. Oxygen-dependent hydroxylation of an asparagine residue has recently been reported to regulate C-TAD function by disrupting the interaction with the CH1 domain of the p300/CBP coactivator at normoxia. Here we have performed alanine-scanning mutagenesis of a predicted alpha-helix within the C-TAD of mouse HIF-1alpha to identify residues important for transactivation and interaction of the C-TAD with transcriptional coactivators. We observed that several hydrophobic residues, Ile(802), Leu(808), Leu(814), Leu(815), and Leu(818), were critical for transactivation and binding to the CH1 domain of CBP in hypoxic cells. Moreover, E812A/E813A and D819A mutations impaired hypoxia-dependent transactivation without disrupting binding to CH1. In the context of full-length HIF-1alpha, mutation of the leucine residues conferred conformational changes to the protein and significantly reduced the transactivation function as well as functional interaction with the transcriptional coactivators CBP and SRC-1. These mutations also affected intranuclear redistribution of HIF-1alpha in the presence of CBP, indicating that the integrity of the C-TAD is critical for intracellular localization of mouse HIF-1alpha.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.		Pereira, Teresa/AAP-8197-2020; Ruas, Jorge/AAE-6094-2019	Pereira, Teresa/0000-0001-8654-2385; Ruas, Jorge/0000-0002-1110-2606				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845	47	93	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38723	38730		10.1074/jbc.M205051200	http://dx.doi.org/10.1074/jbc.M205051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12133832	hybrid			2022-12-27	WOS:000178529600091
J	Chen, XH; Christopher, A; Jones, JP; Bell, SG; Guo, Q; Xu, F; Rao, ZH; Wong, LL				Chen, XH; Christopher, A; Jones, JP; Bell, SG; Guo, Q; Xu, F; Rao, ZH; Wong, LL			Crystal structure of the F87W/Y96F/V247L mutant of cytochrome P-450cam with 1,3,5-trichlorobenzene bound and further protein engineering for the oxidation of pentachlorobenzene and hexachlorobenzene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCHLORINATED BENZENES; PSEUDOMONAS SP; P450(CAM); PENTACHLOROPHENOL; DEGRADATION; BIOREMEDIATION; BIODEGRADATION; DIOXYGENASE; PREDICTION; RESOLUTION	We reported previously that the F87W/Y96F/V247L mutant of cytochrome P-450cam (CYP101) from Pseudomonas putida catalyzed the rapid oxidation of lightly chlorinated benzenes, but pentachlorobenzene oxidation was slow (Jones, J. P., O'Hare, E. J., and Wong, L. L. (2001) Eur. J. Biochem. 268, 1460-1467). In the present work, we determined the crystal structure of this mutant with bound 1,3,5-trichlorobenzene. The substrate was bound to crystallographically independent CYP101 molecules in at least three different orientations, which were distinguished by the angle between the benzene ring and the porphyrin, and one orientation contained an Fe-Cl interaction. In another orientation, the substrate was almost parallel to the heme, with a C-H bond closest to the iron. The enzyme/substrate contacts suggested that the L244A mutation should promote the binding of pentachlorobenzene and hexachlorobenzene by creating space to accommodate the extra chlorines. The F87W/Y96F/L244A/V247L mutant thus designed was found to oxidize pentachlorobenzene at a rate of 82.5 nmol (nmol CYP101)(-1) min(-1), 45 times faster than the F87W/Y96F/V247L parent mutant. The rate of hexachlorobenzene oxidation was increased 200-fold, to 2.0 min(-1). Both substrates are oxidized to pentachlorophenol, which is degraded by micro-organisms. In principle, the F87W/Y96FA/L244A/V247L mutant could have applications in the bioremediation of polychlorinated benzenes.	Tsinghua Univ, Dept Biol Sci & Technol, Struct Biol Lab, Beijing 100084, Peoples R China; Tsinghua Univ, Minist Educ, Lab Prot Sci, Beijing 100084, Peoples R China; Univ Oxford, Dept Chem, Inorgan Chem Lab, Oxford OX1 3QR, England	Tsinghua University; Tsinghua University; University of Oxford	Wong, LL (corresponding author), Tsinghua Univ, Dept Biol Sci & Technol, Struct Biol Lab, Beijing 100084, Peoples R China.	wong@chem.ox.ac.uk	Hu, Ruogu/B-2203-2008; Bell, Stephen/E-8222-2011; Rao, Zihe/HCH-6944-2022	Bell, Stephen/0000-0002-7457-9727; 				Beil S, 1997, EUR J BIOCHEM, V247, P190, DOI 10.1111/j.1432-1033.1997.00190.x; Bell SG, 1997, J MOL CATAL B-ENZYM, V3, P293, DOI 10.1016/S1381-1177(97)00009-X; BRODERICK JB, 1991, BIOCHEMISTRY-US, V30, P7349, DOI 10.1021/bi00243a040; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DEVOSS JJ, 1995, J AM CHEM SOC, V117, P4185, DOI 10.1021/ja00119a041; DeVoss JJ, 1997, J AM CHEM SOC, V119, P5489, DOI 10.1021/ja970349v; England PA, 1998, FEBS LETT, V424, P271, DOI 10.1016/S0014-5793(98)00189-6; FEIDIEKER D, 1994, FEMS MICROBIOL ECOL, V15, P265, DOI 10.1111/j.1574-6941.1994.tb00250.x; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; French KJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P188, DOI 10.1006/abbi.2001.2732; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HAIGLER BE, 1988, APPL ENVIRON MICROB, V54, P294, DOI 10.1128/AEM.54.2.294-301.1988; Harford-Cross CF, 2000, PROTEIN ENG, V13, P121, DOI 10.1093/protein/13.2.121; Hartmann S, 1999, P NATL ACAD SCI USA, V96, P7831, DOI 10.1073/pnas.96.14.7831; Jones JP, 2001, EUR J BIOCHEM, V268, P1460, DOI 10.1046/j.1432-1327.2001.02018.x; Jones JP, 2000, CHEM COMMUN, P247, DOI 10.1039/a909536e; Kellner DG, 1997, CURR OPIN BIOTECH, V8, P274, DOI 10.1016/S0958-1669(97)80003-1; Lee SG, 1998, J APPL MICROBIOL, V85, P1; Leung KT, 1997, WORLD J MICROB BIOT, V13, P305, DOI 10.1023/A:1018587108422; LI HY, 1995, J AM CHEM SOC, V117, P6297, DOI 10.1021/ja00128a019; MARINUCCI AC, 1979, APPL ENVIRON MICROB, V38, P811, DOI 10.1128/AEM.38.5.811-817.1979; Miles CS, 2000, BBA-PROTEIN STRUCT M, V1543, P383, DOI 10.1016/S0167-4838(00)00236-3; Mueller Ernest J., 1995, P83; Neilson AH, 1996, INT BIODETER BIODEGR, V37, P3, DOI 10.1016/0964-8305(95)00092-5; Nickerson DP, 1997, PROTEIN ENG, V10, P1357, DOI 10.1093/protein/10.12.1357; Nickerson DP, 1997, FEBS LETT, V405, P153, DOI 10.1016/S0014-5793(97)00174-9; Orser C. S., 1994, Biodegradation, V5, P277, DOI 10.1007/BF00696465; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; Potrawfke T, 1998, APPL ENVIRON MICROB, V64, P3798; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RADEHAUS PM, 1992, APPL ENVIRON MICROB, V58, P2879, DOI 10.1128/AEM.58.9.2879-2885.1992; Robinson G K, 1994, Biotechnol Genet Eng Rev, V12, P139; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Solyanikova IP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P365; Stevenson JA, 1996, J AM CHEM SOC, V118, P12846, DOI 10.1021/ja963087q; Stevenson JA, 1998, NEW J CHEM, V22, P551, DOI 10.1039/a801637b; Westlake ACG, 1999, EUR J BIOCHEM, V265, P929, DOI 10.1046/j.1432-1327.1999.00793.x; Wong LL, 1998, CURR OPIN CHEM BIOL, V2, P263, DOI 10.1016/S1367-5931(98)80068-9; YASUKOCHI T, 1994, BBA-PROTEIN STRUCT M, V1204, P84, DOI 10.1016/0167-4838(94)90036-1	42	62	66	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37519	37526		10.1074/jbc.M203762200	http://dx.doi.org/10.1074/jbc.M203762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12114516	hybrid			2022-12-27	WOS:000178447100078
J	Li, M; Murphy, DJ; Lee, KHK; Wilson, R; Smith, LJ; Clark, DC; Sung, JY				Li, M; Murphy, DJ; Lee, KHK; Wilson, R; Smith, LJ; Clark, DC; Sung, JY			Purification and structural characterization of the central hydrophobic domain of oleosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; TRANSFORM INFRARED-SPECTROSCOPY; CIRCULAR-DICHROISM SPECTRA; STORAGE LIPID BODIES; CHAIN PLEATED SHEET; AMIDE-ONE VIBRATION; SEED OIL-BODIES; RESONANCE INTERACTION; PROTEOLYTIC PEPTIDES; OILSEED RAPE	The oil bodies of rapeseeds contain a triacylglycerol matrix surrounded by a monolayer of phospholipids embedded with abundant structural alkaline proteins termed oleosins and some other minor proteins. Oleosins are unusual proteins because they contain a 70-80-residue uninterrupted nonpolar domain flanked by relatively polar G and N-terminal domains. Although the. hydrophilic N-terminal domain had been studied, the structural feature of the central hydrophobic domain remains unclear due to its high hydrophobicity. In the present study, we reported the generation, purification, and characterization of a 9-kDa central hydrophobic domain from rapeseed oleosin (19 kDa). The 9-kDa central hydrophobic domain was produced by selectively degrading the N and C termini with enzymes and then purifying the digest by SDS-PAGE and electroelution. We have also reconstituted the central domain into liposomes and synthetic oil bodies to determine the secondary structure of the domain using CD and Fourier transform infrared (FTIR) spectroscopy. The spectra obtained from CD and FTIR were analyzed with reference to structural information of the N-terminal domain and the full-length rapeseed oleosin. Both CD and FTIR analysis revealed that 50-63% of the domain was composed of beta-sheet structure. Detailed analysis of the FTIR spectra indicated that 80% of the beta-sheet structure, present in the central domain, was arranged in parallel to the intermolecular beta-sheet structure. Therefore, interactions between adjacent oleosin proteins would give rise to a stable beta-sheet structure that would extend around the surface of the sped oil bodies stabilizing them in emulsion systems. The strategies used in our present study are significant in that it could be generally used to study difficult proteins with different independent structural domains, especially with long hydrophobic domains.	Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China; John Innes Ctr, Cambridge Lab, Norwich NR4 7UH, Norfolk, England; Chinese Univ Hong Kong, Dept Anat, Sha Tin, Hong Kong, Peoples R China; Inst Food Res, Norwich NR4 7UA, Norfolk, England	Chinese University of Hong Kong; Prince of Wales Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Chinese University of Hong Kong; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Li, M (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, 9-F Clin Bldg, Sha Tin, Hong Kong, Peoples R China.	b976711@mailserv.cuhk.edu.hk	Murphy, Denis J/ABC-1734-2020; Lee, Kenneth Ka Ho/H-6698-2013	Lee, Kenneth Ka Ho/0000-0002-6520-304X; Murphy, Denis J/0000-0002-5291-2445				ABBOTT TP, 1991, APPL SPECTROSC, V45, P1665, DOI 10.1366/0003702914335265; Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; AU DMY, 1989, BIOCHIM BIOPHYS ACTA, V1005, P97, DOI 10.1016/0005-2760(89)90037-4; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P627, DOI 10.1002/bip.1976.360150403; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; Chu HL, 2001, AQUAT TOXICOL, V55, P171, DOI 10.1016/S0166-445X(01)00177-1; CLARK DC, 1989, J AGR FOOD CHEM, V37, P627, DOI 10.1021/jf00087a011; CUMMINS I, 1993, PLANT MOL BIOL, V23, P1015, DOI 10.1007/BF00021816; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; HILLS MJ, 1993, PLANTA, V189, P24, DOI 10.1007/BF00201339; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; Ishiguro K, 2001, LAB INVEST, V81, P509, DOI 10.1038/labinvest.3780259; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KONNO T, 1975, ANAL BIOCHEM, V67, P226, DOI 10.1016/0003-2697(75)90290-0; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; Lacey DJ, 1998, BIOCHEM J, V334, P469, DOI 10.1042/bj3340469; LAGANT P, 1984, EUR J BIOCHEM, V139, P137, DOI 10.1111/j.1432-1033.1984.tb07987.x; LAGANT P, 1984, EUR J BIOCHEM, V139, P149, DOI 10.1111/j.1432-1033.1984.tb07988.x; LEE DC, 1990, BIOCHEMISTRY-US, V29, P9185, DOI 10.1021/bi00491a012; LEE K, 1995, PLANT J, V7, P603, DOI 10.1046/j.1365-313X.1995.7040603.x; LEE KY, 1994, PLANT MOL BIOL, V26, P1981, DOI 10.1007/BF00019508; LI M, 1992, J BIOL CHEM, V267, P8245; LI M, 1993, J BIOL CHEM, V268, P17504; Lorenz VA, 2001, BIOCHEMISTRY-US, V40, P8821, DOI 10.1021/bi010091s; MUKHERJEE KD, 1993, LIPASES THEIR STRUCT, P49; Murphy Denis J., 1995, P558; MURPHY DJ, 1990, PROG LIPID RES, V29, P299; MURPHY DJ, 1989, PHYTOCHEMISTRY, V28, P2063, DOI 10.1016/S0031-9422(00)97921-4; MURPHY DJ, 1993, PROG LIPID RES, V32, P247, DOI 10.1016/0163-7827(93)90009-L; MURPHY DJ, 1989, PLANT SCI, V60, P47, DOI 10.1016/0168-9452(89)90042-3; Napier JA, 1996, PLANT MOL BIOL, V31, P945, DOI 10.1007/BF00040714; ORBAN J, 1992, BIOCHEMISTRY-US, V31, P3604, DOI 10.1021/bi00129a008; PANCOSKA P, 1995, PROTEIN SCI, V4, P1384, DOI 10.1002/pro.5560040713; PARKER FS, 1983, APPL INFRARED RAMAN, P349; Parmenter DL, 1995, PLANT MOL BIOL, V29, P1167, DOI 10.1007/BF00020460; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; Rahmelow K, 1998, ANAL BIOCHEM, V257, P1, DOI 10.1006/abio.1997.2502; Raussens V, 1997, J BIOL CHEM, V272, P262; RENUGOPALAKRISHNAN V, 1985, BIOCHEM BIOPH RES CO, V126, P1029, DOI 10.1016/0006-291X(85)90288-8; RENUGOPALAKRISHNAN V, 1985, J BIOL CHEM, V260, P1406; RitcoVonsovici M, 1995, BIOCHEMISTRY-US, V34, P16543, DOI 10.1021/bi00051a002; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; SARVER RW, 1991, ANAL BIOCHEM, V199, P61, DOI 10.1016/0003-2697(91)90269-Y; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEATON BA, 1983, THESIS MIT CAMBRIDGE; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; TZEN JTC, 1990, PLANT PHYSIOL, V94, P1282, DOI 10.1104/pp.94.3.1282; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; VANROOIJEN GJH, 1995, BIO-TECHNOL, V13, P72, DOI 10.1038/nbt0195-72; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; Wessels JGH, 1996, TRENDS PLANT SCI, V1, P9, DOI 10.1016/S1360-1385(96)80017-3; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHANG Z, 1992, BIOCHEMISTRY-US, V31, P4426; [No title captured]	66	60	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37888	37895		10.1074/jbc.M202721200	http://dx.doi.org/10.1074/jbc.M202721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12124381	hybrid			2022-12-27	WOS:000178447100125
J	Vantieghem, A; Xu, Y; Assefa, Z; Piette, J; Vandenheede, JR; Merlevede, W; de Witte, PAM; Agostinis, P				Vantieghem, A; Xu, Y; Assefa, Z; Piette, J; Vandenheede, JR; Merlevede, W; de Witte, PAM; Agostinis, P			Phosphorylation of Bcl-2 in G(2)/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; CYTOCHROME-C; GROWTH-FACTOR; HELA-CELLS; P38 MAPK; MICROTUBULES; MECHANISM; INACTIVATION; INVOLVEMENT	The role of Bcl-2 in photodynamic therapy (PDT) is controversial, and some photosensitizers have been shown to induce Bcl-2 degradation with loss of its protective function. Hypericin is a naturally occurring photosensitizer with promising properties for the PDT of cancer. Here we show that, in HeLa cells, photoactivated hypericin does not cause Bcl-2 degradation but induces Bcl-2 phosphorylation in a dose- and time-dependent manner. Bcl-2 phosphorylation is induced by sublethal PDT doses; increasing the photodynamic stress promptly leads to apoptosis, during which Bcl-2 is neither phosphorylated nor degraded. Bcl-2 phosphorylation involves mitochondrial Bcl-2 and correlates with the kinetics of a G(2)/M cell cycle arrest, preceding apoptosis. The co-localization of hypericin with alpha-tubulin and the aberrant mitotic spindles observed following sublethal PDT doses suggest that photodamage to the microtubule network provokes the G(2)/M phase arrest. PDT-induced Bcl-2 phosphorylation is not altered by either the overexpression or inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun NH2-terminal protein kinase 1 (JNK1) nor by inhibiting the extracellular signal-regulated kinases (ERKs) or protein kinase C. By contrast, Bcl-2 phosphorylation is selectively suppressed by the cyclin-dependent protein kinase (CDK)-inhibitor roscovitine, completely blocked by the protein synthesis inhibitor cycloheximide and enhanced by the overexpression. of CDK1, suggesting a role for this pathway. However, in an in vitro kinase assay, active CDK1/cyclin B1 complex failed to phosphorylate immunoprecipitated Bcl-2, suggesting that this protein kinase may not directly modify Bcl-2. Mutation of serine-70 to alanine in Bcl-2 abolishes PDT-induced phosphorylation and restores the caspase-3 activation to the same levels of the vector-transfected cells, indicating that Bcl-2 phosphorylation may be a signal to delay apoptosis in G(2)/M phase-arrested cells.	Catholic Univ Louvain, Div Biochem, Fac Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharm, B-3000 Louvain, Belgium; Univ Liege, Lab Virol & Immunol, B-4000 Cointe Ougree, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; University of Liege	Agostinis, P (corresponding author), Catholic Univ Louvain, Div Biochem, Fac Med, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	agostinis@med.kuleuven.ae.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020; Assefa, Zerihun/V-5641-2017	Agostinis, Patrizia/0000-0003-1314-2115; Assefa, Zerihun/0000-0001-7803-5228; de Witte, Peter/0000-0002-9989-9567				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Ahmad N, 2000, METHOD ENZYMOL, V319, P342; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Basu A, 1998, INT J ONCOL, V13, P659; Basu A, 2000, INT J ONCOL, V16, P497; Berg K, 1997, PHOTOCHEM PHOTOBIOL, V65, P403, DOI 10.1111/j.1751-1097.1997.tb08578.x; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DENG X, 2000, J NATL CANC I MONOGR, V28, P30; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; Juarranz A, 2001, PHOTOCHEM PHOTOBIOL, V73, P283, DOI 10.1562/0031-8655(2001)073<0283:PIBZIP>2.0.CO;2; Kamuhabwa AR, 2001, PHOTOCHEM PHOTOBIOL, V74, P126, DOI 10.1562/0031-8655(2001)074&lt;0126:CPIBHI&gt;2.0.CO;2; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ngan VK, 2001, MOL PHARMACOL, V60, P225, DOI 10.1124/mol.60.1.225; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poruchynsky MS, 1998, CANCER RES, V58, P3331; RIALET V, 1991, ANTICANCER RES, V11, P1581; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stein Gary S., 1989, P133; Stockert JC, 1996, CANCER CHEMOTH PHARM, V39, P167, DOI 10.1007/s002800050554; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; Vantieghem A, 2001, PHOTOCHEM PHOTOBIOL, V74, P133, DOI 10.1562/0031-8655(2001)074&lt;0133:DPMCCR&gt;2.0.CO;2; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YAN MH, 1994, NATURE, V372, P798; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026; ZHUO S, 1993, J BIOL CHEM, V268, P17754	76	103	108	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37718	37731		10.1074/jbc.M204348200	http://dx.doi.org/10.1074/jbc.M204348200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12101183	Green Published, hybrid			2022-12-27	WOS:000178447100104
J	Chen, AJ; Zhou, GS; Juan, T; Colicos, SM; Cannon, JP; Cabriera-Hansen, M; Meyer, CF; Jurecic, R; Copeland, NG; Gilbert, DJ; Jenkins, NA; Fletcher, F; Tan, TH; Belmont, JW				Chen, AJ; Zhou, GS; Juan, T; Colicos, SM; Cannon, JP; Cabriera-Hansen, M; Meyer, CF; Jurecic, R; Copeland, NG; Gilbert, DJ; Jenkins, NA; Fletcher, F; Tan, TH; Belmont, JW			The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PROTEIN-TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; MITOGEN; MAP; JNK; PHOSPHORYLATION; RAF-1; CELLS; APOPTOSIS	The involvement of dual specificity phosphatases (DSPs) in the mitogen-activated protein kinase (MAPK) signaling has been mostly limited to the inactivation of MAPKs by the direct dephosphorylation of the TXY motif within their activation loop. We report the cloning and characterization of a murine DSP, called JNK pathway-associated phosphatase (JKAP), which lacks the regulatory region present in most other MAP kinase phosphatases (MKPs) and is preferentially expressed in murine Lin(-)Sca-1(+) stem cells. Overexpression of JKAP in human embryonic kidney 293T cells specifically activated c-Jun N-terminal kinase (JNK) but not p38 and extracellular signal-regulated kinase 2. Overexpression of a mutant JKAP, JKAP-C88S, blocked tumor necrosis factor-a-induced JNK activation. Targeted gene disruption in murine embryonic stem cells abolished JNK activation by tumor necrosis factor-a and transforming growth factor-beta, but not by ultraviolet-C irradiation, indicating that JKAP is necessary for optimal JNK activation. JKAP associated with JNK and MKK7, but not SEK1, in vivo. However, JKAP did not interact with JNK in vitro, suggesting that JKAP exerts its effect on JNK in an indirect manner. Taken together, these studies identify a positive regulator for the JNK pathway and suggest a novel role for DSP in mitogen-activated protein kinase regulation.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Amgen Inc, Dept Expt Hematol, Newbury Pk, CA 91320 USA; NCI, Frederick Canc Res & Dev Ctr, Mammalian Genet Lab, ABL Basic Res Program, Ft Detrick, MD 21702 USA	Baylor College of Medicine; Baylor College of Medicine; Amgen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Belmont, JW (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Tan, Tse-Hua/ABD-7080-2021; Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Belmont, John W/0000-0001-7409-3578; Tan, Tse-Hua/0000-0003-4969-3170	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA087076] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008307] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA87076] Funding Source: Medline; NHGRI NIH HHS [T32 HG00003] Funding Source: Medline; NIAID NIH HHS [R01 AI42532] Funding Source: Medline; NICHD NIH HHS [HD36280] Funding Source: Medline; NIDDK NIH HHS [R01 DK48647] Funding Source: Medline; NIGMS NIH HHS [T32 GM08307] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Batard P, 2000, J CELL SCI, V113, P383; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dorfman K, 1996, ONCOGENE, V13, P925; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	51	79	82	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36592	36601		10.1074/jbc.M200453200	http://dx.doi.org/10.1074/jbc.M200453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138158	hybrid			2022-12-27	WOS:000178275100103
J	Chow, D; Srikakulam, R; Chen, Y; Winkelmann, DA				Chow, D; Srikakulam, R; Chen, Y; Winkelmann, DA			Folding of the striated muscle myosin motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; MOLECULAR MOTORS; LEVER ARM; SUBFRAGMENT-1; CHAPERONIN; MUTATIONS; KINESIN	We have investigated the folding of the myosin motor domain using a chimera of an embryonic striated muscle myosin II motor domain fused on its COOH terminus to a thermal stable, fast folding variant of green fluorescent protein (GFP). In in vitro expression assays, the GFP domain of the chimeric protein, S1(795)GFP, folds rapidly enabling us to monitor the folding of the motor domain using fluorescence. The myosin motor domain folds very slowly and transits through multiple intermediates that are detectable by gel filtration chromatography. The distribution of the nascent protein among these intermediates is strongly dependent upon temperature. At 25degreesC and above the predominant product is an aggregate of S1(795)GFP or a complex with other lysate proteins. At 0degreesC, the motor domain folds slowly via an energy independent pathway. The unusual temperature dependence and slow rate suggests that folding of the myosin motor is highly susceptible to off-pathway interactions and aggregation. Expression of the S1(795)GFP in the C2C12 muscle cell line yields a folded and functionally active protein that exhibits Mg2+ ATP-sensitive actin-binding and myosin motor activity. In contrast, expression of S1795GFP in kidney epithelial cell lines (human 293 and COS 7 cells) results in an inactive and aggregated protein. The results of the in vitro folding assay suggest that the myosin motor domain does not fold spontaneously under physiological conditions and probably requires cytosolic chaperones. The expression studies support this conclusion and demonstrate that these factors are optimized in muscle cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Winkelmann, DA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038454, R29AR038454] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38454] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Barral JM, 1998, J CELL BIOL, V143, P1215, DOI 10.1083/jcb.143.5.1215; Barral JM, 1999, BIOESSAYS, V21, P813, DOI 10.1002/(SICI)1521-1878(199910)21:10<813::AID-BIES3>3.0.CO;2-0; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; BOURDIEU L, 1995, PHYS REV E, V52, P6573, DOI 10.1103/PhysRevE.52.6573; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iwane AH, 1997, FEBS LETT, V407, P235, DOI 10.1016/S0014-5793(97)00359-1; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LEVITSKY DI, 1990, FEBS LETT, V264, P176, DOI 10.1016/0014-5793(90)80242-B; Norcum MT, 1996, PROTEIN SCI, V5, P1366, DOI 10.1002/pro.5560050715; PRICE MG, 2002, IN PRESS J CELL SCI; Rayment I, 1996, STRUCTURE, V4, P501, DOI 10.1016/S0969-2126(96)00055-X; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; Srikakulam R, 1999, J BIOL CHEM, V274, P27265, DOI 10.1074/jbc.274.38.27265; Suzuki Y, 2000, METHODS, V22, P355, DOI 10.1006/meth.2000.1087; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Venolia L, 1999, CELL MOTIL CYTOSKEL, V42, P163, DOI 10.1002/(SICI)1097-0169(1999)42:3&lt;163::AID-CM1&gt;3.0.CO;2-E; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	27	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36799	36807		10.1074/jbc.M204101200	http://dx.doi.org/10.1074/jbc.M204101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12110670	hybrid			2022-12-27	WOS:000178275100131
J	Levit, MN; Grebe, TW; Stock, JB				Levit, MN; Grebe, TW; Stock, JB			Organization of the receptor-kinase signaling array that regulates Escherichia coli chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; CYTOPLASMIC DOMAIN; HISTIDINE KINASE; METHYLTRANSFERASE CHER; CHEMORECEPTOR COMPLEX; METHYLESTERASE CHEB; NUCLEOTIDE-BINDING; ASPARTATE RECEPTOR; PROTEIN; TRANSDUCTION	Motor behavior in prokaryotes is regulated by a phosphorelay network involving a histidine protein kinase, CheA, whose activity is controlled by a family of Type I membrane receptors. In a typical Escherichia coli cell, several thousand receptors are organized together with CheA and an Src homology 3-like protein, CheW, into complexes that tend to be localized at the cell poles. We found that these complexes have at least 6 receptors per CheA. CheW is not required for CheA binding to receptors, but is essential for kinase activation. The kinase activity per mole of bound CheA is proportional to the total bound CheW. Similar results were obtained with the E. coli serine receptor, Tsr, and the Salmonella typhimurium aspartate receptor, Tar. In the case of Tsr, under conditions optimal for kinase activation, the ratio of subunits in complexes is similar to6 Tsr:4 CheW:1 CheA. Our results indicate that information from numerous receptors is integrated to control the activity of a relatively small number of kinase molecules.	Princeton Univ, Lewis Thomas Labs, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Stock, JB (corresponding author), Princeton Univ, Lewis Thomas Labs, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	jstock@princeton.edu						Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BARNAKOV AN, 1994, J STRUCT BIOL, V112, P117, DOI 10.1006/jsbi.1994.1013; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CLARKE S, 1979, J BIOL CHEM, V254, P9695; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Djordjevic S, 1998, NAT STRUCT BIOL, V5, P446, DOI 10.1038/nsb0698-446; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Falke JJ, 2000, CURR OPIN STRUC BIOL, V10, P462, DOI 10.1016/S0959-440X(00)00115-9; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; Francis NR, 2002, J BIOL CHEM, V277, P36755, DOI 10.1074/jbc.M204324200; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gestwicki JE, 2000, J BACTERIOL, V182, P6499, DOI 10.1128/JB.182.22.6499-6502.2000; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grebe TW, 1998, CURR BIOL, V8, pR154, DOI 10.1016/S0960-9822(98)00098-0; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; HAZELBAUER GL, 1981, J BACTERIOL, V145, P43, DOI 10.1128/JB.145.1.43-49.1981; Heldin CH, 1996, CANCER SURV, V27, P7; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Levit MN, 2002, J BIOL CHEM, V277, P36760, DOI 10.1074/jbc.M204325200; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Lybarger SR, 2000, P NATL ACAD SCI USA, V97, P8057, DOI 10.1073/pnas.130195397; Lybarger SR, 1999, J BACTERIOL, V181, P5527, DOI 10.1128/JB.181.17.5527-5529.1999; MADDOCK JR, 1993, SCIENCE, V259, P1717; Mourey L, 2001, J BIOL CHEM, V276, P31074, DOI 10.1074/jbc.M101943200; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; Stock J, 1999, CURR BIOL, V9, pR364, DOI 10.1016/S0960-9822(99)80228-0; Stock J, 2000, CURR BIOL, V10, pR11, DOI 10.1016/S0960-9822(99)00248-1; STOCK JB, 1996, ESCHERICHIA COLI SAL, V2, P1103; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; WEST AH, 1995, PROTEINS, V21, P345, DOI 10.1002/prot.340210407; WOLANIN PM, 2002, HISTIDINE KINASES SI, P73; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhulin IB, 2001, ADV MICROB PHYSIOL, V45, P157, DOI 10.1016/S0065-2911(01)45004-1	59	75	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36748	36754		10.1074/jbc.M204317200	http://dx.doi.org/10.1074/jbc.M204317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119289	hybrid			2022-12-27	WOS:000178275100122
J	Chi, YH; Kumar, TKS; Chiu, IM; Yu, C				Chi, YH; Kumar, TKS; Chiu, IM; Yu, C			Identification of rare partially unfolded states in equilibrium with the native conformation in an all beta-barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MOLTEN GLOBULE STATE; KINETIC FOLDING PATHWAY; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; INTERMEDIATE; STABILITY; EVENTS; SHEET; THERMODYNAMICS	Human acidic fibroblast growth factor 1 (hFGF-1) is an all beta-barrel protein, and the secondary structural elements in the protein include 12 antiparallel beta-strands arranged into a beta-trefoil fold. In the present study, we investigate the stability of hFGF-1 by hydrogen-deuterium exchange as a function of urea concentration. Urea-induced equilibrium unfolding of hFGF-1 monitored by fluorescence and CD spectroscopy suggests that the protein unfolds by a two-state (native to denatured) mechanism. Hydrogen exchange in hFGF-1, under the experimental conditions used, occurs by the EX2 mechanism. In contrast to the equilibrium unfolding events monitored by optical probes, native state hydrogen exchange data show that the beta-trefoil architecture of hFGF-1 does not behave as a single cooperative unit. There are at least two structurally independent units with differing stabilities in hFGF-1. beta-Strands I, II, III, VI, VII, X, XI, and XII fit into the global unfolding isotherm. By contrast, residues in beta-strands IV, V, VIII, and IX exchange by the subfolding isotherm and could be responsible for the occurrence of high-energy partially unfolded state(s) in hFGF-1. There appears to be a broad continuum of stabilities among the four beta-strands (beta-strands IV, V, VIII, and IX) constituting the subglobal folding unit. The slow exchanging residues in hFGF-1 do not represent the folding nucleus of the protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	National Tsing Hua University; University System of Ohio; Ohio State University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.	cyu@mx.nthu.edu.tw	Chi, Ya-Hui/B-1080-2010; Chi, Ya-Hui/ABE-8550-2020; Kumar, Suresh Thallapuranam/R-5606-2016; Kumar, Dr Suresh/HHZ-2615-2022; Chiu, Ing-Ming/B-1534-2008; KUMAR, P. SURESH/AAT-8951-2020	Chi, Ya-Hui/0000-0002-9216-0938; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604				AGASHE VR, 1995, BIOCHEMISTRY-US, V34, P3286, DOI 10.1021/bi00010a019; Arrington CB, 2000, METHOD ENZYMOL, V323, P104; Arunkumar AI, 2002, PROTEIN SCI, V11, P1050, DOI 10.1110/ps.2270102; Bachmann A, 2001, J MOL BIOL, V306, P375, DOI 10.1006/jmbi.2000.4399; Bai YW, 1997, PROTEIN SCI, V6, P1449, DOI 10.1002/pro.5560060709; Bai YW, 1996, PROTEINS, V24, P145, DOI 10.1002/(SICI)1097-0134(199602)24:2<145::AID-PROT1>3.0.CO;2-I; BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Baldwin RL, 2001, NAT STRUCT BIOL, V8, P92, DOI 10.1038/84189; Bhuyan AK, 1998, PROTEINS, V30, P295, DOI 10.1002/(SICI)1097-0134(19980215)30:3<295::AID-PROT9>3.0.CO;2-J; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Cavagnero S, 2001, BIOCHEMISTRY-US, V40, P14459, DOI 10.1021/bi011500n; Chakraborty S, 2000, J MOL BIOL, V298, P1, DOI 10.1006/jmbi.2000.3660; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; Chi YH, 2001, BIOCHEMISTRY-US, V40, P7746, DOI 10.1021/bi002364+; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; Clark PL, 1997, NAT STRUCT BIOL, V4, P883, DOI 10.1038/nsb1197-883; Clarke J, 1998, CURR OPIN STRUC BIOL, V8, P112, DOI 10.1016/S0959-440X(98)80018-3; Clarke J, 1997, TRENDS BIOCHEM SCI, V22, P284, DOI 10.1016/S0968-0004(97)01087-6; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Englander SW, 2001, NAT STRUCT BIOL, V8, P741, DOI 10.1038/nsb0901-741; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; Forge V, 2000, J MOL BIOL, V296, P1039, DOI 10.1006/jmbi.1999.3515; Fuentes EJ, 1998, BIOCHEMISTRY-US, V37, P3687, DOI 10.1021/bi972579s; Griko YV, 2000, J MOL BIOL, V297, P1259, DOI 10.1006/jmbi.2000.3625; Heidary DK, 1997, NAT STRUCT BIOL, V4, P725, DOI 10.1038/nsb0997-725; HOUHSTON RS, 2002, BIOCHEMISTRY-US, V41, P1182; Huyghues-Despointes B M, 2001, Methods Mol Biol, V168, P69; Itzhaki LS, 1997, J MOL BIOL, V270, P89, DOI 10.1006/jmbi.1997.1049; JACKSON SE, 1991, BIOCHEMISTRY-US, V33, P6356; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Kim J, 2002, PROTEIN SCI, V11, P459, DOI 10.1110/ps.43802; Kim S, 1999, J MOL BIOL, V294, P551, DOI 10.1006/jmbi.1999.3250; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kuwata K, 2001, NAT STRUCT BIOL, V8, P151, DOI 10.1038/84145; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; Liu CS, 2002, PROTEIN SCI, V11, P669, DOI 10.1110/ps.31702; Llinas M, 1999, NAT STRUCT BIOL, V6, P1072; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MAYO AK, 1993, SCIENCE, V262, P813; Mullins LS, 1997, PROTEIN SCI, V6, P1387, DOI 10.1002/pro.5560060702; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Neira JL, 1997, J MOL BIOL, V270, P99, DOI 10.1006/jmbi.1997.1088; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; Ponting CP, 2000, J MOL BIOL, V302, P1041, DOI 10.1006/jmbi.2000.4087; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Radford SE, 2000, TRENDS BIOCHEM SCI, V25, P611, DOI 10.1016/S0968-0004(00)01707-2; Raschke TM, 1997, NAT STRUCT BIOL, V4, P298, DOI 10.1038/nsb0497-298; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; Roder H, 1999, CURR OPIN STRUC BIOL, V9, P620, DOI 10.1016/S0959-440X(99)00015-9; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; Smith DA, 2000, CURR BIOL, V10, pR662, DOI 10.1016/S0960-9822(00)00681-3; Spudich G, 2002, PROTEIN SCI, V11, P522, DOI 10.1110/ps.37202; Srisailam S, 2002, J BIOL CHEM, V277, P19027, DOI 10.1074/jbc.M110762200; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; van Nuland NAJ, 1998, J MOL BIOL, V283, P883, DOI 10.1006/jmbi.1998.2009; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; WOODWARD C, 1993, TRENDS BIOCHEM SCI, V18, P359, DOI 10.1016/0968-0004(93)90086-3; Yi Q, 1996, PROTEIN SCI, V5, P1060	68	16	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34941	34948		10.1074/jbc.M205446200	http://dx.doi.org/10.1074/jbc.M205446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12118009	hybrid			2022-12-27	WOS:000178117000038
J	Elmore, LW; Rehder, CW; Di, X; McChesney, PA; Jackson-Cook, CK; Gewirtz, DA; Holt, SE				Elmore, LW; Rehder, CW; Di, X; McChesney, PA; Jackson-Cook, CK; Gewirtz, DA; Holt, SE			Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; TERMINAL PROLIFERATION ARREST; C-MYC EXPRESSION; ANTHRACYCLINE ANTIBIOTICS; HUMAN FIBROBLASTS; IMMORTAL CELLS; RNA COMPONENT; GROWTH ARREST; LIFE-SPAN; DNA	Direct experimental evidence implicates telomere erosion as a primary cause of cellular senescence. Using a well characterized model system for breast cancer, we define here the molecular and cellular consequences of adriamycin treatment in breast tumor cells. Cells acutely exposed to adriamycin exhibited an increase in p53 activity, a decline in telomerase activity, and a dramatic increase in beta-galactosidase, a marker of senescence. Inactivation of wild-type p53 resulted in a transition of the cellular response to adriamycin treatment from replicative senescence to delayed apoptosis, demonstrating that p53 plays an integral role in the fate of breast tumor cells treated with DNA-damaging agents. Stable introduction of hTERT, the catalytic protein component of telomerase, into MCF-7 cells caused an increase in telomerase activity and telomere length. Treatment of MCF-7-hTERT cells with adriamycin produced an identical senescence response as controls without signs of telomere shortening, indicating that the senescence after treatment is telomere length-independent. However, we found that exposure to adriamycin resulted in an overrepresentation of cytogenetic changes involving telomeres, showing an altered telomere state induced by adriamycin is probably a causal factor leading to the senescence phenotype. To our knowledge, these data are the first to demonstrate that the mechanism of adriamycin-induced senescence is dependent on both functional p53 and telomere dysfunction rather than overall shortening.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Holt, SE (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, 1101 E Marshall St, Richmond, VA 23298 USA.				NCI NIH HHS [CA 85159-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA085159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barch M, 1991, AGT CYTOGENETICS LAB, P263; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEVITA VT, 1998, CANC PRINCIPLES PRAC; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAN SJ, 1995, CANCER RES, V55, P1649; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FORNARI FA, 1994, CELL GROWTH DIFFER, V5, P723; Fornari FA, 1996, BIOCHEM PHARMACOL, V51, P931, DOI 10.1016/0006-2952(96)00050-0; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LING YH, 1993, CANCER RES, V53, P1845; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; ROONEY DE, 1992, HUMAN CYTOGENETICS P, V1, P55; Savre-Train I, 2000, P SOC EXP BIOL MED, V223, P379, DOI 10.1046/j.1525-1373.2000.22354.x; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Tawn EJ, 1992, HUMAN CYTOGENETICS P, P189; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wei S, 1999, CANCER RES, V59, P1539; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; ZALESKIS G, 1994, MOL PHARMACOL, V46, P901	42	200	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35509	35515		10.1074/jbc.M205477200	http://dx.doi.org/10.1074/jbc.M205477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12101184	hybrid			2022-12-27	WOS:000178117000109
J	Nordstrom, T; Forsgren, A; Riesbeck, K				Nordstrom, T; Forsgren, A; Riesbeck, K			The immunoglobulin D-binding part of the outer membrane protein MID from Moraxella catarrhalis comprises 238 amino acids and a tetrameric structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE PROTEIN; IGD; PEPTIDE; DOMAIN	Moraxella catarrhalis IgD-binding protein (MID), a 200-kDa outer membrane protein comprising 2,139 amino acids, has recently been isolated and shown to display a unique and specific affinity for human IgD. To identify the IgD-binding region, MID was digested with proteases. In addition, a series of truncated fragments of MID were manufactured and expressed in Escherichia coli followed by analysis for IgD binding in Western and dot blots. The smallest fragment with essentially preserved IgD binding was comprised of 238 amino acid residues (MID962-1200). Shorter recombinant proteins gradually lost IgD-binding capacity, and the shortest IgD-binding fragment comprising 157 amino acids (MID985-1142) displayed a 1,000-fold reduced IgD binding compared with the full-length molecule. The truncated MID962-1200 was efficiently attracted to a standard IgD serum and to purified myeloma IgD(K) and IgD(A) sera but not to IgG, IgM, or IgA myeloma sera. Furthermore, the fragment specifically bound to peripheral blood B lymphocytes, and the binding was inhibited by preincubation with anti-IgD-Fab polyclonal antibodies. Results obtained by introducing five amino acids randomly into MID962-1200 using transposons suggested that a-helix structures were important for IgD binding. Ultracentrifugation experiments and gel electrophoresis revealed that native MID962-1200 was a tetramer. Interestingly, tetrameric MID962-1200 attracted IgD more than 20-fold more efficiently than the monomeric form. Thus, a tetrameric structure of MID962-1200 is crucial for optimal IgD-binding capacity.	Lund Univ, Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Riesbeck, K (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden.	kristian.riesbeck@mikrobiol.mas.lu.se		Riesbeck, Kristian/0000-0001-6274-6965				BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1984, J IMMUNOL, V133, P969; BRANDTZAEG P, 1979, J IMMUNOL, V122, P503; FORSGREN A, 1988, CELL IMMUNOL, V112, P78, DOI 10.1016/0008-8749(88)90277-8; FORSGREN A, 1979, J IMMUNOL, V122, P1468; Forsgren A, 2001, J IMMUNOL, V167, P2112, DOI 10.4049/jimmunol.167.4.2112; FORSGREN A, 1966, J IMMUNOL, V97, P822; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Johnsson E, 1999, J BIOL CHEM, V274, P14521, DOI 10.1074/jbc.274.21.14521; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KRONVALL G, 1969, J IMMUNOL, V103, P828; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; NIELSEN K, 1982, J IMMUNOL, V129, P366; ROBEN PW, 1995, J IMMUNOL, V154, P6437; ROWE DS, 1965, J EXP MED, V121, P171, DOI 10.1084/jem.121.1.171; Sandt CH, 1997, INFECT IMMUN, V65, P4572, DOI 10.1128/IAI.65.11.4572-4579.1997; SASSO EH, 1991, J IMMUNOL, V147, P1877; SJOBRING U, 1991, J BIOL CHEM, V266, P399; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; STENBERG L, 1994, J BIOL CHEM, V269, P13458; Vladutiu AO, 2000, CLIN DIAGN LAB IMMUN, V7, P131, DOI 10.1128/CDLI.7.2.131-140.2000; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; WIDDERS PR, 1988, J MED MICROBIOL, V26, P307, DOI 10.1099/00222615-26-4-307; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	26	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34692	34699		10.1074/jbc.M203858200	http://dx.doi.org/10.1074/jbc.M203858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110669	hybrid			2022-12-27	WOS:000178117000007
J	Smyth, JT; Abbott, AL; Lee, B; Sienaert, I; Kasri, NN; De Smedt, H; Ducibella, T; Missiaen, L; Parys, JB; Fissore, RA				Smyth, JT; Abbott, AL; Lee, B; Sienaert, I; Kasri, NN; De Smedt, H; Ducibella, T; Missiaen, L; Parys, JB; Fissore, RA			Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL MUCOSAL CELLS; SMOOTH-MUSCLE CELLS; CA2+ RELEASE; 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM OSCILLATIONS; PHOSPHOLIPASE-C; DOWN-REGULATION; SPERM FACTOR; CALMODULIN ANTAGONIST; GENE-EXPRESSION	KN-93, a Ca(2+)calmodulin-dependent protein kinase II (CaMKII) inhibitor, concentration-dependently and reversibly inhibited inositol 1,4,5-trisphosphate receptor (IP3R)-mediated [Ca2+](i) signaling in mouse eggs and permeabilized A7r5 smooth muscle cells, two cell types predominantly expressing type-1 IP3R (IP3R-1). KN-92, an inactive analog, was ineffective. The inhibitory action of KN-93 on Ca2+ signaling depended neither on effects on IP3 metabolism nor on the filling grade of Ca2+ stores, suggesting a direct action on the IP3R. Inhibition was independent of CaMKII, since in identical conditions other CaMKII inhibitors (KN-62, peptide 281-309, and autocamtide-related inhibitory peptide) were ineffective and since CaMKII activation was precluded in permeabilized cells. Moreover, KN-93 was most effective in the absence of Ca2+. Analysis of Ca2+ release in A7r5 cells at varying [IP3], of IP3H-1 degradation in eggs, and of [H-3]IP3 binding in Sf9 microsomes all indicated that KN-93 did not affect IP3 binding. Comparison of the inhibition of Ca2+ release and of [H-3]IP3 binding by KN-93 and calmodulin (CaM), either separately or combined, was compatible with a specific interaction of KN-93 with a CaM-binding site on IP3R-1. This was also consistent with the much smaller effect of KN-93 in permeabilized 16HBE14o(-) cells that predominantly express type 3 IP3R, which lacks the high affinity CaM-binding site. These findings indicate that KN-93 inhibits IP3R-1 directly and may therefore be a useful tool in the study of IP3R functional regulation.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Tufts Univ New England Med Ctr, Sackler Sch Biomed Sci, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Obstet & Gynecol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Tufts Medical Center; Tufts Medical Center; Tufts University; KU Leuven	Parys, JB (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.		Nadif Kasri, Nael/E-2270-2012	Nadif Kasri, Nael/0000-0002-7448-9289; Parys, Jan/0000-0002-3591-4967	NICHD NIH HHS [HD-24191] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024191] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adkins CE, 2000, BIOCHEM J, V345, P357, DOI 10.1042/0264-6021:3450357; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhatt HS, 2000, BIOCHEM PHARMACOL, V60, P1655, DOI 10.1016/S0006-2952(00)00483-4; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Fissore RA, 1999, BIOL REPROD, V60, P49, DOI 10.1095/biolreprod60.1.49; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Jones KT, 2000, BIOCHEM J, V346, P743, DOI 10.1042/0264-6021:3460743; Jones KT, 1998, FEBS LETT, V437, P297, DOI 10.1016/S0014-5793(98)01254-X; Ledoux J, 1999, J PHARMACOL EXP THER, V290, P1165; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Lin C, 2000, J BIOL CHEM, V275, P2305, DOI 10.1074/jbc.275.4.2305; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matifat F, 2001, PFLUG ARCH EUR J PHY, V441, P796, DOI 10.1007/s004240000479; MCGUINESS OM, 1996, DEVELOPMENT, V122, P179; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 2000, MOL PHARMACOL, V57, P564, DOI 10.1124/mol.57.3.564; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Missiaen L, 1996, Subcell Biochem, V26, P59; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Mohri T, 2001, CELL CALCIUM, V29, P311, DOI 10.1054/ceca.2000.0196; Nosyreva E, 2002, BIOCHEM J, V365, P659, DOI 10.1042/bj20011789; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Parys JB, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P179; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Richard EA, 1997, P NATL ACAD SCI USA, V94, P14095, DOI 10.1073/pnas.94.25.14095; Sienaert I, 1998, PFLUG ARCH EUR J PHY, V436, P40, DOI 10.1007/s004240050602; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Sipma H, 1999, J BIOL CHEM, V274, P12157, DOI 10.1074/jbc.274.17.12157; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; Wang YP, 2001, CIRC RES, V88, P202; WAWRZYNCZAK EJ, 1984, BIOCHEM INT, V9, P177; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Wu H, 1997, MOL REPROD DEV, V46, P176, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;176::AID-MRD8&gt;3.0.CO;2-N; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; Xu Z, 1996, DEV BIOL, V180, P594, DOI 10.1006/dbio.1996.0331; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yue CP, 2001, MOL CELL ENDOCRINOL, V175, P149, DOI 10.1016/S0303-7207(01)00383-5; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; Zhang XC, 2001, BIOCHEM J, V360, P395, DOI 10.1042/0264-6021:3600395; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h	58	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35061	35070		10.1074/jbc.M202928200	http://dx.doi.org/10.1074/jbc.M202928200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121980	hybrid			2022-12-27	WOS:000178117000052
J	Volpert, O; Luo, WP; Liu, TJ; Estrera, VT; Logothetis, C; Lin, SH				Volpert, O; Luo, WP; Liu, TJ; Estrera, VT; Logothetis, C; Lin, SH			Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; LEWIS-LUNG-CARCINOMA; ANTIGEN GENE FAMILY; PLATELET FACTOR-IV; X-C CHEMOKINE; BILIARY GLYCOPROTEIN; POTENT INHIBITOR; DIFFERENTIAL EXPRESSION; COLORECTAL CARCINOMAS; INDUCIBLE PROTEIN-10	We have previously shown that CEACAM1, a cell-adhesion molecule, acts as a tumor suppressor in prostate carcinoma. Expression of CEACAM1 in prostate cancer cells suppresses their growth in vivo. However, CEACAM1 has no effect on the growth of prostate cancer cells in vitro. This difference suggests that the antitumor effect of CEACAM1 may be due to inhibition of tumor angiogenesis, perhaps by increased secretion of antiangiogenic molecules from the cells. In this study, we have demonstrated that expression of CEACAM1. in DU145 prostate cancer cells induced the production of a factor or factors that specifically blocked the growth of endothelial but not epithelial cells. Conditioned medium from the CEACAM1-expressing cells but not control luciferase-expressing cells inhibited endothelial cell migration up a gradient of stimulatory vascular endothelial growth factor in vitro and inhibited corneal neovascularization induced by basic fibroblast growth factor in vivo. Moreover, conditioned medium from CEACAM1-expressing cells induced endothelial cell apoptosis in vitro. Only medium conditioned by CEACAM1 mutants that were able to suppress tumor growth in vivo could cause endothelial cell apoptosis. These observations suggest that CEACAM1-mediated tumor suppression in vivo is, at least in part, due to the ability of CEACAM1 to inhibit tumor angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Northwestern Univ, Sch Med, Rh Lurie Canc Ctr, Dept Immunol Microbiol, Chicago, IL 60611 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Lin, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.			Volpert, Olga/0000-0003-1381-5543	NATIONAL CANCER INSTITUTE [R01CA064856, T32CA067759, R01CA086342, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64856, CA 86342, T32 CA 67759, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Bielenberg DR, 1999, INT J ONCOL, V14, P401; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; Dong ZY, 1999, CANCER RES, V59, P872; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HAHNEL E, 1993, INT J CANCER, V55, P771, DOI 10.1002/ijc.2910550513; HIXSON DC, 1985, CANCER RES, V45, P3742; Hsieh JT, 1999, PROSTATE, V41, P31; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Kaban LB, 1999, PEDIATRICS, V103, P1145, DOI 10.1542/peds.103.6.1145; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pluda JM, 1997, SEMIN ONCOL, V24, P203; POLETTE M, 1993, INVAS METAST, V13, P31; POLVERINI PJ, 1985, J LEUKOCYTE BIOL, V37, P279, DOI 10.1002/jlb.37.3.279; Pu YS, 1999, J UROLOGY, V162, P892, DOI 10.1097/00005392-199909010-00085; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303	54	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35696	35702		10.1074/jbc.M205319200	http://dx.doi.org/10.1074/jbc.M205319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122002	hybrid			2022-12-27	WOS:000178117000131
J	Kobayashi, S; Valentine, MR; Pham, P; O'Donnell, M; Goodman, MF				Kobayashi, S; Valentine, MR; Pham, P; O'Donnell, M; Goodman, MF			Fidelity of Escherichia coli DNA polymerase IV - Preferential generation of small deletion mutations by dNTP-stabilized misalignment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POL-II; Y-FAMILY; NUCLEOTIDE INCORPORATION; TRANSLESION SYNTHESIS; REPLICATION RESTART; ADAPTIVE MUTATION; KINETIC-ANALYSIS; WILD-TYPE; MUTAGENESIS; LESION	Escherichia coli DNA polymerase IV (pol IV), a member of the error-prone Y family, predominantly generates -1 frameshifts when copying DNA in vitro. T --> G transversions and T --> C transitions are the most frequent base substitutions observed. The in vitro data agree with mutational spectra obtained when pol IV is overexpressed in vivo. Single base deletion and base substitution rates measured in the lacZalpha gene in vitro are, on average, 2 x 10(-4) and 5 x 10(-5), respectively. The range of misincorporation and mismatch extension efficiencies determined kinetically are 10(-3) to 10(-5). The presence of beta sliding clamp and gamma-complex clamp loading proteins strongly enhance pol IV processivity but have no discernible influence on fidelity. By analyzing changes in fluorescence of a 2-aminopurine template base undergoing replication in real time, we show that a "dNTP-stabilized" misalignment mechanism is responsible for making -1 frameshift mutations on undamaged DNA. In this mechanism, a dNTP substrate is paired "correctly" opposite a downstream template base, on a "looped out" template strand instead of mispairing opposite a next available template base. By using the same mechanism, pol IV "skips" past an abasic template lesion to generate a -1 frameshift. A crystal structure depicting dNTP-stabilized misalignment was reported recently for Sulfolubus solfataricus Dpo4, a Y family homolog of Escherichia coli pol IV.	Univ So Calif, Hedco Mol Biol Labs, Dept Chem & Biol Sci, Los Angeles, CA 90089 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	University of Southern California; Rockefeller University; Howard Hughes Medical Institute	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, SHS Rm 172,Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@mizar.usc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42554, GM 21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Beechem JM, 1998, BIOCHEMISTRY-US, V37, P10144, DOI 10.1021/bi980074b; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; Courcelle J, 2001, GENETICS, V158, P41; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; Efrati E, 1997, J BIOL CHEM, V272, P2559; Ellenberger T, 2001, NAT STRUCT BIOL, V8, P827, DOI 10.1038/nsb1001-827; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Foster PL, 2000, COLD SPRING HARB SYM, V65, P21, DOI 10.1101/sqb.2000.65.21; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P467; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; Qiu ZH, 1997, J BIOL CHEM, V272, P8611, DOI 10.1074/jbc.272.13.8611; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2000, EMBO REP, V1, P484; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199	48	113	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34198	34207		10.1074/jbc.M204826200	http://dx.doi.org/10.1074/jbc.M204826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097328	hybrid			2022-12-27	WOS:000177959100088
J	Kozak, L; Gopal, G; Yoon, JH; Sauna, ZE; Ambudkar, SV; Thakurta, AG; Dhar, R				Kozak, L; Gopal, G; Yoon, JH; Sauna, ZE; Ambudkar, SV; Thakurta, AG; Dhar, R			Elf1p, a member of the ABC class of ATPases, functions as a mRNA export factor in Schizosacchromyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR EXPORT; POLY(A)(+) RNA; FISSION YEAST; RAE1 GENE; TRANSPORT; MEX67P; INTERACTS; NUP116P	Rae1p and Mex67p/Tap are conserved mRNA export factors. We have used synthetic lethal genetic screens in Schizosaccharomyces pombe to identify mutations in genes that are functionally linked to rae1 and mex67 in mRNA export. From these screens, we have isolated mutations in a putative S. pombe homologue of the Candida albicans elf1 gene. The elf1 of S. pombe is not an essential gene. When elt1 mutations are combined with rae1-167 mutation, growth and mRNA export is inhibited in the double mutants. This inhibition can be suppressed by the multicopy expression of mex67 suggesting that Mex67p can substitute for the loss of Elf1p function. Elf1p is a non-membrane member of the ATP-binding cassette (ABC) class of ATPase and the GFP-Elf1p fusion localizes to the cytoplasm. Elf1p, expressed and purified from Escherichia coli, binds and hydrolyzes ATP. A mutant Elf1p that carries a glycine to aspartic acid (G731D) mutation within the Walker A domain of the second ATP site retains the ATP binding but loses its ATPase activity in vitro. This mutant protein no longer functions in mRNA export. Taken together, our results show that Elf1p functions as a mRNA export factor along with Rae1p and Mex67p in S. pombe.	NCI, Canc Res Ctr, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NCI, Canc Res Ctr, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dhar, R (corresponding author), NCI, Canc Res Ctr, Basic Res Lab, NIH, Bldg 37,Rm 6138B,9000 Rockville Pike, Bethesda, MD 20892 USA.	dharr@mail.nih.gov	Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019					Alfa C., 1993, EXPT FISSION YEAST; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Bharathi A, 1997, GENE, V198, P251, DOI 10.1016/S0378-1119(97)00322-3; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Chakraburtty K, 2001, RES MICROBIOL, V152, P391, DOI 10.1016/S0923-2508(01)01210-4; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Gadal O, 2001, EMBO J, V20, P3695, DOI 10.1093/emboj/20.14.3695; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kraemer D, 2001, EUR J CELL BIOL, V80, P733, DOI 10.1078/0171-9335-00216; Li Y, 2001, P NATL ACAD SCI USA, V98, P441, DOI 10.1073/pnas.021555498; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Sturtevant J, 1998, MICROBIOL-SGM, V144, P2311, DOI 10.1099/00221287-144-8-2311; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Whalen WA, 1999, GENETICS, V152, P827; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Yoon JH, 1997, MOL CELL BIOL, V17, P7047, DOI 10.1128/MCB.17.12.7047; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6	36	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33580	33589		10.1074/jbc.M205415200	http://dx.doi.org/10.1074/jbc.M205415200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110682	hybrid			2022-12-27	WOS:000177959100008
J	Min, GS; Kim, HJ; Bae, YJ; Petz, L; Kemper, JK				Min, GS; Kim, HJ; Bae, YJ; Petz, L; Kemper, JK			Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR) - CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTORS; RETINOID-X-RECEPTOR; THYROID-HORMONE; TRANSCRIPTION; BINDING; GENE; TRANSACTIVATION; INDUCTION; LIGAND; DOMAIN	Estrogen receptor (ER) activity can be modulated by the action of other nuclear receptors. To study whether ER activity is altered by orphan nuclear receptors that mediate the cellular response to xenobiotics, cross-talk between ER and constitutive androstane receptor (CAR), steroid and xenobiotic receptor, or peroxisome proliferator-activated receptor gamma was examined in HepG2 cells. Of these receptors, CAR substantially inhibited ER-mediated transcriptional activity of the vitellogenin B1 promoter as well as a synthetic estrogen responsive element (ERE)-containing promoter. Treatment with an agonist of CAR, 1,4-bis-(2-(3,5-dichloropyridoxyl))benzene, potentiated CAR-mediated transcriptional repression. In contrast, an antagonist of CAR, androstenol, alleviated the repression effect. Although CAR interacted with the ER in solution, CAR did not interact with the ER bound to the ERE. CAR/retinoid X receptor bound to the ERE but with much lower affinity than ER. Incremental amounts of CAR elicited a progressive reduction of the ER activity induced by the p160 coactivator glucocorticoid receptor interacting protein 1 (GRIP-1). In turn, increasing amounts of GRIP-1 progressively reversed the depression of ER activity by CAR. An agonist or antagonist of CAR potentiated or alleviated, respectively, the CAR-mediated repression of the GRIP-1-enhanced ER activity, which is consistent with the ability of theses ligands to increase or decrease, respectively, the interaction of CAR with GRIP-1. A CAR mutant that did not interact with GRIP-1 did not inhibit ER-mediated transactivation. Our data demonstrate that xenobiotic nuclear receptor CAR antagonizes ER-mediated transcriptional activity by squelching limiting amounts of p160 coactivator and imply that xenobiotics may influence ER function of female reproductive physiology, cell differentiation, tumorigenesis, and lipid metabolism.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kemper, JK (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.	jongsook@uiuc.edu	Bae, Yangjin/AAO-1866-2021	Bae, Yangjin/0000-0003-2397-0192				ARCHER TK, 1986, J BIOL CHEM, V261, P5067; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Croston GE, 1997, ENDOCRINOLOGY, V138, P3779, DOI 10.1210/en.138.9.3779; Duan RQ, 1999, MOL ENDOCRINOL, V13, P1511, DOI 10.1210/me.13.9.1511; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Lamon-Fava S, 1999, ARTERIOSCL THROM VAS, V19, P2960, DOI 10.1161/01.ATV.19.12.2960; Mao CJ, 2000, ENDOCRINOLOGY, V141, P2361, DOI 10.1210/en.141.7.2361; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Nichols M, 1998, EMBO J, V17, P765, DOI 10.1093/emboj/17.3.765; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Ricci MS, 1999, J BIOL CHEM, V274, P3430, DOI 10.1074/jbc.274.6.3430; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P36, DOI 10.1016/S0753-3322(01)00155-X; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112	36	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34626	34633		10.1074/jbc.M205239200	http://dx.doi.org/10.1074/jbc.M205239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114525	hybrid			2022-12-27	WOS:000177959100137
J	Voets, T; Prenen, J; Vriens, J; Watanabe, H; Janssens, A; Wissenbach, U; Bodding, M; Droogmans, G; Nilius, B				Voets, T; Prenen, J; Vriens, J; Watanabe, H; Janssens, A; Wissenbach, U; Bodding, M; Droogmans, G; Nilius, B			Molecular determinants of permeation through the cation channel TRPV4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CA2+ CHANNEL; CAPSAICIN-RECEPTOR; VANILLOID RECEPTOR; PATCH-CLAMP; ION-CHANNEL; HEAT; ACTIVATION; RESIDUE; OTRPC4; TRP12	We have studied the molecular determinants of ion permeation through the TRPV4 channel (VRL-2, TRP12, VR-OAC, and OTRPC4). TRPV4 is characterized by both inward and outward rectification, voltage-dependent block by Ruthenium Red, a moderate selectivity for divalent versus monovalent cations, and an Eisenman IV permeability sequence. We identify two aspartate residues,Asp(672) and AsP682, as important determinants of the Ca2+ sensitivity of the TRPV4 pore. Neutralization of either aspartate to alanine caused a moderate reduction of the relative permeability for divalent cations and of the degree of outward rectification. Neutralizing both aspartates simultaneously caused a much stronger reduction of Ca2+ permeability and channel rectification and additionally altered the permeability order for monovalent cations toward Eisenman sequence II or I. Moreover, neutralizing Asp(682) but not AsP672 strongly reduces the affinity of the channel for Ruthenium Red. Mutations to Met(680), which is located at the center of a putative selectivity filter, strongly reduced whole cell current amplitude and impaired Ca2+ permeation. In contrast, neutralizing the only positively charged residue in the putative pore region, Lys(675), had no obvious effects on the properties of the TRPV4 channel pore. Our findings delineate the pore region of TRPV4 and give a first insight into the possible architecture of its permeation pathway.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	KU Leuven; Saarland University	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Herestr 49,Campus Gasthuisberg, B-3000 Louvain, Belgium.		Vriens, Joris/G-9966-2018; Voets, Thomas/AAD-4389-2019; Voets, Thomas/E-2466-2012	Vriens, Joris/0000-0002-2502-0409; Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248				BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; NILIUS B, 2000, J PHYSIOL-LONDON, V1, P2239; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	24	220	232	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33704	33710		10.1074/jbc.M204828200	http://dx.doi.org/10.1074/jbc.M204828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093812	hybrid			2022-12-27	WOS:000177959100025
J	Pinakoulaki, E; Soulimane, T; Varotsis, C				Pinakoulaki, E; Soulimane, T; Varotsis, C			Fourier transform infrared (FTIR) and step-scan time-resolved FTIR spectroscopies reveal a unique active site in cytochrome caa(3) oxidase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-COPPER OXIDASES; C-OXIDASE; BINUCLEAR CENTER; RESONANCE RAMAN; PARACOCCUS-DENITRIFICANS; STRUCTURAL-CHANGES; CARBON-MONOXIDE; PHOTODISSOCIATION; REDUCTION; INTERMEDIATE	Fourier transform infrared (FTIR) and step-scan time-resolved FTIR difference spectra are reported for the [carbonmonoxyl]cytochrome caa(3) from Thermus thermophilus. A major C-O mode of heme a(3) at 1958 cm(-1) and two minor modes at 1967 and 1975 cm(-1) (7:1:1) have been identified at room temperature and remained unchanged in H2O/D2O exchange. The observed C-O frequencies are 10 cm(-1) higher than those obtained previously at 21 K (Einarsdottir, O., Killough, P. M., Fee, J. A., and Woodruff, W. H. (1989) J. Biol. Chem. 264,2405-2408). The time-resolved FTIR data indicate that the transient Cu-B(1+)-CO complex is formed at room temperature as revealed by the CO stretching mode at 2062 cm(-1). Therefore, the caa(3) enzyme is the only documented member of the heme-copper superfamily whose binuclear center consists of an a(3)-type heme of a beta-form and a Cu-B atom of an a-form. These results illustrate that the properties of the binuclear center in other oxidases resulting in the a-form are not required for enzymatic activity. Dissociation of the transient Cu-B(1+)-CO complex is biphasic. The rate of decay is 2.3 X 10(4) s(1) (fast phase, 35%) and 36.3 s(-1) (slow phase, 65%). The observed rate of rebinding to heme a(3) is 34.1 s(-1). The implications of these results with respect to the molecular motions that are general to the photodynamics of the binuclear center in heme-copper oxidases are discussed.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.		Hu, Ruogu/B-2203-2008	Varotsis, Constantinos/0000-0003-2771-8891; Pinakoulaki, Eftychia/0000-0003-3320-6112				Bailey JA, 2002, BIOCHEMISTRY-US, V41, P2675, DOI 10.1021/bi010823g; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; EINARSDOTTIR O, 1989, J BIOL CHEM, V264, P2405; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; Gerscher S, 1998, BIOSPECTROSCOPY, V4, P365, DOI 10.1002/(SICI)1520-6343(1998)4:6<365::AID-BSPY2>3.0.CO;2-C; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; HAN S, 1989, J BIOL CHEM, V264, P6604; Han S, 2000, J BIOL CHEM, V275, P1910, DOI 10.1074/jbc.275.3.1910; Heitbrink D, 2002, BIOPHYS J, V82, P1, DOI 10.1016/S0006-3495(02)75368-X; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; Iwase T, 1999, J AM CHEM SOC, V121, P1415, DOI 10.1021/ja983242w; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KOUTSOUPAKIS K, 2002, J BIOL CHEM; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; OERTLING WA, 1994, BIOCHEMISTRY-US, V33, P3128, DOI 10.1021/bi00176a048; Park S, 1996, BIOPHYS J, V71, P1036, DOI 10.1016/S0006-3495(96)79304-9; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Rich PR, 2001, BIOCHEMISTRY-US, V40, P6441, DOI 10.1021/bi0027332; Rost B, 1999, BIOCHEMISTRY-US, V38, P7565, DOI 10.1021/bi990225q; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Than M. E., 2001, HDB METALLOPROTEINS, P363; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS CA, 1995, J AM CHEM SOC, V117, P11260, DOI 10.1021/ja00150a025; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, J AM CHEM SOC, V117, P9363, DOI 10.1021/ja00141a033; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	35	29	29	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32867	32874		10.1074/jbc.M205568200	http://dx.doi.org/10.1074/jbc.M205568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12107185	hybrid			2022-12-27	WOS:000177859000063
J	Boudrez, A; Beullens, M; Waelkens, E; Stalmans, W; Bollen, M				Boudrez, A; Beullens, M; Waelkens, E; Stalmans, W; Bollen, M			Phosphorylation-dependent interaction between the splicing factors SAP155 and NIPP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE-1; SR PROTEINS; NUCLEAR-ORGANIZATION; BRANCH SITE; FHA DOMAIN; U2 SNRNP; RNA; KINASE; INHIBITOR; COMPLEX	NIPP1. is a ubiquitously expressed nuclear protein that functions both as a regulator of protein Ser/Thr phosphatase-1 and as a splicing factor. The N-terminal part of NIPP1 consists of a phosphothreonine-interacting Forkhead-associated (FHA) domain. We show here that the FHA domain of NIPP1. interacts in vitro and in vivo with a TP dipeptide-rich fragment of the splicing factor SAP155/SF3b(155), a component of the U2 small nuclear ribonucleoprotein particle. The NIPP1-SAP155 interaction was entirely dependent on the phosphorylation of specific TP motifs in SAP155. Mutagenesis and competition studies revealed that various phosphorylated TP motifs competed for binding to the same site in the FHA domain. The SAP155 kinases in cell lysates were blocked by the Ca2+ chelator EGTA and by the cyclin-dependent protein kinase inhibitor roscovitine. The phosphorylation level of SAP155 was dramatically increased during mitosis, and accordingly the activity of SAP155 kinases was augmented in mitotic lysates. We discuss how the interaction between NIPP1 and SAP155 could contribute to spliceosome (dis)assembly and the catalytic steps of splicing.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.							Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Brede G, 2000, GENOMICS, V70, P82, DOI 10.1006/geno.2000.6365; Das BK, 1999, MOL CELL BIOL, V19, P6796; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; Habara Y, 1998, NUCLEIC ACIDS RES, V26, P5662, DOI 10.1093/nar/26.24.5662; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Jagiello I, 2000, J CELL SCI, V113, P3761; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Li J, 2000, J CELL SCI, V113, P4143; Ljungman M, 2001, MOL PHARMACOL, V60, P785; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; MURRAY MV, 1999, POST TRANSCRIPTIONAL, V25, P83; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Pauling MH, 2000, MOL CELL BIOL, V20, P2176, DOI 10.1128/MCB.20.6.2176-2185.2000; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Takagi M, 2001, J BIOL CHEM, V276, P25386, DOI 10.1074/jbc.M102227200; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Will CL, 2001, EMBO J, V20, P4536, DOI 10.1093/emboj/20.16.4536; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7	40	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31834	31841		10.1074/jbc.M204427200	http://dx.doi.org/10.1074/jbc.M204427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105215	hybrid			2022-12-27	WOS:000177718700067
J	Gilquin, B; Racape, J; Wrisch, A; Visan, V; Lecoq, A; Grissmer, S; Menez, A; Gasparini, S				Gilquin, B; Racape, J; Wrisch, A; Visan, V; Lecoq, A; Grissmer, S; Menez, A; Gasparini, S			Structure of the BgK-Kv1.1 complex based on distance restraints identified by double mutant cycles - Molecular basis for convergent evolution of Kv1 channel blockers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-CONOTOXIN PVIIA; PROTEIN-PROTEIN INTERACTIONS; GATED POTASSIUM CHANNELS; K+ CHANNEL; ION CONDUCTION; PORE; CHARYBDOTOXIN; DENDROTOXIN; RECEPTOR; TOXINS	A structural model of BgK, a sea anemone toxin, complexed with the S5-S6 region of Kv1.1, a voltage-gated potassium channel, was determined by flexible docking under distance restraints identified by a double mutant cycles approach. This structure provides the molecular basis for identifying the major determinants of the BgK-Kv1.1 channel interactions involving the BgK dyad residues Lys(25) and Tyr(26). These interactions are (i) electrostatic interactions between the extremity of Lys(25) side chain and carbonyl oxygen atoms of residues from the channel selectivity filter that may be strengthened by solvent exclusion provided by (ii) hydrophobic interactions involving BgK residues Tyr(26) and Phe(6) and Kv1.1 residue Tyr(379). whose side chain protrudes in the channel vestibule. In other Kv1 channel-BgK complexes, these interactions are likely to be conserved, implicating both conserved and variable residues from the channels. The data suggest that the conservation in sea anemone and scorpion potassium channel blockers of a functional dyad composed of a lysine, and a hydrophobic residue reflects their use of convergent binding solutions based on a crucial interplay between these important conserved interactions.	CEA Saclay, Dept Ingn Etudes & Prot, F-91191 Gif Sur Yvette, France; Univ Ulm, Dept Appl Physiol, D-89081 Ulm, Germany	CEA; UDICE-French Research Universities; Universite Paris Saclay; Ulm University	Gilquin, B (corresponding author), CEA Saclay, Dept Ingn Etudes & Prot, Bat 152, F-91191 Gif Sur Yvette, France.	bgilquin@cea.fr; gasparin@dsvidf.cea.fr	Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Alessandri-Haber N, 1999, J BIOL CHEM, V274, P35653, DOI 10.1074/jbc.274.50.35653; Berneche S, 2000, BIOPHYS J, V78, P2900, DOI 10.1016/S0006-3495(00)76831-7; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chakrabarti P, 2002, PROTEINS, V47, P334, DOI 10.1002/prot.10085; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Garcia E, 1999, J GEN PHYSIOL, V114, P141, DOI 10.1085/jgp.114.1.141; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; Jager H, 1998, J PHYSIOL-LONDON, V506, P291, DOI 10.1111/j.1469-7793.1998.291bw.x; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kim M, 1997, J NEUROSCI, V17, P8213; KLEANTHOUS C, 2000, PROTEIN PROTEIN RECO, P280; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Racape J, 2002, J BIOL CHEM, V277, P3886, DOI 10.1074/jbc.M109886200; RACAPE J, 2001, THESIS U PARIS SUD 1; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Savarin P, 1999, PROTEIN SCI, V8, P2672; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; Wrisch A, 2000, J BIOL CHEM, V275, P39345, DOI 10.1074/jbc.M006827200; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37406	37413		10.1074/jbc.M206205200	http://dx.doi.org/10.1074/jbc.M206205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133841	hybrid			2022-12-27	WOS:000178447100064
J	Hunter, HN; Fulton, DB; Ganz, T; Vogel, HJ				Hunter, HN; Fulton, DB; Ganz, T; Vogel, HJ			The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; CYSTEINE RESIDUES; GENE; IDENTIFICATION; CONTAINS; PROGRAM; ANEMIA; SITE	The antibacterial and antifungal peptide hepcidin (LEAP-1) is expressed in the liver. This circulating peptide has recently been found to also act as a signaling molecule in iron metabolism. As such, it plays an important role in hereditary hemochromatosis, a serious iron overload disease. In this study, we report the solution structures of the hepcidin-20 and -25 amino acid peptides determined by standard two-dimensional H-1 NMR spectroscopy. These small cysteine-rich peptides form a distorted beta-sheet with an unusual vicinal disulfide bridge found at the turn of the hairpin, which is probably of functional significance. Both peptides exhibit an overall amphipathic structure with six of the eight Cys involved in maintaining interstrand connectivity. Hepcidin-25 assumes major and minor conformations centered about the Pro residue near the N-terminal end. Further NMR diffusion studies indicate that hepcidin-20 exists as a monomer in solution, whereas hepcidin-25 readily aggregates, a property that may contribute to the different activities of the two peptides. The nuclear Overhauser enhancement spectroscopy spectra of the hepcidin-25 aggregates indicate an interface for peptide interactions that again involves the first five residues from the N-terminal end.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90059 USA	University of Calgary; Iowa State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca	Ganz, Tomas/AAN-3308-2020; Girelli, Domenico/B-1183-2008; Ganz, Tomas/D-4567-2009	Girelli, Domenico/0000-0001-9684-1899; Ganz, Tomas/0000-0002-2830-5469				Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Berrocal-Lobo M, 2002, PLANT PHYSIOL, V128, P951, DOI 10.1104/pp.010685; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; KAO PN, 1986, J BIOL CHEM, V261, P8085; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029; MERRILL MR, 1993, J MAGN RESON SER A, V103, P223, DOI 10.1006/jmra.1993.1157; MOORE MJ, 1992, BIOCHEMISTRY-US, V31, P1677, DOI 10.1021/bi00121a015; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Park C, 2001, PROTEIN ENG, V14, P939, DOI 10.1093/protein/14.11.939; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zahn R, 2001, J MOL BIOL, V313, P923, DOI 10.1006/jmbi.2001.5099	32	306	363	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37597	37603		10.1074/jbc.M205305200	http://dx.doi.org/10.1074/jbc.M205305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138110	hybrid			2022-12-27	WOS:000178447100088
J	Zoll, WL; Horton, LE; Komar, AA; Hensold, JO; Merrick, WC				Zoll, WL; Horton, LE; Komar, AA; Hensold, JO; Merrick, WC			Characterization of mammalian eIF2A and identification of the yeast homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; START-SITE; PURIFICATION; SUBUNIT; EXPRESSION; RIBOSOMES; SELECTION; ENCODES; BINDING	To begin the physical characterization of eukaryotic initiation factor (eIF) 2A, a translation initiation factor that binds Met-tRNA., tryptic peptides from rabbit reticulocyte eIF2A were analyzed to obtain amino acid sequence information. Sequences for 8 peptides were matched to three different expressed sequence tag clones. The sequence predicted for eIF2A is 585 amino acids. Matching of the cDNA sequence to the human genome revealed that the eIF2A mRNA is made up of 15 or 16 exons, and the gene is contained on chromosome 3. A homolog in Saccharomyces cerevisiae was identified, YGR054W, which is a non-essential gene. Hemagglutinin-tagged yeast eIF2A localizes on both 40 S and 80 S ribosomes. A knockout of both eIF2A and eIF5B yielded a "synthetically sick" yeast strain with a severe slow growth phenotype. The phenotype of this double mutant and the biochemical localization suggest that eIF2A participates in translation initiation. eIF2A does not appear to participate in re-initiation as the DeltaeIF2A strain shows the same level of GCN4 induction with amino acid starvation as seen in wild type yeast. The lack of any apparent phenotype in the DeltaeIF2A strain suggests that eIF2A functions in a minor pathway, perhaps internal initiation or in the translation of a small number of specific mRNAs.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	wcm2@po.ewru.edu		Komar, Anton/0000-0003-4188-0633	NIDDK NIH HHS [DK43414, DK09915] Funding Source: Medline; NIGMS NIH HHS [GM26796, GM08056] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; BECKER D M, 1991, P182; BENNE R, 1978, J BIOL CHEM, V253, P3078; Castilho-Valavicius Beatriz, 1992, Gene Expression, V2, P297; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; Donahue TF, 2000, COLD SPRING HARBOR M, V39, P487; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GUPTA NK, 1973, J BIOL CHEM, V248, P4500; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; LEVIN DH, 1973, P NATL ACAD SCI USA, V70, P41, DOI 10.1073/pnas.70.1.41; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1975, J BIOL CHEM, V250, P1197; MERRICK WC, 1979, J BIOL CHEM, V254, P3708; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonenberg N, 2000, TRANSLATIONAL CONTRO; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	35	47	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37079	37087		10.1074/jbc.M207109200	http://dx.doi.org/10.1074/jbc.M207109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133843	hybrid			2022-12-27	WOS:000178447100024
J	Andrews, RP; Ericksen, MB; Cunningham, CM; Daines, MO; Hershey, GKK				Andrews, RP; Ericksen, MB; Cunningham, CM; Daines, MO; Hershey, GKK			Analysis of the life cycle of Stat6 - Continuous cycling of Stat6 is required for IL-4 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; GENE-EXPRESSION; TYROSINE-PHOSPHATASE; CUTTING EDGE; INHIBITION; ACTIVATION; PROTEIN; MICE; TRANSCRIPTION; TRANSDUCTION	Signal transducer and activator of transcription (Stat)6 is a transcription factor important for the development of Th2 cells and regulation of gene expression by IL-4 and IL-13. It is known that Stat6 is rapidly activated in response to IL-4; however, the fate of activated Stat6 is less clear. We examined the fate of activated Stat6 and found that during continuous exposure to IL-4, Stat6 activity was sustained for 72 h and that the maintenance of a constant level of activated Stat6 did not require new protein synthesis. In contrast, when cells were pulsed with IL-4 and then incubated in the absence of IL-4, the half-life of Stat6 phosphorylation and DNA binding activity was less than 1 h. Stat6 did not accumulate in the nucleus, and protein degradation did not play a major role in the disappearance of activated Stat6. Inhibition of kinase activity by staurosporine or the JAK inhibitor, AG490, revealed that maintenance of Stat6 activation in the continuous presence of IL-4 required ongoing phosphorylation of latent cytoplasmic Stat6 molecules. Cells treated with an inhibitor of nuclear export, leptomycin B, were unable to maintain Stat6 activation. Thus, the maintenance of Stat6 activation requires a constant cycle of activation, deactivation, nuclear export, and reactivation.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Khurana Hershey, Gurjit/0000-0001-6663-977X; Daines, Michael/0000-0003-2464-9034				Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KHURANA HGK, 1989, J BIOL CHEM, V264, P11981; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Losman JA, 1999, J IMMUNOL, V162, P3770; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang HY, 1999, J IMMUNOL, V162, P4385; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	34	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36563	36569		10.1074/jbc.M200986200	http://dx.doi.org/10.1074/jbc.M200986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121972	hybrid			2022-12-27	WOS:000178275100099
J	del Campo, EM; Sabater, B; Martin, M				del Campo, EM; Sabater, B; Martin, M			Post-transcriptional control of chloroplast gene expression - Accumulation of stable psaC mRNA is due to downstream RNA cleavages in the ndhD gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTS; COMPLEX; IDENTIFICATION; DEHYDROGENASE; SEQUENCES; GENOME; OPERON; START	Intergenic cleavages, intron splicing, and editing of primary transcripts of the plastid ndhH-D operon produce multiple overlapping RNAs, of which the most abundant by far is the monocistronic 400-nucleotide mRNA of psaC (encoding the PsaC protein of photosystem I), in contrast with the low level of transcripts of the six ndh genes. Like other plastid operons containing genes for functionally unrelated proteins, the contrasting accumulation of ndh and psaC transcripts provides a model to investigate the mechanisms of the post-transcriptional control of gene expression, a feature of chloroplast genetic machinery, with a minimum of interference by transcriptional control. In leek (Allium porrum L), the ndhD transcript (which follows the psaC gene and ends the ndhH-D operon) requires C --> U editing to restore its start codon and may be used as a marker for the processing of psaC and ndhD transcripts. By determining the editing state and 5' end sequences of specific transcripts, we demonstrated that stable monocistronic psaC mRNA results from downstream cleavages in the ndhD sequence, which renders non-functional ndhD transcripts as by-products. Alternative psaC-ndhD intergenic cleavages produce complete mRNAs for both genes, but only take place in precursors containing editing-restored ndhD start codons. Hence, post-transcriptional control acts by promoting the ndhD cleavage alternative, which allows the accumulation of psaC mRNA at the expense of ndhD mRNA levels.	Univ Alcala de Henares, Dept Biol Vegetal, Madrid 28871, Spain	Universidad de Alcala	Martin, M (corresponding author), Univ Alcala de Henares, Dept Biol Vegetal, Madrid 28871, Spain.	mercedes.martin@uah.es	DEL CAMPO, EVA MARIA/M-3003-2014; Sabater, Bartolome/B-6039-2008	DEL CAMPO, EVA MARIA/0000-0003-4796-6227; Sabater, Bartolome/0000-0002-8586-1226				Ausubel FM, 1988, MOL REPROD DEV; Barkan A, 2000, BIOCHIMIE, V82, P559, DOI 10.1016/S0300-9084(00)00602-7; BARKAN A, 1988, EMBO J, V7, P2637, DOI 10.1002/j.1460-2075.1988.tb03116.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Casano LM, 2000, J BIOL CHEM, V275, P942, DOI 10.1074/jbc.275.2.942; del Campo EM, 2000, NUCLEIC ACIDS RES, V28, P1092, DOI 10.1093/nar/28.5.1092; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Hirose T, 1997, EMBO J, V16, P6804, DOI 10.1093/emboj/16.22.6804; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; KANNO A, 1993, CURR GENET, V23, P166, DOI 10.1007/BF00352017; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Lopez-Serrano M, 2001, J EXP BOT, V52, P179, DOI 10.1093/jexbot/52.354.179; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; Martin M, 1996, PLANT CELL PHYSIOL, V37, P293, DOI 10.1093/oxfordjournals.pcp.a028945; Meurer J, 1996, PLANT CELL, V8, P1193, DOI 10.1105/tpc.8.7.1193; NECKERMANN K, 1994, GENE, V146, P177, DOI 10.1016/0378-1119(94)90290-9; Sazanov LA, 1998, P NATL ACAD SCI USA, V95, P1319, DOI 10.1073/pnas.95.3.1319; SCHANTZ R, 1988, PLANT MOL BIOL, V11, P239, DOI 10.1007/BF00027381; Schmitz-Linneweber C, 2001, EMBO J, V20, P4874, DOI 10.1093/emboj/20.17.4874; STERN DB, 1989, J BIOL CHEM, V264, P18742; Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	23	32	35	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36457	36464		10.1074/jbc.M204500200	http://dx.doi.org/10.1074/jbc.M204500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118005	hybrid			2022-12-27	WOS:000178275100087
J	Doerrler, WT; Raetz, CRH				Doerrler, WT; Raetz, CRH			ATPase activity of the MsbA lipid flippase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-DEFICIENT MUTANT; SALMONELLA-TYPHIMURIUM; TANGIER-DISEASE; ANTIBACTERIAL AGENTS; ABC TRANSPORTERS; INNER MEMBRANE; A PRECURSORS; GENE; BINDING; RECONSTITUTION	Escherichia coli MsbA, the proposed inner membrane lipid flippase, is an essential ATP-binding cassette transporter protein with homology to mammalian multidrug resistance proteins. Depletion or loss of function of MsbA results in the accumulation of lipopolysaccharide and phospholipids in the inner membrane of E. coli. MsbA modified with an N-terminal hexahistidine tag was overexpressed, solubilized with a nonionic detergent, and purified by nickel affinity chromatography to similar to95% purity. The ATPase activity of the purified protein was stimulated by phospholipids. When reconstituted into liposomes prepared from E. coli phospholipids, MsbA displayed an apparent K-m of 878 mum and a V-max of 37 nmol/min/mg for ATP hydrolysis in the presence of 10 mm Mg2+. Preincubation of MsbA-containing liposomes with 3-deoxy-D-mannooctulosonic acid (Kdo)(2)-lipid A increased the ATPase activity 4-5-fold, with half-maximal stimulation seen at 21 mum Kdo(2)-lipid A. Addition of Kdo(2)- lipid A increased the V-max to 154 nmol/min/mg and decreased the K-m to 379 mum. Stimulation was only seen with hexaacylated lipid A species and not with precursors, such as diacylated lipid X or tetraacylated lipid IVA. MsbA containing the A270T substitution, which renders cells temperature-sensitive for growth and lipid export, displayed ATPase activity similar to that of the wild type protein at 30 degreesC but was significantly reduced at 42 degreesC. These results provide the first in vitro evidence that MsbA is a lipid-activated ATPase and that hexaacylated lipid A is an especially potent activator.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI-10613-01] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Kol MA, 2001, BIOCHEMISTRY-US, V40, P10500, DOI 10.1021/bi010627+; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Miller J. H., 1972, EXPT MOL GENETICS, P433; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1981, J BIOL CHEM, V256, P690; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; OSBORN MJ, 1980, J BIOL CHEM, V255, P4246; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	64	173	182	2	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36697	36705		10.1074/jbc.M205857200	http://dx.doi.org/10.1074/jbc.M205857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119303	Green Published, hybrid			2022-12-27	WOS:000178275100116
J	Kim, YJ; Kim, KP; Han, SK; Munoz, NM; Zhu, XD; Sano, H; Leff, AR; Cho, WH				Kim, YJ; Kim, KP; Han, SK; Munoz, NM; Zhu, XD; Sano, H; Leff, AR; Cho, WH			Group V phospholipase A(2) induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; COLONY-STIMULATING FACTOR; PROTEIN-KINASE KINASE; HUMAN PLATELETS; FATTY-ACIDS; MAP KINASE; PHOSPHORYLATION; CALCIUM; BINDING	We reported previously that exogenously added human group V phospholipase A(2) (hVPLA(2)) could elicit leukotriene B-4 (LTB4) biosynthesis in human neutrophils (Han, S. K., Kim, K. P., Koduri, R., Bittova, L., Munoz, N. M., Leff, A. R., Wilton, D. C., Gelb, M. H., and Cho, W. (1999) J. Biol. Chem. 274, 11881-11888). To determine the mechanism of the hVPLA(2)-induced LTB4 biosynthesis in neutrophils, we thoroughly examined the effects of hVPLA(2) and their lipid products on the activity of group IVA cytosolic PLA(2) (cPLA(2)) and LTB4 biosynthesis under different conditions. As low as 1 nm exogenous hVPLA(2) was able to induce the release of arachidonic acid (AA) and LTB4. Typically, AA and LTB4 were released in two phases, which were synchronized with a rise in intracellular calcium concentration ([Ca2+](i)) near the perinuclear region and cPLA(2) phosphorylation. A cellular PLA(2) assay showed that hVPLA(2) acted primarily on the outer plasma membrane, liberating fatty acids and lysophosphatidylcholine (lyso-PC), whereas cPLA(2) acted on the perinuclear membrane. Lyso-PC and polyunsaturated fatty acids including AA activated cPLA(2) and 5-lipoxygenase by increasing [Ca2+](i) and inducing cPLA(2) phosphorylation, which then led to LTB4 biosynthesis. The delayed phase was triggered by the binding of secreted LTB4 to the cell surface LTB4 receptor, which resulted in a rise in [Ca2+](i) and cPLA(2) phosphorylation through the activation of mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2. These results indicate that a main role of exogenous hVPLA(2) in neutrophil activation and LTB4 biosynthesis is to activate cPLA(2) and 5-lipoxygenase primarily by liberating from the outer plasma membrane lyso-PC that induces [Ca2+](i) increase and cPLA(2) phosphorylation and that hVPLA(2)-induced LTB4 production is augmented by the positive feedback activation of cPLA, by LTB4.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WH (corresponding author), Univ Illinois, Dept Chem, 845 W Taylor St,M-C 111, Chicago, IL 60607 USA.			zhu, xiangdong/0000-0002-5627-8082; Kim, Kwang Pyo/0000-0003-0095-3787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399, R01HL046368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399, HL46368] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095; GOLDMAN DW, 1985, J IMMUNOL, V135, P525; Golfman LS, 1999, J LIPID RES, V40, P1818; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hendrickson HS, 1999, ANAL BIOCHEM, V276, P27, DOI 10.1006/abio.1999.4280; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kim K, 1998, BIOCHEM PHARMACOL, V55, P975, DOI 10.1016/S0006-2952(97)00613-8; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD JIS, 1989, J BIOL CHEM, V264, P17718; Marshall J, 2000, J IMMUNOL, V164, P2084, DOI 10.4049/jimmunol.164.4.2084; MCDONALD PP, 1994, BRIT J PHARMACOL, V111, P852, DOI 10.1111/j.1476-5381.1994.tb14816.x; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NACCACHE PH, 1989, BRIT J PHARMACOL, V97, P461, DOI 10.1111/j.1476-5381.1989.tb11973.x; Nahas N, 1996, BIOCHEM J, V313, P503, DOI 10.1042/bj3130503; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Robinson BS, 1998, BIOCHEM J, V336, P611, DOI 10.1042/bj3360611; Sala A, 1999, J BIOL CHEM, V274, P28264, DOI 10.1074/jbc.274.40.28264; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Syrbu SI, 1999, J IMMUNOL, V162, P2334; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090	52	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36479	36488		10.1074/jbc.M205399200	http://dx.doi.org/10.1074/jbc.M205399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124392	Green Accepted, hybrid			2022-12-27	WOS:000178275100090
J	Ominato, K; Akita, H; Suzuki, A; Kijima, F; Yoshino, T; Yoshino, M; Chiba, Y; Onouchi, H; Naito, S				Ominato, K; Akita, H; Suzuki, A; Kijima, F; Yoshino, T; Yoshino, M; Chiba, Y; Onouchi, H; Naito, S			Identification of a short highly conserved amino acid sequence as the functional region required for Posttranscriptional autoregulation of the cystathionine gamma-synthase gene in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE BIOSYNTHESIS; SOLUBLE METHIONINE; THALIANA; RNA; MUTAGENESIS; ACCUMULATION; SPECIFICITY; EXPRESSION; ALIGNMENT; MUTATION	Cystathionine gamma-synthase (CGS) catalyzes the first committed step of Met biosynthesis in plants. We have previously shown that expression of the gene for CGS is feedback-regulated at the level of mRNA stability, and that the amino acid sequence encoded by the first exon of the CGS gene itself is responsible for the regulation (Chiba, Y., Ishikawa, M., Kijima, F., Tyson, R. H., Kim, J., Yamamoto, A., Nambara, E., Leustek, T., Wallsgrove, R. M., and Naito, S. (1999) Science 286, 1371-1374). To identify the functional region within CGS exon 1, deletion analysis was performed. The results showed that the 41-amino acid region of exon 1 highly conserved among plants is necessary and sufficient for the regulation. Analyses of in vivo and in vitro generated mutations that abolish the regulation identified the functionally important amino acids as 11-13 residues within this conserved region. The importance of these residues was confirmed by deletion analysis within the conserved region. These studies identified the functional region of CGS exon 1 required for the posttranscriptional autoregulation of the CGS gene as (A)RRNCSNIGVAQ(I), with uncertainty of the first and last residues. This sequence is almost perfectly conserved among CGS sequences of higher plants but cannot be found elsewhere in the public databases.	Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan	Hokkaido University	Naito, S (corresponding author), Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	naito@abs.agr.hokudai.ac.jp	Chiba, Yukako/AAA-9238-2019; Chiba, Yukako/B-7057-2009	Chiba, Yukako/0000-0002-7329-2775; Naito, Satoshi/0000-0001-7006-5609				ALIX JH, 1982, HILGARDIA, V24, P235; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bartlem D, 2000, PLANT PHYSIOL, V123, P101, DOI 10.1104/pp.123.1.101; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; BURNS PA, 1986, GENETICS, V113, P811; Chiba Y, 1999, SCIENCE, V286, P1371, DOI 10.1126/science.286.5443.1371; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; FUJIWARA T, 1991, PLANT CELL REP, V9, P602, DOI 10.1007/BF00231797; GIOVANELLI J, 1985, PLANT PHYSIOL, V77, P450, DOI 10.1104/pp.77.2.450; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; GUZMAN P, 1988, NUCLEIC ACIDS RES, V16, P11091, DOI 10.1093/nar/16.23.11091; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; ISHIKAWA M, 1993, J VIROL, V67, P5328, DOI 10.1128/JVI.67.9.5328-5338.1993; KOHALMI SE, 1988, J MOL BIOL, V204, P561, DOI 10.1016/0022-2836(88)90355-5; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Matthews BF, 1999, BOOK SOIL P, P205; Minami M, 2001, PLANT BIOTECHNOL-NAR, V18, P71; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NAITO S, 1994, PLANT PHYSIOL, V104, P497, DOI 10.1104/pp.104.2.497; Pogulis R J, 1996, Methods Mol Biol, V57, P167; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Rogers EE, 1997, PLANT CELL, V9, P305, DOI 10.1105/tpc.9.3.305; Suzuki A, 2001, PLANT CELL PHYSIOL, V42, P1174, DOI 10.1093/pcp/pce146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	31	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36380	36386		10.1074/jbc.M204645200	http://dx.doi.org/10.1074/jbc.M204645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121993	hybrid			2022-12-27	WOS:000178275100077
J	Palancade, B; Dubois, MF; Bensaude, O				Palancade, B; Dubois, MF; Bensaude, O			FCP1 phosphorylation by casein kinase 2 enhances binding to TFIIF and RNA polymerase II carboxyl-terminal domain phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CODING GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ELONGATION COMPLEXES; LARGEST SUBUNIT; HELA-CELLS; P-TEFB; CK2; DEPHOSPHORYLATION; YEAST	Dephosphorylation of RNA polymerase H carboxyl-terminal domain (CTD) is required to resume sequential transcription cycles. FCP1 (TFIIF-dependent CTD phosphatase 1) is the only known phosphatase targeting RNAP H CTD. Here we show that in Xenopus laevis cells, xFCP1 is a phosphoprotein. On the basis of biochemical fractionation and drug sensitivity, casein kinase 2 (CK2) is shown to be the major kinase involved in xFCP1 phosphorylation in X. laevis egg extracts. CK2 phosphorylates xFCP1 mainly at a cluster of serines centered on Ser(457). CK2-dependent phosphorylation enhances 4-fold the CTD phosphatase activity of FCP1 and its binding to the RAP74 subunit of general transcription factor TFIIF. These findings unravel a new mechanism regulating CTD phosphorylation and hence class II gene transcription.	Ecole Normale Super, CNRS, UMR 8541, F-75230 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bensaude, O (corresponding author), Ecole Normale Super, CNRS, UMR 8541, 46 Rue Ulm, F-75230 Paris 05, France.	bensaude@wotan.ens.fr		Bensaude, Olivier/0000-0002-0259-6608; PALANCADE, Benoit/0000-0002-3894-9735				Ackermann K, 2001, MOL CELL BIOCHEM, V227, P59, DOI 10.1023/A:1013104705100; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; CARDENAS ME, 1993, J CELL SCI, V104, P219; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dubois MF, 1999, NUCLEIC ACIDS RES, V27, P1338, DOI 10.1093/nar/27.5.1338; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hirose Y, 2000, GENE DEV, V14, P1415; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Licciardo P, 2001, AIDS, V15, P301, DOI 10.1097/00002030-200102160-00002; Maldonado E, 1999, FEBS LETT, V443, P256, DOI 10.1016/S0014-5793(98)01734-7; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rossignol M, 1999, J BIOL CHEM, V274, P22387, DOI 10.1074/jbc.274.32.22387; Saez-Vasquez J, 2001, PLANT MOL BIOL, V47, P449, DOI 10.1023/A:1011619413393; SELDIN DC, 1995, SCIENCE, V267, P834; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Trott RL, 2001, J BIOL CHEM, V276, P2159, DOI 10.1074/jbc.M005996200; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	47	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36061	36067		10.1074/jbc.M205192200	http://dx.doi.org/10.1074/jbc.M205192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138108	hybrid			2022-12-27	WOS:000178275100039
J	Akgul, B; Tu, CPD				Akgul, B; Tu, CPD			Evidence for a stabilizer element in the untranslated regions of Drosophila glutathione S-Transferase D1 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; MAMMALIAN-CELLS; GENE FAMILY; TURNOVER; PROTEIN; YEAST; DEADENYLATION; MELANOGASTER; INTRONLESS; EXOSOME	The neighboring genes gstD1 and gstD21 share 70% sequence identity. gstD1 encodes a 1,1,1-trichloro-2,2-bis-(P-chlorophenyl)ethane dehydrochlorinase; gstD21, a ligandin. Both of their mRNAs are inducible by pentobarbital but otherwise behave very differently. Intact gstD21 mRNA is intrinsically labile, but becomes stabilized when separated from its native untranslated region (UTR). In contrast, whereas gstD1 mRNA is very stable in its entirety, without its native UTRs it becomes even more labile than that of gstD21. Decay patterns from four chimeric D1-D21 mRNAs, designed to reveal the individual importance of each molecular region to stability, strongly indicate the presence of destabilizing elements in the coding region of gstD1 mRNA. Thus, the UTRs of this molecule must contain a dominant stabilizer element that overrides the destabilizing influence of the coding region and confers overall stability to the entire molecule. The suspected presence of such a stabilizer element in gstD1 mRNA extends a concept from mRNA metabolism in yeast and cultured mammalian cells to include a multicellular organism, Drosophila melanogaster. The complementary presence of destabilizing and stabilizer elements on the same mRNA reveals a regulatory mechanism by which an abundant mRNA can be further induced by a chemical stimulus, or otherwise be returned to normal levels during recovery.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 106, Intercoll Grad Program Genet, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Tu, CPD (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 106, Intercoll Grad Program Genet, University Pk, PA 16802 USA.		Akgül, Bünyamin/AAY-2958-2020	Akgül, Bünyamin/0000-0001-9877-9689	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002678] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 02678] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; BOISSONNEAULT G, 1990, BIOSCIENCE REP, V10, P179, DOI 10.1007/BF01116577; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; Lougarre A, 1999, INSECT MOL BIOL, V8, P141, DOI 10.1046/j.1365-2583.1999.810141.x; MANDL CW, 1991, BIOTECHNIQUES, V10, P484; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Ruiz-Echevarria MJ, 2001, J BIOL CHEM, V276, P30995, DOI 10.1074/jbc.M010833200; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TANG AH, 1995, J BIOL CHEM, V270, P13819, DOI 10.1074/jbc.270.23.13819; TANG AH, 1994, J BIOL CHEM, V269, P27876; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	27	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34700	34707		10.1074/jbc.M200985200	http://dx.doi.org/10.1074/jbc.M200985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12118001	hybrid, Green Published			2022-12-27	WOS:000178117000008
J	Aubert, E; Sbarra, V; Le Petit-Thevenin, J; Valette, A; Lombardo, D				Aubert, E; Sbarra, V; Le Petit-Thevenin, J; Valette, A; Lombardo, D			Site-directed mutagenesis of the basic N-terminal cluster of pancreatic bile salt-dependent lipase - Functional significance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL ESTER LIPASE; STIMULATED CHOLESTEROL ESTERASE; LIPOPROTEIN-LIPASE; HEPARIN-BINDING; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ACTIVATED LIPASE; HEPG2 CELLS; HUMAN-MILK; HYDROLASE	Previous studies have postulated the presence of a heparin-binding site on the bile salt-dependent lipase (BSDL), whereas two bile salt-binding sites regulate the enzyme activity. One of these sites may overlap with the tentative heparin-binding site at the level of an N-terminal basic cluster consisting of positive residues Lys(32), Lys(56), Lys(61), Lys(62), and Arg(63). The present study uses specific site-directed mutagenesis to determine the functional significance of this basic cluster. Mutations in this sequence resulted in recombinant enzymes that were able to bind to immobilized and to cell-associated heparin before moving throughout intestinal cells. Recombinant BSDL was fully active on soluble substrate, but mutants were less active on micellar cholesteryl. oleate in comparison with the wild-type enzyme. Activation studies by primary (sodium taurocholate) and by secondary (sodium taurodeoxycholate) bile salts revealed that the activation of BSDL by sodium taurocholate at concentrations below the critical micellar concentration, and not that evoked by micellar bile salts, was affected by substitutions, suggesting that this N-terminal basic cluster likely represents the specific bile salt-binding site of BSDL. Substitutions also affected the activation of the enzyme promoted by anionic phospholipids, extending the function of this site to that of a cationic regulatory site susceptible to accommodate anionic ligands.	Fac Med Timone, INSERM, U559, Unite Rech Physiopathol Cellules Epitheliales, F-13385 Marseille 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lombardo, D (corresponding author), Fac Med Timone, INSERM, U559, Unite Rech Physiopathol Cellules Epitheliales, 27 Blv Jean Moulin, F-13385 Marseille 05, France.							AHO HJ, 1989, INT J PANCREATOL, V5, P123; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BLACKBERG L, 1993, FEBS LETT, V323, P207, DOI 10.1016/0014-5793(93)81340-6; BLACKBERG L, 1981, FEBS LETT, V136, P284, DOI 10.1016/0014-5793(81)80636-9; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; Bruneau N, 2001, EXP CELL RES, V271, P94, DOI 10.1006/excr.2001.5361; Caillol N, 1997, LIPIDS, V32, P1147, DOI 10.1007/s11745-997-0147-4; CAMPESE D, 1984, BIOCHIM BIOPHYS ACTA, V784, P147, DOI 10.1016/0167-4838(84)90121-3; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; Falt H, 2001, ARCH BIOCHEM BIOPHYS, V386, P188, DOI 10.1006/abbi.2000.2071; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; ISHII I, 1995, J LIPID RES, V36, P2303; KATZ SS, 1980, J BIOL CHEM, V255, P9753; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Petit-Thevenin J, 2001, BBA-MOL CELL BIOL L, V1530, P184, DOI 10.1016/S1388-1981(00)00181-5; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; Liang Y, 2000, J BIOL CHEM, V275, P24040, DOI 10.1074/jbc.M003187200; LOMBARDO D, 1983, EUR J BIOCHEM, V133, P327, DOI 10.1111/j.1432-1033.1983.tb07466.x; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; LOMBARDO D, 1981, BIOCHIM BIOPHYS ACTA, V657, P425, DOI 10.1016/0005-2744(81)90328-4; LOMBARDO D, 1993, PANCREAS, V8, P581, DOI 10.1097/00006676-199309000-00009; Lookene A, 2000, BIOCHEM BIOPH RES CO, V271, P15, DOI 10.1006/bbrc.2000.2530; Moore SA, 2001, J MOL BIOL, V312, P511, DOI 10.1006/jmbi.2001.4979; Sbarra V, 1998, BBA-LIPID LIPID MET, V1393, P80, DOI 10.1016/S0005-2760(98)00067-8; Sendak RA, 1998, J LIPID RES, V39, P1310; Sendak RA, 2000, J LIPID RES, V41, P260; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SPILBURG CA, 1995, BIOCHEMISTRY-US, V34, P15532, DOI 10.1021/bi00047a019; Terzyan S, 2000, PROTEIN SCI, V9, P1783, DOI 10.1110/ps.9.9.1783; VERINE A, 1982, AM J PHYSIOL, V243, pE175, DOI 10.1152/ajpendo.1982.243.3.E175; Verine A, 2001, J BIOL CHEM, V276, P12356, DOI 10.1074/jbc.M008658200; Verine A, 1999, BIOCHEM J, V342, P179, DOI 10.1042/0264-6021:3420179; Wang XQ, 1997, STRUCTURE, V5, P1209, DOI 10.1016/S0969-2126(97)00271-2; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151	39	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34987	34996		10.1074/jbc.M202893200	http://dx.doi.org/10.1074/jbc.M202893200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110666	hybrid			2022-12-27	WOS:000178117000043
J	Delerive, P; Chin, WW; Suen, CS				Delerive, P; Chin, WW; Suen, CS			Identification of Reverb alpha as a novel ROR alpha target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; AMINO-TERMINAL DOMAINS; ERBA-ALPHA; THYROID-HORMONE; DNA-BINDING; MUSCLE DIFFERENTIATION; UNCOUPLING PROTEIN-3; RESPONSE ELEMENTS; OPPOSITE STRAND; SKELETAL-MUSCLE	The nuclear receptor superfamily comprises a large number of ligand-activated transcription factors that are involved in numerous biological processes such as cell proliferation, differentiation, and homeostasis. RORalpha (NR1F1) and Reverbalpha (NR1D1) are two members of this family whose biological functions are largely unknown. In addition, no ligand has been yet identified for these two receptors; therefore, they are referred as orphan receptors. Here, we show that RORalpha and Reverbalpha are expressed with a similar tissue distribution and are both induced during the differentiation of rat L6 myoblastic cells. Ectopic expression of RORalpha1 in L6 cells significantly induces Reverbalpha expression as demonstrated by Northern blot analysis. Using reverse transcription-PCR to analyze Reverbalpha gene expression from staggerer mice, we found that there was a significant reduction of Reverbalpha mRNA in the skeletal muscle comparing it with the wild-type mice, which suggests that RORalpha is involved in the regulation of Reverbalpha gene expression. Transient transfection assays using the Reverbalpha promoter demonstrate that RORalpha regulates the Reverbalpha gene at the transcriptional level. Furthermore, mutagenesis experiments indicate that RORalpha regulates Reverbalpha transcription via a monomeric ROR response element located in the Reverbalpha gene promoter. Electrophoretic mobility shift assays show that RORalpha binds strongly to this site in a specific-manner. Finally, overexpression of GRIP-1/TIF-2, but not SRC-1, potentiates RORalpha-stimulated Reverbalpha promoter activity in transient transfection experiments. Together, our results identify Reverbalpha as a novel target gene for RORalpha.	Lilly Corp Ctr, Eli Lilly Res Labs, Dept Gene Regulat Bone Inflammat Res, Indianapolis, IN 46285 USA	Eli Lilly	Delerive, P (corresponding author), Lilly Corp Ctr, Eli Lilly Res Labs, Dept Gene Regulat Bone Inflammat Res, Indianapolis, IN 46285 USA.	delerive@hotmail.com						Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Andre E, 1998, EMBO J, V17, P3867, DOI 10.1093/emboj/17.14.3867; Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; Austin S, 1998, CELL GROWTH DIFFER, V9, P267; Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Chomez P, 2000, DEVELOPMENT, V127, P1489; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KOPMELS B, 1990, J NEUROCHEM, V55, P1980, DOI 10.1111/j.1471-4159.1990.tb05785.x; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Lawson MA, 2000, CELLS TISSUES ORGANS, V167, P130, DOI 10.1159/000016776; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; Medvedev A, 1997, GENOMICS, V46, P93, DOI 10.1006/geno.1997.4980; Meyer T, 2000, P NATL ACAD SCI USA, V97, P9197, DOI 10.1073/pnas.150246097; Moraitis AN, 1999, MOL ENDOCRINOL, V13, P431, DOI 10.1210/me.13.3.431; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Raspe E, 1999, J LIPID RES, V40, P2099; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; Yoshida N, 1998, J CELL SCI, V111, P769	55	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35013	35018		10.1074/jbc.M202979200	http://dx.doi.org/10.1074/jbc.M202979200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12114512	hybrid			2022-12-27	WOS:000178117000046
J	Demettre, E; Bastide, L; D'Haese, A; De Smet, K; De Meirleir, K; Tiev, KP; Englebienne, P; Lebleu, B				Demettre, E; Bastide, L; D'Haese, A; De Smet, K; De Meirleir, K; Tiev, KP; Englebienne, P; Lebleu, B			Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; 2-5A-DEPENDENT RNASE-L; PROTEIN; APOPTOSIS; CLEAVAGE	A 37-kDa binding polypeptide accumulates in peripheral blood mononuclear cell (PBMC) extracts from chronic fatigue syndrome (CFS) patients and is being considered as a potential diagnostic marker (De Meirleir, K., Bisbal, C., Campine, I., De Becker, P., Salehzada, T., Demettre, E., and Lebleu, B. (2000) Ant. J. Med. 108, 99-105). We establish here that this low molecular weight 2-5A-binding polypeptide is a truncated form of the native 2-5A-dependent ribonuclease L (RNase L), generated by an increased proteolytic activity in CFS PBMC extracts. RNase L proteolysis in CFS PBMC extracts can be mimicked in a model system in which recombinant RNase L is treated with human leukocyte elastase. RNase L proteolysis leads to the accumulation of two major fragments with molecular masses of 37 and 30 kDa. The 37-kDa fragment includes the 2-5A binding site and the N-terminal end of native RNase L. The 30-kDa fragment includes the catalytic site in the C-terminal part of RNase L. Interestingly, RNase L remains active and 2-5A-dependent when degraded into its 30- and 37-kDa fragments by proteases of CFS PBMC extract or by purified human leukocyte elastase. The 2-5A-dependent nuclease activity of the truncated RNase L could result from the association of these digestion products, as suggested in pull down experiments.	Univ Montpellier 2, CNRS, UMR 5124, F-34293 Montpellier, France; RED Labs, B-1731 Zellik, Belgium; Free Univ Brussels, Dept Human Physiol & Med, B-1090 Brussels, Belgium; Free Univ Brussels, Dept Nucl Med, B-1050 Brussels, Belgium; Hop St Antoine, Serv Med Interne, F-75571 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Lebleu, B (corresponding author), Univ Montpellier 2, CNRS, UMR 5124, F-34293 Montpellier, France.	lebleu@igm.cnrs-mop.fr						Ablashi DV, 2000, J CLIN VIROL, V16, P179, DOI 10.1016/S1386-6532(99)00079-7; BASTIDE L, 2002, CHRONIC FATIGUE SYND, P1; Cannon JG, 1999, J CLIN IMMUNOL, V19, P414, DOI 10.1023/A:1020558917955; Carroll SS, 1996, J BIOL CHEM, V271, P4988; De Meirleir K, 2000, AM J MED, V108, P99, DOI 10.1016/S0002-9343(99)00300-9; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; Dong BH, 1997, J BIOL CHEM, V272, P22236, DOI 10.1074/jbc.272.35.22236; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; Komaroff AL, 1998, ANNU REV MED, V49, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLEU B, 2000, EUR CYTOKINE NETW, V11, P101; Nasralla M, 1999, EUR J CLIN MICROBIOL, V18, P859, DOI 10.1007/s100960050420; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; ROELENS S, 2001, AM ASS CHRON FAT SYN, P70; Roelens S., 2001, J CHRONIC FATIGUE SY, V8, P63; Rusch L, 2000, J INTERF CYTOK RES, V20, P1091, DOI 10.1089/107999000750053762; Shetzline SE, 2002, J INTERF CYTOK RES, V22, P443, DOI 10.1089/10799900252952235; Shetzline SE, 2001, J BIOL CHEM, V276, P23707, DOI 10.1074/jbc.M101243200; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; STEIN RL, 1986, BIOCHEMISTRY-US, V25, P5414, DOI 10.1021/bi00367a011; SUHADOLNIK RJ, 1994, CLIN INFECT DIS, V18, pS96, DOI 10.1093/clinids/18.Supplement_1.S96; Suhadolnik RJ, 1997, J INTERF CYTOK RES, V17, P377, DOI 10.1089/jir.1997.17.377; SWANINK CMA, 1994, CLIN INFECT DIS, V19, P860, DOI 10.1093/clinids/19.5.860; Vojdani A, 1997, J INTERN MED, V242, P465, DOI 10.1111/j.1365-2796.1997.tb00019.x; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	29	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35746	35751		10.1074/jbc.M201263200	http://dx.doi.org/10.1074/jbc.M201263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12118002	hybrid			2022-12-27	WOS:000178117000137
J	Fung, TK; Sin, WY; Yam, CH; Lau, A; Poon, RYC				Fung, TK; Sin, WY; Yam, CH; Lau, A; Poon, RYC			Cyclin F is degraded during G(2)-M by mechanisms fundamentally different from other cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX PROTEIN SKP2; CDK INHIBITOR P27; KAPPA-B P105; UBIQUITIN LIGASE; CELL-CYCLE; RETINOIC ACID; QUIESCENT CELLS; RECEPTOR-GAMMA; S-PHASE; DEGRADATION	Cyclin F, a cyclin that can form SCF complexes and bind to cyclin B, oscillates in the cell cycle with a pattern similar to cyclin A and cyclin B. Ectopic expression of cyclin F arrests the cell cycle in G(2)/M. How the level of cyclin F is regulated during the cell cycle is completely obscure. Here we show that, similar to cyclin A, cyclin F is degraded when the spindle assembly checkpoint is activated and accumulates when the DNA damage checkpoint is activated. Cyclin F is a very unstable protein throughout much of the cell cycle. Unlike other cyclins, degradation of cyclin F is independent of ubiquitination and proteasome-mediated pathways. Interestingly, proteolysis of cyclin F is likely to involve metalloproteases. Rapid destruction of cyclin F does not require the N-terminal F-box motif but requires the COOH-terminal PEST sequences. The PEST region alone is sufficient to interfere with the degradation of cyclin F and confer instability when fused to cyclin A. These data show that although cyclin F is degraded at similar time as the mitotic cyclins, the underlying mechanisms are entirely distinct.	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.			Poon, Randy/0000-0001-5571-6231				Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BAST RC, 2000, CANC MED; Boudjelal M, 2000, CANCER RES, V60, P2247; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Mathias N, 1999, MOL CELL BIOL, V19, P1759; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1997, CANCER RES, V57, P5168; POON RYC, 2002, IN PRESS ENCY CANC; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Su TT, 2001, CURR BIOL, V11, P8, DOI 10.1016/S0960-9822(00)00042-7; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; YAM CH, 2002, IN PRESS CELL MOL LI, V59; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	46	63	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35140	35149		10.1074/jbc.M205503200	http://dx.doi.org/10.1074/jbc.M205503200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122006	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000178117000062
J	Johnson, KR; Becker, KP; Facchinetti, MM; Hannun, YA; Obeid, LM				Johnson, KR; Becker, KP; Facchinetti, MM; Hannun, YA; Obeid, LM			PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane - Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND MESSENGER; CELL-GROWTH; 1-PHOSPHATE; CERAMIDASE; EXPRESSION; STRESS; SPHINGOMYELINASE; DIFFERENTIATION; PROLIFERATION; SURVIVAL	Sphingosine-1-phosphate (S1P) is a highly bioactive sphingolipid involved in diverse biological processes leading to changes in cell growth, differentiation, motility, and survival. S1P generation is regulated via sphingosine kinase (SK), and many of its effects are mediated through extracelluar action on G-protein-coupled receptors. In this study, we have investigated the mechanisms regulating SK, where this occurs in the cell, and whether this leads to release of S1P extracellularly. The protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), induced early activation of SK in HEK 293 cells, and this activation was more specific to the membrane-associated SK. Therefore, we next investigated whether PMA induced translocation of SK to the plasma membrane. PMA induced translocation of both endogenous and green fluorescent protein (GFP)-tagged human SKI (hSK1) to the plasma membrane. PMA also induced phosphorylation of GFP-hSK1. The PMA-induced translocation was abrogated by preincubation with known PKC inhibitors (bisindoylmaleimide and calphostin-c) as well as by the indirect inhibitor of PKC, C-6-ceramide, supporting a role for PKC in mediating translocation of SK to the plasma membrane. SK activity was not necessary for translocation, because a dominant negative G82D mutation also translocated in response to PMA. Importantly, PKC regulation of SK was accompanied by a 4-fold increase in S1P in the media. These results demonstrate a novel mechanism by which PKC regulates SK and increases secretion of S1P, allowing for autocrine/paracrine signaling.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Dept Vet Affairs, Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Buenos Aires, Fac Farm & Bioquim, Dept Biol Sci, RA-1113 Buenos Aires, DF, Argentina	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; University of Buenos Aires	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.			obeid, lina/0000-0002-0734-0847; Facchinetti, Maria/0000-0001-7596-4769	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43707, HL07260] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BEUHRER BM, 1996, BIOCHIM BIOPHYS ACTA, V1303, P233; Boujaoude LC, 2001, J BIOL CHEM, V276, P35258, DOI 10.1074/jbc.M105442200; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Edsall LC, 1997, J NEUROSCI, V17, P6952; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Hayter HL, 2001, FEBS LETT, V507, P151, DOI 10.1016/S0014-5793(01)02967-2; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	30	242	251	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35257	35262		10.1074/jbc.M203033200	http://dx.doi.org/10.1074/jbc.M203033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12124383	hybrid			2022-12-27	WOS:000178117000077
J	Larsen, AKR; Moller, MTN; Blankson, H; Samari, HR; Holden, L; Seglen, PO				Larsen, AKR; Moller, MTN; Blankson, H; Samari, HR; Holden, L; Seglen, PO			Naringin-sensitive phosphorylation of plectin, a cytoskeletal cross-linking protein, in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASE INHIBITORS; EPITHELIAL-CELL APOPTOSIS; CYCLIN-DEPENDENT KINASES; ACID-INDUCED APOPTOSIS; P70 S6 KINASE; OKADAIC ACID; INTERMEDIATE FILAMENTS; MAP KINASE; RETINOBLASTOMA PROTEIN; BCL2 PHOSPHORYLATION	To identify phosphoproteins that might play a role in naringin-sensitive hepatocellular cytoskeletal disruption and apoptosis induced by algal toxins, hepatocyte extracts were separated by gel electrophoresis and immunostained with a phosphothreonine-directed antibody. Use of dilute (5%) polyacrylamide gels containing 6 m urea allowed the resolution of one very large (similar to500-kDa) okadaic acid- and naringin-sensitive phosphoprotein, identified by tryptic fingerprinting, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and immunostaining as the cytolinker protein, plectin. The naringin-sensitive phosphorylation induced by okadaic acid and microcystin-LR probably reflected inhibition of a type 2A protein phosphatase, whereas the naringin-resistant phosphorylation induced by calyculin A, tautomycin, and cantharidin probably involved a type 1 phosphatase. Okadaic acid caused a collapse of the plectin-immunostaining bile canalicular sheaths and the general cytoskeletal plectin network into numerous medium-sized plectin aggregates. Inhibitors of protein kinase C, cAMP-dependent protein kinase, or Ca2+/calmodulin-dependent kinase II had moderate or no protective effects on plectin network disruption, whereas naringin offered 86% protection. Okadaic acid induced a naringin-sensitive phosphorylation of AMP-activated protein kinase (AMPK), the stress-activated protein kinases SEK1 and JNK, and S6 kinase. The AMPK-activating kinase (AMPKK) is likely to be the target of inhibition by naringin, the other kinases serving as downstream components of an AMPKK-initiated signaling pathway.	Norwegian Radium Hosp, Inst Canc Res, Dept Cell Biol, Proteom & Mammalian Cell Biol Sect, N-0310 Oslo, Norway	University of Oslo	Seglen, PO (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Cell Biol, Proteom & Mammalian Cell Biol Sect, N-0310 Oslo, Norway.	per.seglen@labmed.uio.no		Moller, Michael Terje Norregaard/0000-0001-7543-0927				Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; Beil M, 2002, AM J PHYSIOL-GASTR L, V282, pG450, DOI 10.1152/ajpgi.00042.2001; Berven G, 2001, TOXICON, V39, P349, DOI 10.1016/S0041-0101(00)00137-9; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLANKSON H, 1995, EXP CELL RES, V218, P522, DOI 10.1006/excr.1995.1187; Blankson H, 2000, CELL DEATH DIFFER, V7, P739, DOI 10.1038/sj.cdd.4400705; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BROWN KD, 1990, CELL MOTIL CYTOSKEL, V17, P19, DOI 10.1002/cm.970170105; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DUPONT-WALLOIS L, 1995, FEBS LETT, V357, P197, DOI 10.1016/0014-5793(94)01361-4; ERDODI F, 1995, AM J PHYSIOL-CELL PH, V269, pC1176, DOI 10.1152/ajpcell.1995.269.5.C1176; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; ERIKSSON JE, 1990, BIOCHIM BIOPHYS ACTA, V1025, P60, DOI 10.1016/0005-2736(90)90190-Y; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Fladmark KE, 1998, TOXICON, V36, P1101, DOI 10.1016/S0041-0101(98)00083-X; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Fontao L, 2001, J CELL SCI, V114, P2065; GJESSING R, 1980, EXP CELL RES, V129, P239, DOI 10.1016/0014-4827(80)90347-X; GORDON PB, 1995, J BIOL CHEM, V270, P5830, DOI 10.1074/jbc.270.11.5830; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Haldar S, 1998, CANCER RES, V58, P1609; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; HERRMANN H, 1987, J BIOL CHEM, V262, P1320; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HOLEN I, 1995, BIOCHEM J, V311, P317, DOI 10.1042/bj3110317; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; LEE WC, 1992, J CELL BIOCHEM, V49, P378, DOI 10.1002/jcb.240490408; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; Malecz N, 1996, J BIOL CHEM, V271, P8203, DOI 10.1074/jbc.271.14.8203; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Mellgren G, 1997, ENDOCRINOLOGY, V138, P4373, DOI 10.1210/en.138.10.4373; Moore WT, 1997, METHOD ENZYMOL, V289, P520; Muenchbach M, 1998, BIOCHEM BIOPH RES CO, V249, P304, DOI 10.1006/bbrc.1998.9138; Niessen CM, 1997, J CELL SCI, V110, P1705; OHTA T, 1992, CARCINOGENESIS, V13, P2443, DOI 10.1093/carcin/13.12.2443; Okumura M, 1999, J BIOCHEM-TOKYO, V126, P1144, DOI 10.1093/oxfordjournals.jbchem.a022560; ONODA K, 1993, J BIOL CHEM, V268, P4106; PUGAZHENTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1179, P271, DOI 10.1016/0167-4889(93)90082-Z; PYTELA R, 1980, P NATL ACAD SCI-BIOL, V77, P4808, DOI 10.1073/pnas.77.8.4808; Riordan FA, 1998, FEBS LETT, V435, P195, DOI 10.1016/S0014-5793(98)01070-9; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Runden E, 1998, J NEUROSCI, V18, P7296; RUNNEGAR MTC, 1991, TOXICON, V29, P43, DOI 10.1016/0041-0101(91)90038-S; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shea TB, 1996, FEBS LETT, V380, P63, DOI 10.1016/0014-5793(95)01411-X; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; SUGANUMA M, 1992, TOXICON, V30, P873, DOI 10.1016/0041-0101(92)90385-I; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Toivola DM, 1997, J CELL SCI, V110, P23; TOIVOLA DM, 1994, FEBS LETT, V344, P175, DOI 10.1016/0014-5793(94)00382-3; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Velasco G, 1998, FEBS LETT, V439, P317, DOI 10.1016/S0014-5793(98)01400-8; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; vonZezschwitz C, 1997, FEBS LETT, V413, P147, DOI 10.1016/S0014-5793(97)00896-X; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; WICHE G, 1983, J CELL BIOL, V97, P887, DOI 10.1083/jcb.97.3.887; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; YATSUNAMI J, 1991, BIOCHEM BIOPH RES CO, V177, P1165, DOI 10.1016/0006-291X(91)90662-Q; YATSUNAMI J, 1993, CANCER RES, V53, P239; YATSUNAMI J, 1993, CANCER RES, V53, P992	91	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34826	34835		10.1074/jbc.M205028200	http://dx.doi.org/10.1074/jbc.M205028200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095991	hybrid, Green Published			2022-12-27	WOS:000178117000024
J	Michaelevski, L; Chikvashvili, D; Tsuk, S; Fili, O; Lohse, MJ; Singer-Lahat, D; Lotan, I				Michaelevski, L; Chikvashvili, D; Tsuk, S; Fili, O; Lohse, MJ; Singer-Lahat, D; Lotan, I			Modulation of a brain voltage-gated K+ channel by syntaxin 1A requires the physical interaction of G beta gamma with the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM CHANNELS; PROTEIN-KINASE-A; XENOPUS-OOCYTES; POTASSIUM CHANNELS; CA2+ CHANNELS; SUBUNIT; INACTIVATION; PHOSPHORYLATION; RELEASE; DEPHOSPHORYLATION	Recently we suggested that direct interactions between voltage-gated K+ channels and proteins of the exocytotic machinery, such as those observed between the Kv1.1/Kvbeta channel, syntaxin 1A, and SNAP-25 may be involved in neurotransmitter release. Furthermore, we demonstrated that the direct interaction with syntaxin 1A enhances the fast inactivation of Kv1.1/Kvbeta1.1 in oocytes. Here we show that G-protein betagamma subunits play a crucial role in the enhancement of inactivation by syntaxin 1A. The effect caused by overexpression of syntaxin 1A is eliminated in the presence of chelators of endogenous betagamma subunits in the whole cell and at the plasma membrane. Conversely, enhancement of inactivation caused by overexpression of beta(1)gamma(2) subunits is eliminated upon knock-down of endogenous syntaxin or its scavenging at the plasma membrane. We further show that the N terminus of Kv1.1 binds brain synaptosomal and recombinant syntaxin 1A and concomitantly binds beta(1)gamma(2); the binding of beta(1)gamma(2) enhances that of syntaxin 1A. Taken together, we suggest a mechanism whereby syntaxin and G protein betagamma subunits interact concomitantly with a Kv channel to regulate its inactivation.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, D-97078 Wurzburg, Germany	Tel Aviv University; Sackler Faculty of Medicine; University of Wurzburg	Lotan, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Lohse, Martin J/A-7160-2012; Michaelevski, Izhak/G-8940-2018	Lohse, Martin J/0000-0002-0599-3510; Michaelevski, Izhak/0000-0002-0783-1443				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bergsman JB, 2000, J NEUROSCI, V20, P4368, DOI 10.1523/JNEUROSCI.20-12-04368.2000; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DASCAL N, 1992, J PHYSIOL-LONDON, V450, P469, DOI 10.1113/jphysiol.1992.sp019137; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Ji JZ, 2002, J BIOL CHEM, V277, P20195, DOI 10.1074/jbc.M201034200; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; Levy M, 1998, J BIOL CHEM, V273, P6495, DOI 10.1074/jbc.273.11.6495; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Meir A, 1999, PHYSIOL REV, V79, P1019, DOI 10.1152/physrev.1999.79.3.1019; Mochida S, 1998, P NATL ACAD SCI USA, V95, P14523, DOI 10.1073/pnas.95.24.14523; Nakahira K, 1998, J MOL NEUROSCI, V11, P199, DOI 10.1385/JMN:11:3:199; PEARCE LB, 1991, J NEUROCHEM, V57, P636, DOI 10.1111/j.1471-4159.1991.tb03795.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roeper J, 1996, CURR OPIN NEUROBIOL, V6, P338, DOI 10.1016/S0959-4388(96)80117-6; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Singer-Lahat D, 1999, PFLUG ARCH EUR J PHY, V439, P18, DOI 10.1007/s004240051123; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Xu J, 1998, P NATL ACAD SCI USA, V95, P1846, DOI 10.1073/pnas.95.4.1846	29	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34909	34917		10.1074/jbc.M203943200	http://dx.doi.org/10.1074/jbc.M203943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12114518	hybrid			2022-12-27	WOS:000178117000034
J	Postovit, LM; Adams, MA; Lash, GE; Heaton, JP; Graham, CH				Postovit, LM; Adams, MA; Lash, GE; Heaton, JP; Graham, CH			Oxygen-mediated regulation of tumor cell invasiveness - Involvement of a nitric oxide signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR EXPRESSION; SMOOTH-MUSCLE CELLS; INDUCIBLE FACTOR-I; GENE-EXPRESSION; ERYTHROPOIETIN GENE; CARBON-MONOXIDE; HEME PROTEIN; HYPOXIA; INHIBITION; INVASION	Tumor hypoxia is associated with a poor prognosis for patients with various cancers, often resulting in an increase in metastasis. Moreover, exposure to hypoxia increases the ability of breast carcinoma cells to invade the extracellular matrix, an important aspect of metastasis. Here, we demonstrate that the hypoxic upregulation of invasiveness is linked to reduced nitric oxide signaling. Incubation of human breast carcinoma cells in 0.5% versus 20% oxygen increased their in vitro invasiveness and their expression of the urokinase receptor, an invasion-associated molecule. These effects of hypoxia were inhibited by nitric oxidemimetic drugs; and in a manner similar to hypoxia, pharmacological inhibition of nitric oxide synthesis increased urokinase receptor expression. The nitric oxide signaling pathway involves activation of soluble guanylyl cyclase (sGC) and the subsequent activation of protein kinase G (PKG). Culture of tumor cells under hypoxic conditions (0.5% versus 20% oxygen) resulted in lower cGMP levels, an effect that could be prevented by incubation with glyceryl trinitrate. Inhibition of sGC activity with a selective blocker or with the heme biosynthesis inhibitor desferrioxamine increased urokinase receptor expression. These compounds also prevented the glyceryl trinitrate-mediated suppression of urokinase receptor expression in cells incubated under hypoxic conditions. In contrast, direct activation of PKG using 8-bromo-cGMP prevented the hypoxia- and desferrioxamine-induced increases in urokinase receptor expression as well as the hypoxia-mediated enhanced invasiveness. Further involvement of PKG in the regulation of invasion-associated phenotypes was established using a selective PKG inhibitor, which alone increased urokinase receptor expression. These findings reveal that an important mechanism by which hypoxia increases tumor cell invasiveness (and possibly metastasis) requires inhibition of the nitric oxide signaling pathway involving sGC and PKG activation.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Urol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Graham, CH (corresponding author), Queens Univ, Dept Anat & Cell Biol, Botterell Hall,Rm 859, Kingston, ON K7L 3N6, Canada.			Postovit, Lynne-Marie/0000-0002-8088-4197; Lash, Gendie/0000-0002-3606-1361				Brown JM, 1999, CANCER RES, V59, P5863; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Cairns RA, 2001, CANCER RES, V61, P8903; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Forslund T, 2000, BIOCHEM BIOPH RES CO, V274, P482, DOI 10.1006/bbrc.2000.3156; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Graham CH, 1998, BLOOD, V91, P3300, DOI 10.1182/blood.V91.9.3300.3300_3300_3307; Graham CH, 2000, PLACENTA, V21, P443, DOI 10.1053/plac.2000.0543; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; KARIKO K, 1993, CANCER RES, V53, P3109; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Lo LW, 2001, J CELL PHYSIOL, V188, P304, DOI 10.1002/jcp.1124; Matthews NE, 2001, J NATL CANCER I, V93, P1879, DOI 10.1093/jnci/93.24.1879; Mitani Y, 2000, FASEB J, V14, P805, DOI 10.1096/fasebj.14.5.805; NUNOKAWA Y, 1992, BIOCHEM BIOPH RES CO, V188, P409, DOI 10.1016/0006-291X(92)92400-R; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rofstad EK, 2002, CANCER RES, V62, P1847; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Sogo N, 2000, BIOCHEM BIOPH RES CO, V279, P412, DOI 10.1006/bbrc.2000.3976; Taylor CT, 1998, J PHARMACOL EXP THER, V284, P568; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; WANG GL, 1993, BLOOD, V82, P3610; Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; Yu SM, 1997, CIRCULATION, V95, P1269	37	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35730	35737		10.1074/jbc.M204529200	http://dx.doi.org/10.1074/jbc.M204529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107174	hybrid			2022-12-27	WOS:000178117000135
J	Fujii, R; Yoshida, H; Fukusumi, S; Habata, Y; Hosoya, M; Kawamata, Y; Yano, T; Hinuma, S; Kitada, C; Asami, T; Mori, M; Fujisawa, Y; Fujino, M				Fujii, R; Yoshida, H; Fukusumi, S; Habata, Y; Hosoya, M; Kawamata, Y; Yano, T; Hinuma, S; Kitada, C; Asami, T; Mori, M; Fujisawa, Y; Fujino, M			Identification of a neuropeptide modified with bromine as an endogenous ligand for GPR7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN-RELEASING PEPTIDE; NEUROMEDIN-U; RAT-BRAIN; RECEPTOR; TRYPTOPHAN; CLONING; PRRP	We isolated a novel gene in a search of the Celera data base and found that it encoded a peptidic ligand for a G protein-coupled receptor, GPR7 (O'Dowd, B. F., Scheideler, M. A., Nguyen, T., Cheng, R., Rasmussen, J. S., Marchese, A., Zastawny, R., Heng, H. H., Tsui, L. C., Shi, X., Asa, S., Puy, L., and George, S. R. (1995) Genomics 28,84-91; Lee, D. K., Nguyen, T., Porter, C. A., Cheng, R., George, S. R., and O'Dowd, B. F. (1999) Mol. Brain Res. 71, 96-103). The expression of this gene was detected in various tissues in rats, including the lymphoid organs, central nervous system, mammary glands, and uterus. GPR7 mRNA was mainly detected in the central nervous system and uterus. In situ hybridization showed that the gene encoding the GPR7 ligand was expressed in the hypothalamus and hippocampus of rats. To determine the molecular structure of the endogenous GPR7 ligand, we purified it from bovine hypothalamic tissue extracts on the basis of cAMP production-inhibitory activity to cells expressing GPR7. Through structural analyses, we found that the purified endogenous ligand was a peptide with 29 amino acid residues and that it was uniquely modified with bromine. We subsequently determined that the C-6 position of the indole moiety in the N-terminal Trp was brominated. We believe this is the first report on a neuropeptide modified with bromine and have hence named it neuropeptide B. In in vitro assays, bromination did not influence the binding of neuropeptide B to the receptor.	Takeda Chem Ind Ltd, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Res Labs 1, Pharmaceut Res Div, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries; Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs 1, 10 Wadai, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; England LJ, 1998, SCIENCE, V281, P575, DOI 10.1126/science.281.5376.575; Fujii R, 2000, J BIOL CHEM, V275, P21068, DOI 10.1074/jbc.M001546200; Fujii R, 1999, REGUL PEPTIDES, V83, P1, DOI 10.1016/S0167-0115(99)00028-2; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; Hosoya M, 2000, J BIOL CHEM, V275, P29528, DOI 10.1074/jbc.M004261200; Iijima N, 1999, NEUROREPORT, V10, P1713, DOI 10.1097/00001756-199906030-00016; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; KAMINSKI DL, 1977, AM J PHYSIOL, V233, pE286, DOI 10.1152/ajpendo.1977.233.4.E286; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lee DK, 1999, MOL BRAIN RES, V71, P96, DOI 10.1016/S0169-328X(99)00171-0; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; SHIMOMURA Y, 2002, J BIOL CHEM; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l	19	125	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34010	34016		10.1074/jbc.M205883200	http://dx.doi.org/10.1074/jbc.M205883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12118011	hybrid			2022-12-27	WOS:000177959100065
J	Gray, S; Feinberg, MW; Hull, S; Kuo, CT; Watanabe, M; Sen, S; DePina, A; Haspel, R; Jain, MK				Gray, S; Feinberg, MW; Hull, S; Kuo, CT; Watanabe, M; Sen, S; DePina, A; Haspel, R; Jain, MK			The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE GLYCOGEN-SYNTHESIS; TRANSCRIPTION FACTOR; PPAR-GAMMA; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; C/EBP-ALPHA; OVEREXPRESSING GLUT4; RESISTANCE; LKLF	Resistance to the stimulatory effects of insulin on glucose utilization is a key feature of type 2 diabetes, obesity, and the metabolic syndrome. Recent studies suggest that insulin resistance is primarily caused by a defect in glucose transport. GLUT4 is the main insulin-responsive glucose transporter and is expressed predominantly in muscle and adipose tissues. Whereas GLUT4 has been shown to play a critical role in maintaining systemic glucose homeostasis, the mechanisms regulating its expression are incompletely understood. We have cloned the murine homologue of KLF15, a member of the Kruppel-like family of transcription factors. KLF15 is highly expressed in adipocytes and myocytes in vivo and is induced when 3T3-L1 preadipocytes are differentiated into adipocytes. Overexpression of KLF15 in adipose and muscle cell lines potently induces GLUT4 expression. This effect is specific to KLF15 as overexpression of two other Kruppel-like factors, KLF2/LKLF and KLF4/GKLF, did not induce GLUT4 expression. Both basal (3.3-fold, p < 0.001) and insulin-stimulated (2.4-fold, p < 0.00001) glucose uptake are increased in KLF15-overexpressing adipocytes. In co-transfection assays, KLF15 and MEF2A, a known activator of GLUT4, synergistically activates the GLUT4 promoter. Promoter deletion and mutational analyses provide evidence that this activity requires an intact KLF15-binding site proximal to the MEF2A site. Finally, co-immunoprecipitation assays show that KLF15 specifically interacts with MEF2A. These studies indicate that KLF15 is an important regulator of GLUT4 in both adipose and muscle tissues.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	Harvard University; Brigham & Women's Hospital; University of Chicago	Jain, MK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg,Rm 1123,30 Shattuck St, Boston, MA 02115 USA.	mjain@rics.bwh.harvard.edu		Feinberg, Mark/0000-0001-9523-3859	NHLBI NIH HHS [K08 HL 67755, K08 HL 03747] Funding Source: Medline; NIDDK NIH HHS [DK 57521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067755, K08HL003747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Banz WJ, 1996, HORM METAB RES, V28, P271, DOI 10.1055/s-2007-979790; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; Collins KA, 2001, AM J PHYSIOL-HEART C, V280, pH1954, DOI 10.1152/ajpheart.2001.280.5.H1954; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; GERRITS PM, 1993, J BIOL CHEM, V268, P640; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KIM YC, 1995, BIOCHEM J, V311, P555, DOI 10.1042/bj3110555; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1992, J BIOL CHEM, V267, P11673; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OLSON AL, 1995, ENDOCRINOLOGY, V136, P1962, DOI 10.1210/en.136.5.1962; PATERNOSTRO G, 1995, CARDIOVASC RES, V30, P205, DOI 10.1016/0008-6363(95)00019-4; PERKINS AC, 1995, NATURE, V375, P318; Ranganath S, 1998, J IMMUNOL, V161, P3822; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Rosen ED, 2000, GENE DEV, V14, P1293; Santalucia T, 1999, J BIOL CHEM, V274, P17626, DOI 10.1074/jbc.274.25.17626; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693; Zorzano A, 1997, AM J CARDIOL, V80, pA65, DOI 10.1016/S0002-9149(97)00459-1	48	186	205	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34322	34328		10.1074/jbc.M201304200	http://dx.doi.org/10.1074/jbc.M201304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097321	hybrid			2022-12-27	WOS:000177959100103
J	Meyer, A; Wursten, M; Schmid, A; Kohler, HPE; Witholt, B				Meyer, A; Wursten, M; Schmid, A; Kohler, HPE; Witholt, B			Hydroxylation of indole by laboratory-evolved 2-hydroxybiphenyl 3-monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; PSEUDOMONAS-AZELAICA HBP1; SUBSTRATE-BINDING SITE; DEGRADING BACTERIA; ESCHERICHIA-COLI; PHENOL HYDROXYLASE; INDIGO FORMATION; IDENTIFICATION; OXIDATION; MUTANTS	Directed enzyme evolution of 2-hydroxybiphenyl 3-monooxygenase (HbpA, EC 1.14.13.44) from Pseudomonas azelaica HBP1 resulted in an enzyme variant (HbpA(ind)) that hydroxylates indole and indole derivatives such as hydroxyindoles and 5-bromoindole. The wild-type protein does not catalyze these reactions. HbpA(ind) contains amino acid substitutions D222V and V368A. The activity for indole hydroxylation was increased 18-fold in this variant. Concomitantly, the K-d value for indole decreased from 1.5 mm to 78 mum. Investigation of the major reaction products of HbpA(ind) with indole revealed hydroxylation at the carbons of the pyrrole ring of the substrate. Subsequent enzyme-independent condensation and oxidation of the reaction products led to the formation of indigo and indirubin. The activity of the HbpA(ind) mutant monooxygenase for the natural substrate 2-hydroxybiphenyl was six times lower than that of the wild-type enzyme. In HbpA(ind), there was significantly increased uncoupling of NADH oxidation from 2-hydroxybiphenyl hydroxylation, which could be attributed to the substitution D222V. The position of Asp(222) in HbpA, the chemical properties of this residue, and the effects of its substitution indicate that Asp(222) is involved in substrate activation in HbpA.	ETH Honggerberg, HPT, Swiss Fed Inst Technol, ETH ZUrich,Inst Biotechnol, CH-8093 Zurich, Switzerland; Swiss Fed Inst Environm Sci & Technol, CH-8600 Dubendorf, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)	Witholt, B (corresponding author), ETH Honggerberg, HPT, Swiss Fed Inst Technol, ETH ZUrich,Inst Biotechnol, CH-8093 Zurich, Switzerland.		Kohler, Hans-Peter/C-1456-2015; Witholt, Bernard/A-7340-2012	Kohler, Hans-Peter/0000-0001-7667-0762; 				Bhushan B, 2000, LETT APPL MICROBIOL, V31, P5, DOI 10.1046/j.1472-765x.2000.00754.x; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; CAPDEVIELLE P, 1993, TETRAHEDRON LETT, V34, P2953, DOI 10.1016/S0040-4039(00)60490-2; Carredano E, 2000, J MOL BIOL, V296, P701, DOI 10.1006/jmbi.1999.3462; DEMOSS RD, 1969, J BACTERIOL, V98, P167, DOI 10.1128/JB.98.1.167-171.1969; EATON RW, 1995, J BACTERIOL, V177, P6983, DOI 10.1128/jb.177.23.6983-6988.1995; Enroth C, 1998, STRUCTURE, V6, P605, DOI 10.1016/S0969-2126(98)00062-8; ENSLEY BD, 1983, J BACTERIOL, V155, P505, DOI 10.1128/JB.155.2.505-511.1983; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; FEARON WR, 1950, BIOCHEM J, V46, P62, DOI 10.1042/bj0460062; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Gatti DL, 1996, BIOCHEMISTRY-US, V35, P567, DOI 10.1021/bi951344i; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; HANSCH C, 1969, ACCOUNTS CHEM RES, V2, P232, DOI 10.1021/ar50020a002; HART S, 1992, J GEN MICROBIOL, V138, P211, DOI 10.1099/00221287-138-1-211; Held M, 1998, J MOL CATAL B-ENZYM, V5, P87, DOI 10.1016/S1381-1177(98)00012-5; HESS WM, 1966, STAIN TECHNOL, V41, P27, DOI 10.3109/10520296609116276; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; KOHLER HPE, 1988, APPL ENVIRON MICROB, V54, P2683, DOI 10.1128/AEM.54.11.2683-2688.1988; KOHLER HPE, 1993, J BACTERIOL, V175, P1621, DOI 10.1128/JB.175.6.1621-1628.1993; KULA MR, 1987, METHOD ENZYMOL, V136, P9; LAATSCH H, 1986, LIEBIGS ANN CHEM, P1847; Li QS, 2000, CHEM-EUR J, V6, P1531, DOI 10.1002/(SICI)1521-3765(20000502)6:9<1531::AID-CHEM1531>3.3.CO;2-4; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Maugard T, 2001, PHYTOCHEMISTRY, V58, P897, DOI 10.1016/S0031-9422(01)00335-1; Meyer A, 2002, J BIOL CHEM, V277, P5575, DOI 10.1074/jbc.M110018200; MEYER A, 2002, IN PRESS BIOTECHNOL; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381; O'Connor KE, 1998, BIOTECHNOL LETT, V20, P219, DOI 10.1023/A:1005361415496; OConnor KE, 1997, APPL ENVIRON MICROB, V63, P4287, DOI 10.1128/AEM.63.11.4287-4291.1997; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; RUSSELL GA, 1969, J AM CHEM SOC, V91, P3851, DOI 10.1021/ja01042a028; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; Suske WA, 1999, J BIOL CHEM, V274, P33355, DOI 10.1074/jbc.274.47.33355; Suske WA, 1997, J BIOL CHEM, V272, P24257, DOI 10.1074/jbc.272.39.24257; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1997, FLAVINS FLAVOPROTEIN, V12, P305; WITHOLT B, 1972, J BACTERIOL, V109, P350, DOI 10.1128/JB.109.1.350-364.1972; Xu D, 2001, BIOCHEMISTRY-US, V40, P12369, DOI 10.1021/bi010962y; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	53	59	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34161	34167		10.1074/jbc.M205621200	http://dx.doi.org/10.1074/jbc.M205621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105208	hybrid, Green Published			2022-12-27	WOS:000177959100083
J	Esumi, H; Izuishi, K; Kato, K; Hashimoto, K; Kurashima, Y; Kishimoto, A; Ogura, T; Ozawa, T				Esumi, H; Izuishi, K; Kato, K; Hashimoto, K; Kurashima, Y; Kishimoto, A; Ogura, T; Ozawa, T			Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5 '-AMP-activated protein kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-CELLS; METABOLISM; GLUTAMINE	Hypoxia is a critical event for higher organisms, and cells and tissues react by increasing the oxygen supply by vasodilatation, angiogenesis, and erythropoiesis and maintaining cellular energy by increasing glycolysis and inhibiting anabolic pathways. Stimulation of glycolysis has been regarded as the main response that increases energy production during hypoxia; however, there is an obvious conflict during ischemia, because both the oxygen and glucose supply are insufficient. In this study, we found that exposure of HepG2 cells and normal fibroblasts to hypoxia induces cellular tolerance to glucose starvation. The tolerance induced by hypoxia is dependent on several amino acids, indicating a switch from glucose to amino acids as the energy source. When antisense RNA expression vector for 5'-AMP-activated protein kinase or protein kinase B/Akt was transfected into HepG2 cells, the induction of tolerance to glucose was greatly inhibited, indicating that the tolerance was dependent on 5'-AMP-activated protein kinase and protein kinase B/Akt. Similar tolerance was induced by nitric oxide exposure. The tolerance induced was observed in various cells and may represent a previously unknown physiological response related to hypoxia-preconditioning and tumor progression:austerity.	Natl Canc Ctr, Res Inst E, Investigat Treatment Div, Chiba 2778577, Japan; Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan	National Cancer Center - Japan; Nagoya University	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Investigat Treatment Div, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Esumi H, 1997, BIOCHEM MOL BIOL INT, V42, P779, DOI 10.1080/15216549700203211; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GRINDE B, 1985, EXPERIENTIA, V41, P1089, DOI 10.1007/BF01951685; Hahnfeldt P, 1999, CANCER RES, V59, P4770; HALE SL, 1994, CURR OPIN CARDIOL, V9, P411; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Ioannidis I, 1996, BIOCHEM J, V318, P789, DOI 10.1042/bj3180789; Izuishi K, 2000, CANCER RES, V60, P6201; KALLINOWSKI F, 1987, J CANCER RES CLIN, V113, P209, DOI 10.1007/BF00396375; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; LARSEN PL, 1995, GENETICS, V139, P1567; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Moncada S, 2000, Verh K Acad Geneeskd Belg, V62, P171; Ogura T, 1998, JPN J CANCER RES, V89, P199, DOI 10.1111/j.1349-7006.1998.tb00549.x; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	27	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32791	32798		10.1074/jbc.M112270200	http://dx.doi.org/10.1074/jbc.M112270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091379	hybrid			2022-12-27	WOS:000177859000052
J	Leinala, EK; Davies, PL; Doucet, D; Tyshenko, MG; Walker, VK; Jia, ZC				Leinala, EK; Davies, PL; Doucet, D; Tyshenko, MG; Walker, VK; Jia, ZC			A beta-helical antifreeze protein isoform with increased activity - Structural and functional insights	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINTER FLOUNDER; MACROZOARCES-AMERICANUS; OCEAN POUT; ICE; BINDING; MECHANISM; GENES; POLYPEPTIDE; ADSORPTION; DIVERSITY	The insect spruce budworm (Choristoneura fumiferana)(Cf) produces a number of isoforms of its highly active antifreeze protein (CfAFP). Although most of the CfAFP isoforms are in the 9-kDa range, isoforms containing a 30- or 31-amino acid insertion have also been identified. Here we describe the functional and structural analysis of a selected long isoform, CfAFP-501. Xray crystal structure determination reveals that the 31-amino acid insertion found in CfAFP-501 forms two additional loops within its highly regular beta-helical structure. This effectively extends the area of the two-dimensional Thr array and ice-binding surface of the protein. The larger isoform has 3 times the thermal hysteresis activity of the 9-kDa CfAFP-337. As well, a deletion of the 31-amino acid insertion within CfAFP-501 to form CfAFP-501-Delta-2-loop, results in a protein with reduced activity similar to the shorter CfAFP isoforms. Thus, the enhanced antifreeze activity of CL4LFP-501 is directly correlated to the length of its beta-helical structure and hence the size of its ice-binding face.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							Andorfer CA, 2000, J INSECT PHYSIOL, V46, P365, DOI 10.1016/S0022-1910(99)00189-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH CA, 1981, INT J PEPT PROT RES, V17, P125; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; Chao H, 1996, PROTEIN SCI, V5, P1150; DAVIES PL, 1992, GENE, V112, P163, DOI 10.1016/0378-1119(92)90372-V; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P388, DOI 10.1016/0005-2795(77)90395-6; DEVRIES AL, 1971, J BIOL CHEM, V246, P305; Doucet D, 2000, EUR J BIOCHEM, V267, P6082, DOI 10.1046/j.1432-1327.2000.01694.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; FOURNEY RM, 1984, GEN COMP ENDOCR, V54, P392, DOI 10.1016/0016-6480(84)90153-9; Gauthier SY, 1998, EUR J BIOCHEM, V258, P445, DOI 10.1046/j.1432-1327.1998.2580445.x; Gong ZY, 1996, J BIOL CHEM, V271, P4106, DOI 10.1074/jbc.271.8.4106; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; HEW CL, 1988, J BIOL CHEM, V263, P12049; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Kissinger CR, 2001, ACTA CRYSTALLOGR D, V57, P1474, DOI 10.1107/S0907444901012458; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leinala EK, 2002, STRUCTURE, V10, P619, DOI 10.1016/S0969-2126(02)00745-1; LI XM, 1985, J BIOL CHEM, V260, P2904; Liou YC, 1999, BIOCHEMISTRY-US, V38, P11415, DOI 10.1021/bi990613s; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SCHRAG JD, 1982, BIOCHIM BIOPHYS ACTA, V717, P322, DOI 10.1016/0304-4165(82)90186-6; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0	29	107	117	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33349	33352		10.1074/jbc.M205575200	http://dx.doi.org/10.1074/jbc.M205575200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105229	hybrid			2022-12-27	WOS:000177859000123
J	Sankala, M; Brannstrom, A; Schulthess, T; Bergmann, U; Morgunova, E; Engel, J; Tryggvason, K; Pikkarainen, T				Sankala, M; Brannstrom, A; Schulthess, T; Bergmann, U; Morgunova, E; Engel, J; Tryggvason, K; Pikkarainen, T			Characterization of recombinant soluble macrophage scavenger receptor MARCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; IMMUNE-RESPONSE; INNATE IMMUNITY; HOST-DEFENSE; IN-VITRO; COLLAGEN; BINDING; BACTERIA	MARCO is a type II transmembrane protein of the class A scavenger receptor family. It has a short N-terminal cytoplasmic domain, a transmembrane domain, and a large extracellular part composed of a 75-residue long spacer domain, a 270-residue collagenous domain, and a 99-residue long scavenger receptor cysteine-rich (SRCR) domain. Previous studies have indicated a role for this receptor in anti-microbial host defense functions. In this work we have produced the extracellular part of MARCO as a recombinant protein, and analyzed its binding properties. The production of this protein, soluble MARCO (sMARCO), has made it possible for the first time to study MARCO and its binding properties in a cell-free system. Using circular dichroism analyses, a protease-sensitive assay, and rotary shadowing electron microscopy, sMARCO was shown to have a triple-helical collagenous structure. Rotary shadowing also demonstrated that the molecules often associate with each other via the globes. sMARCO was found to bind avidly both heat-killed and living bacteria. Lipopolysaccharide, an important component of the outer membrane of Gram-negative bacteria, was shown to be a ligand of MARCO. Studies with different bacterial strains indicated that the O-side chain of lipopolysaccharide is not needed for the bacterial recognition. Finally, the C-terminal SRCR domain was also produced as a recombinant protein, and its bacteria-binding capability was studied. Although the transfection experiments with transmembrane MARCO variants have indicated a crucial role for this domain in bacterial binding, the monomeric domain exhibited low, barely detectable bacteria-binding activity. Thus, it is possible that cooperation between the SRCR domain and the collagenous domain is needed for high-affinity bacterial binding, or that the SRCR domain has to be in a trimeric form to effectively bind to bacteria.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Oulu, Dept Biochem, F-90570 Oulu, Finland	Karolinska Institutet; University of Basel; Finland National Institute for Health & Welfare; University of Oulu	Bergmann, U (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.		Morgunova, Ekaterina/G-2479-2018	Morgunova, Ekaterina/0000-0002-7754-9021				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; BULLAS LR, 1983, J BACTERIOL, V156, P471, DOI 10.1128/JB.156.1.471-474.1983; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GOLDBERG JB, 1992, P NATL ACAD SCI USA, V89, P10716, DOI 10.1073/pnas.89.22.10716; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Ito S, 1999, ARCH HISTOL CYTOL, V62, P83, DOI 10.1679/aohc.62.83; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kronman C, 2000, J BIOL CHEM, V275, P29488, DOI 10.1074/jbc.M004298200; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; Mushegian A, 2001, J CELL BIOL, V155, P705, DOI 10.1083/jcb.200107040; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4134, DOI 10.1021/bi00823a016; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; Pikkarainen T, 1999, J BIOL CHEM, V274, P10975, DOI 10.1074/jbc.274.16.10975; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; van der Laan LJW, 1999, J IMMUNOL, V162, P939; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1	36	59	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33378	33385		10.1074/jbc.M204494200	http://dx.doi.org/10.1074/jbc.M204494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12097327	hybrid			2022-12-27	WOS:000177859000127
J	Gaidarova, S; Jimenez, SA				Gaidarova, S; Jimenez, SA			Inhibition of basal and transforming growth factor-beta-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-SCLEROSIS FIBROBLASTS; ALPHA-1(I) PROCOLLAGEN GENE; ALPHA-2(I) COLLAGEN GENE; MESSENGER-RNA LEVELS; PRO-ALPHA-1(I) COLLAGEN; SCLERODERMA FIBROBLASTS; IN-VITRO; EXTRACELLULAR-MATRIX; FUNCTIONAL-ANALYSIS; PROMOTER ACTIVITY	The Sp1 transcription factor plays a crucial role in COL1A1 transcriptional regulation under normal and pathologic conditions and under the effects of transforming growth factor-beta (TGF-beta). Sp1 activity is elevated in numerous diseases characterized by tissue fibrosis. Therefore, inhibition of Sp1 binding to COL1A1 regulatory elements may represent an effective treatment for these diseases. Here we examined the effect of two DNA intercalators that prevent Sp1 binding on the expression of COL1A1 in human dermal fibroblasts. Cultured human adult dermal fibroblasts were treated with WP631 (50 pM/ml to 500 nM/ml) or mitoxantrone (5-500 nM/ml). Cytotoxicity, cellular apoptosis, and collagen deposition were examined by fluorescence microscopy. Collagen production was examined by enzyme-linked immunosorbent assay and metabolic labeling, COL1A1 steady-state mRNA levels, and stability were assessed by Northern hybridizations, and COL1A1 transcription by in vitro nuclear transcription assays and transient transfections. Competition of the drugs for Sp1 binding and their effect on TGF-beta-induced stimulation of COL1A1 transcription was also examined. Both drugs caused a dose-related inhibition of COL1A1 production and mRNA levels without cytotoxicity or apoptosis. COL1A1 transcriptional activity showed a profound reduction mediated by a short proximal promoter region containing an Sp1-binding element at -87 to -82 bp. Furthermore, both drugs inhibited Sp1 DNA complex formation and abrogated the stimulation of COL1A1 transcription induced by TGF-beta. WP631 showed 10-fold higher potency than mitoxantrone. These data indicate that mitoxantrone and WP631 are very potent inhibitors of basal and TGF-beta-stimulated COL1A1 expression and suggest that Sp1-DNA intercalators may be an effective and novel approach for the treatment of fibrotic diseases and modulation of profibrogenic effects of TGF-beta.	Thomas Jefferson Univ, Div Rheumatol, Dept Med, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Div Rheumatol, Dept Med, Rm 509 BLSB,233 S 10th St, Philadelphia, PA 19107 USA.	Sergio.Jimenez@mail.tju.edu		Jimenez, Sergio/0000-0001-5213-1203	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19616] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; BASHEY RI, 1977, BIOCHEM BIOPH RES CO, V76, P1214, DOI 10.1016/0006-291X(77)90985-8; BELLON G, 1985, ANAL BIOCHEM, V150, P188, DOI 10.1016/0003-2697(85)90459-2; BOAST S, 1990, J BIOL CHEM, V265, P13351; Bornstein P, 1996, MATRIX BIOL, V15, P3, DOI 10.1016/S0945-053X(96)90121-3; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaires JB, 1997, J MED CHEM, V40, P261, DOI 10.1021/jm9607414; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1985, J BIOL CHEM, V260, P2315; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; DIAZ A, 1993, J BIOL CHEM, V268, P10364; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gottesfeld JM, 2000, GENE EXPRESSION, V9, P77; Green DR, 2000, METHOD ENZYMOL, V322, P15; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Ihn H, 2000, ARTHRITIS RHEUM, V43, P2240, DOI 10.1002/1529-0131(200010)43:10<2240::AID-ANR11>3.0.CO;2-2; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; KAHARI VM, 1987, FEBS LETT, V215, P331, DOI 10.1016/0014-5793(87)80172-2; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Leng FF, 1998, BIOCHEMISTRY-US, V37, P1743, DOI 10.1021/bi9720742; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liska Deann J., 1992, Gene Expression, V2, P379; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Mitsuyama K, 2001, DIGESTION, V63, P68, DOI 10.1159/000051914; Morgan D M, 1998, Methods Mol Biol, V79, P179; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Norman JT, 1999, EXP NEPHROL, V7, P167; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Poppleton HM, 1997, BIOCHEM J, V323, P225, DOI 10.1042/bj3230225; Portugal J, 2001, CURR MED CHEM, V8, P1; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Robinson H, 1997, BIOCHEMISTRY-US, V36, P8663, DOI 10.1021/bi970842j; Rosenbloom J, 2000, ARTHRITIS RHEUM-US, V43, P1624, DOI 10.1002/1529-0131(200007)43:7<1624::AID-ANR28>3.3.CO;2-5; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Zewail-Foote M, 1999, ANTI-CANCER DRUG DES, V14, P1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	61	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38737	38745		10.1074/jbc.M201742200	http://dx.doi.org/10.1074/jbc.M201742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138160	hybrid			2022-12-27	WOS:000178529600093
J	Brooks, AJ; Johansson, M; John, AV; Xu, YB; Jans, DA; Vasudevan, SG				Brooks, AJ; Johansson, M; John, AV; Xu, YB; Jans, DA; Vasudevan, SG			The interdomain region of dengue NS5 protein that binds to the viral helicase NS3 contains independently functional importin beta 1 and importin alpha/beta-recognized nuclear localization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; DEPENDENT RNA-POLYMERASE; JAPANESE ENCEPHALITIS-VIRUS; YELLOW-FEVER VIRUS; KINASE-II SITE; INFECTED-CELLS; NONSTRUCTURAL PROTEIN; FLAVIVIRUS KUNJIN; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE	Dengue virus NS5 protein is a multifunctional RNA-dependent RNA polymerase that is essential for virus replication. We have shown previously that the 37-amino acid interdomain spacer sequence (residues (X2KKX14KKKX11RKX3405)-X-369) of Dengue2 NS5 contains a functional nuclear localization signal (NLS). In this study, beta-galactosidase fusion proteins carrying point mutations of the positively charged residues or truncations of the interdomain linker region (residues 369-389 or residues 386-405) were analyzed for nuclear import and importin binding activities to show that the N-terminal part of the linker region (residues 369-389, a/bNLS) is critical for nuclear localization and is recognized with high affinity by the conventional NLS-binding importin alpha/beta heterodimeric nuclear import receptor. We also show that the importin beta-binding site (residues 320-368, bNLS) adjacent to the a/bNLS, previously identified by yeast two-hybrid analysis, is functional as an NLS, recognized with high affinity by importin beta, and able to target beta-galactosidase to the nucleus. Intriguingly, the bNLS is highly conserved among Dengue and related flaviviruses, implying a general role for the region and importin beta in the infectious cycle.	James Cook Univ N Queensland, Dept Biochem & Mol Biol, Townsville, Qld 4811, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	James Cook University; Australian National University; John Curtin School of Medical Research; Monash University	Vasudevan, SG (corresponding author), James Cook Univ N Queensland, Dept Biochem & Mol Biol, Townsville, Qld 4811, Australia.	Subhash.Vasudevan@jcu.edu.au	Brooks, Andrew/A-9969-2011	Brooks, Andrew/0000-0002-2691-1668; Vasudevan, Subhash/0000-0002-5083-3831; Jans, David/0000-0001-5115-4745				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; Blackwell JL, 1997, J VIROL, V71, P6433, DOI 10.1128/JVI.71.9.6433-6444.1997; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; CAMMISAPARKS H, 1992, VIROLOGY, V189, P511, DOI 10.1016/0042-6822(92)90575-A; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; EDWARD Z, 1993, MICROBIOL IMMUNOL, V37, P239, DOI 10.1111/j.1348-0421.1993.tb03206.x; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Forwood JK, 1999, BIOCHEM BIOPH RES CO, V257, P731, DOI 10.1006/bbrc.1999.0370; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRUN JB, 1988, J GEN VIROL, V69, P3121, DOI 10.1099/0022-1317-69-12-3121; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Hanley KA, 2002, J VIROL, V76, P525, DOI 10.1128/JVI.76.2.525-531.2002; HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990; Huang KJ, 2000, J GEN VIROL, V81, P2177, DOI 10.1099/0022-1317-81-9-2177; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Johansson M, 2001, J GEN VIROL, V82, P735, DOI 10.1099/0022-1317-82-4-735; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Khromykh AA, 1999, J VIROL, V73, P9247, DOI 10.1128/JVI.73.11.9247-9255.1999; Khromykh AA, 1998, J VIROL, V72, P7270, DOI 10.1128/JVI.72.9.7270-7279.1998; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Lam MHC, 2001, BIOCHEM BIOPH RES CO, V282, P629, DOI 10.1006/bbrc.2001.4607; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Morozova OV, 1997, VIRUS RES, V49, P9, DOI 10.1016/S0168-1702(96)01433-5; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Shi PY, 1996, J VIROL, V70, P6278, DOI 10.1128/JVI.70.9.6278-6287.1996; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Ta M, 2000, J VIROL, V74, P5108, DOI 10.1128/JVI.74.11.5108-5115.2000; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; Truant R, 1999, MOL CELL BIOL, V19, P1210; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Westaway EG, 1997, VIROLOGY, V234, P31, DOI 10.1006/viro.1997.8629; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; ZHAO B, 1986, VIROLOGY, V155, P77, DOI 10.1016/0042-6822(86)90169-8	72	110	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36399	36407		10.1074/jbc.M204977200	http://dx.doi.org/10.1074/jbc.M204977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12105224	hybrid			2022-12-27	WOS:000178275100080
J	Bultmann, H; Brandt, CR				Bultmann, H; Brandt, CR			Peptides containing membrane-transiting motifs inhibit virus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; INTRACELLULAR DELIVERY; PLASMA-MEMBRANE; TYPE-1; LOCALIZATION; PROTEIN; MODEL; CELLS; TAT	Several exceptional peptides have been identified that can cross plasma membranes and deliver various covalently linked moieties into cells. We report the surprising observation that each of four structurally distinct transiting peptides tested displayed antiviral activity and inhibited herpes simplex virus entry into cells. All four peptides inhibited infection at concentrations in the low micromolar range. Some of the peptides selectively and reversibly blocked entry without inactivating virions in a persistent manner. For other peptides, the effects on virus entry were not readily distinguishable from virus inactivation. High concentrations of nearly all peptides lead to irreversible inactivation of virions. By various criteria, the peptides differed in their ability to inactivate virions and in the temperature dependence of inactivation. Testing of peptides with modifications known to disrupt transport revealed that, in some instances, transport activity did not correlate with antiviral activity. These results identify inhibition of viral entry as another common property of membrane-transiting peptides in addition to their ability to cross membranes and transport materials into cells. These or related peptides may be useful as agents to prevent infection and to study the process of viral entry.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Brandt, CR (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 6630 MSC,1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL EYE INSTITUTE [R01EY007336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI052049] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY07336] Funding Source: Medline; NIAID NIH HHS [P01-AI 52049] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brandt CR, 1996, ANTIMICROB AGENTS CH, V40, P1078, DOI 10.1128/AAC.40.5.1078; Bultmann H, 2001, J VIROL, V75, P2634, DOI 10.1128/JVI.75.6.2634-2645.2001; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; FIELDS C G, 1991, Peptide Research, V4, P95; Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P42; GRAU DR, 1989, INVEST OPHTH VIS SCI, V30, P2474; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P7129; Oehlke J, 1996, PROTEIN PEPTIDE LETT, V3, P393; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Stephens DJ, 2001, P NATL ACAD SCI USA, V98, P4295, DOI 10.1073/pnas.081065198; Truant R, 1999, MOL CELL BIOL, V19, P1210; TRYBALA E, 1994, J GEN VIROL, V75, P743, DOI 10.1099/0022-1317-75-4-743; Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184	22	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36018	36023		10.1074/jbc.M204849200	http://dx.doi.org/10.1074/jbc.M204849200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130644	hybrid			2022-12-27	WOS:000178275100033
J	Morosinotto, T; Castelletti, S; Breton, J; Bassi, R; Croce, R				Morosinotto, T; Castelletti, S; Breton, J; Bassi, R; Croce, R			Mutation analysis of Lhca1 antenna complex - Low energy absorption forms originate from pigment-pigment interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLOROPHYLL-PROTEIN COMPLEXES; RESOLVED FLUORESCENCE ANALYSIS; CAROTENOID-BINDING-SITES; IN-VITRO RECONSTITUTION; PHOTOSYSTEM-II; THYLAKOID MEMBRANE; HIGHER-PLANTS; ORIENTATION; ZEAXANTHIN	The light harvesting complex Lhca1, one of the four gene products comprising the photosystem I antenna system, has been analyzed by site-directed mutagenesis with the aim of determining the chromophore(s) responsible for its long wavelength chlorophyll spectral form, a specific characteristic of the LHCI antenna complex. A family of mutant proteins, each carrying a mutation at a single chlorophyll-binding residue, was obtained and characterized by biochemical and spectroscopic methods. A map of the chromophores bound to each of the 10 chlorophyll-binding sites was drawn, and the energy levels of the Q(y) transition were determined in most cases. When compared with Lhcb proteins previously analyzed, Lhca1 is characterized by stronger interactions between individual chromophores as detected by both biochemical and spectroscopic methods; most mutations, although targeted to a single residue, lead to the loss of more than one chromophore and of conservative CD signals typical of chlorophyll-chlorophyll interactions. The lower energy absorption form (686 nm at 100K, 688 nm at room temperature), which is responsible for the red-shifted emission components at 690 and 701 nm, typical of Lhca1, is associated with a chlorophyll a/chlorophyll a excitonic interaction originating from a pigment cluster localized in the protein domain situated between helix C and the helix A/helix B cross. This cluster includes chlorophylls bound to sites A5-B5-B6 and a xanthophyll bound to site L2.	Univ Verona, Dipartimento Sci & Tenol, I-37234 Verona, Italy; CEA Saclay, Serv Bioenerget, F-91191 Gif Sur Yvette, France	University of Verona; CEA; UDICE-French Research Universities; Universite Paris Saclay	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tenol, Strada Le Grazie,15, I-37234 Verona, Italy.	bassi@sci.univr.it	Morosinotto, Tomas/AAC-3188-2019; Croce, Roberta/N-4067-2014; Croce, Roberta/F-1174-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/ABG-3595-2021	Morosinotto, Tomas/0000-0002-0803-7591; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P390; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P421; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GROCE R, 2002, BIOCHEMISTRY-US, V41, P7334; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V682, P152, DOI 10.1016/0005-2728(82)90129-3; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V679, P428, DOI 10.1016/0005-2728(82)90164-5; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KNOX RS, 1975, BIOENERG PHOTOSYNTH, P183; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Melkozernov AN, 1998, J PHYS CHEM B, V102, P8183, DOI 10.1021/jp9810466; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; Simonetto R, 1999, BIOCHEMISTRY-US, V38, P12974, DOI 10.1021/bi991140s; Trinkunas G, 1997, J PHYS CHEM B, V101, P7313, DOI 10.1021/jp963968j; van Amerongen H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/jp0028406; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9	38	74	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36253	36261		10.1074/jbc.M205062200	http://dx.doi.org/10.1074/jbc.M205062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12095992	hybrid			2022-12-27	WOS:000178275100061
J	Sarkar, S; Roy, BC; Hatano, N; Aoyagi, T; Gohji, K; Kiyama, R				Sarkar, S; Roy, BC; Hatano, N; Aoyagi, T; Gohji, K; Kiyama, R			A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL COMPETITIVE REASSOCIATION; DIFFERENTIAL CLONING; GENOMIC DNA; CANCER; HYPERMETHYLATION; HETEROZYGOSITY; TUMORIGENESIS	By a combination of genome subtraction and comprehensive analysis of loss of heterozygosity based on mapping hemizygous deletions for a potential tumor-related locus, a minimum overlapping region of deletions at 9p24 the size of 165 kb was identified and found to harbor a new potential tumor suppressor gene for renal cell carcinoma, the Kank gene. Kank (for kidney ankyrin repeat-containing protein) contains four ankyrin repeats at its C terminus. Expression of the gene was suppressed in 6 of 8 or 6 of 10 cancer tissues examined by reverse transcription-PCR or Western blotting, respectively, and in several kidney tumor cell lines due to methylation at CpG sites in the gene. Epigenetic methylation or imprinting seemed to be the first hit, which was followed by a second hit of deletion, resulting in loss of function in many of these deletion cases. Expression of this gene in expression-negative HEK293 cells induced growth retardation at G(0)/G(1) as well as morphological changes.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Ichikawa Gen Hosp, Dept Urol, Tokyo Dent Coll, Chiba 2728513, Japan; Osaka Med Coll, Dept Urol, Takatsuki, Osaka 5960801, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Dental College; Osaka Medical College	Kiyama, R (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	kiyama.r@aist.go.jp	Hatano, Naoya/F-6147-2011					Aoyagi T, 1996, Int J Urol, V3, P392, DOI 10.1111/j.1442-2042.1996.tb00560.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAIRNS P, 1995, CANCER RES, V55, P224; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Druck T, 1998, ONCOL RES, V10, P341; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Hatano N, 2001, MOL CARCINOGEN, V31, P161, DOI 10.1002/mc.1051; Inoue S, 1996, GENOMICS, V31, P271, DOI 10.1006/geno.1996.0048; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KIYAMA R, 1995, ADV BIOPHYS, V31, P151, DOI 10.1016/0065-227X(95)99389-7; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; MACH H, 1996, CANCER RES, V56, P27; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; MORITA R, 1991, CANCER RES, V51, P820; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ohki R, 1998, MOL CARCINOGEN, V22, P158, DOI 10.1002/(SICI)1098-2744(199807)22:3<158::AID-MC3>3.0.CO;2-H; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; YOKOTA H, 1990, P NATL ACAD SCI USA, V87, P6398, DOI 10.1073/pnas.87.16.6398	29	77	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36585	36591		10.1074/jbc.M204244200	http://dx.doi.org/10.1074/jbc.M204244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133830	hybrid			2022-12-27	WOS:000178275100102
J	Chin, LS; Vavalle, JP; Li, L				Chin, LS; Vavalle, JP; Li, L			Staring, a novel E3 ubiquitin-protein ligase that targets syntaxin 1for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; LONG-TERM POTENTIATION; PROTEASOME PATHWAY; NEUROTRANSMITTER RELEASE; CINGULATE CORTEX; LEUCINE-ZIPPER; HRS INTERACTS; RAT-BRAIN; PARKIN; DISEASE	Syntaxin 1 is an essential component of the neurotransmitter release machinery, and regulation of syntaxin I expression levels is thought to contribute to the mechanism underlying learning and memory. However, the molecular events that control the degradation of syntaxin 1 remain undefined. Here we report the identification and characterization of a novel RING finger protein, Staring, that interacts with syntaxin 1. Staring is expressed throughout the brain, where it exists in both cytosolic and membrane-associated pools. Staring binds and recruits the brain-enriched E2 ubiquitin-conjugating enzyme UbcH8 to syntaxin 1 and facilitates the ubiquitination and proteasome-dependent degradation of syntaxin 1. These findings suggest that Staring is a novel E3 ubiquitin-protein ligase that targets syntaxin 1 for degradation by the ubiquitin-proteasome pathway.	Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	Emory University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, 1510 Clifton Rd, Atlanta, GA 30322 USA.			Chin, Lih-Shen/0000-0002-0817-0368				Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Betz A, 1997, J BIOL CHEM, V272, P2520; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; CHAPMAN A P, 1992, Biochemical Society Transactions, V20, p155S; CHAPMAN AP, 1994, NEUROSCI LETT, V168, P238, DOI 10.1016/0304-3940(94)90459-6; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, ISR MED ASSOC J, V3, P319; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Davis S, 1996, EUR J NEUROSCI, V8, P2068, DOI 10.1111/j.1460-9568.1996.tb00727.x; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Ferrer I, 1999, NEUROBIOL DIS, V6, P92, DOI 10.1006/nbdi.1998.0226; Flann S, 1997, NEUROSCIENCE, V81, P173, DOI 10.1016/S0306-4522(97)00196-6; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gabriel SM, 1997, ARCH GEN PSYCHIAT, V54, P559; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodall AR, 1997, J NEUROCHEM, V68, P1542; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Honer WG, 1997, NEUROSCIENCE, V78, P99, DOI 10.1016/S0306-4522(96)00489-7; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kimura M, 1997, CYTOGENET CELL GENET, V78, P107, DOI 10.1159/000134639; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kushima Y, 1997, J MOL NEUROSCI, V8, P19, DOI 10.1007/BF02736860; Kwong J, 2000, J CELL SCI, V113, P2273; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Miya F, 1996, CELL STRUCT FUNCT, V21, P525, DOI 10.1247/csf.21.525; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Noakes PG, 1999, J COMP NEUROL, V410, P531; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Purkiss JR, 2001, NEUROTOXICOLOGY, V22, P447, DOI 10.1016/S0161-813X(01)00042-0; Richter-Levin G, 1998, NEUROSCI LETT, V251, P41, DOI 10.1016/S0304-3940(98)00476-5; Rieger KJ, 1999, YEAST, V15, P973, DOI 10.1002/(SICI)1097-0061(199907)15:10B<973::AID-YEA402>3.3.CO;2-C; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shimohama S, 1997, BIOCHEM BIOPH RES CO, V236, P239, DOI 10.1006/bbrc.1997.6940; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; VEERANNA GP, 1997, DEV NEUROSCI, V19, P172; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wen H, 2000, BIOCHEM BIOPH RES CO, V275, P141, DOI 10.1006/bbrc.2000.3242; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	66	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35071	35079		10.1074/jbc.M203300200	http://dx.doi.org/10.1074/jbc.M203300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121982	hybrid, Green Published			2022-12-27	WOS:000178117000053
J	Harris, BZ; Venkatasubrahmanyam, S; Lim, WA				Harris, BZ; Venkatasubrahmanyam, S; Lim, WA			Coordinated folding and association of the LIN-2,-7 (L27) domain - An obligate heterodimerization module involved in assembly of signaling and cell polarity complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS VULVAR INDUCTION; EPITHELIAL-CELLS; BASOLATERAL MEMBRANE; PROTEIN LOCALIZATION; MOLECULAR-CLONING; NMDA RECEPTOR; PDZ PROTEINS; MAGUK FAMILY; COILED COILS; LIN-7	(L) under bar IN-(2) under bar, -(7) under bar (L27) homology domains are putative protein-protein interaction modules found in several scaffold proteins involved in the assembly of polarized cell-signaling structures. These specific interaction pairs are well conserved across metazoan species, from worms to man. We have expressed and purified L27 domains from multiple species and find that certain domains from proteins such as Caenorhabditis elegans LIN-2 and LIN-7 can specifically heterodimerize. Biophysical analysis of interacting L27 domains demonstrates that the domains interact with a 1:1 stoichiometry. Circular dichroism studies reveal that the domains appear to function as an obligate heterodimer; individually the domains are largely unfolded, but when associated they show a significant increase in helicity, as well as a cooperative unfolding transition. These novel obligate interacting pairs are likely to play a key role in regulating the organization of signaling proteins at polarized cell structures.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu						Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; BUBB MR, 1994, J BIOL CHEM, V269, P25587; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hoskins R, 1996, DEVELOPMENT, V122, P97; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Ide N, 1998, BIOCHEM BIOPH RES CO, V243, P634, DOI 10.1006/bbrc.1998.8142; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rongo C, 2001, CYTOKINE GROWTH F R, V12, P349, DOI 10.1016/S1359-6101(01)00011-9; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2000, J CELL SCI, V113, P1851; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	43	21	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34902	34908		10.1074/jbc.M205856200	http://dx.doi.org/10.1074/jbc.M205856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110687	hybrid			2022-12-27	WOS:000178117000033
J	Mandelboim, M; Estrano, CL; Tschudi, C; Ullu, E; Michaeli, S				Mandelboim, M; Estrano, CL; Tschudi, C; Ullu, E; Michaeli, S			On the role of Exon and intron sequences in trans-splicing utilization and cap 4 modification of the trypanosomatid Leptomonas collosoma SL RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER RNA; MESSENGER-RNAS; U6 SNRNA; IN-VIVO; GENE; TRANSCRIPTION; U5	In trypanosomatid protozoa the biogenesis of mature mRNA involves addition of the spliced leader (SL) sequence from the SL RNA to polycistronic pre-mRNA via trans-splicing. Here we present a mutational analysis of the trypanosomatid Leptomonas collosoma SL RNA to further our understanding of its functional domains important for trans-splicing utilization. Mutant SL RNAs were analyzed for defects in modification of the hypermethylated cap structure (cap 4) characteristic of trypanosomatid SL RNAs, for defects in the first step of the reaction and overall utilization in trans-splicing. Single substitution of the cap 4 nucleotides led to under-methylation of the cap 4 structure, and these mutants were all impaired in their utilization in trans-splicing. Abrogation of the sequence of the Sm-like site and sequences downstream to it also showed cap modification and trans-splicing defects, thus providing further support for a functional linkage between cap modifications and trans-splicing. Further, we report that in L. collosoma both the exon and intron of the SL RNA contribute information for efficient function of the SL RNA in trans-splicing. This study, however, did not provide support for the putative SL RNA-U6 small nuclear RNA (snRNA) interaction at the Sm site like in the nematodes, suggesting differences in the bridging role of U6 in the two trans-splicing systems.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Bar Ilan University; Yale University; Yale University; Yale University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Estrano, Carlos E./B-3576-2009; Michaeli, Shulamit/AAC-8255-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028798, R37AI028798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; Goncharov I, 1998, NUCLEIC ACIDS RES, V26, P2200, DOI 10.1093/nar/26.9.2200; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; Mair G, 2000, J BIOL CHEM, V275, P28994, DOI 10.1074/jbc.M004193200; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, J BIOL CHEM, V274, P19361, DOI 10.1074/jbc.274.27.19361; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2000, J BIOL CHEM, V275, P27883	25	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35210	35218		10.1074/jbc.M201910200	http://dx.doi.org/10.1074/jbc.M201910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121975	hybrid			2022-12-27	WOS:000178117000071
J	Hu, YC; Shyr, CR; Che, WY; Mu, XM; Kim, E; Chang, C				Hu, YC; Shyr, CR; Che, WY; Mu, XM; Kim, E; Chang, C			Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR; NUCLEAR RECEPTOR; GENE-EXPRESSION; MOLECULAR-CLONING; ANDROGEN RECEPTOR; GENOMIC STRUCTURE; TUMOR-SUPPRESSOR; RESPONSE ELEMENT; MICE LACKING; IDENTIFICATION	The transcriptional activity of the estrogen receptor (ER) is known to be highly modulated by the character and amount of coregulator proteins present in the cells. TR2 orphan receptor (TR2), a member of the nuclear receptor superfamily without identified ligands, is found to be expressed in the breast cancer cell lines and to function as a repressor to suppress ER-mediated transcriptional activity. Utilizing an interaction blocker, ER-6 (amino acids 312-340), responsible for TR2 interaction, the suppression of ER by TR2 could be reversed, suggesting that this suppression is conferred by the direct protein-protein interaction. Administration of antisense TR2, resulting in an enhancement of ER transcriptional activity in MCF7 cells, indicates that endogenous TR2 normally suppresses ER-mediated signaling. To gain insights into the molecular mechanism by which TR2 suppresses ER, we found that TR2 could interrupt ER DNA binding via formation of an ER-TR2 heterodimer that disrupted the ER homodimerization. The suppression of ER transcription by TR2 consequently caused the inhibition of estrogen-induced cell growth and G(1)/S transition in estrogen-dependent breast cancer cells. Taken together in addition to the potential roles in spermatogenesis and neurogenesis, our data provide a novel biological function of TR2 that may exert an important repressor in regulating ER activity in mammary glands.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chang CS, 1998, MOL CELL BIOCHEM, V189, P195, DOI 10.1023/A:1006918402474; Collins LL, 2001, J BIOL CHEM, V276, P27316, DOI 10.1074/jbc.M104145200; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; *EARL BREAST CANC, 1998, LANCET, V351, P145; Faulkner SW, 2000, GYNECOL ONCOL, V77, P283, DOI 10.1006/gyno.2000.5762; Fisk GJ, 1998, CELL, V93, P543, DOI 10.1016/S0092-8674(00)81184-8; Franco PJ, 2001, MOL ENDOCRINOL, V15, P1318, DOI 10.1210/me.15.8.1318; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Huard V, 1998, DNA SEQUENCE, V9, P113, DOI 10.3109/10425179809086435; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; KontrogianniKonstantopoulos A, 1996, DEV BIOL, V177, P371, DOI 10.1006/dbio.1996.0171; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Le Jossic C, 1998, BIOCHEM BIOPH RES CO, V245, P64; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; Lee CH, 2000, BIOCHEM PHARMACOL, V60, P127, DOI 10.1016/S0006-2952(00)00311-7; Lee HJ, 1999, MOL CELL BIOCHEM, V194, P199, DOI 10.1023/A:1006903202089; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; LIN TM, 1995, J BIOL CHEM, V270, P30121; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Mu XM, 2000, J BIOL CHEM, V275, P23877, DOI 10.1074/jbc.M910158199; Murty VVVS, 1996, GENOMICS, V35, P562, DOI 10.1006/geno.1996.0398; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Resnick EM, 2000, J BIOL CHEM, V275, P7158, DOI 10.1074/jbc.275.10.7158; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SAPINO A, 1990, J HISTOCHEM CYTOCHEM, V38, P1541, DOI 10.1177/38.11.2212615; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Wirtanen L, 1997, DIFFERENTIATION, V62, P159; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Young WJ, 1998, J BIOL CHEM, V273, P20877, DOI 10.1074/jbc.273.33.20877; ZELHOF AC, 1995, P NATL ACAD SCI USA, V92, P10477, DOI 10.1073/pnas.92.23.10477; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	62	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33571	33579		10.1074/jbc.M203531200	http://dx.doi.org/10.1074/jbc.M203531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093804	hybrid			2022-12-27	WOS:000177959100007
J	Kobayashi, S; Yamashita, K; Takeoka, T; Ohtsuki, T; Suzuki, Y; Takahashi, R; Yamamoto, K; Kaufmann, SH; Uchiyama, T; Sasada, M; Takahashi, A				Kobayashi, S; Yamashita, K; Takeoka, T; Ohtsuki, T; Suzuki, Y; Takahashi, R; Yamamoto, K; Kaufmann, SH; Uchiyama, T; Sasada, M; Takahashi, A			Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVATION; CELL-DEATH; PROMOTES APOPTOSIS; DNA FRAGMENTATION; CYTOCHROME-C; IN-VITRO; PROTEIN; FAS; DOWNSTREAM; CLEAVAGE	The number of neutrophils in the blood and tissues is controlled by constitutive apoptotic programmed cell death and clearance by phagocytes such as macrophages. Here, we found that calpains cleave the X-linked inhibitor of apoptosis (XIAP) in vitro, producing fragments that are unable to inhibit caspase-3. These fragments were detected in normal neutrophils but were unstable and rapidly degraded. Calpain inhibition delayed tumor necrosis factor-alpha-induced apoptosis of normal neutrophils, consistent with a role for calpains in regulating the onset of apoptosis. Interestingly, neutrophils from three patients with chronic neutrophilic leukemia, a rare syndrome characterized by accumulation of mature neutrophils, exhibited decreased mu-calpain expression, diminished calpain activity, and impaired XIAP degradation. Neutrophils from these patients displayed a delay in spontaneous, Fas-stimulated, and tumor necrosis factor-alpha-induced apoptosis. These observations suggest that calpain-mediated XIAP degradation contributes to initiation of apoptosis in normal neutrophils and dysfunction of this regulatory pathway can lead to pathological neutrophil accumulation.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto 6068507, Japan; Jichi Med Sch, Dept Internal Med, Div Hematol, Minami Kawachi, Tochigi 3290498, Japan; RIKEN, Brain Sci Inst, Lab Motor Syst Neurodegenerat, Wako, Saitama 3510198, Japan; Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Kyoto Univ, Coll Med Technol, Kyoto 6068507, Japan	Kyoto University; Jichi Medical University; RIKEN; Mayo Clinic; Kyoto University	Takahashi, A (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Div 1,Sakyo Ku, Kawara Cho, Kyoto 6068507, Japan.	atakahas@kuhp.kyoto-u.ac.jp	Ohtsuki, Tomoaki/D-7179-2014	Kaufmann, Scott/0000-0002-4900-7145; Takahashi, Atsushi/0000-0003-3340-432X	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Elliott MA, 2001, LEUKEMIA, V15, P35, DOI 10.1038/sj.leu.2401993; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guttmann RP, 2000, METH MOL B, V144, P143; Hara K, 2001, EUR J HAEMATOL, V66, P70, DOI 10.1034/j.1600-0609.2001.00266.x; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kawabata Y, 1999, BLOOD, V94, P3523, DOI 10.1182/blood.V94.10.3523.422k07_3523_3530; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KWONG YL, 1993, BLOOD, V82, P1035; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Murachi T, 1989, Adv Exp Med Biol, V255, P445; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; Pascucci M, 1997, ACTA HAEMATOL-BASEL, V98, P163; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Reilly JT, 2002, BRIT J HAEMATOL, V116, P10, DOI 10.1046/j.1365-2141.2002.03234.x; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rosser BG, 2000, METH MOL B, V144, P245; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi A, 1999, INT J HEMATOL, V70, P226; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YOU W, 1979, AM J CLIN PATHOL, V72, P233; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	71	90	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33968	33977		10.1074/jbc.M203350200	http://dx.doi.org/10.1074/jbc.M203350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12121983	Green Submitted, hybrid			2022-12-27	WOS:000177959100060
J	Lee, H; Park, DS; Wang, XB; Scherer, PE; Schwartz, PE; Lisanti, MP				Lee, H; Park, DS; Wang, XB; Scherer, PE; Schwartz, PE; Lisanti, MP			Src-induced phosphorylation of caveolin-2 on tyrosine 19 - Phospho-caveolin-2 (Tyr(P)(19)) is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; RICH MEMBRANE DOMAINS; IN-VIVO; HUMAN-DISEASE; GENE FAMILY; IDENTIFICATION; EXPRESSION; BINDING	Caveolin-2 is the least well studied member of the caveolin gene family. It is believed that caveolin-2 is an "accessory protein" that functions in conjunction with caveolin-1. At the level of the ER, caveolin-2 interacts with caveolin-1 to form a high molecular mass hetero-oligomeric complex that is targeted to lipid rafts and drives the formation of caveolae. However, caveolin-2 is not required for caveolae formation, implying that it may fulfill some unknown regulatory role. Here, we present the first evidence that caveolin-2 is a phosphoprotein. We show that caveolin-2 undergoes Src-induced phosphorylation on tyrosine 19. To study this phosphorylation event in vivo, we generated a novel phospho-specific antibody probe that only recognizes phosphocaveolin-2 (Tyr(P)(19)). We then used NIH-3T3 cells stably overexpressing c-Src to examine the localization and biochemical properties of phosphocaveolin-2 (Tyr(P)(19)). Our results indicate that phosphocaveolin-2 (Tyr(P)(19)) is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1. Instead, phosphocaveolin-2 (Tyr(P)19) behaves as a monomer/dimer in velocity gradients. Thus, we conclude that the tyrosine phosphorylation of caveolin-2 (Tyr(P)19) may function as a signal that is recognized by the cellular machinery to induce the dissociation of caveolin-2 from caveolin-1 oligomers. We also demonstrate that (i) insulin-stimulation of adipocytes and (ii) integrin ligation of endothelial cells can both induce the tyrosine phosphorylation of caveolin-2 (Tyr(P)19). During integrin ligation, phosphocaveolin-2 (Tyr(P)9) co-localizes with activated FAK at focal adhesions. Thus, phosphocaveolin-2 (Tyr(P)19) may function as a docking site for Src homology domain-2 (SH2) domain containing proteins during signal transduction. In support of this notion, we identify several SH2 domain containing proteins, namely c-Src, NCK, and Ras-GAP, that interact with caveolin-2 in a phosphorylation-dependent manner. Furthermore, our co-immunoprecipitation experiments show that caveolin-2 and Ras-GAP are constitutively associated in c-Src expressing NIH-3T3 cells, but not in untransfected NIH-3T3 cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Affin BioReagents Inc, Golden, CO 80403 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 55758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CORELYMASTICK C, 1997, J BIOL CHEM, V272, P20706; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LAROSE L, 1993, ONCOGENE, V8, P2493; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9	44	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34556	34567		10.1074/jbc.M204367200	http://dx.doi.org/10.1074/jbc.M204367200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091389	hybrid			2022-12-27	WOS:000177959100129
J	Ngo, TT; Bennett, MK; Bourgeois, AL; Toth, JI; Osborne, TF				Ngo, TT; Bennett, MK; Bourgeois, AL; Toth, JI; Osborne, TF			A role for cyclic AMP response element-binding protein (CREB) but not the highly similar ATF-2 protein in sterol regulation of the promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; GENE-EXPRESSION; TRANSCRIPTION; FAMILY; ACTIVATION; SP1; JUN	Sterol regulatory element-binding proteins (SREBPs) activate promoters for key genes of metabolism to keep pace with the cellular demand for lipids. In each SREBP-regulated promoter, at least one ubiquitous coregulatory factor that binds to a neighboring recognition site is also required for efficient gene induction. Some of these putative co-regulatory proteins are members of transcription factor families that all bind to the same DNA sequence elements in vitro and are often expressed in the same cells. These two observations have made it difficult to assign specific and redundant functions to the unique members of a specific gene family. We have used the chromatin immunoprecipitation (ChIP) technique coupled with a transient complementation assay in Drosophila SL2 cells to directly compare the ability of two members of the CREB/ATF family to function as co-regulatory proteins for SREBP-dependent activation of the HMG-CoA reductase promoter. Results from both of these experimental systems demonstrate that CREB is an efficient SREBP co-regulator but ATF-2 is not.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NHLBI NIH HHS [HL 48044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENBROOK DM, 1990, ONCOGENE, V5, P295; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1980, J LIPID RES, V21, P505; CHIVRIA JC, 1993, NATURE, V365, P855; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161	28	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33901	33905		10.1074/jbc.M202135200	http://dx.doi.org/10.1074/jbc.M202135200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110665	hybrid			2022-12-27	WOS:000177959100051
J	Martemyanov, KA; Arshavsky, VY				Martemyanov, KA; Arshavsky, VY			Noncatalytic domains of RGS9-1 center dot G beta 5L play a decisive role in establishing its substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-EFFECTOR COMPLEX; RGS PROTEINS; GTPASE ACCELERATION; BETA-SUBUNIT; TRANSDUCIN; PHOTORECEPTORS; REGULATORS; PURIFICATION; PHOSPHODIESTERASE; PHOTOTRANSDUCTION	The complex between the photoreceptor-specific regulator of G protein signaling (RGS) protein, RGS9-1, and type 5 G protein beta-subunit, Gbeta5L, regulates the duration of the cellular response to light by stimulating the GTPase activity of G protein, transducin. An important property of RGS9-1.Gbeta5L is that it interacts specifically with transducin bound to its effector, cGMP phosphodiesterase, rather than with transducin alone. The minimal structure within the RGS9-1.Gbeta5L complex capable of activating transducin GTPase is the catalytic domain of RGS9. This domain itself is also able to discriminate between free and effector-bound transducin but to a lesser degree than RGS9-1.Gbeta5L. The goal of this study was to determine whether other, noncatalytic domains of RGS9-1.Gbeta5L enhance the intrinsic specificity of the catalytic domain or whether they set the specificity of RGS9-1-G/35L regardless of the specificity of its catalytic domain. We found that a double L353E/R360P amino acid substitution reversed the specificity of the recombinant catalytic domain but did not reverse the specificity of RGS9-1.Gbeta5L. However, the degree of discrimination between free and effector-bound transducin was reduced. Therefore, noncatalytic domains of RGS91.Gbeta5L play a decisive role in establishing its substrate specificity, yet the high degree of this specificity ob. served under physiological conditions requires an additional contribution from the catalytic domain.	Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs,MEEI, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, Howe Labs,MEEI, 243 Charles St, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu			NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; LEFEBVRE B, 1995, BIOTECHNIQUES, V19, P186; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; TING TD, 1993, METH NEUROSCI, V15, P180; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154	31	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32843	32848		10.1074/jbc.M205170200	http://dx.doi.org/10.1074/jbc.M205170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093815	hybrid			2022-12-27	WOS:000177859000059
J	Jiang, L; Lai, LH				Jiang, L; Lai, LH			CH center dot center dot center dot O hydrogen bonds at protein-protein interfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRON-DIFFRACTION DATA; FREE-ENERGY; LIGAND INTERACTIONS; GLOBULAR-PROTEINS; MEAN FORCE; AB-INITIO; CRYSTALLOGRAPHIC EVIDENCE; CRYSTAL-STRUCTURES; POTENTIALS; RECOGNITION	For the first time, a statistical potential has been developed to quantitatively describe the CH...O hydrogen bonding interaction at the protein-protein interface. The calculated energies of the CH...O pair interaction show a favorable valley at similar to3.3 Angstrom, exhibiting a feature typical of an H-bond and similar to the ab initio quantum calculation result (Scheiner, S., Kar, T., and Gu, Y. (2001) J. Biol. Chem. 276, 9832-9837). The potentials have been applied to a set of 469 protein-protein complexes to calculate the contribution of different types of interactions to each protein complex: the average energy contribution of a conventional H-bond is similar to30%; that of a CH...O H-bond is 17%; and that of a hydrophobic interaction is 50%. In some protein-protein complexes, the contribution of the CH...OH-bond can reach as high as similar to40-50%, indicating the importance of the CH...OH-bond at the protein interface. At the interfaces of these complexes, (CH)-H-alpha...OH-bonds frequently occur between adjacent strands in both parallel and antiparallel orientations, having the obvious structural motif of bifurcated H-bonds. Our study suggests that the weak CH...OH-bond makes an important contribution to the association and stability of protein complexes and needs more attention in protein-protein interaction studies.	Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Inst Phys Chem,Dept Chem Biol, Beijing 100871, Peoples R China; Peking Univ, Ctr Theoret Biol, Beijing 100871, Peoples R China	Peking University; Peking University	Lai, LH (corresponding author), Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Inst Phys Chem,Dept Chem Biol, Beijing 100871, Peoples R China.		Jiang, Lin/G-1575-2010					Ash EL, 2000, P NATL ACAD SCI USA, V97, P10371, DOI 10.1073/pnas.97.19.10371; Auffinger P, 1997, J MOL BIOL, V274, P54, DOI 10.1006/jmbi.1997.1370; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Baures PW, 2000, BIOORGAN MED CHEM, V8, P1599, DOI 10.1016/S0968-0896(00)00090-0; Bella J, 1996, J MOL BIOL, V264, P734, DOI 10.1006/jmbi.1996.0673; Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Desiraju G.R., 1999, WEAK HYDROGEN BOND S; Desiraju GR, 1996, ACCOUNTS CHEM RES, V29, P441, DOI 10.1021/ar950135n; DeWitte RS, 1996, J AM CHEM SOC, V118, P11733, DOI 10.1021/ja960751u; DeWitte RS, 1997, J AM CHEM SOC, V119, P4608, DOI 10.1021/ja963689+; EGLI M, 1995, P NATL ACAD SCI USA, V92, P180, DOI 10.1073/pnas.92.1.180; FABIOLA GF, 1997, ACTA CRYSTALLOGR D, V53, P216; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Gu YL, 1999, J AM CHEM SOC, V121, P9411, DOI 10.1021/ja991795g; Ho BK, 2002, J MOL BIOL, V317, P291, DOI 10.1006/jmbi.2001.5385; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jeffrey G.A., 2012, HYDROGEN BONDING BIO; JEFFREY GA, 1982, INT J BIOL MACROMOL, V4, P173, DOI 10.1016/0141-8130(82)90048-4; Jernigan RL, 1996, CURR OPIN STRUC BIOL, V6, P195, DOI 10.1016/S0959-440X(96)80075-3; Jiang L, 2002, PROTEINS, V46, P190, DOI 10.1002/prot.10031; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kim KS, 1997, J AM CHEM SOC, V119, P12952, DOI 10.1021/ja971836d; Mandel-Gutfreund Y, 1998, J MOL BIOL, V277, P1129, DOI 10.1006/jmbi.1998.1660; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mitchell JBO, 1999, J COMPUT CHEM, V20, P1165, DOI 10.1002/(SICI)1096-987X(199908)20:11<1165::AID-JCC7>3.0.CO;2-A; Mitchell JBO, 1999, J COMPUT CHEM, V20, P1177, DOI 10.1002/(SICI)1096-987X(199908)20:11<1177::AID-JCC8>3.0.CO;2-0; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; Muegge I, 1999, J MED CHEM, V42, P791, DOI 10.1021/jm980536j; Musah RA, 1997, J AM CHEM SOC, V119, P9083, DOI 10.1021/ja9716766; MYERS EW, 1989, B MATH BIOL, V51, P5, DOI 10.1007/BF02458834; Novoa JJ, 1997, CHEM PHYS LETT, V266, P23, DOI 10.1016/S0009-2614(96)01514-X; Ornstein RL, 1997, J BIOMOL STRUCT DYN, V14, P657, DOI 10.1080/07391102.1997.10508169; Robert CH, 1998, J MOL BIOL, V283, P1037, DOI 10.1006/jmbi.1998.2152; ROVIRA MC, 1995, CHEM PHYS, V200, P319, DOI 10.1016/0301-0104(95)00210-3; Scheiner S, 2001, J BIOL CHEM, V276, P9832, DOI 10.1074/jbc.M010770200; Scheiner S, 2000, ADV MOL STRUCT RES, V6, P159; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sippl MJ, 1996, J MOL BIOL, V260, P644, DOI 10.1006/jmbi.1996.0427; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SIPPL MJ, 1995, CURR OPIN STRUC BIOL, V5, P229, DOI 10.1016/0959-440X(95)80081-6; STEINER T, 1992, J AM CHEM SOC, V114, P10146, DOI 10.1021/ja00052a009; STEINER T, 1993, J AM CHEM SOC, V115, P4540, DOI 10.1021/ja00064a016; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; Vajda S, 1997, CURR OPIN STRUC BIOL, V7, P222, DOI 10.1016/S0959-440X(97)80029-2; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; WALLQVIST A, 1995, PROTEIN SCI, V4, P1881, DOI 10.1002/pro.5560040923; Wang L, 1996, J MOL BIOL, V262, P283, DOI 10.1006/jmbi.1996.0513; Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999; [No title captured]	61	182	189	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37732	37740		10.1074/jbc.M204514200	http://dx.doi.org/10.1074/jbc.M204514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12119293	hybrid			2022-12-27	WOS:000178447100105
J	Korkmaz, KS; Elbi, C; Korkmaz, CG; Loda, M; Hager, GL; Saatcioglu, F				Korkmaz, KS; Elbi, C; Korkmaz, CG; Loda, M; Hager, GL; Saatcioglu, F			Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; COMPLEX IN-VIVO; HOMEOBOX GENE; GOLGI-COMPLEX; ANTIGEN; CARCINOMA; ORGANIZATION; EXPRESSION; ANDROGENS; XENOGRAFT	We have identified a novel gene, six transmembrane protein of prostate 1 (STAMP1), which is largely specific to prostate for expression and is predicted to code for a 490-amino acid six transmembrane protein. Using a form of STAMP1 labeled with green fluorescent protein in quantitative time-lapse and immunofluorescence confocal microscopy, we show that STAMP1 is localized to the Golgi complex, predominantly to the trans-Golgi network, and to the plasma membrane. STAMP1 also localizes to vesicular tubular structures in the cytosol and colocalizes with the early endosome antigen 1 (EEA1), suggesting that it may be involved in the secretory/endocytic pathways. STAMP1 is highly expressed in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptor-negative prostate cancer cell lines PC-3 and DU145. Furthermore, STAMP1 expression is significantly lower in the androgen-dependent human prostate xenograft CWR22 compared with the relapsed derivative CWR22R, suggesting that its expression may be deregulated during prostate cancer progression. Consistent with this notion, in situ analysis of human prostate cancer specimens indicated that STAMP1 is expressed exclusively in the epithelial cells of the prostate and its expression is significantly increased in prostate tumors compared with normal glands. Taken together, these data suggest that STAMP1 may have an important role in the normal prostate cell as well as in prostate cancer progression.	Univ Oslo, Dept Biol, N-0316 Oslo, Norway; Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of Oslo; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Saatcioglu, F (corresponding author), Univ Oslo, Dept Biol, Postboks 1050 Blindern, N-0316 Oslo, Norway.		Korkmaz, Kemal Sami/ABI-5112-2020	Korkmaz, Kemal Sami/0000-0003-4040-2568				ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; AUSEBEL FM, 1997, CURRENT PROTOCOLS MO; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Catalona WJ, 2000, UROLOGY, V56, P255, DOI 10.1016/S0090-4295(00)00637-3; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Catterall W A, 1999, Adv Neurol, V79, P441; CHAFLIE M, 1994, SCIENCE, V263, P802; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; Concato J, 2000, CANCER J, V6, pS188; Crawford ED, 1999, UROLOGY, V54, P1, DOI 10.1016/S0090-4295(99)00447-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Echevarria M, 1998, J PHYSIOL BIOCHEM, V54, P107; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; ISAACS JT, 1994, VITAM HORM, V49, P433; ISRAELI RS, 1993, CANCER RES, V53, P227; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Korkmaz KS, 2000, DNA CELL BIOL, V19, P499, DOI 10.1089/10445490050128421; Korkmaz KS, 2000, GENE, V260, P25, DOI 10.1016/S0378-1119(00)00453-4; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; Mellman I, 2000, J CELL BIOL, V149, P529, DOI 10.1083/jcb.149.3.529; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; Nagabhushan M, 1996, CANCER RES, V56, P3042; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Oesterling J E, 1991, Oncology (Williston Park), V5, P107; Ordovas JM, 2000, NUTR REV, V58, P76; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Ponnambalam S, 1996, CURR BIOL, V6, P1076, DOI 10.1016/S0960-9822(02)70669-6; Prescott M, 1997, FEBS LETT, V411, P97, DOI 10.1016/S0014-5793(97)00670-4; RABOUILLE C, 1995, J CELL SCI, V108, P1617; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steiner MS, 2000, CANCER RES, V60, P4419; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; WAINSTEIN MA, 1994, CANCER RES, V54, P6049	51	59	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36689	36696		10.1074/jbc.M202414200	http://dx.doi.org/10.1074/jbc.M202414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12095985	hybrid			2022-12-27	WOS:000178275100115
J	Sowa, H; Kaji, H; Yamaguchi, T; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Yamaguchi, T; Sugimoto, T; Chihara, K			Activations of ERK1/2 and JNK by transforming growth factor beta negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FYVE DOMAIN PROTEIN; BONE-FORMATION; MEDIATED TRANSCRIPTION; GENE-EXPRESSION; ONCOGENIC RAS; CROSS-TALK; C-JUN; SMAD; DIFFERENTIATION; PATHWAYS	Transforming growth factor (TGF) beta inhibits alkaline phosphatase (ALP) activity and mineralization in mouse osteoblastic MC3T3-E1 cells, whereas local administration of TGF-beta stimulates bone formation in vivo. We recently demonstrated that Smad3, a TGF-beta signaling molecule, promotes ALP activity and mineralization in MC3T3-E1 cells. Moreover, the target disruption of Smad3 in mouse is reported to cause a decrease in bone mineral density. These findings indicate that Smad3 plays an important role in the regulation of bone formation. However, why the effects of TGF-beta and Smad3 on ALP activity and mineralization are different remains unknown. The purpose of the present study is to clarify the role of mitogen-activated protein kinase (MAPK) in TGF-beta and Smad3 pathways in osteoblast. TGF-beta activated extracellular signal-regulated kinases/p42/p44 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK) in mouse osteoblastic MC3T3-E1 cells. The expression of dominant negative type Smad3, Smad3DeltaC, affected neither TGF-beta-activated ALAPKs nor TGF-beta-inhibited ALP activity. Specific inhibitors of ERK1/2 activation (PD98059 and U0126), as well as JNK inhibitors (curcumin and dicumarol) antagonized the inhibitory effects of TGF-beta on ALP activity and mineralization, whereas the specific inhibitor of p38 MAPK (SB203580) did not affect them. PD98059 and curcumin enhanced Smad3-induced ALP activity and mineralization, whereas SB203580 inhibited them. In the luciferase reporter assay using 3TP-lux with the specific Smad3-responsive element, PD98059, and curcumin enhanced TGF-beta- and Smad3-induced transcriptional activity in MC3T3-E1 cells. On the other hand, TGF-beta-induced production of type I collagen was antagonized by curcumin but not by PD98059. The present study indicated that TGF-beta-responsive ERK1/2 and JNK cascades negatively regulate Smad3-induced transcriptional activity as well as ALP activity and mineralization in osteoblasts.	Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Sugimoto, T (corresponding author), Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	sugimot@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; BECK LS, 1993, J BONE MINER RES, V8, P753; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; ELFORD PR, 1987, BONE, V8, P259, DOI 10.1016/8756-3282(87)90174-8; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SE, 1994, J BONE MINER RES, V9, P855; IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; LOWRY OH, 1954, J BIOL CHEM, V207, P19; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nishimori S, 2001, J BIOL CHEM, V276, P10700, DOI 10.1074/jbc.M007499200; NODA M, 1986, BIOCHEM BIOPH RES CO, V140, P56, DOI 10.1016/0006-291X(86)91057-0; NODA M, 1987, J CELL PHYSIOL, V133, P426, DOI 10.1002/jcp.1041330303; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Reinholz GG, 2000, CANCER RES, V60, P6001; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756-3282(94)90300-X; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yan ZF, 2002, J BIOL CHEM, V277, P9870, DOI 10.1074/jbc.M107646200; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	42	109	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36024	36031		10.1074/jbc.M206030200	http://dx.doi.org/10.1074/jbc.M206030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130649	hybrid			2022-12-27	WOS:000178275100034
J	Clarke, SJ; McStay, GP; Halestrap, AP				Clarke, SJ; McStay, GP; Halestrap, AP			Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; OXIDATIVE STRESS; CELL-DEATH; INNER MEMBRANE; INDUCED DAMAGE; PORE; CALCIUM; CHANNEL; ISOMERASE; LIVER	Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity. Sanglifehrin A (SfA), like CsA, exerts its immunosuppressive action by binding to cyclophilin A but at a different site from CsA, and unlike the latter, SfA does not inhibit calcineurin activity. Here we demonstrate that SfA inhibits the PPIase activity of CyP-D (K-0.5 2 nM) and acts as a potent inhibitor of MPTP opening under both energized and de-energized conditions. However, unlike CsA, the dose-response curve for inhibition by SfA, is sigmoidal rather than hyperbolic, suggesting a multimeric structure for the MPTP with cooperativity between subunits. Furthermore, SfA does not prevent CyP-D binding to submitochondrial particles or detergent-solubilized adenine nucleotide translocase (ANT), implying that CyP-D binding to the ANT does not require PPIase activity but pore opening does. Once bound to the MPTP, SEA is not readily dissociated, and inhibition of pore opening is maintained following extensive washing. To investigate the potential of SEA as an inhibitor of cell death in vivo, we used the Langendorff perfused rat heart. SfA caused a time-dependent inhibition of the MPTP that was maintained on mitochondrial isolation to a greater extent than was CsA inhibition. We demonstrate that SfA, like CsA, improves the recovery of left ventricular developed pressure during reperfusion after 30 min of global ischemia and greatly reduces lactate dehydrogenase release, implying inhibition of necrotic damage. Because SfA does not inhibit calcineurin activity, our data suggest that it may be more desirable than CsA for protecting tissues recovering from ischemic episodes and for studying the role of the MPTP in cell death.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.		Halestrap, Andrew P/G-7275-2011; McStay, Gavin/K-9574-2013	McStay, Gavin/0000-0003-1363-8719; Halestrap, Andrew/0000-0001-5374-2778				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; GARCIAECHEVERRIA C, 1993, BIOCHEM BIOPH RES CO, V191, P70, DOI 10.1006/bbrc.1993.1185; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200; Zhang LH, 2001, J IMMUNOL, V166, P5611, DOI 10.4049/jimmunol.166.9.5611	33	293	321	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34793	34799		10.1074/jbc.M202191200	http://dx.doi.org/10.1074/jbc.M202191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095984	hybrid, Green Accepted			2022-12-27	WOS:000178117000020
J	Chen, BH; Tzen, JTC; Bresnick, AR; Chen, HC				Chen, BH; Tzen, JTC; Bresnick, AR; Chen, HC			Roles of Rho-associated kinase and myosin light chain kinase in morphological and migratory defects of focal adhesion kinase-null cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; GTP-BINDING PROTEIN; SMOOTH-MUSCLE MYOSIN; MLC PHOSPHORYLATION; MAMMALIAN-CELLS; ALPHA-ACTININ; CRUCIAL ROLE; ROCK-I; CYTOSKELETON; GTPASES	Fibroblasts derived from focal adhesion kinase (FAK)-null mouse embryos have a reduced migration rate and an increase in the number and size of peripherally localized adhesions (Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., and Yamamoto, T. (1995) Nature 377, 539-544). In this study, we have found that Y27632, a specific inhibitor for Rho-associated kinase (Rho-kinase), dramatically reversed the round cell morphology of FAK(-/-) cells to a spread fibroblast-like shape in 30 min and significantly enhanced their motility. The effects of Y27632 on the FAK(-/-) cell morphology and motility were concomitant with reorganization of the actin cytoskeleton and redistribution of focal adhesions. Conversely, the expression of the constitutively active Rho-kinase in FAK(+/+) cells led to round cell shape and inhibition of cell motility. Furthermore, coincident with the formation of cortical actin filaments, myosin light chain (MLC), Ser-19-phosphorylated MLC, and MLC kinase mainly accumulated at the FAK(-/-) cell periphery. We found that the disruption of actin filaments by cytoschalasin D prevented the peripheral accumulation of MLC kinase and that inhibition of myosin-mediated contractility by 2,3-butanedione monoxime induced FAK(-/-) cells to spread. Taken together, our results suggest that Rho-kinase may mediate the formation of cortical actomyosin filaments at the FAK(-/-) cell periphery, which further recruits MLC kinase to the cell periphery and generates a non-polar contractile force surrounding the cell, leading to cell rounding and decreased motility.	Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University; Yeshiva University; Albert Einstein College of Medicine	Chen, HC (corresponding author), Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Beqaj S, 2002, J CELL BIOL, V156, P893, DOI 10.1083/jcb.200107049; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Ren XD, 2000, J CELL SCI, V113, P3673; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1994, ONCOGENE, V9, P273; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	58	124	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33857	33863		10.1074/jbc.M204429200	http://dx.doi.org/10.1074/jbc.M204429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105199	hybrid			2022-12-27	WOS:000177959100044
J	Plosch, T; Kok, T; Bloks, VW; Smit, MJ; Havinga, R; Chimini, G; Groen, AK; Kuiper, F				Plosch, T; Kok, T; Bloks, VW; Smit, MJ; Havinga, R; Chimini, G; Groen, AK; Kuiper, F			Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; HIGH-DENSITY-LIPOPROTEIN; NUCLEAR RECEPTOR; LXR-ALPHA; TANGIER-DISEASE; DIETARY-CHOLESTEROL; RESPONSE PATHWAY; DEFICIENT MICE; CULTURED-CELLS; BILE-ACIDS	The ATP-binding cassette transporter ABCA1 is essential for high density lipoprotein (HDL) formation and considered rate-controlling for reverse cholesterol transport. Expression of the Abca1 gene is under control of the liver X receptor (LXR). We have evaluated effects of LXR activation by the synthetic agonist T0901317 on hepatic and intestinal cholesterol metabolism in C57BL/6J and DBA/1 wild-type mice and in ABCA1-deficient DBA/1 mice. In wild-type mice, T0901317 increased expression of Abca1 in liver and intestine, which was associated with a similar to60% rise in HDL. Biliary cholesterol excretion rose 2.7-fold upon treatment, and fecal neutral sterol output was increased by 150-300%. Plasma cholesterol levels also increased in treated Abca1(-/-) mice (+120%), but exclusively in very low density lipoprotein-sized fractions. Despite the absence of HDL, hepatobiliary cholesterol output was stimulated upon LXR activation in Abca1(-/-) mice, leading to a 250% increase in the biliary cholesterol/phospholipid ratio. Most importantly, fecal neutral sterol loss was induced to a similar extent (+300%) by the LXR agonist in DBA/1 wild-type and Abca1(-/-) mice. Expression of Abcg5 and Abcg8, recently implicated in biliary excretion of cholesterol and its intestinal absorption, was induced in T0901317-treated mice. Thus, activation of LXR in mice leads to enhanced hepatobiliary cholesterol secretion and fecal neutral sterol loss independent of (ABCA1-mediated) elevation of HDL and the presence of ABCA1 in liver and intestine.	Univ Groningen, Univ Groningen Hosp, Inst Drug Explorat, Ctr Liver Digest & Metab Dis,Dept Pediat, NL-9713 GZ Groningen, Netherlands; Organon BV, Dept Pharmacol, NL-5340 AM Oss, Netherlands; CNRS, INSERM, Ctr Immunol, F-13288 Marseille, France; Acad Med Ctr, Dept Gastroenterol, NL-1105 BK Amsterdam, Netherlands	University of Groningen; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Amsterdam; Academic Medical Center Amsterdam	Plosch, T (corresponding author), Univ Groningen, Acad Hosp, Inst Drug Explorat, Pediat Lab, CMC 4,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.		Plösch, Torsten/X-6808-2019; Bloks, Vincent/A-7609-2012	Plösch, Torsten/0000-0002-9305-4045; Bloks, Vincent/0000-0001-6493-7482				Alam K, 2001, J BIOL CHEM, V276, P15641, DOI 10.1074/jbc.M010230200; ARCA M, 1983, J LIPID RES, V24, P332; Attie AD, 2001, J LIPID RES, V42, P1717; Bandsma RHJ, 1998, BIOCHEM J, V329, P699, DOI 10.1042/bj3290699; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bloks VW, 2001, J LIPID RES, V42, P41; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Edwards PA, 2002, J LIPID RES, V43, P2; FIELDING CJ, 1995, J LIPID RES, V36, P211; GAMBLE W, 1978, J LIPID RES, V19, P1068; Glomset J A, 1973, Adv Lipid Res, V11, P1; GREFHORST A, 2002, J BIOL CHEM     0703; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jolley CD, 1999, AM J PHYSIOL-GASTR L, V276, pG1117, DOI 10.1152/ajpgi.1999.276.5.G1117; Jolley CD, 1998, J LIPID RES, V39, P2143; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MURPHY GM, 1970, J CLIN PATHOL, V23, P594, DOI 10.1136/jcp.23.7.594; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Osono Y, 1996, P NATL ACAD SCI USA, V93, P4114, DOI 10.1073/pnas.93.9.4114; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SETCHELL KDR, 1983, J LIPID RES, V24, P1085; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; VERKADE HJ, 1995, HEPATOLOGY, V21, P1174; Voshol PJ, 1998, GASTROENTEROLOGY, V114, P1024, DOI 10.1016/S0016-5085(98)70323-3; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	58	164	172	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33870	33877		10.1074/jbc.M206522200	http://dx.doi.org/10.1074/jbc.M206522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105210	Green Published, hybrid			2022-12-27	WOS:000177959100046
J	Schraw, W; Li, Y; McClain, MS; van der Goot, FG; Cover, TL				Schraw, W; Li, Y; McClain, MS; van der Goot, FG; Cover, TL			Association of Helicobacter pylori vacuolating toxin (VacA) with lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNELS; GPI-ANCHORED PROTEIN; MEMBRANE DOMAINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CLINICAL RELEVANCE; EPITHELIAL-CELLS; ACID ACTIVATION; CHOLERA-TOXIN; LOW PH	A variety of extracellular ligands and pathogens interact with raft domains in the plasma membrane of eukaryotic cells. In this study, we examined the role of lipid rafts and raft-associated glycosylphosphatidylinositol (GPI)-anchored proteins in the process by which Helicobacter pylori vacuolating toxin (VaCA) intoxicates cells. We first investigated whether GPI-anchored proteins are required for VacA toxicity by analyzing wildtype Chinese hamster ovary (CHO) cells and CHO-LA1 mutant cells that are defective in production of GPI-anchored proteins. Whereas wild-type and mutant cells differed markedly in susceptibility to aerolysin (a bacterial toxin that binds to GPI-anchored proteins), they were equally susceptible to VacA. We next determined whether VacA physically associates with lipid rafts. CHO or HeLa cells were incubated with VacA, and Triton-insoluble membranes then were separated by sucrose density gradient centrifugation. Immunoblot analysis revealed that a substantial proportion of cellassociated toxin was associated with detergent-resistant membranes (DRMs). DRM association required acid activation of the purified toxin prior to contact with cells, and acid activation also was required for VacA cytotoxicity. Treatment of cells with methyl-beta-cyclodextrin (a cholesterol-depleting agent) did not inhibit VacA-induced depolarization of the plasma membrane, but interfered with the internalization or intracellular localization of VacA and inhibited the capacity of the toxin to induce cell vacuolation. Treatment of cells with nystatin also inhibited VacA-induced cell vacuolation. These data indicate that VacA associates with lipid raft microdomains in the absence of GPI-anchored proteins and suggest that association of the toxin with lipid rafts is important for VacA cytotoxicity.	Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Geneva	Cover, TL (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, A3310 MCN, Nashville, TN 37232 USA.		van der Goot, Gisou G/B-2279-2012; McClain, Mark S/A-6942-2009; Cover, Timothy/I-3814-2015	van der Goot, Gisou G/0000-0002-8522-274X; McClain, Mark S/0000-0002-9857-4883; Cover, Timothy/0000-0001-8503-002X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 39657] Funding Source: Medline; NIDDK NIH HHS [DK 53623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; COVER TL, 2001, PRINCIPLES BACTERIAL, P510; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; De Gusmao VR, 2000, J CLIN MICROBIOL, V38, P2853; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Fischer W, 2001, INFECT IMMUN, V69, P6769, DOI 10.1128/IAI.69.11.6769-6775.2001; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Han SR, 1998, CLIN DIAGN LAB IMMUN, V5, P139, DOI 10.1128/CDLI.5.2.139-145.1998; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955-0674(00)00122-8; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; Montecucco C, 1999, COMPREHENSIVE SOURCE, P264; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Ogura K, 2000, J EXP MED, V192, P1601, DOI 10.1084/jem.192.11.1601; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ricci V, 1997, J PATHOL, V183, P453; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smoot DT, 1996, GUT, V39, P795, DOI 10.1136/gut.39.6.795; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; van Doorn LJ, 1998, GASTROENTEROLOGY, V115, P58, DOI 10.1016/S0016-5085(98)70365-8; van Doorn LJ, 1999, GASTROENTEROLOGY, V116, P823, DOI 10.1016/S0016-5085(99)70065-X; Vinion-Dubiel AD, 2001, INFECT IMMUN, V69, P4329, DOI 10.1128/IAI.69.7.4329-4336.2001; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wang WC, 2001, BIOCHEMISTRY-US, V40, P11887, DOI 10.1021/bi010065u; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	71	120	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34642	34650		10.1074/jbc.M203466200	http://dx.doi.org/10.1074/jbc.M203466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12121984	hybrid			2022-12-27	WOS:000177959100139
J	Winton, MJ; Dubreuil, CI; Lasko, D; Leclerc, N; McKerracher, L				Winton, MJ; Dubreuil, CI; Lasko, D; Leclerc, N; McKerracher, L			Characterization of new cell permeable C3-like proteins that inactivate Rho and stimulate neurite outgrowth on inhibitory substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; LYSOPHOSPHATIDIC-ACID; BINDING-PROTEIN; ANTENNAPEDIA HOMEODOMAIN; ADP-RIBOSYLATION; 3RD HELIX; PC12 CELLS; IN-VIVO; MEMBRANE; PEPTIDES	The activation state of Rho is an important determinant of axon growth and regeneration in neurons. Axons can extend neurites on growth inhibitory substrates when Rho is inactivated by C3-ADP-ribosyltransferase (C3). We found by Rho-GTP pull-down assay that inhibitory substrates activate Rho. To inactivate Rho, scrape. loading of C3 was necessary because it does not freely enter cells. To overcome the poor permeability of C3, we made and characterized five new recombinant C3-like chimeric proteins designed to cross the cell membrane by receptor-independent mechanisms. These proteins were constructed by the addition of short transport peptides to the carboxyl-terminal of C3 and tested using a bioassay measuring neurite outgrowth of PC-12 cells plated on growth inhibitory substrates. All five constructs stimulated neurite outgrowth but with different dose-response profiles. Biochemical properties of the chimeric proteins were examined using C3-05, the most effective construct tested. Gel shift assays showed that C3-05 retained the ability to ADP-ribosylate Rho. Western blots and immunocytochemistry were used to verify the presence of C3 inside treated cells. C3-05 was also effective at promoting neurite outgrowth in primary neuronal cultures, as well as causing the disassembly of actin stress fibers and focal adhesions complexes in fibroblasts. These studies demonstrate that the new C3-like proteins are effective in delivering biologically active C3 into different cell types, thereby, inactivating Rho.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada; Bioaxone Therapeut Inc, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	McKerracher, L (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit,P-906 Pavillon Principal, Montreal, PQ H3T 1J4, Canada.				Grants-in-Aid for Scientific Research [11J05211] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; BLOCHGALLEGO E, 1993, J CELL BIOL, V120, P485, DOI 10.1083/jcb.120.2.485; BOQUET P, 1995, METHOD ENZYMOL, V256, P297; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; del Peso L, 1997, ONCOGENE, V15, P3047; Dergham P, 2002, J NEUROSCI, V22, P6570; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Du CG, 1998, J PEPT RES, V51, P235; ELLEZAM B, 2002, IN PRESS PROG BRAIN, V137; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jin Z, 1997, J NEUROSCI, V17, P6256; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; MORII N, 1995, METHOD ENZYMOL, V256, P196; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Niidome T, 1997, J PEPT RES, V49, P563; OHISHI I, 1992, INFECT IMMUN, V60, P4648, DOI 10.1128/IAI.60.11.4648-4655.1992; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEEKS BS, 1993, J BIOL CHEM, V268, P5279; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	42	105	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32820	32829		10.1074/jbc.M201195200	http://dx.doi.org/10.1074/jbc.M201195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091381	hybrid			2022-12-27	WOS:000177859000056
J	Plo, I; Hernandez, H; Kohlhagen, G; Lautier, D; Pommier, Y; Laurent, G				Plo, I; Hernandez, H; Kohlhagen, G; Lautier, D; Pommier, Y; Laurent, G			Overexpression of the atypical protein kinase C xi reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; NF-KAPPA-B; PKC-ZETA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE-C; ATP HYDROLYSIS; GROWTH-FACTOR; PC12 CELLS	In this study, we evaluated the influence of protein kinase Czeta (PKCzeta) on topoisomerase II inhibitor-induced cytotoxicity in monocytic U937 cells. In U937-zetaJ and U937-zetaB cells, enforced PKCzeta expression, conferred by stable transfection of PKCzeta cDNA, resulted in total inhibition of VP-16- and mitoxantrone-induced apoptosis and decreased drug-induced cytotoxicity, compared with U937-neo control cells. In PKCzeta-overexpressing cells, drug resistance correlated with decreased VP-16-induced DNA strand breaks and DNA protein cross-links measured by alkaline elution. Kinetoplast decatenation assay revealed that PKCzeta overexpression resulted in reduced global topoisomerase 11 activity. Moreover, in PKCzeta-overexpressing cells, we found that PKCzeta interacted with both alpha and beta isoforms of topoisomerase II, and these two enzymes were constitutively phosphorylated. However, when human recombinant PKCzeta (rH-PKCzeta) was incubated with purified topoisomerase II isofoms, rH-PKCzeta interacted with topoisomerase IIbeta but not with topoisomerase IIalpha. PKCzeta/topoisomerase IIbeta interaction resulted in phosphorylation of this enzyme and in decrease of its catalytic activity. Finally, this report shows for the first time that topoisonterase IIbeta is a substrate for PKCzeta, and that PKCzeta may significantly influence topoisomerase II inhibitor-induced cytotoxicity by altering topoisomerase IIbeta activity through its kinase function.	Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Laurent, G (corresponding author), Inst Claudius Regaud, INSERM E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.		Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021; Lautier, Dominique/G-3959-2017	Plo, Isabelle/0000-0002-5915-6910; 				Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Beck W T, 1994, Adv Pharmacol, V29B, P145; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bertolaso L, 1998, BRIT J HAEMATOL, V100, P541, DOI 10.1046/j.1365-2141.1998.00596.x; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P96; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BROWN GA, 1995, CANCER RES, V55, P78; CHEN M, 1992, P AM ASSOC CANC RES, V33, P2707; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DEVORE RF, 1992, CANCER RES, V52, P2156; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Errington F, 1999, MOL PHARMACOL, V56, P1309, DOI 10.1124/mol.56.6.1309; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; FUNAYAMA Y, 1993, ANTICANCER RES, V13, P1981; KOHN KW, 1991, PHARMACOL THERAPEUT, V49, P55, DOI 10.1016/0163-7258(91)90022-E; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Marchisio M, 1999, ANAT REC, V255, P7; MARINI JC, 1980, J BIOL CHEM, V255, P4976; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Moscat J, 2001, ADV ENZYME REGUL, V41, P99, DOI 10.1016/S0065-2571(00)00009-1; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; RITKE MK, 1995, MOL PHARMACOL, V48, P798; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; TAKANO H, 1991, CANCER RES, V51, P3951; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; ZWELLING LA, 1991, CANCER CHEMOTH PHARM, V29, P48, DOI 10.1007/BF00686335	39	25	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31407	31415		10.1074/jbc.M204654200	http://dx.doi.org/10.1074/jbc.M204654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105221	hybrid			2022-12-27	WOS:000177718700017
J	Shiomi, D; Zhulin, IB; Homma, M; Kawagishi, I				Shiomi, D; Zhulin, IB; Homma, M; Kawagishi, I			Dual recognition of the bacterial chemoreceptor by chemotaxis-specific domains of the CheR methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SERINE CHEMORECEPTOR; SIGNAL-TRANSDUCTION; S-ADENOSYLMETHIONINE; CYTOPLASMIC DOMAIN; DOCKING SITE; BINDING-SITE; PROTEIN; RECEPTOR; METHYLATION	Adaptation to persisting stimulation is required for highly sensitive detection of temporal changes of stimuli, and often involves covalent modification of receptors. Therefore, it is of vital importance to understand how a receptor and its cognate modifying enzyme(s) modulate each other through specific protein-protein interactions. In the chemotaxis of Escherichia coli, adaptation requires methylation of chemoreceptors (e.g. Tar) catalyzed by the CheR methyltransferase. CheR binds to the C-terminal NWETF sequence of a chemoreceptor that is distinct from the methylation sites. However, little is known about how CheR recognizes its methylation sites or how it is distributed in a cell. In this study, we used comparative genomics to demonstrate that the CheR chemotaxis methyltransferase contains three structurally and functionally distinct modules: (i) the catalytic domain common to a methyltransferase superfamily; (ii) the N-terminal domain; and (iii) the beta-subdomain of the catalytic domain, both of which are found exclusively in chemotaxis methyltransferases. The only evolutionary conserved motif specific to CheR is the positively charged face of helix alpha2 in the N-terminal domain. The disulfide cross-linking analysis suggested that this face interacts with the methylation helix of Tar. We also demonstrated that CheR localizes to receptor clusters at cell poles via interaction of the beta-subdomain with the NWETF sequence. Thus, the two chemotaxis-specific modules of CheR interact with distinct regions of the chemoreceptor for targeting to the receptor cluster and for recognition of the substrate sites, respectively.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Georgia Inst Technol, Sch Biol, Dept Biol, Atlanta, GA 30332 USA	Nagoya University; University System of Georgia; Georgia Institute of Technology	Kawagishi, I (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Zhulin, Igor B/A-2308-2012; Zhulin, Igor/T-3509-2019	Zhulin, Igor B/0000-0002-6708-5323; Zhulin, Igor/0000-0002-6708-5323; Shiomi, Daisuke/0000-0002-8558-7175				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Barnakov AN, 1999, P NATL ACAD SCI USA, V96, P10667, DOI 10.1073/pnas.96.19.10667; Barnakov AN, 2001, J BIOL CHEM, V276, P32984, DOI 10.1074/jbc.M105925200; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Djordjevic S, 1998, NAT STRUCT BIOL, V5, P446, DOI 10.1038/nsb0698-446; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Feng XH, 1999, J BACTERIOL, V181, P3164, DOI 10.1128/JB.181.10.3164-3171.1999; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; KEHRY MR, 1983, J BIOL CHEM, V258, P5050; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Lybarger SR, 2000, P NATL ACAD SCI USA, V97, P8057, DOI 10.1073/pnas.130195397; Lybarger SR, 1999, J BACTERIOL, V181, P5527, DOI 10.1128/JB.181.17.5527-5529.1999; MADDOCK JR, 1993, SCIENCE, V259, P1717; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1982, J BACTERIOL, V171, P6271; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shiomi D, 2000, MOL MICROBIOL, V36, P132, DOI 10.1046/j.1365-2958.2000.01834.x; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; Skidmore JM, 2000, J BACTERIOL, V182, P967, DOI 10.1128/JB.182.4.967-973.2000; SogaardAndersen L, 1996, P NATL ACAD SCI USA, V93, P2675, DOI 10.1073/pnas.93.7.2675; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; SUBBARAMAIAH K, 1991, J BIOL CHEM, V266, P19023; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YAMAMOTO K, 1990, J BACTERIOL, V172, P383, DOI 10.1128/JB.172.1.383-388.1990	47	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42325	42333		10.1074/jbc.M202001200	http://dx.doi.org/10.1074/jbc.M202001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12101179	hybrid			2022-12-27	WOS:000178985300128
J	Narisawa-Saito, M; Iwakura, Y; Kawamura, M; Araki, K; Kozaki, S; Takei, N; Nawa, H				Narisawa-Saito, M; Iwakura, Y; Kawamura, M; Araki, K; Kozaki, S; Takei, N; Nawa, H			Brain-derived neurotrophic factor regulates surface expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors by enhancing the N-ethylmaleimide-sensitive factor/GluR2 interaction in developing neocortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; AMPA RECEPTORS; SYNAPTIC TRANSMISSION; CORTICAL-NEURONS; BINDING-PROTEIN; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL-NEURONS; SILENT SYNAPSES; KINASE-C; BDNF	In hippocampal neurons, the exocytotic process of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA)-type glutamate receptors is known to depend on activation of N-methyl-D-aspartate channels and its resultant Ca2+ influx from extracellular spaces. Here we found that brain-derived neurotrophic factor (BDNF) induced a rapid surface translocation of AMPA receptors in an activity-independent manner in developing neocortical neurons. The receptor translocation became evident within hours as monitored by [H-3]AMPA binding and was resistant against ionotropic glutamate receptor antagonists as evidenced with surface biotinylation assay. This process required intracellular Ca2+ and was inhibited by the blockers of conventional exocytosis, brefeldin A, botulinuin toxin B, and N-ethylmaleimide. To explore the translocation mechanism of individual AMPA receptor subunits, we utilized the human embryonic kidney (HEK) 293 cells carrying the BDNF receptor TrkB. After the single transfection of GluR2 cDNA or GluR1 cDNA into HEK/TrkB cells, BDNF triggered the translocation of GluR2 but not that of GluR1. Subsequent mutation analysis of GluR2 carboxyl-terminal region indicated that the translocation of GluR2 subunit in HEK293 cells involved its N-ethylmaleimide-sensitive factor-binding domain but not its PDZ-interacting site. Following co-transfection of GluR1 and GluR2 cDNAs, solid phase cell sorting revealed that GluR1 subunits were also able to translocate to the cell surface in response to BDNF. An immunoprecipitation assay confirmed that BDNF stimulation can enhance the interaction of GluR2 with N-ethylmaleimide-sensitive factor. These results reveal a novel role of BDNF in regulating the surface expression of AMPA receptors through a GluR2-NSF interaction.	Niigata Univ, Inst Brain Res, Div Mol Biol, Niigata 9518585, Japan; Niigata Univ, Inst Brain Res, Dept Mol Neurobiol, Niigata 9518585, Japan; Coll Agr, Dept Vet Sci, Sakai, Osaka 5998531, Japan	Niigata University; Niigata University	Nawa, H (corresponding author), Niigata Univ, Inst Brain Res, Div Mol Biol, Asahimachidori 1-757, Niigata 9518585, Japan.							BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Burette A, 2001, J NEUROSCI, V21, P495, DOI 10.1523/JNEUROSCI.21-02-00495.2001; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Griesbeck O, 1999, MICROSC RES TECHNIQ, V45, P262, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<262::AID-JEMT10>3.0.CO;2-K; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HUNTLEY CW, 1994, TRENDS NEUROSCI, V17, P536; Ibaraki K, 1999, J NEUROCHEM, V73, P408, DOI 10.1046/j.1471-4159.1999.0730408.x; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kleiman RJ, 2000, J NEUROPHYSIOL, V84, P472, DOI 10.1152/jn.2000.84.1.472; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liu Y, 2001, J NEUROSCI, V21, P5660, DOI 10.1523/JNEUROSCI.21-15-05660.2001; Lom B, 1999, J NEUROSCI, V19, P9928; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Mammen AL, 1997, J NEUROSCI, V17, P7351; Matveeva EA, 2001, J BIOL CHEM, V276, P12174, DOI 10.1074/jbc.M007394200; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; Narisawa-Saito M, 1999, NEUROSCIENCE, V88, P1009, DOI 10.1016/S0306-4522(98)00496-5; Narisawa-Saito M, 1999, P NATL ACAD SCI USA, V96, P2461, DOI 10.1073/pnas.96.5.2461; Nawa H, 2001, TRENDS NEUROSCI, V24, P683, DOI 10.1016/S0166-2236(00)01955-X; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Sato M, 2001, J NEUROSCI, V21, P3797, DOI 10.1523/JNEUROSCI.21-11-03797.2001; Schinder AF, 2000, NEURON, V25, P151, DOI 10.1016/S0896-6273(00)80879-X; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Takei N, 1997, J NEUROCHEM, V68, P370; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Wang YZ, 1997, NATURE, V389, P502, DOI 10.1038/39062; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xiong HB, 1999, EUR J NEUROSCI, V11, P1567, DOI 10.1046/j.1460-9568.1999.00567.x; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000	57	78	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40901	40910		10.1074/jbc.M202158200	http://dx.doi.org/10.1074/jbc.M202158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12130635	hybrid			2022-12-27	WOS:000178791400096
J	Adachi, M; Sampath, J; Lan, LB; Sun, DX; Hargrove, P; Flatley, R; Tatum, A; Edwards, MZ; Wezeman, M; Matherly, L; Drake, R; Schuetz, J				Adachi, M; Sampath, J; Lan, LB; Sun, DX; Hargrove, P; Flatley, R; Tatum, A; Edwards, MZ; Wezeman, M; Matherly, L; Drake, R; Schuetz, J			Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-THYMIDINE KINASE; GENE-THERAPY; CYTOMEGALOVIRUS DISEASE; SUICIDE GENES; TUMOR-CELLS; IN-VITRO; CYTOTOXICITY; ZIDOVUDINE; LINES; TRANSPORTER	The multidrug resistance protein MRP4, a member of the ATP-binding cassette superfamily, confers resistance to purine-based antiretroviral agents. However, the antiviral agent ganciclovir (GCV) has not been shown to be a substrate of MRP4. GCV is important not only in antiviral therapy, but also in the selective killing of tumor cells modified to express herpes simplex virus thymidine kinase (HSV-TK). We therefore tested the effect of MRP4 on the cytotoxicity of GCV, on the ability of GCV to kill cells genetically modified to express HSV-TK, and on the bystander effect in which unmodified target cells are killed by GCV. Cells overexpressing MRP4 had markedly increased resistance to the cytotoxicity of GCV. Although, expression of recombinant HSV-TK increased the intracellular concentration of GCV nucleotide, cells were rescued by the cytoprotective effect of MRP4. In cells that overexpressed MRP4, intracellular accumulation of GCV metabolites was reduced, efflux of these metabolites was increased, and resistance to bystander killing was increased. Therefore, MRP4 can strongly reduce the susceptibility of HSV-TK-expressing cells to GCV, and its overexpression in adjacent cells protects them from bystander cell death. These findings indicate that a nucleotide transporter, such as MRP4, modulates the cellular response to GCV and thus may influence not only the efficacy of antiviral therapy, but also prodrug-based gene therapy, which is critically dependent upon bystander cell killing.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Arkansas, Ctr Med Sci, Dept Biochem, Little Rock, AR 72205 USA; Eastern Virginia Med Sch, Dept Biochem, Norfolk, VA 23529 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Eastern Virginia Medical School	Schuetz, J (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale Ave, Memphis, TN 38105 USA.	John.schuetz@stjude.org	Schuetz, John D/N-2692-2018		NCI NIH HHS [CA83843, CA-23099, CA53535, P30 CA-21765, CA-63203, R25 CA023944] Funding Source: Medline; NIGMS NIH HHS [GM-60904] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083843, R25CA023944, P30CA021765, P01CA023099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060904, R56GM060904] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai SC, 1999, BIOCHEM BIOPH RES CO, V259, P455, DOI 10.1006/bbrc.1999.0766; Beck C, 1995, HUM GENE THER, V6, P1525, DOI 10.1089/hum.1995.6.12-1525; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Boucher PD, 1998, HUM GENE THER, V9, P801, DOI 10.1089/hum.1998.9.6-801; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; Ding BC, 2001, J BIOL CHEM, V276, P8713, DOI 10.1074/jbc.M005248200; Drake RR, 2000, MOL THER, V2, P515, DOI 10.1006/mthe.2000.0192; Drake RR, 1999, J BIOL CHEM, V274, P37186, DOI 10.1074/jbc.274.52.37186; Freeman SM, 1996, SEMIN ONCOL, V23, P31; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; Grignet-Debrus C, 2000, CANCER GENE THER, V7, P1456, DOI 10.1038/sj.cgt.7700250; Halloran PJ, 1998, CANCER RES, V58, P3855; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; MARTIN JC, 1983, J MED CHEM, V26, P759, DOI 10.1021/jm00359a023; MEDINA DJ, 1992, ANTIMICROB AGENTS CH, V36, P1127, DOI 10.1128/AAC.36.5.1127; Mesnil M, 2000, CANCER RES, V60, P3989; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; PRICHARD MN, 1991, ANTIMICROB AGENTS CH, V35, P1060, DOI 10.1128/AAC.35.6.1060; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; Rubsam LZ, 1999, CANCER RES, V59, P669; SAMEJIMA Y, 1995, GENE THER, V2, P50; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; Sturtz FG, 1997, HUM GENE THER, V8, P1945, DOI 10.1089/hum.1997.8.16-1945; TIBERGHIEN P, 1994, J LEUKOCYTE BIOL, V56, P203, DOI 10.1002/jlb.56.2.203; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; Yang L, 1998, CLIN CANCER RES, V4, P731	32	107	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38998	39004		10.1074/jbc.M203262200	http://dx.doi.org/10.1074/jbc.M203262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12105214	hybrid			2022-12-27	WOS:000178529600124
J	Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Gugiu, B; Fox, PL; Hoff, HF; Salomon, RG; Hazen, SL				Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Gugiu, B; Fox, PL; Hoff, HF; Salomon, RG; Hazen, SL			Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; RETINAL-PIGMENT EPITHELIUM; CORONARY-ARTERY DISEASE; PPAR-GAMMA; ANIONIC PHOSPHOLIPIDS; INSULIN-RESISTANCE; GENE-EXPRESSION; OX-LDL; MYELOPEROXIDASE	The macrophage scavenger receptor CD36 plays an important role in the uptake of oxidized forms of low density lipoprotein (LDL) and contributes to lesion development in murine models of atherosclerosis. However, the structural basis of CD36 lipoprotein ligand recognition is unknown. We now identify a novel class of oxidized phospholipids that serve as high affinity ligands for CD36 and mediate recognition of oxidized forms of LDL by CD36 on macrophages. Small unilamellar vesicles of homogeneous phosphatidylcholine (PC) molecular species were oxidized by the myeloperoxidase (MPO)-H2O2-NO2- system, and products were separated by sequential LC/ESI/MS/MS. In parallel, fractions were tested for their ability to bind to CD36. Four major structurally related phospholipids with CD36 binding activity were identified from oxidized 1-palmitoyl-2-arachidonyl-PC, and four corresponding structural analogs with CD36 binding activity were identified from oxidized 1-palmitoyl-2-linoleoyl-PC. Each was then synthetically prepared, its structure confirmed by multinuclear NMR and high resolution mass spectrometry, and shown to possess identical CD36 binding activity and LC/ESI/MS/MS characteristics in both native and derivatized forms. Based upon the structures of the active compounds identified, and structure-function studies with a variety of synthetic analogs, we conclude that the structural characteristics required for high affinity binding of oxidized PC species to CD36 are a phospholipid with an sn-2 acyl group that incorporates a terminal gamma-hydroxy(or oxo)-alpha,beta-unsaturated carbonyl (oxPC(CD36)). LC/ESI/MS/MS studies demonstrate that oxPC(CD36), are formed during LDL oxidation by multiple distinct pathways. Formation of this novel class of oxidized PC species contributes to CD36-mediated recognition of LDL oxidized by MPO and other biologically relevant mechanisms. The present results offer structural insights into the molecular patterns recognized by the scavenger receptor CD36 and provide a platform for the development of potential therapeutic inhibitory agents.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Prevent Cardiol Sect, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.		Salomon, Robert G/C-3463-2008; Hazen, Stanley L/ABD-5845-2021	Salomon, Robert/0000-0001-9456-3557	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL070621, R01HL053315, R01HL061878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61878, HL62526, HL70621, HL53315] Funding Source: Medline; NIGMS NIH HHS [GM21249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; ASHKENAS J, 1993, J LIPID RES, V34, P983; Baldus S, 2001, J CLIN INVEST, V108, P1759; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e; Ehrenwald E, 1996, J CLIN INVEST, V97, P884, DOI 10.1172/JCI118491; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; Han JH, 1999, J LIPID RES, V40, P830; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huh HY, 1996, BLOOD, V87, P2020; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kashiwagi H, 1996, ARTERIOSCL THROM VAS, V16, P1026, DOI 10.1161/01.ATV.16.8.1026; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; KNAPP DR, 1987, HDB ANAL DERIVATIZAT, P196; Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9; Kutter D, 2000, ACTA HAEMATOL-BASEL, V104, P10, DOI 10.1159/000041062; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LOIDLSTAHLHOFEN A, 1994, BBA-LIPID LIPID MET, V1213, P140, DOI 10.1016/0005-2760(94)90020-5; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; MLAKAR A, 1996, CHEM PHYS LIPIDS, V79, P43; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; Navazo MDP, 1996, ARTERIOSCL THROM VAS, V16, P1033, DOI 10.1161/01.ATV.16.8.1033; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; Nicholson AC, 2000, ANN NY ACAD SCI, V902, P128; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J CELL SCI, V109, P387; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Tanaka T, 1997, JPN CIRC J, V61, P724, DOI 10.1253/jcj.61.724; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Yamaguchi A, 2000, THROMB RES, V97, P317, DOI 10.1016/S0049-3848(99)00179-6; ZHANG R, 2002, BLOOD, V85, P950; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	63	364	389	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38503	38516		10.1074/jbc.M203318200	http://dx.doi.org/10.1074/jbc.M203318200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12105195	hybrid			2022-12-27	WOS:000178529600066
J	Zeng, HY; Hawrot, E				Zeng, HY; Hawrot, E			NMR-based binding screen and structural analysis of the complex formed between alpha-cobratoxin and an 18-mer cognate peptide derived from the alpha 1 subunit of the nicotinic acetylcholine receptor from Torpedo californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; CATION-PI INTERACTIONS; CRYSTAL-STRUCTURE; OPHIOPHAGUS-HANNAH; LONG NEUROTOXIN; PROTON NMR; BUNGAROTOXIN; SPECTROSCOPY; SITE; SENSITIVITY	The alpha18-mer peptide, spanning residues 181-198 of the Torpedo nicotinic acetylcholine receptor alpha1 subunit, contains key binding determinants for agonists and competitive antagonists. To investigate whether the alpha18-mer can bind other alpha-neurotoxins besides alpha-bungarotoxin, we designed a two-dimensional H-1-N-15 heteronuclear single quantum correlation experiment to screen four related neurotoxins for their binding ability to the peptide. Of the four toxins tested (erabutoxin a, erabutoxin b, LSIII, and alpha-cobratoxin), only alpha-cobratoxin binds the alpha18-mer to form a 1:1 complex. The NMR solution structure of the alpha-cobratoxin-alpha18-mer complex was determined with a backbone root mean square deviation of 1.46 Angstrom. In the structure, alpha-cobratoxin contacts the alpha18-mer at the tips of loop I and II and through C-terminal cationic residues. The contact zone derived from the intermolecular nuclear Overhauser effects is in agreement with recent biochemical data. Furthermore, the structural models support the involvement of cation-pi interactions in stabilizing the complex. In addition, the binding screen results suggest that C-terminal cationic residues of alpha-bungarotoxin and a-cobratoxin contribute significantly to binding of the alpha18-mer. Finally, we present a structural model for nicotinic acetylcholine receptor-alpha-cobratoxin interaction by superimposing the alpha-cobratoxin-alpha18-mer complex onto the crystal structure of the acetylcholine-binding protein (Protein Data Bank code 1I9B).	Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Hawrot, E (corresponding author), Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Box G-B391, Providence, RI 02912 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08240] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ENDO T, 1986, BIOCHEMISTRY-US, V25, P395, DOI 10.1021/bi00350a019; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GODDARD TD, 2001, SPARKY 3 VERSION 3 1; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LABHARDT AM, 1988, EUR J BIOCHEM, V177, P295, DOI 10.1111/j.1432-1033.1988.tb14376.x; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; Lin SR, 1996, J PROTEIN CHEM, V15, P95, DOI 10.1007/BF01886815; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MACURA SI, 1994, METHOD ENZYMOL, V239, P100; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Moise L, 2002, J BIOL CHEM, V277, P12406, DOI 10.1074/jbc.M110320200; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; Peng SS, 1997, J BIOL CHEM, V272, P7817, DOI 10.1074/jbc.272.12.7817; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; Scherf T, 2001, P NATL ACAD SCI USA, V98, P6629, DOI 10.1073/pnas.111164298; SCHLEUCHER J, 1993, ANGEW CHEM, V105, P1518; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Thompson GS, 2000, PROTEIN SCI, V9, P846, DOI 10.1110/ps.9.5.846; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	49	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37439	37445		10.1074/jbc.M205483200	http://dx.doi.org/10.1074/jbc.M205483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133834	hybrid			2022-12-27	WOS:000178447100068
J	Bowden, ET; Stoica, GE; Wellstein, A				Bowden, ET; Stoica, GE; Wellstein, A			Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NON-HODGKINS-LYMPHOMA; MOLECULE HB-GAM; TYROSINE KINASE; BREAST-CANCER; BAD PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; IN-VIVO; GROWTH; BINDING	The secreted growth factor pleiotrophin (PTN) can induce mitogenesis in cells that express the receptor for this growth factor, anaplastic lymphoma kinase (ALK). Here we examine the ability of PTN to produce antiapoptotic signals. We demonstrate that PTN is a survival factor for SW-13 epithelial cells and show that ribozymemediated depletion of ALK from SW-13 cells abolishes this effect of PTN. Furthermore, in serum-starved NIH3T3 fibroblasts PTN prevents apoptosis (measured by annexin V staining) with an EC50 of 0.2 ng/ml and induces cell growth at higher concentrations of PTN. A polyclonal antibody against the PTN ligand-binding domain of the ALK receptor (alpha-LBD) was a partial agonist for ALK in NIH3T3 cells. This a-LBD antibody showed high agonist activity for anti-apoptosis (56 +/- 9% relative to PTN), low agonist activity for cell growth (21 +/- 1% relative to PTN), and was an antagonist of PTN-induced cell growth (61 +/- 2% inhibition). Both MAP kinase and phosphatidylinositol (PI) 3-kinase cascades in NIH3T3 cells were activated by PTN, and this effect persisted for up to 3 h. Surprisingly, the anti-apoptotic effect of PTN was completely blocked by the MAP kinase inhibitor U0126, but was not affected by the PI 3-kinase inhibitor LY294002. In contrast, PTN-dependent cell growth required both MAPK and PI3-kinase activity. We conclude that anti-apoptotic signaling of PTN through ALK in NIH3T3 fibroblasts is via the MAP kinase pathway.	Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Res Bldg E311,3970 Reservoir Rd NW, Washington, DC 20007 USA.	wellstea@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBO D, 1994, ANN PLAS SURG, V32, P588, DOI 10.1097/00000637-199406000-00005; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Jager R, 1997, INT J CANCER, V73, P537; KRISTINA S, 1995, J BIOL CHEM, V270, P1881, DOI 10.1074/jbc.270.4.1881; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prat M, 1998, J CELL SCI, V111, P237; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RAULO E, 1994, J BIOL CHEM, V269, P12999; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Stephenson RP, 1997, BRIT J PHARMACOL, V120, P106, DOI 10.1111/j.1476-5381.1997.tb06784.x; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Weber D, 2000, CANCER RES, V60, P5284; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733	35	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35862	35868		10.1074/jbc.M203963200	http://dx.doi.org/10.1074/jbc.M203963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107166	hybrid			2022-12-27	WOS:000178275100015
J	Chen, JF; Steyn, S; Staal, R; Petzer, JP; Xu, K; Van der Schyf, CJ; Castagnoli, K; Sonsalla, PK; Castagnoli, N; Schwarzschild, MA				Chen, JF; Steyn, S; Staal, R; Petzer, JP; Xu, K; Van der Schyf, CJ; Castagnoli, K; Sonsalla, PK; Castagnoli, N; Schwarzschild, MA			8-(3-chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A(2A) receptor antagonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; HUMAN-PLACENTA; CAFFEINE; BRAIN; MICE; MODELS; RISK	Caffeine and more specific antagonists of the adenosine A(2A) receptor recently have been found to be neuroprotective in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease. Here we show that 8-(3-chlorostyryl)caffeine (CSC), a specific A(2A) antagonist closely related to caffeine, also attenuates MPTP-induced neurotoxicity. Because the neurotoxicity of MPTP relies on its oxidative metabolism to the mitochondrial toxin MPP+, we investigated the actions of CSC on striatal MPTP metabolism in vivo. CSC elevated striatal levels of MPTP but lowered levels of the oxidative intermediate MPDP+ and of MPP+, suggesting that CSC blocks the conversion of MPTP to MPDP+ in vivo. In assessing the direct effects of CSC and A(2A) receptors on monoamine oxidase (MAO) activity, we found that CSC potently and specifically inhibited mouse brain mitochondrial MAO-B activity in vitro with a K-i value of 100 nm, whereas caffeine and another relatively specific A(2A) antagonist produced little or no inhibition. The A(2A) receptor independence of MAO-B inhibition by CSC was further supported by the similarity of brain MAO activities derived from A(2A) receptor knockout and wild-type mice and was confirmed by demonstrating potent inhibition of A(2A) receptor knockout-derived MAO-B by CSC. Together, these data indicate that CSC possesses dual actions of MAO-B inhibition and A(2A) receptor antagonism, a unique combination suggesting a new class of compounds with the potential for enhanced neuroprotective properties.	Massachusetts Gen Hosp, Mol Neurobiol Lab, Dept Neurol, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Virginia Tech, Dept Chem, Harvey W Peters Ctr, Blacksburg, VA 24061 USA; Univ Med & Dent New Jersey, Dept Neurol, Piscataway, NJ 08854 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Virginia Polytechnic Institute & State University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schwarzschild, MA (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.	chenjf@bu.edu; michaels@helix.mgh.harvard.edu	Van der Schyf, Cornelis J/I-7310-2017	Petzer, Jacobus/0000-0002-7114-8120; Chen, Jiang-Fan/0000-0003-3582-3448; Staal, Roland/0000-0002-2857-2241	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037403, R01NS041083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008479, R03AG018167] Funding Source: NIH RePORTER; NIA NIH HHS [AG18167, AG08479] Funding Source: Medline; NIEHS NIH HHS [ES10804] Funding Source: Medline; NINDS NIH HHS [NS41083, NS37403] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castagnoli K, 1997, CHEM RES TOXICOL, V10, P364, DOI 10.1021/tx970001d; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng JS, 2001, J RECEPT SIGNAL TR R, V21, P1, DOI 10.1081/RRS-100107138; El Yacoubi M, 2001, BRIT J PHARMACOL, V134, P68, DOI 10.1038/sj.bjp.0704240; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Hettinger BD, 2001, J COMP NEUROL, V431, P331, DOI 10.1002/1096-9861(20010312)431:3<331::AID-CNE1074>3.0.CO;2-W; Ikeda K, 2002, J NEUROCHEM, V80, P262, DOI 10.1046/j.0022-3042.2001.00694.x; Inoue H, 1999, J PHARMACOL EXP THER, V291, P856; JACOBSON KA, 1993, FEBS LETT, V323, P141, DOI 10.1016/0014-5793(93)81466-D; KALGUTKAR AS, 1994, J MED CHEM, V37, P944, DOI 10.1021/jm00033a012; KANTHASAMY AG, NEUROPROTECTION, P603; Khalil AA, 2000, CHEM RES TOXICOL, V13, P31, DOI 10.1021/tx990146f; KITAHAMA K, 1991, NEUROSCIENCE, V44, P185, DOI 10.1016/0306-4522(91)90260-U; KRUEGER MJ, 1995, BIOCHEM BIOPH RES CO, V206, P556, DOI 10.1006/bbrc.1995.1079; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Marian T, 1999, APPL RADIAT ISOTOPES, V50, P887, DOI 10.1016/S0969-8043(98)00162-6; RILEY LA, 1989, MOL PHARMACOL, V36, P54; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; SALACH JI, 1987, METHOD ENZYMOL, V142, P627; Schwarzschild MA, 2002, NEUROLOGY, V58, P1154, DOI 10.1212/WNL.58.8.1154; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Yu PH, 1995, PROG BRAIN RES, V106, P113	28	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36040	36044		10.1074/jbc.M206830200	http://dx.doi.org/10.1074/jbc.M206830200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130655	hybrid			2022-12-27	WOS:000178275100036
J	Cogan, JG; Subramanian, SV; Polikandriotis, JA; Kelm, RJ; Strauch, AR				Cogan, JG; Subramanian, SV; Polikandriotis, JA; Kelm, RJ; Strauch, AR			Vascular smooth muscle alpha-actin gene transcription during myofibroblast differentiation requires Sp1/3 protein binding proximal to the MCAT enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL INTERACTIONS; SINGLE-STRAND; PUR-ALPHA; EXPRESSION; PROMOTER; CELLS; FIBROBLASTS; ACTIVATION	The conversion of stromal. fibroblasts into contractile myofibroblasts is an essential feature of the wound-healing response that is mediated by transforming growth factor beta1 (TGF-beta1) and accompanied by transient activation of the vascular smooth muscle -actin (SmalphaA) gene. Multiple positive-regulatory elements were identified as essential mediators of basal Smalpha-A enhancer activity in mouse AKR-2B stromal fibroblasts. Three of these elements bind transcriptional activating proteins of known identity in fibroblasts. A fourth site, shown previously to be susceptible to single-strand modifying agents in myofibroblasts, was additionally required for enhancer response to TGF-beta1. However, TGF-beta1 activation was not accompanied by a stoichiometric increase in protein binding to any known positive element in the SmaA enhancer. By using oligonucleotide affinity isolation, DNA-binding site competition, gel mobility shift assays, and protein overexpression in SL2 and COS7 cells, we demonstrate that the transcription factors Sp1 and Sp3 can stimulate Sma-A enhancer activity. One of the sites that bind Sp1/3 corresponds to the region of the SmaA enhancer required for TGF-beta1 amplification. Additionally, the TGF-beta1 receptor-regulated Smad proteins, in particular Smad3, are rate-limiting for SmaA enhancer activation. Whereas Smad proteins collaborate with Sp1 in activating several stromal cell-associated promoters, they appear to operate independently from the Sp1/3 proteins in activating the SmaA enhancer. The identification of Sp and Smad proteins as essential, independent activators of the SmaA enhancer provides new insight into the poorly understood process of myofibroblast differentiation.	Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Univ Vermont, Dept Med, Colchester, VT 05446 USA	University System of Ohio; Ohio State University; University of Vermont	Strauch, AR (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Dorothy M Davis Heart & Lung Res Inst, 1645 Neil Ave,Rm 302, Columbus, OH 43210 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281, P01HL070294, R01HL060876] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54281, HL 60876, HL 70294] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando Y, 1999, NEPHROL DIAL TRANSPL, V14, P1408, DOI 10.1093/ndt/14.6.1408; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; CHIAVEGATO A, 1995, VIRCHOWS ARCH, V426, P77; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DARBY I, 1990, LAB INVEST, V63, P21; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dugina V, 1998, EXP CELL RES, V238, P481, DOI 10.1006/excr.1997.3868; Faggin E, 1999, ARTERIOSCL THROM VAS, V19, P1393, DOI 10.1161/01.ATV.19.6.1393; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Frangogiannis NG, 2000, CARDIOVASC RES, V48, P89, DOI 10.1016/S0008-6363(00)00158-9; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; LEE SH, 1995, J CELL PHYSIOL, V164, P172, DOI 10.1002/jcp.1041640122; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIN BH, 1990, J BIOL CHEM, V265, P16667; ORLANDI A, 1994, EXP CELL RES, V214, P528, DOI 10.1006/excr.1994.1290; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; SKALLI O, 1989, LAB INVEST, V60, P275; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; Sowa Y, 1999, CANCER RES, V59, P4266; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	53	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36433	36442		10.1074/jbc.M203232200	http://dx.doi.org/10.1074/jbc.M203232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12110667	hybrid			2022-12-27	WOS:000178275100084
J	Houben, ENG; Urbanus, ML; van der Laan, M; ten Hagen-Jongman, CM; Driessen, AJM; Brunner, J; Oudega, B; Luirink, J				Houben, ENG; Urbanus, ML; van der Laan, M; ten Hagen-Jongman, CM; Driessen, AJM; Brunner, J; Oudega, B; Luirink, J			YidC and SecY mediate membrane insertion of a type I transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; COLI INNER MEMBRANE; ESCHERICHIA-COLI; TRIGGER FACTOR; PROTEIN; TRANSLOCATION; MITOCHONDRIAL; BACTERIAL; PATHWAYS; COMPLEX	YidC has been identified recently as an evolutionary conserved factor that is involved in the integration of inner membrane proteins (IMPs) in Escherichia coli. The discovery of YidC has inspired the reevaluation of membrane protein assembly pathways in E. coli. In this study, we have analyzed the role of YidC in membrane integration of a widely used model IMP, leader peptidase (Lep). Site-directed photocross-linking experiments demonstrate that both YidC and SecY contact nascent Lep very early during biogenesis, at only 50-amino acid nascent chain length. At this length the first transmembrane domain (TM), which acquires a type I topology, is not even fully exposed outside the ribosome. The pattern of interactions appears dependent on the position of the cross-linking probe in the nascent chain. Upon elongation, nascent Lep remains close to YidC and comes into contact with lipids as well. Our results suggest a role for YidC in both the reception and lipid partitioning of type I TMs.	Free Univ Amsterdam, Inst Mol Biol Sci, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	Vrije Universiteit Amsterdam; University of Groningen; Swiss Federal Institutes of Technology Domain; ETH Zurich	Luirink, J (corresponding author), Free Univ Amsterdam, Inst Mol Biol Sci, Dept Microbiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	luirink@bio.vu.nl	Houben, Edith N.G./B-2110-2015; Driessen, Arnold J.M./D-1876-2012; Luirink, Joen/AAB-8658-2021	Houben, Edith N.G./0000-0002-8805-2002; Driessen, Arnold J.M./0000-0001-9258-9104; Luirink, J./0000-0001-8431-0804				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; LEE JI, 1992, J BIOL CHEM, V267, P938; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	26	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35880	35886		10.1074/jbc.M205556200	http://dx.doi.org/10.1074/jbc.M205556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107184	Green Published, hybrid			2022-12-27	WOS:000178275100017
J	Koul, HK; Menon, M; Chaturvedi, LS; Koul, S; Sekhon, A; Bhandari, A; Huang, MY				Koul, HK; Menon, M; Chaturvedi, LS; Koul, S; Sekhon, A; Bhandari, A; Huang, MY			COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXALATE MONOHYDRATE CRYSTALS; COLLECTING DUCT CELLS; MAP KINASE; GENE-EXPRESSION; STRESS; PROLIFERATION; APOPTOSIS; REQUIRES; PHOSPHORYLATION; INHIBITION	Interaction of calcium oxalate monohydrate (COM) crystals with renal cells has been shown to result in altered gene expression, DNA synthesis, and cell death. In the current study the role of a stress-specific p38 MAP kinase-signaling pathway in mediating these effects of COM crystals was investigated. Exposure of cells to COM crystals (20 mug/cm(2)) rapidly stimulated strong phosphorylation and activation of p38 mitogen-activated protein kinase (p38 MAP,P kinase) and re-initiation of DNA synthesis. Inhibition of COM crystal binding to the cells by heparin blocked the effects of COM crystals on p38 MAPK activation. We also show that specific inhibition of p38 MAPK by 4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl) imidazole (SB203580) or by overexpression. of a dominant negative mutant of p38 MAP kinase abolishes COM crystal-induced re-initiation of DNA synthesis. The inhibition is dose-dependent and correlates with in situ activity of native p38 MAP kinase, determined as mitogen-activated protein kinase-activated protein kinase-2 (MAPKAP kinase-2) activity in cell extracts. In summary, inhibiting activation of p38 MAPK pathway abrogated the DNA synthesis in response to COM crystals. These data are the first demonstrations of activation of the p38 MAPKAP signaling pathway by COM crystals and suggest that, in response to COM crystals, this pathway transduces critical signals governing the re-initiation of DNA synthesis in renal epithelial cells.	Henry Ford Hlth Sci Ctr, Vattikuti Urol Inst, Biochem & Mol Biol Lab, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Koul, HK (corresponding author), Henry Ford Hlth Sci Ctr, Vattikuti Urol Inst, Biochem & Mol Biol Lab, 1 Ford Pl,Ste 2D-33, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054084] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-R01-54084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bonventre JV, 1998, CURR OPIN NEPHROL HY, V7, P425, DOI 10.1097/00041552-199807000-00013; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chaturvedi LS, 2002, J BIOL CHEM, V277, P13321, DOI 10.1074/jbc.M108203200; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Finlayson B, 1974, Urol Clin North Am, V1, P181; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HAMMES MS, 1995, KIDNEY INT, V48, P501, DOI 10.1038/ki.1995.320; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hu YH, 1997, J BIOL CHEM, V272, P9113; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; KHAN SR, 1995, UROL RES, V23, P71, DOI 10.1007/BF00307936; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; KOUL H, 1994, BIOCHEM BIOPH RES CO, V205, P1632, DOI 10.1006/bbrc.1994.2854; KOUL H, 1999, P INT CME UR, P89; Koul HK, 1999, J AM SOC NEPHROL, V10, pS417; Koul S, 2002, KIDNEY INT, V61, P525, DOI 10.1046/j.1523-1755.2002.00163.x; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; LIESKE JC, 1993, AM J PHYSIOL, V264, pF800, DOI 10.1152/ajprenal.1993.264.5.F800; LIESKE JC, 1992, AM J PHYSIOL, V262, P622; MENON M, 1992, J CLIN ENDOCR METAB, V74, P703, DOI 10.1210/jc.74.4.703; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIESE RJ, 1988, AM J PHYSIOL, V255, pF1025, DOI 10.1152/ajprenal.1988.255.5.F1025; RIESE RJ, 1992, AM J PHYSIOL, V262, pF177, DOI 10.1152/ajprenal.1992.262.2.F177; ROBERTSON WG, 1972, CLIN SCI, V43, P499, DOI 10.1042/cs0430499; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Sodhi CP, 2000, KIDNEY INT, V58, P691, DOI 10.1046/j.1523-1755.2000.00215.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thamilselvan S, 1998, J NEPHROL, V11, P66; Verkoelen CF, 1998, AM J PHYSIOL-RENAL, V274, pF958, DOI 10.1152/ajprenal.1998.274.5.F958; Verkoelen CF, 1996, J UROLOGY, V155, P749, DOI 10.1016/S0022-5347(01)66514-5; Wiessner JH, 2001, KIDNEY INT, V59, P637, DOI 10.1046/j.1523-1755.2001.059002637.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	55	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36845	36852		10.1074/jbc.M200832200	http://dx.doi.org/10.1074/jbc.M200832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121971	hybrid			2022-12-27	WOS:000178275100137
J	Misra, UK; Akabani, G; Pizzo, SV				Misra, UK; Akabani, G; Pizzo, SV			The role of cAMP-dependent signaling in receptor-recognized forms of alpha(2)-macroglobulin-induced cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ELEVATES INTRACELLULAR CALCIUM; PROTEIN-COUPLED RECEPTORS; HUMAN 5-HT1A RECEPTOR; CYCLIC-AMP; TYROSINE KINASES; S6 KINASE; PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR; CYTOSOLIC ADAPTER; BINDING PROTEINS	Ligation of alpha(2)-macroglobulin receptors by receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) activates various signaling cascades and promotes cell proliferation. It also elevates cAMP in murine peritoneal macrophages. We now report that a significant elevation of cAMP-response element-binding protein (CREB) occurs in alpha(2)M*-stimulated cells, and this effect is potentiated by isobutylmethylxanthine, dibutyryl-cAMP, or forskolin. An a2M* concentration-dependent rapid increase in phosphorylated CREB at Ser(133) also occurred, a necessary event in its activation. Inhibition of Ca2+/calmodulin kinase, protein kinases A and C, tyrosine kinases, ribosomal S6 kinase, farnesyl transferase, extracellular signal-regulated kinases 1/2, phosphatidylinositol 3-kinase, or p38 mitogen-activated protein kinase markedly reduce alpha(2)M*-induced phosphorylation of CREB, indicating a role for the p21(ras)-dependent and phosphatidylinositol 3-kinase signaling pathways in regulating CREB activation by a2M*. Finally, silencing the CREB gene by transfecting cells with a homologous gene sequence double-stranded RNA drastically reduced the expression of CREB and blocked the ability of a alpha(2)M* to promote macrophage cell division. We conclude that cAMP-dependent signal transduction as well as other signaling cascades are essential for alpha(2)M*-induced cell proliferation.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA	Duke University; Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	Pizzo001@mc.duke.edu			NHLBI NIH HHS [HL-24066] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DARDEVET D, 1966, J ENDOCRINOL, V137, P4987; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIYE A, 1999, TRENDS GENET, V15, P358; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Jorgensen MM, 2000, J BIOL CHEM, V275, P33861, DOI 10.1074/jbc.M004663200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1997, J BIOL CHEM, V272, P497; Misra UK, 1999, J BIOL CHEM, V274, P25785, DOI 10.1074/jbc.274.36.25785; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V372, P238, DOI 10.1006/abbi.1999.1521; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; Misra UK, 2002, FASEB J, V16, pA169; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; Misra UK, 2002, CELL SIGNAL, V14, P327, DOI 10.1016/S0898-6568(01)00268-6; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moroi K, 1998, BRAIN RES, V794, P291, DOI 10.1016/S0006-8993(98)00245-5; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang L, 2000, J BIOL CHEM, V275, P7224, DOI 10.1074/jbc.275.10.7224; WU S, 2001, HEMOSTASIS THROMBOSE, P367; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1415; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	94	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36509	36520		10.1074/jbc.M203543200	http://dx.doi.org/10.1074/jbc.M203543200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114513	hybrid			2022-12-27	WOS:000178275100093
J	D'Angelo, M; Montagna, AE; Sanguineti, S; Torres, HN; Flawia, MM				D'Angelo, M; Montagna, AE; Sanguineti, S; Torres, HN; Flawia, MM			A novel calcium-stimulated adenylyl cyclase from Trypanosoma cruzi, which interacts with the structural flagellar protein paraflagellar rod	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SITE INHIBITION; BINDING PROTEINS; MESSENGER-RNA; BLOOD-STREAM; GENE FAMILY; INTRACELLULAR CALCIUM; CATALYTIC MECHANISM; BRUCEI; DIFFERENTIATION; FORMS	Trypanosoma cruzi adenylyl cyclases are encoded by a large polymorphic gene family. Although several genes have been identified in this parasite, little is known about the properties and regulation of these enzymes. Here we report the cloning and characterization of TczAC, a novel member of T. cruzi adenylyl cyclase family. The TczAC gene is expressed in all of the parasite life forms and encodes a 1,313-amino acid protein that can complement a Saccharomyces cerevisiae mutant deficient in adenylyl cyclase activity. The recombinant enzyme expressed in yeasts is constitutively active, has a low affinity for ATP (K-m=406 mum), and requires a divalent cation for catalysis. TczAC is inhibited by Zn2+ and the P-site inhibitor 2'-deoxyadenosine 3'-monophosphate, suggesting some level of conservation in the catalytic mechanism with mammalian adenylyl cyclases. It shows a dose-dependent stimulation by Ca2+ which can be reversed by high concentrations of phenothiazinic calmodulin inhibitors. However, bovine calmodulin fails to stimulate the enzyme. Using a yeast two-hybrid screen it was found that TczAC interacts through its catalytic domain with the paraflagellar rod protein, a component of the flagellar structure. Furthermore, we demonstrate that TczAC can dimerize through the same domain. These results provide novel evidence of the possible localization and regulation of this protein.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Flawia, MM (corresponding author), INGEBI, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Torres, Héctor/GXG-1780-2022	D'Angelo, Maximiliano/0000-0001-7025-0142				Anel AMD, 2000, J EUKARYOT MICROBIOL, V47, P555, DOI 10.1111/j.1550-7408.2000.tb00089.x; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bastin P, 1999, MOL CELL BIOL, V19, P8191; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; D'Orso I, 2001, J BIOL CHEM, V276, P15783, DOI 10.1074/jbc.M010959200; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Docampo Roberto, 1993, Biological Research, V26, P189; EISENSCHLOS C, 1986, BIOCHEM J, V236, P185, DOI 10.1042/bj2360185; ENGMAN DM, 1989, J BIOL CHEM, V264, P18627; FLAWIA MM, 1983, J BIOL CHEM, V258, P8255; Flawia MM, 1997, PARASITOL TODAY, V13, P30, DOI 10.1016/S0169-4758(96)10070-3; FRAIDENRAICH D, 1993, P NATL ACAD SCI USA, V90, P10140, DOI 10.1073/pnas.90.21.10140; Garcia ES, 1995, EXP PARASITOL, V81, P255, DOI 10.1006/expr.1995.1116; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Godsel LM, 1999, EMBO J, V18, P2057, DOI 10.1093/emboj/18.8.2057; Gomez EB, 2001, MOL BIOCHEM PARASIT, V113, P97, DOI 10.1016/S0166-6851(00)00382-0; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; JOHNSON RA, 1990, J BIOL CHEM, V265, P19035; Lammel EM, 1996, EXP PARASITOL, V83, P240, DOI 10.1006/expr.1996.0070; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Lucas KA, 2000, PHARMACOL REV, V52, P375; Maga JA, 1999, TRENDS CELL BIOL, V9, P409, DOI 10.1016/S0962-8924(99)01635-9; Maldonado RA, 1997, EXP PARASITOL, V86, P200, DOI 10.1006/expr.1997.4159; MARTIN BR, 1978, BIOCHEM J, V175, P207, DOI 10.1042/bj1750207; Naula C, 2000, PARASITOL TODAY, V16, P35, DOI 10.1016/S0169-4758(99)01582-3; Naula C, 2001, MOL BIOCHEM PARASIT, V112, P19, DOI 10.1016/S0166-6851(00)00338-8; OUAISSI A, 1992, EUR J CELL BIOL, V59, P68; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495; PESTKA S, 1984, P NATL ACAD SCI-BIOL, V81, P7525, DOI 10.1073/pnas.81.23.7525; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; RANGELALDAO R, 1988, BIOCHEM INT, V17, P337; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; SANCHEZ MA, 1995, J BIOL CHEM, V270, P17551, DOI 10.1074/jbc.270.29.17551; Seebeck T, 2001, INT J PARASITOL, V31, P491, DOI 10.1016/S0020-7519(01)00164-3; Stojdl DF, 1996, EXP PARASITOL, V83, P134, DOI 10.1006/expr.1996.0057; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; TORRUELLA M, 1986, BIOCHEM J, V234, P145, DOI 10.1042/bj2340145; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Vassella E, 1997, J CELL SCI, V110, P2661; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; WU YM, 1994, BIOCHEM J, V304, P833, DOI 10.1042/bj3040833; WU YM, 1992, BIOCHEM J, V287, P187, DOI 10.1042/bj2870187; Zingales B, 1997, PARASITOL TODAY, V13, P16	50	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35025	35034		10.1074/jbc.M204696200	http://dx.doi.org/10.1074/jbc.M204696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121994	hybrid			2022-12-27	WOS:000178117000048
J	Epping, EA; Moye-Rowley, WS				Epping, EA; Moye-Rowley, WS			Identification of interdependent signals required for anterograde traffic of the ATP-binding cassette transporter protein Yor1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE PROTEIN; YEAST ABC PROTEINS; CYSTIC-FIBROSIS; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; METAL RESISTANCE; QUALITY-CONTROL; CFTR	The plasma membrane ATP-binding cassette (ABC) transporter Yor1p mediates oligomycin resistance in Saccharomyces cerevisiae. Its protein sequence places it in the multidrug resistance protein/cystic fibrosis transmembrane conductance regulator subfamily of ABC transporters. A key regulatory step in the biogenesis of this family of ABC transporter proteins is at the level of transport from the endoplasmic reticulum (ER) on through the secretory pathway. To explore the protein sequence requirements for Yor1p to move from the ER to its site of function at the plasma membrane, a series of truncation and alanine replacement mutations were constructed in Yor1p. This analysis detected two sequence motifs similar to the DXE element that has recently been found in other proteins that exit the ER. Loss of the N-terminal DXE element eliminated function of the protein, whereas loss of the C-terminal element only slightly reduced function of the resulting mutant Yor1p. Strikingly, although both of the single mutant proteins were stable, production of the double mutant caused dramatic destabilization of Yor1p. These data suggest that this large polytopic membrane protein requires multiple signals for normal forward trafficking, and elimination of this information may cause the mutant protein to be transferred to a degradative fate.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Mol Biol PhD Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Epping, Eric/0000-0001-7193-3041	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li Y, 1999, MOL CELL BIOL, V19, P3588; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Proff C, 2001, MOL GEN GENET, V264, P883, DOI 10.1007/s004380000378; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Sambrook J., 2002, MOL CLONING LAB MANU; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Sherman F, 1979, METHODS YEAST GENETI; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Taglicht D, 1998, METHOD ENZYMOL, V292, P130; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x	49	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34860	34869		10.1074/jbc.M202987200	http://dx.doi.org/10.1074/jbc.M202987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107161	hybrid			2022-12-27	WOS:000178117000028
J	Esteve, PO; Chicoine, E; Robledo, O; Aoudjit, F; Descoteaux, A; Potworowski, EF; St-Pierre, Y				Esteve, PO; Chicoine, E; Robledo, O; Aoudjit, F; Descoteaux, A; Potworowski, EF; St-Pierre, Y			Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; IV COLLAGENASE; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PRIMARY ASTROCYTES; GLUCOSE-TRANSPORT; PKC-ZETA; EXPRESSION	The regulation of matrix metalloproteinase-9 (MMP-9) expression in glioma cells is one of the key processes in tumor invasion through the brain extracellular matrix. Although some studies have demonstrated the implication of classic protein kinase C (PKC) isoforms in the regulation of AMP-9 production by phorbol esters or lipopolysaccharide, the involvement of specific PKC isoforms in the signaling pathways leading to MMP-9 expression by inflammatory cytokines remains unclear. Here we report that the atypical PKC-zeta isoform participates in the induction of AMP-9 expression by interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) in rat C6 glioma cells. Indeed, zymography and semi-quantitative reverse transcriptase-PCR analysis showed that pretreatment of C6 cells with PKC-zeta pseudosubstrate abolished AMP-9 activity and gene expression induced by IL-1 or TNIF-alpha. Accordingly, IL-1 and TNF-alpha were able to induce PKC-zeta activity, as demonstrated by in vitro kinase assay using immunoprecipitated PKC-zeta. Furthermore, stable C6 clones overexpressing PKC-zeta, but not PKC-epsilon, displayed an up-regulation of NMP-9 constitutive expression as well as an increase of mmp-9 promoter activity. These processes were inhibited by an NF-kappaB-blocking peptide and completely prevented by NF-kappaB-binding site mutation in the mmp-9 promoter. Taken together, these results indicate that PKC-zeta plays a key role in the regulation of MMP-9 expression in C6 glioma cells through NF-kappaB.	Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada; Univ Laval, Ctr Rech Immunol & Rheumatol, St Foy, PQ G1V 4G2, Canada	University of Quebec; Institut national de la recherche scientifique (INRS); Laval University	St-Pierre, Y (corresponding author), Univ Quebec, Inst Armand Frappier, INRS, 531 Boul Prairies, Laval, PQ H7V 1B7, Canada.			St-Pierre, Yves/0000-0002-1948-2041				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Esteve PO, 1998, BBA-MOL CELL RES, V1403, P85, DOI 10.1016/S0167-4889(98)00020-2; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; Han YP, 2001, J CELL SCI, V114, P131; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kondraganti S, 2000, CANCER RES, V60, P6851; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Misse D, 2001, BLOOD, V98, P541, DOI 10.1182/blood.V98.3.541; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P1175, DOI 10.1006/bbrc.1993.1540; RAO JS, 1993, CANCER RES, V53, P2208; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SATO H, 1993, ONCOGENE, V8, P395; Segain JP, 1996, CANCER RES, V56, P5506; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; XIE B, 1994, J IMMUNOL, V152, P3637; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	45	157	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35150	35155		10.1074/jbc.M108600200	http://dx.doi.org/10.1074/jbc.M108600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130632	hybrid			2022-12-27	WOS:000178117000063
J	Venkataraman, K; Riebeling, C; Bodennec, J; Riezman, H; Allegood, JC; Sullard, MC; Merrill, AH; Futerman, AH				Venkataraman, K; Riebeling, C; Bodennec, J; Riezman, H; Allegood, JC; Sullard, MC; Merrill, AH; Futerman, AH			Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B-1-independent manner in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; F-SP LYCOPERSICI; CERAMIDE SYNTHESIS; ENDOPLASMIC-RETICULUM; RAT-BRAIN; SPHINGOSINE; METABOLISM; INHIBITION; ACYLTRANSFERASE; PROTEINS	The longevity assurance gene (LAG1) and its homolog (LAC1) are required for acyl-CoA-dependent synthesis of ceramides containing very long acyl chain (e.g. C26) fatty acids in yeast, and a homolog of LAG1, ASC1, confers resistance in plants to fumonisin B-1 an inhibitor of ceramide synthesis. To understand further the mechanism of regulation of ceramide synthesis, we now characterize a mammalian homolog of LAG1, upstream of growth and differentiation factor-1 (uog1). cDNA clones of uog1 were obtained from expression sequence-tagged clones and sub-cloned into a mammalian expression vector. Transient transfection of human embryonic kidney 293T cells with uog1 followed by metabolic labeling with [4,5-H-3]sphinganine or L-3-[H-3]serine demonstrated that uog1 conferred fumonisin B-1 resistance with respect to the ability of the cells to continue to produce ceramide. Surprisingly, this ceramide was channeled into neutral glycosphingolipids but not into gangliosides. Electrospray tandem mass spectrometry confirmed the elevation in sphingolipids and revealed that the ceramides and neutral glycosphingolipids of uog1-transfected cells contain primarily stearic acid (C18), that this enrichment was further increased by FB1, and that the amount of stearic acid in sphingomyelin was also increased. UOG1 was localized to the endoplasmic reticulum, demonstrating that the fatty acid selectivity and the fumonisin B, resistance are not due to a subcellular localization different from that found previously for ceramide synthase activity. Furthermore, in vitro assays of uog1-transfected cells demonstrated elevated ceramide synthase activity when stearoyl-CoA but not palmitoyl-CoA was used as substrate. We propose a role for UOG1 in regulating C18-ceramide (N-stearoyl-sphinganine) synthesis, and we note that not only is this the first case of ceramide formation in mammalian cells with such a high degree of fatty acid specificity, but also that the N-stearoyl-sphinganine produced by UOG1 most significantly impacts neutral glycosphingolipid synthesis.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	Weizmann Institute of Science; University of Basel; University System of Georgia; Georgia Institute of Technology	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futeran@weizmann.ac.il		Merrill, Alfred/0000-0002-6673-968X; Riebeling, Christian/0000-0003-1991-0170; Futerman, Anthony/0000-0003-0013-0115; Riezman, Howard/0000-0003-4680-9422	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1996, CURRENT PROTOCOLS S, V36; BADIANI K, 1996, BIOCHIM BIOPHYS ACTA, P190; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodennec J, 2000, J LIPID RES, V41, P1524; BOYER J, 1993, YEAST, V9, P279, DOI 10.1002/yea.320090307; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandwagt BF, 2000, P NATL ACAD SCI USA, V97, P4961, DOI 10.1073/pnas.97.9.4961; Brandwagt BF, 2002, MOL PLANT MICROBE IN, V15, P35, DOI 10.1094/MPMI.2002.15.1.35; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; Goslin K., 1998, CULTURING NERVE CELL, P339; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; KISHIMOTO Y, 1983, ENZYMES, V16, P357; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AHJ, 2002, IN PRESS CERAMUDE SI; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MORELL P, 1970, J BIOL CHEM, V245, P342; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; SINGH I, 1983, J NEUROCHEM, V40, P1565, DOI 10.1111/j.1471-4159.1983.tb08127.x; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sullards MC, 2000, METHOD ENZYMOL, V312, P32; SULLARDS MC, 2001, SCI STKE; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; ULLMAN MD, 1972, ARCH BIOCHEM BIOPHYS, V152, P767, DOI 10.1016/0003-9861(72)90272-X; Venkataraman K, 2001, BBA-MOL CELL BIOL L, V1530, P219, DOI 10.1016/S1388-1981(01)00085-3; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Wang E, 2000, METHOD ENZYMOL, V311, P15; WANG E, 1991, J BIOL CHEM, V266, P14486; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x	53	214	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35642	35649		10.1074/jbc.M205211200	http://dx.doi.org/10.1074/jbc.M205211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105227	hybrid			2022-12-27	WOS:000178117000124
J	Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU				Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU			Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL MIGRATION; LUNG METASTASIS; CHLORIDE CHANNEL; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; GENE-EXPRESSION; MELANOMA-CELLS; BREAST-CANCER	Early metastatic growth occurs at sites of vascular arrest of blood-borne cancer cells and is entirely intravascular. Here we show that lung colonization by B16-F10 cells is licensed by beta(4) integrin adhesion to the mouse lung endothelial Ca2+-activated chloride channel protein mCLCA1. In a manner independent of Met, beta(4) integrin-mCLCA1-ligation leads to complexing with and activation of focal adhesion kinase (FAK) and downstream signaling to extracellular signal-regulated kinase (ERK). FAK/ERK signaling is Src-dependent and is interrupted by adhesion blocking antibodies and by dominant-negative (dn)-FAK mutants. Levels of ERK activation in B16-F10 cells transfected with wild-type or mutant FAK are closely associated with rates of proliferation and bromodeoxyuridine (BrdUrd) incorporation of tumor cells grown in mCLCA1-coated dishes, the ability to form tumor cell colonies on CLCA-expressing endothelial cell monolayers, and the extent of pulmonary metastatic growth. Parallel with the transfection rates, B16-F10 cells transfected with dn-FAK mutants and injected intravenously into syngeneic mice generate approximately half the number and size of lung colonies that vector-transfected B16-F10 cells produce. For the first time, beta(4) integrin ligation to its novel CLCA-adhesion partner is shown to be associated with FAK complexing, activation, and signaling to promote early, intravascular, metastatic growth.	Cornell Univ, Coll Vet Med, Canc Biol Labs, Dept Mol Med,Vet Med Ctr C4 161, Ithaca, NY 14853 USA	Cornell University	Pauli, BU (corresponding author), Cornell Univ, Coll Vet Med, Canc Biol Labs, Dept Mol Med,Vet Med Ctr C4 161, Ithaca, NY 14853 USA.				NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CARSON NG, 1997, J BIOL CHEM, V272, P11295; Cheng HC, 1999, CLIN EXP METASTAS, V17, P609, DOI 10.1023/A:1006757525190; Cimino L, 1997, CANCER DETECT PREV, V21, P158; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Elia G, 2001, J CELL BIOCHEM, V81, P477, DOI 10.1002/1097-4644(20010601)81:3<477::AID-JCB1061>3.0.CO;2-B; FALCIONI R, 1986, CANCER RES, V46, P5772; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FIDLER IJ, 1970, J NATL CANCER I, V45, P1867; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gerritsen Mary E., 1995, Microcirculation (New York), V2, P151, DOI 10.3109/10739689509146763; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hemler ME, 2001, DEV CELL, V1, P728, DOI 10.1016/S1534-5807(01)00102-2; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Khanna C, 2001, CANCER RES, V61, P3750; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; LAPIS K, 1988, CLIN EXP METASTAS, V6, P73, DOI 10.1007/BF01580408; Liu JD, 2001, J CELL BIOCHEM, V83, P631, DOI 10.1002/jcb.1261; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PAULI BU, 1988, LAB INVEST, V58, P379; PAULI BU, 2002, IN PRESS CURRENT TOP; PAULI BU, 1997, ENCY CANC, V1, P464; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1999, MOL BIOL, V71, P4356; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VAAGE J, 1987, CANCER RES, V47, P547; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Wong CW, 2001, CANCER RES, V61, P333; Zhao J H, 2000, Prog Mol Subcell Biol, V25, P37; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	49	95	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34391	34400		10.1074/jbc.M205307200	http://dx.doi.org/10.1074/jbc.M205307200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110680	hybrid			2022-12-27	WOS:000177959100112
J	Martin, DSD; Lonergan, PE; Boland, B; Fogarty, MP; Brady, M; Horrobin, DF; Campbell, VA; Lynch, MA				Martin, DSD; Lonergan, PE; Boland, B; Fogarty, MP; Brady, M; Horrobin, DF; Campbell, VA; Lynch, MA			Apoptotic changes in the aged brain are triggered by interleukin-1 beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POLYUNSATURATED FATTY-ACIDS; DIETARY SUPPLEMENTATION; PROTEIN-KINASES; CYTOCHROME-C; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; NITRIC-OXIDE; STRESS; MITOCHONDRIA	Among the several changes that occur in the aged brain is an increase in the concentration of the proinflammatory cytokine interleukin-10 that is coupled with a deterioration in cell function. This study investigated the possibility that treatment with the polyunsaturated fatty acid eicosapentaenoic acid might prevent interleukin-1beta-induced deterioration in neuronal function. Assessment of four markers of apoptotic cell death, cytochrome c translocation, caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and terminal dUTP nick-end staining, revealed an age-related increase in each of these measures, and the evidence presented indicates that treatment of aged rats with eicosapentaenoate reversed these changes as well as the accompanying increases in interleukin-1beta concentration and p38 activation. The data are consistent with the idea that activation of p38 plays a significant role in inducing the changes described since interleukin-1beta-induced activation of cytochrome c translocation and caspase-3 activation in cortical tissue in vitro were reversed by the p38 inhibitor SB203580. The age-related increases in interleukin-1beta concentration and p38 activation in cortex were mirrored by similar changes in hippocampus. These changes were coupled with an age-related deficit in long term potentiation in perforant path-granule cell synapses, while eicosapentaenoate treatment was associated with reversal of age-related changes in interleukin-1beta and p38 and with restoration of long term potentiation.	Univ Dublin Trinity Coll, Dept Physiol, Inst Neurosci, Dublin 2, Ireland; Laxdale Res Ltd, Stirling FK7 9JQ, Scotland	Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Dept Physiol, Inst Neurosci, Dublin 2, Ireland.	lynchma@tcd.ie	Lonergan, Peter E/B-4544-2008; Boland, Barry/D-1235-2010	Lonergan, Peter E/0000-0001-7233-8156; Boland, Barry/0000-0003-2676-4343; Lynch, Marina/0000-0002-4631-0499				Babcock T, 2000, NUTRITION, V16, P1116, DOI 10.1016/S0899-9007(00)00392-0; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; Castagne V, 1999, BRAIN RES, V842, P215, DOI 10.1016/S0006-8993(99)01823-5; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Guay J, 1997, J CELL SCI, V110, P357; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; Hayashi H, 1999, CURR MED RES OPIN, V15, P177, DOI 10.1185/03007999909114089; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hu S, 1997, NEUROCHEM INT, V30, P427, DOI 10.1016/S0197-0186(96)00078-2; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kochevar IE, 2000, PHOTOCHEM PHOTOBIOL, V72, P548, DOI 10.1562/0031-8655(2000)072<0548:SOBNOR>2.0.CO;2; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; Martinou JC, 1996, CURR OPIN NEUROBIOL, V6, P609, DOI 10.1016/S0959-4388(96)80092-4; McCarty MF, 1999, MED HYPOTHESES, V53, P369, DOI 10.1054/mehy.1998.0783; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1998, J NEUROSCI, V18, P2974; Ng DCH, 2001, J BIOL CHEM, V276, P29490, DOI 10.1074/jbc.M100699200; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rapoport SI, 2001, J MOL NEUROSCI, V16, P243, DOI 10.1385/JMN:16:2-3:243; Sadeghi S, 1999, IMMUNOLOGY, V96, P404, DOI 10.1046/j.1365-2567.1999.00701.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TERRACINA L, 1992, MOL CELL BIOCHEM, V115, P35, DOI 10.1007/BF00229093; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Wallace FA, 2000, CYTOKINE, V12, P1374, DOI 10.1006/cyto.2000.0735; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zawada WM, 2001, BRAIN RES, V891, P185; Zhivotovsky B, 1998, CELL DEATH DIFFER, V5, P459, DOI 10.1038/sj.cdd.4400386; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880	52	124	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34239	34246		10.1074/jbc.M205289200	http://dx.doi.org/10.1074/jbc.M205289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091394	hybrid			2022-12-27	WOS:000177959100093
J	Yonetani, T; Park, S; Tsuneshige, A; Imai, K; Kanaori, K				Yonetani, T; Park, S; Tsuneshige, A; Imai, K; Kanaori, K			Global allostery model of hemoglobin - Modulation of O-2 affinity, cooperativity, and Bohr effect by heterotropic allosteric effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING; STEREOCHEMISTRY; RESONANCE; LIGANDS	The O-2 equilibria of human adult hemoglobin have been measured in a wide range of solution conditions in the presence and absence of various allosteric effectors in order to determine how far hemoglobin can modulate its O-2 affinity. The O-2 affinity, cooperative behavior, and the Bohr effect of hemoglobin are modulated principally by tertiary structural changes, which are induced by its interactions with heterotropic allosteric effectors. In their absence, hemoglobin is a high affinity, moderately cooperative O-2 carrier of limited functional flexibility, the behaviors of which are regulated by the homotropic, O-2-linked T/R quaternary structural transition of the Monod-Wyman-Changeux/Perutz model. However, the interactions with allosteric effectors provide such "inert" hemoglobin unprecedented magnitudes of functional diversities not only of physiological relevance but also of extreme nature, by which hemoglobin can behave energetically beyond what can be explained by the Monod-Wyman-Changeux/Perutz model. Thus, the heterotropic effector-linked tertiary structural changes rather than the homotropic ligation-linked T/R quaternary structural transition are energetically more significant and primarily responsible for modulation of functions of hemoglobin.	Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Johnson Res Fdn, Philadelphia, PA 19104 USA; Osaka Univ, Grad Sch Med, Dept Physiol & Biosignaling, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Nanobiol, Suita, Osaka 5650871, Japan; Kyoto Inst Technol, Dept Appl Biol, Kyoto 6068585, Japan	University of Pennsylvania; University of Pennsylvania; Osaka University; Osaka University; Kyoto Institute of Technology	Yonetani, T (corresponding author), Univ Penn, Med Ctr, Dept Biochem & Biophys, 220 Anat Chem Bldg 6059,3600 Hamilton Walk, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL 14508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; Adair GS, 1925, J BIOL CHEM, V63, P529; ANTONINI E, 1961, J BIOL CHEM, V236, P60; BENESCH RE, 1977, BIOCHEMISTRY-US, V16, P2594, DOI 10.1021/bi00631a003; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BRUNORI M, 1973, EUR J BIOCHEM, V39, P563, DOI 10.1111/j.1432-1033.1973.tb03155.x; CHIANCONE E, 1972, J MOL BIOL, V70, P675, DOI 10.1016/0022-2836(72)90566-9; Coletta M, 1999, J BIOL CHEM, V274, P6865, DOI 10.1074/jbc.274.11.6865; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; de Bruin S H, 1973, Biochem Biophys Res Commun, V55, P193, DOI 10.1016/S0006-291X(73)80078-6; DEBRUIN SH, 1971, BIOCHEM BIOPH RES CO, V45, P544, DOI 10.1016/0006-291X(71)90854-0; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; FRIEDMAN J, 1985, J BIOL CHEM, V258, P10564; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GRAY RD, 1971, J BIOL CHEM, V242, P7168; HOPFIELD J, 1973, J MOL BIOL, V77, P208; IMAI K, 1975, J BIOL CHEM, V250, P2227; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; IMAI K, 1973, BIOCHEMISTRY-US, V12, P128, DOI 10.1021/bi00725a021; IMAI K, 1983, J MOL BIOL, V167, P741, DOI 10.1016/S0022-2836(83)80107-7; IMAI K, 1972, BIOCHEMISTRY-US, V11, P114, DOI 10.1021/bi00751a020; Imai K, 2002, BIOPHYS CHEM, V98, P79, DOI 10.1016/S0301-4622(02)00086-8; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P164, DOI 10.1016/0005-2795(77)90116-7; IMAI K, BIOCH BIOPHYS RES CO, V50, P1055; Imai K., 1982, ALLOSTERIC EFFECTS H; IMAIZUMI K, 1979, J BIOCHEM, V86, P1829, DOI 10.1093/oxfordjournals.jbchem.a132705; KISTER J, 1987, J BIOL CHEM, V262, P12085; KISTER J, 1988, BIOPHYS J, V52, P527; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LENFANT C, 1968, J CLIN INVEST, V47, P2652, DOI 10.1172/JCI105948; LINDSTRO.TR, 1973, BIOCHEMISTRY-US, V12, P134; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MINTON A P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1418, DOI 10.1073/pnas.71.4.1418; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUIRHEAD H, 1963, NATURE, V199, P633, DOI 10.1038/199633a0; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1983, LANCET, V2, P881; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; RIGGS A, 1971, P NATL ACAD SCI USA, V68, P2062, DOI 10.1073/pnas.68.9.2062; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SIMON SR, 1969, P NATL ACAD SCI USA, V63, P205, DOI 10.1073/pnas.63.1.205; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	54	145	150	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34508	34520		10.1074/jbc.M203135200	http://dx.doi.org/10.1074/jbc.M203135200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107163	hybrid			2022-12-27	WOS:000177959100124
J	Hu, QH; Yu, ZX; Ferrans, VJ; Takeda, K; Irani, K; Ziegelstein, RC				Hu, QH; Yu, ZX; Ferrans, VJ; Takeda, K; Irani, K; Ziegelstein, RC			Critical role of NADPH oxidase-derived reactive oxygen species in generating Ca2+ oscillations in human aortic endothelial cells stimulated by histamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE ANION RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; PERMEABILIZED HEPATOCYTES; CALCIUM OSCILLATIONS; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; HYPERPOLARIZING FACTOR; OXIDIZED GLUTATHIONE; INTRACELLULAR CA2+; OXIDATIVE STRESS	There is increasing evidence that intracellular reactive oxygen species (ROS) play a role in cell signaling and that the NADPH oxidase is a major source of ROS in endothelial cells. At low concentrations, agonist stimulation of membrane receptors generates intracellular ROS and repetitive oscillations of intracellular Ca2+ concentration ([Ca2+](i)) in human endothelial cells. The present study was performed to examine whether ROS are important in the generation or maintenance of [Ca2+](i) oscillations in human aortic endothelial cells (HAEC) stimulated by histamine. Histamine (1 mum) increased the fluorescence of 2',7'-dihydrodichlorofluorescin diacetate in HAEC, an indicator of ROS production. This was partially inhibited by the NADPH oxidase inhibitor diphenyleneiodonium (DPI, 10 pm), by the farnesyltransferase inhibitor H-Ampamb-Phe-Met-OH (2 mum), and in HAEC transiently expressing Rac1(N17), a dominant negative allele of the protein Rac1, which is essential for NADPH oxidase activity. In indo 1-loaded HAEC, 1 mum histamine triggered [Ca2+](i) oscillations that were blocked by DPI or H-Ampamb-Phe-Met-OH. Histamine-stimulated [Ca2+](i) oscillations were not observed in HAEC lacking functional Rac1 protein but were observed when transfected cells were simultaneously exposed to a low concentration of hydrogen peroxide (10 muM), which by itself did not alter either [Ca2+](i) or levels of inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3). Thus, histamine generates ROS in HAEC at least partially via NADPH oxidase activation. NADPH oxidase-derived ROS are critical to the generation of [Ca2+](i) oscillations in HAEC during histamine stimulation, perhaps by increasing the sensitivity of the endoplasmic reticulum to Ins-1,4,5-P-3.	Johns Hopkins Univ, Dept Med, Div Cardiol, Johns Hopkins Bayview Med Ctr,Sch Med, Baltimore, MD 21224 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hu, QH (corresponding author), Johns Hopkins Univ, Dept Med, Div Cardiol, Johns Hopkins Bayview Med Ctr,Sch Med, 5501 Hopkins Bayview Circle 1A32, Baltimore, MD 21224 USA.			Irani, Kaikobad/0000-0001-9194-7387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063720] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63720] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Anzai K, 2000, ANTIOXID REDOX SIGN, V2, P35, DOI 10.1089/ars.2000.2.1-35; Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; CARTER TD, 1991, BIOCHEM J, V278, P697, DOI 10.1042/bj2780697; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; COSENTINO F, 1994, HYPERTENSION, V23, P229, DOI 10.1161/01.HYP.23.2.229; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; GARDNER CR, 1993, J LEUKOCYTE BIOL, V53, P190, DOI 10.1002/jlb.53.2.190; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HOLLAND JA, 1990, J CELL PHYSIOL, V143, P21, DOI 10.1002/jcp.1041430104; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Hu QH, 2000, J BIOL CHEM, V275, P15749, DOI 10.1074/jbc.M000381200; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kovacic HN, 2001, J BIOL CHEM, V276, P45856, DOI 10.1074/jbc.M107925200; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lang D, 2000, CIRC RES, V86, P463, DOI 10.1161/01.RES.86.4.463; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Lee YW, 2001, J MOL CELL CARDIOL, V33, P83, DOI 10.1006/jmcc.2000.1278; Lee ZW, 2000, CELL SIGNAL, V12, P91, DOI 10.1016/S0898-6568(99)00069-8; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MURPHY HS, 1992, AM J PHYSIOL, V263, P51; Nomura T, 1996, ALCOHOL CLIN EXP RES, V20, pA325, DOI 10.1111/j.1530-0277.1996.tb01166.x; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; Pessah IN, 2000, ANTIOXID REDOX SIGN, V2, P17, DOI 10.1089/ars.2000.2.1-17; POLLOCK WK, 1988, BIOCHEM J, V256, P371, DOI 10.1042/bj2560371; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; RINK TJ, 1989, CELL CALCIUM, V10, P385, DOI 10.1016/0143-4160(89)90064-X; SCHIMIZU SI, 1994, RES COMMUN CHEM PATH, V84, P301; SNEYD J, 1995, FASEB J, V9, P1463, DOI 10.1096/fasebj.9.14.7589988; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Toborek M, 1997, J LIPID RES, V38, P2155; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; VERCELLOTTI GM, 1991, J LAB CLIN MED, V117, P15; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2; ZIEGELSTEIN RC, 1993, AM J PHYSIOL, V265, pH1424, DOI 10.1152/ajpheart.1993.265.4.H1424; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	57	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32546	32551		10.1074/jbc.M201550200	http://dx.doi.org/10.1074/jbc.M201550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093794	hybrid			2022-12-27	WOS:000177859000021
J	Kim, SJ; Hwang, SG; Shin, DY; Kang, SS; Chun, JS				Kim, SJ; Hwang, SG; Shin, DY; Kang, SS; Chun, JS			p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NF kappa B-dependent transcription and stabilization by serine 15 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; BAX TRANSLOCATION; GENE-EXPRESSION; CYTOCHROME-C; INHIBITION; SIGNAL; BCL-2; OSTEOARTHRITIS; DEGRADATION	Nitric oxide (NO) during primary culture of articular chondrocytes causes apoptosis via p38 mitogen-activated protein kinase in association with elevation of p53 protein level, caspase-3 activation, and differentiation status. In this study, we characterized the molecular mechanism by which p38 kinase induces apoptosis through activation of p53. We report here that NO-induced activation of p38 kinase leads to activation of NFkappaB, which in turn induces transcription of the p53 gene. Activated p38 kinase also physically associates and phosphorylates the serine 15 residue of p53, which results in accumulation of p53 protein during NO-induced apoptosis. Ectopic expression of wild-type p53 enhanced NO-induced apoptosis, whereas expression of a dominant negative p53 blocked it, indicating that p53 plays an essential role in NO-induced apoptosis of chondrocytes. The increased accumulation of p53 caused expression of Bax, a pro-apoptotic member of the Bcl-2 family that is known to cause apoptosis via release of cytochrome c and caspase activation. These results suggest that NO-activated p38 kinase activates p53 function in two different ways, transcriptional activation by NFkappaB and direct phosphorylation of p53 protein, leading to apoptosis of articular chondrocytes.	Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea; Dankook Univ, Coll Med, Dept Microbiol, Cheonan 330714, South Korea; Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Dankook University; Kyungpook National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea.	jschun@kjist.ac.kr						Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Brune B, 2001, CELL SIGNAL, V13, P525, DOI 10.1016/S0898-6568(01)00175-9; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Foo SY, 1999, TRENDS GENET, V15, P229; Frenkel SR, 1999, FRONT BIOSCI-LANDMRK, V4, P671, DOI 10.2741/frenkel; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Kibbe MR, 2002, AM J PHYSIOL-CELL PH, V282, pC625, DOI 10.1152/ajpcell.00119.2001; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Taimor G, 2001, FASEB J, V15, P2518, DOI 10.1096/fj.01-0353fje; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xiang H, 1998, J NEUROSCI, V18, P1363; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200	55	142	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33501	33508		10.1074/jbc.M202862200	http://dx.doi.org/10.1074/jbc.M202862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091386	hybrid			2022-12-27	WOS:000177859000140
J	Lorenz, JN; Baird, NR; Judd, LM; Noonan, WT; Andringa, A; Doetschman, T; Manning, PA; Liu, LH; Miller, ML; Shull, GE				Lorenz, JN; Baird, NR; Judd, LM; Noonan, WT; Andringa, A; Doetschman, T; Manning, PA; Liu, LH; Miller, ML; Shull, GE			Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; NA-K-2CL COTRANSPORTER; IN-VIVO; HYPOKALEMIC ALKALOSIS; CL COTRANSPORTER; HENLES LOOP; K+ CHANNEL; NA+-CL; MUTATIONS; REABSORPTION	ROMK is an apical K+ channel expressed in the thick ascending limb of Henle (TALH) and throughout the distal nephron of the kidney. Null mutations in the ROMK gene cause type II Bartter's syndrome, in which abnormalities of electrolyte, acid-base, and fluid-volume homeostasis occur because of defective NaCl reabsorption in the TALH. To understand better the pathogenesis of type II Bartter's syndrome, we developed a mouse lacking ROMK and examined its phenotype. Young null mutants had hydronephrosis, were severely dehydrated, and similar to95% died before 3 weeks of age. ROMK-deficient mice that survived beyond weaning grew to adulthood; however, they had metabolic acidosis, elevated blood concentrations of Na+ and Cl-, reduced blood pressure, polydipsia, polyuria, and poor urinary concentrating ability. Whole kidney glomerular filtration rate was sharply reduced, apparently as a result of hydronephrosis, and fractional excretion of electrolytes was elevated. Micropuncture analysis revealed that the single nephron glomerular filtration rate was relatively normal, absorption of NaCl in the TALH was reduced but not eliminated, and tubuloglomerular feedback was severely impaired. These data show that the loss of ROMK in the mouse causes perturbations of electrolyte, acid-base, and fluid-volume homeostasis, reduced absorption of NaCl in the TALH, and impaired tubuloglomerular feedback.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu		Judd, Louise/0000-0003-3613-4839	NHLBI NIH HHS [HL61974] Funding Source: Medline; NIDDK NIH HHS [DK50594, DK57552] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057552, R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Attmane-Elakeb A, 1998, J BIOL CHEM, V273, P33681, DOI 10.1074/jbc.273.50.33681; Bettinelli A, 2000, PEDIATR NEPHROL, V14, P940, DOI 10.1007/PL00013418; Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; Bleich M, 1999, PFLUG ARCH EUR J PHY, V438, P245, DOI 10.1007/s004240050906; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BRIGGS JP, 1987, ANNU REV PHYSIOL, V49, P251; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; EVELOFF JL, 1986, AM J PHYSIOL, V250, pF176, DOI 10.1152/ajprenal.1986.250.1.F176; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Ghadially FN, 2001, ULTRASTRUCT PATHOL, V25, P243; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; GREGER R, 1981, PFLUG ARCH EUR J PHY, V392, P92, DOI 10.1007/BF00584588; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P38, DOI 10.1007/BF00582708; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; Hebert SC, 1998, AM J PHYSIOL-RENAL, V275, pF325, DOI 10.1152/ajprenal.1998.275.3.F325; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang DY, 2000, BRIT J PHARMACOL, V130, P1255, DOI 10.1038/sj.bjp.0703429; HURST AM, 1994, J GEN PHYSIOL, V103, P1055, DOI 10.1085/jgp.103.6.1055; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Lorenz JN, 1999, AM J PHYSIOL-RENAL, V276, pF172, DOI 10.1152/ajprenal.1999.276.1.F172; Lorenz JN, 1999, AM J PHYSIOL-RENAL, V277, pF447, DOI 10.1152/ajprenal.1999.277.3.F447; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; Mount DB, 1999, AM J PHYSIOL-RENAL, V276, pF347, DOI 10.1152/ajprenal.1999.276.3.F347; Peters M, 2002, AM J MED, V112, P183, DOI 10.1016/S0002-9343(01)01086-5; Plata C, 2001, AM J PHYSIOL-RENAL, V280, pF574, DOI 10.1152/ajprenal.2001.280.4.F574; RAMSAY JA, 1955, J EXP BIOL, V32, P822; SCHNERMANN J, 1995, AM J PHYSIOL-RENAL, V268, pF960, DOI 10.1152/ajprenal.1995.268.5.F960; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; Simon DB, 1998, CURR OPIN CELL BIOL, V10, P450, DOI 10.1016/S0955-0674(98)80057-4; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Vallon V, 1998, KIDNEY INT, V54, pS177, DOI 10.1046/j.1523-1755.1998.06739.x; Walter SJ, 2001, EXP PHYSIOL, V86, P469, DOI 10.1113/eph8602210; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739	43	135	153	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37871	37880		10.1074/jbc.M205627200	http://dx.doi.org/10.1074/jbc.M205627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12122007	hybrid			2022-12-27	WOS:000178447100123
J	Bermudez, VP; MacNeill, SA; Tappin, I; Hurwitz, J				Bermudez, VP; MacNeill, SA; Tappin, I; Hurwitz, J			The influence of the cdc27 subunit on the properties of the Schizosaccharomyces pombe DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; REPLICATION; REPAIR; PROTEIN; EPSILON; GROWTH; MOTIF; PCNA	Schizosaccharomyces pombe DNA polymerase (pol) delta contains four subunits, pol 3, Cdc1, Cdc27, and Cdm1. In this report, we examined the role of Cdc27 on the structure and activity of pol delta. We show that the four-subunit complex is monomeric in structure, in contrast to the previous report that it was a dimer (Zuo, S., Bermudez, V., Zhang, G., Kelman, Z., and Hurwitz, J. (2000) J. Biol Chem. 275, 5153-5162). This discrepancy between the earlier and recent observations was traced to the marked asymmetric shape of Cdc27. Cdc27 contains two critical domains that govern its role in activating pol delta. The N-terminal region (amino acids (aa) 1-160) binds to Cdc1 and its extreme C-terminal end (aa 362-369) interacts with proliferating cell nuclear antigen (PCNA). Mutants of S. pombe pol delta, containing truncated Cdc27 derivatives deficient in binding to PCNA, supported DNA replication less processively than the wild-type complex. Fusion of a minimal PCNA-binding motif (aa 352372) to C-terminally truncated Cdc27 derivatives restored processive DNA synthesis in vitro. In vivo, the introduction of these fused Cdc27 derivatives into cdc27Delta cells conferred viability. These data support the model in which Cdc27 plays an essential role in DNA replication by recruiting PCNA to the pol delta holoenzyme.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Memorial Sloan Kettering Cancer Center; University of Edinburgh	Hurwitz, J (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.			MacNeill, Stuart/0000-0002-0555-0007	NIGMS NIH HHS [GM 58559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BULLOCK PA, 1997, CRIT REV BIOCHEM MOL, V32, P500; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; DONREITER J, 1992, EMBO J, V11, P769; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; HIGES R, 1997, BIOL CHEM, V378, P345; JOHANSSON E, 2001, J BIOL CHEM, V276, P4384; Kang HY, 2000, GENETICS, V155, P1055; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; LEE SH, 1991, J BIOL CHEM, V266, P22701; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MacNeill SA, 2001, TRENDS BIOCHEM SCI, V26, P16, DOI 10.1016/S0968-0004(00)01709-6; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P9712; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; ZLOFKIN T, 1996, EMBO J, V15, P2298; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	35	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36853	36862		10.1074/jbc.M202897200	http://dx.doi.org/10.1074/jbc.M202897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124382	hybrid			2022-12-27	WOS:000178275100138
J	Lin, HK; Altuwaijri, S; Lin, WJ; Kan, PY; Collins, LL; Chang, CS				Lin, HK; Altuwaijri, S; Lin, WJ; Kan, PY; Collins, LL; Chang, CS			Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED APOPTOSIS; 26S PROTEASOME; INHIBITORS; COACTIVATOR; PATHWAY; BINDING; PROTEIN; COMPLEX; CLONING	Upon binding to androgen, the androgen receptor (AR) can translocate into the nucleus and bind to androgen response element(s) to modulate its target genes. Here we have shown that MG132, a 26 S proteasome inhibitor, suppressed AR transactivation in an androgen-dependent manner in prostate cancer LNCaP and PC-3 cells. In contrast, MG132 showed no suppressive effect on glucocorticoid receptor transactivation. Additionally, transfection of PSAU7, a proteasome subunit, enhanced AR transactivation in a dose-dependent manner. The suppression of AR transactivation by MG132 may then result in the suppression of prostate-specific antigen, a well known marker used to monitor the progress of prostate cancer. Further mechanistic studies indicated that MG132 may suppress AR transactivation via inhibition of AR nuclear translocation and/or inhibition of interactions between AR and its coregulators, such as ARA70 or TIF2. Together, our data suggest that the proteasome system plays important roles in the regulation of AR activity in prostate cancer cells and may provide a unique target site for the development of therapeutic drugs to block androgen/AR-mediated prostate tumor growth.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Lin, Wen-Jye/D-1028-2016	Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905, R01DK060948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60948, DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch T, 1998, J IMMUNOL, V161, P35; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lommel L, 2000, NUCLEIC ACIDS RES, V28, P4839, DOI 10.1093/nar/28.24.4839; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Milligan SA, 2001, ANTICANCER RES, V21, P39; Miyamoto H, 2002, J BIOL CHEM, V277, P4609, DOI 10.1074/jbc.M108312200; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schwartz AL, 1999, ANNU REV MED, V50, P57; Sheflin L, 2000, BIOCHEM BIOPH RES CO, V276, P144, DOI 10.1006/bbrc.2000.3424; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Watanabe K, 2000, BIOCHEM PHARMACOL, V60, P823, DOI 10.1016/S0006-2952(00)00387-7; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Zhang Y, 1998, J BIOL CHEM, V273, P1387, DOI 10.1074/jbc.273.3.1387	46	124	130	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36570	36576		10.1074/jbc.M204751200	http://dx.doi.org/10.1074/jbc.M204751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119296	hybrid			2022-12-27	WOS:000178275100100
J	Royle, SJ; Bobanovic, LK; Murrell-Lagnado, RD				Royle, SJ; Bobanovic, LK; Murrell-Lagnado, RD			Identification of a non-canonical tyrosine-based endocytic motif in an ionotropic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; SORTING SIGNALS; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; MU-2 SUBUNIT; INTERNALIZATION; PLASTICITY; RECOGNITION; DETERMINANTS; TRAFFICKING	Rapid modulation of the surface number of certain ionotropic receptors is achieved by altering the relative rates of insertion and internalization. These receptors are internalized by a clathrin-mediated pathway; however, a motif that is necessary for endocytosis of ionotropic receptors has not yet been identified. Here, we identified a motif that is required for constitutive and agonist-regulated internalization of the ionotropic P2X(4) receptor. Three amino acids in the C terminus of P2X(4) (Tyr(378), Gly(381), and Leu(382)) compose a non-canonical tyrosine-based sorting signal of the form YXXGL. We found that P2X(4) protein was present in clathrin-coated vesicles isolated from rat brain and that a glutathione S-transferase fusion of the P2X(4) C terminus pulled down the adaptor protein-2 complex from brain extract. Mutation of either the tyrosine-binding pocket of the mu2 subunit of adaptor protein-2 or the YXXGL motif in the receptor C terminus caused a decrease in receptor internalization and a dramatic increase in the surface expression of P2X(4) receptors. The YXXGL motif represents a non-canonical tyrosine-based sorting signal that is necessary for efficient endocytosis of the P2X(4) receptor. Similar motifs are present in other receptors and may be important for the control of their functional expression.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Murrell-Lagnado, RD (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.			Royle, Stephen/0000-0001-8927-6967; Murrell-Lagnado, Ruth/0000-0003-2743-7977				Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Burrone J, 2001, CURR BIOL, V11, pR274, DOI 10.1016/S0960-9822(01)00137-3; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ennion SJ, 2001, FEBS LETT, V489, P154, DOI 10.1016/S0014-5793(01)02102-0; Follows ER, 2001, BIOCHEM J, V359, P427, DOI 10.1042/0264-6021:3590427; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kittler JT, 2000, J NEUROSCI, V20, P7972; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Turrigiano GG, 2000, NEURON, V26, P5, DOI 10.1016/S0896-6273(00)81131-9; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1	35	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35378	35385		10.1074/jbc.M204844200	http://dx.doi.org/10.1074/jbc.M204844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105201	hybrid			2022-12-27	WOS:000178117000093
J	Tsvetanova, BC; Kiemle, DJ; Price, NPJ				Tsvetanova, BC; Kiemle, DJ; Price, NPJ			Biosynthesis of tunicamycin and metabolic origin of the 11-carbon dialdose sugar, tunicamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; NIKKOMYCIN BIOSYNTHESIS; MASS-SPECTROMETRY; IN-VIVO; ANTIBIOTICS	Tunicamycin is a reversible inhibitor of polyprenolphosphate: N-acetylhexosamine-1-phosphate translocases and is produced by several Streptomyces species. We have examined tunicamycin biosynthesis, an important but poorly characterized biosynthetic pathway. Biosynthetic precursors have been identified by incorporating radioactive and stable isotopes, and by determining the labeling pattern using electrospray ionization-collision. induced dissociation-mass spectrometry (ESI-CID-MS), and proton, deuterium, and C-13 nuclear magnetic resonance (NMR) spectroscopy. Preparation and analysis of [uracil-5-H-2]-labeled tunicamycin established the complete ESI-CID-MS fragmentation pathway for the major components of the tunicamycin complex. Competitive metabolic experiments indicate that 7 deuteriums incorporate into tunicamycin from [6,6'-H-2,H-2]-labeled D-glucose, 6 of which arise from D-GlcNAc and 1 from uridine and/or D-ribose. Inverse correlation NMR experiments (heteronuclear single-quantum coherence (HSQC)) of C-13-labeled tunicamycin enriched from D-[1-C-13]glucose suggest that the unique tunicamine 11-carbon dialdose sugar backbone arises from a 5-carbon furanose precursor derived from uridine and a 6-carbon N-acetylamino-pyranose precursor derived from UDP-D-N-acetylglucosamine. The equivalent incorporation of C-13 into both the alpha-1" and beta-11' anomeric carbons of tunicamycin supports a direct biosynthesis via 6-carbon metabolism. It also indicates that the tunicamine motif and the alpha-1"-linked GlcNAc residue are both derived from the same metabolic pool of UDP-GlcNAc, without significant differential metabolic processing. A biosynthetic pathway is therefore proposed for tunicamycin for the first time: an initial formation of the 11-carbon tunicamine sugar motif from uridine and UDP-GlcNAc via uridine-5'-aldehyde and UDP-4-keto-6-ene-N-acetylhexosamine, respectively, and subsequent formation of the anomeric-to-anomeric alpha, beta-1",11'-glycosidic bond.	SUNY Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry	Price, NPJ (corresponding author), Univ Rochester, Dept Anesthesiol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.							Beale JM, 1996, BIOCHEMISTRY-US, V35, P4492, DOI 10.1021/bi951922v; CRAIK DJ, 1989, AUST J CHEM, V42, P541, DOI 10.1071/CH9890541CO; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; ECKARDT K, 1983, J NAT PROD, V46, P544, DOI 10.1021/np50028a020; Follstad BD, 1998, EUR J BIOCHEM, V252, P360, DOI 10.1046/j.1432-1327.1998.2520360.x; Gross JW, 2000, BIOCHEMISTRY-US, V39, P13633, DOI 10.1021/bi001963d; HABIBIGOUDARZI S, 1995, J AM SOC MASS SPECTR, V6, P102, DOI 10.1016/S1044-0305(94)00108-C; Hegeman AD, 2002, BIOCHEMISTRY-US, V41, P2797, DOI 10.1021/bi011748c; HELLER SR, 1968, BIOCHEM BIOPH RES CO, V32, P998, DOI 10.1016/0006-291X(68)90127-7; ISONO K, 1976, ARCH BIOCHEM BIOPHYS, V173, P141, DOI 10.1016/0003-9861(76)90244-7; ISONO K, 1978, J AM CHEM SOC, V100, P3937, DOI 10.1021/ja00480a052; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; Khosla C, 2000, J ORG CHEM, V65, P8127, DOI 10.1021/jo000849y; Lauer B, 2000, J ANTIBIOT, V53, P385, DOI 10.7164/antibiotics.53.385; Lee WP, 1998, AM J PHYSIOL, V274, P843; MCLUCKEY SA, 1993, J AM CHEM SOC, V115, P12085, DOI 10.1021/ja00078a054; MYERS AG, 1994, J AM CHEM SOC, V116, P4697, DOI 10.1021/ja00090a018; Portais JC, 1999, EUR J BIOCHEM, V265, P473, DOI 10.1046/j.1432-1327.1999.00778.x; SCHUZ TC, 1992, J ANTIBIOT, V45, P199, DOI 10.7164/antibiotics.45.199; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; TAMURA G, 1982, TUNICAMYCINS, P10; TKACZ JS, 1983, ANTIBIOTICS NY, V6, P255; Tsvetanova BC, 2001, ANAL BIOCHEM, V289, P147, DOI 10.1006/abio.2000.4952; WALLACE KK, 1995, FEMS MICROBIOL LETT, V131, P227, DOI 10.1016/0378-1097(95)00263-5; Wallace KK, 1997, J BACTERIOL, V179, P3884, DOI 10.1128/jb.179.12.3884-3891.1997	25	35	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35289	35296		10.1074/jbc.M201345200	http://dx.doi.org/10.1074/jbc.M201345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093793	hybrid			2022-12-27	WOS:000178117000082
J	Waltner-Law, ME; Wang, XHL; Law, BK; Hall, RK; Nawano, M; Granner, DK				Waltner-Law, ME; Wang, XHL; Law, BK; Hall, RK; Nawano, M; Granner, DK			Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CULTURED RAT HEPATOCYTES; TYROSINE-PHOSPHATASE 1B; TUMOR-NECROSIS-FACTOR; VANADATE TREATMENT; INSULIN-RECEPTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; DIABETIC RATS	Herbs have been used for medicinal purposes, including the treatment of diabetes, for centuries. Plants containing flavonoids are used to treat diabetes in Indian medicine and the green tea flavonoid, epigallocatechin gallate (EGCG), is reported to have glucose-lowering effects in animals. We show here that the regulation of hepatic glucose production is decreased by EGCG. Furthermore, like insulin, EGCG increases tyrosine phosphorylation of the insulin receptor and insulin receptor substrate-1 (IRS-1), and it reduces phosphoenolpyruvate carboxykinase gene expression in a phosphoinositide 3-kinase-dependent manner. EGCG also mimics insulin by increasing phosphoinositide 3-kinase, mitogen-activated protein kinase, and p70(s6k) activity. EGCG differs from insulin, however, in that it affects several insulin-activated kinases with slower kinetics. Furthermore, EGCG regulates genes that encode gluconeogenic enzymes and protein-tyrosine phosphorylation by modulating the redox state of the cell. These results demonstrate that changes in the redox state may have beneficial effects for the treatment of diabetes and suggest a potential role for EGCG, or derivatives, as an antidiabetic agent.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 707 Light Hall, Nashville, TN 37232 USA.	daryl.granner@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, R01DK035107, K01DK002887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02887, DK35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1989, ACTA DIABETOL LAT, V26, P291, DOI 10.1007/BF02624640; Ahsan H, 1999, CHEM-BIOL INTERACT, V121, P161, DOI 10.1016/S0009-2797(99)00096-4; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BRICHARD SM, 1993, MOL CELL ENDOCRINOL, V91, P91, DOI 10.1016/0303-7207(93)90259-M; Broadhurst CL, 2000, J AGR FOOD CHEM, V48, P849, DOI 10.1021/jf9904517; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chou FP, 2000, BIOCHEM PHARMACOL, V60, P643, DOI 10.1016/S0006-2952(00)00363-4; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; Christ B, 1996, BIOCHEM J, V320, P161, DOI 10.1042/bj3200161; Craig WJ, 1999, AM J CLIN NUTR, V70, p491S, DOI 10.1093/ajcn/70.3.491s; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fantus IG, 1998, MOL CELL BIOCHEM, V182, P109, DOI 10.1023/A:1006853426679; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; Guo Q, 1999, BBA-GEN SUBJECTS, V1427, P13, DOI 10.1016/S0304-4165(98)00168-8; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HII CST, 1984, DIABETES, V33, P291, DOI 10.2337/diabetes.33.3.291; HILL MR, 1992, INFECT IMMUN, V60, P4040, DOI 10.1128/IAI.60.10.4040-4050.1992; HOFMANN CA, 1992, ENDOCRINOLOGY, V130, P735, DOI 10.1210/en.130.2.735; Hollman PCH, 1997, EUR J CLIN NUTR, V51, pS66; Ikezawa Y, 2001, J LAB CLIN MED, V138, P387, DOI 10.1067/mlc.2001.119434; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Katiyar SK, 1997, J CELL BIOCHEM, P59; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Li JP, 1997, ENDOCRINOLOGY, V138, P2274, DOI 10.1210/en.138.6.2274; LIBERTO M, 1996, CANC LETT, V154, P151; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Mosseri R, 2000, METABOLISM, V49, P321, DOI 10.1016/S0026-0495(00)90132-X; NAKAYAMA M, 1993, ANTIVIR RES, V21, P289, DOI 10.1016/0166-3542(93)90008-7; NOGUCHI T, 1993, FEBS LETT, V328, P145, DOI 10.1016/0014-5793(93)80982-Z; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Robinson KA, 1999, ARCH BIOCHEM BIOPHYS, V365, P211, DOI 10.1006/abbi.1999.1178; Sakagami H, 1997, ANTICANCER RES, V17, P221; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Segasothy M, 1999, QJM-INT J MED, V92, P531, DOI 10.1093/qjmed/92.9.531; SHAFRIR E, 1994, ISRAEL J MED SCI, V30, P32; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; STONER GD, 1995, J CELL BIOCHEM, P169; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Tsiani E, 1998, DIABETES, V47, P1676, DOI 10.2337/diabetes.47.11.1676; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Westergaard N, 1999, ARCH BIOCHEM BIOPHYS, V366, P55, DOI 10.1006/abbi.1999.1181; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	54	347	373	3	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34933	34940		10.1074/jbc.M204672200	http://dx.doi.org/10.1074/jbc.M204672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12118006	hybrid			2022-12-27	WOS:000178117000037
J	Chen, L; Rao, KVN; He, YX; Ramaswamy, K				Chen, L; Rao, KVN; He, YX; Ramaswamy, K			Skin-stage schistosomula of Schistosoma mansoni produce an apoptosis-inducing factor that can cause apoptosis of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRAINING LYMPH-NODES; HOST IMMUNE-RESPONSE; CYTOKINE PRODUCTION; TYPE-2 CYTOKINES; LYMPHOCYTES-T; INFECTION; MICE; CERCARIAE; MACROPHAGES; EXPRESSION	Skin-stage schistosomula of Schistosoma mansoni were found to secrete molecules that are pro-apoptotic for skin T lymphocytes as measured by annexin V staining, caspase-3 activity, caspase-8 activities, and DNA fragmentation. Caspase-8 activities in lymphocytes peaked similar to8 h and caspase-3 activity peaked similar to16 h after exposure to the parasite secretions. Subset analysis showed that mainly CD4(+) and CD8(+) cells (but not B cells) were susceptible to the parasite-induced proapoptotic effect. In situ staining confirmed the presence of apoptotic T cells around challenge parasites in the skin of naive or immunized animals. Analysis of T cells to identify the potential molecular pathway of the parasite-induced apoptosis showed increases in the expression of Fas, FasL, and the Fas-associated death domain. Blocking of FasL with a fusion protein reversed the parasite-induced apoptosis, suggesting a role for the Fas/FasL-mediated pathway in the parasite-induced T cell apoptosis. Subsequent analyses of the secretions of skin-stage schistosomula identified the pro-apoptotic activity as being associated with a protein of similar to23 kDa. This protein was termed S. mansoni-derived apoptosis-inducing factor.	Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA; Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Rockford; Northwestern University	Ramaswamy, K (corresponding author), Univ Illinois, Coll Med, Dept Biomed Sci, 1601 Parkview Ave, Rockford, IL 61107 USA.		Rao, Kola Koteswara/ABE-7163-2021	Rao, Kola Koteswara/0000-0001-6176-7828	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039066, R01AI039066, N01AI055270] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI039066, R01 AI039066-08, R29 AI039066, R01 AI039066-06A2, N01 AI 55270, AI 39066] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDELWAHAB F, 1993, B WORLD HEALTH ORGAN, V71, P657; BENAVIDES GR, 1995, J IMMUNOL METHODS, V181, P145, DOI 10.1016/0022-1759(94)00339-X; Betts CJ, 1998, IMMUNOLOGY, V93, P49, DOI 10.1046/j.1365-2567.1998.00388.x; Carneiro-Santos P, 2000, PARASITE IMMUNOL, V22, P267, DOI 10.1046/j.1365-3024.2000.00294.x; Chen Lin, 2001, Journal of Veterinary Parasitology, V15, P1; Chow SC, 2000, PARASITE IMMUNOL, V22, P21, DOI 10.1046/j.1365-3024.2000.00271.x; Chu CY, 2000, J BIOMED SCI, V7, P58, DOI 10.1159/000025430; COLLEY DG, 1977, INT ARCH ALLER A IMM, V53, P420, DOI 10.1159/000231780; COLLEY DG, 1979, J IMMUNOL, V122, P1447; Damian RT, 1997, PARASITOLOGY, V115, pS169, DOI 10.1017/S0031182097002357; Das G, 1999, SCAND J IMMUNOL, V49, P307, DOI 10.1046/j.1365-3083.1999.00486.x; deAndres B, 1997, BLOOD, V90, P1267, DOI 10.1182/blood.V90.3.1267.1267_1267_1274; DosReis GA, 2001, ADV PARASIT, V49, P133, DOI 10.1016/S0065-308X(01)49039-7; Estaquier J, 1997, BLOOD, V90, P1618, DOI 10.1182/blood.V90.4.1618.1618_1618_1625; Estaquier J, 1997, EUR CYTOKINE NETW, V8, P153; Fallon PG, 1998, EUR J IMMUNOL, V28, P1408, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1408::AID-IMMU1408&gt;3.0.CO;2-H; Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; KOLATA G, 1985, SCIENCE, V227, P285, DOI 10.1126/science.3966154; KROEMER G, 1997, IMMUNOLOGY METHODS M, V2, P1121; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Kumar P., 1999, Parasitology International, V48, P109, DOI 10.1016/S1383-5769(99)00008-2; Lopes MF, 1999, EUR J IMMUNOL, V29, P81, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;81::AID-IMMU81&gt;3.0.CO;2-Y; Lundy SK, 2002, INFECT IMMUN, V70, P812, DOI 10.1128/IAI.70.2.812-819.2002; Lundy SK, 2001, INFECT IMMUN, V69, P271, DOI 10.1128/IAI.69.1.271-280.2001; McKerrow JH, 1997, PARASITOLOGY, V115, pS107, DOI 10.1017/S0031182097001765; MOUNTFORD AP, 1992, IMMUNOLOGY, V75, P250; O'Connell KM, 2000, PARASITOLOGY, V120, P649, DOI 10.1017/S0031182099005971; O'Neill SM, 2000, PARASITE IMMUNOL, V22, P147, DOI 10.1046/j.1365-3024.2000.00290.x; Ojcius DM, 1999, MICROBES INFECT, V1, P1163, DOI 10.1016/S1286-4579(99)00246-4; PEMBERTON RM, 1991, IMMUNOLOGY, V73, P327; Ramaswamy K, 1997, EXP PARASITOL, V86, P118, DOI 10.1006/expr.1997.4178; Ramaswamy K, 1996, J INFLAMM, V46, P13; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Remoue F, 2001, CLIN EXP IMMUNOL, V124, P62, DOI 10.1046/j.1365-2249.2001.01495.x; Rumbley CA, 1998, J IMMUNOL, V161, P4129; Rumbley CA, 1999, MICROBES INFECT, V1, P499, DOI 10.1016/S1286-4579(99)80088-4; Rumbley CA, 2001, AM J TROP MED HYG, V65, P442, DOI 10.4269/ajtmh.2001.65.442; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shin HJ, 2000, CLIN DIAGN LAB IMMUN, V7, P510, DOI 10.1128/CDLI.7.3.510-514.2000; STADECKER MJ, 1990, J IMMUNOL, V145, P2697; Terry R J, 1975, Symp Soc Exp Biol, P453; VIEIRA LQ, 1986, PARASITE IMMUNOL, V8, P333, DOI 10.1111/j.1365-3024.1986.tb00850.x	46	56	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34329	34335		10.1074/jbc.M201344200	http://dx.doi.org/10.1074/jbc.M201344200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107158	Green Accepted, hybrid			2022-12-27	WOS:000177959100104
J	Deng, LW; Ammosova, T; Pumfery, A; Kashanchi, F; Nekhai, S				Deng, LW; Ammosova, T; Pumfery, A; Kashanchi, F; Nekhai, S			HIV-1 tat interaction with RNA polymerase IIC-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; KINASE; BINDING; COMPLEX; PURIFICATION	Human immunodeficiency virus, type I (HIV-1), Tat protein activates viral gene expression through promoting transcriptional elongation by RNA polymerase II (RNAPII). In this process Tat enhances phosphorylation of the C-terminal domain (CTD) of RNAPII by activating cell cycle-dependent kinases (CDKs) associated with general transcription factors of the promoter complex, specifically CDK7 and CDK9. We reported a Tat-associated T-cell-derived kinase, which contained CDK2. Here, we provide further evidence that CDK2 is involved in Tat-mediated CTD phosphorylation and in HIV-1 transcription in vitro. Tat-mediated CTD phosphorylation by CDK2 required cysteine 22 in the activation domain of Tat and amino acids 42-72 of Tat. CDK2 phosphorylated Tat itself, apparently by forming dynamic contacts with amino acids 15-24 and 36-49 of Tat. Also, amino acids 24-36 and 45-72 of Tat interacted with CTD. CDK2 associated with RNAPII and was found in elongation complexes assembled on HIV-1 long-terminal repeat template. Recombinant CDK2/cyclin E stimulated Tat-dependent HIV-1 transcription in reconstituted transcription assay. Immunodepletion of CDK2/cyclin E in HeLa nuclear extract blocked Tat-dependent transcription. We suggest that CDK2 is part of a transcription complex that is required for Tat-dependent transcription and that interaction of Tat with CTD and a dynamic association of Tat with CDK2/cyclin E stimulated CTD phosphorylation by CDK2.	Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Dept Biochem, Washington, DC 20059 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Howard University; Howard University; George Washington University	Nekhai, S (corresponding author), Howard Univ, Ctr Sickle Cell Dis, 2121 Georgia Ave NW, Washington, DC 20059 USA.	snekhai@howard.edu	, nekhai/AFO-2652-2022; , nekhai/AAW-3105-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R29AI044357] Funding Source: NIH RePORTER; NHLBI NIH HHS [UH1 HL 03679] Funding Source: Medline; NIAID NIH HHS [AI 43894, AI 44357] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Huet J, 1996, METHOD ENZYMOL, V273, P249; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LOHMAN TM, 1978, BIOPHYS CHEM, V8, P281, DOI 10.1016/0301-4622(78)80011-8; Majello B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1358, DOI 10.2741/Majello; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nekhai S, 2000, PEPTIDES, V21, P1449, DOI 10.1016/S0196-9781(00)00297-7; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Nekhai S, 2000, VIROLOGY, V266, P246, DOI 10.1006/viro.1999.0035; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; ZHANG J, 1991, J BIOL CHEM, V266, P2297; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	34	79	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33922	33929		10.1074/jbc.M111349200	http://dx.doi.org/10.1074/jbc.M111349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114499	hybrid			2022-12-27	WOS:000177959100054
J	Hendron, E; Patel, P; Hausenfluke, M; Gamper, N; Shapiro, MS; Booth, RE; Stockand, JD				Hendron, E; Patel, P; Hausenfluke, M; Gamper, N; Shapiro, MS; Booth, RE; Stockand, JD			Identification of cytoplasmic domains within the epithelial Na+ channel reactive at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SODIUM-CHANNEL; LIDDLES-SYNDROME; BETA-SUBUNIT; MISSENSE MUTATION; ALPHA-SUBUNIT; ION CHANNELS; WW DOMAINS; PY MOTIF; IN-VIVO	The activity of membrane proteins is controlled, in part, by protein-protein interactions localized to the plasma membrane. In the current study, domains within the epithelial Na+ channel (ENaC) reactive at the plasma membrane were identified using a novel yeast one-hybrid screen. The cytosolic N terminus of alphaENaC and the cytosolic C termini of alpha-, beta-, and gammaENaC contained domains reactive at the plasma membrane. Fluorescent micrographs of epithelial cells overexpressing fusion proteins of enhanced green fluorescent protein and mENaC cytosolic domains were consistent with those in yeast. A novel membrane reactive domain within the cytosolic C terminus of gamma-mENaC was localized to the 17 amino acids between residues Thr(584)-Pro(600). Two overlapping internalization signals within the C terminus of gamma-mENaC, a WW-binding domain (PY motif) and a tyrosine-based endocytic signal, were additive with respect to decreasing complementation and expression levels of hybrid proteins. Decreases in expression levels of hybrid proteins containing the PY and endocytic motif were reversed with latrunculin A, an inhibitor of endosomal movement. Decreases in complementation and expression levels of hybrid proteins mediated by the combined PY and overlapping endocytic motif proceeded in the absence of established ubiquitination sites within ENaC. In addition, the endocytic motif was active in the absence of the PY motif, demonstrating that these two domains, while possibly interacting, also have discrete functions. The novel domains within the cytosolic N terminus of alphaENaC and the C termini of alpha-, beta-, and gammaENaC identified here are likely to be involved in protein-protein and/or protein-lipid interactions localized to the plasma membrane. We hypothesize that these newly identified domains play a role in modulating ENaC activity.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr,7756, San Antonio, TX 78229 USA.			Stockand, James/0000-0002-3817-4319; Gamper, Nikita/0000-0001-5806-0207	NIDDK NIH HHS [R01 DK 59594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Aronheim A, 2000, METHOD ENZYMOL, V328, P47, DOI 10.1016/S0076-6879(00)28389-4; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; Bonny O, 2000, KIDNEY INT, V57, P1313, DOI 10.1046/j.1523-1755.2000.00968.x; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; Dinudom A, 2001, J BIOL CHEM, V276, P13744, DOI 10.1074/jbc.M011273200; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Gupta SS, 2000, FEBS LETT, V481, P77, DOI 10.1016/S0014-5793(00)01977-3; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; Ji HL, 2000, J BIOL CHEM, V275, P27947; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1995, BIOCHEM J, V312, P491, DOI 10.1042/bj3120491; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Munn AL, 2000, MICROSC RES TECHNIQ, V51, P547, DOI 10.1002/1097-0029(20001215)51:6<547::AID-JEMT5>3.0.CO;2-D; PETITJEAN A, 1990, GENETICS, V124, P797; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SHI H, 2002, J BIOL CHEM, V277; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Takacs-Jarrett M, 1998, AM J PHYSIOL-RENAL, V275, pF802, DOI 10.1152/ajprenal.1998.275.5.F802; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Verrey F, 2001, CURR OPIN NEPHROL HY, V10, P39, DOI 10.1097/00041552-200101000-00007; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247	55	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34480	34488		10.1074/jbc.M204615200	http://dx.doi.org/10.1074/jbc.M204615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093811	hybrid			2022-12-27	WOS:000177959100121
J	Kumagai, J; Hsu, SY; Matsumi, H; Roh, JS; Fu, P; Wade, JD; Bathgate, RAD; Hsueh, AJW				Kumagai, J; Hsu, SY; Matsumi, H; Roh, JS; Fu, P; Wade, JD; Bathgate, RAD; Hsueh, AJW			INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSL3 GENE; MUTATIONS; CRYPTORCHIDISM	Several orphan G protein-coupled receptors homologous to gonadotropin and thyrotropin receptors have recently been identified and named as LGR4-8. INSL3, also known as Leydig insulin-like peptide or relaxin-like factor, is a relaxin family member expressed in testis Leydig cells and ovarian theca and luteal cells. Male mice mutant for INSL3 exhibit cryptorchidism or defects in testis descent due to abnormal gubernaculum development whereas overexpression of INSL3 induces ovary descent in transgenic females. Because transgenic mice missing the LGR8 gene are also cryptorchid, INSL3 was tested as the ligand for LGR8. Here, we show that treatment with INSL3 stimulated cAMP production in cells expressing recombinant LGR8 but not LGR7. In addition, interactions between INSL3 and LGR8 were demonstrated following ligand receptor cross-linking. Northern blot analysis indicated that the LGR8 transcripts are expressed in gubernaculum. whereas treatment of cultured gubernacular cells with INSL3 stimulated cAMP production and thymidine incorporation. The present study identified the ligand for an orphan G protein-coupled receptor based on common phenotypes of ligand and receptor null mice. Demonstration of INSL3 as the ligand for LGR8 facilitates understanding of the mechanism of testis descent and allows studies on the role of INSL3 in gonadal and other physiological processes.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia	Stanford University; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.	aaron.hsueh@stanford.edu	Roh, Jaesook/P-1689-2015; Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X; Roh, Jaesook/0000-0002-6286-1071; Wade, John/0000-0002-1352-6568	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adham IM, 2002, MOL ENDOCRINOL, V16, P244, DOI 10.1210/me.16.2.244; Balvers M, 1998, ENDOCRINOLOGY, V139, P2960, DOI 10.1210/en.139.6.2960; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Boockfor FR, 2001, REPRODUCTION, V122, P899, DOI 10.1530/reprod/122.6.899; Bullesbach EE, 1999, J BIOL CHEM, V274, P22354, DOI 10.1074/jbc.274.32.22354; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Ivell R, 1997, Rev Reprod, V2, P133, DOI 10.1530/ror.0.0020133; Koskimies P, 2000, PEDIATR RES, V47, P538, DOI 10.1203/00006450-200004000-00020; Krausz C, 2000, MOL HUM REPROD, V6, P298, DOI 10.1093/molehr/6.4.298; Lim HN, 2001, EUR J ENDOCRINOL, V144, P129, DOI 10.1530/eje.0.1440129; Lynch KR, 1999, NATURE, V399, P789; Marin P, 2001, J ENDOCRINOL INVEST, V24, pRC13, DOI 10.1007/BF03343848; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Overbeek PA, 2001, GENESIS, V30, P26, DOI 10.1002/gene.1029; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Smith KJ, 2001, J PEPT SCI, V7, P495, DOI 10.1002/psc.344; Takahashi T, 2001, PEDIATR INT, V43, P256, DOI 10.1046/j.1442-200x.2001.01390.x; Tomboc M, 2000, J CLIN ENDOCR METAB, V85, P4013, DOI 10.1210/jc.85.11.4013; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	26	322	339	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31283	31286		10.1074/jbc.C200398200	http://dx.doi.org/10.1074/jbc.C200398200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12114498	hybrid			2022-12-27	WOS:000177718700002
J	Vannahme, C; Smyth, N; Miosge, N; Gosling, S; Frie, C; Paulsson, M; Maurer, P; Hartmann, U				Vannahme, C; Smyth, N; Miosge, N; Gosling, S; Frie, C; Paulsson, M; Maurer, P; Hartmann, U			Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NULL MICE EXHIBIT; GROWTH-FACTOR; CRYSTAL-STRUCTURE; ZONA-PELLUCIDA; PROTEOGLYCAN SPOCK; SPARC; FOLLISTATIN; EXPRESSION; BM-40; DEFICIENT	We have isolated the novel gene SMOC-1 that encodes a secreted modular protein containing an EF-hand calcium-binding domain homologous to that in BM-40. It further consists of two thyroglobulin-like domains, a follistatin-like domain and a novel domain. Recombinant expression in human cells showed that SMOC-1 is a glycoprotein with a calcium-dependent conformation. Results from Northern blots, reverse transcriptase-PCR, and immunoblots revealed a widespread expression in many tissues. Immunofluorescence studies with an antiserum directed against recombinant human SMOC-1 demonstrated a basement membrane localization of the protein and additionally its presence in other extracellular matrices. Immunogold electron microscopy confirmed the localization of SMOC-1 within basement membranes in kidney and skeletal muscle as well as its expression in the zona pellucida surrounding the oocyte.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Univ Gottingen, Dept Histol, Ctr Anat, D-37075 Gottingen, Germany	University of Cologne; University of Gottingen	Hartmann, U (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	ursula.hartmann@uni-koeln.de	Miosge, Nicolai/E-3244-2010	Smyth, Neil/0000-0002-3734-2149				ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; BaSalamah MAM, 2001, BIOCHEM BIOPH RES CO, V283, P1083, DOI 10.1006/bbrc.2001.4900; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; Bonnet F, 1996, J BIOL CHEM, V271, P4373; BONNET F, 1992, BIOCHEM J, V288, P565, DOI 10.1042/bj2880565; Bradshaw AD, 2002, J HISTOCHEM CYTOCHEM, V50, P1; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Charbonnier F, 2000, MECH DEVELOP, V90, P317, DOI 10.1016/S0925-4773(99)00255-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cifuentes-Diaz C, 2000, MECH DEVELOP, V94, P277, DOI 10.1016/S0925-4773(00)00285-9; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; Eib DW, 1996, J NEUROCHEM, V67, P1047; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Eppig John J., 1997, Human Reproduction (Oxford), V12, P127; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; Girard JP, 1996, J BIOL CHEM, V271, P4511; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; LENARCIC B, BIOL CHEM HOPPESEYLE, V379, P105; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; Marr HS, 1997, ENDOTHELIUM-NEW YORK, V5, P209, DOI 10.3109/10623329709053399; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MAURER P, 1996, GUIDEBOOK CALCIUM BI, P169; McKinnon PJ, 1996, BRAIN RES, V709, P27, DOI 10.1016/0006-8993(95)01224-9; McKinnon PJ, 2000, MOL CELL BIOL, V20, P656, DOI 10.1128/MCB.20.2.656-660.2000; Miosge N, 2000, J HISTOCHEM CYTOCHEM, V48, P229, DOI 10.1177/002215540004800208; Miosge N, 2001, HISTOL HISTOPATHOL, V16, P1239, DOI 10.14670/HH-16.1239; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; Nakada M, 2001, CANCER RES, V61, P8896; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nischt R, 2001, CANCER LETT, V162, P223, DOI 10.1016/S0304-3835(00)00659-5; Norose K, 2000, EXP EYE RES, V71, P295, DOI 10.1006/exer.2000.0884; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; Rankin T, 2000, REV REPROD, V5, P114, DOI 10.1530/ror.0.0050114; Rankin TL, 2001, DEVELOPMENT, V128, P1119; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Savani RC, 2000, AM J PHYSIOL-LUNG C, V279, pL743, DOI 10.1152/ajplung.2000.279.4.L743; Schneyer A, 2001, MOL CELL ENDOCRINOL, V180, P33, DOI 10.1016/S0303-7207(01)00501-9; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200; Strandjord TP, 1999, AM J PHYSIOL-LUNG C, V277, pL628, DOI 10.1152/ajplung.1999.277.3.L628; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Towers P, 1999, DEV BIOL, V214, P298, DOI 10.1006/dbio.1999.9421; TSCHESCHE H, 1987, BIOL CHEM H-S, V368, P1297, DOI 10.1515/bchm3.1987.368.2.1297; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	67	81	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37977	37986		10.1074/jbc.M203830200	http://dx.doi.org/10.1074/jbc.M203830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12130637	hybrid			2022-12-27	WOS:000178529600003
J	Zanetta, JP; Bindeus, R; Normand, G; Durier, V; Lagant, P; Maes, E; Vergoten, G				Zanetta, JP; Bindeus, R; Normand, G; Durier, V; Lagant, P; Maes, E; Vergoten, G			Evidence for a lectin activity for human interleukin 3 and modeling of its carbohydrate recognition domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; ALPHA-CHAIN; BETA-CHAIN; IN-VITRO; GM-CSF; BINDING; RECEPTOR; OLIGOSACCHARIDES; NITROCELLULOSE	We demonstrate that human interleukin 3 (IL-3) is a lectin recognizing specifically the glycosaminoglycan part of a chondroitin sulfate proteoglycan (PGS3; Normand, G., Kuchler, S., Meyer, A., Vincendon, G., and Zanetta, J. P. (1988) J. Neurochem. 51, 665-676) isolated from the adult rat brain. The specificity of the interaction of this particular proteoglycan with IL-3 is due to the abundance of GlcA(2S)beta1,3GalNAc(4S)beta1 disaccharide units as suggested by H-1 NMR. Computational docking experiments of the lower energy conformers of the different disaccharides from chondroitin sulfates reveal a privileged binding site for GlcA(2S)beta1,3GalNAc(4S)beta1 (involving His-26, Arg-29, Asn-70, and Trp-104) localized in an area of IL-3 different from the receptor-binding domain previously identified by others (Bagley, C. J., Phillips, J., Cambareri, B., Vadas, M. A., and Lopez, A. F. (1996) J. Biol. Chem. 271, 31922-31928). Molecular modeling of the mutation P33G, described as increasing the biological activity of IL-3 without affecting its receptor binding (Lokker, N. A., Movva, N. R., Strittmatter, U., Fagg, B., and Zenke, G. (1991) J. Biol. Chem. 266,1062410631) provokes a change of the three-dimensional structure of IL-3, especially in the area of the putative carbohydrate recognition domain defined above. Computational docking experiments of the different disaccharides of chondroitin sulfates indicate a loss of affinity for the previous ligand but a higher affinity for the classic disaccharide of chondroitin-4-sulfate. This change from a rare and specific ligand to a more abundant constituent of proteoglycans could induce an increased quantitative association between the IL-3 receptors and its ligands and, consequently, an increased signaling.	Univ Sci & Tech Lille Flandres Artois, CNRS, UMR 8576, F-59655 Villeneuve Dascq, France; Hop Univ Strasbourg, INSERM, EPI9918, F-67091 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Zanetta, JP (corresponding author), Univ Sci & Tech Lille Flandres Artois, CNRS, UMR 8576, Batiment C9, F-59655 Villeneuve Dascq, France.	Jean-Pierre.Zanetta@univ-lille1.fr						ARORA N, 1993, INT ARCH ALLERGY IMM, V100, P319, DOI 10.1159/000236432; Bagley CJ, 1996, J BIOL CHEM, V271, P31922, DOI 10.1074/jbc.271.50.31922; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BRUNNGRABER EG, 1969, J NEUROCHEM, V16, P1059, DOI 10.1111/j.1471-4159.1969.tb05950.x; Cebo C, 2002, J BIOL CHEM, V277, P12246, DOI 10.1074/jbc.M106816200; Cebo C, 2001, J BIOL CHEM, V276, P5685, DOI 10.1074/jbc.M008662200; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; CLARKE D, 1995, CYTOKINE, V7, P325, DOI 10.1006/cyto.1995.0041; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; DISCHE Z, 1947, J BIOL CHEM, V167, P189; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; Drickamer K, 1997, STRUCTURE, V5, P465, DOI 10.1016/S0969-2126(97)00202-5; ENDO M, 1979, TOHOKU J EXP MED, V129, P225, DOI 10.1620/tjem.129.225; Feng YP, 1996, J MOL BIOL, V259, P524, DOI 10.1006/jmbi.1996.0337; Feng YQ, 1997, PROTEIN SCI, V6, P1777, DOI 10.1002/pro.5560060821; FINNE J, 1979, J BIOL CHEM, V254, P295; FORSBERG LS, 1988, BIOCHIM BIOPHYS ACTA, V967, P416, DOI 10.1016/0304-4165(88)90105-5; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; Gupta P, 2000, BLOOD, V95, P147; Gustin SE, 2001, EUR J BIOCHEM, V268, P2905, DOI 10.1046/j.1432-1327.2001.02178.x; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kinoshita A, 2001, BIOCHEMISTRY-US, V40, P12654, DOI 10.1021/bi015577n; Klein BK, 1997, J BIOL CHEM, V272, P22630, DOI 10.1074/jbc.272.36.22630; Klein BK, 1999, EXP HEMATOL, V27, P1746, DOI 10.1016/S0301-472X(99)00118-6; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KONISHI Y, 1995, J NEUROSCI RES, V41, P572, DOI 10.1002/jnr.490410503; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOKKER NA, 1991, J BIOL CHEM, V266, P10624; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; Lortat-Jacob H, 1997, CYTOKINE, V9, P101, DOI 10.1006/cyto.1996.0142; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Najjam S, 1997, CYTOKINE, V9, P1013, DOI 10.1006/cyto.1997.0246; NORMAND G, 1988, J NEUROCHEM, V51, P665, DOI 10.1111/j.1471-4159.1988.tb01796.x; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROTHENBERG ME, 1989, ANN NY ACAD SCI, V556, P233; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; SUZUKI K, 1964, LIFE SCI, V3, P1227, DOI 10.1016/0024-3205(64)90040-2; Tabira T, 1998, ANN NY ACAD SCI, V840, P107, DOI 10.1111/j.1749-6632.1998.tb09554.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wen TC, 1998, J EXP MED, V188, P635, DOI 10.1084/jem.188.4.635; Zanetta JP, 1999, GLYCOCONJUGATE J, V16, P617, DOI 10.1023/A:1007076900562; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049; ZANETTA JP, IN PRESS BIOCH BIOPH	54	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38764	38771		10.1074/jbc.M205282200	http://dx.doi.org/10.1074/jbc.M205282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12093816	hybrid			2022-12-27	WOS:000178529600096
J	Davaille, J; Li, LY; Mallat, A; Lotersztajn, S				Davaille, J; Li, LY; Mallat, A; Lotersztajn, S			Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY PROPERTIES; NECROSIS-FACTOR-ALPHA; STELLATE CELLS; ENDOTHELIAL-CELLS; MEDIATED PATHWAY; KINASE PATHWAYS; LIVER FIBROSIS; RECEPTOR EDG-1; ITO CELLS; SPHINGOSINE-1-PHOSPHATE	Hepatic myofibroblasts (hMFs) are central in the development of liver fibrosis during chronic liver diseases, and their removal by apoptosis contributes to the resolution of liver fibrosis. We previously identified Edg receptors for sphingosine 1-phosphate (S1P) in human hMFs. Here, we investigated the effects of S1P on hMF apoptosis. S1P reduced viability of serum-deprived hMFs by an apoptotic process that was unrelated to the conversion of S1P into sphingosine and ceramide. The apoptotic effects of S1P were receptor-independent because dihydro-S1P, an Edg agonist, had no effect. S1P also stimulated a receptor-dependent survival pathway, revealed by enhanced activation of caspase-3 by S1P in the presence of pertussis toxin. Cell survival relied on two pertussis toxin-sensitive events, activation of ERK and activation of phosphatidylinositol 3-kinase (PI3K)/Akt by S1P. Both pathways were also activated by dihydro-S1P. Blunting either ERK or PI3K enhanced caspase-3 stimulation by S1P, and simultaneous inhibition of both pathways resulted in additive effects on caspase-3 activation. In conclusion, S1P induces apoptosis of human hMFs via a receptor-independent mechanism and stimulates a survival pathway following activation of Edg receptors. The survival pathway arises from the sequential activation of G(i)/G(o) proteins and independent stimulations of ERK and PI3K/Akt. Therefore, blocking Edg receptors may sensitize hepatic myofibroblasts to apoptosis by S1P.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Lotersztajn, Sophie/K-9160-2017	lotersztajn, Sophie/0000-0002-0053-7807				An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chin TY, 2002, MOL PHARMACOL, V61, P486, DOI 10.1124/mol.61.3.486; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Fischer R, 2001, GASTROENTEROLOGY, V120, P1212, DOI 10.1053/gast.2001.23260; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gennero I, 2002, J BIOL CHEM, V277, P12724, DOI 10.1074/jbc.M108933200; Gong WR, 1998, HEPATOLOGY, V28, P492, DOI 10.1002/hep.510280229; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hatano E., 2002, AM J PHYSIOL-GASTR L, V282, pG1357; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Iwamoto H, 1999, J LAB CLIN MED, V134, P83, DOI 10.1016/S0022-2143(99)90057-4; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kinloch RA, 1999, TRENDS PHARMACOL SCI, V20, P35, DOI 10.1016/S0165-6147(98)01277-2; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li LY, 2001, J BIOL CHEM, V276, P38152; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	47	83	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37323	37330		10.1074/jbc.M202798200	http://dx.doi.org/10.1074/jbc.M202798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138095	hybrid			2022-12-27	WOS:000178447100054
J	Hadri, L; Ozog, A; Soncin, F; Lompre, AM				Hadri, L; Ozog, A; Soncin, F; Lompre, AM			Basal transcription of the mouse sarco(endo)plasmic reticulum Ca2+-ATPase type 3 gene in endothelial cells is controlled by Ets-1 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP EXPRESSION; MESSENGER-RNA; TRANSGENIC MICE; BINDING-SITES; SMOOTH-MUSCLE; CHICK-EMBRYO; SARCOPLASMIC-RETICULUM; DEPENDENT RELAXATION; TISSUE DISTRIBUTION; CA-2+-ATPASE GENE	We reported previously that the sarco(endo)plasmic reticulum Ca2+-ATPase type 3 (SERCA3) gene is expressed in many tissues and in a subset of cells such as endothelial, epithelial, and lymphoid lineages. Here we analyzed the mechanisms involved in the regulation of transcription of the SERCA3 gene in endothelial cells. The promoter of the murine SERCA3 gene was isolated, and a single transcription initiation site located 301 bp upstream of the translation initiation site was identified. Analysis of the transcriptional activity of fragments of the SERCA3 promoter showed the existence of a minimal promoter region located between bases -97 and +153 that contains one ETS-binding site (EBS) and two Sp1 elements that are essential for basal transcription. Mutation of the EBS or of the Sp1 sites abolished the basal activity of the promoter. We identified Ets-1 and Sp1 among endothelial nuclear factors that recognize the EBS and Sp1 sites on the promoter. Furthermore, transactivation of the -97/+301 promoter fragment by Ets-1 requires the presence of both the EBS and Sp1 sites, suggesting an interaction of the transcription factors on the gene promoter. Finally, overexpression. of Ets-1 induced the expression of SERCA3 in endothelial cells and in fibroblasts.	INSERM, U446 Biochim, Fac Pharm, F-92296 Chatenay Malabry, France; Univ Paris 11, CNRS, EP 1088, F-91405 Orsay, France; Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Lompre, AM (corresponding author), INSERM, U446 Biochim, Fac Pharm, IFR-75,Tour D4,5 Rue JB Clement, F-92296 Chatenay Malabry, France.		SONCIN, Fabrice/A-1475-2009; Hadri, Lahouaria/AAP-6415-2020; LOMPRE, Anne-Marie/H-2872-2013	SONCIN, Fabrice/0000-0001-6312-0673; Hadri, Lahouaria/0000-0001-8108-7993; 				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; Anderson MK, 1999, DEVELOPMENT, V126, P3131; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; Fuentes JM, 2000, ANAL BIOCHEM, V285, P276, DOI 10.1006/abio.2000.4784; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Huang X, 1991, ADV APPL MATH, V12, P373; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; Kappel A, 2000, BLOOD, V96, P3078; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 1997, J BIOL CHEM, V272, P10746; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; Lompre AM, 1998, TRENDS CARDIOVAS MED, V8, P75, DOI 10.1016/S1050-1738(97)00130-8; Mager AM, 1998, INT J DEV BIOL, V42, P561; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; MOUTAIN I, 2001, HYPERTENSION, V37, P135; MOUTIAN I, 1999, CELL CALCIUM, V25, P371; Ozog A, 1998, FEBS LETT, V427, P349, DOI 10.1016/S0014-5793(98)00464-5; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; POGNONEC P, 1990, ONCOGENE, V5, P603; QUEVA C, 1993, ONCOGENE, V8, P2511; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Simonides WS, 1996, J BIOL CHEM, V271, P32048, DOI 10.1074/jbc.271.50.32048; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; VICART P, 1994, EXP CELL RES, V214, P35, DOI 10.1006/excr.1994.1231; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Wuytack F, 1995, BIOSCIENCE REP, V15, P299, DOI 10.1007/BF01788362; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	53	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36471	36478		10.1074/jbc.M204731200	http://dx.doi.org/10.1074/jbc.M204731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119294	hybrid			2022-12-27	WOS:000178275100089
J	Kido, Y; Nakae, J; Hribal, ML; Xuan, SH; Efstratiadis, A; Accili, D				Kido, Y; Nakae, J; Hribal, ML; Xuan, SH; Efstratiadis, A; Accili, D			Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; FACTOR-I RECEPTOR; SKELETAL-MUSCLE; IGF-I; MOUSE PANCREAS; TARGETED DISRUPTION; ENDOCRINE PANCREAS; GLYCOGEN-SYNTHESIS; GENE-EXPRESSION; MICE LACKING	Insulin and insulin-like growth factors (IGF) play overlapping and complementary roles in pancreatic beta-cell function and peripheral metabolism. In this study, we have analyzed mice bearing loss-of-function mutations of the insulin/IGF signaling systems. Combined inactivation of insulin receptor (Insr) and Igf1 receptor (Igf1r), but not of either receptor alone, resulted in a 90% decrease in the size of the exocrine pancreas, because of decreased cellular proliferation. In contrast to the findings in the exocrine compartment, endocrine alpha- and beta-cell development was unperturbed. Combined ablation of Igf1 and Igf2, the ligands for these two receptors, resulted in an identical phenotype. We also examined the effect of heterozygous null Igf1r mutations on glucose homeostasis in adult mice. Igf1r haploinsufficiency did not affect insulin action and compensatory beta-cell growth in insulin-resistant mice with combined Insr and Igf1r heterozygous null mutations, resulting in a considerably milder phenotype than combined haploinsufficiency for Insr and its main signaling substrates, Irs1 and Irs2. We conclude that Igf1r and Insr are required for embryonic development of the exocrine but not of the endocrine pancreas and that defects of Igf1r do not alter glucose homeostasis as long as the insulin receptor system remains intact.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Accili, D (corresponding author), Berrie Res Pavil,1150 St Nicholas Ave,Rm 238, New York, NY 10032 USA.		Nakae, Jun/Q-6141-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057539, R37DK058282, R01DK058282] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57539, DK58282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2001, J CLIN INVEST, V108, P1575, DOI 10.1172/JCI200114454; Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Accili Domenico, 2001, Current Molecular Medicine (Hilversum), V1, P9, DOI 10.2174/1566524013364040; Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BILAN PJ, 1991, ADV EXP MED BIOL, V293, P273; Bonner-Weir S, 2000, ENDOCRINOLOGY, V141, P1926, DOI 10.1210/en.141.6.1926; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Devedjian JC, 2000, J CLIN INVEST, V105, P731, DOI 10.1172/JCI5656; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; DOHM GL, 1990, DIABETES, V39, P1028, DOI 10.2337/diabetes.39.9.1028; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; George M, 2002, J CLIN INVEST, V109, P1153, DOI 10.1172/JCI200212969; Gittes GK, 1996, DEVELOPMENT, V122, P439; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Jullien D, 1996, DIABETES, V45, P869, DOI 10.2337/diabetes.45.7.869; KallooHosein HE, 1997, J BIOL CHEM, V272, P24325, DOI 10.1074/jbc.272.39.24325; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kido Y, 2000, DIABETES, V49, P589, DOI 10.2337/diabetes.49.4.589; Kim JJ, 2001, ENDOCRINOLOGY, V142, P3354, DOI 10.1210/en.142.8.3354; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; KULKARNI RN, 2000, GENETIC MANIPULATION, P129; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Le Bras S, 1998, DIABETES, V47, P1236, DOI 10.2337/diabetes.47.8.1236; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Ludwig CU, 1999, AM J PHYSIOL-GASTR L, V276, pG193, DOI 10.1152/ajpgi.1999.276.1.G193; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Maldonado TS, 2000, J GASTROINTEST SURG, V4, P269, DOI 10.1016/S1091-255X(00)80075-X; Miralles F, 1998, DEVELOPMENT, V125, P1017; Miralles F, 1998, J CELL BIOL, V143, P827, DOI 10.1083/jcb.143.3.827; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Offield MF, 1996, DEVELOPMENT, V122, P983; Park BC, 1999, BIOCHEMISTRY-US, V38, P7517, DOI 10.1021/bi9830718; Rose MI, 1999, J PEDIATR SURG, V34, P774, DOI 10.1016/S0022-3468(99)90372-X; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SANVITO F, 1994, DEVELOPMENT, V120, P3451; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; VILA MR, 1995, LAB INVEST, V73, P409; WILLIAMS JA, 1984, AM J PHYSIOL, V246, pG96, DOI 10.1152/ajpgi.1984.246.1.G96; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wojtaszewski JFP, 1999, J CLIN INVEST, V104, P1257, DOI 10.1172/JCI7961; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	72	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36740	36747		10.1074/jbc.M206314200	http://dx.doi.org/10.1074/jbc.M206314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12101187	hybrid			2022-12-27	WOS:000178275100121
J	Mirshahi, T; Mittal, V; Zhang, H; Linder, ME; Logothetis, DE				Mirshahi, T; Mittal, V; Zhang, H; Linder, ME; Logothetis, DE			Distinct sites on G protein beta gamma subunits regulate different effector functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DEPENDENT ACTIVATION; CALCIUM-CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; IDENTIFICATION; INHIBITION; MODULATION; RESOLUTION; RESIDUES; ALPHA	G proteins interact with effectors at multiple sites and regulate their activity. The functional significance of multiple contact points is not well understood. We previously identified three residues on distinct surfaces of Gbetagamma that are crucial for G protein-coupled inward rectifier K+ (GIRK) channel activation. Here we show that mutations at these sites, S67K, S98T, and T128F, abolished or reduced direct GIRK current activation in inside-out patches, but, surprisingly, all mutants synergized with sodium in activating K+ currents. Each of the three Gbeta(1) mutants bound the channel indicating that the defects reflected mainly functional impairments. We tested these mutants for functional interactions with effectors other than K+ channels. With N-type calcium channels, Gbetagamma wild type and mutants all inhibited basal currents. A depolarizing pre-pulse relieved Gbetagamma inhibition of Ca2+ currents by the wild type and the S98T and T128F mutants but not the S67K mutant. Both wild type and mutant Gbetagamma subunits activated phospholipase C 6, with similar potencies; however, the S67K mutant showed reduced maximal activity. These data establish a pattern where mutations can alter the Gbetagamma regulation of a specific effector function without affecting other Gbetagamma-mediated functions. Moreover, Ser-67 showed this pattern in all three effectors tested, suggesting that this residue participates in a common functional domain on Gbeta(1) that regulates several effectors. These data show that distinct domains within Gbetagamma subserve specific functional roles.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Icahn School of Medicine at Mount Sinai; New York University; Washington University (WUSTL)	Logothetis, DE (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.	Diomedes@inka.mssm.edu	Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NHLBI NIH HHS [HL10307, HL 54185] Funding Source: Medline; NIGMS NIH HHS [GM51466] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010307, R01HL054185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Morris AJ, 1997, BIOCHEM PHARMACOL, V54, P429, DOI 10.1016/S0006-2952(97)00032-4; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	22	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36345	36350		10.1074/jbc.M205359200	http://dx.doi.org/10.1074/jbc.M205359200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124391	hybrid			2022-12-27	WOS:000178275100072
J	Munoz, E; Brewer, M; Baler, R				Munoz, E; Brewer, M; Baler, R			Circadian transcription - Thinking outside the E-Box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; C-MYC; GENE-EXPRESSION; REGULATORY ELEMENTS; FIRST INTRON; IN-VIVO; PROMOTER; LOOP; UPSTREAM; PROTEINS	The E-Box is a widely used DNA control element. Despite its brevity and broad distribution the E-Box is a remarkably versatile sequence that affects many different genetic programs, including proliferation, differentiation, tissue-specific responses, and cell death. The circadian clock is one of the latest pathways shown to employ this element. In this context, E-Boxes are likely to play a key role in establishing the robust waves of gene expression characteristic of circadian transcription. The regulatory flexibility of the E-Box hinges on the sequence ambiguity allowed at its core, the strong influence of the surrounding sequences, and the recruitment of spatially and temporally regulated E-Box-binding factors. Therefore, understanding how a particular E-Box can accomplish a specific task entails the identification and systematic analysis of these cis- and transacting E-Box modifiers. In the present study we compared the E-Box-containing minimal promoters of vasopressin and cyclin B1, two genes that can respond to the transcriptional oscillators driving the circadian clock and cell cycle, respectively. Results of this comparison will help elucidate the manner in which discreet DNA modules associate to either augment or restrain the activation of potential circadian E-Boxes in response to competing regulatory signals.	NIMH, Unit Temporal Gene Express, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Baler, R (corresponding author), NIH, Bldg 36,Rm 2A-09, Bethesda, MD 20892 USA.			Munoz, Estela/0000-0002-6701-1535	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002767] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; BARGMANN WOLFGANG, 1951, AMER SCI, V39, P255; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Camara-Clayette V, 1999, BIOCHEM BIOPH RES CO, V265, P170, DOI 10.1006/bbrc.1999.1634; Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1; Chong NW, 2000, J BIOL CHEM, V275, P32991, DOI 10.1074/jbc.M005671200; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coulson JM, 1999, BIOCHEM J, V344, P961, DOI 10.1042/0264-6021:3440961; Darlington TK, 2000, J BIOL RHYTHM, V15, P462, DOI 10.1177/074873000129001576; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Farina A, 1996, ONCOGENE, V13, P1287; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; FUNK WD, 1991, MOL BIOL MED, V8, P185; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Grace CO, 1999, NEUROPEPTIDES, V33, P81, DOI 10.1054/npep.1999.0018; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang J, 1996, MOL CELL BIOL, V16, P3893; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kraner SD, 1998, J BIOL CHEM, V273, P11327, DOI 10.1074/jbc.273.18.11327; Kyriacou CP, 2000, J BIOL RHYTHM, V15, P483, DOI 10.1177/074873000129001594; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Littlewood T D, 1990, Adv Dent Res, V4, P69; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Lyons LC, 2000, J BIOL RHYTHM, V15, P472, DOI 10.1177/074873000129001585; McDonald MJ, 2001, MOL CELL BIOL, V21, P1207, DOI 10.1128/MCB.21.4.1207-1217.2001; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ripperger JA, 2000, GENE DEV, V14, P679; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493; Wang YG, 2000, INT FED INFO PROC, V47, P161; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	54	64	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36009	36017		10.1074/jbc.M203909200	http://dx.doi.org/10.1074/jbc.M203909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130638	hybrid			2022-12-27	WOS:000178275100032
J	Mayordomo, I; Estruch, F; Sanz, P				Mayordomo, I; Estruch, F; Sanz, P			Convergence of the target of rapamycin and the Snf1 protein kinase pathways in the regulation of the subcellular localization of Msn2, a transcriptional activator of STRE (stress response element)-regulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; GLUCOSE REPRESSION; PHOSPHATASE TYPE-1; SHUTTLE VECTORS; YEAST; TOR; SUBUNIT; EXPRESSION; GLC7	The subcellular localization of Msn2, a transcriptional activator of STRE (stress response element)-regulated genes, is modulated by carbon source availability. In cells growing in glucose, Msn2 is located mainly in the cytosol, whereas in carbon source-starved cells, Msn2 is located largely inside the nucleus. However, in cells lacking Reg1 (the regulatory subunit of the Reg1/Glc7 protein phosphatase complex), the regulation of subcellular distribution is absent, Msn2 being constitutively present in the cytosol. The localization defect in these mutants is specific for carbon starvation stress, and it is because of the presence of an abnormally active Snf1 protein kinase that inhibits the nuclear localization of Msn2 upon carbon starvation. Active Snf1 kinase is also able to avoid the effects of rapamycin, a drug that by inhibiting the TOR kinase pathway leads to a nuclear localization of Msn2 in wild type cells. Therefore, active Snf1 and the TOR kinase pathway may affect similar cytosolic steps in the regulation of the subcellular localization of Msn2.	CSIC, Inst Biomed Valencia, Valencia 46010, Spain; Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; CSIC, Inst Agroquim & Tecnol Alimentos, Dept Biotechnol, E-46100 Burjassot, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of Valencia; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Sanz, P (corresponding author), CSIC, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Sanz, Pascual/K-2751-2014	Sanz, Pascual/0000-0002-2399-4103				Alms GR, 1999, EMBO J, V18, P4157, DOI 10.1093/emboj/18.15.4157; Amoros M, 2001, MOL MICROBIOL, V39, P1523, DOI 10.1046/j.1365-2958.2001.02339.x; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Brocard C, 2001, YEAST, V18, pS178; CANNON JF, 1994, GENETICS, V136, P485; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Cutler NS, 1999, MOL CELL ENDOCRINOL, V155, P135, DOI 10.1016/S0303-7207(99)00121-5; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frederick DL, 1996, MOL CELL BIOL, V16, P2922; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Garreau H, 2000, MICROBIOL-UK, V146, P2113, DOI 10.1099/00221287-146-9-2113; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Huang DQ, 1996, GENETICS, V143, P119; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; RANDEZGIL F, 1995, J CEREAL SCI, V21, P185, DOI 10.1016/0733-5210(95)90034-9; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; ROSE MD, 1990, METHODS YEAST GENETI, P164; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Vincent O, 1999, EMBO J, V18, P6672, DOI 10.1093/emboj/18.23.6672; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700	45	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35650	35656		10.1074/jbc.M204198200	http://dx.doi.org/10.1074/jbc.M204198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093809	hybrid			2022-12-27	WOS:000178117000125
J	Mohajeri, MH; Wollmer, MA; Nitsch, RM				Mohajeri, MH; Wollmer, MA; Nitsch, RM			A beta(42)-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; BRAIN A-BETA; ALZHEIMER-DISEASE; EXTRACELLULAR LEVELS; PRECURSOR PROTEIN; MESSENGER-RNA; APP MUTATIONS; BLOOD-BRAIN; MOUSE MODEL; EXPRESSION	Brain beta-amyloid plaques are principal targets for the development of treatments designed to slow the progression of Alzheimer's disease. Intracranial injections of synthetic beta-amyloid peptide (Abeta(42)) in transgenic mice expressing the Alzheimer's disease-causing Swedish APP double mutations increased neuronal levels of neprilysin, a metalloendopeptidase that degrades Abeta(42) in vivo, on mRNA and protein level. This increase was associated with significant reductions in brain levels of Abeta and with almost complete prevention of amyloid plaque formation throughout the brain. In addition, astrogliosis normally associated with amyloidosis was significantly reduced. Our results suggest that up-regulation of neprilysin in brain may represent an opportunity to reduce or prevent amyloid plaque formation in vivo.	Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland	University of Zurich	Mohajeri, MH (corresponding author), Univ Zurich, Div Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.	mohajeri@bli.unizh.ch	Wollmer, Marc A/B-5038-2009					Akiyama H, 2001, BRAIN RES, V902, P277, DOI 10.1016/S0006-8993(01)02390-3; Alvarez R, 1999, J NEUROL NEUROSUR PS, V67, P733, DOI 10.1136/jnnp.67.6.733; Amouyel P, 2000, ANN NY ACAD SCI, V903, P437, DOI 10.1111/j.1749-6632.2000.tb06395.x; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Eckert A, 1999, PAIN, V83, P487, DOI 10.1016/S0304-3959(99)00152-9; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Glabe C, 2000, NAT MED, V6, P133, DOI 10.1038/72215; Hama E, 2001, J BIOCHEM-TOKYO, V130, P721, DOI 10.1093/oxfordjournals.jbchem.a003040; HENKEN DB, 1990, NEUROSCIENCE, V39, P733, DOI 10.1016/0306-4522(90)90257-5; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kane MD, 2000, J NEUROSCI, V20, P3606, DOI 10.1523/JNEUROSCI.20-10-03606.2000; LI CW, 1995, J BIOL CHEM, V270, P5723, DOI 10.1074/jbc.270.11.5723; Li CW, 1998, ARCH BIOCHEM BIOPHYS, V358, P189, DOI 10.1006/abbi.1998.0855; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Lu B, 1996, ANN NY ACAD SCI, V780, P156, DOI 10.1111/j.1749-6632.1996.tb15119.x; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Yamamoto Y, 2000, PEPTIDES, V21, P503, DOI 10.1016/S0196-9781(00)00174-1; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Yasojima K, 2001, BRAIN RES, V919, P115, DOI 10.1016/S0006-8993(01)03008-6; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	44	60	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35460	35465		10.1074/jbc.M202899200	http://dx.doi.org/10.1074/jbc.M202899200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105192	hybrid			2022-12-27	WOS:000178117000102
J	Chang, JH; Kim, HC; Hwang, KY; Lee, JW; Jackson, SP; Bell, SD; Cho, Y				Chang, JH; Kim, HC; Hwang, KY; Lee, JW; Jackson, SP; Bell, SD; Cho, Y			Structural basis for the NAD-dependent deacetylase mechanism of Sir2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENCING PROTEIN SIR2; SACCHAROMYCES-CEREVISIAE; LONGEVITY; PROGRAM; FAMILY; P53	The NAD-dependent histone/protein deacetylase activity of Sir2 (silent information regulator 2) accounts for its diverse biological roles including gene silencing, DNA damage repair, cell cycle regulation, and life span extension. We provide crystallographic evidence that 2'-O-acetyl ADP-ribose is the reaction product that is formed at the active site of Sir2 from the 2.6-Angstrom co-crystal structure of 2'-O-acetyl-ADP-ribose and Sir2 from Archaeoglobus fulgidus. In addition, we show that His-116 and Phe-159 play critical roles in the catalysis and substrate recognition. The conserved Ser-24 and Asp-101 contribute to the stability for NAD binding rather than being directly involved in the catalysis. The crystal structures of wild type and mutant derivatives of Sir2, in conjunction with biochemical analyses of the mutants, provide novel insights into the reaction mechanism of Sir2-mediated deacetylation.	Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Sturct Biol, Pohang 790784, KyungBook, South Korea; Canc Res United Kingdom Inst Canc & Dev, Wellcome Trust, Cambridge CB2 1QR, England; MRC, Canc Cell Unit, Cambridge CB2 2XZ, England	Pohang University of Science & Technology (POSTECH); Cancer Research UK; Wellcome Trust Sanger Institute	Cho, Y (corresponding author), Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Sturct Biol, Hyoja Dong,San31, Pohang 790784, KyungBook, South Korea.	yunje@postech.ac.kr	Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Bell, Stephen/0000-0002-8474-6592				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Defossez PA, 1998, CURR OPIN MICROBIOL, V1, P707, DOI 10.1016/S1369-5274(98)80119-7; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LETHERBARROW RJ, 1987, ENZFITTER NONLINEAR; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STETTER KO, 1988, SYST APPL MICROBIOL, V10, P172, DOI 10.1016/S0723-2020(88)80032-8; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	34	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34489	34498		10.1074/jbc.M205460200	http://dx.doi.org/10.1074/jbc.M205460200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091395	hybrid			2022-12-27	WOS:000177959100122
J	Gidekel, S; Bergman, Y				Gidekel, S; Bergman, Y			A unique developmental pattern of Oct-3/4 DNA methylation is controlled by a cis-demodification element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC DEMETHYLATION; TRANSCRIPTION FACTOR; MOUSE EMBRYO; GENE-EXPRESSION; CHROMATIN-STRUCTURE; STEM-CELLS; POU-DOMAIN; BINDING; SITES; CHROMOSOME	Oct-3/4 is the earliest expressed transcription factor that is known to be crucial in murine pre-implantation development. In this report we asked whether methylation participates in controlling changes in Oct-3/4 expression and thus may play an important role in controlling normal embryogenesis. We show that the Oct-3/4 gene is unmethylated from the blastula stage but undergoes de novo methylation at 6.5 days post-coitum and remains modified in all adult somatic tissues analyzed. Oct-3/4 remains unmethylated in 6.25 days post-coitum epiblast cells when other genes, such as apoAI, undergo de novo methylation. We show that methylation of the Oct-3/4 promoter sequence strongly compromises its ability to direct efficient transcription. Moreover, DNA methylation inhibits basal transcription of the endogenous Oct-3/4 gene in vivo. We found that the Oct-3/4 gene harbors a cis-specific demodification element that includes the proximal enhancer sequence. This element leads to demethylation in embryonal carcinoma cells when the sequence is initially methylated and protects the local region from de novo methylation in post-implantation embryos. These results indicate that in the embryo protection from de novo methylation is not a unique feature of imprinted or housekeeping genes that carry a CpG island, but is also applicable to tissue-specific genes expressed during early stages of embryogenesis. Methylation of Oct-3/4 may be analogous to methylation of CpG islands on the inactive X chromosome that also occurs at later stages of development.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bergman, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel.	yberg@md2.huji.ac.il						ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Barnea E, 2000, J BIOL CHEM, V275, P6608, DOI 10.1074/jbc.275.9.6608; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; BENSHUSHAN E, 1993, MOL CELL BIOL, V13, P891, DOI 10.1128/MCB.13.2.891; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; Han L, 2001, MOL CELL BIOL, V21, P3416, DOI 10.1128/MCB.21.10.3416-3424.2001; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Lin IG, 2000, MOL CELL BIOL, V20, P2343, DOI 10.1128/MCB.20.7.2343-2349.2000; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MONK M, 1987, DEVELOPMENT, V99, P371; Mostoslavsky R, 1997, BBA-REV CANCER, V1333, pF29, DOI 10.1016/S0304-419X(97)00010-3; NAVEHMANY T, 1981, P NATL ACAD SCI-BIOL, V78, P4246, DOI 10.1073/pnas.78.7.4246; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Santoso B, 2000, J BIOL CHEM, V275, P1952, DOI 10.1074/jbc.275.3.1952; Schmitz A, 1997, J BIOL CHEM, V272, P20850, DOI 10.1074/jbc.272.33.20850; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; STURM K, 1993, METHOD ENZYMOL, V225, P164; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yeom YI, 1996, DEVELOPMENT, V122, P881; YEOM YI, 1991, MECH DEVELOP, V35, P171; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	56	110	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34521	34530		10.1074/jbc.M203338200	http://dx.doi.org/10.1074/jbc.M203338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110668	hybrid			2022-12-27	WOS:000177959100125
J	Johnstone, CN; White, SJ; Tebbutt, NC; Clay, FJ; Ernst, M; Biggs, WH; Viars, CS; Czekay, S; Arden, KC; Heath, JK				Johnstone, CN; White, SJ; Tebbutt, NC; Clay, FJ; Ernst, M; Biggs, WH; Viars, CS; Czekay, S; Arden, KC; Heath, JK			Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; CARBONIC-ANHYDRASE 1; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; HOMEODOMAIN PROTEINS; BINDING PROTEINS; HOMEOBOX GENES; PROMOTER; MOUSE; COLON	The A33 antigen is a transmembrane protein expressed almost exclusively by intestinal epithelial cells. The level of its expression is robust and uniform throughout the rostrocaudal axis of the human and mouse intestines. In the colon, strong expression is found in the basolateral membranes of both the proliferating cells in the lower regions of the crypts and the differentiating cells in the upper regions of crypts. Similarly, in the small intestine, the protein is highly expressed by all the epithelial cells in the crypts and by the differentiated cells migrating over the villi. Thus, the A33 antigen has emerged as a definitive marker for all intestinal epithelial cells, irrespective of cell lineage and differentiation status. To understand the molecular mechanisms mediating this rare tissue-specific expression pattern, we undertook a comprehensive analysis of the 5'-regulatory region of the human A33 antigen gene. This allowed us to point to positive cis-regulatory elements incorporating consensus Kruppel-like factor and caudal-related homeobox (CDX)-binding sites, located just upstream from the human A33 antigen transcription start site, as being important for the intestine-specific expression pattern of this gene. Further analysis provided evidence that the A33 antigen gene may be one of only a few target genes to be described thus far for the intestine-specific homeobox transcription factor, CDX1. Taken together, our data lead us to propose that the activity of CDX1 is pivotal in mediating the exquisite, intestine-specific expression pattern of the A33 antigen gene.	PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Parkville, Vic 3050, Australia; Univ Calif San Diego, Ludwig Inst Canc Res, San Diego Branch, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Heath, JK (corresponding author), PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Parkville, Vic 3050, Australia.	joan.heath@ludwig.edu.au	Ernst, Matthias/D-5111-2012; Heath, Joan/D-3054-2012	Ernst, Matthias/0000-0002-6399-1177; Heath, Joan/0000-0001-6955-232X				Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Di Guglielmo MD, 2001, FEBS LETT, V507, P128, DOI 10.1016/S0014-5793(01)02952-0; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FRANKEL WN, 1994, MAMM GENOME, V5, P275, DOI 10.1007/BF00389541; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; GarinChesa P, 1996, INT J ONCOL, V9, P465; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; IOVANNA JL, 1993, AM J PHYSIOL, V265, pG611, DOI 10.1152/ajpgi.1993.265.4.G611; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Johnstone CN, 2000, AM J PHYSIOL-GASTR L, V279, pG500, DOI 10.1152/ajpgi.2000.279.3.G500; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; KO MSH, 1994, MAMM GENOME, V5, P349, DOI 10.1007/BF00356553; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; ORNER GA, 2002, IN PRESS MUTAT RES; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Park J, 2000, GASTROENTEROLOGY, V119, P89, DOI 10.1053/gast.2000.8520; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; SHIELDS HM, 1986, J LIPID RES, V27, P549; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; WU GD, 1992, J BIOL CHEM, V267, P7863; Zhang YJ, 2001, BIOTECHNIQUES, V31, P1286, DOI 10.2144/01316st02	58	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34531	34539		10.1074/jbc.M204865200	http://dx.doi.org/10.1074/jbc.M204865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114523	hybrid			2022-12-27	WOS:000177959100126
J	Short, JD; Pfarr, CM				Short, JD; Pfarr, CM			Translational regulation of the JunD messenger RNA.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; SECONDARY STRUCTURE; FIBROBLAST-GROWTH; CELL-PROLIFERATION; PROTEIN EXPRESSION; INITIATION CODONS; IN-VITRO; REGION; ENTRY; AUG	JunD, a member of the Jun family of nuclear transcription proteins, dimerizes with Fos family members or other Jun proteins (c-Jun of JunB) to form the activator protein 1 (AP-1) transcription factor. The junD gene contains no introns and generates a single mRNA. Here we show that two predominant JunD isoforms are generated by alternative initiation of translation, a 39-kDa full-length JunD protein (JunD-FL) by initiation at the first AUG condon downstream of the mRNA 5' cap and a shorter, 34-kDa JunD protein (PiJunD) by initiation at a second in-frame AUG condon. The JunD mRNA contains a long, G/C-rich 5'-untranslated region that is predicted to be highly structed and is important for regulating the ratio of JunD-FL and PiJunD protein expression. A third functional out-of-frame AUG directs translation from a short open reading frame positioned between the JunD-FL and PiJunD start sites. In addition, three non-AUG codons also support translation, an ACG condon (in frame with JunD) and a CUG are positioned in the 5'-untranslated region, and a CUG codon (also in-frame with JunD) is located downstream of the short open reading frame. Mutation of these start sites individually had no affect on PiJunD protein levels, but mutation of multiple upstream statr sites led to an increase in PiJunD protein levels, indicating that these condons can function cumulatively to suppress PiJunD translation. Finally, we show that the JunD mRNA does not possess an internal ribosome entry site and is translated in a cap-dependent manner.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, SW Canc Ctr, Univ Med Ctr, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Pfarr, CM (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	curt.pfarr@ttmc.ttuhsc.edu						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGER I, 1991, ONCOGENE, V6, P561; BOECK R, 1994, EMBO J, V13, P3608, DOI 10.1002/j.1460-2075.1994.tb06668.x; Calkhoven CF, 2000, GENE DEV, V14, P1920; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hennecke M, 2001, NUCLEIC ACIDS RES, V29, P3327, DOI 10.1093/nar/29.16.3327; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI S-I, 1989, New Biologist, V1, P181; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Morrish BC, 2001, BIOCHEM BIOPH RES CO, V283, P1091, DOI 10.1006/bbrc.2001.4909; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Niepel M, 1999, FEBS LETT, V462, P79, DOI 10.1016/S0014-5793(99)01514-8; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Roberts TM, 2000, J VIROL, V74, P8111, DOI 10.1128/JVI.74.17.8111-8118.2000; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sehgal A, 2000, ONCOGENE, V19, P2836, DOI 10.1038/sj.onc.1203601; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Sullivan M, 1999, CELL SIGNAL, V11, P735, DOI 10.1016/S0898-6568(99)00037-6; Thepot D, 2000, DEVELOPMENT, V127, P143; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Yazgan O, 2001, CANCER RES, V61, P916; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	56	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32697	32705		10.1074/jbc.M204553200	http://dx.doi.org/10.1074/jbc.M204553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105216	hybrid			2022-12-27	WOS:000177859000040
J	Sondermann, H; Ho, AK; Listenberger, LL; Siegers, K; Moarefi, I; Wente, SR; Hartl, FU; Young, JC				Sondermann, H; Ho, AK; Listenberger, LL; Siegers, K; Moarefi, I; Wente, SR; Hartl, FU; Young, JC			Prediction of novel bag-1 homologs based on structure/function analysis identifies Snl1p as an Hsp70 co-chaperone in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; NUCLEOTIDE EXCHANGE; ATPASE ACTIVITY; MOLECULAR CHAPERONES; STRUCTURAL-ANALYSIS; NEGATIVE REGULATOR; SUBSTRATE-BINDING; REACTION CYCLE; NASCENT CHAIN; PROTEIN HSP70	Polypeptide binding by the chaperone Hsp70 is regulated by its ATPase activity, which is itself regulated by co-chaperones including the Bag domain nucleotide exchange factors. Here, we tested the functional contribution of residues in the Bag domain of Bag-1M that contact Hsp70. Two point mutations, E212A and E219A, partially reduced co-chaperone activity, whereas the point mutation R237A completely abolished activity in vitro. Based on the strict positional conservation of the Arg-237 residue, several Bag domain proteins were predicted from various eukaryotic genomes. One candidate, Snl1p from Saccharomyces cerevisiae, was confirmed as a Bag domain co-chaperone. Snl1p bound specifically to the Ssa and Ssb forms of yeast cytosolic Hsp70, as revealed by two-hybrid screening and co-precipitations from yeast lysate. In vitro, Snl1p also recognized mammalian Hsp70 and regulated the Hsp70 ATPase activity identically to Bag-1M. Point mutations in Snl1p that disrupted the conserved residues Glu-112 and Arg-141, equivalent to Glu-212 and Arg-237 in Bag-1M, abolished the interaction with Hsp70 proteins. In live yeast, mutated Snl1p could not substitute for wild-type Snl1p in suppressing the lethal defect caused by truncation of the Nup116p nuclear pore component. Thus, Snl1p is the first Bag domain protein identified in S. cerevisiae, and its interaction with Hsp70 is essential for biological activity.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Max Planck Society; Washington University (WUSTL)	Young, JC (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	young@biochem.mpg.de	Hartl, F. Ulrich/Y-8206-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57438] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CYR DM, 1992, J BIOL CHEM, V267, P20927; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; James P, 1996, GENETICS, V144, P1425; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lopez-Buesa P, 1998, P NATL ACAD SCI USA, V95, P15253, DOI 10.1073/pnas.95.26.15253; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Moribe Y, 2001, EUR J BIOCHEM, V268, P3432, DOI 10.1046/j.1432-1327.2001.02244.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SIKORSKI RS, 1989, GENETICS, V122, P19; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	56	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33220	33227		10.1074/jbc.M204624200	http://dx.doi.org/10.1074/jbc.M204624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105220	hybrid			2022-12-27	WOS:000177859000106
J	Hung, SP; Baldi, P; Hatfield, GW				Hung, SP; Baldi, P; Hatfield, GW			Global gene expression profiling in Escherichia coli K12 - The effects of leucine-responsive regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY-PHASE SURVIVAL; THREONINE OPERON; NUCLEOTIDE-SEQUENCE; TYPE-1 FIMBRIATION; ISOLEUCINE CODONS; TRANSPORT-SYSTEM; STRESS-RESPONSE; ILVGMEDA OPERON; DNA MICROARRAY; CONTROL REGION	Leucine-responsive regulatory protein (Lrp) is a global regulatory protein that affects the expression of multiple genes and operons in bacteria. Although the physiological purpose of Lrp-mediated gene regulation remains unclear, it has been suggested that it functions to coordinate cellular metabolism with the nutritional state of the environment. The results of gene expression profiles between otherwise isogenic Irp(+) and Irp(-)strains of Escherichia coli support this suggestion. The newly discovered Lrp-regulated genes reported here are involved either in small molecule or macromolecule synthesis or degradation, or in small molecule transport and environmental stress responses. Although many of these regulatory effects are direct, others are indirect consequences of Lrp-mediated changes in the expression levels of other global regulatory proteins. Because computational methods to analyze and interpret high dimensional DNA microarray data are still an early stage, much of the emphasis of this work is directed toward the development of methods to identify differentially expressed genes with a high level of confidence. In particular, we describe a Bayesian statistical framework for a posterior estimate of the standard deviation of gene measurements based on a limited number of replications. We also describe an algorithm to compute a posterior estimate of differential expression for each gene based on the experiment-wide global false positive and false negative level for a DNA microarray data set. This allows the experimenter to compute posterior probabilities of differential expression for each individual differential gene expression measurement.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genomics & Bioinformat, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Informat & Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Engn, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM 55073] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUHAMAD WN, 1991, MOL MICROBIOL, V5, P1035, DOI 10.1111/j.1365-2958.1991.tb01876.x; ALEXANDER DM, 1994, MOL MICROBIOL, V11, P1059, DOI 10.1111/j.1365-2958.1994.tb00383.x; AMBARTSOUMIAN G, 1994, MICROBIOL-UK, V140, P1737, DOI 10.1099/13500872-140-7-1737; Arfin SM, 2000, J BIOL CHEM, V275, P29672, DOI 10.1074/jbc.M002247200; AUSTIN EA, 1989, ABSTR MOL GEN BACT, P153; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412; BAUMINGER ER, 1994, BIOCHEM J, V302, P813, DOI 10.1042/bj3020813; Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Bhagwat SP, 1997, J BACTERIOL, V179, P6254, DOI 10.1128/jb.179.20.6254-6263.1997; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; BLOMFIELD IC, 1993, J BACTERIOL, V175, P27, DOI 10.1128/JB.175.1.27-36.1993; Blomfield IC, 2001, ADV MICROB PHYSIOL, V45, P1, DOI 10.1016/S0065-2911(01)45001-6; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; COLE JA, 1980, J GEN MICROBIOL, V120, P475; Cronan Jr. J. E., 1996, ESCHERICHIA COLI SAL, VI, P206; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DEBARBOUILLE M, 1982, MOL GEN GENET, V185, P88, DOI 10.1007/BF00333795; ERNSTING BR, 1993, J BACTERIOL, V175, P7160, DOI 10.1128/JB.175.22.7160-7169.1993; ERNSTING BR, 1992, J BACTERIOL, V174, P1109, DOI 10.1128/jb.174.4.1109-1118.1992; FERRANTE AA, 1995, P NATL ACAD SCI USA, V92, P7617, DOI 10.1073/pnas.92.17.7617; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Free A, 1997, J BACTERIOL, V179, P909, DOI 10.1128/jb.179.3.909-918.1997; GARDNER JF, 1982, J BIOL CHEM, V257, P3896; GARDNER JF, 1979, P NATL ACAD SCI USA, V76, P1706, DOI 10.1073/pnas.76.4.1706; GAZEAU M, 1992, FEBS LETT, V300, P254, DOI 10.1016/0014-5793(92)80857-D; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; Ghrist AC, 1998, J BACTERIOL, V180, P1803, DOI 10.1128/JB.180.7.1803-1807.1998; Gill RT, 2000, J MOL MICROB BIOTECH, V2, P283; GROSS CA, 1996, ESCHERICHIA COLI SAL, V1, P1382; GUEST JR, 1983, J BACTERIOL, V153, P588, DOI 10.1128/JB.153.2.588-596.1983; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HANEY SA, 1992, J BACTERIOL, V174, P108, DOI 10.1128/jb.174.1.108-115.1992; Hatfield GW, 2002, ANNU REV GENET, V36, P175, DOI 10.1146/annurev.genet.36.032902.111815; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V1, P1497; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; King ND, 1997, J BACTERIOL, V179, P1828, DOI 10.1128/jb.179.5.1828-1831.1997; Landgraf JR, 1999, J BACTERIOL, V181, P6547, DOI 10.1128/JB.181.20.6547-6551.1999; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; Levinthal M, 1996, RES MICROBIOL, V147, P333, DOI 10.1016/0923-2508(96)84708-5; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIN RT, 1992, J BACTERIOL, V174, P1948, DOI 10.1128/jb.174.6.1948-1955.1992; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; LYNN SP, 1987, J MOL BIOL, V194, P59, DOI 10.1016/0022-2836(87)90715-7; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; Maki Y, 2000, GENES CELLS, V5, P965, DOI 10.1046/j.1365-2443.2000.00389.x; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MECSAS J, 1995, J BACTERIOL, V177, P799, DOI 10.1128/jb.177.3.799-804.1995; MILLER CG, 1978, J BACTERIOL, V135, P603, DOI 10.1128/JB.135.2.603-611.1978; Miller J.H., 1972, EXPT MOL GENETICS; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, V1, P1310; NEWMAN EB, 1996, ESCHERICHIA COLI SAL, V1, P1513; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Patte J. C., 1996, ESCHERICHIA COLI SAL, V1, P528; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; PORCO A, 1991, Acta Cientifica Venezolana, V42, P270; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; SAINTGIRONS I, 1978, MOL GEN GENET, V162, P101, DOI 10.1007/BF00333856; Schaechter M, 2001, MICROBIOL MOL BIOL R, V65, P119, DOI 10.1128/MMBR.65.1.119-130.2001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHAO ZQ, 1994, EUR J BIOCHEM, V222, P901, DOI 10.1111/j.1432-1033.1994.tb18938.x; SIRKO A, 1995, J BACTERIOL, V177, P4134, DOI 10.1128/jb.177.14.4134-4136.1995; SPENCER ME, 1982, J BACTERIOL, V151, P542, DOI 10.1128/JB.151.2.542-552.1982; Stathopoulos C, 1998, Membr Cell Biol, V12, P1; STAUFFER LT, 1994, J BACTERIOL, V176, P6159, DOI 10.1128/jb.176.20.6159-6164.1994; Stauffer LT, 1999, MICROBIOL-SGM, V145, P569, DOI 10.1099/13500872-145-3-569; TCHETINA E, 1995, J BACTERIOL, V177, P2679, DOI 10.1128/jb.177.10.2679-2683.1995; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Ussery D, 2001, BIOCHIMIE, V83, P201, DOI 10.1016/S0300-9084(00)01225-6; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WISSENBACH U, 1995, MOL MICROBIOL, V17, P675, DOI 10.1111/j.1365-2958.1995.mmi_17040675.x; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YASUZAWA K, 1992, GENE, V122, P9; Zinser ER, 2000, J BACTERIOL, V182, P4361, DOI 10.1128/JB.182.15.4361-4365.2000	87	109	111	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40309	40323		10.1074/jbc.M204044200	http://dx.doi.org/10.1074/jbc.M204044200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12130640	hybrid			2022-12-27	WOS:000178791400022
J	Matsuda, M; Shimomura, I; Sata, M; Arita, Y; Nishida, M; Maeda, N; Kumada, M; Okamoto, Y; Nagaretani, H; Nishizawa, H; Kishida, K; Komuro, R; Ouchi, N; Kihara, S; Nagai, R; Funahashi, T; Matsuzawa, Y				Matsuda, M; Shimomura, I; Sata, M; Arita, Y; Nishida, M; Maeda, N; Kumada, M; Okamoto, Y; Nagaretani, H; Nishizawa, H; Kishida, K; Komuro, R; Ouchi, N; Kihara, S; Nagai, R; Funahashi, T; Matsuzawa, Y			Role of adiponectin in preventing vascular stenosis - The missing link of adipo-vascular axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PLASMA-PROTEIN; INSULIN-RESISTANCE; OBESITY; EXPRESSION; APOPTOSIS; INJURY; FAT	Obesity is more linked to vascular disease, including atherosclerosis and restenotic change, after balloon angioplasty. The precise mechanism linking obesity and vascular disease is still unclear. Previously we have demonstrated that the plasma levels of adiponectin, an adipose-derived hormone, decreases in obese subjects, and that hypoadiponectinemia is associated to ischemic heart disease. In current the study, we investigated the in vivo role of adiponectin on the neointimal thickening after artery injury using adiponectin-deficient mice and adiponectin-producing adenovirus. Adiponectin-deficient mice showed severe neointimal thickening and increased proliferation of vascular smooth muscle cells in mechanically injured arteries. Adenovirus-mediated supplement of adiponectin attenuated neointimal proliferation. In cultured smooth muscle cells, adiponectin attenuated DNA synthesis induced by growth factors including platelet-derived growth factor, heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), basic fibroblast growth factor, and EGF and cell proliferation and migration induced by HB-EGF. In cultured endothelial cells, adiponectin attenuated HB-EGF expression stimulated by tumor necrosis factor a. The current study suggests an adipo-vascular axis, a direct link between fat and artery. A therapeutic strategy to increase plasma adiponectin should be useful in preventing vascular restenosis after angioplasty.	Osaka Univ, Dept Internal Med & Mol Sci, Grad Sch Med, Osaka 5650871, Japan; Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan	Osaka University; University of Tokyo	Shimomura, I (corresponding author), Osaka Univ, Dept Organismal Biosyst, Grad Sch Frontier Biosci, Dept Med & Pathophysiol, 2-2 Yamadaoka, Osaka 5650871, Japan.		OUCHI, Noriyuki/I-7306-2014	Nisihida, Makoto/0000-0002-0309-7106				Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsumoto S, 2002, BIOCHEM BIOPH RES CO, V292, P781, DOI 10.1006/bbrc.2002.6720; Okamoto Y, 2000, HORM METAB RES, V32, P47, DOI 10.1055/s-2007-978586; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu SM, 1996, CIRCULATION, V94, P547, DOI 10.1161/01.CIR.94.3.547; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134, DOI 10.1681/ASN.V131134	25	651	751	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37487	37491		10.1074/jbc.M206083200	http://dx.doi.org/10.1074/jbc.M206083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138120	hybrid			2022-12-27	WOS:000178447100074
J	Murtazina, D; Puchkaev, AV; Schein, CH; Oezguen, N; Braun, W; Nanavati, A; Pikuleva, IA				Murtazina, D; Puchkaev, AV; Schein, CH; Oezguen, N; Braun, W; Nanavati, A; Pikuleva, IA			Membrane-protein interactions contribute to efficient 27-hydroxylation of cholesterol by mitochondrial cytochrome P450 27A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN; BINDING; ENZYME; DEGRADATION; MUTATIONS; MECHANISM	Mitochondrial cytochrome P450 27A1 (P450 27A1) catalyzes 27-hydroxylation of cholesterol, the first step in the alternative bile acid biosynthetic pathway. Although several crystal structures of P450s are known, no structural information is available for the mammalian, membrane-bound enzymes involved in the removal of cholesterol from the body. We prepared a three-dimensional model of P450 27A1 based on the structure of P450 BM-3. Conservative and non-conservative mutations were introduced at hydrophobic and positively charged residues in the putative F-G loop and the adjacent helix G (positions 219-237). Subicellular distribution of the mutant P450s expressed in Escherichia coli was used as a measure of membrane-protein interactions. Conservative substitutions of residues located on the surface, according to our, model, L219V, L219I, Y220F, F223Y, L224I, R229K, V231L, F234Y, K236R, and R237K weakened the association of the mutant P450s with the membrane and led to the appearance of up to 21% of P450 27A1 in the bacterial cytosol. It is likely that the mutated side chains are involved in binding to membrane phospholipids. Substitutions in the F-G loop did not significantly affect the K. value for cholesterol hydroxylation. However, non-conservative mutants, L219N, Y220A, Y220S, F223A, K226R, and R229A, had significantly impaired catalytic properties, indicating strict requirements for the size and polarity of the side chains at these positions for the catalysis. The results provide insight into the membrane topology of mitochondrial P450s and indicate the importance of membrane-protein interactions in the efficiency of reactions catalyzed by P450 27A1.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Pikuleva, IA (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA.	irpikule@utmb.edu	Oezguen, Numan/C-9267-2009; Braun, Werner/A-6642-2012; Schein, Catherine H/A-1426-2012	Oezguen, Numan/0000-0002-3175-2382; Schein, Catherine/0000-0002-8290-2109; Pikuleva, Irina/0000-0001-9742-6232	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062882] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62882-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; BJORKHEM I, 1992, J LIPID RES, V33, P455; CALI JJ, 1991, J BIOL CHEM, V266, P7779; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; GRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065, DOI 10.1002/pro.5560040605; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; MUMENTHALER C, 1995, PROTEIN SCI, V4, P863; MYANT NB, 1977, J LIPID RES, V18, P135; Nakayama K, 2001, J BIOL CHEM, V276, P31459, DOI 10.1074/jbc.M103943200; Nelson DR, 1998, COMP BIOCHEM PHYS C, V121, P15, DOI 10.1016/S0742-8413(98)10027-0; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peterson JA, 1998, STRUCTURE, V6, P1079, DOI 10.1016/S0969-2126(98)00109-9; Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153; Pikuleva IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123, DOI 10.1006/abbi.1997.0142; Pikuleva IA, 2001, BIOCHEMISTRY-US, V40, P7621, DOI 10.1021/bi010193i; Pikuleva IA, 1999, J BIOL CHEM, V274, P2045, DOI 10.1074/jbc.274.4.2045; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Soman KV, 2000, METH MOL B, V160, P263; Verrips A, 2000, BRAIN, V123, P908, DOI 10.1093/brain/123.5.908; VOET D, 1990, BIOCHEMISTRY-US, P338; WACHENFELDT C, 1995, CYTOCHROME P450 STRU, P183; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6	27	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37582	37589		10.1074/jbc.M204909200	http://dx.doi.org/10.1074/jbc.M204909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12124390	hybrid			2022-12-27	WOS:000178447100086
J	Romero-Isart, N; Jensen, LT; Zerbe, O; Winge, DR; Vasak, M				Romero-Isart, N; Jensen, LT; Zerbe, O; Winge, DR; Vasak, M			Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; NUCLEAR-MAGNETIC-RESONANCE; III MESSENGER-RNA; ALZHEIMERS-DISEASE; BIOLOGICAL-ACTIVITY; THIOLATE CLUSTERS; DOWN-REGULATION; RAT-BRAIN; MT-III; PROTEINS	The third isoform of mammalian metallothioneins (MT-3), mainly expressed in brain and down-regulated in Alzheimer's disease, exhibits neuroinhibitory activity in vitro and a highly flexible structure that distinguishes it from the widely expressed MT-1/-2 isoforms. Previously, we showed that two conserved prolyl residues of MT-3 are crucial for both the bioactivity and cluster dynamics of this isoform. We have now used genetic engineering to introduce these residues into mouse MT-1. The S6P,S8P MT-1 mutant is inactive in neuronal survival assays. However, the additional introduction of the unique Thr5 insert of MT-3 resulted in a bioactive MT-1 form. Temperature-dependent and saturation transfer Cd-113 NMR experiments performed on the Cd-113-reconstituted wild-type and mutant Cd-7-MT-1 forms revealed that the gain of MT-3-like neuronal inhibitory activity is paralleled by an increase in conformational flexibility and intersite metal exchange in the N-terminal Cd-3-thiolate cluster. The observed correlation suggests that structure/cluster dynamics are critical for the biological activity of MT-3. We propose that the interplay between the specific Pro-induced conformational requirements and those of the metal-thiolate bonds gives rise to an alternate and highly fluctuating cluster ensemble kinetically trapped by the presence of the (TCPCP9)-T-5 motif. The functional significance of such heterogeneous cluster ensemble is discussed.	Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich, Dept Pharm, CH-8057 Zurich, Switzerland	Utah System of Higher Education; University of Utah; University of Zurich; University of Zurich	Vasak, M (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010	Jensen, Laran/0000-0003-3199-1743	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amoureux MC, 1997, MOL CHEM NEUROPATHOL, V32, P101, DOI 10.1007/BF02815170; Bogumil R, 1998, EUR J BIOCHEM, V255, P172, DOI 10.1046/j.1432-1327.1998.2550172.x; BRAUN W, 1992, P NATL ACAD SCI USA, V89, P10124, DOI 10.1073/pnas.89.21.10124; Bruinink A, 1998, CHEM-BIOL INTERACT, V115, P167, DOI 10.1016/S0009-2797(98)00062-3; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; CARSON GK, 1981, INORG CHIM A-BIOINOR, V56, P59, DOI 10.1016/S0020-1693(00)88548-5; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; HAGEN KS, 1982, INORG CHEM, V21, P3928, DOI 10.1021/ic00141a015; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kohmura E, 1997, RESTOR NEUROL NEUROS, V11, P169, DOI 10.3233/RNN-1997-11307; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MESSERLE BA, 1992, J MOL BIOL, V225, P433, DOI 10.1016/0022-2836(92)90930-I; Montoliu C, 2000, J NEUROCHEM, V75, P266, DOI 10.1046/j.1471-4159.2000.0750266.x; Otvos J D, 1987, Experientia Suppl, V52, P171; Oz G, 2001, BIOCHEMISTRY-US, V40, P11433, DOI 10.1021/bi010827l; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; Quaife CJ, 1998, TOXICOL APPL PHARM, V148, P148, DOI 10.1006/taap.1997.8321; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031; Smyth E, 2001, BIOPOLYMERS, V58, P138, DOI 10.1002/1097-0282(200102)58:2<138::AID-BIP30>3.0.CO;2-W; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1995, J BIOL CHEM, V270, P3365, DOI 10.1074/jbc.270.7.3365; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLNER H, 1987, BIOCHEMISTRY-US, V26, P6287, DOI 10.1021/bi00393a049; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; Zangger K, 1999, PROTEIN SCI, V8, P2630, DOI 10.1110/ps.8.12.2630; ZHENG H, 1995, NEUROCHEM INT, V27, P43, DOI 10.1016/0197-0186(94)00167-S	45	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37023	37028		10.1074/jbc.M205730200	http://dx.doi.org/10.1074/jbc.M205730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130647	hybrid			2022-12-27	WOS:000178447100017
J	Taylor, MK; Ahmed, R; Begley, M; Uhler, MD				Taylor, MK; Ahmed, R; Begley, M; Uhler, MD			Autoinhibition and isoform-specific dominant negative inhibition of the type II cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; REGULATORY SUBUNIT; CYCLIC-AMP; CAMP; ACTIVATION; ALPHA; BETA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; IDENTIFICATION	In the absence of cyclic nucleotides, the cAMP-dependent protein kinase and cGMP-dependent protein kinases (cGKs) suppress phosphotransfer activity at the catalytic cleft by competitive inhibition of substrate binding with a pseudosubstrate sequence within the holoenzyme. The magnitude of inhibition can be diminished by autophosphorylation near this pseudosubstrate sequence. Activation of type I cGK (cGKI) and type II cGK (cGKII) are differentially regulated by their cyclic nucleotide-binding sites. To address the possibility that the distinct activation mechanisms of cGKII and cGKI result from differences in the autophosphorylation of the inhibitory domain, we investigated the effects of autophosphorylation on the kinetics of activation. Unlike the type I cGKs (cGKIalpha and Ibeta), cGKII autophosphorylation did not alter the basal activity, nor the sensitivity of the enzyme to cyclic nucleotide activation. To determine residues responsible for autoinhibition of cGKII, Ala was substituted for basic residues (Lys(122), Arg(118), and Arg(119)) or a hydrophobic residue (Val(125)) within the putative pseudosubstrate domain of cGKII. The integrity of these residues was essential for full cGKII autoinhibition. Furthermore, a cGKII truncation mutant containing this autoinhibitory region demonstrated a nanomolar IC50 toward a constitutively active form of cGKII. Finally, we present evidence that the dominant negative properties of this truncation mutant are specific to cGKII when compared with cAMP-dependent protein kinase Calpha and cGKIbeta. These findings extend the known differences in the activation mechanisms among cGK isoforms and allow the design of an isoform-specific cGKII inhibitor.	Univ Michigan, Grad Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Uhler, MD (corresponding author), Univ Michigan, Grad Program Neurosci, C560 MSRB 2,1150 W Med Ctr, Ann Arbor, MI 48109 USA.	muhler@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050791] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50791] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arancio O, 2001, J NEUROSCI, V21, P143, DOI 10.1523/JNEUROSCI.21-01-00143.2001; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P14579; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; PoteetSmith CE, 1997, ADV SEC MESS PHOSPH, V31, P219; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; Ruth P, 1997, J BIOL CHEM, V272, P10522; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SCOTT CW, 1985, J BIOL CHEM, V260, P2274; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Taylor MK, 2000, J BIOL CHEM, V275, P28053; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; Yuasa K, 2000, FEBS LETT, V466, P175, DOI 10.1016/S0014-5793(99)01786-X	35	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37242	37253		10.1074/jbc.M202060200	http://dx.doi.org/10.1074/jbc.M202060200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12093798	hybrid			2022-12-27	WOS:000178447100045
J	Kim, MS; Hur, MK; Son, YJ; Park, JI; Chun, SY; D'Elia, AV; Damante, G; Cho, S; Kim, K; Lee, BJ				Kim, MS; Hur, MK; Son, YJ; Park, JI; Chun, SY; D'Elia, AV; Damante, G; Cho, S; Kim, K; Lee, BJ			Regulation of pituitary adenylate cyclase-activating polypeptide gene transcription by TTF-1, a homeodomain-containing transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; DNA RECOGNITION; PACAP; PEPTIDE; NEUROENDOCRINE; PROMOTER; MORPHOGENESIS; SPECIFICITY; EXPRESSION; ENDOCRINE	Pituitary adenylate cyclase-activating polypeptide (PACAP) is an important hypophysiotrophic factor as well as a regulator for immune, reproductive, and neural tissues. We recently found that TTF-1, a homeodomain-containing transcription factor essential for the development of the fetal diencephalon, is postnatally expressed in the hypothalamic area and plays a transcription regulatory role for certain neurohormones. Based on the similarity of synthesis sites between PACAP and TTF-1 and, moreover, on the presence of conserved core TTF-1 binding motifs in the 5'-flanking region of the PACAP gene, we sought to uncover a regulatory role of TTF-1 in PACAP gene transcription. The TTF-1 homeodomain binds to six of the seven putative binding domains observed in the 5'-flanking region of the PACAP gene. In the C6 glioma cell-line, TTF-1 activates the PACAP promoter in a dose-dependent manner. This transactivation of PACAP by TTF-1 was totally removed when the core TTF-1 binding motif at -369 was deleted. RNase protection assays showed that TTF-1 and PACAP mRNAs have daily fluctuations in the rat hypothalamus. They both were at low levels during the day and high levels during the night. Intracerebroventricular administration of an antisense TTF-1 oligodeoxynucleotide significantly decreased the PACAP mRNA level as well as TTF-1 protein content in the rat hypothalamus, suggesting that TTF-1 also regulates PACAP transcription in vivo. Moreover, the TTF-1 promoter was inhibited by molecular oscillators of CLOCK and BMAL-1. Taken together, these data suggest that TTF-1 plays an important regulatory role in the gene transcription for PACAP, which may be important for the generation of a daily rhythm of hypothalamic PACAP gene expression.	Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Ulsan; Chonnam National University; Seoul National University (SNU); University of Udine	Lee, BJ (corresponding author), Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea.	bjlee@mail.ulsan.ac.kr	Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Cagampang FRA, 1998, BRAIN RES, V813, P218, DOI 10.1016/S0006-8993(98)01044-0; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Choi EJ, 2000, MOL BRAIN RES, V80, P35, DOI 10.1016/S0169-328X(00)00116-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; FABBRO D, 1995, BIOCHEM BIOPH RES CO, V213, P781, DOI 10.1006/bbrc.1995.2198; Fukuhara C, 1997, NEUROSCI LETT, V229, P49, DOI 10.1016/S0304-3940(97)00415-1; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gillette MU, 1999, RECENT PROG HORM RES, V54, P33; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Ha CM, 2000, MOL BRAIN RES, V78, P59, DOI 10.1016/S0169-328X(00)00070-X; Hannibal J, 1997, J NEUROSCI, V17, P2637, DOI 10.1523/jneurosci.17-07-02637.1997; Harrington ME, 1999, J NEUROSCI, V19, P6637; HOSOYA M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P199, DOI 10.1016/0167-4781(92)90488-L; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; Kim MS, 2001, BRAIN RES PROTOC, V7, P277, DOI 10.1016/S1385-299X(01)00078-2; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Nakamura K, 2001, DEV BRAIN RES, V130, P159, DOI 10.1016/S0165-3806(01)00226-7; Park JI, 2000, MOL HUM REPROD, V6, P238, DOI 10.1093/molehr/6.3.238; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; SUZUKI N, 1994, EUR J BIOCHEM, V223, P147, DOI 10.1111/j.1432-1033.1994.tb18976.x; van Esseveldt LKE, 2000, BRAIN RES REV, V33, P34, DOI 10.1016/S0165-0173(00)00025-4; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamamoto K, 1998, GENE, V211, P63, DOI 10.1016/S0378-1119(98)00110-3	38	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36863	36871		10.1074/jbc.M206443200	http://dx.doi.org/10.1074/jbc.M206443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122016	hybrid			2022-12-27	WOS:000178275100139
J	Li, XJ; Alvarez, B; Casey, JR; Reithmeier, RAF; Fliegel, L				Li, XJ; Alvarez, B; Casey, JR; Reithmeier, RAF; Fliegel, L			Carbonic anhydrase II binds to and enhances activity of the Na+/H+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ANION-EXCHANGER; INTRACELLULAR PH; TERMINAL REGION; FUNCTIONAL-ROLE; RESIDUES; SITE; IDENTIFICATION; LOCALIZATION; MYOCARDIUM	We examined the ability of carbonic anhydrase II to bind to and affect the transport efficiency of the NHE1 isoform of the mammalian Na+/H+ exchanger. The C-terminal region of NHE1 was expressed in Escherichia coli fused with an N-terminal glutathionine S-transferase or with a C-terminal polyhistidine tag. Using a microtiter plate binding assay we showed that the C-terminal region of NHE1 binds carbonic anhydrase 11 (CAII) and binding was stimulated by low pH and blocked by antibodies against the C-terminal of NHE1 The binding to NHE1 was confirmed by demonstrating protein-protein interaction using affinity blotting with CAII and immobilized NHE1 fusion proteins. CAII co-immunoprecipitated with NHE1 from CHO cells suggesting the proteins form a complex in vivo. In cells expressing CAII and NHE1, the H+ transport rate was almost 2-fold greater than in cells expressing NHE1 alone. The CAII inhibitor acetazolamide significantly decreased the H+ transport rate of NHE1 and transfection with a dominant negative CAII inhibited NHE1 activity. Phosphorylation of the C-terminal of NHE1 greatly increased the binding of CAII. Our study suggests that NHE1 transport efficiency is influenced by CAII, likely through a direct interaction at the C-terminal region. Regulation of NHE1 activity by phosphorylation could involve modulation of CAII binding.	Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Canadian Inst Hlth Res Grp Membrane Biol, Dept Med & Biochem, Toronto, ON M5S 1A8, Canada	University of Alberta; University of Alberta; University of Toronto	Fliegel, L (corresponding author), Univ Alberta, Canadian Inst Hlth Res Membrane Prot Grp, Dept Biochem, 347 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; COUSIN JL, 1975, J PHYSIOL-LONDON, V253, P385, DOI 10.1113/jphysiol.1975.sp011195; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Fliegel L, 1999, J THROMB THROMBOLYS, V8, P9, DOI 10.1023/A:1008934312429; Fliegel L, 2001, BASIC RES CARDIOL, V96, P301, DOI 10.1007/s003950170036; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MASON MJ, 1989, AM J PHYSIOL, V256, pC428, DOI 10.1152/ajpcell.1989.256.2.C428; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Murray G, 2001, BIOTECHNIQUES, V30, P1036, DOI 10.2144/01305rr02; MURTAZINA BR, 2001, EUR J BIOCHEM, V268, P1; Noel J, 1996, J CELL SCI, V109, P929; PEREZ NG, 1995, CIRC RES, V77, P1192, DOI 10.1161/01.RES.77.6.1192; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; ROTIN D, 1989, CANCER RES, V49, P205; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Sterling D, 1999, BIOCHEM J, V344, P221, DOI 10.1042/0264-6021:3440221; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Tang XB, 1999, J BIOL CHEM, V274, P3557, DOI 10.1074/jbc.274.6.3557; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Wang HY, 1998, ARCH BIOCHEM BIOPHYS, V358, P116, DOI 10.1006/abbi.1998.0833; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001; Wu Q, 1998, J MEMBRANE BIOL, V162, P31, DOI 10.1007/s002329900339; Yao H, 1999, J CLIN INVEST, V104, P637, DOI 10.1172/JCI6785	33	167	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36085	36091		10.1074/jbc.M111952200	http://dx.doi.org/10.1074/jbc.M111952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138085	hybrid			2022-12-27	WOS:000178275100042
J	Litterst, CM; Pfitzner, E				Litterst, CM; Pfitzner, E			An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR FUNCTION; CREB-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; COACTIVATOR COMPLEXES; INHIBITION; GENE; IL-4; CELLS; ACETYLTRANSFERASE	Signal transducer and activator of transcription 6 (STAT6) regulates transcriptional activation in response to interleukin-4 (IL-4)-induced tyrosine phosphorylation by direct interaction with coactivators. The CREB-binding protein and the nuclear coactivator 1 (NCoA-1), a member of the p160/steroid receptor coactivator family, bind independently to specific regions of STAT6 and act as coactivators. In this study we show that an LXXLL motif in the STAT6 transactivation domain mediates the interaction with NCoA-1. Peptides representing this motif as well as antibodies generated against this motif inhibited STAT6/NCoA-1 interaction in glutathione S-transferase pulldown assays. Peptides derived from the STAT6 transactivation domain adjacent to the LXXLL motif as well as antibodies against these peptides showed no inhibitory effect. Mutagenesis of the LXXLL motif eliminated the STAT6/NCoA-1 interaction in vitro and in vivo, supporting the specific role of this motif in NCoA-1 binding. Importantly, mutagenesis of the STAT-LXXLL motif strongly diminished the IL-4-regulated activation of the endogenous STAT6 target gene eotaxin-3. Taken together, these results indicate that the STAT6-LXXLL-binding motif mediates the interaction with NCoA-1 in transcriptional activation and represents a new potential drug target for the inhibition of the STAT6 transactivation function in allergic diseases.	Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Germany	Octapharma	Pfitzner, E (corresponding author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Pfitzner, Edith/AAU-7927-2021	Pfitzner, Edith/0000-0002-3484-9649				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen Lin, 1999, Current Opinion in Structural Biology, V9, P48; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Goodman RH, 2000, GENE DEV, V14, P1553; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Igaz P, 2001, INFLAMM RES, V50, P435, DOI 10.1007/PL00000267; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Lu BF, 1997, J IMMUNOL, V159, P1255; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; ONATE SA, 1995, SCIENCE, V270, P1354; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shinkai A, 1999, J IMMUNOL, V163, P1602; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stolzenberger S, 2001, EUR J BIOCHEM, V268, P4809, DOI 10.1046/j.1432-1327.2001.02417.x; Stutz AM, 2001, J BIOL CHEM, V276, P11759, DOI 10.1074/jbc.M010260200; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Worm M, 1998, BLOOD, V92, P1713, DOI 10.1182/blood.V92.5.1713.417k20_1713_1720; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	45	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36052	36060		10.1074/jbc.M203556200	http://dx.doi.org/10.1074/jbc.M203556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138096	hybrid			2022-12-27	WOS:000178275100038
J	Rosenfeld, SS; Xing, J; Jefferson, GM; Cheung, HC; King, PH				Rosenfeld, SS; Xing, J; Jefferson, GM; Cheung, HC; King, PH			Measuring kinesin's first step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; KINETIC MECHANISM; DIMERIC KINESIN; MOLECULAR MOTOR; 8-NM STEP; MYOSIN-V; PROCESSIVITY; RELEASE; PATHWAY; PROTEIN	A variety of models have recently emerged to explain how the molecular motor kinesin is able to maintain processive movement for over 100 steps. Although these models differ in significant features, they all predict that kinesin's catalytic domains intermittently separate from each other as the motor takes 8-nm steps along the microtubule. Furthermore, at some point in this process, one molecule of ATP is hydrolyzed per step. However, exactly when hydrolysis and product release occur in relation to this forward step have not been established. Furthermore, the rate at which this separation occurs as well as the speed of motor stepping onto and release from the microtubule have not been measured. In the absence of this information, it is difficult to critically evaluate competing models of kinesin function. We have addressed this issue by developing spectroscopic probes whose fluorescence is sensitive to motor-motor separation or microtubule binding. The kinetics of these fluorescence changes allow us to directly measure how fast kinesin steps onto and releases from the microtubule and provide insight into how processive movement is maintained by this motor.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Neurol Serv, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, 1813 6th Ave S,RAC M030, Birmingham, AL 35294 USA.	stevensr@uab.edu		King, Peter/0000-0001-9391-7464				BERGER CL, 1991, BIOCHEMISTRY-US, V30, P11036, DOI 10.1021/bi00110a005; Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; del Monte F, 1999, J PHYS CHEM B, V103, P8080, DOI 10.1021/jp991491g; del Monte F, 2000, LANGMUIR, V16, P7377, DOI 10.1021/la000540+; Geoghegan KF, 2000, BIOCONJUGATE CHEM, V11, P71, DOI 10.1021/bc9900845; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Hamman BD, 1996, J BIOL CHEM, V271, P7568, DOI 10.1074/jbc.271.13.7568; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Iwatani S, 1999, BIOCHEMISTRY-US, V38, P10318, DOI 10.1021/bi9904095; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kawaguchi K, 2001, SCIENCE, V291, P667, DOI 10.1126/science.291.5504.667; KOENIG SH, 1975, BIOPOLYMERS, V14, P2421, DOI 10.1002/bip.1975.360141115; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; Packard BZ, 1996, P NATL ACAD SCI USA, V93, P11640, DOI 10.1073/pnas.93.21.11640; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Uemura S, 2002, P NATL ACAD SCI USA, V99, P5977, DOI 10.1073/pnas.092546199; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2000, PHILOS T ROY SOC B, V355, P449, DOI 10.1098/rstb.2000.0586; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Vugmeyster Y, 1998, BIOCHEMISTRY-US, V37, P747, DOI 10.1021/bi971534o; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n	42	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36731	36739		10.1074/jbc.M205261200	http://dx.doi.org/10.1074/jbc.M205261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122000	hybrid			2022-12-27	WOS:000178275100120
J	Lim, W; Nguyen, NH; Yang, HY; Scanlan, TS; Furlow, JD				Lim, W; Nguyen, NH; Yang, HY; Scanlan, TS; Furlow, JD			A thyroid hormone antagonist that inhibits thyroid hormone action in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS METAMORPHOSIS; AMPHIBIAN METAMORPHOSIS; EXPRESSION PATTERN; RESPONSE GENES; BETA GENE; RECEPTOR; CELL; PROGRAMS; TISSUES	We have characterized the newly developed thyroid hormone antagonist NH-3 in both cell culture and in vivo model systems. NH-3 binds Xenopus laevis thyroid hormone receptors directly in vitro and induces a conformation distinct from agonist-bound receptors. Transcriptional activation of a thyroid hormone response element-containing reporter gene is strongly inhibited by NH-3 in a dose-dependent manner. In addition, NH-3 prevents X. laevis thyroid hormone receptors from binding to the p160 family of co-activators GRIP-1 and SRC-1 in a two-hybrid assay. To assess the potency of the compound in vivo, we used induced and spontaneous X. laevis tadpole metamorphosis, a thyroid hormone-dependent developmental process. NH-3 inhibits thyroid hormone-induced morphological changes in a dose-dependent manner and inhibits the up-regulation of endogenous thyroid hormone-responsive genes. Spontaneous metamorphosis is efficiently and reversibly arrested by NH-3 with at least the same effectiveness as the thyroid hormone synthesis inhibitor methimazole. Therefore, NH-3 is the first thyroid hormone antagonist to demonstrate potent inhibition of thyroid hormone action in both cell culture- and whole animal-based assays.	Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA; Univ Calif San Francisco, Program Chem & Chem Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Furlow, JD (corresponding author), Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA.	jdfurlow@ucdavis.edu			NIDDK NIH HHS [R01 DK055511, DK-52798, DK-55511] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, R01DK055511, R01DK052798] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baxter JD, 2002, ENDOCRINOLOGY, V143, P517, DOI 10.1210/en.143.2.517; Berry DL, 1998, DEV BIOL, V203, P12, DOI 10.1006/dbio.1998.8974; Berry DL, 1998, DEV BIOL, V203, P24, DOI 10.1006/dbio.1998.8975; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Brown DD, 1997, P NATL ACAD SCI USA, V94, P13011, DOI 10.1073/pnas.94.24.13011; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Callery EM, 2000, P NATL ACAD SCI USA, V97, P2615, DOI 10.1073/pnas.050501097; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Chiellini G, 2002, BIOORGAN MED CHEM, V10, P333, DOI 10.1016/S0968-0896(01)00284-X; Dodd M.H.I., 1976, P467; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Furlow JD, 1999, MOL ENDOCRINOL, V13, P2076, DOI 10.1210/me.13.12.2076; Huang HC, 1999, P NATL ACAD SCI USA, V96, P962, DOI 10.1073/pnas.96.3.962; Jones I, 2002, GEN COMP ENDOCR, V125, P226, DOI 10.1006/gcen.2001.7745; MACHUCA I, 1995, MOL ENDOCRINOL, V9, P96, DOI 10.1210/me.9.1.96; MARKLEW S, 1994, BBA-GENE STRUCT EXPR, V1218, P267, DOI 10.1016/0167-4781(94)90177-5; Nguyen NH, 2002, J MED CHEM, V45, P3310, DOI 10.1021/jm0201013; NORMAN MF, 1989, J CLIN INVEST, V83, P306, DOI 10.1172/JCI113874; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sachs LM, 2000, COMP BIOCHEM PHYS B, V126, P199, DOI 10.1016/S0305-0491(00)00198-X; Safi R, 1997, J MOL EVOL, V44, P595, DOI 10.1007/PL00006182; Silva JE, 2001, J CLIN INVEST, V108, P35, DOI 10.1172/JCI13397; SPECKER JL, 1984, ENDOCRINOLOGY, V115, P399, DOI 10.1210/endo-115-1-399; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; Tata JR, 1999, BIOCHIMIE, V81, P359, DOI 10.1016/S0300-9084(99)80082-0; van Beeren HC, 2000, FEBS LETT, V481, P213, DOI 10.1016/S0014-5793(00)01970-0; WILSON FE, 1993, J COMP PHYSIOL B, V163, P563, DOI 10.1007/BF00302115; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoshihara HAI, 2001, BIOORG MED CHEM LETT, V11, P2821, DOI 10.1016/S0960-894X(01)00521-2; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97; Youson JH, 1997, J EXP ZOOL, V279, P145, DOI 10.1002/(SICI)1097-010X(19971001)279:2<145::AID-JEZ5>3.3.CO;2-4	34	81	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35664	35670		10.1074/jbc.M205608200	http://dx.doi.org/10.1074/jbc.M205608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095994	hybrid			2022-12-27	WOS:000178117000127
J	Morel, JCM; Park, CC; Zhu, K; Kumar, P; Ruth, JH; Koch, AE				Morel, JCM; Park, CC; Zhu, K; Kumar, P; Ruth, JH; Koch, AE			Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; INTERFERON-GAMMA PRODUCTION; RECEPTOR-ASSOCIATED KINASE; HELPER TYPE-1 CELLS; SRC FAMILY KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; IFN-GAMMA; C-SRC; PHOSPHOINOSITIDE 3-KINASE	Vascular cell adhesion molecule (VCAM)-1 has been implicated in interactions between leukocytes and connective tissue, including rheumatoid arthritis (RA) synovial tissue fibroblasts. Such interactions within the synovium contribute to RA inflammation. Using phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and Src inhibitor PP2, we show that interleukin (IL)-18-induced ERK1/2 activation is Src kinase-dependent. Antisense (AS) c-Src oligonucleotide (ODN) treatment reduced IL-18-induced ERK1/2 expression by 32% compared with control, suggesting an upstream role of Src in ERK1/2 activation. AS c-Src ODN treatment also inhibited Akt expression by 74% compared with sense control. PI3-kinase inhibitor LY294002 or AS PI3-kinase ODN inhibited Akt expression. AS c-Src ODN inhibited Akt phosphorylation, confirming Src is upstream of PI3-kinase in IL-18-induced RA synovial fibroblast signaling. IL-18 induced a time-dependent activation of c-Src, Ras, and Raf-1, suggesting this signaling cascade plays a role in ERK activation. IL-18 directly activated Src kinase by more than 4-fold over basal levels by enzymatic assay. Electrophoretic mobility shift assay showed that activator protein-1 (AP-1) is activated by IL-18 through ERK and Src but not through PI3-kinase. In an alternate pathway, inhibition of IL-1 receptor-associated kinase-1 (IRAK) with AS ODN to IRAK reduced IL-18-induced expression of nuclear factor kappaB (NFkappaB). Finally, IL-18-induced cell surface VCAM-1 expression was inhibited by treatment with AS ODNs to c-Src, IRAK, PI3-kinase, and ERK1/2 by 57,43,41, and 32% compared with control sense ODN treatment, respectively. These data support a role for IL-18 activation of three distinct pathways during RA synovial fibroblast stimulation: two Src-dependent pathways and the IRAK/NFkappaB pathway. Targeting VCAM-1 signaling mechanisms may represent therapeutic approaches to inflammatory and angiogenic diseases characterized by adhesion molecule up-regulation.	Northwestern Univ, Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Vet Adv Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University	Koch, AE (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Rheumatol, 303 E Chicago Ave,Ward 3-315, Chicago, IL 60611 USA.		Kumar, Pawan/H-7777-2013; Park, Christy/AAH-1543-2020; Koch, Alisa E/B-6894-2011		NHLBI NIH HHS [HL-58695] Funding Source: Medline; NIAID NIH HHS [AI-49287, AI-40987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040987, R21AI040987, K08AI049287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Barbulescu K, 1998, J IMMUNOL, V160, P3642; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cambien B, 2001, BLOOD, V97, P2031, DOI 10.1182/blood.V97.7.2031; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Debets R, 2000, J IMMUNOL, V165, P4950, DOI 10.4049/jimmunol.165.9.4950; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Greene CM, 2000, J IMMUNOL, V165, P4718, DOI 10.4049/jimmunol.165.8.4718; Guo FK, 2000, IMMUNOPHARMACOLOGY, V49, P241, DOI 10.1016/S0162-3109(00)00200-9; Guo FK, 2000, ACTA PHARMACOL SIN, V21, P321; Guo FK, 2000, ACTA PHARMACOL SIN, V21, P318; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; Hoshino K, 1999, J IMMUNOL, V162, P5041; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jeschke M, 1998, J BONE MINER RES, V13, P1880, DOI 10.1359/jbmr.1998.13.12.1880; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim SH, 2001, J IMMUNOL, V166, P148; Kim YM, 2000, J IMMUNOL, V165, P3198, DOI 10.4049/jimmunol.165.6.3198; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; Kojima H, 1999, J IMMUNOL, V162, P5063; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; McInnes LB, 2001, ARTHRITIS RHEUM, V44, P1481, DOI 10.1002/1529-0131(200107)44:7<1481::AID-ART268>3.0.CO;2-1; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200; Morel JCM, 2001, LAB INVEST, V81, P1371, DOI 10.1038/labinvest.3780351; Nishibe T, 2001, BLOOD, V97, P692, DOI 10.1182/blood.V97.3.692; Oertli B, 1998, J IMMUNOL, V161, P3431; OKADA T, 1994, J BIOL CHEM, V269, P3568; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; Olee T, 1999, J IMMUNOL, V162, P1096; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; Schindler H, 2001, J IMMUNOL, V166, P3075, DOI 10.4049/jimmunol.166.5.3075; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Thomas JA, 1999, J IMMUNOL, V163, P978; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsuji-Takayama K, 1999, CELL IMMUNOL, V196, P41, DOI 10.1006/cimm.1999.1542; Verbeek BS, 1999, EXP CELL RES, V248, P531, DOI 10.1006/excr.1999.4416; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E	77	93	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34679	34691		10.1074/jbc.M206337200	http://dx.doi.org/10.1074/jbc.M206337200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105209	hybrid			2022-12-27	WOS:000178117000006
J	Lee, DK; Kim, BC; Brady, JN; Jeang, KT; Kim, SJ				Lee, DK; Kim, BC; Brady, JN; Jeang, KT; Kim, SJ			Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of smad proteins with smad-binding element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TAX; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTION; COACTIVATORS CBP/P300; POTENTIAL MECHANISM; TRANSACTIVATOR TAX; DNA-BINDING; LEUKEMIA; GENE; EXPRESSION	The human T-cell lymphotropic virus type I (HTLV-1) oncoprotein Tax is implicated in various clinical manifestations associated with infection by HTLV-1, including an aggressive and fatal T-cell malignancy. Because many human HTLV-1-infected T-cell lines are resistant to the growth inhibitory activity of transforming growth factor beta (TGF-beta), we examined the possibility that the HTVL-1-Tax oncoprotein regulates TGF-beta signaling. We show that Tax significantly decreases transcriptional activity and growth inhibition in response to TGF-beta. Tax inhibits TGF-beta-induced plasminogen activator inhibitor-1 expression and Smad2 phosphorylation. Competitive interaction studies show that Tax inhibits TGF-beta signaling, in part, by disrupting the interaction of the Smads with the transcriptional co-activator p300. Tax directly interacts with Smad2, Smad3, and Smad4; the Smad MH2 domain binds to Tax. Furthermore, Tax inhibits Smad3.Smad4 complex formation and its DNA binding. These results suggest that suppression of Smad-mediated signaling by Tax may contribute to HTLV-1-associated leukemogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; BALLARD DW, 1988, SCIENCE, V241, P652; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; Chang J, 1997, CANCER RES, V57, P2856; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HOLLSBERG P, 1994, J IMMUNOL, V153, P566; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogawa S, 1996, ONCOGENE, V13, P183; Ogawa S, 1996, Hum Cell, V9, P323; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; ROSENBLATT JD, 1995, CURR TOP MICROBIOL, V193, P25; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	54	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33766	33775		10.1074/jbc.M200150200	http://dx.doi.org/10.1074/jbc.M200150200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097320	hybrid			2022-12-27	WOS:000177959100033
J	Wang, NP; Verna, L; Chen, NG; Chen, J; Li, HL; Forman, BM; Stemerman, MB				Wang, NP; Verna, L; Chen, NG; Chen, J; Li, HL; Forman, BM; Stemerman, MB			Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ADENOVIRUS-MEDIATED OVEREXPRESSION; PPAR-GAMMA; C-JUN; EXPRESSION; INHIBIT; LDL; ADHESIVENESS; INDUCTION; PROTEIN-1	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-activated nuclear receptor that has an essential role in adipogenesis and glucose homeostasis. PPAR-gamma is expressed in vascular tissues including endothelial cells (ECs). PPAR-gamma activity can be regulated by many pathophysiological and pharmacological agonists. However, the role of PPAR-gamma activation in ECs remains unclear. In this study, we examined the effect of the constitutive activation of PPAR-gamma on the phenotypic modulation of ECs. Adenovirus-mediated expression of a constitutively active mutant of PPAR-gamma resulted in significant ligand-independent activation of PPAR-gamma and specific induction of the PPAR-gamma target genes. However, PPAR-gamma activation significantly suppressed the expression of vascular adhesion molecules in ECs and the ensuing leukocyte recruitment. Furthermore, constitutive activation of PPAR-gamma resulted in simultaneous repression of AP-1 and NF-kappaB activity, which suggests that PPAR-gamma may reduce pro-inflammatory phenotypes via, at least in part, suppression of the AP-1 and NF-kappaB pathways. Therefore, using a gain-of-function approach, our study provides novel evidence showing that constitutive activation of PPAR-gamma is sufficient to prevent ECs from converting into a pro-inflammatory phenotype. These results also suggest that, in addition to pharmacological agonists, the genetic modification of the PPAR-gamma activity in ECs may be a potential approach for therapeutic intervention in various inflammatory disorders.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Endocrinol & Metab, Duarte, CA 91010 USA	University of California System; University of California Riverside; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Wang, NP (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.		Wang, Nanping/G-1818-2011	Wang, Nanping/0000-0002-8528-8132	NHLBI NIH HHS [HL 33742-15A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen NG, 1999, BIOCHEM BIOPH RES CO, V263, P718, DOI 10.1006/bbrc.1999.1437; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Frenette PS, 1996, NEW ENGL J MED, V335, P43, DOI 10.1056/NEJM199607043350108; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Larcher C, 2001, J INVEST DERMATOL, V116, P150, DOI 10.1046/j.1523-1747.2001.00235.x; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Paludan SR, 2001, J VIROL, V75, P8008, DOI 10.1128/JVI.75.17.8008-8015.2001; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Smalley DM, 1996, ARTERIOSCL THROM VAS, V16, P585, DOI 10.1161/01.ATV.16.4.585; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tang QZ, 1996, J EXP MED, V184, P1435, DOI 10.1084/jem.184.4.1435; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang NP, 1999, ARTERIOSCL THROM VAS, V19, P2078, DOI 10.1161/01.ATV.19.9.2078; Wang NP, 2001, ARTERIOSCL THROM VAS, V21, P1414, DOI 10.1161/hq0901.095549; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097	25	191	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34176	34181		10.1074/jbc.M203436200	http://dx.doi.org/10.1074/jbc.M203436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107164	hybrid			2022-12-27	WOS:000177959100085
J	Zhang, ZX; Qiu, WY; Quinn, SJ; Conigrave, AD; Brown, EM; Bai, M				Zhang, ZX; Qiu, WY; Quinn, SJ; Conigrave, AD; Brown, EM; Bai, M			Three adjacent serines in the extracellular domains of the CaR are required for L-amino acid-mediated potentiation of receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-SENSING RECEPTOR; LIGAND-BINDING DOMAIN; CA2+-SENSING RECEPTOR; STRUCTURAL BASIS; BRAIN-FUNCTION; MUTATIONS; CELLS	The extracellular calcium (Ca-o(2+))-sensing receptor (CaR) is a key player in Ca-o(2+) homeostasis. The activity of CaR can be potentiated by various L-amino acids. In this study, we examined whether conserved amino acid residues involved in the binding of glutamate to metabotropic glutamate receptors (mGluRs) also participate in the potentiation of the activity of CaR by L-phenylalanine. Ser-170 corresponding to Thr-188 in rat mGluR1a appears to be important for the modulating actions of phenylalanine. In the presence of phenylalanine, a mutant CaR with a single mutation S170A showed no Significant decrease in its EC50 for stimulation by Ca-o(2+) and a modest increase in its maximal activity. In addition, mutating Ser-169 and Ser-171 together with Ser-170 yielded a more complete block of the phenylalanine modulation than did the single mutation. The presence of the triple mutation, S169A/S170A/S171A, also eliminated phenylalanine potentiation of the activities of heterodimeric receptors in which one of the monomeric receptors had intact triple serines (A877Stop). The putative amino acid binding site of the CaR is probably close to or structurally dependent on the Ca-o(2+) binding sites of the receptor, because mutant CaRs with mutations in the putative amino acid binding site exhibited severely reduced responses to Ca-o(2+).	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Membrane Biol Program, Boston, MA 02115 USA; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Sydney	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.			Conigrave, Arthur/0000-0002-7232-3891	NIDDK NIH HHS [DK 48330, DK 52005, DK 54934, DK 41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054934, R01DK052005, R01DK048330, R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LH, 1979, AM J CLIN NUTR, V32, P741, DOI 10.1093/ajcn/32.4.741; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Conigrave AD, 2000, TRENDS PHARMACOL SCI, V21, P401, DOI 10.1016/S0165-6147(00)01546-7; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Kerstetter JE, 1997, AM J CLIN NUTR, V66, P1188, DOI 10.1093/ajcn/66.5.1188; KERSTETTER JE, 1990, J NUTR, V120, P134, DOI 10.1093/jn/120.1.134; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341	19	93	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33727	33735		10.1074/jbc.M200976200	http://dx.doi.org/10.1074/jbc.M200976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12095982	hybrid			2022-12-27	WOS:000177959100028
J	Lacoste, N; Utley, RT; Hunter, JM; Poirier, GG; Cote, J				Lacoste, N; Utley, RT; Hunter, JM; Poirier, GG; Cote, J			Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; PROTEIN; ACETYLTRANSFERASE; COMPLEX; H4	Yeast disruptor of telomeric silencing-1 (DOT1) is involved in gene silencing and in the pachytene checkpoint during meiotic cell cycle. Here we show that the Dot1 protein possesses intrinsic histone methyltransferase (HMT) activity. When compared with Rmt1, another putative yeast HMT, Dot1 shows very distinct substrate specificity. While Rmt1 methylates histone H4, Dot1 targets histone H3. In contrast to Rmt1, which can only modify free histones, Dot1 activity is specific to nucleosomal substrates. This was also confirmed using native chromatin purified from yeast cells. We also demonstrate that, like its mammalian homolog PRMT1, Rmt1 specifically dimethylates an arginine residue at position 3 of histone H4 N-terminal tail. In surprising contrast, methylation by Dot1 occurs in the globular domain of nucleosomal histone H3. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis suggests that H3 lysine 79 is trimethylated by Dot1. The intrinsic nucleosomal histone H3 methyltransferase activity of Dot1 is certainly a key aspect of its function in gene silencing at telomeres, most likely by directly modulating chromatin structure and Sir protein localization. In agreement with a role in regulating localization of histone deacetylase complexes like SIR, an increase of bulk histone acetylation is detected in dot1-cells.	Univ Laval, Ctr Canc Res, Hotel Dieu Quebec CHUQ, Quebec City, PQ G1R 2J6, Canada; CHU Laval, Res Ctr, Eastern Quebec Proteom Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Cote, J (corresponding author), Univ Laval, Ctr Canc Res, Hotel Dieu Quebec CHUQ, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.		Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X; Poirier, Guy/0000-0002-4869-1424				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; Dlakic M, 2001, TRENDS BIOCHEM SCI, V26, P405, DOI 10.1016/S0968-0004(01)01856-4; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Ohba R, 1999, MOL CELL BIOL, V19, P2061; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VANFLETEREN JR, 1987, FEBS LETT, V211, P59, DOI 10.1016/0014-5793(87)81274-7; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	21	220	234	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30421	30424		10.1074/jbc.C200366200	http://dx.doi.org/10.1074/jbc.C200366200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12097318	hybrid			2022-12-27	WOS:000177579800004
J	Bailly, V; Zhang, ZW; Meier, W; Cate, R; Sanicola, M; Bonventre, JV				Bailly, V; Zhang, ZW; Meier, W; Cate, R; Sanicola, M; Bonventre, JV			Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL INTERACTIONS; MEDIATED RELEASE; TNF-ALPHA; MATRIX; ECTODOMAIN; INTEGRIN; IDENTIFICATION; EXPRESSION; MUCIN; L1	KIM-1 (kidney injury molecule-1) is a type I transmembrane glycoprotein expressed on dedifferentiated renal proximal tubule epithelial cells undergoing regeneration after toxic or ischemic injury. The extracellular domain of KIM-1 is composed of an immunoglobulin-like domain topping a long mucin-like domain, a structure that points to a possible role in cell adhesion by homology to several known adhesion proteins. Two splice variants (a and b), of the human KIM-1 having identical extracellular domains, differ in their cytoplasmic domains and tissue distributions. In this study, we report that the KIM-1b transcript is expressed predominantly in adult human kidney. We describe the generation of 10 monoclonal antibodies against the extracellular domain of human KIM-1, the mapping of their binding sites, and their use in identifying various forms of the protein. We show that human KIM-1b is expressed in adult kidney cell lines, and we demonstrate that a soluble form of KIM-1 is shed constitutively into the culture medium of the cell lines expressing endogenous or recombinant KIM-1b by membrane-proximal cleavage. A monoclonal antibody that binds at or close to the proteolytic site can partially block the shedding of KIM-1. Release of soluble KIM-1 is enhanced by activating the cells with phorbol 12-myristate 13-acetate and can be inhibited with two metalloproteinase inhibitors, BB-94 (Batimastat) and GM6001 (Ilomastat), suggesting that the cleavage is mediated by a metalloproteinase. We propose that the shedding of KIM-1 in the kidney undergoing regeneration constitutes an active mechanism allowing dedifferentiated regenerating cells to scatter on denuded patches of the basement membrane and reconstitute a continuous epithelial layer.	Harvard Univ, Sch Med,Div Hlth Serv & Technol, Dept Med,Harvard Massachusetts Inst Technol, Massachusetts Gen Hosp,Med Serv, Charlestown, MA 02129 USA; Biogen Inc, Cambridge, MA 02142 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Broad Institute; Biogen	Bailly, V (corresponding author), 14th Cambridge Ctr, Cambridge, MA 02142 USA.	Veronique_Bailly@biogen.com						Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Barclay AN, 1999, P NATL ACAD SCI USA, V96, P14672, DOI 10.1073/pnas.96.26.14672; Beer S, 1999, J CELL SCI, V112, P2667; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; DeLoia JA, 1998, HUM REPROD, V13, P2902, DOI 10.1093/humrep/13.10.2902; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; Han WK, 2002, J AM SOC NEPHROL, V13, p472A; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Jimenez RE, 2000, ANN SURG, V231, P644, DOI 10.1097/00000658-200005000-00004; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kreidberg JA, 2000, AM J PHYSIOL-RENAL, V279, pF233, DOI 10.1152/ajprenal.2000.279.2.F233; LECA G, 1995, J IMMUNOL, V154, P1069; Leung KH, 1999, BIOCHEM BIOPH RES CO, V260, P734, DOI 10.1006/bbrc.1999.0965; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Molina MA, 2001, CANCER RES, V61, P4744; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NYBROE O, 1989, J NEUROCHEM, V53, P1372, DOI 10.1111/j.1471-4159.1989.tb08527.x; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wills-Karp M, 2001, NAT IMMUNOL, V2, P1095, DOI 10.1038/ni1201-1095; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	46	254	292	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39739	39748		10.1074/jbc.M200562200	http://dx.doi.org/10.1074/jbc.M200562200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12138159	hybrid			2022-12-27	WOS:000178662500088
J	Patel, VA; Dunn, MJ; Sorokin, A				Patel, VA; Dunn, MJ; Sorokin, A			Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; COLON-CANCER CELLS; APOPTOSIS; EXPRESSION; ACTIVATION; CARCINOGENESIS; BIOCHEMISTRY; TRANSPORTER; MODULATION; LEUKEMIA	Cyclooxygenase-2 (Cox-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, has been shown to be overexpressed in a wide range of tumors and possesses proangiogenic and antiapoptotic properties. To understand the molecular mechanism of Cox-2 action we used adenovirus-mediated transfer of rat Cox-2 cDNA into renal rat mesangial cells and determined the differential gene expression using cDNA microarrays. One of the several genes that were highly up-regulated by over expressed Cox-2 was MDR1. MDR1 or P-glycoprotein (P-gp), the product of the MDR1 gene, is implicated as the primary cause of multidrug resistance (MDR) in tumors where it acts as an efflux pump for chemotherapeutic agents. It is also expressed in normal tissues of the liver and kidney where it functions to actively transport lipophilic xenobiotics. Reverse transcriptase-PCR analysis confirmed the results of the microarray, showing increased mRNA levels for MDR1 in Cox-2 overexpressing cells. This increase in mRNA translated to an increase in MDR1 protein expression, which was dose-dependent on Cox-2 expression. Furthermore, using rhodamine 123 efflux assay we observed a significant increase in P-gp activity in Cox-2 overexpressing renal mesangial cells. The specific Cox-2 inhibitor NS398 was able to block the Cox-2-mediated increase in MDRI expression and activity, suggesting that Cox-2 products may be implicated in this response. These results prove the existence of a causal link between Cox-2 and P-gp activity, which would have implications for kidney function and multidrug resistance in tumors where Cox-2 is overexpressed.	Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, T32HL007792, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22563, 5T32HL07792] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLOREUSS E, 1994, AM J PHYSIOL-CELL PH, V267, pC1351, DOI 10.1152/ajpcell.1994.267.5.C1351; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; BRUNE K, 1999, CYCLOOXYGENASE INHIB; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Ernest S, 1997, NEPHRON, V77, P284, DOI 10.1159/000190289; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Kawamori T, 1998, CANCER RES, V58, P409; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ratnasinghe D, 2001, ANTICANCER RES, V21, P2141; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Sheng HM, 1998, CANCER RES, V58, P362; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7	25	152	179	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38915	38920		10.1074/jbc.M206855200	http://dx.doi.org/10.1074/jbc.M206855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138126	hybrid			2022-12-27	WOS:000178529600114
J	Soler, F; Fortea, MI; Lax, A; Fernandez-Belda, F				Soler, F; Fortea, MI; Lax, A; Fernandez-Belda, F			Dissecting the hydrolytic activities of sarcoplasmic reticulum ATPase in the presence of acetyl phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; CA2+-ATPASE; TRANSPORT; SUBSTRATE; CYCLE; CA2+; THAPSIGARGIN; MECHANISM; MEMBRANES; VESICLES	Sarcoplasmic reticulum vesicles and purified Ca2+-ATPase hydrolyze acetyl phosphate both in the presence and absence of Ca2+. The Ca2+-independent activity was fully sensitive to vanadate, insensitive to thapsigargin, and proceeded without accumulation of phosphorylated enzyme. Acetyl phosphate hydrolysis in the absence of Ca2+ was activated by dimethyl sulfoxide. The Ca2+-dependent activity was partially sensitive to vanadate, fully sensitive to thapsigargin, and associated with steady phosphoenzyme accumulation. The Ca2+/P-i coupling ratio at neutral pH sustained by 10 mm acetyl phosphate was 0.57. Addition of 30% dimethyl sulfoxide completely blocked Ca2+ transport and partially inhibited the hydrolysis rate. Uncoupling induced by dimethyl sulfoxide included the accumulation of vanadate-insensitive phosphorylated enzyme. When acetyl phosphate was the substrate, the hydrolytic pathway was dependent on experimental conditions that might or might not allow net Ca2+ transport. The interdependence of both Ca2+-dependent and Ca2+-independent hydrolytic activities was demonstrated.	Univ Murcia, Dept Bioquim & Biol Mol A, E-30071 Murcia, Spain	University of Murcia	Fernandez-Belda, F (corresponding author), Univ Murcia, Dept Bioquim & Biol Mol A, Edificio Vet,Campus Espinardo, E-30071 Murcia, Spain.	fbelda@um.es	LAX, ANTONIO MANUEL/AAB-2135-2020; LAX, ANTONIO/Q-3177-2016	LAX, ANTONIO MANUEL/0000-0001-5452-8781; LAX, ANTONIO/0000-0001-5452-8781				ASANO S, 1992, J BIOL CHEM, V267, P6590; BARRABIN H, 1990, BIOCHIM BIOPHYS ACTA, V1023, P266, DOI 10.1016/0005-2736(90)90422-K; BERBERIAN G, 1985, BIOCHIM BIOPHYS ACTA, V821, P17, DOI 10.1016/0005-2736(85)90148-8; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; CHINI EN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P152, DOI 10.1016/0005-2736(90)90250-R; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1969, J BIOL CHEM, V244, P3733; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fernandez-Belda F, 2001, J BIOL CHEM, V276, P7998, DOI 10.1074/jbc.M008648200; Fortea MI, 2001, J BIOL CHEM, V276, P37266, DOI 10.1074/jbc.M103949200; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; Hua SM, 1999, BIOPHYS J, V77, P2217, DOI 10.1016/S0006-3495(99)77062-1; INESI G, 1980, J BIOL CHEM, V255, P6040; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V20, P215, DOI 10.1016/0006-3002(56)90280-3; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LIGURI G, 1980, ARCH BIOCHEM BIOPHYS, V200, P357, DOI 10.1016/0003-9861(80)90365-3; LIPMANN F, 1945, J BIOL CHEM, V159, P21; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; NAKAMURA Y, 1978, J BIOCHEM-TOKYO, V83, P571, DOI 10.1093/oxfordjournals.jbchem.a131945; PUCELL A, 1971, J BIOL CHEM, V246, P3389; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; WANG G, 1977, ARCH BIOCHEM BIOPHYS, V344, P309; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	35	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38127	38132		10.1074/jbc.M203966200	http://dx.doi.org/10.1074/jbc.M203966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12130639	hybrid			2022-12-27	WOS:000178529600021
J	Morosinotto, T; Baronio, R; Bassi, R				Morosinotto, T; Baronio, R; Bassi, R			Dynamics of chromophore binding to Lhc proteins in vivo and in vitro during operation of the xanthophyll cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; II ANTENNA COMPLEX; FEMTOSECOND TRANSIENT ABSORPTION; RESOLVED FLUORESCENCE ANALYSIS; CHLOROPHYLL ENERGY-TRANSFER; VIOLAXANTHIN DE-EPOXIDASE; PHOTOSYSTEM-II; DICYCLOHEXYLCARBODIIMIDE-BINDING; MUTATION ANALYSIS; HIGHER-PLANTS	Three plant xanthophylls are components of the xanthophyll cycle in which, upon exposure of leaves to high light, the enzyme violaxanthin de-epoxidase (VDE) transforms violaxanthin into zeaxanthin via the intermediate antheraxanthin. Previous work (1) showed that xanthophylls are bound to Lhc proteins and that substitution of violaxanthin with zeaxanthin induces conformational changes and fluorescence quenching by thermal dissipation. We have analyzed the efficiency. of different Lhc proteins to exchange violaxanthin with zeaxanthin both in vivo and in vitro. Light stress of Zea mays leaves activates VDE, and the newly formed zeaxanthin is found primarily in CP26 and CP24, whereas other Lhc proteins show a lower exchange capacity. The de-epoxidation system has been reconstituted in vitro by using recombinant Lhc proteins, recombinant VDE, and monogalactosyl diacylglycerol (MGDG) to determine the intrinsic capacity for violaxanthin-to-zeaxanthin exchange of individual Lhc gene products. Again, CP26 was the most efficient in xanthophyll exchange. Biochemical and spectroscopic analysis of individual Lhc proteins after de-epoxidation in vitro showed that xanthophyll exchange occurs at the L2-binding site. Xanthophyll exchange depends on low pH, implying that access to the binding site is controlled by a conformational change via lumenal pH. These findings suggest that the xanthophyll cycle participates in a signal transduction system acting in the modulation of light harvesting versus thermal dissipation in the antenna system of higher plants.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy	University of Verona	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Strada Grazie, I-37134 Verona, Italy.	bassi@sci.univr.it	Morosinotto, Tomas/AAC-3188-2019	Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446				BASSI R, 1987, J BIOL CHEM, V262, P13333; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; CAFFARRI S, 2001, PS2001 P 12 INT C PH, pS31; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 2000, PHOTOSYNTH RES, V64, P221, DOI 10.1023/A:1006455230379; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; Croce R, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P421; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DAINESE P, 1992, RES PHOTOSYNTHESIS, V1, P287; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Dominici P, 2002, J BIOL CHEM, V277, P22750, DOI 10.1074/jbc.M200604200; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Hieber AD, 2002, PLANTA, V214, P476, DOI 10.1007/s00425-001-0704-2; JAHNS P, 1990, EUR J BIOCHEM, V193, P731, DOI 10.1111/j.1432-1033.1990.tb19393.x; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Kok B, 1966, Photochem Photobiol, V4, P215; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SIEFERMANSHARMS.D, 1974, BIOCHIM BIOPHYS ACTA, P144; Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Walters RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/pnas.93.24.14204; YAMAMOTO HY, 1985, METHOD ENZYMOL, V110, P303; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1978, ARCH BIOCHEM BIOPHYS, V190, P514, DOI 10.1016/0003-9861(78)90305-3	52	90	91	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36913	36920		10.1074/jbc.M205339200	http://dx.doi.org/10.1074/jbc.M205339200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12114527	hybrid			2022-12-27	WOS:000178447100003
J	Goldberg, GS; Moreno, AP; Lampe, PD				Goldberg, GS; Moreno, AP; Lampe, PD			Gap junctions between cells expressing connexin 43 or 32 show inverse permselectivity to adenosine and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA-CELLS; CHANNELS; SELECTIVITY; CONDUCTANCE; COMMUNICATION; PERMEABILITY; METABOLITES	Gap junctions, composed of proteins from the connexin family, are the only channels that directly connect the cytoplasm of adjacent cells to allow for the intercellular transfer of small hydrophilic molecules. Gap junctional communication is essential for proper development and health in animals and humans. Whereas the study of biological molecules that pass through gap junctions is extremely important, the identification of endogenous transjunctional metabolites is challenging. To help address this problem, we have developed a layered culture system to identify and quantitate the transfer of endogenous molecules that pass between cells through gap junctions. Using these techniques, we have identified several endogenous molecules that showed differential transfer between channels composed of Cx32 versus Cx43. For example, adenosine passed about 12-fold better through channels formed by Cx32. In contrast, AMP and ADP passed about 8-fold better, and ATP greater than 300-fold better, through channels formed by Cx43. Thus, addition of phosphate to adenosine appears to shift its relative permeability from channels formed by Cx32 to channels formed by Cx43. This suggests functional consequence because the energy status of a cell could be controlled via connexin expression and channel formation.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Indiana University System; Indiana University-Purdue University Indianapolis; Fred Hutchinson Cancer Center	Goldberg, GS (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Basic Sci Tower Level 6,Hlth Sci Complex, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL463469] Funding Source: Medline; NIGMS NIH HHS [R01 GM055632, GM55632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beblo DA, 1997, J GEN PHYSIOL, V109, P509, DOI 10.1085/jgp.109.4.509; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; Cao FL, 1998, J CELL SCI, V111, P31; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; Goldberg GS, 2000, CANCER RES, V60, P6018; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; GOLDBERG GS, 1995, BIOTECHNIQUES, V18, P490; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; Goldberg GS, 2001, METH MOL B, V154, P329; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; MORENO AP, 1991, BIOPHYS J, V60, P1254, DOI 10.1016/S0006-3495(91)82159-2; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; Ressot C, 2000, BRAIN RES REV, V32, P192, DOI 10.1016/S0165-0173(99)00081-8; Revilla A, 1999, BIOPHYS J, V77, P1374, DOI 10.1016/S0006-3495(99)76986-9; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Veenstra RD, 2001, BIOPHYS J, V80, P2231, DOI 10.1016/S0006-3495(01)76196-6; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; Wang HZ, 1997, J GEN PHYSIOL, V109, P491, DOI 10.1085/jgp.109.4.491; White TW, 1999, ANNU REV PHYSIOL, V61, P283, DOI 10.1146/annurev.physiol.61.1.283; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X	26	179	187	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36725	36730		10.1074/jbc.M109797200	http://dx.doi.org/10.1074/jbc.M109797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119284	hybrid, Green Published			2022-12-27	WOS:000178275100119
J	Gougeon, PY; Prosser, DC; Da-Silva, LF; Ngsee, JK				Gougeon, PY; Prosser, DC; Da-Silva, LF; Ngsee, JK			Disruption of Golgi morphology and trafficking in cells expressing mutant prenylated Rab acceptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE; 2-HYBRID SYSTEM; MEMBRANE-FUSION; PROTEIN; YEAST; RECEPTOR; EFFECTOR; NETWORK; HOMOLOG; GTPASE	Prenylated Rab acceptor (PRAI) is a protein that binds Rab GTPases and the v-SNARE VAMP2. The protein is localized to the Golgi complex and post-Golgi vesicles. To determine its functional role, we generated a number of point mutations and divided them into three classes based on cellular localization. Class A mutants were retained in the endoplasmic reticulum (ER) and exerted an inhibitory effect on transport of vesicular stomatitis virus envelope glycoprotein (VSVG) from the ER to Golgi as well as to the plasma membrane. Class B mutants exhibited a highly condensed Golgi complex and inhibited exit of anterograde cargo from this organelle. Class C mutants exhibited an intermediate phenotype with Golgi and ER localization along with extensive tubular structures emanating from the Golgi complex. There was a direct correlation between the cellular phenotype and binding to Rab and VAMP2. Class A and C mutants showed a significant decrease in Rab and VAMP2 binding, whereas an increase in binding was observed in the class B mutants. Thus, PRA1 is required for vesicle formation from the Golgi complex and might be involved in recruitment of Rab effectors and SNARE proteins during cargo sequestration.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute	Ngsee, JK (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada.			Prosser, Derek/0000-0002-6738-2758	Canadian Institutes of Health Research [14642] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Cao H, 2000, J CELL SCI, V113, P1993; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Evans DT, 2002, J VIROL, V76, P327, DOI 10.1128/JVI.76.1.327-337.2002; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Li LY, 2001, J BIOL CHEM, V276, P27354, DOI 10.1074/jbc.M103821200; Mammoto A, 2000, J BIOL CHEM, V275, P13167, DOI 10.1074/jbc.C000096200; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557	33	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36408	36414		10.1074/jbc.M205026200	http://dx.doi.org/10.1074/jbc.M205026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107180	hybrid, Green Accepted			2022-12-27	WOS:000178275100081
J	Le Jeune, IR; Shepherd, M; Van Heeke, G; Houslay, MD; Hall, IP				Le Jeune, IR; Shepherd, M; Van Heeke, G; Houslay, MD; Hall, IP			Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells - Identification and characterization of a novel PDE4D5 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; OBSTRUCTIVE PULMONARY-DISEASE; N-TERMINAL DOMAIN; MOLECULAR-CLONING; NUCLEOTIDE PHOSPHODIESTERASES; CHROMOSOMAL LOCALIZATION; DROSOPHILA-MELANOGASTER; SELECTIVE-INHIBITION; PROTEIN; GENE	Phosphodiesterase 41) (PDE4D), part of the complex cAMP-specific PDE4 family, plays a pivotal role in the regulation of airway smooth muscle relaxation by catalyzing the hydolysis of cAMP. Its gene on chromosome 5q12 encodes 5 splice variants, which show tissue-dependent expression and regulation. The genomic arrangement of PDE4D was determined using in silico methods, and a putative promoter of one of the protein kinase A-activated, long isoforms, PDE4D5 was identified. Promoter-luciferase constructs, transiently transfected into a beta(2) adrenoreceptor-expressing CHO-K1 cell line, were used to demonstrate that the PDE4D5 promoter up-regulated reporter gene expression in response to increased cell cAMP. Site-directed mutagenesis of the cAMP-response element (CRE) at position -201 identified this as the principal component of the mechanism underlying this cAMP responsiveness. In the second part of this study, cAMP-dependent induction of PDE4D5 transcript in primary cultured human airway smooth muscle cells (hASMs) was demonstrated using both qualitative reverse-transcriptase PCR and quantitative real-time PCR. Isolated PDE4D5 isoenzyme activity, measured after selective immunoprecipitation from hASMs, confirmed that this increase in expression led to an up-regulation of functional activity. We present evidence for cAMP-driven PDE4D5 up-regulation in hASMs and suggest a CRE-containing, isoform-specific promoter as the primary mechanism.	Univ Nottingham Hosp, Div Therapeut, Nottingham NG7 2UH, England; Univ Nottingham Hosp, Inst Cell Signalling, Nottingham NG7 2UH, England; Gartnavel Royal Hosp, Dept Resp Med, Glasgow G12, Lanark, Scotland; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England	University of Nottingham; University of Nottingham; Gartnavel Royal Hospital; University of Glasgow; Novartis	Hall, IP (corresponding author), Univ Nottingham Hosp, Div Therapeut, C Floor S Block, Nottingham NG7 2UH, England.	ian.hall@nottingham.ac.uk	Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091; Hall, Ian/0000-0001-9933-3216				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; Barnette M S, 1999, Prog Drug Res, V53, P193; Beard MB, 1999, FEBS LETT, V460, P173, DOI 10.1016/S0014-5793(99)01335-6; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Compton CH, 1999, AM J RESP CRIT CARE, V159, pA522; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DEBOER J, 1992, BRIT J PHARMACOL, V106, P1028; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Giembycz MA, 1996, TRENDS PHARMACOL SCI, V17, P331, DOI 10.1016/0165-6147(96)10039-0; HALL IP, 1992, BRIT J PHARMACOL, V107, P422, DOI 10.1111/j.1476-5381.1992.tb12762.x; HALL IP, 1995, AM J PHYSIOL-LUNG C, V268, pL1, DOI 10.1152/ajplung.1995.268.1.L1; Hay DWP, 2000, CURR OPIN CHEM BIOL, V4, P412, DOI 10.1016/S1367-5931(00)00105-8; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; HORTON YM, 1995, BIOCHEM J, V308, P683, DOI 10.1042/bj3080683; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; Kasuya J, 2000, BIOCHEM BIOPH RES CO, V268, P827, DOI 10.1006/bbrc.2000.2226; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MANGANIELLO VC, 1987, J MOL CELL CARDIOL, V19, P1037, DOI 10.1016/S0022-2828(87)80575-8; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; McDonnell J, 1998, BRIT J PHARMACOL, V125, P717, DOI 10.1038/sj.bjp.0702139; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Mehats C, 1999, ENDOCRINOLOGY, V140, P3228, DOI 10.1210/en.140.7.3228; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Norman P, 1998, EXPERT OPIN THER PAT, V8, P771, DOI 10.1517/13543776.8.7.771; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Rena G, 2001, MOL PHARMACOL, V59, P996, DOI 10.1124/mol.59.5.996; Schmidt D, 1999, CLIN EXP ALLERGY, V29, P99; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; Scott MGH, 1999, BRIT J PHARMACOL, V128, P721, DOI 10.1038/sj.bjp.0702829; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; SETTE C, 1994, J BIOL CHEM, V269, P9245; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sullivan M, 1999, CELL SIGNAL, V11, P735, DOI 10.1016/S0898-6568(99)00037-6; Sullivan M, 1998, BIOCHEM J, V333, P693, DOI 10.1042/bj3330693; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SZPIRER C, 1995, CYTOGENET CELL GENET, V69, P11, DOI 10.1159/000133927; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	61	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35980	35989		10.1074/jbc.M204832200	http://dx.doi.org/10.1074/jbc.M204832200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121997	hybrid			2022-12-27	WOS:000178275100028
J	Xiao, GZ; Jiang, D; Gopalakrishnan, R; Franceschi, RT				Xiao, GZ; Jiang, D; Gopalakrishnan, R; Franceschi, RT			Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOSTEAL BONE-FORMATION; OVARIECTOMIZED RATS; MC3T3-E1 CELLS; ASCORBIC-ACID; IN-VIVO; EXTRACELLULAR-MATRIX; MESSENGER-RNA; EXPRESSION; DIFFERENTIATION	Fibroblast growth factor 2 (FGF-2) is an important regulator of bone formation and osteoblast activity. However, its mechanism of action on bone cells is largely unknown. A major route for FGF signaling is through the mitogen-activated protein kinase (MAPK) pathway. We showed recently that this pathway is important for activation and phosphorylation of Cbfa1/Runx2, an osteoblast-related transcription factor (Xiao, G., Jiang, D., Thomas, P., Benson, M. D., Guan, K., Karsenty, G., and Franceschi, R. T. (2000) J. Biol. Chem. 275, 4453-4459). The present study examined the mechanism of FGF-2 regulation of the mouse osteocalcin gene in MC3T3-E1 preosteoblastic cells. FGF-2 stimulated osteocalcin mRNA and promoter activity in a dose- and time-dependent manner in MC3T3-E1 preosteoblastic cells. Similar results were obtained in mouse bone marrow stromal cells. This stimulation required Runx2 and its DNA binding site in the osteocalcin promoter. FGF-2 also dramatically increased phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) followed by phosphorylation of Runx2. Furthermore, a specific ERK1/2 phosphorylation inhibitor, U0126, completely blocked both FGF-2-stimulated Runx2 phosphorylation. and osteocalcin promoter activity, indicating that this regulation requires the MAPK pathway. Deletion studies showed that the C-terminal PST domain of Runx2 is required for the FGF-2 response. This study is the first demonstration that Runx2 is phosphorylated and activated by FGF-2 via the MAPK pathway and suggests that FGF-2 plays an important role in regulation of Runx2 function and bone formation.	Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Franceschi, RT (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014454, R01DE012211, R56DE011723, R01DE013386] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12211, DE13386, DE14454-01, DE 11723] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dunstan CR, 1999, J BONE MINER RES, V14, P953, DOI 10.1359/jbmr.1999.14.6.953; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANCESCHI RT, 1992, NUTR REV, V50, P65; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Lomri A, 1998, J CLIN INVEST, V101, P1310; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756-3282(94)00049-2; Nakamura K, 1998, INT ORTHOP, V22, P49, DOI 10.1007/s002640050207; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PITARU S, 1993, J BONE MINER RES, V8, P919; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; Rice DPC, 2000, DEVELOPMENT, V127, P1845; RODAN SB, 1989, J BIOL CHEM, V264, P19934; Shimizu-Sasaki K, 2001, J BIOL CHEM, V276, P5459, DOI 10.1074/jbc.M008971200; Suzuki A, 1996, J CELL BIOCHEM, V63, P491, DOI 10.1002/(SICI)1097-4644(19961215)63:4<491::AID-JCB10>3.0.CO;2-H; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Tsuji K, 2001, J BONE MINER METAB, V19, P213, DOI 10.1007/s007740170023; WINNARD RG, 1995, J BONE MINER RES, V10, P1969; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101	46	308	326	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36181	36187		10.1074/JBC.m206057200	http://dx.doi.org/10.1074/JBC.m206057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12110689	hybrid			2022-12-27	WOS:000178275100054
J	Horke, S; Reumann, K; Rang, A; Heise, T				Horke, S; Reumann, K; Rang, A; Heise, T			Molecular characterization of the human La protein-hepatitis B virus RNA.B interaction in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; SS-B; RECOGNITION MOTIF; ANTIGEN; AUTOANTIGEN; RIBONUCLEOPROTEIN; SEQUENCE; REGION; LIVER; SITE	The La protein was recently identified as a host factor potentially involved in the cytokine-induced post-transcriptional down-regulation of hepatitis B virus (HBV) RNA. The La binding site was mapped to a predicted stem-loop structure within a region shared by all HBV RNAs, and it was concluded that the La protein might be an HBV RNA-stabilizing factor. To characterize the RNA binding mediated by the different RNA recognition motifs (RRMs) of the human La protein, several La deletion mutants were produced and analyzed for HBV RNA binding ability. The data demonstrate that the first RRM is not required for binding, whereas the RNP-1 and RNP-2 consensus sequences of the RRM-2 and RRM-3 are separately required for binding, indicating a cooperative function of these two RRMs. Furthermore, the results suggest that multimeric La disassembles into monomeric La upon binding of HBV RNA.B. By gel retardation assay the affinity of the wild type human La.HBV RNA.B interaction was determined in the nanomolar range, comparable to the affinity determined for the mouse La.HBV RNA.B interaction. This study identified small regions within the human La protein mediating the binding of HBV RNA. Hence, these binding sites might represent targets for novel antiviral strategies based on the disruption of the human La.HBV RNA interaction, thereby leading to HBV RNA degradation.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	heise@hpi.uni-hamburg.de						Aigner S, 2000, EMBO J, V19, P6230, DOI 10.1093/emboj/19.22.6230; Ali N, 2000, J BIOL CHEM, V275, P27531; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1976, ARTHRITIS RHEUM-US, V19, P216, DOI 10.1002/art.1780190214; ANDO K, 1994, J IMMUNOL, V153, P482; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1987, MOL CELL BIOL, V7, P2588, DOI 10.1128/MCB.7.7.2588; CHAN EKL, 1989, NUCLEIC ACIDS RES, V17, P2233, DOI 10.1093/nar/17.6.2233; CHANG YN, 1995, J VIROL, V69, P618, DOI 10.1128/JVI.69.1.618-619.1995; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; Chisari FV, 2000, AM J PATHOL, V156, P1117, DOI 10.1016/S0002-9440(10)64980-2; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GUIDOTTI LG, 1994, P NATL ACAD SCI USA, V91, P3764, DOI 10.1073/pnas.91.9.3764; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; HABETS WJ, 1983, EMBO J, V2, P1625, DOI 10.1002/j.1460-2075.1983.tb01636.x; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Heise T, 2001, J VIROL, V75, P6874, DOI 10.1128/JVI.75.15.6874-6883.2001; Heise T, 1999, J VIROL, V73, P474, DOI 10.1128/JVI.73.1.474-481.1999; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Intine RVA, 2000, MOL CELL, V6, P339, DOI 10.1016/S1097-2765(00)00034-4; James MC, 1999, EUR J BIOCHEM, V266, P151, DOI 10.1046/j.1432-1327.1999.00839.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Spangberg K, 1999, J HUMAN VIROL, V2, P296; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; TOPFER F, 1993, J IMMUNOL, V150, P3091; Tsui LV, 1995, P NATL ACAD SCI USA, V92, P12398, DOI 10.1073/pnas.92.26.12398; Wang JN, 2000, PHYSICA E, V8, P141, DOI 10.1016/S1386-9477(00)00131-4; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	56	38	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34949	34958		10.1074/jbc.M201911200	http://dx.doi.org/10.1074/jbc.M201911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121976	hybrid			2022-12-27	WOS:000178117000039
J	Rafiee, P; Johnson, CP; Li, MS; Ogawa, H; Heidemann, J; Fisher, PJ; Lamirand, TH; Otterson, MF; Wilson, KT; Binion, DG				Rafiee, P; Johnson, CP; Li, MS; Ogawa, H; Heidemann, J; Fisher, PJ; Lamirand, TH; Otterson, MF; Wilson, KT; Binion, DG			Cyclosporine a enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS - Paradoxical proinflammatory effect on the microvascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; CROHNS-DISEASE; DOUBLE-BLIND; KAPPA-B; EXPRESSION; ADHESION; ACTIVATION; TRIAL; HYPERTENSION	The calcineurin inhibitor cyclosporine A (CsA) modulates leukocyte cytokine production but may also effect nonimmune cells, including microvascular endothelial cells, which regulate the inflammatory process through leukocyte recruitment. We hypothesized that CsA would promote a proinflammatory phenotype in human intestinal microvascular endothelial cells (HIMEC), by inhibiting inducible nitric-oxide synthase (iNOS, NOS2)-derived NO, normally an important mechanism in limiting endothelial activation and leukocyte adhesion. Primary cultures of HIMEC were used to assess CsA effects on endothelial activation, leukocyte interaction, and the expression of iNOS as well as cell adhesion molecules. CsA significantly increased leukocyte binding to activated HIMEC, but paradoxically decreased endothelial expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule-1). In contrast, CsA completely inhibited the expression of iNOS in tumor necrosis factor-alpha/lipopolysaccharide-activated HIMEC. CsA blocked p38 MAPK phosphorylation in activated HIMEC, a key pathway in iNOS expression, but failed to inhibit NFkappaB activation. These studies demonstrate that CsA exerts a proinflammatory effect on HIMEC by blocking iNOS expression. CsA exerts a proinflammatory effect on the microvascular endothelium, and this drug-induced endothelial dysfunction may help explain its lack of efficacy in the long-term treatment of chronically active inflammatory bowel disease.	Med Coll Wisconsin, Milwaukee Vet Affairs Med Ctr, Froedtert Mem Lutheran Hosp, Digest Dis Ctr,Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Milwaukee Vet Affairs Med Ctr, Froedtert Mem Lutheran Hosp, Dept Surg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Milwaukee Vet Affairs Med Ctr, Froedtert Mem Lutheran Hosp, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Maryland, Sch Med, Div Gastroenterol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Binion, DG (corresponding author), Med Coll Wisconsin, Milwaukee Vet Affairs Med Ctr, Froedtert Mem Lutheran Hosp, Digest Dis Ctr,Div Gastroenterol & Hepatol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	dbinion@mcw.edu		Wilson, Keith/0000-0003-4421-1830	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002469, R03DK056234] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02417, DK02469, DK56234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARNDT H, 1993, GASTROENTEROLOGY, V105, P675, DOI 10.1016/0016-5085(93)90882-D; Binion DG, 2000, FREE RADICAL BIO MED, V29, P881, DOI 10.1016/S0891-5849(00)00391-9; Binion DG, 1998, AM J PHYSIOL-GASTR L, V275, pG592, DOI 10.1152/ajpgi.1998.275.3.G592; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; BRYNSKOV J, 1991, SCAND J GASTROENTERO, V26, P689, DOI 10.3109/00365529108998585; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DE CR, 1995, J CLIN INVEST, V96, P60; FARUQI R, 1994, J CLIN INVEST, V94, P592, DOI 10.1172/JCI117374; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; Gao F, 2002, CARDIOVASC RES, V53, P414, DOI 10.1016/S0008-6363(01)00488-6; GAO SZ, 1989, CIRCULATION, V80, P100; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P646; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; KUROSE I, 1995, CIRC RES, V76, P30, DOI 10.1161/01.RES.76.1.30; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAWRENCE MB, 1987, BLOOD, V70, P1284; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; MARKS RM, 1985, IN VITRO CELL DEV B, V21, P627; Murley JS, 2001, FREE RADICAL BIO MED, V30, P1426, DOI 10.1016/S0891-5849(01)00554-8; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; Niwa K, 2001, FREE RADICAL RES, V35, P519, DOI 10.1080/10715760100301531; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Rasmussen LM, 2001, BIOCHEM J, V360, P363, DOI 10.1042/0264-6021:3600363; Riley TR, 1997, AM J GASTROENTEROL, V92, P279; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Sandborn WJ, 1996, AM J GASTROENTEROL, V91, P423; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; STANGE EF, 1995, GASTROENTEROLOGY, V109, P774, DOI 10.1016/0016-5085(95)90384-4; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI M, 1991, J LEUKOCYTE BIOL, V50, P488, DOI 10.1002/jlb.50.5.488; TEXTOR SC, 1994, MAYO CLIN PROC, V69, P1182, DOI 10.1016/S0025-6196(12)65772-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ventura HO, 1997, CURR OPIN CARDIOL, V12, P375, DOI 10.1097/00001573-199707000-00005; Wallace JL, 1999, GASTROENTEROLOGY, V117, P557, DOI 10.1016/S0016-5085(99)70448-8; Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; Yorek MA, 2002, METABOLISM, V51, P225, DOI 10.1053/meta.2002.29958; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	48	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35605	35615		10.1074/jbc.M205826200	http://dx.doi.org/10.1074/jbc.M205826200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110686	hybrid			2022-12-27	WOS:000178117000120
J	Yang, HP; Zeng, Y; Lee, TD; Yang, Y; Ou, XP; Chen, LX; Haque, M; Rippe, R; Lu, SC				Yang, HP; Zeng, Y; Lee, TD; Yang, Y; Ou, XP; Chen, LX; Haque, M; Rippe, R; Lu, SC			Role of AP-1 in the coordinate induction of rat glutamate-cysteine ligase and glutathione synthetase by tert-butylhydroquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; AMINO-ACID-SEQUENCE; GENE-EXPRESSION; LIGHT SUBUNIT; HEAVY SUBUNIT; C-JUN; RESPONSIVE ELEMENT; MESSENGER-RNA; HEPG2 CELLS; PROMOTER	GSH synthesis occurs via two enzymatic steps catalyzed by glutamate-cysteine ligase (GCL, made up of two subunits) and GSH synthetase (GS). Recently, we described coordinate induction of GCL subunits and GS. To study GS transcriptional regulation, we have cloned and characterized a 2.2-kb 5'-flanking region of the rat GS(GenBank(TM) accession number AF333982). One transcriptional start site is located at 51 nucleotides upstream of the translational start site. The rat GS promoter drove efficiently luciferase expression in H4IIE cells. Sequential deletion analysis revealed DNA regions that are involved in positive and negative regulation. One repressor identified was NF1. tert-Butylhydroquinone (TBH) exerted a dose- and time-dependent increase in the mRNA level and promoter activity of both GCL subunits and GS. TBH increased protein binding to several regions of the GS promoter, c-jun expression, and activator protein 1 (AP-1) binding activity to several of the putative AP-1-binding sites of the GS promoter. Blocking AP-1 binding with dominant-negative c-jun led to decreased basal expression and significantly blocked the TBH-induced increase in promoter activity and mRNA level of all three genes. In conclusion, AP-1 is required for basal expression of GCL and GS; while NF1 serves as a repressor of GS, increased AP-1 transactivation is the predominant mechanism for coordinate induction of GCL and GS expression by TBH.	Univ So Calif, Keck Sch Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Liver Dis Res Ctr,Div Gastroenterol & Liver Dis, Los Angeles, CA 90033 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Southern California; University of North Carolina; University of North Carolina Chapel Hill	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, HMR Bldg,415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu	Lu, Shelly/AAH-5937-2021	Lu, Shelly/0000-0003-2128-5407	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R56DK045334, R01DK045334, R29DK045334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010459, T32AA007578, R29AA010459] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32 AA07578, AA10459] Funding Source: Medline; NIDDK NIH HHS [P30 DK48522, DK-45334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; Galloway DC, 1998, BIOCHEM J, V336, P535, DOI 10.1042/bj3360535; Galloway DC, 1997, BIOCHEM J, V328, P99; HUANG CS, 1995, P NATL ACAD SCI USA, V92, P1232, DOI 10.1073/pnas.92.4.1232; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Huang ZZ, 2000, BBA-GENE STRUCT EXPR, V1493, P48, DOI 10.1016/S0167-4781(00)00156-1; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; Kang KW, 2001, MOL PHARMACOL, V59, P1147, DOI 10.1124/mol.59.5.1147; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; LU SC, 1992, J CLIN INVEST, V90, P524, DOI 10.1172/JCI115890; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Luo JL, 1998, AM J PHYSIOL-ENDOC M, V275, pE359, DOI 10.1152/ajpendo.1998.275.2.E359; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; SAKAI M, 1989, CANCER RES, V49, P5633; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; Shi ZZ, 1996, NAT GENET, V14, P361, DOI 10.1038/ng1196-361; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; YAN N, 1990, J BIOL CHEM, V265, P1588; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Yang HP, 2001, BIOCHEM BIOPH RES CO, V285, P476, DOI 10.1006/bbrc.2001.5190	31	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35232	35239		10.1074/jbc.M203812200	http://dx.doi.org/10.1074/jbc.M203812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093805	hybrid			2022-12-27	WOS:000178117000074
J	Marshall, HE; Stamler, JS				Marshall, HE; Stamler, JS			Nitrosative stress-induced apoptosis through inhibition of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; NITRIC-OXIDE; S-NITROSYLATION; BCL-X; ACTIVATION; TRANSCRIPTION; INDUCTION; GENE	Nitrosative stress produced by cytokines predisposes to apoptotic cell death. However, the molecular mechanism by which this occurs is not well understood. We have shown previously that nitric oxide (NO) regulates the activity of the anti-apoptotic transcription factor NF-kappaB. Here we demonstrate that the inhibition of NF-kappaB by NO sensitizes A549 and Jurkat T cells to tumor necrosis factor-alpha (TNFalpha)-induced apoptosis. The molecular basis of NF-kappaB inhibition is different in the two cell types. In A549 cells, NO functions at the nuclear level to inhibit NF-kappaB by S-nitrosylation. In Jurkat cells, NO inhibits the NF-kappaB activating pathway in the cytoplasm at a step proximal to the degradation of IkappaBalpha. The inhibition of NF-kappaB is reflected in the level of intracellular S-nitrosothiols, which are constitutively metabolized. These data suggest that NO can influence cell death by modulating NF-kappaB activity with the sites of inhibition being cell type-specific. The data also show that NO bioactivity regulates tumor necrosis factor-a signaling.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Room 321,MSRB,Box 2612, Durham, NC 27710 USA.			Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004287] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL 04287] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; delaTorre A, 1999, J IMMUNOL, V162, P4101; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Klatt P, 2000, BIOCHEM J, V349, P567, DOI 10.1042/0264-6021:3490567; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680	38	84	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34223	34228		10.1074/jbc.M201638200	http://dx.doi.org/10.1074/jbc.M201638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091382	hybrid			2022-12-27	WOS:000177959100091
J	Papo, N; Oren, Z; Pag, U; Sahl, HG; Shai, Y				Papo, N; Oren, Z; Pag, U; Sahl, HG; Shai, Y			The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE CYTOTOXICITY; PHOSPHOLIPID-MEMBRANES; ANTIBACTERIAL ACTIVITY; INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; AMPHIBIAN SKIN; OUTER-MEMBRANE; AMINO-ACIDS; PROTEINS; ANALOGS	The search for antibiotics with a new mode of action led to numerous studies on antibacterial peptides. Most of the studies were carried out with L-amino acid peptides possessing amphipathic alpha-helix or beta-sheet structures, which are known to be important for biological activities. Here we compared the effect of significantly altering the sequence of an amphipathic a-helical peptide (15 amino acids long) and its diastereomer (composed of both L- and D-amino acids) regarding their structure, function, and interaction with model membranes and intact bacteria. Interestingly, the effect of sequence alteration on biological function was similar for the L-amino acid peptides and the diastereomers, despite some differences in their structure in the membrane as revealed by attenuated total reflectance Fourier-transform infrared spectroscopy. However, whereas the all L-amino acid peptides were highly hemolytic, had low solubility, lost their activity in serum, and were fully cleaved by trypsin and proteinase K, the diastereomers were nonhemolytic and maintained full activity in serum. Furthermore, sequence alteration allowed making the diastereomers either fully, partially, or totally protected from degradation by the enzymes. Transmembrane potential depolarization experiments in model membranes and intact bacteria indicate that although the killing mechanism of the diastereomers is via membrane perturbation, it is also dependent on their ability to diffuse into the inner bacterial membrane. These data demonstrate the advantage of the diastereomers over their all L-amino acid counterparts as candidates for developing a repertoire of new target antibiotics with a potential for systemic use.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Bonn, Inst Med Microbiol & Immunol, D-53127 Bonn, Germany	Weizmann Institute of Science; University of Bonn	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yeehiel.Shai@weizmann.ac.il	Papo, Niv/R-3946-2017; Pag, Ulrike/C-1492-2008					ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; BARRA D, 1995, TRENDS BIOTECHNOL, V13, P205, DOI 10.1016/S0167-7799(00)88947-7; BESSALLE R, 1992, ANTIMICROB AGENTS CH, V36, P313, DOI 10.1128/AAC.36.2.313; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P923, DOI 10.1002/bip.360230509; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MANTSCH HH, 1993, BIOPOLYMERS, V33, P201, DOI 10.1002/bip.360330202; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MIYAZAWA T, 1960, J MOL SPECTROSC, V4, P168, DOI 10.1016/0022-2852(60)90076-X; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1999, EUR J BIOCHEM, V259, P360, DOI 10.1046/j.1432-1327.1999.00047.x; PEZOLET M, 1992, FEBS LETT, V299, P247, DOI 10.1016/0014-5793(92)80125-Z; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; RUSSELL PE, 1995, 50 YEARS ANTIMICROBI, P67; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; Tossi A, 2000, BIOPOLYMERS, V55, P4; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zhang LJ, 2000, BIOCHEMISTRY-US, V39, P14504, DOI 10.1021/bi0011173	55	193	213	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33913	33921		10.1074/jbc.M204928200	http://dx.doi.org/10.1074/jbc.M204928200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110678	hybrid			2022-12-27	WOS:000177959100053
J	Muller, R; Altmann, F; Zhou, DP; Hennet, T				Muller, R; Altmann, F; Zhou, DP; Hennet, T			The Drosophila melanogaster brainiac protein is a glycolipid-specific beta 1,3N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; EXPRESSION ANALYSIS; CELL-GROWTH; CLONING; FRINGE; GENE; IDENTIFICATION; RECEPTOR; NOTCH	Mutations at the Drosophila melanogaster brainiac locus lead to defective formation of the follicular epithelium during oogenesis and to neural hyperplasia. The brainiac gene encodes a type H transmembrane protein structurally similar to mammalian beta1,3-glycosyltransferases. We have cloned the brainiac gene from D. melanogaster genomic DNA and expressed it as a FLAG-tagged recombinant protein in Sf9 insect cells. Glycosyltransferase assays showed that brainiac is capable of transferring N-acetylglucosamine (GlcNAc) to beta-linked mannose (Man), with a marked preference for the disaccharide Man(beta1,4)Glc, the core of arthro-series glycolipids. The activity of brainiac toward arthro-series glycolipids was confirmed by showing that the enzyme efficiently utilized glycolipids from insects as acceptors whereas it did not with glycolipids from mammalian cells. Methylation analysis of the brainiac reaction product revealed a beta1,3 linkage between GlcNAc and Man, proving that brainiac is a beta1,3GlcNAc-transferase. Human beta1,3GlcNAc-transferases structurally related to brainiac were unable to transfer GlcNAc to Man(beta1,4)Glc-based acceptor substrates and failed to rescue a homozygous lethal brainiac allele, indicating that these proteins are paralogous and not orthologous to brainiac.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria	University of Zurich; University of Natural Resources & Life Sciences, Vienna	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Zhou, Dapeng/A-6446-2019; zhou, dapeng/GXG-9715-2022	Zhou, Dapeng/0000-0003-1347-3811; Altmann, Friedrich/0000-0002-0112-7877				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Cole SE, 2001, MAMM GENOME, V12, P177, DOI 10.1007/s003350010241; Dennis R D, 1986, Biomed Chromatogr, V1, P31, DOI 10.1002/bmc.1130010108; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Egan S, 2000, GLYCOCONJUGATE J, V17, P867, DOI 10.1023/A:1010921313314; GANS M, 1975, GENETICS, V81, P683; Gerdt S, 1997, GLYCOBIOLOGY, V7, P265, DOI 10.1093/glycob/7.2.265; Goode S, 1997, COLD SPRING HARB SYM, V62, P177; GOODE S, 1992, DEVELOPMENT, V116, P177; Goode S, 1996, DEVELOPMENT, V122, P3863; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Hacker U, 1997, DEVELOPMENT, V124, P3565; Henion TR, 2001, J BIOL CHEM, V276, P30261, DOI 10.1074/jbc.M102979200; Hennet T, 1999, BBA-GEN SUBJECTS, V1473, P123, DOI 10.1016/S0304-4165(99)00173-7; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; Marroquin LD, 2000, GENETICS, V155, P1693; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERRIMON N, 1989, GENETICS, V121, P333; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Swan A, 2001, GENOME RES, V11, P67, DOI 10.1101/gr.156001; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; WIEGANDT H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P117, DOI 10.1016/0005-2760(92)90101-Z; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	45	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32417	32420		10.1074/jbc.C200381200	http://dx.doi.org/10.1074/jbc.C200381200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12130631	hybrid			2022-12-27	WOS:000177859000004
J	Rokhlin, OW; Glover, RA; Taghiyev, AF; Guseva, NV; Seftor, REB; Shyshynova, I; Gudkov, AV; Cohen, MB				Rokhlin, OW; Glover, RA; Taghiyev, AF; Guseva, NV; Seftor, REB; Shyshynova, I; Gudkov, AV; Cohen, MB			Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SELECTIVE INHIBITOR; APOPTOSIS; P53; TRAIL; LINES; RESISTANCE; POTENT; DRUGS	Bisindolylmaleimides (Bis) were originally described as protein kinase C inhibitors. Several studies have shown that Bis potentiate tumor necrosis factor (TNF) receptor family-mediated apoptosis in lymphoid and dendritic cells, but the inhibition of protein kinase C cannot account for these effects (Zhou, T., Song, L., Yang, P., Wang, Z., Lui, D., and Jope, R. S. (1999) Nat. Med. 5, 42-48). We investigated the effect of four Bis derivatives (I, II, VIII, and IX) in human prostatic carcinoma cell lines and found that Bis IX was the most potent inducer of apoptosis under simultaneous treatment with TNF-alpha, agonistic anti-Fas monoclonal antibody, and TNF-related apoptosis-inducing ligand (TRAIL). Bis IX synergistically induced caspase activity in combination with apoptosis-inducing ligands and converted the phenotype of cell lines from apoptosis-resistant to -sensitive. Bis IX induced p53 accumulation in LNCaP (lymph node carcinoma of prostate), which expresses wild-type p53 that was not accompanied by the induction of p53-responsive genes, p21/WAF1, and Mdm2. Moreover, the induction of p21/WAF1 and Mdm2 by doxorubicin was abrogated by simultaneous treatment with Bis IX. These effects apparently result from general inhibition of transcription by Bis IX. We have shown by Northern blot analysis that the transcription activity of the hygromycin gene after transient transfection of pcDNA3.1-Hygro plasmid in 293 and HeLa cells was inhibited by Bis IX in a dose-dependent manner. Moreover, DNA binding activity of Bis IX was prevented by actinomycin D, suggesting that actinomycin D and Bis IX have similar mechanisms of interaction with DNA. In addition, we found that actinomycin D and Bis IX induced caspase activity to the same extent during TRAIL-mediated apoptosis. In summary, these results suggest that Bis IX potentiates TNF receptor family-mediated cell death in part as an inhibitor of transcription.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Anat, Iowa City, IA 52242 USA; Univ Iowa, Dept Cell Biol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Cleveland Clinic Foundation	Rokhlin, OW (corresponding author), Univ Iowa, Dept Pathol, 145 MRC, Iowa City, IA 52242 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 87717] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; CHEN CS, 1993, J BIOL CHEM, V268, P15812; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Gewies A, 2000, CANCER RES, V60, P2163; JACOBSON PB, 1995, J PHARMACOL EXP THER, V275, P995; Kim KH, 2000, CLIN CANCER RES, V6, P335; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 1997, CANCER RES, V57, P3941; Rokhlin OW, 2002, PROSTATE, V52, P1, DOI 10.1002/pros.10074; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Rokhlin OW, 1997, CANCER RES, V57, P1758; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	20	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33213	33219		10.1074/jbc.M204612200	http://dx.doi.org/10.1074/jbc.M204612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12091392	hybrid			2022-12-27	WOS:000177859000105
J	An, XL; Lecomte, MC; Chasis, JA; Mohandas, N; Gratzer, W				An, XL; Lecomte, MC; Chasis, JA; Mohandas, N; Gratzer, W			Shear-response of the spectrin dimer-tetramer equilibrium in the red blood cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION; ERYTHROCYTE SPECTRIN; HEREDITARY ELLIPTOCYTOSIS; MOLECULAR-STRUCTURE; SKELETON; MUTANT	The red cell membrane derives its elasticity and resistance to mechanical stresses from the membrane skeleton, a network composed of spectrin tetramers. These are formed by the head-to-head association of pairs of heterodimers attached at their ends to junctional complexes of several proteins. Here we examine the dynamics of the spectrin dimer-dimer association in the intact membrane. We show that univalent fragments of spectrin, containing the dimer self-association site, will bind to spectrin on the membrane and thereby disrupt the continuity of the protein network. This results in impairment of the mechanical stability of the membrane. When, moreover, the cells are subjected to a continuous low level of shear, even at room temperature, the incorporation of the fragments and the consequent destabilization of the membrane are greatly accentuated. It follows that a modest shearing force, well below that experienced by the red cell in the circulation, is sufficient to sever dimer-dimer links in the network. Our results imply 1) that the membrane accommodates the enormous distortions imposed on it during the passage of the cell through the microvasculature by means of local dissociation of spectrin tetramers to dimers, 2) that the network in situ is in a dynamic state and undergoes a "breathing" action of tetramer dissociation and re-formation.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA; Fac Med Bichat, INSERM U409, F-75870 Paris 18, France; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Kings Coll London, Randall Ctr, Med Council Cell Biophys Unit, London SE1 1UL, England	New York Blood Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of London; King's College London	An, XL (corresponding author), New York Blood Ctr, Red Cell Physiol Lab, 310 E 67th St, New York, NY 10021 USA.	xiuli_an@nybc.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKMAN L, 1991, J BIOL CHEM, V266, P3835; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DISHER DE, 1996, BIOPHYS J, V71, P1680; Hansen JC, 1996, BIOPHYS J, V70, P146, DOI 10.1016/S0006-3495(96)79556-5; HANSPAL M, 1982, BIOCHIM BIOPHYS ACTA, V709, P105, DOI 10.1016/0167-4838(82)90427-7; HENNIKER A, 1994, BIOPHYS CHEM, V52, P251, DOI 10.1016/0301-4622(94)00094-Z; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; LANE PA, 1987, J CLIN INVEST, V79, P989, DOI 10.1172/JCI112911; Lecomte MC, 1999, EUR BIOPHYS J BIOPHY, V28, P208, DOI 10.1007/s002490050201; LIU SC, 1984, J BIOL CHEM, V259, P1556; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1982, BLOOD, V59, P768; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; MORROW JS, 1980, P NATL ACAD SCI USA, V77, P6952; Nicolas G, 1998, BIOCHEM J, V332, P81, DOI 10.1042/bj3320081; OHANIAN V, 1984, BIOCHEMISTRY-US, V23, P4416, DOI 10.1021/bi00314a027; REICH MH, 1982, BIOPHYS CHEM, V16, P307, DOI 10.1016/0301-4622(82)87035-X; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SHAHBAKHTI F, 1986, BIOCHEMISTRY-US, V25, P5969, DOI 10.1021/bi00368a020; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SKALAK R, 1969, SCIENCE, V164, P717, DOI 10.1126/science.164.3880.717; STOKKE BT, 1981, BIOCHIM BIOPHYS ACTA, V640, P640, DOI 10.1016/0005-2736(81)90094-8; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; VERTESSY BG, 1989, BIOPHYS J, V55, P255, DOI 10.1016/S0006-3495(89)82800-0; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	30	76	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31796	31800		10.1074/jbc.M204567200	http://dx.doi.org/10.1074/jbc.M204567200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105217	hybrid			2022-12-27	WOS:000177718700062
J	Leavey, PJ; Gonzalez-Aller, C; Thurman, G; Kleinberg, M; Rinckel, L; Ambruso, DW; Freeman, S; Kuypers, FA; Ambruso, DR				Leavey, PJ; Gonzalez-Aller, C; Thurman, G; Kleinberg, M; Rinckel, L; Ambruso, DW; Freeman, S; Kuypers, FA; Ambruso, DR			A 29-kDa protein associated with p67(phox) expresses both peroxiredoxin and phospholipase A(2) activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; HYDROGEN-PEROXIDE; MAMMALIAN PEROXIREDOXIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; BINDING-SITE; CYTOCHROME-B; ACTIVATION; COMPONENTS; P67-PHOX	Production of toxic oxygen metabolites provides a mechanism for microbicidal activity of the neutrophil. The NADPH oxidase enzyme system initiates the production of oxygen metabolites by reducing oxygen to form superoxide anion (O-2(.-)). With stimulation of the respiratory burst, cytosolic oxidase components, p47(phox), p67(phox), and Rac, translocate to the phagolysomal and plasma membranes where they form a complex with cytochrome b(558) and express enzyme activity. A 29-kDa neutrophil protein (P29) was identified by co-immuno-precipitation with p67(phox). N-terminal sequence analysis of p29 revealed homology to an open reading frame gene described in a myeloid leukemia cell line. A cDNA for p29 identical to the open reading frame protein was amplified from RNA of neutrophils. Significant interaction between p29 and p67(phox) was demonstrated using a yeast two-hybrid system. A recombinant (rh) p29 was expressed in Sf9 cells resulting in a protein with an apparent molecular weight of 34,000. The rh-p29 showed immunoreactivity with the original rabbit antiserum. that detected p47(phox) and p67(phox). In addition, rh-p29 exhibited PLA(2) activity, which was Ca2+ independent, optimal at low pH, and preferential for phosphatidylcholine substrates. The recombinant protein protected glutathione synthetase and directly inactivated H2O2. By activity and sequence homology, rh-p29 can be classified as a peroxiredoxin. Finally, O-2(.-) production by plasma membrane and recombinant cytosolic oxidase components in the SDS-activated, cell-free NADPH oxidase system were enhanced by rh-p29. This effect was not inhibited by PLA2 inhibitors. Thus, p29 is a novel protein that associates with p67 and has peroxiredoxin activity. This protein has a potential role in protecting the NADPH oxidase by inactivating H2O2 or altering signaling pathways affected by H2O2.	Bonfils Blood Ctr, Denver, CO 80230 USA; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Maryland; University of Maryland Baltimore; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Ambruso, DR (corresponding author), Bonfils Blood Ctr, 717 Yosemite St, Denver, CO 80230 USA.			Leavey, Patrick/0000-0002-0541-2536	NCI NIH HHS [P30-CA46954] Funding Source: Medline; NHLBI NIH HHS [HL66355, HL20985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, R01HL066355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1992, J BIOL CHEM, V267, P16767; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; AMBRUSO DR, 1998, DISORDERS RESP TRACT, P1107; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BLANCHARD SG, 1994, ANAL BIOCHEM, V222, P435, DOI 10.1006/abio.1994.1513; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen L, 1998, MOL CELL, V1, P795, DOI 10.1016/S1097-2765(00)80079-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMARZO AM, 1992, BIOCHEMISTRY-US, V31, P10491, DOI 10.1021/bi00158a012; DINAUER M, 1998, HEMATOLOGY INFANCY C, P890; Faris SL, 1998, BIOCHEM BIOPH RES CO, V247, P271, DOI 10.1006/bbrc.1998.8775; Fisher AB, 1997, AM J PHYSIOL-LUNG C, V272, pL238, DOI 10.1152/ajplung.1997.272.2.L238; FRUTON JS, 1992, INT J PEPT PROT RES, V39, P189; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TS, 1997, J BIOL CHEM, V272, P2542; Leavey PJ, 1998, BLOOD, V92, P4366, DOI 10.1182/blood.V92.11.4366.423k23_4366_4374; Leavey PJ, 1998, BLOOD, V92, p498A; MCDERMOT.JA, 1968, BIOCHIM BIOPHYS ACTA, V151, P541, DOI 10.1016/0005-2744(68)90001-6; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Rosenthal J, 1996, BLOOD, V88, P4321; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	41	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45181	45187		10.1074/jbc.M202869200	http://dx.doi.org/10.1074/jbc.M202869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12121978	hybrid			2022-12-27	WOS:000179404800076
J	Junankar, PR; Karjalainen, A; Kirk, K				Junankar, PR; Karjalainen, A; Kirk, K			The role of P2Y(1) purinergic receptors and cytosolic Ca2+ in hypotonically activated osmolyte efflux from a rat hepatoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ATP RELEASE; FREE CALCIUM-CONCENTRATION; VOLUME REGULATION; POTASSIUM CHANNELS; EPITHELIAL-CELLS; EXTRACELLULAR NUCLEOTIDES; HUMAN HEPATOCYTES; ANION CHANNELS; PROTEIN; IDENTIFICATION	Exposure of HTC rat hepatoma cells to a 33% decrease in extracellular osmolality caused the cytosolic Ca2+ concentration ([Ca2+](i)) to increase transiently by similar to90 nm. This rise in [Ca2+](i) was inhibited strongly by apyrase, grade VII (which has a low ATP/ADPase ratio) but not by apyrase grade VI (which has a high ATP/ADPase ratio) or hexokinase, indicating that extracellular ADP and/or ATP play a role in the [Ca2+](i) increase. The hypotonically induced rise in [Ca2+](i) was prevented by the prior discharge of the intracellular Ca2+ store of the cells by thapsigargin. Removal of extracellular Ca2+ or inhibition of Ca2+ influx by 1-10 muM Gd3+ depleted the thapsigargin-sensitive Ca2+ stores and thereby diminished the rise in [Ca2+](i). The hypotonically induced rise in [Ca2+](i) was prevented by adenosine 2'-phosphate-5'-phosphate (AMP) and pyridoxyl-5'-phosphate-6-azophenyl-2',4'-disulfonate, inhibitors of purinergic P2Y(1) receptors for which ADP is a major agonist. Both inhibitors also blocked the rise in [Ca2+](i) elicited by addition of ADP to cells in isotonic medium, whereas A2P5P had no effect on the rise in [Ca2+](i) elicited by the addition of the P2Y(2) and P2Y(4) receptor agonist, UTP. HTC cells were shown to express mRNA encoding for rat P2Y1, P2Y(2), and P2Y(6) receptors. Inhibition of the hypotonically induced rise in [Ca2+](i) blocked hypotonically induced K+ (Rb-86(+)) efflux, modulated the hypotonically induced efflux of taurine, but had no significant effect on Cl- (I-125-) efflux. The interaction of extracellular ATP and/or ADP with P2Y(1) purinergic receptors therefore plays a role in the response of HTC cells to osmotic swelling but does not account for activation of all the efflux pathways involved in the volume-regulatory response.	Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University	Junankar, PR (corresponding author), Australian Natl Univ, Fac Sci, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Kirk, Kiaran/C-8299-2009	Kirk, Kiaran/0000-0002-5613-2622				Bergeron LJ, 1996, AM J PHYSIOL-REG I, V270, pR801, DOI 10.1152/ajpregu.1996.270.4.R801; Bodily K, 1997, HEPATOLOGY, V25, P403; Boudreault F, 2002, AM J PHYSIOL-CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Chen ZP, 1996, ENDOCRINOLOGY, V137, P1833, DOI 10.1210/en.137.5.1833; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Dezaki K, 2000, JPN J PHYSIOL, V50, P235, DOI 10.2170/jjphysiol.50.235; Dixon CJ, 2000, BRIT J PHARMACOL, V130, P664, DOI 10.1038/sj.bjp.0703350; Dixon CJ, 2000, BRIT J PHARMACOL, V129, P764, DOI 10.1038/sj.bjp.0703103; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FOSKETT JK, 1994, CELLULAR MOL PHYSL C, P259; Galietta LJV, 1997, AM J PHYSIOL-CELL PH, V273, pC57, DOI 10.1152/ajpcell.1997.273.1.C57; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamill OP, 1996, PHARMACOL REV, V48, P231; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1998, CONTRIB NEPHROL, V123, P185, DOI 10.1159/000059913; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; Junankar PR, 2000, CELL PHYSIOL BIOCHEM, V10, P355, DOI 10.1159/000016368; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; Kirk K, 1997, J MEMBRANE BIOL, V158, P1, DOI 10.1007/s002329900239; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; LIPPMANN BJ, 1995, BRAIN RES, V686, P29, DOI 10.1016/0006-8993(95)00447-X; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; Mongin AA, 1999, AM J PHYSIOL-CELL PH, V277, pC823, DOI 10.1152/ajpcell.1999.277.4.C823; Morris H P, 1965, Adv Cancer Res, V9, P227, DOI 10.1016/S0065-230X(08)60448-0; Nicholas RA, 2001, MOL PHARMACOL, V60, P416; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Oike M, 2000, AM J PHYSIOL-HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630; Pasantes-Morales H, 2000, NEPHRON, V86, P414, DOI 10.1159/000045829; Ralevic V, 1998, PHARMACOL REV, V50, P413; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Schlenker T, 1997, AM J PHYSIOL-GASTR L, V273, pG1108, DOI 10.1152/ajpgi.1997.273.5.G1108; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Schofl C, 1999, AM J PHYSIOL-GASTR L, V276, pG164, DOI 10.1152/ajpgi.1999.276.1.G164; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; Sevigny J, 2000, J BIOL CHEM, V275, P5640, DOI 10.1074/jbc.275.8.5640; Shinozuka K, 2001, CLIN EXP PHARMACOL P, V28, P799, DOI 10.1046/j.1440-1681.2001.03525.x; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Vohringer C, 2000, BIOCHEM PHARMACOL, V59, P791, DOI 10.1016/S0006-2952(99)00390-1; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	60	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40324	40334		10.1074/jbc.M204712200	http://dx.doi.org/10.1074/jbc.M204712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12138101	hybrid			2022-12-27	WOS:000178791400023
J	Lawton, DG; Longstaff, C; Wallace, BA; Hill, J; Leary, SEC; Titball, RW; Brown, KA				Lawton, DG; Longstaff, C; Wallace, BA; Hill, J; Leary, SEC; Titball, RW; Brown, KA			Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; CIRCULAR-DICHROISM SPECTRA; V-ANTIGEN; SECONDARY STRUCTURE; LOW-CA2+ RESPONSE; VIRULENCE; SYSTEMS; MODEL; CELL; TRANSLOCATION	The type III secretion system is used by pathogenic Yersinia to translocate virulence factors into the host cell. A key component is the multifunctional LcrV protein, which is present on the bacterial surface prior to host cell contact and up-regulates translocation by blocking the repressive action of the LcrG protein on the cytosolic side of the secretion apparatus. The functions of LcrV are proposed to involve self-interactions (multimerization) and interactions with other proteins including LcrG. Coiled-coil motifs predicted to be present are thought to play a role in mediating these protein-protein interactions. We have purified recombinant LcrV, LcrG, and site-directed mutants of LcrV and demonstrated the structural integrity of these proteins using circular dichroism spectroscopy. We show that LcrV interacts both with itself and with LcrG and have obtained micromolar and nanomolar affinities for these interactions, respectively. The effects of LcrV mutations upon LcrG binding suggest that coiled-coil interactions indeed play a significant role in complex formation. In addition, comparisons of secretion patterns of effector proteins in Yersinia, arising from wild type and mutants of LcrV, support the proposed role of LcrG in titration of LcrV in vivo but also suggest that other factors may be involved.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Ctr Mol Microbiol & Infect, London SW7 2AY, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England	Imperial College London; National Institute for Biological Standards & Control; University of London; Birkbeck University London; Defence Science & Technology Laboratory	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Ctr Mol Microbiol & Infect, Flowers Bldg, London SW7 2AY, England.		Longstaff, Colin/D-2413-2013; Wallace, B A/C-3753-2008	Longstaff, Colin/0000-0001-7608-208X; Wallace, B A/0000-0001-9649-5092				*BIACORE LTD, 2001, BIAT HDB, P41; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; BURROWS TW, 1956, BRIT J EXP PATHOL, V37, P481; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; Daniell SJ, 2001, INFECT IMMUN, V69, P4055, DOI 10.1128/IAI.69.6.4055-4064.2001; Delahay RM, 1999, J BIOL CHEM, V274, P35969, DOI 10.1074/jbc.274.50.35969; Fields KA, 1999, INFECT IMMUN, V67, P4801, DOI 10.1128/IAI.67.9.4801-4813.1999; FISCHETTI VA, 1993, INFORM PROCESS LETT, V45, P11, DOI 10.1016/0020-0190(93)90245-5; FORSBERG A, 1987, MICROB PATHOGENESIS, V2, P123, DOI 10.1016/0882-4010(87)90104-5; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEARY SEC, 1995, INFECT IMMUN, V63, P2854, DOI 10.1128/IAI.63.8.2854-2858.1995; Leary SEC, 1999, MICROB PATHOGENESIS, V26, P159, DOI 10.1006/mpat.1998.0261; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; Markey F, 1999, BIA J, V1, P14; Matson JS, 2001, J BACTERIOL, V183, P5082, DOI 10.1128/JB.183.17.5082-5091.2001; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; Miller JF, 1999, CURR OPIN MICROBIOL, V2, P15; Neyt C, 1999, SYMP SOC GEN MICROBI, V57, P215; Nilles ML, 1997, J BACTERIOL, V179, P1307, DOI 10.1128/jb.179.4.1307-1316.1997; Nilles ML, 1998, J BACTERIOL, V180, P3410, DOI 10.1128/JB.180.13.3410-3420.1998; Pallen MJ, 1997, MOL MICROBIOL, V25, P423, DOI 10.1046/j.1365-2958.1997.4901850.x; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; PRICE SB, 1989, J BACTERIOL, V171, P5646, DOI 10.1128/jb.171.10.5646-5653.1989; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Sambrook J., 2002, MOL CLONING LAB MANU; Sarker MR, 1998, J BACTERIOL, V180, P1207, DOI 10.1128/JB.180.5.1207-1214.1998; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; SKRZYPEK E, 1993, J BACTERIOL, V175, P3520, DOI 10.1128/jb.175.11.3520-3528.1993; SKRZYPEK E, 1995, J BACTERIOL, V177, P2530, DOI 10.1128/jb.177.9.2530-2542.1995; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tito MA, 2001, BIOPHYS J, V81, P3503, DOI 10.1016/S0006-3495(01)75981-4; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; WOOLLEY GA, 1993, BIOCHEMISTRY-US, V32, P9819, DOI 10.1021/bi00088a037; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419	47	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38714	38722		10.1074/jbc.M203632200	http://dx.doi.org/10.1074/jbc.M203632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12107165	Green Submitted, hybrid			2022-12-27	WOS:000178529600090
J	Piper, MDW; Daran-Lapujade, P; Bro, C; Regenberg, B; Knudsen, S; Nielsen, J; Pronk, JT				Piper, MDW; Daran-Lapujade, P; Bro, C; Regenberg, B; Knudsen, S; Nielsen, J; Pronk, JT			Reproducibility of oligonucleotide microarray transcriptome analyses - An interlaboratory comparison using chemostat cultures of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; ENVIRONMENTAL-CHANGES; OXYGEN REQUIREMENTS; DNA MICROARRAYS; YEAST; GENOME; METABOLISM; ACTIVATOR; PATHWAY; CELLS	Assessment of reproducibility of DNA-microarray analysis from published data sets is complicated by the use of different microbial strains, cultivation techniques, and analytical procedures. Because intra- and interlaboratory reproducibility is highly relevant for application of DNA-microarray analysis in functional genomics and metabolic engineering, we designed a set of experiments to specifically address this issue. Saccharomyces cerevisiae CEN.PK113-7D was grown under defined,conditions in, glucose-limited chemostats, followed by transcriptome analysis with Affymetrix Gene-Chip arrays. In each of the laboratories, three independent replicate cultures were grown aerobically as well as anaerobically. Although variations introduced by in vitro handling steps were small and unbiased, greater variation from replicate cultures underscored that, to obtain reliable information, experimental replication is essential. Under aerobic conditions, 86% of the most highly expressed yeast genes showed an average intra-laboratory coefficient of variation of 0.23. This is significantly lower than previously reported for shake-flask-culture transcriptome analyses and probably reflects the strict control of growth conditions in chemostats. Using the triplicate data sets and appropriate statistical analysis, the change calls from anaerobic versus aerobic comparisons yielded an over 95% agreement between the laboratories for transcripts that changed by over 2-fold, leaving only a small fraction of genes that exhibited laboratory bias.	Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; Tech Univ Denmark, Ctr Proc Biotechnol, Biocentrum, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Ctr Proc Biotechnol, Biocentrum, DK-2800 Lyngby, Denmark; Tech Univ Denmark, Ctr Biol Sequence Anal, Biocentrum, DK-2800 Lyngby, Denmark	Delft University of Technology; Technical University of Denmark; Technical University of Denmark; Technical University of Denmark	Pronk, JT (corresponding author), Delft Univ Technol, Kluyver Lab Biotechnol, Julianalaan 26, NL-2628 BC Delft, Netherlands.		Regenberg, Brigit/C-2699-2009; Piper, Matthew/C-1714-2008; Nielsen, Jens/Q-1347-2017	Regenberg, Brigit/0000-0003-4996-7012; Piper, Matthew/0000-0003-3245-7219; Daran-Lapujade, Pascale/0000-0002-4097-7831; Pronk, Jack/0000-0002-5617-4611; Nielsen, Jens/0000-0002-9955-6003				Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; Bakker BM, 2000, J BACTERIOL, V182, P4730, DOI 10.1128/JB.182.17.4730-4737.2000; Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Diderich JA, 1999, J BIOL CHEM, V274, P15350, DOI 10.1074/jbc.274.22.15350; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Keller G, 2001, J BIOL CHEM, V276, P38697, DOI 10.1074/jbc.M107131200; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lonnstedt I, 2002, STAT SINICA, V12, P31; Lopez MC, 2000, J BACTERIOL, V182, P4970, DOI 10.1128/JB.182.17.4970-4978.2000; Marc P, 2001, Nucleic Acids Res, V29, pE63, DOI 10.1093/nar/29.13.e63; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Nielsen J, 2002, FEMS YEAST RES, V2, P175; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rodrigues F, 2001, APPL ENVIRON MICROB, V67, P2123, DOI 10.1128/AEM.67.5.2123-2128.2001; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; Verduyn C, 1990, MICROBIOL REV, V58, P616; VISSER W, 1990, APPL ENVIRON MICROB, V56, P3785, DOI 10.1128/AEM.56.12.3785-3792.1990; Wu TD, 2001, J PATHOL, V195, P53, DOI 10.1002/1096-9896(200109)195:1<53::AID-PATH891>3.0.CO;2-H; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; 2000, AFFYMETRIX GENECHIP	44	187	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37001	37008		10.1074/jbc.M204490200	http://dx.doi.org/10.1074/jbc.M204490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12121991	hybrid			2022-12-27	WOS:000178447100014
J	deCarvalho, ACV; Gansheroff, LJ; Teem, JL				deCarvalho, ACV; Gansheroff, LJ; Teem, JL			Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator Delta F508	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL ACTIVITY; MULTIDRUG-RESISTANCE; ABC TRANSPORTERS; WILD-TYPE; MOLECULAR-BASIS; ATP HYDROLYSIS; CFTR; PROTEIN; ACTIVATION; GENISTEIN	The gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), an ATP binding cassette (ABC) transporter that functions as a phosphorylationand nucleotide-regulated chloride channel, is mutated in cystic fibrosis (CF) patients. Deletion of a phenylalanine at amino acid position 508 (AF508) in the first nucleotide binding domain (NBD1) is the most prevalent CF-causing mutation and results in defective protein processing and reduced CFTR function, leading to chloride impermeability in CF epithelia and heterologous systems. Using a STE6/CFTRAF508 chimera system in yeast, we isolated two novel AF508 revertant mutations, I539T and G550E, proximal to and within the conserved ABC signature motif of NBD1, respectively. Western blot and functional analysis in mammalian cells indicate that mutations 1539T and G550E each partially rescue the CFTRAF508 defect. Furthermore, a combination of both revertant mutations resulted in a 38-fold increase in CFTRAF508-mediated chloride current, representing 29% of wild type channel activity. The G550E mutation increased the sensitivity of CFTRAF508 and wild type CFTR to activation by cAMP agonists and blocked the enhancement of CFTRAF508 channel activityby.2 mm 3-isobutyl-1-methylxanthine. The data show that the AF508 defect can be significantly rescued by second-site mutations in the nucleotide binding domain 1 region, that includes the LSGGQ consensus motif.	Florida State Univ, Dept Biol Sci, Biounit 238, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University	Teem, JL (corresponding author), Florida State Univ, Dept Biol Sci, Biounit 238, B-157, Tallahassee, FL 32306 USA.	teem@bio.fsu.edu		deCarvalho, Ana C/0000-0003-1183-4548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Nakkash L, 1999, PFLUG ARCH EUR J PHY, V437, P553, DOI 10.1007/s004240050817; Andersson C, 2000, EUR RESPIR J, V15, P937, DOI 10.1034/j.1399-3003.2000.15e21.x; Baldursson O, 2000, AM J PHYSIOL-LUNG C, V279, pL835, DOI 10.1152/ajplung.2000.279.5.L835; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Brown CR, 1997, J BIOENERG BIOMEMBR, V29, P491, DOI 10.1023/A:1022491124939; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cohen BE, 1997, BIOCHEMISTRY-US, V36, P6455, DOI 10.1021/bi970150v; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; Falcon-Perez JM, 2001, J BACTERIOL, V183, P4761, DOI 10.1128/JB.183.16.4761-4770.2001; FISCHER H, 1994, J GEN PHYSIOL, V104, P541, DOI 10.1085/jgp.104.3.541; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Frossard PM, 1999, J TROP PEDIATRICS, V45, P158, DOI 10.1093/tropej/45.3.158; Frossard PM, 1999, EUR RESPIR J, V13, P100; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GIBSON AL, 1991, SCIENCE, V254, P109, DOI 10.1126/science.1718037; Goddard CA, 2000, AM J PHYSIOL-CELL PH, V279, pC383, DOI 10.1152/ajpcell.2000.279.2.C383; Goldman BS, 1997, J BACTERIOL, V179, P7869, DOI 10.1128/jb.179.24.7869-7871.1997; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; He ZP, 1998, AM J PHYSIOL-CELL PH, V275, pC958, DOI 10.1152/ajpcell.1998.275.4.C958; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Illek B, 1996, AM J PHYSIOL-CELL PH, V270, pC265, DOI 10.1152/ajpcell.1996.270.1.C265; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Kaminski WE, 2001, BIOCHEM BIOPH RES CO, V285, P1295, DOI 10.1006/bbrc.2001.5326; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; Ketchum CJ, 2001, J BIOL CHEM, V276, P29007, DOI 10.1074/jbc.M100810200; KOPITO RR, 1999, PHYSIOL REV, V79, P167; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Lansdell KA, 2000, J PHYSIOL-LONDON, V524, P317, DOI 10.1111/j.1469-7793.2000.t01-1-00317.x; Leung DW, 1989, TECHNIQUE, V1, P11; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOGAN J, 1994, J CLIN INVEST, V94, P228, DOI 10.1172/JCI117311; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Massiah MA, 1999, BIOCHEMISTRY-US, V38, P7453, DOI 10.1021/bi9903603; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; Ostedgaard LS, 2001, J BIOL CHEM, V276, P7689, DOI 10.1074/jbc.R100001200; Paddon C, 1996, MOL MICROBIOL, V19, P1007, DOI 10.1046/j.1365-2958.1996.444973.x; Parad RB, 1996, J MED GENET, V33, P711, DOI 10.1136/jmg.33.8.711; Proff C, 2001, MOL GEN GENET, V264, P883, DOI 10.1007/s004380000378; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROXO RM, 2001, PEDIATR PULM, V22, P187; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Schultz BD, 1999, J MEMBRANE BIOL, V170, P51, DOI 10.1007/s002329900537; Sears CL, 1995, AM J PHYSIOL-GASTR L, V269, pG874, DOI 10.1152/ajpgi.1995.269.6.G874; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; Teem JL, 1996, RECEPTOR CHANNEL, V4, P63; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Van Oene M, 2000, J BIOL CHEM, V275, P19577, DOI 10.1074/jbc.M002186200; VANDOORNINCK JH, 1995, EMBO J, V14, P4403, DOI 10.1002/j.1460-2075.1995.tb00119.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang F, 2000, J PHYSIOL-LONDON, V524, P637, DOI 10.1111/j.1469-7793.2000.00637.x; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	79	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35896	35905		10.1074/jbc.M205644200	http://dx.doi.org/10.1074/jbc.M205644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12110684	hybrid			2022-12-27	WOS:000178275100019
J	Manya, H; Inomata, M; Fujimori, T; Dohmae, N; Sato, Y; Takio, K; Nabeshima, Y; Endo, T				Manya, H; Inomata, M; Fujimori, T; Dohmae, N; Sato, Y; Takio, K; Nabeshima, Y; Endo, T			Klotho protein deficiency leads to overactivation of mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC-RENAL-FAILURE; TRANSCRIPTS ENCODING MEMBRANE; ENDOTHELIAL DYSFUNCTION; ALPHA-FODRIN; DOWN-REGULATION; GENE; SPECTRIN; PROTEOLYSIS; ACTIVATION; EXPRESSION	The klotho mouse is an animal model that prematurely shows phenotypes resembling human aging. Here we report that in homozygotes for the klotho mutation (kl(-/-)), alpha(II)-spectrin is highly cleaved, even before the occurrence of aging symptoms such as calcification and arteriosclerosis. Because an-spectrin is susceptible to proteolysis by calpain, we examined the activation of calpain in kl(-/-) mice. m-Calpain was not activated, but mu-calpain was activated at an abnormally high level, and an endogenous inhibitor of calpain, calpastatin, was significantly decreased. Proteolysis of alpha(II)-spectrin increased with decreasing level of Klotho protein. Similar phenomena were observed in normal aged mice. Our results indicate that the abnormal activation of calpain due to the decrease of Klotho protein leads to degradation of cytoskeletal elements such as alpha(II)-spectrin. Such deterioration may trigger renal abnormalities in kl(-1-) mice and aged mice, but Klotho protein may suppress these processes.	Fdn Res Aging & Promot Human Welf, Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Itabashi Ku, Tokyo 1730015, Japan; Fdn Res Aging & Promot Human Welf, Tokyo Metropolitan Inst Gerontol, Biomembrane Res Grp, Itabashi Ku, Tokyo 1730015, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto 6068501, Japan; Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; CREST, Kawaguchi, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Kyoto University; RIKEN; Japan Science & Technology Agency (JST)	Endo, T (corresponding author), Fdn Res Aging & Promot Human Welf, Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.		Dohmae, Naoshi/C-2040-2011; Fujimori, Toshihiko/L-7711-2016	Dohmae, Naoshi/0000-0002-5242-9410; Fujimori, Toshihiko/0000-0001-5200-4634; Manya, Hiroshi/0000-0003-1573-9177				Aizawa H, 1998, BIOCHEM BIOPH RES CO, V249, P865, DOI 10.1006/bbrc.1998.9246; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; Averna M, 2001, J BIOL CHEM, V276, P38426, DOI 10.1074/jbc.M101936200; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; De Matteis MA, 2000, J CELL SCI, V113, P2331; DOCTOR RB, 1993, AM J PHYSIOL, V264, pC1003, DOI 10.1152/ajpcell.1993.264.4.C1003; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226; Koh TJ, 2000, AM J PHYSIOL-CELL PH, V279, pC806, DOI 10.1152/ajpcell.2000.279.3.C806; Kuizon BD, 1999, J BONE MINER RES, V14, P1680, DOI 10.1359/jbmr.1999.14.10.1680; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liu XL, 2001, AM J PHYSIOL-RENAL, V281, pF728, DOI 10.1152/ajprenal.2001.281.4.F728; London GM, 1997, KIDNEY INT, V51, P1678, DOI 10.1038/ki.1997.233; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Nagai R, 2000, CELL MOL LIFE SCI, V57, P738, DOI 10.1007/s000180050038; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Rostand SG, 1999, KIDNEY INT, V56, P383, DOI 10.1046/j.1523-1755.1999.00575.x; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Saito Y, 2000, BIOCHEM BIOPH RES CO, V276, P767, DOI 10.1006/bbrc.2000.3470; Saito Y, 1998, BIOCHEM BIOPH RES CO, V248, P324, DOI 10.1006/bbrc.1998.8943; Shiraki-Iida T, 2000, J GENE MED, V2, P233, DOI 10.1002/1521-2254(200007/08)2:4<233::AID-JGM110>3.0.CO;2-5; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Suga T, 2000, AM J RESP CELL MOL, V22, P26, DOI 10.1165/ajrcmb.22.1.3554; Takano J, 1999, BIOCHEM BIOPH RES CO, V260, P339, DOI 10.1006/bbrc.1999.0903; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Tsuji T, 2001, AM J PHYSIOL-HEART C, V281, pH1286, DOI 10.1152/ajpheart.2001.281.3.H1286; Urena P, 1999, KIDNEY INT, V55, P2141, DOI 10.1046/j.1523-1755.1999.00461.x; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WIDADA JS, 1989, J MOL BIOL, V205, P455, DOI 10.1016/0022-2836(89)90355-0; WINKELMANN JC, 1993, BLOOD, V81, P3173; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683	50	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35503	35508		10.1074/jbc.M206033200	http://dx.doi.org/10.1074/jbc.M206033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12119304	hybrid			2022-12-27	WOS:000178117000108
J	Gemperli, AC; Dimroth, P; Steuber, J				Gemperli, AC; Dimroth, P; Steuber, J			The respiratory complex I (NDH I) from Klebsiella pneumoniae, a sodium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NA+-TRANSLOCATING NADH; QUINONE OXIDOREDUCTASE; ESCHERICHIA-COLI; VIBRIO-ALGINOLYTICUS; OXALOACETATE DECARBOXYLASE; PROPIONIGENIUM-MODESTUM; STRUCTURAL GENES; CLUSTER N2; MECHANISM	The electrogenic NADH:Q oxidoreductase from the enterobacterium Klebsiella pneumoniae transports Na+ ions. The complex was purified with an increase of the specific Na+ transport activity from 0.2 mumol min(-1) mg(-1) in native membrane vesicles to 4.7 mumol min(-1) mg(-1) in reconstituted enzyme specimens. The subunit pattern resembled that of complex I from Escherichia coli, and two prominent polypeptides were identified as the NuoF and NuoG subunits of complex I. During purification the typical cofactors of complex I were enriched to yield similar to17 nmol mg(-1) iron, 24 nmol mg(-1) acid-labile sulfide, and 0.79 nmol mg(-1) FMN in the purified sample. The enzyme contained similar to1.2 nmol mg(-1) Q6 and 1.5 nmol mg(-1) Q8. The reduction of ubiquinone by NADH was Na+-dependent, which indicates coupling of the chemical and the vectorial reaction of the pump. The Na+ activation profile corresponded to the Hill equation with a Hill coefficient K-H(Na+) = 1.96 and with a half-maximal saturation at 0.33 mm Na+. The reconstituted complex I from Klebsiella pneumoniae catalyzed deamino-NADH oxidation, Q1 reduction, and Na+ translocation with specific activities of 2.6 units mg(-1), 2.4 units mg(-1), and 4.7 units mg(-1), respectively, which indicate a Na+/electron stoichiometry of one.	ETH Zentrum, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Steuber, J (corresponding author), ETH Zentrum, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.							Albracht SPJ, 1997, BBA-BIOENERGETICS, V1318, P92, DOI 10.1016/S0005-2728(96)00153-3; AMES BN, 1960, J BIOL CHEM, V235, P769; BEATTIE P, 1994, FEBS LETT, V356, P333, DOI 10.1016/0014-5793(94)01275-X; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Boffelli D, 1997, BIOCHEMISTRY-US, V36, P10784, DOI 10.1021/bi970625i; Bogachev AV, 1996, J BACTERIOL, V178, P6233, DOI 10.1128/jb.178.21.6233-6237.1996; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; DIMROTH P, 1989, ARCH MICROBIOL, V151, P439, DOI 10.1007/BF00416604; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DIMROTH P, 1986, EUR J BIOCHEM, V156, P157, DOI 10.1111/j.1432-1033.1986.tb09561.x; DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; ESPOSTI MD, 1994, BBA-BIOENERGETICS, V1187, P116, DOI 10.1016/0005-2728(94)90095-7; Esposti MD, 1999, BIOCHEM SOC T, V27, P606, DOI 10.1042/bst0270606; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P219; HAYASHI M, 1995, FEBS LETT, V363, P75, DOI 10.1016/0014-5793(95)00283-F; Krebs W, 1999, MOL MICROBIOL, V33, P590, DOI 10.1046/j.1365-2958.1999.01506.x; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Nakamaru-Ogiso E, 2002, J BIOL CHEM, V277, P1680, DOI 10.1074/jbc.M108796200; Nakayama Y, 1999, BIOL PHARM BULL, V22, P1064; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Okun JG, 2000, BBA-BIOENERGETICS, V1459, P77, DOI 10.1016/S0005-2728(00)00115-8; Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625; Paula S, 1998, BIOPHYS J, V74, P319, DOI 10.1016/S0006-3495(98)77789-6; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P697, DOI 10.1111/j.1432-1033.1992.tb16976.x; RAGAN CI, 1975, J BIOL CHEM, V250, P8472; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Schuler F, 2001, BBA-BIOENERGETICS, V1506, P79, DOI 10.1016/S0005-2728(01)00183-9; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; Steuber J, 2001, J BIOENERG BIOMEMBR, V33, P179, DOI 10.1023/A:1010774701327; Steuber J, 1997, EUR J BIOCHEM, V249, P770, DOI 10.1111/j.1432-1033.1997.t01-2-00770.x; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; TOKUDA H, 1989, J GEN MICROBIOL, V135, P703; Unden G, 2002, J MOL MICROB BIOTECH, V4, P263; Ushakova AV, 1999, BBA-BIOENERGETICS, V1409, P143, DOI 10.1016/S0005-2728(98)00156-X; Vinogradov AD, 1998, BBA-BIOENERGETICS, V1364, P169, DOI 10.1016/S0005-2728(98)00026-7; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WHISTANC.GR, 1969, BIOCHEM J, V111, P461, DOI 10.1042/bj1110461; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 2001, J BIOENERG BIOMEMBR, V33, P213, DOI 10.1023/A:1010782903144; Yano T, 2000, BBA-BIOENERGETICS, V1459, P299, DOI 10.1016/S0005-2728(00)00164-X	54	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33811	33817		10.1074/jbc.M204860200	http://dx.doi.org/10.1074/jbc.M204860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110677	hybrid			2022-12-27	WOS:000177959100038
J	Hayes, CS				Hayes, CS			Proline residues at the C terminus of nascent chains induce SsrA tagging during translation termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE FACTOR RF3; L-AZETIDINE-2-CARBOXYLIC ACID RESIDUE; PEPTIDYL-TRANSFER-RNA; ESCHERICHIA-COLI; P-SITE; CIS/TRANS ISOMERIZATION; FUNCTIONAL INTERACTION; PROTEIN CONFORMATION; MESSENGER-RNA; AMINO-ACIDS	The SsrA or tmRNA quality control system relieves ribosome stalling and directs the addition of a degradation tag to the C terminus of the nascent chain. In some instances, SsrA tagging of otherwise full-length proteins occurs when the ribosome pauses at stop codons during normal translation termination. Here, the identities of the C-terminal residues of the nascent chain are shown to play an important role in full-length protein tagging. Specifically, a subset of C-terminal Xaa-Pro sequences caused SsrA tagging of the full-length YbeL protein from Escherichia coli. This tagging increased when a less efficient stop codon was used, increased in cells lacking protein release factor-3, and decreased when protein release factor-1 was overexpressed. Incorporation of the analog azetidine-2-carboxylic acid in place of proline suppressed tagging, whereas incorporation of 3,4-dehydroproline increased SsrA tagging of full-length YbeL. These results suggest that the detailed chemical or conformational properties of the C-terminal residues of the nascent polypeptide can affect the rate of translation termination, thereby influencing ribosome pausing and SsrA tagging at stop codons.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Hayes, CS (corresponding author), MIT, Dept Biol, Rm 68-571,77 Massachusetts Ave, Cambridge, MA 02139 USA.		Hayes, Christopher/A-5505-2009	Sauer, Robert/0000-0002-1719-5399	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16892] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; ADAMSKI FM, 1994, J MOL BIOL, V238, P302, DOI 10.1006/jmbi.1994.1293; ARKOV AL, 1993, NUCLEIC ACIDS RES, V21, P2891, DOI 10.1093/nar/21.12.2891; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Budisa N, 1998, P NATL ACAD SCI USA, V95, P455, DOI 10.1073/pnas.95.2.455; Crawford DJG, 1999, EMBO J, V18, P727, DOI 10.1093/emboj/18.3.727; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; Felden B, 1997, RNA, V3, P89; Freistroffer DV, 2000, P NATL ACAD SCI USA, V97, P2046, DOI 10.1073/pnas.030541097; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GRANT MM, 1975, BIOCHIM BIOPHYS ACTA, V404, P180, DOI 10.1016/0304-4165(75)90324-4; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; HENTZEN D, 1972, BIOCHIM BIOPHYS ACTA, V281, P228, DOI 10.1016/0005-2787(72)90174-8; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kern D, 1997, J AM CHEM SOC, V119, P8403, DOI 10.1021/ja970606w; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MottaguiTabar S, 1997, FEBS LETT, V414, P165, DOI 10.1016/S0014-5793(97)00978-2; MOTTAGUITABAR S, 1994, EMBO J, V13, P249, DOI 10.1002/j.1460-2075.1994.tb06255.x; Muto A, 1998, TRENDS BIOCHEM SCI, V23, P25, DOI 10.1016/S0968-0004(97)01159-6; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Roche ED, 2001, J BIOL CHEM, V276, P28509, DOI 10.1074/jbc.M103864200; Tate WP, 1996, MOL MICROBIOL, V21, P213, DOI 10.1046/j.1365-2958.1996.6391352.x; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1996, RNA, V2, P1306; ZAGARI A, 1990, BIOPOLYMERS, V30, P961, DOI 10.1002/bip.360300910; ZAGARI A, 1990, BIOPOLYMERS, V30, P951, DOI 10.1002/bip.360300909; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; Zhang SP, 1998, J MOL BIOL, V284, P1243, DOI 10.1006/jmbi.1998.2319; Zhang SP, 1996, J MOL BIOL, V261, P98, DOI 10.1006/jmbi.1996.0444; Zhang SP, 1999, FEBS LETT, V455, P355, DOI 10.1016/S0014-5793(99)00912-6	40	128	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33825	33832		10.1074/jbc.M205405200	http://dx.doi.org/10.1074/jbc.M205405200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105207	hybrid			2022-12-27	WOS:000177959100040
J	Morishima, N; Nakanishi, K; Takenouchi, H; Shibata, T; Yasuhiko, Y				Morishima, N; Nakanishi, K; Takenouchi, H; Shibata, T; Yasuhiko, Y			An endoplasmic reticulum stress-specific caspase cascade in apoptosis - Cytochrome c-independent activation of caspase-9 by caspase-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; CELL-DEATH; MITOCHONDRIA; CLEAVAGE; PROTEIN; IDENTIFICATION; PROCASPASE-9; MECHANISM; UPSTREAM; RELEASE	Activation of caspase-12 from procaspase-12 is specifically induced by insult to the endoplasmic reticulum (ER) (Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., and Yuan, J. (2000) Nature 403, 98-103), yet the functional consequences of caspase-12 activation have been unclear. We have shown that recombinant caspase-12 specifically cleaves and activates procaspase-9 in cytosolic extracts. The activated caspase-9 catalyzes cleavage of procaspase-3, which is inhibitable by a caspase-9-specific inhibitor. Although cytochrome c released from mitochondria has been believed to be required for caspase-9 activation during apoptosis (Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell 90, 405-413, Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489), caspase-9 as well as caspase-12 and -3 are activated in cytochrome c-free cytosols in murine myoblast cells under ER stress. These results suggest that caspase-12 can activate caspase-9 without involvement of cytochrome c. To examine the role of caspase-12 in the activation of downstream caspases, we used a caspase-12-binding protein, which we identified in a yeast two-hybrid screen, for regulation of caspase-12 activation. The binding protein protects procaspase-12 from processing in vitro. Stable expression of the binding protein renders procaspase-12 insensitive to ER stress, thereby suppressing apoptosis and the activation of caspase-9 and -3. These data suggest that procaspase-9 is a substrate of caspase-12 and that ER stress triggers a specific cascade involving caspase-12, -9, and -3 in a cytochrome c-independent manner.	RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Mol & Cellular Biol Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Fac Sci & Engn, Dept Biol & Environm Sci, Urawa, Saitama 3388570, Japan	RIKEN; RIKEN; Saitama University	Morishima, N (corresponding author), RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	morishim@postman.riken.go.jp	Nakanishi, Keiko/B-9963-2013; Morishima, Nobuhiro/D-3946-2017					Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KOCHER T, 1995, CANCER RES, V55, P2236; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 2000, METHOD ENZYMOL, V322, P177; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	753	814	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34287	34294		10.1074/jbc.M204973200	http://dx.doi.org/10.1074/jbc.M204973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097332				2022-12-27	WOS:000177959100099
J	Ricard-Blum, S; Bernocco, S; Font, B; Moali, C; Eichenberger, D; Farjanel, J; Burchardt, ER; van der Rest, M; Kessler, E; Hulmes, DJS				Ricard-Blum, S; Bernocco, S; Font, B; Moali, C; Eichenberger, D; Farjanel, J; Burchardt, ER; van der Rest, M; Kessler, E; Hulmes, DJS			Interaction properties of the procollagen C-proteinase enhancer protein shed light on the mechanism of stimulation of BMP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; CALCIUM-BINDING PROTEINS; LAMININ-5 GAMMA-2 CHAIN; ORDER KINETIC-BEHAVIOR; BIOSENSOR TECHNOLOGY; CARTILAGE MATRIX; COLLAGEN; DOMAINS; GLYCOPROTEIN; FIBROBLASTS	Procollagen C-proteinase enhancer (PCPE) is an extracellular matrix glycoprotein that binds to the C-propeptide of procollagen I and can enhance the activities of procollagen C-proteinases up to 20-fold. To determine the molecular mechanism of PCPE activity, the interactions of the recombinant protein with the procollagen molecule as well as with its isolated C-propeptide domain were studied using surface plasmon resonance (BIAcore) technology. Binding required the presence of divalent metal cations such as calcium and manganese. By ligand blotting, calcium was found to bind to the C-propeptide domains of procollagens I and III but not to PCPE. By chemical cross-linking, the stoichiometry of the PCPE/C-propeptide interaction was found to be 1:1 in accordance with enzyme kinetic data. The use of a monoclonal antibody directed against the N-terminal region of the C-propeptide suggested that this region is probably not involved in binding to PCPE. Association and dissociation kinetics of the C-propeptide domains of procollagens I and III on immobilized PCPE were rapid. Extrapolation to saturation equilibrium yielded apparent equilibrium dissociation constants in the range 150-400 nM. In contrast, the association/dissociation. kinetics of intact procollagen molecules on immobilized PCPE were relatively slow, corresponding to a dissociation constant of I nM. Finally, pN-collagen (i.e. procollagen devoid of the C-terminal propeptide domain) was also found to bind to immobilized PCPE, suggesting that PCPE binds to sites on either side of the procollagen cleavage site, thereby facilitating the action of procollagen C-proteinases.	Inst Biol & Chim Prot, CNRS UMR 5075, Lab Ingn Macromol, F-69367 Lyon 1, France; Univ Lyon 1, CNRS UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon, France; FibroSys Pharmaceut, D-42113 Wuppertal, Germany; Tel Aviv Univ, Chaim Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, Sackler Fac Med, IL-52621 Tel Hashomer, Israel	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Hulmes, DJS (corresponding author), Inst Biol & Chim Prot, CNRS UMR 5075, Lab Ingn Macromol, F-69367 Lyon 1, France.			Hulmes, David/0000-0002-0651-1317; RICARD-BLUM, Sylvie/0000-0001-9263-1851; MOALI, Catherine/0000-0003-2479-4290				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bowles MR, 1997, ANAL BIOCHEM, V244, P133, DOI 10.1006/abio.1996.9888; Burchardt ER, 1998, MATRIX BIOL, V17, P673, DOI 10.1016/S0945-053X(98)90118-4; CHOGLAY AA, 1993, J BIOL CHEM, V268, P6107; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dale L, 1999, SEMIN CELL DEV BIOL, V10, P319, DOI 10.1006/scdb.1999.0308; Decline F, 2001, J CELL SCI, V114, P811; HINEK A, 1987, J CELL BIOL, V104, P1435, DOI 10.1083/jcb.104.5.1435; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Kadler KE, 1996, BIOCHEM J, V316, P1; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Kanaki T, 2000, BIOCHEM BIOPH RES CO, V270, P1049, DOI 10.1006/bbrc.2000.2555; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; Kozyraki R, 2001, J MOL MED, V79, P161, DOI 10.1007/s001090100193; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Martin R, 2000, ANAL BIOCHEM, V277, P276, DOI 10.1006/abio.1999.4395; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Masuda M, 1998, CELL GROWTH DIFFER, V9, P381; Maurer P, 1997, MATRIX BIOL, V15, P569, DOI 10.1016/S0945-053X(97)90033-0; Maurer P, 1996, CURR OPIN CELL BIOL, V8, P609, DOI 10.1016/S0955-0674(96)80101-3; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; POOLE AR, 1989, ANAT REC, V224, P167; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Thielens NM, 1999, IMMUNOPHARMACOLOGY, V42, P3, DOI 10.1016/S0162-3109(99)00019-3; Topfer-Petersen E, 1998, ANDROLOGIA, V30, P217; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Xu H, 2000, GENOMICS, V66, P264, DOI 10.1006/geno.2000.6229; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yu K, 2000, DEVELOPMENT, V127, P2143; Zafarullah K, 1997, MATRIX BIOL, V16, P201, DOI 10.1016/S0945-053X(97)90009-3	57	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33864	33869		10.1074/jbc.M205018200	http://dx.doi.org/10.1074/jbc.M205018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105202	hybrid			2022-12-27	WOS:000177959100045
J	Thomas, LR; Stillman, DJ; Thorburn, A				Thomas, LR; Stillman, DJ; Thorburn, A			Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; FADD; APOPTOSIS; BINDING; SYSTEM; INITIATION; SELECTION; RECEPTORS; MUTATIONS; STRAINS	The adapter protein FADD consists of two protein interaction domains and is an essential component of the death inducing signaling complex (DISC) that is formed by activated death receptors of the tumor necrosis factor (TNF) receptor family. The FADD death domain binds to activated receptors such as Fas or other adapters such as TRADD, whereas the FADD death effector domain binds to procaspase 8. Each domain can interact with its target in the absence of the other domain, and this has led to the idea that the two domains function independently. FADD death domain interactions with Fas and TRADD are thought to occur on the same surface; however, the regulation of these interactions is poorly understood. We developed a modified reverse two-hybrid method that can identify mutations, which inhibit some protein-protein interactions without affecting other interactions. Using this method, we identified mutations in FADD that prevent binding to Fas but do not affect binding to TRADD. Surprisingly, these mutations were in the death effector domain rather than the death domain. To test whether the mutants function in mammalian cells, we expressed wild type or mutant FADD molecules in FADD-deficient cells. Wild type FADD rescued both Fas ligand- and TNF-dependent signaling, whereas the FADD death effector domain mutants rescued only TNF signaling. These data indicate that in contrast to current models, the death effector domain of FADD is involved in interaction with Fas.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA	Wake Forest University; Wake Forest University; Utah System of Higher Education; University of Utah	Thorburn, A (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Stillman, David/0000-0002-5268-2416				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Rose MD., 1990, METHODS YEAST GENETI; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; SIKORSKI RS, 1989, GENETICS, V122, P19; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Voth WP, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e59; Weber CH, 2001, FEBS LETT, V492, P171, DOI 10.1016/S0014-5793(01)02162-7	25	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34343	34348		10.1074/jbc.M204169200	http://dx.doi.org/10.1074/jbc.M204169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107169	hybrid			2022-12-27	WOS:000177959100106
J	Thompson, J; Lichtenthaler, FW; Peters, S; Pikis, A				Thompson, J; Lichtenthaler, FW; Peters, S; Pikis, A			beta-glucoside kinase (BglK) from Klebsiella pneumoniae - Purification, properties, and preparative synthesis of 6-phospho-beta-D-glucosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FAMILY 4; PHOSPHOTRANSFERASE SYSTEM; FUSOBACTERIUM-MORTIFERUM; GLYCOSYL HYDROLASES; ALPHA-GLUCOSIDASE; ESCHERICHIA-COLI; D-FRUCTOSES; BACTERIA; PHOSPHORYLATION	ATP-dependent beta-glucoside kinase (BgIK) has been purified from cellobiose-grown cells of Klebsiella pneumoniae. In solution, the enzyme (EC 2.7.1.85) exists as a homotetramer composed of non-covalently linked subunits of M-r similar to 33,000. Determination of the first 28 residues from the N terminus of the protein allowed the identification and cloning of bglK from genomic DNA of K pneumoniae. The open reading frame (ORF) of bglK encodes a 297-residue polypeptide of calculated Mr 32,697. A motif of 7 amino acids (AFD(7)IG(9)GT) near the N terminus may comprise the ATP-binding site, and residue changes D7G and G9A yielded catalytically inactive proteins. BglK was progressively inactivated (t(1/2) similar to 19 min) by N-ethylmaleimide, but ATP afforded considerable protection against the inhibitor. By the presence of a centrally located signature sequence, BgIK can be assigned to the ROK (Repressor, ORF, Kinase) family of proteins. Preparation of (His6)BglK by nickel-nitrilotriacetic acid-agarose chromatography provided high purity enzyme in quantity sufficient for the preparative synthesis (200-500 mg) of ten 6-phospho-beta-D-glucosides, including cellobiose-6'-P, gentiobiose-6'-P, cellobiitol-6-P, salicin-6-P, and arbutin-6-P. These (and other) derivatives are substrates for phospho-beta-glucosidase(s) belonging to Families 1 and 4 of the glycosylhydrolase superfamily. The structures, physicochemical properties, and phosphorylation site(s) of the 6-phospho-beta-D-glucosides have been determined by fast atom bombardment-negative ion spectrometry, thin-layer chromatography, and H-1 and C-13 NMR spectroscopy. The recently sequenced genomes of two Listeria species, L. monocytogenes EGD-e and L. innocua CLIP 11262, contain homologous genes (lmo2764 and lin2907, respectively) that encode a 294-residue polypeptide (M-r similar to 32,200) that exhibits similar to58% amino acid identity with BgIK. The protein encoded by the two genes exhibits beta-glucoside kinase activity and cross-reacts with polyclonal antibody to (His6)BglK from K pneumoniae. The location of lmo2764 and lin2907 within a beta-glucoside (cellobiose):phosphotransferase system operon, may presage both enzymatic (kinase) and regulatory functions for the BgIK homolog in Listeria species.	NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Tech Univ Darmstadt, Inst Organ Chem, D-64287 Darmstadt, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Technical University of Darmstadt	Thompson, J (corresponding author), NIDCR, Microbial Biochem & Genet Unit, Oral Infect & Immun Branch, NIH, Bldg 30,Rm 528,30 Convent Dr,MSC 4350, Bethesda, MD 20892 USA.		PIKIS, ANDREAS/AFU-1192-2022					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P5324; Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BREG J, 1988, CARBOHYD RES, V174, P23, DOI 10.1016/0008-6215(88)85078-X; Concha MI, 2000, FEMS MICROBIOL LETT, V186, P97, DOI 10.1111/j.1574-6968.2000.tb09088.x; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Glaser P, 2001, SCIENCE, V294, P849; Gutknecht R, 1998, J BIOL CHEM, V273, P25745, DOI 10.1074/jbc.273.40.25745; HENGSTEN.W, 1969, CARBOHYD RES, V10, P463, DOI 10.1016/S0008-6215(00)80909-X; HENGSTENBERG W, 1968, CARBOHYD RES, V7, P180, DOI 10.1016/S0008-6215(00)81135-0; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEANS GE, 1971, CHEM MODIFICATION PR, P110; NAGAO Y, 1988, BIOCHEM BIOPH RES CO, V151, P236, DOI 10.1016/0006-291X(88)90584-0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMER RE, 1972, J BIOL CHEM, V247, P3415; Park SY, 2000, FEMS MICROBIOL LETT, V188, P209, DOI 10.1016/S0378-1097(00)00238-X; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Raasch C, 2000, EXTREMOPHILES, V4, P189, DOI 10.1007/PL00010711; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SAPICO V, 1968, J BACTERIOL, V96, P51, DOI 10.1128/JB.96.1.51-54.1968; TARELLI E, 1994, CARBOHYD RES, V261, P25, DOI 10.1016/0008-6215(94)80003-0; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Thompson J, 2001, J BIOL CHEM, V276, P37415, DOI 10.1074/jbc.M106504200; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J, 2001, CARBOHYD RES, V331, P149, DOI 10.1016/S0008-6215(01)00028-3; Thompson J., 1987, SUGAR TRANSPORT META, P13; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; Varrot A, 1999, ACTA CRYSTALLOGR D, V55, P1212, DOI 10.1107/S0907444999003790; WADE HE, 1953, NATURE, V171, P529, DOI 10.1038/171529a0; Wiesmann C, 1997, J MOL BIOL, V269, P851, DOI 10.1006/jmbi.1997.1084; WILSON G, 1974, J BIOL CHEM, V249, P5586; WITT E, 1993, PROTEIN ENG, V6, P913, DOI 10.1093/protein/6.8.913	39	18	24	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34310	34321		10.1074/jbc.M206397200	http://dx.doi.org/10.1074/jbc.M206397200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110692	hybrid			2022-12-27	WOS:000177959100102
J	Welm, AL; Timchenko, NA; Ono, Y; Sorimachi, H; Radomska, HS; Tenen, DG; Lekstrom-Himes, J; Darlington, GJ				Welm, AL; Timchenko, NA; Ono, Y; Sorimachi, H; Radomska, HS; Tenen, DG; Lekstrom-Himes, J; Darlington, GJ			C/EBP alpha is required for proteolytic cleavage of cyclin a by calpain 3 in myeloid precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MUSCLE-SPECIFIC CALPAIN; BINDING PROTEIN-ALPHA; GRANULOCYTIC DIFFERENTIATION; PHYSIOLOGICAL-FUNCTION; TRANSCRIPTION FACTORS; DEFICIENT MICE; BETA ISOFORMS; RAT LENS; GENE	In this report, we present novel findings that implicate CCAAT/enhancer-binding protein (C/EBPalpha) in regulating the expression and activity of calpain 3 in vivo and data showing a new physiological substrate for calpain 3, cyclin A. Our results demonstrate that cleavage of cyclin A by calpain 3 occurs in mouse and human myeloid precursor cells. Calpain 3 cleaves cyclin A in vitro and in vivo, resulting in the production of a truncated product that lacks the N-terminal destruction box required for its degradation at the end of mitosis. The cleaved form of cyclin A retains the cyclin-dependent kinase (cdk) binding domain and forms active complexes with cdk2. Calpain 3-mediated cleavage of cyclin A is lacking in C/EBPalpha-/- mice, which are not able to produce mature granulocytes. Our data support a model in which calpain 3-mediated cleavage of cyclin A in dividing myeloid progenitor cells is important for the onset of differentiation. Deficits in this pathway in C/EBPalpha-/- mice might contribute to the failure of these mice to produce mature granulocytes. These data reveal a new pathway involving tightly controlled post-translational processing of cyclin A during differentiation of granulocytes.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Univ Arizona, Coll Med, Tucson, AZ 85724 USA; Harvard Univ, Sch Med, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA; NIH, Bethesda, MD 20892 USA	Baylor College of Medicine; Baylor College of Medicine; University of Tokyo; University of Arizona; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA	Darlington, GJ (corresponding author), Baylor Coll Med, Huffington Ctr Aging, N803,1 Baylor Plaza, Houston, TX 77030 USA.		Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727; Tenen, Daniel/0000-0002-6423-3888	NIA NIH HHS [AG 00766] Funding Source: Medline; NIDDK NIH HHS [DK 07696, R01 DK 53045] Funding Source: Medline; NIGMS NIH HHS [GM 55188] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696, R01DK053045] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Arthur JSC, 2000, METH MOL B, V144, P109; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Bastians H, 1998, P NATL ACAD SCI USA, V95, P15374, DOI 10.1073/pnas.95.26.15374; Chen XN, 1997, BLOOD, V90, P156; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Kaufmann H, 2001, J BIOL CHEM, V276, P29987, DOI 10.1074/jbc.M005452200; Kinbara K, 1998, BIOCHEM PHARMACOL, V56, P415; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Richard I, 1996, MAMM GENOME, V7, P377, DOI 10.1007/s003359900108; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Yam CH, 2001, P NATL ACAD SCI USA, V98, P497, DOI 10.1073/pnas.240461397; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	43	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33848	33856		10.1074/jbc.M204096200	http://dx.doi.org/10.1074/jbc.M204096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105198	hybrid			2022-12-27	WOS:000177959100043
J	Brown, LJ; Koza, RA; Everett, C; Reitman, ML; Marshall, L; Fahien, LA; Kozak, LP; MacDonald, MJ				Brown, LJ; Koza, RA; Everett, C; Reitman, ML; Marshall, L; Fahien, LA; Kozak, LP; MacDonald, MJ			Normal thyroid thermogenesis but reduced viability and adiposity in mice lacking the mitochondrial glycerol phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL-3-PHOSPHATE DEHYDROGENASE; SN-GLYCEROL-3-PHOSPHATE DEHYDROGENASE; 3-PHOSPHATE DEHYDROGENASE; LACTATE-DEHYDROGENASE; PANCREATIC-ISLETS; METABOLISM; MILK; EXPRESSION; GLUCOSE; NADH	The mitochondrial glycerol phosphate dehydrogenase (mGPD) is important for metabolism of glycerol phosphate for gluconeogenesis or energy production and has been implicated in thermogenesis induced by cold and thyroid hormone treatment. mGPD in combination with the cytosolic glycerol phosphate dehydrogenase (cGPD) is proposed to form the glycerol phosphate shuttle, catalyzing the interconversion of dihydroxyacetone phosphate and glycerol phosphate with net oxidation of cytosolic NADH. We made a targeted deletion in Gdm1 and produced mice lacking mGPD. On a C57BL/6J background these mice showed a 50% reduction in viability compared with wild-type littermates. Uncoupling protein-1 mRNA levels in brown adipose tissue did not differ between mGPD knockout and control pups, suggesting normal thermogenesis. Pups lacking mGPD had decreased liver ATP and slightly increased liver glycerol phosphate. In contrast, liver and muscle metabolites were normal in adult animals. Adult mGPD knockout animals had a normal cold tolerance, normal circadian rhythm in body temperature, and demonstrated a normal temperature increase in response to thyroid hormone. However, they were found to have a lower body mass index, a 40% reduction in the weight of white adipose tissue, and a slightly lower fasting blood glucose than controls. The phenotype may be secondary to consequences of the obligatory production of cytosolic NADH from glycerol metabolism in the mGPD knockout animal. We conclude that, although mGPD is not essential for thyroid thermogenesis, variations in its function affect viability and adiposity in mice.	Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Brown, LJ (corresponding author), Univ Wisconsin, Dept Pediat, 3550 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475; Grueter, Carrie/0000-0002-1913-2527	NICHD NIH HHS [HD008431] Funding Source: Medline; NIDDK NIH HHS [DK 28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK028348] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARINZE IJ, 1973, J BIOL CHEM, V248, P2266; BARTNESS TJ, 1987, PHYSIOL BEHAV, V39, P721, DOI 10.1016/0031-9384(87)90256-3; BERGMEYER HU, 1985, METHODS ENZYMATIC AN; BERRY MN, 1973, EUR J BIOCHEM, V33, P407, DOI 10.1111/j.1432-1033.1973.tb02697.x; Brown LJ, 2002, J BIOL CHEM, V277, P32899, DOI 10.1074/jbc.M202409200; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; BURCH HB, 1970, J BIOL CHEM, V245, P2092; COOK JR, 1982, DEV BIOL, V92, P440, DOI 10.1016/0012-1606(82)90189-0; EICHER EM, 1976, MOUSE NEWS LETT, V54, P41; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Fahien LA, 1999, ARCH BIOCHEM BIOPHYS, V364, P185, DOI 10.1006/abbi.1999.1117; FERNANDEZALVAREZ J, 1994, DIABETOLOGIA, V37, P177, DOI 10.1007/s001250050090; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; Ishikawa A, 2000, MAMM GENOME, V11, P824, DOI 10.1007/s003350010145; Jost B, 1999, NAT BIOTECHNOL, V17, P160, DOI 10.1038/6158; KNIGHT CH, 1986, COMP BIOCHEM PHYS A, V84, P127, DOI 10.1016/0300-9629(86)90054-X; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Koza RA, 1996, ARCH BIOCHEM BIOPHYS, V336, P97, DOI 10.1006/abbi.1996.0536; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; KOZAK LP, 1982, DEV GENET, V3, P1, DOI 10.1002/dvg.1020030102; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; LARDY HA, 1965, P NATL ACAD SCI USA, V53, P1410, DOI 10.1073/pnas.53.6.1410; LEE YP, 1965, J BIOL CHEM, V240, P1427; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MacDonald MJ, 2000, ARCH BIOCHEM BIOPHYS, V384, P143, DOI 10.1006/abbi.2000.2107; MILLER SA, 1970, FED PROC, V29, P1497; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAGASAWA H, 1989, P SOC EXP BIOL MED, V191, P78, DOI 10.3181/00379727-191-42892; OSTENSON CG, 1993, DIABETOLOGIA, V36, P722, DOI 10.1007/BF00401142; Ovadi Judit, 1997, V9, P237; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRAC; PROCHAZKA M, 1989, J BIOL CHEM, V264, P4679; Ravier MA, 2000, J BIOL CHEM, V275, P1587, DOI 10.1074/jbc.275.3.1587; SNELL K, 1973, ENZYME, V15, P40, DOI 10.1159/000481053; SRIVASTAVA DK, 1989, P NATL ACAD SCI USA, V86, P6464, DOI 10.1073/pnas.86.17.6464; TETER BB, 1992, LIPIDS, V27, P912, DOI 10.1007/BF02535872; Wojtas K, 1997, MOL BIOL CELL, V8, P1665, DOI 10.1091/mbc.8.9.1665	41	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32892	32898		10.1074/jbc.M202408200	http://dx.doi.org/10.1074/jbc.M202408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093799	hybrid			2022-12-27	WOS:000177859000066
J	Koutsoupakis, K; Stavrakis, S; Pinakoulaki, E; Soulimane, T; Varotsis, C				Koutsoupakis, K; Stavrakis, S; Pinakoulaki, E; Soulimane, T; Varotsis, C			Observation of the equilibrium Cu-B-CO complex and functional implications of the transient heme a(3) propionates in cytochrome ba(3)-CO from Thermus thermophilus - Fourier transform infrared (FTIR) and time-resolved step-scan FTIR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER OXIDASES; PARACOCCUS-DENITRIFICANS; PROTON TRANSLOCATION; ESCHERICHIA-COLI; BINUCLEAR CENTER; CARBON-MONOXIDE; RHODOBACTER-SPHAEROIDES; STRUCTURAL-CHANGES; ELECTRON-TRANSFER; RESONANCE RAMAN	We report the first evidence for the existence of the equilibrium Cu-B(1+)-CO species of CO-bound reduced cytochrome ba(3) from Thermus thermophilus at room temperature. The frequency of the C-O stretching mode of Cu-B(1+)-CO is located at 2053 cm(-1) and remains unchanged in H2O/D2O exchanges and, between pD 5.5 and 9.7, indicating that the chemical environment does not alter the protonation state of the Cu-B histidine ligands. The data and conclusions reported here are in contrast to the changes in protonation state of Cu-B-His-290, reported recently (Das, T. K., Tomson, F. K., Gennis, R. B., Gordon, M., and Rousseau, D. L. (2001) Biophys. J. 80, 2039-2045 and Das, T. P., Gomes, C. M., Teixeira, M., and Rousseau, D. L. (1999) Proc. Natl. Acad. Sci. U. S. A 96, 9591-9596). The time-resolved step-scan FTIR difference spectra indicate that the rate of decay of the transient Cu-B(1+)-CO complex is 34.5 s(-1) and rebinding to heme a(3) occurs with k(2) = 28.6 s(-1). The rate of decay of the transient Cu-B(1+)-CO complex displays a similar time constant as the absorption changes at 1694(+)/1706(-), attribute to perturbation of the heme alpha(3) propionates (COOH). The nu(C-O) of the transient Cu-B(1+)-CO species is the same as that of the equilibrium Cu-B(1+)-CO species and remains unchanged in the pD range 5.5-9.7 indicating that no structural change takes place at Cu-B between these states. The implications of these results with respect to proton pathways in heme-copper oxidases are discussed.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, L Knossou 300,POB 1470, Iraklion 71409, Crete, Greece.		Stavrakis, Stavros/P-6267-2019	Stavrakis, Stavros/0000-0002-0888-5953; Pinakoulaki, Eftychia/0000-0003-3320-6112; Varotsis, Constantinos/0000-0003-2771-8891				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Das TK, 1999, P NATL ACAD SCI USA, V96, P9591, DOI 10.1073/pnas.96.17.9591; EINARSDOTTIR O, 1989, J BIOL CHEM, V264, P2405; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; EINARSDOTTIR O, 1992, P NATL ACAD SCI USA, V89, P6934, DOI 10.1073/pnas.89.15.6934; FAGER LY, 1994, BIOCHEMISTRY-US, V33, P1433; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; GOLDBECK RA, 1992, BIOCHEMISTRY-US, V31, P9376, DOI 10.1021/bi00154a008; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P9648, DOI 10.1021/bi9903401; Iwase T, 1999, J AM CHEM SOC, V121, P1415, DOI 10.1021/ja983242w; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kannt A, 1998, FEBS LETT, V434, P17, DOI 10.1016/S0014-5793(98)00942-9; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMON DD, 1993, BIOCHEMISTRY-US, V32, P11953, DOI 10.1021/bi00096a002; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Park S, 1996, BIOPHYS J, V71, P1036, DOI 10.1016/S0006-3495(96)79304-9; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Puustinen A, 1997, BIOCHEMISTRY-US, V36, P13195, DOI 10.1021/bi971091o; Puustinen A, 1999, P NATL ACAD SCI USA, V96, P35, DOI 10.1073/pnas.96.1.35; Rost B, 1999, BIOCHEMISTRY-US, V38, P7565, DOI 10.1021/bi990225q; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Than M. E., 2001, HDB METALLOPROTEINS, P363; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; Varotsis C, 1996, BIOSPECTROSCOPY, V2, P331; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhang HM, 2000, J PHYS CHEM B, V104, P10738, DOI 10.1021/jp000745r	40	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32860	32866		10.1074/jbc.M204943200	http://dx.doi.org/10.1074/jbc.M204943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12097331	hybrid			2022-12-27	WOS:000177859000062
J	Zhao, XX; Bey, EA; Wientjes, FB; Cathcart, MK				Zhao, XX; Bey, EA; Wientjes, FB; Cathcart, MK			Cytosolic phospholipase A(2) (cPLA(2)) regulation of human monocyte NADPH oxidase activity - cPLA(2) affects translocation but not phosphorylation of p67(phox) and p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; ACTIVATED HUMAN MONOCYTES; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE ANION PRODUCTION; CELL-FREE SYSTEM; ARACHIDONIC-ACID; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE	The NADPH oxidase of human monocytes is activated upon exposure to opsonized zymosan and a variety of other stimuli to catalyze the formation of superoxide anion. Assembly of the NADPH oxidase complex is believed to be a highly regulated process, and molecular mechanisms responsible for this regulation have yet to be fully elucidated. We have previously reported that cytosolic phospholipase A(2), (cPLA(2)) expression and activity are essential for superoxide anion production in activated human monocytes. In this study, we investigated the mechanisms involved in cPLA(2) regulation of NADPH oxidase activation by evaluating the effects of cPLA, on translocation. and phosphorylation of p67(phoz), and p47(phox). We report that translocation. and phosphorylation of p67(phox), as well as p47(phox), occur upon activation of human monocytes and that decreased cPLA, protein expression, mediated by antisense oligodeoxyribonucleotides (AS-ODN) specific for cPLA(2) mRNA, blocked the stimulation-induced translocation of p47(phox) and p67(phox) from the cytosol to the membrane fraction. Inhibition of translocation of both p47(phox) and p67(phox) by cPLA(2) AS-ODN was above 85%. Arachidonic acid (AA), a product of cPLA(2) enzymatic activity, completely restored translocation of both of these oxidase components in the AS-ODN-treated, cPLA(2)-deficient human monocytes. These results represent the first report that cPLA(2) activity or AA is required for p67(phox) and p47(phox), translocation in human monocytes. Although cPLA(2) was required for translocation of p47(phoz) and p67(phox), it did not influence phosphorylation of these components. These results suggest that one mechanism of cPLA(2) regulation of NADPH oxidase activity is to control the arachidonate-sensitive assembly of the complete oxidase complex through modulating the translocation of both p47(phox) and p67(phox),. These studies provide insight into the mechanisms by which activation signals are transduced to allow the induction of superoxide anion production in human monocytes.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; UCL, Dept Med, London WC1E 6JJ, England	Cleveland Clinic Foundation; University of London; University College London	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	cathcam@ccf.org			NHLBI NIH HHS [HL61972] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061972] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Bauldry SA, 1996, BBA-LIPID LIPID MET, V1299, P223, DOI 10.1016/0005-2760(95)00207-3; Bey EA, 2000, J LIPID RES, V41, P489; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN MS, 1994, CLIN INFECT DIS, V18, pS170, DOI 10.1093/clinids/18.Supplement_2.S170; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DANESCH U, 1994, J BIOL CHEM, V269, P27258; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; ELY EW, 1995, BBA-LIPID LIPID MET, V1258, P135; Forbes LV, 1999, FEBS LETT, V449, P225, DOI 10.1016/S0014-5793(99)00444-5; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; IYER SS, 1994, J BIOL CHEM, V269, P22405; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; KADRIHASSANI N, 1995, J BIOL CHEM, V270, P15111, DOI 10.1074/jbc.270.25.15111; KAPUS A, 1994, J BIOL CHEM, V269, P4736; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; LI Q, 1994, J BIOL CHEM, V269, P17508; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; Lowenthal A, 1999, J BIOL CHEM, V274, P21603, DOI 10.1074/jbc.274.31.21603; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; Park HS, 1998, BBA-PROTEIN STRUCT M, V1387, P406, DOI 10.1016/S0167-4838(98)00152-6; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; Sellmayer A, 1996, CELL SIGNAL, V8, P397, DOI 10.1016/0898-6568(96)00077-0; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	55	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25385	25392		10.1074/jbc.M203630200	http://dx.doi.org/10.1074/jbc.M203630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12101222	hybrid			2022-12-27	WOS:000176747000071
J	Ehses, JA; Pelech, SL; Pederson, RA; McIntosh, CHS				Ehses, JA; Pelech, SL; Pederson, RA; McIntosh, CHS			Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GLUCAGON-LIKE PEPTIDE-1; MAP KINASE; BETA(2)-ADRENERGIC RECEPTOR; GROWTH-FACTOR; B-RAF; FUNCTIONAL EXPRESSION; COUPLED RECEPTORS; LIGAND-BINDING; CELL-GROWTH	The gastrointestinal hormone, glucose-dependent insulinotropic polypeptide (GIP), is one of the most important regulators of insulin secretion following ingestion of a meal. GIP stimulates insulin secretion from the pancreatic beta-cell via its G protein-coupled receptor activation of adenylyl cyclase and other signal transduction pathways, but there is little known regarding subsequent protein kinase pathways that are activated. A screening technique was used to determine the relative abundance of 75 protein kinases in CHO-K1 cells expressing the GIP receptor and in two pancreatic beta-cell lines (PTC-3 and INS-1 (832/13) cells). This information was used to identify kinases that are potentially regulated following GIP stimulation, with a focus on GIP regulation of the ERK1/2 MAPK pathway. In CHO-K1 cells, GIP induced phosphorylation of Raf-1 (Ser-259), Mek1/2 (Ser-217/Ser-221), ERK1/2 (Thr-202 and Tyr-204), and p90 RSK (Ser-380) in a concentration-dependent manner. Activation of ERK1/2 was maximal at 4 min and was cAMP-dependent protein kinase-dependent and protein kinase C-independent. Studies using a beta-cell line (INS-1 clone 832/13) corroborated these findings, and it was also demonstrated that the ERK1/2 module could be activated by GIP in the absence of glucose. Finally, we have shown that GIP regulation of the ERK1/2 module is via Rap1 but does not involve Gbetagamma subunits nor Src tyrosine kinase, and we propose that cAMP-based regulation occurs via B-Raf in both CHO-K1 and beta-cells. These results establish the importance of GIP in the cellular regulation of the ERK1/2 module and identify a role for cAMP in coupling its G protein-coupled receptors to ERK1/2 activity in pancreatic beta-cells.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Kinexus Bioinformat Corp, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Ehses, Jan/AAK-1635-2020	Ehses, Jan/0000-0001-9066-7607				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Ehses JA, 2002, DIABETES, V51, pA339; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Hui HX, 2001, DIABETES, V50, P785, DOI 10.2337/diabetes.50.4.785; Jiang YW, 2001, P NATL ACAD SCI USA, V98, P10102, DOI 10.1073/pnas.131200398; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Kubota A, 1997, BIOCHEM BIOPH RES CO, V235, P171, DOI 10.1006/bbrc.1997.6743; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PELECH SL, 2002, METHODS MOL MED SERI; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; Tourrel C, 2001, DIABETES, V50, P1562, DOI 10.2337/diabetes.50.7.1562; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	58	102	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37088	37097		10.1074/jbc.M205055200	http://dx.doi.org/10.1074/jbc.M205055200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138104	hybrid			2022-12-27	WOS:000178447100025
J	Teramachi, S; Imagawa, T; Kaya, S; Taniguchi, K				Teramachi, S; Imagawa, T; Kaya, S; Taniguchi, K			Replacement of several single amino acid side chains exposed to the inside of the ATP-binding pocket induces different extents of affinity change in the high and low affinity ATP-binding sites of rat Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-ATPASE; SARCOPLASMIC-RETICULUM; ION-TRANSPORT; OLIGOMERIC STRUCTURE; ALPHA-SUBUNIT; BETA-SUBUNIT; NA,K-ATPASE; NA+,K+-ATPASE; PHOSPHORYLATION; FLUORESCEIN	To investigate the relationship between the high and the low affinity ATP-binding site, which appears during the Na+/K+-ATPase reaction, four amino acids were mutated, the side chains of which are exposed to inside of the ATP-binding pocket. Six mutants, F475Y, K480A, K480E, K501A, K501E, and R544A, where the numbers correspond to the pig Na+/K+-ATPase alpha-chain, were expressed in HeLa cells. The apparent affinities were determined by high affinity ATP-dependent phosphorylation and by the low affinity activation of Na+/K+-ATPase or low affinity ATP inhibition of K+-para-nitrophenylphosphatase (pNPPase). For the mutants K480A and K501A, little affinity change was detected for either the high affinity or the low affinity effect. In contrast, the other four mutants reduced both apparent affinities. Strikingly, R544A had a 30-fold greater effect on the high affinity ATP site than the low affinity site. For the F475Y mutant, it is likely that there was a greater effect on the low affinity site than the high affinity site, but for both F475Y and K480E the affinity for the low affinity ATP effect was reduced so much that it was not possible to estimate a K-0.5. However, both the affinities for the K480E were reduced to similar to1/20. The turnover number of the Na+/K+-ATPase and the apparent affinity for Na+ and pNPP was reduced slightly or not at all for these mutants, but the turnover number of K+-pNPPase and the apparent affinity for K+ were increased. These and other data suggest the presence of only one ATP-binding site, which can change its conformation to accept ATP with a high and low affinity. The requirement of Arg-544 and possibly Lys-501 is more important in forming a high affinity ATP binding conformation, and Phe-475 and possibly Lys-480 are more important in forming the low affinity ATP binding conformation.	Hokkaido Univ, Div Chem,Dept Biol Chem, Grad Sch Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Imagawa, T (corresponding author), Hokkaido Univ, Div Chem,Dept Biol Chem, Grad Sch Sci, Kita Ku, Kita 10,Nishi 8, Sapporo, Hokkaido 0600810, Japan.	toshi@sci.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					Abe K, 2002, BIOCHEMISTRY-US, V41, P2438, DOI 10.1021/bi015622r; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Askari A, 2000, INT CONGR SER, V1207, P17; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; ELLISDAVIES GCR, 1993, J BIOL CHEM, V268, P11622; Ettrich R, 2001, J MOL MODEL, V7, P184; Faller LD, 2000, INT CONGR SER, V1207, P389; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; Imagawa T, 1998, JPN J PHARMACOL, V76, P415, DOI 10.1254/jjp.76.415; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nakamura J, 2002, J BIOL CHEM, V277, P24180, DOI 10.1074/jbc.M111834200; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; POST RL, 1972, J BIOL CHEM, V247, P6530; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER W, 1994, SODIUM PUMP, P332; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; Tao Bernard Y., 1994, P69; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; WANG K, 1992, J BIOL CHEM, V267, P3577; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	50	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37394	37400		10.1074/jbc.M204772200	http://dx.doi.org/10.1074/jbc.M204772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138102	hybrid			2022-12-27	WOS:000178447100062
J	Antonin, W; Dulubova, I; Arac, D; Pabst, S; Plitzner, J; Rizo, J; Jahn, R				Antonin, W; Dulubova, I; Arac, D; Pabst, S; Plitzner, J; Rizo, J; Jahn, R			The N-terminal domains of syntaxin 7 and vti1b form three-helix bundles that differ in their ability to regulate SNARE complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; T-SNARE; 3-DIMENSIONAL STRUCTURE; PROTEINS; EXOCYTOSIS; IDENTIFICATION; SPECIFICITY; SECRETION; MECHANISM; VESICLES	The SNAREs syntaxin 7, syntaxin 8, vti1b, and endobrevin/VAMP8 function in the fusion of late endosomes. Although the core complex formed by these SNAREs is very similar to the neuronal SNARE complex, it differs from the neuronal complex in that three of the four SNAREs contain extended N-terminal regions of unknown structure and function. Here we show that the N-terminal regions of syntaxin 7, syntaxin 8, and vti1b contain well folded a-helical domains. Multidimensional NAIR spectroscopy revealed that in syntaxin 7 and vti1b, the domains form three-helix bundles resembling those of syntaxin 1, Sso1p, and Vam3p. The three-helix bundle domain of vti1b is the first of its kind identified in a SNARE outside the syntaxin family. Only syntaxin 7 adopts a closed conformation, whereas in vti1b and syntaxin 8, the N-terminal domains do not interact with the adjacent SNARE motifs. Accordingly, the rate of SNARE complex assembly is retarded about 7-fold when syntaxin 7 contains its N-terminal domain, whereas the N-terminal domains of vti1b and syntaxin 8 have no influence on assembly kinetics. We conclude that three-helix bundles represent a common fold for SNARE N-terminal domains, not restricted to the syntaxin family. However, they differ in their ability to adopt closed conformations and thus to regulate the assembly of SNARE complexes.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany.		Antonin, Wolfram/A-8656-2014; Antonin, Wolfram/P-3648-2019	Antonin, Wolfram/0000-0003-4669-379X; Antonin, Wolfram/0000-0003-4669-379X; Jahn, Reinhard/0000-0003-1542-3498	NINDS NIH HHS [NS37200] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Tishgarten T, 1999, PROTEIN SCI, V8, P2465; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	41	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36449	36456		10.1074/jbc.M204369200	http://dx.doi.org/10.1074/jbc.M204369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114520	Green Published, hybrid			2022-12-27	WOS:000178275100086
J	Thess, A; Hutschenreiter, S; Hofmann, M; Tampe, R; Baumeister, W; Guckenberger, R				Thess, A; Hutschenreiter, S; Hofmann, M; Tampe, R; Baumeister, W; Guckenberger, R			Specific orientation and two-dimensional crystallization of the proteasome at metal-chelating lipid interfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPE; 20S PROTEASOME; HIGH-RESOLUTION; RNA-POLYMERASE; CYTOCHROME-C; 2-DIMENSIONAL CRYSTALLIZATION; 26S PROTEASOME; PROTEIN; IMMOBILIZATION; MONOLAYERS	The potential of a protein-engineered His tag to immobilize macromolecules in a predictable orientation at metal-chelating lipid interfaces was investigated using recombinant 20 S proteasomes His-tagged in various positions. Electron micrographs demonstrated that the orientation of proteasomes bound to chelating lipid films could be controlled via the location of their His tags: proteasomes His-tagged at their sides displayed exclusively side-on views, while proteasomes His-tagged at their ends displayed exclusively end-on views. The activity of proteasomes immobilized at chelating lipid interfaces was well preserved. In solution, His-tagged proteasomes hydrolyzed casein at rates comparable with wild-type proteasomes, unless the His tags were located in the vicinity of the N termini of alpha-subunits. The N termini of a-subunits might partly occlude the entrance channel in a-rings through which substrates enter the proteasome for subsequent degradation. A combination of electron micrographs and atomic force microscope topographs revealed a propensity of vertically oriented proteasomes to crystallize in two dimensions on fluid lipid films. The oriented immobilization of His-tagged proteins at biocompatible lipid interfaces will assist structural studies as well as the investigation of biomolecular interaction via a wide variety of surface-sensitive techniques including single-molecule analysis.	Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany; Univ Frankfurt, Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Guckenberger, R (corresponding author), Max Planck Inst Biochem, Abt Mol Strukturbiol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Barklis E, 1997, EMBO J, V16, P1199, DOI 10.1093/emboj/16.6.1199; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bischler N, 1998, BIOPHYS J, V74, P1522, DOI 10.1016/S0006-3495(98)77864-6; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; BOS MA, 1995, BIOPHYS J, V68, P2566, DOI 10.1016/S0006-3495(95)80439-X; BOS MA, 1995, BIOPHYS J, V68, P2573, DOI 10.1016/S0006-3495(95)80440-6; BUTT HJ, 1990, BIOPHYS J, V58, P1473, DOI 10.1016/S0006-3495(90)82492-9; Celia H, 1999, P NATL ACAD SCI USA, V96, P5634, DOI 10.1073/pnas.96.10.5634; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; DIETRICH C, 1995, P NATL ACAD SCI USA, V92, P9014, DOI 10.1073/pnas.92.20.9014; Dorn IT, 1999, J MOL BIOL, V288, P1027, DOI 10.1006/jmbi.1999.2714; Dorn IT, 1998, J AM CHEM SOC, V120, P2753, DOI 10.1021/ja9735620; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; IWAKURA M, 1993, J BIOCHEM-TOKYO, V114, P339, DOI 10.1093/oxfordjournals.jbchem.a124178; KARRASCH S, 1994, P NATL ACAD SCI USA, V91, P836, DOI 10.1073/pnas.91.3.836; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; Osmulski PK, 2000, J BIOL CHEM, V275, P13171, DOI 10.1074/jbc.C901035199; PERSSON M, 1990, FEBS LETT, V270, P41, DOI 10.1016/0014-5793(90)81230-L; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Scheuring S, 1999, J MICROSC-OXFORD, V193, P28, DOI 10.1046/j.1365-2818.1999.00434.x; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; SCHMITT L, 1994, J AM CHEM SOC, V116, P8485, DOI 10.1021/ja00098a008; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHNEK DR, 1994, LANGMUIR, V10, P2382, DOI 10.1021/la00019a058; Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023; STAYTON PS, 1992, J AM CHEM SOC, V114, P9298, DOI 10.1021/ja00050a008; Thomson NH, 1999, BIOPHYS J, V76, P1024, DOI 10.1016/S0006-3495(99)77267-X; Venien-Bryan C, 1997, J MOL BIOL, V274, P687, DOI 10.1006/jmbi.1997.1431; Viani MB, 2000, NAT STRUCT BIOL, V7, P644, DOI 10.1038/77936; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Wood LL, 1997, J AM CHEM SOC, V119, P571, DOI 10.1021/ja9623673; YANG J, 1993, J MOL BIOL, V229, P286, DOI 10.1006/jmbi.1993.1033; Yeung C, 1999, LANGMUIR, V15, P6829, DOI 10.1021/la990019j; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	50	44	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36321	36328		10.1074/jbc.M202145200	http://dx.doi.org/10.1074/jbc.M202145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114506	hybrid			2022-12-27	WOS:000178275100069
J	Cong, F; Tang, J; Hwang, BJ; Vuong, BQ; Chu, G; Goff, SP				Cong, F; Tang, J; Hwang, BJ; Vuong, BQ; Chu, G; Goff, SP			Interaction between UV-damaged DNA binding activity proteins and the c-Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; IONIZING-RADIATION; TRANSFORMING ACTIVITY; RECOGNITION PROTEIN; APOPTOTIC RESPONSE; NUCLEAR TRANSPORT; MAMMALIAN-CELLS; PRIMATE CELLS; LOCALIZATION	The c-Abl tyrosine kinase is activated by some forms of DNA damage, including ionizing radiation, but not UV radiation. The functions of this activation in the damage response pathways remain obscure. To identify potential targets of c-Abl kinase, we utilized the yeast two-hybrid system to screen a murine cDNA library. One c-Abl binding protein of particular interest was the large subunit (DDB1) of the heterodimeric complex with UV-damaged DNA binding activity (UV-DDB). This complex binds with high specificity to DNA damaged by UV, is absent in a subset of xeroderma pigmentosum group E cells, and is required for global genomic repair of UV-induced damage. The association of c-Abl with DDB1 required the kinase domain of c-Abl and preserved the interaction between DDB1 and the small subunit (DDB2) of the UV-DDB complex. Significantly, overexpression of c-Abl increased tyrosine phosphorylation of DDB2 and suppressed UV-DDB activity. Conversely, a dominant negative, kinase-deficient allele of c-Abl decreased tyrosine phosphorylation of DDB2 and dramatically stimulated LTV-DDB activity. These results suggest that one role of c-Abl may be to negatively regulate LTV-DDB activity by phosphorylation of DDB2.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Stanford University; Stanford University	Chu, G (corresponding author), Ctr Clin Sci Res 1140, 269 Campus Dr, Stanford, CA 94305 USA.	chu@cmgm.stanford.edu; goff@cancereenter.columbia.edu	Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Tang, Jean/0000-0002-5510-6502; Vuong, Bao/0000-0001-5416-9635	NCI NIH HHS [R01 CA077302-04] Funding Source: Medline; NIGMS NIH HHS [R01 GM58120, R01 GM058120] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORNACE AJ, 1986, RADIAT RES, V106, P73, DOI 10.2307/3576562; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gong JG, 1999, NATURE, V399, P806; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1997, BIOCHIM BIOPHYS ACTA, V1333, pO1; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Leadon SA, 1996, RADIAT RES, V146, P123, DOI 10.2307/3579583; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; PAYNE A, 1994, MUTAT RES-FUND MOL M, V310, P89, DOI 10.1016/0027-5107(94)90012-4; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PEREGO R, 1991, ONCOGENE, V6, P1899; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; REARDON JT, 1993, J BIOL CHEM, V268, P21301; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vaisman A, 1996, ONCOL RES, V8, P7; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	55	24	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34870	34878		10.1074/jbc.M204416200	http://dx.doi.org/10.1074/jbc.M204416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107171	Green Accepted, hybrid			2022-12-27	WOS:000178117000029
J	Fiorentino, L; Stehlik, C; Oliveira, V; Ariza, ME; Godzik, A; Reed, JC				Fiorentino, L; Stehlik, C; Oliveira, V; Ariza, ME; Godzik, A; Reed, JC			A novel PAAD-containing protein that modulates NF-kappa B induction by cytokines tumor necrosis factor-alpha and interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; PYRIN DOMAIN; APOPTOSIS; FAMILY; ACTIVATION; GENE; RESPONSES; MEMBER; INFLAMMATION; HOMOLOGY	PAAD domains are found in diverse proteins of unknown function and are structurally related to a superfamily of protein interaction modules that includes death domains, death effector domains, and Caspase activation and recruitment domains. Using bioinformatics strategies, cDNAs were identified that encode a novel protein of 110 kDa containing a PAAD domain followed by a putative nucleotide-hinding (NACHT) domain and several leucine-rich repeat domains. This protein thus resembles Cryopyrin, a protein implicated in hereditary hyperinflammation syndromes, and was termed PAN2 for PAAD and NACHT-containing protein 2. When expressed in HEK293 cells, PAN2 suppressed NF-kappaB induction by the cytokines tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta), suggesting that this protein operates at a point of convergence in these two cytokine signaling pathways. This PAN2-mediated suppression of NF-kappaB was evident both in reporter gene assays that measured NF-kappaB transcriptional activity and electromobility shift assays that measured NF-kappaB DNA binding activity. PAN2 also suppressed NF-kappaB induction resulting from overexpression of several adapter proteins and protein kinases involved in the TNF or IL-1 receptor signal transduction, including TRAF2, TRAF6, RIP, IRAK2, and NF-kappaB-inducing kinase as well as the IkappaB kinases IKKalpha and IKKbeta. PAN2 also inhibited the cytokine-mediated activation of IKKalpha and IKKbeta as measured by in vitro kinase assays. Furthermore, PAN2 association with IKKalpha was demonstrated by co-immunoprecipitation assays, suggesting a direct effect on the IKK complex. These observations suggest a role for PAN2 in modulating NF-kappaB activity in cells, thus providing the insights into the potential functions of PAAD family proteins and their roles in controlling inflammatory responses.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/A-7279-2009; Stehlik, Christian/AAG-2132-2021; Godzik, Adam/AAW-1467-2020	Godzik, Adam/0000-0002-2425-852X; Stehlik, Christian/0000-0002-3782-2484; Godzik, Adam/0000-0002-2425-852X				Aksentijevich I, 1997, CELL, V90, P797; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Inohara N, 2000, CELL DEATH DIFFER, V7, P509, DOI 10.1038/sj.cdd.4400679; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastner DL, 2001, NAT GENET, V29, P241, DOI 10.1038/ng1101-241; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Li WZ, 2000, BIOINFORMATICS, V16, P1105, DOI 10.1093/bioinformatics/16.12.1105; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5	30	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35333	35340		10.1074/jbc.M200446200	http://dx.doi.org/10.1074/jbc.M200446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093792	hybrid			2022-12-27	WOS:000178117000087
J	Fraser, DJ; Podvinec, M; Kaufmann, MR; Meyer, UA				Fraser, DJ; Podvinec, M; Kaufmann, MR; Meyer, UA			Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE-X-RECEPTOR; CYTOCHROME-P450 GENES; SIGNALING PATHWAY; HEME; INDUCTION; CAR; BINDING; PXR; HEPATOCYTES	Heme is an essential component in oxygen transport and metabolism in living systems. In non-erythropoietic cells, 5-aminolevulinate synthase (ALAS1) is the first and rate-limiting enzyme in the heme biosynthesis pathway. ALAS1 expression and heme levels are increased in vivo by drugs and other chemical inducers of cytochrome P450 hemoproteins through mechanisms that are poorly understood. In the present studies, a chicken genomic cosmid library was employed to isolate a major portion of the ALAS1 gene. Two drug-responsive enhancer sequences, 176 and 167 base pairs in length, were identified in the W-flanking region of the gene in reporter gene assays in the hepatoma cell line LMH. The relative potency of inducers to activate these enhancers corresponds to induction of ALAS1 mRNA levels in LMH cells. Analysis of putative transcription factor binding sites within the enhancers revealed DR5 and DR4 type recognition sequences for nuclear receptors. Drug activation of the enhancer elements was reduced at least 60% after mutagenesis of individual nuclear receptor binding sites and was virtually eliminated following alteration of both recognition sites within the respective elements. Electrophoretic mobility shift assays and transactivation studies demonstrate direct interactions between the nuclear receptor binding sites and the recently described chicken xenobiotic-sensing receptor, (CXR) implicating drug activation mechanisms for ALAS1 similar to those found in inducible cytochrome(s) P450. This is the first report describing direct transcriptional activation of ALAS1 by drugs via drug-responsive enhancer sequences.	Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Fraser, DJ (corresponding author), Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Podvinec, Michael/0000-0002-3267-2173				Baader M, 2002, J BIOL CHEM, V277, P15647, DOI 10.1074/jbc.M109882200; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Cable EE, 2000, ARCH BIOCHEM BIOPHYS, V384, P280, DOI 10.1006/abbi.2000.2117; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; GRANICK S, 1975, J BIOL CHEM, V250, P9215; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAMILTON JW, 1988, BIOCHEM J, V255, P267; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jover R, 1996, BIOCHEM BIOPH RES CO, V226, P152, DOI 10.1006/bbrc.1996.1325; Jover R, 2000, EUR J BIOCHEM, V267, P7128, DOI 10.1046/j.1432-1327.2000.01815.x; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Sassa S, 2000, INT J HEMATOL, V71, P1; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	36	46	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34717	34726		10.1074/jbc.M204699200	http://dx.doi.org/10.1074/jbc.M204699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121995	hybrid			2022-12-27	WOS:000178117000010
J	Qian, YM; Grant, CE; Westlake, CJ; Zhang, DW; Lander, PA; Shepard, RL; Dantzig, AH; Cole, SPC; Deeley, RG				Qian, YM; Grant, CE; Westlake, CJ; Zhang, DW; Lander, PA; Shepard, RL; Dantzig, AH; Cole, SPC; Deeley, RG			Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [I-125]LY475776 and azidophenacyl-[3(5S)]glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; AMINO-ACID RESIDUE; LEUKOTRIENE C-4; DRUG-RESISTANCE; MRP GENE; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; SUBSTRATE-SPECIFICITY; CONJUGATE TRANSPORT; DEPENDENT TRANSPORT	Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-dependent transporter of structurally diverse organic anion conjugates. The protein also actively transports a number of non-conjugated chemotherapeutic drugs and certain anionic conjugates by a presently poorly understood GSH-dependent mechanism. LY475776is a newly developed I-125-labeled azido tricyclic isoxazole that binds toMRP1 with high affinity and specificity in a GSH-dependent manner. The compound has also been shown to photolabel a site in the COOH-proximal region of MRP1's third membrane spanning domain (MSD). It is presently not known where GSH interacts with the protein. Here, we demonstrate that the photactivateable GSH derivative azidophenacyl-GSH can substitute functionally for GSH in supporting the photolabeling of MRP1 by LY475776 and the transport of another GSH-dependent substrate, estrone 3-sulfate. In contrast to LY475776, azidophenacyl [S-35] photolabels both halves of the protein. Photolabeling of the COOH-proximal site can be markedly stimulated by low concentrations of estrone 3-sulfate, suggestive of cooperativity between the binding of these two compounds. We show that photolabeling of the COOH-proximal site by LY475776 and the labeling of both NH2- and COOH- proximal sites by azidophenacyl-GSH requires the cytoplasmic linker (CL3) region connecting the first and second MSDs of the protein, but not the first MSD itself. Although required for binding, CL3 is not photolabeled by azidophenacyl-GSH. Finally, we identify non-conserved amino acids in the third MSD that contribute to the high affinity with which LY475776 binds to MRP1.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Eli Lilly	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Rm A315 Botterell Hall,Stuart & George St, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Westlake, Christopher/0000-0001-7476-2014; Zhang, Dawei/0000-0001-8279-8041; Qian, Yueming/0000-0001-7340-6421				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chen ZS, 2001, INT J CANCER, V93, P107, DOI 10.1002/ijc.1290; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V222, P111, DOI 10.1006/bbrc.1996.0706; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gustafsson A, 2001, BIOCHEMISTRY-US, V40, P15835, DOI 10.1021/bi010429i; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOESCH RM, 1989, J BIOL CHEM, V264, P17712; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Keppler D, 1999, ADV ENZYME REGUL, V39, P237, DOI 10.1016/S0065-2571(98)00015-6; Kool M, 1997, CANCER RES, V57, P3537; Kool M, 1999, CANCER RES, V59, P175; KUNST M, 1989, BIOCHIM BIOPHYS ACTA, V982, P15, DOI 10.1016/0005-2736(89)90168-5; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MAO Q, 2002, IN PRESS J BIOL CHEM; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Norman BH, 2002, BIOORG MED CHEM LETT, V12, P883, DOI 10.1016/S0960-894X(02)00051-3; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; WILSON GM, 1995, PLASMID, V33, P198, DOI 10.1006/plas.1995.1021; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	54	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35225	35231		10.1074/jbc.M206058200	http://dx.doi.org/10.1074/jbc.M206058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12138119	hybrid			2022-12-27	WOS:000178117000073
J	Muto, A; Ruland, J; McAllister-Lucas, LM; Lucas, PC; Yamaoka, S; Chen, FF; Lin, A; Mak, TW; Nunez, G; Inohara, N				Muto, A; Ruland, J; McAllister-Lucas, LM; Lucas, PC; Yamaoka, S; Chen, FF; Lin, A; Mak, TW; Nunez, G; Inohara, N			Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; RIP-LIKE KINASE; DEATH DOMAIN; CELL-DEATH; FAMILY MEMBER; TERMINAL KINASE; NUCLEAR-FACTOR; COMPLEX; PHOSPHORYLATION; APOPTOSIS	Protein kinase C-associated kinase (PKK) is a recently described kinase of unknown function that was identified on the basis of its specific interaction with PKCbeta. PKK contains N-terminal kinase and C-terminal ankyrin repeats domains linked to an intermediate region. Here we report that the kinase domain of PKK is highly homologous to that of two mediators of nuclear factor-kappaB (NF-kappaB) activation, RICK and RIP, but these related kinases have different C-terminal domains for binding to upstream factors. We find that expression of PKK, like RICK and RIP, induces NF-kappaB activation. Mutational analysis revealed that the kinase domain of PKK is essential for NF-kappaB activation, whereas replacement of serine residues in the putative activation loop did not affect the ability of PKK to activate NF-kappaB. A catalytic inactive PKK mutant inhibited NF-kappaB activation induced by phorbol ester and Ca2+-ionophore, but it did not block that mediated by tumor necrosis factor alpha, interleukin-1beta, or Nod1. Inhibition of NF-kappaB activation by dominant negative PKK was reverted by co-expression of PKCbetaI, suggesting a functional association between PKK and PKCbetaI. PKK-mediated NF-kappaB activation required IKKalpha and IKKbeta but not IKKgamma, the regulatory subunit of the IKK complex. Moreover, NF-kappaB activation induced by PKK was not inhibited by dominant negative Bimp1. and proceeded in the absence of Bcl10, two components of a recently described PKC signaling pathway. These results suggest that PKK is a member of the RICK/RIP family of kinases, which is involved in a PKC-activated NF-kappaB signaling pathway that is independent of Bcl10 and IKKgamma.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Amgen Inst, Toronto, ON M5G 2C1, Canada; Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Tokyo Medical & Dental University (TMDU)	Inohara, N (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Ruland, Jürgen/Q-6680-2018; Lin, Amy Erica/ABG-4745-2020; Nuñez, Gabriel/A-7160-2014	Ruland, Jürgen/0000-0002-8381-3597; Lin, Amy Erica/0000-0002-0554-2832; Lucas, Peter/0000-0003-4880-7172	NCI NIH HHS [F23-CA88470-01, CA84064] Funding Source: Medline; NHLBI NIH HHS [T32-HL07622] Funding Source: Medline; NIGMS NIH HHS [GM60421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084064, F32CA088470] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahr C, 2000, J BIOL CHEM, V275, P36350, DOI 10.1074/jbc.M004771200; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chen LJ, 2001, J BIOL CHEM, V276, P21737, DOI 10.1074/jbc.M008069200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kumar A, 2001, AM J PHYSIOL-RENAL, V281, pF613, DOI 10.1152/ajprenal.2001.281.4.F613; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Li QT, 2000, GENE DEV, V14, P1729; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Liu YC, 1997, J BIOL CHEM, V272, P168; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Malhotra A, 2001, DIABETES, V50, P1918, DOI 10.2337/diabetes.50.8.1918; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31871	31876		10.1074/jbc.M202222200	http://dx.doi.org/10.1074/jbc.M202222200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12091384	hybrid			2022-12-27	WOS:000177718700072
J	Muoio, DM; MacLean, PS; Lang, DB; Li, S; Houmard, JA; Way, JM; Winegar, DA; Corton, JC; Dohm, GL; Kraus, WE				Muoio, DM; MacLean, PS; Lang, DB; Li, S; Houmard, JA; Way, JM; Winegar, DA; Corton, JC; Dohm, GL; Kraus, WE			Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice - Evidence for compensatory regulation by PPAR delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; UNCOUPLING PROTEIN-3 GENE; TARGETED DISRUPTION; ADIPOSE-TISSUE; POTENTIAL ROLE; IN-VIVO; ALPHA; EXPRESSION; GAMMA; METABOLISM	Ablation of peroxisome proliferator activated receptor (PPAR) alpha, a lipid-activated transcription factor that regulates expression of beta-oxidative genes, results in profound metabolic abnormalities in liver and heart. In the present study we used PPARalpha knockout (KO) mice to determine whether this transcription factor is essential for regulating fuel metabolism in skeletal muscle. When animals were challenged with exhaustive exercise or starvation, KO mice exhibited lower serum levels of glucose, lactate, and ketones and higher nonesterified fatty acids than wild type (WT) littermates. During exercise, KO mice exhausted earlier than WT and exhibited greater rates of glycogen depletion in liver but not skeletal muscle. Fatty acid oxidative capacity was similar between muscles of WT and KO when animals were fed and only 28% lower in KO muscles when animals were starved. Exercise-induced regulation and starvation-induced regulation of pyruvate-dehydrogenase kinase 4 and uncoupling protein 3, two classical and robustly responsive PPARalpha target genes, were similar between WT and KO in skeletal muscle but markedly different between genotypes in heart. Real time quantitative PCR analyses showed that unlike in liver and heart, in mouse skeletal muscle PPARdelta is severalfold more abundant than either PPARalpha or PPARgamma. In both human and rodent myocytes, the highly selective PPARdelta agonist GW742 increased fatty acid oxidation about 2-fold and induced expression of several lipid regulatory genes, including pyruvate-dehydrogenase kinase 4 and uncoupling protein 3, responses that were similar to those elicited by the PPARa agonist GW647. These results show redundancy in the functions of PPARs alpha and delta as transcriptional regulators of fatty acid homeostasis and suggest that in skeletal muscle high levels of the delta-subtype can compensate for deficiency of PPARalpha.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; E Carolina Univ, Dept Biochem, Greenville, NC 27858 USA; E Carolina Univ, Human Performance Lab, Greenville, NC 27858 USA; GlaxoSmithKline, Dept Metab Dis, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Nucl Receptor Biol, Res Triangle Pk, NC 27709 USA; Chem Ind Inst Toxicol, Ctr Hlth Res, Res Triangle Pk, NC 27709 USA	Duke University; Duke University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; GlaxoSmithKline; GlaxoSmithKline	Muoio, DM (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3327, Durham, NC 27710 USA.	muoio@duke.edu	MacLean, Paul/A-7887-2008; Muoio, Debbie Marie/E-1147-2012	MacLean, Paul/0000-0002-1123-6612; Kraus, William E/0000-0003-1930-9684; Muoio, Deborah/0000-0003-3760-9277	NHLBI NIH HHS [HL57354] Funding Source: Medline; NIDDK NIH HHS [F32DK 10017-01] Funding Source: Medline; PHS HHS [46121-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010017, P30DK048520] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Berthon PM, 1998, J APPL PHYSIOL, V85, P148, DOI 10.1152/jappl.1998.85.1.148; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; Chevillotte E, 2001, J BIOL CHEM, V276, P10853, DOI 10.1074/jbc.M008010200; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Henry RR, 1996, J CLIN INVEST, V98, P1231, DOI 10.1172/JCI118906; Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V279, pE348, DOI 10.1152/ajpendo.2000.279.2.E348; Jones JP, 1997, AM J PHYSIOL-ENDOC M, V273, pE682, DOI 10.1152/ajpendo.1997.273.4.E682; JONES PS, 1995, EUR J BIOCHEM, V233, P219, DOI 10.1111/j.1432-1033.1995.219_1.x; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Lee SST, 1996, ANN NY ACAD SCI, V804, P524, DOI 10.1111/j.1749-6632.1996.tb18642.x; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; Muoio DM, 2002, DIABETES, V51, P901, DOI 10.2337/diabetes.51.4.901; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Scholte HR, 1997, MOL CELL BIOCHEM, V174, P61, DOI 10.1023/A:1006803807814; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Su JL, 1998, HYBRIDOMA, V17, P47, DOI 10.1089/hyb.1998.17.47; SUGDEN MC, 1994, FASEB J, V8, P54, DOI 10.1096/fasebj.8.1.8299890; Sugden MC, 2000, BIOCHEM J, V346, P651, DOI 10.1042/0264-6021:3460651; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; VEERKAMP JH, 1986, BIOCHEM MED METAB B, V35, P248, DOI 10.1016/0885-4505(86)90080-0; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Wu PF, 2001, BIOCHEM BIOPH RES CO, V287, P391, DOI 10.1006/bbrc.2001.5608; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593	48	318	335	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26089	26097		10.1074/jbc.M203997200	http://dx.doi.org/10.1074/jbc.M203997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12118038	hybrid			2022-12-27	WOS:000176908700035
J	Cheong, CG; Escalante-Semerena, JC; Rayment, I				Cheong, CG; Escalante-Semerena, JC; Rayment, I			Capture of a labile substrate by expulsion of water molecules from the active site of nicotinate mononucleotide: 5,6dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella enterica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE LOOP; TYPHIMURIUM LT2; COBALAMIN; PURIFICATION; MOLSCRIPT; ENZYME	Nicotinate mononucleotide (NaMN):5,6-dimethylbenzimidazole (DMB) phosphoribosyltransferase (CobT) from Salmonella enterica plays a central role in the synthesis of alpha-ribazole-5'-phosphate, an intermediate for the lower ligand of cobalamin. In earlier studies it proved difficult to obtain the structure of CobT bound to NaMN because it is hydrolyzed in the crystal lattice in the absence of the second substrate DMB. In an effort to map the reaction pathway of this enzyme, NaMN was captured in the active site with the substrate analogs 4,5-dimethyl-1,2-phenylenediamine, 4-methylcatechol, indole, 3,4-dimethylaniline, 2,5-dimethylaniline, 3,4-dimethylphenol, and 2-amino-p-cresol. Structures of these complexes reveal that they exclude water molecules responsible for the hydrolysis from the active site. These structures, together with the early complexes with alpha-ribazole-5'-phosphate and DMB, provide a complete description of the reaction pathway. They demonstrate that the nicotinate moiety and phosphate do not appear to move significantly between reactants and products but that the aromatic base and ribose moiety each move similar to1.2 Angstrom toward each other in the transformation. This study also reveals that, like many other nucleotide binding proteins, coordination of DMB is accompanied by a disorder-order transition in a surface loop. The structure of apo-CobT is also reported.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Escalante@bact.wisc.edu; Ivan-Rayment@biochem.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R01GM058281, R37GM040313] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040313, GM 40313, GM 58281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheong CG, 1999, BIOCHEMISTRY-US, V38, P16125, DOI 10.1021/bi991752c; Cheong CG, 2001, J BIOL CHEM, V276, P37612, DOI 10.1074/jbc.M105390200; Craig SP, 2000, J BIOL CHEM, V275, P20231, DOI 10.1074/jbc.R000002200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Grubmeyer CT, 1999, METHOD ENZYMOL, V308, P28; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Keck B, 2000, ARCH MICROBIOL, V173, P76, DOI 10.1007/s002030050011; Keck K, 1998, ARCH MICROBIOL, V171, P66, DOI 10.1007/s002030050679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; MUSIK WD, 1981, CRC CRIT REV BIOCH; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; OTOOLE GA, 1994, THESIS U WISCONSIN M; PERLMAN D, 1958, CAN J MICROBIOL, V4, P9, DOI 10.1139/m58-002; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Trzebiatowski JR, 1997, J BIOL CHEM, V272, P17662, DOI 10.1074/jbc.272.28.17662	24	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41120	41127		10.1074/jbc.M203535200	http://dx.doi.org/10.1074/jbc.M203535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12101181	hybrid			2022-12-27	WOS:000178791400122
J	Bou-Abdallah, F; Lewin, AC; Le Brun, NE; Moore, GR; Chasteen, ND				Bou-Abdallah, F; Lewin, AC; Le Brun, NE; Moore, GR; Chasteen, ND			Iron detoxification properties of Escherichia coli bacterioferritin - Attenuation of oxyradical chemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN; FERROXIDASE KINETICS; HYDROGEN-PEROXIDE; INTERMEDIATE-X; FERRITIN; OXIDATION; STORAGE; HYDROLYSIS; MINERALIZATION; INVOLVEMENT	Bacterioferritin (EcBFR) of Escherichia coli is an iron-mineralizing hemoprotein composed of 24 identical subunits, each containing a dinuclear metal-binding site known as the "ferroxidase center." The chemistry of Fe(II) binding and oxidation and Fe(III) hydrolysis using H2O2 as oxidant was studied by electrode oximetry, pH-stat, UV-visible spectrophotometry, and electron paramagnetic resonance spin trapping experiments. Absorption spectroscopy data demonstrate the oxidation of two Fe(II) per H2O2 at the ferroxidase center, thus avoiding hydroxyl radical production via Fenton chemistry. The oxidation reaction with H2O2 corresponds to [Fe(II)(2)-P](Z) + H2O2 --> [Fe(III)(2)O-P](Z) + H2O, where [Fe(II)(2)-P](Z) represents a diferrous ferroxidase center complex of the protein P with net charge Z and [Fe(III)(2)O-P](Z) a mu-oxo-bridged diferric ferroxidase complex. The mineralization reaction is given by 2Fe(2+) + H2O2 + 2H(2)O --> 2FeOOH((core)) + 4H(+), where two Fe(II) are again oxidized by one H2O2. Hydrogen peroxide is shown to be an intermediate product of dioxygen reduction when O-2 is used as the oxidant in both the ferroxidation and mineralization reactions. Most of the H2O2 produced from O-2 is rapidly consumed in a subsequent ferroxidase reaction with Fe(II) to produce H2O. EPR spin trapping experiments show that the presence of EcBFR greatly attenuates the production of hydroxyl radical during Fe(II) oxidation by H2O2, consistent with the ability of the bacterioferritin to facilitate the pairwise oxidation of Fe(II) by H2O2, thus avoiding odd electron reduction products of oxygen and therefore oxidative damage to the protein and cellular components through oxygen radical chemistry.	Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Univ E Anglia, Sch Chem Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University System Of New Hampshire; University of New Hampshire; University of East Anglia	Chasteen, ND (corresponding author), Univ New Hampshire, Dept Chem, Parsons Hall, Durham, NH 03824 USA.	ndc@cisunix.unh.edu		Le Brun, Nick/0000-0001-9780-4061	NIGMS NIH HHS [R37 GM20194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1991, J GEN MICROBIOL, V137, P361, DOI 10.1099/00221287-137-2-361; ANDREWS SC, 1995, J BIOL CHEM, V270, P23268, DOI 10.1074/jbc.270.40.23268; ANDREWS SC, 1991, FEBS LETT, V293, P164, DOI 10.1016/0014-5793(91)81177-A; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BI X, 1991, J BIOL CHEM, V266, P19965; Bou-Abdallah F, 2002, BIOCHEM J, V364, P57, DOI 10.1042/bj3640057; Chasteen ND, 1998, MET IONS BIOL SYST, V35, P479; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Chen CY, 1999, MICROBIOL-SGM, V145, P2967, DOI 10.1099/00221287-145-10-2967; Dautant A, 1998, ACTA CRYSTALLOGR D, V54, P16, DOI 10.1107/S0907444997006811; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hawkins C, 1996, NUOVO CIMENTO D, V18, P347, DOI 10.1007/BF02458916; Hsu HF, 1999, J AM CHEM SOC, V121, P5230, DOI 10.1021/ja983666q; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; LEBRUN NE, 1993, FEBS LETT, V333, P197, DOI 10.1016/0014-5793(93)80404-I; LeBrun NE, 1997, STRUCT BOND, V88, P103; Ma JF, 1999, J BACTERIOL, V181, P3730, DOI 10.1128/JB.181.12.3730-3742.1999; Moenne-Loccoz P, 1999, BIOCHEMISTRY-US, V38, P5290, DOI 10.1021/bi990095l; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; PROULXCURRY PM, 1995, COORDIN CHEM REV, V144, P347, DOI 10.1016/0010-8545(95)01148-I; QUE L, 1990, PROG INORG CHEM, V38, P97; Riggs-Gelasco PJ, 1998, J AM CHEM SOC, V120, P849, DOI 10.1021/ja9718230; SUN S, 1992, J BIOL CHEM, V267, P25160; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Yang XK, 1996, BIOPHYS J, V71, P1587, DOI 10.1016/S0006-3495(96)79361-X; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Yang XO, 2000, BIOCHEMISTRY-US, V39, P4915, DOI 10.1021/bi992631f; Zhang H, 2000, FEBS LETT, V473, P58, DOI 10.1016/S0014-5793(00)01498-8; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j; Zhao ZW, 1997, J CHEM SOC DALTON, P3977, DOI 10.1039/a703675b	35	68	70	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37064	37069		10.1074/jbc.M205712200	http://dx.doi.org/10.1074/jbc.M205712200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12124394	hybrid			2022-12-27	WOS:000178447100022
J	Kato, U; Emoto, K; Fredriksson, C; Nakamura, H; Ohta, A; Kobayashi, T; Murakami-Murofushi, K; Kobayashi, T; Umeda, M				Kato, U; Emoto, K; Fredriksson, C; Nakamura, H; Ohta, A; Kobayashi, T; Murakami-Murofushi, K; Kobayashi, T; Umeda, M			A novel membrane protein, Ros3p, is required for phospholipid translocation across the plasma membrane in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE-LABELED PHOSPHOLIPIDS; ENDOPLASMIC-RETICULUM; TRANSBILAYER MOVEMENT; INTRACELLULAR-TRANSPORT; P-GLYCOPROTEIN; CELL-SURFACE; YEAST-CELLS; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; IDENTIFICATION	Ro09-0198 (Ro) is a tetracyclic peptide antibiotic that binds specifically to phosphatidylethanolamine (PE) and causes cytolysis. To investigate the molecular basis of transbilayer movement of PE in biological membranes, we have isolated a series of budding yeast mutants that are hypersensitive to the Ro peptide. One of the most sensitive mutants, designated ros3 (Ro-sensitive 3), showed no significant change in the cellular phospholipid composition or in the sensitivity to amphotericin B, a sterol-binding polyene macrolide antibiotic. These results suggest that the mutation of ros3 affects the PE organization on the plasma membrane, rather than PE synthesis or overall organization of the membrane structures. By functional complementation screening, we identified the gene ROS3 affected in the mutant, and we showed that the hypersensitive phenotype was caused by the defective expression of the ROS3 gene product, Ros3p, an evolutionarily conserved protein with two putative transmembrane domains. Disruption of the ROS3 gene resulted in a marked decrease in the internalization of fluorescence-labeled analogs of PE and phosphatidylcholine, whereas the uptake of fluorescence-labeled phosphatidylserine and endocytic markers was not affected. Neither expression levels nor activities of ATP-binding cassette transporters of the ros3Delta cells differed from those of wild type cells, suggesting that Ros3p is not related to the multidrug resistance activities. Immunochemical analyses of the structure and subcellular localization showed that Ros3p was a glycosylated membrane protein localized in both the plasma membrane and the endoplasmic reticulum, and that a part of Ros3p was associated with the detergentin-soluble glycolipid-enriched complexes. These results indicate that Ros3p is a membrane glycoprotein that plays an important role in the phospholipid translocation across the plasma membrane.	Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; RIKEN, Suprabiomol Syst Res Grp, Frontier Res Syst, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Tokyo Metropolitan Institute of Medical Science; Ochanomizu University; RIKEN; University of Tokyo	Umeda, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	umeda@rinshoken.or.jp	EMOTO, KAZUO/G-4992-2014; KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270				AOKI Y, 1994, J BIOCHEM-TOKYO, V116, P291, DOI 10.1093/oxfordjournals.jbchem.a124522; BACKER JM, 1987, NATURE, V327, P341, DOI 10.1038/327341a0; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P183, DOI 10.1128/AAC.34.2.183; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DULIC V, 1990, J CELL SCI, V97, P517; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hanson PK, 2001, J BIOL CHEM, V276, P9861, DOI 10.1074/jbc.M009065200; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO S, 1984, AGR BIOL CHEM TOKYO, V48, P2181, DOI 10.1080/00021369.1984.10866492; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; Marx U, 1999, EUR J BIOCHEM, V263, P254, DOI 10.1046/j.1432-1327.1999.00497.x; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MOIR D, 1982, GENETICS, V100, P547; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Nicolson T, 2000, FEBS LETT, V476, P277, DOI 10.1016/S0014-5793(00)01684-7; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SATOH O, 1990, J LIPID RES, V31, P1293; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Siegmund A, 1998, J BIOL CHEM, V273, P34399, DOI 10.1074/jbc.273.51.34399; Sitcheran R, 2000, GENETICS, V156, P963; SLEIGHT RG, 1989, J CELL SCI, V93, P363; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Umeda M, 1999, CHEM PHYS LIPIDS, V101, P81, DOI 10.1016/S0009-3084(99)00057-2; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; VANHELVOORT A, 1996, CELL, V87, P504; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WAKAMATSU K, 1990, BIOCHEMISTRY-US, V29, P113, DOI 10.1021/bi00453a013; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	53	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37855	37862		10.1074/jbc.M205564200	http://dx.doi.org/10.1074/jbc.M205564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133835	hybrid			2022-12-27	WOS:000178447100121
J	del Pulgar, TG; de Ceballos, ML; Guzman, M; Velasco, G				del Pulgar, TG; de Ceballos, ML; Guzman, M; Velasco, G			Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO-SYNTHESIZED CERAMIDE; IN-VIVO; RECEPTOR; ACTIVATION; BRAIN; ANANDAMIDE; NEUROPROTECTION; IDENTIFICATION; STIMULATION; INHIBITION	Cannabinoids, the active components of marijuana and their endogenous counterparts, exert many of their actions on the central nervous system by binding to the CB, cannabinoid receptor. Different studies have shown that cannabinoids can protect neural cells from different insults. However, those studies have been performed in neurons, whereas no attention has been focused on glial cells. Here we used the pro-apoptotic lipid ceramide to induce apoptosis in astrocytes, and we studied the protective effect exerted by cannabinoids. Results show the following: (i) cannabinoids rescue primary astrocytes from C-2-ceramide-induced apoptosis in a dose- and time-dependent manner; (ii) triggering of this antiapoptotic signal depends on the phosphatidylinositol 3-kinase/protein kinase B pathway; (iii) ERK and its downstream target p90 ribosomal S6 kinase might be also involved in the protective effect of cannabinoids; and (iv) cannabinoids protect astrocytes from the cytotoxic effects of focal C-2-ceramide administration in vivo. In summary, results show that cannabinoids protect astrocytes from ceramide-induced apoptosis via stimulation of the phosphatidylinositol 3-kinase/protein kinase B pathway. These findings constitute the first evidence for an "astroprotective" role of cannabinoids.	Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; CSIC, Inst Cajal, Neurodegenerat Grp, Madrid 28002, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Velasco, G (corresponding author), Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	gvd@bbm1.ucm.es	Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020; Gomez del Pulgar, Teresa/GXV-5256-2022; de Ceballos, María L./B-4598-2008	Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; de Ceballos, María L./0000-0003-4067-9700; Guzman, Manuel/0000-0001-7475-118X				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Marsicano G, 2002, J NEUROCHEM, V80, P448, DOI 10.1046/j.0022-3042.2001.00716.x; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Pertwee RG, 2000, EXPERT OPIN INV DRUG, V9, P1553, DOI 10.1517/13543784.9.7.1553; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 2001, MOL PHARMACOL, V59, P955, DOI 10.1124/mol.59.5.955; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; van der Stelt M, 2001, J NEUROSCI, V21, P6475, DOI 10.1523/JNEUROSCI.21-17-06475.2001; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	43	129	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36527	36533		10.1074/jbc.M205797200	http://dx.doi.org/10.1074/jbc.M205797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133838	hybrid			2022-12-27	WOS:000178275100095
J	Levit, MN; Stock, JB				Levit, MN; Stock, JB			Receptor methylation controls the magnitude of stimulus-response coupling in bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; ASPARTATE RECEPTOR; LIGAND-BINDING; METHYLTRANSFERASE CHER; COVALENT MODIFICATION; METHYLESTERASE CHEB; CHEMORECEPTOR COMPLEX; FLAGELLAR ROTATION; CRYSTAL-STRUCTURE	Motile prokaryotes employ a chemoreceptor-kinase array to sense changes in the media and properly adjust their swimming behavior. This array is composed of a family of Type I membrane receptors, a histidine protein kinase (CheA), and an Src homology 3-like protein (CheW). Binding of an attractant to the chemoreceptors inhibits CheA, which results in decreased phosphorylation of the chemotaxis response regulator (CheY). Sensitivity of the system to stimuli is modulated by a protein methyltransferase (CheR) and a protein methylesterase (CheB) that catalyze the methylation and demethylation of specific glutamyl residues in the cytoplasmic domain of the receptors. One of the most fundamental unanswered questions concerning the bacterial chemotaxis mechanism is the quantitative relationship between ligand binding to receptors and CheA inhibition. We show that the receptor glutamyl modifications cause adaptation by changing the gain (magnitude amplification) between attractant binding and kinase inhibition without substantially affecting ligand binding affinity. The mechanism adjusts receptor sensitivity to background stimulus intensity over several orders of magnitude of attractant concentrations. The cooperative effects of ligand binding appear to be minimal with Hill coefficients for kinase inhibition less than 2, independent of the state of glutamyl modification.	Princeton Univ, Lewis Thomas Labs, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Stock, JB (corresponding author), Princeton Univ, Lewis Thomas Labs, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	jstock@princeton.edu						Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; Anand GS, 1998, BIOCHEMISTRY-US, V37, P14038, DOI 10.1021/bi980865d; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; Bornhorst JA, 2000, BIOCHEMISTRY-US, V39, P9486, DOI 10.1021/bi0002737; Bornhorst JA, 2001, J GEN PHYSIOL, V118, P693, DOI 10.1085/jgp.118.6.693; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Djordjevic S, 1998, NAT STRUCT BIOL, V5, P446, DOI 10.1038/nsb0698-446; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; Francis NR, 2002, J BIOL CHEM, V277, P36755, DOI 10.1074/jbc.M204324200; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gestwicki JE, 2000, J BACTERIOL, V182, P6499, DOI 10.1128/JB.182.22.6499-6502.2000; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; Jasuja R, 1999, P NATL ACAD SCI USA, V96, P11346, DOI 10.1073/pnas.96.20.11346; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; Levit MN, 2002, J BIOL CHEM, V277, P36748, DOI 10.1074/jbc.M204317200; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Lybarger SR, 2000, P NATL ACAD SCI USA, V97, P8057, DOI 10.1073/pnas.130195397; Lybarger SR, 1999, J BACTERIOL, V181, P5527, DOI 10.1128/JB.181.17.5527-5529.1999; MADDOCK JR, 1993, SCIENCE, V259, P1717; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Osborn M J, 1974, Methods Enzymol, V31, P642; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; RICE MS, 1991, J BIOL CHEM, V266, P9746; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J, 1999, TRENDS MICROBIOL, V7, P1, DOI 10.1016/S0966-842X(98)01429-2; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; WEST AH, 1995, PROTEINS, V21, P345, DOI 10.1002/prot.340210407; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376; WOLANIN PM, 2002, HISTIDINE KINASES SI, P73; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	52	80	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36760	36765		10.1074/jbc.M204325200	http://dx.doi.org/10.1074/jbc.M204325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119291	hybrid			2022-12-27	WOS:000178275100124
J	Liu, JC; Baker, RE; Sun, C; Sundmark, VC; Elsholtz, HP				Liu, JC; Baker, RE; Sun, C; Sundmark, VC; Elsholtz, HP			Activation of G(o)-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells - A key step in the transcriptional suppression of the prolactin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; LACTOTROPH HYPERPLASIA; RESPONSE ELEMENT; DEFICIENT MICE; KINASE PATHWAY; DNA-SYNTHESIS; BETA-GAMMA; STIMULATE	In pituitary lactotrophs the prolactin gene is stimulated by neuropeptides and estrogen and is suppressed by dopamine via D2-type receptors. Stimulatory signals converge on activation of the mitogen-activated protein kinases ERK1/2, but dopamine regulation of this pathway is not well defined. Paradoxically, D2 agonists activate ERK1/2 in many cell types. Here we show that in prolactin-secreting GH4ZR7 cells and primary pituitary cells, dopamine treatment leads to a rapid, pronounced, and specific decrease in activated ERK112. The response is blocked by D2-specific antagonists and pertussis toxin. Interestingly, in stable lines expressing specific pertussis toxin-resistant Get subunits, toxin treatment blocks dopamine suppression of MAPK in Galpha(i2)- but not Galphao-expressing cells, demonstrating that Go-dependent pathways can effect the inhibitory MAPK response. At the nuclear level, the MEK1 inhibitor U0126 mimics the D2-agonist bromocryptine in suppressing levels of endogenous prolactin transcripts. Moreover, a good correlation is seen between the IC50 values for inhibition of MEK1 and suppression of prolactin promoter function (PD184352 > U0126 > U0125). Both dopamine and U0126 enhance the nuclear localization of ERF, a MAPK-sensitive ETS repressor that inhibits prolactin promoter activity. In addition, U0126 suppression is transferred by tandem copies of the Pit-l-binding site, consistent with mapping experiments for dopamine responsiveness. Our data suggest that ERK1/2 suppression is an obligatory step in the dopaminergic control of prolactin gene transcription and that bidirectional control of ERK1/2 function in the pituitary may provide a key mechanism for endocrine gene control.	Univ Toronto, Banting & Best Diabet Ctr, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Hlth Network, Toronto, ON M5G 1L5, Canada	University of Toronto; University of Toronto; University Health Network Toronto	Elsholtz, HP (corresponding author), Banting & Best Inst, Room 110,100 Coll St, Toronto, ON M5G 1L5, Canada.							ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Asa SL, 1999, ENDOCRINOLOGY, V140, P5348, DOI 10.1210/en.140.11.5348; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Calabresi P, 2001, J NEUROSCI, V21, P5110, DOI 10.1523/JNEUROSCI.21-14-05110.2001; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FAURE M, 1994, J BIOL CHEM, V269, P7851; FLORIO T, 1992, J BIOL CHEM, V267, P24169; Ghahremani MH, 2000, MOL CELL BIOL, V20, P1497, DOI 10.1128/MCB.20.5.1497-1506.2000; Guerrero C, 2001, AM J PHYSIOL-LUNG C, V281, pL79, DOI 10.1152/ajplung.2001.281.1.L79; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Le Pechon-Vallee C, 2000, NEUROENDOCRINOLOGY, V72, P46, DOI 10.1159/000054570; LEW AM, 1994, J BIOL CHEM, V269, P12007; Luo YQ, 1998, J NEUROCHEM, V71, P980; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Manfroid I, 2001, MOL ENDOCRINOL, V15, P625, DOI 10.1210/me.15.4.625; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCCHESNEY R, 1991, MOL CELL ENDOCRINOL, V79, pR1, DOI 10.1016/0303-7207(91)90110-E; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Saiardi A, 1997, NEURON, V19, P115, DOI 10.1016/S0896-6273(00)80352-9; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; VALLAR L, 1990, J BIOL CHEM, V265, P10320; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Yan Z, 1999, P NATL ACAD SCI USA, V96, P11607, DOI 10.1073/pnas.96.20.11607	37	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35819	35825		10.1074/jbc.M202920200	http://dx.doi.org/10.1074/jbc.M202920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121979	hybrid			2022-12-27	WOS:000178275100009
J	Oh, HS; Kwon, H; Sun, SK; Yang, CH				Oh, HS; Kwon, H; Sun, SK; Yang, CH			QM, a putative tumor suppressor, regulates proto-oncogene c-Yes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVEL; PROTEIN; GENE; SRC; SH3; EXPRESSION; PROLINE; BINDING; SUBUNIT; GROWTH	The QM gene encodes a 24.5 kDa ribosomal protein L10 known to be highly homologous to a Jun-binding protein (Jif-1), which inhibits the formation of Jun-Jun dimers. Here we have carried out screening with the c-Yes protein and found that a QM homologous protein showed interactions with c-Yes and other Src family members. We have found that two different regions of QM protein were associated with the SH3 domain of c-Yes. The QM protein does not contain canonical SH3 binding motifs or previously reported amino acid fragments showing interaction with SH3 domains. Several c-Yes kinase activity assays indicated that the QM protein reduced c-Yes kinase activity by 70% and that this suppression is related not only to the two SH3 binding regions but also to the C-terminal region of QM. Moreover, our autophosphorylation assays clarified that this regulation resulted from the inhibition of c-Yes autophosphorylation. Immunofluorescence studies showed that the QM proteins and c-Yes are able to interact in various tumor cell lines in vivo. The increases of the c-Yes protein and mRNA levels were detected when the QM was transfected. These results suggest that the QM protein might be a regulator for various signal transduction pathways involving SH3 domain-containing membrane proteins.	Seoul Natl Univ, Div Chem & Mol Engn, Seoul 151742, South Korea; Georgetown Univ, Inst Mol & Human Genet, Washington, DC 20057 USA	Seoul National University (SNU); Georgetown University	Yang, CH (corresponding author), Seoul Natl Univ, Div Chem & Mol Engn, Shinlim Dong San 56-1, Seoul 151742, South Korea.	chulyang@plaza.snu.ac.kr		Oh, Hyung Suk/0000-0002-1739-0389				Aghazadeh B, 1999, CHEM BIOL, V6, pR241, DOI 10.1016/S1074-5521(99)80108-2; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; BRANKA K, 1998, J BIOL CHEM, V273, P35185; BRIGGS SD, 1997, J BIOL CHEM, V172, P17699; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; EISINGER DP, 1993, BIOCHEM BIOPH RES CO, V196, P1227, DOI 10.1006/bbrc.1993.2383; Eisinger DP, 1997, MOL CELL BIOL, V17, P5136, DOI 10.1128/MCB.17.9.5136; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; FARMER AA, 1994, HUM MOL GENET, V3, P723, DOI 10.1093/hmg/3.5.723; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fujishima H, 1998, INT J CANCER, V76, P423; Green H, 2000, J BONE MINER RES, V15, P1066, DOI 10.1359/jbmr.2000.15.6.1066; Han NM, 1996, CLIN CANCER RES, V2, P1397; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; Inada H, 1997, BIOCHEM BIOPH RES CO, V230, P331, DOI 10.1006/bbrc.1996.5955; KANEKO K, 1992, HUM MOL GENET, V1, P529, DOI 10.1093/hmg/1.7.529; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Karl T, 1999, CURR GENET, V34, P419, DOI 10.1007/s002940050416; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KRUEGER J, 1991, ONCOGENE, V6, P933; Loftus TM, 1997, BIOCHEMISTRY-US, V36, P8224, DOI 10.1021/bi970288d; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Mills AA, 1999, DIFFERENTIATION, V64, P161, DOI 10.1046/j.1432-0436.1999.6430161.x; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Nguyen YH, 1998, J CELL BIOCHEM, V68, P281, DOI 10.1002/(SICI)1097-4644(19980201)68:2<281::AID-JCB14>3.3.CO;2-Y; OKADA M, 1989, J BIOL CHEM, V264, P20886; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN K, 2001, J BIOL CHEM, V176, P37573; Shima T, 2001, J BIOL CHEM, V276, P42233, DOI 10.1074/jbc.M102699200; STANBRIDGE E, 1994, COLD SPRING HARB SYM, V59, P573, DOI 10.1101/SQB.1994.059.01.064; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TRON T, 1995, J BIOL CHEM, V270, P9961, DOI 10.1074/jbc.270.17.9961	40	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36489	36498		10.1074/jbc.M201859200	http://dx.doi.org/10.1074/jbc.M201859200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138090	hybrid			2022-12-27	WOS:000178275100091
J	Adachi, N; Kimura, A; Horikoshi, M				Adachi, N; Kimura, A; Horikoshi, M			A conserved motif common to the histone acetyltransferase Esa1 and the histone deacetylase Rpd3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HUMAN GENES; N-COR; YEAST; ACETYLATION; PROTEIN; COMPLEX; NUCLEOSOME; REPRESSION; DROSOPHILA	Post-translational modification of histones enables dynamic regulation of chromatin structure in eukaryotes. Histone acetyltransferase (HAT) and histone deacetylase (HDAC) modify the N-terminal tails of histones by adding or removing acetyl groups to specific lysine residues. A particular pair of HAT (Esa1) and HDAC (Rpd3) is proposed to modify the same lysine residue in vitro and in vivo. Thus, HAT and HDAC might have similar structural and functional motifs. Here we show that HAT (Esa1 family) and HDAC (Rpd3 family) have similar amino acid stretches in the primary structures through evolution. We refer to this region as the "ER (Esa1-Rpd3) motif." In the tertiary structure of Esa1, the ER motif is located near the active center. In Rpd3, for which the tertiary structure remains unclear, we demonstrate that the ER motif contains the same secondary structure as found in Esa1 by circular dichroism analysis. We did alanine-scanning mutagenesis and found that the ER motif regions of Esa1 or Rpd3 are required for HAT activity of Esa1 or HDAC activity of Rpd3, respectively. Our discovery of the ER motif present in the pair of enzymes (HAT and HDAC) indicates that HAT and HDAC have common structural bases, although they catalyze the reaction with opposite functions.	JST, ERATO, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), JST, ERATO, Horikoshi Gene Selector Project, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	horikosh@iam.u-tokyo.ac.jp						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; DeRubertis F, 1996, NATURE, V384, P589; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014-5793(98)00752-2; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAN Y, 1999, NATURE, V400, P86; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; O'Neill LP, 1999, EMBO J, V18, P2897, DOI 10.1093/emboj/18.10.2897; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	54	16	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35688	35695		10.1074/jbc.M204640200	http://dx.doi.org/10.1074/jbc.M204640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110674	hybrid			2022-12-27	WOS:000178117000130
J	Holmen, SL; Salic, A; Zylstra, CR; Kirschner, MW; Williams, BO				Holmen, SL; Salic, A; Zylstra, CR; Kirschner, MW; Williams, BO			A novel set of Wnt-frizzled fusion proteins identifies receptor components that activate beta-catenin-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-EMBRYOS; WNT/BETA-CATENIN; SPEMANN ORGANIZER; WINGLESS PROTEIN; PLANAR POLARITY; EXPRESSION; PATHWAYS; CANCER; AXIS; OVEREXPRESSION	Wnt proteins initiate the canonical (beta-catenin-regulated) signaling cascade by binding to seven-transmembrane spanning receptors of the Frizzled (Fz) family together with the coreceptors LRP5 and -6, members of the low density lipoprotein receptor-related protein family (LRP). Several reports have shown physical and functional associations between various Wnt, LRP, and Frizzled molecules; however, the underlying mechanisms for selectivity remain poorly understood. We present data on a novel set of Wnt-Fz fusion constructs that are useful for elucidating mechanisms of Wnt signal transduction specificity in both Xenopus embryos and 293T cells. In 293T cells, coexpression of several Wnt-Fz fusion proteins with LRP6, but not LRP5, significantly activated a Wnt-responsive promoter, Optimized TOPFlash. Interestingly, Wnt proteins from both the Wnt1 and Wnt5A classes, when fused to the same Frizzled, can synergize with LRP6 to activate signaling and induce secondary axes in Xenopus embryos. However, when several Wnt-Fz constructs containing different Frizzled molecules were tested, it was found that all Frizzled molecules are not equivalent in their ability to activate the canonical Wnt pathway in this context. The data suggest that the distinction between the two Wnt classes lies not in intrinsic differences in the molecules but via the Frizzled molecules with which they interact.	Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Van Andel Institute; Harvard University; Harvard Medical School	Williams, BO (corresponding author), Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA.		Williams, Bart/A-3539-2013; Salic, Adrian/GXG-1611-2022	Williams, Bart/0000-0002-5261-5301; Diegel, Cassandra/0000-0002-6526-9372				Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Binari RC, 1997, DEVELOPMENT, V124, P2623; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1993, DEVELOPMENT, V119, P97; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	52	82	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34727	34735		10.1074/jbc.M204989200	http://dx.doi.org/10.1074/jbc.M204989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121999	hybrid			2022-12-27	WOS:000178117000011
J	Ko, HS; Uehara, T; Nomura, Y				Ko, HS; Uehara, T; Nomura, Y			Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CHAPERONE ACTIVITY; MOLECULAR CHAPERONES; OXIDATIVE STRESS; CHOP GADD153; ACTIVATION; DEGRADATION; CASPASE-12; EXPRESSION; HYPOXIA; BINDS	Up-regulation of several stress proteins such as heat-shock proteins and glucose-regulated proteins participate in tolerance against environmental stress. Previously, we found that protein-disulfide isomerase (PDI) is specifically up-regulated in response to hypoxia/brain ischemia in astrocytes. In addition, the overexpression of this gene into neurons protects against apoptotic cell death induced by hypoxia/brain ischemia. To address the detailed function of PDI, we screened for proteins that interact with PDI using the yeast two-hybrid system. We report here that PDI interacts with ubiquilin, which has a ubiquitin-like domain and a ubiquitin-associated domain. Interestingly, ubiquilin is also up-regulated in response to hypoxia in glial cells with a time course similar to that of PDI induction. In hypoxia-treated glial cells, the endogenous ubiquilin and PDI were almost completely co-localized, suggesting that ubiquilin is an endoplasmic reticulum-associated protein. Overexpression of this gene in neuronal cells resulted in significant inhibition of the DNA fragmentation triggered by hypoxia, but not that induced by nitric oxide or staurosporine. Moreover, ubiquilin has the ability to attenuate CHOP induction by hypoxia. These observations suggested that ubiquilin together with PDI have critical functions as regulatory proteins for CHOP-mediated cell death, and therefore up-regulation of these proteins may result in acquisition of tolerance against ischemic stress in glial cells.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Nomura, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan.	nomura@pharm.hokudai.ac.jp		Uehara, Takashi/0000-0002-8545-4006				Ahn SJ, 1998, BIOCHEM BIOPH RES CO, V244, P62, DOI 10.1006/bbrc.1998.8220; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Bando Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1172, DOI 10.1152/ajpcell.2000.278.6.C1172; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FERRER I, 1994, BRAIN PATHOL, V4, P115, DOI 10.1111/j.1750-3639.1994.tb00821.x; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Matsuda M, 2001, BIOCHEM BIOPH RES CO, V280, P535, DOI 10.1006/bbrc.2000.4149; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Ozaki T, 1997, BIOCHEM BIOPH RES CO, V237, P245, DOI 10.1006/bbrc.1997.7122; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Uehara T, 1999, J BIOL CHEM, V274, P15875, DOI 10.1074/jbc.274.22.15875; Uehara T, 1999, BRAIN RES, V823, P226, DOI 10.1016/S0006-8993(99)01178-6; VUORI K, 1992, J BIOL CHEM, V267, P7211; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Wu SL, 2002, BBA-MOL CELL RES, V1542, P41, DOI 10.1016/S0167-4889(01)00164-1; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	51	137	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35386	35392		10.1074/jbc.M203412200	http://dx.doi.org/10.1074/jbc.M203412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095988	hybrid			2022-12-27	WOS:000178117000094
J	Kowalski, K; Liew, CK; Matthews, JM; Gell, DA; Crossley, M; Mackay, JP				Kowalski, K; Liew, CK; Matthews, JM; Gell, DA; Crossley, M; Mackay, JP			Characterization of the conserved interaction between GATA and FOG family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; COFACTOR FOG; NMR; BINDING; DROSOPHILA; DIFFERENTIATION; MUTATION; DNA; THROMBOCYTOPENIA	The N-terminal zinc finger (ZnF) from GATA transcription factors mediates interactions with FOG family proteins. In FOG proteins, the interacting domains are also ZnFs; these domains are related to classical CCHH fingers but have an His --> Cys substitution at the final zinc-ligating position. Here we demonstrate that different CCHC fingers in the FOG family protein U-shaped contact the N-terminal ZnF of GATA-1 in the same fashion although with different affinities. We also show that these interactions are of moderate affinity, which is interesting given the presumed low concentrations of these proteins in the nucleus. Furthermore, we demonstrate that the variant CCHC topology enhances binding affinity, although the His --> Cys change is not essential for the formation of a stably folded domain. To ascertain the structural basis for the contribution of the CCHC arrangement, we have determined the structure of a CCHH mutant of finger nine from U-shaped. The structure is very similar overall to the wild-type domain, with subtle differences at the C terminus that result in loss of the interaction in vivo. Taken together, these results suggest that the CCHC zinc binding topology is required for the integrity of GATA-FOG interactions and that weak interactions can play important roles in vivo.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Matthews, Jacqueline/A-7322-2013; Liew, Chu Kong/H-1437-2011; Mackay, Joel/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Gell, David/0000-0003-0382-1181; Mackay, Joel/0000-0001-7508-8033; Matthews, Jacqueline/0000-0001-8518-3472				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Billeter M, 1995, J BIOMOL NMR, V5, P1; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; FEENEY J, 1979, J MAGN RESON, V33, P519, DOI 10.1016/0022-2364(79)90163-X; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Freson K, 2002, HUM MOL GENET, V11, P147, DOI 10.1093/hmg/11.2.147; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V9, P1; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Newton A, 2001, J BIOL CHEM, V276, P35794, DOI 10.1074/jbc.M106256200; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; PELTON JG, 1993, PROTEIN SCI, V2, P543; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WEISS MJ, 1995, EXP HEMATOL, V23, P99	46	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35720	35729		10.1074/jbc.M204663200	http://dx.doi.org/10.1074/jbc.M204663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110675	hybrid			2022-12-27	WOS:000178117000134
J	Smith, L; Parizi-Robinson, M; Zhu, MS; Zhi, G; Fukui, R; Kamm, KE; Stull, JT				Smith, L; Parizi-Robinson, M; Zhu, MS; Zhi, G; Fukui, R; Kamm, KE; Stull, JT			Properties of long myosin light chain kinase binding to F-actin in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; EXPRESSION; PROTEIN; FILAMENTS; PHOSPHORYLATION; LOCALIZATION; ORGANIZATION; CYTOSKELETON; CALDESMON; ISOFORMS	Short and long myosin light chain kinases (MLCKs) are Ca2+/calmodulin-dependent enzymes that phosphorylate the regulatory light chain of myosin II in thick filaments but bind with high affinity to actin thin filaments. Three repeats of a motif made up of the sequence DFRXXL at the N terminus of short MLCK are necessary for actin binding (Smith, L., Su, X., Lin, P., Zhi, G., and Stull, J. T. (1999) J. Biol. Chem. 274, 29433-29438). The long MLCK has two additional DFRXXL motifs and six Ig-like modules in an N-terminal extension, which may confer unique binding properties for cellular localization. Two peptides containing either five or three DFRXXL motifs bound to F-actin and smooth muscle myofilaments with maximal binding stoichiometries consistent with each motif binding to an actin monomer in the filaments. Both peptides cross-linked F-actin and bound to stress fibers in cells. Long MLCK with an internal deletion of the five DFRXXL motifs and the unique NH2-terminal fragment containing six Ig-like motifs showed weak binding. Cell fractionation and extractions with MgCl2 indicate that the long MLCK has a greater affinity for actin-containing filaments than short MLCK in vitro and in vivo. Whereas DFRXXL motifs are necessary and sufficient for short MLCK binding to actin-containing filaments, the DFRXXL motifs and the N-terminal extension of long MLCK confer high affinity binding to stress fibers in cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL26093] Funding Source: Medline; NICHD NIH HHS [HD07190] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Birukov KG, 1998, J CELL BIOCHEM, V70, P402, DOI 10.1002/(SICI)1097-4644(19980901)70:3<402::AID-JCB13>3.0.CO;2-M; Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001; Bozem M, 2000, CELL CALCIUM, V28, P73, DOI 10.1054/ceca.2000.0133; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; DABROWSKA R, 1982, BIOCHEM BIOPH RES CO, V107, P1524, DOI 10.1016/S0006-291X(82)80172-1; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; Fisher SA, 1995, BIOCHEM BIOPH RES CO, V217, P696, DOI 10.1006/bbrc.1995.2829; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Hatch V, 2001, J CELL BIOL, V154, P611, DOI 10.1083/jcb.200105079; Hayakawa K, 1999, BBA-MOL CELL RES, V1450, P12, DOI 10.1016/S0167-4889(99)00034-8; HAYAKAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P786, DOI 10.1006/bbrc.1994.1298; Herring BP, 2000, AM J PHYSIOL-CELL PH, V279, pC1656, DOI 10.1152/ajpcell.2000.279.5.C1656; Jian XY, 1996, J NEUROBIOL, V31, P379, DOI 10.1002/(SICI)1097-4695(199611)31:3<379::AID-NEU10>3.0.CO;2-B; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; Kudryashov DS, 1999, FEBS LETT, V463, P67, DOI 10.1016/S0014-5793(99)01591-4; Lin PJ, 1999, J BIOL CHEM, V274, P5987, DOI 10.1074/jbc.274.9.5987; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; MARSTON SB, 1991, BIOCHEM J, V279, P1; Numata T, 2001, J BIOCHEM-TOKYO, V129, P437, DOI 10.1093/oxfordjournals.jbchem.a002875; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Smith L, 1999, J BIOL CHEM, V274, P29433, DOI 10.1074/jbc.274.41.29433; Smith L, 2000, FEBS LETT, V480, P298, DOI 10.1016/S0014-5793(00)01931-1; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; WATTERSON DM, 1995, FEBS LETT, V373, P217; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104	37	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35597	35604		10.1074/jbc.M206483200	http://dx.doi.org/10.1074/jbc.M206483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110694	hybrid			2022-12-27	WOS:000178117000119
J	Tasab, M; Jenkinson, L; Bulleid, NJ				Tasab, M; Jenkinson, L; Bulleid, NJ			Sequence-specific recognition of collagen triple helices by the collagen-specific molecular chaperone HSP47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEIN HSP47; III PROCOLLAGEN; MOUSE EMBRYO; PEPTIDES; BIOSYNTHESIS; REQUIREMENTS; ASSOCIATION; PROPEPTIDE; EXPRESSION; STABILITY	HSP47 is a molecular chaperone that plays an unknown role during the assembly and transport of procollagen. Our previous studies showed that, unlike most chaperones, HSP47 interacts with a correctly folded substrate. We suggested that HSP47 either stabilizes the correctly folded collagen helix from heat denaturation or prevents lateral aggregation prior to its transport from the endoplasmic reticulum. In this study we have addressed the role of triple helix stability in the binding of HSP47 to procollagen by expressing procollagen molecules with differing thermal stabilities and analyzing their ability to interact with HSP47 within the endoplasmic reticulum. Our results show that HSP47 interacts with thermostable procollagen molecules, suggesting that helix stabilization is not the primary function of HSP47 and that the interaction of HSP47 with procollagen depends upon the presence of a minimum of one Gly-X-Arg triplet within the triple helical domain. Interestingly, procollagen chains containing high proportions of stabilizing triplets formed triple helices and interacted with HSP47 even in the absence of proline hydroxylation, demonstrating that recognition does not depend upon this modification. Our results support the view that HSP47 functions early in the secretory pathway by preventing the lateral aggregation of procollagen chains.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Bulleid, Neil/0000-0002-9839-5279				BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P397, DOI 10.1111/j.1432-1033.1984.tb08115.x; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; ElThaher TSH, 1996, PROTEIN PEPTIDE LETT, V3, P1; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Loones MT, 1998, CELL STRESS CHAPERON, V3, P237, DOI 10.1379/1466-1268(1998)003<0237:HACDDE>2.3.CO;2; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Masuda H, 1998, CELL STRESS CHAPERON, V3, P256, DOI 10.1379/1466-1268(1998)003<0256:EALOCB>2.3.CO;2; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mironov A, 1998, FASEB J, V12, P249; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Thomson CA, 2001, PROTEIN EXPRES PURIF, V23, P8, DOI 10.1006/prep.2001.1470; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	33	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35007	35012		10.1074/jbc.M202782200	http://dx.doi.org/10.1074/jbc.M202782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12114508	hybrid			2022-12-27	WOS:000178117000045
J	Zhang, LS; Gray, L; Novick, RP; Ji, GY				Zhang, LS; Gray, L; Novick, RP; Ji, GY			Transmembrane topology of AgrB, the protein involved in the post-translational modification of AgrD in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; GENE REGULATOR AGR; MEMBRANE TOPOLOGY; VIRULENCE GENES; PHEROMONE; EXPRESSION; RNAIII; PEPTIDES; SYSTEM; IDENTIFICATION	The accessory gene regulator (agr) of Staphylococcus aureus is the central regulatory system that controls the gene expression for a large set of virulence factors. This global regulatory locus consists of two transcripts: RNAII and RNAIII. RNAII encodes four genes (agrA, B, C, and D) whose gene products assemble a quorum sensing system. RNAIII is the effector of the Agr response. Both the agrB and agrD genes are essential for the production of the autoinducing peptide, which functions as a signal for the quorum sensing system. In this study, we demonstrated the transmembrane nature of AgrB protein in S. aureus. A transmembrane topology model of AgrB was proposed based on AgrB-PhoA fusion analyses in Escherichia coli. Two hydrophilic regions with several highly conserved positively charged amino acid residues among various AgrBs were found to be located in the cytoplasmic membrane as suggested by PhoA-AgrB fusion studies. However, this finding is inconsistent with the putative transmembrane profile of AgrB by computer analysis. Furthermore, we detected an intermediate peptide of processed AgrD from S. aureus cells expressing AgrB and a 6 histidine-tagged AgrD. These results provide direct evidence that AgrB is involved in the proteolytic processing of AgrD. We speculate that AgrB is a novel protein with proteolytic enzyme activity and a transporter facilitating the export of the processed AgrD peptide.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA	Uniformed Services University of the Health Sciences - USA; New York University	Ji, GY (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gji@usuhs.mil		Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [R01AI46445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benito Y, 2000, RNA, V6, P668, DOI 10.1017/S1355838200992550; Brurberg MB, 1997, MOL MICROBIOL, V26, P347, DOI 10.1046/j.1365-2958.1997.5821951.x; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; Chan PF, 1998, MICROBIOL-SGM, V144, P2469, DOI 10.1099/00221287-144-9-2469; Cheung AL, 1997, J BACTERIOL, V179, P3963, DOI 10.1128/jb.179.12.3963-3971.1997; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Franke CM, 1999, J BIOL CHEM, V274, P8484, DOI 10.1074/jbc.274.13.8484; Ginn SL, 1997, J BACTERIOL, V179, P3786, DOI 10.1128/jb.179.11.3786-3789.1997; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; JANZON L, 1990, EMBO J, V9, P1391, DOI 10.1002/j.1460-2075.1990.tb08254.x; Jarraud S, 2000, J BACTERIOL, V182, P6517, DOI 10.1128/JB.182.22.6517-6522.2000; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lyon GJ, 2000, P NATL ACAD SCI USA, V97, P13330, DOI 10.1073/pnas.97.24.13330; Lyon GJ, 2002, J BIOL CHEM, V277, P6247, DOI 10.1074/jbc.M109989200; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McDowell P, 2001, MOL MICROBIOL, V41, P503, DOI 10.1046/j.1365-2958.2001.02539.x; Morfeldt E, 1996, FEMS MICROBIOL LETT, V143, P195, DOI 10.1016/0378-1097(96)00310-2; Morfeldt E, 1996, MOL MICROBIOL, V21, P1227, DOI 10.1046/j.1365-2958.1996.751447.x; Novick RP, 1999, CELL-CELL SIGNALING IN BACTERIA, P129; Novick RP, 2000, GRAM-POSITIVE PATHOGENS, P392; Novick RP, 1999, CURR OPIN MICROBIOL, V2, P40, DOI 10.1016/S1369-5274(99)80007-1; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; Otto M, 1998, FEBS LETT, V424, P89, DOI 10.1016/S0014-5793(98)00145-8; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x; PROJAN SJ, 1997, STAPHYLOCOCCI HUMAN, P55; Saenz HL, 2000, ARCH MICROBIOL, V174, P452, DOI 10.1007/s002030000223; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Tegmark K, 1998, J BACTERIOL, V180, P3181, DOI 10.1128/JB.180.12.3181-3186.1998; VANDENESCH F, 1993, FEMS MICROBIOL LETT, V111, P115, DOI 10.1016/0378-1097(93)90191-4; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Zhang SP, 2000, J BACTERIOL, V182, P2321, DOI 10.1128/JB.182.8.2321-2325.2000	46	89	98	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34736	34742		10.1074/jbc.M205367200	http://dx.doi.org/10.1074/jbc.M205367200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122003	hybrid			2022-12-27	WOS:000178117000012
J	Litovchick, L; Friedmann, E; Shaltiel, S				Litovchick, L; Friedmann, E; Shaltiel, S			A selective interaction between OS-9 and the carboxyl-terminal tail of meprin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLITTING MEMBRANAL PROTEINASE; ENDOPLASMIC-RETICULUM; C-2-DOMAIN PROTEINS; CATALYTIC SUBUNIT; CARGO SELECTION; BINDING PROTEIN; KINASE-A; N-COPINE; GENE; EXPRESSION	OS-9, a protein previously uncharacterized, was shown to interact specifically with the intracellular region of the membrane proteinase meprin beta found in brush border membranes of kidney and small intestine. We have shown previously that this cytoplasmic region is indispensable for the maturation of meprin beta, which included an endoplasmic reticulum. (ER)-to-Golgi translocation. We characterized OS-9 and found that it is associated with ER membranes and that it is exposed to the cytoplasm. Consistent with the kinetics of maturation of meprin beta, OS-9 associates with meprin beta only transiently, coinciding with ER-to-Golgi transport of meprin beta. The OS-9-binding site in the cytoplasmic domain of meprin beta overlaps the region essential for this transport. We characterized alternatively spliced forms of rat and mouse OS-9, and we found that only the non-spliced form of OS-9 binds to meprin beta, implicating the spliced out segment in the binding, and suggesting the possible mechanism of the regulation of OS-9 function. Taken together, our results indicated that OS-9 may be involved in the ER-to-Golgi transport of meprin beta. Ubiquitous expression of OS-9 raises the possibility that it may interact with other membrane proteins that possess the cytoplasmic moiety homologous to that of meprin beta during their ER-to-Golgi transition.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Harvard University; Dana-Farber Cancer Institute; Weizmann Institute of Science	Litovchick, L (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St,Mayer Bldg 444, Boston, MA 02115 USA.	larisa_litovchick@dfci.harvard.edu		Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fleischer S, 1974, Methods Enzymol, V31, P6; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Kimura Y, 1997, J BIOCHEM-TOKYO, V122, P1190; Kimura Y, 1998, J BIOCHEM-TOKYO, V123, P876; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGE Y, 1991, J LIPID RES, V32, P329; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Litovchick L, 1998, J BIOL CHEM, V273, P29043, DOI 10.1074/jbc.273.44.29043; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nakayama T, 1999, FEBS LETT, V453, P77, DOI 10.1016/S0014-5793(99)00700-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949	40	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34413	34423		10.1074/jbc.M203986200	http://dx.doi.org/10.1074/jbc.M203986200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093806	hybrid			2022-12-27	WOS:000177959100114
J	Liu, B; Krieger, M				Liu, B; Krieger, M			Highly purified scavenger receptor class B type I reconstituted into posphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER TRANSFER; SR-BI; PLASMA-MEMBRANES; DEFICIENT MICE; HDL; EXPRESSION; CD36; METABOLISM; CELLS; RAT	The murine class B, type I scavenger receptor mSR-BI is a high and low density lipoprotein (HDL and LDL) receptor that mediates selective uptake of cholesteryl esters. Here we describe a reconstituted phospholipid/ cholesterol liposome assay of the binding and selective uptake activities of SR-BI derived from detergent-solubilized cells. The assay, employing lysates from epitope-tagged receptor (mSR-BI-t1)-expressing mammalian and insect cells, recapitulated many features of SR-BI activity in intact cells, including high affinity and saturable I-125-HDL binding, selective lipid uptake from [H-3]cholesteryl ether-labeled HDL, and poor inhibition of HDL receptor activity by LDL. The novel properties of a mutated receptor (Q402R/Q418R, normal LDL binding but loss of most HDL binding) were reproduced in the assay, as was the ability of the SR-BI homologue CD36 to bind HDL but not mediate efficient lipid uptake. In this assay, essentially homogeneously pure mSR-BI-t1, prepared by single-step immunoaffinity chromatography, mediated high affinity HDL binding and efficient selective lipid uptake from HDL. Thus, SR-BI-mediated HDL binding and selective lipid uptake are intrinsic properties of the receptor that do not require the intervention of other proteins or specific cellular structures or compartments.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483, Cambridge, MA 02139 USA.		Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL 52212] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Azhar S, 2002, J LIPID RES, V43, P861; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Calvo D, 1998, J LIPID RES, V39, P777; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liu T, 2002, J BIOL CHEM, V277, P21576, DOI 10.1074/jbc.M112103200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mardones P, 2001, J LIPID RES, V42, P170; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARKES JG, 1990, BIOCHEM CELL BIOL, V68, P870, DOI 10.1139/o90-129; PIETERS NM, 1994, BIOCHIM BIOPHYS ACTA, V1225, P125; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Reeves PJ, 1996, P NATL ACAD SCI USA, V93, P11487, DOI 10.1073/pnas.93.21.11487; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P284, DOI 10.1016/0005-2760(93)90109-M; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHI XY, 1992, BIOCHEMISTRY-US, V31, P3230, DOI 10.1021/bi00127a026; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; VELAN B, 1993, BIOCHEM J, V296, P649, DOI 10.1042/bj2960649; Werder M, 2001, BIOCHEMISTRY-US, V40, P11643, DOI 10.1021/bi0109820; Williams DL, 2002, J LIPID RES, V43, P544	55	54	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34125	34135		10.1074/jbc.M204265200	http://dx.doi.org/10.1074/jbc.M204265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110672	hybrid			2022-12-27	WOS:000177959100079
J	Silver, DL				Silver, DL			A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I Is essential for cell surface expression in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SR-BI; CRYSTAL-STRUCTURES; HDL CHOLESTEROL; TRANSGENIC MICE; LIPID TRANSFER; PROTGF-ALPHA; PROTEIN; IDENTIFICATION; RECOGNITION	Scavenger receptor B, type I (SR-BI) was recently shown to interact with a PDZ domain-containing protein, PDZK1 (CLAMP/Diphor-1/CAP70/NaPi-Cap1), but the importance of this interaction in vivo in terms of SR-BI function has not been determined. In an effort to elucidate the role of this interaction in vivo, the PDZK1-interacting domain of SR-BI was identified and mutated and expressed liver-specifically in mice. The PDZK1-interacting domain on SR-BI was identified as the last three carboxyl-terminal amino acids, Arg-Lys-Leu. A mutant SR-BI (SR-BIdel509) that lacked only the leucine in the PDZ-interacting domain failed to interact with PDZK1 in vitro, while showing normal selective uptake function in nonpolarized cells. Transgenic mice with liver overexpression of SR-BIdel509 showed marked accumulation of SR-BI mRNA with only a moderate increase in SR-BI protein in liver, with no reduction in plasma cholesterol levels. Measurement of cell surface SR-BI levels and HDL cholesteryl ester-selective uptake in primary hepatocytes from transgenic mice revealed that SR-BIdel509 was not expressed at the plasma membrane correlating with normal levels of selective uptake compared with hepatocytes from nontransgenic litter-mates. This study indicates that the PDZK1-interacting domain of SR-BI is essential for cell surface expression of SR-BI in liver and suggests that PDZK1 or other PDZ domain proteins may play an important role in regulating SR-BI cell surface expression and hence reverse cholesterol transport.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Silver, DL (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	dls5l@columbia.edu	Eckhardt, Erik/G-1567-2010	Silver, David/0000-0002-7289-9890				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kocher O, 1998, LAB INVEST, V78, P117; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; REAVEN E, 1989, J LIPID RES, V30, P1551; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Urena JM, 1999, J CELL SCI, V112, P773; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	32	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34042	34047		10.1074/jbc.M206584200	http://dx.doi.org/10.1074/jbc.M206584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12119305	hybrid			2022-12-27	WOS:000177959100070
J	Tsui-Pierchala, BA; Ahrens, RC; Crowder, RJ; Milbrandt, J; Johnson, EM				Tsui-Pierchala, BA; Ahrens, RC; Crowder, RJ; Milbrandt, J; Johnson, EM			The long and short isoforms of ret function as independent signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR; DOCKING SITE; PHOSPHATIDYLINOSITOL 3-KINASE; AUTOPHOSPHORYLATION SITES; NEUROTROPHIC FACTOR; CELL-LINE; RAT TRKC; PROTEIN	Ret, the receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family ligands (GFLs), is alternatively spliced to yield at least two isoforms, Ret9 and Ret51, which differ only in their C termini. To identify tyrosines in Ret that are autophosphorylation sites in neurons, we generated antibodies specific to phosphorylated Y905Ret, Y1015Ret, Y1062Ret, and Y1096Ret, all of which are autophosphorylated in cell lines. All four of these tyrosines in Ret became phosphorylated rapidly upon activation by GFLs in sympathetic neurons. These tyrosines remained phosphorylated in sympathetic neurons in the continued presence of GFLs, albeit at a lower level than immediately after GFL treatment. Comparison of GFL activation of Ret9 and Ret51 revealed that phosphorylation of Tyr 905 and Tyr(1062) was greater and more sustained in Ret9 as compared with Ret51. In contrast, Tyr(1015) was more highly phosphorylated over time in Ret5l than in Ret9. Surprisingly, Ret9 and Ret51 did not associate with each other in sympathetic neurons after glial cell line-derived neurotrophic factor stimulation, even though they share identical extracellular domains. Furthermore, the signaling complex associated with Ret9 was markedly different from the Ret51-associated signaling complex. Taken together, these data provide a biochemical basis for the dramatic functional differences between Ret9 and Ret 51 in vivo.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Johnson, EM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.			Milbrandt, Jeffrey/0000-0002-5477-7689	NIA NIH HHS [AG 13730, AG 13729] Funding Source: Medline; NIMH NIH HHS [F32 MH 65111] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013730, R01AG013729] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; De Vita G, 2000, CANCER RES, V60, P3727; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; TAHIRA T, 1990, ONCOGENE, V5, P97; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Tang XX, 1998, ONCOGENE, V17, P521, DOI 10.1038/sj.onc.1201960; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Yamamoto M, 2001, BRAIN RES, V912, P89, DOI 10.1016/S0006-8993(01)02542-2	39	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34618	34625		10.1074/jbc.M203580200	http://dx.doi.org/10.1074/jbc.M203580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091387	hybrid			2022-12-27	WOS:000177959100136
J	Constant, P; Perez, E; Malaga, W; Laneelle, MA; Saurel, O; Daffe, M; Guilhot, C				Constant, P; Perez, E; Malaga, W; Laneelle, MA; Saurel, O; Daffe, M; Guilhot, C			Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex - Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frameshift mutation in the pks15/1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOCEROSIC ACID SYNTHASE; GRAM-NEGATIVE BACTERIA; PHENOLIC GLYCOLIPID-1; PHTHIOCEROL DIMYCOCEROSATE; SUICIDE VECTORS; BOVIS BCG; VIRULENCE; LEPRAE; SEQUENCE; MYCOSIDE	Diesters of phthiocerol and phenolphthiocerol are important virulence factors of Mycobacterium tuberculosis and Mycobacterium leprae, the two main mycobacterial pathogens in humans. They are both long-chain beta-diols, and their biosynthetic pathway is beginning to be elucidated. Although the two classes of molecules share a common lipid core, phthiocerol diesters have been found in all the strains of the M. tuberculosis complex examined although phenolphthiocerol diesters are produced by only a few groups of strains. To address the question of the origin of this diversity 8 reference strains and 10 clinical isolates of M. tuberculosis were analyzed. We report the presence of glycosylated p-hydroxybenzoic acid methyl esters, structurally related to the type-specific phenolphthiocerol glycolipids, in the culture media of all reference strains of M. tuberculosis, suggesting that the strains devoid of phenolphthiocerol derivatives are unable to elongate the putative p-hydroxybenzoic acid precursor. We also show that all the strains of M. tuberculosis examined and deficient in the production of phenolphthiocerol derivatives are natural mutants with a frameshift mutation in pks15/1 whereas a single open reading frame for pks15/1 is found in Mycobacterium bovis BCG, M. leprae, and strains of M. tuberculosis that produce phenolphthiocerol derivatives. Complementation of the H37Rv strain of M. tuberculosis, which is devoid of phenolphthiocerol derivatives, with the fused pks15/1 gene from M. bovis BCG restored phenolphthiocerol glycolipids production. Conversely, disruption of the pks15/1 gene in M. bovis BCG led to the abolition of the synthesis of type-specific phenolphthiocerol glycolipid. These data indicate that Pks15/1 is involved in the elongation of p-hydroxybenzoic acid to give p-hydroxyphenylalkanoates, which in turn are converted, presumably by the PpsA-E synthase, to phenolphthiocerol. derivatives.	CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Toulouse 3, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Daffe, M (corresponding author), CNRS, Dept Mecanismes Mol Infect Mycobacteriennes, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		Olivier, Saurel/AAQ-7007-2020	Saurel, Olivier/0000-0003-1439-4103				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ancian B, 1997, J MAGN RESON, V125, P348, DOI 10.1006/jmre.1997.1112; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Belisle JT, 1998, METH MOL B, V101, P31, DOI 10.1385/0-89603-471-2:31; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; BLAKENEY AB, 1985, CARBOHYD RES, V140, P319, DOI 10.1016/0008-6215(85)85132-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHO SN, 1992, J CLIN MICROBIOL, V30, P3065, DOI 10.1128/JCM.30.12.3065-3069.1992; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1991, J INFECT DIS, V163, P161, DOI 10.1093/infdis/163.1.161; DAFFE M, 1992, J GEN MICROBIOL, V138, P131, DOI 10.1099/00221287-138-1-131; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1989, EUR J BIOCHEM, V185, P157, DOI 10.1111/j.1432-1033.1989.tb15097.x; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daffe M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; FOURNIE JJ, 1989, INFECT IMMUN, V57, P3653, DOI 10.1128/IAI.57.11.3653-3659.1989; GAYLORD H, 1987, ANNU REV MICROBIOL, V41, P645; GOREN MB, 1974, INFECT IMMUN, V9, P150, DOI 10.1128/IAI.9.1.150-158.1974; Goren MB, 1979, TUBERCULOSIS, P62; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Le Dantec C, 2001, J BACTERIOL, V183, P2157, DOI 10.1128/JB.183.7.2157-2164.2001; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; Martin Casabona N, 1989, Acta Leprol, V7 Suppl 1, P89; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; NEILL MA, 1988, J EXP MED, V167, P30, DOI 10.1084/jem.167.1.30; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; SIMONNEY N, 1995, EUR J CLIN MICROBIOL, V14, P883, DOI 10.1007/BF01691495; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THURMAN PF, 1993, EUR J BIOCHEM, V212, P705, DOI 10.1111/j.1432-1033.1993.tb17708.x; TORGALGARCIA J, 1988, ANN INST PASTEUR MIC, V139, P289, DOI 10.1016/0769-2609(88)90020-8; WATANABE M, 1994, BBA-LIPID LIPID MET, V1210, P174, DOI 10.1016/0005-2760(94)90118-X	52	193	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38148	38158		10.1074/jbc.M206538200	http://dx.doi.org/10.1074/jbc.M206538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138124	hybrid			2022-12-27	WOS:000178529600024
J	Kim, DG; You, KR; Liu, MJ; Choi, YK; Won, YS				Kim, DG; You, KR; Liu, MJ; Choi, YK; Won, YS			GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GADD153 MESSENGER-RNA; ENDOPLASMIC-RETICULUM STRESS; TRANS-RETINOIC ACID; NF-KAPPA-B; DNA-DAMAGE; GROWTH-ARREST; CARCINOMA-CELLS; GENE GADD153; CANCER-CELLS; HEPATOCELLULAR CARCINOMAS	The anticancer effects of N-(4-hydroxyphenyl)retinamide (4HPR), a potential chemopreventive or chemotherapeutic retinamide, are thought to be derived from its ability to induce apoptosis. However, the mechanism of apoptosis induced by 4HPR remains unclear. Thus, this study was designed to identify the gene(s) responsible for induction of apoptosis by 4HPR. Apoptosis was effectively induced by 4HPR in human hepatoma cells. Using the differential display-PCR method, a gene involved in the response to 4HPR was identified, and cells in which the expression of that gene was modulated were analyzed for survival, induction of apoptosis, and cell cycle. GADD153, a gene involved in growth arrest and apoptosis, was preferentially expressed in human hepatoma cells as well as in other cancer cells during 4HPR-induced apoptosis. 4HPR regulates GADD153 expression at the post-transcriptional level in Hep 3B cells and at the transcriptional and post-transcriptional levels in SK-HEP-1 cells, when assayed by in vitro transfection and mRNA stability experiments. To determine the role of the GADD153 protein overexpression that is induced by 4HPR, Hep 3B cells with ectopic overexpression. of GADD153 were found to be growth-arrested (at G,) and readily underwent apoptosis following treatment with 4HPR or even when they reached confluence. N-Acetyl-L-cysteine or GADD153 antisense significantly protected the cells from 4HPR-induced apoptosis, accompanying by the inhibition of GADD153 overexpression. Parthenolide-mediated overexpression of GADD153 resulted in enhanced 4HPR-induced apoptosis. These results suggest that GADD153 overexpression induced by 4HPR may contribute to the anticancer effects (induction of apoptosis and growth arrest) of 4HPR on cancer cells.	Chonbuk Natl Univ Med Sch & Hosp, Inst Mol Biol & Genet, Dept Internal Med, Div Gastroenterol & Hepatol, Chonju 561712, Chonbuk, South Korea; Korea Res Inst Biosci & Biotechnol, ICLAS Monitoring Subctr Korea, Taejon 305600, South Korea	Jeonbuk National University; Jeonbuk National University Hospital; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, DG (corresponding author), Chonbuk Natl Univ Med Sch & Hosp, Res Inst Clin Med, Dept Internal Med, Div Gastroenterol & Hepatol, 634-18 Keumam Dong, Chonju 561172, Chonbuk, South Korea.	daeghon@moak.chonbuk.ac.kr						BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Eastman HB, 1996, SHOCK, V6, P286, DOI 10.1097/00024382-199610000-00011; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Friedman AD, 1996, CANCER RES, V56, P3250; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Igase M, 2001, CLIN SCI, V100, P275, DOI 10.1042/CS20000220; JACKMAN J, 1994, CANCER RES, V54, P5656; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Kim MY, 2001, ONCOGENE, V20, P4568, DOI 10.1038/sj.onc.1204626; Kim R, 1999, ANTICANCER RES, V19, P1779; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; Los G, 1999, CLIN CANCER RES, V5, P1610; LUETHY JD, 1994, CANCER RES, V54, pS1902; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; OConnor PM, 1997, CANCER RES, V57, P4285; Oridate N, 1996, CLIN CANCER RES, V2, P855; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Oridate N, 1995, J CELL BIOCHEM, P80; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; PONZONI M, 1995, CANCER RES, V55, P853; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Sun SY, 1999, MOL PHARMACOL, V55, P403; Sun SY, 1999, CANCER RES, V59, P2493; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; VINCI AD, 1994, INT J CANCER, V59, P422; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; You KR, 2001, HEPATOLOGY, V34, P1119, DOI 10.1053/jhep.2001.29199; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	53	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38930	38938		10.1074/jbc.M205941200	http://dx.doi.org/10.1074/jbc.M205941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138118	hybrid			2022-12-27	WOS:000178529600116
J	Munshi, S; Kornienko, M; Hall, DL; Reid, JC; Waxman, L; Stirdivant, SM; Darke, PL; Kuo, LC				Munshi, S; Kornienko, M; Hall, DL; Reid, JC; Waxman, L; Stirdivant, SM; Darke, PL; Kuo, LC			Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase - Implication for inhibitor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; DOMAIN; TUMOR; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM; SUBSTRATE; PEPTIDE; COMPLEX; VIVO	The x-ray structure of the unactivated kinase domain of insulin-like growth factor-1 receptor (IGFRK-0P) is reported here at 2.7 Angstrom resolution. IGFRK-0P is composed of two lobes connected by a hinge region. The N-terminal lobe of the kinase is a twisted beta-sheet flanked by a single helix, and the C-terminal lobe comprises eight alpha-helices and four short beta-strands. The ATP binding pocket and the catalytic center reside at the interface of the two lobes. Despite the overall similarity to other receptor tyrosine kinases, three notable conformational modifications are observed: 1) this kinase adopts a more closed structure, with its two lobes rotated further toward each other; 2) the conformation of the proximal end of the activation loop (residues 1121-1129) is different; 3) the orientation of the nucleotide-binding loop is altered. Collectively, these alterations lead to a different ATP-binding pocket that might impact on inhibitor designs for IGFRK-0P. Two molecules of IGFRK-0P are seen in the asymmetric unit; they are associated as a dimer with their ATP binding clefts facing each other. The ordered N terminus of one monomer approaches the active site of the other, suggesting that the juxtamembrane region of one molecule could come into close proximity to the active site of the other.	Merck Res Labs, Dept Biol Struct, West Point, PA 19486 USA; Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA	Merck & Company; Merck & Company	Munshi, S (corresponding author), Merck Res Labs, Dept Biol Struct, West Point, PA 19486 USA.		ID, IMCACAT/D-5867-2014					Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; BHATAVDEKAR JM, 1994, NEOPLASMA, V41, P101; BINNS KL, 2000, SCIENCE, V275, P1640; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; DAmbrosio C, 1996, CANCER RES, V56, P4013; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; GANSLER T, 1989, AM J PATHOL, V135, P961; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 2001, MOL CELL, V8, P481, DOI 10.1016/S1097-2765(01)00350-1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MACAULAY VM, 1990, CANCER RES, V50, P2511; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; MERCOLA D, 1995, CANCER GENE THER, V2, P47; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OH Y, 1993, GROWTH REGULAT, V3, P113; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Patti Mary-Elizabeth, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P89; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	43	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38797	38802		10.1074/jbc.M205580200	http://dx.doi.org/10.1074/jbc.M205580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138114	hybrid			2022-12-27	WOS:000178529600100
J	Askari, B; Carroll, MA; Capparelli, M; Kramer, F; Gerrity, RG; Bornfeldt, KE				Askari, B; Carroll, MA; Capparelli, M; Kramer, F; Gerrity, RG; Bornfeldt, KE			Oleate and linoleate enhance the growth-promoting effects of insulin-like growth factor-I through a phospholipase D-dependent pathway in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIPOPROTEIN-LIPASE; OLEIC-ACID; ANGIOTENSIN-II; ATHEROSCLEROSIS; ACTIVATION; MIGRATION; METABOLISM; EXPRESSION; GLUCOSE	Diabetes causes accelerated atherosclerosis and subsequent cardiovascular disease through mechanisms that are poorly understood. We have previously shown, using a porcine model of diabetes-accelerated atherosclerosis, that diabetes leads to an increased accumulation and proliferation of arterial smooth muscle cells in atherosclerotic lesions and that this is associated with elevated levels of plasma triglycerides. We therefore used the same model to investigate the mechanism whereby diabetes may stimulate smooth muscle cell proliferation. We show that lesions from diabetic pigs fed a cholesterol-rich diet contain abundant insulin-like growth factor-I (IGF-I), in contrast to lesions from nondiabetic pigs. Furthermore, two fatty acids common in triglycerides, oleate and linoleate, enhance the growth-promoting effects of IGF-I in smooth muscle cells isolated from these animals. These fatty acids accumulate predominantly in the membrane phospholipid pool; oleate accumulates preferentially in phosphatidylcholine and phosphatidylethanolamine, whereas linoleate is found mainly in phosphatidylethanolamine. The growth-promoting effects of oleate and linoleate depend on phospholipid hydrolysis by phospholipase D and subsequent generation of diacylglycerol. Thus, concurrent increases in levels of IGF-I and triglyceride-derived oleate and linoleate in lesions may contribute to accumulation and proliferation of smooth muscle cells and lesion progression in diabetes-accelerated atherosclerosis.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	University of Washington; University of Washington Seattle; New York Medical College; University System of Georgia; Augusta University	Bornfeldt, KE (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.		Bornfeldt, Karin/AAI-2241-2019	Bornfeldt, Karin/0000-0001-9208-6523	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, R01HL062887, R01HL055789, R37HL025394, P01HL034300] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312, HL25394, HL34300, HL55789, HL62887] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen TJ, 2001, J VASC RES, V38, P276, DOI 10.1159/000051056; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Carroll MA, 1997, KIDNEY INT, V51, P1696, DOI 10.1038/ki.1997.234; Clee SM, 2000, J LIPID RES, V41, P521; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Du XN, 2001, BIOCHEM J, V357, P275, DOI 10.1042/0264-6021:3570275; Erkelens DW, 1998, EUR HEART J, V19, pH27; Esenabhalu VE, 2002, BRIT J PHARMACOL, V135, P143, DOI 10.1038/sj.bjp.0704440; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; Godessart N, 1996, J INVEST DERMATOL, V107, P726, DOI 10.1111/1523-1747.ep12365616; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; Greene EL, 2001, HYPERTENSION, V37, P308, DOI 10.1161/01.HYP.37.2.308; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879; Kwok CF, 2000, METABOLISM, V49, P1386, DOI 10.1053/meta.2000.17719; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; Lu G, 1998, HYPERTENSION, V31, P978, DOI 10.1161/01.HYP.31.4.978; Lu G, 1998, HYPERTENSION, V32, P1003, DOI 10.1161/01.HYP.32.6.1003; Marignani PA, 1996, BIOCHEM BIOPH RES CO, V225, P469, DOI 10.1006/bbrc.1996.1196; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; RYDZEWSKA G, 1995, PANCREAS, V10, P59, DOI 10.1097/00006676-199501000-00008; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; SMITH EB, 1980, ATHEROSCLEROSIS, V37, P579, DOI 10.1016/0021-9150(80)90065-9; Suzuki LA, 2001, DIABETES, V50, P851, DOI 10.2337/diabetes.50.4.851; Van Eck M, 2000, ARTERIOSCL THROM VAS, V20, pE53, DOI 10.1161/01.ATV.20.9.e53; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	36	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36338	36344		10.1074/jbc.M205112200	http://dx.doi.org/10.1074/jbc.M205112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138107	hybrid			2022-12-27	WOS:000178275100071
J	Ayora, S; Missich, R; Mesa, P; Lurz, R; Yang, SX; Egelman, EH; Alonso, JC				Ayora, S; Missich, R; Mesa, P; Lurz, R; Yang, SX; Egelman, EH; Alonso, JC			Homologous-pairing activity of the Bacillus subtilis bacteriophage SPP1 replication protein G35P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAK-INDUCED REPLICATION; HUMAN RAD52 PROTEIN; COLI RECT PROTEIN; ESCHERICHIA-COLI; DNA-REPLICATION; NUCLEOTIDE-SEQUENCE; PHAGE-LAMBDA; RECOMBINATION; ORIGIN; REPAIR	Genetic evidence suggests that the SPP1-encoded gene 35 product (G35P) is essential for phage DNA replication. Purified G35P binds single-strand DNA (ssDNA) and double-strand (dsDNA) and specifically interacts with SPP1-encoded replicative DNA helicase G40P and SSB protein G36P. G35P promotes joint molecule formation between a circular ssDNA and a homologous linear dsDNA with an ssDNA tail. Joint molecule formation requires a metal ion but is independent of a nucleotide cofactor. Joint molecules formed during these reactions contain a displaced linear ssDNA strand. Electron microscopic analysis shows that G35P forms a multimeric ring structure in ssDNA tails of dsDNA molecules and left-handed filaments on ssDNA. G35P promotes strand annealing at the AT-rich region of SPP1 oriL on a supercoiled template. These results altogether are consistent with the hypothesis that the homologous pairing catalyzed by G35P is an integral part of SPP1 DNA replication. The loading of G40P at a D-100p (ori DNA or at any stalled replication fork) by G35P could lead to replication fork reactivation.	CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Madrid 28049, Spain; Univ Autonoma Madrid, Dept Biol Mol, E-28049 Madrid, Spain; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Max Planck Society; University of Virginia	Alonso, JC (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Campus Univ Autonoma Madrid, Madrid 28049, Spain.	jcalonso@cnb.uam.es	Egelman, Edward H/A-2488-2009; Alonso, Juan Carlos/D-2595-2009; Ayora, Silvia/D-2552-2009; yang, shixin/B-4015-2010	Alonso, Juan Carlos/0000-0002-5178-7179; Ayora, Silvia/0000-0003-3121-1786; yang, shixin/0000-0002-3639-7818; Mesa, Pablo/0000-0002-9218-3144; Egelman, Edward/0000-0003-4844-5212				Alonso JC, 1997, GENE, V204, P201, DOI 10.1016/S0378-1119(97)00547-7; ALONSO JC, 1992, MOL GEN GENET, V236, P60, DOI 10.1007/BF00279643; ALONSO JC, 1986, EMBO J, V5, P3723, DOI 10.1002/j.1460-2075.1986.tb04706.x; Ayora S, 1998, FEBS LETT, V439, P59, DOI 10.1016/S0014-5793(98)01337-4; Ayora S, 1999, J MOL BIOL, V288, P71, DOI 10.1006/jmbi.1999.2662; Ayora S, 2002, NUCLEIC ACIDS RES, V30, P2280, DOI 10.1093/nar/30.11.2280; Baranska S, 2001, MICROBIOL-UK, V147, P535, DOI 10.1099/00221287-147-3-535; Barcena M, 1998, J MOL BIOL, V283, P809, DOI 10.1006/jmbi.1998.2128; BASTIA D, 1975, J MOL BIOL, V98, P305, DOI 10.1016/S0022-2836(75)80120-3; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P4651, DOI 10.1093/nar/18.16.4651; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; BURGER KJ, 1978, MOL GEN GENET, V166, P277, DOI 10.1007/BF00267619; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; Ganesan A.T., 1976, MICROBIOLOGY 1976, P319; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; KLOTZ G, 1973, MOL GEN GENET, V120, P95, DOI 10.1007/BF00332987; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAKSHMINARAYAM MI, 2002, BMC GENOMICS, V3, P8; Malkova A, 2001, GENE DEV, V15, P1055, DOI 10.1101/gad.875901; Marians KJ, 2000, CURR OPIN GENET DEV, V10, P151, DOI 10.1016/S0959-437X(00)00059-9; MCINTOSH PK, 1978, J VIROL, V28, P865, DOI 10.1128/JVI.28.3.865-876.1978; Missich R, 1997, J MOL BIOL, V270, P50, DOI 10.1006/jmbi.1997.1060; Muyrers JPP, 2000, GENE DEV, V14, P1971; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; PEDRE X, 1994, J MOL BIOL, V236, P1324, DOI 10.1016/0022-2836(94)90061-2; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; Skaliter R, 1996, J VIROL, V70, P1132, DOI 10.1128/JVI.70.2.1132-1136.1996; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; SKALKA AM, 1977, CURR TOP MICROBIOL, P201; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; STAHL FW, 1985, J MOL BIOL, V181, P199, DOI 10.1016/0022-2836(85)90085-3; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAYLOR K, 1995, FEMS MICROBIOL REV, V17, P109; THRESHER RJ, 1995, J MOL BIOL, V254, P364, DOI 10.1006/jmbi.1995.0623; VIRET JF, 1991, MICROBIOL REV, V55, P675, DOI 10.1128/MMBR.55.4.675-683.1991; WEISE F, 1994, VIROLOGY, V202, P1046, DOI 10.1006/viro.1994.1436; WEISE F, 1997, THESIS FREIE U BERLI; Xu LW, 2002, J BIOL CHEM, V277, P14321, DOI 10.1074/jbc.M112418200; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	46	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35969	35979		10.1074/jbc.M204467200	http://dx.doi.org/10.1074/jbc.M204467200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124388	hybrid			2022-12-27	WOS:000178275100027
J	Colmenares, M; Puig-Kroger, A; Pello, OM; Corbi, AL; Rivas, L				Colmenares, M; Puig-Kroger, A; Pello, OM; Corbi, AL; Rivas, L			Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS LEISHMANIASIS; T-CELLS; MAJOR AMASTIGOTES; LANGERHANS CELLS; IMMUNE-RESPONSES; IN-VITRO; ANTIGEN; PANAMENSIS; ACTIVATION; MEXICANA	Dendritic cells (DCs) play a critical role in the initiation of the immunological response against Leishmania parasites. However, the receptors involved in amastigote-dendritic cell interaction are unknown, especially in absence of opsonizing antibodies. We have studied the interaction of Leishmania pifanoi axenic amastigotes with the C-type lectin DC-specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin (DC-SIGN, CD209), a receptor for ICAM-2, ICAM-3, human immunodeficiency virus gp120, and Ebola virus. L. pifanoi amastigotes interact with immature human dendritic cells and CD209-transfected K562 cells in a time- and dose-dependent manner. Leishmania amastigote binding to human dendritic cells and DC-SIGN-transfected cells is inhibited by a function-blocking DC-SIGN-specific monoclonal antibody. More importantly, this monoclonal antibody dramatically reduces internalization of Leishmania amastigotes by immature human DCs. These results constitute the first description of a non-viral pathogen ligand for DC-SIGN and provide evidence for a relevant role of DC-SIGN in Leishmania amastigote uptake by dendritic cells. Our finding has important implications for Leishmania host-cell interaction and the immunoregulation of cutaneous leishmaniasis.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Puig, Amaya/B-6164-2015; Pello, Oscar M/Y-6272-2019; Corbí, Angel L./ABC-8146-2020; Rivas, Luis/O-8657-2017; Colmenares, Maria Isabel/H-2848-2017; Corbi, Angel/B-7194-2011	Puig, Amaya/0000-0003-2943-9757; Pello, Oscar M/0000-0002-8718-9920; Corbí, Angel L./0000-0003-1980-5733; Rivas, Luis/0000-0002-2958-3233; Colmenares, Maria Isabel/0000-0003-4114-277X; Corbi, Angel/0000-0003-1980-5733				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BLANK C, 1993, J INFECT DIS, V167, P418, DOI 10.1093/infdis/167.2.418; ElHassan AM, 1995, T ROY SOC TROP MED H, V89, P647, DOI 10.1016/0035-9203(95)90428-X; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; Isaza DM, 1996, AM J TROP MED HYG, V55, P365, DOI 10.4269/ajtmh.1996.55.365; Kamau Sarah W., 2001, BMC Pharmacology, V1, P1, DOI 10.1186/1471-2210-1-1; Kane MM, 2000, CURR OPIN HEMATOL, V7, P26, DOI 10.1097/00062752-200001000-00006; Konecny P, 1999, EUR J IMMUNOL, V29, P1803, DOI 10.1002/(SICI)1521-4141(199906)29:06&lt;1803::AID-IMMU1803&gt;3.0.CO;2-F; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; PAN AA, 1984, EXP PARASITOL, V58, P72, DOI 10.1016/0014-4894(84)90022-5; Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Qi H, 2001, J IMMUNOL, V167, P4534, DOI 10.4049/jimmunol.167.8.4534; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; RIDLEY MJ, 1986, AM J PATHOL, V123, P79; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; von Stebut E, 1998, J EXP MED, V188, P1547, DOI 10.1084/jem.188.8.1547; WILLIAMS RO, 1988, J PARASITOL, V74, P186, DOI 10.2307/3282496; WINTER G, 1994, J CELL SCI, V107, P2471; Zawadzki J, 1998, J MOL BIOL, V282, P287, DOI 10.1006/jmbi.1998.2014	30	126	134	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36766	36769		10.1074/jbc.M205270200	http://dx.doi.org/10.1074/jbc.M205270200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12122001	hybrid, Green Published			2022-12-27	WOS:000178275100125
J	Garcia-Ruiz, C; Colell, A; Morales, A; Calvo, M; Enrich, C; Fernandez-Checa, JC				Garcia-Ruiz, C; Colell, A; Morales, A; Calvo, M; Enrich, C; Fernandez-Checa, JC			Trafficking of ganglioside GD3 to mitochondria by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CERAMIDE-INDUCED APOPTOSIS; PERMEABILITY TRANSITION; CASPASE ACTIVATION; CELL-DEATH; GLUTATHIONE DEPLETION; SIGNAL-TRANSDUCTION; RAT HEPATOCYTES; CANCER-CELLS; PROTEIN	The interaction of mitochondria with proapoptotic proteins activates apoptosis pathways. Previous findings have identified ganglioside GD3 (GD3) as an emerging apoptotic lipid intermediate that targets mitochondria in response to death signals. Using immunoelectron and laser scanning confocal microscopy, we characterize the trafficking of GD3 to mitochondria in response to tumor necrosis factor-alpha (TNF-alpha) in rat hepatocytes. In control hepatocytes, GD3 is present predominantly at the plasma membrane as well as in the endosomal/Golgi network, as verified by its colocalization with the asialoglycoprotein receptor. Following TNF-a exposure, GD3 undergoes a rapid cellular redistribution with a gradual loss from the plasma membrane before its colocalization with mitochondria. This process is mimicked by acidic sphingomyelinase and ionizing radiation but not by neutral sphingomyelinase or staurosporin. TNF-alpha stimulated the colocalization of GD3 with early and late endosomal markers, Rab 5 and Rab 7, whereas perturbation of plasma membrane cholesterol or actin cytoskeleton or inhibition of glucosylceramide synthase prevented the trafficking of GD3 to mitochondria. Finally, prevention of the TNF-alpha-stimulated neosynthesis of GD3, cyclosporin A, and latrunculin A or filipin protected sensitized hepatocytes from TNF-alpha-mediated cell death. Thus, the intracellular redistribution and mitochondrial targeting of GD3 during TNF-alpha signaling occurs through actin cytoskeleton vesicular trafficking and contributes to TNF-alpha-mediated hepatocellular cell death.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Dis, Barcelona 08036, Spain; Univ Barcelona, Dept Cell Biol, Sch Med, Inst Invest Biomed August Pi Suner, E-08036 Barcelona, Spain; CSIC, Dept Expt Pathol, Inst Invest Biomed, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Dis, Villarroel 170, Barcelona 08036, Spain.		Morales, Albert/E-2988-2013; Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014; Colell, Anna/N-8710-2014; Calvo, Maria/I-1872-2015	Morales, Albert/0000-0001-8702-2269; Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990; Colell, Anna/0000-0001-5236-1834; Calvo, Maria/0000-0002-7473-0474; Enrich, Carlos/0000-0003-0382-2993				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Calvo M, 2001, HEPATOLOGY, V33, P1259, DOI 10.1053/jhep.2001.23937; Chigorno V, 2000, EUR J BIOCHEM, V267, P4187, DOI 10.1046/j.1432-1327.2000.01454.x; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Colell Anna, 2001, FASEB Journal, V15, P1068; Copani A, 2002, J NEUROSCI, V22, P3963, DOI 10.1523/JNEUROSCI.22-10-03963.2002; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; ENRICH C, 1989, EUR J CELL BIOL, V48, P344; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2000, HEPATOLOGY, V32, P56, DOI 10.1053/jhep.2000.8267; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GHAROURIFAR P, 1999, J BIOL CHEM, V274, P6080; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KOLLER T, 2002, J BIOL CHEM, V277, P25859; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Krammer P H, 1999, Adv Immunol, V71, P163; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANDSMANN S, 1996, FEBS LETT, V399, P227; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	56	117	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36443	36448		10.1074/jbc.M206021200	http://dx.doi.org/10.1074/jbc.M206021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118012	hybrid			2022-12-27	WOS:000178275100085
J	Hicks, SW; Machamer, CE				Hicks, SW; Machamer, CE			The NH2-terminal domain of golgin-160 contains both Golgi and nuclear targeting information	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL PROTEINS; MOLECULAR CHARACTERIZATION; MEMBRANE-PROTEIN; MATRIX PROTEIN; BREFELDIN-A; CYTOPLASMIC DOMAIN; COMPLEX; GM130; IDENTIFICATION; APPARATUS	Golgin-160 is a member of the golgin family of Golgilocalized membrane proteins. The COOH-terminal twothirds of golgin-160 is predicted to form a coiled-coil, with an NH2-terminal "head" domain. To identify the Golgi targeting information in golgin-160, full-length and deletion constructs tagged with green fluorescent protein were generated. The head domain alone was targeted to the Golgi complex in the absence of assembly with endogenous golgin-160. Further truncations from both ends of the head domain narrowed the Golgi targeting information to 85 amino acids between residues 172 and 257. Surprisingly, certain truncations of the head domain also specifically accumulated in the nucleus. Both a nuclear localization signal (masked in the full-length protein) and information for nuclear retention contributed to the nuclear localization of these truncations. Because the golgin-160 head is cleaved by caspases during apoptosis, we examined the localization of epitope-tagged proteins corresponding to all potential caspase cleavage fragments. Our data suggest that three of six fragments could be targeted to the nucleus, provided that they are released from Golgi membranes after cleavage. The finding that both Golgi and nuclear targeting information is present in the same region of golgin-160 suggests that this protein may have more than one function.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Machamer, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.		Hicks, Stuart/R-9815-2019		NIGMS NIH HHS [GM42522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; Beck KA, 1997, J CELL SCI, V110, P1239; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; De Matteis MA, 2000, J CELL SCI, V113, P2331; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; Infante C, 1999, J CELL BIOL, V145, P83, DOI 10.1083/jcb.145.1.83; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Matsukuma S, 1999, MAMM GENOME, V10, P1, DOI 10.1007/s003359900932; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; MOLLENHAUER HH, 1966, J CELL BIOL, V29, P373, DOI 10.1083/jcb.29.2.373; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045	38	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35833	35839		10.1074/jbc.M206280200	http://dx.doi.org/10.1074/jbc.M206280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130652	hybrid			2022-12-27	WOS:000178275100011
J	McDermott, NB; Gordon, DF; Kramer, CA; Liu, Q; Linney, E; Wood, WM; Haugen, BR				McDermott, NB; Gordon, DF; Kramer, CA; Liu, Q; Linney, E; Wood, WM; Haugen, BR			Isolation and functional analysis of the mouse RXR gamma 1 gene promoter in anterior pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-BETA PROMOTER; THYROID-HORMONE RECEPTOR; DIFFERENTIAL EXPRESSION; GENOMIC ORGANIZATION; RETINOID RECEPTORS; NUCLEAR RECEPTOR; PIT-1; IDENTIFICATION; ISOFORMS; ACID	The retinoid X receptor (RXR) isoform RYRgamma has limited tissue expression, including brain, skeletal muscle, and anterior pituitary gland. Within the anterior pituitary gland, RXRgamma expression is limited primarily to the thyrotropes. In this report, we have isolated similar to3 kb of 5'-flanking DNA of the mouse RXRgamma1 gene. We have identified the major transcription start site in the thyrotrope-derived TtT-97 cells. Transient transfection studies show that a 1.4-kb promoter fragment has full promoter activity in TtT-97 cells. This promoter has much less activity in thyrotrope-derived aTSH cells, pituitary-derived GH3 somatomammotropes, and non-pituitary CV-1 cells. None of these cell lines has detectable RXRgamma1 mRNA. A previous report has identified a nonconsensus direct repeat (DR-1) element in the RXRgamma2 gene promoter region that mediates stimulation of promoter activity by 9-cis-retinoic acid (9-cis-RA). Inspection of the RXRgamma1 promoter region revealed a non-consensus DR-1 element at -232 bp from the transcription start site. Interestingly, RXRgamma1 promoter activity was suppressed 50% by 9-cis-RA in the TtT-97 thyrotropes. Further experiments in non-pituitary cells showed that suppression of RYRgamma1 promoter activity was RXR-dependent. Mutagenesis of the DR-1 element abrogated suppression of promoter activity by 9-cis-RA, suggesting that this negative regulation requires both RXR and this specific DR-1 element. In summary, we have isolated the mouse RXRgamma1 gene promoter region and identified the major start site in thyrotropes. Promoter activity is uniquely suppressed by 9-cis-RA through a DR-1 element. Isolation and characterization of the mouse RXRgamma1 promoter region provides a tool for further investigation focusing on thyrotrope-specific gene expression as well as negative regulation of genes by retinoic acid.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Denver, CO 80262 USA; Rinat Neurosci Corp, Palo Alto, CA 94304 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Duke University; Duke University	Haugen, BR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, B 151,4200 E 9th Ave, Denver, CO 80262 USA.				NIDDK NIH HHS [R01 DK54383] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054383] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; Barger PM, 1997, J BIOL CHEM, V272, P2722, DOI 10.1074/jbc.272.5.2722; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Breen JJ, 1997, MOL CELL ENDOCRINOL, V131, P137, DOI 10.1016/S0303-7207(97)00099-3; Brown NS, 2000, J CLIN INVEST, V106, P73, DOI 10.1172/JCI9422; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Haugen BR, 1997, MOL ENDOCRINOL, V11, P481, DOI 10.1210/me.11.4.481; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Krezel W, 1999, NEUROSCIENCE, V89, P1291, DOI 10.1016/S0306-4522(98)00342-X; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NAGATA T, 1994, GENE, V142, P183, DOI 10.1016/0378-1119(94)90259-3; NAGATA T, 1995, IMMUNOGENETICS, V41, P83, DOI 10.1007/BF00182317; Sanno N, 1997, NEUROENDOCRINOLOGY, V65, P299, DOI 10.1159/000127188; Sherman SI, 1999, NEW ENGL J MED, V340, P1075, DOI 10.1056/NEJM199904083401404; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; Sugawara A, 1998, ENDOCRINOLOGY, V139, P3030, DOI 10.1210/en.139.6.3030; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; VanderHeyden TC, 2000, MOL CELL ENDOCRINOL, V159, P89, DOI 10.1016/S0303-7207(99)00200-2; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049; Wood WM, 1996, J BIOL CHEM, V271, P24213, DOI 10.1074/jbc.271.39.24213	27	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36839	36844		10.1074/jbc.M203689200	http://dx.doi.org/10.1074/jbc.M203689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114515	hybrid			2022-12-27	WOS:000178275100136
J	Suh, ER; Ha, CS; Rankin, EB; Toyota, M; Traber, PG				Suh, ER; Ha, CS; Rankin, EB; Toyota, M; Traber, PG			DNA methylation down-regulates CDX1 gene expression in colorectal cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; HMLH1 PROMOTER; HISTONE DEACETYLASE; HOMEOBOX GENE; COLON-CANCER; MICROSATELLITE INSTABILITY; HYPERMETHYLATION; TRANSCRIPTION; CARCINOMA; COMPLEX	CDX1 is a homeobox protein that inhibits proliferation of intestinal epithelial cells and regulates intestine-specific genes involved in differentiation. CDX1 expression is developmentally and spatially regulated, and its expression is aberrantly down-regulated in colorectal cancers and colon cancer-derived cell lines. However, very little is known about the molecular mechanism underlying the regulation of CDX1 gene expression. In this study, we characterized the CDX1 gene structure and identified that its gene promoter contained a typical CpG island with a CpG observed/expected ratio of 0.80, suggesting that the CDX1 gene is a target of aberrant methylation. Alterations of DNA methylation in the CDX1 gene promoter were investigated in a series of colorectal cancer cell lines. Combined Bisulfite Restriction Analysis (COBRA) and bisulfite sequencing analysis revealed that the CDX1 promoter is methylated in CDX1 non-expressing colorectal cancer cell lines but not in human normal colon tissue and T84 cells, which express CDX1. Treatment with 5'-aza-2'-deoxycytidine (5-azaC), a DNA methyltransferase inhibitor, induced CDX1 expression in the colorectal cancer cell lines. Furthermore, de novo methylation was determined by establishing stably transfected clones of the CDX1 promoter in SW480 cells and demethylation by 5-azaC-activated reporter gene expression. These results indicate that aberrant methylation of the CpG island in the CDX1 promoter is one of the mechanisms that mediate CDX1 down-regulation in colorectal cancer cell lines.	Univ Penn, Dept Internal Med, Sch Med, Philadelphia, PA 19104 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine	Suh, ER (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 600 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.		Kim, Il/L-6481-2019; Ha, C/GZL-9046-2022	Rankin, Erinn/0000-0002-2045-2296	NCI NIH HHS [R01-CA-81342] Funding Source: Medline; NIDDK NIH HHS [R01-DK46704, P30-DK-50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046704, P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1998, CANCER RES, V58, P5489; Baldwin RL, 2000, CANCER RES, V60, P5329; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bender CM, 1998, CANCER RES, V58, P95; Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO;2-I; BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Brauch H, 2000, CANCER RES, V60, P1942; Corn PG, 2000, CLIN CANCER RES, V6, P4243; Cunningham JM, 1998, CANCER RES, V58, P3455; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Grady WM, 2001, CANCER RES, V61, P900; Herman JG, 1996, CANCER RES, V56, P722; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HU YL, 1993, J BIOL CHEM, V268, P27214; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Lantry LE, 1999, CARCINOGENESIS, V20, P343, DOI 10.1093/carcin/20.2.343; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Stirzaker C, 1997, CANCER RES, V57, P2229; Suh E, 1996, MOL CELL BIOL, V16, P619; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	38	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35795	35800		10.1074/jbc.M205567200	http://dx.doi.org/10.1074/jbc.M205567200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12124393	hybrid			2022-12-27	WOS:000178275100005
J	Tahallah, N; van den Heuvel, RHH; van den Berg, WAM; Maier, CS; van Berkel, WJH; Heck, AJR				Tahallah, N; van den Heuvel, RHH; van den Berg, WAM; Maier, CS; van Berkel, WJH; Heck, AJR			Cofactor-dependent assembly of the flavoenzyme vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; FAD-BINDING DOMAIN; MASS-SPECTROMETRY; PENICILLIUM-SIMPLICISSIMUM; ELECTROSPRAY-IONIZATION; HYDROXYBENZOATE HYDROXYLASE; SUBSTRATE-SPECIFICITY; PROTEIN ASSEMBLIES; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI	The oligomerization of the flavoprotein vanillyl-alcohol oxidase (VAO) and its site-directed mutant H61T was studied by mass spectrometry. Native VAO has a covalently bound FAD and forms primarily octameric assemblies of 507 kDa. H61T is purified as a FAD-free apoprotein and mainly exists as a dimeric species of 126 kDa. Binding of FAD to apoH61T rapidly restores enzyme activity and induces octamerization, although association of H61T dimers seems not to be crucial for enzyme activity. Reconstitution of H61T with the cofactor analog 5'-ADP also promotes octamerization. FAM on the other hand, interacts with apoH61T without stimulating dimer association. These results are in line with observations made for several other flavoenzymes, which contain a Rossmann fold. Members of the VAO flavoprotein family do not contain a Rossmann fold but do share two conserved loops that are responsible for binding the pyrophosphate moiety of FAD. Therefore, the observed FAD-induced oligomerization might be general for this family. We speculate that upon FAD binding, small conformational changes in the ADP-binding pocket of the dimeric VAO species are transmitted to the protein surface, promoting oligomerization.	Univ Utrecht, Dept Biomol Mass Spectrometry, Bijvoet Ctr Biomol Res, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Biochem Lab, Dept Agrotechnol & Food Sci, NL-6703 HA Wageningen, Netherlands	Utrecht University; Utrecht University; Wageningen University & Research	Heck, AJR (corresponding author), Univ Utrecht, Dept Biomol Mass Spectrometry, Bijvoet Ctr Biomol Res, Sorbnnelaan 16, NL-3584 CA Utrecht, Netherlands.		Heck, Albert/D-7098-2011; van Berkel, Willem J.H./O-2431-2014	Heck, Albert/0000-0002-2405-4404; van Berkel, Willem J.H./0000-0002-6551-2782; Maier, Claudia S./0000-0003-0743-8956				Benen JAE, 1998, J BIOL CHEM, V273, P7865, DOI 10.1074/jbc.273.14.7865; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; DECKER KF, 1994, NUTR BIOCH, P443; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; Fitzgerald MC, 1996, P NATL ACAD SCI USA, V93, P6851, DOI 10.1073/pnas.93.14.6851; Fleischmann G, 2000, EUR J BIOCHEM, V267, P5156, DOI 10.1046/j.1432-1327.2000.01584.x; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Fraaije MW, 2000, J BIOL CHEM, V275, P38654, DOI 10.1074/jbc.M004753200; GANEM B, 1991, J AM CHEM SOC, V113, P7818, DOI 10.1021/ja00020a085; GHISLA S, 1986, BIOCHEM J, V239, P1; Green BN, 1999, J BIOL CHEM, V274, P28206, DOI 10.1074/jbc.274.40.28206; Gremer L, 2000, J BIOL CHEM, V275, P1864, DOI 10.1074/jbc.275.3.1864; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; Lindsay H, 2000, J BIOL CHEM, V275, P36665, DOI 10.1074/jbc.M004777200; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MASSEY V, 1966, J BIOL CHEM, V241, P3417; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P201; Raibekas AA, 1996, P NATL ACAD SCI USA, V93, P7546, DOI 10.1073/pnas.93.15.7546; Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x; Rostom Adam A., 1999, Current Opinion in Structural Biology, V9, P135, DOI 10.1016/S0959-440X(99)80018-9; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SMITH RD, 1994, NATURE, V369, P137, DOI 10.1038/369137a0; Smith RD, 1997, CHEM SOC REV, V26, P191, DOI 10.1039/cs9972600191; SWOBODA BEP, 1969, BIOCHIM BIOPHYS ACTA, V175, P365, DOI 10.1016/0005-2795(69)90014-2; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Van Berkel WJH, 2000, PROTEIN SCI, V9, P435; van den Heuvel RHH, 2000, J BIOL CHEM, V275, P14799, DOI 10.1074/jbc.275.20.14799; van den Heuvel RHH, 1998, J BACTERIOL, V180, P5646, DOI 10.1128/JB.180.21.5646-5651.1998; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; VANBERKEL WJH, 1988, EUR J BIOCHEM, V178, P197; VANBERKEL WJH, 1994, FLAVINS FLAVOPROTEIN, V11, P709; Vis H, 1999, PROTEIN SCI, V8, P1368, DOI 10.1110/ps.8.6.1368; Vis H, 1998, J AM CHEM SOC, V120, P6427, DOI 10.1021/ja9811187; VISSER J, 1970, BIOCHIM BIOPHYS ACTA, V206, P224, DOI 10.1016/0005-2744(70)90106-3; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Yorita K, 2000, P NATL ACAD SCI USA, V97, P2480, DOI 10.1073/pnas.040559797; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	52	29	29	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36425	36432		10.1074/jbc.M205841200	http://dx.doi.org/10.1074/jbc.M205841200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12107187	hybrid			2022-12-27	WOS:000178275100083
J	Chen, LI; Sommer, KM; Swisshelm, K				Chen, LI; Sommer, KM; Swisshelm, K			Downstream Codons in the retinoic acid receptor beta-2 and beta-4 mRNAs initiate translation of a protein isoform that disrupts retinoid-activated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; LUNG-CANCER; GROWTH-INHIBITION; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; CARCINOMA CELL; UP-REGULATION; EXPRESSION; GENE	Retinoic acid receptors (RARs) are essential for the differentiation and maintenance of normal epithelium. In studies of RARs in breast cancer, there are striking differences in the expression of certain protein isoforms of the RARbeta gene between cells derived from normal human mammary glands and those derived from breast tumors. While the protein isoforms RARbeta2 and RARbeta4 consist of the longest open reading frames of the RARbeta2 and RARbeta4 mRNAs, respectively, we find that a fraction of scanning ribosomes bypass these upstream RARbeta2 and RARbeta4 protein start codons and initiate translation downstream. This downstream translation initiation site is identical in the RARbeta2 and RARbeta4 transcripts and generates a third RARbeta protein isoform, here termed RARbeta' (formerly human RARbeta4). RARbeta' lacks protein domains found in the N terminus of RARbeta2 and RARbeta4, including one of two zinc fingers required for DNA binding. However, RARbeta' retains the ability to heterodimerize with RXRalpha and interact with transcription cofactors. In reporter gene assays, RARbeta' repressed retinoic acid-activated transcription of co-transfected RARbeta2, RARbeta4, and RARalpha. This repression required the presence of acidic amino acids within the AF2 domain. These findings demonstrate an antagonistic role for RARbeta' in signaling by retinoic acid.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Swisshelm, K (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA082455] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BLANER WS, 1994, RETINOIDS BIOL CHEM, V2, P229; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Crowe DL, 1998, CANCER RES, V58, P142; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBERT JF, 1991, ONCOGENE, V6, P1859; Geisen C, 2000, INT J CANCER, V85, P289, DOI 10.1002/(SICI)1097-0215(20000115)85:2<289::AID-IJC22>3.0.CO;2-T; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOULE B, 1994, CANCER RES, V54, P365; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Kaiser A, 1997, GASTROENTEROLOGY, V113, P920, DOI 10.1016/S0016-5085(97)70188-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lawrence JA, 1998, CANCER EPIDEM BIOMAR, V7, P29; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Liu Y, 1996, MOL CELL BIOL, V16, P1138; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; Newman SP, 2000, ONCOGENE, V19, P490, DOI 10.1038/sj.onc.1203416; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Raught B, 1996, CANCER RES, V56, P4382; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; Rosenauer A, 1998, CANCER RES, V58, P5110; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; Sorrells DL, 1999, J SURG RES, V85, P37, DOI 10.1006/jsre.1999.5653; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEI LL, 1990, MOL ENDOCRINOL, V4, P1833, DOI 10.1210/mend-4-12-1833; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1997, CANCER RES, V57, P4992; XU XC, 1999, HDB EXPT PHARM, P139; Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	64	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35411	35421		10.1074/jbc.M202717200	http://dx.doi.org/10.1074/jbc.M202717200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12118004	hybrid			2022-12-27	WOS:000178117000097
J	Verrijdt, G; Schauwaers, K; Haelens, A; Rombauts, W; Claessens, F				Verrijdt, G; Schauwaers, K; Haelens, A; Rombauts, W; Claessens, F			Functional interplay between two response elements with distinct binding characteristics dictates androgen specificity of the mouse sex-limited protein enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY COMPONENT GENE; DIFFERENTIAL DNA-BINDING; GLUCOCORTICOID RECEPTORS; FIRST EXON; SLP GENE; ACTIVATION; UPSTREAM; TRANSCRIPTION; COACTIVATOR; CLONING	Many of the aspects involved in steroid-specific transcriptional regulation are still unsolved to date. We describe here the detailed characterization of the mouse sex-limited protein enhancer as a paradigm for androgen-specific control of gene expression. By deletion analysis, we delineate the minimal enhancer region displaying androgen sensitivity and specificity. We also show that each of the three hormone response elements (HRE), which constitute this minimal enhancer region, is essential but not sufficient for its functionality. When investigated as isolated elements, HRE1 is inactive and HRE3 is a potent androgen response element as well as GRE. Only the non-canonical HRE2 (5-TGGTCAgccAGTTCT-3') is capable of conferring an androgen-specific transcriptional response to a heterologous promoter. This finding is correlated with the fact that HRE2 is recognized in binding assays in vitro by the DNA-binding domain (DBD) of the androgen but not the glucocorticoid receptor, while HRE3 is recognized by both DBDs. Differential binding of the androgen receptor to HRE2 in the context of the enhancer was analyzed in more detail in footprinting assays in vitro. In transient transfection experiments using chimeric receptors, the inability of the glucocorticoid receptor to transactivate via the slp-ARU as well as the isolated slp-HRE2 was rescued by the replacement of its DNA-binding domain with that of the androgen receptor. Our data suggest that the functional interplay between the weak, but highly androgen-specific HRE2 and the adjacent strong, but non-selective HRE3 is the major determinant in the generation of androgen specificity of transcriptional response via the sex-limited protein enhancer.	Univ Louvain, Fac Med, Div Biochem, B-3000 Louvain, Belgium		Claessens, F (corresponding author), Univ Louvain, Fac Med, Div Biochem, Campus Gasthuisberg, B-3000 Louvain, Belgium.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Alen P, 1999, MOL CELL BIOL, V19, P6085; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; Gonzalez MI, 2001, J BIOL CHEM, V276, P6420, DOI 10.1074/jbc.M008689200; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Haelens A, 1999, MOL CELL ENDOCRINOL, V153, P91, DOI 10.1016/S0303-7207(99)00079-9; Haelens A, 2001, BIOCHEM J, V353, P611, DOI 10.1042/0264-6021:3530611; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROBINS DM, 1994, J STEROID BIOCHEM, V49, P251, DOI 10.1016/0960-0760(94)90265-8; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Sui XM, 1999, J BIOL CHEM, V274, P9449, DOI 10.1074/jbc.274.14.9449; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; ZILHACUS J, 1995, MOL ENDOCRINOL, V9, P389	40	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35191	35201		10.1074/jbc.M205928200	http://dx.doi.org/10.1074/jbc.M205928200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107189	hybrid			2022-12-27	WOS:000178117000069
J	Wojtowicz, WM; Farzan, M; Joyal, JL; Carter, K; Babcock, GJ; Israel, DI; Sodroski, J; Mirzabekov, T				Wojtowicz, WM; Farzan, M; Joyal, JL; Carter, K; Babcock, GJ; Israel, DI; Sodroski, J; Mirzabekov, T			Stimulation of enveloped virus infection by beta-amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; NEUTRALIZATION SENSITIVITY; HIV-INFECTION; TYPE-1 RNA; CELL-LINE; DEMENTIA; CCR5; RECEPTOR	Alzheimer's disease is characterized by deposition of beta-amyloid peptide (Abeta) into plaques in the brain, leading to neuronal toxicity and dementia. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system can also cause a dementia, and amyloid deposition in the central nervous system is significantly higher in HIV-1-infected individuals compared with uninfected controls. Here we report that Abeta fibrils stimulated, by 5-20-fold, infection of target cells expressing CD4 and an appropriate coreceptor by multiple HIV-1 isolates but did not permit infection of cells lacking these receptors. Abeta enhanced infection at the stage of virus attachment or entry into the cell. Abeta fibrils also stimulated infection by amphotrophic Moloney leukemia virus, herpes simplex virus, and viruses pseudotyped with the envelope glycoprotein of vesicular stomatitis virus. Other synthetic fibril-forming peptides similarly enhanced viral infection and may be useful in gene delivery applications utilizing retroviral vectors. These data suggest that Abeta deposition may increase the vulnerability of the central nervous system to enveloped viral infection and that amyloidogenic peptides could be useful in enhancing gene transfer by enveloped viral vectors.	Praecis Pharmaceut Inc, Waltham, MA 02451 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Mirzabekov, T (corresponding author), Praecis Pharmaceut Inc, 830 Winter St, Waltham, MA 02451 USA.			Farzan, Michael/0000-0002-2990-5319	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, U01AI046725, R01AI031783, R01AI041851] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46725, AI42848, AI31783, AI41851] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bell JE, 1998, REV NEUROL-FRANCE, V154, P816; BRAND D, 1995, J VIROL, V69, P166, DOI 10.1128/JVI.69.1.166-171.1995; Brew BJ, 1997, J INFECT DIS, V175, P963, DOI 10.1086/514001; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Chretien F, 1996, NEUROPATH APPL NEURO, V22, P394, DOI 10.1111/j.1365-2990.1996.tb00909.x; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dobson CB, 1999, NEUROBIOL AGING, V20, P457, DOI 10.1016/S0197-4580(99)00055-X; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; Ellis RJ, 1997, ANN NEUROL, V42, P679, DOI 10.1002/ana.410420503; Esiri MM, 1998, J NEUROL NEUROSUR PS, V65, P29, DOI 10.1136/jnnp.65.1.29; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; Gearing M, 1996, ANN NEUROL, V39, P395, DOI 10.1002/ana.410390320; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Itzhaki RF, 1998, BIOCHEM SOC T, V26, P273, DOI 10.1042/bst0260273; Jobbagy Z, 2000, J VIROL, V74, P2847, DOI 10.1128/JVI.74.6.2847-2854.2000; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kolchinsky P, 2001, J VIROL, V75, P3435, DOI 10.1128/JVI.75.7.3435-3443.2001; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Labonte JA, 2000, J VIROL, V74, P10690, DOI 10.1128/JVI.74.22.10690-10698.2000; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; Means RE, 2001, J VIROL, V75, P3903, DOI 10.1128/JVI.75.8.3903-3915.2001; Morner A, 1999, J VIROL, V73, P2343; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; Nebuloni M, 2001, AIDS, V15, P571, DOI 10.1097/00002030-200103300-00005; Parolin C, 1996, VIROLOGY, V222, P415, DOI 10.1006/viro.1996.0438; Pedersen S, 1996, BIOPHYS J, V71, P554, DOI 10.1016/S0006-3495(96)79279-2; Rafalowska J, 1998, FOLIA NEUROPATHOL, V36, P211; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; Smits HA, 2000, EUR J CLIN INVEST, V30, P526; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TOYOSHIMA K, 1969, VIROLOGY, V38, P414, DOI 10.1016/0042-6822(69)90154-8; Villar AV, 1998, FEBS LETT, V432, P150, DOI 10.1016/S0014-5793(98)00853-9; VOGT PK, 1967, VIROLOGY, V33, P175, DOI 10.1016/0042-6822(67)90109-2; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7; Zink MC, 1999, J VIROL, V73, P10480, DOI 10.1128/JVI.73.12.10480-10488.1999	50	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35019	35024		10.1074/jbc.M203518200	http://dx.doi.org/10.1074/jbc.M203518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12119288	hybrid			2022-12-27	WOS:000178117000047
J	Fleckenstein, B; Molberg, Y; Qiao, SW; Schmid, DG; von der Mullbe, F; Elgstoen, K; Jung, G; Sollid, LM				Fleckenstein, B; Molberg, Y; Qiao, SW; Schmid, DG; von der Mullbe, F; Elgstoen, K; Jung, G; Sollid, LM			Gliadin T cell epitope selection by tissue transglutaminase in Celiac disease - Role of enzyme specificity and pH influence on the transamidation versus deamidation reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-INTESTINAL MUCOSA; RECOGNIZE GLIADIN; IDENTIFICATION; FIBRONECTIN; MECHANISM; ADHESION; GENE	Tissue transglutaminase (TG2) can modify proteins by transamidation or deamidation of specific glutamine residues. TG2 has a major role in the pathogenesis of celiac disease as it is both the target of disease-specific autoantibodies and generates deamidated gliadin peptides that are recognized by CD4(+), DQ2-restricted T cells from the celiac lesions. Capillary electrophoresis with fluorescence-labeled gliadin peptides was used to separate and quantify deamidated and transamidated products. In a competition assay, the affinity of TG2 to a set of overlapping gamma-gliadin peptides was measured and compared with their recognition by celiac lesion T cells. Peptides differed considerably in their competition efficiency. Those peptides recognized by intestinal T cell lines showed marked competition indicating them as excellent substrates for TG2. The enzyme fine specificity of TG2 was characterized by synthetic peptide libraries and mass spectrometry. Residues in positions -1, +1, +2, and +3 relative to the targeted glutamine residue influenced the enzyme activity, and proline in position +2 had a particularly positive effect. The characterized sequence specificity of TG2 explained the variation between peptides as TG2 substrates indicating that the enzyme is involved in the selection of gluten T cell epitopes. The enzyme is mainly localized extracellularly in the small intestine where primary amines as substrates for the competing transamidation reaction are present. The deamidation could possibly take place in this compartment as an excess of primary amines did not completely inhibit deamidation of gluten peptides at pH 7.3. However, lowering of the pH decreased the reaction rate of the TG2-catalyzed transamidation, whereas the rate of the deamidation reaction was considerably increased. This suggests that the deamidation of gluten peptides by TG2 more likely takes place in slightly acidic environments.	Univ Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway; Univ Oslo, Rikshosp, Inst Clin Biochem, N-0027 Oslo, Norway; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Eberhard Karls University of Tubingen	Sollid, LM (corresponding author), Univ Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway.		Sollid, Ludvig/N-9691-2015; Qiao, Shuo-Wang/ABE-8148-2020	Sollid, Ludvig/0000-0001-8860-704X; Qiao, Shuo-Wang/0000-0002-0935-8397; Elgstoen, Katja Benedikte Presto/0000-0002-0087-0714				Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; ARENTZHANSEN H, 2002, IN PRESS GASTROENTER; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Janatuinen EK, 2000, GUT, V46, P327, DOI 10.1136/gut.46.3.327; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; Leblanc A, 2001, BIOCHEMISTRY-US, V40, P8335, DOI 10.1021/bi0024097; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Liu T, 1997, PROTEIN SCI, V6, P1937, DOI 10.1002/pro.5560060914; LUNDIN KEA, 1994, HUM IMMUNOL, V41, P285, DOI 10.1016/0198-8859(94)90047-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 2001, EUR J IMMUNOL, V31, P1317, DOI 10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; MYCEK MJ, 1960, J BIOL CHEM, V235, P3513; Osman AA, 2000, CLIN EXP IMMUNOL, V121, P248, DOI 10.1046/j.1365-2249.2000.01312.x; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; PUCCI P, 1988, BIOCHEM BIOPH RES CO, V154, P735, DOI 10.1016/0006-291X(88)90201-X; SCHEETS K, 1988, PLANT SCI, V57, P141, DOI 10.1016/0168-9452(88)90080-5; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Sjostrom H, 1998, SCAND J IMMUNOL, V48, P111; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; Sollid LM, 1997, GUT, V41, P851, DOI 10.1136/gut.41.6.851; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; van de Wal Y, 1998, J IMMUNOL, V161, P1585; [No title captured]	33	182	187	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34109	34116		10.1074/jbc.M204521200	http://dx.doi.org/10.1074/jbc.M204521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12093810	hybrid			2022-12-27	WOS:000177959100077
J	Hagge, SO; de Cock, H; Gutsmann, T; Beckers, F; Seydel, U; Wiese, A				Hagge, SO; de Cock, H; Gutsmann, T; Beckers, F; Seydel, U; Wiese, A			Pore formation and function of phosphoporin PhoE of Escherichia coli are determined by the core sugar moiety of lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN PHOE; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; MOLECULAR ARCHITECTURE; OMPF PORIN; LIPID-A; TRIMERIZATION; MICROSCOPY; ACTIVATION	The lipid matrix of the outer membrane of Gram-negative bacteria is an asymmetric bilayer composed of a phospholipid inner leaflet and a lipopolysaccharide outer leaflet. Incorporated into this lipid matrix are, among other macromolecules, the porins, which have a sieve-like function for the transport or exclusion of hydrophilic substances. It is known that a reduced amount of porins is found in the outer membrane of rough mutants as compared with wild-type bacteria. This observation was discussed to be caused by a reduced number of insertion sites in the former. We performed electrical measurements on reconstituted planar bilayers composed of lipopolysaccharide on one side and a phospholipid mixture on the other side using lipopolysaccharide from various rough mutant, strains of Salmonella enterica serovar Minnesota. We found that pore formation by PhoE trimers that were added to the phospholipid side of the bilayers increased with the increasing length of the lipopolysaccharide core sugar moiety. These results allow us to conclude that the length of the sugar moiety of lipopolysaccharide is the parameter governing pore formation and that no particular insertion sites are required. Furthermore, we found that the voltage gating of the porin channels is strongly dependent on the composition of the lipid matrix.	Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, D-23845 Borstel, Germany; Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands	Forschungszentrum Borstel; Utrecht University	Wiese, A (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Dept Immunochem & Biochem Microbiol, Parkallee 10, D-23845 Borstel, Germany.		Gutsmann, Thomas/E-6100-2011; de Cock, Hans/B-7790-2011	de Cock, Hans/0000-0002-8420-6764				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; Berrier C, 1997, J MEMBRANE BIOL, V156, P105, DOI 10.1007/s002329900193; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; Brandenburg K, 1998, CHEM PHYS LIPIDS, V91, P53, DOI 10.1016/S0009-3084(97)00093-5; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; deCock H, 1996, J BIOL CHEM, V271, P12885, DOI 10.1074/jbc.271.22.12885; Eppens EF, 1997, FEBS LETT, V415, P317, DOI 10.1016/S0014-5793(97)01150-2; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; Jansen C, 2000, EUR J BIOCHEM, V267, P3792, DOI 10.1046/j.1432-1327.2000.01417.x; Kawahara K, 1990, Jpn J Med Sci Biol, V43, P250; KORTELAND J, 1984, BIOCHIM BIOPHYS ACTA, V774, P119, DOI 10.1016/0005-2736(84)90282-7; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Muller DJ, 1999, J MOL BIOL, V285, P1347, DOI 10.1006/jmbi.1998.2359; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OVERBEEKE N, 1980, FEBS LETT, V112, P229, DOI 10.1016/0014-5793(80)80186-4; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SEN K, 1988, J BIOL CHEM, V263, P1182; SEN K, 1991, J BIOL CHEM, V266, P11295; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; TOMMASSEN J, 1981, J BACTERIOL, V147, P118, DOI 10.1128/JB.147.1.118-123.1981; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; Wiese A, 2000, METH MOL B, V145, P355; WIESE A, 1994, BBA-BIOMEMBRANES, V1190, P231, DOI 10.1016/0005-2736(94)90079-5; Wiese A, 1996, BIOPHYS J, V70, P321, DOI 10.1016/S0006-3495(96)79573-5; Wiese A, 2001, J ENDOTOXIN RES, V7, P147, DOI 10.1179/096805101101532657	35	22	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34247	34253		10.1074/jbc.M201950200	http://dx.doi.org/10.1074/jbc.M201950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091383	hybrid			2022-12-27	WOS:000177959100094
J	Upadhyaya, AB; Khan, M; Mou, TC; Junker, M; Gray, DM; DeJong, J				Upadhyaya, AB; Khan, M; Mou, TC; Junker, M; Gray, DM; DeJong, J			The germ cell-specific transcription factor ALF - Structural properties and stabilization of the TATA-binding protein (TBP)-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CIRCULAR-DICHROISM SPECTROSCOPY; YEAST TFIIA/TBP/DNA COMPLEX; ACTIVATED TRANSCRIPTION; FACTOR TFIIA; IN-VIVO; CRYSTAL-STRUCTURE; REINITIATION RATE; GENE-EXPRESSION; DNA-BINDING	The assembly and stability of the RNA polymerase H transcription preinitiation complex on a eukaryotic core promoter involves the effects of TFIIA on the interaction between TATA-binding protein (TBP) and DNA. To extend our understanding of these interactions, we characterized properties of ALF, a germ cell-specific TFIIA-like factor. ALF was able to stabilize the binding of TBP to DNA, but it could not stabilize TBP mutants A184E, N189E, E191R, and R205E nor could it facilitate binding of the TBP-like factor TRF2/TLF to a consensus TATA element. However, phosphorylation of ALF with casein kinase II resulted in the partial restoration of complex formation using mutant TBPs. Studies of ALF-TBP complexes formed on the Adenovirus Major Late (AdML) promoter revealed protection of the TATA box and upstream sequences from -38 to -20 (top strand) and -40 to -22 (bottom strand). The half-life and apparent K-D of this complex was determined to be 650 min and 4.8 +/- 2.7 nm, respectively. The presence of ALF or TFIIA did not significantly alter the ability of TBP to bind TATA elements from several testis-specific genes. Finally, analysis of the distinct, nonhomologous internal regions of ALF and TFIIAalpha/beta using circular dichroism spectroscopy provided the first evidence to suggest that these domains are unordered, a result consistent with other genetic and biochemical properties. Overall, the results show that while the sequence and regulation of the ALF gene are distinct from its somatic cell counterpart TFIIAalpha/beta, the TFIIAgamma-dependent interactions of these factors with TBP are nearly indistinguishable in vitro. Thus, a role for ALF in the assembly and stabilization of initiation complexes in germ cells is likely to be similar or identical to the role of TFIIA in somatic cells.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75080 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Carey M., 2000, TRANSCRIPTIONAL REGU, P263; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GRAY DM, 1995, METHOD ENZYMOL, V246, P19; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Hutchens JA, 1997, MOL BIOL CELL, V8, P481, DOI 10.1091/mbc.8.3.481; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; LAMBERT WC, 1981, ADV CELL BIOL, P1077; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maldonado E, 1999, J BIOL CHEM, V274, P12963, DOI 10.1074/jbc.274.19.12963; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Moore PA, 1999, MOL CELL BIOL, V19, P7610; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Ohbayashi T, 1999, BIOCHEM BIOPH RES CO, V255, P137, DOI 10.1006/bbrc.1999.0159; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Persengiev SP, 1996, MOL ENDOCRINOL, V10, P742, DOI 10.1210/me.10.6.742; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; Ramboarina S, 1998, PROTEIN ENG, V11, P729, DOI 10.1093/protein/11.9.729; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sandaltzopoulos R, 1998, MOL CELL BIOL, V18, P361, DOI 10.1128/MCB.18.1.361; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Solow S, 2001, J BIOL CHEM, V276, P15886, DOI 10.1074/jbc.M009385200; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stargell LA, 2001, PROTEINS, V43, P227, DOI 10.1002/1097-0134(20010501)43:2<227::AID-PROT1033>3.0.CO;2-C; Stewart JJ, 2001, J BIOL CHEM, V276, P30078, DOI 10.1074/jbc.M105276200; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Yean D, 1999, NUCLEIC ACIDS RES, V27, P831, DOI 10.1093/nar/27.3.831; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	58	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34208	34216		10.1074/jbc.M204808200	http://dx.doi.org/10.1074/jbc.M204808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107178	hybrid			2022-12-27	WOS:000177959100089
J	Wilson, HL; Wilson, SA; Surprenant, A; North, RA				Wilson, HL; Wilson, SA; Surprenant, A; North, RA			Epithelial membrane proteins induce membrane blebbing and interact with the P2X(7) receptor C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE RECEPTOR; SCHWANN-CELLS; GROWTH ARREST; GENE; MOUSE; EXPRESSION; FAMILY; GAS3/PMP22; NEUROPATHY; CHANNELS	The binding of extracellular ATP to the P2X(7) receptor opens an integral cation-permeable channel; it also leads to membrane blebbing and, in certain immune cells, interleukin-1beta secretion and eventual death. The latter three effects are unique to the P2X(7) receptor; also unique among P2X receptors is the long intracellular C terminus of the protein. We have shown that the C-terminal domain of the P2X(7) receptor is responsible for the cell blebbing phenotype. A screen for proteins that associate with the C-terminal domain of the P2X(7) receptor and might mediate the blebbing phenotype, identified epithelial membrane protein 2 (EMP-2). The interaction between EMP-2 and P2X(7) was confirmed biochemically by co-immunoprecipitation, co-purification, and glutathione S-transferase pull-down assays, and this interaction was entirely dependent on the C-terminal domain of P2X(7). The P2X(7) receptor also interacted with the other members of the epithelial membrane protein family (EMP-1, EMP-3, and PMP-22). All four EMPs were found to be expressed in HEK-293 cells and in THP-1 monocytes, which express P2X(7) receptors. Interestingly, the constitutive overexpression of any of the EMPs in HEK-293 cells led to cell blebbing, annexin V binding, and cell death, by a caspase-dependent pathway. These findings suggest that the P2X(7) C-terminal domain associates with EMPs, and this interaction may mediate some aspects of the downstream signaling following P2X(7) receptor activation.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Sheffield; University of Manchester	Wilson, HL (corresponding author), Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England.		North, Richard/GQA-6156-2022; Wilson, Heather/O-5909-2019	Wilson, Heather/0000-0002-7892-3425; wilson, stuart/0000-0003-3073-258X				Baechner D, 1995, J NEUROSCI RES, V42, P733, DOI 10.1002/jnr.490420602; Brancolini C, 1999, MOL BIOL CELL, V10, P2441, DOI 10.1091/mbc.10.7.2441; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Collo G, 1996, J NEUROSCI, V16, P2495; Colomar A, 2001, EUR J NEUROSCI, V14, P927, DOI 10.1046/j.0953-816x.2001.01714.x; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Dubyak GR, 2000, J AUTONOM NERV SYST, V81, P64, DOI 10.1016/S0165-1838(00)00155-7; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Grafe P, 1999, J PHYSIOL-LONDON, V515, P377, DOI 10.1111/j.1469-7793.1999.377ac.x; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Lobsiger CS, 1996, GENOMICS, V36, P379, DOI 10.1006/geno.1996.0482; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Moss FJ, 2002, EMBO J, V21, P1514, DOI 10.1093/emboj/21.7.1514; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Ryan MC, 2000, J NEUROCHEM, V75, P1465, DOI 10.1046/j.1471-4159.2000.0751465.x; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; Taylor V, 1996, GENE, V175, P115, DOI 10.1016/0378-1119(96)00134-5; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wang CX, 2001, BLOOD, V97, P3890, DOI 10.1182/blood.V97.12.3890; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053	31	151	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34017	34023		10.1074/jbc.M205120200	http://dx.doi.org/10.1074/jbc.M205120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107182	hybrid			2022-12-27	WOS:000177959100066
J	Makino, Y; Kanopka, A; Wilson, WJ; Tanaka, H; Poellinger, L				Makino, Y; Kanopka, A; Wilson, WJ; Tanaka, H; Poellinger, L			Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3 alpha locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLATION; FACTOR 1-ALPHA; HIF-ALPHA; BINDING; UBIQUITYLATION; TRANSCRIPTION; RECRUITMENT; HOMEOSTASIS; EXPRESSION	The inhibitory PAS (Per/Arnt/Sim) domain protein, IPAS, functions as a dominant negative regulator of hypoxia-inducible transcription factors (HIFs) by forming complexes with those proteins that fail to bind to hypoxia response elements of target genes. We have previously observed that IPAS is predominantly expressed in mice in Purkinje cells of the cerebellum and in corneal epithelium of the eye where it appears to play a role in negative regulation of angiogenesis and maintenance of an avascular phenotype. Sequencing of the mouse IPAS genomic structure revealed that IPAS is a splicing variant of the HIF-3alpha locus. Thus, in addition to three unique exons (1a, 4a, and 16) IPAS shares three exons (2, 4, and 5) with HIF-3alpha as well as alternatively spliced variants of exons 3 and 6. In experiments using normal mice and mice exposed to hypoxia (6% O-2) for 6 h we observed alternative splicing of the HIF-3alpha transcript in the heart and lung. The alternatively spliced transcript was only observed under hypoxic conditions, thus defining a novel mechanism of hypoxia-dependent regulation of gene expression. Importantly, this mechanism may establish negative feedback loop regulation of adaptive responses to hypoxia/ischemia in these tissues.	Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, S-17177 Stockholm, Sweden; Inst Biotechnol, LT-2028 Vilnius, Lithuania; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan	Karolinska Institutet; Vilnius University; University of Tokyo	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, S-17177 Stockholm, Sweden.		Wilson, William/A-3631-2009	Wilson, William/0000-0001-5658-0997				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	19	276	291	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32405	32408		10.1074/jbc.C200328200	http://dx.doi.org/10.1074/jbc.C200328200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12119283	hybrid			2022-12-27	WOS:000177859000001
J	Okazaki, I; Suzuki, N; Nishi, N; Utani, A; Matsuura, H; Shinkai, H; Yamashita, H; Kitagawa, Y; Nomizu, M				Okazaki, I; Suzuki, N; Nishi, N; Utani, A; Matsuura, H; Shinkai, H; Yamashita, H; Kitagawa, Y; Nomizu, M			Identification of biologically active sequences in the laminin alpha 4 chain G domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL GLOBULAR DOMAIN; CELL-BINDING SEQUENCES; SYNTHETIC PEPTIDES; NEURITE OUTGROWTH; GAMMA-1 CHAIN; BETA-1 CHAIN; EXPRESSION; HEPARIN; MIGRATION; INTEGRINS	Laminins are a family of trimeric extracellular matrix proteins consisting of alpha, beta, and gamma chains. So far five different laminin alpha chains have been identified. The laminin alpha4 chain, which is present in laminin-8/9, is expressed in cells of mesenchymal origin, such as endothelial cells and adipocytes. Previously, we identified heparin-binding sites in the C-terminal globular domain (G domain) of the laminin alpha4 chain. Here we have focused on the biological functions of the laminin alpha4 chain G domain and screened active sites using a recombinant protein and synthetic peptides. The rec-alpha4G protein, comprising the entire G domain, promoted cell attachment activity. The cell attachment activity of rec-alpha4G was completely blocked by heparin and partially inhibited by EDTA. We synthesized 116 overlapping peptides covering the entire G domain and tested their cell attachment activity. Twenty peptides showed cell attachment activity, and 16 bound to heparin. We further tested the effect of the 20 active peptides in competition assays for cell attachment and heparin binding to rec-alpha4G protein. A4G6 (LAIKNDNLVYVY), A4G20 (DVISLYNFKHIY), A4G82 (TLFLAHGRLVFM), and A4G83 (LVFMFNVGHKKL), which promoted cell attachment and heparin binding, significantly inhibited both cell attachment and heparin binding to rec-alpha4G. These results suggest that the four active sites are involved in the biological functions of the laminin alpha4 chain G domain. Furthermore, rec-alpha4G, A4G6, and A4G20 were found to interact with syndecan-4. These active peptides may be useful for defining of the molecular mechanism laminin-receptor interactions and laminin-mediated cellular signaling pathways.	Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; Chiba Univ, Sch Med, Dept Dermatol, Chiba 2608670, Japan; Nagoya Univ, Grad Course Regulat Biol Signals, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Hokkaido University; Chiba University; Nagoya University	Nomizu, M (corresponding author), Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Kita 10,Nishi 5, Sapporo, Hokkaido 0600810, Japan.			Yamashita, Hironobu/0000-0003-2587-7100				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MAKINO M, 1999, CONNECT TISSUE, V31, P227; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Niimi T, 1997, MATRIX BIOL, V16, P223, DOI 10.1016/S0945-053X(97)90011-1; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200	39	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37070	37078		10.1074/jbc.M201672200	http://dx.doi.org/10.1074/jbc.M201672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130633	hybrid			2022-12-27	WOS:000178447100023
J	Propst, SM; Estell, K; Schwiebert, LM				Propst, SM; Estell, K; Schwiebert, LM			CD40-mediated activation of NF-kappa B in airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED FACTOR-3; TERMINAL KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CD40; TNF; PROTEIN; FAMILY; IDENTIFICATION; INDUCTION	We have reported previously that airway epithelial cells (AEC) express CD40 and that activation of this molecule stimulates the expression of inflammatory mediators, including the chemokine RANTES (regulated on activation normal T cell expressed and secreted). Because NF-kappaB regulates the expression of many inflammatory mediators, such as RANTES, we utilized CD40-mediated induction of RANTES expression to investigate the mechanisms that underlie CD40-mediated activation of NF-kappaB in AEC. Results demonstrate that, in AEC, intact NF-kappaB sites were required for CD40-mediated activation of the RANTES promoter. To examine activation of NF-kappaB binding directly, electrophoretic mobility shift analyses were performed. These analyses revealed that CD40 ligation stimulated NF-kappaB binding and that the activated NF-kappaB complexes were composed of p65 subunits. Additional studies focused on the CD40-triggered signaling pathways that facilitate NF-kappaB activation. Findings show that CD40 engagement activated the IkappaB kinases IKK-alpha and IKK-beta and stimulated IkappaBalpha phosphorylation. Analyses also examined the role of tumor necrosis factor-associated factor (TRAF) molecules in CD40-mediated NF-kappaB activation within AEC. Stable transfectants expressing wild-type or mutant forms of the cytoplasmic domain of CD40 suggested that TRAF3, but not TRAF2, binding was essential for CD40-mediated RANTES expression. Further studies indicated that exogenous expression of wild-type TRAF3 enhanced activation of the RANTES promoter, whereas exogenous expression of wild-type TRAF2 inhibited this activation; TRAF3-mediated enhancement was dependent upon NF-kappaB. Together, these findings suggest that, in AEC, ligation of CD40 regulates the expression of inflammatory mediators, such as RANTES, via activation of NF-kappaB. Moreover, these results suggest that CD40-mediated signaling in AEC differs with previously reported findings observed in other cell models, such as B lymphocytes.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Schwiebert, LM (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, McCallum Bldg,Rm 966,1918 Univ Blvd, Birmingham, AL 35294 USA.	lschwieb@uab.edu						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAR CE, 1991, J BIOL CHEM, V266, P19142; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Clark LB, 1996, ADV IMMUNOL, V63, P43; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Dong YS, 2001, J IMMUNOL, V167, P311, DOI 10.4049/jimmunol.167.1.311; Grammer AC, 1998, J IMMUNOL, V161, P1183; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Hostager BS, 1999, J IMMUNOL, V162, P6307; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lapointe R, 1996, EUR J IMMUNOL, V26, P2376, DOI 10.1002/eji.1830261016; Lazaar AL, 1998, J IMMUNOL, V161, P3120; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Ling L, 2000, J BIOL CHEM, V275, P23852, DOI 10.1074/jbc.M001095200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; Propst SM, 2000, J IMMUNOL, V165, P2214, DOI 10.4049/jimmunol.165.4.2214; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Ray P, 1997, J BIOL CHEM, V272, P20191, DOI 10.1074/jbc.272.32.20191; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; van Eyndhoven WG, 1999, MOL IMMUNOL, V36, P647, DOI 10.1016/S0161-5890(99)00079-6; VANCOOTEN C, 1996, ADV IMMUNOL, V61, P1; vanKooten C, 1997, KIDNEY INT, V51, P711, DOI 10.1038/ki.1997.102; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	45	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37054	37063		10.1074/jbc.M205778200	http://dx.doi.org/10.1074/jbc.M205778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12122011	hybrid			2022-12-27	WOS:000178447100021
J	Rutledge, TW; Whiteheart, SW				Rutledge, TW; Whiteheart, SW			SNAP-23 is a target for calpain cleavage in activated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GRANULE SECRETION; HUMAN BLOOD-PLATELETS; NEUTRAL PROTEASE; MU-CALPAIN; MOLECULAR MECHANISMS; CYSTEINE PROTEINASES; MEMBRANE-FUSION; EXOCYTOSIS; PROTEOLYSIS; AGGREGATION	The role of calpain in platelet function is generally associated with aggregation and clot retraction. In this report, data are presented to show that one component of the platelet secretory machinery, SNAP-23, is specifically cleaved by calpain in activated cells. Other proteins of the membrane fusion machinery, e.g. syntaxins 2 and 4 and alpha-SNAP, are not affected. In vitro studies, using permeabilized platelets, demonstrate that cleavage is time- and calcium-dependent. Analysis of SNAP-23 cleavage products suggests that the calpain cleavage site(s) is in the C-terminal third of the molecule potentially between the cysteine-rich acyl attachment sites and the C-terminal coiled-coil domain. The time course of cleavage is most consistent with late calpain-mediated events such as pp60(c-src) cleavage, but not early events such as protein-tyrosine phosphatase-1B activation. SNAP-23 cleavage is inhibited by calpeptin, calpastatin, calpain inhibitor IV, and E-64d, but not by caspase 3 inhibitor III or cathepsin inhibitor I. When tested for their effect on secretion, none of the calpain-specific inhibitors significantly affected release of soluble components from any of the three platelet granule storage pools. These results indicate that SNAP-23 cleavage occurs after granule release and therefore may play a role in affecting granule membrane exteriorization. This is consistent with the ultrastructural morphology of calpeptin-treated platelets after activation.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Whiteheart, SW (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	whitehe@pop.uky.edu		Whiteheart, Sidney/0000-0001-5577-0473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56652-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARIYOSHI H, 1995, PLATELETS, V6, P185, DOI 10.3109/09537109509078452; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BECKERLE MC, 1986, J CELL BIOCHEM, V30, P259, DOI 10.1002/jcb.240300307; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; BROMME D, 1994, METHOD ENZYMOL, V244, P671; Chen D, 1999, BRAIN RES, V831, P11, DOI 10.1016/S0006-8993(99)01371-2; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen D, 1999, BIOCHEM BIOPH RES CO, V255, P340, DOI 10.1006/bbrc.1999.0173; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; Demuth HU, 1996, BBA-PROTEIN STRUCT M, V1295, P179, DOI 10.1016/0167-4838(96)00038-6; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; Flaumenhaft R, 1999, J CELL PHYSIOL, V179, P1; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; INOMATA M, 1988, J BIOL CHEM, V263, P19783; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; NACHMIAS VT, 1979, BLOOD, V53, P63; ODA A, 1993, J BIOL CHEM, V268, P12603; Plow Edward F., 1995, P1524; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; Schrantz N, 1999, CELL DEATH DIFFER, V6, P445, DOI 10.1038/sj.cdd.4400508; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKAHASHI T, 1990, INTRACELLULAR CALCIU, P55; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUJINAKA T, 1983, BIOCHEM INT, V6, P71; WHITE JG, 1991, EUR J CELL BIOL, V56, P233; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Zimmerman UJP, 1999, IUBMB LIFE, V48, P453, DOI 10.1080/713803537	53	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37009	37015		10.1074/jbc.M204526200	http://dx.doi.org/10.1074/jbc.M204526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12121992	hybrid			2022-12-27	WOS:000178447100015
J	Francis, NR; Levit, MN; Shaikh, TR; Melanson, LA; Stock, JB; DeRosier, DJ				Francis, NR; Levit, MN; Shaikh, TR; Melanson, LA; Stock, JB; DeRosier, DJ			Subunit organization in a soluble complex of Tar, CheW, and CheA by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SIGNAL-TRANSDUCTION; BACTERIAL CHEMOTAXIS; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; CYTOPLASMIC DOMAIN; HISTIDINE KINASE; SALMONELLA-TYPHIMURIUM; BINDING DOMAIN; PROTEIN; MECHANISM	The Salmonella and Escherichia coli aspartate receptor, Tar, is representative of a large class of membrane receptors that generate chemotaxis responses by regulating the activity of an associated histidine protein kinase, CheA. Tar is composed of an NH2-terminal periplasmic ligand-binding domain linked through a transmembrane sequence to a COOH-terminal coiled-coil signaling domain in the cytoplasm. The isolated cytoplasmic domain of Tar fused to a leucine zipper sequence forms a soluble complex with CheA and the Src homology 3-like kinase activator, CheW. Activity of the CheA kinase in the soluble complex is essentially the same as in fully active complexes with the intact receptor in the membrane. The soluble complex is composed of similar to28 receptor cytoplasmic domain chains, 6 CheW chains, and 4 CheA chains. It has a molecular weight of 1,400,000 (Liu, I., Levit, M., Lurz, R., Surette, M.G., and Stock, J.B. (1997) EMBO J. 16, 7231-7240). Electron microscopy reveals an elongated barrel-like structure with a largely hollow center. Immunoelectron microscopy has provided a general picture of the subunit and domain organization of the complex. CheA and CheW appear to be in the middle of the complex with the leucine zippers of the receptor construct at the ends. These findings show that the receptor signaling complex forms higher ordered structures with defined geometric architectures. Coupled with atomic models of the subunits, our results provide insights into the functional architecture by which the receptor regulates CheA kinase activity during bacterial chemotaxis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Brandeis University; Brandeis University; Princeton University	DeRosier, DJ (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA.				NIGMS NIH HHS [5R01-GM5773, R01-GM35433] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DEROSIER DJ, 1984, J MOL BIOL, V175, P57, DOI 10.1016/0022-2836(84)90445-5; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Falke JJ, 2000, CURR OPIN STRUC BIOL, V10, P462, DOI 10.1016/S0959-440X(00)00115-9; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gestwicki JE, 2000, J BACTERIOL, V182, P6499, DOI 10.1128/JB.182.22.6499-6502.2000; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Levit MN, 2002, J BIOL CHEM, V277, P36748, DOI 10.1074/jbc.M204317200; Levit MN, 2002, J BIOL CHEM, V277, P36760, DOI 10.1074/jbc.M204325200; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; Lybarger SR, 2001, J BACTERIOL, V183, P3261, DOI 10.1128/JB.183.11.3261-3267.2001; MADDOCK JR, 1993, SCIENCE, V259, P1717; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; Mourey L, 2001, J BIOL CHEM, V276, P31074, DOI 10.1074/jbc.M101943200; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; STALLMEYER MJB, 1989, J MOL BIOL, V205, P519, DOI 10.1016/0022-2836(89)90223-4; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J, 1999, CELL CALCIUM, V26, P157, DOI 10.1054/ceca.1999.0075; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; TRUS BL, 1984, ULTRAMICROSCOPY, V15, P325, DOI 10.1016/0304-3991(84)90127-X; UNWIN PNT, 1975, J MOL BIOL, V98, P235, DOI 10.1016/S0022-2836(75)80111-2; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; WOLANIN PM, 2002, HISTIDINE KINASES SI, P73; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	42	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36755	36759		10.1074/jbc.M204324200	http://dx.doi.org/10.1074/jbc.M204324200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12119290	hybrid			2022-12-27	WOS:000178275100123
J	Reches, M; Porat, Y; Gazit, E				Reches, M; Porat, Y; Gazit, E			Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBULAR-PROTEINS; 2-DIMENSIONAL NMR; SALMON-CALCITONIN; PEPTIDE; STATE; SPECTROSCOPY; POLYPEPTIDE; MECHANISM; DISEASE; DOMAIN	The process of amyloid fibril formation by the human calcitonin hormone is associated with medullary thyroid carcinoma. Based on the effect of pH on the fibrillization of human calcitonin, the analysis of conformationally constrained analogues of the hormone, and our suggestion regarding the role of aromatic residues in the process of amyloid fibril formation, we studied the ability of a short aromatic charged peptide fragment of calcitonin (NH2-DFNKF-COOH) to form amyloid fibrils. Here, using structural and biophysical analysis, we clearly demonstrate the ability of this short peptide to form well ordered amyloid fibrils. A shorter truncated tetrapeptide, NH2-DFNK-COOH, also formed fibrils albeit less ordered than those formed by the pentapeptide. We could not detect amyloid fibril formation by the NH2-FNKF-COOH tetrapeptide, the NH2-DFN-COOH tripeptide, or the NH2-DANKA-COOH phenylalanine to the alanine analogue of the pentapeptide. The formation of amyloid fibrils by rather hydrophilic peptides is quite striking, because it was speculated that hydrophobic interactions might play a key role in amyloid formation. This is the first reported case of fibril formation by a peptide as short as a tetrapeptide and one of very few cases of amyloid formation by pentapeptides. Because the aromatic nature seems to be the only common property of the various very short amyloid-forming peptides, it further supports our hypothesis on the role of aromatic interactions in the process of amyloid fibril formation.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Reches, Meital/B-2348-2013; Gazit, Ehud/AHE-9332-2022; Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019	Reches, Meital/0000-0001-5652-9868; Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720				ARVINTE T, 1993, J BIOL CHEM, V268, P6415; AUSTIN LA, 1981, NEW ENGL J MED, V304, P269, DOI 10.1056/NEJM198101293040505; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Balbirnie M, 2001, P NATL ACAD SCI USA, V98, P2375, DOI 10.1073/pnas.041617698; BAUER HH, 1994, BIOCHEMISTRY-US, V33, P12276, DOI 10.1021/bi00206a034; BENVENGA S, 1994, J ENDOCRINOL INVEST, V17, P119, DOI 10.1007/BF03347697; BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Copp D H, 1970, Annu Rev Physiol, V32, P61, DOI 10.1146/annurev.ph.32.030170.000425; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gazit E, 2002, ANGEW CHEM INT EDIT, V41, P257, DOI 10.1002/1521-3773(20020118)41:2<257::AID-ANIE257>3.0.CO;2-M; Gazit E, 2002, CURR MED CHEM, V9, P1725; Gazit E, 2002, BIOINFORMATICS, V18, P880, DOI 10.1093/bioinformatics/18.6.880; Gross M, 1999, PROTEIN SCI, V8, P1350, DOI 10.1110/ps.8.6.1350; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; Kamihira M, 2000, PROTEIN SCI, V9, P867, DOI 10.1110/ps.9.5.867; KANAORI K, 1995, BIOCHEMISTRY-US, V34, P12138, DOI 10.1021/bi00038a006; Kapurniotu A, 2002, J MOL BIOL, V315, P339, DOI 10.1006/jmbi.2001.5244; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; KEIZMAN IK, 1976, ISRAEL J MED SCI, V12, P1137; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luckey M, 2000, FEBS LETT, V468, P23, DOI 10.1016/S0014-5793(00)01184-4; Lyon RP, 2001, J AM CHEM SOC, V123, P4408, DOI 10.1021/ja0040417; MAZOR Y, 2002, IN PRESS J MOL BIOL; MEADOWS RP, 1991, BIOCHEMISTRY-US, V30, P1247, DOI 10.1021/bi00219a012; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P10444, DOI 10.1021/bi00107a012; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P2364, DOI 10.1021/bi00223a010; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756-3282(02)00688-9	41	279	294	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35475	35480		10.1074/jbc.M206039200	http://dx.doi.org/10.1074/jbc.M206039200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095997	hybrid			2022-12-27	WOS:000178117000104
J	Varghese, J; Sade, H; Vandenabeele, P; Sarin, A				Varghese, J; Sade, H; Vandenabeele, P; Sarin, A			Head involution defective (Hid)-triggered apoptosis requires caspase-8 but not FADD (Fas-associated death domain) and is regulated by Erk in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; KINASE KINASE; CYTOCHROME-C; DROSOPHILA; PROTEIN; PATHWAY; HID; RAS; SURVIVAL; ACTIVATION	The molecular machinery of apoptosis is evolutionarily conserved with some exceptions. One such example is the Drosophila proapoptotic gene Head involution defective (Hid), whose mammalian homologue is not known. Hid is apoptotic to mammalian cells, and we have examined the mechanism by which Hid induces death. We demonstrate for the first time a role for the extracellular signal-related kinase-1/2 (Erk-1/2) in the regulation of Hid function in mammalian cells. Bcl-2 and an inhibitor of caspase-9 blocked apoptosis, indicative of a role for the mitochondrion in this pathway, and we provide evidence for a role for caspase-8 in Hid-induced apoptosis. Thus, apoptosis was blocked by an inhibitor of caspase-8, deletion of caspase-8 rendered cells resistant to Hid-induced apoptosis, and Hid associated with caspase-8 in cell lysates. The Fas-associated death domain (FADD) was dispensable for the apoptotic function of Hid, indicating that Hid does not require extracellular death receptor signaling for the activation of caspase-8. In activated T cells, the cytokine interleukin-2 blocked caspase-8 processing and apoptosis, suggesting that survival cues from trophic factors may target a Hid-like intermediate present in mammalian cells. Thus, this study shows that Hid engages with conserved components of cellular death machinery and suggests that apoptotic paradigms characterized by FADD-independent activation of caspase-8 may involve a Hid-like molecule in mammalian cells.	Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Dept Mol Biol, Mol Signalling & Cell Death Unit, B-9000 Ghent, Belgium	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore	Sarin, A (corresponding author), Univ Agr Sci Bangalore, Natl Ctr Biol Sci, GKVK Campus, Bangalore 560065, Karnataka, India.		Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Varghese, Jishy/0000-0002-5947-3094				Alnemri ES, 1999, NAT CELL BIOL, V1, pE40, DOI 10.1038/10034; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bantel H, 1999, CANCER RES, V59, P2083; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen P, 2000, J CELL BIOL, V148, P625, DOI 10.1083/jcb.148.4.625; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; De Laurenzi V, 2000, NATURE, V406, P135, DOI 10.1038/35018190; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hisahara S, 1998, J CELL SCI, V111, P667; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McNeill H, 1999, CURR BIOL, V9, pR176, DOI 10.1016/S0960-9822(99)80107-9; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SARIN A, 1995, J IMMUNOL, V154, P5806; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van Parijs L, 1998, SCIENCE, V280, P243; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	44	12	12	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35097	35104		10.1074/jbc.M206445200	http://dx.doi.org/10.1074/jbc.M206445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122017	hybrid			2022-12-27	WOS:000178117000056
J	Huang, CYF; Wu, YM; Hsu, CY; Lee, WS; Lai, MD; Lu, TJ; Huang, CL; Leu, TH; Shih, HM; Fang, HI; Robinson, DR; Kung, HJ; Yuan, CJ				Huang, CYF; Wu, YM; Hsu, CY; Lee, WS; Lai, MD; Lu, TJ; Huang, CL; Leu, TH; Shih, HM; Fang, HI; Robinson, DR; Kung, HJ; Yuan, CJ			Caspase activation of mammalian Sterile 20-like kinase 3 (Mst3) - Nuclear translocation and induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; FOCAL ADHESION KINASE; MEDIATED ACTIVATION; PROTEOLYTIC ACTIVATION; CELL-DEATH; C-DELTA; CASPASE-3-MEDIATED CLEAVAGE; STE20-RELATED KINASE; ROCK-I; PHOSPHORYLATION	Mammalian Sterile 20-like kinase 3 (Mst3), the physiological functions of which are unknown, is a member of the germinal center kinase-III family. It contains a conserved kinase domain at its NH2 terminus, whereas there is a regulatory domain at its COOH terminus. In this study we demonstrate that endogenous Mst3 is specifically cleaved when Jurkat cells were treated with anti-Fas antibody or staurosporine and that this cleavage is inhibited by the caspase inhibitor, Ac-DEVD-CHO. Using apoptotic Jurkat cell extracts and recombinant caspases, we mapped the caspase cleavage site, AETD(313), which is at the junction of the NH2-terminal kinase domain and the COOH-terminal regulatory domain. Caspase-mediated cleavage of. Mst3 activates its intrinsic kinase activity, suggesting that the COOH-terminal domain of Mst3 negatively regulates the kinase domain. Furthermore, proteolytic removal of the Mst3 COOH-terminal domain by caspases promotes nuclear translocation. Ectopic expression of either wild-type or COOH-terminal truncated Mst3 in cells results in DNA fragmentation and morphological changes characteristic of apoptosis. By contrast, no such changes were exhibited for catalytically inactive Mst3, implicating the involvement of Mst3 kinase activity for mediation of these effects. Collectively, these results support the notion that caspase-mediated proteolytic activation of Mst3 contributes to apoptosis.	Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; China Jr Coll Med Technol, Dept Med Technol, Tainan 717, Taiwan; Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University; University of California System; University of California Davis; University of California System; University of California Davis	Yuan, CJ (corresponding author), Natl Chiao Tung Univ, Dept Biol Sci & Technol, 75 Po Ai St, Hsinchu 300, Taiwan.		Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022; Lai, Ming-Derg/M-8028-2014; Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; 				Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GLUCKSMANN A., 1965, AFCH BIOL, V76, P419; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Kakeya H, 1998, CANCER RES, V58, P4888; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rubtsov YP, 1997, FEBS LETT, V413, P135, DOI 10.1016/S0014-5793(97)00824-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; SARRAF CE, 1988, CELL TISSUE KINET, V21, P45, DOI 10.1111/j.1365-2184.1988.tb00770.x; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sekimoto T, 1998, CYTOKINE GROWTH F R, V9, P205, DOI 10.1016/S1359-6101(98)00012-4; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRUMAN JW, 1984, ANNU REV NEUROSCI, V7, P171; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Willett CG, 1999, CURR CLIN ONCOL, V1, P65; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	55	147	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34367	34374		10.1074/jbc.M202468200	http://dx.doi.org/10.1074/jbc.M202468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107159	hybrid			2022-12-27	WOS:000177959100109
J	Loranger, SS; Linder, ME				Loranger, SS; Linder, ME			SNAP-25 traffics to the plasma membrane by a syntaxin-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SNARE COMPLEX; PROTEIN SNAP-25; FUSION COMPLEX; PALMITOYLATION; BINDING; TRANSPORT; EXOCYTOSIS; COMPONENT; SYNDET; OCCURS	SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) are essential for vesicle docking and fusion. SNAP-25, syntaxin 1A, and synaptobrevin/vesicle-associated membrane protein (VAMP) are SNARE proteins that mediate fusion of synaptic vesicles with the plasma membrane. It has been proposed that interactions of SNAP-25 with syntaxin 1A are required for initial membrane attachment of SNAP-25 (Vogel, K., Cabaniols, J.-P., and Roche, P. (2000) J. Biol. Chem. 275, 2959-2965). However, we have shown previously that residues 85-120 of the SNAP-25 interhelical domain, which do not interact with syntaxin, are necessary and sufficient for palmitoylation and plasma membrane localization of a green fluorescent protein reporter molecule (Gonzalo, S., Greentree, W. K., and Linder, M. E. (1999) J. BioL Chem. 274, 21313-21318). To clarify the role of syntaxin in membrane targeting of SNAP-25, we studied a SNAP-25 point mutant (G43D) that does not interact with syntaxin. SNAP-25 G43D/green fluorescent protein was palmitoylated and localized at the plasma membrane. Newly synthesized SNAP-25 G43D had the same kinetics of membrane association as the wild-type protein. Furthermore, expression of a cytosolic mutant syntaxin 1A did not interfere with SNAP-25 membrane interactions or palmitoylation in the neuronal cell line NG108-15. Exogenously expressed SNAP-25 targets efficiently to the plasma membrane in cells of neuronal origin but only partially in HeLa cells, a neurosecretion-incompetent line. This phenotype was not rescued when syntaxin 1A was co-expressed with SNAP-25. Our data support a syntaxin-independent mechanism of membrane targeting for SNAP-25.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8228, St Louis, MO 63110 USA.	mlinder@cellbio.wustl.edu	Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NIGMS NIH HHS [T32 GM 07067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Gonelle-Gispert C, 2000, J CELL SCI, V113, P3197; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Lane SR, 1997, J NEUROCHEM, V69, P1864; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; Rowe J, 1999, J CELL SCI, V112, P1865; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Veit M, 2000, BIOCHEM J, V345, P145, DOI 10.1042/0264-6021:3450145; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x	34	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34303	34309		10.1074/jbc.M202125200	http://dx.doi.org/10.1074/jbc.M202125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114505	hybrid			2022-12-27	WOS:000177959100101
J	Shimizugawa, T; Ono, M; Shimamura, M; Yoshida, K; Ando, Y; Koishi, R; Ueda, K; Inaba, T; Minekura, H; Kohama, T; Furukawa, H				Shimizugawa, T; Ono, M; Shimamura, M; Yoshida, K; Ando, Y; Koishi, R; Ueda, K; Inaba, T; Minekura, H; Kohama, T; Furukawa, H			ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-C-III; TRANSGENIC MICE; HEPATIC LIPASE; SERUM; METABOLISM; PLASMA; LIPIDS; HYPERTRIGLYCERIDEMIA; ANGIOPOIETIN-1; OVEREXPRESSION	KK/San is a mutant mouse strain established in our laboratory from KK obese mice. KK/San mice show low plasma lipid levels compared with wild-type KK mice despite showing signs of hyperglycemia and hyperinsulinemia. Recently, we identified a mutation in the gene encoding angiopoietin-like protein 3 (Angptl3) in KK/San mice, and injection of adenoviruses encoding Angptl3 or recombinant ANGPTL3 protein to mutant KK/San mice raised plasma lipid levels. To elucidate the regulatory mechanism of ANGPTL3 on lipid metabolism, we focused on the metabolic pathways of triglyceride in the present study. Overexpression of Angptl3 in KK/San mice resulted in a marked increase of triglyceride-enriched very low density lipoprotein (VLDL). In vivo studies using Triton WR1339 revealed that there is no significant difference between mutant and wild-type KK mice in the hepatic VLDL triglyceride secretion rate. However, turnover studies using radiolabeled VLDL revealed that the clearance of 3 H-triglyceride-labeled VLDL was significantly enhanced in KK/San mice, whereas the clearance of 125 I-labeled VLDL was only slightly enhanced. In vitro analysis of recombinant protein revealed that ANGPTL3 directly inhibits LPL activity. These data strongly support the hypothesis that ANGPTL3 is a new class of lipid metabolism modulator, which regulates VLDL triglyceride levels through the inhibition of LPL activity.	Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Shimizugawa, T (corresponding author), Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.			Kohama, Takafumi/0000-0002-6822-8170; Ando, Yukio/0000-0001-7115-9105				Amar MJA, 1998, J LIPID RES, V39, P2436; AUSTIN MA, 1987, AM J EPIDEMIOL, V125, P308, DOI 10.1093/oxfordjournals.aje.a114531; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUCHER KD, 1988, GENET EPIDEMIOL, V5, P17, DOI 10.1002/gepi.1370050103; CRAWFORD GA, 1981, CLIN SCI, V60, P73, DOI 10.1042/cs0600073; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; Jong MC, 1996, J CLIN INVEST, V98, P2259, DOI 10.1172/JCI119036; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Kondo K., 1957, B EXP ANIM, V6, P107; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MCCONATHY WJ, 1992, J LIPID RES, V33, P995; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MURASE T, 1975, METABOLISM, V24, P1279, DOI 10.1016/0026-0495(75)90066-9; NAKAMURA M, 1962, P JPN ACAD, V38, P348, DOI 10.2183/pjab1945.38.348; Nakamura M, 1967, Diabetologia, V3, P212, DOI 10.1007/BF01222198; Naoumova RP, 2002, LANCET, V359, P2215, DOI 10.1016/S0140-6736(02)09315-7; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Okazaki M, 1998, J CHROMATOGR B, V709, P179, DOI 10.1016/S0378-4347(98)00064-4; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P321, DOI 10.1113/jphysiol.1967.sp008211; PERUSSE L, 1989, ARTERIOSCLEROSIS, V9, P308, DOI 10.1161/01.ATV.9.3.308; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; Reue K, 1996, J LIPID RES, V37, P1387; RICE T, 1991, HUM HERED, V41, P107, DOI 10.1159/000153987; Rossetti L, 2002, NAT MED, V8, P112, DOI 10.1038/nm0202-112; SHIRAKI T, 1993, DIABETES FRONTIER, V4, P641; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; Welch CL, 1996, J LIPID RES, V37, P1406	35	271	299	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33742	33748		10.1074/jbc.M203215200	http://dx.doi.org/10.1074/jbc.M203215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097324	hybrid			2022-12-27	WOS:000177959100030
J	Lorey, S; Faust, J; Mrestani-Klaus, C; Kahne, T; Ansorge, S; Neubert, K; Buhling, F				Lorey, S; Faust, J; Mrestani-Klaus, C; Kahne, T; Ansorge, S; Neubert, K; Buhling, F			Transcellular proteolysis demonstrated by novel cell surface-associated substrates of dipeptidyl peptidase IV (CD26)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FLAVOBACTERIUM-MENINGOSEPTICUM; FLUOROGENIC SUBSTRATE; SERINE PROTEINASES; FUNCTIONAL-ROLE; T-LYMPHOCYTES; HUMAN SERUM; RAT-LIVER; EXPRESSION; RHODAMINE	Proteolytic enzymes contribute to the regulation of cellular functions such as cell proliferation and death, cytokine production, and matrix remodeling. Dipeptidyl peptidase IV (DP IV) catalyzes the cleavage of several cytokines and thereby contributes to the regulation of cytokine production and the proliferation of immune cells. Here we show for the first time that cell surface-bound DP IV catalyzes the cleavage of specific substrates that are associated with the cellular surface of neighboring cells. Rhodamine 110 (R110), a highly fluorescent xanthene dye, was used to synthesize dipeptidyl peptidase IV (DP IV/CD26) substrates Gly(Ala)-Pro-R110-R, thus facilitating a stable binding of the fluorescent moiety on the cell surface. The fixation resulted from the interaction with the reactive anchor rhodamine and allowed the quantification of cellular DP IV activity on single cells. The reactivity, length, and hydrophobicity of rhodamine was characterized as the decisive factor that facilitated the determination of cellular DP IV activity. Using fluorescence microscopy, it was possible to differentiate between different DP IV activities. The hydrolysis of cell-bound substrates Xaa-Pro-R110-R by DP IV of neighboring cells and by soluble DP IV was shown using flow cytometry. These data demonstrate that ectopeptidases such as DP IV may be involved in communication between blood cells via proteolysis of cell-associated substrates.	Univ Halle Wittenberg, Inst Biochem, Dept Biochem & Biotechnol, D-06120 Halle Saale, Germany; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany	Martin Luther University Halle Wittenberg; Otto von Guericke University; Otto von Guericke University	Lorey, S (corresponding author), Univ Halle Wittenberg, Inst Biochem, Dept Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle Saale, Germany.		Kaehne, Thilo/E-4858-2012					ASSFALGMACHLEIDT I, 1992, BIOL CHEM H-S, V373, P433, DOI 10.1515/bchm3.1992.373.2.433; Blanco J, 1998, EUR J BIOCHEM, V256, P369, DOI 10.1046/j.1432-1327.1998.2560369.x; Born Ilona, 1994, European Journal of Cell Biology, V63, P23; BRYNES PJ, 1981, ANAL BIOCHEM, V116, P408, DOI 10.1016/0003-2697(81)90381-X; BUHLING F, 1994, NAT IMMUN, V13, P270; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; DANG NH, 1991, J IMMUNOL, V147, P2825; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1994, BIOCHEM BIOPH RES CO, V203, P1224, DOI 10.1006/bbrc.1994.2313; DEFFNER M, 1974, METHODEN ORGANISCHEN; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; FUJIWARA T, 1992, BIOCHEM BIOPH RES CO, V185, P776, DOI 10.1016/0006-291X(92)91693-K; GOSSRAU R, 1985, HISTOCHEM J, V17, P737, DOI 10.1007/BF01003312; HEINS J, 1988, BIOCHIM BIOPHYS ACTA, V954, P161, DOI 10.1016/0167-4838(88)90067-2; HONG WJ, 1989, BIOCHEMISTRY-US, V28, P8474, DOI 10.1021/bi00447a030; HOPSUHAV.VK, 1966, HISTOCHEMISTRY, V7, P197, DOI 10.1007/BF00577838; Hug H, 1999, BIOCHEMISTRY-US, V38, P13906, DOI 10.1021/bi9913395; IKEHARA Y, 1994, METHOD ENZYMOL, V244, P215; Iwaki-Egawa S, 1998, J BIOCHEM, V124, P428, DOI 10.1093/oxfordjournals.jbchem.a022130; Juillerat-Jeanneret L, 1997, J LAB CLIN MED, V130, P603, DOI 10.1016/S0022-2143(97)90110-4; Kahne T, 1999, INT J MOL MED, V4, P3; Klobusicka M, 1999, Gen Physiol Biophys, V18 Suppl 1, P34; KOJIMA K, 1979, ANAL BIOCHEM, V100, P43, DOI 10.1016/0003-2697(79)90106-4; KUHN J, 1999, CELL IMMUNOL, V192, P33; LEYTUS SP, 1983, BIOCHEM J, V209, P299, DOI 10.1042/bj2090299; LEYTUS SP, 1983, BIOCHEM J, V215, P253, DOI 10.1042/bj2150253; Liu JX, 1999, BIOORG MED CHEM LETT, V9, P3231; Lorey S, 1997, ADV EXP MED BIOL, V421, P157; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; OGATA S, 1989, J BIOL CHEM, V264, P3596; OHKUBO I, 1994, J BIOCHEM-TOKYO, V116, P1182, DOI 10.1093/oxfordjournals.jbchem.a124647; Reinhold D, 1997, IMMUNOL LETT, V58, P29, DOI 10.1016/S0165-2478(97)02716-8; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; ROTHE G, 1992, BIOL CHEM H-S, V373, P547, DOI 10.1515/bchm3.1992.373.2.547; Ruiz P, 1998, CYTOMETRY, V34, P30, DOI 10.1002/(SICI)1097-0320(19980215)34:1<30::AID-CYTO5>3.0.CO;2-I; SANDSTROM C, 1976, INT J CANCER, V17, P565; SCHON E, 1990, BIOL CHEM H-S, V371, P699, DOI 10.1515/bchm3.1990.371.2.699; Stano J, 1997, PHARMAZIE, V52, P319; ULBRICHT B, 1995, BIOL CHEM H-S, V376, P407, DOI 10.1515/bchm3.1995.376.7.407; VanNoorden CJF, 1997, ANAL BIOCHEM, V252, P71, DOI 10.1006/abio.1997.2312; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; YOSHIMOTO T, 1982, J BIOCHEM, V91, P1899, DOI 10.1093/oxfordjournals.jbchem.a133884	44	17	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33170	33177		10.1074/jbc.M200798200	http://dx.doi.org/10.1074/jbc.M200798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12095981	hybrid			2022-12-27	WOS:000177859000100
J	Doublet, P; Grangeasse, C; Obadia, B; Vaganay, E; Cozzone, AJ				Doublet, P; Grangeasse, C; Obadia, B; Vaganay, E; Cozzone, AJ			Structural organization of the protein-tyrosine autokinase Wzc within Escherichia coli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE BIOSYNTHESIS; BACTERIUM ACINETOBACTER-JOHNSONII; STREPTOCOCCUS-PNEUMONIAE; AUTOPHOSPHORYLATING PROTEIN; CROSS-LINKING; EXOP PROTEIN; PHOSPHORYLATION; EXPRESSION; KINASE; EXOPOLYSACCHARIDE	Protein Wzc from Escherichia coli is a member of a newly defined family of protein-tyrosine autokinases that are essential for surface polysaccharide production in both Gram-negative and Gram-positive bacteria. Although the catalytic mechanism of the autophosphorylation of Wzc was recently described, the in vivo structural organization of this protein remained unclear. Here, we have determined the membrane topology of Wzc by performing translational fusions of lacZ and phoA reporter genes to the wzc gene. It has been shown that Wzc consists of two main structural domains: an N-terminal domain, bordered by two transmembrane helices, which is located in the periplasm of cells, and a C-terminal domain, harboring all phosphorylation sites of the protein, which is located in the cytoplasm. In addition, it has been demonstrated for the first time that Wzc can oligomerize in vivo to form essentially trimers and hexamers. Cross-linking experiments performed on strains expressing various domains of Wzc have shown that the cytoplasmic C-terminal domain is sufficient to generate oligomerization of Wzc. Mutant proteins, modified in either the ATP-binding site or the different phosphorylation sites, i.e. rendered unable to undergo autophosphorylation, have appeared to oligomerize into high molecular mass species identical to those formed by the wild-type protein. It was concluded that phosphorylation of Wzc is not essential to its oligomerization. These data, connected with the phosphorylation mechanism of Wzc, may be of biological significance in the regulatory role played by this kinase in polysaccharide synthesis.	Univ Lyon, Inst Biol & Chim Prot, CNRS, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS)	Cozzone, AJ (corresponding author), Univ Lyon, Inst Biol & Chim Prot, CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.	aj.cozzone@ibcp.fr	Doublet, Patricia/L-9480-2014	Doublet, Patricia/0000-0001-5848-4317; Grangeasse, Christophe/0000-0002-5484-4589				AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; BAYER ME, 1977, J BACTERIOL, V130, P911, DOI 10.1128/JB.130.2.911-936.1977; BECKER A, 1995, MOL MICROBIOL, V16, P191, DOI 10.1111/j.1365-2958.1995.tb02292.x; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; Bender MH, 2001, J BIOL CHEM, V276, P47966, DOI 10.1074/jbc.M105448200; BINGLE WH, 1993, CAN J MICROBIOL, V39, P70, DOI 10.1139/m93-010; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Duclos B, 1996, J MOL BIOL, V259, P891, DOI 10.1006/jmbi.1996.0366; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Grangeasse C, 1999, IUBMB LIFE, V48, P339; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBlanc HN, 1996, J BACTERIOL, V178, P4801, DOI 10.1128/jb.178.16.4801-4806.1996; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller J. H, 1972, EXPT MOL GENETICS; Morona JK, 1999, J BACTERIOL, V181, P5355, DOI 10.1128/JB.181.17.5355-5364.1999; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 2002, J BACTERIOL, V184, P577, DOI 10.1128/JB.184.2.577-583.2002; Niemeyer D, 2001, J BACTERIOL, V183, P5163, DOI 10.1128/JB.183.17.5163-5170.2001; Preneta R, 2002, COMP BIOCHEM PHYS B, V131, P103, DOI 10.1016/S1096-4959(01)00490-0; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37339	37348		10.1074/jbc.M204465200	http://dx.doi.org/10.1074/jbc.M204465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138098	hybrid			2022-12-27	WOS:000178447100056
J	Du, K; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Laburthe, M				Du, K; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Laburthe, M			Human VPAC1 receptor selectivity filter - Identification of a critical domain for restricting secretin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-COUPLED RECEPTORS; N-TERMINAL DOMAIN; ADENYLATE-CYCLASE; FUNCTIONAL EXPRESSION; AGONIST BINDING; VIP RECEPTOR; CLONING; MEMBERS	The human VPAC1 receptor for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) belongs to the class II family of G protein coupled receptors with seven transmembrane segments. It recognizes several VIP-related peptides and displays a very low affinity for secretin despite >70% homology between VIP and secretin. Conversely, the human secretin receptor has high affinity for secretin but low affinity for VIP. We took advantage of this reversed selectivity to identify a domain of the VPAC1 receptor responsible for selectivity toward secretin by constructing human VPAC1-secretin receptor chimeras. A first set of chimeras consisted of exchanging the entire N-terminal ectodomain or large parts of this domain. They were constructed by overlap PCR, transfected in COS-7 cells, and their ligand selectivity, expressed as the ratio of EC50 for secretin/EC50 for VIP (referred to as S/V), in stimulating cAMP production was measured. Two very informative chimeras respectively referred to as S144V and S123V were obtained by replacing the entire ectodomain or only the first 123 amino acids of the VPAC1 receptor by the corresponding sequences of the secretin receptor. Whereas S144V no longer discriminated between VIP and secretin (S/V = 1.2), S123V discriminated between the two peptides (S/V = 300) in the same manner as the wild-type VPAC1 receptor. The motif responsible for discrimination was determined by introducing small blocks or individual amino acids of secretin receptor in the 123-144 sequence of the S123V chimera. The data obtained from 14 new chimeras sustained that two nonadjacent pairs of amino acids, Gln(135) Thr(136) and Gly(140) Ser(141) in the C-terminal end of the N-terminal VPAC1 receptor ectodomain constitute a selective filter that strongly restricts access of secretin to the VPAC1 receptor.	Univ Paris 07, INSERM, Unite Neuroendocrinol & Biol Cellulaire Digest U4, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Univ Paris 07, INSERM, Unite Neuroendocrinol & Biol Cellulaire Digest U4, F-75018 Paris, France.		couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JIANG SP, 1995, BIOCHEM BIOPH RES CO, V207, P883, DOI 10.1006/bbrc.1995.1268; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LABURTHE M, 2002, IN PRESS RECEPT CHAN; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LABURTHE M, 2002, IN PRESS ENDO SERIES; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Park CG, 2000, J PHARMACOL EXP THER, V295, P682; ROBBERECHT P, 1988, PANCREAS, V3, P529, DOI 10.1097/00006676-198810000-00004; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SALOMON R, 1993, AM J PHYSIOL, V264, pE294, DOI 10.1152/ajpendo.1993.264.2.E294; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895	21	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37016	37022		10.1074/jbc.M203049200	http://dx.doi.org/10.1074/jbc.M203049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133828	hybrid			2022-12-27	WOS:000178447100016
J	Angata, K; Suzuki, M; Fukuda, M				Angata, K; Suzuki, M; Fukuda, M			ST8Sia II and ST8Sia IV polysialyltransferases exhibit marked differences in utilizing various acceptors containing oligosialic acid and short polysialic acid - The basis for cooperative polysialylation by two enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; CENTRAL-NERVOUS-SYSTEM; N-CAM; 2 POLYSIALYLTRANSFERASES; SYNAPTIC PLASTICITY; NEURITE OUTGROWTH; IN-VITRO; STX; EXPRESSION	Polysialylation of the neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development. Two polysialyltransferases, ST8Sia 11 and ST8Sia IV, play dominant roles in polysialic acid synthesis on NCAM. However, the individual roles and mechanisms by which these two enzymes form large amounts of polysialic acid on NCAM were heretofore unknown. Previous studies indicate that ST8Sia IV forms more highly polysialylated N-glycans on NCAM than ST8Sia II in vitro. In the present study, we first demonstrated that a combination of STSSia 11 and STSSia IV cooperatively polysialylated NCAM, resulting in NCAM N-glycans containing more, and thus longer, polysialic acid than when the enzymes were used individually. There was also an increase in polysialylated NCAM when we used ST8Sia 11 and ST8Sia IV sequentially, whereas there appeared to be a subtle increase when the enzymes were used in the reverse order. Furthermore, ST8Sia IV was able to add polysialic acid to oligosialylated oligosaccharides and unpolysialylated antennas in N-glycans attached to NCAM, even when polysialic acid was attached to at least one of the other antennas. By contrast, ST8Sia 11 added little polysialic acid to the same acceptors. On the other hand, neither ST8Sia 11 nor ST8Sia IV could add polysialic acid to a polysialylated antenna of NCAM N-glycans. These combined results indicate that the synergistic effect of ST8Sia 11 and ST8Sia IV is caused by: 1) the ability of ST8Sia IV to add polysialic acid to oligosialic acid formed by STSSia 11, 2) the potential of ST8Sia IV to act on more antennas of N-glycans than ST8Sia 11, and 3) the ability of ST8Sia 11 and ST8Sia IV in combination to act on the fifth and sixth N-glycosylation sites of NCAM.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NCI NIH HHS [CA 33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Bruses JL, 1998, J CELL BIOL, V140, P1177, DOI 10.1083/jcb.140.5.1177; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FINNE J, 1982, J BIOL CHEM, V257, P1966; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; Hildebrandt H, 1998, CANCER RES, V58, P779; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; IMMONS DL, 1993, CELLULAR INTERACTION, P93; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; Kitazume-Kawaguchi S, 2001, J BIOL CHEM, V276, P15696, DOI 10.1074/jbc.M010371200; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Phillips GR, 1997, DEV BRAIN RES, V102, P143, DOI 10.1016/S0165-3806(97)00069-2; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Tanaka F, 2000, CANCER RES, V60, P3072; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; von der Ohe M, 2002, GLYCOBIOLOGY, V12, P47, DOI 10.1093/glycob/12.1.47; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	52	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36808	36817		10.1074/jbc.M204632200	http://dx.doi.org/10.1074/jbc.M204632200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138100	hybrid			2022-12-27	WOS:000178275100132
J	Fjeldstad, K; Pedersen, ME; Vuong, TT; Kolsett, SO; Nordstrand, LM; Prydz, K				Fjeldstad, K; Pedersen, ME; Vuong, TT; Kolsett, SO; Nordstrand, LM; Prydz, K			Sulfation in the Golgi lumen of Madin-Darby canine kidney cells is inhibited by brefeldin A and depends on a factor present in the cytoplasm and on Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; HAMSTER OVARY CELLS; HEPARAN-SULFATE; CHONDROITIN SULFATE; MDCK CELLS; ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; SECRETORY PROTEINS; PAPS TRANSLOCASE; RAT HEPATOCYTES	Madin-Darby canine kidney cells are more resistant than most other cell types to the classical effects of brefeldin A (BFA) treatment, the induction of retrograde transport of Golgi cisternae components to the endoplasmic reticulum. Here we show that sulfation of heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), and proteins in the Golgi apparatus is dramatically reduced by low concentrations of BFA in which Golgi morphology is unaffected and secretion still takes place. BFA treatment seems to reduce sulfation by inhibition of the uptake of adenosine W-phosphate 5'-phosphosulfate (PAPS) into the Golgi lumen, and the inhibitory effect of BFA was similar for HSPGs, CSPGs, and proteins. This was different from the effect of chlorate, a well known inhibitor of PAPS synthesis in the cytoplasm. Low concentrations of chlorate (2-5 nM) inhibited sulfation of CSPGs and proteins only, whereas higher concentrations (15-30 nM) were required to inhibit sulfation of HSPGs. Golgi fractions pretreated with BFA had a reduced Capacity for the synthesis of glycosaminoglycans (GAGs), but control level capacity could be restored by the addition of cytosol from various sources. This indicates that the PAPS pathway to the Golgi lumen depends on a BFA-sensitive factor that is present both on Golgi membranes and in the cytoplasm.	Univ Oslo, Dept Biochem, N-0316 Oslo, Norway; Univ Oslo, Inst Nutr Res, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Prydz, K (corresponding author), Univ Oslo, Dept Biochem, N-0316 Oslo, Norway.							BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAUERLE PA, 1987, J CELL BIOL, V105, P2655; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CALABRO A, 1994, J BIOL CHEM, V269, P22764; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garred O, 2001, TRAFFIC, V2, P26, DOI 10.1034/j.1600-0854.2001.020105.x; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Halvorsen B, 1999, BIOCHEM J, V343, P533, DOI 10.1042/0264-6021:3430533; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; Kolset SO, 2002, BIOCHEM J, V362, P359, DOI 10.1042/0264-6021:3620359; Kolset SO, 1999, J CELL SCI, V112, P1797; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; Prydz K, 2000, J CELL SCI, V113, P193; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGUMARAN G, 1995, J BIOL CHEM, V270, P22483, DOI 10.1074/jbc.270.38.22483; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; VOS JP, 1994, BBA-LIPID LIPID MET, V1211, P125, DOI 10.1016/0005-2760(94)90262-3	42	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36272	36279		10.1074/jbc.M206365200	http://dx.doi.org/10.1074/jbc.M206365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138122	hybrid			2022-12-27	WOS:000178275100063
J	Gogg, S; Smith, U				Gogg, S; Smith, U			Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; TRANSGENIC 3T3-L1 ADIPOCYTES; INDUCED GLUCOSE-TRANSPORT; PROTEIN-KINASE-B; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; FACTOR RECEPTORS; MOLECULAR MECHANISMS; DIABETES-MELLITUS; DOCKING PROTEIN; RAT ADIPOCYTES	The ability of the growth factors epidermal growth factor (EGF), transforming growth factor a, and platelet-derived growth factor to exert insulin-like effects on glucose transport and lipolysis were examined in human and rat fat cells. No effects were found in rat fat cells, whereas EGF (EC50 for glucose transport similar to0.02 nm) and transforming growth factor alpha (EC50 similar to0.2 nM), but not platelet-derived growth factor, mimicked the effects of insulin (EC50 similar to0.2 nM) on both pathways. EGF receptors, but not EGF, were abundantly expressed in human fat cells as well as in human skeletal muscle. EGF increased the tyrosine phosphorylation of several proteins (the EGF receptor, insulin receptor substrate (IRS)-1, IRS-2, and Grb2-associated binder 1), whereas She and Gab2 were only weakly and inconsistently phosphorylated. p85, the regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), was also found to associate with all of these docking molecules, showing that EGF activated PI 3-kinase pools that were additional to those of insulin. EGF and/or insulin increased protein kinase B/Akt serine phosphorylation to a similar extent, whereas mitogen-activated protein kinase phosphorylation was more pronounced for EGF than for insulin. The impaired insulin-stimulated downstream signaling, measured as protein kinase B/Akt serine phosphorylation, in insulin-resistant cells (Type 2 diabetes) was improved by the addition of EGF. Thus, EGF receptors, but not EGF, are abundantly expressed in human fat cells and skeletal muscle. EGF mimics the effects of insulin on both the metabolic and mitogenic pathways but utilize in part different signaling pathways. Both insulin and EGF increase the tyrosine phosphorylation and activation of IRS-1 and IRS-2, whereas EGF is also capable of activating additional PI 3-kinase pools and, thus, can augment the downstream signaling of insulin in insulin-resistant states like Type 2 diabetes.	Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, Dept Internal Med, SE-41345 Gothenburg, Sweden.		Gogg, Silvia/R-4549-2019					Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; Carvalho E, 2000, DIABETOLOGIA, V43, P1107, DOI 10.1007/s001250051501; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Fujioka T, 2001, EUR J BIOCHEM, V268, P4158, DOI 10.1046/j.1432-1327.2001.02327.x; Fujioka T, 2001, EUR J BIOCHEM, V268, P25, DOI 10.1046/j.1432-1327.2001.01831.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hill MM, 1999, MOL CELL BIOL, V19, P7771; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; OKADA T, 1994, J BIOL CHEM, V269, P3568; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Rondinone CM, 1999, DIABETOLOGIA, V42, P819, DOI 10.1007/s001250051232; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SIMPSON IA, 1984, DIABETES, V33, P13, DOI 10.2337/diabetes.33.1.13; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; SMITH U, 1972, J LIPID RES, V13, P822; STAGSTED J, 1993, J BIOL CHEM, V268, P1770; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VanEppsFung M, 1996, DIABETES, V45, P1619, DOI 10.2337/diabetes.45.11.1619; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	48	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36045	36051		10.1074/jbc.M200575200	http://dx.doi.org/10.1074/jbc.M200575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138086	hybrid			2022-12-27	WOS:000178275100037
J	MacFarlane, M; Merrison, W; Bratton, SB; Cohen, GM				MacFarlane, M; Merrison, W; Bratton, SB; Cohen, GM			Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT CASPASE CASCADES; PROTEIN LIGASE ACTIVITY; CYTOCHROME-C; SERINE-PROTEASE; STRUCTURAL BASIS; DEATH RECEPTORS; ACTIVE CASPASES; CELL-DEATH; ACTIVATION; MITOCHONDRIA	During apoptosis, Smac (second mitochondria-derived activator of caspases)/DIABLO, an IAP (inhibitor of apoptosis protein)-binding protein, is released from mitochondria and potentiates apoptosis by relieving IAP inhibition of caspases. We demonstrate that exposure of MCF-7 cells to the death-inducing ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), results in rapid Smac release from mitochondria, which occurs before or in parallel with loss of cytochrome c. Smac release is inhibited by Bcl-2/Bcl-xL or by a pan-caspase inhibitor demonstrating that this event is caspase-dependent and modulated by Bcl-2 family members. Following release, Smac is rapidly degraded by the proteasome, an effect suppressed by co-treatment with a proteasome inhibitor. As the RING finger domain of XIAP possesses ubiquitin-protein ligase activity and XIAP binds tightly to mature Smac, an in vitro ubiquitination assay was performed which revealed that XIAP functions as a ubiquitin-protein ligase (E3) in the ubiquitination of Smac. Both the association of XIAP with Smac and the RING finger domain of XIAP are essential for ubiquitination, suggesting that the ubiquitin-protein ligase activity of XIAP may promote the rapid degradation of mitochondrial-released Smac. Thus, in addition to its well characterized role in inhibiting caspase activity, XIAP may also protect cells from inadvertent mitochondrial damage by targeting pro-apoptotic molecules for proteasomal degradation.	Univ Leicester, MRC Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008	Bratton, Shawn/0000-0003-2895-5020				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang HK, 2000, J BIOL CHEM, V275, P26661; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	47	238	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36611	36616		10.1074/jbc.M200317200	http://dx.doi.org/10.1074/jbc.M200317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121969	hybrid			2022-12-27	WOS:000178275100105
J	Chiang, TM; Cole, F; Woo-Rasberry, V				Chiang, TM; Cole, F; Woo-Rasberry, V			Cloning, characterization, and functional studies of a 47-kDa platelet receptor for type III collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I COLLAGEN; REACTIVE SITES; SEQUENCE	A 1.2-kb cDNA fragment encoding a platelet 47-kDa protein has been isolated from a human bone marrow cDNA library by using a degenerate oligonucleotide of the sequenced amino terminus of the purified platelet protein with a poly(dT)(12).(dG) by polymerase chain reaction. A computer search revealed that the cDNA represents the coding sequence of a protein with a fragmentary homology to several proteins. Using a prokaryotic expression system, pBad TOPO-47 cDNA, a 47-kDa recombinant protein was obtained and purified to apparent homogeneity by nickel-nitrilotriacetic acid resin and collagen affinity column. The recombinant protein binds to type III but not type I collagen-Sepharose 2B affinity columns. Anti-47-kDa but not anti-65-kDa antibody inhibits the binding of the recombinant protein to the type III collagen-coated micro titer wells in a dose-dependent manner. Like the receptor protein purified from platelet membranes, the recombinant protein inhibits type III collagen-induced platelet aggregation also in a dose-dependent manner. We have defined two active peptides from the cloned deduced amino acid sequence. Both peptides inhibit type III but not type I collagen-induced platelet aggregation in a dose-dependent fashion. These results suggest that the active binding site of the platelet receptor to type III collagen resides in these portions of the protein.	Vet Affairs Med Ctr, Res Serv 151, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Chiang, TM (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	TChiang@utmen.edu						BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; Chiang TM, 1997, J CLIN INVEST, V100, P2079, DOI 10.1172/JCI119741; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; CHIANG TM, 1993, THROMB RES, V71, P443, DOI 10.1016/0049-3848(93)90118-8; CHIANG TM, 1975, J BIOL CHEM, V250, P6916; CHIANG TM, 1984, J IMMUNOL, V133, P872; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; KANG AH, 1969, BIOCHEMISTRY-US, V8, P3648, DOI 10.1021/bi00837a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; SEYER JM, 1980, BIOCHEMISTRY-US, V19, P1583, DOI 10.1021/bi00549a008; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	16	15	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34896	34901		10.1074/jbc.M205311200	http://dx.doi.org/10.1074/jbc.M205311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110681	hybrid			2022-12-27	WOS:000178117000032
J	Matsumoto, S; Tanaka, E; Nemoto, TK; Ono, T; Takagi, T; Imai, J; Kimura, Y; Yahara, I; Kobayakawa, T; Ayuse, T; Oi, K; Mizuno, A				Matsumoto, S; Tanaka, E; Nemoto, TK; Ono, T; Takagi, T; Imai, J; Kimura, Y; Yahara, I; Kobayakawa, T; Ayuse, T; Oi, K; Mizuno, A			Interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; STEROID-RECEPTOR; GLUCOCORTICOID RECEPTOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING; DOMAIN; SEQUENCE	At the primary structure level, the 90-kDa heat shock protein (HSP90) is composed of three regions: the N-terminal (Met(1)-Arg(400)), middle (Glu(401)-Lys(615)), and C-terminal (Asp(621)-Asp(732)) regions. In the present study, we investigated potential subregion structures of these three regions and their roles. Limited proteolysis revealed that the N-terminal region could be split into two fragments carrying residues Met(1) to Lys(281) (or Lys(283)) and Glu(282) (or Tyr(284)) to Arg(400). The former is known to carry the ATP-binding domain. The fragments carrying the N-terminal two-thirds (Glu(401)-Lys(546)) and C-terminal one-third of the middle region were sufficient for the interactions with the N- and C-terminal regions, respectively. Yeast HSC82 that carried point mutations in the middle region causing deficient binding to the N-terminal region could not support the growth of HSP82-depleted cells at an elevated temperature. Taken together, our data show that the N-terminal and middle regions of the HSP90 family protein are structurally divided into two respective subregions. Moreover, the interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 in yeast.	Nagasaki Univ, Sch Dent, Dept Oral Biochem, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Dent Anesthesiol, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Oral & Maxillofacial Surg 1, Nagasaki 8528588, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808578, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan; Med & Biol Lab Co Ltd, Ina Inst, Ina, Saitama 3960002, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Tohoku University; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Nemoto, TK (corresponding author), Nagasaki Univ, Sch Dent, Dept Oral Biochem, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.		Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753; Nemoto, Takayuki K./0000-0002-5007-6260				BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; Karimova G, 2001, J MOL MICROB BIOTECH, V3, P73; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1995, ANAL BIOCHEM, V227, P396, DOI 10.1006/abio.1995.1300; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nemoto T, 1997, J BIOL CHEM, V272, P26179, DOI 10.1074/jbc.272.42.26179; Nemoto T, 1996, J BIOCHEM-TOKYO, V120, P249; Nemoto TK, 2001, EUR J BIOCHEM, V268, P5258, DOI 10.1046/j.0014-2956.2001.02457.x; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V188, P424, DOI 10.1016/0006-291X(92)92402-J; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Tanaka E, 2001, EUR J BIOCHEM, V268, P5270, DOI 10.1046/j.0014-2956.2001.02458.x; YAMAZAKI M, 1990, AGR BIOL CHEM TOKYO, V54, P3163, DOI 10.1080/00021369.1990.10870468; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Yue L, 1999, GENETICS, V151, P1065	49	20	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34959	34966		10.1074/jbc.M203038200	http://dx.doi.org/10.1074/jbc.M203038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121981	Green Submitted, hybrid			2022-12-27	WOS:000178117000040
J	Sanceau, J; Boyd, DD; Seiki, M; Bauvois, B				Sanceau, J; Boyd, DD; Seiki, M; Bauvois, B			Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; GELATINASE-B; IFN-BETA; INFLAMMATORY CYTOKINES; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTORS; 92-KDA GELATINASE; TISSUE INHIBITORS; PROMOTER ACTIVITY; NUCLEAR-FACTOR	Enhanced expression of matrix metalloproteinase-9 (MMP-9) correlates with invasion during tumor progression. Interferons (IFNs) inhibit MMP-9 activation in response to tumor necrosis factor-alpha (TNF-alpha), and the latter activates the MMP-9 gene through NF-kappaB. Understanding the molecular basis for MMP-9 inhibition may provide tools to control cell invasion. The data reported here show the critical role of interferon regulatory factor-1 (IRF1) in the inhibition of MMP-9. (i) IFN treatment suppresses TNF-alpha-induced MMP-9 reporter activity in STAT1(+/+) cells but not in STAT1(-/-) cells. (ii) IRF1 transfection blocks TNF-alpha-mediated MMP-9 activation. (iii) IFNs phosphorylate STAT1 and induce IRF1 but do not affect Ikappa-B degradation nor NF-kappaB nuclear translocation. (iv) Nuclear NF-kappaB (p50/p65) and IRF1, but not STAT1, bind to the MMP-9 promoter region containing an IFN-responsive-like element overlapping the NF-kappaB-binding site. (v) Recombinant IRFI, although unable to bind to an NF-kappaB consensus sequence, competes with NF-kappaB proteins for binding to the MMP-9 promoter. (vi) Conversely recombinant p50/p65 proteins reduce IRFI-DNA binding. (vii) In cells cotransfected with IRF1 and/or p65 expression vectors, an excess of IRF1 reduces MMP-9 reporter activity, whereas an excess of p65 blocks the inhibitory effect of IFN-gamma. Thus, in contrast to the known synergism between IRF1 and NF-kappaB, our data identify a novel role for IRF1 as a competitive inhibitor of NF-kappaB binding to the particular MMP-9 promoter context.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center; University of Tokyo	Bauvois, B (corresponding author), Inst Curie, INSERM, U365, Sect Rech, Pavillon Pastuer,26 Rue Ulm, F-75248 Paris 05, France.		Seiki, Motoharu/K-9443-2015; Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; BARTHOLOME EJ, 2000, PHARM CYTOKINES, P279; BAUVOIS B, 2002, LEUKEMIA BALTIMORE, V16, P144; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BILLIAU A, 2000, PHARM CYTOKINES, P641; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dinney CPN, 1998, CANCER RES, V58, P808; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Imanishi D, 2000, J IMMUNOL, V165, P3907, DOI 10.4049/jimmunol.165.7.3907; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Kirchhoff S, 1999, EUR J BIOCHEM, V261, P546, DOI 10.1046/j.1432-1327.1999.00308.x; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; Kossakowska AE, 2000, LEUKEMIA LYMPHOMA, V39, P485, DOI 10.3109/10428190009113379; Kupferman ME, 2000, AM J PATHOL, V157, P1777, DOI 10.1016/S0002-9440(10)64815-8; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Lou JN, 1999, LAB INVEST, V79, P1015; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Makela M, 1998, BIOCHEM BIOPH RES CO, V253, P325, DOI 10.1006/bbrc.1998.9641; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; PINE R, 1997, NUCLEIC ACIDS RES, V25, P4338; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; SIM SH, 1993, MOL CELL BIOL, V13, P690; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Slaton JW, 2001, CLIN CANCER RES, V7, P2840; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Tossing G, 2001, EUR J MED RES, V6, P47; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200	59	92	93	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35766	35775		10.1074/jbc.M202959200	http://dx.doi.org/10.1074/jbc.M202959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105194	hybrid			2022-12-27	WOS:000178117000140
J	Hong, YS; Park, SY; Geng, CX; Baek, KH; Bowman, JD; Yoon, JS; Pak, WL				Hong, YS; Park, SY; Geng, CX; Baek, KH; Bowman, JD; Yoon, JS; Pak, WL			Single amino acid change in the fifth transmembrane segment of the TRP Ca2+ channel causes massive degeneration of photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-SENSITIVE CHANNELS; MOLECULAR CHARACTERIZATION; POTASSIUM CHANNEL; DROSOPHILA GENE; CALCIUM; SHAKER; HOMOLOGY; PROTEIN; STORE	The trp gene encodes subunits of a highly Ca2+-permeable class of light-activated channels of Drosophila photoreceptors. The recently characterized mutation in this gene, Trp(P365), is semidominant and causes massive degeneration of photoreceptors by making the TRP channel constitutively active. We show that a single amino acid change, Phe-550 to Ile, near the beginning of the fifth transmembrane domain of TRP channel subunits is necessary to induce, and sufficient to closely mimic, the original mutant phenotypes of Trp(P365). Hypotheses are presented as to why the amino acid residues at position 550 and its immediate vicinity might be important in influencing the regulation of the TRP channel and why the substitution of Phe for Ile at this position, in particular, could result in constitutive activity of the channel.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Kyung Hee Univ, Dept Genet Engn, Yongin 449471, Kyungki Do, South Korea; Kyung Hee Univ, Inst Genet Engn, Yongin 449471, Kyungki Do, South Korea	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Kyung Hee University; Kyung Hee University	Pak, WL (corresponding author), Purdue Univ, Dept Biol Sci, 1392 Lilly Hall, W Lafayette, IN 47907 USA.	wpak@biblo.bio.purdue.edu			NEI NIH HHS [EY 00033] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000033, R37EY000033, R56EY000033] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agam K, 2000, J NEUROSCI, V20, P5748, DOI 10.1523/JNEUROSCI.20-15-05748.2000; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Hardie RC, 1996, CURR BIOL, V6, P1371, DOI 10.1016/S0960-9822(96)00733-6; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MONTELL C, 2001, SCI STKE, V90, P1; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PERETZ A, 1994, J GEN PHYSIOL, V104, P1057, DOI 10.1085/jgp.104.6.1057; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHULZ GE, 1985, PRINCIPLES PROTEIN S, P11; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Yoon J, 2000, J NEUROSCI, V20, P649, DOI 10.1523/JNEUROSCI.20-02-00649.2000; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	28	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33884	33889		10.1074/jbc.M204075200	http://dx.doi.org/10.1074/jbc.M204075200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12107168	hybrid			2022-12-27	WOS:000177959100048
J	Qiu, HQ; Miller, WT				Qiu, HQ; Miller, WT			Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; CRYSTAL-STRUCTURE; SH2 DOMAIN; PROTEIN; FAMILY; HCK; ACTIVATION; BINDING; PHOSPHORYLATION; SITES	Brk (breast tumor kinase) is a nonreceptor tyrosine kinase that is most closely related to the Frk family of kinases, and more distantly to Src family kinases. Brk was originally identified in a screen for tyrosine kinases that are overexpressed in human metastatic breast tumors. To shed light on the activity and regulation of Brk and related tyrosine kinases, we expressed and purified Brk using the Sf9/baculovirus system. We characterized the substrate specificity of Brk using synthetic peptides, and we show that the kinetic parameters K-m and k(cat) both play a role in specificity. We carried out mass spectrometry experiments to show that Brk autophosphorylates within the predicted kinase activation loop and at additional sites in the N terminus. Autophosphorylation increases enzyme activity of wild-type Brk but not of a Y342A mutant form of Brk. We also carried out experiments to address the possible involvement of the Src homology (SH) 2 and SH3 domains of Brk in enzyme regulation. Mutation of a C-terminal tyrosine (Tyr-447) increases enzyme activity and SH2 domain accessibility, consistent with a role for this residue in autoinhibition. A proline-rich peptide activates Brk, suggesting that the SH3 domain is also involved in maintaining an inactive form of Brk. These biochemical results for Brk may aid in the understanding of other tyrosine kinases in the Frk family.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA 58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058530, R01CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LIU XQ, 1993, ONCOGENE, V8, P1119; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	36	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34634	34641		10.1074/jbc.M203877200	http://dx.doi.org/10.1074/jbc.M203877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12121988	hybrid			2022-12-27	WOS:000177959100138
J	Sauvaget, D; Chauffeton, V; Citadelle, D; Chatelet, FP; Cywiner-Golenzer, C; Chambaz, J; Pincon-Raymond, M; Cardot, P; Le Beyec, J; Ribeiro, A				Sauvaget, D; Chauffeton, V; Citadelle, D; Chatelet, FP; Cywiner-Golenzer, C; Chambaz, J; Pincon-Raymond, M; Cardot, P; Le Beyec, J; Ribeiro, A			Restriction of apolipoprotein A-IV gene expression to the intestine villus depends on a-hormone-responsive element and parallels differential expression of the hepatic nuclear factor 4 alpha and gamma isoforms.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; PHLORHIZIN HYDROLASE GENE; CIS-ACTING ELEMENTS; HUMAN APOCIII GENE; TRANSGENIC MICE; C-III; GUT EPITHELIUM; B GENE; TRANSCRIPTIONAL REGULATION; PROXIMAL PROMOTER	The apoA-I/C-III/A-IV gene cluster, like most intestine-specific genes, displays a specific pattern of expression along the intestinal cephalocaudal and crypt-to-villus axes. We have shown that this specific pattern of expression requires the distal apoA-IV promoter and the apoC-III enhancer. Using a new set of transgenic mice, we demonstrate here that the restriction of apoA-IV gene transcription to villus enterocytes requires a hormone-responsive element (HRE) located within the apoA-IV distal promoter. We showed, using nuclear extracts from villus or crypt epithelial cells, that this HRE bound the transcription factor hepatic nuclear factor 4 (HNF-4). We also found that the HNF-4gamma isoform was produced only in the villus, whereas the HNF-4alpha isoform was produced along the entire length of the crypt-to-villus axis. Our results demonstrate that the HRE of the distal apoA-IV promoter is responsible for the restriction of gene expression to villus epithelial cells and that this HRE binds HNF-4 isoforms. The in vivo observation of parallel gradients for apoA-IV and HNF-4gamma gene expression raises questions concerning whether this transcription factor plays a specific role in the control of enterocyte differentiation.	Univ Paris 06, INSERM, U 505, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Ribeiro, A (corresponding author), Univ Paris 06, INSERM, U 505, 15 Rue Ecole Med, F-75006 Paris, France.		Ribeiro, Agnès/Q-9702-2017	Ribeiro, Agnès/0000-0003-2063-6084; Le Beyec - Le Bihan, johanne/0000-0002-5647-2002				Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6720, DOI 10.1021/bi010073a; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; Antes TJ, 2000, J BIOL CHEM, V275, P26637, DOI 10.1074/jbc.M003025200; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BISAHA JG, 1995, J BIOL CHEM, V270, P19978; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Carriere V, 2001, BIOCHEM J, V354, P301, DOI 10.1042/0264-6021:3540301; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COLNOT S, 1998, J BIOL CHEM, V271, P16820; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; Drewes T, 1996, MOL CELL BIOL, V16, P925; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fitzgerald K, 1998, AM J PHYSIOL-GASTR L, V274, pG314, DOI 10.1152/ajpgi.1998.274.2.G314; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lacorte JM, 1996, BIOCHEM J, V318, P681, DOI 10.1042/bj3180681; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUER SJ, 1991, CIRCULATION, V84, P1390; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Le Beyec J, 1998, TRANSGENICS, V2, P211; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; ROMAGNOLO B, 1996, J BIOL CHEM, V273, P31939; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Taraviras S, 2000, BBA-GENE STRUCT EXPR, V1490, P21, DOI 10.1016/S0167-4781(99)00232-8; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	52	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34540	34548		10.1074/jbc.M206074200	http://dx.doi.org/10.1074/jbc.M206074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105231	hybrid			2022-12-27	WOS:000177959100127
J	Hashimoto, M; Sagara, Y; Langford, D; Everall, IP; Mallory, M; Everson, A; Digicaylioglu, M; Masliah, E				Hashimoto, M; Sagara, Y; Langford, D; Everall, IP; Mallory, M; Everson, A; Digicaylioglu, M; Masliah, E			Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3 beta pathway - Implications for neuroprotection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; CELL-SURVIVAL PATHWAY; ERK MAP KINASE; OXIDATIVE STRESS; NERVOUS-SYSTEM; ALZHEIMER-DISEASE; GLUCOSE-TRANSPORT; NEURITE OUTGROWTH; CORTICAL-NEURONS; MAMMALIAN-CELLS	We hypothesize that in neurodegenerative disorders such as Alzheimer's disease and human immunodeficiency virus encephalitis the neuroprotective activity of fibroblast growth factor 1 (FGF1) against several neurotoxic agents might involve regulation of glycogen synthase kinase-3beta (GSK3beta), a pathway important in determining cell fate. In primary rat neuronal and HT22 cells, FGF1 promoted a time-dependent inactivation of GSK3beta by phosphorylation at serine 9. Blocking FGF1 receptors with heparinase reduced this effect. The effects of FGF1 on GSK3beta were dependent on phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) because inhibitors of this pathway or infection with dominant negative Akt adenovirus blocked inactivation. Furthermore, treatment of neuronal cells with FGF1 resulted in ERK-independent Akt phosphorylation and beta-catenin translocation into the nucleus. On the other hand, infection with wild-type GSK3beta recombinant adenovirus-associated virus increased activity of GSK3A and cell death, both of which were reduced by FGF1 treatment. Moreover, FGF1 protection against glutamate toxicity was dependent on GSK3beta inactivation by the PI3K-Akt but was independent of ERK. Taken together these results suggest that neuroprotective effects of FGF1 might involve inactivation of GSK3beta by a pathway involving activation of the PI3K-Akt cascades.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Inst Psychiat, Sect Exptl Neuropathol & Psychiat, London SE5 8AF, England; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of London; King's College London; Sanford Burnham Prebys Medical Discovery Institute	Masliah, E (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	emasliah@ucsd.edu	Digicaylioglu, Murat H/D-3302-2009	Everall, Ian/0000-0003-3957-3861	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH045294, R24MH059745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012065] Funding Source: NIH RePORTER; NIA NIH HHS [AG01029] Funding Source: Medline; NIDA NIH HHS [DA12065] Funding Source: Medline; NIMH NIH HHS [MH62963, MH45294, MH58164, MH59745] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abe K, 2000, DEV BRAIN RES, V122, P81, DOI 10.1016/S0165-3806(00)00054-7; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baum L, 1996, MOL CHEM NEUROPATHOL, V29, P253, DOI 10.1007/BF02815006; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carballada R, 2001, DEVELOPMENT, V128, P35; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chevet E, 1999, J BIOL CHEM, V274, P20901, DOI 10.1074/jbc.274.30.20901; CLARKE MSF, 1993, J CELL SCI, V106, P121; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Derkinderen P, 1999, NEUROREPORT, V10, pR24; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; ECKSTEIN FP, 1994, J NEUROBIOL, V25, P1467; Everall IP, 2001, J NEUROPATH EXP NEUR, V60, P293, DOI 10.1093/jnen/60.3.293; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Guo ZH, 2000, CEREB CORTEX, V10, P50, DOI 10.1093/cercor/10.1.50; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hetman M, 2000, J NEUROSCI, V20, P2567; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; Mora A, 1999, EUR J BIOCHEM, V266, P886, DOI 10.1046/j.1432-1327.1999.00919.x; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pappas IS, 1997, EXP NEUROL, V144, P302, DOI 10.1006/exnr.1997.6411; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Peterson DA, 1996, J NEUROSCI, V16, P886; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; Sagara Y, 1998, J NEUROSCI, V18, P6662; Sanders VJ, 2000, J NEUROSCI RES, V59, P671, DOI 10.1002/(SICI)1097-4547(20000301)59:5<671::AID-JNR10>3.0.CO;2-B; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Thorns V, 1999, J NEUROPATH EXP NEUR, V58, P296, DOI 10.1097/00005072-199903000-00009; Torres MA, 1999, MOL CELL BIOL, V19, P1427; WALICKE PA, 1988, DEV BRAIN RES, V40, P71, DOI 10.1016/0165-3806(88)90009-0; Williams EJ, 1999, MOL CELL NEUROSCI, V13, P272, DOI 10.1006/mcne.1999.0750; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J	58	110	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32985	32991		10.1074/jbc.M202803200	http://dx.doi.org/10.1074/jbc.M202803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12095987	hybrid			2022-12-27	WOS:000177859000078
J	Waheed, AA; Jones, TLZ				Waheed, AA; Jones, TLZ			Hsp90 interactions and acylation target the G protein G alpha(12) but not G alpha(13) to lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; HETEROTRIMERIC G-PROTEINS; THROMBIN RECEPTOR; TRANSFORMING ACTIVITY; MEDIATES ACTIVATION; SIGNAL-TRANSDUCTION; MEMBRANE RAFTS; P115 RHOGEF; IN-VIVO; PALMITOYLATION	The heterotrimeric G proteins, G(12) and G(13), are closely related in their sequences, signaling partners, and cellular effects such as oncogenic transformation and cytoskeletal reorganization. Yet G(12) and G(13) can act through different pathways, bind different proteins, and show opposing actions on some effectors. We investigated the compartmentalization of G(12) and G(13) at the membrane because other G proteins reside in lipid rafts, membrane microdomains enriched in cholesterol and sphingolipids. Lipid rafts were isolated after cold, nonionic detergent extraction of cells and gradient centrifugation. Galpha(12) was in the lipid raft fractions, whereas Galpha(13) was not associated with lipid rafts. Mutation of Cys-11 on Galpha(12), which prevents its palmitoylation, partially shifted Galpha(12) from the lipid rafts. Geldanamycin treatment, which specifically inhibits Hsp90, caused a partial loss of wild-type Galpha(12) and a complete loss of the Cys-11 mutant from the lipid rafts and the appearance of a higher molecular weight form of Galpha(12) in the soluble fractions. These results indicate that acylation and Hsp90 interactions localized Galpha(12) to lipid rafts. Hsp90 may act as both a scaffold and chaperone to maintain a functional Galpha(12) only in discrete membrane domains and thereby explain some of the nonoverlapping functions of G(12) and G(13) and control of these potent cell regulators.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Busconi L, 2000, J BIOL CHEM, V275, P1565, DOI 10.1074/jbc.275.3.1565; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Meyer TN, 2002, J BIOL CHEM, V277, P24855, DOI 10.1074/jbc.C200240200; Miura Y, 2001, BIOCHEMISTRY-US, V40, P15418, DOI 10.1021/bi015574a; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; Postma FR, 2001, CURR BIOL, V11, P121, DOI 10.1016/S0960-9822(01)00030-6; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	41	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32409	32412		10.1074/jbc.C200383200	http://dx.doi.org/10.1074/jbc.C200383200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12117999	hybrid			2022-12-27	WOS:000177859000002
J	Zou, MH; Hou, XY; Shi, CM; Nagata, D; Walsh, K; Cohen, RA				Zou, MH; Hou, XY; Shi, CM; Nagata, D; Walsh, K; Cohen, RA			Modulation by peroxynitrite of Akt- and AMP-activated kinase-dependent Ser(1179) phosphorylation of endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE NITRATION; SKELETAL-MUSCLE; NO SYNTHASE; CELLS; IDENTIFICATION; SUPEROXIDE; COA	Peroxynitrite (ONOO-), a nitric oxide-derived oxidant, uncouples endothelial nitric oxide synthase (eNOS) and increases enzymatic production of superoxide anions (O-2 (Zou, M. H., Shi, C., and Cohen, R. A. (2002) J. Clin. Invest. 109, 817-826). Here we studied how ONOO- influences eNOS activity. In cultured bovine aortic endothelial cells (BAEC), ONOO- increased basal and agonist-stimulated Ser(1179) phosphorylation of eNOS, whereas it decreased nitric oxide production and bioactivity. However, ONOO- strongly inhibited the phosphorylation and activity of Akt, which is known to phosphorylate eNOS-Ser(1179). Moreover, expression of an Akt dominant-negative mutant did not prevent ONOO--enhanced eNOS-Ser(1179) phosphorylation. In contrast to Akt, ONOO- significantly activated 5'-AMP-activated kinase (AMPK), as evidenced by its increased Thr(172) phosphorylation as well as increased Ser(92) phosphorylation of acetylcoenzyme A carboxylase, a downstream target of AMPK, Associated with the increased release of O-2, ONOO- significantly increased the co-immunoprecipitation of eNOS with AMPK Further, overexpression of the AMPK-constitutive active adenovirus significantly enhanced ONOO(-)up-regulated eNOS-Ser(P)(1179). In contrast, overexpression of a dominant-negative AMPK mutant attenuated the ONOO--enhanced eNOS-Ser(1179) phosphorylation as well as 07 release. We conclude that ONOO- inhibits Akt and increases AMPK-dependent Ser(1179) phosphorylation of eNOS resulting in enhanced O-2 release.	Boston Univ, Sch Med, Dept Med, Vasc Biol Unit X708,Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University	Zou, MH (corresponding author), Boston Univ, Sch Med, Dept Med, Vasc Biol Unit X708,Whitaker Cardiovasc Inst, 650 Albany St, Boston, MA 02118 USA.			/0000-0002-1070-6408	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620, R01HL068812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55620, HL68812] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARTER JM, 1994, CURR BIOL, V4, P315; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Dagher Z, 1999, BIOCHEM BIOPH RES CO, V265, P112, DOI 10.1006/bbrc.1999.1635; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	32	164	170	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32552	32557		10.1074/jbc.M204512200	http://dx.doi.org/10.1074/jbc.M204512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12107173	hybrid			2022-12-27	WOS:000177859000022
J	Gizard, F; Lavallee, B; DeWitte, F; Teissier, E; Staels, B; Hum, DW				Gizard, F; Lavallee, B; DeWitte, F; Teissier, E; Staels, B; Hum, DW			The transcriptional regulating protein of 132 kDa (TReP-132) enhances P450scc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CREB-BINDING-PROTEIN; MESSENGER-RIBONUCLEIC-ACID; CHAIN-CLEAVAGE ENZYME; NUCLEAR RECEPTOR COACTIVATORS; THYROID-HORMONE RECEPTOR; VITAMIN-D-RECEPTOR; BOVINE CYP17 GENE; FACTOR-I; TRANSACTIVATION DOMAIN; DEPENDENT TRANSACTIVATION	The human P450scc gene is regulated by the tissue-specific orphan nuclear receptor, steroidogenic factor-1 (SF-1), which plays a key role in several physiologic processes including steroid synthesis, adrenal and gonadal development, and sexual differentiation. Several studies have demonstrated the interaction of SF-1 with different proteins. However, it is clear that additional factors not yet identified are involved with SF-1 to regulate different target genes. Recently, it was demonstrated that a novel transcriptional regulating protein of 132 kDa (TReP-132) regulates expression of the human P450scc gene. The overexpression of TReP-132 in adrenal cells increases the production of pregnenolone, which is associated with the activation of P450scc gene expression. Considering the colocalization of TReP-132 and SF-1 in steroidogenic tissues such as the adrenal and testis, and the presence of two putative LXXLL motifs in TReP-132 that can potentially interact with SF-1, the relationship between these two factors on the P450scc gene promoter was determined. The coexpression of SF-1 and TReP-132 in adrenal NCI-H295 cells cooperates to increase promoter activity. Pull-down experiments demonstrated the interaction between TReP132 and SF-1, and this was further confirmed in intact cells by coimmunoprecipitation/Western blot and two-hybrid analyses. Deletions and mutations of the TReP132 cDNA sequence demonstrate that SF-1 interaction requires the LXXLL motif found at the amino-terminal region of the protein. Also, the "proximal activation domain" and the "AF-2 hexamer" motif of SF-1 are involved in interaction with TReP-132. Consistent with previous studies showing interaction between CBP/p300 and SF-1 or TReP-132, the coexpression of these three proteins results in a synergistic effect on P450scc gene promoter activity. Taken together the results in this study identify a novel function of TReP-132 as a partner in a complex with SF-1 and CBP/p300 to regulate gene transcription involved in steroidogenesis.	Genfit, F-59120 Loos, France; Univ Laval, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1K 7P4, Canada; Inst Pasteur, Dept Atherosclerose, U545 INSERM, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59019 Lille, France	Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille	Hum, DW (corresponding author), Genfit, Parc Eurasante,885 Ave Eugene Avinee, F-59120 Loos, France.	Dean.Hum@genfit.com	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; Chung BC, 1997, STEROIDS, V62, P37, DOI 10.1016/S0039-128X(96)00156-0; CLARK AJL, 1993, LANCET, V341, P461, DOI 10.1016/0140-6736(93)90208-X; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CONLEY AJ, 1992, ENDOCRINOLOGY, V131, P896, DOI 10.1210/en.131.2.896; CONLEY AJ, 1994, J MOL ENDOCRINOL, V12, P155, DOI 10.1677/jme.0.0120155; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DONOHOUE PA, 1995, METABOLIC MOL BASES, P2929; DOODY KJ, 1990, J CLIN ENDOCR METAB, V70, P1041, DOI 10.1210/jcem-70-4-1041; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gizard F, 2001, J BIOL CHEM, V276, P33881, DOI 10.1074/jbc.M100113200; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Guo IC, 1999, J STEROID BIOCHEM, V69, P329, DOI 10.1016/S0960-0760(99)00080-1; GUO IC, 1993, DNA CELL BIOL, V12, P849, DOI 10.1089/dna.1993.12.849; Hammer GD, 1999, FRONT NEUROENDOCRIN, V20, P199, DOI 10.1006/frne.1999.0182; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HONDA S, 1993, J BIOL CHEM, V268, P7494; Hu MC, 2001, MOL ENDOCRINOL, V15, P812, DOI 10.1210/me.15.5.812; Huang YY, 2001, MOL CELL ENDOCRINOL, V175, P205, DOI 10.1016/S0303-7207(01)00388-4; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Jacob AL, 1998, J BIOL CHEM, V273, P13391, DOI 10.1074/jbc.273.22.13391; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; Li LA, 1999, MOL ENDOCRINOL, V13, P1588, DOI 10.1210/me.13.9.1588; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; Lopez D, 2001, ENDOCRINOLOGY, V142, P5097, DOI 10.1210/en.142.12.5097; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mellon SH, 1998, ENDOCRINOLOGY, V139, P3026, DOI 10.1210/en.139.6.3026; MELLON SH, 1991, DNA CELL BIOL, V10, P339, DOI 10.1089/dna.1991.10.339; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Mesiano S, 1996, J CLIN ENDOCR METAB, V81, P340, DOI 10.1210/jc.81.1.340; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1995, J STEROID BIOCHEM, V53, P81, DOI 10.1016/0960-0760(95)00041-W; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PIKULEVA L, 1999, MOL ASPECTS MED, V20, P33; Ramayya MS, 1997, J CLIN ENDOCR METAB, V82, P1799, DOI 10.1210/jc.82.6.1799; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; SPARKES RS, 1991, DNA CELL BIOL, V10, P359, DOI 10.1089/dna.1991.10.359; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay AJ, 2001, BIOL REPROD, V64, P1191, DOI 10.1095/biolreprod64.4.1191; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VOUTILAINEN R, 1987, P NATL ACAD SCI USA, V84, P1590, DOI 10.1073/pnas.84.6.1590; VOUTILAINEN R, 1988, J CLIN ENDOCR METAB, V66, P383, DOI 10.1210/jcem-66-2-383; WATERMAN MR, 1986, ENDOCR RES, V12, P393, DOI 10.3109/07435808609035447; Westin S, 2000, ADV PHARMACOL, V47, P89; Wong M, 1996, J MOL ENDOCRINOL, V17, P139, DOI 10.1677/jme.0.0170139; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	109	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39144	39155		10.1074/jbc.M205786200	http://dx.doi.org/10.1074/jbc.M205786200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12101186	hybrid			2022-12-27	WOS:000178662500013
J	Belli, G; Polaina, J; Tamarit, J; de la Torre, MA; Rodriguez-Manzaneque, MT; Ros, J; Herrero, E				Belli, G; Polaina, J; Tamarit, J; de la Torre, MA; Rodriguez-Manzaneque, MT; Ros, J; Herrero, E			Structure-function analysis of yeast Grx5 monothiol glutaredoxin defines essential amino acids for the function of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; SITE-DIRECTED MUTAGENESIS; NF-KAPPA-B; MIXED DISULFIDE; THIOLTRANSFERASE GLUTAREDOXIN; SACCHAROMYCES-CEREVISIAE; ENZYMATIC MECHANISM; T4 GLUTAREDOXIN	Grx5 defines a family of yeast monothiol glutaredoxins that also includes Grx3 and Grx4. All three proteins display significant sequence homology with proteins found from bacteria to humans. Grx5 is involved in iron/ sulfur cluster assembly at the mitochondria, but the function of Grx3 and Grx4 is unknown. Three-dimensional modeling based on known dithiol glutaredoxin structures predicted a thioredoxin fold structure for Grx5. Positionally conserved amino acids in this glutaredoxin family were replaced in Grx5, and the effect on the biological function of the protein has been tested. For all changes studied, there was a correlation between the effects on several different phenotypes: sensitivity to oxidants, constitutive protein oxidation, ability for respiratory growth, auxotrophy for a number of amino acids, and iron accumulation. Cys(60) and Gly(61) are essential for Grx5 function, whereas other single or double substitutions in the same region had no phenotypic effects. Gly(115) and Gly(116) could be important for the formation of a glutathione cleft on the Grx5 surface, in contrast to adjacent Cys(117). Substitution of Phe(50) alters the beta-sheet in the thioredoxin fold structure and inhibits Grx5 function. None of the substitutions tested affect the structure at a significant enough level to reduce protein, stability.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Valencia 46980, Spain	Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Herrero, E (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Rovira Roure 44, Lleida 25198, Spain.		ROS, Joaquim/ABG-7487-2020; Rodriguez-Manzaneque Martinez, Maria Teresa/C-6449-2011; Tamarit, Jordi/C-6316-2008; Herrero, Enrique/B-5592-2009; belli, gemma/A-7424-2011; Ros, Joaquim/A-7507-2010; de la Torre, M Angeles/A-7357-2010; Polaina, Julio/H-4498-2012; Bellí, Gemma/AAD-5325-2019	ROS, Joaquim/0000-0003-0901-8648; Tamarit, Jordi/0000-0003-3227-6928; Herrero, Enrique/0000-0002-6763-111X; belli, gemma/0000-0002-4161-3204; de la Torre, M Angeles/0000-0002-6111-1359; Bellí, Gemma/0000-0002-4161-3204; Polaina, Julio/0000-0001-9912-0640				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Berardi MJ, 1999, J MOL BIOL, V292, P151, DOI 10.1006/jmbi.1999.3067; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz RD., 1988, GENE, V74, P3065; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herrero E, 2002, METHOD ENZYMOL, V348, P136, DOI 10.1016/S0076-6879(02)48633-8; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; INGELMAN M, 1995, FEBS LETT, V370, P209, DOI 10.1016/0014-5793(95)00806-K; Isakov N, 2000, TRENDS BIOCHEM SCI, V25, P537, DOI 10.1016/S0968-0004(00)01685-6; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kaiser C., 1998, METHODS YEAST GENETI, DOI DOI 10.1016/j.copbio.2011.03.007; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; SODANO P, 1991, J MOL BIOL, V221, P1311; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weiner Michael P., 1995, P613; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; XIA TH, 1992, PROTEIN SCI, V1, P310; YANG YF, 1991, J BIOL CHEM, V266, P12759	44	62	62	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37590	37596		10.1074/jbc.M201688200	http://dx.doi.org/10.1074/jbc.M201688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138088	hybrid, Green Published			2022-12-27	WOS:000178447100087
J	Fam, SS; Murphey, LJ; Terry, ES; Zackert, WE; Chen, Y; Gao, L; Pandalai, S; Milne, GL; Roberts, LJ; Porter, NA; Montine, TJ; Morrow, JD				Fam, SS; Murphey, LJ; Terry, ES; Zackert, WE; Chen, Y; Gao, L; Pandalai, S; Milne, GL; Roberts, LJ; Porter, NA; Montine, TJ; Morrow, JD			Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A(4)/J(4)-neuroprostanes) in vivo from docosahexaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; ELECTROSPRAY MASS-SPECTROMETRY; IN-VIVO; ALZHEIMERS-DISEASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); FATTY-ACIDS; PROSTAGLANDIN J(2); OXYGEN-TENSION; CANCER CELLS; KAPPA-B	Free radical-initiated oxidant injury and lipid peroxidation have been implicated in a number of neural disorders. Docosahexaenoic acid is the most abundant unsaturated fatty acid in the central nervous system. We have shown previously that this 22-carbon fatty acid can yield, upon oxidation, isoprostane-like compounds termed neuroprostanes, with E/D-type prostane rings (E-4/D-4-neuroprostanes). Eicosanoids with E/D-type prostane rings are unstable and dehydrate to cyclopentenone-containing compounds possessing A-type and J-type prostane rings, respectively. We thus explored whether cyclopentenone neuroprostanes (A(4)/(4)-neuroprostanes) are formed from the dehydration of E-4/D-4-neuroprostanes. Indeed, oxidation of docosahexaenoic acid in vitro increased levels of putative A(4)/J(4)-neuroprostanes 64-fold from 88 +/- 43 to 5463 +/- 2579 ng/mg docosahexaenoic acid. Chemical approaches and liquid chromatography/electrospray ionization tandem mass spectrometry definitively identified them as A(4)/J(4)-neuroprostanes. We subsequently showed these compounds are formed in significant amounts from a biological source, rat brain synaptosomes. A(4)/J(4)-neuroprostanes increased 13-fold, from a basal level of 89 +/- 72 ng/mg protein to 1187 +/- 217 ng/mg (n = 4), upon oxidation. We also detected these compounds in very large amounts in fresh brain tissue from rats at levels of 97 +/- 25 ng/g brain tissue (n = 3) and from humans at levels of 98 +/- 26 ng/g brain tissue (n = 5), quantities that are nearly an order of magnitude higher than other classes of neuroprostanes. Because of the fact that A(4)/J(4)-neuroprostanes contain highly reactive cyclopentenone ring structures, it would be predicted that they readily undergo Michael addition with glutathione and adduct covalently to proteins. Indeed, incubation of A(4)/J(4)-neuroprostanes in vitro with excess glutathione resulted in the formation of large amounts of adducts. Thus, these studies have identified novel, highly reactive A/J-ring isoprostane-like compounds that are derived from docosahexaenoic acid in vivo.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 526 RRB, Nashville, TN 37232 USA.		Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X	NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007569, R37GM042056, P01GM015431, R01GM042056, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005144, R01AG016835] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839] Funding Source: Medline; NIA NIH HHS [AG16835, AG05144] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM07569, GM15431, GM42056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKELY RD, 1986, J NEUROCHEM, V47, P1013; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; CARLSON SE, 2001, SEMIN NEUNATOL, V5, P437; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chinery R, 1999, CANCER RES, V59, P2739; Clay CE, 2001, J INVEST MED, V49, P413, DOI 10.2310/6650.2001.33786; CONNOR WE, 1992, NUTR REV, V50, P21; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; Kerwin JL, 1996, J MASS SPECTROM, V31, P184, DOI 10.1002/(SICI)1096-9888(199602)31:2<184::AID-JMS283>3.0.CO;2-2; Kerwin JL, 1996, ANAL BIOCHEM, V237, P56, DOI 10.1006/abio.1996.0200; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHAHABI NA, 1987, EXP CELL BIOL, V55, P18; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; SIMONIAN NA, 1997, PROG LIPID RES, V36, P1; SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; ZIROLLI JA, 1990, J AM SOC MASS SPECTR, V1, P325	42	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36076	36084		10.1074/jbc.M205638200	http://dx.doi.org/10.1074/jbc.M205638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133837	hybrid			2022-12-27	WOS:000178275100041
J	Shimomura, Y; Harada, M; Goto, M; Sugo, T; Matsumoto, Y; Abe, M; Watanabe, T; Asami, T; Kitada, C; Mori, M; Onda, H; Fujino, M				Shimomura, Y; Harada, M; Goto, M; Sugo, T; Matsumoto, Y; Abe, M; Watanabe, T; Asami, T; Kitada, C; Mori, M; Onda, H; Fujino, M			Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; MAMMALIAN-CELLS; UROTENSIN-II; CUG CODONS; INITIATION; TRANSLATION; PEPTIDE; BRAIN; OBESITY; GHRELIN	The structurally related orphan G-protein-coupled receptors GPR7 and GPR8 are expressed in the central nervous system, and their ligands have not been identified. Here, we report the identification of the endogenous ligand for both of these receptors. We purified the peptide ligand from porcine hypothalamus using stable Chinese hamster ovary cell lines expressing human GPR8 and cloned the cDNA encoding its precursor protein. The cDNA encodes two forms of the peptide ligand with lengths of 23 and 30 amino acid residues as mature peptides. We designated the two ligands neuropeptide W-23 (NPW23) and neuropeptide W-30 (NPW30). The amino acid sequence of NPW23 is completely identical to that of the N-terminal 23 residues of NPW30. Synthetic NPW23 and NPW30 activated and bound to both GPR7 and GPR8 at similar effective doses. Intracerebroventricular administration of NPW23 in rats increased food intake and stimulated prolactin release. These findings indicate that neuropeptide W is the endogenous ligand for both GPR7 and GPR8 and acts as a mediator of the central control of feeding and the neuroendocrine system.	Takeda Chem Ind Ltd, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Discovery Res Labs 2, Pharmaceut Res Div, Tsukuba, Ibaraki 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Discovery Ctr, Yodogawa Ku, Osaka 5328686, Japan; Takeda Chem Ind Ltd, Pharmaceut Res Div, Strateg Res Planning, Yodogawa Ku, Osaka 5328686, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Shimomura, Y (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs 1, 10 Wadai, Tsukuba, Ibaraki 3004293, Japan.							Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Beck B, 2000, NUTRITION, V16, P916, DOI 10.1016/S0899-9007(00)00410-X; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee DK, 1999, MOL BRAIN RES, V71, P96, DOI 10.1016/S0169-328X(99)00171-0; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; Meiron M, 2001, BIOCHEM BIOPH RES CO, V282, P1053, DOI 10.1006/bbrc.2001.4684; Mori M, 1999, BIOCHEM BIOPH RES CO, V265, P123, DOI 10.1006/bbrc.1999.1640; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimomura Y, 1999, BIOCHEM BIOPH RES CO, V261, P622, DOI 10.1006/bbrc.1999.1104; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Takekawa S, 2002, EUR J PHARMACOL, V438, P129, DOI 10.1016/S0014-2999(02)01314-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wynick D, 1998, P NATL ACAD SCI USA, V95, P12671, DOI 10.1073/pnas.95.21.12671; Yang SP, 2000, NEUROENDOCRINOLOGY, V72, P20, DOI 10.1159/000054567	32	142	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35826	35832		10.1074/jbc.M205337200	http://dx.doi.org/10.1074/jbc.M205337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12130646	hybrid			2022-12-27	WOS:000178275100010
J	Vial, S; Lu, H; Allen, S; Savory, P; Thornton, D; Sheehan, J; Tokatlidis, K				Vial, S; Lu, H; Allen, S; Savory, P; Thornton, D; Sheehan, J; Tokatlidis, K			Assembly of Tim9 and Tim10 into a functional chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; ADP-ATP CARRIER; PROTEIN IMPORT RECEPTOR; MEDIATES INSERTION; PRECURSOR PROTEINS; OUTER-MEMBRANE; TOM COMPLEX; MUC5B MUCIN; ACID CHAIN; TRANSLOCATION	The TIM10 complex is localized in the mitochondrial intermembrane space and mediates insertion of hydrophobic proteins at the inner membrane. We have characterized TIM10 assembly and analyzed the structural properties of its subunits, Tim9 and Tim10. Both proteins are a-helical with a protease-resistant central domain, and each self-associates to form mainly dimers and trimers in solution. Tim9 and Tim10 bound to one another with submicromolar affinity in equimolar amounts and assembled in a stable, significantly extended complex that was indistinguishable from the native mitochondrial TIM10 complex. Importantly, the reconstituted TIM10 complex is functional because it bound to the physiological substrate ADP/ATP carrier and displayed chaperone activity in refolding the model substrate firefly luciferase. These data demonstrate that the individual subunits can exist as independent, dynamically self-associating proteins. Assembly into the thermodynamically stable hexameric complex is necessary for the TIM10 chaperone function.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Crete, Dept Chem, Iraklion, Greece; Inst Mol Biol & Biotechnol, Iraklion, Greece	University of Manchester; University of Manchester; University of Crete			Lu, Hui/AAB-5476-2021	Tokatlidis, Kostas/0000-0001-6295-8183; Allen, Scott/0000-0003-4418-7375; Lu, Hui/0000-0002-7029-2681; Thornton, David/0000-0001-7148-1970	Medical Research Council [G0000153] Funding Source: Medline; MRC [G0000153] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rost B, 1996, METHOD ENZYMOL, V266, P525; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	54	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36100	36108		10.1074/jbc.M202310200	http://dx.doi.org/10.1074/jbc.M202310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138093	hybrid			2022-12-27	WOS:000178275100044
J	Wu, Q; Kirschmeier, P; Hockenberry, T; Yang, TY; Brassard, DL; Wang, LQ; McClanahan, T; Black, S; Rizzi, G; Musco, ML; Mirza, A; Liu, SX				Wu, Q; Kirschmeier, P; Hockenberry, T; Yang, TY; Brassard, DL; Wang, LQ; McClanahan, T; Black, S; Rizzi, G; Musco, ML; Mirza, A; Liu, SX			Transcriptional regulation during p21(WAF1/CIP1)-induced apoptosis in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; CYCLE ARREST; GENE-EXPRESSION; P53-INDEPENDENT EXPRESSION; E2F-1-MEDIATED APOPTOSIS; GROWTH ARREST; ADENOVIRUS; P21; PROTEIN; INDUCTION	In this study we used adenovirus vector-mediated transduction of either the p53 gene (rAd-p53) or the p21(WAF1/CIP1) gene (rAd-p21) to mimic both p53-dependent and -independent up-regulation of p21(WAF1/CIP1) within a human ovarian cancer cell line, 2774, and the derivative cell lines, 2774qw1 and 2774qw2. We observed that rAd-p53 can induce apoptosis in both 2774 and 2774qw1 cells but not in 2774qw2 cells. Surprisingly, overexpression of p21(WAF1/CIP1) also triggered apoptosis within these two cell lines. Quantitative reverse transcription-PCR analysis revealed that the differential expression of BAX, BCL2, and caspase 3 genes, specific in rAd-p53-induced apoptotic cells, was not altered in rAd-p21-induced apoptotic cells, suggesting p21(WAF1/CIP1)-induced apoptosis through a pathway distinguishable from p53-induced apoptosis. Expression analysis of 2774qw1 cells infected with rAd-p21 on 60,000 cDNA microarrays identified 159 genes in response to p21(WAF1/CIP1) expression in at least one time point with 2.5-fold change as a cutoff. Integration of the data with the parallel microarray experiments with rAd-p53 infection allowed us to extract 66 genes downstream of both p53 and p21(WAF1/CIP1) and 93 genes in response to p21(WAF1/CIP1) expression in a p53-independent pathway. The genes in the former set may play a dual role in both p53-dependent and p53-independent pathways, and the genes in the latter set gave a mechanistic molecular explanation for p53-independent p21(WAF1/CIP1)-induced apoptosis. Furthermore, promoter sequence analysis suggested that transcription factor E2F family is partially responsible for the differential expression of genes following p21(WAF1/CIP1). This study has profound significance toward understanding the role of p21(WAF1/CIP1) in p53-independent apoptosis.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res dept, Kenilworth, NJ 07033 USA; Schering Plough Res Inst, Biotechnol Dev, Union, NJ 07083 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering-Plough Research Institute; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com	McClanahan, Tim/K-4998-2019					Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Boulaire J, 2000, PATHOL BIOL, V48, P190; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ding ZH, 2001, CLIN CANCER RES, V7, P3336; Draus JM, 2001, EXP MOL MED, V33, P209, DOI 10.1038/emm.2001.35; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elliott MJ, 2002, CANCER GENE THER, V9, P453, DOI 10.1038/sj.cgt.7700458; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grassilli E, 1999, CANCER RES, V59, P2451; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; Hatoum A, 2001, CARCINOGENESIS, V22, P1955, DOI 10.1093/carcin/22.12.1955; Hsu SL, 1999, EXP CELL RES, V248, P87, DOI 10.1006/excr.1999.4397; Hussain SP, 1998, CANCER RES, V58, P4023; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MICHIELI P, 1994, CANCER RES, V54, P3391; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakashima S, 2000, ANTICANCER RES, V20, P1933; Park JS, 2000, J BIOL CHEM, V275, P18, DOI 10.1074/jbc.275.1.18; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Ramondetta L, 2000, CLIN CANCER RES, V6, P278; SANTOSO JT, 1995, GYNECOL ONCOL, V59, P171; Sato T, 2002, INFECT IMMUN, V70, P528, DOI 10.1128/IAI.70.2.528-534.2002; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Ueta E, 2001, INT J CANCER, V94, P545, DOI 10.1002/ijc.1513; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WIGENDER E, 1996, NUCLEIC ACIDS RES, V24, P238; WIGENDER E, 2001, NUCLEIC ACIDS RES, V29, P281; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; ZHANG W, 1995, CANCER RES, V55, P668	49	93	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36329	36337		10.1074/jbc.M204962200	http://dx.doi.org/10.1074/jbc.M204962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138103	hybrid			2022-12-27	WOS:000178275100070
J	Coady, MJ; Wallendorff, B; Gagnon, DG; Lapointe, JY				Coady, MJ; Wallendorff, B; Gagnon, DG; Lapointe, JY			Identification of a novel Na+/myo-inositol cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL TRANSPORT; XENOPUS-OOCYTES; DOUBLE-BLIND; CONTROLLED TRIAL; ENZYMATIC ASSAY; GLUCOSE; NA+; CLONING; EXPRESSION; CELLS	rkST1, an orphan cDNA of the SLC5 family (43% identical in sequence to the sodium myo-inositol cotransporter SMIT), was expressed in Xenopus laevis oocytes that were subsequently voltage-clamped and exposed to likely substrates. Whereas superfusion with glucose and other sugars produced a small inward current, the largest current was observed with myo-inositol. The expressed protein, which we have named SMIT2, cotransports myo-inositol with a K-m of 120 muM and displays a current-voltage relationship similar to that seen with SMIT (now called SMIT1). The transport is Na+-dependent, with a K-m of 13 mM. SMIT2 exhibits phlorizin-inhibitable presteady-state currents and substrate-independent "Na+ leak" currents similar to those of related cotransporters. The steady-state cotransport current is also phlorizin-inhibitable with a K-i of 76 muM. SMIT2 exhibits stereospecific cotransport of both D-glucose and D-xylose but does not transport fucose. In addition, SMIT2 (but not SMIT1) transports D-chiro-inositol. Based on previous publications, the tissue distribution of SMIT2 is different from that of SMIT1, and the existence of this second cotransporter may explain much of the heterogeneity that has been reported for inositol transport.	Univ Montreal, Grp Rech Transport Membranaire, Montreal, PQ H3T 1J4, Canada	Universite de Montreal	Coady, MJ (corresponding author), Grp Rech Transport Membranaire, POB 6128 Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.							Ashizawa N, 2000, J BIOCHEM BIOPH METH, V44, P89, DOI 10.1016/S0165-022X(00)00069-5; Barak Y, 1996, PROG NEURO-PSYCHOPH, V20, P729, DOI 10.1016/0278-5846(96)00043-7; BENJAMIN J, 1995, AM J PSYCHIAT, V152, P1084; CAMMARATA PR, 1992, INVEST OPHTH VIS SCI, V33, P3572; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; DOLHOFER R, 1987, J CLIN CHEM CLIN BIO, V25, P733; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; Eid SR, 2002, INT J DEV BIOL, V46, P177; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Fux M, 1996, AM J PSYCHIAT, V153, P1219; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HITOMI K, 1994, BBA-BIOMEMBRANES, V1190, P469, DOI 10.1016/0005-2736(94)90110-4; KALUZ S, 1992, NUCLEIC ACIDS RES, V20, P4369, DOI 10.1093/nar/20.16.4369; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEVINE J, 1995, AM J PSYCHIAT, V152, P792; MACGREGOR LC, 1984, ANAL BIOCHEM, V141, P382, DOI 10.1016/0003-2697(84)90058-7; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Nagata K, 1999, AM J PHYSIOL-GASTR L, V276, pG1251, DOI 10.1152/ajpgi.1999.276.5.G1251; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; NAKANISHI T, 1988, AM J PHYSIOL, V255, pC181, DOI 10.1152/ajpcell.1988.255.2.C181; Noh SJ, 1998, J CELL PHYSIOL, V176, P412, DOI 10.1002/(SICI)1097-4652(199808)176:2<412::AID-JCP20>3.0.CO;2-3; Novak JE, 1999, J NEUROCHEM, V72, P1431, DOI 10.1046/j.1471-4159.1999.721431.x; OSTLUND RE, 1993, P NATL ACAD SCI USA, V90, P9988, DOI 10.1073/pnas.90.21.9988; Ostlund RE, 1996, J BIOL CHEM, V271, P10073, DOI 10.1074/jbc.271.17.10073; PAJOR AM, 1994, BBA-BIOMEMBRANES, V1194, P349, DOI 10.1016/0005-2736(94)90319-0; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Porcellati F, 1999, AM J PHYSIOL-CELL PH, V276, pC1325, DOI 10.1152/ajpcell.1999.276.6.C1325; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; Roll P, 2002, GENE, V285, P141, DOI 10.1016/S0378-1119(02)00416-X; SCHMOLKE M, 1990, BIOL CHEM H-S, V371, P909, DOI 10.1515/bchm3.1990.371.2.909; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; SILBERNAGL S, 2001, IUPS 34 INT C; Sima AAF, 1997, DIABETES, V46, P301, DOI 10.2337/diabetes.46.2.301; SPECTOR R, 1975, AM J PHYSIOL, V228, P1510, DOI 10.1152/ajplegacy.1975.228.5.1510; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRACHTMAN H, 1992, PEDIATR NEPHROL, V6, P104, DOI 10.1007/BF00856852; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WARFIELD A, 1978, J NEUROCHEM, V31, P957, DOI 10.1111/j.1471-4159.1978.tb00133.x; Wiese TJ, 1996, AM J PHYSIOL-CELL PH, V270, pC990, DOI 10.1152/ajpcell.1996.270.4.C990; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Wright EM, 2001, AM J PHYSIOL-RENAL, V280, pF10, DOI 10.1152/ajprenal.2001.280.1.F10; YOREK MA, 1991, DIABETES, V40, P1016, DOI 10.2337/diabetes.40.8.1016	48	127	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35219	35224		10.1074/jbc.M204321200	http://dx.doi.org/10.1074/jbc.M204321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133831	hybrid			2022-12-27	WOS:000178117000072
J	Patel-King, RS; Benashski, SE; King, SM				Patel-King, RS; Benashski, SE; King, SM			A bipartite Ca2+-regulated nucleoside-diphosphate kinase system within the Chlamydomonas flagellum - The regulatory subunit p72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN; CALMODULIN; CHAIN; INVERSUS; PROTEIN	Regulation of flagellar activity in Chlamydomonas involves both Ca2+ and cAMP-mediated signaling pathways. However, Chlamydomonas and sea urchin sperm flagella also exhibit nucleoside-diphosphate kinase (NDK) activity, suggesting a requirement for GTP within this highly conserved organelle. In sea urchin sperm, the NDK catalytic subunit is an integral component of the outer dynein arm. Here we describe a modular protein (p72) from the Chlamydomonas flagellum that consists of three domains closely related to the presumptive regulatory segment of rat NDK-7 followed by two EF-hands that are predicted to bind Ca2+. There are close homologues of p72 in both mammalian and insect genomes. The p72 protein is tightly associated with the flagellar axoneme and is located along the entire length except at the transition zone. Cross-linking experiments suggest that p72 interacts with two or three additional axonemal polypeptides. The sensitivity of p72 to tryptic digestion differed considerably in the presence and the absence of Ca2+, suggesting that it indeed binds this ligand. These studies indicate that the flagellar NDK system is bipartite with the regulatory and catalytic components residing on different polypeptides. We propose that Ca2+ regulation of flagellar motility in Chlamydomonas may be achieved in part through a downstream GTP-mediated signaling pathway.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	King, SM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, 263 Farmington Ave, Farmington, CT 06030 USA.	steve@king2.uchc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51293] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casey DM, 1998, MOL BIOL CELL, V9, p155A; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; GITELMAN SE, 1980, J CELL BIOL, V87, P764, DOI 10.1083/jcb.87.3.764; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; KAMIYA R, 1984, J CELL BIOL, V98, P97, DOI 10.1083/jcb.98.1.97; KING SM, 1995, METHOD CELL BIOL, V47, P9, DOI 10.1016/S0091-679X(08)60783-9; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Marshall WF, 2001, J CELL BIOL, V155, P405, DOI 10.1083/jcb.200106141; Mitchell DR, 2000, J PHYCOL, V36, P261, DOI 10.1046/j.1529-8817.2000.99218.x; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; RANUM LPW, 1988, GENETICS, V120, P109; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; SAKATO M, 2001, MOL BIOL CELL, V12, P313; SCHLOSS JA, 1984, MOL CELL BIOL, V4, P424, DOI 10.1128/MCB.4.3.424; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; VANELDIK LJ, 1980, P NATL ACAD SCI-BIOL, V77, P4779; WATANABE T, 1976, J BIOL CHEM, V251, P182; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E	32	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34271	34279		10.1074/jbc.M204137200	http://dx.doi.org/10.1074/jbc.M204137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12095989	hybrid			2022-12-27	WOS:000177959100097
J	Waters, BM; Eide, DJ				Waters, BM; Eide, DJ			Combinatorial control of yeast FET4 gene expression by iron, zinc, and oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HYPOXIC GENES; TRANSCRIPTIONAL ACTIVATOR; COPPER TRANSPORTER; OXIDATIVE STRESS; LACZ FUSIONS; CLONED GENES; PROTEIN; ENCODES; ENDOCYTOSIS	Acquisition of metals such as iron, copper, and zinc by the yeast Saccharomyces cerevisiae is tightly regulated. High affinity uptake systems are induced under metal-limiting conditions to maintain an adequate supply of these essential nutrients. Low affinity uptake systems function when their substrates are in greater supply. The FET4 gene encodes a low affinity iron and copper uptake transporter. FET4 expression is regulated by several environmental factors. In this report, we describe the molecular mechanisms underlying this regulation. First, we found that FET4 expression is induced in iron-limited cells by the Aft1 iron-responsive transcriptional activator. Second, FET4 is regulated by zinc status via the Zap1 transcription factor. We present evidence that FET4 is a physiologically relevant zinc transporter and this provides a rationale for its regulation by Zap1. Finally, FET4 expression is regulated in response to oxygen by the Rox1 repressor. Rox1 attenuates activation by Aft1 and Zap1 in aerobic cells. Derepression of FET4 may allow the Fet4 transporter to play an even greater role in metal acquisition under anaerobic conditions. Thus, Fet4 is a multisubstrate metal ion transporter under combinatorial control by iron, zinc, and oxygen.	Univ Missouri, Dept Nutrit Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Agron, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutrit Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		Waters, Brian/H-4805-2015	Waters, Brian/0000-0002-1422-238X	NIGMS NIH HHS [GM 56285] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Avery SV, 2001, ADV APPL MICROBIOL, V49, P111, DOI 10.1016/S0065-2164(01)49011-3; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; DECKERT J, 1995, GENETICS, V139, P1149; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; Jensen LT, 2002, J MOL BIOL, V318, P251, DOI 10.1016/S0022-2836(02)00093-1; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; KUNES S, 1987, GENETICS, V115, P73; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; LIU HP, 1992, GENETICS, V132, P665; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; LOWRY CV, 1986, MOL CELL BIOL, V6, P4145, DOI 10.1128/MCB.6.12.4145; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Senior NM, 1996, BIOCHEM J, V320, P401; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; Zitomer RS, 1997, METHODS, V11, P279, DOI 10.1006/meth.1996.0422	51	99	105	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33749	33757		10.1074/jbc.M206214200	http://dx.doi.org/10.1074/jbc.M206214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12095998	Green Published, hybrid			2022-12-27	WOS:000177959100031
J	Gautreau, A; Manent, J; Fievet, B; Louvard, D; Giovannini, M; Arpin, M				Gautreau, A; Manent, J; Fievet, B; Louvard, D; Giovannini, M; Arpin, M			Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-2; TERMINAL DOMAIN; MERLIN; MEMBRANE; PROTEIN; EXPRESSION; SCHWANNOMAS; CYTOSKELETON; ASSOCIATIONS; MENINGIOMAS	Neurofibromatosis type. 2 (NF2), a syndrome associated with multiple tumors of the nervous system, mostly schwannomas, is caused by mutations in the NF2 tumor suppressor gene that encodes schwannomin (Sch). Here we examined NF2 pathogenetic mutations that result in misfolding of the FERM domain. We found that these mutant forms of Sch were efficiently degraded by the ubiquitin-proteasome pathway. In transfected cells, SchDeltaF118 was 3-fold more efficiently degraded than the related molecule ezrin bearing the equivalent mutation. In heterozygous Nf2 knock-out mouse fibroblasts, endogenous mutant SchDelta81-121, but not wild type Sch, was also degraded by proteasomes. We further show that this degradation pathway is functional in primary Schwann cells. We analyzed SchDelta39-121 expressed in a transgenic mouse model of NF2 and found that SchDelta39-121, but not the endogenous wild type Sch, was unstable due to proteasome-mediated degradation. Altogether these results suggest that degradation of mutant Sch mediated by the ubiquitin-proteasome pathway is a physiopathological pathway contributing to the loss of Sch function in NF2 patients.	Inst Curie, UMR144 CNRS, F-75248 Paris 05, France; INSERM, U434, CEPH, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Arpin, M (corresponding author), Inst Curie, UMR144 CNRS, 26 Rue Ulm, F-75248 Paris 05, France.		Gautreau, Alexis/AAT-2751-2020	Gautreau, Alexis/0000-0002-2369-4362; Manent, Jan/0000-0001-9152-5459				Brault E, 2001, J CELL SCI, V114, P1901; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; den Bakker MA, 2001, NEUROPATHOLOGY, V21, P168; Faudoa R, 2000, HUM MUTAT, V15, P474, DOI 10.1002/(SICI)1098-1004(200005)15:5<474::AID-HUMU9>3.0.CO;2-7; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hogan B, 1994, MANIPULATING MOUSE E; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; StemmerRachamimov AO, 1997, AM J PATHOL, V151, P1649; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7	27	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31279	31282		10.1074/jbc.C200125200	http://dx.doi.org/10.1074/jbc.C200125200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12130630	hybrid			2022-12-27	WOS:000177718700001
J	Lu, M; Wang, T; Yan, QS; Yang, XB; Dong, K; Knepper, MA; Wang, WH; Giebisch, G; Shull, GE; Hebert, SC				Lu, M; Wang, T; Yan, QS; Yang, XB; Dong, K; Knepper, MA; Wang, WH; Giebisch, G; Shull, GE; Hebert, SC			Absence of small conductance K+ channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter's) knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; POTASSIUM CHANNEL; RAT-KIDNEY; GENETIC-HETEROGENEITY; NACL TRANSPORT; MOUSE KIDNEY; HENLES-LOOP; MUTATIONS; SECRETION; TUBULE	The ROMK (Kir1.1; Kcnj1) gene is believed to encode the apical small conductance K+ channels (SK) of the thick ascending limb (TAL) and cortical collecting duct (CCD). Loss-of-function mutations in the human ROMK gene cause Bartter's syndrome with renal Na+ wasting, consistent with the role of this channel in apical K+ recycling in the TAL that is crucial for NaCl reabsorption. However, the mechanism of renal K+ wasting and hypokalemia that develop in individuals with ROMK Bartter's syndrome is not apparent given the proposed loss of the collecting duct SK channel. Thus, we generated a colony of ROMK null mice with similar to25% survival to adulthood that provides a good model for ROMK Bartter's syndrome. The remaining 75% of null mice die in less than 14 days after birth. The surviving ROMK null mice have normal gross renal morphology with no evidence of significant hydronephrosis, whereas non-surviving null mice exhibit marked hydronephrosis. ROMK protein expression was absent in TAL and CCD from null mice but exhibited normal abundance and localization in wild-type littermates. ROMK null mice were polyuric and natriuretic with an elevated hematocrit consistent with mild extracellular volume depletion. SK channel activity in TAL and CCD was assessed by patch clamp analysis in ROMK wild-type ROMK(+/+), heterozygous ROMK(+/-), and null ROMK(-/-) mice. In 313 patches with successful seals from the three ROMK genotypes, SK channel activity in ROMK (+/+ and +/-) exhibited normal single channel kinetics. The expression frequencies are as follows: 67 (TAL) and 58% (CCD) in ROMK(+/+); about half that of the wild-type in ROMK(+/-), being 38 (TAL) and 25% (CCD); absent in both TAL or CCD in ROMK(-/-) between 2 and 5 weeks in 15 mice (61 and 66 patches, respectively). The absence of SK channel activity in ROMK null mice demonstrates that ROMK is essential for functional expression of SK channels in both TAL and CCD. Despite loss of ROMK expression, the normokalemic null mice exhibited significantly increased kaliuresis, indicating alternative mechanisms for K+ absorption/secretion in the nephron.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Yale University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); New York Medical College	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	steven.hebert@yale.edu	Knepper, Mark/AAF-8412-2020		Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline; NIDDK NIH HHS [DK54998, DK54999, DK54983, R01 DK054999, R01 DK050594, DK50594, R01 DK054998, R37 DK050594, R01 DK054983] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054983, R01DK054999, R01DK054998, R01DK050594, R37DK050594] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asteria C, 1997, EUR J ENDOCRINOL, V137, P613, DOI 10.1530/eje.0.1370613; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Derst C, 1997, BIOCHEM BIOPH RES CO, V230, P641, DOI 10.1006/bbrc.1996.6024; Derst C, 1998, J BIOL CHEM, V273, P23884, DOI 10.1074/jbc.273.37.23884; Ecelbarger CA, 2001, J AM SOC NEPHROL, V12, P10, DOI 10.1681/ASN.V12110; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; GILL JR, 1980, ANNU REV MED, V31, P405, DOI 10.1146/annurev.me.31.020180.002201; GILL JR, 1978, AM J MED, V65, P766, DOI 10.1016/0002-9343(78)90794-5; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; GORDON JA, 1994, HOSP PRACT, V29, P103, DOI 10.1080/21548331.1994.11443023; GREGER R, 1981, PFLUG ARCH EUR J PHY, V392, P92, DOI 10.1007/BF00584588; GREGER R, 1991, KIDNEY INT, V40, pS119; Guay-Woodford LM, 1998, AM J MED, V105, P151, DOI 10.1016/S0002-9343(98)00196-X; GUGGINO SE, 1987, AM J PHYSIOL, V252, pC121, DOI 10.1152/ajpcell.1987.252.2.C121; HEBERT SC, 1986, J GEN PHYSIOL, V87, P567, DOI 10.1085/jgp.87.4.567; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; Hebert TE, 1998, BIOCHEM J, V330, P287; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HROPOT M, 1985, KIDNEY INT, V28, P477, DOI 10.1038/ki.1985.154; Karolyi L, 1997, HUM MOL GENET, V6, P17; Karolyi L, 1998, J MOL MED, V76, P317, DOI 10.1007/s001090050223; Kohda Y, 1998, KIDNEY INT, V54, P1214, DOI 10.1046/j.1523-1755.1998.00120.x; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; Lu M, 2000, J GEN PHYSIOL, V116, P299, DOI 10.1085/jgp.116.2.299; Lu M, 1996, J GEN PHYSIOL, V108, P537, DOI 10.1085/jgp.108.6.537; Lu M, 2000, KIDNEY BLOOD PRESS R, V23, P75, DOI 10.1159/000025957; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Schwalbe RA, 1998, HUM MOL GENET, V7, P975, DOI 10.1093/hmg/7.6.975; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; Simon DB, 1998, CURR OPIN CELL BIOL, V10, P450, DOI 10.1016/S0955-0674(98)80057-4; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; STEIN JH, 1985, KIDNEY INT, V28, P85, DOI 10.1038/ki.1985.123; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Taniguchi J, 1998, J MEMBRANE BIOL, V164, P35, DOI 10.1007/s002329900391; TSUKAMOTO T, 1995, AM J KIDNEY DIS, V25, P637, DOI 10.1016/0272-6386(95)90137-X; VELAZQUEZ H, 1987, AM J PHYSIOL, V253, pF555, DOI 10.1152/ajprenal.1987.253.3.F555; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; Vollmer M, 1998, PEDIATR NEPHROL, V12, P69, DOI 10.1007/s004670050408; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809; Zolotnitskaya A, 1999, AM J PHYSIOL-RENAL, V276, pF825, DOI 10.1152/ajprenal.1999.276.6.F825	68	136	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37881	37887		10.1074/jbc.M206644200	http://dx.doi.org/10.1074/jbc.M206644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12130653	Green Accepted, hybrid			2022-12-27	WOS:000178447100124
J	Macri, V; Proenza, C; Agranovich, E; Angoli, D; Accili, EA				Macri, V; Proenza, C; Agranovich, E; Angoli, D; Accili, EA			Separable gating mechanisms in a mammalian pacemaker channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CATION CURRENT; SINOATRIAL NODE CELLS; CALF PURKINJE-FIBERS; K+ CHANNEL; POTASSIUM CHANNELS; SIGNATURE SEQUENCE; SELECTIVITY FILTER; ION PERMEATION; OPEN-STATE; I-H	Despite permeability to both K+ and Na+, hyperpolarization-activated cyclic nucleotide-gated (HCN) pacemaker channels contain the K+ channel signature sequence, GYG, within the selectivity filter of the pore. Here, we show that this region is involved in regulating gating in a mouse isoform of the pacemaker channel (mHCN2). A mutation in the GYG sequence of the selectivity filter (G404S) had different effects on the two components of the wild-type current; it eliminated the slowly activating current (Id but, surprisingly, did not affect the instantaneous current Confocal imaging and immunocytochemistry showed G404S protein on the periphery of the cells, consistent with the presence of channels on the plasma membrane. Experiments with the wild-type channel showed that the rate of If deactivation and If amplitude had a parallel dependence on the ratio of K+/Na+ driving forces. In addition, the amplitude of fully activated I-f, unlike I-inst, was not well predicted by equal and independent flow of K+ and Na+. The data are consistent with two separable gating mechanisms associated with pacemaker channels: one (Id that is sensitive to voltage, to a mutation in the selectivity filter, and to driving forces for permeating cations and another (I-inst) that is insensitive to these influences.	Simon Fraser Univ, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Accili, EA (corresponding author), Simon Fraser Univ, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada.	eaaccili@sfu.ca		Proenza, Catherine/0000-0003-4324-6206; Macri, Vincenzo/0000-0003-3463-2877				Altomare C, 2001, J GEN PHYSIOL, V117, P519, DOI 10.1085/jgp.117.6.519; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; Bal T, 1997, J NEUROPHYSIOL, V77, P3145, DOI 10.1152/jn.1997.77.6.3145; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Choate JK, 2001, EXP PHYSIOL, V86, P19, DOI 10.1113/eph8602062; Choe H, 1999, BIOPHYS J, V76, P1988, DOI 10.1016/S0006-3495(99)77357-1; DIETZEL I, 1982, EXP BRAIN RES, V46, P73; DIFRANCESCO D, 1984, J PHYSIOL-LONDON, V348, P341, DOI 10.1113/jphysiol.1984.sp015114; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1982, J PHYSIOL-LONDON, V329, P485, DOI 10.1113/jphysiol.1982.sp014315; Dreyer I, 2001, FEBS LETT, V505, P233, DOI 10.1016/S0014-5793(01)02832-0; HAGIWARA N, 1992, J PHYSIOL-LONDON, V448, P53, DOI 10.1113/jphysiol.1992.sp019029; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; Kiss L, 1999, BIOPHYS J, V76, P253, DOI 10.1016/S0006-3495(99)77194-8; KLEBER AG, 1983, CIRC RES, V52, P442, DOI 10.1161/01.RES.52.4.442; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; LIPKIND GM, 1995, P NATL ACAD SCI USA, V92, P9215, DOI 10.1073/pnas.92.20.9215; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; Lu T, 2001, J GEN PHYSIOL, V118, P509, DOI 10.1085/jgp.118.5.509; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Magee JC, 1998, J NEUROSCI, V18, P7613; MAROUKA F, 1994, J PHYSL, V477, P423; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; Monteggia LM, 2000, MOL BRAIN RES, V81, P129, DOI 10.1016/S0169-328X(00)00155-8; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Moroni A, 2000, PFLUG ARCH EUR J PHY, V439, P618, DOI 10.1007/s004240050985; NOBLE D, 1992, P ROY SOC B-BIOL SCI, V250, P199, DOI 10.1098/rspb.1992.0150; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Paterson DJ, 1996, J APPL PHYSIOL, V80, P1853, DOI 10.1152/jappl.1996.80.6.1853; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Shi WM, 1999, CIRC RES, V85, pE1; So I, 2001, J PHYSIOL-LONDON, V531, P37, DOI 10.1111/j.1469-7793.2001.0037j.x; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; SYKOVA E, 1983, PROG BIOPHYS MOL BIO, V42, P135, DOI 10.1016/0079-6107(83)90006-8; Vang ZR, 1999, J PHYSIOL-LONDON, V515, P331, DOI 10.1111/j.1469-7793.1999.331ac.x; WOLLMUTH LP, 1995, PFLUG ARCH EUR J PHY, V430, P34, DOI 10.1007/BF00373837; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Zheng J, 1998, J GEN PHYSIOL, V112, P457, DOI 10.1085/jgp.112.4.457; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	49	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35939	35946		10.1074/jbc.M203485200	http://dx.doi.org/10.1074/jbc.M203485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121985	hybrid			2022-12-27	WOS:000178275100024
J	Aarnisalo, P; Kim, CH; Lee, JW; Perlmann, T				Aarnisalo, P; Kim, CH; Lee, JW; Perlmann, T			Defining requirements for heterodimerization between the retinoid X receptor and the orphan nuclear receptor Nurr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; NGFI-B; ACTIVATION FUNCTION-2; ACID; GENE; RXR; IDENTIFICATION; ALPHA	Nurr1, an orphan nuclear receptor mainly expressed in the central nervous system, is essential for the development of the midbrain dopaminergic neurons. Nurr1 binds DNA as a monomer and exhibits constitutive transcriptional activity. Nurr1 can also regulate transcription as a heterodimer with the retinoid X receptor (RXR) and activate transcription in response to RXR ligands. However, the specific physiological roles of Nurr1 monomers and RXR-Nurr1 heterodimers remain to be elucidated. The aim of this study was to define structural requirements for RXR-Nurr1 heterodimerization. Several amino acid substitutions were introduced in both Nurr1 and RXR in the I-box, a region previously shown to be important for nuclear receptor dimerization. Single amino acid substitutions introduced in either Nurr1 or RXR abolished heterodimerization. Importantly, heterodimerization-deficient Nurr1 mutants exhibited normal activities as monomers. Thus, by introducing specific amino acid substitutions in Nurr1, monomeric and heterodimeric properties of Nurr1 can be distinguished. Interestingly, substitutions in the RXR I-box differentially affected heterodimerization with Nurr1, retinoic acid receptor, thyroid hormone receptor, and constitutive androstane receptor demonstrating that the dimerization interfaces in these different heterodimers are functionally unique. Furthermore, heterodimerization between RXR and Nurr1 had a profound influence on the constitutive activity of Nurr1, which was diminished as a result of RXR interaction. In conclusion, our data show unique structural and functional properties of RXR-Nurr1 heterodimers and also demonstrate that specific mutations in Nurr1 can abolish heterodimerization without affecting other essential functions.	Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Pohang University of Science & Technology (POSTECH)	Perlmann, T (corresponding author), Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se						Botling J, 1997, J BIOL CHEM, V272, P9443; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Depoix C, 2001, J BIOL CHEM, V276, P9452, DOI 10.1074/jbc.M008004200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gorla-Bajszczak A, 1999, MOL CELL ENDOCRINOL, V147, P37, DOI 10.1016/S0303-7207(98)00217-2; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Kakizawa T, 1997, J BIOL CHEM, V272, P23799, DOI 10.1074/jbc.272.38.23799; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee SK, 2000, J BIOL CHEM, V275, P33522, DOI 10.1074/jbc.M006418200; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35118	35123		10.1074/jbc.M201707200	http://dx.doi.org/10.1074/jbc.M201707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130634	hybrid			2022-12-27	WOS:000178117000059
J	Duggan, MJ; Quinn, CP; Chaddock, JA; Purkiss, JR; Alexander, FCG; Doward, S; Fooks, SJ; Friis, LM; Hall, YHJ; Kirby, ER; Leeds, N; Moulsdale, HJ; Dickenson, A; Green, GM; Rahman, W; Suzuki, R; Shone, CC; Foster, KA				Duggan, MJ; Quinn, CP; Chaddock, JA; Purkiss, JR; Alexander, FCG; Doward, S; Fooks, SJ; Friis, LM; Hall, YHJ; Kirby, ER; Leeds, N; Moulsdale, HJ; Dickenson, A; Green, GM; Rahman, W; Suzuki, R; Shone, CC; Foster, KA			Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTOXIN TYPE-A; SENSORY NEURONS; SPINAL-CORD; PROTEIN; PURIFICATION; EXPRESSION; CHANNELS; RECEPTOR; TETANUS; SNAP-25	Clostridial neurotoxins potently and specifically inhibit neurotransmitter release in defined cell types. Here we report that a catalytically active derivative (termed LH(N)/A) of the type A neurotoxin from Clostridium botulinum has been coupled to a lectin obtained from Erythrina cristagalli to form a novel conjugate. This conjugate exhibits an in vitro selectivity for nociceptive afferents compared with the anatomically adjacent spinal neurons, as assessed using in vitro primary neuronal culture systems to measure inhibition of release of neurotransmitters. Chemical conjugates prepared between E. cristagalli lectin and either natively sourced LH(N)/A or recombinant LH(N)/A purified from Escherichia coli are assessed, and equivalence of the recombinant material are demonstrated. Furthermore, the dependence of inhibition of neurotransmitter release on the cleavage of SNAP-25 is demonstrated through the use of an endopeptidase-deficient LH(N)/A conjugate variant. The duration of action of inhibition of neurotransmitter released by the conjugate in vitro is assessed and is comparable with that observed with Clostridium botulinum neurotoxin. Finally, in vivo electrophysiology shows that these in vitro actions have biological relevance in that sensory transmission from nociceptive afferents through the spinal cord is significantly attenuated. These data demonstrate that the potent endopeptidase activity of clostridial neurotoxins can be selectively retargeted to cells of interest and that inhibition of release of neurotransmitters from a neuronal population of therapeutic relevance to the treatment of pain can be achieved.	Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England; UCL, London WC1E 6BT, England	University of London; University College London	Chaddock, JA (corresponding author), Publ Hlth Lab Serv, Ctr Appl Microbiol & Res, Porton Down, Salisbury SP4 0JG, Wilts, England.	john.chaddock@camr.org.uk		Hall, Yper/0000-0002-8537-8920				BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; Brashear A, 2000, CLIN THER, V22, P1516, DOI 10.1016/S0149-2918(00)83049-0; Chaddock JA, 2000, GROWTH FACTORS, V18, P147, DOI 10.3109/08977190009003240; Chaddock JA, 2000, INFECT IMMUN, V68, P2587, DOI 10.1128/IAI.68.5.2587-2593.2000; Chaddock JA, 2002, PROTEIN EXPRES PURIF, V25, P219, DOI 10.1016/S1046-5928(02)00002-5; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DICKENSON AH, 1986, PAIN, V24, P211, DOI 10.1016/0304-3959(86)90044-8; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; Hallis B, 1996, J CLIN MICROBIOL, V34, P1934, DOI 10.1128/JCM.34.8.1934-1938.1996; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; Johnson EA, 1999, ANNU REV MICROBIOL, V53, P551, DOI 10.1146/annurev.micro.53.1.551; Li L, 1998, J NAT TOXINS, V7, P215; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; Matthews EA, 2001, PAIN, V92, P235, DOI 10.1016/S0304-3959(01)00255-X; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Neale EA, 1999, J CELL BIOL, V147, P1249, DOI 10.1083/jcb.147.6.1249; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; Notermans S., 1989, BOTULINUM NEUROTOXIN, P319, DOI [10.1016/b978-0-12-644445-2.50021-0, DOI 10.1016/B978-0-12-644445-2.50021-0]; Purkiss John R., 1998, Biochemical Society Transactions, V26, pS108; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHONE CC, 1987, EUR J BIOCHEM, V167, P175, DOI 10.1111/j.1432-1033.1987.tb13320.x; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STREIT WJ, 1986, BRAIN RES, V377, P1, DOI 10.1016/0006-8993(86)91185-6; STREIT WJ, 1985, J HISTOCHEM CYTOCHEM, V33, P1042, DOI 10.1177/33.10.4045182; TSE CK, 1982, EUR J BIOCHEM, V122, P493; WELCH M, 1999, IBRO HB S M, V18, P389; Welch MJ, 2000, TOXICON, V38, P245, DOI 10.1016/S0041-0101(99)00153-1; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; ZHOU LQ, 1995, BIOCHEMISTRY-US, V34, P15175, DOI 10.1021/bi00046a025	34	91	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34846	34852		10.1074/jbc.M202902200	http://dx.doi.org/10.1074/jbc.M202902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105193	hybrid			2022-12-27	WOS:000178117000026
J	Sacchetti, P; Dwornik, H; Formstecher, P; Rachez, C; Lefebvre, P				Sacchetti, P; Dwornik, H; Formstecher, P; Rachez, C; Lefebvre, P			Requirements for heterodimerization between the orphan nuclear receptor Nurr1 and retinoid X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER GENE; NGFI-B; ACID RECEPTOR; DIFFERENTIAL EXPRESSION; NURR1-DEFICIENT MICE; TETRAMER FORMATION; HORMONE RECEPTORS; PROGENITOR CELLS; DNA RECOGNITION; BRAIN	The nuclear receptor nurr1 is a transcription factor involved in the development and maintenance of neurons synthesizing the neurotransmitter dopamine. Although the lack of nurr1 expression has dramatic consequences for these cells either in terms of differentiation or survival, the mechanisms by which nurr1 controls gene transcription still remain unclear. In the intent to understand better the modalities of action of this nuclear receptor, we have undertaken a systematic analysis of the transcriptional effects and DNA binding properties of nurr1 as a monomer or when forming dimers with the different isotypes of the retinoic X receptor (RXR). Here, we show that nurr1 acts as a gene activator independently of RXR and through an AF2-independent mechanism. In addition, heterodimerization with RXR is isotype-specific, involves multiple domains in the C-terminal region of nurr1, and requires RXR binding to DNA. RXRalpha-nurr1 and RXRgamma-nurr1 heterodimers bind direct repeat response elements and display no specific requirements with respect to half-site spacing. However, the retinoid responsiveness of DNA-bound heterodimers requires the reiteration of at least three nurr1 binding sites, thereby limiting retinoid-induced nurr1 transcriptional activity to specific direct response elements.	Fac Med Henri Warembourg, INSERM, U459, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Lefebvre, P (corresponding author), Fac Med Henri Warembourg, INSERM, U459, 1 Pl Verdun, F-59045 Lille, France.	p.lefebvre@lille.inserm.fr	Lefebvre, Philippe/F-2685-2010; Sacchetti, Paola/ABC-8884-2021; Rachez, Christophe/GLR-0102-2022	Lefebvre, Philippe/0000-0002-9366-5129; Sacchetti, Paola/0000-0002-6390-2744; Rachez, Christophe/0000-0001-8502-4738				Bannon MJ, 2002, P NATL ACAD SCI USA, V99, P6382, DOI 10.1073/pnas.092654299; Bannon MJ, 2001, EUR NEUROPSYCHOPHARM, V11, P449, DOI 10.1016/S0924-977X(01)00122-5; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Castro DS, 2001, J BIOL CHEM, V276, P43277, DOI 10.1074/jbc.M107013200; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Depoix C, 2001, J BIOL CHEM, V276, P9452, DOI 10.1074/jbc.M008004200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Krezel W, 1999, NEUROSCIENCE, V89, P1291, DOI 10.1016/S0306-4522(98)00342-X; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Le WD, 1999, EXP NEUROL, V159, P451, DOI 10.1006/exnr.1999.7191; Lin BC, 1997, J BIOL CHEM, V272, P9860; Maira M, 1999, MOL CELL BIOL, V19, P7549; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maruyama K, 1998, INT J ONCOL, V12, P1237; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Rachez C, 1996, J BIOL CHEM, V271, P17996, DOI 10.1074/jbc.271.30.17996; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Wallen A, 1999, EXP CELL RES, V253, P737, DOI 10.1006/excr.1999.4691; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Witta J, 2000, MOL BRAIN RES, V84, P67, DOI 10.1016/S0169-328X(00)00211-4; Xiao Q, 1996, NEUROSCIENCE, V75, P221, DOI 10.1016/0306-4522(96)00159-5; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1999, EUR J NEUROSCI, V11, P407, DOI 10.1046/j.1460-9568.1999.00444.x; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	36	34	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35088	35096		10.1074/jbc.M205816200	http://dx.doi.org/10.1074/jbc.M205816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122012	hybrid			2022-12-27	WOS:000178117000055
J	Tron, AE; Bertoncini, CW; Chan, RL; Gonzalez, DH				Tron, AE; Bertoncini, CW; Chan, RL; Gonzalez, DH			Redox regulation of plant homeodomain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING ACTIVITY; HD-ZIP PROTEIN; ANTENNAPEDIA HOMEODOMAIN; LEUCINE-ZIPPER; THIOREDOXIN REDUCTASE; SUNFLOWER HOMEODOMAIN; DIRECT ASSOCIATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	Several families of plant transcription factors contain a conserved DNA binding motif known as the homeodomain. In two of these families, named Hd-Zip and glabra2, the homeodomain is associated with a leucine zipper-like dimerization motif. A group of Hd-Zip proteins, namely Hd-ZipII, contain a set of conserved cysteines within the dimerization motif and adjacent to it. Incubation of one of these proteins, Hahb-10, in the presence of thiol-reducing agents such as dithiothreitol or reduced glutathione produced a significant increase in DNA binding. Under such conditions, the protein migrated as a monomer in non-reducing SDS-polyacrylamide gels. Under oxidizing conditions, a significant proportion of the protein migrated as dimers, suggesting the formation of intermolecular disulfide bonds. A similar behavior was observed for the glabra2 protein HAHR1, which also contains two conserved cysteines within its dimerization domain. Site-directed mutagenesis of the cysteines to serines indicated that each of them has different roles in the activation of the proteins. Purified thioredoxin was able to direct the NADPH-dependent activation of Hahb-10 and HAHR1 in the presence of thioredoxin reductase. The results suggest that redox conditions may operate to regulate the activity of these groups of plant transcription factors within plant cells.	Univ Nacl Litoral, Fac Bioquim & Ciencias Biol, Catedra Biol Celular & Mol, RA-3000 Santa Fe, Argentina	National University of the Littoral	Gonzalez, DH (corresponding author), Univ Nacl Litoral, Fac Bioquim & Ciencias Biol, Catedra Biol Celular & Mol, CC 242 Paraje El Pozo, RA-3000 Santa Fe, Argentina.		Chan, Raquel/AAO-2682-2020	Chan, Raquel/0000-0002-3264-0008; Bertoncini, Carlos/0000-0001-7695-2882				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; CARABELLI M, 1993, PLANT J, V4, P469, DOI 10.1046/j.1365-313X.1993.04030469.x; Chan RL, 1998, BBA-GENE STRUCT EXPR, V1442, P1, DOI 10.1016/S0167-4781(98)00119-5; Di Cristina M, 1996, PLANT J, V10, P393, DOI 10.1046/j.1365-313X.1996.10030393.x; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gonzalez DH, 1997, BBA-GENE STRUCT EXPR, V1351, P137, DOI 10.1016/S0167-4781(96)00186-8; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hung CY, 1998, PLANT PHYSIOL, V117, P73, DOI 10.1104/pp.117.1.73; Ingram GC, 1999, PLANT MOL BIOL, V40, P343, DOI 10.1023/A:1006271332400; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Lu PZ, 1996, PLANT CELL, V8, P2155, DOI 10.1105/tpc.8.12.2155; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Manzara Thianda, 1995, P233; Masucci JD, 1996, DEVELOPMENT, V122, P1253; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Ohashi Y, 2002, PLANT J, V29, P359, DOI 10.1046/j.0960-7412.2001.01214.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; Palena CM, 1997, BBA-GENE STRUCT EXPR, V1352, P203, DOI 10.1016/S0167-4781(97)00012-2; Palena CM, 1999, BIOCHEM J, V341, P81, DOI 10.1042/0264-6021:3410081; Palena CM, 1998, PROTEIN EXPRES PURIF, V13, P97, DOI 10.1006/prep.1998.0875; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1994, J MOL BIOL, V238, P333, DOI 10.1006/jmbi.1994.1296; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; SanchezFernandez R, 1997, P NATL ACAD SCI USA, V94, P2745, DOI 10.1073/pnas.94.6.2745; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHENA M, 1993, GENE DEV, V7, P367, DOI 10.1101/gad.7.3.367; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steindler C, 1999, DEVELOPMENT, V126, P4235; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tron AE, 2001, NUCLEIC ACIDS RES, V29, P4866, DOI 10.1093/nar/29.23.4866; TSAO DHH, 1995, J MOL BIOL, V251, P297, DOI 10.1006/jmbi.1995.0435; Valle EM, 1997, GENE, V196, P61, DOI 10.1016/S0378-1119(97)00193-5; Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	52	71	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34800	34807		10.1074/jbc.M203297200	http://dx.doi.org/10.1074/jbc.M203297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093803	hybrid, Green Published			2022-12-27	WOS:000178117000021
J	Yu, Y; Sreenivas, A; Ostrander, DB; Carman, GA				Yu, Y; Sreenivas, A; Ostrander, DB; Carman, GA			Phosphorylation of Saccharomyces cerevisiae choline kinase on Ser(30) and Ser(85) by protein kinase A regulates phosphatidylcholine synthesis by the CDP-choline pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATASE-ACTIVITY; ESCHERICHIA-COLI; SHUTTLE VECTORS; CKI GENE; IN-VIVO; YEAST; PURIFICATION; INOSITOL; CLONING	The Saccharomyces cerevisiae CKI-encoded choline kinase is phosphorylated on a serine residue and stimulated by protein kinase A. We examined the hypothesis that amino acids Ser(30) and Ser(85) contained in a protein kinase A sequence motif in choline kinase are target sites for protein kinase A. The synthetic peptides SQR-RHSLTRQ (V-max/K-m = 10.8 muM(-1) nmol min(-1) mg(-1)) and GPRRASATDV (V-max/K-m= 0.15 muM(-1) nmol min(-1) mg(-1)) containing the protein kinase A motif for Ser(30) and Ser(85), respectively, within the choline kinase protein were substrates for protein kinase A. Choline kinase with Ser(30) to Ala (S30A) and Ser(85) to Ala (S85A) mutations were constructed alone and in combination by site-directed mutagenesis and expressed in a cki1Delta eki1Delta double mutant that lacks choline kinase activity. The mutant enzymes were expressed normally, but the specific activity of choline kinase in cells expressing the S30A, S85X and S30A, S85A mutant enzymes was reduced by 44, 8, and 60%, respectively, when compared with the control. In vivo labeling experiments showed that the extent of phosphorylation of the S30A, S85A, and S30A,S85A mutant enzymes was reduced by 70, 17, and 83%, respectively. Phosphorylation of the S30A, S85A, and S30A,S85A mutant enzymes by protein kinase A in vitro was reduced by 60, 7, and 96%, respectively, and peptide mapping analysis of the mutant enzymes confirmed the phosphorylation sites in the enzyme. The incorporation of H-3-labeled choline into phosphocholine and phosphatidylcholine in cells bearing the S30A, S85A, and S30A,S85A mutant enzymes was reduced by 56, 27, and 81%, respectively, and by 58, 33, and 84%, respectively, when compared with control cells. These data supported the conclusion that phosphorylation of choline kinase on Ser30 and Ser(85) by protein kinase A regulates PC synthesis by the CDP-choline pathway.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GA (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Campos J, 2000, BIOORG MED CHEM LETT, V10, P767, DOI 10.1016/S0960-894X(00)00080-9; Campos JM, 2002, BIOORGAN MED CHEM, V10, P2215, DOI 10.1016/S0968-0896(02)00054-8; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; DeGrado TR, 2001, J NUCL MED, V42, P1805; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hara T, 2002, J NUCL MED, V43, P187; Harlow E., 1988, ANTIBODIES LAB MANUA; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; Howe AG, 2001, BBA-MOL CELL BIOL L, V1534, P65, DOI 10.1016/S1388-1981(01)00181-0; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Nakagami K, 1999, JPN J CANCER RES, V90, P1212, DOI 10.1111/j.1349-7006.1999.tb00698.x; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PORTER TJ, 1990, J BIOL CHEM, V265, P414; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RAMIREZ DM, 2001, BIOCHEM BIOPH RES CO, V285, P873; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; SUMMERS EF, 1988, GENETICS, V120, P909; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Xie ZH, 2001, MOL BIOL CELL, V12, P1117, DOI 10.1091/mbc.12.4.1117; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P63, DOI 10.1016/S0005-2760(97)00104-5; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	79	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34978	34986		10.1074/jbc.M205316200	http://dx.doi.org/10.1074/jbc.M205316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12105205	hybrid			2022-12-27	WOS:000178117000042
J	Callahan, MK; Chaillot, D; Jacquin, C; Clark, PR; Menoret, A				Callahan, MK; Chaillot, D; Jacquin, C; Clark, PR; Menoret, A			Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR IMMUNOGENICITY; MOLECULAR CHAPERONES; SUBSTRATE-BINDING; REDOX SWITCH; IN-VIVO; GP96; STRESS; EXPRESSION; MECHANISM	Hsp70 and Hsc70 are two chaperones of high homology expressed under contrasting situations. Hsc70 is constitutively expressed and poorly stress-inducible, whereas Hsp70 is unabundant in normal physiological situations and strongly induced under oxidative stress. In the present study we show that the chaperoning activity of purified Hsp70 and Hsc70 is minimal under reducing conditions and increases in environments that mimic oxidative stress. Association with peptides is more pronounced for Hsp70 than for Hsc70 in every condition tested and is accompanied with a gradual change in secondary structure during oxidation. The binding of peptides to Hsp70 and Hsc70 under oxidative conditions is not reversible by treatment with a reducing agent, confirming that other chaperone-associated factors are required for substrate release. These findings support the idea that formation of HSP70-peptide complexes and possibly their immunogenicity is enhanced in conditions of stress.	Univ Connecticut, Sch Med, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT 06030 USA	University of Connecticut	Menoret, A (corresponding author), Univ Connecticut, Sch Med, Ctr Immunotherapy Canc & Infect Dis, Farmington, CT 06030 USA.				NCI NIH HHS [R01 CA/AI 84042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelidis CE, 1999, EUR J BIOCHEM, V259, P505, DOI 10.1046/j.1432-1327.1999.00078.x; Barbirz S, 2000, J BIOL CHEM, V275, P18759, DOI 10.1074/jbc.M001089200; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; CALLAHAN M, 2001, 11 INT M IMM STOCKH; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Clark PR, 2001, CELL STRESS CHAPERON, V6, P121, DOI 10.1379/1466-1268(2001)006<0121:TIHAAM>2.0.CO;2; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUANG LE, 1994, J BIOL CHEM, V269, P30718; Ishii T, 1999, J IMMUNOL, V162, P1303; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu H, 1996, J BIOL CHEM, V271, P4805; McDuffee AT, 1997, J CELL PHYSIOL, V171, P143, DOI 10.1002/(SICI)1097-4652(199705)171:2<143::AID-JCP4>3.0.CO;2-O; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Menoret A, 2000, J IMMUNOL METHODS, V237, P119, DOI 10.1016/S0022-1759(00)00137-X; MENORET A, 1995, J IMMUNOL, V155, P740; Menoret A, 1999, BIOCHEM BIOPH RES CO, V262, P813, DOI 10.1006/bbrc.1999.1306; MENORET A, 2002, IN PRESS INT J HYPER; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Peng P, 1997, J IMMUNOL METHODS, V204, P13, DOI 10.1016/S0022-1759(97)00017-3; Raman B, 2001, FEBS LETT, V489, P19, DOI 10.1016/S0014-5793(01)02074-9; Ruddock LW, 1999, CURR BIOL, V9, pR400, DOI 10.1016/S0960-9822(99)80253-X; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; SRIVASTAVA PK, 1994, EXPERIENTIA, V50, P1054, DOI 10.1007/BF01923461; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Wells AD, 1998, INT IMMUNOL, V10, P609, DOI 10.1093/intimm/10.5.609; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	35	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33604	33609		10.1074/jbc.M202890200	http://dx.doi.org/10.1074/jbc.M202890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12114509	hybrid			2022-12-27	WOS:000177959100011
J	Tran, NL; Adams, DG; Vaillancourt, RR; Heimark, RL				Tran, NL; Adams, DG; Vaillancourt, RR; Heimark, RL			Signal transduction from N-cadherin increases Bcl-2 - Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; INTERCELLULAR ADHERENS JUNCTIONS; PROSTATE-CANCER PROGRESSION; PROTEIN-KINASE-B; EPITHELIAL-CELLS; CARCINOMA-CELLS; ALPHA-CATENIN; EXPRESSION; SURVIVAL; APOPTOSIS	Associated with the metastatic progression of epithelial tumors is the dynamic regulation of cadherins. Whereas E-cadherin is expressed in most epithelium and carcinomas, recent studies suggest that the up-regulation of other cadherin subtypes in carcinomas, such as N-cadherin, may function in cancer progression. We demonstrate that a signal transduction cascade links the N-cadherin-catenin adhesion complex to up-regulation of the anti-apoptotic protein Bcl-2. In suspension, aggregates of DU-145 cells, an E-cadherin expressing human prostate carcinoma line, survive loss of integrin-dependent adhesion by a different anti-apoptotic signaling pathway than the N-cadherin expressing lines PC3 and PC3N. N-cadherin intercellular adhesion mediates a 3.5-fold increase in Bcl-2 protein expression, whereas the level of the proapoptotic protein Bax remains constant. Only N-cadherin ligation in PC3 cells, which express both N-cadherin and E-cadherin, is sufficient to induce activation of Akt/protein kinase B. N-cadherin homophilic ligation initiates phosphatidylinositol 3-kinase-dependent activation of Akt resulting in Akt phosphorylation of Bad on serine 136. Following N-cadherin homophilic adhesion phosphatidylinositol 3-kinase was identified in immunoprecipitates of the N-cadherin-catenin complex. The recruitment of phosphatidylinositol 3-kinase to the adhesion complex is dependent on ligation of N-cadherin and an organized actin cytoskeleton because cytochalasin D blocks the recruitment. We propose that N-cadherin homophilic adhesion can initiate anti-apoptotic signaling, which enhances the Akt cell survival pathway in metastatic cancer.	Univ Arizona, Ctr Hlth Sci, Canc Biol Grad Program, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Arizona, Ctr Hlth Sci, Dept Surg, Tucson, AZ 85724 USA; Univ Arizona, Ctr Hlth Sci, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona	Heimark, RL (corresponding author), Univ Arizona, Ctr Hlth Sci, Canc Biol Grad Program, Dept Pharmacol & Toxicol, POB 245084,1501 N Campbell Ave, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019710] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09213, CA5666] Funding Source: Medline; NIA NIH HHS [AG19710] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Arregui C, 2000, J CELL BIOL, V149, P1263, DOI 10.1083/jcb.149.6.1263; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Chan B, 1998, J DIGIT IMAGING, V11, P199, DOI 10.1007/BF03168304; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHOI YS, 1990, J CELL BIOL, V110, P1575, DOI 10.1083/jcb.110.5.1575; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; DEL PL, 1997, SCIENCE, V278, P687; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kurosu H, 2001, J BIOCHEM-TOKYO, V130, P73, DOI 10.1093/oxfordjournals.jbchem.a002964; Lambert M, 2000, J CELL SCI, V113, P2207; Larue L, 1996, DEVELOPMENT, V122, P3185; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Luo Y, 2001, DEVELOPMENT, V128, P459; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MORTON RA, 1993, CANCER RES, V53, P3585; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sechi AS, 2000, J CELL SCI, V113, P3685; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Troyanovsky RB, 1999, J CELL SCI, V112, P4379; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; VOLK T, 1984, EMBO J, V3, P2249, DOI 10.1002/j.1460-2075.1984.tb02123.x; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	73	135	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32905	32914		10.1074/jbc.M200300200	http://dx.doi.org/10.1074/jbc.M200300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12095980	hybrid			2022-12-27	WOS:000177859000068
J	Lee, SH; Jin, JB; Song, JH; Min, MK; Park, DS; Kim, YW; Hwang, IH				Lee, SH; Jin, JB; Song, JH; Min, MK; Park, DS; Kim, YW; Hwang, IH			The intermolecular interaction between the PH domain and the C-terminal domain of Arabidopsis dynamin-like 6 determines lipid binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CLATHRIN-MEDIATED ENDOCYTOSIS; CELL PLATE FORMATION; TRANS-GOLGI NETWORK; RATE-LIMITING STEP; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOINOSITIDE-BINDING; MITOCHONDRIAL FISSION; MOLECULAR-CLONING	Dynamin and its related proteins are a group of mechanochemical proteins involved in the modulation of lipid membranes in various biological processes. Here we investigate the nature of membrane binding of the Arabidopsis dynamin-like 6 (ADL6) involved in vesicle trafficking from the trans-Golgi network to the central vacuole. Fractionation experiments by continuous sucrose gradients and gel filtration revealed that the majority of ADL6 is associated with membranes in vivo. Amino acid sequence analysis revealed that ADL6 has a putative pleckstrin homology (PH) domain. In vitro lipid binding assays demonstrated that ADL6 showed high affinity binding to phosphatidylinositol 3-phosphate (PtdIns-3-P) and that the PH domain was responsible for this interaction. However, the PH domain alone binds equally well to both PtdIns-3-P and phosphatidylinositol 4-phosphate (PtdIns-4-P). Interestingly, the high affinity binding of the PH domain to PtdIns-3-P was restored by a protein-protein interaction between the PH domain and the C-terminal region. In addition, deletion of the inserted regions within the PH domain results in high affinity binding of the PH domain to PtdIns-3-P. These results suggest that ADL6 binds specifically to PtdIns-3-P and that the lipid binding specificity is determined by the interaction between the PH domain and the C-terminal domain of ADL6.	Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Hwang, IH (corresponding author), Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea.			Lee, Sunghoon/0000-0002-8916-2035; Lee, Sunghoon/0000-0002-6682-119X				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DOMBROWSKI JE, 1995, PLANT MOL BIOL, V28, P1121, DOI 10.1007/BF00032672; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; Gu XJ, 1997, PLANT CELL, V9, P157, DOI 10.1105/tpc.9.2.157; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Kang SG, 1998, PLANT MOL BIOL, V38, P437, DOI 10.1023/A:1006099718761; Kim DH, 2001, PLANT CELL, V13, P287, DOI 10.1105/tpc.13.2.287; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim YW, 2001, PLANT PHYSIOL, V127, P1243, DOI 10.1104/pp.010450; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Park JM, 1997, PLANT PHYSIOL, V115, P763, DOI 10.1104/pp.115.2.763; Park JM, 1998, EMBO J, V17, P859, DOI 10.1093/emboj/17.4.859; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; SI SA, 2002, P NATL ACAD SCI USA, V99, P5727; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; SOISSON SM, 1988, CELL, V16, P259; Stenmark H, 1999, J CELL SCI, V112, P4175; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Zhang ZM, 2000, J BIOL CHEM, V275, P8779, DOI 10.1074/jbc.275.12.8779	48	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31842	31849		10.1074/jbc.M204770200	http://dx.doi.org/10.1074/jbc.M204770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105222	hybrid			2022-12-27	WOS:000177718700068
J	Gudi, T; Chen, JC; Casteel, DE; Seasholtz, TM; Boss, GR; Pilz, RB				Gudi, T; Chen, JC; Casteel, DE; Seasholtz, TM; Boss, GR; Pilz, RB			cGMP-dependent protein kinase inhibits serum-response element-dependent transcription by inhibiting Rho activation and functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; REQUIRES NUCLEAR TRANSLOCATION; LIGHT-CHAIN PHOSPHORYLATION; GENE-EXPRESSION; CYCLIC-GMP; NITRIC-OXIDE; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; NEURITE RETRACTION; POTENTIAL EFFECTOR	RhoA, in its active GTP-bound form, stimulates transcription through activation of the serum-response factor (SRF). We found that cGMP inhibited serum-induced Rho-GTP loading and transcriptional activation of SRF-dependent reporter genes in smooth muscle and glial cells in a cGMP-dependent protein kinase (G-kinase)-dependent fashion. Serum stimulation of the SRF target gene vinculin was also blocked by cGMP/G-kinase. G-kinase activation inhibited SRF-dependent transcription induced by upstream RhoA activators including Galpha(13) and p115RhoGEF, with Galpha(13)-induced Rho-GTP loading inhibited by G-kinase. G-kinase had no effect on the high activation levels of RhoA(63L) or the double mutant RhoA(63L,188A) but inhibited transcriptional activation by these two RhoA mutants to a similar extent, suggesting an effect downstream of RhoA and independent of RhoA Ser(188) phosphorylation. Constitutively active forms of the Rho effectors Rho kinase (ROK), PKN, and PRK-2 induced SRF-dependent transcription in a cell type-specific fashion with ROK being the most efficient; G-kinase inhibited transcription induced by all three effectors without affecting ROK catalytic activity. G-kinase had no effect on RhoA(63L)induced morphological changes in glial cells, suggesting distinct transcriptional and cytoskeletal effectors of RhoA. We conclude that G-kinase inhibits SRF-dependent transcription by interfering with RhoA signaling; G-kinase acts both upstream of RhoA, inhibiting serum- or Galpha(13)-induced Rho activation, and downstream of RhoA, inhibiting steps distal to the Rho targets ROK, PKN, and PRK-2.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA89828] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Beqaj S, 2002, J CELL BIOL, V156, P893, DOI 10.1083/jcb.200107049; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Clancy RM, 1997, J CLIN INVEST, V100, P1789, DOI 10.1172/JCI119706; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V278, pC942, DOI 10.1152/ajpcell.2000.278.5.C942; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ingram AJ, 2000, J BIOL CHEM, V275, P40301, DOI 10.1074/jbc.M007018200; Kim SO, 2000, BBA-MOL CELL RES, V1496, P277, DOI 10.1016/S0167-4889(00)00026-4; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; Sobue K, 1999, MOL CELL BIOCHEM, V190, P105, DOI 10.1023/A:1006941621170; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tigyi G, 1996, J NEUROCHEM, V66, P549; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Yao J, 1998, KIDNEY INT, V53, P598, DOI 10.1046/j.1523-1755.1998.00793.x; Yu SM, 1997, CIRCULATION, V95, P1269; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	74	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37382	37393		10.1074/jbc.M204491200	http://dx.doi.org/10.1074/jbc.M204491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12119292	hybrid			2022-12-27	WOS:000178447100061
J	Hamano, Y; Kuzuyama, T; Itoh, N; Furihata, K; Seto, H; Dairi, T				Hamano, Y; Kuzuyama, T; Itoh, N; Furihata, K; Seto, H; Dairi, T			Functional analysis of eubacterial diterpene cyclases responsible for biosynthesis of a diterpene antibiotic, terpentecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUALENE-HOPENE CYCLASE; ENT-KAURENE SYNTHASE; BACTERIUM PRODUCING HOPANOIDS; HIGH-LEVEL EXPRESSION; PHAEOSPHAERIA SP L487; FIR ABIES GRANDIS; GIBBERELLIN BIOSYNTHESIS; ABIETADIENE SYNTHASE; LANOSTEROL SYNTHASE; MOLECULAR-CLONING	Eubacterial diterpene cyclase genes had previously been cloned from a diterpenoid antibiotic terpentecin producer (Dairi, T., Hamano, Y., Kuzuyama, T., Itoh, N., Furihata, K., and Seto, H. (2001) J. BacterioL 183, 60856094). Their products, open reading frame 11 (ORF11) and ORF12, were essential for the conversion of geranylgeranyl diphosphate (GGDP) into terpentetriene (TTE) that had the same basic skeleton as terpentecin. In this study, functional analyses of these two enzymes were performed by using purified recombinant enzymes. The ORF11 product converted GGDP into a cyclized intermediate, terpentedienol diphosphate (TDP), which was then transformed into TTE by the ORF12 product. Interestingly, the ORF12 product directly catalyzed the conversion of GGDP into three olefinic compounds. Moreover, the ORF12 product utilized farnesyl diphosphate as a substrate to give three olefinic compounds, which had the same structures as those formed from GGDP with the exception of the chain lengths. These results suggested that the ORF11 product with a DXDD motif converted GGDP into TDP by a protonation-initiated cyclization and that the ORF12 product with a DDXXD motif completed the transformation of TDP to the olefin, terpentetriene by an ionization-initiated reaction followed by deprotonation. The kinetics of the ORF12 product indicated that the affinity for TDP and GGDP were higher than that of farnesyl diphosphate and that the relative activity of the reaction converting TDP into TTE was highest among the reactions using TDP, GGDP, or farnesyl diphosphate as the substrate. These results suggested that an actual reaction catalyzed by the ORF12 was the conversion of TDP into TTE in vivo.	Toyama Prefectural Univ, Biotechnol Res Ctr, Toyama 9390398, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Div Agr & Agr Life Sci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Univ Agr, Fac Appl Biosci, Setagaya Ku, Tokyo 1568502, Japan	Toyama Prefectural University; University of Tokyo; University of Tokyo; Tokyo University of Agriculture	Dairi, T (corresponding author), Toyama Prefectural Univ, Biotechnol Res Ctr, Toyama 9390398, Japan.	dairi@pu-toyama.ac.jp	Dairi, Tohru/A-5448-2012	Dairi, Tohru/0000-0002-3406-7970; Kuzuyama, Tomohisa/0000-0002-7221-5858; Hamano, Yoshimitsu/0000-0001-5117-5116				ABE E, 1980, NIPPON NOGEI KAGAKU, V54, P761; ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; AitAli T, 1997, PLANT J, V11, P443, DOI 10.1046/j.1365-313X.1997.11030443.x; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; BURGER BV, 1981, Z NATURFORSCH C, V36, P340; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; Connolly J. D., 1992, DICT TERPENOIDS; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Dairi T, 2001, J BACTERIOL, V183, P6085, DOI 10.1128/JB.183.20.6085-6094.2001; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; FROST RG, 1977, PLANT PHYSIOL, V59, P22, DOI 10.1104/pp.59.1.22; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Hill AM, 1996, ARCH BIOCHEM BIOPHYS, V336, P283, DOI 10.1006/abbi.1996.0559; Hoshino T, 2002, CHEM COMMUN, P291, DOI 10.1039/b108995c; Huang KX, 1998, ARCH BIOCHEM BIOPHYS, V352, P144, DOI 10.1006/abbi.1998.0578; Kawaide H, 2000, J BIOL CHEM, V275, P2276, DOI 10.1074/jbc.275.4.2276; Kawaide H, 1997, J BIOL CHEM, V272, P21706, DOI 10.1074/jbc.272.35.21706; KLEEMANN G, 1994, BBA-LIPID LIPID MET, V1210, P317, DOI 10.1016/0005-2760(94)90235-6; KOEPP AE, 1995, J BIOL CHEM, V270, P8686, DOI 10.1074/jbc.270.15.8686; KUSANO M, 1995, BIOL PHARM BULL, V18, P195; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MACMILLAN J, 1999, COMPREHENSIVE NATURA, V2, P217; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; McCaskill D, 1997, Adv Biochem Eng Biotechnol, V55, P107; NABETA K, 1990, J NAT PROD, V53, P1241, DOI 10.1021/np50071a016; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; Perzl M, 1997, MICROBIOL-UK, V143, P1235, DOI 10.1099/00221287-143-4-1235; Peters RJ, 2002, BIOCHEMISTRY-US, V41, P1836, DOI 10.1021/bi011879d; Peters RJ, 2002, P NATL ACAD SCI USA, V99, P580, DOI 10.1073/pnas.022627099; Peters RJ, 2001, J AM CHEM SOC, V123, P8974, DOI 10.1021/ja010670k; Peters RJ, 2000, BIOCHEMISTRY-US, V39, P15592, DOI 10.1021/bi001997l; RAILTON ID, 1984, PHYTOCHEMISTRY, V23, P1261, DOI 10.1016/S0031-9422(00)80438-0; Ravn MM, 2000, ORG LETT, V2, P573, DOI 10.1021/ol991230p; REIPEN IG, 1995, MICROBIOL-SGM, V141, P155, DOI 10.1099/00221287-141-1-155; SASAOKA S, 1985, CHEM LETT, P315, DOI 10.1246/cl.1985.315; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; Tippelt A, 1998, BBA-LIPID LIPID MET, V1391, P223, DOI 10.1016/S0005-2760(97)00212-9; Vogel BS, 1996, J BIOL CHEM, V271, P23262, DOI 10.1074/jbc.271.38.23262; Waterhouse JS, 1996, J CHEM ECOL, V22, P1307, DOI 10.1007/BF02266967; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201	46	75	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37098	37104		10.1074/jbc.M206382200	http://dx.doi.org/10.1074/jbc.M206382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138123	hybrid			2022-12-27	WOS:000178447100026
J	Ramos, M; Alvarez, I; Sesma, L; Logean, A; Rognan, D; de Castro, JAL				Ramos, M; Alvarez, I; Sesma, L; Logean, A; Rognan, D; de Castro, JAL			Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; HLA-B27 TRANSGENIC RATS; OUTER-MEMBRANE PROTEIN; HL-A 27; ANKYLOSING-SPONDYLITIS; PEPTIDE BINDING; LYMPHOCYTE EPITOPES; DEVELOPMENTAL CYCLE; REACTIVE ARTHRITIS; MUTANTS MIMICKING	HLA-B27 is strongly associated with spondyloarthropathies, including ankylosing spondylitis and reactive arthritis. The latter disease is triggered by various Gram-negative bacteria. A dodecamer derived from the intracytoplasmic tail of HLA-B27 was a natural ligand of three disease-associated subtypes (B*2702, B*2704, and B*2705) but not of two (B*2706 and B*2709), weakly or not associated to spondyloarthropathy. This peptide was strikingly homologous to protein sequences from arthritogenic bacteria, particularly to a region of the DNA primase from Chlamydia trachomatis. A synthetic peptide with this bacterial sequence bound in vitro disease-associated subtypes equally as the natural B27-derived ligand. The chlamydial peptide was generated by the 20 S proteasome from a synthetic 28-mer with the sequence of the corresponding region of the bacterial DNA primase. Molecular modeling suggested that the B27-derived and chlamydial peptides adopt very similar conformations in complex with B*2705. The results demonstrate that an HLA-B27-derived peptide mimicking arthritogenic bacterial sequences is a natural ligand of disease-associated HLA-B27 subtypes and suggest that the homologous chlamydial peptide might be presented by HLA-B27 on Chlamydia-infected cells.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; CNRS, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Centre National de la Recherche Scientifique (CNRS)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Alvarez, Iñaki/A-6684-2011; Rognan, Didier/B-9939-2014; Ramos, Manuel/F-5076-2016	Alvarez, Iñaki/0000-0001-9484-0868; Ramos, Manuel/0000-0002-0404-7936				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Alvarez I, 2001, J BIOL CHEM, V276, P32729, DOI 10.1074/jbc.M104663200; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; BURMESTER GR, 1995, ANNU REV IMMUNOL, V13, P229, DOI 10.1146/annurev.iy.13.040195.001305; CALVO V, 1990, J IMMUNOL, V144, P4038; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; DICK LR, 1994, J IMMUNOL, V152, P3884; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Fling SP, 2001, P NATL ACAD SCI USA, V98, P1160, DOI 10.1073/pnas.98.3.1160; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia F, 1997, TISSUE ANTIGENS, V49, P23, DOI 10.1111/j.1399-0039.1997.tb02705.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Garcia-Fernandez S, 2001, TISSUE ANTIGENS, V58, P259, DOI 10.1034/j.1399-0039.2001.580407.x; Gerard HC, 2001, MOL MICROBIOL, V41, P731, DOI 10.1046/j.1365-2958.2001.02550.x; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; Kessler JH, 2001, J EXP MED, V193, P73, DOI 10.1084/jem.193.1.73; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kim SK, 1999, J IMMUNOL, V162, P6855; Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5; Kuon W, 2001, J IMMUNOL, V167, P4738, DOI 10.4049/jimmunol.167.8.4738; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; Logean A, 2001, BIOORG MED CHEM LETT, V11, P675, DOI 10.1016/S0960-894X(01)00021-X; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Marti M, 1999, Curr Rheumatol Rep, V1, P78, DOI 10.1007/s11926-999-0029-x; May E, 1996, INT IMMUNOL, V8, P1815, DOI 10.1093/intimm/8.11.1815; Nasution AR, 1997, J RHEUMATOL, V24, P1111; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PLAUNT MR, 1988, INFECT IMMUN, V56, P3021, DOI 10.1128/IAI.56.12.3021-3025.1988; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Ren EC, 1997, TISSUE ANTIGENS, V49, P67, DOI 10.1111/j.1399-0039.1997.tb02713.x; Rognan D, 1999, J MED CHEM, V42, P4650, DOI 10.1021/jm9910775; Scidmore MA, 1996, INFECT IMMUN, V64, P5366, DOI 10.1128/IAI.64.12.5366-5372.1996; SCOFIELD RH, 1995, LANCET, V345, P1542, DOI 10.1016/S0140-6736(95)91089-1; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; Shaw EI, 2000, MOL MICROBIOL, V37, P913, DOI 10.1046/j.1365-2958.2000.02057.x; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Ugrinovic S, 1997, J IMMUNOL, V159, P5715; VILLADANGOS JA, 1994, J IMMUNOL, V152, P2317; WICHLAN DG, 1993, J BACTERIOL, V175, P2936, DOI 10.1128/JB.175.10.2936-2942.1993; Yague J, 2000, J EXP MED, V191, P2083, DOI 10.1084/jem.191.12.2083; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zhang L, 1998, INFECT IMMUN, V66, P1167, DOI 10.1128/IAI.66.3.1167-1173.1998; Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935; Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525; Zhou M, 1998, J EXP MED, V188, P877, DOI 10.1084/jem.188.5.877	68	63	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37573	37581		10.1074/jbc.M205470200	http://dx.doi.org/10.1074/jbc.M205470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12122005	hybrid			2022-12-27	WOS:000178447100085
J	Akbarzadeh, S; Ji, H; Frecklington, D; Marmy-Conus, N; Mok, YF; Bowes, L; Devereux, L; Linsenmeyer, M; Simpson, RJ; Dorow, DS				Akbarzadeh, S; Ji, H; Frecklington, D; Marmy-Conus, N; Mok, YF; Bowes, L; Devereux, L; Linsenmeyer, M; Simpson, RJ; Dorow, DS			Mixed lineage kinase 2 interacts with clathrin and influences clathrin-coated vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; ZIPPER-BEARING KINASE; LEUCINE-ZIPPER; MEDIATED ENDOCYTOSIS; TERMINAL DOMAIN; RECEPTOR ACTIVATION; SIGNALING PROTEINS; MOLECULAR-CLONING; SH3 DOMAINS; C-JUN	Mixed lineage kinase 2 (MLK2) is a protein kinase that signals in the stress-activated Jun N-terminal kinase signal transduction pathway. We used immunoprecipitation and mass spectrometric analysis to identify MLK2-binding proteins in cell lines with inducible expression of green fluorescent protein-tagged MLK2. Here we report the identification of clathrin as a binding partner for MLK2 in both cultured cells and mammalian brain. We demonstrate that clathrin binding requires a motif (LLDMD) located near the MLK2 C terminus, which is similar to "clathrin box" motifs important for binding of clathrin coat assembly and accessory proteins to the clathrin heavy chain. A C-terminal fragment of MLK2 containing this motif binds strongly to clathrin, and mutation of the LLDMD sequence to LAAAD completely abrogates clathrin binding. We isolated clathrin-coated vesicles from green fluorescent protein-MLK2-expressing cells and from mouse brain lysates and found that MLK2 is enriched along with clathrin in these vesicles. In addition, we demonstrated that endogenous MLK2 co-immunoprecipitates with clathrin heavy chain from the vesicle-enriched fraction of mouse brain lysate. Furthermore, overexpression of MLK2 in cultured cells inhibits accumulation of labeled transferrin in recycling endosomes during receptor-mediated endocytosis. These findings suggest a role for MLK2 and the stress-signaling pathway at sites of clathrin activity in vesicle formation or trafficking.	Peter MacCallum Canc Inst, Trescowthick Res Ctr, Melbourne, Vic 8006, Australia; Ludwig Inst Canc Res, Joint Proteom Lab, Parkville, Vic 3042, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3042, Australia	Peter Maccallum Cancer Center; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute	Dorow, DS (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Ctr, Locked Bag 1 A Beckett St, Melbourne, Vic 8006, Australia.	d.dorow@pmci.unimelb.edu.au		akbarzadeh, shivaa/0000-0002-2787-3317; Simpson, Richard/0000-0002-9834-0796; Devereux, Lisa/0000-0003-2435-5888				BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coffey ET, 2000, J NEUROSCI, V20, P7602; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Greene B, 2000, TRAFFIC, V1, P69, DOI 10.1034/j.1600-0854.2000.010110.x; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Phelan DR, 1999, MOL REPROD DEV, V52, P135, DOI 10.1002/(SICI)1098-2795(199902)52:2&lt;135::AID-MRD3&gt;3.0.CO;2-N; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Rasmussen RK, 1998, ELECTROPHORESIS, V19, P809, DOI 10.1002/elps.1150190535; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V205, P1494, DOI 10.1006/bbrc.1994.2834; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Shanavas A, 2000, P NATL ACAD SCI USA, V97, P14139, DOI 10.1073/pnas.97.26.14139; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Tawadros T, 2002, J CELL SCI, V115, P385; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; Zhu HJ, 1999, J BIOL CHEM, V274, P29220, DOI 10.1074/jbc.274.41.29220	73	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36280	36287		10.1074/jbc.M204626200	http://dx.doi.org/10.1074/jbc.M204626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12105200	hybrid			2022-12-27	WOS:000178275100064
J	Hashimoto, G; Inoki, I; Fujii, Y; Aoki, T; Ikeda, E; Okada, Y				Hashimoto, G; Inoki, I; Fujii, Y; Aoki, T; Ikeda, E; Okada, Y			Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; PLATELET FACTOR-IV; ENZYMATIC-PROPERTIES; TYROSINE KINASE; CARCINOMA-CELLS; TGF-BETA; EXPRESSION; IDENTIFICATION; PURIFICATION; ACTIVATION	Vascular endothelial growth factor (VEGF), a potent angiogenic mitogen, plays a crucial role in angiogenesis under various pathophysiological conditions. We have recently demonstrated that VEGF(165), one of the VEGF isoforms, binds connective tissue growth factor (CTGF) and that its angiogenic activity is inhibited in the VEGF(165).CTGF complex form (Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakamura, H., Makino, K., Ikeda, E., Takata, S., Kobayashi, K. and Okada, Y. (2002) FASEB J. 16, 219-221). In the present study, We further examined the susceptibility of the VEGF(165).CTGF complex to matrix metalloproteinases (MMP-1, -2, -39 -7, -9, and -13), ADAMTS4 (aggrecanase-1), and serine proteinases, and evaluated the recovery of the angiogenic activity of VEGF,65 after the treatment. Among the MMPs, MMP-1, -3, -7, and -13 processed CTGF of the complex into the major NH2- and COOH-terminal fragments, whereas VEGF(165) was completely resistant to the MMPs. On the other hand, elastase and plasmin cleaved both CTGF and VEGF(165) of the complex, but they were completely resistant to ADAMTS4. By digestion of the immobilized VEGF(165).CTGF complex with MMP-3 or MMP-7, both NH2- and COOH-terminal fragments of CTGF were dissociated and released from the complex into the liquid phase. The in vitro angiogenic activity of VEGF(165) blocked in the VEGF(165).CTGF complex was reactivated to original levels after CTGF digestion of the complex with MMP-1, -3, and -13. Recovery of angiogenic activity was further confirmed by in vivo angiogenesis assay using a Matrigel injection model in mice. These results demonstrate for the first time that CTGF is a substrate of MMPs and that the angiogenic activity of VEGF(165) suppressed by the complex formation with CTGF is recovered through the selective degradation of CTGF by MMPs. MMPs may play a novel role through CTGF degradation in VEGF-induced angiogenesis during embryonic development, tissue maintenance, and/or pathological processes of various diseases.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan; Fukui Med Univ, Dept Chem, Fukui 9101193, Japan; Daiichi Fine Chem Co Ltd, Takaoka, Toyama 9338511, Japan	Keio University; University of Fukui	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	Okada@se.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755; Fujii, Yutaka/0000-0001-6357-3795				BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen MM, 2000, J MOL CELL CARDIOL, V32, P1805, DOI 10.1006/jmcc.2000.1215; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ikeda M, 2000, J PATHOL, V191, P426; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOCH AE, 1994, J IMMUNOL, V152, P4149; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lauer G, 2000, J INVEST DERMATOL, V115, P12, DOI 10.1046/j.1523-1747.2000.00036.x; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mitsiades N, 2001, CANCER RES, V61, P577; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; Oemar BS, 1997, CIRCULATION, V95, P831; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 2001, KELLEYS TXB RHEUMATO, P55; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Pufe T, 2001, ARTHRITIS RHEUM, V44, P1082, DOI 10.1002/1529-0131(200105)44:5<1082::AID-ANR188>3.0.CO;2-X; Sang Q X, 1998, Cell Res, V8, P171; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; SHIOZAWA S, 1992, ANN RHEUM DIS, V51, P869, DOI 10.1136/ard.51.7.869; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yang DH, 1998, J CLIN ENDOCR METAB, V83, P2593, DOI 10.1210/jc.83.7.2593	53	283	314	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36288	36295		10.1074/jbc.M201674200	http://dx.doi.org/10.1074/jbc.M201674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12114504	hybrid			2022-12-27	WOS:000178275100065
J	Liu, R; Pidikiti, R; Ha, CE; Petersen, CE; Bhagavan, NV; Eckenhoff, RG				Liu, R; Pidikiti, R; Ha, CE; Petersen, CE; Bhagavan, NV; Eckenhoff, RG			The role of electrostatic interactions in human serum albumin binding and stabilization by halothane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; GENERAL-ANESTHETICS; MOLECULAR-INTERACTIONS; RESOLUTION; STABILITY; PROTEINS; BIOLOGY; SITES	Electrostatic interactions have been proposed as a potentially important force for anesthetics and protein binding but have not yet been tested directly. In the present study, we used wild-type human serum albumin (HSA) and specific site-directed mutants as a native protein model to investigate the role of electrostatic interactions in halothane binding. Structural geometry analysis of the HSA-halothane complex predicted an absence of significant electrostatic interactions, and direct binding (tryptophan fluorescence and zonal elution chromatography) and stability experiments (hydrogen exchange) confirmed that loss of charge in the binding sites, by charged to uncharged mutations and by changing ionic strength of the buffer, generally increased both regional (tryptophan region) and global halothane/HSA affinity. The results indicate that electrostatic interactions (full charges) either do not contribute or diminish halothane binding to HSA, leaving only the more general hydrophobic and van der Waals forces as the major contributors to the binding interaction.	Univ Penn, Med Ctr, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Hawaii, John A Burns Sch Med, Dept Biochem & Biophys, Honolulu, HI 96822 USA	University of Pennsylvania; University of Hawaii System	Liu, R (corresponding author), Univ Penn, Med Ctr, Dept Anesthesia, 3400 Spruce St,7 Dulles, Philadelphia, PA 19104 USA.	liu@mail.med.upenn.edu		Eckenhoff, Roderic/0000-0002-5581-746X	PHS HHS [55876, 51595] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Chan K, 2002, ANAL BIOCHEM, V301, P308, DOI 10.1006/abio.2001.5506; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Eckenhoff RG, 2000, J BIOL CHEM, V275, P30439, DOI 10.1074/jbc.M005052200; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GURSKY O, 1994, P NATL ACAD SCI USA, V91, P12388, DOI 10.1073/pnas.91.26.12388; Hameroff S, 1998, TOXICOL LETT, V101, P31, DOI 10.1016/S0378-4274(98)00162-3; HAMEROFF SR, 1982, PHYSIOL CHEM PHYS M, V14, P183; Johansson JS, 1999, ANESTHESIOLOGY, V90, P235, DOI 10.1097/00000542-199901000-00030; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Manderson GA, 2002, BIOCHEMISTRY-US, V41, P4080, DOI 10.1021/bi0160718; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V214, P1121, DOI 10.1006/bbrc.1995.2402; SANDORFY C, 1978, ANESTHESIOLOGY, V48, P357, DOI 10.1097/00000542-197805000-00010; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; Tang P, 2000, BIOPHYS J, V78, P1804, DOI 10.1016/S0006-3495(00)76730-0; Tang P, 2001, J COMPUT CHEM, V22, P436, DOI 10.1002/1096-987X(200103)22:4<436::AID-JCC1014>3.0.CO;2-U; Tanner JW, 1999, BBA-PROTEIN STRUCT M, V1430, P46, DOI 10.1016/S0167-4838(98)00258-1; Trivedi VD, 1999, J PHARM PHARMACOL, V51, P591, DOI 10.1211/0022357991772691; WULF RJ, 1957, ANESTHESIOLOGY, V18, P97, DOI 10.1097/00000542-195701000-00010	27	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36373	36379		10.1074/jbc.M205479200	http://dx.doi.org/10.1074/jbc.M205479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12118010	hybrid			2022-12-27	WOS:000178275100076
J	Wang, JH; Doyle, M; Manning, BJ; Wu, QD; Blankson, S; Redmond, HP				Wang, JH; Doyle, M; Manning, BJ; Wu, QD; Blankson, S; Redmond, HP			Induction of bacterial lipoprotein tolerance is associated with suppression of Toll-like receptor 2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BORRELIA-BURGDORFERI LIPOPROTEINS; GRAM-NEGATIVE BACTERIA; TUMOR-NECROSIS-FACTOR; LPS BINDING-PROTEIN; CUTTING EDGE; ENDOTOXIN TOLERANCE; LIPOPOLYSACCHARIDE LPS; SIGNAL-TRANSDUCTION; CYTOKINE PRODUCTION	Tolerance to bacterial cell wall components including lipopolysaccharide (LPS) may represent an essential regulatory mechanism during bacterial infection. Two members of the Toll-like receptor (TLR) family, TLR2 and TLR4, recognize the specific pattern of bacterial cell wall components. TLR4 has been found to be responsible for LPS tolerance. However, the role of TLR2 in bacterial lipoprotein (BLP) tolerance and LPS tolerance is unclear. Pretreatment of human THP-1 monocytic cells with a synthetic bacterial lipopeptide induced tolerance to a second BLP challenge with diminished tumor necrosis factor-alpha and interleukin-6 production, termed BLP tolerance. Furthermore, BLP-tolerized THP-1 cells no longer responded to LPS stimulation, indicating a cross-tolerance to LPS. Induction of BLP tolerance was CD14-independent, as THP-1 cells that lack membrane-bound CD14 developed tolerance both in serum-free conditions and in the presence of a specific CD14 blocking monoclonal antibody (MEM-18). Pre-exposure of THP-1 cells to BLP suppressed mitogen-activated protein kinase phosphorylation and nuclear factor-kappaB activation in response to subsequent BLP and LPS stimulation, which is comparable with that found in LPS-tolerized cells, indicating that BLP tolerance and LPS tolerance may share similar intracellular pathways. However, BLP strongly enhanced TLR2 expression in non-tolerized THP-1 cells, whereas LPS stimulation had no effect. Furthermore, a specific TLR2 blocking monoclonal antibody (2392) attenuated BLP-induced, but not LPS-induced, tumor necrosis factor-a and interleukin-6 production, indicating BLP rather than LPS as a ligand for TLR2 engagement and activation. More importantly, pretreatment of THP-1 cells with BLP strongly inhibited TLR2 activation in response to subsequent BLP stimulation. In contrast, LPS tolerance did not prevent BLP-induced TLR2 overexpression. These results demonstrate that BLP tolerance develops through down-regulation of TLR2 expression.	Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Acad Dept Surg, Cork, Ireland	University College Cork	Wang, JH (corresponding author), Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Acad Dept Surg, Wilton, Cork, Ireland.		Eckhardt, Erik/G-1567-2010					Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Biberstine KJ, 1996, INFECT IMMUN, V64, P3641, DOI 10.1128/IAI.64.9.3641-3645.1996; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; DeFranco AL, 1998, PROG CLIN BIOL RES, V397, P119; DIRIENZO JM, 1978, ANNU REV BIOCHEM, V47, P481, DOI 10.1146/annurev.bi.47.070178.002405; DOYLE M, 2000, SURG FORUM, V51, P191; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; HAZIOT A, 1993, J IMMUNOL, V151, P1500; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Heine H, 1999, J IMMUNOL, V162, P6971; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Kohler NG, 1997, BIOCHEM BIOPH RES CO, V232, P602, DOI 10.1006/bbrc.1997.6337; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kraatz J, 1999, J SURG RES, V83, P158, DOI 10.1006/jsre.1999.5587; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; LABETA MO, 1993, IMMUNOLOGY, V80, P415; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; MANTHEY CL, 1992, REV MED MICROBIOL, V3, P72; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Perera PY, 1997, J IMMUNOL, V158, P4422; Plotz SG, 2001, BLOOD, V97, P235, DOI 10.1182/blood.V97.1.235; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SANCHEZCANTU L, 1989, ARCH SURG-CHICAGO, V124, P1432; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; SCHADE FU, 1999, ENDOTOXIN HLTH DIS, P50; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Sessler CN, 1996, CLIN CHEST MED, V17, P213, DOI 10.1016/S0272-5231(05)70310-5; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Tominaga K, 1999, BBA-MOL CELL RES, V1450, P130, DOI 10.1016/S0167-4889(99)00037-3; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; Wooten RM, 1998, J IMMUNOL, V160, P5485; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x; Zhang HW, 1997, J IMMUNOL, V159, P4868; Zhang HW, 1998, INFECT IMMUN, V66, P5196, DOI 10.1128/IAI.66.11.5196-5201.1998	53	99	109	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36068	36075		10.1074/jbc.M205584200	http://dx.doi.org/10.1074/jbc.M205584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12133836	hybrid			2022-12-27	WOS:000178275100040
J	Gomes, AV; Guzman, G; Zhao, JJ; Potter, JD				Gomes, AV; Guzman, G; Zhao, JJ; Potter, JD			Cardiac troponin T Isoforms affect the Ca2+ sensitivity and inhibition of force development - Insights into the role of troponin T isoforms in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CONTRACTION; HUMAN LEFT-VENTRICLE; I PHOSPHORYLATION; CALCIUM SENSITIVITY; REGULATORY SITES; ATPASE ACTIVITY; MOLECULAR-BASIS; FAILING HEART; RABBIT HEART; EXPRESSION	At least four isoforms of troponin T (TnT) exist in the human heart, and they are expressed in a developmentally regulated manner. To determine whether the different N-terminal isoforms are functionally distinct with respect to structure, Ca2+ sensitivity, and inhibition of force development, the four known human cardiac troponin T isoforms, TnT1 (all exons present), TnT2 (missing exon 4), TnT3 (missing exon 5), and TnT4 (missing exons 4 and 5), were expressed, purified, and utilized in skinned fiber studies and in reconstituted actomyosin ATPase assays. TnT3, the adult isoform, had a slightly higher a-helical content than the other three isoforms. The variable region in the N terminus of cardiac TnT was found to contribute to the determination of the Ca2+ sensitivity of force development in a charge-dependent manner; the greater the charge the higher the Ca2+ sensitivity, and this was primarily because of exon 5. These studies also demonstrated that removal of either exon 4 or exon 5 from TnT increased the cooperativity of the pCa force relationship. Troponin complexes reconstituted with the four TnT isoforms all yielded the same maximal actin-tropomyosin-activated myosin ATPase activity. However, troponin complexes containing either TnT1 or TnT2 (both containing exon 5) had a reduced ability to inhibit this ATPase activity when compared with wild type troponin (which contains TnT3). Interestingly, fibers containing these isoforms also showed less relaxation suggesting that exon 5 of cardiac TnT affects the ability of Tn to inhibit force development and ATPase activity. These results suggest that the different N-terminal TnT isoforms would produce different functional properties in the heart that would directly affect myocardial contraction.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.		Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NHLBI NIH HHS [HL42325] Funding Source: Medline; NIAMS NIH HHS [AR45391] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1992, BASIC RES CARDIOL, V87, P117; ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Chen ZY, 1997, J MOL CELL CARDIOL, V29, P2345, DOI 10.1006/jmcc.1997.0468; COOPER TA, 1985, J BIOL CHEM, V260, P1140; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; GODT RE, 1991, CAN J PHYSIOL PHARM, V69, P1692, DOI 10.1139/y91-251; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; GULATI J, 1994, BIOCHEM BIOPH RES CO, V202, P384, DOI 10.1006/bbrc.1994.1939; GUTH K, 1987, J BIOL CHEM, V262, P13627; HILL LE, 1992, J BIOL CHEM, V267, P16106; Jin JP, 2000, AM J PHYSIOL-CELL PH, V279, pC1067, DOI 10.1152/ajpcell.2000.279.4.C1067; Jin JP, 2000, BIOCHEMISTRY-US, V39, P11702, DOI 10.1021/bi9927437; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Moore DD, 1995, GLOB MOB SURV; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; ONOYAMA Y, 1986, J BIOCHEM-TOKYO, V100, P517, DOI 10.1093/oxfordjournals.jbchem.a121742; PAGANI ED, 1988, CIRC RES, V63, P380, DOI 10.1161/01.RES.63.2.380; Parsons B, 1997, J MUSCLE RES CELL M, V18, P599, DOI 10.1023/A:1018623604365; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; STAFFORD WF, 1978, BIOCHEMISTRY-US, V17, P607, DOI 10.1021/bi00597a008; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Vanburen P, 2002, AM J PHYSIOL-HEART C, V282, pH1665, DOI 10.1152/ajpheart.00938.2001; Wolff MR, 1996, J CLIN INVEST, V98, P167, DOI 10.1172/JCI118762; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	49	100	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35341	35349		10.1074/jbc.M204118200	http://dx.doi.org/10.1074/jbc.M204118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093807	hybrid			2022-12-27	WOS:000178117000088
J	Guglielmi, B; Werner, M				Guglielmi, B; Werner, M			The yeast homolog of human PinX1 is involved in rRNA and small nucleolar RNA maturation, not in telomere elongation inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; ENVIRONMENTAL-CHANGES; ANGSTROM RESOLUTION; PRERIBOSOMAL RNA; GENE DELETION; EXOSOME; PROTEIN; SUBUNIT; EXPRESSION	In human cells, PinX1 protein has recently been shown to regulate telomere length by repressing the telomerase. In this work, we show that the putative yeast homolog of PinX1, encoded by the YGR280c open reading frame (ORF), is a new component of the ribosomal RNA processing machinery. The protein has a KK(E/D) C-terminal domain typical of nucleolar proteins and bears a putative RNA interacting domain widespread in eukaryotes called the G-patch. The protein was hence renamed Gno1p (G-patch nucleolar protein). GNO1 deletion results in a large growth defect due to the inhibition of the pre-ribosomal RNA processing first cleavage steps at sites A(0), A(1), and A(2). Furthermore, Gno1p is involved in the final 3'-end trimming of U18 and U24 small nucleolar RNAs. A mutational analysis showed that the G-patch of Gno1p is essential for both functions, whereas the KK(E/D) repeats are only required for U18 small nucleolar RNA maturation. We found that PinX1 complemented the gno1-Delta mutation, suggesting that it has a dual function in telomere length regulation and ribosomal RNA maturation in agreement with its telomeric and nucleolar localization in human cells. Conversely, we found that Gno1p does not exhibit the in vivo telomerase inhibitor activity of PinX1.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Werner, M (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 44, F-91191 Gif Sur Yvette, France.	mwerner@cea.fr	Werner, Michel/B-7316-2009	Werner, Michel/0000-0002-2965-5858				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Briand JF, 2001, MOL CELL BIOL, V21, P189, DOI 10.1128/MCB.21.1.189-195.2001; CARLES C, 1998, TRANSCRIPTION RIBOSO, V1, P9; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Delage Y., 1903, HEREDITE GRANDS PROB; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gadal O, 1997, MOL CELL BIOL, V17, P1787, DOI 10.1128/MCB.17.4.1787; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lafontaine DLJ, 2001, NAT REV MOL CELL BIO, V2, P514, DOI 10.1038/35080045; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zanchin NIT, 1999, NUCLEIC ACIDS RES, V27, P1283, DOI 10.1093/nar/27.5.1283; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	40	68	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35712	35719		10.1074/jbc.M205526200	http://dx.doi.org/10.1074/jbc.M205526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12107183	hybrid			2022-12-27	WOS:000178117000133
J	Hess, JF; Voss, JV; FitzGerald, PG				Hess, JF; Voss, JV; FitzGerald, PG			Real-time observation of coiled-coil domains and subunit assembly in intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; ROD DOMAIN; MOLECULAR-BIOLOGY; ATOMIC-STRUCTURE; PROTEINS; VIMENTIN; SEQUENCE; SITE; MUTATIONS; DISEASE	We have utilized electron paramagnetic resonance spectroscopy to study secondary structure, subunit interaction, and molecular orientation of vimentin molecules within intact intermediate filaments and assembly intermediates. Spectroscopy data prove alpha-helical coiled-coil structures at individual amino acids 316-336 located in rod 2B. Analysis of positions 305, 309, and 312 identify this region as conforming to the helical pattern identified within 316-336 and thus demonstrates that, contrary to some previous predictions, this region is in an alpha-helical conformation. We show that by varying the position of the spin label, we can identify both intra- and inter-dimer interactions. With a label attached to the outside of the alpha-helix, we have been able to measure interactions between positions 348 of separate dimers as they align together in intact filaments, identifying the exact point of overlap. By mixing different spin-labeled proteins, we demonstrate that the interaction at position 348 is the result of an anti-parallel arrangement of dimers. This approach provides high resolution structural information (<2 nm resolution), can be used to identify molecular arrangements between subunits in an intact intermediate filament, and should be applicable to other noncrystallizable filamentous systems as well as to the study of protein fibrils.	Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	FitzGerald, PG (corresponding author), Univ Calif Davis, Sch Med, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.			Voss, John/0000-0001-9279-209X	NATIONAL EYE INSTITUTE [R01EY015560, P30EY012576, R01EY008747] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY08747, P30 EY012576, R01 EY008747, R01 EY015560-01A3, R01 EY015560, P30EY-12576] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Conley YP, 2000, AM J HUM GENET, V66, P1426, DOI 10.1086/302871; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; HESS JF, 1993, CURR EYE RES, V12, P77, DOI 10.3109/02713689308999499; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Irvine AD, 1997, NAT GENET, V16, P184, DOI 10.1038/ng0697-184; Jakobs PM, 2000, AM J HUM GENET, V66, P1432, DOI 10.1086/302872; KOKORIN AI, 1972, BIOFIZIKA+, V17, P34; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; LIKHTENSHTEIN GI, 1993, BIOPHYSICAL LABELING, P57; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MENG JJ, 1994, J BIOL CHEM, V269, P18679; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; POTSCHKA M, 1990, EUR J BIOCHEM, V190, P503, DOI 10.1111/j.1432-1033.1990.tb15602.x; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rogers KR, 1996, J STRUCT BIOL, V117, P55, DOI 10.1006/jsbi.1996.0069; Sandilands A, 1998, Subcell Biochem, V31, P291; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35516	35522		10.1074/jbc.M206500200	http://dx.doi.org/10.1074/jbc.M206500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12122019	Green Accepted, hybrid			2022-12-27	WOS:000178117000110
J	Koc, EC; Spremulli, LL				Koc, EC; Spremulli, LL			Identification of mammalian mitochondrial translational initiation factor 3 and examination of its role in initiation complex formation with natural mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							30S RIBOSOMAL-SUBUNIT; GRACILIS CHLOROPLAST RIBOSOMES; 5'-TERMINAL START CODONS; FACTOR IF3; MESSENGER-RNA; EUGLENA-GRACILIS; PROTEIN-SYNTHESIS; SEQUENCE-ANALYSIS; FACTOR-III; DOMAINS	Human mitochondrial translational initiation factor 3 (IF3(mt)) has been identified from the human expressed sequence tag data base. Using consensus sequences derived from conserved regions of the bacterial IF3, several partially sequenced cDNA clones were identified, and the complete sequence was assembled in silico from overlapping clones. IF3(mt) is 278 amino acid residues in length. MitoProt II predicts a 97% probability that this protein will be localized in mitochondria and further predicts that the mature protein will be 247 residues in length. The cDNA for the predicted mature form of IF3(mt) was cloned, and the protein was expressed in Escherichia coli in a His-tagged form. The mature form of IF3(mt) has short extensions on the N and C termini surrounding a region homologous to bacterial IF3. The region of IF3(mt) homologous to prokaryotic factors ranges between 21-26% identical to the bacterial proteins. Purified IF3(mt) promotes initiation complex formation on mitochondrial 55 S ribosomes in the presence of mitochondrial initiation factor 2 (IF2(mt)), [S-35]fMet-tRNA, and either poly(A,U,G) or an in vitro transcript of the cytochrome oxidase subunit II gene as mRNA. IF3(mt) shifts the equilibrium between the 55 S mitochondrial ribosome and its subunits toward subunit dissociation. In addition, the ability of E. coli initiation factor 1 to stimulate initiation complex formation on E. coli 70 S and mitochondrial 55 S ribosomes was investigated in the presence of IF2(mt) and IF3(mt).	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; BERKHOUT B, 1986, BIOCHIM BIOPHYS ACTA, V866, P144, DOI 10.1016/0167-4781(86)90111-9; BIOU V, 1995, EMBO J, V14, P4056, DOI 10.1002/j.1460-2075.1995.tb00077.x; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; de Cock E, 1999, MOL MICROBIOL, V32, P193, DOI 10.1046/j.1365-2958.1999.01350.x; DENSLOW ND, 1988, BIOCHEMISTRY-US, V27, P3521, DOI 10.1021/bi00409a059; DOTTAVIOMARTIN D, 1979, FEBS LETT, V97, P105, DOI 10.1016/0014-5793(79)80062-9; GARCIA C, 1995, J MOL BIOL, V254, P247, DOI 10.1006/jmbi.1995.0615; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GRAVES MC, 1980, ARCH BIOCHEM BIOPHYS, V204, P444, DOI 10.1016/0003-9861(80)90055-7; Grill S, 2001, FEBS LETT, V495, P167, DOI 10.1016/S0014-5793(01)02378-X; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAPKE B, 1976, J MOL BIOL, V105, P97, DOI 10.1016/0022-2836(76)90196-0; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; Hua YX, 1998, J MOL BIOL, V278, P871, DOI 10.1006/jmbi.1998.1736; KISSELEV OI, 1977, NUCLEIC ACIDS RES, V4, P4411, DOI 10.1093/nar/4.12.4411; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; KYCIA JH, 1995, BIOCHEMISTRY-US, V34, P6183, DOI 10.1021/bi00018a022; LIAO HX, 1991, J BIOL CHEM, V266, P20714; LIAO HX, 1990, J BIOL CHEM, V265, P13618; LIAO HX, 1989, J BIOL CHEM, V264, P7518; LIN Q, 1994, J BIOL CHEM, V269, P9436; Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805; MA JH, 1995, BBA-GENE STRUCT EXPR, V1261, P321, DOI 10.1016/0167-4781(95)00041-E; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; Moll I, 1998, FEBS LETT, V436, P213, DOI 10.1016/S0014-5793(98)01131-4; MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0; Moreau M, 1997, J MOL BIOL, V266, P15, DOI 10.1006/jmbi.1996.0756; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; Mortensen KK, 1998, BIOCHEM MOL BIOL INT, V46, P1027; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PACI M, 1984, J BIOL CHEM, V259, P9628; PEL HJ, 1994, MOL BIOL REP, V19, P183, DOI 10.1007/BF00986960; Petrelli D, 2001, EMBO J, V20, P4560, DOI 10.1093/emboj/20.16.4560; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sacerdot C, 1999, J MOL BIOL, V288, P803, DOI 10.1006/jmbi.1999.2737; Sette M, 1999, RNA, V5, P82, DOI 10.1017/S1355838299981487; Shapkina TG, 2000, J MOL BIOL, V299, P615, DOI 10.1006/jmbi.2000.3774; SPREMULLI L, 1987, BIOCHEM BIOPH RES CO, V147, P1077, DOI 10.1016/S0006-291X(87)80180-8; Sussman JK, 1996, MOL MICROBIOL, V21, P347, DOI 10.1046/j.1365-2958.1996.6371354.x; TEANA A, 1995, RNA, V1, P772; Tedin K, 1997, MOL MICROBIOL, V25, P189, DOI 10.1046/j.1365-2958.1997.4421810.x; Tedin K, 1999, MOL MICROBIOL, V31, P67, DOI 10.1046/j.1365-2958.1999.01147.x; VANKNIPPENBERG PH, 1990, RIBOSOME, P265; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; Yu NJ, 1998, J BIOL CHEM, V273, P3871, DOI 10.1074/jbc.273.7.3871	60	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35541	35549		10.1074/jbc.M202498200	http://dx.doi.org/10.1074/jbc.M202498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12095986	Green Published, hybrid			2022-12-27	WOS:000178117000113
J	Maitra, M; Gudzelak, A; Li, SX; Matsumoto, Y; Eckert, KA; Jager, J; Sweasy, JB				Maitra, M; Gudzelak, A; Li, SX; Matsumoto, Y; Eckert, KA; Jager, J; Sweasy, JB			Threonine 79 is a hinge residue that governs the fidelity of DNA polymerase beta by helping to position the DNA within the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; DEOXYRIBOSE PHOSPHATE RESIDUES; ESCHERICHIA-COLI; MUTATOR MUTANT; CATALYTIC MECHANISM; CRYSTAL-STRUCTURES; KINETIC-ANALYSIS; GAPPED DNA; BINDING; CELLS	DNA polymerase beta (pol beta) is an ideal system for studying the role of its different amino acid residues in the fidelity of DNA synthesis. In this study, the T79S variant of pol beta was identified using an in vivo genetic screen. T79S is located in the N-terminal 8-kDa domain of pol beta and has no contact with either the DNA template or the incoming dNTP substrate. The T79S protein produced 8-fold more multiple mutations in the herpes simplex virus type 1-thymidine kinase assay than wild-type pol beta. Surprisingly, T79S is a misincorporation mutator only when using a 3'-recessed primer-template. In the presence of a single nucleotide-gapped DNA substrate, T79S displays an antimutator phenotype when catalyzing DNA synthesis opposite template C and has similar fidelity as wild type opposite templates A, G, or T. Threonine 79 is located directly between two helix-hairpin-helix motifs located within the 8-kDa an thumb domains of pol beta. As the pol beta enzyme closes into its active form, the helix-hairpin-helix motifs appear to assist in the production and stabilization of a 90degrees bend of the DNA. The function of the bent DNA is to present the templating base to the incoming nucleotide substrate. We propose that Thr-79 is part of a hydrogen bonding network within the helix-hairpin-helix motifs that is important for positioning the DNA within the active site. We suggest that alteration of Thr-79 to Ser disrupts this hydrogen bonding network and results in an enzyme that is unable to bend the DNA into the proper geometry for accurate DNA synthesis.	Yale Univ, Sch Med, Dept Therapeut Radiol & Genet, New Haven, CT 06520 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Jake Gittlen Canc Res Inst, Hershey, PA 17033 USA; Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Leeds	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,POB 208240, New Haven, CT 06520 USA.			Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R01CA080830] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA080830, CA80830] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Clairmont CA, 1999, P NATL ACAD SCI USA, V96, P9580, DOI 10.1073/pnas.96.17.9580; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Eckert KA, 1997, NUCLEIC ACIDS RES, V25, P1450, DOI 10.1093/nar/25.7.1450; ECKERT KA, 1987, MUTAT RES, V178, P1, DOI 10.1016/0027-5107(87)90079-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Kosa JL, 1999, J BIOL CHEM, V274, P3851, DOI 10.1074/jbc.274.6.3851; Kosa JL, 1999, J BIOL CHEM, V274, P35866, DOI 10.1074/jbc.274.50.35866; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mullen GP, 1997, BIOCHEMISTRY-US, V36, P4713, DOI 10.1021/bi962363a; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; REM DC, 1990, EUKARYOTIC NUCL MOL, P95; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; SWEASY JB, 1995, MOL GEN GENET, V248, P217, DOI 10.1007/BF02190803; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	43	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35550	35560		10.1074/jbc.M204953200	http://dx.doi.org/10.1074/jbc.M204953200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12121998	hybrid			2022-12-27	WOS:000178117000114
J	Mayer, SM; Gormal, CA; Smith, BE; Lawson, DM				Mayer, SM; Gormal, CA; Smith, BE; Lawson, DM			Crystallographic analysis of the MoFe protein of nitrogenase from a nifV mutant of Klebsiella pneumoniae identifies citrate as a ligand to the molybdenum of iron molybdenum cofactor (FeMoco)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN EVOLUTION; CARBON-MONOXIDE; ALPHA-SUBUNIT; BINDING; HOMOCITRATE; SUBSTRATE; PURIFICATION; REFINEMENT; INVITRO; MAPS	The x-ray crystal structure of NifV(-) Klebsiella pneumoniae nitrogenase MoFe protein (NifV(-) Kp1) has been determined and refined to a resolution of 1.9 Angstrom. This is the first structure for a nitrogenase MoFe protein with an altered cofactor. Moreover, it is the first direct evidence that the organic acid citrate is not just present, but replaces homocitrate as a ligand to the molybdenum atom of the iron molybdenum cofactor (FeMoco). Subsequent refinement of the structure revealed that the citrate was present at reduced occupancy.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Lawson, DM (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.	david.lawson@bbsrc.ac.uk	Lawson, David M/D-1810-2009					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Christiansen J, 2000, J BIOL CHEM, V275, P36104, DOI 10.1074/jbc.M004889200; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; George SJ, 1997, J AM CHEM SOC, V119, P6450, DOI 10.1021/ja971088s; Gronberg KLC, 1998, J AM CHEM SOC, V120, P10613, DOI 10.1021/ja981832o; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawson DM, 2002, MET IONS BIOL SYST, V39, P75; Lee HI, 1997, J AM CHEM SOC, V119, P10121, DOI 10.1021/ja9715096; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; MA L, 1994, J BIOL CHEM, V269, P18007; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; MCLEAN PA, 1983, BIOCHEM J, V211, P589, DOI 10.1042/bj2110589; MCLEAN PA, 1981, NATURE, V292, P655, DOI 10.1038/292655a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEWTON WE, 2002, 13 INT C NITR FIX; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; POLLOCK RC, 1995, J AM CHEM SOC, V117, P8686, DOI 10.1021/ja00138a033; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SCOTT DJ, 1992, J BIOL CHEM, V267, P20002; Shen J, 1997, BIOCHEMISTRY-US, V36, P4884, DOI 10.1021/bi9628578; STRASSMAN M, 1964, BIOCHEM BIOPH RES CO, V14, P262, DOI 10.1016/0006-291X(64)90446-2; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	36	63	68	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35263	35266		10.1074/jbc.M205888200	http://dx.doi.org/10.1074/jbc.M205888200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12133839	hybrid			2022-12-27	WOS:000178117000078
J	Meir, K; Kitsberg, D; Alkalay, I; Szafer, F; Rosen, H; Shpitzen, S; Ben Avi, L; Staels, B; Fievet, C; Meiner, V; Bjorkhem, I; Leitersdorf, E				Meir, K; Kitsberg, D; Alkalay, I; Szafer, F; Rosen, H; Shpitzen, S; Ben Avi, L; Staels, B; Fievet, C; Meiner, V; Bjorkhem, I; Leitersdorf, E			Human sterol 27-hydroxylase (CYP27) overexpressor transgenic mouse model - Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYMETHYLGLUTARYL-COA REDUCTASE; DILUTION MASS-SPECTROMETRY; NUCLEAR RECEPTOR LXR; MITOCHONDRIAL CYTOCHROME-P-450; DIETARY-CHOLESTEROL; STABLE-ISOTOPE; OXYSTEROLS; BILE; MICE; LIVER	CYP27-overexpressed transgenic mice were generated with the use of a human full-length CYP27 coding region cloned into a ubiquitous expression vector. Positive transgenic mice were identified by tail DNA genotyping and high fecal 27-hydroxycholesterol content. The levels of 27-hydroxycholesterol were found to be 3-5 times higher in the circulation and the tissues of the overexpressed mice when compared with littermate controls. There were no gross morphological differences between the overexpressed mice and their controls. Total cholesterol and triglyceride levels were not affected by overexpression of CYP27. Serum lathosterol was also normal, suggesting a normal rate of cholesterol synthesis. Serum levels of 7alpha-hydroxycholesterol were unaffected, suggesting a normal rate of bile acid formation in the pathway involving cholesterol 7alpha-hydroxylase. Biliary bile acid composition was slightly affected by CYP27 overexpression in female but not in male mice. Fecal levels of neutral steroids were slightly but significantly increased in overexpressor female mice but not in male mice. Levels of 24-hydroxycholesterol in the circulation were significantly reduced in the overexpressed mice, probably as a consequence of a recently described catabolic pathway involving CYP27. Combined with the results of our previous work on mice with a disruption of the CYP27 gene, the present results suggest that the levels of 27-hydroxycholesterol are not of critical importance for cholesterol homeostasis in mice.	Hadassah Univ Hosp, Dept Med B, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Human Genet, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Mol Virol, IL-91120 Jerusalem, Israel; Inst Pasteur, Dept Atherosclerosis, F-59000 Lille, France; Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, SE-14186 Huddinge, Sweden	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Karolinska Institutet	Leitersdorf, E (corresponding author), Hadassah Univ Hosp, Dept Med B, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel.		Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Bjorkhem I, 1999, CURR OPIN LIPIDOL, V10, P161, DOI 10.1097/00041433-199904000-00010; BJORKHEM I, 1992, J LIPID RES, V33, P455; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, P231; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Duane WC, 1999, J LIPID RES, V40, P1194; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Hall E, 2001, AM J PHYSIOL-GASTR L, V281, pG293, DOI 10.1152/ajpgi.2001.281.1.G293; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JAVITT NB, 1990, J LIPID RES, V31, P1527; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND E, 1989, SCAND J CLIN LAB INV, V49, P165, DOI 10.3109/00365518909105417; LUND E, 1992, J BIOL CHEM, V267, P25092; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Meaney S, 2000, BBA-MOL CELL BIOL L, V1486, P293, DOI 10.1016/S1388-1981(00)00070-6; Meaney S, 2001, J LIPID RES, V42, P70; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; Souidi M, 2001, J NUTR, V131, P1803, DOI 10.1093/jn/131.6.1803; Zhang Z, 2001, J LIPID RES, V42, P649	32	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34036	34041		10.1074/jbc.M201122200	http://dx.doi.org/10.1074/jbc.M201122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12119285	hybrid			2022-12-27	WOS:000177959100069
J	Zhang, L; Kudo, T; Takaya, N; Shoun, H				Zhang, L; Kudo, T; Takaya, N; Shoun, H			The B' helix determines cytochrome P450nor specificity for the electron donors NADH and NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; FUSARIUM-OXYSPORUM; CRYSTAL-STRUCTURE; CYLINDROCARPON-TONKINENSE; PURIFICATION; FUNGUS; CDNA; RESOLUTION	Nitric oxide reductase (Nor) cytochrome P450nor (P450nor) is unique because it is catalytically self-sufficient, receiving electrons directly from NADH or NADPH. However, little is known about the direct binding of NADH to cytochrome. Here, we report that oxidized pyridine nucleotides (NAD(+) and NADP(+)) and an analogue induce a spectral perturbation in bound heme when mixed with P450nor. The P450nor isoforms are classified according to electron donor specificity for NADH or NADPH. One type (Fnor, a P450nor of Fusarium oxysporum) utilizes only NADH. We found that NAD(+) induced a type I spectral change in Fnor, whereas NADP(+) induced a reverse type I spectral change, although the K(d) values for both were comparable. In contrast, NADP(+) as well as NAD(+) caused a type I spectral change in Tnor, a P450nor isozyme from Trichosporon cutaneum that utilizes both NADH and NADPH as electron donors. The B' helix region of Tnor ((73)SAGGKAAA(80)) contains some Ala and Gly residues, whereas the sequence is replaced at a few sites with more bulky amino acid residues in Fnor ((73)SASGKQAA(80)). A single mutation (S75G) significantly improved the NADPH-dependent Nor activity of Fnor, and the overall activity was accelerated via the NADPH-enhanced reduction step. These results showed that pyridine nucleotide cofactors can bind P450nor and that only a few residues in the B' helix region determine cofactor specificity. We further showed that a poor electron donor (NADPH) could also bind Fnor, but an appropriate configuration for electron transfer is blocked by steric hindrance mainly by Ser(75) against the 2'-phosphate moiety. The present results along with previous observations together revealed a novel motif for cofactor binding.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tokyo; University of Tsukuba	Shoun, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	ahshoun@mail.ecc.u-tokyo.ac.jp						CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Daiber A, 2002, J INORG BIOCHEM, V88, P343, DOI 10.1016/S0162-0134(01)00386-5; GOTOH O, 1992, J BIOL CHEM, V267, P83; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; Kudo T, 1996, BIOCHIMIE, V78, P792, DOI 10.1016/S0300-9084(97)82538-2; Kudo T, 2001, J BIOL CHEM, V276, P5020, DOI 10.1074/jbc.M007244200; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Nakahara K, 1996, J BIOCHEM-TOKYO, V120, P1082, DOI 10.1093/oxfordjournals.jbchem.a021525; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NISHIYAMA M, 1993, J BIOL CHEM, V268, P4656; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; Okamoto N, 1998, BIOCHEMISTRY-US, V37, P8839, DOI 10.1021/bi980469v; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; OMURA T, 1964, J BIOL CHEM, V239, P2379; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu H, 2000, J BIOL CHEM, V275, P4816, DOI 10.1074/jbc.275.7.4816; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Takaya N, 1998, KEIO UNIV SYMP LIFE, V1, P156; USUDA K, 1995, APPL ENVIRON MICROB, V61, P883, DOI 10.1128/AEM.61.3.883-889.1995; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAYOI T, 1996, J BIOCH, V119, P1014; YOSHIDA Y, 1993, CYTOCHROME P 450, P1; Zhang L, 2001, EUR J BIOCHEM, V268, P3198, DOI 10.1046/j.1432-1327.2001.02206.x	31	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33842	33847		10.1074/jbc.M203923200	http://dx.doi.org/10.1074/jbc.M203923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105197	hybrid			2022-12-27	WOS:000177959100042
J	Eberhardt, W; Akool, ES; Rebhan, J; Frank, S; Beck, KF; Franzen, R; Hamada, FMA; Pfeilschifter, J				Eberhardt, W; Akool, ES; Rebhan, J; Frank, S; Beck, KF; Franzen, R; Hamada, FMA; Pfeilschifter, J			Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; SMOOTH-MUSCLE-CELLS; MESANGIAL CELLS; PPAR-ALPHA; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; PHOSPHOLIPASE A(2); BINDING PROTEIN; CROSS-TALK	Rat renal mesangial cells express high levels of matrix metalloproteinase 9 (MMP-9) in response to inflammatory cytokines such as interleukin 1beta (IL-1beta). We tested whether ligands of the peroxisome proliferator-activated receptor (PPARalpha) could influence the cytokine-induced expression of MMP-9. Different PPARalpha agonists dose-dependently inhibited the IL-1beta-triggered increase in gelatinolytic activity mainly by decreasing the MMP-9 steady-state mRNA levels. PPARalpha agonists on their own had no effects on MMP-9 mRNA levels and gelatinolytic activity. Surprisingly, the reduction of MMP-9 mRNA levels by PPARa activators contrasted with an amplification of cytokine-mediated MMP-9 gene promoter activity and mRNA expression. The potentiation of MMP-9 promoter activity functionally depends on an upstream peroxisome proliferator-responsive clement-like binding site, which displayed an increased DNA binding of a PPARalpha immunopositive complex. In contrast, the IL-1beta-induced DNA-binding of nuclear factor kappaB was significantly impaired by PPARalpha agonists. Most interestingly, in the presence of an inducible nitric-oxide synthase (iNOS) inhibitor, the PPARalpha-mediated suppression switched to a strong amplification of IL-1beta-triggered MMP-9 mRNA expression. Concomitantly, activators of PPARa potentiated the cytokine-induced iNOS expression. Using actinomycin D, we found that NO, but not PPARa activators, strongly reduced the stability of MMP-9 mRNA. In contrast, the stability of MMP-9 protein was not affected by PPARa activators. In summary, our data suggest that the inhibitory effects of PPARa agonists on cytokine-induced MMP-9 expression are indirect and primarily due to a superinduction of iNOS with high levels of NO reducing the half-life of MMP-9 mRNA.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Al Azhar Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Egyptian Knowledge Bank (EKB); Al Azhar University	Eberhardt, W (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Theodar Stern Kai 7, D-60590 Frankfurt, Germany.	w.eberhardt@em.uni-frankfurt.de	Akool, El-Sayed/ABB-7729-2021	Akool, El-Sayed/0000-0003-4216-5164				Abdelaziz N, 2001, HYPERTENSION, V38, P261, DOI 10.1161/01.HYP.38.2.261; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; DAVIES M, 1992, KIDNEY INT, V41, P671, DOI 10.1038/ki.1992.103; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Djouadi F, 2001, J AM SOC NEPHROL, V12, P1197, DOI 10.1681/ASN.V1261197; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Fogo AB, 2001, KIDNEY INT, V59, P804, DOI 10.1046/j.1523-1755.2001.059002804.x; Gurjar MV, 2001, J APPL PHYSIOL, V91, P1380, DOI 10.1152/jappl.2001.91.3.1380; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; Kunz D, 1996, BRIT J PHARMACOL, V118, P1621, DOI 10.1111/j.1476-5381.1996.tb15583.x; LANDER HM, 1993, J IMMUNOL, V151, P7182; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MUHL H, 1993, EUR J PHARMACOL, V249, P95, DOI 10.1016/0014-2999(93)90666-6; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 2001, EUR J PHARMACOL, V429, P279, DOI 10.1016/S0014-2999(01)01326-7; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Scholz-Pedretti K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133611; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Upchurch GR, 2001, J VASC SURG, V34, P76, DOI 10.1067/mva.2001.115598; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Walpen S, 2001, FASEB J, V15, P571; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	42	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33518	33528		10.1074/jbc.M202008200	http://dx.doi.org/10.1074/jbc.M202008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12093797	hybrid			2022-12-27	WOS:000177859000142
J	Strick, DJ; Francescutti, DM; Zhao, YL; Elferink, LA				Strick, DJ; Francescutti, DM; Zhao, YL; Elferink, LA			Mammalian suppressor of Sec4 modulates the inhibitory effect of Rab15 during early endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; FACTOR HUMAN MSS4; NUCLEOTIDE-EXCHANGE; ENDOSOME FUSION; MEMBRANE-FUSION; SYNAPTOTAGMIN MUTANTS; SYNAPTIC VESICLES; RABAPTIN-5; PATHWAY; RELEASE	Rab15 is a novel endocytic Rab that counters the stimulatory effect of Rab5-GTP on early endocytic trafficking. Rab15 may interfere with Rab5 function directly by sequestering Rab5 effectors or indirectly through novel sets of effector interactions. To distinguish between these possibilities, we examined the effector binding properties of Rab15. Rab15 does not interact directly with the Rab5 effectors rabex-5 and rabaptin-5 in a yeast two-hybrid binding assay. Rather mammalian suppressor of Sec4 (Mss4) was identified as a binding partner for Rab15. Mss4 preferentially binds GDP-bound (T22N) and nucleotide-free (N121I)Rab15, consistent with the proposed role of Mss4 as a chaperone that stabilizes target Rabs in their nucleotide-free form. Mutational analysis of Rab15 indicates that lysine at position 48 (K48Q) is important for the binding of Rab15-GDP to Mss4. Moreover, the mutation K48Q counters the inhibitory phenotype of wild type Rab15 on receptor-mediated endocytosis in HeLa cells and homotypic endosome fusion in vitro without altering the relative amount of cell surface-associated transferrin receptor. Together, these data indicate a novel role for Mss4 as an effector for Rab15 in early endocytic trafficking.	Univ Texas, Med Branch, Dept Physiol & Biophys, Inst Marine Biomed, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Elferink, LA (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Inst Marine Biomed, Galveston, TX 77555 USA.	Lisa.Elferink@utmb.edu						BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Coppola T, 2001, J CELL SCI, V114, P1757; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kolonin MG, 2000, METHOD ENZYMOL, V328, P26, DOI 10.1016/S0076-6879(00)28388-2; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1993, J BIOL CHEM, V268, P24475; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Nuoffer C, 1997, MOL BIOL CELL, V8, P1305, DOI 10.1091/mbc.8.7.1305; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Reist NE, 1998, J NEUROSCI, V18, P7662; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; SIMONSEN A, 1998, NATURE, V394, P484; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Trischler M, 1999, J CELL SCI, V112, P4773; Valsdottir R, 2001, FEBS LETT, V508, P201, DOI 10.1016/S0014-5793(01)02993-3; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zheng JY, 1998, J CELL SCI, V111, P1061; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P15699, DOI 10.1021/bi0116792; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P3027, DOI 10.1021/bi002680o; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303; Zuk PA, 2000, J BIOL CHEM, V275, P26754	56	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32722	32729		10.1074/jbc.M205101200	http://dx.doi.org/10.1074/jbc.M205101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12105226	hybrid			2022-12-27	WOS:000177859000043
J	Hartsough, MT; Morrison, DK; Salerno, M; Palmieri, D; Ouatas, T; Mair, M; Patrick, J; Steeg, PS				Hartsough, MT; Morrison, DK; Salerno, M; Palmieri, D; Ouatas, T; Mair, M; Patrick, J; Steeg, PS			Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras via a histidine protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOSIDE-DIPHOSPHATE KINASE; GTP-BINDING PROTEINS; CARCINOMA-CELL-LINE; KSR-1 GENE ENCODES; TUMOR-METASTASIS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PHOSPHOTRANSFERASE ACTIVITY; NEUROBLASTOMA-CELLS	The metastasis-suppressive activity of Nm23-H1 was previously correlated with its in vitro histidine protein kinase activity, but physiological substrates have not been identified. We hypothesized that proteins that interact with histidine kinases throughout evolution may represent partners for Nm23-H1 and focused on the interaction of Arabidopsis "two-component" histidine kinase ERS with CTR1. A mammalian homolog of CTR1 was previously reported to be c-Raf; we now report that CTR1 also exhibits homology to the kinase suppressor of Ras (KSR), a scaffold protein for the mitogen-activated protein kinase (MAPK) cascade. Nm23-H1 co-immuno-precipitated KSR from lysates of transiently transfected 293T cells and at endogenous protein expression levels in MDA-MB-435 breast carcinoma cells. Autophosphorylated recombinant Nm23-H1 phosphorylated KSR in vitro. Phosphoamino acid analysis identified serine as the major target, and two peaks of Nm23-H1 phosphorylation were identified upon high performance liquid chromatography analysis of KSR tryptic peptides. Using site-directed mutagenesis, we found that Nm23-H1 phosphorylated KSR serine 392, a 14-3-3-binding site, as well as serine 434 when serine 392 was mutated. Phosphorylated MAPK but not total MAPK levels were reduced in an nm23-H1 transfectant of MDA-MB-435 cells. The data identify a complex in vitro histidine-to-serine protein kinase pathway, which may contribute to signal transduction and metastasis.	NCI, Pathol Lab, Womens Canc Sect,Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Steeg, PS (corresponding author), NCI, Pathol Lab, Womens Canc Sect,Ctr Canc Res, NIH, Bldg 10,Rm 2A33, Bethesda, MD 20892 USA.	steegp@mail.nih.gov	Palmieri, Diane/B-4258-2015	SALERNO, Massimiliano/0000-0002-1093-5454				Amendola R, 1997, JNCI-J NATL CANCER I, V89, P1300, DOI 10.1093/jnci/89.17.1300; BABA H, 1995, CANCER RES, V55, P1977; Backer MV, 2000, ANTICANCER RES, V20, P1743; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; Barthel TK, 1999, J BIOL CHEM, V274, P36670, DOI 10.1074/jbc.274.51.36670; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bemis LT, 2000, CANCER RES, V60, P3414; Bhujwalla ZM, 1999, MAGN RESON MED, V41, P897, DOI 10.1002/(SICI)1522-2594(199905)41:5<897::AID-MRM7>3.0.CO;2-T; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Chang C, 2001, BIOESSAYS, V23, P619, DOI 10.1002/bies.1087; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Cho SJ, 2001, BIOCHEM BIOPH RES CO, V289, P738, DOI 10.1006/bbrc.2001.6042; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; CLARK K, 1988, P NATL ACAD SCI USA, V95, P5401; CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hohenegger M, 1996, MOL PHARMACOL, V49, P73; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Inoue H, 1996, BIOCHEM BIOPH RES CO, V218, P887, DOI 10.1006/bbrc.1996.0158; Ishijima Y, 1999, FEBS LETT, V445, P155, DOI 10.1016/S0014-5793(99)00116-7; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KANTOR JD, 1993, CANCER RES, V53, P1971; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kowluru A, 1996, BIOCHEM J, V313, P97, DOI 10.1042/bj3130097; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P227, DOI 10.1023/A:1005580828141; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; Levit MN, 2002, J BIOL CHEM, V277, P5163, DOI 10.1074/jbc.M111170200; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; LOMBARDI D, 1995, EXP CELL RES, V217, P267, DOI 10.1006/excr.1995.1086; Lombardi D, 2001, CELL DEATH DIFFER, V8, P470, DOI 10.1038/sj.cdd.4400842; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Miele ME, 1997, CLIN EXP METASTAS, V15, P259, DOI 10.1023/A:1018473415458; Miyazaki H, 1999, CLIN CANCER RES, V5, P4301; Morrison DK, 2001, J CELL SCI, V114, P1609; Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; Nederkoorn PHJ, 1998, J MOL STRUC-THEOCHEM, V452, P25, DOI 10.1016/S0166-1280(98)00073-6; Negroni A, 2000, CELL DEATH DIFFER, V7, P843, DOI 10.1038/sj.cdd.4400720; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; Otero ADS, 1999, BBA-MOL CELL RES, V1449, P157, DOI 10.1016/S0167-4889(99)00009-9; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Paravicini G, 1996, BIOCHEM BIOPH RES CO, V227, P82, DOI 10.1006/bbrc.1996.1471; PARHAR RS, 1995, INT J CANCER, V60, P204; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Roymans D, 2000, EXP CELL RES, V261, P127, DOI 10.1006/excr.2000.5037; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SHANKAR S, 1995, J BIOL CHEM, V270, P28246; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Subramanian C, 2001, NAT MED, V7, P350, DOI 10.1038/85499; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Tagashira H, 1998, INT J MOL MED, V2, P65; Thelen JJ, 2000, BIOCHEM J, V349, P195, DOI 10.1042/0264-6021:3490195; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 2000, BIOCHEM J, V346, P623, DOI 10.1042/0264-6021:3460623; Wagner PD, 2000, J BIOL CHEM, V275, P35570, DOI 10.1074/jbc.M006106200; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBER B, 1995, INT J BIOCHEM CELL B, V27, P215, DOI 10.1016/1357-2725(94)00078-P; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xing HR, 2000, J BIOL CHEM, V275, P17276, DOI 10.1074/jbc.C900989199; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Yan F, 2001, CANCER RES, V61, P963; Yano M, 1999, J BIOL CHEM, V274, P34375, DOI 10.1074/jbc.274.48.34375; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	117	158	170	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32389	32399		10.1074/jbc.M203115200	http://dx.doi.org/10.1074/jbc.M203115200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12105213	hybrid			2022-12-27	WOS:000177718700135
J	Minami, K; Yokokura, M; Ishizuka, N; Seino, S				Minami, K; Yokokura, M; Ishizuka, N; Seino, S			Normalization of intracellular Ca2+ induces a glucose-responsive state in glucose-unresponsive beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RAT PANCREATIC-ISLETS; GENE-EXPRESSION; POTASSIUM CHANNELS; DIABETES-MELLITUS; INSULIN-SECRETION; CALCIUM CHANNELS; DOWN-REGULATION; MESSENGER-RNAS; SUBUNIT	Although intracellular Ca2+ in pancreatic beta-cells is the principal signal for insulin secretion, the effect of chronic elevation of the intracellular Ca2+ concentration ([Ca2+](i)) on insulin secretion is poorly understood. We recently established two pancreatic beta-cell MIN6 cell lines that are glucose-responsive (MIN6-m9) and glucose-unresponsive (MIN6-m14). In the present study we have determined the cause of the glucose unresponsiveness in MIN6-m14. Initially, elevated [Ca2+] was observed in MIN6-m14, but normalization of the [Ca2+](i) by nifedipine, a Ca2+ channel blocker, markedly improved the intracellular Ca2+ response to glucose and the glucose-induced insulin secretion. The expression of subunits of ATP-sensitive K+ channels and voltage-dependent Ca2+ channels were increased at both mRNA and protein levels in MIN6-m14 treated with nifedipine. As a consequence, the functional expression of these channels at the cell surface, both of which are decreased in MIN6-m14 without nifedipine treatment, were increased significantly. Contrariwise, Bay K8644, a Ca2+ channel agonist, caused severe impairment of glucose-induced insulin secretion in glucose-responsive MIN6-m9 due to decreased expression of the channel subunits. Chronically elevated [Ca2+](i), therefore, is responsible for the glucose unresponsiveness of MIN6-ml4. The present study also suggests normalization of [Ca2+](i) in pancreatic beta-cells as a therapeutic strategy in treatment of impaired insulin secretion.	Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Sch Med, Dept Med Genet Novo Nordisk Pharma, Chuo Ku, Chiba 2608670, Japan	Chiba University; Chiba University	Seino, S (corresponding author), Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	seino@med.m.chiba-u.ac.jp		Minami, Kohtaro/0000-0003-4698-6250				ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bjorklund A, 2000, DIABETES, V49, P1840, DOI 10.2337/diabetes.49.11.1840; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Griffith LC, 2001, CURR BIOL, V11, pR226, DOI 10.1016/S0960-9822(01)00111-7; Hardingham GE, 1999, MICROSC RES TECHNIQ, V46, P348, DOI 10.1002/(SICI)1097-0029(19990915)46:6<348::AID-JEMT3>3.3.CO;2-1; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; IWASHIMA Y, 1993, DIABETES, V42, P948, DOI 10.2337/diabetes.42.7.948; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Kato S, 1996, J CLIN INVEST, V97, P2417, DOI 10.1172/JCI118688; Kawaki J, 1999, DIABETES, V48, P2001, DOI 10.2337/diabetes.48.10.2001; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Levy J, 1999, ENDOCRINE, V10, P1, DOI 10.1385/ENDO:10:1:1; MALAISSE WJ, 1973, DIABETOLOGIA, V9, P1, DOI 10.1007/BF01225992; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Moritz W, 2001, ENDOCRINOLOGY, V142, P129, DOI 10.1210/en.142.1.129; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; PANTEN U, 1985, N-S ARCH PHARMACOL, V328, P351, DOI 10.1007/BF00515566; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; ROE MW, 1994, J BIOL CHEM, V269, P18279; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Suzuki M, 1997, DIABETES, V46, P1440, DOI 10.2337/diabetes.46.9.1440; Tokuyama Y, 1996, BIOCHEM BIOPH RES CO, V220, P532, DOI 10.1006/bbrc.1996.0439; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; TSUJI K, 1993, METABOLISM, V42, P1424, DOI 10.1016/0026-0495(93)90193-R; Verkhratsky A, 1998, TRENDS NEUROSCI, V21, P2, DOI 10.1016/S0166-2236(97)01156-9; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25277	25282		10.1074/jbc.M203988200	http://dx.doi.org/10.1074/jbc.M203988200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12101221	hybrid			2022-12-27	WOS:000176747000057
J	Louet, JF; Hayhurst, G; Gonzalez, FJ; Girard, J; Decaux, JF				Louet, JF; Hayhurst, G; Gonzalez, FJ; Girard, J; Decaux, JF			The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; BROWN ADIPOSE-TISSUE; CYCLIC-AMP; CPT-I; TRANSCRIPTIONAL REGULATION; FATTY-ACIDS; KINASE-A; RAT HEPATOCYTES; C-FOS; PROMOTER	Liver carnitine palmitoyltransferase I catalyzes the transfer of long-chain fatty acids into mitochondria. L-CPT I is considered the rate-controlling enzyme in fatty acid oxidation. Expression of the L-CPT I gene is induced by starvation in response to glucagon secretion from the pancreas, an effect mediated by cAMP. Here, the molecular mechanisms underlying the induction of L-CPT I gene expression by cAMP were characterized. We demonstrate that the cAMP response unit of the L-CPT I gene is composed of a cAMP-response element motif and a DR1 sequence located 3 kb upstream of the transcription start site. Our data strongly suggest that the coactivator PGC-1 is involved in the regulation of this gene expression by cAMP in combination with HNF4alpha and cAMP-response element-binding protein (CREB). Indeed, (i) cotransfection of CREB or HNF4alpha dominant negative mutants completely abolishes the effect of cAMP on the L-CPT I promoter, and (ii) the cAMP-responsive unit binds HNF4alpha and CREB through the DR1 and the cAMP-response element sequences, respectively. Moreover, cotransfection of PGC-1 strongly activates the L-CPT I promoter through HNF4alpha bound at the DR1 element. Finally, we show that the transcriptional induction of the PGC-1 gene by glucagon through cAMP in hepatocytes precedes that of L-CPT-1. In addition to the key role that PGC-1 plays in glucose homeostasis, it may also be critical for lipid homeostasis. Taken together these observations suggest that PGC-1 acts to coordinate the process of metabolic adaptation in the liver.	Inst Cochin, Dept Endocrinol, F-75014 Paris, France; Inst Pasteur, Dept Dev Biol, Unite Genet Differenciat, F-75015 Paris, France; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Decaux, JF (corresponding author), Inst Cochin, Dept Endocrinol, 24 Rue Faubourg St Jacques, F-75014 Paris, France.			Louet, Jean-Francois/0000-0002-1626-7098; DECAUX, Jean-Francois/0000-0003-0014-4197				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BOON MR, 1988, BIOCHEM J, V249, P645, DOI 10.1042/bj2490645; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; GRANTHAM BD, 1988, BIOCHEM J, V249, P409, DOI 10.1042/bj2490409; Groussin L, 2000, J CLIN ENDOCR METAB, V85, P345, DOI 10.1210/jc.85.1.345; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Li JX, 2000, GENE DEV, V14, P464; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; Louet JF, 2001, BIOCHEM SOC T, V29, P310, DOI 10.1042/0300-5127:0290310; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MeunierDurmort C, 1997, GENE THER, V4, P808, DOI 10.1038/sj.gt.3300450; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Montminy M, 1996, Adv Pharmacol, V36, P1, DOI 10.1016/S1054-3589(08)60573-6; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NARKEWICZ MR, 1990, BIOCHEM J, V271, P585, DOI 10.1042/bj2710585; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Park EA, 1998, BIOCHEM J, V330, P217; PENICAUD L, 1991, METABOLISM, V40, P873, DOI 10.1016/0026-0495(91)90018-R; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Soubt MK, 1998, MOL CELL BIOL, V18, P4698, DOI 10.1128/MCB.18.8.4698; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; Streeper RS, 2001, J BIOL CHEM, V276, P19111, DOI 10.1074/jbc.M101442200; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	50	124	137	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37991	38000		10.1074/jbc.M205087200	http://dx.doi.org/10.1074/jbc.M205087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12107181	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000178529600005
J	Chariot, A; Leonardi, A; Muller, J; Bonif, M; Brown, K; Siebenlist, U				Chariot, A; Leonardi, A; Muller, J; Bonif, M; Brown, K; Siebenlist, U			Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED FACTOR-2; SEVERE LIVER DEGENERATION; EMBRYONIC LETHALITY; DEFICIENT MICE; TAX PROTEIN; T-CELLS; ACTIVATION; ALPHA; PHOSPHORYLATION; SUBUNIT	Canonical activation of NF-kappaB is mediated via phosphorylation of the inhibitory IkappaB proteins by the IkappaB kinase complex (IKK). IKK is composed of a heterodimer of the catalytic IKKalpha and IKKbeta subunits and a presumed regulatory protein termed NEMO (NF-kappaB essential modulator) or IKKgamma. NEMO/IKKgamma is indispensable for activation of the IKKs in response to many signals, but its mechanism of action remains unclear. Here we identify TANK (TRAF family member-associated NF-kappaB activator) as a NEMO/IKKgamma-interacting protein via yeast two-hybrid analyses. This interaction is confirmed in mammalian cells, and the domains required are mapped. TANK was previously shown to assist NF-kappaB activation in a complex with TANK-binding kinase 1 (TBK1) or IKKepsilon, two kinases distantly related to IKKalpha/beta, but the underlying mechanisms remained unknown. Here we show that TBK1 and IKKepsilon synergize with TANK to promote interaction with the IKKs. The TANK binding domain within NEMO/IKKgamma is required for proper functioning of this IKK subunit. These results indicate that TANK can synergize with IKKepsilon or TBK1 to link them to IKK complexes, where the two kinases may modulate aspects of NF-kappaB activation.	NIAID, Lab Immunoregulat, NIH, Bethesda, MD 20892 USA; CHU Sart Tilman, Med Chem Lab, Ctr Cellular & Mol Therapy Pathol, B-4000 Liege, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Liege	Siebenlist, U (corresponding author), NIAID, Lab Immunoregulat, NIH, Bldg 10,Rm 11B16, Bethesda, MD 20892 USA.		leonardi, antonio/A-2887-2009	leonardi, antonio/0000-0001-8636-9623; Chariot, Alain/0000-0002-1691-4347				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nomura F, 2000, GENES CELLS, V5, P191; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	41	134	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37029	37036		10.1074/jbc.M205069200	http://dx.doi.org/10.1074/jbc.M205069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12133833	Green Submitted, hybrid			2022-12-27	WOS:000178447100018
J	Cedazo-Minguez, A; Popescu, BO; Ankarcrona, M; Nishimura, T; Cowburn, RF				Cedazo-Minguez, A; Popescu, BO; Ankarcrona, M; Nishimura, T; Cowburn, RF			The presenilin 1 Delta E9 mutation gives enhanced basal phospholipase C activity and a resultant increase in intracellular calcium concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; ALZHEIMERS-DISEASE; MEDIATED ENHANCEMENT; SIGNAL-TRANSDUCTION; RYANODINE RECEPTOR; PC12 CELLS; PROTEIN; ACTIVATION; ADHESION; EXON-9	We studied effects of the familial Alzheimer's disease presenilin 1 (PS1) exon 9 deletion (PS1-DeltaE9) mutation on basal and carbachol-stimulated phosphoinositide (PI) hydrolysis and intracellular Ca2+ concentrations ([Ca2+](i)) in human SH-SY5Y neuroblastoma cells. We demonstrate that PS1-DeltaE9 cells have an enhanced basal PI hydrolysis and [Ca2+](i) as compared with both wild type PS1 (PS1-WT) and nontransfected (NT) cells. Both were reversed by the phospholipase C (PLC) inhibitor neomycin. The PS1-DeltaE9-related high basal [Ca2+](i) was also reversed by xestospongin C confirming that this effect was inositol trisphosphate receptor-mediated. Carbachol gave a greater stimulation of [Ca2+](i) in PS1-DeltaE9 cells that took longer to return to basal as compared with responses seen in NT and PS1-WT cells. This long tail-off effect seen in PS1-DeltaE9 cells after carbachol stimulation was reversed by xestospongin C and dantrolene, suggesting that it was mediated by inositol trisphosphate receptor and ryanodine receptor amplification of Ca2+. Ruthenium red only reduced carbachol peak elevations of [Ca2+](i) in NT and PS1-WT cells and not in PS1-DeltaE9 cells. No significant between cell type differences were seen for basal and carbachol-stimulated [Ca2+](i) with either ryanodine or the endoplasmic reticulum Ca2+ ATPase inhibitor cyclopiazonic acid. Immunostaining experiments revealed that for all the cell types PSI is present at the plasma membrane and colocalizes with N-cadherin, a component of the cell-cell adhesion complex. Immunoblotting of cell extracts for PLC-beta1 showed that, compared with NT and PS1-WT cells, the PS1-DeltaE9 transfectants gave a relative increase in levels of the calpain generated N-terminal fragment (100 kDa) over full-length (150 kDa) PLC-beta1. Our results suggest that the PS1-DeltaE9 mutation causes upstream changes in PI signaling with enhanced basal PLC activity as a primary effect that leads to a higher [Ca2+](i). This may provide a novel mechanism by which the PS1-DeltaE9 mutation sensitizes cells to apoptotic stimuli and enhanced amyloid beta generation.	Karolinska Inst, Novum, Neurotec, Sect Expt Geriatr,Klin Forskningscentrum, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Sect Expt Geriatr, Neurotec,Sumitomo Pharmaceut Alzheimer Ctr KASPAC, S-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Cedazo-Minguez, A (corresponding author), Karolinska Inst, Novum, Neurotec, Sect Expt Geriatr,Klin Forskningscentrum, Plan 4, S-14186 Huddinge, Sweden.	angel.cedazo-minguez@neurotec.ki.se	Cedazo-Minguez, Angel/C-6707-2012	Cedazo-Minguez, Angel/0000-0003-4626-4864; Ankarcrona, Maria/0000-0002-7022-3694				Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; BERRIDGE MJ, 1982, CELL CALCIUM, V3, P385, DOI 10.1016/0143-4160(82)90025-2; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cedazo-Minguez A, 2001, FEBS LETT, V504, P45, DOI 10.1016/S0014-5793(01)02761-2; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FOWLER CJ, 1987, PHARMACOL TOXICOL, V60, P274, DOI 10.1111/j.1600-0773.1987.tb01751.x; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; Jope RS, 1997, NEUROBIOL AGING, V18, P111, DOI 10.1016/S0197-4580(96)00205-9; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kolasa K, 2000, NEUROSCIENCE, V99, P25, DOI 10.1016/S0306-4522(00)00164-0; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Leissring MA, 1999, J NEUROCHEM, V72, P1061, DOI 10.1046/j.1471-4159.1999.0721061.x; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Leissring MA, 2001, NEUROBIOL DIS, V8, P469, DOI 10.1006/nbdi.2001.0382; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Mackrill JJ, 1997, BIOCHEM J, V327, P251, DOI 10.1042/bj3270251; Mann DMA, 2001, NEUROPATH APPL NEURO, V27, P189, DOI 10.1046/j.1365-2990.2001.00316.x; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; Mehta ND, 1998, ANN NEUROL, V43, P256, DOI 10.1002/ana.410430217; Moerman AM, 1999, J NEUROSCI RES, V57, P962, DOI 10.1002/(SICI)1097-4547(19990915)57:6<962::AID-JNR22>3.3.CO;2-D; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; PARK DG, 1993, J BIOL CHEM, V268, P4573; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; Popescu BO, 2001, J NEUROSCI RES, V66, P122, DOI 10.1002/jnr.1204; Querfurth HW, 1997, J NEUROCHEM, V69, P1580; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; SCHACHT J, 1976, J ACOUST SOC AM, V59, P940, DOI 10.1121/1.380929; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; SMITH IF, 2002, IN PRESS BRAIN RES; Tanii H, 2000, NEUROSCIENCE, V95, P593; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vossmeyer D, 2002, J BIOL CHEM, V277, P4636, DOI 10.1074/jbc.M105415200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrenn RW, 1996, BIOCHEM BIOPH RES CO, V226, P876, DOI 10.1006/bbrc.1996.1443; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	53	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36646	36655		10.1074/jbc.M112117200	http://dx.doi.org/10.1074/jbc.M112117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121968	hybrid			2022-12-27	WOS:000178275100110
J	Oza, SL; Tetaud, E; Ariyanayagam, MR; Warnon, SS; Fairlamb, AH				Oza, SL; Tetaud, E; Ariyanayagam, MR; Warnon, SS; Fairlamb, AH			A single enzyme catalyses formation of trypanothione from glutathione and spermidine in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFUNCTIONAL GLUTATHIONYLSPERMIDINE SYNTHETASE/AMIDASE; CRITHIDIA-FASCICULATA; ESCHERICHIA-COLI; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; REDUCTASE; PURIFICATION; BIOSYNTHESIS; METABOLISM; POLYAMINES	Protozoa of the order Kinetoplastida differ from other organisms in their ability to conjugate glutathione (L-y-glutamyl-cysteinyl-glycine) and spermidine to form trypanothione [N-1,N-8-bis(glutathionyl)spermidinel, a metabolite involved in defense against chemical and oxidant stress and other biosynthetic functions. In Crithidia fasciculata, trypanothione is synthesized from GSH and spermidine via the intermediate glutathionylspermidine in two distinct ATP-dependent reactions catalyzed by glutathionylspermidine synthetase (GspS; EC 6.3.1.8) and trypanothione synthetase (TryS; EC 6.3.1.9), respectively. Here we have cloned a single copy gene (TcTryS) from Trypanosoma cruzi encoding a protein with 61% sequence identity with Cf TryS but only 31% with CfGspS. Saccharomyces cerevisiae transformed with TcTryS were able to synthesize glutathionylspermidine and trypanothione, suggesting that this enzyme is able to catalyze both biosynthetic steps, unlike Cf TryS. When cultures were supplemented with aminopropylcadaverine, yeast transformants contained glutathionylaminopropylcadaverine and homotrypanothione [N-1,N-9-bis(glutathionyl)aminopropylcadaverinel, metabolites that have been previously identified in T. cruzi, but not in C. fasciculata. Kinetic studies on recombinant TcTryS purified from Escherichia coli revealed that the enzyme displays highsubstrate inhibition with glutathione (K-m and K-i of 0.57 and 1.2 mm, respectively, and k(cat) of 3.4 s(-1)), but obeys Michaelis-Menten kinetics with spermidine, aminopropylcadaverine, glutathionylspermidine, and MgATP as variable substrate. The recombinant enzyme possesses weak amidase activity and can hydrolyze trypanothione, homotrypanothione, or glutathionylspermidine to glutathione and the corresponding polyamine.	Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland.		Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329; Oza, Sandra/0000-0001-9404-7931				Allaoui A, 1999, MOL MICROBIOL, V32, P1273, DOI 10.1046/j.1365-2958.1999.01440.x; Ariyanayagam MR, 1997, MOL BIOCHEM PARASIT, V84, P111, DOI 10.1016/S0166-6851(96)02788-0; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; Fairlamb AH, 1999, MEDICINA-BUENOS AIRE, V59, P179; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Koenig K, 1997, J BIOL CHEM, V272, P11908, DOI 10.1074/jbc.272.18.11908; KRAUTHSIEGEL RL, 1995, FASEB J, V9, P1138, DOI 10.1096/fasebj.9.12.7672506; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Kwon DS, 1997, J BIOL CHEM, V272, P2429; LeQuesne SA, 1996, BIOCHEM J, V316, P481; Lin CH, 1997, BIOCHEMISTRY-US, V36, P14930, DOI 10.1021/bi9714464; Lopez JA, 2000, FREE RADICAL BIO MED, V28, P767, DOI 10.1016/S0891-5849(00)00159-3; Machado CA, 2001, P NATL ACAD SCI USA, V98, P7396, DOI 10.1073/pnas.121187198; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A., 1989, METABOLISM FUNCTIONS, P367; Moutiez M, 1997, BIOCHEM J, V322, P43, DOI 10.1042/bj3220043; Oza SL, 2002, BIOCHEM J, V364, P679, DOI 10.1042/BJ20011370; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1975, J BIOL CHEM, V250, P2648; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; Thomson L, 1999, MOL BIOCHEM PARASIT, V98, P81, DOI 10.1016/S0166-6851(98)00149-2; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; Tovar J, 1998, P NATL ACAD SCI USA, V95, P5311, DOI 10.1073/pnas.95.9.5311; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755	45	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35853	35861		10.1074/jbc.M204403200	http://dx.doi.org/10.1074/jbc.M204403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12121990	hybrid			2022-12-27	WOS:000178275100014
J	Ambrogelly, A; Ahel, I; Polycarpo, C; Bunjun-Srihari, S; Krett, B; Jacquin-Becker, C; Ruan, BF; Kohrer, C; Stathopoulos, C; RajBhandary, UL; Soll, D				Ambrogelly, A; Ahel, I; Polycarpo, C; Bunjun-Srihari, S; Krett, B; Jacquin-Becker, C; Ruan, BF; Kohrer, C; Stathopoulos, C; RajBhandary, UL; Soll, D			Methanocaldococcus jannaschii prolyl-tRNA synthetase charges tRNA(Pro) with cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; SEQUENCE; ACIDS; SITE; DISCRIMINATION; MECHANISM; DOMAIN	Methanocaldococcus jannaschii prolyl-tRNA synthetase (ProRS) was previously reported to also catalyze the synthesis of cysteinyl-tRNA(Cys) (Cys-tRNA(Cys)) to make up for the absence of the canonical cysteinyl-tRNA synthetase in this organism (Stathopoulos, C., Li, T., Longman, R., Vothknecht, U. C., Becker, H., Ibba, M., and Soll, D. (2000) Science 287, 479-482; Lipman, R. S., Sowers, K. R., and Hou, Y. M. (2000) Biochemistry 39, 7792-7798). Here we show by acid urea gel electrophoresis that pure heterologously expressed recombinant M. jannaschii ProRS misaminoacylates M. jannaschii tRNA(Pro), with cysteine. The enzyme is unable to aminoacylate purified mature M. jannaschii tRNA(Cys) with cysteine in contrast to facile aminoacylation of the same tRNA with cysteine by Methanococcus maripaludis cysteinyl-tRNA synthetase. Although M. jannaschii ProRS catalyzes the synthesis of Cys-tRNA(Pro) readily, the enzyme is unable to edit this misaminoacylated tRNA. We discuss the implications of these results on the in vivo activity of the M. jannaschii ProRS and on the nature of the enzyme involved in the synthesis of Cys-tRNA(Cys) in M. jannaschii.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Yale University; Yale University; Massachusetts Institute of Technology (MIT)	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.		Polycarpo, Carla R/G-2832-2011	Ahel, Ivan/0000-0002-9446-3756; Stathopoulos, Constantinos/0000-0002-5699-4118; Polycarpo, Carla/0000-0001-9663-3563	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022854, R56GM017151, F32GM017151, R01GM017151, R37GM017151, R37GM022854] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151, GM22854] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Bovee ML, 1999, BIOCHEMISTRY-US, V38, P13725, DOI 10.1021/bi991182g; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fabrega C, 2001, NATURE, V411, P110, DOI 10.1038/35075121; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; HECHT SM, 1976, P NATL ACAD SCI USA, V73, P405, DOI 10.1073/pnas.73.2.405; Helm M, 1998, NUCLEIC ACIDS RES, V26, P1636, DOI 10.1093/nar/26.7.1636; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Lipman RSA, 2002, J MOL BIOL, V315, P943, DOI 10.1006/jmbi.2001.5297; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Newberry KJ, 2002, EMBO J, V21, P2778, DOI 10.1093/emboj/21.11.2778; RIBEIRO S, 1995, ANAL BIOCHEM, V228, P330, DOI 10.1006/abio.1995.1359; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SPRINZL M, 1975, P NATL ACAD SCI USA, V72, P3049, DOI 10.1073/pnas.72.8.3049; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, P NATL ACAD SCI USA, V98, P14292, DOI 10.1073/pnas.201540498; Stathopoulos C, 2001, BIOCHEMISTRY-US, V40, P46, DOI 10.1021/bi002108x; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712; Yarus M, 2000, SCIENCE, V287, P440, DOI 10.1126/science.287.5452.440	43	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34749	34754		10.1074/jbc.M206929200	http://dx.doi.org/10.1074/jbc.M206929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130658	hybrid			2022-12-27	WOS:000178117000014
J	Kimberly, WT; LaVoie, MJ; Ostaszewski, BL; Ye, WJ; Wolfe, MS; Selkoe, DJ				Kimberly, WT; LaVoie, MJ; Ostaszewski, BL; Ye, WJ; Wolfe, MS; Selkoe, DJ			Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; PRECURSOR PROTEIN; PRESENILIN-1; NOTCH; ENDOPROTEOLYSIS; DROSOPHILA; CLEAVAGE	The intramembranous proteolysis of Notch and the amyloid precursor protein by gamma-secretase exemplifies an unusual and newly recognized mechanism of signal transduction in multicellular organisms. Here, we show that only a form of nicastrin (NCT) containing N-linked complex oligosaccharides is present in active gamma-secretase complexes. Overexpression of NCT does not generate more of this mature protein, a phenomenon analogous to the strictly regulated formation of mature presenilin heterodimers from immature holoprotein. The absence of presenilin severely limits the maturation of NCT, yet combined overexpression of both proteins does not increase respective mature types. Taken together, our findings describe unusual regulatory features of this key signaling protease: the association of NCT with gamma-secretase is tightly regulated via glycosylation; at least one other cofactor exists; the least abundant member of the complex becomes limiting; and the cofactor that serves this role may vary by cell type.	Brigham & Womens Hosp, Ctr Neurol Dis, Harvard Inst Med 730, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Harvard Inst Med 730, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017574, R01AG012749] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12749, AG 17574] Funding Source: Medline; NINDS NIH HHS [NS 41355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	34	103	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35113	35117		10.1074/jbc.M204446200	http://dx.doi.org/10.1074/jbc.M204446200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12130643	hybrid			2022-12-27	WOS:000178117000058
J	Qu, XH; Wei, HD; Zhai, Y; Que, HP; Chen, Q; Tang, F; Wu, Y; Xing, GC; Zhu, YP; Liu, SJ; Fan, M; He, FC				Qu, XH; Wei, HD; Zhai, Y; Que, HP; Chen, Q; Tang, F; Wu, Y; Xing, GC; Zhu, YP; Liu, SJ; Fan, M; He, FC			Identification, characterization, and functional study of the two novel human members of the semaphorin gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SEMAPHORIN; LUNG-CANCER; PROTEIN; CELL; RECEPTORS; EXPRESSION; MIGRATION; CLONING; VERTEBRATES; COLLAPSIN	We cloned two novel human transmembrane semaphorins, (HSA)SEMA6C and (HSA)SEMA6D, that belong to the class VI subgroup of the semaphorin family. The genes for SEMA6C and SEMA6D are mapped on chromosome 1q12-21.1 and 15q21.1, respectively. Among the adult tissues, SEMA6C is expressed only in skeletal muscle, whereas SEMA6D is expressed abundantly in kidney, brain, and placenta and moderately in the heart and skeletal muscles. During murine development, neither SEMA6C nor SEMA6D was expressed in embryonic day 10.5 (E10.5) embryos, but both were highly expressed in the areas of the lateral ventricle, the striatum, the wall of the midbrain, the pons/midbrain junction, and the choroid plexus of E13 embryos. Were neurons, neither axons nor astrocytes, highly expressed both semaphorins. Three isoforms of SEMA6C and five isoforms of SEMA6D derived from alternative splicing were identified, and their expression was regulated in a tissue- and development-dependent manner. Deletion analysis indicated that a sema domain and a PSI domain are integrally necessary for correct post-translation modification and subcellular localization. The extracellular domain of SEMA6C inhibited axonal extension of nerve growth factor-differentiated PC12 cells and induced the growth cone collapse of chicken dorsal root ganglion, rat hippocampal neurons, and rat cortical neurons in a dose-responsive manner. SEMA6D acted like SEMA6C except it had no significant effect on the growth cones of rat cortical neurons.	Chinese Natl Human Genome Ctr, Beijing Inst Radiat Med, Dept Genom & Proteom, Beijing 100850, Peoples R China; Beijing Inst Basic Med Sci, Dept Neurosci, Beijing 100850, Peoples R China	Academy of Military Medical Sciences - China; Academy of Military Medical Sciences - China	He, FC (corresponding author), Chinese Natl Human Genome Ctr, Beijing Inst Radiat Med, Dept Genom & Proteom, 27 Taiping Rd, Beijing 100850, Peoples R China.							Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Correa RG, 2001, GENOMICS, V73, P343, DOI 10.1006/geno.2001.6525; Delaire S, 2001, J IMMUNOL, V166, P4348, DOI 10.4049/jimmunol.166.7.4348; Encinas JA, 1999, P NATL ACAD SCI USA, V96, P2491, DOI 10.1073/pnas.96.5.2491; ENOKIDO Y, 1992, BRAIN RES, V599, P261, DOI 10.1016/0006-8993(92)90400-4; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Harlow E., 1988, ANTIBODIES LAB MANUA; Holder N, 1999, DEVELOPMENT, V126, P2033; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Kikuchi K, 1999, MOL CELL NEUROSCI, V13, P9, DOI 10.1006/mcne.1998.0732; Klostermann A, 2000, J BIOL CHEM, V275, P39647, DOI 10.1074/jbc.M006316200; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; Kramer SG, 2001, SCIENCE, V292, P737, DOI 10.1126/science.1058766; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Qu XH, 2001, GENE, V264, P37, DOI 10.1016/S0378-1119(01)00324-9; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Roche J, 1996, ONCOGENE, V12, P1289; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Xu XM, 2000, J NEUROSCI, V20, P2638; Yu YT, 2001, GENOME RES, V11, P1392, DOI 10.1101/gr.175501	31	55	66	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35574	35585		10.1074/jbc.M206451200	http://dx.doi.org/10.1074/jbc.M206451200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12110693	hybrid			2022-12-27	WOS:000178117000117
J	Yun, SS; Dardik, A; Haga, M; Yamashita, A; Yamaguchi, S; Koh, Y; Madri, JA; Sumpio, BE				Yun, SS; Dardik, A; Haga, M; Yamashita, A; Yamaguchi, S; Koh, Y; Madri, JA; Sumpio, BE			Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PRO-GELATINASE-A; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; INDUCIBLE EXPRESSION; TISSUE INHIBITOR; GENE-EXPRESSION; CELL INVASION; DNA-BINDING; ACTIVATION	Membrane type 1-matrix metalloproteinase (MT1-MMP) plays a key role in endothelial cell migration, matrix remodeling, and angiogenesis. Previous studies demonstrated that a mechanical force, cyclic strain, increases MT1-MMP expression by displacing Sp1 with increased Egr-1 expression and binding to the promoter site. However, the effect of shear stress (SS) on MT1-MMP expression is poorly understood. Although Egr-1 mRNA transcription and protein was induced (7.6-fold) in response to SS (n = 5, 0-8 h, p < 0.05), SS decreased MT1-MMP mRNA transcription and protein levels in a time-dependent fashion (10, 50, and 90% reduction at 1, 4, and 8 h, respectively; n = 5, p < 0.05). Egr-1 protein was increased after SS and cyclic strain, but Sp1 was serine-phosphorylated only after SS. SS increased Sp1 DNA binding (3.8-, 5.8-, and 2.4-fold increase at 1, 4, and 8 h, respectively; n = 5, p < 0.05) that was inhibitable by calf intestinal phosphatase. Thus, SS inhibits MT1-MMP expression despite Egr-1 up-regulation by inducing the serine phosphorylation of Sp1, which in turn increases its binding affinity for its site on the MT1-MMP promoter, reducing the ability of Egr-1 to displace it. These data illustrate the complex control of microvascular endothelial cell MT1-MMP expression in response to distinct environmental stimuli (cyclic strain versus shear stress), consisting of both the modulation of specific transcription factor expression (Egr-1) as well as transcription factor post-translational modification (serine phosphorylation of Sp1).	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Catholic Univ, Sch Med, Dept Surg, Seoul 121817, South Korea	Yale University; Yale University; Catholic University of Korea	Sumpio, BE (corresponding author), Yale Univ, Sch Med, Dept Vasc Surg, 333 Cedar St,FMB 137, New Haven, CT 06510 USA.				NHLBI NIH HHS [R01 HL-54732, R01 HL-51018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054732, R01HL051018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORJA PF, 2001, EMBO J, V20, P5737; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; FOK J, 1972, MOL PHARMACOL, V8, P65; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hofmann UB, 2000, J PATHOL, V191, P245; Ihn H, 2001, J INVEST DERMATOL, V117, P301, DOI 10.1046/j.0022-202x.2001.01371.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22637; Kinoh H, 1996, J CELL SCI, V109, P953; Kraiss LW, 2000, AM J PHYSIOL-HEART C, V278, pH1537, DOI 10.1152/ajpheart.2000.278.5.H1537; LEY K, 1989, BLOOD, V73, P1324; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mignatti P, 1996, CURR TOP MICROBIOL, V213, P33; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Nagase H, 1998, Cell Res, V8, P179; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Palumbo R, 2000, CIRCULATION, V102, P225, DOI 10.1161/01.CIR.102.2.225; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; WEB Z, 1997, CELL, V91, P439; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Yamaguchi S, 2002, LAB INVEST, V82, P949, DOI 10.1097/01.LAB.0000020408.77307.E9	46	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34808	34814		10.1074/jbc.M205417200	http://dx.doi.org/10.1074/jbc.M205417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12093818	hybrid			2022-12-27	WOS:000178117000022
J	Illing, ME; Rajan, RS; Bence, NF; Kopito, RR				Illing, ME; Rajan, RS; Bence, NF; Kopito, RR			A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN AGGREGATION; INCLUSION-BODIES; CELL-DEATH; MUTATIONS; GENE; DEGRADATION; DISEASE; MODEL; DEGENERATION; INHIBITION	The inherited retinal degenerations are typified by retinitis pigmentosa (RP), a heterogeneous group of inherited disorders that causes the destruction of photoreceptor cells, the retinal pigmented epithelium, and choroid. This group of blinding conditions affects over 1.5 million persons worldwide. Approximately 30-40% of human autosomal dominant (AD) RP is caused by dominantly inherited missense mutations in the rhodopsin gene. Here we show that P23H, the most frequent RP mutation in American patients, renders rhodopsin extremely prone to form high molecular weight oligomeric species in the cytoplasm of transfected cells. Aggregated P23H accumulates in aggresomes, which are pericentriolar inclusion bodies that require an intact microtubule cytoskeleton to form. Using fluorescence resonance energy transfer (FRET), we observe that P23H aggregates in the cytoplasm even at extremely low expression levels. Our data show that the P23H mutation destabilizes the protein and targets it for degradation by the ubiquitin proteasome system. P23H is stabilized by proteasome inhibitors and by co-expression of a dominant negative form of ubiquitin. We show that expression of P23H, but not wild-type rhodopsin, results in a generalized impairment of the ubiquitin proteasome system, suggesting a mechanism for photoreceptor degeneration that links RP to a broad class of neurodegenerative diseases.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	kopito@stanford.edu			NIDDK NIH HHS [1R01 DK 43994, 1R01 DK 52795] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994, R01DK052795] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Crow MK, 2001, BIOTECHNIQUES, V30, P311, DOI 10.2144/01302st04; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; DOWNER NW, 1985, BIOPHYS J, V47, P277, DOI 10.1016/S0006-3495(85)83917-5; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FLANNERY JG, 1989, INVEST OPHTH VIS SCI, V30, P191; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JOHNSTON J, 2002, IN PRESS CELL MOTIL; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P367; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Milam AH, 1998, PROG RETIN EYE RES, V17, P175; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Sung CH, 2000, INT REV CYTOL, V195, P215; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	55	232	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34150	34160		10.1074/jbc.M204955200	http://dx.doi.org/10.1074/jbc.M204955200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12091393	hybrid			2022-12-27	WOS:000177959100082
J	Jiang, Z; Grichtchenko, II; Boron, WF; Aronson, PS				Jiang, Z; Grichtchenko, II; Boron, WF; Aronson, PS			Specificity of anion exchange mediated by mouse Slc26a6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLUS MEMBRANE-VESICLES; BRUSH-BORDER MEMBRANE; PROXIMAL TUBULE; TRANSPORT; FORMATE; OXALATE; RAT; REABSORPTION; SALAMANDER; ABSORPTION	Recently, CFEX, the mouse orthologue of human SLC26A6, was localized to the brush border membrane of proximal tubule cells and was demonstrated to mediate Cl--formate exchange when expressed in Xenopus oocytes. The purpose of the present study was to examine whether mouse Slc26a6 can mediate one or more of the additional anion exchange processes observed to take place across the apical membrane of proximal tubule cells. Influx of [C-14]formate into Slc26a6-expressing oocytes was inhibited by sulfate, oxalate, and p-aminohippurate (PAH), indicating affinity for these anions. Measurements of uptake of [C-14]oxalate, [C-14]PAH, and [S-35] sulfate indicated that Slc26a6 can mediate transport of oxalate and sulfate but not PAH. Studies of the effect of external anions on [C-14]oxalate efflux demonstrated Slc26a6-mediated Cl--oxalate, oxalate-formate, oxalate-oxalate, and oxalate-sulfate exchange. Two-electrode voltage clamp measurements indicated that Slc26a6-mediated Cl--oxalate exchange is electrogenic. Intracellular pH recordings demonstrated that Slc26a6 can mediate Cl--HCO3- exchange, but Cl--OH- exchange was not detected. The presence of 100 pm oxalate inhibited the rate of Cl--HCO3- exchange by 60%. We conclude that mouse SIc26a6 has affinity for oxalate, sulfate, and HCO3- in addition to Cl- and formate and can function in multiple exchange modes involving pairs of these anions. In the presence of high oxalate concentrations as found in renal tubular fluid and urine, Slc26a6 may largely function as an electrogenic Cl--oxalate exchanger.	Yale Univ, Sch Med, Dept Internal Med, Sect Nephrol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Aronson, PS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Nephrol, 333 Cedar St,LMP 2073, New Haven, CT 06520 USA.	peter.aronoson@yale.edu	Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Grichtchenko, Irina/0000-0002-6708-6916	NIDDK NIH HHS [DK 17433, DK 33793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033793, R37DK033793, P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aronson PS, 1997, AM J PHYSIOL-RENAL, V273, pF179, DOI 10.1152/ajprenal.1997.273.2.F179; ARONSON PS, 1989, ANN N Y ACAD SCI, V574, P96; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; CHAO P, 1988, PFLUG ARCH EUR J PHY, V411, P216, DOI 10.1007/BF00582318; Grichtchenko II, 2000, J GEN PHYSIOL, V115, P533, DOI 10.1085/jgp.115.5.533; Grichtchenko II, 2001, J BIOL CHEM, V276, P8358, DOI 10.1074/jbc.C000716200; GUGGINO SE, 1983, AM J PHYSIOL, V244, pF612, DOI 10.1152/ajprenal.1983.244.6.F612; KAHN AM, 1983, AM J PHYSIOL, V244, pF56, DOI 10.1152/ajprenal.1983.244.1.F56; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; Karniski LP, 1998, AM J PHYSIOL-RENAL, V274, pF189, DOI 10.1152/ajprenal.1998.274.1.F189; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; Kuo SM, 1996, J BIOL CHEM, V271, P15491, DOI 10.1074/jbc.271.26.15491; KURTZ I, 1994, J CLIN INVEST, V94, P173, DOI 10.1172/JCI117304; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; MCCONNELL KR, 1994, J BIOL CHEM, V269, P21489; SCHILD L, 1987, J CLIN INVEST, V79, P32, DOI 10.1172/JCI112803; SEIFTER JL, 1984, AM J PHYSIOL, V247, pF753, DOI 10.1152/ajprenal.1984.247.5.F753; SHEU JN, 1995, AM J PHYSIOL-RENAL, V268, pF847, DOI 10.1152/ajprenal.1995.268.5.F847; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; WANG T, 1992, AM J PHYSIOL, V263, pF37, DOI 10.1152/ajprenal.1992.263.1.F37; Wang T, 1996, AM J PHYSIOL-RENAL, V271, pF446, DOI 10.1152/ajprenal.1996.271.2.F446; Wang T, 2001, AM J PHYSIOL-RENAL, V281, pF288, DOI 10.1152/ajprenal.2001.281.2.F288; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; WAREING M, 1994, J PHYSIOL-LONDON, V477, P347, DOI 10.1113/jphysiol.1994.sp020196; WARNOCK DG, 1981, J CLIN INVEST, V67, P103, DOI 10.1172/JCI110002	27	127	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33963	33967		10.1074/jbc.M202660200	http://dx.doi.org/10.1074/jbc.M202660200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12119287	hybrid			2022-12-27	WOS:000177959100059
J	Olsen, A; Herwald, H; Wikstrom, M; Persson, K; Mattsson, E; Bjorck, L				Olsen, A; Herwald, H; Wikstrom, M; Persson, K; Mattsson, E; Bjorck, L			Identification of two protein-binding and functional regions of curli, a surface organelle and virulence determinant of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN AGGREGATIVE FIMBRIAE; SPECTROSCOPY HR-DOSY; FIBRONECTIN-BINDING; SALMONELLA-ENTERITIDIS; CONTACT SYSTEM; ACTIVATION; FIBERS; BRADYKININ; EXPRESSION; SEPSIS	Curli are surface organelles of Escherichia coli. These fibrous proteins, formed by polymerization of a 15-kDa subunit, are expressed by E. coli strains associated with severe infections in humans. A remarkable property of curli is their ability to interact with a wide range of human proteins, interactions that contribute to the enhanced virulence of curli-expressing E. coli. To define the protein-binding region(s) of curli, we investigated the binding properties of overlapping synthetic peptides covering the curli subunit. Two peptides, one covering a 24-amino acid residue sequence in the NH2-terminal half of the subunit (NNS24) and one corresponding to the 26 COOH-terminal residues (VDQ26), were found to bind a number of human proteins. Physiochemical analysis revealed that NNS24 adopts a thermally stable beta-structure, and in solution the peptide forms soluble multimers, predominantly octamers. Intact curli are known to activate the proinflammatory and procoagulant contact system, and when added to human plasma, the NNS24 and VDQ26 peptides induced the release of the potent vasoactive peptide bradykinin. The results map important curli functions to the regions corresponding to the NNS24 and VDQ26 sequences.	Lund Univ, Dept Cell & Mol Biol, Sect Mol Pathogenesis, SE-22184 Lund, Sweden; Biovitrum, SE-11287 Stockholm, Sweden; Univ Lund Hosp, Dept Med Microbiol Dermatol & Infect, SE-22185 Lund, Sweden	Lund University; Lund University; Skane University Hospital	Olsen, A (corresponding author), Gothenburg Univ, Dept Clin Immunol, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden.	arne.olsen@immuno.gu.se	Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842				ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; BARJAT H, 1995, J MAGN RESON SER B, V108, P170, DOI 10.1006/jmrb.1995.1118; BenNasr A, 1996, MOL MICROBIOL, V20, P927; Bian Z, 2000, J INFECT DIS, V181, P602, DOI 10.1086/315233; Bian Z, 2001, J INFECT DIS, V183, P612, DOI 10.1086/318528; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; Brown PK, 2001, MOL MICROBIOL, V41, P349, DOI 10.1046/j.1365-2958.2001.02529.x; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991; COLLINSON SK, 1992, J BACTERIOL, V174, P4490, DOI 10.1128/JB.174.13.4490-4495.1992; COLLINSON SK, 1993, J BACTERIOL, V175, P12, DOI 10.1128/JB.175.1.12-18.1993; DORAN JL, 1993, J CLIN MICROBIOL, V31, P2263, DOI 10.1128/JCM.31.9.2263-2273.1993; Gophna U, 2001, INFECT IMMUN, V69, P2659, DOI 10.1128/IAI.69.4.2659-2665.2001; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hammar M, 1995, MOL MICROBIOL, V18, P661, DOI 10.1111/j.1365-2958.1995.mmi_18040661.x; Hammar M, 1996, P NATL ACAD SCI USA, V93, P6562, DOI 10.1073/pnas.93.13.6562; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; Olsen A, 1998, INFECT IMMUN, V66, P944; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; Pelta MD, 1998, MAGN RESON CHEM, V36, P706, DOI 10.1002/(SICI)1097-458X(199810)36:10<706::AID-OMR363>3.0.CO;2-W; Persson K, 2000, J EXP MED, V192, P1415, DOI 10.1084/jem.192.10.1415; PHEIL W, 1986, THERMODYNAMIC DATA B, P349; PIXLEY RA, 1995, CRIT CARE MED, V23, P41, DOI 10.1097/00003246-199501000-00010; Sakellaris H, 2000, INFECT IMMUN, V68, P3780, DOI 10.1128/IAI.68.6.3780-3783.2000; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU DH, 1995, J MAGN RESON SER A, V115, P123, DOI 10.1006/jmra.1995.1156	34	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34568	34572		10.1074/jbc.M206353200	http://dx.doi.org/10.1074/jbc.M206353200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12097335	hybrid			2022-12-27	WOS:000177959100130
J	Berditchevski, F; Odintsova, E; Sawada, S; Gilbert, E				Berditchevski, F; Odintsova, E; Sawada, S; Gilbert, E			Expression of the palmitoylation-deficient CD151 weakens the association of alpha(3)beta(1) integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-ADHESION; C-SRC; LIPID RAFTS; PROTEINS; COMPLEXES; SUPERFAMILY; MEMBRANES; PATHWAYS	Transmembrane proteins of the tetraspartin superfamily are assembled in multimeric complexes on the cell surface. Spatial orientation of tetraspanins within these complexes may affect signaling functions of the associated transmembrane receptors (e.g. integrins, receptor-type tyrosine kinases). The structural determinants that control assembly of the tetraspanin complexes are unknown. We have found that various tetraspanins and the a, integrin subunit are palmitoylated. The stability and molecular composition of the palmitoylated alpha(3)beta(1)-tetraspanin complexes are not affected by adhesion. To assess the significance of palmitoylation in the function of the alpha(3)beta(1)-tetraspanin complexes we mapped the sites of palmitoylation for CD151. Mutation of six cysteines, Cys(11), Cys(15), Cys(79), Cys(80), Cys(242), and Cys(243) was necessary to completely abolish palmitoylation of CD151. The association of the palmitoylation-deficient mutant of CD151 (CD151Cys8) with CD81 and CD63 was markedly decreased, but the interaction of the alpha(3)beta(1)-CD151Cys8 complex with phosphatidylinositol 4-kinase was not affected. Ectopic expression of CD151Cys8 in Rat-1 cells impaired the interactions of the endogenous CD63 and CD81 with the alpha(3)beta(1) integrin. Although the expression of the palmitoylation-deficient CD151 does not change cell spreading on the extracellular matrix, the number of focal adhesions increased. Adhesion-induced phosphorylation of PYB/c-Akt is markedly increased in cells expressing a palmitoylation-deficient mutant, thereby providing direct evidence for the role of the tetraspanin microdomains in regulation of the integrin-dependent phosphatidylinositol 3-kinase signaling pathway. In contrast, activation of FAK and ERK1/2 were not affected by the expression of CD151Cys8. Our results demonstrate that palmitoylation of tetraspanins is critical not only for the organization of the integrin-tetraspanin microdomains but also has a specific role in modulation of adhesion-dependent signaling.	Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	Cancer Research UK; University of Birmingham	Berditchevski, F (corresponding author), Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	f.berditchevski@bham.ac.uk						Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Berditchevski F, 2001, J BIOL CHEM, V276, P41165, DOI 10.1074/jbc.M104041200; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Brown D, 2002, INT J MED MICROBIOL, V291, P433; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cantrell DA, 2001, J CELL SCI, V114, P1439; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Delaguillaumie A, 2002, J CELL SCI, V115, P433; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kurita-Taniguchi M, 2002, MOL IMMUNOL, V38, P689, DOI 10.1016/S0161-5890(01)00100-6; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Leitinger B, 2002, J CELL SCI, V115, P963; LEVY S, 1991, J BIOL CHEM, V266, P14597; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maile LA, 2002, J BIOL CHEM, V277, P1800, DOI 10.1074/jbc.M108380200; Mannion BA, 1996, J IMMUNOL, V157, P2039; Munshi UM, 2001, EUR J BIOCHEM, V268, P1631, DOI 10.1046/j.1432-1033.2001.02032.x; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V957, P399, DOI 10.1016/0167-4838(88)90231-2; SEEHAFER JG, 1990, BIOCHIM BIOPHYS ACTA, V1039, P218, DOI 10.1016/0167-4838(90)90189-M; SHEARER M, 1992, INT J CANCER, V51, P602, DOI 10.1002/ijc.2910510417; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	45	162	173	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36991	37000		10.1074/jbc.M205265200	http://dx.doi.org/10.1074/jbc.M205265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12110679	hybrid			2022-12-27	WOS:000178447100013
J	Karasawa, T; Yokokura, H; Kitajewski, J; Lombroso, PJ				Karasawa, T; Yokokura, H; Kitajewski, J; Lombroso, PJ			Frizzled-9 is activated by Wnt-2 and functions in Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; AXIS FORMATION; PROTEIN INTERACTIONS; NEGATIVE REGULATOR; COLON-CARCINOMA; PATHWAY; FAMILY; GENE; DROSOPHILA; RECEPTOR	Frizzled has been known to function as a Wnt receptor. Although there have been a number of mammalian Frizzled members identified, their binding specificities with Wnt and functions in mammalian cells have been poorly understood. Here, we demonstrate that rat Frizzled-9 (Rfz9) functions in Wnt/beta-catenin signaling in 293T cells. Rfz9 overexpression induces the hyperphosphorylation and relocalization of mouse Dishevelled-1 (Dvl-1) from the cytoplasm to the cell membrane and the accumulation of cytosolic beta-catenin. Transfections of Rfz9 with each of several Wnt members show that only Wnt-2 activates Rfz9 in T cell factor (TCF)-dependent transcription. Deletion mutant analysis determines that there is a difference in Rfz9 C-terminal residues required for the modifications of Dvl-1 and those required for the inductions of beta-catenin stabilization and TCF transactivation. Deletion of the Wnt-binding domain does not abolish Rfz9 activity completely, although it causes the inactivation of Wnt-2-dependent TCF transcription. Rfz9 also relocalizes Axin from the cytoplasm to the plasma membrane in the presence of Dvl-1, suggesting that one of the consequences of Dvl-1 relocalization by Rfz9 is to bring Axin to the cell membrane.	Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdept Neurosci Program, New Haven, CT 06520 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Obstet Gynecol, New York, NY 10032 USA	Yale University; Yale University; Columbia University; Columbia University	Lombroso, PJ (corresponding author), Yale Univ, Sch Med, Ctr Child Study, SHM I-270,230 S Frontage Rd, New Haven, CT 06520 USA.							Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; Tago K, 2000, GENE DEV, V14, P1741; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wang YK, 1999, GENOMICS, V57, P235, DOI 10.1006/geno.1999.5773; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	44	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37479	37486		10.1074/jbc.M205658200	http://dx.doi.org/10.1074/jbc.M205658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138115	hybrid			2022-12-27	WOS:000178447100073
J	Ward, PD; Klein, RR; Troutman, MD; Desai, S; Thakker, DR				Ward, PD; Klein, RR; Troutman, MD; Desai, S; Thakker, DR			Phospholipase C-gamma modulates epithelial tight junction permeability through hyperphosphorylation of tight junction proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CACO-2 CELL MONOLAYERS; CANINE KIDNEY-CELLS; TYROSINE PHOSPHORYLATION; KINASE-C; PARACELLULAR PERMEABILITY; MDCK; OCCLUDIN; BARRIER; ZO-1; REDISTRIBUTION	Phospholipase C-gamma (PLC-gamma) is stimulated by epidermal growth factor via activation of the epidermal growth factor receptors. The PLC inhibitor, 3-nitrocoumarin (3-NC), selectively inhibited PLC-gamma in Madin-Darby canine kidney cells without affecting the activity of PLC-beta. In contrast, inhibitors of PLC-beta, hexadecylphosphocholine and U73122, had no effect on the activity of PLC-gamma. Inhibition of PLC-gamma by 3-NC was associated with an increase in tight junction permeability across Madin-Darby canine kidney cell monolayers, as evidenced by 3-NC-induced decrease in transepithelial electrical resistance and increase in mannitol flux over a concentration range that was inhibitory to PLC-gamma. An analog of 3-NC, 7-hydroxy-3-NC (7-OH-3-NC), which was inactive as an inhibitor of PLC-gamma, also had no effect on tight junction permeability. Treatment with 3-NC caused punctate disruption in the cortical actin filaments. The PLC-gamma inhibitor, 3-NC, but not the inactive analog, 7-OH-3-NC, caused hyperphosphorylation of the tight junction proteins, occludin, ZO-1, and ZO-2. The serine/threonine kinase inhibitor, staurosporine (50-200 nM), significantly attenuated 3-NC-induced hyperphosphorylation of ZO-2. This corresponded with attenuation by staurosporine of 3-NC-induced increase in tight junction permeability, suggesting a relationship between ZO-2 phosphorylation and tight junction permeability.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; Qual Chem Labs, Wilmington, NC 28405 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; GlaxoSmithKline	Thakker, DR (corresponding author), Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, CB 7360,Beard Hall, Chapel Hill, NC 27599 USA.	dhiren_thakker@unc.edu						AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BALLARD ST, 1995, ANNU REV NUTR, V15, P35, DOI 10.1146/annurev.nu.15.070195.000343; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHO MJ, 1989, PHARMACEUT RES, V6, P71, DOI 10.1023/A:1015807904558; Clarke HM, 1999, MOL BIOL CELL, V10, p410A; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; HOWARTH AG, 1994, J MEMBRANE BIOL, V137, P261; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Leroy A, 2000, FASEB J, V14, P1139, DOI 10.1096/fasebj.14.9.1139; Liu DZ, 1999, J PHARM SCI, V88, P1161, DOI 10.1021/js990094e; Liu DZ, 1999, J PHARM SCI, V88, P1169, DOI 10.1021/js9900957; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Nozu F, 1999, AM J PHYSIOL-GASTR L, V276, pG915, DOI 10.1152/ajpgi.1999.276.4.G915; PERRELLA FW, 1994, J MED CHEM, V37, P2232, DOI 10.1021/jm00040a016; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STADDON JM, 1995, J CELL SCI, V108, P609; STEVENSON BR, 1989, BIOCHEM J, V263, P597, DOI 10.1042/bj2630597; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Tai YH, 1996, J MEMBRANE BIOL, V149, P71; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859	37	32	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35760	35765		10.1074/jbc.M203134200	http://dx.doi.org/10.1074/jbc.M203134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12101180	Green Published, hybrid			2022-12-27	WOS:000178117000139
J	Roy, K; de la Serna, IL; Imbalzano, AN				Roy, K; de la Serna, IL; Imbalzano, AN			The myogenic basic helix-loop-helix family of transcription factors shows similar requirements for SWI/SNF chromatin remodeling enzymes during muscle differentiation in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; SWI-SNF COMPLEX; SKELETAL-MUSCLE; DNA-BINDING; REGULATORY FACTORS; RHABDOID TUMORS; NUCLEOSOMAL DNA; GENE-EXPRESSION; MYOD; PROTEIN	The myogenic basic helix-loop-helix family of transcription factors, MyoD, Myf5, myogenin, and MRF4, can each activate the muscle differentiation program when ectopically expressed in non-muscle cells. SWI/SNF complexes are ATP-dependent chromatin remodeling enzymes. We demonstrated previously that SWI/SNF enzymes promote MyoD-mediated muscle differentiation. To ascertain the requirement for SWI/SNF enzymes in muscle differentiation mediated by different MyoD family members, we examined MyoD, Myf5, MRF4, and myogenin-mediated induction of muscle differentiation in cells expressing dominant negative versions of BRG1 or BRM-based SWI/SNF enzymes. We demonstrated that expression of dominant negative BRG1 or BRM inhibited the induction of muscle-specific gene expression by Myf5 and MRF4; however, myogenin failed to induce measurable quantities of muscle-specific mRNAs, even in cells not expressing dominant negative SWI/SNF. In contrast, all four myogenic regulators induced expression of the cell cycle regulators p21, Rb, and cyclin D3 and promoted cell cycle arrest independently of the SWI/SNF enzymes. We proposed that SWI/SNF enzymes are required for the induction of all muscle-specific gene expression by MyoD, Myf5, and MRF4, whereas induction of the cell cycle regulators, p21, Rb, and cyclin D3 occurred independently of SWI/SNF function.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Imbalzano, AN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056244, GM 20371, GM 56244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V9; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 1999, CANCER RES, V59, P74; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; BUCKINGHAM ME, 1994, CURR OPIN GENET DEV, V4, P745, DOI 10.1016/0959-437X(94)90142-P; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Grand F, 1999, CANCER RES, V59, P3870; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Javed A, 1999, MOL CELL BIOL, V19, P7491; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Lindon C, 2000, MOL CELL BIOL, V20, P8923, DOI 10.1128/MCB.20.23.8923-8932.2000; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wong AKC, 2000, CANCER RES, V60, P6171; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	78	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33818	33824		10.1074/jbc.M205159200	http://dx.doi.org/10.1074/jbc.M205159200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12105204	hybrid			2022-12-27	WOS:000177959100039
J	Sot, B; Galan, A; Valpuesta, JM; Bertrand, S; Muga, A				Sot, B; Galan, A; Valpuesta, JM; Bertrand, S; Muga, A			Salt bridges at the inter-ring interface regulate the thermostat of GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; COOPERATIVITY; MECHANISM; BINDING; COMMUNICATION; HYDROLYSIS	The chaperonin GroEL consists of a double-ring structure made of identical subunits and displays unusual allosteric properties caused by the interaction between its constituent subunits. Cooperative binding of ATP to a protein ring allows binding of GroES to that ring, and at the same time negative inter-ring cooperativity discharges the ligands from the opposite ring, thus driving the protein-folding cycle. Biochemical and electron microscopy analysis of wild type GroEL, a single-ring mutant (SR1), and two mutants with one inter-ring salt bridge of the chaperonin disrupted (E461K and E434K) indicate that these ion pairs form part of the interactions that allow the inter-ring allosteric signal to be transmitted. The wild type-like activities of the ion pair mutants at 25 degreesC are in contrast with their lack of interring communication and folding activity at physiological temperatures. These salt bridges stabilize the interring interface and maintain the inter-ring spacing so that functional communication between protein heptamers takes place. The characterization of GroEL hybrids containing different amounts of wild type and mutant subunits also indicates that as the number of inter-ring salt bridges increases the functional properties of the hybrids recover. Taken together, these results strongly suggest that inter-ring salt bridges form a stabilizing ring-shaped, ionic zipper that ensures interring communication at the contact sites and therefore a functional protein-folding cycle. Furthermore, they regulate the chaperonin thermostat, allowing GroEL to distinguish physiological (37 degreesC) from stress temperatures (42 degreesC).	Univ Basque Country, Euskal Herriko Univ, CSIC, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Muga, A (corresponding author), Univ Basque Country, Euskal Herriko Univ, CSIC, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Valpuesta, José M/T-1977-2017; Sot, Begoña/H-2882-2015; Valpuesta, Jose M/AAA-6002-2019; Muga, Arturo/N-1174-2014	Valpuesta, José M/0000-0001-7468-8053; Sot, Begoña/0000-0001-8763-0651; Muga, Arturo/0000-0003-0345-6882				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Horovitz A, 2001, J STRUCT BIOL, V135, P104, DOI 10.1006/jsbi.2001.4377; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; MARTIN A, 1995, NUCLEIC ACIDS RES, V23, P1642, DOI 10.1093/nar/23.9.1642; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Russo R, 2001, J BIOL CHEM, V276, P13628, DOI 10.1074/jbc.M010009200; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Shiseki K, 2001, J BIOL CHEM, V276, P11335, DOI 10.1074/jbc.M010348200; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	30	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34024	34029		10.1074/jbc.M205733200	http://dx.doi.org/10.1074/jbc.M205733200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12110685	hybrid			2022-12-27	WOS:000177959100067
J	Morley, SJ; Naegele, S				Morley, SJ; Naegele, S			Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT TRANSLATION; MESSENGER-RNA; FACTOR 4G; KINASE; BINDING; AFFINITY; MNK1; SITE; STIMULATION; INHIBITION	Previous work has suggested that increased phosphorylation of eukaryotic initiation factor (eIF) 4E at Ser-209 in the C-terminal loop of the protein often correlates with increased translation rates. However, the functional consequences of phosphorylation have remained contentious with our understanding of the role of eIF4E phosphorylation in translational control far from complete. To investigate the role for eIF4E phosphorylation in de novo translation, we studied the recovery of human kidney cells from hypertonic stress. Results show that hypertonic shock caused a rapid inhibition of protein synthesis and the disaggregation of polysomes. These changes were associated with the dephosphorylation of eIF4G, eIF4E, 4E-binding protein 1 (4E-BP1), and ribosomal protein S6. In addition, decreased levels of the eIF4F complex and increased association of 4E-BP1 with eIF4E were observed over a similar time course. The return of cells to isotonic medium rapidly promoted the phosphorylation of these initiation factors, increased levels of eIF4F complexes, promoted polysome assembly, and increased rates of translation. However, by using a cell-permeable, specific inhibitor of eIF4E kinase, Mnk1 (CGP57380), we show that de novo initiation of translation and eIF4F complex assembly during this recovery phase did not require eIF4E phosphorylation.	Univ Sussex, Sch Biol Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England	University of Sussex	Morley, SJ (corresponding author), Univ Sussex, Sch Biol Sci, Biochem Lab, Brighton BN1 9QG, E Sussex, England.	s.j.morley@sussex.ac.uk						DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; KRUPPA J, 1984, EMBO J, V3, P95, DOI 10.1002/j.1460-2075.1984.tb01767.x; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Morley SJ, 2001, PROG MOLEC, V27, P1; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Morley SJ, 1997, RNA, V3, P1085; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; Novoa I, 1999, MOL CELL BIOL, V19, P2445; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Tomoo K, 2002, BIOCHEM J, V362, P539, DOI 10.1042/0264-6021:3620539; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	43	76	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32855	32859		10.1074/jbc.C200376200	http://dx.doi.org/10.1074/jbc.C200376200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12138083	hybrid			2022-12-27	WOS:000177859000061
J	Datta, P; Dasgupta, A; Bhakta, S; Basu, J				Datta, P; Dasgupta, A; Bhakta, S; Basu, J			Interaction between FtsZ and FtsW of Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI; PROTEIN FTSZ; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; Z RING; POLYMERIZATION; IDENTIFICATION; PROTOFILAMENT; ELONGATION	The recruitment of FtsZ to the septum and its subsequent interaction with other cell division proteins in a spatially and temporally controlled manner are the keys to bacterial cell division. In the present study, we have tested the hypothesis that FtsZ and FtsW of Mycobacterium tuberculosis could be binding partners. Using gel renaturation, pull-down, and solid-phase assays, we confirm that FtsZ and FtsW interact through their C-terminal tails, which carry extensions absent in their Escherichia coli counterparts. Crucial to these interactions is the cluster of aspartate residues Asp(367) to Asp(370) of FtsZ, which most likely interact with a cluster of positively charged residues in the C-terminal tail of FtsW. Mutations of the aspartate residues 367-370 showed that changing three aspartate residues to alanine resulted in complete loss of interaction. This is the first demonstration of the direct interaction between FtsZ and FtsW. We speculate that this interaction between FtsZ and FtsW could serve to anchor FtsZ to the membrane and link septum formation to peptidoglycan synthesis in M. tuberculosis. The findings assume particular significance in view of the global efforts to explore new targets in M. tuberculosis for chemotherapeutic intervention.	Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India	Department of Science & Technology (India); Bose Institute	Basu, J (corresponding author), Bose Inst, Dept Chem, 93-1 APC Rd, Kolkata 700009, W Bengal, India.	joyoti@bosemain.boseinst.ac.in	Datta, Pratik/O-4400-2016	Datta, Pratik/0000-0001-6713-9961				Boyle DS, 1997, MOL MICROBIOL, V24, P1263, DOI 10.1046/j.1365-2958.1997.4091773.x; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; Dziadek J, 2002, MICROBIOL-SGM, V148, P961, DOI 10.1099/00221287-148-4-961; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Erickson HP, 2001, CURR OPIN CELL BIOL, V13, P55, DOI 10.1016/S0955-0674(00)00174-5; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Gerard P, 2002, J BACTERIOL, V184, P1925, DOI 10.1128/JB.184.7.1925-1931.2002; Henriques AO, 1998, MOL MICROBIOL, V28, P235, DOI 10.1046/j.1365-2958.1998.00766.x; IKEDA M, 1989, J BACTERIOL, V171, P6375, DOI 10.1128/jb.171.11.6375-6378.1989; ISHINO F, 1989, J BACTERIOL, V171, P5523, DOI 10.1128/jb.171.10.5523-5530.1989; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KHATTAR MM, 1994, J BACTERIOL, V176, P7140, DOI 10.1128/JB.176.23.7140-7147.1994; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; MA X, 1997, P NATL ACAD SCI USA, V93, P12998; Margolin W, 1999, ASM NEWS, V65, P137; Mercer KLN, 2002, J BACTERIOL, V184, P904, DOI 10.1128/jb.184.4.904-912.2002; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Park J. T., 1992, NATURE, V359, P251; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000	28	69	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24983	24987		10.1074/jbc.M203847200	http://dx.doi.org/10.1074/jbc.M203847200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12101218	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000176747000020
